Updated on 2024/04/09

写真a

 
FUJIWARA Toshiyoshi
 
Organization
Faculty of Medicine, Dentistry and Pharmaceutical Sciences Professor
Position
Professor
External link

Degree

  • Doctor(medicive) ( Okayama University )

Research Interests

  • Gastroenterological Surgery

  • 遺伝子治療

  • Gene Theuapy

  • Surgical Oncology

  • 腫瘍外科

  • 消化器外科

Research Areas

  • Life Science / Tumor diagnostics and therapeutics

  • Life Science / Biomedical engineering

  • Life Science / Digestive surgery

Education

  • Okayama University   医学研究科   外科学

    - 1990

      More details

    Country: Japan

    researchmap

  • Okayama University    

    - 1990

      More details

  • Okayama University   医学部   医学科

    - 1985

      More details

    Country: Japan

    researchmap

  • Okayama University    

    - 1985

      More details

Research History

  • - Professor,Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Okayama University

    2010

      More details

  • - 岡山大学医歯薬学総合研究科 教授

    2010

      More details

  • テキサス大学MDアンダーソン癌センター 研究員

    1991 - 1993

      More details

  • Researcher,The University of Texas M. D. Anderson Cancer Center

    1991 - 1993

      More details

  • 岡山済生会総合病院 未設定

    1985 - 1987

      More details

Professional Memberships

▼display all

Committee Memberships

  • 日本消化器外科学会   評議員  

    2015   

      More details

    Committee type:Academic society

    日本消化器外科学会

    researchmap

  • 日本外科学会   理事  

    2014   

      More details

    Committee type:Academic society

    日本外科学会

    researchmap

  • 日本がん治療認定医機構   理事  

    2012   

      More details

    Committee type:Academic society

    日本がん治療認定医機構

    researchmap

  • 日本癌治療学会   理事  

    2011 - 2017   

      More details

    Committee type:Academic society

    日本癌治療学会

    researchmap

  • 日本外科学会   代議員  

    2011   

      More details

    Committee type:Academic society

    日本外科学会

    researchmap

  • 日本癌治療学会   代議員  

    2009   

      More details

    Committee type:Academic society

    日本癌治療学会

    researchmap

  • 日本胃癌学会   評議員  

    2009   

      More details

    Committee type:Academic society

    日本胃癌学会

    researchmap

  • 日本遺伝子治療学会   理事  

    2007 - 2011   

      More details

    Committee type:Academic society

    日本遺伝子治療学会

    researchmap

  • 独立行政法人新エネルギー・産業技術総合開発機構(NEDO)   技術委員  

    2007 - 2008   

      More details

    Committee type:Academic society

    独立行政法人新エネルギー・産業技術総合開発機構(NEDO)

    researchmap

  • 日本癌学会   評議員  

    2006   

      More details

    Committee type:Academic society

    日本癌学会

    researchmap

  • 日本再生医療学会   評議員  

    2001   

      More details

    Committee type:Academic society

    日本再生医療学会

    researchmap

  • 日本遺伝子治療学会   評議員  

    1998   

      More details

    Committee type:Academic society

    日本遺伝子治療学会

    researchmap

▼display all

 

Papers

  • Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity. International journal

    Masaaki Akai, Kazuhiro Noma, Takuya Kato, Seitaro Nishimura, Hijiri Matsumoto, Kento Kawasaki, Tomoyoshi Kunitomo, Teruki Kobayashi, Noriyuki Nishiwaki, Hajime Kashima, Satoru Kikuchi, Toshiaki Ohara, Hiroshi Tazawa, Peter L Choyke, Hisataka Kobayashi, Toshiyoshi Fujiwara

    British journal of cancer   2024.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) play a critical role in tumor immunosuppression. However, targeted depletion of CAFs is difficult due to their diverse cells of origin and the resulting lack of specific surface markers. Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that leads to rapid cell membrane damage. METHODS: In this study, we used anti-mouse fibroblast activation protein (FAP) antibody to target FAP+ CAFs (FAP-targeted NIR-PIT) and investigated whether this therapy could suppress tumor progression and improve tumor immunity. RESULTS: FAP-targeted NIR-PIT induced specific cell death in CAFs without damaging adjacent normal cells. Furthermore, FAP-targeted NIR-PIT treated mice showed significant tumor regression in the CAF-rich tumor model accompanied by an increase in CD8+ tumor infiltrating lymphocytes (TILs). Moreover, treated tumors showed increased levels of IFN-γ, TNF-α, and IL-2 in CD8+ TILs compared with non-treated tumors, suggesting enhanced antitumor immunity. CONCLUSIONS: Cancers with FAP-positive CAFs in their TME grow rapidly and FAP-targeted NIR-PIT not only suppresses their growth but improves tumor immunosuppression. Thus, FAP-targeted NIR-PIT is a potential therapeutic strategy for selectively targeting the TME of CAF+ tumors.

    DOI: 10.1038/s41416-024-02639-1

    PubMed

    researchmap

  • Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles. International journal

    Kazuya Yasui, Toshiaki Toshima, Ryo Inada, Yuzo Umeda, Shuya Yano, Hiroaki Tanioka, Akihiro Nyuya, Toshiyoshi Fujiwara, Takeshi Yamada, Yoshio Naomoto, Ajay Goel, Takeshi Nagasaka

    Molecular cancer   23 ( 1 )   1 - 1   2024.1

     More details

    Language:English  

    This study investigates methylation patterns in circulating cell-free DNA (ccfDNA) for their potential role in colorectal cancer (CRC) detection and the monitoring of treatment response. Through methylation microarrays and quantitative PCR assays, we analyzed 440 samples from The Cancer Genome Atlas (TCGA) and an additional 949 CRC samples. We detected partial or extensive methylation in over 85% of cases within three biomarkers: EFEMP1, SFRP2, and UNC5C. A methylation score for at least one of the six candidate regions within these genes' promoters was present in over 95% of CRC cases, suggesting a viable detection method. In evaluating ccfDNA from 97 CRC patients and 62 control subjects, a difference in methylation and recovery signatures was observed. The combined score, integrating both methylation and recovery metrics, showed high diagnostic accuracy, evidenced by an area under the ROC curve of 0.90 (95% CI = 0.86 to 0.94). While correlating with tumor burden, this score gave early insight into disease progression in a small patient cohort. Our results suggest that DNA methylation in ccfDNA could serve as a sensitive biomarker for CRC, offering a less invasive and potentially more cost-effective approach to augment existing cancer detection and monitoring modalities, possibly supporting comprehensive genetic mutation profiling.

    DOI: 10.1186/s12943-023-01910-y

    PubMed

    researchmap

  • Epidural versus patient-controlled intravenous analgesia on pain relief and recovery after laparoscopic gastrectomy for gastric cancer: randomized clinical trial. International journal

    Satoru Kikuchi, Takashi Matsusaki, Toshiharu Mitsuhashi, Shinji Kuroda, Hajime Kashima, Nobuo Takata, Ema Mitsui, Yoshihiko Kakiuchi, Kazuhiro Noma, Yuzo Umeda, Hiroshi Morimatsu, Toshiyoshi Fujiwara

    BJS open   8 ( 1 )   2024.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Epidural analgesia (EDA) is a main modality for postoperative pain relief in major open abdominal surgery within the Enhanced Recovery After Surgery protocol. However, it remains unclear whether EDA is an imperative modality in laparoscopic gastrectomy (LG). This study examined non-inferiority of patient-controlled intravenous analgesia (PCIA) to EDA in terms of postoperative pain and recovery in patients who underwent LG. METHODS: In this open-label, non-inferiority, parallel, individually randomized clinical trial, patients who underwent elective LG for gastric cancer were randomized 1:1 to receive either EDA or PCIA after surgery. The primary endpoint was pain score using the Numerical Rating Scale at rest 24 h after surgery, analysed both according to the intention-to-treat (ITT) principle and per protocol. The non-inferiority margin for pain score was set at 1. Secondary outcomes were postoperative parameters related to recovery and adverse events related to analgesia. RESULTS: Between 3 July 2017 and 29 September 2020, 132 patients were randomized to receive either EDA (n = 66) or PCIA (n = 66). After exclusions, 64 patients were included in the EDA group and 65 patients in the PCIA group for the ITT analysis. Pain score at rest 24 h after surgery was 1.94 (s.d. 2.07) in the EDA group and 2.63 (s.d. 1.76) in the PCIA group (P = 0.043). PCIA was not non-inferior to EDA for the primary endpoint (difference 0.69, one side 95% c.i. 1.25, P = 0.184) in ITT analysis. Postoperative parameters related to recovery were similar between groups. More EDA patients (21 (32.8%) versus 1 (1.5%), P < 0.001) developed postoperative hypotension as an adverse event. CONCLUSIONS: PCIA was not non-inferior to EDA in terms of early-phase pain relief after LG.Registration number: UMIN000027643 (https://www.umin.ac.jp/ctr/index-j.htm).

    DOI: 10.1093/bjsopen/zrad161

    PubMed

    researchmap

  • Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus. International journal

    Koji Uotani, Hiroshi Tazawa, Joe Hasei, Tomohiro Fujiwara, Aki Yoshida, Yasuaki Yamakawa, Toshinori Omori, Kazuhisa Sugiu, Tadashi Komatsubara, Hiroya Kondo, Takuya Morita, Masahiro Kiyono, Suguru Yokoo, Toshiaki Hata, Toshiyuki Kunisada, Ken Takeda, Yasuo Urata, Toshiyoshi Fujiwara, Toshifumi Ozaki

    PloS one   19 ( 2 )   e0298292   2024

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Bone and soft-tissue sarcomas are rare malignancies with histological diversity and tumor heterogeneity, leading to the lack of a common molecular target. Telomerase is a key enzyme for keeping the telomere length and human telomerase reverse transcriptase (hTERT) expression is often activated in most human cancers, including bone and soft-tissue sarcomas. For targeting of telomerase-positive tumor cells, we developed OBP-301, a telomerase-specific replication-competent oncolytic adenovirus, in which the hTERT promoter regulates adenoviral E1 gene for tumor-specific viral replication. In this study, we present the diagnostic potential of green fluorescent protein (GFP)-expressing oncolytic adenovirus OBP-401 for assessing virotherapy sensitivity using bone and soft-tissue sarcomas. OBP-401-mediated GFP expression was significantly associated with the therapeutic efficacy of OBP-401 in human bone and soft-tissue sarcomas. In the tumor specimens from 68 patients, malignant and intermediate tumors demonstrated significantly higher expression levels of coxsackie and adenovirus receptor (CAR) and hTERT than benign tumors. OBP-401-mediated GFP expression was significantly increased in malignant and intermediate tumors with high expression levels of CAR and hTERT between 24 and 48 h after infection. Our results suggest that the OBP-401-based GFP expression system is a useful tool for predicting the therapeutic efficacy of oncolytic virotherapy on bone and soft-tissue sarcomas.

    DOI: 10.1371/journal.pone.0298292

    PubMed

    researchmap

  • ASO Author Reflections: The Role of Robotic Surgery in Patients with Portal Annular Pancreas. International journal

    Kosei Takagi, Tomokazu Fuji, Kazuya Yasui, Yuzo Umeda, Toshiyoshi Fujiwara

    Annals of surgical oncology   2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1245/s10434-023-14778-5

    PubMed

    researchmap

  • Robotic Pancreatoduodenectomy in Portal Annular Pancreas Using a Hanging Maneuver with Indocyanine Green Fluorescence Imaging. International journal

    Kosei Takagi, Tomokazu Fuji, Motohiko Yamada, Jiro Kimura, Kazuya Yasui, Yuzo Umeda, Toshiyoshi Fujiwara

    Annals of surgical oncology   2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Sufficient knowledge and surgical management of portal annular pancreas (PAP) are essential for pancreatic surgery. As PAP is a relatively rare pancreatic anomaly, few studies have described surgical techniques for patients with PAP undergoing robotic pancreatoduodenectomy (RPD). PATIENTS AND METHODS: An 82-year-old female patient who underwent RPD presented with distal cholangiocarcinoma and type III PAP (the fusion of the uncinate process with the anteportal main pancreatic duct). After the Kocher maneuver and stomach transection, the pancreas was transected into the neck of the anteportal portion. The retroportal portion was dissected, encircled with hanging tape, and compressed. Blood supply from the mesenteric vessels was confirmed using indocyanine green (ICG) fluorescence imaging. Subsequently, the retroportal portion was stapled. CONCLUSIONS: This study demonstrates a unique surgical technique for type III PAP using the hanging maneuver with ICG fluorescence imaging. Surgeons should decide on the surgical strategy on the basis of the fusion and ductal anatomy of the pancreas.

    DOI: 10.1245/s10434-023-14685-9

    PubMed

    researchmap

  • Clinical Impact of Prehabilitation on Elective Laparoscopic Surgery in Frail Octogenarians With Colorectal Cancer. International journal

    Fuminori Teraishi, Kunitoshi Shigeyasu, Yoshitaka Kondo, Shunsuke Kagawa, Rie Tamura, Yoshikazu Matsuoka, Hiroshi Morimatsu, Toshiyoshi Fujiwara

    Anticancer research   43 ( 12 )   5597 - 5604   2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: The aim of the present study was to clarify the clinical impact of prehabilitation by the perioperative management center (PERIO) at our hospital in severely frail octogenarians with colorectal cancer. PATIENTS AND METHODS: We compared the clinicopathological characteristics of octogenarians who underwent surgery for colorectal cancer before the establishment of PERIO intervention (Control group) with those who received prehabilitation (PERIO group). All patients were classified as American Society of Anesthesiologists (ASA) class 3 or higher. The primary outcome was the incidence of postoperative complications. RESULTS: There were 21 patients in the Control group and 19 patients in the PERIO group. Operative time was significantly longer in the PERIO group (Control group, 200 min vs. PERIO group, 230 min; p=0.03) and blood loss was significantly higher in the PERIO group (Control group, 5 ml vs. PERIO group, 30 ml; p=0.02). Postoperative complications occurred in 10 patients (47.6%) in the Control group and 3 patients (15.8%) in the PERIO group and were significantly lower in the PERIO group (p=0.03). Postoperative hospital stay was 13 days (range=7-31 days) in the Control group and 11 days (range=8-70 days) in the PERIO group (p=0.39). The rate of discharge directly to home was 81% in the Control group and 93.3% in the PERIO group (p=0.29). CONCLUSION: In frail octogenarians with colorectal cancer of ASA class 3 or higher, the incidence of postoperative complications was significantly lower after PERIO intervention.

    DOI: 10.21873/anticanres.16762

    PubMed

    researchmap

  • Intraperitoneal Administration of p53-armed Oncolytic Adenovirus Inhibits Peritoneal Metastasis of Diffuse-type Gastric Cancer Cells. International journal

    Naoto Hori, Hiroshi Tazawa, Yuncheng Li, Tomohiro Okura, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Masahiko Nishizaki, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Anticancer research   43 ( 11 )   4809 - 4821   2023.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Diffuse-type gastric cancer (GC) frequently exhibits peritoneal metastasis, leading to poor prognosis. However, efforts to develop antitumor strategies for preventing the peritoneal metastasis of GC have been unsuccessful. As diffuse-type GC cells often carry a genetic alteration in the tumor suppressor p53 gene, p53 restoration may be a potent strategy for preventing peritoneal metastasis of GC. In this study, we investigated the therapeutic potential of p53-expressing adenoviral vectors against peritoneal metastasis of diffuse-type GC cells. MATERIALS AND METHODS: Three diffuse-type human GC cell types with different p53 statuses (p53-wild type NUGC-4, p53-mutant type GCIY, and p53-null type KATOIII) were used to evaluate the therapeutic potential of p53 activation induced by the p53-expressing, replication-deficient adenovirus Ad-p53 and oncolytic adenovirus OBP-702. Viability, apoptosis, and autophagy of virus-treated GC cells were analyzed under normal and sphere-forming culture conditions using the XTT assay and western blot analysis. The in vivo antitumor effects of OBP-702 and Ad-p53 were assessed using xenograft tumor models involving peritoneal metastasis of NUGC-4 and GCIY cells. RESULTS: Under normal and sphere-forming culture conditions, OBP-702 induced a significantly greater antitumor effect in GC cells compared with Ad-p53 by strongly inducing p53-mediated apoptosis and autophagy and receptor tyrosine kinase suppression. In vivo experiments demonstrated that intraperitoneal administration of OBP-702 significantly suppressed the peritoneal metastasis of NUGC-4 and GCIY cells compared with Ad-p53, leading to prolonged survival of mice. CONCLUSION: Intraperitoneal administration of OBP-702 inhibits the peritoneal metastasis of GC cells by inducing p53-mediated cytopathic activity.

    DOI: 10.21873/anticanres.16678

    PubMed

    researchmap

  • 膵頭十二指腸切除術後の胸部食道癌に対して遊離空腸間置再建を伴うロボット支援下食道亜全摘術を施行し得た1例

    森分 和也, 野間 和広, 松本 佑, 河崎 健人, 橋本 将志, 加藤 卓也, 前田 直見, 菊地 覚次, 重安 邦俊, 田辺 俊介, 近藤 喜太, 黒田 新士, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   84 ( 11 )   1829 - 1830   2023.11

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 病理組織学的に膵浸潤を認めた壁外発育型胃GISTの1例

    新田 薫, 垣内 慶彦, 庄司 良平, 重安 邦俊, 菊地 覚次, 近藤 喜太, 黒田 新士, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   84 ( 11 )   1829 - 1829   2023.11

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • Prognostic nutritional index is a prognostic factor for patients with gastric cancer and esophagogastric junction cancer undergoing proximal gastrectomy with esophagogastrostomy by the double-flap technique: A secondary analysis of the rD-FLAP study. International journal

    Yoshihiko Kakiuchi, Shinji Kuroda, Yasuhiro Choda, Shinya Otsuka, Satoshi Ueyama, Norimitsu Tanaka, Atsushi Muraoka, Shinji Hato, Yasuaki Kamikawa, Toshiyoshi Fujiwara

    Surgical oncology   50   101990 - 101990   2023.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Although proximal gastrectomy (PG) is commonly used in patients with upper gastric cancer (GC) and esophagogastric junction (EGJ) cancer, long-term prognostic factors in these patients are poorly understood. The double-flap technique (DFT) is an esophagogastrostomy with anti-reflux mechanism after PG; we previously conducted a multicenter retrospective study (rD-FLAP) to evaluate the short-term outcomes of DFT reconstruction. Here, we evaluated the long-term prognostic factors in patients with upper GC and EGJ cancer. METHODS: The study was conducted as a secondary analysis of the rD-FLAP Study, which enrolled patients who underwent PG with DFT reconstruction, irrespective of disease type, between January 1996 and December 2015. RESULTS: A total of 509 GC and EGJ cancer patients were enrolled. Univariate and multivariate analyses of overall survival demonstrated that a preoperative prognostic nutritional index (PNI) < 45 (p < 0.001, hazard ratio [HR]: 3.59, 95% confidential interval [CI]: 1.93-6.67) was an independent poor prognostic factor alongside pathological T factor ([pT] ≥2) (p = 0.010, HR: 2.29, 95% CI: 1.22-4.30) and pathological N factor ([pN] ≥1) (p = 0.001, HR: 3.27, 95% CI: 1.66-6.46). In patients with preoperative PNI ≥45, PNI change (<90%) at 1-year follow-up (p = 0.019, HR: 2.54, 95%CI: 1.16-5.54) was an independent poor prognostic factor, for which operation time (≥300 min) and blood loss (≥200 mL) were independent risk factors. No independent prognostic factors were identified in patients with preoperative PNI <45. CONCLUSIONS: PNI is a prognostic factor in upper GC and EGJ cancer patients. Preoperative nutritional enhancement and postoperative nutritional maintenance are important for prognostic improvement in these patients.

    DOI: 10.1016/j.suronc.2023.101990

    PubMed

    researchmap

  • 膵臓癌間質に対する腫瘍融解アデノウイルス製剤の治療効果

    永井 康雄, 田澤 大, 菊地 覚次, 黒田 新士, 野間 和広, 浦田 泰生, 香川 俊輔, 藤原 俊義

    癌と化学療法   50 ( 10 )   1102 - 1103   2023.10

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    膵臓癌は豊富な間質を有する予後不良な悪性疾患である。膵臓癌の間質環境にはがん関連線維芽細胞(CAFs)が存在し,悪性化の進展,治療抵抗性や再発に寄与している。しかし膵臓癌間質を制御する有効な治療法は未だ確立していない。著者らは,癌抑制遺伝子p53を搭載した腫瘍融解アデノウイルス製剤(OBP-702)を開発し,膵臓癌に対する治療効果を明らかにしてきた。本研究では,膵臓癌CAFに対するOBP-702の治療効果を検討する。(著者抄録)

    researchmap

  • [Therapeutic Effect of Oncolytic Adenovirus on Pancreatic Cancer Stroma].

    Yasuo Nagai, Hiroshi Tazawa, Satoru Kikuchi, Shinji Kuroda, Kazuhiro Noma, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   50 ( 10 )   1102 - 1103   2023.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Pancreatic ductal adenocarcinoma(PDAC)is lethal malignancy with abundant stroma. Cancer-associated fibroblasts (CAFs) exist in the PDAC stroma and contribute to progression of malignant transformation, treatment resistance, and recurrence. However, effective treatment to control PDAC stroma has not been established. We have developed tumor suppressor gene p53-armed oncolytic adenovirus(OBP-702), and have clarified therapeutic effects on PDAC cells. In this study, we investigate the therapeutic effect of OBP-702 on PDAC CAF.

    PubMed

    researchmap

  • 食道癌術後長期腸瘻サポートのリスク因子

    橋本 将志, 野間 和広, 河崎 健人, 加藤 卓也, 前田 直見, 菊地 覚次, 重安 邦俊, 田辺 俊介, 近藤 喜太, 黒田 新士, 寺石 文則, 楳田 祐三, 白川 靖博, 香川 俊輔, 藤原 俊義

    日本癌治療学会学術集会抄録集   61回   O31 - 2   2023.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 当院における高齢者食道癌に対する手術を基盤とした集学的治療

    森分 和也, 野間 和広, 前田 直見, 橋本 将志, 加藤 卓也, 菊地 覚次, 重安 邦俊, 田辺 俊介, 近藤 喜太, 黒田 新士, 寺石 文則, 香川 俊輔, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   61回   O7 - 6   2023.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • バイパス術の有効性の検証

    松本 祐, 野間 和広, 前田 直見, 橋本 将志, 加藤 卓也, 菊池 覚次, 重安 邦俊, 田辺 俊介, 近藤 喜太, 黒田 新士, 楳田 祐三, 寺石 文則, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   61回   O7 - 1   2023.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 症例報告からPrecision Medicineへ-第1部-(BRAF-mutant microsatellite stable rectal cancer with KRAS mutation in liver metastasis)

    重安 邦俊, 山本 英喜, 楳田 祐三, 黒田 新士, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本癌治療学会学術集会抄録集   61回   ICCJ1 - 4   2023.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • Exosomes as a drug delivery tool for cancer therapy: a new era for existing drugs and oncolytic viruses. International journal

    Yoshihiko Kakiuchi, Shinji Kuroda, Nobuhiko Kanaya, Shunsuke Kagawa, Hiroshi Tazawa, Toshiyoshi Fujiwara

    Expert opinion on therapeutic targets   1 - 10   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: Exosomes are cell-derived nanovesicles involved in cell-to-cell communications. These nanovesicles are generally considered to contain important carriers of information such as DNA and RNA, and show specific tropism. AREAS COVERED: The combination of existing therapeutic agents with exosomes enhances therapeutic effects by increasing uptake into the tumor. Induction of immunogenic cell death (ICD) may also be triggered more strongly than with the drug alone. Oncolytic viruses (OVs) are even more effective as a drug in combination with exosomes. Although OVs are more likely to cause immune activity, combination with exosomes can exert synergistic effects. OVs have potent anti-tumor effects, but many limitations, such as being limited to local administration and vulnerability to attack by antibodies. Incorporation into exosomes can overcome these limitations and may allow effects against distant tumors. EXPERT OPINION: Novel therapies using exosomes are very attractive in terms of enhancing therapeutic efficacy and reducing side effects. This approach also contains elements overcoming disadvantages in OVs, which have not been used clinically until now, and may usher in a new era of cancer treatments.

    DOI: 10.1080/14728222.2023.2259102

    PubMed

    researchmap

  • Stroke volume variation and dynamic arterial elastance predict fluid responsiveness even in thoracoscopic esophagectomy: a prospective observational study

    Yukiko Hikasa, Satoshi Suzuki, Shunsuke Tanabe, Kazuhiro Noma, Yasuhiro Shirakawa, Toshiyoshi Fujiwara, Hiroshi Morimatsu

    Journal of Anesthesia   37 ( 6 )   930 - 937   2023.9

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s00540-023-03256-7

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s00540-023-03256-7/fulltext.html

  • PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer. International journal

    Kento Kawasaki, Kazuhiro Noma, Takuya Kato, Toshiaki Ohara, Shunsuke Tanabe, Yasushige Takeda, Hijiri Matsumoto, Seitaro Nishimura, Tomoyoshi Kunitomo, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Hajime Kashima, Naoaki Maeda, Satoru Kikuchi, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Cancer immunology, immunotherapy : CII   72 ( 11 )   3787 - 3802   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The programmed cell death 1 protein (PD-1)/programmed cell death ligand 1 (PD-L1) axis plays a crucial role in tumor immunosuppression, while the cancer-associated fibroblasts (CAFs) have various tumor-promoting functions. To determine the advantage of immunotherapy, the relationship between the cancer cells and the CAFs was evaluated in terms of the PD-1/PD-L1 axis. Overall, 140 cases of esophageal cancer underwent an immunohistochemical analysis of the PD-L1 expression and its association with the expression of the α smooth muscle actin, fibroblast activation protein, CD8, and forkhead box P3 (FoxP3) positive cells. The relationship between the cancer cells and the CAFs was evaluated in vitro, and the effect of the anti-PD-L1 antibody was evaluated using a syngeneic mouse model. A survival analysis showed that the PD-L1+ CAF group had worse survival than the PD-L1- group. In vitro and in vivo, direct interaction between the cancer cells and the CAFs showed a mutually upregulated PD-L1 expression. In vivo, the anti-PD-L1 antibody increased the number of dead CAFs and cancer cells, resulting in increased CD8+ T cells and decreased FoxP3+ regulatory T cells. We demonstrated that the PD-L1-expressing CAFs lead to poor outcomes in patients with esophageal cancer. The cancer cells and the CAFs mutually enhanced the PD-L1 expression and induced tumor immunosuppression. Therefore, the PD-L1-expressing CAFs may be good targets for cancer therapy, inhibiting tumor progression and improving host tumor immunity.

    DOI: 10.1007/s00262-023-03531-2

    PubMed

    researchmap

  • チーム医療 効果的な周術期管理チーム介入を見据えた高齢大腸癌患者の術前機能評価の有用性

    寺石 文則, 庄司 良平, 松三 雄騎, 重安 邦俊, 近藤 喜太, 田村 利枝, 松岡 義和, 藤原 俊義

    日本大腸肛門病学会雑誌   76 ( 9 )   A100 - A100   2023.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 術前治療と手術アプローチから検討した直腸癌術後骨盤内局所再発の治療成績

    庄司 良平, 寺石 文則, 近藤 喜太, 松三 雄騎, 重安 邦俊, 藤原 俊義

    日本大腸肛門病学会雑誌   76 ( 9 )   A194 - A194   2023.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • CAFsを標的にした光免疫療法によるドラッグデリバリー改善効果(Drug delivery improvement of CAFs targeted photoimmunotherapy)

    西村 星多郎, 野間 和広, 高橋 達也, 竹田 泰茂, 松本 聖, 國友 知義, 河崎 健人, 赤井 正明, 小林 照貴, 賀島 肇, 加藤 卓也, 菊地 覚次, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   82回   131 - 131   2023.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 鉄キレート効果を持つHIF-PH阻害薬は抗腫瘍免疫応答を向上させる(HIF-PH inhibitors with iron chelating ability enhance the tumor immune response)

    大原 利章, 陳 悦華, 王 宇沢, 濱田 祐輔, 菊地 覚次, 野間 和広, 田澤 大, 藤澤 真義, 藤原 俊義, 松川 昭博

    日本癌学会総会記事   82回   248 - 248   2023.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 胃がん腹膜転移の生物学的解明を目的とした腹膜構造3Dモデルの開発(Development of the 3D model of peritoneum structure to explore the biology of gastric cancer peritoneal metastasis)

    宇根 悠太, 菊地 覚次, 田澤 大, 黒田 新士, 大原 利章, 野間 和広, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   82回   1858 - 1858   2023.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 術前治療と手術アプローチから検討した直腸癌術後骨盤内局所再発の治療成績

    庄司 良平, 寺石 文則, 近藤 喜太, 松三 雄騎, 重安 邦俊, 藤原 俊義

    日本大腸肛門病学会雑誌   76 ( 9 )   A194 - A194   2023.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • チーム医療 効果的な周術期管理チーム介入を見据えた高齢大腸癌患者の術前機能評価の有用性

    寺石 文則, 庄司 良平, 松三 雄騎, 重安 邦俊, 近藤 喜太, 田村 利枝, 松岡 義和, 藤原 俊義

    日本大腸肛門病学会雑誌   76 ( 9 )   A100 - A100   2023.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • Robotic Pancreaticoduodenectomy Using the Right Posterior Superior Mesenteric Artery Approach. International journal

    Kosei Takagi, Yuzo Umeda, Tomokazu Fuji, Kazuya Yasui, Toshiyoshi Fujiwara

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s11605-023-05806-6

    PubMed

    researchmap

  • 【まずはこれだけ 消化器ナースがかかわる「ERAS」】

    田邊 俊介, 野間 和広, 藤原 俊義

    消化器ナーシング   28 ( 8 )   788 - 795   2023.8

  • Dual antiplatelet therapy inhibits neutrophil extracellular traps to reduce liver micrometastases of intrahepatic cholangiocarcinoma. International journal

    Masashi Yoshimoto, Shunsuke Kagawa, Hiroki Kajioka, Atsuki Taniguchi, Shinji Kuroda, Satoru Kikuchi, Yoshihiko Kakiuchi, Tomohiko Yagi, Shohei Nogi, Fuminori Teraishi, Kunitoshi Shigeyasu, Ryuichi Yoshida, Yuzo Umeda, Kazuhiro Noma, Hiroshi Tazawa, Toshiyoshi Fujiwara

    Cancer letters   567   216260 - 216260   2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The involvement of neutrophil extracellular traps (NETs) in cancer metastasis is being clarified, but the relationship between intrahepatic cholangiocarcinoma (iCCA) and NETs remains unclear. The presence of NETs was verified by multiple fluorescence staining in clinically resected specimens of iCCA. Human neutrophils were co-cultured with iCCA cells to observe NET induction and changes in cellular characteristics. Binding of platelets to iCCA cells and its mechanism were also examined, and their effects on NETs were analyzed in vitro and in in vivo mouse models. NETs were present in the tumor periphery of resected iCCAs. NETs promoted the motility and migration ability of iCCA cells in vitro. Although iCCA cells alone had a weak NET-inducing ability, the binding of platelets to iCCA cells via P-selectin promoted NET induction. Based on these results, antiplatelet drugs were applied to these cocultures in vitro and inhibited the binding of platelets to iCCA cells and the induction of NETs. Fluorescently labeled iCCA cells were injected into the spleen of mice, resulting in the formation of liver micrometastases coexisting with platelets and NETs. These mice were treated with dual antiplatelet therapy (DAPT) consisting of aspirin and ticagrelor, which dramatically reduced micrometastases. These results suggest that potent antiplatelet therapy prevents micrometastases of iCCA cells by inhibiting platelet activation and NET production, and it may contribute to a novel therapeutic strategy.

    DOI: 10.1016/j.canlet.2023.216260

    PubMed

    researchmap

  • Innovative suture technique for robotic hepaticojejunostomy: double-layer interrupted sutures. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Tomokazu Fuji, Kazuya Yasui, Takahito Yagi, Toshiyoshi Fujiwara

    Langenbeck's archives of surgery   408 ( 1 )   284 - 284   2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Biliary reconstruction remains a technically demanding and complicated procedure in minimally invasive hepatopancreatobiliary surgeries. No optimal hepaticojejunostomy (HJ) technique has been demonstrated to be superior for preventing biliary complications. This study aimed to investigate the feasibility of our unique technique of posterior double-layer interrupted sutures in robotic HJ. METHODS: We performed a retrospective analysis of a prospectively collected database. Forty-two patients who underwent robotic pancreatoduodenectomy using this technique between September 2020 and November 2022 at our center were reviewed. In the posterior double-layer interrupted technique, sutures were placed to bite the bile duct, posterior seromuscular layer of the jejunum, and full thickness of the jejunum. RESULTS: The median operative time was 410 (interquartile range [IQR], 388-478) min, and the median HJ time was 30 (IQR, 28-39) min. The median bile duct diameter was 7 (IQR, 6-10) mm. Of the 42 patients, one patient (2.4%) had grade B bile leakage. During the median follow-up of 12.6 months, one patient (2.4%) with bile leakage developed anastomotic stenosis. Perioperative mortality was not observed. A surgical video showing the posterior double-layer interrupted sutures in the robotic HJ is included. CONCLUSIONS: Posterior double-layer interrupted sutures in robotic HJ provided a simple and feasible method for biliary reconstruction with a low risk of biliary complications.

    DOI: 10.1007/s00423-023-03020-1

    PubMed

    researchmap

  • Adenocarcinoma arising from widespread heterotopic gastric mucosa in the cervicothoracic esophagus: a case report. International journal

    Shohei Nogi, Kazuhiro Noma, Masashi Hashimoto, Takuya Kato, Naoaki Maeda, Shunsuke Tanabe, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Surgical case reports   9 ( 1 )   132 - 132   2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: In Japan, about 6% of esophageal cancers are adenocarcinomas, although most of them arise from Barrett's epithelium. Adenocarcinoma arising from heterotopic gastric mucosa (HGM) is very rare. Due to its rarity, there is no unified view on its treatment strategy and prognosis. CASE PRESENTATION: A 57-year-old man presented with a protruding lesion in the cervicothoracic esophagus that was detected by an upper gastrointestinal series at a medical checkup. Esophagoscopy revealed a 30 mm Type 1 tumor circumferentially surrounded by widespread HGM. Computed tomography (CT) and fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT showed no metastasis or invasion of the surrounding organs. We diagnosed the lesion as cT2N0M0 cStageIIB [Union for International Cancer Control (UICC) 8th Ed] cancer and performed subtotal esophagectomy with three-field lymph node dissection. The tumor was determined to be a well-differentiated adenocarcinoma arising from HGM, with deep invasion of the submucosa. The patient underwent no adjuvant therapy and has currently survived without any evidence of recurrence for 15 months. CONCLUSIONS: Although the treatment for adenocarcinoma arising from HGM is basically the same as that for squamous cell carcinoma (SCC) of the esophagus, it is important to determine the treatment strategy based on the characteristics of the adenocarcinoma arising from HGM.

    DOI: 10.1186/s40792-023-01707-7

    PubMed

    researchmap

  • 当院における化学放射線治療後ロボット支援下直腸手術の現状と課題

    松三 雄騎, 寺石 文則, 半澤 俊哉, 山田 元彦, 賀島 肇, 重安 邦俊, 藤原 俊義

    日本消化器外科学会総会   78回   P019 - 6   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 腹腔鏡下に十二指腸前壁を開放し切除を行った十二指腸Brunner腺過誤腫の一例

    加藤 貴光, 垣内 慶彦, 庄司 良平, 近藤 喜太, 黒田 新士, 野間 和宏, 楳田 祐三, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   78回   P018 - 4   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 当院の直腸癌に対する肛門温存手術アプローチの変遷と術後排便障害の発生状況

    庄司 良平, 寺石 文則, 近藤 喜太, 重安 邦俊, 菊地 覚次, 黒田 新士, 田邊 俊介, 野間 和広, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   78回   P244 - 8   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 進行食道癌症例に対する微量元素に着目した術前から術後外来までのseamlessな多職種周術期管理

    田邊 俊介, 野間 和広, 橋本 将志, 加藤 卓也, 前田 直見, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   78回   P032 - 5   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【総論】サルコペニア・フレイルに対する周術期・外来管理の工夫 食道癌周術期の早期多職種チーム医療介入は術後合併症を軽減させる

    河崎 健人, 野間 和広, 橋本 将志, 加藤 卓也, 前田 直見, 田辺 俊介, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   78回   WS4 - 2   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【上部】【Challenges beyond borders】高度進行胃癌に対するconversion surgeryの現状と新たな治療戦略 Stage IV因子と腫瘍マーカー変化率から見えたStage IV胃癌の予後を改善するための至適手術介入条件

    垣内 慶彦, 黒田 新士, 菊地 覚次, 重安 邦俊, 賀島 肇, 野間 和広, 楳田 祐三, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   78回   PD3 - 6   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【肝胆膵】切除可能膵癌に対する術前化学療法の至適戦略 血中循環腫瘍DNA内KRAS mutation profileとCA19-9値を組み合わせた膵癌予後の層別化戦略

    安井 和也, 吉田 龍一, 宮本 耕吉, 藤 智和, 高木 弘誠, 寺石 文則, 黒田 新士, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   78回   WS30 - 10   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【下部】切除不能な遠隔転移を有する局所進行大腸癌に対する集学的治療戦略 大腸癌患者の長期生存を目指した遠隔転移臓器別の切除適応と化学療法レジメンの選択

    重安 邦俊, 高橋 利明, 楳田 祐三, 垣内 慶彦, 松三 雄騎, 近藤 喜太, 寺石 文則, 黒田 新士, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   78回   WS20 - 9   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • クローン病における肛門機能温存のための至適治療戦略

    近藤 喜太, 黒田 新士, 田辺 俊介, 菊地 覚次, 野間 和広, 吉田 龍一, 楳田 祐三, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   78回   O13 - 8   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 非大腸癌由来の少数肝転移症例の切除適応を見極める

    岡田 尚大, 藤 智和, 楳田 祐三, 吉田 龍一, 高木 弘誠, 安井 和也, 黒田 新士, 野間 和広, 寺石 文則, 藤原 俊義

    日本消化器外科学会総会   78回   O11 - 6   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 周術期管理チーム介入後にみえてきたフレイル高齢者大腸癌治療の課題 術前機能評価を用いた新たな取り組み

    寺石 文則, 山田 元彦, 庄司 良平, 賀島 肇, 垣内 慶彦, 松三 雄騎, 重安 邦俊, 近藤 喜太, 黒田 新士, 藤原 俊義

    日本消化器外科学会総会   78回   O33 - 5   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道癌術後補助免疫療法中の早期再発リスクと免疫関連有害事象の検討

    橋本 将志, 野間 和広, 加藤 卓也, 前田 直見, 田辺 俊介, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   78回   O27 - 5   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 過不足ない縦郭腹部リンパ郭清と機能温存術後再建の両立を目指して 岡山大学病院の現状と展望

    加藤 卓也, 野間 和広, 橋本 将志, 前田 直見, 田辺 俊介, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   78回   O44 - 3   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Precision laparoscopic sentinel node navigation surgery for femoral skin cancer.

    Shunya Hanzawa, Fuminori Teraishi, Yuki Matsumi, Kota Tachibana, Toshiyoshi Fujiwara

    Asian journal of endoscopic surgery   16 ( 3 )   523 - 527   2023.7

     More details

    Language:English  

    Navigation surgery using indocyanine green (ICG) fluorescence imaging has been used in thoracoabdominal surgery, and its usefulness has been reported in many cases. In this study, laparoscopic lateral lymph node dissection was performed using ICG fluorescence imaging in a patient with left femoral spinous cell carcinoma with inguinal and external iliac lymph node metastases. Spinous cell carcinoma is classified as a rare cancer in Japan, and there is a scarcity of evidence for pelvic lymph node dissection, as well as a lack of studies that mention the dissection area. We hypothesized that visualization of lymph nodes and lymph flow using intraoperative ICG fluorescence imaging would indicate the area of dissection and lead to more efficient dissection. In conclusion, intraoperative ICG fluorescence imaging may be useful in this area where there is limited evidence, although there are some limitations.

    DOI: 10.1111/ases.13159

    PubMed

    researchmap

  • 進行食道癌症例に対する微量元素に着目した術前から術後外来までのseamlessな多職種周術期管理

    田邊 俊介, 野間 和広, 橋本 将志, 加藤 卓也, 前田 直見, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   78回   P032 - 5   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 当院の直腸癌に対する肛門温存手術アプローチの変遷と術後排便障害の発生状況

    庄司 良平, 寺石 文則, 近藤 喜太, 重安 邦俊, 菊地 覚次, 黒田 新士, 田邊 俊介, 野間 和広, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   78回   P244 - 8   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Case of robot-assisted salvage surgery for esophageal cancer with a mediastinal fistula after definitive chemoradiotherapy.

    Daisuke Kadowaki, Kazuhiro Noma, Masashi Hashimoto, Naoaki Maeda, Shunsuke Tanabe, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Asian journal of endoscopic surgery   16 ( 3 )   505 - 509   2023.7

     More details

    Language:English  

    Salvage surgery for esophageal cancer after definitive chemoradiotherapy (dCRT) is effective, but it is associated with a high rate of perioperative complications. The indications for robot-assisted minimally invasive esophagectomy (RAMIE) are expanding. However, there are few reports of salvage RAMIE. A 73-year-old man was referred to our hospital for residual esophageal cancer with a mediastinal fistula after dCRT. The perioperative diagnosis was T3N1M0-Stage III, and the salvage RAMIE was performed. Although the dissection was difficult due to fibrosis caused by dCRT and the esophageal mediastinal fistula, RAMIE was performed safely with no complications. Multiple features of RAMIE contributed to stable surgery. The monopolar dissection is effective for hard scar tissue caused by CRT and inflammation.

    DOI: 10.1111/ases.13155

    PubMed

    researchmap

  • 【上部】【Challenges beyond borders】高度進行胃癌に対するconversion surgeryの現状と新たな治療戦略 Stage IV因子と腫瘍マーカー変化率から見えたStage IV胃癌の予後を改善するための至適手術介入条件

    垣内 慶彦, 黒田 新士, 菊地 覚次, 重安 邦俊, 賀島 肇, 野間 和広, 楳田 祐三, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   78回   PD3 - 6   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【総論】サルコペニア・フレイルに対する周術期・外来管理の工夫 食道癌周術期の早期多職種チーム医療介入は術後合併症を軽減させる

    河崎 健人, 野間 和広, 橋本 将志, 加藤 卓也, 前田 直見, 田辺 俊介, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   78回   WS4 - 2   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【総論】大腸癌以外のoligometastasisに対する集学的治療の現状と課題 食道がん術後再発のOligomatastasisにおける長期予後に関わる因子の解明

    松本 祐, 野間 和広, 橋本 将志, 加藤 卓也, 前田 直見, 田辺 俊介, 菊地 覚次, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   78回   WS5 - 8   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【上部】進行食道胃接合部癌に対する集学的治療への取り組み 進行食道胃接合部癌における術前化学療法,至適術式の検討

    森分 和也, 野間 和広, 橋本 将志, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   78回   WS11 - 6   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【肝胆膵】切除可能膵癌に対する術前化学療法の至適戦略 血中循環腫瘍DNA内KRAS mutation profileとCA19-9値を組み合わせた膵癌予後の層別化戦略

    安井 和也, 吉田 龍一, 宮本 耕吉, 藤 智和, 高木 弘誠, 寺石 文則, 黒田 新士, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   78回   WS30 - 10   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 切除不能食道癌に対する根治を目指した治療戦略

    前田 直見, 野間 和広, 橋本 将志, 加藤 卓也, 菊地 覚次, 黒田 新士, 田辺 俊介, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   78回   O8 - 5   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 非大腸癌由来の少数肝転移症例の切除適応を見極める

    岡田 尚大, 藤 智和, 楳田 祐三, 吉田 龍一, 高木 弘誠, 安井 和也, 黒田 新士, 野間 和広, 寺石 文則, 藤原 俊義

    日本消化器外科学会総会   78回   O11 - 6   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • クローン病における肛門機能温存のための至適治療戦略

    近藤 喜太, 黒田 新士, 田辺 俊介, 菊地 覚次, 野間 和広, 吉田 龍一, 楳田 祐三, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   78回   O13 - 8   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 体脂肪分布からみた減量代謝改善手術の効果

    賀島 肇, 菊地 覚次, 香川 俊輔, 黒田 新士, 垣内 慶彦, 松三 雄騎, 山田 元彦, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   78回   O18 - 2   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道癌術後補助免疫療法中の早期再発リスクと免疫関連有害事象の検討

    橋本 将志, 野間 和広, 加藤 卓也, 前田 直見, 田辺 俊介, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   78回   O27 - 5   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 過不足ない縦隔腹部リンパ郭清と機能温存術後再建の両立を目指して 岡山大学病院の現状と展望

    加藤 卓也, 野間 和広, 橋本 将志, 前田 直見, 田辺 俊介, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   78回   O44 - 3   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Total upper GI surgeonによるJz癌へのsurgical approach

    桂 佑貴, 白川 靖博, 石田 道拡, 丁田 泰宏, 井谷 史嗣, 松川 啓義, 塩崎 滋弘, 田邊 俊介, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   78回   O44 - 5   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 地域基幹病院における一子相伝のロボット支援食道悪性腫瘍手術トレーニング

    白川 靖博, 桂 佑貴, 石田 道拡, 丁田 泰宏, 井谷 史嗣, 松川 啓義, 塩崎 滋弘, 田辺 俊介, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   78回   P031 - 3   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 当院における化学放射線治療後ロボット支援下直腸手術の現状と課題

    松三 雄騎, 寺石 文則, 半澤 俊哉, 山田 元彦, 賀島 肇, 重安 邦俊, 藤原 俊義

    日本消化器外科学会総会   78回   P019 - 6   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【下部】切除不能な遠隔転移を有する局所進行大腸癌に対する集学的治療戦略 大腸癌患者の長期生存を目指した遠隔転移臓器別の切除適応と化学療法レジメンの選択

    重安 邦俊, 高橋 利明, 楳田 祐三, 垣内 慶彦, 松三 雄騎, 近藤 喜太, 寺石 文則, 黒田 新士, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   78回   WS20 - 9   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 周術期管理チーム介入後にみえてきたフレイル高齢者大腸癌治療の課題 術前機能評価を用いた新たな取り組み

    寺石 文則, 山田 元彦, 庄司 良平, 賀島 肇, 垣内 慶彦, 松三 雄騎, 重安 邦俊, 近藤 喜太, 黒田 新士, 藤原 俊義

    日本消化器外科学会総会   78回   O33 - 5   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Safe and curative modified two-stage operation for T4 esophageal cancer after definitive chemoradiotherapy: a case report. International journal

    Tasuku Matsumoto, Kazuhiro Noma, Naoaki Maeda, Takuya Kato, Kazuya Moriwake, Kento Kawasaki, Masashi Hashimoto, Shunsuke Tanabe, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Surgical case reports   9 ( 1 )   119 - 119   2023.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The prognosis of esophageal cancer (EC) with organ invasion is extremely poor. In these cases, definitive chemoradiotherapy (CRT) followed by salvage surgery can be planned; however, the issue of high morbidity and mortality rates persists. Herein, we report the long-term survival of a patient with EC and T4 invasion who underwent a modified two-stage operation after definitive CRT. CASE PRESENTATION: A 60-year-old male presented with type 2 upper thoracic EC with tracheal invasion. First, definitive CRT was performed, which resulted in tumor shrinkage and improvement in the tracheal invasion. However, an esophagotracheal fistula subsequently developed, and the patient was treated with fasting and antibiotics. Although the fistula recovered, severe esophageal stenoses made oral intake impossible. To improve quality of life and cure the EC, a modified two-stage operation was planned. In the first surgery, an esophageal bypass was performed using a gastric tube with cervical and abdominal lymph node dissections. After confirming improved nutritional status and absence of distant metastasis, the second surgery was performed with subtotal esophagectomy, mediastinal lymph node dissection, and tracheobronchial coverage of the fistula. The patient discharged without major complications after radical resection and has been recurrence-free for 5 years since the start of treatment. CONCLUSION: A standard curative strategy could be difficult for EC with T4 invasion due to differences in the invaded organs, presence of complications, and patient condition. Therefore, patient-tailored treatment plans are needed, including a modified two-stage operation.

    DOI: 10.1186/s40792-023-01692-x

    PubMed

    researchmap

  • 形成外科医による縦隔気管孔作成 安全かつ低侵襲なTangentially sternal osteotomy

    松本 洋, 太田 智之, 木股 敬裕, 野間 和広, 田辺 俊介, 前田 直見, 橋本 将志, 加藤 卓也, 藤原 俊義, 白川 靖博

    日本食道学会学術集会プログラム・抄録集   77回   265 - 265   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌根治切除時における再建経路がQOLに与える影響についての比較

    國友 知義, 野間 和広, 川崎 健人, 橋本 将志, 賀島 肇, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   77回   125 - 125   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • ロボット支援下食道切除術のエビデンス われわれのロボット支援食道切除術定型化の変遷

    白川 靖博, 桂 佑貴, 井谷 史嗣, 松川 啓義, 橋本 将志, 加藤 卓也, 前田 直見, 田辺 俊介, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   77回   7 - 7   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • ロボット支援下食道切除術のエビデンス ロボット支援化食道切除180例の検討 定型化とNIM導入の短期成績とその課題

    野間 和広, 河崎 健人, 國友 知義, 橋本 将志, 賀島 肇, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   77回   7 - 7   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • cT4食道癌に対する根治を目指した治療戦略

    前田 直見, 野間 和広, 河崎 健人, 國友 知義, 橋本 将志, 賀島 肇, 加藤 卓也, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   77回   134 - 134   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 高齢者食道癌患者に対する根治的手術戦略

    河崎 健人, 野間 和広, 國友 知義, 橋本 将志, 賀島 肇, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   77回   169 - 169   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 滑脱型食道裂孔ヘルニアを伴う胃噴門部粘膜下腫瘍に対してLECSが有用であった1例

    賀島 肇, 野間 和広, 半澤 俊哉, 河崎 健人, 國友 知義, 橋本 将志, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   77回   231 - 231   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道がん術後患者のQOL向上に向けた多職種、施設間連携の強化と介入の仕組みづくり

    山本 有美, 野間 和広, 青井 美由紀, 川上 雅弘, 橋本 将志, 加藤 卓也, 前田 直見, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   77回   259 - 259   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 形成外科医による縦隔気管孔作成 安全かつ低侵襲なTangentially sternal osteotomy

    松本 洋, 太田 智之, 木股 敬裕, 野間 和広, 田辺 俊介, 前田 直見, 橋本 将志, 加藤 卓也, 藤原 俊義, 白川 靖博

    日本食道学会学術集会プログラム・抄録集   77回   265 - 265   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 逆流防止機構を備えたDouble Flap Techniqueの挑戦

    加藤 卓也, 野間 和広, 河崎 健人, 國友 知義, 橋本 将志, 賀島 肇, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   77回   327 - 327   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • cStage II/IIIA食道癌:DCF NAC後の術後補助療法とその適応 pN2以上の再発リスクに対する術後補助免疫療法の短期成績

    橋本 将志, 野間 和広, 河崎 健人, 國友 知義, 賀島 肇, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   77回   45 - 45   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 巨大食道裂孔ヘルニアに対する治療の工夫と成績 巨大食道裂孔ヘルニアの腹腔鏡根治術における再発軽減のための手術手技の工夫と成績

    田辺 俊介, 野間 和広, 河崎 健人, 國友 知義, 橋本 将志, 賀島 肇, 加藤 卓也, 前田 直見, 菊地 覚次, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   77回   60 - 60   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 当院におけるJz癌に対するoptimum surgical approach strategy

    桂 佑貴, 白川 靖博, 石田 道拡, 丁田 泰宏, 井谷 史嗣, 松川 啓義, 塩崎 滋弘, 田邊 俊介, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   77回   93 - 93   2023.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • Conventional Cancer Therapies Can Accelerate Malignant Potential of Cancer Cells by Activating Cancer-Associated Fibroblasts in Esophageal Cancer Models. International journal

    Satoshi Komoto, Kazuhiro Noma, Takuya Kato, Teruki Kobayashi, Noriyuki Nishiwaki, Toru Narusaka, Hiroaki Sato, Yuki Katsura, Hajime Kashima, Satoru Kikuchi, Toshiaki Ohara, Hiroshi Tazawa, Toshiyoshi Fujiwara

    Cancers   15 ( 11 )   2023.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Esophageal cancer is one of the most aggressive tumors, and the outcome remains poor. One contributing factor is the presence of tumors that are less responsive or have increased malignancy when treated with conventional chemotherapy, radiotherapy, or a combination of these. Cancer-associated fibroblasts (CAFs) play an important role in the tumor microenvironment. Focusing on conventional cancer therapies, we investigated how CAFs acquire therapeutic resistance and how they affect tumor malignancy. In this study, low-dose chemotherapy or radiotherapy-induced normal fibroblasts showed enhanced activation of CAFs markers, fibroblast activation protein, and α-smooth muscle actin, indicating the acquisition of malignancy in fibroblasts. Furthermore, CAFs activated by radiotherapy induce phenotypic changes in cancer cells, increasing their proliferation, migration, and invasion abilities. In in vivo peritoneal dissemination models, the total number of tumor nodules in the abdominal cavity was significantly increased in the co-inoculation group of cancer cells and resistant fibroblasts compared to that in the co-inoculation group of cancer cells and normal fibroblasts. In conclusion, we demonstrated that conventional cancer therapy causes anti-therapeutic effects via the activation of fibroblasts, resulting in CAFs. It is important to select or combine modalities of esophageal cancer treatment, recognizing that inappropriate radiotherapy and chemotherapy can lead to resistance in CAF-rich tumors.

    DOI: 10.3390/cancers15112971

    PubMed

    researchmap

  • Impact of sarcopenia on clinical outcomes for patients with resected hepatocellular carcinoma: A retrospective comparison of eastern and western cohorts. International journal

    Berend Robert Beumer, Kosei Takagi, Stefan Buettner, Yuzo Umeda, Takahito Yagi, Toshiyoshi Fujiwara, Jeroen Laurens Ad van Vugt, Jan Nicolas Maria IJzermans

    International journal of surgery (London, England)   109 ( 8 )   2258 - 2266   2023.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Patient fitness is important for guiding treatment. Muscle mass, as a reflection thereof, can be objectively measured. However, the role of east-west differences remains unclear. Therefore, we compared the impact of muscle mass on clinical outcomes after liver resection for HCC in a Dutch (NL) and Japanese (JP) setting and evaluated the predictive performance of different cut-off values for sarcopenia. METHOD: In this multicenter retrospective cohort study patients with hepatocellular carcinoma (HCC) undergoing liver resection were included. The skeletal muscle mass index (SMI) was determined on CT scans obtained within 3 months before surgery. The primary outcome measure was overall survival (OS). Secondary outcome measures were: 90-day mortality, severe complications, length of stay, and recurrence free survival. The predictive performance of several sarcopenia cut-off values was studied using the c-index and area under the curve. Interaction terms were used to study geographic effect modification of muscle mass. RESULTS: Demographics differed between NL and JP. Gender, age, and body mass index were associated with SMI. Significant effect modification between NL and JP was found for BMI. The predictive performance of sarcopenia for both short- and long-term outcomes was higher in JP compared to NL (max c-index: 0.58 vs 0.55, respectively). However, differences between cut-off values were small. For the association between sarcopenia and OS, a strong association was found in JP (Hazard ratio (HR) 2.00 95%CI[1.230 ; 3.08], P=0.002), where this was not found in NL (0.76 [0.42 ; 1.36], P=0.351). The interaction term confirmed that this difference was significant (HR 0.37 95%CI[0.19 ; 0.73], P=0.005). CONCLUSIONS: The impact of sarcopenia on survival differs between the east and west. Clinical trials and treatment guidelines using sarcopenia for risk stratification should be validated in race-dependent populations prior to clinical adoption.

    DOI: 10.1097/JS9.0000000000000458

    PubMed

    researchmap

  • Clinical implications and optimal extent of lymphadenectomy for intrahepatic cholangiocarcinoma: A multicenter analysis of the therapeutic index.

    Yuzo Umeda, Kosei Takagi, Tatsuo Matsuda, Tomokazu Fuji, Toru Kojima, Daisuke Satoh, Masayoshi Hioki, Yoshikatsu Endo, Masaru Inagaki, Masahiro Oishi, Takahito Yagi, Toshiyoshi Fujiwara

    Annals of gastroenterological surgery   7 ( 3 )   512 - 522   2023.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIMS: Lymph node metastases (LNM) are associated with lethal prognosis in intrahepatic cholangiocarcinoma (ICC). Lymphadenectomy is crucial for accurate staging and hopes of possible oncological treatment. However, the therapeutic implications and optimal extent of lymphadenectomy remain contentious. METHODS: To clarify the prognostic value and optimal extent of lymphadenectomy, the therapeutic index (TI) for each lymph node was analyzed for 279 cases that had undergone lymphadenectomy in a multi-institutional database. Tumor localization was divided into hilar lesions (n = 130), right peripheral lesions (n = 60), and left peripheral lesions (n = 89). In addition, the lymph node station was classified as Level 1 (LV1: hepatoduodenal ligament node), Level 2 (LV2: postpancreatic or common hepatic artery nodes), or Level 3 (LV3: gastrocardiac, left gastric artery, or celiac artery nodes). RESULTS: Lymph node metastases were confirmed in 109 patients (39%). Five-y survival rates were 45.3% for N0 disease, 27.1% for LV1-LNM, 22.9% for LV2-LNM, and 7.3% for LV3-LNM (P < 0.001). LV3-LNM were the most frequent and earliest recurrence outcome, including multisite recurrence, followed by LV2, LV1, and N0 disease. The 5-year TI (5year-TI) for lymphadenectomy was 7.2 for LV1, 5.5 for LV2, and 1.9 for LV3. Regarding tumor location, hilar lesions showed 5-year TI >5.0 in LV1 and LV2, whereas bilateral peripheral lesions showed 5-year TI > 5.0 in LV1. CONCLUSION: The implications and extent of lymphadenectomy for ICC appear to rely on tumor location. In the peripheral type, the benefit of lymphadenectomy would be limited and dissection beyond LV1 should be avoided, while in the hilar type, lymphadenectomy up to LV2 could be recommended.

    DOI: 10.1002/ags3.12642

    PubMed

    researchmap

  • 【イラストで見る消化器癌手術アトラス】食道・胃 ロボット支援下食道切除術における標準化と手技の工夫

    野間 和広, 田辺 俊介, 前田 直見, 藤原 俊義

    手術   77 ( 6 )   757 - 762   2023.5

     More details

    Language:Japanese   Publisher:金原出版(株)  

    researchmap

  • 【消化器外科における各種デバイスの使い方とピットフォール】上部消化管 食道・胃切除術における自動縫合器の使い方とピットフォール

    田邊 俊介, 垣内 慶彦, 前田 直見, 菊地 覚次, 黒田 新士, 野間 和広, 藤原 俊義

    外科   85 ( 4 )   345 - 350   2023.4

     More details

    Language:Japanese   Publisher:(株)南江堂  

    <文献概要>近年,自動縫合器を使用した臓器の切離,および再建が普及している.一方で,従来行われていた手縫い吻合と異なり,各臓器において使用の際のピットフォールが存在すると思われる.今回,当科で行っている食道および胃切除術時のサーキュラーステープラおよびリニアステープラの使い方およびそのピットフォールを説明する.

    researchmap

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J00393&link_issn=&doc_id=20230414270006&doc_link_id=10.15106%2Fj_geka85_345&url=https%3A%2F%2Fdoi.org%2F10.15106%2Fj_geka85_345&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  • Locally Advanced Rectal Cancer Invading the Gluteus Maximus Muscle Completely Responded to Total Neoadjuvant Therapy.

    Masaki Sakamoto, Fuminori Teraishi, Kunitoshi Shigeyasu, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Acta medica Okayama   77 ( 2 )   209 - 213   2023.4

     More details

    Language:English  

    A 70-year-old male with anal pain and fever was diagnosed with rectal cancer perforation and abscess in the right gluteus maximus (GM) muscle. He underwent a transverse colon colostomy followed by preoperative capecitabine+oxaliplatin. Some local control was achieved but a residual abscess was observed in the right GM muscle. To secure circumferential resection margin by tumor reduction, he received chemoradiotherapy as total neoadjuvant therapy (TNT) and underwent laparoscopic abdominoperineal resection, D3 lymph node dissection, combined coccyx resection, and partial resection of the right GM muscle. The skin defect and pelvic dead space were filled with a right lateral vastus lateral great muscle flap. Histopathologically, the resected specimen showed no tumor cells in the primary tumor or lymph nodes, indicating a pathological complete response (pCR). This case suggests that TNT might improve the R0 resection and pCR rates and overall survival.

    DOI: 10.18926/AMO/65152

    PubMed

    researchmap

  • 食道癌術前化学療法時から介入する多職種チーム医療と微量元素に着目した栄養管理

    田辺 俊介, 野間 和広, 橋本 将志, 前田 直見, 重安 邦俊, 菊地 覚次, 黒田 新士, 近藤 喜太, 吉田 龍一, 櫻間 教文, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   123回   DP - 6   2023.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道良性疾患に対する手術の限界と挑戦 高齢者に対する食道裂孔ヘルニアの腹腔鏡根治術における現状と手技の工夫

    藤田 脩斗, 野間 和広, 橋本 将志, 前田 直見, 菊地 覚次, 重安 邦俊, 黒田 新士, 近藤 喜太, 田辺 俊介, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   123回   WS - 6   2023.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • ロボット手術と多科合同手術で食道癌に挑む

    門脇 大輔, 野間 和広, 橋本 将志, 前田 直見, 重安 邦俊, 菊地 覚次, 近藤 喜太, 黒田 新士, 田辺 俊介, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   123回   DP - 5   2023.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 【mRNAワクチンやゲノム編集で注目が集まる遺伝子治療】遺伝子治療技術を用いた疾患治療 消化器がんに対する腫瘍融解ウイルス療法

    藤原 俊義, 黒田 新士, 田澤 大

    医学のあゆみ   285 ( 5 )   446 - 452   2023.4

     More details

    Language:Japanese   Publisher:医歯薬出版(株)  

    がんは1981年以来,わが国の死亡原因の第1位であり,なかでも消化器がんは半数以上を占めており,消化器がん治療の進歩は国民衛生の向上に非常に重要である.遺伝子工学技術が進歩した今,遺伝子改変ウイルスをがん細胞のみを殺傷する治療用医薬品として用いることが可能となってきた.ウイルスはその生活環として本来,ヒトの細胞に感染・増殖し,その細胞をさまざまな機序により破壊する.この細胞傷害性をがん細胞に標的化することで安全性を担保できれば,臨床的にがん治療用ウイルスとしての使用が期待できる.また最近では,ウイルス製剤が宿主の免疫を活性化するという分子機構が明らかとなってきており,複合免疫療法としての開発も進んでいる.本稿では,筆者らが開発しているアデノウイルス製剤を中心に,消化器がんに対するがん治療用ウイルスの可能性を概説する.(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J00060&link_issn=&doc_id=20230502010024&doc_link_id=issn%3D0039-2359%26volume%3D285%26issue%3D5%26spage%3D446&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D0039-2359%26volume%3D285%26issue%3D5%26spage%3D446&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

  • 厳しい局所進行食道癌に対するロボット支援下手術の経験

    白川 靖博, 桂 佑貴, 清水 彰人, 實金 悠, 森内 俊行, 吉本 匡志, 澤田 紘幸, 石田 道拡, 佐藤 太祐, 丁田 泰宏, 吉満 政義, 中野 敢友, 松川 啓義, 井谷 史嗣, 塩崎 滋弘, 橋本 将志, 前田 直見, 田辺 俊介, 野間 和広, 藤原 俊義

    日本外科学会定期学術集会抄録集   123回   DP - 2   2023.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科医療におけるサルコペニア・フレイル対策の最前線 胃切除術後の認知行動療法を応用したサルコペニア予防策の効果

    菊地 覚次, 高田 暢夫, 半澤 俊哉, 賀島 肇, 松三 雄騎, 垣内 慶彦, 黒田 新士, 前田 直見, 田辺 俊介, 野間 和広, 楳田 祐三, 藤原 俊義

    日本外科学会定期学術集会抄録集   123回   SY - 1   2023.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Impact of educational video on performance in robotic simulation training (TAKUMI-1): a randomized controlled trial. International journal

    Kosei Takagi, Nanako Hata, Jiro Kimura, Satoru Kikuchi, Kazuhiro Noma, Kazuya Yasui, Tomokazu Fuji, Ryuichi Yoshida, Yuzo Umeda, Takahito Yagi, Toshiyoshi Fujiwara

    Journal of robotic surgery   17 ( 4 )   1547 - 1553   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The use of virtual reality for simulations plays an important role in the initial training for robotic surgery. This randomized controlled trial aimed to investigate the impact of educational video on the performance of robotic simulation. Participants were randomized into the intervention (video) group that received an educational video and robotic simulation training or the control group that received only simulation training. The da Vinci® Skills Simulator was used for the basic course, including nine drills. The primary endpoint was the overall score of nine drills in cycles 1-10. Secondary endpoints included overall, efficiency, and penalty scores in each cycle, as well as the learning curves evaluated by the cumulative sum (CUSUM) analysis. Between September 2021 and May 2022, 20 participants were assigned to the video (n = 10) and control (n = 10) groups. The video group had significantly higher overall scores than the control group (90.8 vs. 72.4, P < 0.001). Significantly higher overall scores and lower penalty scores were confirmed, mainly in cycles 1-5. CUSUM analysis revealed a shorter learning curve in the video group. The present study demonstrated that educational video training can be effective in improving the performance of robotic simulation training and shortening the learning curve.

    DOI: 10.1007/s11701-023-01556-4

    PubMed

    researchmap

  • Role of the Pfannenstiel Incision in Robotic Hepato-Pancreato-Biliary Surgery. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Tomokazu Fuji, Kazuya Yasui, Jiro Kimura, Nanako Hata, Takahito Yagi, Toshiyoshi Fujiwara

    Journal of clinical medicine   12 ( 5 )   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Studies remain limited on the role of the Pfannenstiel incision in minimally invasive hepato-pancreato-biliary (HPB) surgery, especially robotic surgery. The role of various extraction sites in robotic HPB surgery should be understood. Herein, we describe the surgical techniques, outcomes, advantages, and disadvantages of the Pfannenstiel incision in robotic pancreatic surgery. Seventy patients underwent robotic pancreatectomy at our institution between September 2020 and October 2022. The Pfannenstiel incision was used for specimen retrieval in 55 patients. Advantages of the Pfannenstiel incision include less pain, cosmetic benefits, and a lower incidence of complications. Moreover, the specimen could be removed using the robotic system docked. However, all complex reconstructions should be performed intra-abdominally during robotic pancreatoduodenectomies. The incidence of mortality and postoperative pancreatic fistula (grade B) was 0% and 9.1%, respectively. During the median follow-up (11.2 months) after surgery, complications at the Pfannenstiel incision site included surgical site infection (n = 1, 1.8%) and incisional hernia (n = 1, 1.8%). The Pfannenstiel incision can be a useful option for specimen retrieval in minimally invasive HPB surgery, according to the surgeon's preferences and the patient's condition.

    DOI: 10.3390/jcm12051971

    PubMed

    researchmap

  • 【転移性肝癌を極める】大腸癌肝転移に対する肝切除

    楳田 祐三, 吉田 龍一, 藤 智和, 高木 弘誠, 安井 和也, 重安 邦俊, 寺石 文則, 八木 孝仁, 藤原 俊義

    消化器外科   46 ( 3 )   277 - 288   2023.3

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • Removing the Esophageal Stump During Reconstruction for Esophagojejunostomy in Total Gastrectomy for Gastric Cancer: the Modified Overlap Method. International journal

    Yoshihiko Kakiuchi, Shinji Kuroda, Satoru Kikuchi, Hajime Kashima, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract   27 ( 3 )   643 - 645   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s11605-023-05600-4

    PubMed

    researchmap

  • Robotic surgery for congenital biliary dilatation using the scope switch technique (with video). International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Tomokazu Fuji, Kazuya Yasui, Takahito Yagi, Toshiyoshi Fujiwara

    Asian journal of surgery   2023.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    TECHNIQUE: Minimally invasive congenital biliary dilatation (CBD) surgery is technically demanding. However, few studies have reported surgical approaches of robotic surgery for CBD. This report presents robotic CBD surgery using a scope-switch technique. Our robotic surgery technique for CBD consisted of four steps: step 1, Kocher's maneuver; step 2, dissection of the hepatoduodenal ligament using the scope switch technique; step 3, preparation for the Roux-en-Y loop; and step 4, hepaticojejunostomy. RESULTS: The scope switch technique can provide different surgical approaches for dissecting the bile duct, including anterior approach by the standard position and right approach by the scope switch position. When approaching the ventral and left side of the bile duct, anterior approach with the standard position is suitable. In contrast, the lateral view by the scope switch position is preferable for approaching the bile duct laterally and dorsally. Using this technique, the dilated bile duct can be dissected circumferentially from four directions: anterior, medial, lateral, and posterior. Thereafter, complete resection of the choledochal cyst can be achieved. CONCLUSIONS: The scope switch technique in robotic surgery for CBD can be useful for dissecting around the bile duct with different surgical views, leading to the complete resection of the choledochal cyst.

    DOI: 10.1016/j.asjsur.2023.02.021

    PubMed

    researchmap

  • Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody. International journal

    Noriyuki Nishiwaki, Kazuhiro Noma, Toshiaki Ohara, Tomoyoshi Kunitomo, Kento Kawasaki, Masaaki Akai, Teruki Kobayashi, Toru Narusaka, Hajime Kashima, Hiroaki Sato, Satoshi Komoto, Takuya Kato, Naoaki Maeda, Satoru Kikuchi, Shunsuke Tanabe, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Cancer immunology, immunotherapy : CII   2023.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cancer-associated fibroblasts (CAFs) are a critical component of the tumor microenvironment and play a central role in tumor progression. Previously, we reported that CAFs might induce tumor immunosuppression via interleukin-6 (IL-6) and promote tumor progression by blocking local IL-6 in the tumor microenvironment with neutralizing antibody. Here, we explore whether an anti-IL-6 receptor antibody could be used as systemic therapy to treat cancer, and further investigate the mechanisms by which IL-6 induces tumor immunosuppression. In clinical samples, IL-6 expression was significantly correlated with α-smooth muscle actin expression, and high IL-6 cases showed tumor immunosuppression. Multivariate analysis showed that IL-6 expression was an independent prognostic factor. In vitro, IL-6 contributed to cell proliferation and differentiation into CAFs. Moreover, IL-6 increased hypoxia-inducible factor 1α (HIF1α) expression and induced tumor immunosuppression by enhancing glucose uptake by cancer cells and competing for glucose with immune cells. MR16-1, a rodent analog of anti-IL-6 receptor antibody, overcame CAF-induced immunosuppression and suppressed tumor progression in immunocompetent murine cancer models by regulating HIF1α activation in vivo. The anti-IL-6 receptor antibody could be systemically employed to overcome tumor immunosuppression and improve patient survival with various cancers. Furthermore, the tumor immunosuppression was suggested to be induced by IL-6 via HIF1α activation.

    DOI: 10.1007/s00262-023-03378-7

    PubMed

    researchmap

  • ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer. International journal

    Nanako Hata, Kunitoshi Shigeyasu, Yuzo Umeda, Shuya Yano, Sho Takeda, Kazuhiro Yoshida, Tomokazu Fuji, Ryuichi Yoshida, Kazuya Yasui, Hibiki Umeda, Toshiaki Takahashi, Yoshitaka Kondo, Hiroyuki Kishimoto, Yoshiko Mori, Fuminori Teraishi, Hideki Yamamoto, Hiroyuki Michiue, Keiichiro Nakamura, Hiroshi Tazawa, Toshiyoshi Fujiwara

    Scientific reports   13 ( 1 )   2078 - 2078   2023.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Adenosine-to-inosine RNA editing is a process mediated by adenosine deaminases that act on the RNA (ADAR) gene family. It has been discovered recently as an epigenetic modification dysregulated in human cancers. However, the clinical significance of RNA editing in patients with liver metastasis from colorectal cancer (CRC) remains unclear. The current study aimed to systematically and comprehensively investigate the significance of adenosine deaminase acting on RNA 1 (ADAR1) expression status in 83 liver metastatic tissue samples collected from 36 patients with CRC. The ADAR1 expression level was significantly elevated in liver metastatic tissue samples obtained from patients with right-sided, synchronous, or RAS mutant-type CRC. ADAR1-high liver metastasis was significantly correlated with remnant liver recurrence after hepatic metastasectomy. A high ADAR1 expression was a predictive factor of remnant liver recurrence (area under the curve = 0.72). Results showed that the ADAR1 expression level could be a clinically relevant predictive indicator of remnant liver recurrence. Patients with liver metastases who have a high ADAR1 expression requires adjuvant chemotherapy after hepatic metastasectomy.

    DOI: 10.1038/s41598-023-29397-z

    PubMed

    researchmap

  • A Case Report of Non-typical Annular Pancreas Diagnosed during Laparoscopic Gastric Surgery.

    Toshiaki Takahashi, Yoshihiko Kakiuchi, Satoru Kikuch, Shinji Kuroda, Sho Takeda, Kunitoshi Shigeyasu, Yoshitaka Kondo, Fuminori Teraishi, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Acta medica Okayama   77 ( 1 )   91 - 95   2023.2

     More details

    Language:English  

    An annular pancreas is a rare anomaly of the pancreas, defined as pancreatic tissue that totally or partly encircles the duodenum, usually the descending portion. A 76-year-old man who was diagnosed with gastric cancer cT3N0M0 Stage IIB underwent laparoscopic distal gastrectomy with D2 lymph node dissection. Intraoperatively, the dorsal half of the duodenal bulb was seen to be half surrounded by the pancreas, and a non-typical annular pancreas was diagnosed. Because of the risk to the pancreas, it was considered impossible to perform anastomosis by a linear stapler as in the usual laparoscopic procedure. Therefore, we performed laparoscopically assisted distal gastrectomy and Billroth-I reconstruction using a circular stapler, and the surgery was completed without difficulties. His postoperative course was good despite the development of a pancreatic fistula, which was an International Study Group for Pancreas Fistula biochemical leak. Some APs can be diagnosed preoperatively, but the rarer subtypes such as ours are more difficult to visualize on imaging. In gastrectomy, it is both oncologically important and technically challenging to perform lymph node dissection around the pancreas. In this case with an especially proximal pancreas, a circular stapler was considered better suited for gastroduodenal anastomosis and required a broader field than that afforded by laparoscopy. A case of non-typical annular pancreas diagnosed during laparoscopic gastric surgery is described.

    DOI: 10.18926/AMO/64368

    PubMed

    researchmap

  • Fabry病患者におけるサイトメガロウイルス感染による小腸穿孔の1例

    中村 峻輔, 菊地 覚次, 垣内 慶彦, 黒田 新士, 野間 和広, 楳田 祐三, 都地 友紘, 藤原 俊義

    日本消化器外科学会雑誌   56 ( 2 )   87 - 93   2023.2

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    症例は66歳の男性で,Fabry病による慢性腎不全に対して維持透析中であった.右肺癌に対して肺部分切除を施行後膿胸の増悪のため,ICUで全身管理中に小腸穿孔,汎発性腹膜炎を来し当科紹介となった.原因不明の小腸穿孔として緊急手術を施行した.術中所見では,Treitz靱帯より約200cmの部位での小腸穿孔,腸間膜側から腹腔内への穿破を認め,腹腔内汚染は著明であった.小腸を約20cm切除し,洗浄ドレナージ,回腸人工肛門造設を行った.切除標本では粘膜面に多発潰瘍を認め,その1ヶ所に穿孔を認めた.病理組織学的検査では,サイトメガロウイルス(cytomegalovirus;以下,CMVと略記)免疫染色検査で潰瘍部に一致して陽性細胞が検出され,CMV感染による小腸穿孔と診断した.CMV感染による消化管穿孔はまれであるが,免疫不全患者ではその存在を常に念頭に置く必要があり,早期診断・治療が重要である.(著者抄録)

    researchmap

  • Fabry病患者におけるサイトメガロウイルス感染による小腸穿孔の1例

    中村 峻輔, 菊地 覚次, 垣内 慶彦, 黒田 新士, 野間 和広, 楳田 祐三, 都地 友紘, 藤原 俊義

    日本消化器外科学会雑誌   56 ( 2 )   87 - 93   2023.2

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    症例は66歳の男性で,Fabry病による慢性腎不全に対して維持透析中であった.右肺癌に対して肺部分切除を施行後膿胸の増悪のため,ICUで全身管理中に小腸穿孔,汎発性腹膜炎を来し当科紹介となった.原因不明の小腸穿孔として緊急手術を施行した.術中所見では,Treitz靱帯より約200cmの部位での小腸穿孔,腸間膜側から腹腔内への穿破を認め,腹腔内汚染は著明であった.小腸を約20cm切除し,洗浄ドレナージ,回腸人工肛門造設を行った.切除標本では粘膜面に多発潰瘍を認め,その1ヶ所に穿孔を認めた.病理組織学的検査では,サイトメガロウイルス(cytomegalovirus;以下,CMVと略記)免疫染色検査で潰瘍部に一致して陽性細胞が検出され,CMV感染による小腸穿孔と診断した.CMV感染による消化管穿孔はまれであるが,免疫不全患者ではその存在を常に念頭に置く必要があり,早期診断・治療が重要である.(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J01117&link_issn=&doc_id=20230308270006&doc_link_id=10.5833%2Fjjgs.2022.0036&url=https%3A%2F%2Fdoi.org%2F10.5833%2Fjjgs.2022.0036&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 【こだわりの体腔内縫合・吻合術】胃外科 腹腔鏡下/ロボット支援下噴門側胃切除後の観音開き法による再建

    黒田 新士, 菊地 覚次, 垣内 慶彦, 香川 俊輔, 藤原 俊義

    手術   77 ( 2 )   189 - 195   2023.2

     More details

    Language:Japanese   Publisher:金原出版(株)  

    researchmap

  • Oncologic Emergencyに対する二期的腹腔鏡下・ロボット支援下手術の実際 閉塞・穿孔を伴う高度進行左側大腸癌に対する二期的低侵襲手術の治療成績

    寺石 文則, 半澤 俊哉, 松三 雄騎, 庄司 良平, 重安 邦俊, 近藤 喜太, 香川 俊輔, 藤原 俊義

    日本腹部救急医学会雑誌   43 ( 2 )   329 - 329   2023.2

     More details

    Language:Japanese   Publisher:(一社)日本腹部救急医学会  

    researchmap

  • Surgical Techniques of Gastrojejunostomy in Robotic Pancreatoduodenectomy: Robot-Sewn versus Stapled Gastrojejunostomy Anastomosis. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Tomokazu Fuji, Kazuya Yasui, Jiro Kimura, Nanako Hata, Takahito Yagi, Toshiyoshi Fujiwara

    Journal of clinical medicine   12 ( 2 )   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Delayed gastric emptying (DGE) is a major complication of pancreatoduodenectomy (PD). Several efforts have been made to decrease the incidence of DGE. However, the optimal anastomotic method for gastro/duodenojejunostomy (GJ) remains debatable. Moreover, few studies have reported the impact of GJ surgical techniques on outcomes following robotic pancreatoduodenectomy (RPD). This study aimed to investigate the surgical outcomes of robot-sewn and stapled GJ anastomoses in RPD. METHODS: Forty patients who underwent RPD at the Okayama University Hospital between September 2020 and October 2022 were included. The outcomes between robot-sewn and stapled anastomoses were compared. RESULTS: The mean [standard deviation (SD)] operative and GJ time were 428 (63.5) and 34.0 (15.0) minutes, respectively. Postoperative outcomes included an overall incidence of DGE of 15.0%, and the mean postoperative hospital stays were 11.6 (5.3) days in length. The stapled group (n = 21) had significantly shorter GJ time than the robot-sewn group (n = 19) (22.7 min versus 46.5 min, p &lt; 0.001). Moreover, stapled GJ cases were significantly associated with a lower incidence of DGE (0% versus 21%, p = 0.01). Although not significant, the stapled group tended to have shorter postoperative hospital stays (9.9 days versus 13.5 days, p = 0.08). CONCLUSIONS: Our findings suggest that stapled GJ anastomosis might decrease anastomotic GJ time and incidence of DGE after RPD. Surgeons should select a suitable method for GJ anastomosis based on their experiences with RPD.

    DOI: 10.3390/jcm12020732

    PubMed

    researchmap

  • Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Tomokazu Fuji, Kazuya Yasui, Takahito Yagi, Toshiyoshi Fujiwara

    Journal of clinical medicine   12 ( 2 )   2023.1

     More details

    Language:English  

    The incidence and mortality rates of pancreatic ductal adenocarcinoma (PDAC) have increased in recent years worldwide [...].

    DOI: 10.3390/jcm12020465

    PubMed

    researchmap

  • Survival Impact of Postoperative Skeletal Muscle Loss in Gastric Cancer Patients Who Underwent Gastrectomy. International journal

    Kazuya Kuwada, Satoru Kikuchi, Shinji Kuroda, Ryuichi Yoshida, Kosei Takagi, Kazuhiro Noma, Masahiko Nishizaki, Shunsuke Kagawa, Yuzo Umeda, Toshiyoshi Fujiwara

    Anticancer research   43 ( 1 )   223 - 230   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: It has recently been recognized that preoperative sarcopenia contributes to postoperative complications and overall survival in gastric cancer (GC). However, few studies have investigated the relationship between postoperative skeletal muscle loss (SML) and survival in GC, despite the inevitability of body weight loss after gastrectomy in most GC patients. Herein, we studied the impact of postoperative SML on GC prognosis. PATIENTS AND METHODS: A total of 370 patients with GC who underwent curative gastrectomy were retrospectively evaluated in this study. Postoperative SML was assessed on computed tomography (CT) images taken before surgery and 1 year after surgery. The impact of postoperative SML on survival was evaluated. RESULTS: Postoperative severe SML was significantly associated with presence of comorbidities, higher tumor stage, higher postoperative complication rate and longer hospital stay. Univariate and multivariate analyses of prognostic factors for overall survival revealed that SML was an independent indicator of poor prognosis, along with age, tumor stage, preoperative sarcopenia, and operation time (hazard ratio, 2.65; 95% confidence interval, 1.68-4.20, p<0.0001). There was a strong association of severe postoperative SML with decreased overall survival in patients with preoperative sarcopenia. CONCLUSION: To improve the prognosis of GC patients after surgery, it is important to prevent postoperative SML as well as preoperative sarcopenia. Perioperative multimodal interventions including nutritional counseling, oral nutritional supplements, and exercise are required to prevent SML after gastrectomy.

    DOI: 10.21873/anticanres.16153

    PubMed

    researchmap

  • Impact of cancer-associated fibroblasts on survival of patients with ampullary carcinoma. International journal

    Kosei Takagi, Kazuhiro Noma, Yasuo Nagai, Satoru Kikuchi, Yuzo Umeda, Ryuichi Yoshida, Tomokazu Fuji, Kazuya Yasui, Takehiro Tanaka, Hajime Kashima, Takahito Yagi, Toshiyoshi Fujiwara

    Frontiers in oncology   13   1072106 - 1072106   2023

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Cancer-associated fibroblasts (CAFs) reportedly enhance the progression of gastrointestinal surgery; however, the role of CAFs in ampullary carcinomas remains poorly examined. This study aimed to investigate the effect of CAFs on the survival of patients with ampullary carcinoma. MATERIALS AND METHODS: A retrospective analysis of 67 patients who underwent pancreatoduodenectomy between January 2000 and December 2021 was performed. CAFs were defined as spindle-shaped cells that expressed α-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP). The impact of CAFs on survival, including recurrence-free (RFS) and disease-specific survival (DSS), as well as prognostic factors associated with survival, was analyzed. RESULTS: The high-α-SMA group had significantly worse 5-year RFS (47.6% vs. 82.2%, p = 0.003) and 5-year DSS (67.5% vs. 93.3%, p = 0.01) than the low-α-SMA group. RFS (p = 0.04) and DSS (p = 0.02) in the high-FAP group were significantly worse than those in the low-FAP group. Multivariable analyses found that high α-SMA expression was an independent predictor of RFS [hazard ratio (HR): 3.68; 95% confidence intervals (CI): 1.21-12.4; p = 0.02] and DSS (HR: 8.54; 95% CI: 1.21-170; p = 0.03). CONCLUSIONS: CAFs, particularly α-SMA, can be useful predictors of survival in patients undergoing radical resection for ampullary carcinomas.

    DOI: 10.3389/fonc.2023.1072106

    PubMed

    researchmap

  • p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells. International journal

    Shuta Tamura, Hiroshi Tazawa, Naoto Hori, Yuncheng Li, Motohiko Yamada, Satoru Kikuchi, Shinji Kuroda, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    PloS one   18 ( 11 )   e0294491   2023

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Colorectal cancer (CRC) cells harboring KRAS or BRAF mutations show a more-malignant phenotype than cells with wild-type KRAS and BRAF. KRAS/BRAF-wild-type CRCs are sensitive to epidermal growth factor receptor (EGFR)-targeting agents, whereas KRAS/BRAF-mutant CRCs are resistant due to constitutive activation of the EGFR-downstream KRAS/BRAF signaling pathway. Novel therapeutic strategies to treat KRAS/BRAF mutant CRC cells are thus needed. We recently demonstrated that the telomerase-specific replication-competent oncolytic adenoviruses OBP-301 and p53-armed OBP-702 exhibit therapeutic potential against KRAS-mutant human pancreatic cancer cells. In this study, we evaluated the therapeutic potential of OBP-301 and OBP-702 against human CRC cells with differing KRAS/BRAF status. Human CRC cells with wild-type KRAS/BRAF (SW48, Colo320DM, CACO-2), mutant KRAS (DLD-1, SW620, HCT116), and mutant BRAF (RKO, HT29, COLO205) were used in this study. The antitumor effect of OBP-301 and OBP-702 against CRC cells was analyzed using the XTT assay. Virus-mediated modulation of apoptosis, autophagy, and the EGFR-MEK-ERK and AKT-mTOR signaling pathways was analyzed by Western blotting. Wild-type and KRAS-mutant CRC cells were sensitive to OBP-301 and OBP-702, whereas BRAF-mutant CRC cells were sensitive to OBP-702 but resistant to OBP-301. Western blot analysis demonstrated that OBP-301 induced autophagy and that OBP-702 induced autophagy and apoptosis in human CRC cells. In BRAF-mutant CRC cells, OBP-301 and OBP-702 suppressed the expression of EGFR, MEK, ERK, and AKT proteins, whereas mTOR expression was suppressed only by OBP-702. Our results suggest that p53-armed oncolytic virotherapy is a viable therapeutic option for treating KRAS/BRAF-mutant CRC cells via induction of autophagy and apoptosis.

    DOI: 10.1371/journal.pone.0294491

    PubMed

    researchmap

  • チームでベッドサイドに寄り添う周術期栄養管理 食道癌外科治療予後向上のための院内横断的周術期管理 術前から術後までサポート

    野間 和広, 河崎 健人, 國友 知義, 橋本 将志, 加藤 卓也, 前田 直見, 菊地 覚次, 藤原 俊義

    外科と代謝・栄養   57 ( 3 )   89 - 89   2023

     More details

    Language:Japanese   Publisher:日本外科代謝栄養学会  

    researchmap

  • RNA editing is a valuable biomarker for predicting carcinogenesis in ulcerative colitis. International journal

    Kazutaka Takahashi, Kunitoshi Shigeyasu, Yoshitaka Kondo, Kazuyoshi Gotoh, Shuya Yano, Yuzo Umeda, Toshihiro Inokuchi, Caiming Xu, Kazuhiro Yoshida, Hibiki Umeda, Toshiaki Takahashi, Sho Takeda, Ryuichi Yoshida, Fuminori Teraishi, Hiroyuki Kishimoto, Yoshiko Mori, Kazuhiro Noma, Yoshinaga Okugawa, Sakiko Hiraoka, Hiroyuki Michiue, Hiroshi Tazawa, Osamu Matsushita, Ajay Goel, Toshiyoshi Fujiwara

    Journal of Crohn's & colitis   17 ( 5 )   754 - 766   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND AIMS: Ulcerative colitis (UC) can develop colitis-associated colorectal neoplasm (CAN). Adenine-to-inosine RNA editing, which is regulated by adenosine deaminase acting on RNA (ADAR), induces the posttranscriptional modification of critical oncogenes, including antizyme inhibitor 1 (AZIN1), leading to colorectal carcinogenesis. Therefore, we hypothesized that ADAR1 might be involved in the development of CAN in UC. METHODS: We systematically analyzed a cohort of 139 UC cases (40 acute phase, 73 remission phase, 26 CAN). The degree of inflammation was evaluated using the Mayo endoscopic score (MES). RESULTS: The type 1 IFN-related inflammation pathway was upregulated in the rectum of active UC, rectum of UC-CAN, and tumor site of UC-CAN patients. ADAR1 expression was upregulated in the entire colon of CAN cases, while it was down-regulated in non-CAN MES0 cases. ADAR1 expression in the rectum predicted the development of CAN better than p53 or β-catenin, with an area under the curve of 0.93. The high expression of ADAR1 and high AZIN1 RNA editing in UC was triggered by type 1 IFN stimulation from UC-specific microbiomes, such as Fusobacterium in vitro analyses. The induction of AZIN1 RNA editing by ADAR1, whose expression is promoted by Fusobacterium, may induce carcinogenesis in UC. CONCLUSIONS: The risk of CAN can be evaluated by assessing ADAR1 expression in the rectum of MES0 UC patients, freeing UC patients from unnecessary colonoscopy and reducing their physical burden. RNA editing may be involved in UC carcinogenesis, and may be used to facilitate the prevention and treatment of CAN in UC.

    DOI: 10.1093/ecco-jcc/jjac186

    PubMed

    researchmap

  • Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. International journal

    Hiroyuki Araki, Hiroshi Tazawa, Nobuhiko Kanaya, Yoshinori Kajiwara, Motohiko Yamada, Masashi Hashimoto, Satoru Kikuchi, Shinji Kuroda, Ryuichi Yoshida, Yuzo Umeda, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Molecular therapy oncolytics   27   3 - 13   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Immune checkpoint inhibitors, including anti-programmed cell death 1 (PD-1) antibody, provide improved clinical outcome in certain cancers. However, pancreatic ductal adenocarcinoma (PDAC) is refractory to PD-1 blockade therapy due to poor immune response. Oncolytic virotherapy is a novel approach for inducing immunogenic cell death (ICD). We demonstrated the therapeutic potential of p53-expressing telomerase-specific oncolytic adenovirus OBP-702 to induce ICD and anti-tumor immune responses in human PDAC cells with different p53 status (Capan-2, PK-59, PK-45H, Capan-1, MIA PaCa-2, BxPC-3) and murine PDAC cells (PAN02). OBP-702 significantly enhanced ICD with secretion of extracellular adenosine triphosphate and high-mobility group box protein B1 by inducing p53-mediated apoptosis and autophagy. OBP-702 significantly promoted the tumor infiltration of CD8+ T cells and the anti-tumor efficacy of PD-1 blockade in a subcutaneous PAN02 syngeneic tumor model. Our results suggest that oncolytic adenovirus-mediated p53 overexpression augments ICD and the efficacy of PD-1 blockade therapy against cold PDAC tumors. Further in vivo experiments would be warranted to evaluate the survival benefit of tumor-bearing mice in combination therapy with OBP-702 and PD-1 blockade.

    DOI: 10.1016/j.omto.2022.09.003

    PubMed

    researchmap

  • An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma. International journal

    Shunsuke Gohara, Kosuke Shinohara, Ryoji Yoshida, Ryusho Kariya, Hiroshi Tazawa, Masashi Hashimoto, Junki Inoue, Ryuta Kubo, Hikaru Nakashima, Hidetaka Arita, Sho Kawaguchi, Keisuke Yamana, Yuka Nagao, Asuka Iwamoto, Junki Sakata, Yuichiro Matsuoka, Hisashi Takeshita, Masatoshi Hirayama, Kenta Kawahara, Masashi Nagata, Akiyuki Hirosue, Yoshikazu Kuwahara, Manabu Fukumoto, Seiji Okada, Yasuo Urata, Toshiyoshi Fujiwara, Hideki Nakayama

    Molecular therapy oncolytics   27   141 - 156   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We evaluated the usefulness of an oncolytic virus (Suratadenoturev; OBP-301) against radioresistant oral squamous cell carcinoma. We confirmed the expression of human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor in cell lines. Also, we examined the potential presence in a patient who has received existing therapy that is amenable to treatment with OBP-301. We evaluated: (1) the antitumor effects of OBP-301 alone and in combination with radiotherapy on radioresistant cell lines, (2) the molecular mechanism underlying the radiosensitizing effect and cell death increased by the combination therapy, and (3) the antitumor effect of the combination therapy in vivo using xenograft models (a radioresistant cell line-derived xenograft in mouse and a patient-derived xenograft). Human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor were expressed in all cell lines. OBP-301 decreased the proliferative activity of these cell lines in a concentration-dependent manner, and significantly enhanced the antitumor effect of irradiation. Phosphorylated STAT3 and its downstream molecules, which correlated with apoptosis and autophagy, showed significant changes in expression after treatment with OBP-301. The combination therapy exerted a significant antitumor effect versus radiotherapy alone in both xenograft models. Combination of OBP-301 with radiotherapy exerts a synergistic effect and may represent a promising treatment for radioresistant oral squamous cell carcinoma.

    DOI: 10.1016/j.omto.2022.10.001

    PubMed

    researchmap

  • 縦隔郭清を伴う食道胃接合部癌に対する岡山大学病院での取り組み

    橋本 将志, 野間 和広, 前田 直見, 菊地 覚次, 重安 邦俊, 近藤 喜太, 田辺 俊介, 黒田 新士, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   27 ( 7 )   789 - 789   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 術後再発困難症例に対する前方臓器温存のための集学的治療を併用したTaAPRの有用性

    庄司 良平, 近藤 喜太, 垣内 慶彦, 賀島 肇, 松三 雄騎, 寺石 文則, 菊地 覚次, 黒田 新士, 田辺 俊介, 野間 和広, 吉田 龍一, 楳田 祐三, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   27 ( 7 )   775 - 775   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 神経モニタリングを用いたより低侵襲なロボット支援下食道手術

    野間 和広, 橋本 将志, 前田 直見, 菊地 覚次, 田辺 俊介, 近藤 喜太, 黒田 新士, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   27 ( 7 )   1150 - 1150   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 術前治療後の腹腔鏡下直腸癌手術の治療成績

    寺石 文則, 庄司 良平, 賀島 肇, 垣内 慶彦, 松三 雄騎, 重安 邦俊, 近藤 喜太, 黒田 新士, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   27 ( 7 )   1138 - 1138   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 胸腔鏡下食道癌手術のコンセプトと成績、教育方法

    前田 直見, 野間 和広, 橋本 将志, 菊地 覚次, 黒田 新士, 近藤 喜太, 田辺 俊介, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   27 ( 7 )   1722 - 1722   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 内視鏡外科手術における遠隔医療の現状と課題 内視鏡外科手術におけるカダバーサージカルトレーニング遠隔手術指導シミュレーションの実際

    近藤 喜太, 庄司 良平, 垣内 慶彦, 前田 直見, 菊地 覚次, 重安 邦俊, 黒田 新士, 田辺 俊介, 野間 和広, 吉田 龍一, 寺石 文則, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   27 ( 7 )   1268 - 1268   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 胃癌に対する噴門側胃切除:手技の工夫と成績 観音開き法(上川法)再建における吻合部狭窄ゼロを目指した手技の改変

    黒田 新士, 菊地 覚次, 垣内 慶彦, 野間 和広, 楳田 祐三, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   27 ( 7 )   1848 - 1848   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 食道良性疾患に対する胸腔鏡・腹腔鏡手術:手技の工夫と成績 食道裂孔ヘルニアの腹腔鏡下根治手術における手技の工夫とQOL改善への貢献

    田辺 俊介, 野間 和広, 橋本 将志, 前田 直見, 菊地 覚次, 重安 邦俊, 黒田 新士, 近藤 喜太, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   27 ( 7 )   86 - 86   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 低侵襲食道癌手術における専門医制度:食道外科専門医vs技術認定医 食道外科医における技術認定制度、認定医とは?技術認定合格に必須なコンセプト

    野間 和広, 橋本 将志, 前田 直見, 菊地 覚次, 田辺 俊介, 近藤 喜太, 黒田 新士, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   27 ( 7 )   428 - 428   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 症例数の限られた地方病院での安全かつ有効な新規代謝改善手術導入の課題

    賀島 肇, 菊地 覚次, 香川 俊輔, 黒田 新士, 半澤 俊哉, 庄司 良平, 垣内 慶彦, 松三 雄騎, 野間 和広, 楳田 祐三, 寺石 文則, 藤原 俊義

    日本内視鏡外科学会雑誌   27 ( 7 )   298 - 298   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 切除可能膵癌における血中循環腫瘍DNA内Kras遺伝子変異とCA19-9値による予後層別化の試み

    宮本 耕吉, 吉田 龍一, 重安 邦俊, 安井 和也, 高木 弘誠, 藤 智和, 楳田 祐三, 八木 孝仁, 藤原 俊義

    日本分子腫瘍マーカー研究会誌   38   20 - 21   2022.12

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • 十二指腸腫瘍の局在や特性に応じたLECSのアプローチ法や切除法の工夫と成績

    菊地 覚次, 西崎 正彦, 黒田 新士, 賀島 肇, 松三 雄騎, 半澤 俊哉, 垣内 慶彦, 田辺 俊介, 野間 和広, 香川 俊輔, 楳田 祐三, 藤原 俊義

    日本内視鏡外科学会雑誌   27 ( 7 )   730 - 730   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • チームで極める栄養管理-急性期から回復期まで- 食道癌周術期管理における早期包括的介入の有用性岡山大学病院におけるPERiOの取り組み

    野間 和広, 橋本 将志, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    学会誌JSPEN   4 ( Suppl.2 )   128 - 129   2022.12

     More details

    Language:Japanese   Publisher:(一社)日本臨床栄養代謝学会  

    researchmap

  • Involvement in the tumor-infiltrating CD8+ T cell expression by the initial disease of remnant gastric cancer. International journal

    Yoshihiko Kakiuchi, Satoru Kikuchi, Shinji Kuroda, Shunsuke Kagawa, Toshiyoshi Fujiwara

    World journal of surgical oncology   20 ( 1 )   374 - 374   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Remnant gastric cancer (RGC) has been increasing for various reasons such as a longer life span, medical progress, and others. It generally has a poor prognosis, and its mechanism of occurrence is unknown. The purpose of this study was to evaluate the clinicopathological features of and clarify the oncological features of RGC. METHODS: Between January 2002 and January 2017, 39 patients with RGC following distal gastrectomy underwent curative surgical resection at the Okayama University Hospital; their medical records and immunohistochemically stained extracted specimens were used for retrospective analysis. RESULTS: On univariate analysis, initial gastric disease, pathological lymph node metastasis, and pathological stage were the significant factors associated with poor overall survival (p=0.014, 0.0061, and 0.016, respectively). Multivariate analysis of these 3 factors showed that only initial gastric disease caused by malignant disease was an independent factor associated with a poor prognosis (p=0.014, hazard ratio: 4.2, 95% confidence interval: 1.3-13.0). In addition, tumor-infiltrating CD8+ T cells expression was higher in the benign disease group than in the malignant group (p=0.046). CONCLUSIONS: Initial gastrectomy caused by malignant disease was an independent poor prognostic factor of RGC, and as one of the causes, lower level of tumor-infiltrating CD8+ T cells in RGC may involve in.

    DOI: 10.1186/s12957-022-02853-2

    PubMed

    researchmap

  • Surgical Strategies to Dissect around the Superior Mesenteric Artery in Robotic Pancreatoduodenectomy. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Tomokazu Fuji, Kazuya Yasui, Jiro Kimura, Nanako Hata, Kento Mishima, Takahito Yagi, Toshiyoshi Fujiwara

    Journal of clinical medicine   11 ( 23 )   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The concept of the superior mesenteric artery (SMA)-first approach has been widely accepted in pancreatoduodenectomy. However, few studies have reported surgical approaches to the SMA in robotic pancreatoduodenectomy (RPD). Herein, we present our surgical strategies to dissect around the SMA in RPD. Among the various approaches, our standard protocol for RPD included the right approach to the SMA, which can result in complete tumor resection in most cases. In patients with malignant diseases requiring lymphadenectomy around the SMA, we developed a novel approach by combining the left and right approaches in RPD. Using this approach, circumferential dissection around the SMA can be achieved through both the left and right sides. This approach can also be helpful in patients with obesity or intra-abdominal adhesions. The present study summarizes the advantages and disadvantages of both the approaches during RPD. To perform RPD safely, surgeons should understand the different surgical approaches and select the best approach or a combination of different approaches, depending on demographic, anatomical, and oncological factors.

    DOI: 10.3390/jcm11237112

    PubMed

    researchmap

  • Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. International journal

    Yoshinori Kajiwara, Hiroshi Tazawa, Motohiko Yamada, Nobuhiko Kanaya, Takuro Fushimi, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Ryuichi Yoshida, Yuzo Umeda, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Cancer immunology, immunotherapy : CII   72 ( 5 )   1285 - 1300   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Pancreatic ductal adenocarcinoma (PDAC) is often refractory to treatment with gemcitabine (GEM) and immune checkpoint inhibitors including anti-programmed cell death ligand 1 (PD-L1) antibody. However, the precise relationship between GEM-resistant PDAC and development of an immunosuppressive tumor microenvironment (TME) remains unclear. In this study, we investigated the immunosuppressive TME in parental and GEM-resistant PDAC tumors and assessed the therapeutic potential of combination therapy with the telomerase-specific replication-competent oncolytic adenovirus OBP-702, which induces tumor suppressor p53 protein and PD-L1 blockade against GEM-resistant PDAC tumors. Mouse PDAC cells (PAN02) and human PDAC cells (MIA PaCa-2, BxPC-3) were used to establish GEM-resistant PDAC lines. PD-L1 expression and the immunosuppressive TME were analyzed using parental and GEM-resistant PDAC cells. A cytokine array was used to investigate the underlying mechanism of immunosuppressive TME induction by GEM-resistant PAN02 cells. The GEM-resistant PAN02 tumor model was used to evaluate the antitumor effect of combination therapy with OBP-702 and PD-L1 blockade. GEM-resistant PDAC cells exhibited higher PD-L1 expression and produced higher granulocyte-macrophage colony-stimulating factor (GM-CSF) levels compared with parental cells, inducing an immunosuppressive TME and the accumulation of myeloid-derived suppressor cells (MDSCs). OBP-702 significantly inhibited GEM-resistant PAN02 tumor growth by suppressing GM-CSF-mediated MDSC accumulation. Moreover, combination treatment with OBP-702 significantly enhanced the antitumor efficacy of PD-L1 blockade against GEM-resistant PAN02 tumors. The present results suggest that combination therapy involving OBP-702 and PD-L1 blockade is a promising antitumor strategy for treating GEM-resistant PDAC with GM-CSF-induced immunosuppressive TME formation.

    DOI: 10.1007/s00262-022-03334-x

    PubMed

    researchmap

  • Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment. International journal

    Hiroaki Sato, Kazuhiro Noma, Toshiaki Ohara, Kento Kawasaki, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Toru Narusaka, Satoshi Komoto, Hajime Kashima, Yuki Katsura, Takuya Kato, Satoru Kikuchi, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Hisataka Kobayashi, Toshiyoshi Fujiwara

    Scientific reports   12 ( 1 )   20152 - 20152   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cancer-associated fibroblasts (CAFs) play a significant role in tumor progression within the tumor microenvironment. Previously, we used near-infrared photoimmunotherapy (NIR-PIT), a next-generation cancer cell-targeted phototherapy, to establish CAF-targeted NIR-PIT. In this study, we investigated whether dual-targeted NIR-PIT, targeting cancer cells and CAFs, could be a therapeutic strategy. A total of 132 cases of esophageal cancer were analyzed for epidermal growth factor receptor (EGFR), human epidermal growth factor 2 (HER2), and fibroblast activation protein (FAP) expression using immunohistochemistry. Human esophageal cancer cells and CAFs were co-cultured and treated with single- or dual-targeted NIR-PIT in vitro. These cells were co-inoculated into BALB/c-nu/nu mice and the tumors were treated with single-targeted NIR-PIT or dual-targeted NIR-PIT in vivo. Survival analysis showed FAP- or EGFR-high patients had worse survival than patients with low expression of FAP or EGFR (log-rank, P < 0.001 and P = 0.074, respectively), while no difference was observed in HER2 status. In vitro, dual (EGFR/FAP)-targeted NIR-PIT induced specific therapeutic effects in cancer cells and CAFs along with suppressing tumor growth in vivo, whereas single-targeted NIR-PIT did not show any significance. Moreover, these experiments demonstrated that dual-targeted NIR-PIT could treat cancer cells and CAFs simultaneously with a single NIR light irradiation. We demonstrated the relationship between EGFR/FAP expression and prognosis of patients with esophageal cancer and the stronger therapeutic effect of dual-targeted NIR-PIT than single-targeted NIR-PIT in experimental models. Thus, dual-targeted NIR-PIT might be a promising therapeutic strategy for cancer treatment.

    DOI: 10.1038/s41598-022-24313-3

    PubMed

    researchmap

  • 腹腔鏡下スリーブ状胃切除(LSG)の安全な導入と普及への課題

    菊地 覚次, 賀島 肇, 香川 俊輔, 江口 潤, 中司 敦子, 高橋 絢子, 黒田 新士, 半澤 俊哉, 庄司 良平, 垣内 慶彦, 松三 雄騎, 野間 和広, 楳田 祐三, 和田 淳, 藤原 俊義

    肥満研究   28 ( Suppl. )   354 - 354   2022.11

     More details

    Language:Japanese   Publisher:(一社)日本肥満学会  

    researchmap

  • マジンドール(Mazindol:MZD)先行導入後に腹腔鏡下スリーブ胃切除術を行った高度肥満の2例

    賀島 肇, 菊地 覚次, 香川 俊輔, 江口 潤, 中司 敦子, 高橋 絢子, 黒田 新士, 半澤 俊哉, 庄司 良平, 垣内 慶彦, 松三 雄騎, 野間 和広, 楳田 祐三, 和田 淳, 藤原 俊義

    肥満研究   28 ( Suppl. )   352 - 352   2022.11

     More details

    Language:Japanese   Publisher:(一社)日本肥満学会  

    researchmap

  • ASO Visual Abstract: Effect of Patient-Participation Continuous Nutritional Counseling in Gastric Cancer Patients Who Underwent Gastrectomy. International journal

    Nobuo Takata, Satoru Kikuchi, Shinji Kuroda, Shunsuke Tanabe, Naoaki Maeda, Kazuhiro Noma, Ayako Takahashi, Yuzo Umeda, Kenichi Shikata, Kazuhide Ozaki, Toshiyoshi Fujiwara

    Annals of surgical oncology   30 ( 2 )   1119 - 1119   2022.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1245/s10434-022-12645-3

    PubMed

    researchmap

  • Genomically stable gastric cancer characterized by hypomethylation in Wnt signal cascade. International journal

    Hiroaki Tanioka, Yoshiko Mori, Takehiro Tanaka, Kazuya Yasui, Keisuke Kimura, Yuzo Umeda, Toshiyoshi Fujiwara, Akihiro Nyuya, Shuya Yano, Takeshi Nagasaka, Takeshi Nagasaka

    Oncology   101 ( 2 )   105 - 116   2022.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Introduction Gastric cancer is divided into four subtypes by their molecular features linked with genetic alterations, e.g., Epstein-Barr virus (EBV), microsatellite instability-high (MSI-high), chromosomal instability (CIN), and genomically stable (GS), called as TCGA classification. In this study, we tried to clarify the epigenetic features of the four GC subtypes according to aberrant methylation status in 23 loci. Methods A total of 98 gastric cancers and their normal gastric mucosa samples were included in this study. We divided gastric cancers into TCGA subtypes which were determined in line with MSI-high, EBV, CIN, to GS by their molecular features. The 13 loci of polymorphic microsatellite sequences were used to determine loss of heterogeneity (LOH) for the detection of CIN. The MSI status was determined by three mononucleotide repeat markers. Infection of EBV was determined by recovering EBV BNRF1 sequence from genomic DNA collected from gastric cancers. Methylation status of 23 loci was investigated by the combined bisulfite restriction analysis (COBRA). Status of other findings, e.g., KRAS mutations, HER2 expression status and infection of helicobacter pylori were confirmed. Results Gastric cancers were divided into MSI (13%), EBV (7%), CIN (53%), and GS (27%). By histological classification, poorly differentiated adenocarcinoma (por) was more in tumors categorized in MSI-high, and GS and signet-ring cell carcinoma (sig) was more in GS. Among the 23 loci investigated their methylation status, 18 loci were significantly hypermethylated in caner tissues. A unsupervised clustering divided gastric cancers into two clusters, and revealed that most GS tumors clustered together in a cluster that exhibited lower methylation levels, distinct from the other subtypes. The inter-variable clustering revealed that a cluster contained the three loci (SFRP2-region 1/2 and APC) belonging to the Wnt signal cascade (Wnt-associated loci). The mean methylation score of Wnt-associated loci was the lowest in GS tumors (MSI-high: 2.7 [95% confidence interval (CI), 2.3-2.9]; EBV:2.1[1.2-3.1]; CIN: 2.4 [2.2-2.7]; GS: 1.3 [0.8-0.7]). In contrast, the mean methylation score of the other 15 loci was significantly higher in MSI-high, while that in GS was as same as that in EBV or CIN (MSI- high: 10.4 [8.3-12.4]; EBV:5.7 [1.7-9.7]; CIN: 4.4 [3.6-5.1]; GS: 3.4 [2.2-4.6]). Additionally, the lower methylation score of Wnt-associated loci was observed only in sig tumors. Conclusions GS subtype tumors have the potential to possess distinct signatures in DNA hypomethylation profiles in Wnt signaling pathway, especially in signet-ring cell carcinoma.

    DOI: 10.1159/000527098

    PubMed

    researchmap

  • Prognostic risk factors for postoperative long-term outcomes in elderly stage IA gastric cancer patients. International journal

    Yoshihiko Kakiuchi, Shinji Kuroda, Satoru Kikuchi, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Journal of gastrointestinal oncology   13 ( 5 )   2178 - 2185   2022.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The number of gastric cancer (GC) patients with other diseases is increasing due to the aging of the population. In particular, in stage IA GC patients who have multiple diseases, surgical indications should be considered after identifying prognostic factors. We therefore investigated prognostic factors for stage IA GC in the elderly. METHODS: Patient characteristics were collected and analyzed retrospectively for elderly patients with stage IA GC who underwent curative surgical treatment at Okayama University Hospital between 2010 and 2015, and an elderly group (EG; 75-79 years old) and very elderly group (VEG; ≥80 years old) were compared. RESULTS: Fifty-three patient in the EG and 31 patients in the VEG were compared. No factors associated with clinicopathological characteristics or surgical or postoperative short-term outcomes differed significantly between groups. Although no factors in the EG appeared significantly associated with poor overall survival (OS), severe comorbidity [Charlson Comorbidity Index (CCI) ≥2; P=0.019], open gastrectomy (P=0.012), high volume of blood loss (≥300 mL; P=0.013) and long postoperative hospital stay (≥14 days; P=0.041) were significantly associated with poor OS. Furthermore, only CCI ≥2 [hazard ratio (HR) =9.2; 95% confidence interval (CI): 1.2-68.9; P=0.032] was an independent prognostic factor associated with poor OS. Five-year OS was 88.9% for CCI 0/1 patients and 62.3% for CCI ≥2 patients, representing very impressive results. CONCLUSIONS: CCI ≥2 is an important prognostic factor in clinical decisions in stage IA GC patients ≥2, so careful determination of surgical indications is desirable.

    DOI: 10.21037/jgo-22-527

    PubMed

    researchmap

  • [Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer].

    Masashi Hashimoto, Shinji Kuroda, Nobuhiko Kanaya, Yoshihiko Kakiuchi, Satoru Kikuchi, Hiroshi Tazawa, Shunsuke Kagawa, Yasuo Urata, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   49 ( 10 )   1127 - 1129   2022.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Pancreatic cancer has poor prognosis despite the various developed multimodal treatment strategies. Currently, neoadjuvant chemotherapy and immunotherapy have attracted substantial attention as effective treatment strategies. However, amplifying immune response with existing treatments is difficult. We developed telomerase-specific oncolytic adenoviruses (OAs), including OBP-301 that is currently tested in a clinical trial of combined anti-PD-1 antibody and p53-armed OBP- 301 variant(OBP-702). OAs have immune-modulation functions and induce CD8+ T cells into tumors by releasing immunogenic cell death markers, such as extracellular adenosine triphosphate. Here, we investigated the effectiveness of OBP- 702 in pancreatic cancer treatments, focusing on the influence on CD8+ memory T cells.

    PubMed

    researchmap

  • 高齢者に対する大腸がん治療の個別化を考える 周術期管理チーム介入により高齢Frail大腸癌患者に対する手術の安全性は向上したか

    寺石 文則, 庄司 良平, 賀島 肇, 松三 雄騎, 重安 邦俊, 近藤 喜太, 黒田 新士, 香川 俊輔, 松岡 義和, 森松 博史, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   OWS9 - 3   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 腸内細菌叢からがんを考える 腸内細菌叢は潰瘍性大腸炎においてRNA編集を介し発癌を促進する

    重安 邦俊, 高橋 一剛, 近藤 喜太, 梅田 響, 田澤 大, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   WS17 - 4   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • RNA編集は大腸癌の発癌や進展を促進するのみならず免疫療法のターゲットとなり得る

    重安 邦俊, 武田 正, 高橋 一剛, 小松 泰浩, 畑 七々子, 梅田 響, 高橋 利明, 田澤 大, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   P40 - 5   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.

    Noriyuki Nishiwaki, Kazuhiro Noma, Tomoyoshi Kunitomo, Masashi Hashimoto, Naoaki Maeda, Shunsuke Tanabe, Kazufumi Sakurama, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Esophagus : official journal of the Japan Esophageal Society   19 ( 4 )   626 - 638   2022.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The standard treatment for locally advanced esophageal cancer is preoperative chemotherapy with cisplatin and 5-fluorouracil (CF), followed by surgery. Although docetaxel plus cisplatin and 5-fluorouracil (DCF) has been reported to have favorable outcomes, no study has compared its therapeutic efficacy to that of standard treatment. This study aimed to compare the therapeutic effects of CF and DCF in the real world by matching patient background factors using propensity scores. METHODS: We retrospectively reviewed the data of 237 patients with esophageal squamous cell carcinoma who underwent esophagectomy between January 2008 and December 2018. Patients were divided into two groups based on the preoperative chemotherapy regimens of CF (79 patients) or DCF (158 patients), and 49 matched pairs were finally analyzed using propensity score matching. Short- and long-term outcomes were compared between groups. RESULTS: After matching, although no significant differences in survival were observed among the groups, patients receiving DCF showed a significantly high histological response (P < 0.001). Subgroup analyses demonstrated that DCF therapy had better overall survival (P = 0.046) and relapse-free survival (P = 0.010) among pathological T3 and T4 cases. Whereas, adverse effects of chemotherapy were more frequent in the DCF group. CONCLUSIONS: Patients receiving DCF had higher pathological response and better survival than those receiving CF, especially in pathological T3 and T4 cases matched using propensity scores. Thus, the DCF regimen might be an effective treatment for locally advanced esophageal cancer. However, the adverse side effects of chemotherapy remain high and should be handled appropriately.

    DOI: 10.1007/s10388-022-00934-5

    PubMed

    researchmap

  • Surgical Resection for Local and Lateral Lymph Node Recurrence of MSI-high Cecal Cancer with the BRAF V600E Mutation.

    Fuminori Teraishi, Atsushi Jikuhara, Ryunosuke Ogawa, Toshiyoshi Fujiwara

    Acta medica Okayama   76 ( 5 )   605 - 608   2022.10

     More details

    Language:English  

    An 84-year-old female underwent open right hemicolectomy with D3 lymph node dissection for cecal cancer, pathologically identified as pT4aN2M0 Stage IIIc and BRAF mutation-positive. Due to early recurrence of abdominal wall and right lateral lymph nodes, the patient was treated with FOLFOXIRI+Bevacizumab. Imaging after 5 courses of chemotherapy found tumor shrinkage and no new metastases. The patient did not tolerate chemotherapy well, and tumor resection was performed. Microsatellite instability (MSI) testing using multiplex polymerase chain reaction (PCR) fragment analysis revealed MSI-high status. The patient is currently recurrence-free without chemotherapy at 1 year postoperatively. BRAF-mutated colorectal cancer has a poor prognosis, and may require resection of the metastatic or recurrent tumor after comprehensive evaluation.

    DOI: 10.18926/AMO/64043

    PubMed

    researchmap

  • OBP-702を用いたウイルス治療による膵癌の長期抗腫瘍免疫賦活効果

    橋本 将志, 黒田 新士, 金谷 信彦, 垣内 慶彦, 菊地 覚次, 田澤 大, 香川 俊輔, 浦田 泰生, 藤原 俊義

    癌と化学療法   49 ( 10 )   1127 - 1129   2022.10

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    膵癌は予後不良な癌であり,近年話題の癌免疫療法に対しても免疫細胞の浸潤が乏しい腫瘍として知られている。また,近年術前化学療法の有効性が注目されている。我々は,腫瘍特異的に増殖する腫瘍融解アデノウイルス製剤(OBP-301)を開発し,食道癌において放射線療法+OBP-301治療の臨床試験が進行中である。臨床試験のなかで腫瘍浸潤リンパ球やPD-L1の発現増強を認め,免疫学的な治療効果も期待されている。次世代の薬剤としてOBP-301にp53遺伝子を搭載したOBP-702を開発し,膵癌に対して強力な治療効果を発揮することを確認した。今回,膵癌におけるOBP-702の有効性に関し,長期抗腫瘍免疫の指標としてCD8陽性メモリーT細胞に注目して検討した。(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2022&ichushi_jid=J00296&link_issn=&doc_id=20221021370020&doc_link_id=issn%3D0385-0684%26volume%3D49%26issue%3D10%26spage%3D1127&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D0385-0684%26volume%3D49%26issue%3D10%26spage%3D1127&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

  • Current status and future perspectives of minimally invasive and open radical antegrade modular pancreatosplenectomy for pancreatic ductal adenocarcinoma: a review

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Tomokazu Fuji, Kazuya Yasui, Takahito Yagi, Toshiyoshi Fujiwara

    Laparoscopic Surgery   6   39 - 39   2022.10

     More details

    Publishing type:Research paper (scientific journal)   Publisher:AME Publishing Company  

    DOI: 10.21037/ls-22-39

    researchmap

  • OBP-702を用いたウイルス治療による膵癌の長期抗腫瘍免疫賦活効果

    橋本 将志, 黒田 新士, 金谷 信彦, 垣内 慶彦, 菊地 覚次, 田澤 大, 香川 俊輔, 浦田 泰生, 藤原 俊義

    癌と化学療法   49 ( 10 )   1127 - 1129   2022.10

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    膵癌は予後不良な癌であり,近年話題の癌免疫療法に対しても免疫細胞の浸潤が乏しい腫瘍として知られている。また,近年術前化学療法の有効性が注目されている。我々は,腫瘍特異的に増殖する腫瘍融解アデノウイルス製剤(OBP-301)を開発し,食道癌において放射線療法+OBP-301治療の臨床試験が進行中である。臨床試験のなかで腫瘍浸潤リンパ球やPD-L1の発現増強を認め,免疫学的な治療効果も期待されている。次世代の薬剤としてOBP-301にp53遺伝子を搭載したOBP-702を開発し,膵癌に対して強力な治療効果を発揮することを確認した。今回,膵癌におけるOBP-702の有効性に関し,長期抗腫瘍免疫の指標としてCD8陽性メモリーT細胞に注目して検討した。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J00296&link_issn=&doc_id=20221021370020&doc_link_id=%2Fab8gtkrc%2F2022%2F004910%2F021%2F1127-1129%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2022%2F004910%2F021%2F1127-1129%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • がんの微小環境を考える CAFsを標的にした光免疫療法による薬物動態改善効果の検証

    西村 星多郎, 野間 和広, 竹田 泰茂, 松本 聖, 國友 知義, 河崎 健人, 赤井 正明, 小林 照貴, 前田 直見, 菊地 覚次, 田辺 俊介, 大原 利章, 田澤 大, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   WS4 - 2   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 食道癌患者における30秒椅子起立試験の運動耐容能指標としての妥当性 多施設共同研究

    池田 朋大, 野間 和広, 大倉 和貴, 片山 翔, 高橋 裕介, 前田 直見, 田邊 俊介, 脇田 晃行, 濱田 全紀, 藤原 俊義, 千田 益生

    日本癌治療学会学術集会抄録集   60回   MSA P32 - 4   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • RNA編集は大腸癌の発癌や進展を促進するのみならず免疫療法のターゲットとなり得る

    重安 邦俊, 武田 正, 高橋 一剛, 小松 泰浩, 畑 七々子, 梅田 響, 高橋 利明, 田澤 大, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   P40 - 5   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 外科医不足に対してCadaver Surgical Trainingが果たす役割

    近藤 喜太, 庄司 良平, 垣内 慶彦, 黒田 新士, 前田 直見, 田辺 俊介, 菊地 覚次, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   83 ( 増刊 )   S32 - S32   2022.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 当施設における大腸憩室炎に対する手術治療成績

    寺石 文則, 垣内 慶彦, 重安 邦俊, 近藤 喜太, 黒田 新士, 野間 和広, 香川 俊輔, 藤原 俊義

    日本消化器外科学会雑誌   55 ( Suppl.2 )   255 - 255   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道癌に対するロボット支援下手術の治療成績 進行食道癌におけるロボット支援下食道手術の有用性

    野間 和広, 橋本 将志, 前田 直見, 菊地 覚次, 田辺 俊介, 近藤 喜太, 黒田 新士, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   83 ( 増刊 )   S118 - S118   2022.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道癌手術における周術期チーム医療について 呼吸筋機能評価と重点的呼吸筋リハビリは食道癌術後呼吸器合併症を低減する

    前田 直見, 野間 和広, 橋本 将志, 菊地 覚次, 黒田 新士, 近藤 喜太, 田辺 俊介, 櫻間 教文, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   83 ( 増刊 )   S116 - S116   2022.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 術前DCF療法を行った食道癌切除後の再発パターンと再発リスク因子

    橋本 将志, 野間 和広, 前田 直見, 菊地 覚次, 重安 邦俊, 田辺 俊介, 近藤 喜太, 黒田 新士, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   83 ( 増刊 )   S223 - S223   2022.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 根治性とQOL維持の両立を目指した食道胃接合部癌に対する至適術式の検討

    田辺 俊介, 野間 和広, 橋本 将志, 前田 直見, 菊地 覚次, 重安 邦俊, 黒田 新士, 近藤 喜太, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   83 ( 増刊 )   S209 - S209   2022.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 高齢者に対する大腸がん治療の個別化を考える 周術期管理チーム介入により高齢Frail大腸癌患者に対する手術の安全性は向上したか

    寺石 文則, 庄司 良平, 賀島 肇, 松三 雄騎, 重安 邦俊, 近藤 喜太, 黒田 新士, 香川 俊輔, 松岡 義和, 森松 博史, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   OWS9 - 3   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 食道胃接合部がんの集学的治療のこれから 食道胃接合部癌に対する集学的治療の後方視的解析と食道浸潤長から導かれる至適術式

    野間 和広, 橋本 将志, 前田 直見, 菊地 覚次, 田辺 俊介, 近藤 喜太, 黒田 新士, 吉田 龍一, 櫻間 教文, 寺石 文則, 楳田 祐三, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   OWS16 - 2   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 食道癌術後オリゴ転移に対する集学的治療

    橋本 将志, 野間 和広, 前田 直見, 田辺 俊介, 菊地 覚次, 近藤 喜太, 黒田 新士, 櫻間 教文, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   OF - 2   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 呼吸筋サルコペニア・フレイル評価とリハビリは食道癌術後呼吸器合併症を減少させる

    前田 直見, 野間 和広, 橋本 将志, 菊地 覚次, 黒田 新士, 近藤 喜太, 田辺 俊介, 櫻間 教文, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   OF - 2   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • がん治療におけるトランスレーショナルリサーチの新展開 難治性膵臓癌に対するミトコンドリア阻害剤と腫瘍融解アデノウイルスの併用療法

    庄司 良平, 田澤 大, 菊地 覚次, 黒田 新士, 吉田 龍一, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   WS10 - 6   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 腸内細菌叢からがんを考える 腸内細菌叢は潰瘍性大腸炎においてRNA編集を介し発癌を促進する

    重安 邦俊, 高橋 一剛, 近藤 喜太, 梅田 響, 田澤 大, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   WS17 - 4   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • がん治療におけるサルコペニアとフレイルの意義 患者参加型継続的栄養指導による胃癌術後のサルコペニア予防効果

    菊地 覚次, 高田 暢夫, 黒田 新士, 田辺 俊介, 前田 直見, 賀島 肇, 垣内 慶彦, 野間 和広, 香川 俊輔, 高橋 絢子, 楳田 祐三, 四方 賢一, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   WS19 - 2   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 膵がんの治療成績は向上したか? 切除可能膵癌に対するNAC-GS療法は予後を改善したか? 非切除例を含む全コホート解析

    安井 和也, 吉田 龍一, 楳田 祐三, 藤 智和, 高木 弘誠, 宮本 耕吉, 黒田 新士, 野間 和広, 八木 孝仁, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   OWS15 - 5   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 進行胸部食道癌に対するMIEの適応と工夫 強力な導入DCF療法とロボット支援下手術を用いたcT3.5食道癌症例に対する治療戦略

    田辺 俊介, 野間 和広, 橋本 将志, 前田 直見, 白川 靖博, 藤原 俊義

    日本胸部外科学会定期学術集会   75回   EVS1 - 5   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本胸部外科学会  

    researchmap

  • 内視鏡外科手術時代における開胸手技の意義 Cadaverを用いた開胸手術トレーニング

    前田 直見, 野間 和広, 橋本 将志, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本胸部外科学会定期学術集会   75回   EPD1 - 4   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本胸部外科学会  

    researchmap

  • Developing the academic surgeons-キャリアパス形成-大学(院)での研究は必要か? 創造性を育む外科医の基礎研究

    野間 和広, 橋本 将志, 前田 直見, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本胸部外科学会定期学術集会   75回   CDPD2 - 6   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本胸部外科学会  

    researchmap

  • 術後補助免疫療法に向けた術前DCF療法の再発リスク解析

    橋本 将志, 野間 和広, 前田 直見, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本胸部外科学会定期学術集会   75回   EOP2 - 3   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本胸部外科学会  

    researchmap

  • 食道胃接合部癌に対する集学的治療 食道浸潤長から導かれる食道胃接合部癌の至適術式と集学的治療の検討

    田辺 俊介, 野間 和広, 藤原 俊義

    日本消化器外科学会雑誌   55 ( Suppl.2 )   91 - 91   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道がん集学的治療におけるチーム医療の実践とこれから 食道癌周術期管理における多職種チーム医療の早期介入の有用性と今後の展望

    田辺 俊介, 野間 和広, 橋本 将志, 前田 直見, 菊地 覚次, 黒田 新士, 近藤 喜太, 櫻間 教文, 吉田 龍一, 寺石 文明, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   60回   OWS8 - 2   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 消化管外科のSSI チームで取り組む食道外科手術における周術期感染症対策

    田辺 俊介, 野間 和広, 橋本 将志, 前田 直見, 白川 靖博, 藤原 俊義

    日本外科感染症学会雑誌   19 ( 1 )   150 - 150   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本外科感染症学会  

    researchmap

  • Robotic Spleen-Preserving Distal Pancreatectomy with Preservation of Splenic Vessels Using the Gastrohepatic Ligament Approach: The Superior Window Approach in the Kimura Technique. International journal

    Kosei Takagi, Ryuichi Yoshida, Yuzo Umeda, Tomokazu Fuji, Kazuya Yasui, Takahito Yagi, Toshiyoshi Fujiwara

    Digestive surgery   39 ( 4 )   137 - 140   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Minimally invasive spleen-preserving distal pancreatectomy (SPDP) is technically challenging, and only a few reports have described surgical approaches for minimally invasive SPDP. This report demonstrates our novel gastrohepatic ligament approach in robotic SPDP with preservation of the splenic vessels (the superior window approach in the Kimura technique). Our gastrohepatic ligament approach for robotic SPDP included four steps. First, the gastrohepatic ligament was divided extensively, and the pancreas was confirmed (step 1). In this step, we did not lift the stomach, nor did we divide the gastrocolic ligament. Next, the superior and inferior borders of the pancreas were dissected, and tunneling of the pancreas on the superior mesenteric vein was performed (step 2). Following the division of the pancreas (step 3), the pancreatic body and tail were dissected from the medial to the lateral side with preservation of the splenic vessels (step 4). Using this approach, the pancreas can be directly accessed via the gastrohepatic ligament route and dissected without division of the gastrocolic ligament or retraction of the stomach. The present approach for robotic SPDP preserves splenic vessels, facilitating easy access to the pancreas with minimal dissection, and may be optional in selected patients, including those with low body mass index.

    DOI: 10.1159/000527249

    PubMed

    researchmap

  • Effect of Patient-Participation Continuous Nutritional Counseling in Gastric Cancer Patients who Underwent Gastrectomy. International journal

    Nobuo Takata, Satoru Kikuchi, Shinji Kuroda, Shunsuke Tanabe, Naoaki Maeda, Kazuhiro Noma, Ayako Takahashi, Yuzo Umeda, Kenichi Shikata, Kazuhide Ozaki, Toshiyoshi Fujiwara

    Annals of surgical oncology   30 ( 2 )   1110 - 1118   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Body weight loss (BWL) and skeletal muscle loss (SML) are inevitable after gastrectomy for gastric cancer (GC) and can decrease patients' quality of life (QOL) and survival. OBJECTIVE: The aim of this retrospective study was to evaluate the effect of perioperative and post-discharge patient participation in continuous nutritional counseling (CNC) on post-gastrectomy BWL and SML. METHODS: Ninety-three patients with GC who underwent curative gastrectomy between March 2018 and July 2019 were analyzed. Patients received either pre-discharge nutritional counseling alone (control group, n = 49) or patient-participation CNC (CNC group, n = 44) after gastrectomy. Differences between percentage BWL (%BWL), percentage SML (%SML), and nutrition-related blood parameters between the preoperative values and those at 12 months after surgery were compared between the groups. RESULTS: Compared with the control group, %BWL was significantly lower in the CNC group at 1 month (-6.2 ± 2.5% vs. -7.9 ± 3.3%, p = 0.005), 6 months (-7.8 ± 6.6% vs. -12.3 ± 6.4%, p = 0.001) and 12 months (-7.9 ± 7.6% vs. -13.2 ± 8.2%, p = 0.002), and %SML was significantly lower in the CNC group at 12 months (-5.3 ± 10.3% vs. -12.8 ± 12%, p = 0.002). Regarding nutrition-related blood parameters, change in total cholesterol was significantly lower in the CNC group than the control group at 12 months after surgery (p = 0.02). Multivariate analysis identified no CNC as an independent risk factor for severe BWL (p = 0.001) and SML (p = 0.006) at 12 months after surgery. CONCLUSIONS: Following gastrectomy, patient-participation CNC prevented postoperative BWL and SML after surgery. These results support the induction of such a CNC program in these patients.

    DOI: 10.1245/s10434-022-12572-3

    PubMed

    researchmap

  • Surgical Strategies to Approaching the Splenic Artery in Robotic Distal Pancreatectomy. International journal

    Kosei Takagi, Kenjiro Kumano, Yuzo Umeda, Ryuichi Yoshida, Tomokazu Fuji, Kazuya Yasui, Takahito Yagi, Toshiyoshi Fujiwara

    Anticancer research   42 ( 9 )   4471 - 4476   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Understanding different surgical approaches and anatomical landmarks adjacent to the splenic artery (SpA) is important for safe robotic distal pancreatectomy (RDP). Herein, we propose our standardized RDP techniques, focusing on these issues. PATIENTS AND METHODS: Between April 2021 and April 2022, 19 patients who underwent RDP at our Institution were reviewed. Anatomical patterns of the SpA were classified into three types: Type 1, no pancreatic parenchyma on the root of the SpA; type 2, any pancreatic parenchyma on the root of the SpA; and type 3, dorsal pancreatic artery around the bifurcation of the common hepatic artery and SpA. Next, the surgical strategy for approaching the SPA was determined according to the location of the pancreatic transection line: On the superior mesenteric vein (SMV) or on the left side of the root of the SpA. RESULTS: There were seven cases of type 1, nine cases of type 2, and three cases of type 3. When transecting the pancreas on the SMV, the SpA-first ligation technique was used for type 1 SpA anatomy, and the pancreas-first division technique was applied for types 2 and 3. In patients in whom the pancreas was transected at the left side of the root of the SpA, the SpA-first ligation technique was used. CONCLUSION: Our standardized surgical strategy based on anatomical landmarks and focusing on the approach to the SpA in RDP is demonstrated. Our strategy should help trainees approach the SpA and perform RDP safely.

    DOI: 10.21873/anticanres.15947

    PubMed

    researchmap

  • EMTバイオセンサーを用いたリアルタイムイメージングによる難治性膵臓癌の治療戦略(Real-time imaging of EMT biosensor provide a therapeutic strategy for refractory pancreatic cancer)

    谷 悠真, 田澤 大, 重安 邦俊, 藤原 俊義

    日本癌学会総会記事   81回   P - 3146   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 直腸癌低位前方切除後の縫合不全に対する取り組みと課題

    寺石 文則, 半澤 俊哉, 庄司 良平, 松三 雄騎, 重安 邦俊, 近藤 喜太, 香川 俊輔, 藤原 俊義

    日本大腸肛門病学会雑誌   75 ( 9 )   A163 - A163   2022.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 男女を問わず外科医が輝き続けるために ステレオタイプ・スレットという問題とニュースレターの果たす役割

    竹原 裕子, 溝尾 妙子, 小林 純子, 坂本 美咲, 新田 薫, 工藤 由里絵, 安井 和也, 菊池 覚次, 黒田 新士, 吉田 龍一, 岡崎 幹生, 枝園 忠彦, 山根 正修, 小谷 恭弘, 豊岡 伸一, 笠原 真悟, 土井原 博義, 藤原 俊義

    日本外科学会雑誌   123 ( 5 )   501 - 502   2022.9

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道癌単独肝転移、肺転移の治療戦略は? 食道癌根治切除術後の肝転移、肺転移切除についての検討

    陶守 貴人, 野間 和広, 橋本 将志, 最所 公平, 賀島 肇, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   57 - 57   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 癌細胞と癌関連線維芽細胞は互いにPD-L1を増強させ予後に影響する(Cancer cell and cancer-associated fibroblast mutually enhance PD-L1 expression and affect survival in esophageal cancer)

    河崎 健人, 野間 和広, 西村 星多郎, 松本 聖, 國友 知義, 赤井 正明, 小林 照貴, 菊地 覚次, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   81回   P - 2187   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 転移性骨肉腫細胞はCCL2によるM2マクロファージの腫瘍内浸潤を誘導して肺転移を促進する(Metastatic osteosarcoma cells facilitate lung metastasis by inducing CCL2-mediated tumor infiltration of M2 macrophages)

    近藤 宏也, 田澤 大, 久禮 美穂, 藤原 智洋, 国定 俊之, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   81回   J - 2087   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 血清エクソソームE1A-DNAはテロメラーゼ特異的腫瘍融解アデノウイルスの治療効果予測バイオマーカーとして有用である(Exosomal E1A-DNA in serum as a predictive biomarker of telomerase-specific oncolytic adenovirus)

    八木 千晶, 黒田 新士, 吉田 有佑, 坂本 真樹, 濱田 侑紀, 杉本 龍馬, 橋本 将志, 垣内 慶彦, 菊地 覚次, 香川 俊輔, 田澤 大, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   81回   E - 3068   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 腫瘍免疫の改善に関わる、FAPを標的とした光免疫療法の可能性(Fibroblast Activation Protein targeted Near-Infrared Photoimmunotherapy improves tumor immunosuppression)

    赤井 正明, 野間 和広, 大原 利章, 松本 聖, 西村 星多郎, 國友 知義, 河崎 健人, 小林 照貴, 賀島 肇, 菊地 覚次, 田澤 大, 藤原 俊義

    日本癌学会総会記事   81回   J - 3010   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道癌・接合部癌における免疫チェックポイント 阻害剤の意義と課題 術前DCF療法を施行した食道根治術術後再発に対するNivolumabの有効性

    橋本 将志, 野間 和広, 最所 公平, 賀島 肇, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   7 - 7   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • p53搭載テロメラーゼ特異的腫瘍融解アデノウイルスの抗腫瘍効果予測スコアリングシステム(Scoring system to predict antitumor effects of p53-armed telomerase-specific oncolytic adenovirus)

    杉本 龍馬, 黒田 新士, 吉田 有佑, 坂本 真樹, 濱田 侑紀, 八木 千晶, 橋本 将志, 垣内 慶彦, 菊地 覚次, 香川 俊輔, 田澤 大, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   81回   P - 3347   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道癌手術における安全で確実な胸部操作 アプローチ法による特性を理解し、安全で確実な胸部操作を行う

    前田 直見, 野間 和広, 橋本 将志, 最所 公平, 賀島 肇, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   39 - 39   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • ロボット手術における現状と課題 ロボット支援下手術の導入により見えてきた一歩先の食道癌手術とその課題

    野間 和広, 白川 靖博, 橋本 将志, 最所 公平, 賀島 肇, 前田 直見, 菊地 覚次, 田辺 俊介, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   9 - 9   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 骨・軟部腫瘍の基礎科学のトピックス 転移性骨肉腫は臓器指向性サイトカインの分泌を介して微小環境を変化させ前転移ニッチを形成する

    近藤 宏也, 田澤 大, 藤原 智洋, 近藤 彩奈, 片山 晴喜, 佐藤 浩平, 畑 利彰, 中田 英二, 国定 俊之, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   96 ( 8 )   S1532 - S1532   2022.9

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 食道癌手術における腹腔鏡下腹部郭清の定型化とその有用性

    菊地 覚次, 野間 和広, 田辺 俊介, 前田 直見, 橋本 将志, 最所 公平, 賀島 肇, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   108 - 108   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 胃管作製法と吻合法に着目した当科における食道切除後再建の変遷と工夫

    國友 知義, 野間 和広, 橋本 将志, 最所 公平, 賀島 肇, 前田 直見, 菊池 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   100 - 100   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 当院における高齢者進行食道癌に対する治療戦略

    竹田 泰茂, 野間 和広, 橋本 将志, 最所 公平, 賀島 肇, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   300 - 300   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌に対するサルベージロボット支援下胸腔鏡下食道亜全摘術5症例の検討

    門脇 大輔, 野間 和広, 橋本 将志, 最所 公平, 賀島 肇, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   186 - 186   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 喉頭温存を目指した頸部進行食道癌の集学的治療戦略

    田辺 俊介, 野間 和広, 橋本 将志, 最所 公平, 賀島 肇, 前田 直見, 菊地 覚次, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   302 - 302   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌に対するウイルス治療、ワクチン治療の最前線 抗腫瘍免疫賦活を介した腫瘍融解アデノウイルス製剤による免疫チェックポイント阻害薬治療増強効果の検討

    橋本 将志, 黒田 新士, 金谷 信彦, 田辺 俊介, 前田 直見, 野間 和広, 田澤 大, 白川 靖博, 浦田 泰生, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   59 - 59   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌に対するウイルス治療、ワクチン治療の最前線 食道癌に対する腫瘍融解ウイルス併用放射線療法の臨床研究の成果と展望

    田辺 俊介, 野間 和広, 橋本 将志, 最所 公平, 賀島 肇, 前田 直見, 菊地 覚次, 田澤 大, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   59 - 59   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • エクソソームを用いた食道扁平上皮癌のリンパ節転移メカニズムの解明(Elucidation for the mechanism of lymph node metastasis of esophageal squamous cell carcinoma by extracellular vesicles)

    木谷 嘉孝, 吉岡 祐亮, 賀島 肇, 野間 和広, 田澤 大, 藤原 俊義, 永川 裕一, 落谷 孝広

    日本癌学会総会記事   81回   P - 2122   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 【ここまで進んだERAS】ERASにおけるチーム医療

    野間 和広, 田邊 俊介, 藤原 俊義

    消化器外科   45 ( 9 )   961 - 966   2022.9

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • 切除可能膵癌における血中循環腫瘍DNA内Kras遺伝子変異とCA19-9値による予後層別化の試み

    宮本 耕吉, 吉田 龍一, 重安 邦俊, 安井 和也, 高木 弘誠, 藤 智和, 楳田 祐三, 八木 孝二, 藤原 俊義

    日本分子腫瘍マーカー研究会プログラム・講演抄録   42回   78 - 79   2022.9

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • EMTバイオセンサーを用いたリアルタイムイメージングによる難治性膵臓癌の治療戦略(Real-time imaging of EMT biosensor provide a therapeutic strategy for refractory pancreatic cancer)

    谷 悠真, 田澤 大, 重安 邦俊, 藤原 俊義

    日本癌学会総会記事   81回   P - 3146   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 男女を問わず外科医が輝き続けるために ステレオタイプ・スレットという問題とニュースレターの果たす役割

    竹原 裕子, 溝尾 妙子, 小林 純子, 坂本 美咲, 新田 薫, 工藤 由里絵, 安井 和也, 菊池 覚次, 黒田 新士, 吉田 龍一, 岡崎 幹生, 枝園 忠彦, 山根 正修, 小谷 恭弘, 豊岡 伸一, 笠原 真悟, 土井原 博義, 藤原 俊義

    日本外科学会雑誌   123 ( 5 )   501 - 502   2022.9

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 直腸癌低位前方切除後の縫合不全に対する取り組みと課題

    寺石 文則, 半澤 俊哉, 庄司 良平, 松三 雄騎, 重安 邦俊, 近藤 喜太, 香川 俊輔, 藤原 俊義

    日本大腸肛門病学会雑誌   75 ( 9 )   A163 - A163   2022.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 骨・軟部腫瘍の基礎科学のトピックス 転移性骨肉腫は臓器指向性サイトカインの分泌を介して微小環境を変化させ前転移ニッチを形成する

    近藤 宏也, 田澤 大, 藤原 智洋, 近藤 彩奈, 片山 晴喜, 佐藤 浩平, 畑 利彰, 中田 英二, 国定 俊之, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   96 ( 8 )   S1532 - S1532   2022.9

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 転移性骨肉腫細胞はCCL2によるM2マクロファージの腫瘍内浸潤を誘導して肺転移を促進する(Metastatic osteosarcoma cells facilitate lung metastasis by inducing CCL2-mediated tumor infiltration of M2 macrophages)

    近藤 宏也, 田澤 大, 久禮 美穂, 藤原 智洋, 国定 俊之, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   81回   J - 2087   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道癌に対するウイルス治療、ワクチン治療の最前線 抗腫瘍免疫賦活を介した腫瘍融解アデノウイルス製剤による免疫チェックポイント阻害薬治療増強効果の検討

    橋本 将志, 黒田 新士, 金谷 信彦, 田辺 俊介, 前田 直見, 野間 和広, 田澤 大, 白川 靖博, 浦田 泰生, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   59 - 59   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • p53搭載テロメラーゼ特異的腫瘍融解アデノウイルスの抗腫瘍効果予測スコアリングシステム(Scoring system to predict antitumor effects of p53-armed telomerase-specific oncolytic adenovirus)

    杉本 龍馬, 黒田 新士, 吉田 有佑, 坂本 真樹, 濱田 侑紀, 八木 千晶, 橋本 将志, 垣内 慶彦, 菊地 覚次, 香川 俊輔, 田澤 大, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   81回   P - 3347   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道癌に対するウイルス治療、ワクチン治療の最前線 食道癌に対する腫瘍融解ウイルス併用放射線療法の臨床研究の成果と展望

    田辺 俊介, 野間 和広, 橋本 将志, 最所 公平, 賀島 肇, 前田 直見, 菊地 覚次, 田澤 大, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   59 - 59   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • p53感作樹状細胞ワクチンは大腸癌に対するp53搭載腫瘍融解ウイルスの治療効果を増強する(Ad-p53-transduced dendritic cell vaccine enhances the efficacy of p53-armed oncolytic virotherapy in colorectal cancer)

    山田 元彦, 田澤 大, 庄司 良平, 永井 康雄, 井上 弘章, 菊地 覚次, 黒田 新士, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   81回   P - 2177   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 血清エクソソームE1A-DNAはテロメラーゼ特異的腫瘍融解アデノウイルスの治療効果予測バイオマーカーとして有用である(Exosomal E1A-DNA in serum as a predictive biomarker of telomerase-specific oncolytic adenovirus)

    八木 千晶, 黒田 新士, 吉田 有佑, 坂本 真樹, 濱田 侑紀, 杉本 龍馬, 橋本 将志, 垣内 慶彦, 菊地 覚次, 香川 俊輔, 田澤 大, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   81回   E - 3068   2022.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 切除可能膵癌における血中循環腫瘍DNA内Kras遺伝子変異とCA19-9値による予後層別化の試み

    宮本 耕吉, 吉田 龍一, 重安 邦俊, 安井 和也, 高木 弘誠, 藤 智和, 楳田 祐三, 八木 孝二, 藤原 俊義

    日本分子腫瘍マーカー研究会プログラム・講演抄録   42回   78 - 79   2022.9

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • 食道癌に対するサルベージロボット支援下胸腔鏡下食道亜全摘術5症例の検討

    門脇 大輔, 野間 和広, 橋本 将志, 最所 公平, 賀島 肇, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   186 - 186   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 当院における高齢者進行食道癌に対する治療戦略

    竹田 泰茂, 野間 和広, 橋本 将志, 最所 公平, 賀島 肇, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   300 - 300   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 喉頭温存を目指した頸部進行食道癌の集学的治療戦略

    田辺 俊介, 野間 和広, 橋本 将志, 最所 公平, 賀島 肇, 前田 直見, 菊地 覚次, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   76回   302 - 302   2022.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • RNA editing facilitates the enhanced production of neoantigens during the simultaneous administration of oxaliplatin and radiotherapy in colorectal cancer. International journal

    Yasuhiro Komatsu, Kunitoshi Shigeyasu, Shuya Yano, Sho Takeda, Kazutaka Takahashi, Nanako Hata, Hibiki Umeda, Kazuhiro Yoshida, Yoshiko Mori, Kazuya Yasui, Ryuichi Yoshida, Yoshitaka Kondo, Hiroyuki Kishimoto, Fuminori Teraishi, Yuzo Umeda, Shunsuke Kagawa, Hiroyuki Michiue, Hiroshi Tazawa, Ajay Goel, Toshiyoshi Fujiwara

    Scientific reports   12 ( 1 )   13540 - 13540   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Most cases of colorectal cancers (CRCs) are microsatellite stable (MSS), which frequently demonstrate lower response rates to immune checkpoint inhibitors (ICIs). RNA editing produces neoantigens by altering amino acid sequences. In this study, RNA editing was induced artificially by chemoradiation therapy (CRT) to generate neoantigens in MSS CRCs. Altogether, 543 CRC specimens were systematically analyzed, and the expression pattern of ADAR1 was investigated. In vitro and in vivo experiments were also performed. The RNA editing enzyme ADAR1 was upregulated in microsatellite instability-high CRCs, leading to their high affinity for ICIs. Although ADAR1 expression was low in MSS CRC, CRT including oxaliplatin (OX) treatment upregulated RNA editing levels by inducing ADAR1. Immunohistochemistry analyses showed the upregulation of ADAR1 in patients with CRC treated with CAPOX (capecitabine + OX) radiation therapy relative to ADAR1 expression in patients with CRC treated only by surgery (p < 0.001). Compared with other regimens, CRT with OX effectively induced RNA editing in MSS CRC cell lines (HT29 and Caco2, p < 0.001) via the induction of type 1 interferon-triggered ADAR1 expression. CRT with OX promoted the RNA editing of cyclin I, a neoantigen candidate. Neoantigens can be artificially induced by RNA editing via an OX-CRT regimen. CRT can promote proteomic diversity via RNA editing.

    DOI: 10.1038/s41598-022-17773-0

    PubMed

    researchmap

  • Verrucous carcinoma of the esophagus with complete response after chemoradiotherapy. International journal

    Masashi Hashimoto, Yasuhiro Shirakawa, Shunsuke Tanabe, Takehiro Tanaka, Naoaki Maeda, Kazufumi Sakurama, Kazuhiro Noma, Toshiyoshi Fujiwara

    Surgical case reports   8 ( 1 )   128 - 128   2022.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Verrucous carcinoma of the esophagus (VCE) is a rare tumor that is difficult to diagnose. In most cases, biopsies show nonspecific inflammatory and hyperkeratotic changes and do not show malignant findings. Most VCEs are slowly growing, locally advanced tumors with few metastases. Treatments for VCE are the same as for normal esophageal cancer, involving combined chemotherapy, surgical resection, and radiation therapy. However, it has been reported that VCE has a poor response to radiation or chemoradiotherapy (CRT). A case of VCE with complete response (CR) after CRT is presented. CASE PRESENTATION: A 70-year-old man was found to have white, irregular esophageal mucosa 4 years earlier. He had been followed up as an outpatient as having candidal esophagitis. However, his tumor grew gradually, and biopsy was performed by endoscopic mucosal resection (EMR). He was finally diagnosed with VCE. He had no metastases to distant organs, but some lymph node metastases were suspected. The tumor invaded his left bronchus. The esophagostomy and gastrostomy were constructed as emergent procedures. The patient then underwent definitive CRT. 4 weeks after the end of CRT, two-stage esophagectomy was performed. First, he underwent esophagectomy with thoracic lymph node dissection. A latissimus dorsi flap was patched to the bronchus after primary suture of the hole. 6 weeks later, reconstruction of the gastric tube was performed through the antethoracic route. The pathological findings showed CR to CRT, with no proliferative cancer cells in the specimen. The patient has had no recurrence for three and half years after the resection. CONCLUSIONS: We presented a locally advanced VCE that achieved CR to CRT. In cases that have some difficulty for local resection, CRT might be an appropriate treatment for VCE.

    DOI: 10.1186/s40792-022-01486-7

    PubMed

    researchmap

  • 【上部】噴門側胃切除の手術手技・再建 噴門側胃切除術+観音開き法再建を施行した胃癌・食道胃接合部癌症例の長期予後因子に関する検討

    垣内 慶彦, 黒田 新士, 丁田 泰宏, 大塚 眞哉, 上山 聰, 田中 則光, 村岡 篤, 羽藤 慎二, 上川 康明, 藤原 俊義

    日本消化器外科学会総会   77回   WS10 - 4   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 継続的な栄養指導と術後早期アミノ酸投与による胃切除術後の体重・筋肉量減少抑制効果

    菊地 覚次, 高田 暢夫, 黒田 新士, 垣内 慶彦, 田辺 俊介, 前田 直見, 野間 和広, 楳田 祐三, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   77回   O4 - 3   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高度肥満症に対する減量・代謝改善手術の効果と安全性

    香川 俊輔, 菊地 覚次, 黒田 新士, 武田 正, 垣内 慶彦, 寺石 文則, 近藤 喜太, 重安 邦俊, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   77回   P276 - 6   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Impact of Amino Acids Nutrition Following Gastrectomy in Gastric Cancer Patients. International journal

    Satoru Kikuchi, Nobuo Takata, Shinji Kuroda, Hibiki Umeda, Shunsuke Tanabe, Naoaki Maeda, Kosei Takagi, Kazuhiro Noma, Yuko Hasegawa, Kumiko Nawachi, Shunsuke Kagawa, Yuzo Umeda, Kenichi Shikata, Toshiyoshi Fujiwara

    Anticancer research   42 ( 7 )   3637 - 3643   2022.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Postoperative body weight loss (BWL) and skeletal muscle loss (SML) after gastrectomy are associated with a decline in quality of life and worse longterm prognosis in gastric cancer (GC) patients. This study aimed to evaluate the efficacy of amino acids nutrition on BWL and SML in the early period following gastrectomy. PATIENTS AND METHODS: The parameters of body composition were measured by bioelectrical impedance analysis in the patients undergoing radical gastrectomy for GC and analyzed retrospectively. Patients received either peripheral parenteral nutrition (PPN) of 4.3% glucose fluid with regular diet (control group, n=43) or PPN of 7.5% glucose fluid containing amino acids plus oral nutritional supplement (ONS) rich in protein with regular diet (amino acids group, n=40) following gastrectomy. The percentages of BWL and SML from preoperative values to those at 7 days and 1 month after surgery were compared between the two groups. RESULTS: The %BWL and %SML at 7 days after surgery were significantly lower in the amino acids group than those in the control group (%BWL, -2.4±1.7% vs. -4.2±1.8%; p<0.0001, %SML, -4.1±3.8 vs. -6.5±3.8; p=0.006). Moreover, the %BWL at 1 month after surgery was significantly lower in the amino acids group compared to that in the control group (- 4.6±2.9% vs. -6.1±2.6%; p=0.01); however, the %SML was similar between the two groups. The hematological nutritional parameters were similar between the two groups. CONCLUSION: Amino acids nutrition by PPN and ONS following gastrectomy prevented postoperative BWL and SML in the early period after surgery in GC patients.

    DOI: 10.21873/anticanres.15852

    PubMed

    researchmap

  • 狭窄を伴う食道癌患者における術前胃瘻造設と周術期管理チームの有用性

    橋本 将志, 野間 和広, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   77回   P147 - 3   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • T4b食道癌に対する治療戦略についての検討 induction DCF vs.induction DCF-RTを中心に

    最所 公平, 野間 和広, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   77回   P163 - 4   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【下部】IBDに対するMIS 炎症性腸疾患に対する経肛門的低侵襲手術は患者因子によらない安定した手術を可能にする

    近藤 喜太, 寺石 文則, 菊地 覚次, 田邊 俊介, 黒田 新士, 吉田 龍一, 野間 和広, 楳田 祐三, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   77回   WS14 - 5   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道癌術後肺転移に対して外科的切除を行った16例の検討

    大亀 正義, 野間 和広, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   77回   P195 - 6   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道狭窄、食道気道瘻に対する食道バイパス術の成績と新たな術式の構築

    陶守 貫人, 野間 和広, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   77回   P195 - 3   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高度肥満症に対する減量・代謝改善手術の効果と安全性

    香川 俊輔, 菊地 覚次, 黒田 新士, 武田 正, 垣内 慶彦, 寺石 文則, 近藤 喜太, 重安 邦俊, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   77回   P276 - 6   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 根治的CRT後の食道縦隔瘻を伴う食道癌に対してロボット支援下胸腔鏡下食道切除術を施行した1例

    門脇 大輔, 野間 和広, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   77回   P243 - 6   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【肝胆膵】大腸癌肝転移におけるBRとURの定義 BR大腸癌肝転移に対する肝切除アプローチ Vessel-Skeletonized Parenchyma-sparing Hepatectomyの有用性

    楳田 祐三, 藤 智和, 高木 弘誠, 安井 和也, 黒田 新士, 吉田 龍一, 野間 和広, 寺石 文則, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   77回   PD1 - 10   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 術中神経刺激装置が有用であった右鎖骨下動脈起始異常を合併した胸部食道癌の一例

    竹田 泰茂, 野間 和広, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   77回   P065 - 6   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高齢大腸癌患者の手術および長期予後についての検討

    武田 正, 寺石 文則, 重安 邦俊, 菊地 覚次, 近藤 喜太, 黒田 新士, 野間 和広, 楳田 祐三, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   77回   P151 - 1   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 狭窄を伴う食道癌患者における術前胃瘻造設と周術期管理チームの有用性

    橋本 将志, 野間 和広, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   77回   P147 - 3   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【総論】各臓器サブサブスペシャルティ外科医の育成法 食道外科におけるサブサブスペシャリティ取得への取組み

    前田 直見, 野間 和広, 菊地 覚次, 田辺 俊介, 黒田 新士, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   77回   WS15 - 9   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 肝転移に焦点を置いた大腸癌多臓器転移症例の治療戦略

    重安 邦俊, 楳田 祐三, 寺石 文則, 武田 正, 藤 智和, 黒田 新士, 近藤 喜太, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   77回   P009 - 2   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高度局所進行食道癌に対する術前DCF療法plusロボット支援下手術

    野間 和広, 西脇 紀之, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   77回   O1 - 5   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 難治性食道狭窄に対して食道亜全摘を施行した関節リウマチ合併Sjogren症候群の1例

    柚木 宏介, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   77回   S1 - 7   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 術前化学療法を施行した膵癌患者における代謝栄養学的指標の意義に関する検討

    佐藤 博紀, 吉田 龍一, 安井 和也, 楳田 祐三, 藤 智和, 高木 弘誠, 黒田 新士, 野間 和広, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   77回   P224 - 3   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Modulation of p53 expression in cancer-associated fibroblasts prevents peritoneal metastasis of gastric cancer. International journal

    Toshihiro Ogawa, Satoru Kikuchi, Motoyasu Tabuchi, Ema Mitsui, Yuta Une, Hiroshi Tazawa, Shinji Kuroda, Kazuhiro Noma, Toshiaki Ohara, Shunsuke Kagawa, Yasuo Urata, Toshiyoshi Fujiwara

    Molecular therapy oncolytics   25   249 - 261   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are associated with the establishment and progression of peritoneal metastasis. This study investigated the efficacy of replicative oncolytic adenovirus-mediated p53 gene therapy (OBP-702) against CAFs and peritoneal metastasis of gastric cancer (GC). Higher CAF expression in the primary tumor was associated with poor prognosis of GC, and higher CAF expression was also observed with peritoneal metastasis in immunohistochemical analysis of clinical samples. And, we found transcriptional alteration of p53 in CAFs relative to normal gastric fibroblasts (NGFs). CAFs increased the secretion of cancer-promoting cytokines, including interleukin-6, and gained resistance to chemotherapy relative to NGFs. OBP-702 showed cytotoxicity to both GC cells and CAFs but not to NGFs. Overexpression of wild-type p53 by OBP-702 infection caused apoptosis and autophagy of CAFs and decreased the secretion of cancer-promoting cytokines by CAFs. Combination therapy using intraperitoneal administration of OBP-702 and paclitaxel synergistically inhibited the tumor growth of peritoneal metastases and decreased CAFs in peritoneal metastases. OBP-702, a replicative oncolytic adenovirus-mediated p53 gene therapy, offers a promising biological therapeutic strategy for peritoneal metastasis, modulating CAFs in addition to achieving tumor lysis.

    DOI: 10.1016/j.omto.2022.04.009

    PubMed

    researchmap

  • Favorable control of hepatocellular carcinoma with peritoneal dissemination by surgical resection using indocyanine green fluorescence imaging: a case report and review of the literature. International journal

    Yuma Tani, Hiroki Sato, Ryuichi Yoshida, Kazuya Yasui, Yuzo Umeda, Kazuhiro Yoshida, Tomokazu Fuji, Kenjiro Kumano, Kosei Takagi, Masaaki Kagoura, Takahito Yagi, Toshiyoshi Fujiwara

    Journal of medical case reports   16 ( 1 )   222 - 222   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The optimal management for peritoneal dissemination in patients with hepatocellular carcinoma remains unclear. Although several reports have described the usefulness of surgical resection, the indications should be carefully considered. Herein, we report the case of a patient with hepatocellular carcinoma with peritoneal recurrence who underwent surgical resection using an indocyanine green fluorescence navigation system and achieved favorable disease control. CASE PRESENTATION: A 45-year-old Asian woman underwent left hemihepatectomy for a ruptured hepatocellular carcinoma. Seventeen months after the initial surgery, a single nodule near the cut surface of the liver was detected on computed tomography, along with elevation of tumor markers. The patient was diagnosed with peritoneal metastasis and underwent a surgical resection. Twelve months later, a single nodule on the dorsal side of the right hepatic lobe was detected on computed tomography, and we performed surgical resection. Indocyanine green (0.5 mg/kg) was intravenously administered 3 days before surgery, and the indocyanine green fluorescence imaging system revealed clear green fluorescence in the tumor, which helped us perform complete resection. Indocyanine green fluorescence enabled the detection of additional lesions that could not be identified by preoperative imaging, especially in the second metastasectomy. There was no further recurrence at 3 months postoperatively. CONCLUSION: When considering surgical intervention for peritoneal recurrence in patients with hepatocellular carcinoma, complete resection is mandatory. Given that disseminated nodules are sometimes too small to be detected by preoperative imaging studies, intraoperative indocyanine green fluorescence may be an essential tool for determining the indications for surgical resection.

    DOI: 10.1186/s13256-022-03440-5

    PubMed

    researchmap

  • [The Chugoku-Shikoku GanPro Produces Advanced Cancer Specialists to Provide Whole Person Medical Care].

    Shunsuke Kagawa, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   49 ( 6 )   638 - 641   2022.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    The 3rd Chugoku-Shikoku GanPro has set a plan to train advanced cancer specialists to provide whole person medical care, and 11 partner universities have formed a consortium, and 18 working groups have been working to provide graduate school education. Through a unique e-learning system and an exercise to learn team medicine, we trained medical professionals who have advanced expertise and can provide cancer care through multidisciplinary team medicine. The project has produced a wide range of personnel including doctors, dentists, pharmacists, nurses, radiologists, medical physicists, and nutritionists. The graduates who have acquired various specialized cancer qualifications practice at regional cancer treatment centers, contributing to the enhancement and improvement of cancer treatment in the Chugoku and Shikoku regions.

    PubMed

    researchmap

  • Tumor-targeted fluorescence labeling systems for cancer diagnosis and treatment. International journal

    Hiroshi Tazawa, Kunitoshi Shigeyasu, Kazuhiro Noma, Shunsuke Kagawa, Fuminori Sakurai, Hiroyuki Mizuguchi, Hisataka Kobayashi, Takeshi Imamura, Toshiyoshi Fujiwara

    Cancer science   113 ( 6 )   1919 - 1929   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Conventional imaging techniques are available for clinical identification of tumor sites. However, detecting metastatic tumor cells that are spreading from primary tumor sites using conventional imaging techniques remains difficult. In contrast, fluorescence-based labeling systems are useful tools for detecting tumor cells at the single-cell level in cancer research. The ability to detect fluorescent-labeled tumor cells enables investigations of the biodistribution of tumor cells for the diagnosis and treatment of cancer. For example, the presence of fluorescent tumor cells in the peripheral blood of cancer patients is a predictive biomarker for early diagnosis of distant metastasis. The elimination of fluorescent tumor cells without damaging normal tissues is ideal for minimally invasive treatment of cancer. To capture fluorescent tumor cells within normal tissues, however, tumor-specific activated target molecules are needed. This review focuses on recent advances in tumor-targeted fluorescence labeling systems, in which indirect reporter labeling using tumor-specific promoters is applied to fluorescence labeling of tumor cells for the diagnosis and treatment of cancer. Telomerase promoter-dependent fluorescence labeling using replication-competent viral vectors produces fluorescent proteins that can be used to detect and eliminate telomerase-positive tumor cells. Tissue-specific promoter-dependent fluorescence labeling enables identification of specific tumor cells. Vimentin promoter-dependent fluorescence labeling is a useful tool for identifying tumor cells that undergo epithelial-mesenchymal transition (EMT). The evaluation of tumor cells undergoing EMT is important for accurately assessing metastatic potential. Thus, tumor-targeted fluorescence labeling systems represent novel platforms that enable the capture of tumor cells for the diagnosis and treatment of cancer.

    DOI: 10.1111/cas.15369

    PubMed

    researchmap

  • 臓器指向性分泌サイトカイン/細胞外小胞を介したcell-cell communicationによる骨肉腫の新しい肺転移形成機構の同定

    近藤 宏也, 藤原 智洋, 田澤 大, 吉田 晶, 片山 晴喜, 近藤 彩奈, 佐藤 浩平, 畑 利彰, たき平 将太, 中田 英二, 国定 俊之, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   96 ( 6 )   S1424 - S1424   2022.6

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • Descending Colon Cancer Coincident with Schistosoma japonicum in an 89-year-old Male.

    Fuminori Teraishi, Atsushi Jikuhara, Ryunosuke Ogawa, Toshiyoshi Fujiwara

    Acta medica Okayama   76 ( 3 )   355 - 358   2022.6

     More details

    Language:English  

    An 89-year-old male came to the hospital with a complaint of abdominal distension. Abdominal computed tomography showed wall thickening in the descending colon and marked dilatation of the proximal colon, and lower gastrointestinal endoscopy demonstrated a stenosis in the descending colon. Although a biopsy from the stenotic lesion showed calcified eggs of Schistosoma japonicum with no malignant findings, we suspected malignant involvement, so we performed a descending colectomy with regional lymph node dissection. Pathological examination revealed a moderately differentiated adenocarcinoma. The colon cancer was diagnosed as pT4bN0M0, Stage IIc. The patient's history as a resident of one of the formerly endemic areas of Japan suggests that he may have carried S. japonicum for a long time, and that it may have contributed to carcinogenesis.

    DOI: 10.18926/AMO/63748

    PubMed

    researchmap

  • H.pylori未感染胃粘膜を背景に発生したリンパ節転移を伴う低分化型進行胃癌の一例

    倉岡 紗樹子, 川野 誠司, 小橋 真由, 岡上 昇太郎, 里見 拓也, 稲生 祥子, 濱田 健太, 河野 吉泰, 神崎 洋光, 岩室 雅也, 河原 祥朗, 岡田 裕之, 垣内 慶彦, 黒田 新士, 藤原 俊義, 田中 健大, 池田 宣聖

    日本消化器病学会中国支部例会プログラム・抄録集   117回   75 - 75   2022.6

     More details

    Language:Japanese   Publisher:日本消化器病学会-中国支部  

    researchmap

  • Adenomatoid mesothelioma arising from the diaphragm: a case report and review of the literature. International journal

    Kenta Kawabe, Hiroki Sato, Akiko Kitano, Ryuichi Yoshida, Kazuya Yasui, Yuzo Umeda, Kazuhiro Yoshida, Tomokazu Fuji, Kenjiro Kumano, Kosei Takagi, Masaaki Kagoura, Takahito Yagi, Toshiyoshi Fujiwara

    Journal of medical case reports   16 ( 1 )   228 - 228   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Adenomatoid mesothelioma is a rare subtype of malignant mesothelioma that can be confused with adenomatoid tumors, which are classified as benign. The clinical features and optimal management of adenomatoid mesothelioma have not been elucidated in the literature. In this report, we present an extremely rare case of adenomatoid mesothelioma that developed on the peritoneal surface of the diaphragm as well as a literature review of adenomatoid mesothelioma in the abdominal cavity. CASE PRESENTATION: The patient was a 61-year-old Japanese woman who had undergone resection of a malignant peripheral nerve sheath tumor of the hand 18 years prior. She was diagnosed with clinical stage I lung adenocarcinoma on follow-up chest radiography. Simultaneously, a 20-mm enhancing nodule with slow growth on the right diaphragm was detected on contrast-enhanced computed tomography. She presented no specific clinical symptoms. At this point, the lesion was suspected to be a hypervascular tumor of borderline malignancy, such as a solitary fibrous tumor. After a left upper lobectomy for lung adenocarcinoma, she was referred to our department, and laparoscopic tumor resection was performed. Adenomatoid tumors were also considered based on the histopathological and immunohistochemical analyses, but we made the final diagnosis of adenomatoid mesothelioma using the results of the genetic profile. The patient remains alive, with no recurrence noted 6 months after surgery. CONCLUSION: We encountered a valuable case of adenomatoid mesothelioma of peritoneal origin. There are some previously reported cases of adenomatoid mesothelioma and adenomatoid tumors that may need to be recategorized according to the current classification. It is important to accumulate and share new findings to clarify the clinicopathological characteristics and genetic status of adenomatoid mesothelioma.

    DOI: 10.1186/s13256-022-03420-9

    PubMed

    researchmap

  • Optimal surveillance of intraductal papillary mucinous neoplasms of the pancreas focusing on remnant pancreas recurrence after surgical resection. International journal

    Tomokazu Fuji, Yuzo Umeda, Kosei Takagi, Ryuichi Yoshida, Kazuhiro Yoshida, Kazuya Yasui, Kazuyuki Matsumoto, Hironari Kato, Takahito Yagi, Toshiyoshi Fujiwara

    BMC cancer   22 ( 1 )   588 - 588   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The international consensus guidelines for intraductal papillary mucinous neoplasm of the pancreas (IPMN) presented clinical features as indications for surgery. Whereas surveillance for recurrence, including de novo lesions, is essential, optimal surveillance protocols have not been established. AIM AND METHODS: This study aimed to assess the clinical features of recurrence at the remnant pancreas (Rem-Panc) and extra-pancreas (Ex-Panc) after surgery for IPMN. Ninety-one patients of IPMN that underwent detailed preoperative assessment and pancreatectomy were retrospectively analyzed, focusing especially on the type of recurrence. RESULTS: The IPMNs were finally diagnosed as low-grade dysplasia (LDA, n = 42), high-grade dysplasia (HAD, n = 19), and invasive carcinoma (IPMC, n = 30). Recurrence was observed in 26 patients (29%), of which recurrence was seen at Rem-Panc in 19 patients (21%) and Ex-Panc in 7 patients (8%). The frequency of Rem-Panc recurrence was 10% in LDA, 21% in HDA, and 37% in IPMC. On the other hand, Ex-Panc recurrence was observed only in IPMC (23%). Ex-Panc recurrence showed shorter median recurrence-free survival (RFS) and overall survival (OS) than Rem-Panc recurrence (median RFS 8 months vs. 35 months, p < 0.001; median OS 25 months vs. 72 months, p < 0.001). Regarding treatment for Rem-Panc recurrence, repeat pancreatectomy resulted in better OS than no repeat pancreatectomy (MST 36 months vs. 15.5 months, p = 0.033). On multivariate analysis, main duct stenosis or disruption as a preoperative feature (hazard ratio [HR] 10.6, p = 0.002) and positive surgical margin (HR 4.4, p = 0.018) were identified as risk factors for Rem-Panc recurrence. CONCLUSIONS: The risk factors for Rem-Panc and Ex-Panc recurrence differ. Therefore, optimal surveillance on these features is desirable to ensure that repeat pancreatectomy for Rem-Panc recurrence can be an appropriate surgical intervention.

    DOI: 10.1186/s12885-022-09650-w

    PubMed

    researchmap

  • Feasibility of local therapy for recurrent pancreatic cancer. International journal

    Hiroki Sato, Ryuichi Yoshida, Kazuya Yasui, Yuzo Umeda, Kazuhiro Yoshida, Tomokazu Fuji, Kenjiro Kumano, Kosei Takagi, Takahito Yagi, Toshiyoshi Fujiwara

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]   22 ( 6 )   774 - 781   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Despite advances in perioperative management, recurrence after curative pancreatectomy is a critical issue in the treatment of pancreatic ductal adenocarcinoma (PDAC). The significance of local therapy for recurrent PDAC remains unclear. METHODS: We reviewed the medical records of patients with PDAC who underwent curative resection at our institution between January 2009 and December 2019. We examined the patterns of relapse and assessed the clinical outcomes of patients with recurrence who underwent local therapy, including surgical resection, radiotherapy, and radiofrequency ablation. RESULTS: A total of 246 patients with PDAC who underwent R0 or R1 resection were included in this study. The 3-year overall survival (OS) rate was 39.8%, and the 1-year recurrence-free survival rate was 51.2% for the entire population. Recurrence was observed in 172/246 (69.9%) patients, including multiple site recurrences in 50, liver metastasis in 41, locoregional recurrence in 34, and peritoneal dissemination in 27. Of the 172 patients, treatment was administered in 137 (79.7%), and 16 received local therapy, including surgical resection (n = 13), radiotherapy (n = 5), and RFA (n = 1). PS-matched analysis revealed that patients with recurrence who were treated with chemotherapy combined with local therapy showed better post-recurrence survival rates than those treated with chemotherapy alone (P = 0.016). Detailed clinical courses of these patients are presented in the main manuscript. CONCLUSIONS: Our results suggest that a multimodal approach may improve the clinical outcomes of patients with recurrent PDAC.

    DOI: 10.1016/j.pan.2022.05.004

    PubMed

    researchmap

  • Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma. International journal

    Daisuke Konishi, Yuzo Umeda, Kazuhiro Yoshida, Kunitoshi Shigeyasu, Shuya Yano, Tomohiro Toji, Sho Takeda, Ryuichi Yoshida, Kazuya Yasui, Tomokazu Fuji, Kazuyuki Matsumoto, Hiroyuki Kishimoto, Hiroyuki Michiue, Fuminori Teraishi, Hironari Kato, Hiroshi Tazawa, Hiroyuki Yanai, Takahito Yagi, Ajay Goel, Toshiyoshi Fujiwara

    British journal of cancer   127 ( 4 )   757 - 765   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Emerging evidence indicates that immunogenicity plays an important role in intrahepatic cholangiocarcinoma (ICC). Herein, we systematically evaluated the clinical relevance of immunogenicity in ICC. METHODS: Highly immunogenic ICCs identified in the public dataset and the Cancer Immunome Atlas (TCIA) were assessed to determine the prognostic impact of immunogenicity in ICC and key components after curative resection. We also investigated the clinical relevance of the immune milieu in ICC. RESULTS: Using the Gene Expression Omnibus dataset 89749 and TCIA, we identified CD8+/forkhead box P3 (FoxP3)+ tumour-infiltrating lymphocytes (TILs), T-cell immunoglobulin and mucin domain 3 (TIM-3) and human leukocyte antigen-A (HLA-A) in highly immunogenic ICCs. Immunohistochemical analysis of the in-house cohort showed that intratumoral FoxP3+ TILs correlated with CD8+ TILs (P = 0.045, Fisher's exact test) and that high FoxP3+/CD8+ ratio (FCR) was an important marker for poor survival (P < 0.001, log-rank test). Furthermore, the FCR was higher in tumour-free lymph nodes in ICCs with lymph node metastases than in those without lymph node metastases (P = 0.003, Mann-Whitney U test). CONCLUSIONS: FCR should be considered an important biomarker that represents the immune environment of ICC based on its potentially important role in tumour progression, especially lymph node metastasis.

    DOI: 10.1038/s41416-022-01838-y

    PubMed

    researchmap

  • Prognostic Value of the Regional Lymph Node Station in Pancreatic Neuroendocrine Tumor. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Kazuhiro Yoshida, Tomokazu Fuji, Kenjiro Kumano, Kazuya Yasui, Takahito Yagi, Toshiyoshi Fujiwara

    Anticancer research   42 ( 5 )   2797 - 2801   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Little is known regarding the impact of lymph node dissection on survival benefit after curative resection for pancreatic neuroendocrine tumor (PNET). This study aimed to evaluate the efficacy of lymph node dissection based on tumor location of PNET. PATIENTS AND METHODS: A retrospective study, including 50 patients with surgical resection for PNET between 2004 and 2020, was performed. The efficacy index (EI) was calculated by multiplication of the incidence of lymph node metastasis (LNM) at the station and the 5-year survival rate of patients with LNM at the station. RESULTS: In the pancreatic head tumors, the peri-pancreatic head and superior mesenteric artery lymph node stations had high EI of 13.3 and 25, respectively. In contrast, other stations, including stations 8 and 12, had zero EI. In the pancreatic body and tail tumors, only the splenic artery lymph node station had a survival benefit from lymph node dissection with an EI of 6.7. CONCLUSION: The extent of lymph node dissection for PNET should be decided based on the efficacy of lymph node dissection in accordance with tumor location. Our findings may be helpful in determining the extent of lymph node dissection required.

    DOI: 10.21873/anticanres.15760

    PubMed

    researchmap

  • Anorectal leiomyoma with GLUT1 overexpression mimicking malignancy on FDG-PET/CT. International journal

    Fuminori Teraishi, Kunitoshi Shigeyasu, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Journal of surgical case reports   2022 ( 5 )   rjac101   2022.5

     More details

    Language:English  

    A 43-year-old female underwent pelvic magnetic resonance imaging for uterine myoma that incidentally revealed a 4.6 × 2.8 cm soft tissue mass in the anorectal region. Rectal endoscopy showed a submucosal tumor just above the anal canal. Fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) revealed an anorectal tumor with very high FDG uptake. Aspiration cytology and needle biopsy were inconclusive, and the patient underwent trans-perineal tumor resection. The excised tumor was a 4.6 × 3.5 × 2.7 cm gray-white bifurcated nodular tumor. Light microscopy revealed fenestrated growth of poorly dysmorphic short spindle-shaped cells with eosinophilic sporophytes. Immunohistochemical staining was positive for αSMA and desmin, negative for CD117 (KIT) and S100, and the patient was diagnosed with benign leiomyoma. Tumor cells were also positive for glucose transporter-1 (GLUT1) immunohistochemically. It is important to keep in mind that FDG-PET/CT may show false-positive results even in benign anal leiomyoma for various reasons, including GLUT1 overexpression.

    DOI: 10.1093/jscr/rjac101

    PubMed

    researchmap

  • 食道胃接合部癌に対する下縦隔郭清と再建 食道胃接合部癌に対する腹臥位胸腔鏡下併用の下縦隔郭清および食道残胃吻合

    野間 和広, 橋本 将志, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科系連合学会誌   47 ( 3 )   414 - 414   2022.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    researchmap

  • 多職種チーム医療による周術期管理 術前から術後まで幅広くサポートする多職種チーム医療による食道がん周術期管理

    田辺 俊介, 野間 和広, 橋本 将志, 前田 直見, 櫻間 教文, 白川 靖博, 藤原 俊義

    日本外科系連合学会誌   47 ( 3 )   361 - 361   2022.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    researchmap

  • 多職種チーム医療による周術期管理 術前から術後まで幅広くサポートする多職種チーム医療による食道がん周術期管理

    田辺 俊介, 野間 和広, 橋本 将志, 前田 直見, 櫻間 教文, 白川 靖博, 藤原 俊義

    日本外科系連合学会誌   47 ( 3 )   361 - 361   2022.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    researchmap

  • 食道胃接合部癌に対する下縦隔郭清と再建 食道胃接合部癌に対する腹臥位胸腔鏡下併用の下縦隔郭清および食道残胃吻合

    野間 和広, 橋本 将志, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科系連合学会誌   47 ( 3 )   414 - 414   2022.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    researchmap

  • トランスレーショナル研究における外科医の役割 外科医が思う「あったらいいな」をTranslational researchで解決する

    垣内 慶彦, 黒田 新士, 橋本 将志, 八木 千晶, 杉本 龍馬, 濱田 侑紀, 坂本 真樹, 吉田 侑佑, 菊地 覚次, 香川 俊輔, 田澤 大, 藤原 俊義

    日本外科学会定期学術集会抄録集   122回   DB - 4   2022.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • ステレオタイプ・スレットという問題とニュースレターの果たす役割

    竹原 裕子, 溝尾 妙子, 小林 純子, 坂本 美咲, 新田 薫, 工藤 由里絵, 安井 和也, 菊池 覚次, 黒田 新士, 吉田 龍一, 岡崎 幹生, 杉本 誠一郎, 枝園 忠彦, 小谷 恭弘, 豊岡 伸一, 笠原 真悟, 藤原 俊義, 土井原 博義

    日本外科学会定期学術集会抄録集   122回   SP - 6   2022.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道癌に対するロボット支援手術の手技と成績【Video】2施設にわたるロボット支援下食道悪性腫瘍手術導入100例の経験

    白川 靖博, 桂 佑貴, 石田 道拡, 丁田 泰宏, 矢野 琢也, 佐藤 太佑, 吉満 政義, 中野 敢友, 松川 啓義, 井谷 史嗣, 岡島 正純, 橋本 将志, 前田 直見, 田辺 俊介, 野間 和広, 藤原 俊義, 塩崎 滋弘

    日本外科学会定期学術集会抄録集   122回   SY - 5   2022.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Overexpression of Adenovirus E1A Reverses Transforming Growth Factor-β-induced Epithelial-mesenchymal Transition in Human Esophageal Cancer Cells.

    Tomoya Masuda, Hiroshi Tazawa, Yuuri Hashimoto, Takeshi Ieda, Satoru Kikuchi, Shinji Kuroda, Kazuhiro Noma, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Acta medica Okayama   76 ( 2 )   203 - 215   2022.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The epithelial-mesenchymal transition (EMT), a normal biological process by which epithelial cells acquire a mesenchymal phenotype, is associated with migration, metastasis, and chemoresistance in cancer cells, and with poor prognosis in patients with esophageal cancer. However, therapeutic strategies to inhibit EMT in tumor environments remain elusive. Here, we show the therapeutic potential of telomerase-specific replication- competent oncolytic adenovirus OBP-301 in human esophageal cancer TE4 and TE6 cells with an EMT phenotype. Transforming growth factor-β (TGF-β) administration induced the EMT phenotype with spindleshaped morphology, upregulation of mesenchymal markers and EMT transcription factors, migration, and chemoresistance in TE4 and TE6 cells. OBP-301 significantly inhibited the EMT phenotype via E1 accumulation. EMT cancer cells were susceptible to OBP-301 via massive autophagy induction. OBP-301 suppressed tumor growth and lymph node metastasis of TE4 cells co-inoculated with TGF-β-secreting fibroblasts. Our results suggest that OBP-301 inhibits the TGF-β-induced EMT phenotype in human esophageal cancer cells. OBP-301-mediated E1A overexpression is a promising antitumor strategy to inhibit EMT-mediated esophageal cancer progression.

    DOI: 10.18926/AMO/63425

    PubMed

    researchmap

  • 80歳以上の高齢者食道癌症例に対する安全性と根治性を担保した外科的治療戦略

    松本 聖, 野間 和広, 前田 直見, 菊地 覚次, 田辺 俊介, 黒田 新士, 近藤 喜太, 吉田 龍一, 櫻間 教文, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   122回   DP - 6   2022.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道浸潤長から導かれる食道胃接合部癌の至適術式と集学的治療の後方視的解析

    田辺 俊介, 野間 和広, 前田 直見, 菊地 覚次, 黒田 新士, 近藤 喜太, 吉田 龍一, 櫻間 教文, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   122回   SF - 1   2022.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 経口摂取不能上部消化管癌に対し外科医は何ができるのか? 食道バイパス術の有用性に関する検討

    前田 直見, 野間 和広, 菊地 覚次, 黒田 新士, 近藤 喜太, 田辺 俊介, 吉田 龍一, 櫻間 教文, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   122回   PD - 6   2022.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • The Gastrohepatic Ligament Approach in Robotic Spleen-Preserving Distal Pancreatectomy with Resection of the Splenic Vessels: The Superior Window Approach in the Warshaw Technique. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Takahito Yagi, Toshiyoshi Fujiwara

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract   26 ( 6 )   1342 - 1344   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: There have been few studies reporting on the surgical approaches of minimally invasive spleen-preserving distal pancreatectomy (SPDP). Herein, we present two cases who underwent robotic SPDP with resection of the splenic vessels using our novel gastrohepatic ligament approach (the superior window approach in the Warshaw technique). METHODS: Our gastrohepatic ligament approach in robotic SPDP consists of four steps: step 1, the gastrohepatic ligament transection; step 2, dissection around the pancreas; step 3, transection of the pancreas; and step 4, resection of the splenic vessels (the Warshaw technique). RESULTS: Starting with the gastrohepatic ligament transection, the pancreas was directly dissected with neither dissecting the gastrocolic ligament nor retracting the stomach. The mean operative time was 217 min with minimal estimated blood loss. Both of the patients had no postoperative morbidity. CONCLUSIONS: The gastrohepatic ligament approach may be helpful and optional in robotic SPDP with the Warshaw technique.

    DOI: 10.1007/s11605-022-05286-0

    PubMed

    researchmap

  • Surgical resection of mixed neuroendocrine-non-neuroendocrine neoplasm in the biliary system: a report of two cases. International journal

    Ayano Tamaki, Yuma Tani, Hiroki Sato, Ryuichi Yoshida, Kazuya Yasui, Shigeru Horiguchi, Takashi Kuise, Yuzo Umeda, Kazuhiro Yoshida, Tomokazu Fuji, Kenjiro Kumano, Kosei Takagi, Takahito Yagi, Toshiyoshi Fujiwara

    Surgical case reports   8 ( 1 )   38 - 38   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Mixed neuroendocrine-non-neuroendocrine neoplasm (MINEN) is a rare disease and there is scarce literature on its diagnosis, treatment, and prognosis. We encountered two unusual cases of MINEN in the biliary tract, one in the ampulla of Vater and the other in the distal bile duct. In this report, we describe the clinical course of these two cases in detail. CASE PRESENTATION: Case 1: A 69-year-old woman presented with a chief complaint of epigastric pain. When endoscopic sphincterotomy and retrograde biliary drainage were performed for gallstone pancreatitis, an ulcerated lesion was found in the ampulla of the Vater. Based on the biopsy results, the lesion was diagnosed as the ampulla of Vater carcinoma and subtotal stomach-preserving pancreatoduodenectomy (SSPPD) was performed. Postoperative histopathological examination revealed the coexistence of adenocarcinoma and neuroendocrine carcinoma components, consistent with the diagnosis of MINEN. In addition, lymph node metastasis was found on the dorsal side of the pancreas and the metastatic component was adenocarcinoma. Adjuvant chemotherapy with etoposide and cisplatin was administered for 6 months, and presently the patient is alive without recurrence 64 months after surgery. Case 2: A 79-year-old man presented with a chief complaint of anorexia. Cholangiography showed severe stenosis of the distal bile duct. A biopsy was conducted from the stenotic lesion and it revealed the lesion to be adenocarcinoma. A diagnosis of distal bile duct carcinoma was made, and SSPPD was performed. Histopathological examination revealed the coexistence of adenocarcinoma and neuroendocrine carcinoma components, and the tumor was confirmed as MINEN of the distal bile duct. No adjuvant chemotherapy was administered due to the poor performance status. 7 months later, the patient was found to have a liver metastasis. CONCLUSION: We experienced two valuable cases of biliary MINEN. To identify better treatments, it is important to consider the diversity of individual cases and to continue sharing a variety of cases with different presentations.

    DOI: 10.1186/s40792-022-01386-w

    PubMed

    researchmap

  • 高齢者胃癌症例(80歳以上)に対する周術期管理:合併症を予防するには 高齢胃癌患者に対する周術期多職種介入の効果(The efficacy of the perioperative management for elderly gastric cancer patient by multiple experts)

    垣内 慶彦, 黒田 新士, 菊地 覚次, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   94回   195 - 195   2022.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 腹腔鏡下スリーブ状胃切除術導入から4年間での治療成績

    香川 俊輔, 菊地 覚次, 黒田 新士, 垣内 慶彦, 武田 正, 江口 潤, 中司 敦子, 山口 哲志, 和田 淳, 藤原 俊義

    肥満研究   27 ( Suppl. )   358 - 358   2022.3

     More details

    Language:Japanese   Publisher:(一社)日本肥満学会  

    researchmap

  • Surgical technique of suprapancreatic D2 lymphadenectomy focusing on the posterior hepatic plexus for advanced gastric cancer. International journal

    Nobuhiko Kanaya, Shinji Kuroda, Yoshihiko Kakiuchi, Sho Takeda, Satoru Kikuchi, Kazuhiro Noma, Ryuichi Yoshida, Yuzo Umeda, Fuminori Teraishi, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Langenbeck's archives of surgery   407 ( 2 )   871 - 877   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Although D2 lymphadenectomy is currently considered a standard procedure for advanced gastric cancer (GC) worldwide, there is room for discussion about the appropriate range of suprapancreatic D2 lymphadenectomy. Focusing on the posterior hepatic plexus (PHP), which is not well recognized, we developed a surgical technique of suprapancreatic D2 lymphadenectomy, which we have called PHP-D2, and its short-term and long-term efficacies were evaluated in comparison with non-PHP-D2. METHODS: GC patients who underwent distal gastrectomy with D2 lymphadenectomy between July 2006 and May 2013 were enrolled, from which patients who had peritoneal metastasis and/or were peritoneal cytology-positive during surgery were excluded. Their medical records were retrospectively reviewed. RESULTS: Ninety-two patients (non-PHP-D2: 48, PHP-D2: 44) were enrolled. Shorter operation time (330 min vs 275 min, p < 0.0001) and less blood loss (290 mL vs 125 mL, p < 0.0001) were observed in PHP-D2, and no pancreatic fistulas were observed in PHP-D2. More lymph nodes of #11p (1 vs 1.5, p = 0.0328) and #12a lymph nodes (0 vs 1, p = 0.0034) were retrieved in PHP-D2, with no significant differences in #8a and #9 lymph nodes. Lymphatic recurrence was significantly less in PHP-D2 (p = 0.0166), and univariate and multivariate analyses showed that non-PHP-D2 was a significant risk factor for lymphatic recurrence (p = 0.0158), although there were no significant differences between non-PHP-D2 and PHP-D2 in 5-year overall survival and 5-year relapse-free survival. CONCLUSION: PHP-D2 was a safe and feasible procedure that had the potential to reduce lymphatic recurrence, and it can be a standard procedure of D2 lymphadenectomy for advanced GC.

    DOI: 10.1007/s00423-022-02437-4

    PubMed

    researchmap

  • 進行・再発胃癌患者に対するNivolumabの実臨床での治療成績の検討(Clinical outcomes of nivolumab in patients with advanced or recurrent gastric cancer)

    香川 俊輔, 黒田 新士, 菊地 覚次, 野間 和広, 田辺 俊介, 重安 邦俊, 前田 直見, 垣内 慶彦, 武田 正, 近藤 喜太, 寺石 文則, 藤原 俊義

    日本胃癌学会総会記事   94回   425 - 425   2022.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 腹腔鏡下スリーブ状胃切除術導入から4年間での治療成績

    香川 俊輔, 菊地 覚次, 黒田 新士, 垣内 慶彦, 武田 正, 江口 潤, 中司 敦子, 山口 哲志, 和田 淳, 藤原 俊義

    肥満研究   27 ( Suppl. )   358 - 358   2022.3

     More details

    Language:Japanese   Publisher:(一社)日本肥満学会  

    researchmap

  • 進行・再発胃癌患者に対するNivolumabの実臨床での治療成績の検討(Clinical outcomes of nivolumab in patients with advanced or recurrent gastric cancer)

    香川 俊輔, 黒田 新士, 菊地 覚次, 野間 和広, 田辺 俊介, 重安 邦俊, 前田 直見, 垣内 慶彦, 武田 正, 近藤 喜太, 寺石 文則, 藤原 俊義

    日本胃癌学会総会記事   94回   425 - 425   2022.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • A Systematic Review of Minimally Invasive Versus Open Radical Antegrade Modular Pancreatosplenectomy for Pancreatic Cancer. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Takahito Yagi, Toshiyoshi Fujiwara

    Anticancer research   42 ( 2 )   653 - 660   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: The aim of this study was to investigate surgical and oncological outcomes of minimally invasive (MI) and open radical antegrade modular pancreatosplenectomy (RAMPS) for the treatment of left-sided pancreatic cancer. MATERIALS AND METHODS: A systematic literature search and meta-analyses were performed focusing on short-term surgical oncology of MI- and open-RAMPS. RESULTS: A total of seven studies with 423 patients were included in this review. The equivalent short-term and long-term outcomes of the groups were confirmed. The results of meta-analyses found no significant difference in R0 resection rates (OR=1.78, 95%CI=0.76-4.15, p=0.18), although MI-RAMPS was associated with a smaller number of dissected lymph nodes (MD=-3.14, 95%CI=-4.75 - -1.53, p<0.001) and lymph node metastases (OR=0.55, 95%CI=0.31-0.97, p=0.04). CONCLUSION: MI-RAMPS could provide surgically and oncologically feasible outcomes for well-selected left-sided pancreatic cancer as compared to open-RAMPS. However, further high-level evidence should be needed to confirm survival benefits following MI-RAMPS.

    DOI: 10.21873/anticanres.15523

    PubMed

    researchmap

  • Effectiveness of early exercise on reducing skeletal muscle loss during preoperative neoadjuvant chemotherapy for esophageal cancer.

    Tomohiro Ikeda, Kazuhiro Noma, Naoaki Maeda, Shunsuke Tanabe, Yoko Sakamoto, Yoshimi Katayama, Yasuhiro Shirakawa, Toshiyoshi Fujiwara, Masuo Senda

    Surgery today   52 ( 8 )   1143 - 1152   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To investigate if early exercise can help prevent skeletal muscle loss and improve the clinical outcomes of esophageal cancer patients receiving preoperative neoadjuvant chemotherapy (NAC). METHODS: This was a single-center, retrospective observational cohort study of 110 patients with advanced esophageal cancer. We analyzed the effect of early exercise on the risk of skeletal muscle loss (defined as > 2.98%) during NAC and the subsequent clinical outcomes. Patients in the early exercise group (n = 71) started exercise therapy 8 days earlier than those the late exercise group (n = 39). RESULTS: The median age of the patients was 65.4 years, the mean BMI was 21.1 kg/m2, and 92 (84%) of the 110 patients were men. Skeletal muscle loss occurred in 34% and 67% of the early and late exercise groups, respectively (p < 0.001). There was a lower risk of surgical site infection in the early exercise group (1% vs 16%, p = 0.021). Multivariate analysis revealed that early exercise reduced the risk of skeletal muscle loss (OR = 0.25, 95% CI 0.09-0.65, p = 0.006). CONCLUSIONS: Our results suggest that early exercise reduces the risk of both skeletal muscle loss during NAC and subsequent surgical site infection in patients with esophageal cancer.

    DOI: 10.1007/s00595-021-02449-5

    PubMed

    researchmap

  • 【消化器外科 ロボット支援手術の導入と手術教育】ロボット支援下膵切除術の導入と手術教育

    高木 弘誠, 楳田 祐三, 吉田 龍一, 藤原 俊義, 八木 孝仁

    手術   76 ( 1 )   69 - 77   2022.1

     More details

    Language:Japanese   Publisher:金原出版(株)  

    researchmap

  • 《外科学再興特別企画》癌に対する免疫治療New Era がん微小環境内のマクロファージ、好中球を癌の治療標的として解析する

    香川 俊輔, 吉本 匡志, 伊藤 雅典, 梶岡 裕樹, 坂本 修一, 桑田 和也, 吉田 龍一, 野間 和広, 楳田 祐三, 菊地 覚次, 黒田 新士, 矢野 修也, 重安 邦俊, 寺石 文則, 田澤 大, 藤原 俊義

    日本外科学会雑誌   123 ( 1 )   80 - 82   2022.1

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Acute acalculous cholecystitis caused by SARS-CoV-2 infection: A case report and literature review. International journal

    Hana Futagami, Hiroki Sato, Ryuichi Yoshida, Kazuya Yasui, Takahito Yagi, Toshiyoshi Fujiwara

    International journal of surgery case reports   90   106731 - 106731   2022.1

     More details

    Language:English  

    BACKGROUND: Emerging data indicate that gastrointestinal disorders, in addition to pulmonary dysfunction, are also hallmarks of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. CASE PRESENTATION: A 42-year-old man with maintenance hemodialysis developed high fever and dyspnea. He was positive for SARS-CoV-2 and was diagnosed with pneumonia. After treatment for SARS-CoV-2, his respiratory condition improved. However, he developed right upper quadrant pain with elevated inflammatory markers (white blood cells, 21,160/μL; c-reactive protein, 163.9 mg/L) on the 13th day. Abdominal computed tomography revealed acute acalculous cholecystitis. Percutaneous transhepatic gallbladder drainage (PTGBD) was performed together with antibiotic therapy, which resulted in improvement of symptoms. Laparoscopic cholecystectomy was performed 36 days after PTGBD. CONCLUSION: We report a rare case of acute acalculous cholecystitis (AAC) following pneumonia caused by SARS-CoV-2 infection. We also conducted a literature search to characterize SARS-CoV-2-related cholecystitis. Infection with SARS-CoV-2 is an important trigger for AAC, and appropriate therapeutic alternatives should be cautiously selected according to individual cases.

    DOI: 10.1016/j.ijscr.2021.106731

    PubMed

    researchmap

  • 大腸癌肝転移におけるRNA編集酵素ADAR1発現は肝転移切除後の残肝再発を予測するバイオマーカーになる

    畑 七々子, 重安 邦俊, 高橋 一剛, 梅田 響, 武田 正, 矢野 修也, 楳田 祐三, 田澤 大, 藤原 俊義

    日本分子腫瘍マーカー研究会誌   37   23 - 24   2022

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • Association between Advanced T Stage and Thick Rectus Abdominis Muscle and Outlet Obstruction and High-Output Stoma after Ileostomy in Patients with Rectal Cancer

    Yasuhiro Komatsu, Kunitoshi Shigeyasu, Sho Takeda, Yoshiko Mori, Kazutaka Takahashi, Nanako Hata, Kokichi Miyamoto, Hibiki Umeda, Yoshihiko Kakiuchi, Satoru Kikuchi, Shuya Yano, Shinji Kuroda, Yoshitaka Kondo, Hiroyuki Kishimoto, Fuminori Teraishi, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    International Surgery   106 ( 3 )   102 - 111   2022

     More details

    Publishing type:Research paper (scientific journal)  

    Objective: This study aimed to identify factors associated with outlet obstruction and high-output stoma (HOS) after ileostomy creation. Summary of background data: Ileostomy creation is effective in preventing leakage among patients undergoing low anterior resection for rectal cancer. However, major complications such as outlet obstruction and HOS can occur after surgery. Moreover, these complications cannot be prevented. Methods: This retrospective study included 34 patients with rectal cancer who underwent low anterior resection and ileostomy creation at Okayama University Hospital from January 2015 to December 2018. Then, the risk factors associated with outlet obstruction and HOS were analyzed. Results: Of 34 patients, 7 (21%) experienced outlet obstruction. In a multivariate logistic regression analysis, advanced T stage (P ¼ 0.10), ileostomy with a short horizontal diameter (P ¼ 0.01), and thick rectus abdominis (RA) muscle (P ¼ 0.0005) were considered independent risk factors for outlet obstruction. There was a significant correlation between outlet obstruction and HOS (P ¼ 0.03). Meanwhile, the independent risk factors of HOS were advanced T stage (P ¼ 0.03) and thick RA muscle (P ¼ 0.04). Conclusions: Thick RA muscle and advanced T stage were the common risk factors of outlet obstruction and HOS. Therefore, in high-risk patients, these complications can be prevented by choosing an appropriate ileostomy location according to RA muscle thickness and by preventing tubing into the ileostomy.

    DOI: 10.9738/INTSURG-D-21-00012.1

    Scopus

    researchmap

  • Prognostic Value of the Regional Lymph Node Station in Pancreatoduodenectomy for Ampullary Carcinoma. International journal

    Kosei Takagi, Yasuo Nagai, Yuzo Umeda, Ryuichi Yoshida, Kazuhiro Yoshida, Tomokazu Fuji, Kenjiro Kumano, Kazuya Yasui, Takahito Yagi, Toshiyoshi Fujiwara

    In vivo (Athens, Greece)   36 ( 2 )   973 - 978   2022

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: The optimal extent of lymph node dissection for ampullary carcinoma is controversial. The aim of this study was to investigate the efficacy of lymph node dissection for ampullary carcinoma. PATIENTS AND METHODS: Between 2000 and 2020, a total of 75 patients undergoing radical resection for ampullary carcinoma were included. The efficacy index (EI) was calculated by multiplication of the frequency of lymph node metastasis (LNM) at the station and the 5-year survival rate of patients with metastasis at the station. RESULTS: Out of 75 patients, 14 had LNM. The EI for the peri-pancreatic head (station 13 and 17) and superior mesenteric artery (station 14) lymph node were 4.4 and 3.5, respectively. Whereas the peri-gastric (station 5 and 6), common hepatic artery (station 8), and liver hilum (station 12) lymph node stations had zero EI. Although the number of patients with the station 16 dissected was small (9%), the para-aortic (station 16) lymph nodes had the highest EI of 14.3 despite being distant lymph nodes. CONCLUSION: We identified the distribution of LNM and survival benefit of lymph node dissection for ampullary carcinoma. Our results suggest that the optimal extent of lymph node dissection for ampullary carcinoma could be reconsidered.

    DOI: 10.21873/invivo.12789

    PubMed

    researchmap

  • 鏡視下での噴門側胃切除、胃全摘後の再建術 腹腔鏡下噴門側胃切除後の観音開き法再建

    西崎 正彦, 黒田 新士, 菊地 覚次, 垣内 慶彦, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   WS19 - 1   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 術前診断が困難であった膵炎を伴った胃異所性膵に対して腹腔鏡下胃切除を行った1例

    成田 周平, 菊地 覚次, 垣内 慶彦, 黒田 新士, 西崎 正彦, 田辺 俊介, 野間 和広, 寺石 文則, 香川 俊輔, 楳田 祐三, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   MO200 - 7   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡下幽門側胃切除において技術認定医取得は手術成績を改善する

    菊地 覚次, 香川 哲也, 黒田 新士, 西崎 正彦, 垣内 慶彦, 田辺 俊介, 寺石 文則, 野間 和広, 香川 俊輔, 楳田 祐三, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   MO126 - 2   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • Initial introduction of robot-assisted, minimally invasive esophagectomy using the microanatomy-based concept in the upper mediastinum. International journal

    Yasuhiro Shirakawa, Kazuhiro Noma, Tomoyoshi Kunitomo, Masashi Hashimoto, Naoaki Maeda, Shunsuke Tanabe, Kazufumi Sakurama, Toshiyoshi Fujiwara

    Surgical endoscopy   35 ( 12 )   6568 - 6576   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: We have recently standardized upper mediastinal lymph node dissection (UMLND) using a microanatomy-based concept in thoracoscopic esophagectomy in the prone position (TEPP), and introduced robot-assisted minimally invasive esophagectomy (RAMIE) using the same concept as in TEPP while aiming at solo surgery. The purpose of this study was to investigate the outcomes of RAMIE using the microanatomy-based concept in the initial introduction phase. METHODS: We have performed more than 500 TEPP procedures as minimally invasive esophagectomy (MIE). After performing about 400 cases of MIE, we established a microanatomy-based standardization of UMLND. In October 2018, we introduced RAMIE, and have performed 75 procedures in 20 months. Two groups were analyzed: a group after microanatomy-based standardization in TEPP (100 cases after completing 400 cases of TEPP) and a RAMIE group (75 cases). Finally, 51 paired cases were matched using a propensity score. Furthermore, the change in postoperative short-term outcome for RAMIE in the initial introduction phase was analyzed. RESULTS: Although there were no significant differences between the two groups in the number of upper mediastinal lymph nodes dissected, there was a significant decrease (P = 0.036) in intraoperative blood loss volume with RAMIE, representing a definite benefit for patients. The thoracoscopic operative time for RAMIE decreased by almost 100 min following less than 50 cases of experience, reaching the same level as that for recent TEPP, but with only one-tenth the operator experience. There were no significant differences in the total postoperative morbidity rate including the recurrent laryngeal nerve palsy rate. CONCLUSION: RAMIE has been introduced safely and smoothly using the microanatomy-based concept established in TEPP.

    DOI: 10.1007/s00464-020-08154-7

    PubMed

    researchmap

  • Paraesophageal hernia repair can decrease BNP levels. International journal

    Shunsuke Tanabe, Yasuhiro Shirakawa, Naoaki Maeda, Kazufumi Sakurama, Kazuhiro Noma, Toshiyoshi Fujiwara

    Surgical endoscopy   35 ( 12 )   6921 - 6929   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Although the main manifestation of giant paraesophageal hernia (PEH) is disordered meal passage due to gastric torsion, the contents of the hernia sometimes squeeze the heart and lungs and induce the symptoms of respiratory or heart failure. Furthermore, the quality of life (QOL) of patients with a heavy cardiac load deteriorates. In this study, changes in a heart failure marker and symptoms of cases with a giant PEH from before to after laparoscopic surgery were examined. METHODS: Levels of brain natriuretic peptide (BNP) as a heart failure marker were measured before and after radical laparoscopic surgery in cases of type III, IV type of giant PEH. Changes of the symptoms due to heart failure were also investigated. RESULTS: A total of 75 hiatal hernia surgeries were performed in 2012-2019. Of them, 50 had a giant PEH, and 20 (40.0%) had heart failure symptoms such as fatigue and exertional dyspnea. In the giant PEH cases, BNP could be measured before and after surgery to evaluate the presence of heart failure in 23 cases; postoperative BNP levels decreased from the preoperative values in 18 of them. Furthermore, in many cases, chest symptoms also improved. CONCLUSIONS: Radical laparoscopic surgery can reduce heart failure due to giant PEH. Therefore, in addition to conventional surgical indication criteria such as vomiting and food loss, increased cardiac load may be added to the new surgical indication criteria.

    DOI: 10.1007/s00464-020-08202-2

    PubMed

    researchmap

  • Left Hemihepatectomy for Hepatocellular Carcinoma Following Esophagectomy with Retrosternal Gastric Tube Reconstruction for Esophageal Cancer.

    Kosei Takagi, Takashi Kuise, Yuzo Umeda, Ryuichi Yoshida, Kazuhiro Yoshida, Yasuo Nagai, Kazuhiro Noma, Shunsuke Tanabe, Naoaki Maeda, Takahito Yagi, Toshiyoshi Fujiwara

    Acta medica Okayama   75 ( 6 )   755 - 758   2021.12

     More details

    Language:English  

    Approximately 4% of patients with esophageal cancer develop a second primary malignancy in the upper gastrointestinal trunk. However, hepatectomy following esophagectomy for esophageal cancer has rarely been reported. We report the case of a 70-year-old man who underwent an esophagectomy for esophageal cancer with retrosternal gastric tube reconstruction. Nine years later, he developed hepatocellular carcinoma with tumor thrombus involving the left portal vein, and was successfully treated with left hemihepatectomy. Special attention should be paid to avoiding incidental injury of the gastric tube as well as the right gastroepiploic artery during the hepatectomy.

    DOI: 10.18926/AMO/62818

    PubMed

    researchmap

  • Multiple Hepatolithiasis Following Hepaticojejunostomy Successfully Treated with Left Hemihepatectomy and Double Hepaticojejunostomy Reconstruction.

    Yasuo Nagai, Kosei Takagi, Takashi Kuise, Yuzo Umeda, Ryuichi Yoshida, Kazuhiro Yoshida, Kazuya Yasui, Takahito Yagi, Toshiyoshi Fujiwara

    Acta medica Okayama   75 ( 6 )   735 - 739   2021.12

     More details

    Language:English  

    Surgical intervention for hepatolithiasis following hepaticojejunostomy (HJ) has rarely been reported. Herein, we present a case of post-HJ multiple hepatolithiasis treated with left hemihepatectomy with double HJ reconstruction. A 72-year-old woman who had undergone HJ for iatrogenic bile duct injury developed repeated cholangitis due to complicated hepatolithiasis accompanied by an atrophied left hepatic lobe and HJ stricture. Since endoscopic intervention was unsuccessful, the patient underwent left hemihepatectomy with HJ re-anastomoses of the common hepatic duct and left hepatic duct (double HJ technique). The double HJ technique with hepatectomy can be a useful option for treating complicated hepatolithiasis following HJ.

    DOI: 10.18926/AMO/62814

    PubMed

    researchmap

  • Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer. International journal

    Fumitaka Taniguchi, Akihiro Nyuya, Toshiaki Toshima, Kazuya Yasui, Yoshiko Mori, Makoto Okawaki, Hiroyuki Kishimoto, Yuzo Umeda, Toshiyoshi Fujiwara, Hiroaki Tanioka, Yoshiyuki Yamaguchi, Ajay Goel, Takeshi Nagasaka

    Future science OA   7 ( 10 )   FSO757   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Aim: To evaluate whether PCR-reverse sequence-specific oligonucleotide can examine the concordance between liquid biopsy and metastatic lesions with acquired resistance. Materials & methods: We examined acquired mutations in chemoresistant lesions and blood obtained from four patients with RAS wild-type metastatic colorectal cancer who underwent treatment with anti-epidermal growth factor receptor antibodies. Results: In one patient, metastatic lesions harbored diverse acquired mutations in KRAS in all seven metastases; the two acquired mutations were detectable in blood collected after the patient acquired resistance. None of the other patients exhibited liquid biopsy mutations, except one, with a BRAF mutation confirmed in primary tumor and peritoneal dissemination. Conclusion: Liquid biopsy based on PCR-reverse sequence-specific oligonucleotide is a successful procedure for capturing acquired mutations with precise information on the RAS mutational spectrum.

    DOI: 10.2144/fsoa-2021-0059

    PubMed

    researchmap

  • 【conversion surgeryのすべて 切除不能を切除可能に!】切除不能大腸癌肝転移に対するconversion surgery

    楳田 祐三, 高木 弘誠, 藤 智和, 吉田 一博, 安井 和也, 吉田 龍一, 八木 孝仁, 藤原 俊義

    消化器外科   44 ( 13 )   1897 - 1913   2021.12

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • 横行結腸・脾彎曲・下行結腸癌に対する郭清手技と治療成績 脾彎曲 結腸脾彎曲進行癌D3は下腸間膜静脈を軸にする腸間膜化を行うと郭清範囲が明確になる

    矢野 修也, 重安 邦俊, 近藤 喜太, 寺石 文則, 黒田 新士, 菊地 覚次, 吉田 有佑, 垣内 慶彦, 武田 正, 野間 和広, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   PD17 - 3   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 術中ドプラ超音波腹腔鏡により腹腔動脈の乱流と流速を評価した正中弓状靱帯圧迫症候群の1例

    吉田 有佑, 矢野 修也, 菊地 覚次, 高木 弘誠, 高橋 利明, 垣内 慶彦, 武田 正, 重安 邦俊, 近藤 喜太, 黒田 新士, 野間 和広, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   MO073 - 7   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 大腸癌術前Frail評価と腹腔鏡手術 高Frail大腸癌患者に対する周術期管理チーム介入により腹腔鏡手術の安全性は向上したか

    寺石 文則, 成田 周平, 武田 正, 高橋 利明, 吉田 有佑, 重安 邦俊, 矢野 修也, 近藤 喜太, 黒田 新士, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   WS24 - 7   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 術前CAPOX+RTを施行した局所進行直腸癌に対する鏡視下手術成績の検討

    武田 正, 寺石 文則, 高橋 利明, 成田 周平, 吉田 有佑, 垣内 慶彦, 重安 邦俊, 菊地 覚次, 矢野 修也, 近藤 喜太, 黒田 新士, 野間 和広, 楳田 祐三, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   MO206 - 3   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 輪状膵を伴う進行胃癌において術式変更にて術中対応した腹腔鏡補助下幽門側胃切除を施行した1例

    高橋 利明, 垣内 慶彦, 菊地 覚次, 黒田 新士, 武田 正, 矢野 修也, 重安 邦俊, 近藤 喜太, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   MO123 - 9   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 食道胃接合部癌に対する鏡視下手術と再建術:胃外科vs食道外科の立場より 食道食道浸潤が2cmを超える食道胃接合部進行癌に対する胸腔鏡下操作を先行した手術手技

    白川 靖博, 久保田 哲史, 石田 道拡, 丁田 泰宏, 松川 啓義, 井谷 史嗣, 岡島 正純, 塩崎 滋弘, 橋本 将志, 前田 直見, 田辺 俊介, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   SY1 - 5   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 地域基幹病院における高難度鏡視下手術の安全な実践と後進への教育について 地域基幹病院での高難度鏡視下手術に対するCadaver Surgical Trainingの意義

    近藤 喜太, 前田 直見, 矢野 修也, 菊地 覚次, 田辺 俊介, 黒田 新士, 野間 和広, 吉田 龍一, 楳田 祐三, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   CSY11 - 6   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 食道裂孔ヘルニアに対する腹腔鏡下手術 食道裂孔ヘルニアの腹腔鏡下根治手術による心負荷軽減への貢献

    田辺 俊介, 野間 和広, 前田 直見, 菊地 覚次, 黒田 新士, 近藤 喜太, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   WS27 - 6   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 定型的鏡視下食道癌根治術:術後合併症回避のための適切な剥離層を目指して 左反回神経麻痺軽減のための適切な剥離層の確保

    前田 直見, 野間 和広, 菊地 覚次, 黒田 新士, 田辺 俊介, 近藤 喜太, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   PD6 - 3   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 右胸腔アプローチ困難例に対する縦隔鏡下食道切除術の治療成績

    最所 公平, 野間 和広, 前田 直見, 菊地 覚次, 黒田 新士, 田辺 俊介, 近藤 喜太, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   MO251 - 6   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 胸腔鏡手術の利点を活かした食道癌サルベージ手術の治療成績

    松本 聖, 野間 和広, 前田 直見, 菊地 覚次, 黒田 新士, 田辺 俊介, 近藤 喜太, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   MO249 - 3   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • ロボット支援食道切除術の工夫と周術期治療成績 ロボット支援下手術による立体的微細解剖の理解を基礎とした安全で合理的な食道上縦隔郭清術

    野間 和広, 橋本 将志, 最所 公平, 前田 直見, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   26 ( 7 )   WS21 - 5   2021.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases

    Yuzo Umeda, Takeshi Nagasaka, Kosei Takagi, Ryuichi Yoshida, Kazuhiro Yoshida, Tomokazu Fuji, Tatsuo Matsuda, Kazuya Yasui, Kenjiro Kumano, Hiroki Sato, Takahito Yagi, Toshiyoshi Fujiwara

    Langenbeck's Archives of Surgery   2021.11

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    <title>Abstract
    </title><sec>
    <title>Background</title>
    To aid in the oncological management of multiple bilobar colorectal liver metastases (CRLMs), we describe a new surgical procedure, VEssel-Skeletonized PArenchyma-sparing Hepatectomy (VESPAH).


    </sec><sec>
    <title>Study design</title>
    Of 152 patients with CRLMs treated with hepatectomy, 33 patients had multiple bilobar liver metastases (≥8 liver metastases); their surgical procedures and clinical outcomes were retrospectively summarized and compared between those who underwent VESPAH and those who underwent major hepatectomy (Major Hx).


    </sec><sec>
    <title>Results</title>
    Of the 33 patients, 20 patients were resected by VESPAH (the VESPAH group) and 13 patients by major hepatectomy (Major Hx group). The median number of CRLMs was 13 (range, 8–53) in the VESPAH group and 10 (range, 8–41) in the Major Hx group (<italic>P</italic>=0.511). No operative mortality nor severe morbidity was observed in either group. The VESPAH group showed earlier recovery of remnant liver function after surgery than the Major Hx group; the incidence of grade B/C post hepatectomy liver failure was 5% in the VESPAH group and 38% in the Major Hx group, <italic>P</italic>=0.048). Intrahepatic tumor recurrence was confirmed in 14 (70%) and 7 (54%) patients in the VESPAH and Major Hx groups, respectively (<italic>P</italic>=0.416). There was no significant difference in median overall survival (OS) after hepatectomy between the two groups; the median OS was 47 months in the VESPAH group and 33 months in the Major Hx group (<italic>P</italic>=0.481). The VESPAH group showed the higher induction rate of adjuvant chemotherapy within 2 months after surgery (<italic>P</italic>=0.002) and total number of repeat hepatectomy for intrahepatic recurrence (<italic>P</italic>=0.060) than the Major Hx group.


    </sec><sec>
    <title>Conclusions</title>
    VESPAH enables us to clear surgical navigation by hepatic vessel skeletonization and may enhance patient tolerability of not only adjuvant chemotherapy but also repeat hepatectomies during the patients’ lifetimes.


    </sec>

    DOI: 10.1007/s00423-021-02373-9

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s00423-021-02373-9/fulltext.html

  • 胆嚢結石症術後に診断された胃癌の異時性胆嚢転移の1例

    杉本 龍馬, 垣内 慶彦, 黒田 新士, 菊地 覚次, 庄司 良平, 西田 賢司, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会雑誌   54 ( 11 )   788 - 794   2021.11

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    症例は77歳の男性で,検診にて発見された胃癌に対してロボット支援下胃全摘術,D2郭清,Roux-en Y再建術を施行した.術後病理組織学的診断は,pT4a(SE)N3aM0 Stage IIIBであった.術後補助化学療法として,S-1を3コース施行した時点でCEAの上昇を認めたが,画像検査にて明らかな再発を認めなかったため治療を継続し,1年後の補助化学療法終了時には正常値まで低下した.術後26ヵ月経過時に急性胆管炎,胆嚢結石を認めたため,保存的加療後に待機的に腹腔鏡下胆嚢摘出術を行った.術前画像所見や術中所見で胆嚢に特記すべき所見は認めなかったが,術後病理組織学的診断にて,胃癌の胆嚢転移と診断された.極めてまれな胃癌の異時性胆嚢転移の1例を経験したため報告する.(著者抄録)

    researchmap

  • 情熱・努力を継続できる外科教育 外科生涯教育におけるCSTの果たす役割

    近藤 喜太, 前田 直見, 黒田 新士, 信岡 大輔, 武田 正, 重安 邦俊, 菊地 覚次, 矢野 修也, 田辺 俊介, 野間 和広, 楳田 祐三, 寺石 文則, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   122 ( 6 )   674 - 676   2021.11

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 80歳以上高齢者食道癌症例に対する安全性と根治性の両立を目指した外科治療戦略

    田辺 俊介, 野間 和広, 前田 直見, 菊地 覚次, 黒田 新士, 近藤 喜太, 櫻間 教文, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会雑誌   54 ( Suppl.2 )   243 - 243   2021.11

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Application of convolutional neural networks for evaluating the depth of invasion of early gastric cancer based on endoscopic images. International journal

    Kenta Hamada, Yoshiro Kawahara, Takayoshi Tanimoto, Akimitsu Ohto, Akira Toda, Toshiaki Aida, Yasushi Yamasaki, Tatsuhiro Gotoda, Taiji Ogawa, Makoto Abe, Shotaro Okanoue, Kensuke Takei, Satoru Kikuchi, Shinji Kuroda, Toshiyoshi Fujiwara, Hiroyuki Okada

    Journal of gastroenterology and hepatology   2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND AIM: Recently, artificial intelligence (AI) has been used in endoscopic examination and is expected to help in endoscopic diagnosis. We evaluated the feasibility of AI using convolutional neural network (CNN) systems for evaluating the depth of invasion of early gastric cancer (EGC), based on endoscopic images. METHODS: This study used a deep CNN model, ResNet152. From patients who underwent treatment for EGC at our hospital between January 2012 and December 2016, we selected 100 consecutive patients with mucosal (M) cancers and 100 consecutive patients with cancers invading the submucosa (SM cancers). A total of 3508 non-magnifying endoscopic images of EGCs, including white-light imaging, linked color imaging, blue laser imaging-bright, and indigo-carmine dye contrast imaging, were included in this study. A total of 2288 images from 132 patients served as the development dataset, and 1220 images from 68 patients served as the testing dataset. Invasion depth was evaluated for each image and lesion. The majority vote was applied to lesion-based evaluation. RESULTS: The sensitivity, specificity, and accuracy for diagnosing M cancer were 84.9% (95% confidence interval [CI] 82.3%-87.5%), 70.7% (95% CI 66.8%-74.6%), and 78.9% (95% CI 76.6%-81.2%), respectively, for image-based evaluation, and 85.3% (95% CI 73.4%-97.2%), 82.4% (95% CI 69.5%-95.2%), and 83.8% (95% CI 75.1%-92.6%), respectively, for lesion-based evaluation. CONCLUSIONS: The application of AI using CNN to evaluate the depth of invasion of EGCs based on endoscopic images is feasible, and it is worth investing more effort to put this new technology into practical use.

    DOI: 10.1111/jgh.15725

    PubMed

    researchmap

  • Splenic and Peritoneal Metastases with Para-aortic and Virchow Lymph Node Metastases: Late Recurrence of Ovarian Cancer 30 Years after Initial Treatment.

    Kosei Takagi, Takahito Yagi, Toshiyoshi Fujiwara

    JMA journal   4 ( 4 )   428 - 431   2021.10

     More details

  • Early intervention of the perioperative multidisciplinary team approach decreases the adverse events during neoadjuvant chemotherapy for esophageal cancer patients.

    Yasuhiro Shirakawa, Kazuhiro Noma, Naoaki Maeda, Shunsuke Tanabe, Kazufumi Sakurama, Ayumi Sonoyama-Hanaoka, Aiko Yoshitomi, Reiko Kohno-Yamanaka, Yoshihiko Soga, Toshiyoshi Fujiwara

    Esophagus : official journal of the Japan Esophageal Society   18 ( 4 )   797 - 805   2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Multidisciplinary team (MDT) approach has become a standard for perioperative patient care, including in esophageal cancer. In our institution, the Perioperative Management Center (PERiO) has been doing an MDT approach for patients undergoing esophageal cancer surgery since 2009. On the other hand, neoadjuvant therapy has also been becoming standard for many malignancies, including esophageal cancer. In Japan, neoadjuvant chemotherapy (NAC) for esophageal cancer is standard now. However, there have been no reports about when is the best time to start the MDT approach for patients with neoadjuvant therapy. In this study, the best start time for the MDT approach for esophageal cancer patients with NAC was examined from the perspective of adverse events during chemotherapy and perioperative period. METHODS: All cases underwent thoracoscopic esophagectomy in the prone position (TEPP) after NAC. The PERiO Intervention group that started before NAC (n = 100) was compared with the PERiO Intervention group that started after NAC (n = 77). Eventually, 54 paired cases were matched by propensity score matching. RESULTS: The adverse event rate during chemotherapy, especially oral complications, was significantly decreased in the PERiO Intervention started before the NAC group (P = 0.007). Furthermore, weight loss during the period from chemotherapy to surgery was significantly reduced in the group that started before NAC (P = 0.033). CONCLUSION: The MDT approach should be started before NAC in patients undergoing esophageal cancer surgery to prevent adverse events during chemotherapy and provide safe perioperative conditions.

    DOI: 10.1007/s10388-021-00844-y

    PubMed

    researchmap

  • 臓器移植におけるNew Normalを考える 肝移植における免疫抑制のニューノーマル これからの時代を見据えた免疫抑制の最適化

    楳田 祐三, 八木 孝仁, 藤原 俊義

    Organ Biology   28 ( 3 )   56 - 56   2021.10

     More details

    Language:Japanese   Publisher:(一社)日本臓器保存生物医学会  

    researchmap

  • ロボット支援下手術における私の工夫 ロボット支援下手術の導入により見えてきた新たなアプローチ食道癌左上縦隔郭清術

    野間 和広, 最所 公平, 前田 直見, 菊地 覚次, 黒田 新士, 近藤 喜太, 櫻間 教文, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   59回   WS9 - 3   2021.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • Charlson comorbidity indexは80歳高齢者stage IA胃癌の予後因子である

    黒田 新士, 垣内 慶彦, 武田 正, 菊地 覚次, 重安 邦俊, 矢野 修也, 近藤 喜太, 田辺 俊介, 野間 和広, 吉田 龍一, 楳田 祐三, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本癌治療学会学術集会抄録集   59回   O48 - 6   2021.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 切除不能消化器癌に対するconversion surgeryの適応とタイミング 骨盤内臓全摘術が高度進行大腸癌へのコンバージョン手術となるかはRAS statusで決まる

    矢野 修也, 重安 邦俊, 垣内 慶彦, 武田 正, 菊地 覚次, 近藤 喜太, 黒田 新士, 田辺 俊介, 野間 和広, 吉田 龍一, 楳田 祐三, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本癌治療学会学術集会抄録集   59回   WS18 - 4   2021.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 周術期管理における多職種チーム医療 管理栄養士による患者教育プロトコールの胃癌術後体重減少、サルコペニア抑制効果

    今井 祥子, 菊地 覚次, 高田 暢夫, 黒田 新士, 田辺 俊介, 前田 直見, 西崎 正彦, 野間 和広, 香川 俊輔, 楳田 祐三, 縄稚 久美子, 高橋 絢子, 長谷川 祐子, 四方 賢一, 藤原 俊義

    日本癌治療学会学術集会抄録集   59回   WS7 - 6   2021.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 胃切除後食道癌再建のベストプラクティス 結腸vs.空腸 胃を使用できない症例に対する安全で生理的な再建を目指した有茎空腸を用いた食道再建術

    白川 靖博, 桂 佑貴, 石田 道拡, 丁田 泰宏, 矢野 琢也, 佐藤 大祐, 義満 政義, 中野 敢友, 松川 啓義, 井谷 史嗣, 岡島 正純, 塩崎 滋弘, 橋本 将志, 前田 直見, 田辺 俊介, 野間 和広, 藤原 俊義

    日本胸部外科学会定期学術集会   74回   EDB1 - 3   2021.10

     More details

    Language:Japanese   Publisher:(一社)日本胸部外科学会  

    researchmap

  • 岡山大学外科広域外科専門研修プログラム関連病院における専攻医の産前産後休暇・育児休業/休暇・介護休業/休暇、その他支援についての実態調査

    竹原 裕子, 溝尾 妙子, 小林 純子, 菊地 覚次, 池田 宏国, 岡崎 幹生, 吉田 龍一, 黒田 新士, 枝園 忠彦, 小谷 恭弘, 山根 正修, 豊岡 伸一, 笠原 真悟, 土井原 博義, 藤原 俊義

    日本臨床外科学会雑誌   82 ( 増刊 )   S24 - S24   2021.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 局所進行食道がんに対する治療戦略 局所進行食道がんに対するDCF併用放射線療法を用いた治療戦略

    白川 靖博, 橋本 将志, 前田 直見, 田辺 俊介, 野間 和広, 藤原 俊義

    日本癌治療学会学術集会抄録集   59回   SY6 - 3   2021.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 食道胃接合部癌に対する治療戦略 食道胃接合部癌に対する至適術式と術前療法の有用性に関する検討

    田辺 俊介, 野間 和広, 前田 直見, 菊地 覚次, 黒田 新士, 近藤 喜太, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   82 ( 増刊 )   S111 - S111   2021.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 胃切除後食道癌再建のベストプラクティス 結腸vs.空腸 胃を使用できない症例に対する安全で生理的な再建を目指した有茎空腸を用いた食道再建術

    白川 靖博, 桂 佑貴, 石田 道拡, 丁田 泰宏, 矢野 琢也, 佐藤 大祐, 義満 政義, 中野 敢友, 松川 啓義, 井谷 史嗣, 岡島 正純, 塩崎 滋弘, 橋本 将志, 前田 直見, 田辺 俊介, 野間 和広, 藤原 俊義

    日本胸部外科学会定期学術集会   74回   EDB1 - 3   2021.10

     More details

    Language:Japanese   Publisher:(一社)日本胸部外科学会  

    researchmap

  • 食道癌に対するロボット支援下手術 ロボット支援手術の特性を生かした上縦隔郭清手技

    野間 和広, 前田 直見, 菊地 覚次, 田辺 俊介, 近藤 喜太, 黒田 新士, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   82 ( 増刊 )   S318 - S318   2021.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 術前から術後まで幅広くサポートする多職種による食道がん周術期管理

    田辺 俊介, 野間 和広, 前田 直見, 菊地 覚次, 黒田 新士, 近藤 喜太, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   82 ( 増刊 )   S550 - S550   2021.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道癌に対する内視鏡下手術の技術取得と向上 胸腔鏡下食道癌手術の技術習得と向上への取り組み

    前田 直見, 野間 和広, 菊地 覚次, 黒田 新士, 田辺 俊介, 近藤 喜太, 吉田 龍一, 櫻間 教文, 寺石 文則, 白川 靖博, 楳田 祐三, 藤原 俊義

    日本臨床外科学会雑誌   82 ( 増刊 )   S480 - S480   2021.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道癌術後乳糜胸に対する治療マネージメント

    永久 成一, 野間 和広, 前田 直見, 菊地 覚次, 黒田 新士, 田邊 俊介, 近藤 喜太, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   82 ( 増刊 )   S603 - S603   2021.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 高齢者癌に対する外科治療 80歳以上高齢者食道癌症例に対する外科治療戦略

    田辺 俊介, 野間 和広, 前田 直見, 菊地 覚次, 黒田 新士, 近藤 喜太, 櫻間 教文, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   59回   WS13 - 1   2021.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • ロボット支援下手術における私の工夫 ロボット支援下手術の導入により見えてきた新たなアプローチ食道癌左上縦隔郭清術

    野間 和広, 最所 公平, 前田 直見, 菊地 覚次, 黒田 新士, 近藤 喜太, 櫻間 教文, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   59回   WS9 - 3   2021.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 頭頸部・消化器疾患の治療における栄養管理の工夫(外科・内科) 頭頸部癌集学的治療に対する胃瘻を有効に活用した栄養管理確立への道のり

    田辺 俊介, 今井 祥子, 開原 裕子, 長谷川 祐子, 岡野 寛子, 大木 晴美, 三浦 太郎, 金 聖暎, 前田 直見, 菊地 覚次, 野間 和広, 白川 靖博, 四方 賢一, 藤原 俊義

    学会誌JSPEN   3 ( Suppl.1 )   233 - 233   2021.10

     More details

    Language:Japanese   Publisher:(一社)日本臨床栄養代謝学会  

    researchmap

  • Impact of lymph node dissection on clinical outcomes of intrahepatic cholangiocarcinoma: inverse probability of treatment weighting with survival analysis.

    Yuzo Umeda, Toshiharu Mitsuhashi, Toru Kojima, Daisuke Satoh, Kenta Sui, Yoshikatsu Endo, Masaru Inagaki, Masahiro Oishi, Takahito Yagi, Toshiyoshi Fujiwara

    Journal of hepato-biliary-pancreatic sciences   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Lymph node metastasis (LNM) has been established as a critical risk factor for prognosis in intrahepatic cholangiocarcinoma (ICC). The clinical implications of lymph-node dissection (LND) have been debated. This study aimed to clarify the prognostic impact of LND by multicenter-retrospective analysis. METHODS: A total of 310 ICC patients who had undergone curative resection between 2000 and 2016 were retrospectively analyzed. The prognostic impact of LND was estimated under an inverse probability of treatment weighting (IPTW) approach using propensity scores. RESULTS: LND was performed for 224 patients (72%), with LNM pathologically confirmed in 90 patients (40%). Prognosis was poorer for patients with LNM (median survival, 16.9 months) than for those without (57.2 months; p<0.0001). One-, 3-, and 5-year overall survival rates (OS) were comparable among the LND+ (81.6%, 48.0%, and 37.5%, respectively) and the LND- groups (81.6%, 55.4%, and 44.6%, respectively). However, advanced tumor, as characterized by larger tumor, multinodular lesions, and serosal invasion, was significantly more frequent in the LND+ group than in the LND- group. After IPTW adjusting for imbalances, 1-, 3-, and 5-year OS were better in the LND+ group (83.5%, 52.2%, and 42.8%, respectively) than in the LND- group (71.9%, 32.4%, and 23.4%, respectively; p=0.046). LND thus showed significant prognostic impact (hazard ratio = 0.58, 95%CI = |0.39|-|0.84|, p=0.005). Especially in hilar ICC, LND showed significant prognostic impact. However, peripheral ICC displayed no therapeutic benefit from LND. CONCLUSIONS: LND could have significant role to improve oncologic outcomes. Therapeutic LND should be implemented on the basis of tumor location and tumor advancement.

    DOI: 10.1002/jhbp.1038

    PubMed

    researchmap

  • 腫瘍融解アデノウイルスによる治療機序の次なる一手 細胞外小胞を介して全身免疫賦活と局所細胞毒性を誘発するウイルス療法

    垣内 慶彦, 黒田 新士, 金谷 信彦, 公文 剣斗, 津村 朋子, 橋本 将志, 八木 千晶, 杉本 龍馬, 濱田 侑紀, 菊地 覚次, 西崎 正彦, 香川 俊輔, 田澤 大, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   80回   [IS1 - 6]   2021.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression. International journal

    Kazuhisa Sugiu, Hiroshi Tazawa, Joe Hasei, Yasuaki Yamakawa, Toshinori Omori, Tadashi Komatsubara, Yusuke Mochizuki, Hiroya Kondo, Shuhei Osaki, Tomohiro Fujiwara, Aki Yoshida, Toshiyuki Kunisada, Koji Ueda, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    Cancer chemotherapy and pharmacology   88 ( 3 )   513 - 524   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Osteosarcoma (OS) is a malignant bone tumor primarily affecting children and adolescents. The prognosis of chemotherapy-refractory OS patients is poor. We developed a tumor suppressor p53-expressing oncolytic adenovirus (OBP-702) that exhibits antitumor effects against human OS cells. Here, we demonstrate the chemosensitizing effect of OBP-702 in human OS cells. MATERIALS AND METHODS: The in vitro and in vivo antitumor activities of doxorubicin (DOX) and OBP-702 were assessed using parental and DOX-resistant OS cells (U2OS, MNNG/HOS) and a DOX-resistant MNNG/HOS xenograft tumor model. RESULTS: DOX-resistant OS cells exhibited high multidrug resistant 1 (MDR1) expression, which was suppressed by OBP-702 or MDR1 siRNA, resulting in enhanced DOX-induced apoptosis. Compared to monotherapy, OBP-702 and DOX combination therapy significantly suppressed tumor growth in the DOX-resistant MNNG/HOS xenograft tumor model. CONCLUSION: Our results suggest that MDR1 is an attractive therapeutic target for chemoresistant OS. Tumor-specific virotherapy is thus a promising strategy for reversing chemoresistance in OS patients via suppression of MDR1 expression.

    DOI: 10.1007/s00280-021-04310-5

    PubMed

    researchmap

  • これからのハイパーサーミアに向けた研究のトピックス 同所性ヌードマウスモデルにおける腹膜播種に対する磁性体ナノ粒子を用いた温熱療法

    松三 雄騎, 香川 哲也, 矢野 修也, 田澤 大, 重安 邦俊, 武田 正, 大原 利章, 青野 宏通, Hoffman Robert M., 藤原 俊義, 岸本 浩行

    Thermal Medicine   37 ( Suppl. )   S7 - 2   2021.9

     More details

    Language:Japanese   Publisher:(一社)日本ハイパーサーミア学会  

    researchmap

  • テロメラーゼ特異的腫瘍融解アデノウイルス製剤の免疫賦活剤としての有用性と抗PD-1抗体との相乗効果

    橋本 将志, 黒田 新士, 金谷 信彦, 津村 朋子, 垣内 慶彦, 菊地 覚次, 田澤 大, 香川 俊輔, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   80回   [IS10 - 6]   2021.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • Drug repositioningによる新規がん治療の開発に向けて がん関連線維芽細胞由来IL-6の作用と制御

    國友 知義, 野間 和広, 西脇 紀之, 河崎 健人, 小林 照貴, 菊地 覚次, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   80回   [J13 - 3]   2021.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 大腸癌肝転移におけるRNA編集酵素ADAR1発現は肝転移切除後の残肝再発を予測するバイオマーカーになる

    畑 七々子, 重安 邦俊, 高橋 一剛, 梅田 響, 武田 正, 矢野 修也, 楳田 祐三, 田澤 大, 藤原 俊義

    日本分子腫瘍マーカー研究会プログラム・講演抄録   41回   58 - 59   2021.9

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • 高齢者大腸癌患者に対する周術期管理と術後化学療法の現況

    寺石 文則, 武田 正, 矢野 修也, 重安 邦俊, 近藤 喜太, 香川 俊輔, 藤原 俊義

    日本大腸肛門病学会雑誌   74 ( 9 )   A166 - A166   2021.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 食道胃接合部癌に対する外科治療 食道胃接合部癌に対する至適術式と集学的治療に関する後方視的解析

    田辺 俊介, 野間 和広, 前田 直見, 櫻間 教文, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   75回   5 - 5   2021.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 80歳以上の高齢者食道癌症例に対する安全性と根治性を担保した外科治療戦略

    松本 聖, 野間 和広, 前田 直見, 田辺 俊介, 櫻間 教文, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   75回   124 - 124   2021.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌手術後再建方法の工夫 下咽頭喉頭食道全摘における遊離空腸間置胃管再建の検討

    松本 洋, 太田 智之, 野間 和広, 田邊 俊介, 前田 直見, 白川 靖博, 藤原 俊義, 木股 敬裕

    日本食道学会学術集会プログラム・抄録集   75回   42 - 42   2021.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌術後再建胃管切除の諸問題と対策

    白川 靖博, 久保田 哲史, 石田 道拡, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 井谷 史嗣, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   75回   230 - 230   2021.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道外科専門医取得のための各施設の取り組み 食道外科専門医育成に向けた当院の取り組み

    前田 直見, 野間 和広, 田辺 俊介, 櫻間 教文, 白川 靖博, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   75回   33 - 33   2021.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道良性疾患に対する外科的治療の創意工夫 高齢者食道裂孔ヘルニアの安全でQOL改善に貢献する至適な腹腔鏡下根治術

    田辺 俊介, 野間 和広, 前田 直見, 櫻間 教文, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   75回   27 - 27   2021.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌手術における合理的なリンパ節郭清 食道切除における合理的な上縦隔郭清da Vinci導入により見えてきた新たなアプローチ

    野間 和広, 前田 直見, 田辺 俊介, 櫻間 教文, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   75回   23 - 23   2021.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 大腸癌肝転移におけるRNA編集酵素ADAR1発現は肝転移切除後の残肝再発を予測するバイオマーカーになる

    畑 七々子, 重安 邦俊, 高橋 一剛, 梅田 響, 武田 正, 矢野 修也, 楳田 祐三, 田澤 大, 藤原 俊義

    日本分子腫瘍マーカー研究会プログラム・講演抄録   41回   58 - 59   2021.9

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • 腸内細菌が誘導するRNA編集は炎症関連発癌におけるfield cancerizationを促進する

    高橋 一剛, 重安 邦俊, 奥川 喜永, 畑 七々子, 梅田 響, 武田 正, 矢野 修也, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   80回   [IS6 - 6]   2021.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • これからのハイパーサーミアに向けた研究のトピックス 同所性ヌードマウスモデルにおける腹膜播種に対する磁性体ナノ粒子を用いた温熱療法

    松三 雄騎, 香川 哲也, 矢野 修也, 田澤 大, 重安 邦俊, 武田 正, 大原 利章, 青野 宏通, Hoffman Robert M., 藤原 俊義, 岸本 浩行

    Thermal Medicine   37 ( Suppl. )   S7 - 2   2021.9

     More details

    Language:Japanese   Publisher:(一社)日本ハイパーサーミア学会  

    researchmap

  • 高齢者大腸癌患者に対する周術期管理と術後化学療法の現況

    寺石 文則, 武田 正, 矢野 修也, 重安 邦俊, 近藤 喜太, 香川 俊輔, 藤原 俊義

    日本大腸肛門病学会雑誌   74 ( 9 )   A166 - A166   2021.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • テロメラーゼ特異的腫瘍融解アデノウイルス製剤の免疫賦活剤としての有用性と抗PD-1抗体との相乗効果

    橋本 将志, 黒田 新士, 金谷 信彦, 津村 朋子, 垣内 慶彦, 菊地 覚次, 田澤 大, 香川 俊輔, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   80回   [IS10 - 6]   2021.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 肺転移能を有する骨肉腫細胞はM2様マクロファージへの分化を強力に誘導する

    近藤 宏也, 田澤 大, 久禮 美穂, 藤原 智洋, 国定 俊之, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   80回   [J14 - 4]   2021.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • Adult Bochdalek hernia following living donor left hepatectomy repaired by thoracoscopy-assisted surgery: A case report.

    Kosei Takagi, Takashi Kuise, Kazuhiro Yoshida, Ryuichi Yoshida, Yuzo Umeda, Toshiyoshi Fujiwara, Takahito Yagi

    Asian journal of endoscopic surgery   15 ( 1 )   220 - 224   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Bochdalek hernia is a congenital diaphragmatic hernia (DH). Herein, we report a case of adult Bochdalek hernia following living donor hepatectomy repaired by thoracoscopy-assisted surgery. A 36-year-old man underwent living donor left hepatectomy. Four months later, the patient presented with acute epigastric pain. Computed tomography found the left-sided DH in which the stomach was incarcerated into the pleural cavity without ischemic changes. As endoscopic intervention was unsuccessful, the herniated stomach was repositioned by thoracoscopy-assisted surgery. The 3-cm hernia orifice was found to have a smooth edge with no hernia sac, suggesting Bochdalek hernia, and the defect was primarily closed. The patient was followed up for 20 months without hernia recurrence. This is the first presentation of a case of Bochdalek hernia following donor hepatectomy. In cases of early detected DH, primary repair via a transthoracic approach with thoracoscopy-assisted surgery is safe and feasible.

    DOI: 10.1111/ases.12981

    PubMed

    researchmap

  • Robotic Radical Antegrade Modular Pancreatosplenectomy Using the Supracolic Anterior Superior Mesenteric Artery Approach. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Takahito Yagi, Toshiyoshi Fujiwara

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract   25 ( 11 )   3015 - 3018   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Radical antegrade modular pancreatosplenectomy (RAMPS) is the standardized approach in open pancreatic resection for pancreatic body and tail cancer. However, few studies have described regarding robotic RAMPS for pancreatic cancer. We herein present our techniques of robotic RAMPS using the supracolic anterior superior mesenteric artery (SMA) approach with the ventral view. METHODS: The patient was a 75-year-old female with a diagnosis of pancreatic body cancer. Following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel, robotic RAMPS was performed. Our techniques of robotic RAMPS include four steps: (1) gastrocolic ligament division, (2) dissection of superior and inferior border of the pancreas, (3) division of the pancreas, and (4) retroperitoneal dissection. RESULTS: The operative time was 251 min with an estimated blood loss of 10 mL. The uneventful postoperative course was observed. The final pathology confirmed R0 surgical resection. CONCLUSIONS: Robotic RAMPS using the supracolic anterior SMA approach is safe and feasible for pancreatic body and tail cancer. Standardization and precise anatomical knowledge are key elements of performing robotic RAMPS.

    DOI: 10.1007/s11605-021-05112-z

    PubMed

    researchmap

  • 膵・胆管合流異常に対する術後中長期的な経過観察の検討

    熊野 健二郎, 藤 智和, 金平 典之, 佐藤 博紀, 高木 弘誠, 安井 和也, 吉田 一博, 吉田 龍一, 楳田 祐三, 八木 孝仁, 藤原 俊義

    日本膵・胆管合流異常研究会プロシーディングス   44   36 - 36   2021.8

  • 先天性胆道拡張症術後46年目に発生し根治切除が可能であった肝門部胆管癌の1例

    吉田 龍一, 野田 卓男, 安井 和也, 佐藤 博紀, 楳田 祐三, 吉田 一博, 藤 智和, 熊野 健二郎, 高木 弘誠, 金平 典之, 納所 洋, 谷本 光隆, 八木 孝仁, 藤原 俊義

    日本膵・胆管合流異常研究会プロシーディングス   44   42 - 43   2021.8

  • CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment. International journal

    Tomohiro Fujiwara, Mohamed A Yakoub, Andrew Chandler, Alexander B Christ, Guangli Yang, Ouathek Ouerfelli, Vinagolu K Rajasekhar, Aki Yoshida, Hiroya Kondo, Toshiaki Hata, Hiroshi Tazawa, Yildirim Dogan, Malcolm A S Moore, Toshiyoshi Fujiwara, Toshifumi Ozaki, Ed Purdue, John H Healey

    Molecular cancer therapeutics   20 ( 8 )   1388 - 1399   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Colony-stimulating factor 1 (CSF1) is a primary regulator of the survival, proliferation, and differentiation of monocyte/macrophage that sustains the protumorigenic functions of tumor-associated macrophages (TAMs). Considering current advances in understanding the role of the inflammatory tumor microenvironment, targeting the components of the sarcoma microenvironment, such as TAMs, is a viable strategy. Here, we investigated the effect of PLX3397 (pexidartinib) as a potent inhibitor of the CSF1 receptor (CSF1R). PLX3397 was recently approved by the Food and Drug Administration (FDA) to treat tenosynovial giant cell tumor and reprogram TAMs whose infiltration correlates with unfavorable prognosis of sarcomas. First, we confirmed by cytokine arrays of tumor-conditioned media (TCM) that cytokines including CSF1 are secreted from LM8 osteosarcoma cells and NFSa fibrosarcoma cells. The TCM, like CSF1, stimulated ERK1/2 phosphorylation in bone marrow-derived macrophages (BMDMs), polarized BMDMs toward an M2 (TAM-like) phenotype, and strikingly promoted BMDM chemotaxis. In vitro administration of PLX3397 suppressed pERK1/2 stimulation by CSF1 or TCM, and reduced M2 polarization, survival, and chemotaxis in BMDMs. Systemic administration of PLX3397 to the osteosarcoma orthotopic xenograft model significantly suppressed the primary tumor growth and lung metastasis, and thus improved metastasis-free survival. PLX3397 treatment concurrently depleted TAMs and FOXP3+ regulatory T cells and, surprisingly, enhanced infiltration of CD8+ T cells into the microenvironments of both primary and metastatic osteosarcoma sites. Our preclinical results show that PLX3397 has strong macrophage- and T-cell-modulating effects that may translate into cancer immunotherapy for bone and soft-tissue sarcomas.

    DOI: 10.1158/1535-7163.MCT-20-0591

    PubMed

    researchmap

  • Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments. International journal

    Yasuhiro Shirakawa, Hiroshi Tazawa, Shunsuke Tanabe, Nobuhiko Kanaya, Kazuhiro Noma, Takeshi Koujima, Hajime Kashima, Takuya Kato, Shinji Kuroda, Satoru Kikuchi, Shunsuke Kagawa, Kuniaki Katsui, Susumu Kanazawa, Yasuo Urata, Toshiyoshi Fujiwara

    European journal of cancer (Oxford, England : 1990)   153   98 - 108   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: OBP-301 (Telomelysin) is an attenuated type-5 adenovirus that contains the human telomerase reverse transcriptase promoter to regulate viral replication. OBP-301 sensitises human cancer cells to ionising radiation by inhibiting DNA repair, and radiation enhances coxsackievirus and adenovirus receptor-mediated OBP-301 infection on the contrary. We assessed OBP-301 with radiotherapy in oesophageal cancer patients unfit for standard chemoradiation treatments. METHODS: A phase I dose-escalation study of OBP-301 with radiotherapy was conducted in 13 histologically confirmed oesophageal cancer patients deemed unfit to undergo surgery or chemotherapy. Study treatment consisted of OBP-301 administration by intratumoural needle injection using a flexible endoscope on days 1, 18 and 32. Radiotherapy was administered concurrently over 6 weeks, beginning on day 4, to a total of 60 Gy. RESULTS: Of the 13 patients, 7, 3 and 3 patients were treated with 1010, 1011 and 1012 virus particles, respectively. Study group comprised 10 males and 3 females, with a median age of 82 years (range, 53-91 years). All patients developed a transient, self-limited lymphopenia. Distribution studies revealed transient virus shedding in the plasma. Eight patients had local complete response (CR); all of them exhibited no pathologically viable malignant cells in biopsy specimens, and 3 patients had a partial response. The objective response rate was 91.7%. The clinical CR rate was 83.3% in stage I and 60.0% in stage II/III. Histopathological examination revealed massive infiltration of CD8+ cells and increased PD-L1 expression. CONCLUSION: Multiple courses of endoscopic intratumoural OBP-301 injection with radiotherapy are feasible and provide clinical benefits in patients with oesophageal cancer unfit for standard treatments.

    DOI: 10.1016/j.ejca.2021.04.043

    PubMed

    researchmap

  • 【分子標的治療の最前線】ウイルスによるがん治療 食道がんに対するウイルス療法の現状と今後の展望

    藤原 俊義, 田澤 大, 田辺 俊介, 白川 靖博

    腫瘍内科   28 ( 2 )   179 - 184   2021.8

     More details

    Language:Japanese   Publisher:(有)科学評論社  

    researchmap

  • Usefulness of Middle Colic Artery Transposition Technique for Hepatic Arterial Reconstruction in Conversion Surgery for an Initially Unresectable, Locally Advanced Pancreatic Cancer.

    Ryuichi Yoshida, Takahito Yagi, Kazuya Yasui, Yuzo Umeda, Kazuhiro Yoshida, Tomokazu Fuji, Kosei Takagi, Kenjiro Kumano, Masashi Yoshimoto, Toshiyoshi Fujiwara

    Acta medica Okayama   75 ( 4 )   543 - 548   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The outcomes of pancreatectomy with resection and reconstruction of the involved arteries for locally advanced pancreatic cancer following chemotherapy have improved in recent years. In pancreatic head cancers in which there is contact with the common and proper hepatic arteries, margin-negative resection requires pancreati-coduodenectomy, with the resection of these arteries and the restoration of hepatic arterial flow. Here, we describe a middle colic artery transposition technique in hepatic arterial reconstruction during pancreatoduo-denectomy for an initially unresectable locally advanced pancreatic cancer. This technique was effective and may provide a new option for hepatic artery reconstruction in such cases.

    DOI: 10.18926/AMO/62410

    PubMed

    researchmap

  • 骨肉腫における腫瘍関連マクロファージの役割とin vitro実験による検証

    近藤 宏也, 田澤 大, 久禮 美穂, 藤原 智洋, 佐藤 浩平, 畑 利彰, 中田 英二, 国定 俊之, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   95 ( 8 )   S1556 - S1556   2021.8

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • Prediction of Early Recurrence After Surgery for Liver Tumor (ERASL): An International Validation of the ERASL Risk Models. International journal

    Berend R Beumer, Kosei Takagi, Bastiaan Vervoort, Stefan Buettner, Yuzo Umeda, Takahito Yagi, Toshiyoshi Fujiwara, Ewout W Steyerberg, Jan N M IJzermans

    Annals of surgical oncology   28 ( 13 )   8211 - 8220   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: This study aimed to assess the performance of the pre- and postoperative early recurrence after surgery for liver tumor (ERASL) models at external validation. Prediction of early hepatocellular carcinoma (HCC) recurrence after resection is important for individualized surgical management. Recently, the preoperative (ERASL-pre) and postoperative (ERASL-post) risk models were proposed based on patients from Hong Kong. These models showed good performance although they have not been validated to date by an independent research group. METHODS: This international cohort study included 279 patients from the Netherlands and 392 patients from Japan. The patients underwent first-time resection and showed a diagnosis of HCC on pathology. Performance was assessed according to discrimination (concordance [C] statistic) and calibration (correspondence between observed and predicted risk) with recalibration in a Weibull model. RESULTS: The discriminatory power of both models was lower in the Netherlands than in Japan (C statistic, 0.57 [95% confidence interval {CI} 0.52-0.62] vs 0.69 [95% CI 0.65-0.73] for the ERASL-pre model and 0.62 [95% CI 0.57-0.67] vs 0.70 [95% CI 0.66-0.74] for the ERASL-post model), whereas their prognostic profiles were similar. The predictions of the ERASL models were systematically too optimistic for both cohorts. Recalibrated ERASL models improved local applicability for both cohorts. CONCLUSIONS: The discrimination of ERASL models was poorer for the Western patients than for the Japanese patients, who showed good performance. Recalibration of the models was performed, which improved the accuracy of predictions. However, in general, a model that explains the East-West difference or one tailored to Western patients still needs to be developed.

    DOI: 10.1245/s10434-021-10235-3

    PubMed

    researchmap

  • Heterogeneous distribution of Fusobacterium nucleatum in the progression of colorectal cancer. International journal

    Shumpei Yamamoto, Hideaki Kinugasa, Mami Hirai, Hiroyuki Terasawa, Eriko Yasutomi, Shohei Oka, Masayasu Ohmori, Yasushi Yamasaki, Toshihiro Inokuchi, Keita Harada, Sakiko Hiraoka, Kazuhiro Nouso, Takehiro Tanaka, Fuminori Teraishi, Toshiyoshi Fujiwara, Hiroyuki Okada

    Journal of gastroenterology and hepatology   36 ( 7 )   1869 - 1876   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND AIM: Fusobacterium nucleatum (Fn) is involved in colorectal cancer (CRC) growth and is a biomarker for patient prognosis and management. However, the ecology of Fn in CRC and the distribution of intratumoral Fn are unknown. METHODS: We evaluated Fn and the status of KRAS and BRAF in 200 colorectal neoplasms (118 adenomas and 82 cancers) and 149 matched adjacent normal mucosas. The differentiation status between "surface" and "deep" areas of cancer tissue and matched normal mucosa were analyzed in 46 surgical samples; the Ki-67 index was also evaluated in these samples. RESULTS: Fusobacterium nucleatum presence in the tumor increased according to pathological stage (5.9% [adenoma] to 81.8% [stage III/IV]), while Fn presence in normal mucosa also increased (7.6% [adenoma] to 40.9% [stage III/IV]). The detection rates of Fn on the tumor surface and in deep areas were 45.7% and 32.6%, while that of normal mucosa were 26.1% and 23.9%, respectively. Stage III/IV tumors showed high Fn surface area expression (66.7%). Fn intratumoral heterogeneity (34.8%) was higher than that of KRAS (4.3%; P < 0.001) and BRAF (2.2%; P < 0.001). The Ki-67 index in Fn-positive cases was higher than that in negative cases (93.9% vs 89.0%; P = 0.01). CONCLUSIONS: Fusobacterium nucleatum was strongly present in CRC superficial areas at stage III/IV. The presence of Fn in the deep areas of adjacent normal mucosa also increased. The intratumoral heterogeneity of Fn is important in the use of Fn as a biomarker, as Fn is associated with CRC proliferative capacity.

    DOI: 10.1111/jgh.15361

    PubMed

    researchmap

  • 肥満症に対する腹腔鏡下スリーブ状胃切除術の治療成績

    香川 俊輔, 黒田 新士, 菊地 覚次, 垣内 慶彦, 寺石 文則, 矢野 修也, 吉田 龍一, 楳田 祐三, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   76回   P270 - 3   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高齢者胃癌に対する治療の工夫 高齢者Stage IA胃癌の治療適応を考える

    垣内 慶彦, 菊地 覚次, 黒田 新士, 近藤 喜太, 野間 和広, 楳田 祐三, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   WS10 - 6   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • ロボット支援下観音開き法再建の手技上の有用性と注意点

    黒田 新士, 菊地 覚次, 垣内 慶彦, 近藤 喜太, 野間 和広, 楳田 祐三, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   P174 - 7   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Intracorporeal semi-hand-sewn Billroth I reconstruction in total laparoscopic distal gastrectomy.

    Satoru Kikuchi, Shinji Kuroda, Masahiko Nishizaki, Kazuya Kuwada, Nobuo Takata, Yoshihiko Kakiuchi, Shuya Yano, Kazuhiro Noma, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Asian journal of endoscopic surgery   14 ( 3 )   640 - 643   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: Intracorporeal Billroth I (B-I) reconstruction using an endoscopic linear stapler (ELS) is widely performed in total laparoscopic distal gastrectomy. However, conventional procedures require many ELSs for anastomosis. Here, we introduce the novel intracorporeal semi-hand-sewn (SHS) B-I reconstruction. MATERIALS AND SURGICAL TECHNIQUE: After the transection of stomach and duodenum using ELS following adequate lymph node dissection, small entry holes were made on the anterior wall in the greater curvature of the stomach and the duodenal stump. The posterior walls of both the remnant stomach and the duodenum were attached with the ELS and fired to create the posterior wall of the B-I anastomosis. All the transection line of the duodenum and one-third of the transection line of the stomach were dissected; finally the anterior wall suturing at the anastomotic site was performed by the laparoscopic hand-sewn technique. DISCUSSION: SHS procedure was performed for 17 gastric cancer patients. There were no intraoperative complications or conversions to open surgery. One intra-abdominal abscess was observed although there was no anastomotic leakage. The median reconstruction time was 48 minutes (32-63). The SHS procedure was safe, feasible, and economical, although it requires sufficient laparoscopic suturing and ligation skill.

    DOI: 10.1111/ases.12887

    PubMed

    researchmap

  • 高度なHCCの治療を目的とする粒子線治療を先行させた肝移植

    八木 孝仁, 吉田 龍一, 安井 和也, 佐藤 博紀, 楳田 祐三, 吉田 一博, 杭瀬 崇, 高木 弘誠, 藤原 俊義

    日本消化器外科学会総会   76回   P143 - 6   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 肥満症に対する腹腔鏡下スリーブ状胃切除術の治療成績

    香川 俊輔, 黒田 新士, 菊地 覚次, 垣内 慶彦, 寺石 文則, 矢野 修也, 吉田 龍一, 楳田 祐三, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   76回   P270 - 3   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • IBD治療における外科医の役割 Colitis-associated neoplasiaに対する早期治療介入を目指した診療科横断的連携の重要性

    高橋 一剛, 近藤 喜太, 重安 邦俊, 菊地 覚次, 矢野 修也, 黒田 新士, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   O33 - 5   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • スキルス胃癌の制圧に向けての進歩 癌および癌関連線維芽細胞を標的とした胃癌腹膜播種の新規治療戦略

    菊地 覚次, 小川 俊博, 田渕 幹康, 光井 恵麻, 黒田 新士, 野間 和広, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   WS8 - 1   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Frailな高齢者大腸癌患者に対する周術期管理チーム介入後のアウトカムの検証と最近の取り組み

    寺石 文則, 武田 正, 重安 邦俊, 矢野 修也, 近藤 喜太, 黒田 新士, 野間 和広, 楳田 祐三, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   P233 - 7   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 術前診断に苦慮した、稀な形態を呈した胃粘膜下腫瘍の治療経験

    猿渡 和也, 野間 和広, 前田 直見, 菊地 覚次, 田邊 俊介, 黒田 新士, 楳田 祐三, 寺石 文則, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   76回   P230 - 1   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Cadaverトレーニングの現状と課題 岡山大学における過去8年のCSTの傾向から見たCSTプログラム作成における要点

    近藤 喜太, 前田 直見, 黒田 新士, 田辺 俊介, 野間 和広, 楳田 祐三, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   PD1 - 1   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 家庭運営と消化器外科医を両立するリーダーを育てる 男性消化器外科医のワークライフバランス実現に向けて 男性育休を取得した経験から

    坂本 真樹, 黒田 新士, 菊地 覚次, 近藤 喜太, 野間 和広, 楳田 祐三, 寺石 文則, 仁熊 健文, 片岡 正文, 藤原 俊義

    日本消化器外科学会総会   76回   WS1 - 5   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 切除後再発時期・生存期間に着目した膵癌治療成績の検討 今後の治療方向性を探る

    安井 和也, 吉田 龍一, 佐藤 博紀, 楳田 祐三, 吉田 一博, 高木 弘誠, 黒田 新士, 野間 和広, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   P224 - 4   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 膵癌術後再発巣に対する局所療法の有用性の検討

    佐藤 博紀, 吉田 龍一, 安井 和也, 楳田 祐三, 吉田 一博, 高木 弘誠, 黒田 新士, 野間 和広, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   P224 - 3   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 切除可能大腸癌肝転移に対する治療戦略 大腸癌肝転移における術前化学療法の適応選別 RAS/RAF変異による肝外進展リスク

    岡林 弘樹, 楳田 祐三, 吉田 龍一, 吉田 一博, 高木 弘誠, 安井 和也, 黒田 新士, 野間 和広, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   RS24 - 1   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胆管空腸吻合術後の難治性肝内結石症に対する治療経験

    永井 康雄, 杭瀬 崇, 高木 弘誠, 楳田 祐三, 吉田 龍一, 黒田 新士, 野間 和広, 寺石 文則, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   P184 - 5   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • ロボット支援下観音開き法再建の手技上の有用性と注意点

    黒田 新士, 菊地 覚次, 垣内 慶彦, 近藤 喜太, 野間 和広, 楳田 祐三, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   P174 - 7   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 進行膵癌集学的治療における術前血中KRAS遺伝子変異の新規バイオマーカーとしての有用性に関する検討

    吉田 龍一, 安井 和也, 楳田 祐三, 吉田 一博, 高木 弘誠, 佐藤 博紀, 黒田 新士, 野間 和広, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   P167 - 3   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • T4食道癌への最適な治療Strategyの模索 cT4食道癌に対する導入療法後手術症例の検討

    宇根 悠太, 野間 和広, 前田 直見, 田邊 俊介, 菊地 覚次, 黒田 新士, 楳田 祐三, 寺石 文則, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   76回   RS17 - 4   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高齢者食道癌患者に対する治療戦略 高齢者食道癌に対する包括的治療戦略

    前田 直見, 野間 和広, 田辺 俊介, 菊地 覚次, 黒田 新士, 櫻間 教文, 楳田 祐三, 寺石 文則, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   76回   O21 - 3   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 肝細胞癌治療における肝移植の役割 肝癌肝移植の長期予後に向けて 肝移植適応の選別と再発時治療

    楳田 祐三, 吉田 龍一, 吉田 一博, 高木 弘誠, 安井 和也, 黒田 新士, 野間 和広, 香川 俊輔, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   WS20 - 6   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Pittsburgh styleによるロボット支援下膵頭十二指腸切除術 術式の定型化と手技の工夫

    高木 弘誠, 楳田 祐三, 吉田 龍一, 吉田 一博, 安井 和也, 黒田 新士, 野間 和広, 寺石 文則, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   P147 - 4   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高齢者胃癌に対する治療の工夫 高齢者Stage IA胃癌の治療適応を考える

    垣内 慶彦, 菊地 覚次, 黒田 新士, 近藤 喜太, 野間 和広, 楳田 祐三, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   WS10 - 6   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道裂孔ヘルニア、逆流性食道炎に対する外科的治療法 80歳以上の高齢者に対する食道裂孔ヘルニア手術の安全性と有効性の検討

    井上 弘章, 野間 和広, 前田 直見, 菊池 覚次, 田辺 俊介, 黒田 新士, 楳田 祐三, 寺石 文則, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   76回   RS2 - 1   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 局所進行直腸癌における術前FOLFOXIRIおよびCAPOX+RT療法の治療成績

    武田 正, 寺石 文則, 重安 邦俊, 矢野 修也, 近藤 喜太, 黒田 新士, 野間 和広, 楳田 祐三, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   P010 - 2   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 予後を左右する進行大腸癌再発形式の抽出と治療戦略の検討

    重安 邦俊, 矢野 修也, 武田 正, 近藤 喜太, 黒田 新士, 野間 和広, 楳田 祐三, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   P296 - 1   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高齢者に対する肝臓外科治療 高齢者に対する肝切除術前評価における5-Item Modified Frailty Indexの有用性

    吉田 一博, 楳田 祐三, 吉田 龍一, 高木 弘誠, 安井 和也, 黒田 新士, 野間 和広, 香川 俊輔, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   PD5 - 3   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 横行結腸癌手術におけるアプローチ法と至適郭清範囲 横行結腸癌D3郭清範囲の明確化に発生由来の理解が、術式の定型化には大腸、胃、膵臓外科の融合が重要である

    矢野 修也, 重安 邦俊, 近藤 喜太, 寺石 文則, 黒田 新士, 菊地 覚次, 岸本 浩行, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   76回   WS13 - 5   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【上部消化管・こんなときどうする?高難度手術手技をマスターしよう】食道残胃吻合(観音開き法)

    黒田 新士, 西崎 正彦, 菊地 覚次, 野間 和広, 香川 俊輔, 藤原 俊義

    消化器外科   44 ( 8 )   1343 - 1351   2021.7

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • The treatment strategies for esophagogastric junction cancer Retrospective study of induction chemotherapy and surgery for esophagogastric junction cancer(和訳中)

    Tanabe Shunsuke, Noma Kazuhiro, Maeda Naoaki, Kikuchi Satoru, Kuroda Shinji, Sakurama Kazufumi, Umeda Yuzo, Teraishi Fuminori, Shirakawa Yasuhiro, Fujiwara Toshiyoshi

    日本消化器外科学会総会   76回   SY4 - 4   2021.7

     More details

    Language:English   Publisher:(一社)日本消化器外科学会  

    researchmap

  • The progress of minimally invasive surgery for esophageal cancer Standardization of robotic-assisted thoracoscopic esophagectomy(和訳中)

    Noma Kazuhiro, Maeda Naoaki, Kikuchi Satoru, Tanabe Shunsuke, Kuroda Shinji, Sakurama Kazufumi, Teraishi Fuminori, Umeda Yuzo, Shirakawa Yasuhiro, Fujiwara Toshiyoshi

    日本消化器外科学会総会   76回   SY3 - 6   2021.7

     More details

    Language:English   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 術後アミノ酸輸液投与による胃切除後体重・筋肉量減少抑制効果

    梅田 響, 菊地 覚次, 藤原 俊義

    日本消化器外科学会総会   76回   S4 - 4   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【上部消化管・こんなときどうする?高難度手術手技をマスターしよう】食道残胃吻合(観音開き法)

    黒田 新士, 西崎 正彦, 菊地 覚次, 野間 和広, 香川 俊輔, 藤原 俊義

    消化器外科   44 ( 8 )   1343 - 1351   2021.7

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • 切除後再発時期・生存期間に着目した膵癌治療成績の検討 今後の治療方向性を探る

    安井 和也, 吉田 龍一, 佐藤 博紀, 楳田 祐三, 吉田 一博, 高木 弘誠, 黒田 新士, 野間 和広, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   P224 - 4   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 膵癌術後再発巣に対する局所療法の有用性の検討

    佐藤 博紀, 吉田 龍一, 安井 和也, 楳田 祐三, 吉田 一博, 高木 弘誠, 黒田 新士, 野間 和広, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   P224 - 3   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 切除可能大腸癌肝転移に対する治療戦略 大腸癌肝転移における術前化学療法の適応選別 RAS/RAF変異による肝外進展リスク

    岡林 弘樹, 楳田 祐三, 吉田 龍一, 吉田 一博, 高木 弘誠, 安井 和也, 黒田 新士, 野間 和広, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   RS24 - 1   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 進行膵癌集学的治療における術前血中KRAS遺伝子変異の新規バイオマーカーとしての有用性に関する検討

    吉田 龍一, 安井 和也, 楳田 祐三, 吉田 一博, 高木 弘誠, 佐藤 博紀, 黒田 新士, 野間 和広, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   P167 - 3   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 肝細胞癌治療における肝移植の役割 肝癌肝移植の長期予後に向けて 肝移植適応の選別と再発時治療

    楳田 祐三, 吉田 龍一, 吉田 一博, 高木 弘誠, 安井 和也, 黒田 新士, 野間 和広, 香川 俊輔, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   WS20 - 6   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Pittsburgh styleによるロボット支援下膵頭十二指腸切除術 術式の定型化と手技の工夫

    高木 弘誠, 楳田 祐三, 吉田 龍一, 吉田 一博, 安井 和也, 黒田 新士, 野間 和広, 寺石 文則, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   P147 - 4   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高度なHCCの治療を目的とする粒子線治療を先行させた肝移植

    八木 孝仁, 吉田 龍一, 安井 和也, 佐藤 博紀, 楳田 祐三, 吉田 一博, 杭瀬 崇, 高木 弘誠, 藤原 俊義

    日本消化器外科学会総会   76回   P143 - 6   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高齢者に対する肝臓外科治療 高齢者に対する肝切除術前評価における5-Item Modified Frailty Indexの有用性

    吉田 一博, 楳田 祐三, 吉田 龍一, 高木 弘誠, 安井 和也, 黒田 新士, 野間 和広, 香川 俊輔, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   PD5 - 3   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 予後を左右する進行大腸癌再発形式の抽出と治療戦略の検討

    重安 邦俊, 矢野 修也, 武田 正, 近藤 喜太, 黒田 新士, 野間 和広, 楳田 祐三, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   P296 - 1   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 局所進行直腸癌における術前FOLFOXIRIおよびCAPOX+RT療法の治療成績

    武田 正, 寺石 文則, 重安 邦俊, 矢野 修也, 近藤 喜太, 黒田 新士, 野間 和広, 楳田 祐三, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   P010 - 2   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 横行結腸癌手術におけるアプローチ法と至適郭清範囲 横行結腸癌D3郭清範囲の明確化に発生由来の理解が、術式の定型化には大腸、胃、膵臓外科の融合が重要である

    矢野 修也, 重安 邦俊, 近藤 喜太, 寺石 文則, 黒田 新士, 菊地 覚次, 岸本 浩行, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   76回   WS13 - 5   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • IBD治療における外科医の役割 Colitis-associated neoplasiaに対する早期治療介入を目指した診療科横断的連携の重要性

    高橋 一剛, 近藤 喜太, 重安 邦俊, 菊地 覚次, 矢野 修也, 黒田 新士, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   O33 - 5   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Frailな高齢者大腸癌患者に対する周術期管理チーム介入後のアウトカムの検証と最近の取り組み

    寺石 文則, 武田 正, 重安 邦俊, 矢野 修也, 近藤 喜太, 黒田 新士, 野間 和広, 楳田 祐三, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   P233 - 7   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 家庭運営と消化器外科医を両立するリーダーを育てる 男性消化器外科医のワークライフバランス実現に向けて 男性育休を取得した経験から

    坂本 真樹, 黒田 新士, 菊地 覚次, 近藤 喜太, 野間 和広, 楳田 祐三, 寺石 文則, 仁熊 健文, 片岡 正文, 藤原 俊義

    日本消化器外科学会総会   76回   WS1 - 5   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Cadaverトレーニングの現状と課題 岡山大学における過去8年のCSTの傾向から見たCSTプログラム作成における要点

    近藤 喜太, 前田 直見, 黒田 新士, 田辺 俊介, 野間 和広, 楳田 祐三, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   76回   PD1 - 1   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 術前診断に苦慮した、稀な形態を呈した胃粘膜下腫瘍の治療経験

    猿渡 和也, 野間 和広, 前田 直見, 菊地 覚次, 田邊 俊介, 黒田 新士, 楳田 祐三, 寺石 文則, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   76回   P230 - 1   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高齢者食道癌患者に対する治療戦略 高齢者食道癌に対する包括的治療戦略

    前田 直見, 野間 和広, 田辺 俊介, 菊地 覚次, 黒田 新士, 櫻間 教文, 楳田 祐三, 寺石 文則, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   76回   O21 - 3   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道裂孔ヘルニア、逆流性食道炎に対する外科的治療法 80歳以上の高齢者に対する食道裂孔ヘルニア手術の安全性と有効性の検討

    井上 弘章, 野間 和広, 前田 直見, 菊池 覚次, 田辺 俊介, 黒田 新士, 楳田 祐三, 寺石 文則, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   76回   RS2 - 1   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胆管空腸吻合術後の難治性肝内結石症に対する治療経験

    永井 康雄, 杭瀬 崇, 高木 弘誠, 楳田 祐三, 吉田 龍一, 黒田 新士, 野間 和広, 寺石 文則, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   76回   P184 - 5   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • T4食道癌への最適な治療Strategyの模索 cT4食道癌に対する導入療法後手術症例の検討

    宇根 悠太, 野間 和広, 前田 直見, 田邊 俊介, 菊地 覚次, 黒田 新士, 楳田 祐三, 寺石 文則, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   76回   RS17 - 4   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Gastroenteropancreatic neuroendocrine tumor of the accessory papilla of the duodenum: a case report. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Kazuhiro Yoshida, Kazuya Yasui, Hiroki Sato, Takahito Yagi, Toshiyoshi Fujiwara

    Surgical case reports   7 ( 1 )   156 - 156   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Contrary to the increasing incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), GEP-NETs of the accessory papilla of the duodenum are extremely rare. Furthermore, there have been no recommendations regarding the treatment strategy for GEP-NETs of the accessory papilla of the duodenum. We present a case of GEP-NET of the accessory papilla of the duodenum successfully treated with robotic pancreatoduodenectomy. CASE PRESENTATION: A case of a 70-year-old complaining of no symptoms was diagnosed with GEP-NET of the accessory papilla of the duodenum. A 8-mm tumor was located at the submucosal layer with a biopsy demonstrating a neuroendocrine tumor grade 1. The patient underwent robotic pancreatoduodenectomy as curative resection for the tumor. The total operative time was 406 min with an estimated blood loss of 150 mL. The histological examination revealed a well-differentiated neuroendocrine tumor with low Ki-67 index (< 1%). In the posterior areas of the pancreas, the lymph node metastases were detected. The patient was followed up for 6 months with no recurrence postoperatively. CONCLUSIONS: Considering the potential risks of the lymph node metastases, the standard treatment strategy for GEP-NETs of the accessory papilla of the duodenum should be radical resection with pancreatoduodenectomy. Minimally invasive approach can be the alternative to the conventional open surgery.

    DOI: 10.1186/s40792-021-01241-4

    PubMed

    researchmap

  • ASO Visual Abstract: Prediction of Early Hepatocellular Carcinoma Recurrence After Resection-An International Validation of the ERASL Risk Models. International journal

    Berend R Beumer, Kosei Takagi, Bastiaan Vervoort, Stefan Buettner, Yuzo Umeda, Takahito Yagi, Toshiyoshi Fujiwara, Ewout W Steyerberg, Jan N M IJzermans

    Annals of surgical oncology   28 ( Suppl 3 )   505 - 506   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1245/s10434-021-10132-9

    PubMed

    researchmap

  • Immuno-hyperthermia effected by antibody-conjugated nanoparticles selectively targets and eradicates individual cancer cells. International journal

    Tetsuya Kagawa, Yuki Matsumi, Hiromichi Aono, Toshiaki Ohara, Hiroshi Tazawa, Kunitoshi Shigeyasu, Shuya Yano, Sho Takeda, Yasuhiro Komatsu, Robert M Hoffman, Toshiyoshi Fujiwara, Hiroyuki Kishimoto

    Cell cycle (Georgetown, Tex.)   20 ( 13 )   1 - 11   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Hyperthermia has been used for cancer therapy for along period of time, but has shown limited clinical efficacy. Induction-heating hyperthermia using the combination of magnetic nanoparticles (MNPs) and an alternating magnetic field (AMF), termed magnetic hyperthermia (MHT), has previously shown efficacy in an orthotopic mouse model of disseminated gastric cancer. In the present study, superparamagnetic iron oxide nanoparticles (SPIONs), atype of MNP, were conjugated with an anti-HER2 antibody, trastuzumab and termed anti-HER2-antibody-linked SPION nanoparticles (anti-HER2 SPIONs). Anti-HER2 SPIONs selectively targeted HER2-expressing cancer cells co-cultured along with normal fibroblasts and HER2-negative cancer cells and caused apoptosis only in the HER2-expressing individual cancer cells. The results of the present study show proof-of-concept of anovel hyperthermia technology, immuno-MHT for selective cancer therapy, that targets individual cancer cells.AbbreviationsAMF:alternating magnetic fieldDDW:double distilled waterDMEM:Dulbecco's Modified Eagle's Mediumf:frequencyFBS:fetal bovine serumFITC:Fluorescein isothiocyanateGFP:green fluorescent proteinH:amplitudeHsp:heat shock proteinMHT:magnetic hyperthermiaMNPs:magnetic nanoparticlesPI:propidium iodideRFP:red fluorescent proteinSPION:superparamagnetic iron oxide (Fe3O4) nanoparticle.

    DOI: 10.1080/15384101.2021.1915604

    PubMed

    researchmap

  • Preoperative prognostic nutritional index predicts postoperative infectious complications and oncological outcomes after hepatectomy in intrahepatic cholangiocarcinoma. International journal

    Tatsuo Matsuda, Yuzo Umeda, Tadakazu Matsuda, Yoshikatsu Endo, Daisuke Sato, Toru Kojima, Kenta Sui, Masaru Inagaki, Tetsuya Ota, Masayoshi Hioki, Masahiro Oishi, Masashi Kimura, Toshihiro Murata, Nobuhiro Ishido, Takahito Yagi, Toshiyoshi Fujiwara

    BMC cancer   21 ( 1 )   708 - 708   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: In the surgical treatment of intrahepatic cholangiocarcinoma (ICC), postoperative complications may be predictive of long-term survival. This study aimed to identify an immune-nutritional index (INI) that can be used for preoperative prediction of complications. PATIENTS AND METHODS: Multi-institutional data from 316 patients with ICC who had undergone surgical resection were retrospectively analysed, with a focus on various preoperative INIs. RESULTS: Severe complications (Clavien-Dindo grade III-V) were identified in 66 patients (20.8%), including Grade V complications in 7 patients (2.2%). Comparison of areas under the receiver operating characteristic curve (AUCs) among various INIs identified the prognostic nutritional index (PNI) as offering the highest predictive value for severe complications (AUC = 0.609, cut-off = 50, P = 0.008). Multivariate analysis revealed PNI <  50 (odds ratio [OR] = 2.22, P = 0.013), hilar lesion (OR = 2.46, P = 0.026), and long operation time (OR = 1.003, P = 0.029) as independent risk factors for severe complications. In comparing a high-PNI group (PNI ≥ 50, n = 142) and a low-PNI group (PNI <  50, n = 174), the low-PNI group showed higher rates of both major complications (27% vs. 13.4%; P = 0.003) and infectious complications (14.9% vs. 3.5%; P = 0.0021). Furthermore, median survival time and 1- and 5-year overall survival rates were 34.2 months and 77.4 and 33.8% in the low-PNI group, respectively, and 52.4 months and 89.3 and 47.5% in the high-PNI group, respectively (P = 0.0017). CONCLUSION: Preoperative PNI appears useful as an INI correlating with postoperative severe complications and as a prognostic indicator for ICC.

    DOI: 10.1186/s12885-021-08424-0

    PubMed

    researchmap

  • Hyperthermia generated by magnetic nanoparticles for effective treatment of disseminated peritoneal cancer in an orthotopic nude-mouse model. International journal

    Yuki Matsumi, Tetsuya Kagawa, Shuya Yano, Hiroshi Tazawa, Kunitoshi Shigeyasu, Sho Takeda, Toshiaki Ohara, Hiromichi Aono, Robert M Hoffman, Toshiyoshi Fujiwara, Hiroyuki Kishimoto

    Cell cycle (Georgetown, Tex.)   20 ( 12 )   1 - 12   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Magnetic hyperthermia (MHT), which combines magnetic nanoparticles (MNPs) with an alternating magnetic field (AMF), holds promise as a cancer therapy. There have been many studies about hyperthermia, most of which have been performed by direct injection of MNPs into tumor tissues. However, there have been no reports of treating peritoneal disseminated disease with MHT to date. In the present study, we treated peritoneal metastasis of gastric cancer with MHT using superparamagnetic iron oxide (Fe3O4) nanoparticle (SPION) coated with carboxydextran as an MNP, in an orthotopic mouse model mimicking early peritoneal disseminated disease of gastric cancer. SPIONs of an optimal size were intraperitoneally administered, and an AMF (390 kHz, 28 kAm-1) was applied for 10 minutes, four times every three days. Three weeks after the first MHT treatment, the peritoneal metastases were significantly inhibited compared with the AMF-alone group or the untreated-control group. The results of the present study show that MHT can be applied as a new treatment option for disseminated peritoneal gastric cancer.Abbreviations: AMF: alternating magnetic field; Cy1: cytology-positive; DMEM: Dulbecco's Modified Eagle's Medium; FBS: fetal bovine serum; H&E: hematoxylin and eosin; HIPEC: hyperthermic intraperitoneal chemotherapy; MEM: Minimum Essential Medium; MHT: magnetic hyperthermia; MNPs: magnetic nanoparticles; P0: macroscopic peritoneal dissemination; RFP: red fluorescent protein; SPION: superparamagnetic iron oxide (Fe3O4) nanoparticle.

    DOI: 10.1080/15384101.2021.1919441

    PubMed

    researchmap

  • 細胞外小胞がもたらす腫瘍融解アデノウイルス療法の全身性免疫賦活と局所細胞毒性

    垣内 慶彦, 黒田 新士, 津村 朋子, 橋本 将志, 八木 千晶, 杉本 龍馬, 菊地 覚次, 香川 俊輔, 田澤 大, 藤原 俊義

    日本DDS学会学術集会プログラム予稿集   37回   96 - 96   2021.6

     More details

    Language:Japanese   Publisher:日本DDS学会  

    researchmap

  • Accreditation as a qualified surgeon improves surgical outcomes in laparoscopic distal gastrectomy.

    Satoru Kikuchi, Tetsuya Kagawa, Shinji Kuroda, Masahiko Nishizaki, Nobuo Takata, Kazuya Kuwada, Ryohei Shoji, Yoshihiko Kakiuchi, Toshiharu Mitsuhashi, Yuzo Umeda, Kazuhiro Noma, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Surgery today   51 ( 12 )   1978 - 1984   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The Endoscopic Surgical Skill Quantification System for qualified surgeons (QSs) was introduced in Japan to improve surgical outcomes. This study reviewed the surgical outcomes after initial experience performing laparoscopic distal gastrectomy (LDG) and evaluated the improvement in surgical outcomes following accreditation as a QS. METHODS: Eighty-seven consecutive patients who underwent LDG for gastric cancer by a single surgeon were enrolled in this study. The cumulative sum method was used to analyze the learning curve for LDG. The surgical outcomes were evaluated according to the two phases of the learning curve (learning period vs. mastery period) and accreditation (non-QS period vs. QS period). RESULTS: The learning period for LDG was 48 cases. Accreditation was approved at the 67th case. The operation time and estimated blood loss were significantly reduced in the QS period compared to the non-QS period (230 vs. 270 min, p < 0.001; 20.5 vs. 59.8 ml, p = 0.024, respectively). Furthermore, the major complication rate was significantly lower in the QS period than in the non-QS period (0 vs. 10.6%, p = 0.044). CONCLUSIONS: Experience performing approximately 50 cases is required to reach proficiency in LDG. After receiving accreditation as a QS, the surgical outcomes, including the complication rate, were improved.

    DOI: 10.1007/s00595-021-02309-2

    PubMed

    researchmap

  • Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations. International journal

    Takashi Kawai, Akihiro Nyuya, Yoshiko Mori, Takehiro Tanaka, Hiroaki Tanioka, Kazuya Yasui, Toshiaki Toshima, Fumitaka Taniguchi, Kunitoshi Shigeyasu, Yuzo Umeda, Toshiyoshi Fujiwara, Makoto Okawaki, Yoshiyuki Yamaguchi, Ajay Goel, Takeshi Nagasaka

    Clinical epigenetics   13 ( 1 )   117 - 117   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Mutations in the POLE gene result in an ultra-hypermutated phenotype in colorectal cancer (CRC); however, the molecular characterisation of epigenetic alterations remains unclear. We examined the genetic and epigenetic profiles of POLE-mutant CRC to elucidate the clinicopathological features of the associated genetic and epigenetic alterations. RESULTS: Tumour tissues (1,013) obtained from a cohort of patients with CRC were analysed to determine associations between the proofreading domain mutations of POLE with various clinicopathological variables, microsatellite instability (MSI) status, BRAF and KRAS mutations, and the methylation status of key regions of MLH1, MGMT, and SFRP2 promoters by calculating the methylation scores (range 0-6). Only four cases (0.4%) exhibited pathogenic POLE hotspot mutations (two p.P286R [c.857C > G], one p.V411L [c.1231G > C], and p.S459F [c.1376C > T] each), which were mutually exclusive to BRAF and KRAS mutations and MSI. CRC patients were divided into four subgroups: patients with POLE mutations (POLE, 0.4%, n = 4), patients with both MSI and extensive methylation in MLH1 (MSI-M, 2.9%, n = 29), patients with MSI but no extensive methylation in MLH1 (MSI-U, 3.6%, n = 36), and patients without MSI (non-MSI, 93.2%, n = 944). The POLE group was younger at diagnosis (median 52 years, P < 0.0001), with frequent right-sided tumour localisation (frequency of tumours located in the right colon was 100%, 93.1%, 36.1%, and 29.9% in POLE, MSI-M, MSI-U, and non-MSI, respectively; P < 0.0001), and was diagnosed at an earlier stage (frequency of stages I-II was 100%, 72.4%, 77.8%, and 46.6% in POLE, MSI-M, MSI-U, and non-MSI, respectively, P < 0.0001). The mean methylation score in POLE was not different from that in MSI-U and non-MSI, but the methylation signature was distinct from that of the other subgroups. Additionally, although the examined number of POLE-mutant tumours was small, the number of CD8-positive cells increased in tumours with partial methylation in the MLH1 gene. CONCLUSIONS: CRC patients with POLE proofreading mutations are rare. Such mutations are observed in younger individuals, and tumours are primarily located in the right colon. Diagnosis occurs at an earlier stage, and distinct epigenetic alterations may be associated with CD8 cell infiltration.

    DOI: 10.1186/s13148-021-01104-7

    PubMed

    researchmap

  • Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles. International journal

    Yoshihiko Kakiuchi, Shinji Kuroda, Nobuhiko Kanaya, Kento Kumon, Tomoko Tsumura, Masashi Hashimoto, Chiaki Yagi, Ryoma Sugimoto, Yuki Hamada, Satoru Kikuchi, Masahiko Nishizaki, Shunsuke Kagawa, Hiroshi Tazawa, Yasuo Urata, Toshiyoshi Fujiwara

    Molecular therapy : the journal of the American Society of Gene Therapy   29 ( 10 )   2920 - 2930   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Extracellular vesicles (EVs) play important roles in various intercellular communication processes. The abscopal effect is an interesting phenomenon in cancer treatment, in which immune activation is generally considered a main factor. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301), and occasionally observed therapeutic effects on distal tumors after local treatment in immunodeficient mice. Here, we hypothesized that EVs may be involved in the abscopal effect of OBP-301. EVs isolated from the supernatant of HCT116 human colon carcinoma cells treated with OBP-301 were confirmed to contain OBP-301, and showed cytotoxic activity (apoptosis and autophagy) similar to OBP-301. In bilateral subcutaneous HCT116 and CT26 tumor models, intratumoral administration of OBP-301 produced potent antitumor effects on tumors that were not directly treated with OBP-301, involving direct mediation by tumor-derived EVs containing OBP-301. This indicates that immune activation is not the main factor in this abscopal effect. Moreover, tumor-derived EVs exhibited high tumor tropism in orthotopic HCT116 rectal tumors, in which adenovirus E1A and adenovirus type 5 proteins were observed in metastatic liver tumors after localized rectal tumor treatment. In conclusion, local treatment with OBP-301 has the potential to produce abscopal effects via tumor-derived EVs.

    DOI: 10.1016/j.ymthe.2021.05.015

    PubMed

    researchmap

  • SMAD4 Germline Pathogenic Variant-Related Gastric Juvenile Polyposis with Adenocarcinoma Treated with Laparoscopic Total Gastrectomy: A Case Report

    Yuya Sakurai, Satoru Kikuchi, Kunitoshi Shigeyasu, Yoshihiko Kakiuchi, Takehiro Tanaka, Hibiki Umeda, Masaki Sakamoto, Sho Takeda, Shuya Yano, Mashu Futagawa, Fumino Kato, Reimi Sogawa, Hideki Yamamoto, Shinji Kuroda, Yoshitaka Kondo, Fuminori Teraishi, Hiroyuki Kishimoto, Masahiko Nishizaki, Shunsuke Kagawa, Akira Hirasawa, Toshiyoshi Fujiwara

    American Journal of Case Reports   22   2021.5

     More details

    Publishing type:Research paper (scientific journal)   Publisher:International Scientific Information, Inc.  

    DOI: 10.12659/ajcr.932241

    researchmap

  • Long-term survival without recurrence after surgery for gastric yolk sac tumor-like carcinoma: a case report. International journal

    Hibiki Umeda, Satoru Kikuchi, Shinji Kuroda, Shuya Yano, Takehiro Tanaka, Kazuhiro Noma, Masahiko Nishizaki, Shunsuke Kagawa, Yuzo Umeda, Toshiyoshi Fujiwara

    Surgical case reports   7 ( 1 )   111 - 111   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Gastric yolk sac tumor (YST)-like carcinoma is extremely rare, and its prognosis is poor, because most patients have widespread metastases at the time of diagnosis. We report a case of gastric YST-like carcinoma with an adenocarcinoma component without metastases in which curative resection was performed. CASE PRESENTATION: A 77-year-old man complaining of melena and dizziness due to anemia was diagnosed with poorly differentiated adenocarcinoma in the gastric cardia, with a benign ulcer in the gastric body. He underwent total gastrectomy with D2 lymph node dissection for the tumor. Histological examination of the resected specimens revealed a mixture of reticular and glandular neoplastic components morphologically. In the reticular area, an endodermal sinus pattern and some Schiller-Duval bodies were confirmed. Gastric YST-like carcinoma with adenocarcinoma components, T2N0M0 Stage IB, was diagnosed. Immunohistochemical analysis showed that the YST was positive for carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP) and p53. In contrast, the adenocarcinoma was positive for p53 and negative for CEA and AFP. The patient remained healthy as of 7 years postoperatively, with no recurrence. CONCLUSIONS: Routine medical examinations or endoscopic examinations for accidental symptom may be helpful for early diagnosis and good prognosis for gastric YST-like carcinoma, although the prognosis is generally poor.

    DOI: 10.1186/s40792-021-01199-3

    PubMed

    researchmap

  • Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma. International journal

    Yusuke Mochizuki, Hiroshi Tazawa, Koji Demiya, Miho Kure, Hiroya Kondo, Tadashi Komatsubara, Kazuhisa Sugiu, Joe Hasei, Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    Cancer immunology, immunotherapy : CII   70 ( 5 )   1405 - 1417   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Immune checkpoint inhibitors including anti-programmed cell death 1 (PD-1) antibody have recently improved clinical outcome in certain cancer patients; however, osteosarcoma (OS) patients are refractory to PD-1 blockade. Oncolytic virotherapy has emerged as novel immunogenic therapy to augment antitumor immune response. We developed a telomerase-specific replication-competent oncolytic adenovirus OBP-502 that induces lytic cell death via binding to integrins. In this study, we assessed the combined effect of PD-1 blockade and OBP-502 in OS cells. The expression of coxsackie and adenovirus receptor (CAR), integrins αvβ3 and αvβ5, and programmed cell death ligand 1 (PD-L1) was analyzed in two murine OS cells (K7M2, NHOS). The cytopathic activity of OBP-502 in both cells was analyzed using the XTT assay. OBP-502-induced immunogenic cell death was assessed by analyzing the level of extracellular ATP and high-mobility group box protein B1 (HMGB1). Subcutaneous tumor models for K7M2 and NHOS cells were used to evaluate the antitumor effect and number of tumor-infiltrating CD8+ cells in combination therapy. K7M2 and NHOS cells showed high expression of integrins αvβ3 and αvβ5, but not CAR. OBP-502 significantly suppressed the viability of both cells, in which PD-L1 expression and the release of ATP and HMGB1 were significantly increased. Intratumoral injection of OBP-502 significantly augmented the efficacy of PD-1 blockade on subcutaneous K2M2 and NHOS tumor models via enhancement of tumor-infiltrating CD8+  T cells. Our results suggest that telomerase-specific oncolytic virotherapy is a promising antitumor strategy to promote the efficacy of PD-1 blockade in OS.

    DOI: 10.1007/s00262-020-02774-7

    PubMed

    researchmap

  • Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study. International journal

    Shinji Kuroda, Satoru Kikuchi, Yoshihiko Kakiuchi, Megumi Watanabe, Kazuya Kuwada, Tomoko Tsumura, Masahiko Nishizaki, Shunsuke Kagawa, Shiro Hinotsu, Toshiyoshi Fujiwara

    International journal of surgery (London, England)   89   105946 - 105946   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Pharmacologic prophylaxis such as enoxaparin for venous thromboembolism (VTE) is rarely used in Japan, even following abdominal cancer surgery, for which it is recommended in relevant guidelines (at least 7 days of use) along with mechanical prophylaxis with intermittent pneumatic compression. Reasons for enoxaparin's unpopularity include concerns over postoperative bleeding and its inconvenience in clinical practice. Here, we conducted a prospective clinical study of short-term (3 days) use of enoxaparin, which is considered to minimally impact postoperative management without increasing bleeding risk. METHODS: Gastric cancer patients who underwent gastrectomy received enoxaparin for 3 days from postoperative day (POD) 1-4. The primary endpoint was the incidence of deep vein thrombosis (DVT), which was examined primarily via Doppler ultrasonography of the lower limbs between POD 8 and 14. The planned sample size was 70, which was calculated based on an estimated incidence rate of 9% and an upper limit of incidence rate of 20%, with alpha of 0.05 and beta of 0.2. RESULTS: A total of 70 gastric cancer patients were enrolled, and ultimately, 68 patients received the protocol intervention and DVT evaluation. Sixty-seven patients completed 6 enoxaparin injections, but 1 patient did not complete the course due to abdominal bleeding after initiation. The incidence of DVT was 4.4% (3/68), and the 95% upper confidence interval was 12.2%, lower than the 20% threshold we set as the upper limit of DVT incidence. DVT was detected only in the peripheral veins of the lower extremities in all 3 affected patients. The incidence of bleeding-related complications, which were not severe, was 1.5% (1/68). CONCLUSIONS: Short-term (3 days) use of enoxaparin was shown to be effective and safe for VTE prophylaxis, comparable to regular use (at least 7 days), in postoperative management of gastric cancer surgery.

    DOI: 10.1016/j.ijsu.2021.105946

    PubMed

    researchmap

  • 【消化器癌;診断と治療のすべて】消化器癌の診断・病期分類・治療・成績 食道癌 外科治療と成績

    野間 和広, 田辺 俊介, 藤原 俊義

    消化器外科   44 ( 6 )   659 - 666   2021.5

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • 肺癌と直腸癌の同時性重複癌にpembrolizumabが著効した1例

    寺石 文則, 岡 凌也, 武田 正, 高田 暢夫, 重安 邦俊, 菊地 覚次, 矢野 修也, 近藤 喜太, 黒田 新士, 香川 俊輔, 藤原 俊義

    日本大腸肛門病学会雑誌   74 ( 5 )   346 - 346   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis.

    Naohiro Oda, Masahiro Tabata, Masatoshi Uno, Yuzo Umeda, Hironari Kato, Toshio Kubo, Satoru Senoo, Takahito Yagi, Toshiyoshi Fujiwara, Yoshinobu Maeda, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   60 ( 18 )   2967 - 2971   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Mucinous cystic neoplasm (MCN) of the pancreas is a rare cystic tumor occurring in the pancreatic body and tail in young to middle-aged women that is pathologically characterized by an ovarian-like stroma. Chemotherapy for recurrent/advanced pancreatic MCN has been based on chemotherapy regimens for pancreatic ductal adenocarcinoma, but the prognosis is poor. We herein report a 37-year-old woman with pancreatic mucinous cystadenocarcinoma with liver metastasis that responded dramatically to carboplatin plus paclitaxel therapy (CBDCA + PTX). CBDCA + PTX may be a treatment option for recurrent/advanced pancreatic MCN with an ovarian-like stroma.

    DOI: 10.2169/internalmedicine.6730-20

    PubMed

    researchmap

  • Laparoscopic Hepatectomy for the Patient with Hemophilia A with High Titer Factor VIII Inhibitor.

    Tatsuo Matsuda, Yuzo Umeda, Kazuhiro Yoshida, Tadakazu Matsuda, Masatoshi Uno, Masaya Abe, Noboru Asada, Yoshinobu Maeda, Takahito Yagi, Toshiyoshi Fujiwara

    Acta medica Okayama   75 ( 2 )   199 - 204   2021.4

     More details

    Language:English  

    We present the first case of laparoscopic left lateral segmentectomy for hepatocellular carcinoma (HCC) in a patient with hemophilia A, acquired hepatitis C, and high-titer factor VIII inhibitor, which was confirmed by preoperative diagnosis. He underwent laparoscopic left lateral segmentectomy with the administration of recombinant activated factor VII. Surgery could be performed with reduced intraoperative hemorrhage. He experienced postoperative intra-abdominal wall hemorrhage, which was successfully managed with red cell concentrates transfusion and administration of recombinant activated factor VII. Laparoscopic hepatectomy can be applied for hemophilia patients with high titer inhibitors.

    DOI: 10.18926/AMO/61901

    PubMed

    researchmap

  • Long-term Survival with a Rare Advanced Primary Gastrointestinal Malignant Melanoma Treated with Laparoscopic Surgery/Immune Checkpoint Inhibitor.

    Motochika Endo, Shuya Yano, Hiroaki Asano, Sho Takeda, Yuki Hamada, Yoshitaka Kondo, Shinji Kuroda, Kunitoshi Shigeyasu, Satoru Kikuchi, Takehiro Tanaka, Fuminori Teraishi, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Acta medica Okayama   75 ( 2 )   231 - 238   2021.4

     More details

    Language:English  

    Targeted therapies for malignant melanoma have improved patients' prognoses. A primary gastrointestinal malignant melanoma is very rare, with no standard treatment strategy. We treated a 78-year-old Japanese female with advanced primary gastrointestinal melanoma of the descending colon and gallbladder. We administered a multidisciplinary treatment: surgical resection of the descending colon and gallbladder tumors, resection of the metastatic lymph nodes behind the pancreas head, and immune checkpoint antibody-blockade therapy (nivolumab) for ~4 years. PET/CT demonstrated no recurrent lesion for > 3 years. Multidisciplinary therapies (e.g., surgery, chemotherapy, radiotherapy, target therapy, and immune checkpoint antibody-blockade therapy) can successfully treat primary gastrointestinal malignant melanoma.

    DOI: 10.18926/AMO/61906

    PubMed

    researchmap

  • 食道癌におけるこだわりの手術手技 従来の胸腔鏡下手術における上縦隔微細解剖コンセプトを応用したロボット支援下食道悪性腫瘍手術

    白川 靖博, 大下 航, 久保田 哲史, 矢野 琢也, 石田 道拡, 佐藤 太佑, 丁田 泰宏, 吉満 政義, 中野 敢友, 松川 哲義, 井谷 史嗣, 塩崎 滋弘, 岡島 正純, 前田 直見, 田辺 俊介, 野間 和広, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   PD - 3   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • pT3 or pN1以上の局所進行直腸癌に対する術前化学療法の有効性

    武田 正, 寺石 文則, 遠藤 福力, 濱田 侑紀, 畑 七々子, 高橋 一剛, 小松 泰浩, 三村 直毅, 垣内 慶彦, 重安 邦俊, 菊地 覚次, 矢野 修也, 近藤 喜太, 黒田 新士, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   PS - 7   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 再発直腸癌に対するICG蛍光ナビゲーション腹腔鏡下骨盤内臓全摘術

    矢野 修也, 近藤 喜太, 重安 邦俊, 寺石 文則, 菊地 覚次, 黒田 新士, 濱田 侑紀, 遠藤 福力, 武田 正, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SF - 4   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 転移に関わる上皮間葉移行を制御する薬剤スクリーニングシステムの開発と転移予防効果の検討

    岡林 弘樹, 田澤 大, 家田 偉史, 矢野 修也, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 今村 健志, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SF - 3   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 岡山大学外科GRAPESの活動とこれから

    竹原 裕子, 吉田 龍一, 溝尾 妙子, 剱持 礼子, 小林 純子, 新田 薫, 工藤 由里絵, 元木 崇之, 片岡 正文, 池田 宏国, 菊池 覚次, 黒田 新士, 枝園 忠彦, 山根 正修, 小谷 恭弘, 大澤 晋, 土井原 博義, 豊岡 伸一, 笠原 慎悟, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SF - 5   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 腫瘍組織浸潤T細胞は残胃癌の予後予測因子となりえる

    垣内 慶彦, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SF - 4   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科周術期管理におけるサルコペニア対策 患者教育と栄養・運動強化プロトコールが胃癌術後体重減少に与える影響

    高田 暢夫, 菊地 覚次, 黒田 新士, 田辺 俊介, 垣内 慶彦, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   PD - 5   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道胃接合部癌に対する至適な手術術式 Siewert type I/II食道胃接合部癌に対する至適手術 郭清から再建まで

    野間 和広, 赤井 正明, 國友 知義, 西脇 紀之, 前田 直見, 田邊 俊介, 黒田 新士, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SY - 3   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科における多施設臨床試験の意義と方向性 消化器外科における多施設共同研究の意義 地方からのevidence発信を目指して

    楳田 祐三, 黒田 新士, 香川 俊輔, 吉田 龍一, 菊池 覚次, 杭瀬 崇, 吉田 一博, 高木 弘誠, 安井 和也, 西崎 正彦, 八木 孝仁, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   NES - 4   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • がん微小環境内のマクロファージ、好中球を癌の治療標的として解析する

    香川 俊輔, 吉本 匡志, 伊藤 雅典, 坂本 修一, 桑田 和也, 吉田 龍一, 野間 和広, 楳田 祐三, 菊地 覚次, 黒田 新士, 矢野 修也, 重安 邦俊, 寺石 文則, 田澤 大, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SP - 1   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科マネージメントセンターによる情熱のある外科医教育・育成システム

    菊地 覚次, 吉田 龍一, 黒田 新士, 野間 和広, 安井 和也, 笠原 真悟, 豊岡 伸一, 土井原 博義, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SP - 6   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科生涯教育におけるCSTの果たす役割

    近藤 喜太, 前田 直見, 黒田 新士, 信岡 大輔, 武田 正, 重安 邦俊, 菊地 覚次, 矢野 修也, 田辺 俊介, 野間 和広, 楳田 祐三, 寺石 文則, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SP - 4   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科マネージメントセンターによる情熱のある外科医教育・育成システム

    菊地 覚次, 吉田 龍一, 黒田 新士, 野間 和広, 安井 和也, 笠原 真悟, 豊岡 伸一, 土井原 博義, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SP - 6   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • A case of esophageal cancer with an aberrant right subclavian artery treated with mediastinoscopic esophagectomy.

    Masashi Hashimoto, Yasuhiro Shirakawa, Naoaki Maeda, Shunsuke Tanabe, Kazufumi Sakurama, Kazuhiro Noma, Toshiyoshi Fujiwara

    Asian journal of endoscopic surgery   14 ( 2 )   293 - 296   2021.4

     More details

    Language:English  

    An aberrant right subclavian artery (ARSA) is one of the famous anatomical abnormalities with a prevalence of 0.16-4.4%. In esophagectomy, anatomical abnormalities of the ARSA could cause complications with some surgical procedures. An 85-year old man was referred to our department for esophageal adenocarcinoma that was at a slightly high position for esophagectomy with the abdominal approach. However, he had a significant past medical history. This risk factor made it difficult to perform thoracoscopic esophagectomy. He underwent mediastinoscopic esophagectomy (ME) with the left cervical and laparoscopic approach. The ARSA presented no difficulties with the ME surgical technique including the dissection of the left recurrent laryngeal nerve lymph node. Although this patient had a respiratory dysfunction and some difficulties in a prone position, ME enabled a safe esophagectomy with lymph node dissection.

    DOI: 10.1111/ases.12859

    PubMed

    researchmap

  • pT3 or pN1以上の局所進行直腸癌に対する術前化学療法の有効性

    武田 正, 寺石 文則, 遠藤 福力, 濱田 侑紀, 畑 七々子, 高橋 一剛, 小松 泰浩, 三村 直毅, 垣内 慶彦, 重安 邦俊, 菊地 覚次, 矢野 修也, 近藤 喜太, 黒田 新士, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   PS - 7   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 再発直腸癌に対するICG蛍光ナビゲーション腹腔鏡下骨盤内臓全摘術

    矢野 修也, 近藤 喜太, 重安 邦俊, 寺石 文則, 菊地 覚次, 黒田 新士, 濱田 侑紀, 遠藤 福力, 武田 正, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SF - 4   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 転移に関わる上皮間葉移行を制御する薬剤スクリーニングシステムの開発と転移予防効果の検討

    岡林 弘樹, 田澤 大, 家田 偉史, 矢野 修也, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 今村 健志, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SF - 3   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 腫瘍組織浸潤T細胞は残胃癌の予後予測因子となりえる

    垣内 慶彦, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SF - 4   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道癌手術周術期における心合併症の発生とリスク因子の解析

    山田 元彦, 野間 和広, 西脇 紀之, 前田 直見, 田辺 俊介, 菊地 覚次, 櫻間 教文, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SF - 3   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科周術期管理におけるサルコペニア対策 患者教育と栄養・運動強化プロトコールが胃癌術後体重減少に与える影響

    高田 暢夫, 菊地 覚次, 黒田 新士, 田辺 俊介, 垣内 慶彦, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   PD - 5   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • がん微小環境内のマクロファージ、好中球を癌の治療標的として解析する

    香川 俊輔, 吉本 匡志, 伊藤 雅典, 坂本 修一, 桑田 和也, 吉田 龍一, 野間 和広, 楳田 祐三, 菊地 覚次, 黒田 新士, 矢野 修也, 重安 邦俊, 寺石 文則, 田澤 大, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SP - 1   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科生涯教育におけるCSTの果たす役割

    近藤 喜太, 前田 直見, 黒田 新士, 信岡 大輔, 武田 正, 重安 邦俊, 菊地 覚次, 矢野 修也, 田辺 俊介, 野間 和広, 楳田 祐三, 寺石 文則, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SP - 4   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • ハイリスク症例への大腸手術-いかに安全に行うか- ハイリスク高齢者大腸癌への周術期管理チーム介入による術後アウトカムの変化

    寺石 文則, 垣内 慶彦, 武田 正, 重安 邦俊, 矢野 修也, 近藤 喜太, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   WS - 8   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道胃接合部癌に対する至適な手術術式 Siewert type I/II食道胃接合部癌に対する至適手術 郭清から再建まで

    野間 和広, 赤井 正明, 國友 知義, 西脇 紀之, 前田 直見, 田邊 俊介, 黒田 新士, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SY - 3   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科における多施設臨床試験の意義と方向性 消化器外科における多施設共同研究の意義 地方からのevidence発信を目指して

    楳田 祐三, 黒田 新士, 香川 俊輔, 吉田 龍一, 菊池 覚次, 杭瀬 崇, 吉田 一博, 高木 弘誠, 安井 和也, 西崎 正彦, 八木 孝仁, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   NES - 4   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 切除不能局所進行食道癌に対するDCFを軸にした集学的治療による根治への挑戦

    田辺 俊介, 野間 和広, 國友 知義, 前田 直見, 櫻間 教文, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SF - 8   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • ハイリスク食道癌手術症例に対する包括的治療戦略

    前田 直見, 野間 和広, 國友 知義, 田辺 俊介, 櫻間 教文, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SF - 8   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • T1/T2膵癌の術前治療適応に関する検討 多施設共同後方視的研究

    吉田 龍一, 日置 勝義, 須井 健太, 佐藤 太佑, 児島 亨, 國府島 健, 安井 和也, 八木 孝仁, 藤原 俊義

    日本外科学会定期学術集会抄録集   121回   SF - 2   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Nanog is a promising chemo-resistant stemness marker and therapeutic target by iron chelators for esophageal cancer. International journal

    Toru Narusaka, Toshiaki Ohara, Kazuhiro Noma, Noriyuki Nishiwaki, Yuki Katsura, Takuya Kato, Hiroaki Sato, Yasuko Tomono, Satoru Kikuchi, Hiroshi Tazawa, Yasuhiro Shirakawa, Akihiro Matsukawa, Toshiyoshi Fujiwara

    International journal of cancer   149 ( 2 )   347 - 357   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Esophageal cancer is a disease showing poor prognosis. Although combination chemotherapy using cisplatin and 5-fluorouracil is standard for unresectable esophageal cancer, the response rate is 35%. Cancer stem cells (CSCs) and inflammation are reportedly responsible for the poor prognosis of esophageal cancer. However, comprehensive analyses have not been conducted and proposals for progress remain lacking. Iron is known to be a key factor in the stemness of CSCs. This study focused on the therapeutic potential of iron control using iron chelators for CSCs in esophageal cancer. Among 134 immunohistochemically analyzed cases, Nanog expression was high in 98 cases and low in 36 cases. High Nanog expression correlated with low overall and disease-free survivals. The iron chelators deferasirox (DFX) and SP10 suppressed the proliferation and expression of stemness markers in TE8 and OE33 cells. DFX and SP10 did not induce compensatory interleukin (IL)-6 secretion, although cisplatin did result in high induction. Moreover, BBI608 and SSZ, as other CSC-targeting drugs, could not suppress the expression of stemness markers. Together, Nanog expression appears related to poor prognosis in esophageal cancer patients, and inhibition of stemness and compensatory IL-6 secretion by iron chelators may offer a novel therapeutic strategy for esophageal cancer.

    DOI: 10.1002/ijc.33544

    PubMed

    researchmap

  • Role of Tumor-Associated Macrophages in Sarcomas. International journal

    Tomohiro Fujiwara, John Healey, Koichi Ogura, Aki Yoshida, Hiroya Kondo, Toshiaki Hata, Miho Kure, Hiroshi Tazawa, Eiji Nakata, Toshiyuki Kunisada, Toshiyoshi Fujiwara, Toshifumi Ozaki

    Cancers   13 ( 5 )   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Sarcomas are complex tissues in which sarcoma cells maintain intricate interactions with their tumor microenvironment. Tumor-associated macrophages (TAMs) are a major component of tumor-infiltrating immune cells in the tumor microenvironment and have a dominant role as orchestrators of tumor-related inflammation. TAMs promote tumor growth and metastasis, stimulate angiogenesis, mediate immune suppression, and limit the antitumor activity of conventional chemotherapy and radiotherapy. Evidence suggests that the increased infiltration of TAMs and elevated expression of macrophage-related genes are associated with poor prognoses in most solid tumors, whereas evidence of this in sarcomas is limited. Based on these findings, TAM-targeted therapeutic strategies, such as inhibition of CSF-1/CSF-1R, CCL2/CCR2, and CD47/SIRPα, have been developed and are currently being evaluated in clinical trials. While most of the therapeutic challenges that target sarcoma cells have been unsuccessful and the prognosis of sarcomas has plateaued since the 1990s, several clinical trials of these strategies have yielded promising results and warrant further investigation to determine their translational benefit in sarcoma patients. This review summarizes the roles of TAMs in sarcomas and provides a rationale and update of TAM-targeted therapy as a novel treatment approach for sarcomas.

    DOI: 10.3390/cancers13051086

    PubMed

    researchmap

  • 胃癌治療における栄養治療戦略 患者教育プログラムが胃癌術後の体および骨格筋量の変化に及ぼす影響(Effect of patient education protocol on body weight and skeletal muscle reduction after gastrectomy)

    高田 暢夫, 菊地 覚次, 黒田 新士, 垣内 慶彦, 田辺 俊介, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   93回   216 - 216   2021.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 観音開き法再建の技術的進化 更なる患者QOLの向上を目指して(Technical evolution of the double-flap reconstruction for further improvement of patient's QOL)

    黒田 新士, 西崎 正彦, 菊地 寛次, 垣内 慶彦, 武田 正, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   93回   300 - 300   2021.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 【胆膵領域のロボット支援下手術:ベストプラックティスを求めて】海外におけるロボット支援下膵頭十二指腸切除の現状

    高木 弘誠, 楳田 祐三, 吉田 龍一, 八木 孝仁, 藤原 俊義

    胆と膵   42 ( 3 )   217 - 221   2021.3

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    近年、内視鏡手術は肝胆膵外科領域で急速に普及しつつあり、高難度手術の膵頭十二指腸切除術においても腹腔鏡手術が定着し今後はロボット支援下手術への展開が期待されている。一方、欧米では、世界に先駆けてロボット支援下膵切除が導入され、とくに膵頭部領域の良性・悪性疾患に対するロボット支援下膵頭十二指腸切除(robotic pancreatoduodenectomy:RPD)は、その安全性と有効性の報告とともに、近年は腹腔鏡手術を凌駕して増加傾向にある。本邦においてもロボット支援下膵切除術が保険収載されたが、RPDの安全な導入には、肝胆膵外科手術の豊富な経験に加え、ロボット支援下手術の特性に精通する必要があるため、術前の系統的トレーニングが重要である。海外におけるわれわれの経験を基に、RPDの現状、トレーニングシステム、手術成績に関して報告する。(著者抄録)

    researchmap

  • 【「課題解決型医療人養成プログラム「国内初の、肝移植を担う医療人養成-6大学連携プログラム-」の成果」】SNUC-LT Program外科履修生の成果と課題、キャリアパス形成

    高木 弘誠, 杭瀬 崇, 楳田 祐三, 藤原 俊義, 八木 孝仁

    移植   55 ( 4 )   361 - 369   2021.3

  • 食道疾患に対する低侵襲手術(Current status and perspective of minimally invasive surgery for esophageal cancer)

    Shirakawa Yasuhiro, Noma Kazuhiro, Tanabe Shunsuke, Maeda Naoaki, Kawasaki Kento, Kunitomo Tomoyoshi, Nishie Naoki, Yamada Motohiko, Kikuchi Satoru, Kuroda Shinji, Nishizaki Masahiko, Kagawa Shunsuke, Fujiwara Toshiyoshi

    日本内視鏡外科学会雑誌   25 ( 7 )   SY6 - 5   2021.3

     More details

    Language:English   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 術前療法が直腸癌鏡視下手術に与える短期、長期治療成績の検討

    武田 正, 畑 七々子, 高橋 一剛, 小松 泰浩, 三村 直毅, 垣内 慶彦, 重安 邦俊, 菊地 覚次, 矢野 修也, 近藤 喜太, 黒田 新士, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   25 ( 7 )   DP77 - 3   2021.3

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡下胃全摘術および噴門側胃切除術における再建法 腹腔鏡下噴門側胃切除術における観音開き法食道残胃吻合

    西崎 正彦, 黒田 新士, 菊地 覚次, 垣内 慶彦, 香川 俊輔, 前田 直見, 田邊 俊介, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   25 ( 7 )   SY12 - 3   2021.3

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • カダバーサージカルトレーニングにおける遠隔手術指導の実際

    近藤 喜太, 前田 直見, 菊地 覚次, 矢野 修也, 黒田 新士, 野間 和弘, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   25 ( 7 )   BSP4 - 4   2021.3

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 岡山大学における消化器外科領域鏡視下カダバートレーニングの現状と未来

    近藤 喜太, 前田 直見, 黒田 新士, 楳田 祐三, 矢野 修也, 菊地 覚次, 田辺 俊介, 野間 和広, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   25 ( 7 )   SP9 - 1   2021.3

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 観音開き法再建の技術的進化 更なる患者QOLの向上を目指して(Technical evolution of the double-flap reconstruction for further improvement of patient's QOL)

    黒田 新士, 西崎 正彦, 菊地 寛次, 垣内 慶彦, 武田 正, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   93回   300 - 300   2021.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 進行・再発胃癌に対するNivolumabの実臨床での治療成績(Clinical Outcome of Nivolumab for Advanced or Recurrent Gastric Cancer)

    香川 俊輔, 黒田 新士, 菊地 覚次, 西崎 正彦, 野間 和広, 田辺 俊介, 重安 邦俊, 前田 直見, 垣内 慶彦, 武田 正, 近藤 喜太, 矢野 修也, 寺石 文則, 藤原 俊義

    日本胃癌学会総会記事   93回   284 - 284   2021.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 癌細胞および癌関連線維芽細胞を標的とした腹腔内ウイルス療法(Intraperitoneal oncolytic virotherapy targeting cancer cells and cancer-associated fibroblasts)

    菊地 覚次, 小川 俊博, 田渕 幹康, 黒田 新士, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   93回   246 - 246   2021.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 胃癌治療における栄養治療戦略 患者教育プログラムが胃癌術後の体および骨格筋量の変化に及ぼす影響(Effect of patient education protocol on body weight and skeletal muscle reduction after gastrectomy)

    高田 暢夫, 菊地 覚次, 黒田 新士, 垣内 慶彦, 田辺 俊介, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   93回   216 - 216   2021.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • Minimally invasive approach for gastric SMT depending on the characteristics of tumor(和訳中)

    Kikuchi Satoru, Nishizaki Masahiko, Kuroda Shinji, Takata Nobuhiko, Takeda Sho, Kakiuchi Yoshihiko, Sugimoto Ryoma, Kagawa Shunsuke, Shirakawa Yasuhiro, Fujiwara Toshiyoshi

    日本内視鏡外科学会雑誌   25 ( 7 )   OS55 - 6   2021.3

     More details

    Language:English   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 胃癌に対する内視鏡外科手術手技の工夫(Present position and future possibility of the double-flap reconstruction after proximal gastrectomy)

    Kuroda Shinji, Nishizaki Masahiko, Choda Yasuhiro, Ishida Michihiro, Muraoka Atsushi, Tanaka Norimitsu, Hato Shinji, Kikuchi Satoru, Takata Nobuo, Kakiuchi Yoshihiko, Tanabe Shunsuke, Noma Kazuhiro, Kagawa Shunsuke, Shirakawa Yasuhiro, Kamikawa Yasuaki, Fujiwara Toshiyoshi

    日本内視鏡外科学会雑誌   25 ( 7 )   WS33 - 7   2021.3

     More details

    Language:English   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 進行・再発胃癌に対するNivolumabの実臨床での治療成績(Clinical Outcome of Nivolumab for Advanced or Recurrent Gastric Cancer)

    香川 俊輔, 黒田 新士, 菊地 覚次, 西崎 正彦, 野間 和広, 田辺 俊介, 重安 邦俊, 前田 直見, 垣内 慶彦, 武田 正, 近藤 喜太, 矢野 修也, 寺石 文則, 藤原 俊義

    日本胃癌学会総会記事   93回   284 - 284   2021.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 術前療法が直腸癌鏡視下手術に与える短期、長期治療成績の検討

    武田 正, 畑 七々子, 高橋 一剛, 小松 泰浩, 三村 直毅, 垣内 慶彦, 重安 邦俊, 菊地 覚次, 矢野 修也, 近藤 喜太, 黒田 新士, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   25 ( 7 )   DP77 - 3   2021.3

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 岡山大学における消化器外科領域鏡視下カダバートレーニングの現状と未来

    近藤 喜太, 前田 直見, 黒田 新士, 楳田 祐三, 矢野 修也, 菊地 覚次, 田辺 俊介, 野間 和広, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   25 ( 7 )   SP9 - 1   2021.3

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • カダバーサージカルトレーニングにおける遠隔手術指導の実際

    近藤 喜太, 前田 直見, 菊地 覚次, 矢野 修也, 黒田 新士, 野間 和弘, 寺石 文則, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   25 ( 7 )   BSP4 - 4   2021.3

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • Surgical training model and safe implementation of robotic pancreatoduodenectomy in Japan: a technical note. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Takahito Yagi, Toshiyoshi Fujiwara, Amer H Zureikat, Melissa E Hogg, Bas Groot Koerkamp

    World journal of surgical oncology   19 ( 1 )   55 - 55   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Growing evidence for the advantages of robotic pancreatoduodenectomy (RPD) has been demonstrated internationally. However, there has been no structured training program for RPD in Japan. Herein, we present the surgical training model of RPD and a standardized protocol for surgical technique. METHODS: The surgical training model and surgical technique were standardized in order to implement RPD safely, based on the Dutch training system collaborated with the University of Pittsburgh Medical Center. RESULTS: The surgical training model included various trainings such as basic robotic training, simulation training, biotissue training, and a surgical video review. Furthermore, a standardized protocol on the surgical technique was established to understand the tips, tricks, and pitfalls of RPD. CONCLUSIONS: Safe implementation of RPD can be achieved through the completion of a structured training program and learning surgical technique. A nationwide structured training system should be developed to implement the program safely in Japan.

    DOI: 10.1186/s12957-021-02167-9

    PubMed

    researchmap

  • Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis. International journal

    Hiroki Kajioka, Shunsuke Kagawa, Atene Ito, Masashi Yoshimoto, Shuichi Sakamoto, Satoru Kikuchi, Shinji Kuroda, Ryuichi Yoshida, Yuzo Umeda, Kazuhiro Noma, Hiroshi Tazawa, Toshiyoshi Fujiwara

    Cancer letters   497   1 - 13   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Surgery is the only curative treatment option for pancreatic cancer, but patients often develop postoperative recurrence. Surgical invasiveness might be involved in the mechanism of recurrence. The associations among inflammation caused by surgery, neutrophils, and cancer metastasis were investigated. At first, neutrophil extracellular traps (NETs) were examined in clinical specimens, and NETs were observed around metastatic tumors. To explore how NETs were induced, neutrophils were cultured with pancreatic cancer or in cancer-conditioned medium. Neutrophils formed NETs when they were cultured with pancreatic cancer or even its conditioned medium. The effects of NETs on cancer cells were further investigated in vitro and in vivo. NETs induced the epithelial to mesenchymal transition in cancer cells and thereby promoted their migration and invasion. HMGB1 derived from NETs appeared to potentiate the malignancy of cancer cells. In a mouse model of liver metastasis with inflammation, NETs participated in the metastatic process by enhancing extravasation. Interestingly, thrombomodulin degraded HMGB1 and consequently inhibited the induction of NETs, thereby preventing pancreatic cancer metastasis to the liver. In conclusion, NETs interact reciprocally with pancreatic cancer cells, which play a pivotal role in inflammation-associated metastasis. Targeting NETs with thrombomodulin can be a novel strategy to improve the surgical outcome of pancreatic cancer patients.

    DOI: 10.1016/j.canlet.2020.10.015

    PubMed

    researchmap

  • Extracellular vesicles shed from gastric cancer mediate protumor macrophage differentiation. International journal

    Atene Ito, Shunsuke Kagawa, Shuichi Sakamoto, Kazuya Kuwada, Hiroki Kajioka, Masashi Yoshimoto, Satoru Kikuchi, Shinji Kuroda, Ryuichi Yoshida, Hiroshi Tazawa, Toshiyoshi Fujiwara

    BMC cancer   21 ( 1 )   102 - 102   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Peritoneal dissemination often develops in gastric cancer. Tumor-associated macrophages (TAMs) are present in the peritoneal cavity of gastric cancer patients with peritoneal dissemination, facilitating tumor progression. However, the mechanism by which macrophages differentiate into tumor-associated macrophages in the peritoneal cavity is not well understood. In this study, the interplay between gastric cancer-derived extracellular vesicles (EVs) and macrophages was investigated. METHODS: The association between macrophages and EVs in peritoneal ascitic fluid of gastric cancer patients, or from gastric cancer cell lines was examined, and their roles in differentiation of macrophages and potentiation of the malignancy of gastric cancer were further explored. RESULTS: Immunofluorescent assays of the ascitic fluid showed that M2 macrophages were predominant along with the cancer cells in the peritoneal cavity. EVs purified from gastric cancer cells, as well as malignant ascitic fluid, differentiated peripheral blood mononuclear cell-derived macrophages into the M2-like phenotype, which was demonstrated by their morphology and expression of CD163/206. The macrophages differentiated by gastric cancer-derived EVs promoted the migration ability of gastric cancer cells, and the EVs carried STAT3 protein. CONCLUSION: EVs derived from gastric cancer play a role by affecting macrophage phenotypes, suggesting that this may be a part of the underlying mechanism that forms the intraperitoneal cancer microenvironment.

    DOI: 10.1186/s12885-021-07816-6

    PubMed

    researchmap

  • Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer. International journal

    Ryoichi Katsube, Kazuhiro Noma, Toshiaki Ohara, Noriyuki Nishiwaki, Teruki Kobayashi, Satoshi Komoto, Hiroaki Sato, Hajime Kashima, Takuya Kato, Satoru Kikuchi, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Hisataka Kobayashi, Toshiyoshi Fujiwara

    Scientific reports   11 ( 1 )   1693 - 1693   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cancer-associated fibroblasts (CAFs) have an important role in the tumor microenvironment. CAFs have the multifunctionality which strongly support cancer progression and the acquisition of therapeutic resistance by cancer cells. Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that uses a highly selective monoclonal antibody (mAb)-photosensitizer conjugate. We developed fibroblast activation protein (FAP)-targeted NIR-PIT, in which IR700 was conjugated to a FAP-specific antibody to target CAFs (CAFs-targeted NIR-PIT: CAFs-PIT). Thus, we hypothesized that the control of CAFs could overcome the resistance to conventional chemotherapy in esophageal cancer (EC). In this study, we evaluated whether EC cell acquisition of stronger malignant characteristics and refractoriness to chemoradiotherapy are mediated by CAFs. Next, we assessed whether the resistance could be rescued by eliminating CAF stimulation by CAFs-PIT in vitro and in vivo. Cancer cells acquired chemoradiotherapy resistance via CAF stimulation in vitro and 5-fluorouracil (FU) resistance in CAF-coinoculated tumor models in vivo. CAF stimulation promoted the migration/invasion of cancer cells and a stem-like phenotype in vitro, which were rescued by elimination of CAF stimulation. CAFs-PIT had a highly selective effect on CAFs in vitro. Finally, CAF elimination by CAFs-PIT in vivo demonstrated that the combination of 5-FU and NIR-PIT succeeded in producing 70.9% tumor reduction, while 5-FU alone achieved only 13.3% reduction, suggesting the recovery of 5-FU sensitivity in CAF-rich tumors. In conclusion, CAFs-PIT could overcome therapeutic resistance via CAF elimination. The combined use of novel targeted CAFs-PIT with conventional anticancer treatments can be expected to provide a more effective and sensible treatment strategy.

    DOI: 10.1038/s41598-021-81465-4

    PubMed

    researchmap

  • Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment. International journal

    Shuya Yano, Hiroshi Tazawa, Hiroyuki Kishimoto, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert M Hoffman

    International journal of molecular sciences   22 ( 2 )   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Oncolytic virotherapy is one of the most promising, emerging cancer therapeutics. We generated three types of telomerase-specific replication-competent oncolytic adenovirus: OBP-301; a green fluorescent protein (GFP)-expressing adenovirus, OBP-401; and Killer-Red-armed OBP-301. These oncolytic adenoviruses are driven by the human telomerase reverse transcriptase (hTERT) promoter; therefore, they conditionally replicate preferentially in cancer cells. Fluorescence imaging enables visualization of invasion and metastasis in vivo at the subcellular level; including molecular dynamics of cancer cells, resulting in greater precision therapy. In the present review, we focused on fluorescence imaging applications to develop precision targeting for oncolytic virotherapy. Cell-cycle imaging with the fluorescence ubiquitination cell cycle indicator (FUCCI) demonstrated that combination therapy of an oncolytic adenovirus and a cytotoxic agent could precisely target quiescent, chemoresistant cancer stem cells (CSCs) based on decoying the cancer cells to cycle to S-phase by viral treatment, thereby rendering them chemosensitive. Non-invasive fluorescence imaging demonstrated that complete tumor resection with a precise margin, preservation of function, and prevention of distant metastasis, was achieved with fluorescence-guided surgery (FGS) with a GFP-reporter adenovirus. A combination of fluorescence imaging and laser ablation using a KillerRed-protein reporter adenovirus resulted in effective photodynamic cancer therapy (PDT). Thus, imaging technology and the designer oncolytic adenoviruses may have clinical potential for precise cancer targeting by indicating the optimal time for administering therapeutic agents; accurate surgical guidance for complete resection of tumors; and precise targeted cancer-specific photosensitization.

    DOI: 10.3390/ijms22020879

    PubMed

    researchmap

  • Prognostic Utility of the Glasgow Prognostic Score for the Long-Term Outcomes After Liver Resection for Intrahepatic Cholangiocarcinoma: A Multi-institutional Study. International journal

    Kenta Sui, Takehiro Okabayashi, Yuzo Umeda, Masahiro Oishi, Toru Kojima, Daisuke Sato, Yoshikatsu Endo, Tetsuya Ota, Katsuyoshi Hioki, Masaru Inagaki, Tadakazu Matsuda, Ryuji Hirai, Masashi Kimura, Takahito Yagi, Toshiyoshi Fujiwara

    World journal of surgery   45 ( 1 )   279 - 290   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The usefulness of the modified Glasgow prognostic score (GPS) as a prognostic tool remains unclear for patients undergoing curative surgery for intrahepatic cholangiocarcinoma (ICC). Therefore, this study investigated the prognostic usefulness of the GPS for patients who underwent ICC surgery. METHOD: All ICC patients who had a curative-intent hepatectomy at 17 institutions between 2000 and 2016 were included. The correlation was assessed between the preoperative GPS and the baseline characteristics of the patients, histopathological parameters, surgical parameters, and the postresection overall survival (OS). RESULT: There were 273 patients who met the eligibility criteria between the years 2000 and 2016. The postoperative OS rates at 1, 3, and 5 years were 83.8%, 56.3%, and 41.5%, respectively (median OS, 47.7 months). A multivariate analysis revealed the factors that were associated with a worse OS, which included an increased GPS (hazard ratio = 1.62; 95% confidence interval [CI]: 1.01-2.53; P = 0.03), an elevated carcinoembryonic antigen level (hazard ratio = 1.60; 95% CI: 1.06-2.41; P = 0.02), an elevated carbohydrate antigen 19-9 level (hazard ratio = 1.55; 95% CI: 1.05-2.30; P = 0.03), undifferentiated carcinoma (hazard ratio = 2.41; 95% CI: 1.56-3.67; P < 0.01), and positive metastasis to the lymph nodes (hazard ratio = 2.54; 95% CI: 1.76-3.67; P < 0.01). In ICC patients after a hepatectomy, an elevated GPS was associated with poorer OS, even if the tumour factors that affected GPS were eliminated by propensity-score matching. CONCLUSION: Preoperative GPS can be useful to predict the postoperative outcomes of ICC patients. Therefore, this relatively simple and inexpensive scoring system can be utilized to further refine patient stratification as well as to predict survival.

    DOI: 10.1007/s00268-020-05797-4

    PubMed

    researchmap

  • 【消化器・一般外科領域の手術教育を考える】総論 手術教育における手術記録の活用法

    楳田 祐三, 杭瀬 崇, 吉田 龍一, 吉田 一博, 藤原 俊義, 八木 孝仁

    手術   75 ( 1 )   43 - 53   2021.1

     More details

    Language:Japanese   Publisher:金原出版(株)  

    researchmap

  • 【徹底解説 術後後遺症をいかに防ぐか-コツとポイント】胃癌 ダンピング症候群 その病態と機能温存手術による予防のポイント

    菊地 覚次, 黒田 新士, 藤原 俊義

    臨床外科   76 ( 1 )   38 - 42   2021.1

     More details

    Language:Japanese   Publisher:(株)医学書院  

    <文献概要>ポイント ◆胃切除後障害の代表的な一つであるダンピング症候群予防は,胃切除後のQOL向上において重要である.◆ダンピング症候群を予防する機能温存手術の適応や手術手技のコツを正しく理解する.◆管理栄養士などの医療スタッフと連携したチーム医療体制の構築と患者教育が重要である.

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01539&link_issn=&doc_id=20210108600008&doc_link_id=10.11477%2Fmf.1407213236&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1407213236&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  • Microanatomy-based standardization of left upper mediastinal lymph node dissection in thoracoscopic esophagectomy in the prone position. International journal

    Yasuhiro Shirakawa, Kazuhiro Noma, Naoaki Maeda, Shunsuke Tanabe, Kazufumi Sakurama, Toshiyoshi Fujiwara

    Surgical endoscopy   35 ( 1 )   349 - 357   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Although thoracoscopic esophagectomy in the prone position (TEPP) has become a standard procedure for esophageal cancer surgery, upper mediastinal lymph node dissection (UMLND) on the left side remains an issue. We have recently developed a new standardized approach to left UMLND in TEPP based on the microanatomy of the membranes and layers with the aim of achieving quick and safe surgery. The purpose of this study was to establish and evaluate our new standardized procedure in left UMLND. PATIENTS AND METHODS: Patients were divided into 2 groups: a pre-standardization group (n = 100) and a post-standardization group (n = 100). Eventually, 83 paired cases were matched using propensity score matching. In our new standardized procedure, left UMLND was performed while focusing on the visceral sheath, vascular sheath, and the fusion layer between them using a magnified view. RESULTS: The thoracoscopic operative time was significantly shorter (P < 0.001) in the post-standardization group [n = 83; 209.0 (176.0-235.0) min] than in the pre-standardization group [n = 83; 235.5 (202.8-264.5) min]. No significant differences were found in the number of mediastinal lymph nodes dissected or intraoperative blood loss between the two groups. There was a tendency for the total postoperative morbidity to decrease in the post-standardization group. Furthermore, the left recurrent laryngeal nerve palsy rate was significantly lower in the post-standardization group (18.1% to 8.7%, P = 0.015). CONCLUSION: Microanatomy-based standardization contributes to safe and efficient left UMLND.

    DOI: 10.1007/s00464-020-07407-9

    PubMed

    researchmap

  • 外科系新専門医制度のあるべきグランドデザイン 地域枠医師に対する外科専門研修のあり方 充実した地域医療の実現を目指して

    黒田 新士, 吉田 龍一, 池田 宏国, 岡崎 幹生, 大澤 晋, 小谷 恭弘, 山根 正修, 杉本 誠一郎, 菊地 覚次, 安井 和也, 野田 卓男, 笠原 真悟, 豊岡 伸一, 土井原 博義, 藤原 俊義

    日本外科学会雑誌   122 ( 1 )   83 - 85   2021.1

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科系新専門医制度のあるべきグランドデザイン 地域枠医師に対する外科専門研修のあり方 充実した地域医療の実現を目指して Reviewed

    黒田 新士, 吉田 龍一, 池田 宏国, 岡崎 幹生, 大澤 晋, 小谷 恭弘, 山根 正修, 杉本 誠一郎, 菊地 覚次, 安井 和也, 野田 卓男, 笠原 真悟, 豊岡 伸一, 土井原 博義, 藤原 俊義

    日本外科学会雑誌   122 ( 1 )   83 - 85   2021.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(一社)日本外科学会  

    researchmap

  • がん関連線維芽細胞由来IL-6制御による免疫応答の効率化バイオマーカーとしてのIL-6の可能性

    西脇 紀之, 野間 和広, 大原 利章, 河崎 健人, 赤井 正明, 小林 照貴, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 田澤 大, 白川 靖博, 藤原 俊義

    日本分子腫瘍マーカー研究会誌   36   32 - 33   2021

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • がん関連線維芽細胞由来IL-6制御による免疫応答の効率化バイオマーカーとしてのIL-6の可能性

    西脇 紀之, 野間 和広, 大原 利章, 河崎 健人, 赤井 正明, 小林 照貴, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 田澤 大, 白川 靖博, 藤原 俊義

    日本分子腫瘍マーカー研究会誌   36   32 - 33   2021

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression. International journal

    Toshinori Omori, Hiroshi Tazawa, Yasuaki Yamakawa, Shuhei Osaki, Joe Hasei, Kazuhisa Sugiu, Tadashi Komatsubara, Tomohiro Fujiwara, Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    PloS one   16 ( 4 )   e0250643   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Soft tissue sarcoma (STS) is a rare cancer that develops from soft tissues in any part of the body. Despite major advances in the treatment of STS, patients are often refractory to conventional radiotherapy, leading to poor prognosis. Enhancement of sensitivity to radiotherapy would therefore improve the clinical outcome of STS patients. We previously revealed that the tumor-specific, replication-competent oncolytic adenovirus OBP-301 kills human sarcoma cells. In this study, we investigated the radiosensitizing effect of OBP-301 in human STS cells. The in vitro antitumor effect of OBP-301 and ionizing radiation in monotherapy or combination therapy was assessed using highly radiosensitive (RD-ES and SK-ES-1) and moderately radiosensitive (HT1080 and NMS-2) STS cell lines. The expression of markers for apoptosis and DNA damage were evaluated in STS cells after treatment. The therapeutic potential of combination therapy was further analyzed using SK-ES-1 and HT1080 cells in subcutaneous xenograft tumor models. The combination of OBP-301 and ionizing radiation showed a synergistic antitumor effect in all human STS cell lines tested, including those that show different radiosensitivity. OBP-301 was found to enhance irradiation-induced apoptosis and DNA damage via suppression of anti-apoptotic myeloid cell leukemia 1 (MCL1), which was expressed at higher levels in moderately radiosensitive cell lines. The combination of OBP-301 and ionizing radiation showed a more profound antitumor effect compared to monotherapy in SK-ES-1 (highly radiosensitive) and HT1080 (moderately radiosensitive) subcutaneous xenograft tumors. OBP-301 is a promising antitumor reagent to improve the therapeutic potential of radiotherapy by increasing radiation-induced apoptosis in STS.

    DOI: 10.1371/journal.pone.0250643

    PubMed

    researchmap

  • リアルタイムイメージングによる予後不良間葉型大腸癌の治療抵抗性EMTマーカーの発現の時空間的意義

    三村 直毅, 矢野 修也, 田澤 大, 家田 偉史, 岡林 弘樹, 重安 邦俊, 武田 正, 吉田 一博, 寺石 文則, 楳田 祐三, 香川 俊輔, 藤原 俊義

    日本分子腫瘍マーカー研究会誌   36   18 - 20   2021

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    上皮間葉転換(EMT)可視化プローベを用い、間葉型大腸癌がhybrid E/Mで最も化学療法抵抗性であるかをイメージングによって明らかにするとともに、時間的にEMTマーカーを追跡した。Vimentinプロモーター下に赤色蛍光タンパク遺伝子(rfp)がドライブさせるEMT可視化プローベを作成した。大腸癌細胞株HCT116、RKOにEMT可視化プローベを導入した。大腸癌の代表的な抗癌剤5-FU、オキサリプラチン(L-OHP)、シスプラチン(CDDP)、イリノテカン(CPT-11)を曝露させた。その結果、RKOではL-OHP、CDDP、5-FUの順で赤色を呈するEMTを起こし、HCT116では5-FU、L-OHP、CDDPの順でEMTを起こした。また、時間軸では化学療法後48時間するとEMTを起こし赤色になったが、化学療法終了後48時間経過するとEMTを起こし無色に戻った。化学療法施行前にEMT阻害剤で前治療しておくと、化学療法に曝露しても赤色にならず(EMTは阻害され)、さらに化学療法への感受性も増加していた。

    researchmap

  • Hemobilia after bile duct resection: perforation of pseudoaneurysm into intra-pancreatic remnant bile duct: a case report. International journal

    Kazuhiro Yoshida, Yuzo Umeda, Masaya Iwamuro, Kazuyuki Matsumoto, Hironari Kato, Mayu Uka, Yusuke Matsui, Ryuichi Yoshida, Takashi Kuise, Kazuya Yasui, Kosei Takagi, Hiroyuki Araki, Takahito Yagi, Toshiyoshi Fujiwara

    BMC surgery   20 ( 1 )   307 - 307   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Hemobilia occurs mainly due to iatrogenic factors such as impairment of the right hepatic or cystic artery, and/or common bile duct in hepatobiliary-pancreatic surgery. However, little or no cases with hemobilia from the intra-pancreatic remnant bile duct after bile duct resection (BDR) has been reported. Here, we report a case of massive hemobilia due to the perforation of psuedoaneurysm of the gastroduodenal artery (GDA) to the intra-pancreatic remnant bile duct after hepatectomy with BDR. CASE PRESENTATION: A 68-year-old male underwent extended right hepatectomy with BDR for gallbladder carcinoma. He presented with upper gastrointestinal bleeding 2 months after the initial surgery. Upper endoscopy identified a blood clot from the ampulla of Vater and simultaneous endoscopic balloon tamponade contributed to temporary hemostasis. Abdominal CT and angiography revealed a perforation of the psuedoaneurysm of the GDA to the intra-pancreatic remnant bile duct resulting in massive hemobilia. Subsequent selective embolization of the pseudoaneurysm with micro-coils could achieve complete hemostasis. He survived without any recurrence of cancer and bleeding. CONCLUSION: Hemobilia could occur in a patient with BDR due to perforation of the pseudoaneurysm derived from the GDA to the intra-pancreatic remnant bile duct. Endoscopic balloon tamponade was useful for a temporal hemostasis and a subsequent radiologic interventional approach.

    DOI: 10.1186/s12893-020-00981-8

    PubMed

    researchmap

  • フェルカルボトランを用いた胃癌腹膜播種に対する磁気温熱療法

    松三 雄騎, 岸本 浩行, 香川 哲也, 矢野 修也, 重安 邦俊, 岡林 弘樹, 大原 利章, 田澤 大, 藤原 俊義

    日本消化器外科学会総会   75回   P077 - 3   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 周術期管理チーム介入後の高齢者大腸癌症例のアウトカムの検証 PERIO介入によりアウトカムは向上したか

    寺石 文則, 杉本 龍馬, 武田 正, 重安 邦俊, 矢野 修也, 近藤 喜太, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   75回   P210 - 3   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • OS延長を目指した局所進行直腸癌に対するoxaliplatinを用いた術前化学放射線療法の治療成績

    武田 正, 寺石 文則, 重安 邦俊, 矢野 修也, 近藤 喜太, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   75回   P135 - 6   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • プレシジョンメディシン時代に備えた大腸癌リンパ節郭清範囲の統一化

    矢野 修也, 重安 邦俊, 近藤 喜太, 寺石 文則, 黒田 新士, 菊地 覚次, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   75回   P147 - 1   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • フェルカルボトランを用いた胃癌腹膜播種に対する磁気温熱療法

    松三 雄騎, 岸本 浩行, 香川 哲也, 矢野 修也, 重安 邦俊, 岡林 弘樹, 大原 利章, 田澤 大, 藤原 俊義

    日本消化器外科学会総会   75回   P077 - 3   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 直腸癌術前後の白血球数は予防的回腸人工肛門の閉塞やHigh output stoma発症を予測する指標となる

    重安 邦俊, 小松 泰浩, 武田 正, 矢野 修也, 近藤 喜太, 寺石 文則, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   75回   P129 - 1   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Short-term and long-term outcomes in living donors for liver transplantation: Cohort study. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Nobuyuki Watanabe, Takashi Kuise, Kazuhiro Yoshida, Kazuya Yasui, Tatsuo Matsuda, Toshiyoshi Fujiwara, Takahito Yagi

    International journal of surgery (London, England)   84   147 - 153   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Although perioperative outcomes following donor hepatectomy (DH) have been reported, little is known about the long-term outcomes in living donors of liver transplantation. The aim of this study was to investigate the short-term and long-term outcomes following DH. METHODS: A total of 408 living donors who underwent DH between 1996 and 2019 were analyzed in this retrospective study, focusing on short-term outcomes with respect to the operation period (era) and the graft type, as well as long-term outcomes. RESULTS: The overall incidence of postoperative complications was 40.4%. These included minor (30.4%), major (10.0%), and biliary (14.0%) complications. Short-term outcomes after DH slightly improved over time, and outcomes did not differ significantly between the graft types. With regards to long-term outcomes, the incidence of surgery-related complications such as keloids, incisional hernias, and mechanical bowel obstructions was 6.6% over a median follow-up of 7.2 years. In addition, some donors developed comorbidities such as lifestyle diseases and cancers during the follow-up period. CONCLUSIONS: Our study confirmed an improvement of perioperative outcomes in living donors. There was no significant association between the graft type and postoperative outcomes. Donors could develop various morbidities during long-term follow-up. Therefore, a careful perioperative management and long-term follow-up should be provided to living donors.

    DOI: 10.1016/j.ijsu.2020.11.013

    PubMed

    researchmap

  • 食道癌に対する低侵襲手術の現況と展望

    白川 靖博, 野間 和広, 河崎 健人, 西江 尚貴, 山田 元彦, 前田 直見, 田辺 俊介, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   74回   8 - 8   2020.12

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 周術期管理チーム介入後の高齢者大腸癌症例のアウトカムの検証 PERIO介入によりアウトカムは向上したか

    寺石 文則, 杉本 龍馬, 武田 正, 重安 邦俊, 矢野 修也, 近藤 喜太, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   75回   P210 - 3   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • OS延長を目指した局所進行直腸癌に対するoxaliplatinを用いた術前化学放射線療法の治療成績

    武田 正, 寺石 文則, 重安 邦俊, 矢野 修也, 近藤 喜太, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   75回   P135 - 6   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 直腸癌術前後の白血球数は予防的回腸人工肛門の閉塞やHigh output stoma発症を予測する指標となる

    重安 邦俊, 小松 泰浩, 武田 正, 矢野 修也, 近藤 喜太, 寺石 文則, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   75回   P129 - 1   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 有茎広背筋弁移植による胸部食道癌術後気管瘻の予防

    太田 智之, 松本 洋, 前田 直見, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義, 木股 敬裕

    日本食道学会学術集会プログラム・抄録集   74回   326 - 326   2020.12

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 重度呼吸機能障害のある食道がん患者の意思決定支援を振りかえる

    廣川 万里子, 板垣 栞, 田村 利枝, 前田 直見, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   74回   228 - 228   2020.12

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • より安全で生理的な経路を追求した有茎空腸を用いた食道再建術における工夫

    國友 知義, 白川 靖博, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   74回   158 - 158   2020.12

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 新規技術の開発とカダバートレーニングの実際 食道癌手術におけるCadaver Surgical Trainingの現状と課題

    前田 直見, 白川 靖博, 橋本 将志, 田辺 俊介, 野間 和広, 櫻間 教文, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   74回   75 - 75   2020.12

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • MM、SM1食道癌の治療 手術か化学放射線療法か(領域横断的セッション) 食道ESD後追加手術例と再発後手術例から考える食道ESD後の適切な追加治療

    田辺 俊介, 白川 靖博, 國友 知義, 前田 直見, 櫻間 教文, 野間 和広, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   74回   54 - 54   2020.12

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌周術期チーム医療の現況と将来展望

    白川 靖博, 國友 知義, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   74回   12 - 12   2020.12

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • Risk factor of mediastinal lymph node metastasis of Siewert type I and II esophagogastric junction carcinomas. International journal

    Noriyuki Nishiwaki, Kazuhiro Noma, Tatsuo Matsuda, Naoaki Maeda, Shunsuke Tanabe, Kazufumi Sakurama, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Langenbeck's archives of surgery   405 ( 8 )   1101 - 1109   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Incidence of esophagogastric junction (EGJ) carcinoma has been increasing worldwide. Several studies revealed that the distance from the EGJ to the proximal edge of the primary tumor (esophageal invasion: EI) may be a significant indicator of metastasis in the mediastinal lymph nodes in patients with Siewert type II carcinomas. However, few studies have been conducted in patients with carcinomas located at Siewert type II sequentially to upper carcinomas (Siewert type I) for mediastinal metastasis regardless of histological types. METHODS: This was a single-center retrospective cohort study. EGJ carcinomas located at Siewert type I and II regions including both squamous cell carcinoma (SCC) and adenocarcinoma were analyzed in terms of lymph node metastasis patterns. RESULTS: We included 121 patients in this study. Thirty-three (27.3%) patients had SCC. In multivariate analysis, the distance of EI (> 20 mm) was an independent risk factor (OR 11.80, p = 0.005) for lower mediastinal lymph node metastasis. In terms of above the middle mediastinal metastasis, the distance of EI (> 30 m), histological type (SCC), and tumor size (> 40 mm) were risk factors in univariate analysis. Furthermore, EI was significant (OR 13.50, p = 0.026) in multivariate analysis. CONCLUSIONS: The distance of EI was the independent risk factor for mediastinal lymph node metastasis, especially > 20 mm related with a higher risk for mediastinal lymph node metastasis. Furthermore, EGJ carcinoma patients who have EI > 30 mm, large SCC carcinoma, and multiple lymph node metastasis might be considered the middle-upper mediastinal lymph node dissection by transthoracic approach.

    DOI: 10.1007/s00423-020-02017-4

    PubMed

    researchmap

  • プレシジョンメディシン時代に備えた大腸癌リンパ節郭清範囲の統一化

    矢野 修也, 重安 邦俊, 近藤 喜太, 寺石 文則, 黒田 新士, 菊地 覚次, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   75回   P147 - 1   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 観音開き法(上川法)再建における胃食道逆流予防と吻合部狭窄予防に重要な手技上のポイント

    黒田 新士, 西崎 正彦, 菊地 覚次, 高田 暢夫, 垣内 慶彦, 田辺 俊介, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   75回   RSV6 - 1   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • ERASプロトコールにおける腹腔鏡下胃切除術後の最適な鎮痛法

    菊地 覚次, 黒田 新士, 西崎 正彦, 高田 暢夫, 武田 正, 垣内 慶彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   75回   RS21 - 6   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • [胃]胃切除後のQOL向上を目指したエビデンスの創生 胃癌周術期の継続的な栄養指導が術後体重や栄養指標に与える影響

    高田 暢夫, 菊地 覚次, 武田 正, 垣内 慶彦, 黒田 新士, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   75回   WS3 - 10   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 消化器外科におけるロボット支援下手術 ロボット支援下低侵襲食道切除術の現状と展望(Robotic surgery in the field of gastroenterological surgery Current status and perspective of robot-assisted minimally invasive esophagectomy for cancer)

    Shirakawa Yasuhiro, Noma Kazuhiro, Kawasaki Kento, Nishie Naoki, Yamada Motohiko, Maeda Naoaki, Tanabe Shunsuke, Kuroda Shinji, Umeda Yuzo, Fujiwara Toshiyoshi

    日本消化器外科学会総会   75回   VSY9 - 3   2020.12

     More details

    Language:English   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 局所進行食道癌に対するDCF-RT後の食道切除術の有用性と安全性の検討

    山田 元彦, 白川 靖博, 河崎 健人, 橋本 将志, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   75回   O1 - 5   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 術前化学療法後に手術を行った食道胃接合部癌症例の検討

    赤井 正明, 野間 和広, 西江 尚貴, 前田 直見, 田辺 俊介, 櫻間 教文, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   75回   P010 - 2   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道がん症例におけるチームによる周術期管理の介入開始の至適時期の検討

    河崎 健人, 白川 靖博, 西江 尚貴, 山田 元彦, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   75回   RS5 - 6   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 腹臥位胸腔鏡下食道切除における微細解剖に基づいた上縦隔リンパ節郭清手技の定形化

    前田 直見, 白川 靖博, 河崎 健人, 西江 尚貴, 山田 元彦, 田辺 俊介, 櫻間 教文, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   75回   O2 - 4   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 局所進行切除不能膵癌における予後規定因子の検討 非切除例を含めたall cohort解析

    安井 和也, 吉田 龍一, 楳田 祐三, 杭瀬 崇, 吉田 一博, 高木 弘誠, 松田 達雄, 荒木 宏之, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   75回   O16 - 2   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 再手術症例から学ぶ形成外科的手技を用いた合併症回避のための術式の工夫

    松本 洋, 太田 智之, 川本 幸司, 木股 敬裕, 白川 靖博, 野間 和広, 田邊 俊介, 前田 直見, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   74回   327 - 327   2020.12

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 切除可能/切除可能境界膵癌における術前後血中KRAS遺伝子変異検出とその意義に関する検討

    吉田 龍一, 安井 和也, 楳田 祐三, 杭瀬 崇, 吉田 一博, 松田 達雄, 高木 弘誠, 荒木 宏之, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   75回   P276 - 4   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 切除可能膵癌における術後早期再発予測因子の解析 多施設共同後方視的研究

    須井 健太, 吉田 龍一, 日置 勝義, 佐藤 太祐, 児島 亨, 國府島 健, 久保 孝文, 安井 和也, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   75回   RS19 - 1   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 膵頭十二指腸切除術における周術期栄養療法のエビデンス

    高木 弘誠, 楳田 祐三, 吉田 龍一, 杭瀬 崇, 吉田 一博, 安井 和也, 松田 達雄, 荒木 宏之, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   75回   O17 - 6   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer. International journal

    Kunitoshi Shigeyasu, Shusuke Toden, Tsuyoshi Ozawa, Takatoshi Matsuyama, Takeshi Nagasaka, Toshiaki Ishikawa, Debashis Sahoo, Pradipta Ghosh, Hiroyuki Uetake, Toshiyoshi Fujiwara, Ajay Goel

    Molecular cancer   19 ( 1 )   155 - 155   2020.11

     More details

    Language:English  

    Accumulating evidence suggests that dysregulation of transcriptional enhancers plays a significant role in cancer pathogenesis. Herein, we performed a genome-wide discovery of enhancer elements in colorectal cancer (CRC). We identified PVT1 locus as a previously unrecognized transcriptional regulator in CRC with a significantly high enhancer activity, which ultimately was responsible for regulating the expression of MYC oncogene. High expression of the PVT1 long-non-coding RNA (lncRNA) transcribed from the PVT1 locus was associated with poor survival among patients with stage II and III CRCs (p < 0.05). Aberrant methylation of the PVT1 locus inversely correlated with the reduced expression of the corresponding the PVT1 lncRNA, as well as MYC gene expression. Bioinformatic analyses of CRC-transcriptomes revealed that the PVT1 locus may also broadly impact the expression and function of other key genes within two key CRC-associated signaling pathways - the TGFβ/SMAD and Wnt/β-Catenin pathways. We conclude that the PVT1 is a novel oncogenic enhancer of MYC and its activity is controlled through epigenetic regulation mediated through aberrant methylation in CRC. Our findings also suggest that the PVT1 lncRNA expression is a promising prognostic biomarker and a potential therapeutic target in CRC.

    DOI: 10.1186/s12943-020-01277-4

    PubMed

    researchmap

  • 超高齢者食道癌症例のサルコペニアと術後合併症の関連の検討

    田辺 俊介, 白川 靖博, 前田 直見, 野間 和広, 藤原 俊義

    学会誌JSPEN   2 ( Suppl.1 )   819 - 819   2020.11

     More details

    Language:Japanese   Publisher:(一社)日本臨床栄養代謝学会  

    researchmap

  • 胃 周術期管理・合併症

    高田 暢夫, 菊地 覚次, 武田 正, 垣内 慶彦, 黒田 新士, 田辺 俊介, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会雑誌   53 ( Suppl.2 )   280 - 280   2020.11

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 夢を実現するためのキャリアパス・教育システム 進化する外科マネージメントセンター それぞれの夢を実現するためのキャリアパス支援システム

    菊地 覚次, 黒田 新士, 吉田 龍一, 香川 俊輔, 山根 正修, 小谷 恭弘, 笠原 真悟, 豊岡 伸一, 藤原 俊義

    日本外科学会雑誌   121 ( 6 )   669 - 671   2020.11

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 腫瘍融解ウイルスによるp53の発現増強は骨肉腫に対する全身性の抗腫瘍免疫反応を増強する

    近藤 宏也, 田澤 大, 出宮 光二, 久禮 美穂, 望月 雄介, 長谷井 嬢, 國定 俊之, 浦田 泰生, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   79回   OE14 - 2   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 癌関連線維芽細胞由来IL-6制御による免疫応答の効率化 "Drug repositioning"による癌治療の可能性

    西脇 紀之, 野間 和広, 大原 利章, 小林 照貴, 菊地 覚次, 田澤 大, 藤原 俊義

    日本癌学会総会記事   79回   OE12 - 7   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 癌関連線維芽細胞を標的とした光免疫療法の新たな開発

    小林 照貴, 野間 和広, 河崎 健人, 赤井 正明, 西脇 紀之, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   79回   OJ12 - 3   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 胃癌サブタイプと癌関連線維芽細胞の相互作用

    李 云成, 田澤 大, 野間 和広, 大原 利章, 黒田 新士, 菊地 覚次, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   79回   OE14 - 7   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • エクソソームを用いた革新的治療法 腫瘍融解アデノウイルス局所療法後に産生されるエクソソームはアブスコパル効果を起こす

    垣内 慶彦, 黒田 新士, 金谷 信彦, 公文 剣斗, 津村 朋子, 橋本 将志, 八木 千晶, 杉本 龍馬, 菊地 覚次, 西崎 正彦, 香川 俊輔, 田澤 大, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   79回   IS5 - 7   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • ゲムシタビン耐性膵癌細胞は免疫抑制性の微小環境を増強する

    梶原 義典, 田澤 大, 西山 岳芳, 庄司 良平, 伏見 卓郎, 菊地 覚次, 黒田 新士, 野間 和広, 吉田 龍一, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   79回   OJ17 - 6   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 腫瘍融解ウイルスによるp53の発現増強は膵癌微小環境における腫瘍間質ネットワークを遮断する

    西山 岳芳, 田澤 大, 梶原 義典, 庄司 良平, 菊地 覚次, 黒田 新士, 野間 和広, 吉田 龍一, 西崎 正彦, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   79回   OE14 - 4   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道切除後の消化管再建 胃管作成不能例に対する有茎空腸を用いた食道再建術の工夫と成績

    田辺 俊介, 白川 靖博, 西村 星多郎, 菅野 令子, 光井 恵麻, 國友 知義, 前田 直見, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   81 ( 増刊 )   241 - 241   2020.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 腫瘍溶解ウイルスを介したp53遺伝子治療による腹腔内免疫環境改善を利用した胃癌腹膜播種治療

    田渕 幹康, 菊地 覚次, 小川 俊博, 田澤 大, 黒田 新士, 野間 和広, 西崎 正彦, 香川 俊輔, 大塚 旬子, 大木 理恵子, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   79回   OE14 - 8   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • テロメラーゼ特異的腫瘍融解アデノウイルス製剤の併用による抗PD-1抗体治療効果の増強

    橋本 将志, 黒田 新士, 金谷 信彦, 八木 千晶, 津村 朋子, 公文 剣斗, 垣内 慶彦, 菊地 覚次, 田澤 大, 香川 俊輔, 水口 裕之, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   79回   OE12 - 10   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 腫瘍融解アデノウイルスで治療した腫瘍から得られる細胞外小胞は樹状細胞を活性化する能力を有する

    津村 朋子, 黒田 新士, 金谷 信彦, 垣内 慶彦, 公文 剣斗, 橋本 将志, 八木 千晶, 杉本 龍馬, 菊地 覚次, 西崎 正彦, 香川 俊輔, 田澤 大, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   79回   OJ11 - 2   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 好中球と血小板の相互作用が胆管癌の悪性形質転換を促進する

    吉本 匡志, 香川 俊輔, 梶原 義典, 西山 岳芳, 李 云成, 岡林 弘樹, 菊地 覚次, 黒田 新士, 田澤 大, 藤原 俊義

    日本癌学会総会記事   79回   OJ10 - 2   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道癌の治療戦略 食道胃接合部癌に対する術前化学療法治療効果予測因子の解析

    野間 和広, 赤井 正明, 前田 直見, 菊地 覚次, 田邊 俊介, 黒田 新士, 楳田 祐三, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   58回   WS24 - 5   2020.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 【早わかり縫合・吻合のすべて】(4章)術式別の縫合・吻合法 胃 噴門側胃切除術 食道-残胃吻合 観音開き法

    西崎 正彦, 黒田 新士, 菊地 覚次, 藤原 俊義

    臨床外科   75 ( 11 )   142 - 144   2020.10

     More details

    Language:Japanese   Publisher:(株)医学書院  

    researchmap

  • 【食道胃接合部癌update】治療 噴門側胃切除後再建法 食道残胃吻合の手技と成績

    黒田 新士, 西崎 正彦, 菊地 覚次, 野間 和広, 香川 俊輔, 藤原 俊義

    外科   82 ( 11 )   1144 - 1148   2020.10

     More details

    Language:Japanese   Publisher:(株)南江堂  

    <文献概要>観音開き法再建は,1998年に上川らにより報告された逆流防止機構を付加した食道残胃吻合である.漿膜筋層フラップ下に埋没した食道が胃内圧の上昇に伴い押しつぶされることで,逆流防止弁としての機能を発揮することを特徴としている.多施設共同後ろ向き臨床試験において,逆流性食道炎発生予防の観点から良好な成績が報告されており,また縫合不全の発生頻度も非常に低率であることから,食道胃接合部癌などの縦隔内再建を要する症例に対しても非常に有用な再建法と考えられる.

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J00393&link_issn=&doc_id=20201001100010&doc_link_id=10.15106%2Fj_geka82_1144&url=https%3A%2F%2Fdoi.org%2F10.15106%2Fj_geka82_1144&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  • 食道癌術後肺転移に対する外科的切除の意義

    田辺 俊介, 白川 靖博, 野間 和広, 前田 直見, 國友 知義, 藤原 俊義

    日本癌治療学会学術集会抄録集   58回   O56 - 3   2020.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 転移性肺腫瘍の外科治療up to date 食道癌術後肺転移再発に対する外科的切除の役割

    國友 知義, 白川 靖博, 西村 星多郎, 管野 令子, 光井 恵麻, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   81 ( 増刊 )   283 - 283   2020.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 高度進行食道癌、再発食道癌に対する治療戦略-薬物療法と手術との融合- T4進行食道癌に対するDCF併用放射線療法を用いた治療戦略

    白川 靖博, 國友 知義, 橋本 将志, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   81 ( 増刊 )   269 - 269   2020.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 肝癌に対する肝移植の長期成績と再発予防 肝癌肝移植の長期予後に向けて 肝移植適応の選別と再発時治療

    楳田 祐三, 吉田 龍一, 杭瀬 崇, 吉田 一博, 高木 弘誠, 安井 和也, 荒木 宏之, 八木 孝仁, 藤原 俊義

    日本臨床外科学会雑誌   81 ( 増刊 )   246 - 246   2020.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 術前臨床情報を用いた切除可能膵癌の層別化 多施設共同後方視的研究

    佐藤 太佑, 吉田 龍一, 日置 勝義, 須井 健太, 児島 亨, 國府島 健, 久保 孝文, 安井 和也, 八木 孝仁, 藤原 俊義

    日本臨床外科学会雑誌   81 ( 増刊 )   331 - 331   2020.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer. International journal

    Wataru Ishikawa, Satoru Kikuchi, Toshihiro Ogawa, Motoyasu Tabuchi, Hiroshi Tazawa, Shinji Kuroda, Kazuhiro Noma, Masahiko Nishizaki, Shunsuke Kagawa, Yasuo Urata, Toshiyoshi Fujiwara

    Molecular therapy oncolytics   18   262 - 271   2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Peritoneal metastasis is the most frequent form of distant metastasis and recurrence in gastric cancer, and the prognosis is extremely poor due to the resistance of systemic chemotherapy. Here, we demonstrate that intraperitoneal (i.p.) administration of a green fluorescence protein (GFP)-expressing attenuated adenovirus with oncolytic potency (OBP-401) synergistically suppressed the peritoneal metastasis of gastric cancer in combination with paclitaxel (PTX). OBP-401 synergistically suppressed the viability of human gastric cancer cells in combination with PTX. PTX enhanced the antitumor effect of OBP-401 due to enhanced viral replication in cancer cells. The combination therapy increased induction of mitotic catastrophe, resulting in accelerated autophagy and apoptosis. Peritoneally disseminated nodules were selectively visualized as GFP-positive spots by i.p. administration of OBP-401 in an orthotopic human gastric cancer peritoneal dissemination model. PTX enhanced the deep penetration of OBP-401 into the disseminated nodules. Moreover, a non-invasive in vivo imaging system demonstrated that the combination therapy of i.p. OBP-401 administration with PTX significantly inhibited growth of peritoneal metastatic tumors and the amount of malignant ascites. i.p. virotherapy with PTX may be a promising treatment strategy for the peritoneal metastasis of gastric cancer.

    DOI: 10.1016/j.omto.2020.06.021

    PubMed

    researchmap

  • Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression. International journal

    Terutaka Tanimoto, Hiroshi Tazawa, Takeshi Ieda, Hiroshi Nouso, Morimichi Tani, Takanori Oyama, Yasuo Urata, Shunsuke Kagawa, Takuo Noda, Toshiyoshi Fujiwara

    Molecular therapy oncolytics   18   14 - 23   2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Neuroblastoma (NB) is a primary malignant tumor of the peripheral sympathetic nervous system. High-risk NB is characterized by MYCN amplification and human telomerase reverse transcriptase (hTERT) rearrangement, contributing to hTERT activation and a poor outcome. For targeting hTERT-activated tumors, we developed two oncolytic adenoviruses, OBP-301 and tumor suppressor p53-armed OBP-702, in which the hTERT promoter drives expression of the viral E1 gene for tumor-specific virus replication. In this study, we demonstrate the therapeutic potential of the hTERT-driven oncolytic adenoviruses OBP-301 and OBP-702 using four human MYCN-amplified NB cell lines (IMR-32, CHP-134, NB-1, LA-N-5) exhibiting high hTERT expression. OBP-301 and OBP-702 exhibited a strong antitumor effect in association with autophagy in NB cells. Virus-mediated activation of E2F1 protein suppressed MYCN expression. OBP-301 and OBP-702 significantly suppressed the growth of subcutaneous CHP-134 tumors. Thus, these hTERT-driven oncolytic adenoviruses are promising antitumor agents for eliminating MYCN-amplified NB cells via E2F1-mediated suppression of MYCN protein.

    DOI: 10.1016/j.omto.2020.05.015

    PubMed

    researchmap

  • FUCCI Real-Time Cell-Cycle Imaging as a Guide for Designing Improved Cancer Therapy: A Review of Innovative Strategies to Target Quiescent Chemo-Resistant Cancer Cells. International journal

    Shuya Yano, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert M Hoffman

    Cancers   12 ( 9 )   2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Progress in chemotherapy of solid cancer has been tragically slow due, in large part, to the chemoresistance of quiescent cancer cells in tumors. The fluorescence ubiquitination cell-cycle indicator (FUCCI) was developed in 2008 by Miyawaki et al., which color-codes the phases of the cell cycle in real-time. FUCCI utilizes genes linked to different color fluorescent reporters that are only expressed in specific phases of the cell cycle and can, thereby, image the phases of the cell cycle in real-time. Intravital real-time FUCCI imaging within tumors has demonstrated that an established tumor comprises a majority of quiescent cancer cells and a minor population of cycling cancer cells located at the tumor surface or in proximity to tumor blood vessels. In contrast to most cycling cancer cells, quiescent cancer cells are resistant to cytotoxic chemotherapy, most of which target cells in S/G2/M phases. The quiescent cancer cells can re-enter the cell cycle after surviving treatment, which suggests the reason why most cytotoxic chemotherapy is often ineffective for solid cancers. Thus, quiescent cancer cells are a major impediment to effective cancer therapy. FUCCI imaging can be used to effectively target quiescent cancer cells within tumors. For example, we review how FUCCI imaging can help to identify cell-cycle-specific therapeutics that comprise decoy of quiescent cancer cells from G1 phase to cycling phases, trapping the cancer cells in S/G2 phase where cancer cells are mostly sensitive to cytotoxic chemotherapy and eradicating the cancer cells with cytotoxic chemotherapy most active against S/G2 phase cells. FUCCI can readily image cell-cycle dynamics at the single cell level in real-time in vitro and in vivo. Therefore, visualizing cell cycle dynamics within tumors with FUCCI can provide a guide for many strategies to improve cell-cycle targeting therapy for solid cancers.

    DOI: 10.3390/cancers12092655

    PubMed

    researchmap

  • がん関連線維芽細胞由来IL-6制御による免疫応答の効率化バイオマーカーとしてのIL-6の可能性

    西脇 紀之, 野間 和広, 大原 利章, 河崎 健人, 赤井 正明, 小林 照貴, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 田澤 大, 白川 靖博, 藤原 俊義

    日本分子腫瘍マーカー研究会プログラム・講演抄録   40回   72 - 73   2020.9

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • 骨肉腫に対するp53誘導性腫瘍融解ウイルスを用いたアブスコパル効果・ワクチン効果の誘導

    出宮 光二, 田澤 大, 近藤 宏也, 久禮 美穂, 長谷井 嬢, 中田 英二, 国定 俊之, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   94 ( 8 )   S1855 - S1855   2020.9

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • リアルタイムイメージングによる予後不良間葉型大腸癌の治療抵抗性EMTマーカーの発現の時空間的意義

    三村 直毅, 矢野 修也, 田澤 大, 家田 偉史, 岡林 弘樹, 重安 邦俊, 武田 正, 吉田 一博, 寺石 文則, 楳田 祐三, 香川 俊輔, 藤原 俊義

    日本分子腫瘍マーカー研究会プログラム・講演抄録   40回   56 - 58   2020.9

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • 【肝胆膵外科におけるConversion Surgery】大腸癌肝転移に対するConversion Surgery

    楳田 祐三, 吉田 龍一, 杭瀬 崇, 吉田 一博, 藤原 俊義, 八木 孝仁

    手術   74 ( 10 )   1427 - 1434   2020.9

  • High incidence of tracheobronchial diverticulum in esophageal cancer patients: a retrospective survey alerting pitfall during thoracoscopic esophagectomy.

    Noriyuki Nishiwaki, Kazuhiro Noma, Naoaki Maeda, Shunsuke Tanabe, Kazufumi Sakurama, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    General thoracic and cardiovascular surgery   68 ( 9 )   1018 - 1023   2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: Although tracheobronchial diverticulum (DV) rarely cause problems, attention should be paid during esophagectomy, which requires careful dissection around the trachea and bronchi. Here, we retrospectively review cases of tracheobronchial DVs among esophageal cancer patients and report two cases of bronchial DV injury during thoracoscopic esophagectomy that were successfully repaired. METHODS: The thin-section CT images of esophageal cancer patients who underwent thoracoscopic esophagectomy from January 2013 to December 2015 were retrospectively reviewed. The localization, number, and size (largest axial diameter) of all detected DVs were recorded. RESULTS: A total of 180 patients were enrolled in this study. The incidence of tracheal DV was 5.0%, and that of bronchial DV was 40.0%. The median diameter of the tracheal diverticula was 2.45 [interquartile range (IQR) 2.00-8.17] mm and that of the bronchial diverticula was 1.90 (IQR 1.51-2.46) mm. All tracheal diverticula presented at the right tracheal wall 4.5-6.0 cm below the vocal cords; bronchial diverticula presented at the subcarinal lesions. We experienced two cases with bronchial diverticulum injuries during thoracoscopic esophagectomy, which were repaired by primary closure and confirmed that there was no air leak. No postoperative complications associated with bronchial injury occurred in either patient. CONCLUSION: Since tracheobronchial DVs are not as rare as previously thought, careful evaluation of thin-slice CT scans is necessary before thoracoscopic esophagectomy. If a tracheobronchial DV is injured during surgery, it is important to carefully repair it and confirm that there is no air leak to avoid complications.

    DOI: 10.1007/s11748-020-01421-3

    PubMed

    researchmap

  • Fibroblast activation protein-α(FAP)を標的とした癌関連線維芽細胞(CAFs)に対する光免疫療法 Sunrise of targeting tumor microenvironment therapy

    小林 照貴, 野間 和広, 赤井 正明, 西脇 紀之, 鳴坂 徹, 河本 慧, 前田 直見, 大原 利章, 田辺 俊介, 田澤 大, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 8   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 発生学・拡大視局所微細解剖に基づく最新の手術手技【Video】進行横行結腸癌に対する複雑な幅広いD3郭清手技を結腸の成り立ちから理解することにより単純化し定型手術として言語化する

    矢野 修也, 近藤 喜太, 寺石 文則, 黒田 新士, 重安 邦俊, 母里 淑子, 菊池 覚次, 藤本 卓也, 岸本 浩行, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   WS - 5   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 噴門側胃切除術後再建法-食道残胃吻合 vs 食道空腸吻合-【食道残胃】噴門側胃切除術後標準再建法としての観音開き法再建の可能性

    黒田 新士, 西崎 正彦, 丁田 泰宏, 石田 道拡, 村岡 篤, 田中 則光, 羽藤 慎二, 菊地 覚次, 高田 暢夫, 庄司 良平, 重安 邦俊, 矢野 修也, 近藤 喜太, 田辺 俊介, 野間 和広, 寺石 文則, 香川 俊輔, 白川 靖博, 上川 康明, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   DB - 2   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 局所進行直腸癌に対する術前治療における放射線治療の意義 放射線療法を併用しない術前化学療法との治療成績の比較

    寺石 文則, 藤本 卓也, 重安 邦俊, 矢野 修也, 近藤 喜太, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 7   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 肝内胆管癌における免疫微小環境と治療予後の関連性

    小西 大輔, 吉田 一博, 楳田 祐三, 重安 邦俊, 矢野 修也, 武田 正, 吉田 龍一, 杭瀬 崇, 藤 智和, 安井 和也, 松田 達雄, 田澤 大, 白川 靖博, 八木 孝仁, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 3   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 直腸癌に対するtaTMEの意義-あり vs なし-【なし】解剖学的知識と内視鏡技術に卓越しなければtaTMEの意義はない

    近藤 喜太, 重安 邦俊, 矢野 修也, 寺石 文則, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   DB - 3   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 腹腔内アプローチ困難と予想される症例に対する、taTMEの役割と安全性

    藤本 卓也, 近藤 喜太, 矢野 修也, 重安 邦俊, 母里 淑子, 寺石 文則, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   DP - 2   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 病的肥満症に対する腹腔鏡下スリーブ状胃切除術導入と初期10例の治療成績

    香川 俊輔, 黒田 新士, 菊地 覚次, 高田 暢夫, 庄司 良平, 西崎 正彦, 寺石 文則, 近藤 喜太, 矢野 修也, 重安 邦俊, 野間 和広, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   DP - 5   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 癌微小環境が引き起こす腫瘍免疫抑制の解明 "Drug repositioning"による免疫応答賦活化の可能性

    西脇 紀之, 野間 和広, 赤井 正明, 小林 照貴, 鳴坂 徹, 河本 慧, 加藤 卓也, 前田 直見, 田辺 俊介, 大原 利章, 田澤 大, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 4   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Systematic review on immunonutrition in partial pancreatoduodenectomy. International journal

    Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Takahito Yagi, Toshiyoshi Fujiwara

    Langenbeck's archives of surgery   405 ( 5 )   585 - 593   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The effect of immunonutrition (IM) on postoperative outcomes has been investigated in gastrointestinal cancer surgery; however, strong evidence regarding IM in partial pancreatoduodenectomy (PD) is lacking. This study evaluated the effect of IM on short-term outcomes in patients undergoing PD. METHODS: A systematic literature review of randomized controlled trials was conducted to identify the studies investigating the IM effect on outcomes in PD. Random-effects meta-analyses were conducted to calculate the pooled risk ratio (RR). Studies were evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. RESULTS: Five studies were included in the meta-analysis. IM was associated with a lower incidence of overall complications (RR 0.74; 95% confidence interval (CI) 0.58, 0.94; P = 0.01; I2 = 0%) and infectious complications (RR 0.60; 95% CI 0.42, 0.84; P = 0.003; I2 = 0%). However, no significant association was noted in the incidence of major complications (RR 0.68; 95% CI 0.41, 1.12; P = 0.13), mortality (RR 0.79; 95% CI 0.16, 3.99; P = 0.78), postoperative pancreatic fistula (RR 0.92, 95% CI 0.59, 1.46; P = 0.74), and delayed gastric emptying (RR 1.09; 95% CI 0.55, 2.15; P = 0.81). CONCLUSIONS: IM administration in PD can prevent the incidence of overall and infectious complications postoperatively (GRADE recommendation: moderate). However, IM has no impact on major complications, mortality, and PD-specific complications (GRADE recommendation: low).

    DOI: 10.1007/s00423-020-01916-w

    PubMed

    researchmap

  • 食道胃接合部癌の手術-アプローチ法・郭清範囲・再建術式のdecision making- Siewert I型およびII型食道胃接合部癌の縦隔リンパ節転移に関するリスク因子(Risk factor for mediastinal lymph node metastasis of siewert type I and II esophagogastric junction tumors)

    野間 和広, 白川 靖博, 赤井 正明, 西江 尚貴, 前田 直見, 田辺 俊介, 櫻間 教文, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   PD - 2   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 脳死肝移植マージナルドナーの移植予後の解明と活用への提言

    吉田 一博, 楳田 祐三, 吉田 龍一, 杭瀬 崇, 藤 智和, 安井 和也, 松田 達雄, 畑 七々子, 八木 千晶, 八木 孝仁, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 4   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 局所進行膵癌治療中のliquid biopsyによるKRAS遺伝子変異検出とCA19-9値推移の意義に関する検討

    吉田 龍一, 安井 和也, 楳田 祐三, 杭瀬 崇, 吉田 一博, 藤 智和, 松田 達雄, 八木 孝仁, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 4   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 我が国の肝移植医療の実力と未来【International】生体肝移植における有望な外科的イノベーション技術と周術期管理(Promising surgical innovation and perioperative management in living donor liver transplantation)

    楳田 祐三, 八木 孝仁, 吉田 龍一, 杭瀬 崇, 吉田 一博, 藤 智和, 安井 和也, 松田 達雄, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SY - 3   2020.8

     More details

    Language:English   Publisher:(一社)日本外科学会  

    researchmap

  • 一人前の肝胆膵外科医をめざして 中堅肝胆膵外科医からみる岡山大学育成システムの回顧と展望

    杭瀬 崇, 楳田 祐三, 吉田 龍一, 吉田 一博, 藤 智和, 安井 和也, 松田 達雄, 畑 七々子, 八木 千晶, 白川 靖博, 八木 孝仁, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SSF - 2   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 術前化学療法開始前から始めるチームによる食道がん周術期管理の有用性についての検討

    田辺 俊介, 白川 靖博, 赤井 正明, 西江 尚貴, 前田 直見, 櫻間 教文, 野間 和広, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 5   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 発生学・拡大視局所微細解剖に基づく最新の手術手技【Video】腹臥位胸腔鏡下食道癌手術における微細解剖に基づいた上縦隔リンパ節郭清定型化の工夫

    白川 靖博, 赤井 正明, 西江 尚貴, 橋本 将志, 前田 直見, 田辺 俊介, 楳田 祐三, 香川 俊輔, 野間 和広, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   WS - 2   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 局所進行食道癌・胃癌に対する内視鏡外科の手術手技【Video】気管前リンパ節転移、心膜T4症例に対する胸腔鏡下食道切除術

    前田 直見, 白川 靖博, 赤井 正明, 西江 尚貴, 田辺 俊介, 櫻間 教文, 野間 和広, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   WS - 8   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 肝動脈浸潤を伴う局所進行切除不能膵頭部癌に対する膵頭十二指腸切除術 結腸動脈を用いた肝動脈再建の適応と手術手技

    安井 和也, 吉田 龍一, 楳田 祐三, 杭瀬 崇, 吉田 一博, 藤 智和, 松田 達雄, 畑 七々子, 八木 千晶, 八木 孝仁, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   DP - 5   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 胃粘膜下腫瘍に対するClosed-LECSの成績と早期胃癌、十二指腸病変への応用

    菊地 覚次, 西崎 正彦, 黒田 新士, 高田 暢夫, 庄司 良平, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 7   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 化学療法反応性の症例に対するR0切除はstage IV胃癌の予後を改善する

    庄司 良平, 香川 俊輔, 高田 暢夫, 菊地 覚次, 黒田 新士, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 8   2020.8

     More details

    Language:English   Publisher:(一社)日本外科学会  

    researchmap

  • 解熱剤のアスピリン投与によるEMT阻害作用を介した大腸がん腹膜播種の抑制効果

    岡林 弘樹, 田澤 大, 家田 偉史, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 今村 健志, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 8   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 臨床医学の教育と研究における献体使用の現状と将来 Cadaver surgical trainingが果たすべき役割と未来

    近藤 喜太, 黒田 新士, 前田 直見, 楳田 祐三, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   CST - 3   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Immuno-Oncologyが変えるがん集学的治療【International】テロメラーゼ特異的腫瘍融解アデノウイルス製剤と抗PD-1抗体を併用した集学的免疫療法(Multidisciplinary immunotherapy with telomerase-specific oncolytic adenovirus and anti-PD-1 antibody)

    黒田 新士, 金谷 信彦, 垣内 慶彦, 公文 剣斗, 津村 朋子, 橋本 将志, 菊地 覚次, 西崎 正彦, 香川 俊輔, 田澤 大, 浦田 泰生, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SY - 5   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科の輝ける「未来」のために、我々が「今」できること

    竹原 裕子, 吉田 龍一, 溝尾 妙子, 剱持 礼子, 光井 恵麻, 佃 和寧, 土井原 博義, 豊岡 伸一, 笠原 真悟, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SSF - 2   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 大腸癌以外の肝転移の切除成績 切除適応を見極める

    畑 七々子, 藤 智和, 楳田 祐三, 吉田 龍一, 杭瀬 崇, 吉田 一博, 安井 和也, 白川 靖博, 八木 孝仁, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   DP - 6   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 局所進行下部直腸癌に対する術前化学療法の治療成績

    寺石 文則, 高橋 一剛, 重安 邦俊, 矢野 修也, 母里 淑子, 近藤 喜太, 岸本 浩行, 香川 俊輔, 藤原 俊義

    日本大腸肛門病学会雑誌   73 ( 7 )   341 - 341   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 有茎広背筋弁移植による胸部食道癌術後気管瘻の予防

    太田 智之, 松本 洋, 前田 直見, 田邊 俊介, 野間 和広, 白川 靖博, 藤原 俊義, 木股 敬裕

    頭頸部癌   46 ( 2 )   180 - 180   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • Skeletal muscle loss in the postoperative acute phase after esophageal cancer surgery as a new prognostic factor. International journal

    Naoaki Maeda, Yasuhiro Shirakawa, Shunsuke Tanabe, Kazufumi Sakurama, Kazuhiro Noma, Toshiyoshi Fujiwara

    World journal of surgical oncology   18 ( 1 )   143 - 143   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The postoperative survival rate of patients with esophageal squamous cell carcinoma (ESCC) remains poor compared with other gastrointestinal cancers. We hypothesized that skeletal muscle loss in the postoperative acute phase might be a new predictor for long-term prognosis after highly invasive surgery such as ESCC surgery. METHODS: The following items were retrospectively investigated. First, whether skeletal muscle loss occurred in the postoperative acute phase of ESCC was verified. Second, the preoperative and intraoperative factors involved in skeletal muscle loss in the postoperative acute phase of ESCC were investigated. Then, whether skeletal muscle loss in the postoperative acute phase affected long-term prognosis was examined. The medical records of consecutive patients who underwent radical esophagectomy for ESCC between January 2010 and February 2015 were retrospectively reviewed; 72 cases were eligible for this study. The total psoas major muscle mass index (TPI) at the level of the third lumbar vertebra (L3) was measured using computed tomography (CT) before surgery and 3 days after surgery. The long-term prognosis was estimated by the Kaplan-Meier method and the multivariate logistic regression model. RESULTS: There was already a significant reduction of TPI in the acute phase up to POD 3 after ESCC surgery in comparison with the preoperative baseline TPI (P < 0.001). The TPI reduction rate was significantly milder in cases with less blood loss during surgery and in cases that underwent thoracoscopic esophagectomy than in cases that underwent open esophagectomy. The 3-year overall survival rate was significantly different between the TPI reduction rate severe group and the TPI reduction rate mild group. CONCLUSION: Skeletal muscle loss occurred even in the postoperative acute phase. Furthermore, it is very significant that skeletal muscle loss in the postoperative acute phase of ESCC surgery is involved in the long-term prognosis.

    DOI: 10.1186/s12957-020-01908-6

    PubMed

    researchmap

  • 肺癌と直腸癌の同時性重複癌にpembrolizumabが著効した1例

    岡 凌也, 寺石 文則, 杉本 龍馬, 武田 正, 垣内 慶彦, 高田 暢夫, 重安 邦俊, 菊地 覚次, 矢野 修也, 近藤 喜太, 黒田 新士, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   81 ( 6 )   1202 - 1203   2020.6

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 整形トピックス 骨肉腫に対する抗PD-1抗体の効果増強をめざした腫瘍融解ウイルス併用複合免疫療法の開発

    望月 雄介, 田澤 大, 出宮 光二, 久禮 美穂, 長谷井 嬢, 中田 英二, 国定 俊之, 浦田 泰生, 藤原 俊義, 尾崎 敏文

    整形外科   71 ( 7 )   786 - 786   2020.6

  • 横隔膜上食道憩室に対して胸腔鏡下憩室切除術を施行した1例

    久松 加寿也, 白川 靖博, 赤井 正明, 西江 尚貴, 前田 直見, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   81 ( 6 )   1202 - 1202   2020.6

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 女性外科医の生活の現状と展望

    八木 千晶, 吉田 龍一, 黒田 新士, 藤原 俊義

    日本臨床外科学会雑誌   81 ( 6 )   1204 - 1204   2020.6

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 腹腔鏡下胃全摘術における食道空腸吻合の手技と治療成績

    高田 暢夫, 黒田 新士, 庄司 良平, 菊地 覚次, 西崎 正彦, 香川 俊輔, 白川 博靖, 藤原 俊義

    日本臨床外科学会雑誌   81 ( 6 )   1202 - 1202   2020.6

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • Intraoperative fluid therapy and postoperative complications during minimally invasive esophagectomy for esophageal cancer: a single-center retrospective study.

    Yukiko Hikasa, Satoshi Suzuki, Yuko Mihara, Shunsuke Tanabe, Yasuhiro Shirakawa, Toshiyoshi Fujiwara, Hiroshi Morimatsu

    Journal of anesthesia   34 ( 3 )   404 - 412   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Compared with open thoracotomy, minimally invasive esophagectomy (MIE) methods, such as transhiatal or thoracoscopic esophagectomy, likely have lower morbidity. However, the relationship between intraoperative fluid management and postoperative complications after MIE remains unclear. Thus, we investigated the association of cumulative intraoperative fluid balance and postoperative complications in patients undergoing MIE. METHODS: This single-center retrospective cohort study examined patients undergoing thoracoscopic esophagectomy for esophageal cancer in the prone position. Postoperative complications included pneumonia, arrhythmia, thrombotic events and acute kidney injury (AKI). We compared patients with higher and lower intraoperative fluid balance (higher and lower than the median). Multivariable logistic regression analyses were performed to estimate the odds ratio of intraoperative fluid balance status on the incidence of postoperative complications. RESULTS: In total, 135 patients were included in the study. Postoperative complications occurred in 43 (32%), including cardiac arrhythmia (n = 12, 9%), thrombosis (n = 20, 15%), pneumonia (n = 13, 10%), and AKI required hemodialysis (n = 1, 1%). Patients with a higher fluid balance had higher incidence of complications than those with a lower fluid balance (46% vs. 18%, p < 0.001). After adjusting for age, ASA-PS ≥ III, blood loss, and the use of radical surgery, the higher intraoperative fluid balance group was significantly and independently associated with postoperative complications (adjusted OR 5.31, 95% CI 2.26-13.6, p < 0.0001). CONCLUSIONS: In patients undergoing thoracoscopic esophagectomy in the prone position, a greater intraoperative positive fluid balance was independently associated with a higher incidence of complications.

    DOI: 10.1007/s00540-020-02766-y

    PubMed

    researchmap

  • 希少脾腫瘍の2例 SANT(sclerosing angiomatoid nodular transformation)とIPT(inflammatory pseudotumor)

    村田 光隆, 杭瀬 崇, 畑 七々子, 八木 千晶, 松田 達雄, 安井 和也, 藤 智和, 吉田 一博, 吉田 龍一, 楳田 祐三, 八木 孝仁, 藤原 俊義

    日本臨床外科学会雑誌   81 ( 6 )   1203 - 1203   2020.6

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer. International journal

    Nobuhito Kubota, Fumitaka Taniguchi, Akihiro Nyuya, Yuzo Umeda, Yoshiko Mori, Toshiyoshi Fujiwara, Hiroaki Tanioka, Atsushi Tsuruta, Yoshiyuki Yamaguchi, Takeshi Nagasaka

    Oncology letters   19 ( 4 )   2685 - 2694   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Colorectal cancer (CRC) manifests after the accumulation of genetic and epigenetic alterations along with tumor microenvironments. MicroRNA (miRNA/miR) molecules have been revealed to serve in critical roles in the progression various types of cancer, and their expression level is often an important diagnostic, predictive or prognostic biomarker. The aim of the present study was to evaluate the potential of miRNAs as prognostic biomarkers for patients with advanced CRC. miRNA arrays were performed on CRC specimens obtained from tumors with various molecular statuses [e.g. KRAS proto-oncogene, GTPase (KRAS)/B-Raf proto-oncogene, serine/threonine kinase (BRAF)/microsatellite instability (MSI)], and their paired normal mucosal specimens. The miRNA array revealed that miR-31-5p (miR-31) was specifically upregulated in CRCs with the BRAF V600E mutation, the results of which were supported by subsequent analysis of a dataset retrieved from The Cancer Genome Atlas (TCGA) database, which contained information regarding 170 patients with CRC including 51 BRAF-mutant CRCs. Of our cohort of 67 patients with stage IV CRC, 15 (22%) and 4 (6%) showed KRAS and BRAF V600E mutations, respectively. Since the median miR-31 expression was 3.45 (range, 0.004-6330.531), the cut-off value was chosen as 3.5, and all tumors were categorized into two groups accordingly (high-/low-miR-31 expression). The high miR-31 expression group (n=33) was significantly associated with a poorer mortality (univariate hazard ratio=2.12; 95% confidence interval, 0.23-0.95; P=0.03) and exhibited a shorter median survival time (MST; 20.1 months) compared with the low miR-31 expression group (n=34) (MST, 38.3 months; P=0.03), indicating that miR-31 is a promising prognostic biomarker for patients with advanced CRC. Thus, performing a functional analysis of miR-31 expression may lead to the development of new targeted therapies for the various genetic subtypes of CRC.

    DOI: 10.3892/ol.2020.11365

    PubMed

    researchmap

  • Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.

    Masashi Hashimoto, Yasuhiro Shirakawa, Naoaki Maeda, Shunsuke Tanabe, Kazuhiro Noma, Kazufumi Sakurama, Kuniaki Katsui, Masahiko Nishizaki, Toshiyoshi Fujiwara

    Esophagus : official journal of the Japan Esophageal Society   17 ( 2 )   127 - 134   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Locally advanced esophageal cancer (EC) invading surrounding organs (T4b) is difficult to treat. In general, definitive chemoradiotherapy (d-CRT) has been chosen as treatment for such cases. However, the outcome has not been good. Recently, the effectiveness of d-CRT with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) has been reported. Furthermore, surgery after d-CRT has a better prognosis than d-CRT alone in some reports, although it has a high risk of surgical complications. This study investigated the effectiveness and safety of induction DCF-RT. METHODS: The subjects were EC patients who underwent induction DCF-RT in Okayama University Hospital between January 2011 and December 2017. Their background characteristics, treatment details, histopathological factors, adverse events during CRT, postoperative complications, and overall survival (OS) were assessed. RESULTS: A total of 16 cases were performed induction DCF-RT. In 10 cases, death occurred, with 9 cancer-related deaths, and 1 death due to other disease. For all cases, OS was 37.5% at 3 years. 12 cases underwent esophagectomy after DCF-RT. Their OS was 50% at 3 years. 13 patients (81.3%) had Grade 3 febrile neutropenia. In 7 cases (62.5%), fasting for the treatment of diarrhea was needed. Three patients (25%) developed anastomotic leakage. Some recurrent laryngeal nerve paralysis was observed in 6 cases (50%). CONCLUSION: Although the rates of adverse events and surgical complications were slightly higher than in past reports, they were acceptable. It is useful to perform induction DCF-RT for T4b EC.

    DOI: 10.1007/s10388-019-00709-5

    PubMed

    researchmap

  • 術前SOX療法を施行した進行胃癌症例の治療成績(Outcomes of preoperative S-1 plus oxaliplatin(SOX) therapy for advanced gastric cancer)

    香川 俊輔, 黒田 新士, 菊地 覚次, 高田 暢夫, 垣内 慶彦, 武田 正, 野間 和広, 田辺 俊介, 寺石 文則, 近藤 喜太, 矢野 修也, 重安 邦俊, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本胃癌学会総会記事   92回   288 - 288   2020.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 術前SOX療法を施行した進行胃癌症例の治療成績(Outcomes of preoperative S-1 plus oxaliplatin(SOX) therapy for advanced gastric cancer)

    香川 俊輔, 黒田 新士, 菊地 覚次, 高田 暢夫, 垣内 慶彦, 武田 正, 野間 和広, 田辺 俊介, 寺石 文則, 近藤 喜太, 矢野 修也, 重安 邦俊, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本胃癌学会総会記事   92回   288 - 288   2020.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 食道癌患者に対する腫瘍融解ウイルスの内視鏡的投与の実際 病棟実施にむけた他部署連携

    矢野 朋美, 采女 典子, 森 隆弘, 笠原 由美子, 石川 貴子, 田辺 俊介, 黒田 新士, 野間 和広, 田澤 大, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器内視鏡技師会会報   ( 64 )   111 - 112   2020.3

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡技師会  

    researchmap

  • 高齢者胃癌の治療成績と栄養状態向上を目指した治療戦略(Strategy to improve the outcome and nutritional status for elderly gastric cancer patients)

    高田 暢夫, 伊藤 雅典, 庄司 良平, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   92回   252 - 252   2020.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 【消化器外科手術の論点2020 誌上ディベートと手術手技】胃外科 噴門側胃切除後の再建法 観音開き法の立場から

    黒田 新士, 西崎 正彦, 菊地 覚次, 高田 暢夫, 香川 俊輔, 藤原 俊義

    手術   74 ( 4 )   477 - 483   2020.3

  • Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy. Reviewed International journal

    Hiroshi Tazawa, Joe Hasei, Shuya Yano, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    Cancers   12 ( 2 )   2020.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Adenovirus serotype 5 (Ad5) is widely and frequently used as a virus vector in cancer gene therapy and oncolytic virotherapy. Oncolytic virotherapy is a novel antitumor treatment for inducing lytic cell death in tumor cells without affecting normal cells. Based on the Ad5 genome, we have generated three types of telomerase-specific replication-competent oncolytic adenoviruses: OBP-301 (Telomelysin), green fluorescent protein (GFP)-expressing OBP-401 (TelomeScan), and tumor suppressor p53-armed OBP-702. These viruses drive the expression of the adenoviral E1A and E1B genes under the control of the hTERT (human telomerase reverse transcriptase-encoding gene) promoter, providing tumor-specific virus replication. This review focuses on the therapeutic potential of three hTERT promoter-driven oncolytic adenoviruses against bone and soft-tissue sarcoma cells with telomerase activity. OBP-301 induces the antitumor effect in monotherapy or combination therapy with chemotherapeutic drugs via induction of autophagy and apoptosis. OBP-401 enables visualization of sarcoma cells within normal tissues by serving as a tumor-specific labeling reagent for fluorescence-guided surgery via induction of GFP expression. OBP-702 exhibits a profound antitumor effect in OBP-301-resistant sarcoma cells via activation of the p53 signaling pathway. Taken together, telomerase-specific oncolytic adenoviruses are promising antitumor reagents that are expected to provide novel therapeutic options for the treatment of bone and soft-tissue sarcomas.

    DOI: 10.3390/cancers12020478

    PubMed

    researchmap

  • Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. Reviewed International journal

    Nobuhiko Kanaya, Shinji Kuroda, Yoshihiko Kakiuchi, Kento Kumon, Tomoko Tsumura, Masashi Hashimoto, Toshiaki Morihiro, Tetsushi Kubota, Katsuyuki Aoyama, Satoru Kikuchi, Masahiko Nishizaki, Shunsuke Kagawa, Hiroshi Tazawa, Hiroyuki Mizuguchi, Yasuo Urata, Toshiyoshi Fujiwara

    Molecular therapy : the journal of the American Society of Gene Therapy   28 ( 3 )   794 - 804   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The clinical benefit of monotherapy involving immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 antibody (PD-1 Ab) is limited to small populations. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301), the safety of which was confirmed in a phase I clinical study. Here, we examined the potential of OBP-502, an OBP-301 variant, as an agent for inducing immunogenic cell death (ICD) and synergistically enhancing the efficacy of OBP-502 with PD-1 Ab using CT26 murine colon cancer and PAN02 murine pancreatic cancer cell lines. OBP-502 induced the release of ICD molecules such as adenosine triphosphate (ATP) and high-mobility group box protein 1 (HMGB1) from CT26 and PAN02 cells, leading to recruitment of CD8-positive lymphocytes and inhibition of Foxp3-positive lymphocyte infiltration into tumors. Combination therapy involving OBP-502 intratumoral administration and PD-1 Ab systemic administration significantly suppressed the growth of not only OBP-502-treated tumors but also tumors not treated with OBP-502 (so-called abscopal effect) in CT26 and PAN02 bilateral subcutaneous tumor models, in which active recruitment of CD8-positve lymphocytes was observed even in tumors not treated with OBP-502. This combined efficacy was similar to that observed in a CT26 rectal orthotopic tumor model involving liver metastases. In conclusion, telomerase-specific oncolytic adenoviruses are promising candidates for combined therapies with ICIs.

    DOI: 10.1016/j.ymthe.2020.01.003

    PubMed

    researchmap

  • Development of a Novel Oncolytic Adenovirus Expressing a Short-hairpin RNA Against Cullin 4A. International journal

    Keisaku Wakabayashi, Fuminori Sakurai, Ryosuke Ono, Toshiyoshi Fujiwara, Hiroyuki Mizuguchi

    Anticancer research   40 ( 1 )   161 - 168   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Arming of an oncolytic adenovirus (OAd) by inserting expression cassettes of therapeutic transgenes into the OAd genome is a promising approach to enhance the therapeutic effects of an OAd. Ideally, this approach would simultaneously promote the replication of an OAd in tumor cells and transgene product-mediated antitumor effects by expressing therapeutic transgenes. We previously demonstrated that knockdown of cullin 4A (CUL4A), which is an E3 ubiquitin ligase, significantly promoted adenovirus replication by increasing the c-JUN protein level. In addition, previous studies reported that CUL4A was highly expressed in various types of tumor, and was involved in tumor growth and metastasis. MATERIALS AND METHODS: In this study, we developed a novel OAd expressing a short-hairpin RNA (shRNA) against CUL4A (OAd-shCUL4A). RESULTS: OAd-shCUL4 mediated higher levels of cytotoxic effects on various types of human tumor cell than a conventional OAd. Higher levels of OAd genome copy numbers were found in the tumor cells for OAd-shCUL4A, compared with a conventional OAd. CONCLUSION: OAd-shCUL4A showed efficient antitumor effects by both enhancing OAd replication and inhibiting tumor cell growth.

    DOI: 10.21873/anticanres.13937

    PubMed

    researchmap

  • "伝わる"肝胆膵外科手術記録 iPadを用いた効率的で効果的なイラスト作成法

    楳田 祐三, 藤原 俊義

    日本消化器外科学会雑誌   53 ( 1 )   105 - 115   2020.1

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    手術記録は,診療情報にとどまらず,外科修練における研鑽,医療チーム内での手術情報の共有,そして紹介医へのfeed-backと,その意義は大きい.今回,iPadを用いた効率的で効果的なイラスト作成を中心に,我々が実践している"伝わる"肝胆膵外科手術記録の作成法を紹介する.従来の手描き法と異なり,iPad/Apple pencil/描画アプリを用いることで,自由な描き直し,レイヤー機能や多岐にわたる着色ツール,拡大・縮小機能による微細描画や着色時間の短縮,イラストパーツの貼付など,効率的で効果的なイラストの作成が可能となる.外科修練において,繰り返し手術イラストの作成に取り組むことは,観察力を養い,解剖構造の理解を深め,手術の本質を理解し修得するのに有用である.症例からの学びと反省,患者さん,そして紹介医の患者さんへの思い入れに報いるためにも,手術のみならず,外科医の想いが"伝わる"手術記録の作成に,外科医は一例入魂の精神で臨むことが望まれる.(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J01117&link_issn=&doc_id=20200131210016&doc_link_id=10.5833%2Fjjgs.2020.sr005&url=https%3A%2F%2Fdoi.org%2F10.5833%2Fjjgs.2020.sr005&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • Short-term and long-term comparisons of laparoscopy-assisted proximal gastrectomy with esophagogastrostomy by the double-flap technique and laparoscopy-assisted total gastrectomy for proximal gastric cancer. International journal

    Tomoko Tsumura, Shinji Kuroda, Masahiko Nishizaki, Satoru Kikuchi, Yoshihiko Kakiuchi, Nobuo Takata, Atene Ito, Megumi Watanabe, Kazuya Kuwada, Shunsuke Kagawa, Toshiyoshi Fujiwara

    PloS one   15 ( 11 )   e0242223   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Although proximal gastrectomy (PG) is a recognized surgical procedure for early proximal gastric cancer, total gastrectomy (TG) is sometimes selected due to concern about severe gastroesophageal reflux. Esophagogastrostomy by the double-flap technique (DFT) is an anti-reflux reconstruction after PG, and its short-term effectiveness has been reported. However, little is known about the long-term effects on nutritional status and quality of life (QOL). METHODS: Gastric cancer patients who underwent laparoscopy-assisted PG (LAPG) with DFT or laparoscopy-assisted TG (LATG) between April 2011 and March 2014 were retrospectively analyzed. Body weight (BW), body mass index (BMI), and prognostic nutritional index (PNI) were reviewed to assess nutritional status, and the Postgastrectomy Syndrome Assessment Scale (PGSAS)-45 was used to assess QOL. RESULTS: A total of 36 patients (LATG: 17, LAPG: 19) were enrolled. Four of 17 LATG patients (24%) were diagnosed with Stage ≥II after surgery, and half received S-1 adjuvant chemotherapy. BW and PNI were better maintained in LAPG than in LATG patients until 1-year follow-up. Seven of 16 LATG patients (44%) were categorized as "underweight (BMI<18.5 kg/m2)" at 1-year follow-up, compared to three of 18 LAPG patients (17%; p = 0.0836). The PGSAS-45 showed no significant difference in all QOL categories except for decreased BW (p = 0.0132). Multivariate analysis showed that LATG was the only potential risk factor for severe BW loss (odds ratio: 3.03, p = 0.0722). CONCLUSIONS: LAPG with DFT was superior to LATG in postoperative nutritional maintenance, and can be the first option for early proximal gastric cancer.

    DOI: 10.1371/journal.pone.0242223

    PubMed

    researchmap

  • Efficacy of surgical management for recurrent intrahepatic cholangiocarcinoma: A multi-institutional study by the Okayama Study Group of HBP surgery. International journal

    Toru Kojima, Yuzo Umeda, Tomokazu Fuji, Takefumi Niguma, Daisuke Sato, Yoshikatsu Endo, Kenta Sui, Masaru Inagaki, Masahiro Oishi, Tetsuya Ota, Katsuyoshi Hioki, Tadakazu Matsuda, Hideki Aoki, Ryuji Hirai, Masashi Kimura, Takahito Yagi, Toshiyoshi Fujiwara

    PloS one   15 ( 9 )   e0238392   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The prognosis of intrahepatic cholangiocarcinoma (ICC) has been poor, because of the high recurrence rate even after curative surgery. This study aimed to evaluate the prognostic impact of surgical resection of recurrent ICC. PATIENTS AND METHODS: A total of 345 cases of ICC who underwent hepatectomy with curative intent in 17 institutions were retrospectively analyzed, focusing on recurrence patterns and treatment modalities for recurrent ICC. RESULTS: Median survival time and overall 5-year recurrence-free survival rate were 17.8 months and 28.5%, respectively. Recurrences (n = 223) were classified as early (recurrence at ≤1 year, n = 131) or late (recurrence at >1 year, n = 92). Median survival time was poorer for early recurrence (16.3 months) than for late recurrence (47.7 months, p<0.0001). Treatment modalities for recurrence comprised surgical resection (n = 28), non-surgical treatment (n = 134), and best supportive care (BSC) (n = 61). Median and overall 1-/5-year survival rates after recurrence were 39.5 months and 84.6%/36.3% for surgical resection, 14.3 months and 62.5%/2.9% for non-surgical treatment, and 3 months and 4.8%/0% for BSC, respectively (p<0.0001). Multivariate analysis identified early recurrence, simultaneous intra- and extrahepatic recurrence, and surgical resection of recurrence as significant prognostic factors. In subgroup analyses, surgical resection may have positive prognostic impacts on intra- and extrahepatic recurrences, and even on early recurrence. However, simultaneous intra- and extrahepatic recurrence may not see any survival benefit from surgical management. CONCLUSION: Surgical resection of recurrent ICC could improve survival after recurrence, especially for patients with intra- or extrahepatic recurrence as resectable oligo-metastases.

    DOI: 10.1371/journal.pone.0238392

    PubMed

    researchmap

  • Laparoscopic liver resection of segment seven: A case report and review of surgical techniques. International journal

    Kosei Takagi, Takashi Kuise, Yuzo Umeda, Ryuichi Yoshida, Fuminori Teraishi, Takahito Yagi, Toshiyoshi Fujiwara

    International journal of surgery case reports   73   168 - 171   2020

     More details

    Language:English  

    INTRODUCTION: Laparoscopic liver resection of segment seven (LLR-S7) is a technically challenging procedure due to its anatomical location and difficult accessibility. Herein, we present our experience with LLR-S7, and demonstrate a literature review regarding surgical techniques. PRESENTATION OF CASE: A 28-year-old female was diagnosed with rectosigmoid cancer and synchronous liver metastases at the segment three (S3) and S7, which were treated with laparoscopic procedure. After the completely mobilization of the right lobe, the Glissonean pedicle of S7 (G7) was intrahepatically transected. The right hepatic vein was exposed to identify the venous branch of S7 (V7). Finally the liver parenchyma between RHV and dissection line was divided. DISCUSSION: Various laparoscopic approaches for S7 have been reported including the Glissonian approach from the hilum, the intrahepatic Glissonean approach, the caudate lobe first approach, and the lateral approach from intercostal ports. To perform LLR-S7 safely, it is important to understand the advantage of each technique including the trocar placement and approaches to S7 by laparoscopy. CONCLUSION: We present our experience of LLR-S7 for the tumor located at the top of S7, successfully performed with the intrahepatic Glissonean approach. LLR-S7 can be performed safely with advanced laparoscopic techniques and sufficient knowledge on various approaches for S7.

    DOI: 10.1016/j.ijscr.2020.06.107

    PubMed

    researchmap

  • A novel modified hanging maneuver in laparoscopic left hemihepatectomy. International journal

    Kosei Takagi, Yuzo Umeda, Takashi Kuise, Ryuichi Yoshida, Kazuhiro Yoshida, Kazuya Yasui, Yuma Tani, Takahito Yagi, Toshiyoshi Fujiwara

    International journal of surgery case reports   76   251 - 253   2020

     More details

    Language:English  

    INTRODUCTION: The liver hanging maneuver is an essential technique for controlling bleeding in hepatectomy, however it is often difficult in laparoscopic major hepatectomy. The present study describes a novel modified hanging maneuver in laparoscopic left hemihepatectomy. PRESENTATION OF CASE: A 29-year-old female underwent laparoscopic left hemihepatectomy for mucinous cystic neoplasm. After mobilizing the left lobe, the liver parenchyma was dissected along the demarcation line. For the hanging technique, the upper edge of the hanging tape was placed on the lateral side of the left hepatic vein, and fixed with the Falciform ligament. The lower edge of the tape was extracted outside the abdomen. Accordingly the hanging tape can be controlled extraperitoneally during the liver parenchyma dissection. DISCUSSION: This technique includes several advantages including no need of assistance using forceps, easy control of the hanging tape extraperitoneally, outflow control, better exposure of surgical field, and helpful guide of the liver dissection line toward the root of the left hepatic vein. CONCLUSION: Our novel modified hanging maneuver is easy and reproducible to use in laparoscopic left hemihepatectomy. Moreover, this technique can be applied to other laparoscopic hepatectomy.

    DOI: 10.1016/j.ijscr.2020.10.002

    PubMed

    researchmap

  • 直腸癌腹腔鏡手術における縫合不全と回腸人工肛門合併症の因果関係についての検討 Reviewed

    重安 邦俊, 母里 淑子, 矢野 修也, 近藤 喜太, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   24 ( 7 )   SF055 - 6   2019.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 3D画像構築を元に検討した胸腔鏡下食道癌手術において留意すべき解剖学的亜型

    前田 直見, 白川 靖博, 赤井 正明, 西江 尚貴, 田辺 俊介, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   24 ( 7 )   PT2 - 2   2019.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • LTGにおける食道空腸吻合の手技と治療成績

    高田 暢夫, 黒田 新士, 庄司 良平, 菊地 覚次, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   24 ( 7 )   MO246 - 1   2019.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 残胃癌に対する腹腔鏡下残胃全摘術の検討

    庄司 良平, 高田 暢夫, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   24 ( 7 )   SF041 - 1   2019.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡下観音開き法(上川法)再建の治療成績と吻合部狭窄予防のための取り組み

    黒田 新士, 西崎 正彦, 菊地 覚次, 高田 暢夫, 庄司 良平, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   24 ( 7 )   SF016 - 4   2019.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 食道癌に対するロボット支援手術 ロボット支援下食道癌手術導入におけるわれわれの工夫と今後の展望

    白川 靖博, 野間 和広, 赤井 正明, 西江 尚貴, 前田 直見, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   24 ( 7 )   WS11 - 5   2019.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡内視鏡合同手術(LECS)の新展開 Closed-LECSの新展開 早期胃癌、十二指腸病変への応用

    菊地 覚次, 西崎 正彦, 黒田 新士, 高田 暢夫, 庄司 良平, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   24 ( 7 )   PD18 - 3   2019.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 右鎖骨下動脈起始異常を合併した食道癌症例に対する縦隔鏡下食道亜全摘術の経験

    赤井 正明, 白川 靖博, 西江 尚貴, 前田 直見, 田辺 俊介, 野間 和広, 楳田 祐三, 藤原 俊義

    日本内視鏡外科学会雑誌   24 ( 7 )   MO252 - 3   2019.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 食道裂孔ヘルニア根治術による心負荷改善への貢献

    田辺 俊介, 白川 靖博, 赤井 正明, 西江 尚貴, 前田 直見, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   24 ( 7 )   SF072 - 1   2019.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 食道胃接合部癌に対するcTLA(combined thoracoscopic laparoscopic approach)の検討

    西江 尚貴, 野間 和広, 赤井 正明, 前田 直見, 田辺 俊介, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   24 ( 7 )   SF071 - 4   2019.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 反回神経周囲リンパ節郭清手技と麻痺軽減の工夫 胸腔鏡下手術における反回神経周囲微細解剖に留意した定型化手技

    野間 和広, 白川 靖博, 赤井 正明, 西江 尚貴, 前田 直見, 田辺 俊介, 藤原 俊義

    日本内視鏡外科学会雑誌   24 ( 7 )   PD16 - 2   2019.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • Visualization of epithelial-mesenchymal transition in an inflammatory microenvironment-colorectal cancer network. Reviewed International journal

    Ieda T, Tazawa H, Okabayashi H, Yano S, Shigeyasu K, Kuroda S, Ohara T, Noma K, Kishimoto H, Nishizaki M, Kagawa S, Shirakawa Y, Saitou T, Imamura T, Fujiwara T

    Scientific reports   9 ( 1 )   16378 - 16378   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Epithelial-mesenchymal transition (EMT) is a biological process by which epithelial cells acquire mesenchymal characteristics. In malignant tumors, EMT is crucial for acquisition of a mesenchymal phenotype with invasive and metastatic properties, leading to tumor progression. An inflammatory microenvironment is thought to be responsible for the development and progression of colorectal cancer (CRC); however, the precise role of inflammatory microenvironments in EMT-related CRC progression remains unclear. Here, we show the spatiotemporal visualization of CRC cells undergoing EMT using a fluorescence-guided EMT imaging system in which the mesenchymal vimentin promoter drives red fluorescent protein (RFP) expression. An inflammatory microenvironment including TNF-α, IL-1β, and cytokine-secreting inflammatory macrophages induced RFP expression in association with the EMT phenotype in CRC cells. In vivo experiments further demonstrated the distribution of RFP-positive CRC cells in rectal and metastatic tumors. Our data suggest that the EMT imaging system described here is a powerful tool for monitoring EMT in inflammatory microenvironment-CRC networks.

    DOI: 10.1038/s41598-019-52816-z

    PubMed

    researchmap

  • 周術期管理チーム介入によるリスク評価が高齢者大腸癌患者の術後アウトカムに与える影響

    寺石 文則, 重安 邦俊, 矢野 修也, 母里 淑子, 近藤 喜太, 藤原 俊義

    日本消化器外科学会雑誌   52 ( Suppl.2 )   253 - 253   2019.11

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • トランスレーショナルリサーチとしての外科治療を補完する新たな集学的治療の開発研究

    田澤 大, 田辺 俊介, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   120 ( 6 )   735 - 737   2019.11

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 低侵襲内視鏡治療の今後の展開 上部消化管腫瘍に対するClosed LECSの開発と応用

    西崎 正彦, 菊地 覚次, 藤原 俊義

    日本消化器病学会雑誌   116 ( 臨増大会 )   A503 - A503   2019.11

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  • Comparison of the Effects of Epidural Analgesia and Patient-controlled Intravenous Analgesia on Postoperative Pain Relief and Recovery After Laparoscopic Gastrectomy for Gastric Cancer. International journal

    Satoru Kikuchi, Shinji Kuroda, Masahiko Nishizaki, Takashi Matsusaki, Kazuya Kuwada, Yoshikazu Kimura, Shunsuke Kagawa, Hiroshi Morimatsu, Toshiyoshi Fujiwara

    Surgical laparoscopy, endoscopy & percutaneous techniques   29 ( 5 )   405 - 408   2019.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Epidural analgesia (EDA) is an imperative modality for postoperative pain relief after major open abdominal surgery. However, whether EDA has benefits in laparoscopic surgery has not been clear. In this study, the effects of EDA and patient-controlled intravenous analgesia (PCIA) after laparoscopic distal gastrectomy (LDG) were compared. METHODS: This was a retrospective study that included 82 patients undergoing LDG for gastric cancer. Patients received either EDA (n=67) or PCIA (n=15) for postoperative pain relief. Postoperative outcomes and analgesia-related adverse events were compared between the two modalities. RESULTS: EDA and PCIA patients showed no differences in the incidence of complications [9 (13%) vs. 2 (13%); P=0.99] and the length of postoperative hospital stay (9.6±4.5 d vs. 9.7±4.0 d; P=0.90), although the PCIA included poorer preoperative physical status (PS) patients. The number of additional doses of analgesics was higher in the EDA than in the PCIA (1.8±2.4 vs. 0.9±1.0; P=0.01), although postoperative pain scores were similar in the 2 groups. Though the time to first passage of flatus was shorter in the EDA (P<0.05), more EDA patients developed postoperative hypotension as an adverse event (P<0.01). The full mobilization day and the day of oral intake tolerance were not significantly different between the 2 groups after surgery. CONCLUSIONS: After LDG, EDA may not be indispensable, while PCIA may be the optimal modality for providing safe and effective postoperative analgesia and recovery.

    DOI: 10.1097/SLE.0000000000000605

    PubMed

    researchmap

  • ロボット支援下手術の現状と今後の展開1 胸腔鏡下食道切除に対する合併症ゼロへの挑戦 胸腔鏡下食道切除に対する合併症ゼロへの挑戦 鏡視下からロボット支援手術導入

    野間 和広, 白川 靖博, 西江 尚貴, 赤井 正明, 前田 直見, 田辺 俊介, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   80 ( 増刊 )   365 - 365   2019.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 進行・再発胃癌に対するNivolumab投与例の検討

    香川 俊輔, 黒田 新士, 菊地 覚次, 高田 暢夫, 庄司 良平, 西崎 正彦, 藤原 俊義

    日本癌治療学会学術集会抄録集   57回   P134 - 2   2019.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 【消化器腫瘍に対する腹腔鏡・内視鏡合同手術(LECS)up date】各種LECS手技 Closed LECS

    西崎 正彦, 菊地 覚次, 黒田 新士, 藤原 俊義

    外科   81 ( 11 )   1125 - 1129   2019.10

     More details

    Language:Japanese   Publisher:(株)南江堂  

    <文献概要>管内発育型や壁内発育型消化管間質腫瘍(gastrointestinal stromal tumor:GIST)を主体とした5cm以下の胃粘膜下腫瘍の手術療法は,内視鏡・腹腔鏡合同手術(laparoscopic and endoscopic cooperative surgery:LECS)の登場により必要最小限の胃部分切除を低侵襲手術として行うことが可能となった.しかし,LECS原法(classical LECS)では腫瘍切除の過程で胃内腔と腹腔が交通し,腫瘍も腹腔内に露出するため,潰瘍のあるGISTや早期胃癌は適応外と考えてきた.それらに対応するために胃壁を開放しない,あるいは胃内容物を撒布しない方法として,すでにいくつかの手技が臨床応用されているが,筆者らはclassical LECSを発展させたclosed LECSを考案したので,手術手技について概説する.

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J00393&link_issn=&doc_id=20191003060005&doc_link_id=issn%3D0016-593X%26volume%3D81%26issue%3D11%26spage%3D1125&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D0016-593X%26volume%3D81%26issue%3D11%26spage%3D1125&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

  • 鏡視下手術時代の外科感染対策はどうなる 食道癌に対する鏡視下手術導入による周術期管理の変遷と多職種介入による外科感染対策の現況

    田辺 俊介, 白川 靖博, 前田 直見, 野間 和広, 藤原 俊義

    日本外科感染症学会雑誌   16 ( 5 )   479 - 479   2019.10

     More details

    Language:Japanese   Publisher:(一社)日本外科感染症学会  

    researchmap

  • DCF療法不応の進行食道癌に対する集学的治療の検討

    西江 尚貴, 白川 靖博, 赤井 正明, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 楳田 祐三, 藤原 俊義

    日本臨床外科学会雑誌   80 ( 増刊 )   564 - 564   2019.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 当院における若年発症の食道癌症例の検討

    赤井 正明, 白川 靖博, 西江 尚貴, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 楳田 祐三, 藤原 俊義

    日本臨床外科学会雑誌   80 ( 増刊 )   563 - 563   2019.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 他科との合同手術 形成外科とのコラボレーションによる食道癌手術

    田辺 俊介, 白川 靖博, 西江 尚貴, 赤井 正明, 前田 直見, 櫻間 教文, 野間 和広, 楳田 祐三, 藤原 俊義

    日本臨床外科学会雑誌   80 ( 増刊 )   436 - 436   2019.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道切除術における再建の工夫 有茎空腸を用いた食道再建術における工夫

    前田 直見, 白川 靖博, 赤井 正明, 西江 尚貴, 田辺 俊介, 櫻間 教文, 野間 和広, 楳田 祐三, 藤原 俊義

    日本臨床外科学会雑誌   80 ( 増刊 )   427 - 427   2019.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 消化器外科手術におけるNPWTの最前線 クローン病に対する治療的および予防的NPWT、当院IBDセンターにおける10年の変遷

    近藤 喜太, 藤原 俊義

    日本外科感染症学会雑誌   16 ( 5 )   502 - 502   2019.10

     More details

    Language:Japanese   Publisher:(一社)日本外科感染症学会  

    researchmap

  • がん関連線維芽細胞(CAFs)による腫瘍免疫抑制のメカニズムについて(Exploring the mechanism of cancer-associated fibroblasts(CAFs) induced immunosuppression in tumor microenvironment) Reviewed

    西脇 紀之, 野間 和広, 小林 照貴, 鳴坂 徹, 河本 慧, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   78回   P - 3083   2019.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 鉄キレート剤による幹細胞性制御による新規食道癌治療法(Stemness control by iron chelator is a novel therapeutic strategy for esophageal cancer treatment) Reviewed

    鳴坂 徹, 大原 利章, 桂 佑貴, 野間 和広, 西脇 紀之, 河本 慧, 田澤 大, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   78回   P - 1077   2019.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 骨肉腫に対する抗PD-1抗体と腫瘍融解アデノウイルスの複合免疫療法

    望月 雄介, 田澤 大, 出宮 光二, 久禮 美穂, 長谷井 嬢, 中田 英二, 国定 俊之, 浦田 泰生, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   93 ( 8 )   S1672 - S1672   2019.9

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 骨肉腫に対するp53誘導性腫瘍融解ウイルス療法のアブスコパル効果

    出宮 光二, 田澤 大, 久禮 美穂, 望月 雄介, 長谷井 嬢, 中田 英二, 国定 俊之, 浦田 泰生, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   93 ( 8 )   S1673 - S1673   2019.9

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 骨肉腫に対するテロメラーゼ特異的腫瘍融解ウイルスを用いた複合免疫療法(Combination immunotherapy with telomerase-specific oncolytic adenovirus for osteosarcoma)

    出宮 光二, 田澤 大, 望月 雄介, 久禮 美穂, 近藤 宏也, 長谷井 嬢, 国定 俊之, 浦田 泰生, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   78回   J - 1001   2019.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 【肝内胆管癌のすべて】リンパ節郭清の意義

    稲垣 優, 楳田 祐三, 八木 孝仁, 藤原 俊義

    消化器外科   42 ( 10 )   1417 - 1426   2019.9

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • 化学放射線療法は線維芽細胞の活性化を介して食道癌細胞の悪性度を向上させる(Chemoradiotherapy promotes malignancy of cancer cells via activating fibroblasts in esophageal squamous cell carcinomas) Reviewed

    河本 慧, 野間 和広, 小林 照貴, 西脇 紀之, 鳴坂 徹, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   78回   E - 1038   2019.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • Cureを得るためには ヒト悪性腫瘍に対する集学的腫瘍融解ウイルス療法 現状と次世代の展望(Aiming to cure cancer Multidisciplinary oncolytic virotherapy for human cancer: current status and next-generation perspective)

    藤原 俊義, 田澤 大, 田辺 俊介, 浦田 泰生, 白川 靖博

    日本癌学会総会記事   78回   S8 - 6   2019.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 消化器外科領域に応用可能な分子レベルの技術開発 標準治療が困難な食道がん患者に対する低侵襲なテロメラーゼ標的型分子治療法の開発(Molecular Technology Development for Gastroenterological Diseases Minimally invasive telomerase-targeted molecular therapy in esophageal cancer patients unfit for standard treatments)

    田澤 大, 田辺 俊介, 野間 和広, 黒田 新士, 香川 俊輔, 浦田 泰生, 白川 靖博, 藤原 俊義

    日本癌学会総会記事   78回   SST6 - 7   2019.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 腫瘍融解ウイルス療法にて認められるアブスコパル効果と細胞外小胞の関連性についてのリバーストランスレーショナルリサーチ(Reverse translational research with extracellular vesicles for the abscopal effect of oncolytic adenovirotherapy)

    垣内 慶彦, 黒田 新士, 金谷 信彦, 公文 剣斗, 津村 朋子, 橋本 将志, 菊地 覚次, 西崎 正彦, 香川 俊輔, 田澤 大, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   78回   E - 3056   2019.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • テロメラーゼ依存性腫瘍融解ウイルスは化学療法抵抗性の膵臓がん細胞を破壊する(Telomerase-specific oncolytic virus eliminates chemoresistant pancreatic ductal adenocarcinoma cells)

    伏見 卓郎, 田澤 大, 荒木 宏之, 西山 岳芳, 菊地 覚次, 黒田 新士, 野間 和広, 吉田 龍一, 西崎 正彦, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   78回   E - 3003   2019.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 解熱剤のアスピリンはEMT阻害作用を介して大腸がんの腹膜播種を抑制する(Antipyretic aspirin inhibits peritoneal dissemination of colon cancer cells via suppression of EMT)

    岡林 弘樹, 田澤 大, 家田 偉史, 矢野 修也, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 今村 健志, 藤原 俊義

    日本癌学会総会記事   78回   J - 2032   2019.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 癌微小環境での胃癌に対するp53武装化腫瘍溶解アデノウイルスの影響(The impact of p53-arming multi-potent oncolytic adenovirus on gastric cancer cells in tumor microenvironment)

    小川 俊博, 菊地 覚次, 石川 亘, 田澤 大, 田渕 幹康, 黒田 新士, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   78回   J - 2029   2019.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 膵癌に対する免疫チェックポイント阻害剤を併用したテロメラーゼ特異的腫瘍融解免疫療法(Telomerase-specific oncolytic immunotherapy combined with immune checkpoint inhibitor against pancreatic cancer)

    荒木 宏之, 田澤 大, 金谷 信彦, 伏見 卓郎, 西山 岳芳, 菊地 覚次, 黒田 新士, 吉田 龍一, 西崎 正彦, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   78回   E - 2110   2019.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • Cureを得るためには 好中球細胞外トラップによるEMTを介した消化器癌肝転移促進メカニズムの解明(Aiming to cure cancer Neutrophil extracellular traps promote liver metastasis of gastrointestinal cancer through the induction of EMT)

    梶岡 裕紀, 香川 俊輔, 田澤 大, 伊藤 雅典, 桑田 和也, 菊池 覚次, 黒田 新士, 藤原 俊義

    日本癌学会総会記事   78回   S8 - 5   2019.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道裂孔ヘルニアの腹腔鏡下逆流防止手術後に発症した食道胃接合部癌に対し,腹腔鏡下にredo surgeryを施行した1例

    田辺 俊介, 白川 靖博, 黒田 新士, 野間 和広, 西崎 正彦, 藤原 俊義

    手術   73 ( 10 )   1503 - 1507   2019.9

     More details

    Language:Japanese   Publisher:金原出版(株)  

    70代女。腹腔鏡下逆流防止手術(LARS)の5年後に食道胃接合部癌を認め、腹腔鏡下に噴門側胃切除術と観音開き法による再建を行った。本例では逆流防止手術としてLARSと観音開き法再建という2種類の術式を施行し、いずれも有効であった。

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J00620&link_issn=&doc_id=20190906120017&doc_link_id=10.18888%2Fop.0000001395&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fop.0000001395&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  • 神経芽腫に対するp53発現性腫瘍融解アデノウイルスによる免疫原性細胞死の誘導効果(Induction of immunogenic cell death by p53-armed telomerase-specific oncolytic adenovirus in neuroblastoma)

    谷 守通, 田澤 大, 谷本 光隆, 納所 洋, 浦田 泰生, 香川 俊輔, 野田 卓男, 藤原 俊義

    日本癌学会総会記事   78回   P - 1178   2019.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 本音で話そう、それぞれの手術室プロフェッショナルの思い-安全で低侵襲な手術医療にコミットする手術室多職種チーム- 高難度手術におけるCadaver Surgical Trainingによるチームシミュレーション教育

    近藤 喜太, 藤原 俊義

    日本手術看護学会誌   15 ( 2 )   97 - 97   2019.9

     More details

    Language:Japanese   Publisher:日本手術看護学会  

    researchmap

  • 【微細解剖に基づいた正確な上部消化管リンパ節郭清術】胃癌に対するNo.8a、9膵上縁リンパ節郭清術

    西崎 正彦, 黒田 新士, 菊地 覚次, 藤原 俊義

    消化器外科   42 ( 9 )   1351 - 1358   2019.8

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • 【外科におけるカテーテル管理のコツ】消化管内留置カテーテル イレウス管の留置適応と管理法

    近藤 喜太, 藤原 俊義

    外科   81 ( 9 )   917 - 922   2019.8

     More details

    Language:Japanese   Publisher:(株)南江堂  

    <文献概要>イレウス管の適応決定に造影CTは必須の検査であり,虚血あるいは可逆性の閉塞を示唆する所見があれば,外科的治療を積極的に考慮する.挿入後は吸引器あるいは用手的に,間欠吸引あるいは低圧持続吸引を行い,開存を確認する必要がある.抜去の可否決定には造影検査が有用である.イレウス管は迅速な減圧が可能となる強力な治療であるが,患者にかなりの苦痛を強いる治療であることを医療者は意識する必要がある.

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J00393&link_issn=&doc_id=20190729080003&doc_link_id=issn%3D0016-593X%26volume%3D81%26issue%3D9%26spage%3D917&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D0016-593X%26volume%3D81%26issue%3D9%26spage%3D917&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

  • Endoscopic Ultrasound-Guided Transgastric Drainage of an IntraAbdominal Abscess following Gastrectomy. International journal

    Satoru Kikuchi, Tetsushi Kubota, Shinji Kuroda, Masahiko Nishizaki, Shunsuke Kagawa, Hironari Kato, Hiroyuki Okada, Toshiyoshi Fujiwara

    Clinical endoscopy   52 ( 4 )   373 - 376   2019.7

     More details

    Language:English  

    Endoscopic ultrasound (EUS)-guided transgastric drainage has been performed as a less invasive procedure for pancreatic fistulas and intra-abdominal abscesses occurring after surgery in recent years. However, there are no reports of EUS-guided transgastric drainage of intra-abdominal abscesses following gastrectomy. This case report describes 2 patients who developed an intra-abdominal abscess following gastrectomy and underwent EUS-guided transgastric drainage. Both patients underwent laparoscopy-assisted distal gastrectomy with Billroth-I reconstruction for gastric cancer. The intra-abdominal abscesses were caused by postoperative pancreatic fistula that developed following gastrectomy. One patient underwent naso-cystic drainage and the other underwent only a needle puncture of the abscess cavity. EUS-guided drainage was performed safely and effectively, although 1 patient developed gastroduodenal anastomotic leakage related to this procedure. In summary, EUS-guided transgastric drainage is safe and technically feasible even in post-gastrectomy patients. However, it is necessary to be careful if this procedure is performed in the early period following gastrectomy.

    DOI: 10.5946/ce.2018.134

    PubMed

    researchmap

  • 【大腸】ストーマ造設法と閉鎖法の工夫 回腸双孔式人工肛門の2大合併症である閉塞とhigh output stomaのリスク因子同定と回避のための工夫 Reviewed

    重安 邦俊, 矢野 修也, 母里 淑子, 近藤 喜太, 岸本 浩行, 寺石 文則, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   74回   WS10 - 6   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【徹底解説! 噴門側胃切除術】私の手技 再建 逆流性食道炎が生じにくい観音開き法再建の手技と特徴

    西崎 正彦, 黒田 新士, 菊地 覚次, 藤原 俊義

    臨床外科   74 ( 7 )   832 - 835   2019.7

     More details

    Language:Japanese   Publisher:(株)医学書院  

    <文献概要>ポイント ◆噴門側胃切除後の消化管再建で最も注意すべき点は術後の逆流性食道炎の予防である.◆観音開き法再建(上川法,英語表記double-flap technique)は食道を胃壁に埋め込むことで逆流防止に効果的な一方弁を形成する.◆逆流防止には埋め込む食道の長さを十分にとること,狭窄予防には吻合操作やフラップ縫着時にきつく締めすぎないことが重要である.

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J01539&link_issn=&doc_id=20190628360012&doc_link_id=10.11477%2Fmf.1407212532&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1407212532&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  • 腹腔鏡手術は開腹手術と比較して術後の筋肉量減少を予防できる可能性がある

    桑田 和也, 金谷 信彦, 菊地 覚次, 黒田 新士, 吉田 龍一, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   74回   P46 - 2   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • ERASにおける腹腔鏡下胃切除術後の最適な鎮痛法

    菊地 覚次, 黒田 新士, 西崎 正彦, 桑田 和也, 金谷 信彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   74回   O30 - 4   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胃癌腹膜播種に対する新たな治療戦略としての腹腔内ウイルス療法

    石川 亘, 菊地 覚次, 田澤 大, 桑田 和也, 黒田 新士, 野間 和広, 西崎 正彦, 白川 靖博, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   74回   RS20 - 1   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 上腹部開腹歴を有する胃癌症例への腹腔鏡手術 ポート挿入までの定型化と短期治療成績

    黒田 新士, 津村 朋子, 桑田 和也, 菊地 覚次, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   74回   O14 - 2   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 神経解剖・層構造より解き明かす腹腔鏡下胃癌リンパ節郭清のポイント

    西崎 正彦, 渡邉 めぐみ, 黒田 新士, 菊地 覚次, 桑田 和也, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   74回   RS6 - 5   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 誌上ディベート(第15回) 噴門側胃切除後の再建方法 double tract vs. 観音開き法 観音開き法の立場から

    西崎 正彦, 黒田 新士, 菊地 覚次, 藤原 俊義

    消化器外科   42 ( 8 )   1250 - 1253   2019.7

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • 切除不能食道癌に対し化学放射線療法(CRT)を行いConversion Surgeryを行った11例の検討

    小林 照貴, 白川 靖博, 梅田 将志, 橋本 将志, 前田 直見, 田辺 俊介, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   74回   P18 - 2   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【肝胆膵】肝移植と合併症対策 生体肝移植後における脾動脈盗血症候群に対する治療介入の意義

    松田 達雄, 楳田 祐三, 吉田 一博, 安井 和也, 藤 智和, 杭瀬 崇, 吉田 龍一, 白川 靖博, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   74回   WS12 - 7   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【肝胆膵】大腸癌原発でない転移性肝癌に対する肝切除の適応と治療成績 非大腸癌・非内分泌腫瘍由来肝転移の切除成績 切除適応となる癌腫を見極める

    梶原 義典, 藤 智和, 楳田 祐三, 吉田 龍一, 杭瀬 崇, 吉田 一博, 安井 和也, 白川 靖博, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   74回   WS29 - 2   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【肝】肝移植ハイリスク患者への挑戦 生体肝移植におけるハイリスク症例 MELDは移植予後を反映するか

    楳田 祐三, 八木 孝仁, 吉田 龍一, 杭瀬 崇, 吉田 一博, 藤 智和, 松田 達雄, 安井 和也, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   74回   PD4 - 4   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 切除可能膵頭部癌における早期再発予測因子と転移形式の解析

    安井 和也, 吉田 龍一, 楳田 祐三, 杭瀬 崇, 吉田 一博, 藤 智和, 松田 達雄, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   74回   P246 - 5   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 医原性胆道損傷に対する修復術 Immediate repairと手技の要点

    杭瀬 崇, 楳田 祐三, 松田 達雄, 安井 和也, 藤 智和, 吉田 一博, 吉田 龍一, 白川 靖博, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   74回   P214 - 5   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 膵IPMN術後残膵再発累積リスクに着目した術後至適surveillance法の検討

    藤 智和, 楳田 祐三, 安井 和也, 吉田 一博, 杭瀬 崇, 吉田 龍一, 白川 靖博, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   74回   P237 - 2   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 再肝切除における根治性確保と合併症軽減に向けた工夫

    吉田 一博, 楳田 祐三, 吉田 龍一, 杭瀬 崇, 藤 智和, 松田 達雄, 安井 和也, 白川 靖博, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   74回   O10 - 7   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【食道】食道癌手術における再建のbest practice 有茎空腸を用いた食道再建術

    前田 直見, 白川 靖博, 梅田 将志, 橋本 将志, 小林 照貴, 田辺 俊介, 櫻間 教文, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   74回   PD1 - 8   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 根治をめざした食道癌の再発に対する集学的治療〜外科・内科・放射線科の立場から〜 食道癌術後再発に対する手術療法の意義の検討

    前田 直見, 白川 靖博, 橋本 将志, 小林 照貴, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   73回   24 - 24   2019.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌周術期管理におけるエビデンス創出に向けたPERiOの現況と課題

    白川 靖博, 橋本 将志, 小林 照貴, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   73回   11 - 11   2019.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 超高齢者食道癌症例のサルコペニアの有無は術後合併症の予測因子となり得るか?

    田辺 俊介, 白川 靖博, 橋本 将志, 小林 照貴, 前田 直見, 櫻間 教文, 野間 和広, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   73回   10 - 10   2019.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • トラスツズマブ耐性胃癌に対するHER2標的金ナノ粒子製剤の開発

    公文 剣斗, 黒田 新士, 久保田 哲史, 津村 朋子, 垣内 慶彦, 菊地 覚次, 西崎 正彦, 香川 俊輔, 田澤 大, 藤原 俊義

    日本DDS学会学術集会プログラム予稿集   35回   152 - 152   2019.6

     More details

    Language:Japanese   Publisher:日本DDS学会  

    researchmap

  • 腫瘍融解ウイルス療法によるエクソソームを介したアブスコパル効果の可能性

    垣内 慶彦, 黒田 新士, 金谷 信彦, 公文 剣斗, 津村 朋子, 菊地 覚次, 香川 俊輔, 田澤 大, 浦田 泰生, 藤原 俊義

    日本DDS学会学術集会プログラム予稿集   35回   140 - 140   2019.6

     More details

    Language:Japanese   Publisher:日本DDS学会  

    researchmap

  • 乳児劇症肝炎に対して生体肝移植術を施行した1例

    高木 弘誠, 八木 孝仁, 吉田 龍一, 藤 智和, 杭瀬 崇, 渡辺 信之, 信岡 大輔, 楳田 祐三, 篠浦 先, 藤原 俊義

    肝臓   60 ( 6 )   216 - 216   2019.6

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  • 食道癌術後における抑うつ傾向の頻度と臨床病期についての検討

    櫻間 教文, 平松 聡, 江原 啓太, 前田 直見, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   73回   381 - 381   2019.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 高度局所進行食道癌に対するサルベージ手術の治療成績

    橋本 将志, 白川 靖博, 小林 照貴, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   73回   292 - 292   2019.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 混合型食道裂孔ヘルニアに対する心負荷軽減に着目した新たな手術適応

    田辺 俊介, 白川 靖博, 橋本 将志, 小林 照貴, 前田 直見, 櫻間 教文, 野間 和広, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   73回   69 - 69   2019.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 再建臓器の評価とそれにもとづく再建法の工夫 食道切除における血流評価を元に行う安全な胃管・空腸再建法

    野間 和広, 橋本 将志, 小林 照貴, 前田 直見, 田辺 俊介, 櫻間 教文, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   73回   54 - 54   2019.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • Clinical Impact of Sarcopenia on Gastric Cancer. International journal

    Kazuya Kuwada, Shinji Kuroda, Satoru Kikuchi, Ryuichi Yoshida, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Anticancer research   39 ( 5 )   2241 - 2249   2019.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Sarcopenia is a complex syndrome defined by progressive and generalized loss of skeletal muscle mass and strength. Although sarcopenia is mainly associated with aging, cancer is also one of its causes. Sarcopenia is now drawing attention as a poor prognostic factor in cancer. In patients with gastric cancer associated with eating disorders that often leads to loss of weight and muscle, sarcopenia is particularly important. Its definition and method of assessment, however, vary between studies, thus these need to be standardized. Nevertheless, emerging evidence suggests that sarcopenia contributes independently to postoperative complications and overall survival in gastric cancer. Interventions preventing sarcopenia with targeted nutrition and exercise are currently explored. This review aims to provide an understanding of sarcopenia, emphasizing its importance in the management of gastric cancer.

    DOI: 10.21873/anticanres.13340

    PubMed

    researchmap

  • 岡山大学病院における大腸癌エキスパートパネル診療

    母里 淑子, 矢野 修也, 遠西 大輔, 田端 雅弘, 柳井 広之, 豊岡 伸一, 平沢 晃, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   PS - 1   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • トランスレーショナルリサーチとしての外科治療を補完する新たな集学的治療の開発研究

    田澤 大, 田辺 俊介, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   SP - 5   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 肥満症に対する腹腔鏡下スリーブ状胃切除術の導入とその効果

    香川 俊輔, 黒田 新士, 菊地 覚次, 桑田 和也, 津村 朋子, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   PS - 1   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • テロメラーゼ標的蛍光発現ウイルスを用いた腹腔内腫瘍関連マクロファージの機能解析

    桑田 和也, 香川 俊輔, 菊地 覚次, 黒田 新士, 吉田 龍一, 西崎 正彦, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   SF - 5   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 遺伝子改変ウイルスを用いた胃癌腹膜播種に対する腹腔内治療の可能性

    菊地 覚次, 石川 亘, 小川 俊博, 田澤 大, 黒田 新士, 桑田 和也, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   SF - 6   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 胃切除後の機能評価 噴門側胃切除術後の逆流防止機能を付加した観音開き法(上川法)食道残胃吻合の有効性と安全性を評価する多施設共同後向き研究(rD-FLAP Study)

    丁田 泰宏, 黒田 新士, 石田 道拡, 久保田 哲史, 大塚 眞哉, 上山 聡, 田中 則光, 村岡 篤, 羽藤 慎二, 木村 臣一, 田中屋 宏爾, 上川 康明, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   WS - 10   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 【消化器疾患に対する機能温存・再建手術】上部消化管領域 噴門側胃切除における観音開き法再建

    西崎 正彦, 黒田 新士, 藤原 俊義

    外科   81 ( 5 )   417 - 421   2019.4

  • MELD scoreによる生体肝移植の術後解析 生体肝移植におけるMELD/重症度に応じたDonor/Graft選択の重要性

    楳田 祐三, 八木 孝仁, 吉田 龍一, 杭瀬 崇, 吉田 一博, 藤 智和, 安井 和也, 松田 達雄, 白川 靖博, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   PD - 3   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 80歳以上の超高齢者食道癌に対する包括的治療戦略

    前田 直見, 白川 靖博, 西脇 紀之, 松田 達雄, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   PS - 1   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 肝移植患者の移植後二次発癌

    松田 達雄, 楳田 祐三, 吉田 一博, 吉田 龍一, 野間 和広, 信岡 大輔, 田辺 俊介, 杭瀬 崇, 前田 直見, 安井 和也, 白川 靖博, 八木 孝仁, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   PS - 2   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道外科・頭頸部外科・形成外科の三科合同で行う頸胸部食道癌の拡大切除と消化管・気道再建術におけるチームワークの重要性

    橋本 将志, 白川 靖博, 西脇 紀之, 松田 達雄, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   SF - 4   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 切除不能T4食道癌に対するDCFを用いた化学放射線療法による集学的治療と最適な救済手術のタイミングの検討

    田辺 俊介, 白川 靖博, 西脇 紀之, 松田 達雄, 前田 直見, 櫻間 教文, 野間 和広, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   SF - 3   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道胃接合部癌の外科治療(郭清・再建) 食道胃接合部癌168例の治療経験から導かれる最適な集学的治療

    野間 和広, 白川 靖博, 西脇 紀之, 松田 達雄, 前田 直見, 田辺 俊介, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   SY - 4   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 血中遊離メチル化DNA測定による早期診断、術後再発予測、病勢予測

    戸嶋 俊明, 永坂 岳司, 入谷 光洋, 安井 和也, 吉田 一博, 稲田 涼, 楳田 祐三, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   SF - 2   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科治療成績の向上を目指した感染症対策 IBDセンターにおける外科感染症対策10年の推移、感染率低下のbreakthrough

    近藤 喜太, 藤原 俊義

    日本外科学会定期学術集会抄録集   119回   SY - 3   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. Reviewed International journal

    Toshiaki Morihiro, Shinji Kuroda, Nobuhiko Kanaya, Yoshihiko Kakiuchi, Tetsushi Kubota, Katsuyuki Aoyama, Takehiro Tanaka, Satoru Kikuchi, Takeshi Nagasaka, Masahiko Nishizaki, Shunsuke Kagawa, Hiroshi Tazawa, Toshiyoshi Fujiwara

    Scientific reports   9 ( 1 )   4633 - 4633   2019.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    While the importance of programmed death-ligand 1 (PD-L1), mutation burden caused by microsatellite instability (MSI), and CD8+ tumor infiltrating lymphocytes (TILs) has become evident, the significance of PD-L1 expression on prognosis still remains controversial. We evaluated the usefulness of combined markers of PD-L1 and MSI or CD8+ TILs as a prognostic biomarker in gastric cancer. A total of 283 patients with gastric cancer were reviewed retrospectively. PD-L1 expression on >5% tumor cells was defined as PD-L1-positive. PD-L1-positive rate was 15.5% (44/283). PD-L1 positivity was significantly correlated with invasive and advanced cancer and also significantly correlated with MSI, whereas no significance was observed with CD8+ TILs. Kaplan-Meier analysis showed that PD-L1 positivity significantly correlated with a poor prognosis (p = 0.0025). Multivariate analysis revealed that PD-L1 positivity was an independent poor prognostic factor (hazard ratio [HR]: 1.97, p = 0.0106) along with diffuse histological type and lymph node metastases. Combinations of PD-L1 and MSI (HR: 2.18) or CD8+ TILs (HR: 2.57) were stronger predictive factors for prognosis than PD-L1 alone. In conclusion, combined markers of PD-L1 and MSI or CD8+ TILs may be more useful prognostic biomarkers in gastric cancer, and better clarify the immune status of gastric cancer patients.

    DOI: 10.1038/s41598-019-41177-2

    PubMed

    researchmap

  • Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer. Reviewed

    Takeda S, Shigeyasu K, Okugawa Y, Yoshida K, Mori Y, Yano S, Noma K, Umeda Y, Kondo Y, Kishimoto H, Teraishi F, Nagasaka T, Tazawa H, Kagawa S, Fujiwara T, Goel A

    Cancer letters   444   127 - 135   2019.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER IRELAND LTD  

    Adenosine-to-inosine (A-to-I) RNA editing is a recently described epigenetic modification, which is believed to constitute a key oncogenic mechanism in human cancers. However, its functional role in cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME) and its clinical significance remains unclear. Herein, we systematically analyzed a large cohort of 627 colorectal cancer (CRC) specimens, and investigated the expression pattern of ADAR1 and its biological significance on the antizyme inhIbitor 1 (AZIN1) RNA editing levels. Both ADAR1 expression and AZIN1 RNA editing levels were significantly elevated in CRC tissues vs. normal mucosa, and these findings correlated with the increased expression of mesenchymal markers, Vimentin (p = 0.44) and Fibroblast activation protein (p = 0.38). Intriguingly, ADAR1 expression was specifically upregulated in both cancer cells and fibroblasts from cancerous lesions. Conditioned medium from cancer cells led to induction of ADAR1 expression and activation of AZIN1 RNA editing in fibroblasts (p < 0.05). Additionally, edited AZIN1 enhanced the invasive potential of fibroblasts. In conclusion, we provide novel evidence that hyper-editing of AZIN1 enhances the invasive potential of CAFs within the TME in colon and is an important predictor of tumor invasiveness in CRC.

    DOI: 10.1016/j.canlet.2018.12.009

    Web of Science

    PubMed

    researchmap

  • 多発筋炎/皮膚筋炎でみつかった直腸癌の一例 Reviewed

    重安 邦俊, 母里 淑子, 三村 直毅, 小松 泰浩, 戸嶋 俊明, 矢野 修也, 近藤 喜太, 岸本 浩行, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   80 ( 3 )   607 - 607   2019.3

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 腹腔鏡下胃切除術後出血の1例

    菊地 覚次, 津村 朋子, 桑田 和也, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   80 ( 3 )   606 - 606   2019.3

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • サルベージ手術としての腹臥位胸腔鏡下食道切除術 拡大視効果を最大限に活かして

    松田 達雄, 西脇 紀之, 前田 直見, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   80 ( 3 )   605 - 605   2019.3

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 下大静脈腫瘍栓を有する巨大肝細胞癌に対し積極的な肝切除を施行した2例

    岡 凌也, 信岡 大輔, 小西 大輔, 西山 岳芳, 田渕 幹康, 安井 和也, 吉田 一博, 杭瀬 崇, 吉田 龍一, 楳田 祐三, 八木 孝仁, 藤原 俊義

    日本臨床外科学会雑誌   80 ( 3 )   606 - 606   2019.3

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • A Novel Combination Cancer Therapy with Iron Chelator Targeting Cancer Stem Cells via Suppressing Stemness. Reviewed International journal

    Yuki Katsura, Toshiaki Ohara, Kazuhiro Noma, Takayuki Ninomiya, Hajime Kashima, Takuya Kato, Hiroaki Sato, Satoshi Komoto, Toru Narusaka, Yasuko Tomono, Boyi Xing, Yuehua Chen, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Tomonari Kasai, Masaharu Seno, Akihiro Matsukawa, Toshiyoshi Fujiwara

    Cancers   11 ( 2 )   2019.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Excess iron causes cancer and is thought to be related to carcinogenesis and cancer progression including stemness, but the details remain unclear. Here, we hypothesized that stemness in cancer is related to iron metabolism and that regulating iron metabolism in cancer stem cells (CSCs) may be a novel therapy. In this study, we used murine induced pluripotent stem cells that expressed specific stem cell genes such as Nanog, Oct3/4, Sox2, Klf4, and c-Myc, and two human cancer cell lines with similar stem cell gene expression. Deferasirox, an orally available iron chelator, suppressed expression of stemness markers and spherogenesis of cells with high stemness status in vitro. Combination therapy had a marked antitumor effect compared with deferasirox or cisplatin alone. Iron metabolism appears important for maintenance of stemness in CSCs. An iron chelator combined with chemotherapy may be a novel approach via suppressing stemness for CSC targeted therapy.

    DOI: 10.3390/cancers11020177

    PubMed

    researchmap

  • 胃癌手術患者における術前・術後サルコペニアの予後に与える影響

    桑田 和也, 金谷 信彦, 菊地 覚次, 黒田 新士, 吉田 龍一, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   91回   249 - 249   2019.2

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 進行胃癌に対するネオアジュバント化学療法の治療成績(Outcomes of neoadjuvant chemotherapy for advanced gastric cancer)

    Kagawa Shunsuke, Kuroda Shinji, Kikuchi Satoru, Kuwada Kazuya, Tsumura Tomoko, Nishizaki Masahiko, Fujiwara Toshiyoshi

    日本胃癌学会総会記事   91回   464 - 464   2019.2

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 胃癌の腹膜転移に対する新規の腹腔内ウイルス療法(Novel intraperitoneal virotherapy for the peritoneal metastasis of gastric cancer)

    Kikuchi Satoru, Ishikawa Wataru, Ogawa Toshihiro, Kuroda Shinji, Kuwada Kazuya, Nishizaki Masahiko, Kagawa Shunsuke, Fujiwara Toshiyoshi

    日本胃癌学会総会記事   91回   337 - 337   2019.2

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 観音開き法による食道残胃吻合を行ったLAPGとLATGとの中期および長期成績比較(Mid- and long-term comparison of LAPG with double-flap esophagogastrostomy and LATG)

    Kuroda Shinji, Nishizaki Masahiko, Kikuchi Satoru, Tsumura Tomoko, Kuwada Kazuya, Kagawa Shunsuke, Fujiwara Toshiyoshi

    日本胃癌学会総会記事   91回   302 - 302   2019.2

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 近位胃切除術後のEGJCに対するDFTを使用した弁形成食道胃吻合術(Valvutoplastic esophagogastrostomy using DFT for EGJC after proximal gastrectomy)

    Nishizaki Masahiko, Kuroda Shinji, Noma Kazuhiro, Kikuchi Satoru, Kuwada Kazuya, Tanabe Shunsuke, Kagawa Shunsuke, Shirakawa Yasuhiro, Fujiwara Toshiyoshi

    日本胃癌学会総会記事   91回   273 - 273   2019.2

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 【食道癌集学的治療の最前線】食道癌周術期チーム医療の最前線

    白川 靖博, 田辺 俊介, 藤原 俊義

    日本消化器病学会雑誌   116 ( 2 )   138 - 144   2019.2

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    Enhanced recovery after surgery(ERAS)プロトコールの本質は、エビデンスの検証が行われかつ推奨されている「周術期に特化して作成されたクリニカルパスのアウトライン」である。ERASプロトコールを実践するためには、チーム医療を行うことが必要不可欠である。当院では、ERASプロトコールの多くを取り入れた周術期管理センター(Perioperative management center;PERiO)が周術期チーム医療を行っている。多職種のスタッフが組織横断的に情報を共有しながら業務を行うことにより、より一層安全・安心な周術期管理の環境を提供することを実現している。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J01118&link_issn=&doc_id=20190218280005&doc_link_id=130007595859&url=https%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F130007595859&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_1.gif

  • Multicenter retrospective study to evaluate the efficacy and safety of the double-flap technique as antireflux esophagogastrostomy after proximal gastrectomy (rD-FLAP Study).

    Shinji Kuroda, Yasuhiro Choda, Shinya Otsuka, Satoshi Ueyama, Norimitsu Tanaka, Atsushi Muraoka, Shinji Hato, Toshikazu Kimura, Kohji Tanakaya, Satoru Kikuchi, Shunsuke Tanabe, Kazuhiro Noma, Masahiko Nishizaki, Shunsuke Kagawa, Yasuhiro Shirakawa, Yasuaki Kamikawa, Toshiyoshi Fujiwara

    Annals of gastroenterological surgery   3 ( 1 )   96 - 103   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Aim: As a result of the difficulty in effective prevention of gastroesophageal reflux, no standard reconstruction procedure after proximal gastrectomy (PG) has yet been established. The double-flap technique (DFT), or Kamikawa procedure, is an antireflux reconstruction procedure in esophagogastrostomy. The efficacy of DFT has recently been reported in several studies. However, these were all single-center studies with a limited number of cases. Methods: We conducted a multicenter retrospective study in which patients who underwent DFT, irrespective of disease type and reconstruction approach, at each participating institution between 1996 and 2015 were registered. Primary endpoint was incidence of reflux esophagitis at 1-year after surgery, and secondary endpoint was incidence of anastomosis-related complications. Results: Of 546 patients who were eligible for this study, 464 patients who had endoscopic examination at 1-year follow up were evaluated for reflux esophagitis. Incidence of reflux esophagitis of all grades was 10.6% and that of grade B or higher was 6.0%. Male gender and anastomosis located in the mediastinum/intra-thorax were independent risk factors for grade B or higher reflux esophagitis (odds ratio [OR]: 4.21, 95% confidence interval [CI]: 1.44-10.9, P = 0.0109). Total incidence of anastomosis-related complications was 7.2%, including leakage in 1.5%, strictures in 5.5% and bleeding in 0.6% of cases. Laparoscopic reconstruction was the only independent risk factor for anastomosis-related complications (OR: 3.93, 95% CI: 1.93-7.80, P = 0.0003). Conclusion: Double-flap technique might be a feasible option after PG for effective prevention of reflux, although anastomotic stricture is a complication that must be well-prepared for.

    DOI: 10.1002/ags3.12216

    PubMed

    researchmap

  • 外科医のトレーニング 技術の継承とは カダバートレーニングにおける技術の継承

    近藤 喜太, 信岡 大輔, 黒田 新士, 前田 直見, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   120 ( 1 )   105 - 107   2019.1

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 【腹腔鏡下胃切除後体腔内再建のKnack & Pitfalls】腹腔鏡下噴門側胃切除術 観音開き法(上川法)による再建

    西崎 正彦, 黒田 新士, 野間 和広, 菊地 覚次, 白川 靖博, 藤原 俊義

    手術   73 ( 1 )   55 - 59   2019.1

  • Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma. Reviewed International journal

    Shinichiro Watanabe, Kazuhiro Noma, Toshiaki Ohara, Hajime Kashima, Hiroaki Sato, Takuya Kato, Shinichi Urano, Ryoichi Katsube, Yuuri Hashimoto, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Hisataka Kobayashi, Toshiyoshi Fujiwara

    Cancer biology & therapy   20 ( 9 )   1234 - 1248   2019

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cancer-associated fibroblasts (CAFs) are strongly implicated in tumor progression, including in the processes of tumorigenesis, invasion, and metastasis. The targeting of CAFs using various therapeutic approaches is a novel treatment strategy; however, the efficacy of such therapies remains limited. Recently, near-infrared photoimmunotherapy (NIR-PIT), which is a novel targeted therapy employing a cell-specific mAb conjugated to a photosensitizer, has been introduced as a new type of phototherapy. In this study, we have developed a novel NIR-PIT technique to target CAFs, by focusing on fibroblast activation protein (FAP), and we evaluate the treatment efficacy in vitro and in vivo. Esophageal carcinoma cells exhibited enhanced activation of fibroblasts, with FAP over-expressed in the cytoplasm and on the cell surface. FAP-IR700-mediated PIT showed induced rapid cell death specifically for those cells in vitro and in vivo, without adverse effects. This novel therapy for CAFs, designed as local control phototherapy, was safe and showed a promising inhibitory effect on FAP+ CAFs. PIT targeting CAFs via the specific marker FAP may be a therapeutic option for CAFs in the tumor microenvironment in the future.

    DOI: 10.1080/15384047.2019.1617566

    PubMed

    researchmap

  • Intraperitoneal cancer-immune microenvironment promotes peritoneal dissemination of gastric cancer. Reviewed International journal

    Shuichi Sakamoto, Shunsuke Kagawa, Kazuya Kuwada, Atene Ito, Hiroki Kajioka, Yoshihiko Kakiuchi, Megumi Watanabe, Tetsuya Kagawa, Ryuichi Yoshida, Satoru Kikuchi, Shinji Kuroda, Hiroshi Tazawa, Toshiyoshi Fujiwara

    Oncoimmunology   8 ( 12 )   e1671760   2019

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A solid tumor consists of cancer and stromal cells, which comprise the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) are usually abundant in the TME, contributing to tumor progression. In cases of peritoneal dissemination of gastric cancer (GC), the contribution of intraperitoneal TAMs remains unclear. Macrophages from peritoneal washings of GC patients were analyzed, and the link between intraperitoneal TAMs and GC cells was investigated to clarify the interaction between them in peritoneal dissemination. Macrophages were predominant among leukocytes constituting the microenvironment of the peritoneal cavity. The proportion of CD163-positive TAMs was significantly higher in stage IV than in stage I GC. Co-culture with TAMs potentiated migration and invasion of GC. IL-6 was the most increased in the medium of in vitro co-culture of macrophages and GC, and IL-6 elevation was also observed in the peritoneal washes with peritoneal dissemination. An elevated concentration of intraperitoneal IL-6 was correlated with a poor prognosis in clinical cases. In conclusion, intraperitoneal TAMs are involved in promoting peritoneal dissemination of GC via secreted IL-6. TAM-derived IL-6 could be a potential therapeutic target for peritoneal dissemination of GC.

    DOI: 10.1080/2162402X.2019.1671760

    PubMed

    researchmap

  • The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer. Reviewed International journal

    Kuwada K, Kagawa S, Yoshida R, Sakamoto S, Ito A, Watanabe M, Ieda T, Kuroda S, Kikuchi S, Tazawa H, Fujiwara T

    Journal of experimental & clinical cancer research : CR   37 ( 1 )   307 - 307   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The peritoneum is one of the most frequent metastatic sites in pancreatic cancer patients, and peritoneal dissemination makes this disease refractory due to aggressive progression and chemoresistance. Although the role of the tumor microenvironment in cancer development is recognized, the correlation between the peritoneal environment and refractoriness of peritoneal dissemination remains unclear. The intraperitoneal tumor-microenvironment and its potential role in the progression of peritoneal dissemination and chemo-refractoriness, focusing especially on macrophages, were investigated. MATERIALS AND METHODS: Peritoneal washes were obtained from pancreatic cancer patients, and cellular components were subjected to immunofluorescence assays. The effects of macrophages induced from monocytic THP-1 cells on pancreatic cancer cells were examined in co-culture conditions. The in vivo effects of macrophages on tumor growth and chemo-sensitivity were investigated by subcutaneously or intraperitoneally co-injecting cancer cells with macrophages into mice. RESULTS: CD204-positive macrophages were present along with cancer cells in the peritoneal washes. In in vitro co-culture, tumor-associated macrophages affected pancreatic cancer cells, induced the epithelial-to-mesenchymal transition (EMT), and made them more resistant to chemotherapeutic agents. M2 macrophages promoted growth of both subcutaneous tumors and peritoneal dissemination in mice. Furthermore, co-inoculation of M2 macrophages conferred chemoresistance in the peritoneal dissemination mouse model, which significantly shortened their survival. CONCLUSION: Intraperitoneal tumor-associated macrophages potentially play an important role in promotion of peritoneal dissemination and chemoresistance of pancreatic cancer via EMT induction.

    DOI: 10.1186/s13046-018-0981-2

    PubMed

    researchmap

  • 上腹部開腹歴を有する腹腔鏡下胃切除術における安全性の検討

    津村 朋子, 黒田 新士, 桑田 和也, 菊池 覚次, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   OS115 - 5   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • taTMEを安全に導入、普及させるためのcadaver surgical trainingの役割

    戸嶋 俊明, 近藤 喜太, 信岡 大輔, 黒田 新士, 前田 直見, 寺石 文則, 白川 靖博, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   OS78 - 7   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • Closed-LECS手技の確立と今後の可能性 早期胃癌、十二指腸病変への応用

    菊地 覚次, 西崎 正彦, 黒田 新士, 桑田 和也, 津村 朋子, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   OS23 - 2   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 上部胃癌に対する再建法を考える 腹腔鏡下噴門側胃切除術における観音開き法再建の中長期成績

    西崎 正彦, 黒田 新士, 菊地 覚次, 桑田 和也, 津村 朋子, 田邊 俊介, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   WS12 - 7   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 内視鏡外科におけるCadaver教育が果たすべき役割と未来

    近藤 喜太, 前田 直見, 黒田 新士, 信岡 大輔, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   EDS - 2   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • Prognostic Factors for Pediatric Living Donor Liver Transplantation: Impact of Zero-mortality Transplant for Cholestatic Diseases.

    Takahito Yagi, Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Toshiyoshi Fujiwara

    Acta medica Okayama   72 ( 6 )   567 - 576   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Living donor liver transplantation (LDLT) is the final therapeutic arm for pediatric end-stage liver diseases. Toward the goal of achieving further improvement in LDLT survival, we investigated factors affecting recipient survival. We evaluated the prognostic factors of 60 pediatric recipients (< 16 years old) who underwent LDLT between 1997 and 2015. In a univariate analysis, non-cholestatic (NCS) disease, graft/recipient body weight ratio, cold and warm ischemic times, and intraoperative blood loss were significant factors impacting survival. In a multivariate analysis, NCS disease was the only significant factor worsening survival (p=0.0021). One-and 5-year survival rates for the cholestatic disease (CS, n=43) and NCS (n=17) groups were 100% vs. 70.6% and 97.4% vs. 58.8% (p=0.004, log-rank). Intergroup comparisons revealed that CS was significantly associated with operation time, cold ischemia, hepatomegaly of the native liver, and portal plasty. These data suggest that a cirrhotic, swollen, artery-dominant liver did not increase graft size-related risks despite the surgical complexity of preceding operations. The NCS group's poorer survival originated from recurrence of the primary disease and liver manifestation of systemic disease untreatable by transplantation. Improving the survival of pediatric recipients requires intensive efforts to prevent primary disease relapse and more rapid diagnoses to exclude contraindications from NCS disease.

    DOI: 10.18926/AMO/56374

    PubMed

    researchmap

  • 手術既往を有する炎症性腸疾患に対する腹腔鏡手術完遂のための工夫

    小松 泰浩, 近藤 喜太, 三村 直毅, 戸嶋 俊明, 寺石 文則, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   OS53 - 1   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 鏡視下食道癌手術のヒヤリハットとトラブルシューティング

    西脇 紀之, 野間 和広, 松田 達雄, 前田 直見, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   OS233 - 4   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • サルベージ手術としての腹臥位胸腔鏡下食道切除術 拡大視効果を最大限に活かして

    松田 達雄, 田辺 俊介, 西脇 紀之, 前田 直見, 野間 和広, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   OS230 - 3   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 右肺癌に対する開胸術後に発症した食道癌に対する腹臥位胸腔鏡下食道亜全摘の経験

    前田 直見, 白川 靖博, 西脇 紀之, 松田 達雄, 田辺 俊介, 野間 和広, 楳田 祐三, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   OS229 - 7   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 膜と層を意識した胸腔鏡下食道切除術 胸腔鏡下食道癌手術における交感神経を指標とした上縦隔リンパ節郭清

    白川 靖博, 西脇 紀之, 松田 達雄, 前田 直見, 田辺 俊介, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   PD8 - 1   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 食道胃接合部癌に対する治療戦略 食道胃接合部癌に対する胸腔鏡腹腔鏡を併用した切除再建術式の有用性

    野間 和広, 白川 靖博, 西脇 紀之, 松田 達雄, 前田 直見, 田辺 俊介, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   SY8 - 2   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • チーム医療における人材育成のためのカダバーサージカルトレーニング

    近藤 喜太, 前田 直見, 黒田 新士, 信岡 大輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   OS223 - 1   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 巨大食道裂孔ヘルニアの噴門形成術後に発症した胃噴門部癌に対するRedo surgery

    田辺 俊介, 白川 靖博, 西脇 紀之, 松田 達雄, 前田 直見, 桑田 和也, 菊地 覚次, 黒田 新士, 野間 和広, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   23 ( 7 )   OS148 - 1   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 陰圧閉鎖療法を極める-NPWTの至適使用法(チーム医療、効果的使用法、使用部位、等)- 消化器外科領域における陰圧閉鎖療法の意義と使用時期に関する検討

    近藤 喜太, 藤原 俊義

    日本創傷治癒学会プログラム・抄録集   48回   119 - 119   2018.11

     More details

    Language:Japanese   Publisher:(一社)日本創傷治癒学会  

    researchmap

  • Cancer-Associated Fibroblasts Affect Intratumoral CD8(+) and FoxP3(+) T Cells Via IL6 in the Tumor Microenvironment Reviewed International journal

    Kato Takuya, Noma Kazuhiro, Ohara Toshiaki, Kashima Hajime, Katsura Yuki, Sato Hiroaki, Komoto Satoshi, Katsube Ryoichi, Ninomiya Takayuki, Tazawa Hiroshi, Shirakawa Yasuhiro, Fujiwara Toshiyoshi

    CLINICAL CANCER RESEARCH   24 ( 19 )   4820 - 4833   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Purpose: Cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) play a central role in tumor progression. We investigated whether CAFs can regulate tumor-infiltrating lymphocytes (TILs) and their role in tumor immunosuppression.Experimental Design: A total of 140 cases of esophageal cancer were analyzed for CAFs and CD8+ or forkhead box protein 3 (FoxP3+) TILs by IHC. We analyzed cytokines using murine or human fibroblasts and cancer cells. Murine-derived fibroblasts and cancer cells were also inoculated into BALB/c or BALB/c-nu/nu mice and the tumors treated with recombinant IL6 or anti-IL6 antibody.Results: CD8+ TILs and CAFs were negatively correlated in intratumoral tissues (P < 0.001), whereas FoxP3+ TILs were positively correlated (P < 0.001) in esophageal cancers. Cocultured Colon26 cancer cells and fibroblasts resulted in accelerated tumor growth in BALB/c mice, along with decreased CD8+ and increased FoxP3+ TILs, compared with cancer cells alone. In vitro, IL6 was highly secreted in both murine and human cancer cell/fibroblast cocultures. IL6 significantly increased Colon26 tumor growth in immune-competent BALB/c (P < 0.001) with fewer CD8+ TILs than untreated tumors (P < 0.001), whereas no difference in BALB/c-nu/nu mice. In contrast, FoxP3+ TILs increased in IL6-treated tumors (P < 0.001). IL6 antibody blockade of tumors cocultured with fibroblasts resulted not only in regression of tumor growth but also in the accumulation of CD8+ TILs in intratumoral tissues.Conclusions: CAFs regulate immunosuppressive TIL populations in the TME via IL6. IL6 blockade, or targeting CAFs, may improve preexisting tumor immunity and enhance the efficacy of conventional immunotherapies. Clin Cancer Res; 24(19); 4820-33. ©2018 AACR.

    DOI: 10.1158/1078-0432.CCR-18-0205

    Web of Science

    PubMed

    researchmap

  • Cancer-associated fibroblasts (CAFs) promote the lymph node metastasis of esophageal squamous cell carcinoma. Reviewed International journal

    Kashima H, Noma K, Ohara T, Kato T, Katsura Y, Komoto S, Sato H, Katsube R, Ninomiya T, Tazawa H, Shirakawa Y, Fujiwara T

    International journal of cancer   144 ( 4 )   828 - 840   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Lymph node metastasis is a pathognomonic feature of spreading tumors, and overcoming metastasis is a challenge in attaining more favorable clinical outcomes. Esophageal cancer is an aggressive tumor for which lymph node metastasis is a strong poor prognostic factor, and the tumor microenvironment (TME), and cancer-associated fibroblasts (CAFs) in particular, has been implicated in esophageal cancer progression. CAFs play a central role in the TME and have been reported to provide suitable conditions for the progression of esophageal cancer, similar to their role in other malignancies. However, little is known concerning the relevance of CAFs to the lymph node metastasis of esophageal cancer. Here, we used clinical samples of esophageal cancer to reveal that CAFs promote lymph node metastasis and subsequently verified the intercellular relationships in vitro and in vivo using an orthotopic metastatic mouse model. In the analysis of clinical samples, FAP+ CAFs were strongly associated with lymph node metastasis rather than with other prognostic factors. Furthermore, CAFs affected the ability of esophageal cancer cells to acquire metastatic phenotypes in vitro; this finding was confirmed by data from an in vivo orthotopic metastatic mouse model showing that the number of lymph node metastases increased upon injection of cocultured cancer cells and CAFs. In summary, we verified in vitro and in vivo that the accumulation of CAFs enhances the lymph node metastasis of ESCC. Our data suggest that CAF targeted therapy can reduce lymph node metastasis and improve the prognosis of patients with esophageal cancer in the future.

    DOI: 10.1002/ijc.31953

    PubMed

    researchmap

  • Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer. Reviewed

    Watanabe M, Kagawa S, Kuwada K, Hashimoto Y, Shigeyasu K, Ishida M, Sakamoto S, Ito A, Kikuchi S, Kuroda S, Kishimoto H, Tomida S, Yoshida R, Tazawa H, Urata Y, Fujiwara T

    Cancer science   109 ( 10 )   3263 - 3271   2018.10

  • 食道癌鏡視下手術における拡大視野での新しい外科解剖 胸腔鏡下食道癌手術における高精細画像がもたらす微細解剖

    白川 靖博, 橋本 将志, 西脇 紀之, 松田 達雄, 前田 直見, 田辺 俊介, 野間 和広, 楳田 祐三, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   79 ( 増刊 )   409 - 409   2018.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 胃癌・低侵襲手術-ロボット手術と鏡視下手術- ロボット支援下幽門側胃切除術の導入と噴門側胃切除術・胃全摘術への応用

    西崎 正彦, 黒田 新士, 菊地 覚次, 桑田 和也, 津村 朋子, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   79 ( 増刊 )   394 - 394   2018.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 【消化器外科 ロボット支援手術の実際】ロボット支援腹腔鏡下噴門側胃切除術

    西崎 正彦, 黒田 新士, 菊地 覚次, 野間 和広, 白川 靖博, 藤原 俊義

    手術   72 ( 11 )   1589 - 1594   2018.10

  • 高齢者に対する食道裂孔ヘルニア手術によるQOL改善への貢献

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 野間 和広, 藤原 俊義

    日本老年医学会雑誌   55 ( 4 )   719 - 719   2018.10

     More details

    Language:Japanese   Publisher:(一社)日本老年医学会  

    researchmap

  • 重複癌の治療戦略〜食道癌〜 食道癌手術症例の同時性異時性重複癌の検討

    田辺 俊介, 白川 靖博, 西脇 紀之, 松田 達雄, 前田 直見, 野間 和広, 楳田 祐三, 藤原 俊義

    日本臨床外科学会雑誌   79 ( 増刊 )   335 - 335   2018.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道癌の鏡視下手術のトラブルシューティング 腹臥位鏡視下食道癌手術のヒヤリハットとトラブルシューティング

    野間 和広, 白川 靖博, 西脇 紀之, 松田 達雄, 前田 直見, 田辺 俊介, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   79 ( 増刊 )   308 - 308   2018.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 【食道癌(第2版)-基礎・臨床研究の進歩-】食道癌の治療 外科治療 食道胃接合部癌に対する手術 経裂孔的食道切除術 腹腔鏡手術

    白川 靖博, 前田 直見, 田辺 俊介, 野間 和広, 藤原 俊義

    日本臨床   76 ( 増刊8 食道癌 )   305 - 310   2018.10

     More details

    Language:Japanese   Publisher:(株)日本臨床社  

    researchmap

  • 膵鈎部癌に対する上腸間膜動脈周囲郭清の郭清手技 腫瘍進展に基づいたleft-lateral approach

    吉田 一博, 楳田 祐三, 吉田 龍一, 信岡 大輔, 杭瀬 崇, 安井 和也, 田渕 幹康, 西山 岳芳, 白川 靖博, 八木 孝仁, 藤原 俊義

    日本臨床外科学会雑誌   79 ( 増刊 )   448 - 448   2018.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 遠隔転移を有する膵神経内分泌腫瘍の治療戦略 膵神経内分泌腫瘍(panNEN)における、肝転移症例の検討と外科的治療戦略

    田渕 幹康, 杭瀬 崇, 西山 岳芳, 安井 和也, 吉田 一博, 信岡 大輔, 吉田 龍一, 楳田 祐三, 八木 孝仁, 藤原 俊義

    日本臨床外科学会雑誌   79 ( 増刊 )   332 - 332   2018.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 消化管がん治療の新展開 食道癌におけるがん細胞及びがん関連線維芽細胞に対するDual-targeting Photoimmunotherapy(Developments in gastrointestinal cancer treatments Dual-targeting Photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in tumor microenvironment) Reviewed

    佐藤 浩明, 野間 和広, 鳴坂 徹, 河本 慧, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   77回   96 - 96   2018.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • [The Elucidation of Tumor Immunosuppression Affected by Cancer-Associated Fibroblasts]. Reviewed

    Takuya Kato, Kazuhiro Noma, Yuki Katsura, Hiroaki Sato, Satoshi Kohmoto, Takayuki Ninomiya, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   45 ( 9 )   1279 - 1281   2018.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Development of immunotherapy, especially checkpoint inhibitors, dramatically improved the prognosis of some malignancies. However, problems on the occurrence of severe adverse effects and limited responses to these checkpoint inhibitors remain. Recently, tumor infiltrating lymphocytes(TILs)are the predictive markers of immunotherapies based on clinical evidence. The proportion of cytotoxic T cells in the tumor has been reported to affect the antitumor effect. TILs in the tumor are thought to be controlled by the interaction between cancer and tumor microenvironment. As a cause of tumor immunosuppression, cancer-associated fibroblasts(CAFs)play the main role in the tumor microenvironment. We considered the strong involvement of tumor microenvironment, particularly the role of CAFs, and reported the interaction between CAFs and proliferation, invasion, angiogenesis, and resistance in the conventional therapy. The correlation between CAFs and tumor immunity and the immunosuppression promoted by CAFs were also evaluated. Their effects will be reported in our future studies.

    PubMed

    researchmap

  • 炎症性微小環境-大腸がんクロストークにおけるEMTイメージング(Visualization of epithelial-mesenchymal transition in inflammatory microenvironment-colorectal cancer crosstalk) Reviewed

    田澤 大, 家田 偉史, 矢野 修也, 重安 邦俊, 黒田 新士, 大原 利章, 野間 和広, 岸本 浩行, 西崎 正彦, 香川 俊輔, 斎藤 卓, 今村 健志, 藤原 俊義

    日本癌学会総会記事   77回   1204 - 1204   2018.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 癌関連線維芽細胞が放出するIL-6が腫瘍内に浸潤するCD8+ならびにFoxP3+T細胞に影響を与える(Cancer-associated fibroblasts affect the intra-tumoral infiltration of CD8+ and FoxP3+ T cells via IL-6)

    加藤 卓也, 野間 和広, 佐藤 浩明, 河本 慧, 大原 利章, 田澤 大, 白川 靖博, 藤原 俊義

    日本癌学会総会記事   77回   1860 - 1860   2018.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • HER増幅胃癌におけるアファチニブ耐性機序(Acquired resistant mechanism to afatinib in HER2 amplified gastric cancer cells)

    吉岡 貴裕, 枝園 和彦, 難波 圭, 冨田 秀太, 山本 寛斉, 宗 淳一, 藤原 俊義, 豊岡 伸一

    日本癌学会総会記事   77回   1449 - 1449   2018.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • p53誘導性腫瘍融解ウイルス療法は骨肉腫に強力な免疫原性細胞死を誘導する(Oncolytic adenoviral therapy with p53 transactivation induces profound immunogenic cell death in osteosarcoma)

    出宮 光二, 田澤 大, 望月 雄介, 小松原 将, 杉生 和久, 長谷井 嬢, 国定 俊之, 浦田 泰生, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   77回   2251 - 2251   2018.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 骨肉腫に対する抗PD-1抗体とテロメラーゼ特異的ウイルス療法による新規治療戦略(Novel therapeutic strategy with anti-PD-1 antibody and telomerase-specific oncolytic virotherapy in osteosarcoma)

    望月 雄介, 田澤 大, 出宮 光二, 小松原 将, 杉生 和久, 長谷井 嬢, 国定 俊之, 浦田 泰生, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   77回   1813 - 1813   2018.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 鉄キレート剤の幹細胞性制御による新規癌治療法(Stemness control by iron chelator is a novel strategy for cancer treatment) Reviewed

    大原 利章, 桂 佑貴, 野間 和広, 鳴坂 徹, 佐藤 浩明, 河本 慧, 加藤 卓也, 田澤 大, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   77回   2318 - 2318   2018.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 癌関連線維芽細胞が及ぼす腫瘍免疫逃避の解明 Reviewed

    加藤 卓也, 野間 和広, 桂 佑貴, 佐藤 浩明, 河本 慧, 二宮 卓之, 大原 利章, 田澤 大, 香川 俊輔, 白川 靖博, 藤原 俊義

    癌と化学療法   45 ( 9 )   1279 - 1281   2018.9

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    近年、免疫チェックポイント阻害薬をはじめがん免疫療法の発展により、飛躍的に予後の改善を認める癌腫が散見される。しかしながら、致命的な有害事象の発生や効果の得られる症例が限定的であることなど、克服すべき問題点も指摘されている。免疫チェックポイント阻害薬の治療効果予測因子として腫瘍浸潤リンパ球が注目されており、特に細胞傷害性T細胞の腫瘍内浸潤の程度が抗腫瘍効果に影響を与えていると報告されている。リンパ球の腫瘍浸潤においては、癌とがん微小環境の相互作用によって制御している可能性が指摘されている。そのなかで中心的な役割を担っている癌関連線維芽細胞(cancer-associated fibroblasts:CAFs)が注目されている。以前よりわれわれは、がん微小環境の強い関与を推測し、特にCAFsの作用に注目して癌の増殖・浸潤・血管新生・治療抵抗性について報告してきた。この度CAFsと腫瘍免疫に着目し、CAFsが寄与する腫瘍免疫抑制について検討している。今後、検討結果を随時報告する予定である。(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J00296&link_issn=&doc_id=20180920320008&doc_link_id=%2Fab8gtkrc%2F2018%2F004509%2F010%2F1279-1281%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2018%2F004509%2F010%2F1279-1281%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • ストーマ造設と管理における諸問題 回腸人工肛門狭窄のリスク因子の抽出と予防 Reviewed

    重安 邦俊, 母里 淑子, 戸嶋 俊明, 矢野 修也, 近藤 喜太, 岸本 浩行, 寺石 文則, 藤原 俊義

    日本大腸肛門病学会雑誌   71 ( 抄録号 )   A61 - A61   2018.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 胃癌由来細胞外小胞によるマクロファージ分化誘導を介した腹膜播種の促進(Extracellular vesicles from gastric cancer promote peritoneal dissemination via M2 differentiation of macrophages)

    伊藤 雅典, 香川 俊輔, 梶岡 裕紀, 坂本 修一, クワ田 和也, 菊地 覚次, 黒田 新士, 西崎 正彦, 吉田 龍一, 田澤 大, 藤原 俊義

    日本癌学会総会記事   77回   1021 - 1021   2018.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 腹腔内マクロファージはIL6を分泌し胃癌腹膜播種を促進する(IL6 derived from intraperitoneal macrophages is involved in peritoneal dissemination of gastric cancer)

    香川 俊輔, 坂本 修一, 桑田 和也, 伊藤 雅典, 梶岡 裕紀, 黒田 新士, 菊地 覚次, 吉田 龍一, 田澤 大, 藤原 俊義

    日本癌学会総会記事   77回   1020 - 1020   2018.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 腹膜播種を伴うスキルス胃癌に対する斬新なウイルス療法(Novel virotherapy for scirrhous gastric cancer with peritoneal metastasis)

    石川 亘, 菊地 覚次, 田澤 大, 黒田 新士, 野間 和広, 岸本 浩行, 西崎 正彦, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   77回   952 - 952   2018.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 膵癌に対するp53誘導性腫瘍融解ウイルスによる免疫原性細胞死の誘導効果(Oncolytic adenovirus-mediated p53 transactivation induces profound immunogenic cell death in pancreatic cancer)

    荒木 宏之, 田澤 大, 伏見 卓郎, 金谷 信彦, 菊地 覚次, 黒田 新士, 吉田 龍一, 岸本 浩行, 西崎 正彦, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   77回   949 - 949   2018.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • テロメライシンと抗PD-1抗体を用いた新たな複合免疫療法の開発(Telomelysin as an immunotherapy sensitizing gastrointestinal tumors to anti-PD-1 antibody)

    金谷 信彦, 黒田 新士, 公文 剣斗, 垣内 慶彦, 森廣 俊昭, 久保田 哲史, 菊地 覚次, 田澤 大, 西崎 正彦, 香川 俊輔, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   77回   104 - 104   2018.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 【周術期のリハビリテーション】周術期管理

    田辺 俊介, 白川 靖博, 西脇 紀之, 松田 達雄, 前田 直見, 櫻間 教文, 野間 和広, 藤原 俊義

    Journal of Clinical Rehabilitation   27 ( 10 )   940 - 947   2018.9

     More details

    Language:Japanese   Publisher:医歯薬出版(株)  

    researchmap

  • 神経芽腫に対する抗GD2抗体-光感受性物質結合体を用いた光線免疫療法(Near-infrared photoimmunotherapy using anti-GD2 antibody-photosensitizer conjugate for neuroblastoma)

    納所 洋, 田澤 大, 谷本 光隆, 谷 守通, 尾山 貴徳, 佐藤 浩明, 野間 和広, 香川 俊輔, 小林 久隆, 野田 卓男, 藤原 俊義

    日本癌学会総会記事   77回   1948 - 1948   2018.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 抗ドナーHLA抗体陽性の肝移植の短期・長期成績と問題点 抗ドナー抗体陽性生体肝移植の現状と問題点

    楳田 祐三, 八木 孝仁, 田中 健大, 吉田 龍一, 信岡 大輔, 杭瀬 崇, 吉田 一博, 安井 和也, 吉田 真里, 白川 靖博, 柳井 広行, 高木 章乃夫, 藤原 俊義

    移植   53 ( 総会臨時 )   257 - 257   2018.9

     More details

    Language:Japanese   Publisher:(一社)日本移植学会  

    researchmap

  • Successful wound treatment using negative pressure wound therapy without primary closure in a patient undergoing highly contaminated abdominal surgery. International journal

    Takahiro Yoshioka, Yoshitaka Kondo, Toshiyoshi Fujiwara

    Surgical case reports   4 ( 1 )   85 - 85   2018.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The indications for negative pressure wound therapy (NPWT) continue to expand, and NPWT has become a powerful tool for the treatment of interactive wounds. Recently, the use of NPWT over closed incisions has been shown to prevent surgical site infection (SSI) in patients undergoing contaminated or acute care surgery as prophylactic NPWT. In this article, we present our successful experience using NPWT without primary skin closure for wound treatment after a highly contaminated enterological surgery. The procedure we present in this case report is considerably different from the conventional prophylactic NPWT and a novel method in the field of gastrointestinal surgery. CASE PRESENTATION: A 33-year-old man with Crohn's disease underwent a dirty, infected enterological surgical procedure for the treatment of abdominal wall abscess and multiple fistulas around his colonic stoma. The stoma reconstruction and wound debridement resulted in a broad skin defect, and the incision was strategically left open. In addition to the infected wound condition (class IV), Crohn's disease itself is a risk factor for SSI; consequently, we induced NPWT immediately after the surgery and closed the incision from both ends in a stepwise manner using sutures each time we changed the dressing. This procedure was effective, enabling complete healing and closure at the surgical site on postoperative day 14 without infection or a skin defect. CONCLUSION: For highly contaminated enterological surgery, purposely leaving the incision open and starting NPWT immediately after the procedure is an effective strategy for early wound closure and the prevention of SSI.

    DOI: 10.1186/s40792-018-0493-5

    PubMed

    researchmap

  • HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer Reviewed International journal

    Kubota Tetsushi, Kuroda Shinji, Kanaya Nobuhiko, Morihiro Toshiaki, Aoyama Katsuyuki, Kakiuchi Yoshihiko, Kikuchi Satoru, Nishizaki Masahiko, Kagawa Shunsuke, Tazawa Hiroshi, Fujiwara Toshiyoshi

    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE   14 ( 6 )   1919 - 1929   2018.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    An issue of concern is that no current HER2-targeted therapeutic agent is effective against Trastuzumab (Tmab)-resistant gastric cancer. Gold nanoparticles (AuNPs) are promising drug carriers with unique characteristics of a large surface area available for attachment of materials such as antibodies. Here, we created HER2-targeted AuNPs (T-AuNPs) and examined their therapeutic efficacy and cytotoxic mechanisms using HER2-postive Tmab-resistant (MKN7) or Tmab-sensitive (NCI-N87) gastric cancer cell lines. In vitro, T-AuNPs showed stronger cytotoxic effects than controls against MKN7 and NCI-N87 cells although Tmab had no effect on MKN7 cells. Autophagy played an important role in T-AuNP cytotoxic mechanisms, which was considered to be driven by internalization of T-AuNPs. Finally, T-AuNPs displayed potent antitumor effects against NCI-N87 and MKN7 subcutaneous tumors in in vivo mouse models. In conclusion, HER2-targeted AuNPs with conjugated Tmab is a promising strategy for the development of novel therapeutic agents to overcome Tmab resistance in gastric cancer.

    DOI: 10.1016/j.nano.2018.05.019

    Web of Science

    PubMed

    researchmap

  • Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency Reviewed

    Naosuke Yokomichi, Naoshi Nishida, Yuzo Umeda, Fumitaka Taniguchi, Kazuya Yasui, Toshiaki Toshima, Yoshiko Mori, Akihiro Nyuya, Takehiro Tanaka, Takeshi Yamada, Takahito Yagi, Toshiyoshi Fujiwara, Yoshiyuki Yamaguchi, Ajay Goel, Masatoshi Kudo, Takeshi Nagasaka

    Liver Cancer   2018.8

     More details

    Publishing type:Research paper (scientific journal)  

    researchmap

  • 癌関連線維芽細胞が引き起こす腫瘍免疫抑制の解明 腫瘍浸潤リンパ球とIL-6と代謝の観点から Reviewed

    加藤 卓也, 野間 和広, 賀島 肇, 桂 佑貴, 佐藤 浩明, 河本 慧, 二宮 卓之, 大原 利章, 田澤 大, 白川 靖博, 稲垣 優, 岩垣 博巳, 藤原 俊義

    日本がん免疫学会総会プログラム・抄録集   22回   95 - 95   2018.7

     More details

    Language:Japanese   Publisher:日本がん免疫学会  

    researchmap

  • NCCNガイドラインにおける消化管神経内分泌腫瘍の内視鏡切除・手術適応の妥当性の検討 Reviewed

    重安 邦俊, 母里 淑子, 戸嶋 俊明, 矢野 修也, 近藤 喜太, 浅野 博昭, 岸本 浩行, 寺石 文則, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   73回   496 - 496   2018.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 消化管腫瘍において免疫原性telomelysinは抗PD-1抗体と協働作用する(Immunogenic Telomelysin synergizes with anti-PD-1 antibody in gastrointestinal tumors)

    金谷 信彦, 黒田 新士, 公文 剣斗, 垣内 慶彦, 森廣 俊昭, 久保田 哲史, 菊地 覚次, 西崎 正彦, 浦田 泰生, 田澤 大, 香川 俊輔, 藤原 俊義

    日本がん免疫学会総会プログラム・抄録集   22回   89 - 89   2018.7

     More details

    Language:English   Publisher:日本がん免疫学会  

    researchmap

  • 胃癌腹膜播種に対する新たな治療戦略としてのウイルス療法

    石川 亘, 菊地 覚次, 田澤 大, 桑田 和也, 黒田 新士, 野間 和広, 西崎 正彦, 白川 靖博, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   73回   1005 - 1005   2018.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Closed-LECSの定型化と早期胃癌、十二指腸病変への応用

    菊地 覚次, 西崎 正彦, 黒田 新士, 加藤 大, 桑田 和也, 白川 靖博, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   73回   655 - 655   2018.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 免疫原性がん細胞死を誘導するウイルス製剤と抗PD-1抗体を併用する新たな複合免疫療法の開発

    金谷 信彦, 黒田 新士, 森廣 俊昭, 垣内 慶彦, 菊地 覚次, 西崎 正彦, 浦田 泰生, 田澤 大, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   73回   544 - 544   2018.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 腹腔鏡下観音開き法再建の手技ポイントと長期的QOL評価

    黒田 新士, 西崎 正彦, 菊地 覚次, 桑田 和也, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   73回   455 - 455   2018.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【食道】胸部食道癌患者の周術期チーム医療 食道癌外科診療における周術期チーム連携PERiO:Perioperative management center

    白川 靖博, 小川 俊博, 前田 直見, 二宮 卓之, 田辺 俊介, 野間 和広, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   73回   264 - 264   2018.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道癌におけるoncologic emergencyに対する外科的手術の有用性

    小川 俊博, 白川 靖博, 前田 直見, 二宮 卓之, 田辺 俊介, 櫻間 教文, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   73回   145 - 145   2018.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 当院における食道癌dCRT後Salvage食道切除術の工夫と治療成績

    前田 直見, 白川 靖博, 小川 俊博, 二宮 卓之, 田辺 俊介, 櫻間 教文, 野間 和広, 楳田 祐三, 藤原 俊義

    日本消化器外科学会総会   73回   79 - 79   2018.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【肝】大腸癌多発肝転移に対する手術の工夫 大腸癌多発肝転移に対する治療戦略 遺伝子変異解析を踏まえた術前化学療法の適応選別

    楳田 祐三, 八木 孝仁, 吉田 龍一, 信岡 大輔, 杭瀬 崇, 吉田 一博, 安井 和也, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   73回   72 - 72   2018.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 肝切除における血清アルブミン動態 アルブミン製剤至適投与に向けて臨床指標を再考する

    吉田 一博, 楳田 祐三, 吉田 龍一, 信岡 大輔, 杭瀬 崇, 安井 和也, 香川 俊輔, 白川 靖博, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   73回   914 - 914   2018.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 切除可能膵癌における早期再発予測因子の解析

    吉田 龍一, 楳田 祐三, 信岡 大輔, 杭瀬 崇, 吉田 一博, 安井 和也, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   73回   175 - 175   2018.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • The Outcome of Complex Hepato-Pancreato-Biliary Surgery for Elderly Patients: A Propensity Score Matching Analysis. Reviewed International journal

    Takagi K, Umeda Y, Yoshida R, Nobuoka D, Kuise T, Fushimi T, Fujiwara T, Yagi T

    Digestive surgery   36 ( 4 )   1 - 8   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIMS: Postoperative mortality and morbidity rates after hepato-pancreato-biliary (HPB) surgery remain high, and the number of elderly patients requiring such surgery has been increasing. This study aimed to investigate postoperative outcomes of complex HPB surgery for elderly patients. METHODS: We retrospectively reviewed perioperative data of 721 patients who underwent complex HPB surgery between 2010 and 2015. The patients were divided into 2 groups: elderly (≥75 years) and non-elderly (< 75 years). Surgical outcomes of both groups were compared after propensity score-matching analysis. Subsequently, risk factors for serious postoperative morbidity were identified by multivariate analysis. RESULTS: Before matching, the elderly group (n = 170) had more comorbidities, such as cardiovascular and renal disease, than the non-elderly group (n = 551). Matching yielded elderly (n = 170) and non-elderly groups (n = 170) with similar preoperative backgrounds. The mortality and morbidity rates did not differ significantly between the groups. In multivariate analyses, operative time (OR 1.79; p = 0.005) and blood loss (OR 1.66; p = 0.03) were identified as independent risk factors for serious postoperative morbidity, whereas older age did not have a predictive impact (OR 1.16; p = 0.52). CONCLUSIONS: Although elderly -patients had more comorbidities and higher incidences of postoperative mortality and several complications before matching, their postoperative outcomes were equivalent to those of non-elderly patients after matching.

    DOI: 10.1159/000489826

    PubMed

    researchmap

  • 岡山大学病院における肥満外科治療の導入

    香川 俊輔, 黒田 新士, 菊地 覚次, 桑田 和也, 西崎 正彦, 利根 淳仁, 中司 敦子, 江口 潤, 和田 淳, 小林 求, 藤原 俊義

    日本肥満症治療学会学術集会プログラム・抄録集   36回   129 - 129   2018.6

     More details

    Language:Japanese   Publisher:日本肥満症治療学会  

    researchmap

  • 化学放射線療法の現状と新たなる展望〜制癌剤と照射法の工夫〜 腫瘍融解ウイルス併用放射線療法の臨床研究の中間報告

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 黒田 新士, 野間 和広, 田澤 大, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   72回   59 - 59   2018.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 腹腔鏡下に切除再建を行ったToupet噴門形成術後の胃噴門部癌の一例

    岡 凌也, 白川 靖博, 前田 直見, 桑田 和也, 二宮 卓之, 菊地 覚次, 田辺 俊介, 黒田 新士, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   79 ( 6 )   1342 - 1342   2018.6

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 腹臥位胸腔鏡下食道切除における反回神経麻痺ゼロを目指した上縦隔郭清

    野間 和広, 白川 靖博, 小川 俊博, 前田 直見, 二宮 卓之, 田辺 俊介, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   72回   171 - 171   2018.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌手術ハイボリュームセンターとの連携において後方支援病院で求められる資質

    櫻間 教文, 平松 聡, 二宮 卓之, 前田 直見, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   72回   151 - 151   2018.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道外科教育における臨床応用解剖実習 学習者アンケートから考える可能性

    前田 直見, 白川 靖博, 小川 俊博, 二宮 卓之, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   72回   123 - 123   2018.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 第4版ガイドラインの効果とさらなる普及への検証 食道癌周術期におけるチーム医療のエビデンス創出に向けた取り組みと課題

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   72回   53 - 53   2018.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • チーム医療と地域連携の現状と今後の展開 食道癌手術患者に対して外来から開始する周術期管理センター(PERiO)の現状と展望

    白川 靖博, 小川 俊博, 前田 直見, 二宮 卓之, 田辺 俊介, 野間 和広, 西崎 正彦, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   72回   41 - 41   2018.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌オリゴメタスターシスへの挑戦 食道癌初回手術後の副腎転移に対して外科切除し長期生存を得られた1例

    金谷 信彦, 野間 和広, 岡田 剛, 前田 直見, 二宮 卓之, 田辺 俊介, 櫻間 教文, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   79 ( 6 )   1342 - 1342   2018.6

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • ステルス効果を有する腫瘍融解アデノウイルス搭載リポソーム製剤の開発

    垣内 慶彦, 青山 克幸, 黒田 新士, 金谷 信彦, 菊地 覚次, 西崎 正彦, 香川 俊輔, 田澤 大, 藤原 俊義

    日本DDS学会学術集会プログラム予稿集   34回   145 - 145   2018.5

     More details

    Language:Japanese   Publisher:日本DDS学会  

    researchmap

  • 膵癌における免疫療法の可能性 MSI、PD-1/PD-L1、免疫関連遺伝子多型解析を踏まえて

    藤 智和, 楳田 祐三, 吉田 一博, 杭瀬 崇, 信岡 大輔, 吉田 龍一, 八木 孝仁, 藤原 俊義

    膵臓   33 ( 3 )   472 - 472   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本膵臓学会  

    researchmap

  • 膵腫瘍におけるゲノム解析-病態解明と臨床的意義 包括的アプローチによる浸潤性膵管癌の非侵襲的診断技術の構築

    吉田 一博, 楳田 祐三, 吉田 龍一, 信岡 大輔, 杭瀬 崇, 藤 智和, 安井 和也, Goel Ajay, 八木 孝仁, 藤原 俊義

    膵臓   33 ( 3 )   360 - 360   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本膵臓学会  

    researchmap

  • 神経芽腫に対する腫瘍融解ウイルス療法の研究を通して感じた、基礎研究の楽しさ・難しさ

    谷本 光隆, 田澤 大, 納所 洋, 尾山 貴徳, 谷 守通, 野田 卓男, 藤原 俊義

    日本小児外科学会雑誌   54 ( 3 )   640 - 640   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本小児外科学会  

    researchmap

  • Lynch症候群 子宮体癌におけるMMR statusとLynch症候群関連腫瘍家族歴との相関

    原賀 順子, 永坂 岳司, 春間 朋子, 西田 傑, 入谷 大洋, 母里 淑子, 小川 千加子, 中村 圭一郎, 藤原 俊義, 増山 寿

    日本外科系連合学会誌   43 ( 3 )   401 - 401   2018.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    researchmap

  • 大腸癌多発肝転移に対する肝切除 多回肝切除と化学療法を見据えたParenchymal sparing & skeletonized hepatectomy

    楳田 祐三, 八木 孝仁, 永坂 岳司, 吉田 龍一, 信岡 大輔, 杭瀬 崇, 伏見 卓郎, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   118回   1085 - 1085   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科学の新知見(2)がんの早期診断に向けて がん特異的蛍光ウイルス製剤を用いた簡便な循環がん細胞(CTC)の遺伝子プロファイリング技術の開発 Reviewed

    重安 邦俊, 田澤 大, 橋本 悠里, 母里 淑子, 西崎 正彦, 岸本 浩行, 永坂 岳司, 黒田 新士, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   118回   282 - 282   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Preoperative Controlling Nutritional Status Score Predicts Mortality after Hepatectomy for Hepatocellular Carcinoma. Reviewed International journal

    Takagi K, Umeda Y, Yoshida R, Nobuoka D, Kuise T, Fushimi T, Fujiwara T, Yagi T

    Digestive surgery   36 ( 3 )   226 - 232   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Preoperative nutritional status is reportedly associated with postoperative outcomes in patients with hepatocellular carcinoma. This study aimed to investigate the significance of the controlling nutritional status (CONUT) score and the prognostic nutritional index (PNI) as predictors of postoperative outcomes. METHODS: We retrospectively reviewed data from 331 patients who underwent hepatectomy for hepatocellular carcinoma between January 2007 and December 2015. Patients were divided into 2 groups based on their CONUT score and the PNI. We evaluated the effect of the CONUT score and PNI on perioperative outcomes. Multivariate analysis was performed to identify independent predictors of in-hospital mortality after hepatectomy. -Results: The high CONUT group had a significantly higher -incidence of 30-day mortality (p < 0.001), in-hospital mortality (p = 0.002), ascites (p = 0.006), liver failure (p = 0.02), sepsis (p = 0.01), and enteritis (p < 0.001). The low PNI group was also significantly associated with 30-day mortality (p < 0.001), in-hospital mortality (p = 0.003), liver failure (p < 0.001), sepsis (p = 0.02), enteritis (p = 0.02), and hospital stay (p = 0.01). In multivariate analyses, a high CONUT score was an independent predictor of in-hospital mortality after hepatectomy (hazard ratio [HR] 9.41, p = 0.038), but the PNI was not (HR 5.86, p = 0.08). CONCLUSIONS: Preoperative assessment of the CONUT score is helpful for evaluating patients' nutritional status and mortality risk after liver surgery.

    DOI: 10.1159/000488215

    PubMed

    researchmap

  • 上部消化管癌周術期における予後規定因子 術前併存疾患を有する胃癌サルコペニアの術後他病死に対する予測因子としての有用性

    黒田 新士, 桑田 和也, 菊地 覚次, 楳田 祐三, 西崎 正彦, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   118回   662 - 662   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 外科医のトレーニング-技術の継承とは- カダバートレーニングにおける技術の継承

    近藤 喜太, 信岡 大輔, 黒田 新士, 前田 直見, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   118回   258 - 258   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Closed LECSにおける内視鏡・腹腔鏡手技のこつ

    西崎 正彦, 菊地 覚次, 神崎 洋光, 黒田 新士, 桑田 和也, 田邊 俊介, 野間 和弘, 白川 靖博, 岡田 裕之, 藤原 俊義

    Gastroenterological Endoscopy   60 ( Suppl.1 )   690 - 690   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 【これぞ達人の技!最新の消化器内視鏡外科手術】食道・胃の鏡視下手術 腹腔鏡下噴門側胃切除術

    西崎 正彦, 黒田 新士, 菊地 覚次, 藤原 俊義

    消化器外科   41 ( 5 )   583 - 589   2018.4

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • 【上手な手術をするための基本手技】吻合 腹腔鏡下手術

    西崎 正彦, 黒田 新士, 菊地 覚次, 藤原 俊義

    消化器外科   41 ( 4 )   481 - 488   2018.4

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • 食道癌術後急性期のサルコペニア 食道癌術後急性期の筋肉量減少は予後予測因子となり得る

    前田 直見, 白川 靖博, 鳴坂 徹, 二宮 卓之, 田辺 俊介, 野間 和広, 櫻間 教文, 楳田 祐三, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   118回   2337 - 2337   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道癌外科治療におけるBest mixを目指して

    白川 靖博, 鳴坂 徹, 前田 直見, 二宮 卓之, 田辺 俊介, 櫻間 教文, 楳田 祐三, 西崎 正彦, 香川 俊輔, 野間 和広, 藤原 俊義

    日本外科学会定期学術集会抄録集   118回   1613 - 1613   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 早期回復を目指した腹腔鏡補助下幽門側胃切除術の最適な術後鎮痛法

    菊地 覚次, 黒田 新士, 桑田 和也, 西崎 正彦, 白川 靖博, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   118回   1310 - 1310   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 腫瘍融解ウイルス併用放射線療法による食道癌治療成績向上への取り組み

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 黒田 新士, 野間 和広, 楳田 祐三, 田澤 大, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   118回   944 - 944   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 術前補助化学療法を施行した進行胃癌症例の検討(Outcomes in patients with advanced gastric cancer treated with neoadjuvant chemotherapy)

    香川 俊輔, 黒田 新士, 菊地 覚次, 桑田 和也, 西崎 正彦, 野間 和広, 田辺 俊介, 二宮 卓之, 前田 直見, 白川 靖博, 藤原 俊義

    日本胃癌学会総会記事   90回   375 - 375   2018.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • サルコペニアは胃癌術後の予後に関連する(Sarcopenia is associated with prognosis in gastric cancer patients undergoing gastrectomy)

    桑田 和也, 香川 俊輔, 菊地 覚次, 黒田 新士, 吉田 龍一, 西崎 正彦, 藤原 俊義

    日本胃癌学会総会記事   90回   268 - 268   2018.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 予後因子に基づく残胃癌に対する治療戦略(Treatment strategy for remnant gastric cancer based on the prognostic factor)

    Kikuchi Satoru, Kuroda Shinji, Kakiuchi Yoshihiko, Nishizaki Masahiko, Kuwada Kazuya, Shirakawa Yasuhiro, Kagawa Shunsuke, Fujiwara Toshiyoshi

    日本胃癌学会総会記事   90回   506 - 506   2018.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 高齢胃癌患者に対する胃全摘術は術後QOL低下の危険因子である(Total gastrectomy for elderly gastric cancer patients is a risk factor for QOL decline after surgery)

    Kuroda Shinji, Ito Atene, Kuwada Kazaya, Kikuchi Satoru, Nishizaki Masahiko, Kagawa Shunsuke, Shirakawa Yasuhiro, Fujiwara Toshiyoshi

    日本胃癌学会総会記事   90回   301 - 301   2018.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 胃全摘術と噴門側胃切除 QOLを考慮した再建術 LPG後のダブルフラップ法による弁形成食道胃吻合術(Total gastrectomy and proximal gastrectomy: Reconstructive procedure considering quality of life Valvuloplastic esophagogastrostomy using double flap technique after LPG)

    Nishizaki Masahiko, Kuroda Shinji, Kikuchi Satoru, Kuwada Kazuya, Tanabe Shunsuke, Noma Kazuhiro, Kagawa Shunsuke, Shirakawa Yasuhiro, Fujiwara Toshiyoshi

    日本胃癌学会総会記事   90回   233 - 233   2018.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 【食道胃接合部癌診療の最前線】食道胃接合部癌に対する噴門側胃切除術

    西崎 正彦, 野間 和広, 黒田 新士, 菊地 覚次, 白川 靖博, 藤原 俊義

    消化器外科   41 ( 2 )   177 - 183   2018.2

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • 体成分分析に基づいたNST栄養介入

    田辺 俊介, 櫻根 裕子, 日野 隼人, 谷口 恵子, 長谷川 祐子, 前田 直見, 菊地 覚次, 白川 靖博, 四方 賢一, 藤原 俊義

    日本静脈経腸栄養学会雑誌   33 ( Suppl. )   565 - 565   2018.1

     More details

    Language:Japanese   Publisher:(株)ジェフコーポレーション  

    researchmap

  • 【この手術に欠かせない必須デバイス紹介-こだわりの理由と正しい使用法】腹腔鏡下噴門側胃切除術に欠かせない必須デバイス 超音波凝固切開装置,3D 内視鏡システム

    西崎 正彦, 黒田 新士, 菊地 覚次, 野間 和弘, 白川 靖博, 藤原 俊義

    手術   72 ( 1 )   23 - 29   2018.1

  • Factors Regulating Human Extravillous Trophoblast Invasion: Chemokine-peptidase and CD9-integrin Systems. Reviewed

    Fujiwara H, Matsumoto H, Sato Y, Horie A, Ono M, Nakamura M, Mizumoto Y, Kagami K, Fujiwara T, Hattori A, Maida Y, Daikoku T, Imakawa K, Araki Y

    Current pharmaceutical biotechnology   19 ( 10 )   764 - 770   2018

  • 切離断端の安全域を向上させる殺細胞性を兼ね備えた癌細胞特異的蛍光発現製剤を用いた内視鏡外科手術の開発

    矢野 修也, 岸本 浩行, 藤原 俊義

    日本内視鏡外科学会雑誌   22 ( 7 )   SF011 - 05   2017.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 多発筋炎/皮膚筋炎でみつかり腹腔鏡下に切除し得た直腸癌の一例 Reviewed

    重安 邦俊, 母里 淑子, 矢野 修也, 藤原 俊義

    日本内視鏡外科学会雑誌   22 ( 7 )   EP218 - 02   2017.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹臥位胸腔鏡下食道亜全摘における臨床応用解剖実習の有用性

    前田 直見, 白川 靖博, 鳴坂 徹, 二宮 卓之, 田辺 俊介, 近藤 喜太, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   22 ( 7 )   SF108 - 01   2017.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 完全鏡視下幽門側胃切除におけるBook-binding techniqueによるBillroth-I法再建の検討

    菊地 覚次, 西崎 正彦, 黒田 新士, 桑田 和也, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   22 ( 7 )   EP125 - 07   2017.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡下胃全摘術・腹腔鏡下噴門側胃切除:再建の工夫 完全鏡視下手縫いによる逆流防止弁形成食道残胃吻合(観音開き法)

    西崎 正彦, 黒田 新士, 菊地 覚次, 野間 和広, 桑田 和也, 田邊 俊介, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   22 ( 7 )   WS1 - 1   2017.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 混合型食道裂孔ヘルニア手術のQOL改善への貢献

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   22 ( 7 )   EP036 - 02   2017.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • [Radical Thoracoscopic Esophagectomy for Elderly Patients with Advanced Esophageal Cancer].

    Yuki Matsumi, Yasuhiro Shirakawa, Shunsuke Tanabe, Satoshi Komoto, Naoaki Maeda, Takayuki Ninomiya, Kazuhiro Noma, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   44 ( 12 )   1784 - 1786   2017.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    We report a case of an elderly patient with advanced esophageal cancer who underwent multidisciplinary treatment. An 86-year-old male consulted our hospital with complaints of pharynx discomfort and difficulty in swallowing. He was preoperatively diagnosed with esophageal cancer, T3N2M0, Stage III . We performed 2 courses of cisplatin plus 5-FU therapy as neoadjuvant chemotherapy. The primary tumor and metastatic lymph nodes reduced in size, and thoracoscopic esophagectomy in the prone position was performed. Pathological findings were esophageal cancer, pT3-Ad, INF b, ly2, v1, IM0, pPM0, pDM0, pRM1, pN3, pStage III . As the radical margin was positive, chemoradiotherapy was performed. We continued postoperative chemotherapy for approximately 1 year, and the patient has survived without relapse for 4 years from esophagectomy. Even in patients over 80 years old, long-term prognosis can be expected by performing radical surgery and chemoradiotherapy.

    PubMed

    researchmap

  • [Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula - A Case Report].

    Satoshi Komoto, Kazuhiro Noma, Naoaki Maeda, Yuki Matsumi, Takayuki Ninomiya, Shunsuke Tanabe, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   44 ( 12 )   1053 - 1055   2017.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    The esophagorespiratory fistula(ERF)is a fatal complication ofesophageal cancer, because ofadvanced oncological status and poor conditions due to pneumonia and/or malnutrition.We report here a case of patient who was successfully treated for esophageal cancer with ERF with multimodality therapy including three-stage operation. A 65-year-old woman ofesophageal cancer received preoperative chemotherapy, and developed EFR before operation. Prolonged conservative therapies for ERF let her general condition get worse. Therefore, the patient underwent esophagostomy and gastrostomy to recover her condition. She received chemo-radiotherapy followed by esophagectomy. And she was performed the reconstruction next month. She is still alive without recurrence at 20 months after resection. In previous reports, a total of 6 cases have been performed esophagectomy for esophageal cancer with ERF in Japan. Only one case was reported that had survived longer than 12 months. This multimodality therapy can be one ofthe best strategies for the patients ofesophageal cancer with ERF, even ifthey have poor condition.

    PubMed

    researchmap

  • 放射線治療後の手術創に対する計画的陰圧閉鎖療法の経験

    戸嶋 俊明, 近藤 喜太, 菊地 覚次, 二宮 卓之, 母里 淑子, 黒田 新士, 田邊 俊介, 万代 康弘, 野間 和広, 浅野 博昭, 岸本 浩行, 永坂 岳司, 西崎 正彦, 佃 和憲, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本創傷治癒学会プログラム・抄録集   47回   151 - 151   2017.11

     More details

    Language:Japanese   Publisher:(一社)日本創傷治癒学会  

    researchmap

  • ここを工夫した私の手術手技(食道) Fusionに留意した食道癌に対する胸腔鏡下上縦隔リンパ節郭清

    白川 靖博, 鳴坂 徹, 前田 直見, 二宮 卓之, 田辺 俊介, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   78 ( 増刊 )   436 - 436   2017.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • HER2陽性胃癌に対するS-1+docetaxel+trastuzumab併用療法の多施設共同第II相試験

    香川 俊輔, 村岡 篤, 神原 健, 中山 洋, 濱野 亮輔, 田中 則光, 野間 和広, 田中屋 宏爾, 岸本 浩行, 黒田 新士, 菊地 覚次, 桑田 和也, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本癌治療学会学術集会抄録集   55回   PS - 3   2017.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 切除困難局所進行食道癌に対するDCF併用放射線療法を用いた集学的治療

    白川 靖博, 鳴坂 徹, 前田 直見, 二宮 卓之, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本癌治療学会学術集会抄録集   55回   O19 - 3   2017.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 食道癌術後早期にAeromonas hydrophilaによる壊死性軟部組織感染症を発症した1例

    田辺 俊介, 白川 靖博, 金谷 信彦, 前田 直見, 二宮 卓之, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科感染症学会雑誌   14 ( 5 )   602 - 602   2017.10

     More details

    Language:Japanese   Publisher:(一社)日本外科感染症学会  

    researchmap

  • 腹臥位胸腔鏡下手術での合併症を起こさせない手術手技

    野間 和広, 白川 靖博, 鳴坂 徹, 前田 直見, 二宮 卓之, 田辺 俊介, 藤原 俊義

    日本臨床外科学会雑誌   78 ( 増刊 )   514 - 514   2017.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道・胃癌術前補助療法CR症例[手術vs経過観察] 進行食道癌に対するDCF療法を軸にした集学的治療戦略 著効例にも根治手術は必要か?

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   78 ( 増刊 )   355 - 355   2017.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 新規光線力学療法としての蛍光タンパク質KillerRed誘導腫瘍融解ウイルスのin vivo抗腫瘍効果

    竹原 清人, 田澤 大, 矢野 修也, 岸本 浩行, 水口 裕之, 浦田 泰生, ホフマン・ロバート, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   76回   P - 3386   2017.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 遅発性に肝転移・骨盤内リンパ節転移をきたした直腸神経内分泌腫瘍の1例 Reviewed

    重安 邦俊, 杭瀬 崇, 母里 淑子, 河合 毅, 矢野 修也, 戸嶋 俊明, 浅野 博昭, 近藤 喜太, 佃 和憲, 永坂 岳司, 八木 孝仁, 藤原 俊義

    日本大腸肛門病学会雑誌   70 ( 抄録号 )   A85 - A85   2017.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 抗体結合磁性ナノ粒子による温熱療法 癌播種病変への治療応用へ向けて

    香川 哲也, 岸本 浩行, 松三 雄騎, 田澤 大, 大原 利章, 永坂 岳司, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   76回   P - 2368   2017.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • HER2陽性胃癌に対するアファチニブ・ネラチニブの抗腫瘍効果

    吉岡 貴裕, 枝園 和彦, 高橋 優太, 栗原 英祐, 難波 圭, 鳥越 英次郎, 佐藤 博紀, 山本 寛斉, 宗 淳一, 浅野 博昭, 佃 憲徳, 藤原 俊義, 豊岡 伸一

    日本癌学会総会記事   76回   P - 2336   2017.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • がん免疫療法の一段の進化へむけて 腫瘍浸潤免疫細胞の代謝は抗腫瘍免疫応答を制御する

    鵜殿 平一郎, 榮川 伸吾, 國定 勇希, 上原 健敬, 渡邉 元嗣, 木村 裕司, 佐々木 朗, 尾崎 敏文, 豊岡 伸一, 藤原 俊義

    日本癌学会総会記事   76回   S10 - 5   2017.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction. Reviewed

    Yamakawa Y, Tazawa H, Hasei J, Osaki S, Omori T, Sugiu K, Komatsubara T, Uotani K, Fujiwara T, Yoshida A, Kunisada T, Urata Y, Kagawa S, Ozaki T, Fujiwara T

    Cancer science   108 ( 9 )   1870 - 1880   2017.9

  • インピーダンスモニタリングを用いた難治性胃食道逆流症の手術適応診断

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 櫻間 教文, 野間 和広, 藤原 俊義

    Gastroenterological Endoscopy   59 ( Suppl.2 )   2223 - 2223   2017.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 胃癌患者の腹腔内マクロファージは分化し胃癌細胞の悪性形質を促進する

    坂本 修一, 香川 俊輔, 桑田 和也, 伊藤 雅典, 菊地 覚次, 黒田 新士, 吉田 龍一, 浦田 泰生, 田澤 大, 藤原 俊義

    日本癌学会総会記事   76回   P - 3225   2017.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 抗PD-1抗体の新たな治療戦略 腫瘍選択的融解アデノウイルス療法との相乗効果の可能性

    金谷 信彦, 黒田 新士, 森廣 俊昭, 久保田 哲史, 田澤 大, 菊地 覚次, 西崎 正彦, 香川 俊輔, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   76回   P - 3178   2017.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • スキルス胃癌に対する蛍光発現腫瘍融解ウイルスと化学療法の併用による新たな診断的治療戦略

    石川 亘, 菊地 覚次, 田澤 大, 黒田 新士, 野間 和広, 岸本 浩行, 永坂 岳司, 西崎 正彦, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   76回   E - 3031   2017.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 早期胃癌症例に対するClosed-LECS手技の可能性

    菊地 覚次, 西崎 正彦, 藤原 俊義

    Gastroenterological Endoscopy   59 ( Suppl.2 )   1912 - 1912   2017.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 早期胃癌症例に対するClosed-LECS手技の可能性

    菊地 覚次, 西崎 正彦, 藤原 俊義

    肝臓   58 ( Suppl.2 )   A489 - A489   2017.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  • 早期胃癌症例に対するClosed-LECS手技の可能性

    菊地 覚次, 西崎 正彦, 藤原 俊義

    日本消化器がん検診学会雑誌   55 ( Suppl. )   918 - 918   2017.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器がん検診学会  

    researchmap

  • 早期胃癌症例に対するClosed-LECS手技の可能性

    菊地 覚次, 西崎 正彦, 藤原 俊義

    日本消化器病学会雑誌   114 ( 臨増大会 )   A418 - A418   2017.9

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  • がん個別化医療の革新を目指す新規治療戦略 がんの脆弱性 MYNC増幅神経芽細胞腫のMYCN依存性を標的とするテロメラーゼ特異的腫瘍融解アデノウイルス療法

    谷本 光隆, 田澤 大, 家田 偉史, 納所 洋, 尾山 貴徳, 浦田 泰生, 香川 俊輔, 野田 卓男, 藤原 俊義

    日本癌学会総会記事   76回   S18 - 4   2017.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 軟部肉腫に対するp53発現テロメラーゼ依存型腫瘍融解アデノウイルスの放射線効果増強

    小松原 将, 田澤 大, 望月 雄介, 杉生 和久, 大森 敏規, 山川 泰明, 尾崎 修平, 長谷井 嬢, 藤原 智洋, 国定 俊之, 浦田 泰生, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   76回   J - 2008   2017.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • ドキソルビシン耐性骨肉腫細胞に対するp53発現腫瘍融解アデノウイルスによるMDR1発現抑制を介した薬剤耐性克服機序の検討

    杉生 和久, 田澤 大, 望月 雄介, 小松原 将, 大森 敏規, 山川 泰明, 吉田 晶, 長谷井 嬢, 藤原 智洋, 国定 俊之, 浦田 泰生, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   91 ( 8 )   S1523 - S1523   2017.8

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • p53発現腫瘍融解アデノウイルスによる軟部肉腫に対する放射線治療併用効果の検討

    小松原 将, 望月 雄介, 杉生 和久, 大森 敏規, 長谷井 嬢, 吉田 晶, 藤原 智洋, 国定 俊之, 浦田 泰生, 田澤 大, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   91 ( 8 )   S1499 - S1499   2017.8

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 腫瘍融解ウイルスの骨・軟部腫瘍組織に対する感染効率の評価

    吉田 晶, 魚谷 弘二, 藤原 智洋, 長谷井 嬢, 森田 卓也, 清野 正普, 杉生 和久, 小松原 将, 望月 雄介, 国定 俊之, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   91 ( 8 )   S1823 - S1823   2017.8

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • Hyperthermia at the single-cell level for disseminated cancer disease with immuno-magnetic nanoparticles Reviewed

    Tetsuya Kagawa, Hiroyuki Kishimoto, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Takeshi Nagasaka, Satoshi Nohara, Ichiro Kato, Adarsh Sandhu, Hiromichi Aono, Toshiyoshi Fujiwara

    American Association for Cancer Research   77 ( 13 )   2017.7

     More details

    Language:English   Publishing type:Research paper (international conference proceedings)  

    researchmap

  • 癌細胞内特異的蛍光発現製剤による浸潤部の蛍光標識と殺細胞性を兼ね備えた高精度な低侵襲手術の開発

    矢野 修也, 岸本 浩行, 田澤 大, 竹原 清人, 浦田 泰生, ロバート・ホフマン, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   72回   RS1 - 3   2017.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • PVT1は癌遺伝子MYCを駆動するエンハンサーでありStage II、III大腸癌の予後予測マーカーになりうる Reviewed

    重安 邦俊, 小澤 毅士, 松山 貴俊, 河合 毅, 矢野 修也, 母里 淑子, 岸本 浩行, 永坂 岳司, Goel Ajay, 藤原 俊義

    日本消化器外科学会総会   72回   RS1 - 1   2017.7

     More details

    Language:English   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胃上部癌に対する腹腔鏡下手術の郭清・再建手技の定型化 胃上部早期胃癌に対する逆流防止弁形成食道残胃吻合(観音開き法)再建の定型化

    西崎 正彦, 黒田 新士, 菊地 覚次, 野間 和広, 垣内 慶彦, 田邊 俊介, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   72回   SY10 - 10   2017.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 消化器癌腹膜播種の病態解明と新たな治療戦略 腹腔内腫瘍微小環境におけるマクロファージの消化器癌悪性形質への影響

    香川 俊輔, 桑田 和也, 坂本 修一, 黒田 新士, 菊地 覚次, 伊藤 雅典, 吉田 龍一, 西崎 正彦, 田澤 大, 藤原 俊義

    日本消化器外科学会総会   72回   WS03 - 7   2017.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 関連進行胃癌に対する腹腔鏡下手術は標準化するのか? 現状と今後の展望 神経解剖に基づいたD2リンパ節郭清を伴う腹腔鏡下幽門側胃切除術の短期・長期成績

    黒田 新士, 西崎 正彦, 菊地 覚次, 垣内 慶彦, 桑田 和也, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   72回   O1 - 3   2017.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 当院における根治的放射線化学療法後の食道切除術(サルベージ治療)の検討

    松三 雄騎, 白川 靖博, 河本 慧, 前田 直見, 二宮 卓之, 田辺 俊介, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   72回   PL18 - 3   2017.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道胃接合部腺癌の至適リンパ節郭清と術式選択 食道胃接合部癌125例から導かれる最適な術式 根治性と術後QOLの併存を求めて

    野間 和広, 白川 靖博, 河本 慧, 松三 雄騎, 前田 直見, 二宮 卓之, 田辺 俊介, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   72回   WS02 - 8   2017.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道癌術後再発予測と再発食道癌の治療 食道癌根治術後Oligometastasisに対する治療戦略

    二宮 卓之, 金谷 信彦, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊介, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   72回   O3 - 5   2017.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道癌に対する縦隔リンパ節郭清の手術手技 胸腔鏡下食道癌手術における微細解剖に基づいた上縦隔リンパ節郭清

    白川 靖博, 河本 慧, 松三 雄騎, 前田 直見, 二宮 卓之, 田辺 俊介, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   72回   SY09 - 3   2017.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道切除後再建法の工夫と成績 胃管作製不能例に対する有茎空腸を用いた食道再建術

    前田 直見, 白川 靖博, 河本 慧, 松三 雄騎, 二宮 卓之, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本消化器外科学会総会   72回   O1 - 2   2017.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • R0手術例の予後因子からみた残胃癌の治療戦略

    垣内 慶彦, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   72回   PH8 - 1   2017.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道胃接合部癌に対する術式選択 食道胃接合部癌137例の経験から導かれる手術 根治性と術後QOLの両立

    野間 和広, 白川 靖博, 河本 慧, 松三 雄騎, 前田 直見, 二宮 卓之, 田辺 俊介, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   71回   PD1 - 6   2017.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌に対する化学療法の新しい展望 標準的治療困難な食道癌症例に対する放射線併用ウイルス療法臨床研究の中間報告

    西崎 正彦, 白川 靖博, 前田 直見, 二宮 卓之, 田辺 俊介, 黒田 新士, 野間 和広, 田澤 大, 香川 俊輔, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   71回   W2 - 3   2017.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 病態別に考える食道裂孔ヘルニア症例の手術適応と治療成績

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   71回   P79 - 7   2017.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌切除術施行前後の患者における横隔膜脚部厚値と呼吸機能の変化について

    野澤 康明, 築山 尚司, 太田 晴之, 岩井 賢司, 前田 直見, 二宮 卓之, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   71回   P75 - 4   2017.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 同時性胃癌合併食道癌に対する治療戦略

    二宮 卓之, 河本 慧, 松三 雄騎, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   71回   P74 - 3   2017.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 当科におけるサルベージ食道切除術の検討

    前田 直見, 白川 靖博, 河本 慧, 松三 雄騎, 二宮 卓之, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   71回   P67 - 5   2017.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 80歳以上の超高齢者に対する食道癌手術の成績と周術期管理の工夫

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   71回   P34 - 6   2017.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 胸腔鏡下食道切除の定型化 胸腔鏡下食道癌手術における膜と層に留意した上縦隔リンパ節郭清の定型化

    白川 靖博, 河本 慧, 松三 雄騎, 前田 直見, 二宮 卓之, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   71回   PD2 - 2   2017.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 軟部肉腫に対する腫瘍融解アデノウイルスによる放射線治療増感効果の検討

    小松原 将, 大森 敏規, 望月 雄介, 杉生 和久, 長谷井 嬢, 吉田 晶, 藤原 智洋, 国定 俊之, 浦田 泰生, 田澤 大, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   91 ( 6 )   S1385 - S1385   2017.6

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • p53発現腫瘍融解アデノウイルスの薬剤耐性骨肉腫細胞に対する抗腫瘍効果と耐性克服メカニズムの検討

    杉生 和久, 田澤 大, 望月 雄介, 小松原 将, 大森 敏規, 山川 泰明, 吉田 晶, 長谷井 嬢, 藤原 智洋, 国定 俊之, 浦田 泰生, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   91 ( 6 )   S1385 - S1385   2017.6

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 周術期連携による術後合併症の予防と早期離床をめざして 食道癌周術期におけるチーム医療導入の成果と展望

    白川 靖博, 河本 慧, 松三 雄騎, 前田 直見, 二宮 卓之, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科系連合学会誌   42 ( 3 )   414 - 414   2017.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    researchmap

  • Oncological emergency・がん治療における緊急対応 食道癌診療におけるoncological emergencyに対する外科手術の役割

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科系連合学会誌   42 ( 3 )   485 - 485   2017.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    researchmap

  • 4つのモノヌクレオチドリピートマーカーのミスマッチ修復タンパク欠損を伴う大腸癌・子宮体癌スクリーニングの精確性の検討

    母里 淑子, 永坂 岳司, 谷口 文崇, 河合 毅, 岸本 浩行, 神原 健, 藤原 俊義

    日本大腸肛門病学会雑誌   70 ( 5 )   359 - 359   2017.5

     More details

    Language:English   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • ePTFEを用いた新規カテーテル挿入補助デバイスの開発 Reviewed

    大原 利章, 櫻間 教文, 平松 聡, 野間 和広, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   SF - 7   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 成人横隔膜弛緩症に対し胸腔鏡下にてメッシュを用いて横隔膜形成し得た一例

    神尾 知宏, 白川 靖博, 田辺 俊介, 升田 智也, 前田 直見, 二宮 卓之, 野間 和広, 藤原 俊義

    岡山医学会雑誌   129 ( 1 )   70 - 70   2017.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 進行胃癌に対する術前補助化学療法施行症例の検討

    香川 俊輔, 黒田 新士, 菊地 覚次, 伊藤 雅典, 西崎 正彦, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   PS - 2   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • テロメラーゼ標的蛍光発現ウイルスを用いた膵癌腹腔内微小環境の解析

    桑田 和也, 香川 俊輔, 坂本 修一, 渡邉 めぐみ, 香川 哲也, 菊地 寛次, 黒田 新士, 吉田 龍一, 浦田 泰生, 田澤 大, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   SF - 1   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 胃癌における組織型とPD-L1発現の患者予後および術後再発予測因子としての有用性

    黒田 新士, 森廣 俊昭, 久保田 哲史, 金谷 信彦, 菊地 覚次, 田澤 大, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   SF - 4   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Trastuzumab抵抗性胃癌に対する金ナノ技術を融合した新規HER2標的抗体療法

    久保田 哲史, 黒田 新士, 金谷 信彦, 森廣 俊昭, 田澤 大, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   SF - 4   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • cStage I上部胃癌の術式選択 噴門側胃切除vs胃全摘 噴門側胃切除

    西崎 正彦, 黒田 新士, 菊地 覚次, 野間 和広, 田邊 俊介, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   DB - 1   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 下部消化管手術教育における私の工夫 開腹手術と腹腔鏡下手術 下部消化管領域におけるカダバートレーニングの実際

    近藤 喜太, 信岡 大輔, 黒田 新士, 前田 直見, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   WS - 7   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道胃接合部癌の手術手技 食道胃接合部癌に対する術式の進化 腹臥位併用完全鏡視下観音開き法再建の導入

    野間 和広, 白川 靖博, 升田 智也, 前田 直見, 二宮 卓之, 田辺 俊介, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   PD - 4   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 高齢者胃癌手術症例の検討

    伊藤 雅典, 黒田 新士, 菊地 覚次, 西崎 正彦, 香川 俊輔, 藤原 俊義

    岡山医学会雑誌   129 ( 1 )   71 - 71   2017.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 食道SM癌に対する低侵襲治療 高リスク食道癌症例に対する放射線併用ウイルス療法の臨床研究の中間報告

    田辺 俊介, 白川 靖博, 藤原 俊義

    Gastroenterological Endoscopy   59 ( Suppl.1 )   749 - 749   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 胃管作製不能例に対する空腸を用いた食道再建術

    前田 直見, 白川 靖博, 升田 智也, 二宮 卓之, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   PS - 4   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Dダイマーと造影CT検査を併用した胸部食道癌術後の潜在性血栓症に対するスクリーニングの有用性

    二宮 卓之, 前田 直見, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   PS - 7   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道癌周術期管理におけるPERIOの取り組みと成果、そしてその新展開

    白川 靖博, 升田 智也, 前田 直見, 二宮 卓之, 田辺 俊介, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   PS - 5   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 根治困難な局所進行食道癌に対するDCF併用放射線療法を用いた集学的治療

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   SF - 5   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 成人横隔膜弛緩症に対し胸腔鏡下にてメッシュを用いて横隔膜形成し得た一例

    神尾 知宏, 白川 靖博, 田辺 俊介, 升田 智也, 前田 直見, 二宮 卓之, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   78 ( 3 )   626 - 626   2017.3

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道胃接合部癌に対する腹腔鏡下観音開き法食道残胃吻合(Laparoscopic esophagogastorostomy using double flap technique for esophago-gastric junction cancer)

    西崎 正彦, 黒田 新士, 菊地 覚次, 野間 和広, 田邊 俊介, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本胃癌学会総会記事   89回   286 - 286   2017.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 腹腔鏡補助下幽門側胃切除術の定型化とトレーニングシステム(Standardization and training system of laparoscopy-assisted distal gastrectomy)

    黒田 新士, 菊地 寛次, 堀 直人, 坂本 修一, 香川 哲也, 渡辺 めぐみ, 久保田 哲史, 桑田 和也, 石田 道拡, 岸本 浩行, 宇野 太, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   89回   270 - 270   2017.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 胃粘膜下腫瘍に対するClosed-LECS手技の改良と定型化(Standardization and modification of Closed-LECS procedure for gastric submucosal tumor)

    菊地 覚次, 西崎 正彦, 黒田 新士, 伊藤 雅典, 田邊 俊介, 野間 和広, 香川 俊輔, 白川 靖博, 岡田 裕之, 藤原 俊義

    日本胃癌学会総会記事   89回   269 - 269   2017.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 進行胃癌に対するSOX療法の経験と術前補助化学療法への期待(S-1 and oxaliplatin (SOX) for gastric cancer. Is this appropriated for neoadjuvant chemotherapy?)

    香川 俊輔, 黒田 新士, 菊地 覚次, 伊藤 雅典, 西崎 正彦, 藤原 俊義

    日本胃癌学会総会記事   89回   244 - 244   2017.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 高齢者胃癌手術症例の検討

    伊藤 雅典, 黒田 新士, 菊地 覚次, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   78 ( 3 )   627 - 627   2017.3

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 大腸癌卵巣転移に対する外科治療の検討

    母里 淑子, 永坂 岳司, 岸本 浩行, 近藤 喜太, 工藤 泰崇, 樹下 真希, 浅野 博昭, 佃 和憲, 藤原 俊義

    日本大腸肛門病学会雑誌   70 ( 2 )   145 - 145   2017.2

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • がん化学療法・放射線療法における栄養支持療法 頭頸部癌に対する化学放射線療法完遂率向上を目指したPEGによる栄養管理

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 野間 和広, 藤原 俊義

    日本静脈経腸栄養学会雑誌   32 ( Suppl. )   371 - 371   2017.1

     More details

    Language:Japanese   Publisher:(株)ジェフコーポレーション  

    researchmap

  • 食道癌手術における鏡視下手術導入による術前後の身体的・栄養学的変化についての検討

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 野間 和広, 藤原 俊義

    日本静脈経腸栄養学会雑誌   32 ( Suppl. )   395 - 395   2017.1

     More details

    Language:Japanese   Publisher:(株)ジェフコーポレーション  

    researchmap

  • 胸部食道癌の胸腔鏡下手術 胸部食道癌に対する胸腔鏡下手術の短期成績についての検討

    白川 靖博, 升田 智也, 前田 直見, 二宮 卓之, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊介, 藤原 俊義

    日本内視鏡外科学会雑誌   21 ( 7 )   SY2 - 4   2016.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 反回神経麻痺を起こさせない工夫と治療成績 臓器鞘を意識した腹臥位胸腔鏡下上縦隔郭清手技

    野間 和広, 白川 靖博, 升田 智也, 金谷 信彦, 前田 直見, 二宮 卓之, 田辺 俊介, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   21 ( 7 )   WS14 - 1   2016.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 上部消化管良性疾患に対する内視鏡下手術の工夫 食道裂孔ヘルニアに対する積極的手術適応

    田辺 俊介, 白川 靖博, 土生 智大, 升田 智也, 前田 直見, 二宮 卓之, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   21 ( 7 )   RS4 - 1   2016.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡下胃切除術の定型化および若手医師への教育と進行癌への挑戦

    黒田 新士, 菊地 覚次, 伊藤 雅典, 近藤 喜太, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   21 ( 7 )   DP90 - 2   2016.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡下幽門側胃切除におけるHand-sewn Book-Binding Techniqueによる鏡視下Billroth-I法再建

    菊地 覚次, 黒田 新士, 西崎 正彦, 伊藤 雅典, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   21 ( 7 )   OS106 - 6   2016.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 早期胃癌に対する噴門側胃切除術のメリットとデメリット 噴門側胃切除のデメリットを克服する逆流防止弁形成食道残胃吻合

    西崎 正彦, 黒田 新士, 菊地 覚次, 伊藤 雅典, 田邊 俊介, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   21 ( 7 )   RS40 - 5   2016.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 観音開き法による噴門形成術を行った先天性食道狭窄症の1例

    尾山 貴徳, 野田 卓男, 谷 守通, 納所 洋, 谷本 光隆, 野間 和広, 田邊 俊介, 白川 靖博, 藤原 俊義

    日本小児外科学会雑誌   52 ( 7 )   1376 - 1376   2016.12

     More details

    Language:Japanese   Publisher:(一社)日本小児外科学会  

    researchmap

  • 当院における膵頭十二指腸切除術の治療成績

    高木 弘誠, 八木 孝仁, 吉田 龍一, 藤 智和, 杭瀬 崇, 渡辺 信之, 信岡 大輔, 楳田 祐三, 篠浦 先, 藤原 俊義

    日本消化器外科学会雑誌   49 ( Suppl.2 )   351 - 351   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 腹腔鏡下胃切除術 腹腔鏡下「観音開き法」食道残胃吻合 手技の定型化と工夫

    黒田 新士, 西崎 正彦, 藤原 俊義

    日本消化器外科学会雑誌   49 ( Suppl.2 )   75 - 75   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • [A Case of Multiple Liver Metastasis from Gastric Cancer Successfully Treated with CPT-11 as Third-Line Chemotherapy].

    Satoru Kikuchi, Masahiko Nishizaki, Shinji Kuroda, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   43 ( 12 )   2219 - 2221   2016.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    A 63-year-old man underwent proximal gastrectomy for early gastric cancer(pT1bN0M0, pStage I A). Twenty months after surgery, abdominal CT scans revealed multiple liver metastases. S-1 plus CDDP therapy was administered as first-line chemotherapy. After treatment, CT scans revealed tumor progression and nab-PTX was administrated. This treatment was ineffective; therefore, CPT-11 was administrated as third-line chemotherapy. Treatment with CPT-11 resulted in marked tumor reduction and improved the QOL of the patient; partial response was maintained for 8 months. After 17 courses of CPT-11 treatment, tumor regrowth was detected, and the patient was treated with S-1 plus oxaliplatin, DTX, and ramucirumab. Subsequently, the patient died of cancer 31 months after tumor recurrence. CPT-11 is potentially a key drug for the prevention of liver metastasis of gastric cancer, and using all active agents in patients with advanced gastric cancer over several lines of therapy could prolong survival.

    PubMed

    researchmap

  • 多視点3D映像システムによる次世代の手術解剖教育

    信岡 大輔, 八木 孝仁, 近藤 喜太, 篠浦 先, 楳田 祐三, 吉田 龍一, 渡辺 信之, 杭瀬 崇, 藤 智和, 高木 弘誠, 藤原 俊義

    日本消化器外科学会雑誌   49 ( Suppl.2 )   358 - 358   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高リスク神経芽腫に対するhTERT標的化膿瘍融解ウイルス療法(hTERT-targeted oncolytic virotherapy against high-risk neuroblastomas)

    谷本 光隆, 田澤 大, 家田 偉史, 納所 洋, 尾山 貴徳, 浦田 泰生, 香川 俊輔, 野田 卓男, 藤原 俊義

    日本小児血液・がん学会雑誌   53 ( 4 )   202 - 202   2016.11

     More details

    Language:English   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • p53活性化能を有するテロメラーゼ標的型ウイルス療法による腹腔内胃癌微小環境の浄化作用

    田澤 大, 堀 直人, 國府島 健, 谷本 光隆, 家田 偉史, 渡邉 めぐみ, 黒田 新士, 西崎 正彦, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   75回   E - 2069   2016.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 鉄代謝は癌幹細胞の新規治療ターゲットとなり得る Reviewed

    大原 利章, 二宮 卓之, 桂 佑貴, 賀島 肇, 加藤 卓也, 野間 和広, 田澤 大, 藤原 俊義

    日本癌学会総会記事   75回   E - 1109   2016.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 癌関連線維芽細胞(CAFs)が及ぼす腫瘍免疫逃避の解明 CAFsと腫瘍浸潤リンパ球の検討 Reviewed

    加藤 卓也, 野間 和広, 賀島 肇, 桂 佑貴, 二宮 卓之, 大原 利章, 田澤 大, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本癌学会総会記事   75回   E - 1068   2016.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 腹腔鏡下食道裂孔ヘルニア・逆流性食道炎手術の適応と術式 高齢化社会における食道裂孔ヘルニア手術の積極的適応

    田辺 俊介, 白川 靖博, 土生 智大, 升田 智也, 前田 直見, 二宮 卓之, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   77 ( 増刊 )   348 - 348   2016.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 蛍光ウイルスによる腹腔内の腫瘍関連マクロファージと膵癌細胞の関連性の解析

    桑田 和也, 香川 俊輔, 坂本 修一, 渡邉 めぐみ, 香川 哲也, 菊地 覚次, 黒田 新士, 吉田 龍一, 浦田 泰生, 田澤 大, 藤原 俊義

    日本癌学会総会記事   75回   P - 1320   2016.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 胃癌根治切除後におけるPD-L1発現に基づいた予後および再発パターンの予測

    森廣 俊昭, 黒田 新士, 久保田 哲史, 田澤 大, 菊地 覚次, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   75回   E - 3064   2016.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • Stage 4胃癌の化学療法奏効例に対するconversion surgery

    香川 俊輔, 黒田 新士, 菊地 覚次, 伊藤 雅典, 西崎 正彦, 藤原 俊義

    日本臨床外科学会雑誌   77 ( 増刊 )   708 - 708   2016.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 高齢者胃癌治療の検討 根治性と術後QOLの面から

    伊藤 雅典, 黒田 新士, 菊地 覚次, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   77 ( 増刊 )   530 - 530   2016.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 胃癌外科治療におけるサルコペニアの予後予測因子としての重要性

    黒田 新士, 桑田 和也, 菊地 覚次, 伊藤 雅典, 吉田 龍一, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   77 ( 増刊 )   463 - 463   2016.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 腹腔鏡下胃癌手術における脾門部郭清アプローチ 脾門部の解剖に基づく腹腔鏡下脾温存リンパ節郭清

    西崎 正彦, 黒田 新士, 菊地 覚次, 伊藤 雅典, 田邊 俊介, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   77 ( 増刊 )   446 - 446   2016.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • LECSの現状と課題 胃粘膜下腫瘍に対するClosed-LECSの治療成績と今後の展望

    菊地 覚次, 西崎 正彦, 黒田 新士, 伊藤 雅典, 香川 俊輔, 岡田 裕之, 藤原 俊義

    日本臨床外科学会雑誌   77 ( 増刊 )   404 - 404   2016.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 低侵襲性手術のトレーニング 技の磨練に向けて 内視鏡手術におけるカダバートレーニングシステムの構築

    近藤 喜太, 信岡 大輔, 黒田 新士, 前田 直見, 藤原 俊義

    日本臨床外科学会雑誌   77 ( 増刊 )   361 - 361   2016.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 金ナノ粒子を用いた新規HER2標的抗体療法

    久保田 哲史, 黒田 新士, 森廣 俊昭, 田澤 大, 香川 俊輔, 藤原 俊義

    癌と化学療法   43 ( 10 )   1237 - 1239   2016.10

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    trastuzumab(Tmab)は、human epidermal growth factor receptor 2(HER2)に対するヒト化モノクローナル抗体で、現在乳癌や胃癌に対して臨床使用され予後を改善しているが、HER2の低発現(約20%)やTmab抵抗性の問題がある。Tmab抵抗例に対して新たなHER2標的製剤が開発されているが胃癌に対して臨床的に有効なものはまだなく、新たな治療法が望まれる。ナノ技術はその発展に伴い医療へ応用されてきている。金ナノ粒子は生体内での安定性と表面修飾の容易性などの特性があり、autophagyやoxidative stressを介したアポトーシスを誘導することも報告されている。われわれは、HER2標的金ナノ粒子製剤(Tmab-AuNPs)を作製し、Tmab抵抗性胃癌細胞株に対する抗腫瘍効果とHER2細胞外領域を強制発現させたHER2陰性株に対する抗腫瘍効果を確認しており、Tmab-AuNPsがTmab抵抗性胃癌に対する新たなHER2標的製剤になり得ると考えている。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2016&ichushi_jid=J00296&link_issn=&doc_id=20161104480020&doc_link_id=%2Fab8gtkrc%2F2016%2F004310%2F021%2F1237-1239%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2016%2F004310%2F021%2F1237-1239%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 内視鏡治療と鏡視下手術のコラボレーション 胃粘膜下腫瘍に対するClosed-LECS手技の確立と早期胃癌への応用

    菊地 覚次, 西崎 正彦, 藤原 俊義

    Gastroenterological Endoscopy   58 ( Suppl.2 )   1745 - 1745   2016.10

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 転移性大腸癌における治療標的となりうるマイクロRNAの同定

    河合 毅, 永坂 岳司, 藤 智和, 戸嶋 俊明, 安井 和也, 母里 淑子, 藤原 俊義

    日本癌学会総会記事   75回   P - 1273   2016.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • ウイルスによる遺伝子導入は抗原陰性胃癌に対する光線免疫療法を可能にする

    香川 俊輔, 石田 道拡, 下山 京子, 竹原 清人, 野間 和広, 田辺 俊介, 白川 靖博, 田澤 大, 小林 久隆, 藤原 俊義

    日本癌学会総会記事   75回   E - 2094   2016.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 気管浸潤を伴う局所進行食道癌CRT後遺残に対してsalvage手術を施行した一例

    土生 智大, 白川 靖博, 升田 智也, 前田 直見, 二宮 卓之, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   77 ( 増刊 )   997 - 997   2016.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 合併症ゼロを目指した食道癌周術期チーム医療成功のための外科医の役割

    白川 靖博, 升田 智也, 二宮 卓之, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊介, 藤原 俊義

    日本臨床外科学会雑誌   77 ( 増刊 )   475 - 475   2016.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 高悪性度神経芽細胞種に対するhTERT標的型腫瘍融解ウイルス療法の抗腫瘍活性

    谷本 光隆, 田澤 大, 家田 偉史, 納所 洋, 尾山 貴徳, 浦田 泰生, 香川 俊輔, 野田 卓男, 藤原 俊義

    日本癌学会総会記事   75回   P - 2312   2016.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • Modified FOLFOXIRIの当院における有効性と安全性

    母里 淑子, 永坂 岳司, 河合 毅, 岸本 浩行, 吉岡 貴裕, 佃 和宣, 中谷 紳, 嶋村 廣視, 冨岡 憲明, 森谷 行利, 瀧上 隆夫, 藤原 俊義

    日本大腸肛門病学会雑誌   69 ( 抄録号 )   A206 - A206   2016.10

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • StageIV大腸がんの治療 遺伝子変異情報を考慮したStageIV大腸癌に対する予後の検討及び治療戦略の構築

    永坂 岳司, 母里 淑子, 岸本 浩行, 神原 健, 河合 毅, 中谷 紳, 嶋村 廣視, 富岡 憲明, 森谷 行利, 瀧上 隆夫, 佃 和憲, 藤原 俊義

    日本大腸肛門病学会雑誌   69 ( 抄録号 )   A35 - A35   2016.10

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • circulating cell free DNAのメチル化解析による大腸癌化学療法の治療効果判定の診断

    戸嶋 俊明, 永坂 岳司, 木村 圭佑, 安井 和也, 河合 毅, 母里 淑子, 藤原 俊義

    日本癌学会総会記事   75回   P - 1071   2016.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 腫瘍融解ウイルス療法による骨肉腫のABC Transporterを介した薬剤耐性の克服

    杉生 和久, 田澤 大, 長谷井 嬢, 尾崎 修平, 山川 泰明, 大森 敏規, 小松原 将, 望月 雄介, 藤原 智洋, 国定 俊之, 浦田 泰生, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   75回   J - 3020   2016.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 軟部肉腫に対するテロメラーゼ標的型腫瘍融解アデノウイルスの放射線効果増強

    小松原 将, 大森 敏規, 田澤 大, 杉生 和久, 望月 雄介, 山川 泰明, 尾崎 修平, 長谷井 嬢, 藤原 智洋, 国定 俊之, 浦田 泰生, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   75回   P - 3306   2016.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 臨床検体を用いた腫瘍融解アデノウイルスの骨・軟部腫瘍への適応に関する検討

    吉田 晶, 魚谷 弘二, 藤原 智洋, 長谷井 嬢, 大森 敏規, 杉生 和久, 小松原 将, 森田 卓也, 清野 正晋, 望月 雄介, 武田 健, 国定 俊之, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   90 ( 8 )   S1627 - S1627   2016.8

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 放射線抵抗性を示す骨・軟部肉腫に対する腫瘍融解アデノウイルスの放射線増感作用

    大森 敏規, 山川 泰明, 長谷井 嬢, 田澤 大, 尾崎 修平, 杉生 和久, 藤原 智洋, 吉田 晶, 国定 俊之, 浦田 泰生, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   90 ( 8 )   S1564 - S1564   2016.8

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • p53発現腫瘍融解アデノウイルスはMDR-1発現を抑制することにより薬剤耐性骨肉腫細胞に対して強力な抗腫瘍効果を示す

    杉生 和久, 望月 雄介, 小松原 将, 大森 敏規, 山川 泰明, 吉田 晶, 長谷井 嬢, 藤原 智洋, 国定 俊之, 田澤 大, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   90 ( 8 )   S1554 - S1554   2016.8

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 外科における基礎的研究 セレンディピティーを求めて 鉄コントロールによる新規癌幹細胞治療 Reviewed

    二宮 卓之, 大原 利章, 桂 佑貴, 賀島 肇, 加藤 卓也, 野間 和広, 田辺 俊介, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   71回   WS7 - 2   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • さらなる微細解剖の理解から目指す鏡視下食道手術 根治性と低侵襲性の共存

    野間 和広, 白川 靖博, 金谷 信彦, 岡田 剛, 前田 直見, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   71回   P3 - 7   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • ここまで来た、ESD後狭窄予防策 食道がん周術期チーム医療成功のための外科医の役割

    白川 靖博, 金谷 信彦, 岡田 剛, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   70回   29 - 29   2016.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌術後早期にAeromonas hydrophilaによる壊死性軟部組織感染症を発症した1例

    金谷 信彦, 白川 靖博, 九十九 悠太, 岡田 剛, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   77 ( 7 )   1861 - 1861   2016.7

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • リンパ節転移分布からみた残胃進行癌の治療戦略

    菊地 覚次, 黒田 新士, 渡邉 めぐみ, 白川 靖博, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   71回   P3 - 6   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 膵上縁リンパ節郭清における自律神経解剖の役割

    西崎 正彦, 黒田 新士, 菊地 覚次, 渡邉 めぐみ, 前田 直見, 田辺 俊介, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   71回   P1 - 9   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胃癌腹膜播種の基礎と臨床 新たなエビデンスの創出に向けて 胃癌個別化治療に向けた腹腔内遊離癌細胞イメージング技術の応用

    渡辺 めぐみ, 香川 俊輔, 桑田 和也, 坂本 修一, 菊地 覚次, 黒田 新士, 岸本 浩行, 西崎 正彦, 田澤 大, 藤原 俊義

    日本消化器外科学会総会   71回   WS15 - 6   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 消化器外科領域における最新のトランスレーショナルリサーチ 食道癌に対する放射線併用ウイルス療法の臨床研究 低用量群(Level 1)の薬理動態解析

    藤原 俊義, 香川 俊輔, 田辺 俊介, 田澤 大, 野間 和広, 黒田 新士, 菊地 覚次, 白川 靖博

    日本消化器外科学会総会   71回   WS5 - 1   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 若手外科医育成のための工夫 当科におけるカタバートレーニング運用の実際とその効用

    近藤 喜太, 信岡 大輔, 前田 直見, 黒田 新士, 藤原 俊義

    日本消化器外科学会総会   71回   WS1 - 5   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胃癌における機能温存手術と機能再建手術 「観音開き法」食道残胃吻合 噴門機能の再構築を目指した形態的・機能的再建法

    黒田 新士, 西崎 正彦, 菊地 覚次, 渡邉 めぐみ, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   71回   SY12 - 3   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 明日の食道癌非手術治療 食道癌に対する放射線併用ウイルス療法の臨床研究の中間報告

    田辺 俊介, 白川 靖博, 金谷 信彦, 岡田 剛, 前田 直見, 黒田 新士, 野間 和広, 田澤 大, 香川 俊輔, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   70回   58 - 58   2016.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道胃接合部腺癌の至適郭清範囲と切除範囲 食道胃接合部癌125例の検討から導かれる最適な手術

    野間 和広, 白川 靖博, 金谷 信彦, 岡田 剛, 前田 直見, 田辺 俊介, 櫻間 教文, 香川 俊輔, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   70回   39 - 39   2016.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌術後の縫合不全は再発・予後を増悪させるのか

    金谷 信彦, 白川 靖博, 岡田 剛, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   71回   P2 - 1   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胃切除後の食道再建術式 胃管作成不能例に対する空腸を用いた食道再建術における工夫

    白川 靖博, 金谷 信彦, 岡田 剛, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   71回   PD1 - 2   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 標的陰性癌に対するPhotoimmunotherapy 抗原修飾による抗原陽転化と不均一性の克服

    香川 俊輔, 石田 道拡, 下山 京子, 竹原 清人, 野間 和広, 田辺 俊介, 渡邉 めぐみ, 田澤 大, 小林 久隆, 藤原 俊義

    日本消化器外科学会総会   71回   SS9 - 8   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 術前食道がん患者の抑うつ傾向と心理的適応に関する因子

    伊藤 真理, 廣川 万里子, 市川 あい, 足羽 孝子, 前田 直見, 田辺 俊介, 野間 和宏, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   70回   149 - 149   2016.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌術後患者に分粥食は必要か?

    園井 みか, 足羽 孝子, 伊藤 真理, 廣川 万里子, 前田 直見, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   70回   147 - 147   2016.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • あきらめない食道癌治療 Oligometastasisへの挑戦

    金谷 信彦, 白川 靖博, 岡田 剛, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   70回   104 - 104   2016.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 腹臥位胸腔鏡下食道切除術における拡大視効果と術視野共有の利点と成果

    白川 靖博, 金谷 信彦, 岡田 剛, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   70回   64 - 64   2016.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道切除後再建法 より良い術後QOLをめざして 胃管作製不能例に対する空腸を用いた食道再建術

    前田 直見, 白川 靖博, 金谷 信彦, 岡田 剛, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   70回   51 - 51   2016.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌患者の口腔感染管理と咬合回復が周術期の体重変化に影響した可能性のある一症例

    樋口 智子, 花岡 愛弓, 山中 玲子, 仲田 直樹, 曽我 賢彦, 飯田 征二, 田邊 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   70回   193 - 193   2016.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 腹部外科における慢性感染創治療の現況と未来 クローン病術後創における局所陰圧閉鎖療法の適応と今後の方向性

    吉岡 貴裕, 近藤 喜太, 工藤 泰崇, 河合 毅, 母里 淑子, 岸本 浩行, 永坂 岳司, 藤原 俊義

    日本消化器外科学会総会   71回   WS10 - 8   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高難度手術におけるカダバートレーニングの意義と当科における実際

    近藤 喜太, 吉岡 貴裕, 工藤 泰崇, 母里 淑子, 岸本 浩行, 永坂 岳司, 藤原 俊義

    日本臨床外科学会雑誌   77 ( 7 )   1864 - 1864   2016.7

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • TIL関連遺伝子アッセイを用いた化学療法効果予測および予後予測に関する検討

    河内 麻里子, 岩本 高行, 新倉 直樹, 溝尾 妙子, 野上 智弘, 枝園 忠彦, 元木 崇之, 増田 しのぶ, 土井原 博義, 藤原 俊義, 徳田 裕, 松岡 順治

    日本乳癌学会総会プログラム抄録集   24回   345 - 345   2016.6

     More details

    Language:Japanese   Publisher:(一社)日本乳癌学会  

    researchmap

  • 薬物療法を受けている患者のQOL 多職種からのアプローチ エベロリムス投与における有害事象の評価 患者と医療者の認識の違い、各職種間における認識の違い

    松岡 順治, 河内 麻里子, 岩本 高之, 元木 崇之, 土井原 博義, 平 成人, 露無 祐子, 藤原 俊義

    日本乳癌学会総会プログラム抄録集   24回   209 - 209   2016.6

     More details

    Language:Japanese   Publisher:(一社)日本乳癌学会  

    researchmap

  • 右側肝円索・門脈分枝走行異常を伴った進行胆嚢癌切除の経験

    吉田 龍一, 高木 弘誠, 須井 健太, 藤 智和, 杭瀬 崇, 渡辺 信之, 信岡 大輔, 楳田 佑三, 篠浦 先, 八木 孝仁, 藤原 俊義

    日本肝胆膵外科学会・学術集会プログラム・抄録集   28回   429 - 429   2016.6

     More details

    Language:Japanese   Publisher:(一社)日本肝胆膵外科学会  

    researchmap

  • 骨・軟部肉腫に対する腫瘍融解ウイルスの放射線増感作用

    大森 敏規, 山川 泰明, 長谷井 嬢, 田澤 大, 尾崎 修平, 杉生 和久, 藤原 智洋, 国定 俊之, 浦田 泰生, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   90 ( 6 )   S1260 - S1260   2016.6

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 鉄コントロールによる新規がん幹細胞治療 Reviewed

    二宮 卓之, 大原 利章, 加藤 卓也, 賀島 肇, 野間 和広, 田澤 大, 田辺 俊介, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   116回   PS - 8   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 治癒切除し得た腺癌成分をともなった胃yolk sac tumorの1例

    李 云成, 菊地 覚次, 坂本 修一, 黒田 新士, 西崎 正彦, 白川 靖博, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   116回   RS - 8   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 胃癌におけるPD-L1の臨床病理学的特徴

    黒田 新士, 森廣 俊昭, 久保田 哲史, 田中 健大, 坂本 修一, 菊地 覚次, 田澤 大, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   116回   PS - 4   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 次世代の外科治療における早期探索的医療研究の役割 食道癌外科治療を補完する新たな治療戦略としての腫瘍融解ウイルスと放射線との新規併用療法の臨床研究

    香川 俊輔, 田辺 俊介, 田澤 大, 野間 和広, 國府島 健, 賀島 肇, 加藤 卓也, 黒田 新士, 菊地 覚次, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   116回   WS - 5   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A 胃切除術で起こりやすい逆流症状はどうして起こるの? どう注意すればいい?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   144 - 145   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A 胃切除術で起こりやすい胃内容排出遅延って何? どうして起こるの? どう注意すればいい?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   142 - 143   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A 胃切除術で起こりやすいダンピング症状って何? どうして起こるの? どう注意すればいい?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   140 - 141   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A 胃切除後はなぜ貧血が起こりやすいの? どう注意すればいい?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   138 - 139   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A 胃切除術後にはいつ・どの部位で・何を観察すればいいの?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   136 - 137   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A 胃切除術後に起こりうる合併症にはどのようなものがあるの?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   134 - 135   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A 胃切除術後に生じうるドレーン排液にはどのようなものがあるの? 排液から何がわかるの?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   132 - 133   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A 胃切除術後のドレーン留置部位は? なぜそこに留置されるの?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   130 - 131   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A 胃切除術後の再建法にはどのようなものがある? 各再建法で術後の注意点に違いはある?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   128 - 129   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A 胃切除術ではどこを切除するの? 切除法によって術後の注意点に違いはある?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   126 - 127   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A どのようなときに胃が切除されるの?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   124 - 125   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 【でっかくド〜ン!オールカラー図解でみるみるわかる 新人ナースのための消化器外科 術前術後ケアQ&A102】(4章)胃の手術と術前術後ケアQ&A 胃切除術の術前ケアではどのようなことが行われるの? 注意すべきことは?

    菊地 覚次, 藤原 俊義

    消化器外科Nursing   ( 2016春季増刊 )   122 - 123   2016.4

     More details

    Language:Japanese   Publisher:(株)メディカ出版  

    researchmap

  • 食道癌ESD後の追加治療としての手術症例ならびにESD後再発手術症例の検討 ESD後の適切な追加・補助治療とは

    田辺 俊介, 白川 靖博, 九十九 悠太, 桂 佑貴, 前田 直見, 野間 和広, 櫻間 教文, 藤原 俊義

    日本外科学会定期学術集会抄録集   116回   PS - 3   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 胸部食道癌手術における食道胃管吻合法の比較 Gambee吻合法と三角吻合法

    前田 直見, 白川 靖博, 九十九 悠太, 桂 佑貴, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本外科学会定期学術集会抄録集   116回   PS - 7   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道癌困難症例に対する腹臥位胸腔鏡下手術の工夫

    白川 靖博, 九十九 悠太, 桂 祐貴, 前田 直見, 田辺 俊介, 野間 和広, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   116回   PS - 8   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道表在癌の内視鏡診断・治療の現状と限界 食道ESD後追加手術例と再発後手術例から考える食道ESD後の適切な補助療法

    田辺 俊介, 白川 靖博, 藤原 俊義

    Gastroenterological Endoscopy   58 ( Suppl.1 )   506 - 506   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 食道癌術後早期にAeromonas hydrophilaによる壊死性軟部組織感染症を発症した1例

    金谷 信彦, 白川 靖博, 九十九 悠太, 岡田 剛, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    岡山医学会雑誌   128 ( 1 )   77 - 77   2016.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 切除可能局所進行直腸癌に対する術前化学療法および術前放射線化学療法の検討

    母里 淑子, 永坂 岳司, 岸本 浩行, 河合 毅, 工藤 泰崇, 樹下 真希, 近藤 喜太, 浅野 博昭, 佃 和憲, 藤原 俊義

    日本外科学会定期学術集会抄録集   116回   PS - 2   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 大腸癌脳転移に対する集学的治療で長期生存を得た2例の検討

    吉川 公見子, 母里 淑子, 永坂 岳司, 岸本 浩行, 河合 毅, 藤原 俊義

    日本外科学会定期学術集会抄録集   116回   RS - 9   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 高難度手術におけるカダバートレーニングの意義と当科における実際

    近藤 喜太, 吉岡 貴裕, 工藤 泰崇, 母里 淑子, 岸本 浩行, 永坂 岳司, 藤原 俊義

    岡山医学会雑誌   128 ( 1 )   82 - 82   2016.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. International journal

    Takayuki Iwamoto, Catherine Kelly, Taeko Mizoo, Tomohiro Nogami, Takayuki Motoki, Tadahiko Shien, Naruto Taira, Naoki Hayashi, Naoki Niikura, Toshiyoshi Fujiwara, Hiroyoshi Doihara, Junji Matsuoka

    Clinical breast cancer   16 ( 2 )   95 - 100   2016.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: In estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, first-generation genomic signatures serve predominately as prognostic biomarkers and secondarily as predictors of response to chemotherapy. We compared both the prognostic and predictive value of histologic grades and genomic markers. METHODS: We retrieved publicly available cDNA microarray data from 1373 primary ER(+)/HER2(-) breast cancers and developed a genomic signature simulated from Recurrence Online (http://www.recurrenceonline.com/) to calculate the recurrence score and risk using predefined sets of genes in the cDNA microarray. We then compared the prognostic and predictive information provided by histologic grade and genomic signature. RESULTS: Based on genomic signatures, 55%, 28%, and 17% of breast cancers were classified as low, intermediate, and high risk, respectively, whereas the histologic grades were I, II, and III in 22%, 59%, and 19% of breast cancers, respectively. Univariate analysis in the untreated cohort revealed that both histologic grade (overall P = .007) and genomic signature (P < .001) could predict prognosis. Results were similar using the genomic signature, with pathologic complete response rates of 4.6%, 5.7%, and 16.5% for low-, intermediate-, and high-risk cancers, respectively. Neither biomarker was statistically significant in multivariate analysis for predictive response to neoadjuvant chemotherapy (NAC). CONCLUSION: Genomic signature was better at identifying low-risk cases compared to histologic grade alone, but both markers had similar predictive values for NAC response. Better predictive biomarkers for NAC response are still needed.

    DOI: 10.1016/j.clbc.2015.10.004

    PubMed

    researchmap

  • 腹腔内播種に対する取り組み 外科医の役割 腹膜内播種に関する洞察のための胃がん細胞の蛍光誘導によるイメージング(Challenge to peritoneal dissemination: Role of surgeons Fluorescence-guided imaging of gastric cancer cells for an insight into peritoneal dissemination)

    Kagawa Shunsuke, Watanabe Megumi, Kuwata Kazuya, Kikuchi Satoru, Kuroda Shinji, Sakamoto Shuichi, Nishizaki Masahiko, Tazawa Hiroshi, Fujiwara Toshiyoshi

    日本胃癌学会総会記事   88回   180 - 180   2016.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • スキルス胃癌細胞に対するテロメラーゼ依存的腫瘍融解ウイルス治療の前臨床評価

    堀 直人, 田澤 大, 西崎 正彦, 渡邉 めぐみ, 田村 周太, 國府島 健, 黒田 新士, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   88回   452 - 452   2016.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 腹腔鏡下・ロボット支援下噴門側胃切除後「観音開き法」再建(Esophagogastrostomy with double flap technique after laparoscopic and robotic proximal gastrectomy)

    西崎 正彦, 黒田 新士, 菊地 覚次, 渡邉 めぐみ, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本胃癌学会総会記事   88回   272 - 272   2016.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 低侵襲性と高QOLを追求した腹腔鏡下噴門側胃切除+観音開き法再建の食道胃接合部癌への適応拡大(Laparoscopic proximal gastrectomy with valvuloplastic esophagogastrostomy for EGJ cancer)

    黒田 新士, 西崎 正彦, 野間 和広, 菊地 覚次, 坂本 修一, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本胃癌学会総会記事   88回   261 - 261   2016.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 残胃癌手術症例の予後因子の検討

    菊地 覚次, 黒田 新士, 坂本 修一, 白川 靖博, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   88回   198 - 198   2016.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 食道癌手術における鏡視下手術導入による術前後の身体的変化についての検討

    田辺 俊介, 白川 靖博, 前田 直見, 野間 和広, 藤原 俊義

    日本静脈経腸栄養学会雑誌   31 ( 1 )   611 - 611   2016.1

     More details

    Language:Japanese   Publisher:(株)ジェフコーポレーション  

    researchmap

  • BASIC AND PRACTICAL METHODS FOR SURGICAL CLINICAL STUDY

    Fujiwara Toshiyoshi

    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)   77 ( 5 )   1288 - 1288   2016

     More details

    Language:Japanese   Publisher:Japan Surgical Association  

    DOI: 10.3919/jjsa.77.1288

    CiNii Article

    researchmap

  • A Case of a Fish Bone Detected in the Upper Bile Duct after Gastrectomy and Choledochoduodenostomy

    HORI Naoto, MATSUDA Tadakazu, KATSUBE Ryoichi, LEE JeonUk, KAMIKAWA Yasuaki, FUJIWARA Toshiyoshi

    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)   77 ( 8 )   2033 - 2038   2016

     More details

    Language:Japanese   Publisher:Japan Surgical Association  

    A case of cholangitis of the right hepatic duct caused by an ingested fish bone is reported. A 70-year-old man developed symptoms of acute cholangitis and was admitted to our hospital two times within the space of half a year. Abdominal CT and MRI showed evidence of acute cholangitis with dilatation of the right hepatic duct. Underlying intrahepatic bile duct cancer was considered as the cause of the relapsing cholangitis and dilatation of the right hepatic duct. Under the suspected diagnosis of intrahepatic bile duct cancer, an exploratory laparotomy was performed. The junction between the duodenum and common bile duct was cut, and the intrabiliary wall was observed with a cholangioscope. A foreign body was found to be stuck to the bile duct wall, which was considered to be the cause of the acute cholangitis. The foreign body was removed endoscopically with forceps. Histopathologically, the foreign body was diagnosed as a bone stump, and the needle-shaped appearance suggested that it was a fish bone. This is the first reported case of an ingested fish bone found in the upper bile duct.

    DOI: 10.3919/jjsa.77.2033

    CiNii Article

    researchmap

  • p53 Replacement Therapy for Cancer. Reviewed

    Tazawa H, Kagawa S, Fujiwara T

    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer   209   1 - 15   2016

  • 食道癌への内視鏡外科手術を評価する 低侵襲性と長期成績 食道癌手術における胸腔鏡手術導入による低侵襲化の検討 術後超短期評価と長期評価

    田辺 俊介, 白川 靖博, 九十九 悠太, 桂 佑貴, 前田 直見, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   20 ( 7 )   SY31 - 8   2015.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 進行胃癌に対する審査腹腔鏡のルチーン化と新たな探索的研究

    菊地 覚次, 香川 俊輔, 坂本 修一, 渡邉 めぐみ, 黒田 新士, 岸本 浩行, 西崎 正彦, 藤原 俊義

    日本内視鏡外科学会雑誌   20 ( 7 )   OS312 - 6   2015.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡下噴門側胃切除後の再建 革新を目指して 完全体腔内「観音開き法」食道残胃吻合

    黒田 新士, 西崎 正彦, 菊地 覚次, 坂本 修一, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   20 ( 7 )   PD10 - 5   2015.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 内視鏡外科のこれからの教育 工夫を持ち寄って最善を探る カダバートレーニングにおける指導経験の効用

    近藤 喜太, 前田 直見, 黒田 新士, 信岡 大輔, 吉田 龍一, 藤原 俊義

    日本内視鏡外科学会雑誌   20 ( 7 )   WS2 - 6   2015.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡下噴門側胃切除後の再建 ベストな再建方法はどれか 逆流防止弁形成食道残胃吻合(観音開き法)

    西崎 正彦, 黒田 新士, 菊地 覚次, 田邊 俊介, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   20 ( 7 )   DS12 - 1   2015.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 気管周囲微細解剖に留意した左反回神経リンパ節郭清の工夫

    白川 靖博, 九十九 悠太, 桂 佑貴, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   20 ( 7 )   OS309 - 4   2015.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 内視鏡視下食道手術のピットフォールとその対策 腹臥位胸腔鏡下食道切除における偶発症と当科におけるその対策

    野間 和広, 白川 靖博, 李 云成, 九十九 悠太, 桂 佑貴, 前田 直見, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   20 ( 7 )   WS13 - 3   2015.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹会陰式直腸切断術の術後会陰感染創に対する局所陰圧閉鎖療法の有用性

    近藤 喜太, 母里 淑子, 岸本 浩行, 永坂 岳司, 藤原 俊義

    日本創傷治癒学会プログラム・抄録集   45回   108 - 108   2015.11

     More details

    Language:Japanese   Publisher:(一社)日本創傷治癒学会  

    researchmap

  • [Therapeutic Potential of Targeting Cancer-Associated Fibroblasts in Esophageal Cancer]. Reviewed

    Kazuhiro Noma, Hajime Kashima, Takayuki Ninomiya, Ryoichi Katsube, Shinichiro Watanabe, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   42 ( 10 )   1228 - 30   2015.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Advances in molecular and cellular biochemistry, such as the development of targeted cancer therapy, have dramatically improved the prognosis of cancer patients. Emerging data have suggested that bevacizumab treatment may act by controlling the cancer microenvironment. Many reports have examined the interaction of cancer cells with the tumor microenvironment, and cancer-associated fibroblasts (CAFs) are thought to play a central role in this process. We speculated that the cancer microenvironment and in particular, CAFs, strongly influence the development of esophageal cancer. We have analyzed the signaling pathways of molecular targets. However, inhibition of a single signaling pathway is insufficient to treat cancer effectively. Photoimmunotherapy is a molecular-targeted specific cancer therapy using near-infrared radiation, which was introduced by Mitsunaga et al. in 2011. We are using its specific method of killing cells to target CAFs. We will report the results of its effect on cancer cells in the future.

    PubMed

    researchmap

  • 【LECS(laparoscopy and endoscopy cooperative surgery)の新たな展開】各種LECS手技 Closed LECS

    西崎 正彦, 黒田 新士, 加藤 大, 松村 年久, 岡田 裕之, 藤原 俊義

    臨床消化器内科   30 ( 12 )   1503 - 1509   2015.10

     More details

    Language:Japanese   Publisher:(株)日本メディカルセンター  

    5cm以下の管内発育型GIST(gastrointestinal stromal tumor)を主体とした胃粘膜下腫瘍の手術療法は,LECS(laparoscopy and endoscopy cooperative surgery)の登場により必要最小限の胃部分切除を低侵襲手術として行うことが可能となった.しかし,LECS原法(Classical LECS)では腫瘍切除の過程で胃内腔と腹腔が交通し,腫瘍も腹腔内に露出するため,潰瘍のあるGISTや早期胃癌への応用は禁忌と考えられてきた.胃壁を開放しない,あるいは,胃内容物を撒布しない方法として,すでに,いくつかの手技が臨床応用されているが,筆者らはClassical LECSを発展させたClosed LECSを考案したので,手術手技,臨床応用について概説する.(著者抄録)

    researchmap

  • 喀痰を用いたCpGのメチル化検出による非侵襲的なスクリーニングの開発

    河合 毅, 永坂 岳司, 藤 智和, 谷口 文崇, 戸嶋 俊明, 母里 淑子, 豊岡 伸一, 藤原 俊義

    日本癌学会総会記事   74回   P - 3314   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 循環Ago2-miRNA検出技術を用いた化学療法効果予測の検証

    藤 智和, 永坂 岳司, 母里 淑子, 河合 毅, 谷口 文崇, 戸嶋 俊明, 藤原 俊義

    日本癌学会総会記事   74回   P - 3313   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 血中のcirculating cell-freeDNAのメチル化検出による大腸癌の同定

    戸嶋 俊明, 永坂 岳司, 河合 毅, 藤 智和, 谷口 文崇, 木村 圭佑, 安井 和也, 母里 淑子, 藤原 俊義

    日本癌学会総会記事   74回   P - 2007   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 遺伝性大腸癌における系統的遺伝子解析

    谷口 文崇, 永坂 岳司, 母里 淑子, 河合 毅, 藤 智和, 戸嶋 俊明, 藤原 俊義

    日本癌学会総会記事   74回   P - 1170   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道疾患手術後の吻合・修復部における縫合不全対策 胃管作成不能例に対する空腸を用いた食道再建および吻合の工夫

    白川 靖博, 九十九 悠太, 桂 佑貴, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   76 ( 増刊 )   488 - 488   2015.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道疾患に対する手術手技 気管周囲微細解剖に留意した反回神経リンパ節郭清の工夫

    白川 靖博, 九十九 悠太, 桂 佑貴, 前田 直晃, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   76 ( 増刊 )   382 - 382   2015.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 分化型胃癌細胞による癌関連線維芽細胞の活性化機構

    李 云成, 田澤 大, 西崎 正彦, 橋本 悠里, 堀 直人, 勝部 亮一, 黒田 新士, 野間 和広, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   74回   P - 3127   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 胃癌個別化治療に向けた、蛍光ウイルスによる腹腔内遊離胃癌細胞の検出技術の開発

    渡邉 めぐみ, 香川 俊輔, 桑田 和也, 橋本 悠里, 堀 直人, 菊地 覚次, 黒田 新士, 岸本 浩行, 西崎 正彦, 田澤 大, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   74回   E - 1291   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • ナノ技術と抗体療法の融合による新規HER2標的金ナノ製剤の開発と治療効果の検討

    久保田 哲史, 黒田 新士, 森廣 俊昭, 青山 克幸, 田澤 大, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   74回   E - 1332   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • スキルス胃癌細胞に対する腫瘍特異的p53遺伝子治療の前臨床評価

    堀 直人, 田澤 大, 西崎 正彦, 渡邉 めぐみ, 田村 周太, 國府島 健, 黒田 新士, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   74回   E - 1272   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 基礎研究の外科臨床への応用 早期消化管がんに対する新規リンパ節転移治療の可能性

    菊地 覚次, 岸本 浩行, 田澤 大, 黒田 新士, 西崎 正彦, 香川 俊輔, 浦田 泰生, Hoffman Robert M., 藤原 俊義

    日本癌学会総会記事   74回   S16 - 3   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • KRAS/BRAF変異を持つ大腸癌に対する新たな腫瘍融解ウイルス療法の開発

    田村 周太, 田澤 大, 堀 直人, 國府島 健, 菊地 覚次, 黒田 新士, 岸本 浩行, 永坂 岳司, 西崎 正彦, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   74回   E - 1066   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 遊走能・浸潤能を有する膵臓癌細胞に対する新たな腫瘍融解ウイルス療法の開発

    國府島 健, 田澤 大, 堀 直人, 田村 周太, 黒田 新士, 岸本 浩行, 西崎 正彦, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   74回   E - 1064   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 胃疾患に対する内視鏡外科手術手技 腹腔鏡下噴門側胃切除術におけるリンパ節郭清手技の定型化

    西崎 正彦, 黒田 新士, 菊地 覚次, 坂本 修一, 田邊 俊介, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   76 ( 増刊 )   389 - 389   2015.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 結腸右半切除を伴う拡大膵頭十二指腸切除術後の再建の工夫

    佐藤 博紀, 信岡 大輔, 安井 和也, 高木 弘誠, 杭瀬 崇, 内海 方嗣, 吉田 龍一, 楳田 祐三, 篠浦 先, 八木 孝仁, 藤原 俊義

    日本消化器外科学会雑誌   48 ( Suppl.2 )   203 - 203   2015.10

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 左副腎腺によるCushing症候群にて腹腔鏡下副腎摘出術を施行した1例

    谷本 光隆, 野田 卓男, 尾山 貴徳, 西崎 正彦, 藤原 俊義, 長谷川 高誠

    日本小児外科学会雑誌   51 ( 6 )   1126 - 1126   2015.10

     More details

    Language:Japanese   Publisher:(一社)日本小児外科学会  

    researchmap

  • 腹腔鏡下肝切除の適応拡大に向けたcadaver trainingの実際

    信岡 大輔, 八木 孝仁, 近藤 喜太, 佐藤 博紀, 森廣 俊昭, 高木 弘誠, 安井 和也, 杭瀬 崇, 内海 方嗣, 吉田 龍一, 楳田 祐三, 篠浦 先, 大塚 愛二, 藤原 俊義

    日本消化器外科学会雑誌   48 ( Suppl.2 )   206 - 206   2015.10

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 骨肉腫に対するドキソルビシンとp53発現腫瘍融解アデノウイルス製剤の併用療法

    杉生 和久, 田澤 大, 長谷井 嬢, 尾崎 修平, 山川 泰明, 大森 敏規, 小松原 将, 魚谷 弘二, 藤原 智洋, 国定 俊之, 浦田 泰生, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   74回   P - 1382   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 骨軟部肉腫細胞に対する腫瘍融解ウイルスの放射線増感作用

    大森 敏規, 山川 泰明, 長谷井 嬢, 田澤 大, 尾崎 修平, 佐々木 剛, 杉生 和久, 魚谷 弘二, 藤原 智洋, 国定 俊之, 浦田 泰生, 尾崎 敏文, 藤原 俊義

    日本癌学会総会記事   74回   E - 1276   2015.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 当科における表在型頭頸部癌の長期成績と重複癌の検討

    田辺 俊介, 白川 靖博, 加藤 卓也, 竹原 清人, 前田 直見, 櫻間 教文, 野間 和広, 藤原 俊義

    Gastroenterological Endoscopy   57 ( Suppl.2 )   2115 - 2115   2015.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 胃 胃がんのPDL-1発現と免疫療法 胃癌組織におけるPD-L1発現と予後との関連

    黒田 新士, 森廣 俊昭, 久保田 哲史, 菊地 覚次, 田澤 大, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本癌治療学会誌   50 ( 3 )   141 - 141   2015.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 胃癌合併Bochdalek孔ヘルニアに対する用手補助腹腔鏡下手術による一期的根治手術の1例

    堀 直人, 香川 俊輔, 黒田 新士, 岸本 浩行, 西崎 正彦, 藤原 俊義

    日本内視鏡外科学会雑誌   20 ( 5 )   473 - 479   2015.9

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    患者は65歳,男性.腹痛・嘔吐を主訴に前医を受診し,上部消化管内視鏡検査で早期胃癌を,CTで左横隔膜にBochdalek孔ヘルニアを指摘された.胃癌に対する内視鏡的切除が非治癒切除となり,追加切除目的に当院紹介となった.胃癌のリンパ節郭清と今後のヘルニア嵌頓のリスクを考慮し,同時手術にて腹腔鏡補助下に胃切除およびヘルニア修復術を行った.気腹による胸腔内圧上昇に胸腔トロッカーを要し,ヘルニア門修復での視野確保には用手補助を追加したが,腹腔鏡下に幽門側胃切除とヘルニア根治術を完遂した.これまでに横隔膜ヘルニアと悪性腫瘍とを同時に手術した報告はなく,若干の文献的考察を加えて報告する.(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J03270&link_issn=&doc_id=20150925140005&doc_link_id=10.11477%2Fmf.4426200166&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.4426200166&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  • 手術手技 腹腔鏡下噴門側胃切除後の「観音開き法」による完全体腔内食道残胃吻合

    黒田 新士, 西崎 正彦, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    手術   69 ( 10 )   1487 - 1492   2015.9

     More details

    Language:Japanese   Publisher:金原出版(株)  

    researchmap

  • 新規免疫療法と化学療法 早期消化管癌患者のリンパ節転移に対する生物学的アブレーションの利用可能性(Novel Immunotherapy and Chemothnorty The possibility of biological ablation of lymphatic metastasis for early gastrointestinal cancer patients)

    Kikuchi Satoru, Kishimoto Hiroyuki, Tazawa Hiroshi, Kuroda Shinji, Nishizaki Masahiko, Kagawa Shunsuke, Urata Yasuo, Hoffman Robert M., Fujiwara Toshiyoshi

    日本癌治療学会誌   50 ( 3 )   1117 - 1117   2015.9

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 新規免疫療法と化学療法 食道癌に対する放射線療法との併用におけるテロメラーゼ標的腫瘍溶解性ウイルス、OBP-301の内視鏡的腫瘍内投与の第1/2相研究(Novel Immunotherapy and Chemothnorty A phase I/II study of endoscopic intratumoral administration of a telomerase targeted oncolytic virus, OBP-301, in combination with radiotherapy for esophageal cancer)

    Kagawa Shunsuke, Tanabe Shunsuke, Tazawa Hiroshi, Noma Kazuhiro, Koujima Takeshi, Kashima Hajime, Kato Takuya, Kuroda Shinji, Kikuchi Satoru, Shirakawa Yasuhiro, Fujiwara Toshiyoshi

    日本癌治療学会誌   50 ( 3 )   1116 - 1116   2015.9

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 食道癌と胃癌2 トランスレーショナル研究 新規HER2標的療法としてのtrastuzumab結合金ナノ粒子(Esophageal and Gastric Cancer: Translational Research Trastuzumab-conjugated gold nanoparticles as a novel HER2-targeted therapy)

    Kuroda Shinji, Kubota Tetsushi, Morihiro Toshiaki, Kikuchi Satoru, Tazawa Hiroshi, Nishizaki Masahiko, Kagawa Shunsuke, Fujiwara Toshiyoshi

    日本癌治療学会誌   50 ( 3 )   1076 - 1076   2015.9

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • 大腸癌卵巣転移に対する治療と予後

    母里 淑子, 永坂 岳司, 竹原 裕子, 佃 和憲, 中谷 紳, 嶋村 廣視, 瀧上 隆夫, 冨岡 憲明, 森谷 行利, 藤原 俊義

    日本大腸肛門病学会雑誌   68 ( 9 )   753 - 753   2015.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 骨肉腫に対する化学療法とp53発現腫瘍融解アデノウイルス治療の併用効果

    杉生 和久, 小松原 将, 大森 敏規, 山川 泰明, 吉田 晶, 藤原 智洋, 武田 健, 国定 俊之, 田澤 大, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   89 ( 8 )   S1799 - S1799   2015.9

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 腫瘍融解アデノウイルスの骨・軟部腫瘍臨床組織検体に対する感染効率および適応症例の検討

    吉田 晶, 藤原 智洋, 魚谷 弘二, 長谷井 嬢, 山川 泰明, 大森 敏規, 杉生 和久, 武田 健, 国定 俊之, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   89 ( 8 )   S1673 - S1673   2015.9

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 骨肉腫に対するテロメラーゼ依存性腫瘍融解アデノウイルスと骨周囲環境制御による新規治療戦略

    山川 泰明, 長谷井 嬢, 田澤 大, 杉生 和久, 魚谷 弘二, 大森 敏規, 尾崎 修平, 吉田 晶, 藤原 智洋, 武田 健, 国定 俊之, 浦田 泰生, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   89 ( 8 )   S1798 - S1798   2015.9

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 骨・軟部肉腫に対する腫瘍融解アデノウイルスと放射線療法の併用効果

    大森 敏規, 山川 泰明, 長谷井 嬢, 田澤 大, 尾崎 修平, 杉生 和久, 藤原 智洋, 国定 俊之, 浦田 泰生, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   89 ( 8 )   S1673 - S1673   2015.9

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 超高齢者(95歳)の進行盲腸癌に対して腹腔鏡下回盲部切除を施行した1例

    渡邉 彩子, 稲田 涼, 永坂 岳司, 八木 朝彦, 松本 聖, 戸嶋 俊明, 菊池 覚次, 黒田 新士, 近藤 喜太, 母里 淑子, 岸本 浩行, 藤原 俊義

    岡山医学会雑誌   127 ( 2 )   117 - 121   2015.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    症例は95歳男性で、便秘を主訴に受診した。腹部X線検査にて鏡面像を認めた。CEA、CA19-9の上昇を認めた。下部消化管内視鏡検査では、バウヒン弁にかかる全周性の狭窄を伴う腫瘍を盲腸に認め、スコープは通過不可能であった。ガストログラフィン造影にて狭窄を回盲部に認めた、腫瘍部の生検にて、高分化腺癌と診断した。膜部CT検査では、盲腸の壁肥厚を認め、周囲に腫大したリンパ節を複数認めた。また回盲部付近の脂肪組織の毛羽立ちを認めた。精査の結果、盲腸癌の診断に至った。腹腔鏡下回盲部切除を施行した。術後ICUに入室した。第1病日に一般床に転床後、離床、飲水を開始した。第2病日より流動食を開始した。周術期に大きな合併症は無く経過し、第11病日に自宅退院となった。術後補助化学療法は行わず、経過観察中である。

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J00175&link_issn=&doc_id=20150825270003&doc_link_id=10.4044%2Fjoma.127.117&url=https%3A%2F%2Fdoi.org%2F10.4044%2Fjoma.127.117&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 当科における食道憩室手術症例の検討 Reviewed

    賀島 肇, 白川 靖博, 前田 直見, 田辺 俊介, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   70回   P - 5   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道癌の内視鏡下手術 2015年までの総括 当科における腹臥位胸腔鏡下食道手術200例の総括

    白川 靖博, 加藤 卓也, 前田 直見, 竹原 清人, 田辺 俊介, 櫻間 教史, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   69回   11 - 11   2015.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 内視鏡腹腔鏡併用手術治療の工夫 Closed LECS手術手技のコツとピットフォール

    西崎 正彦, 黒田 新士, 加藤 大, 菊地 覚次, 香川 哲也, 田邊 俊介, 香川 俊輔, 白川 靖博, 岡田 裕之, 藤原 俊義

    日本消化器外科学会総会   70回   RS - 5   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胃癌腹膜播種の病態と診断・治療 腫瘍特異的蛍光発現virus試薬による腹腔洗浄液中の遊離胃癌細胞診断の臨床的意義

    香川 俊輔, 渡邉 めぐみ, 石田 道拡, 桑田 和也, 黒田 新士, 菊地 覚次, 香川 哲也, 西崎 正彦, 田澤 大, 藤原 俊義

    日本消化器外科学会総会   70回   WS - 4   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道癌に対する放射線併用ウイルス療法の臨床研究 レベル1投与量群の中間報告

    田邊 俊介, 白川 靖博, 加藤 卓也, 竹原 清人, 前田 直見, 黒田 新士, 野間 和広, 田澤 大, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   70回   O - 6   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 早期胃癌に対する遺伝子改変ウイルスを用いたリンパ節転移アブレーションによる低侵襲治療の開発

    菊地 覚次, 岸本 浩行, 香川 哲也, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   70回   O - 3   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 術後QOL向上を目指した胃癌手術の工夫 噴門側胃切除+観音開き法再建の術後QOLに及ぼす影響

    黒田 新士, 西崎 正彦, 香川 哲也, 菊地 覚次, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   70回   WS - 7   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 当院における胃GIST手術症例の検討

    香川 哲也, 黒田 新士, 菊地 覚次, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   70回   P - 1   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 腹臥位胸腔鏡下食道切除術における反回神経麻痺を起こさない術野展開と郭清の工夫

    白川 靖博, 加藤 卓也, 前田 直見, 竹原 清人, 田辺 俊介, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   70回   O - 2   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 早期食道胃接合部癌に対する治療戦略 当科におけるcT1食道胃接合部癌に対する治療戦略

    野間 和広, 白川 靖博, 加藤 卓也, 竹原 清人, 前田 直見, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   70回   WS - 7   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高齢者消化器癌に対する治療戦略 80歳以上超高齢者食道癌症例に対する安全な外科治療と手術成績向上のための取り組み

    竹原 清人, 白川 靖博, 加藤 卓也, 前田 直見, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本消化器外科学会総会   70回   RS - 1   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Stage II/III食道癌の治療 DCF vs. CF Stage II/III食道癌100例の検討

    前田 直見, 白川 靖博, 賀島 肇, 加藤 卓也, 竹原 清人, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本消化器外科学会総会   70回   O - 3   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 多視点3D解剖システムを用いた臨床教育

    前田 直見, 白川 靖博, 加藤 卓也, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   69回   205 - 205   2015.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • Y字胃管を用いた食道バイパス術8例の経験 食道ステントと比較して優位性は?

    田辺 俊介, 白川 靖博, 賀島 肇, 加藤 卓也, 竹原 清人, 前田 直見, 櫻間 教文, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   69回   135 - 135   2015.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 迅速果断な術後合併症対応を目指して 術後3日目造影CT検査の有用性

    前田 直見, 白川 靖博, 加藤 卓也, 竹原 清人, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   69回   96 - 96   2015.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道再建法・吻合法 最良の方法は 胃管作成不能例に対する至適再建の検討 手術侵襲とQOLを考慮した空腸再建の有用性

    野間 和広, 白川 靖博, 加藤 卓也, 竹原 清人, 前田 直見, 田辺 俊介, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   69回   37 - 37   2015.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 潰瘍性大腸炎における緊急手術症例の検討

    渡邉 佑介, 近藤 喜太, 母里 淑子, 岸本 浩行, 永坂 岳司, 藤原 俊義

    日本消化器外科学会総会   70回   P - 5   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 内視鏡手術時代における消化器外科医の教育 消化器外科内視鏡手術教育におけるカダバートレーニングの有用性

    近藤 喜太, 渡辺 裕介, 母里 淑子, 岸本 浩行, 永坂 岳司, 藤原 俊義

    日本消化器外科学会総会   70回   SS - 6   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 【食道手術-合併症対処の各施設の工夫-】ハイリスク食道癌手術 当施設の合併症対処の工夫 ハイリスク食道癌手術の対策 低肺機能症例の対策

    白川 靖博, 加藤 卓也, 前田 直見, 田辺 俊介, 野間 和広, 藤原 俊義

    手術   69 ( 7 )   991 - 994   2015.6

     More details

    Language:Japanese   Publisher:金原出版(株)  

    researchmap

  • リポソームを用いたテロメラーゼ特異的全身ウイルス療法の可能性

    森廣 俊昭, 青山 克幸, 久保田 哲史, 黒田 新士, 田澤 大, 香川 俊輔, 藤原 俊義

    日本DDS学会学術集会プログラム予稿集   31回   200 - 200   2015.6

     More details

    Language:Japanese   Publisher:日本DDS学会  

    researchmap

  • 金ナノ粒子を用いたHER2標的抗体療法 新標的化技術の応用

    久保田 哲史, 黒田 新士, 青山 克幸, 森廣 俊昭, 田澤 大, 藤原 俊義

    日本DDS学会学術集会プログラム予稿集   31回   153 - 153   2015.6

     More details

    Language:Japanese   Publisher:日本DDS学会  

    researchmap

  • ゾレドロン酸とテロメラーゼ依存性腫瘍融解アデノウイルスの併用療法は骨肉腫に対する抗腫瘍効果を増強し、骨破壊を抑制する

    山川 泰明, 長谷井 嬢, 田澤 大, 杉生 和久, 魚谷 弘二, 尾崎 修平, 吉田 晶, 藤原 智洋, 武田 健, 国定 俊之, 浦田 泰生, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   89 ( 6 )   S1244 - S1244   2015.6

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 骨・軟部肉腫に対する腫瘍融解アデノウイルスと放射線療法の併用効果

    大森 敏規, 山川 泰明, 長谷井 嬢, 田澤 大, 尾崎 修平, 杉生 和久, 藤原 智洋, 国定 俊之, 浦田 泰生, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   89 ( 6 )   S1244 - S1244   2015.6

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 次世代シーケンサーによるリンチ症候群の解析

    永坂 岳司, 谷口 文崇, 母里 淑子, 藤原 俊義

    家族性腫瘍   15 ( 2 )   A65 - A65   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本遺伝性腫瘍学会  

    researchmap

  • 家族性大腸腺腫症におけるデスモイド腫瘍に対するタモキシフェンの有効性の検討

    母里 淑子, 永坂 岳司, 谷口 文崇, 河合 毅, 藤原 俊義

    家族性腫瘍   15 ( 2 )   A81 - A81   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本遺伝性腫瘍学会  

    researchmap

  • 高齢者大腸癌に対するD3郭清の短期・長期成績の検討

    稲田 涼, 永坂 岳司, 渡邉 彩子, 松本 聖, 戸嶋 俊明, 母里 淑子, 近藤 喜太, 岸本 浩行, 浅野 博昭, 佃 和憲, 藤原 俊義

    日本大腸肛門病学会雑誌   68 ( 5 )   355 - 355   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 上部消化管 超高齢者食道癌手術への取り組みと放射線併用ウイルス療法の可能性 Reviewed

    田辺 俊介, 白川 靖博, 賀島 肇, 国府島 健, 前田 直見, 大原 利章, 黒田 新士, 櫻間 教文, 野間 和広, 田澤 大, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   115回   OP - 2   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • その他 鉄コントロールによるがん幹細胞に対する新規治療 Reviewed

    二宮 卓之, 大原 利章, 浦野 真一, 勝部 亮一, 野間 和広, 田澤 大, 白川 靖博, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   115回   OP - 7   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 上部消化管 HER2陰性癌細胞に対するHER2細胞外ドメインによる非機能性HER2抗原遺伝子修飾とTrastuzumabを用いた分子標的光免疫療法を併用した治療戦略

    石田 道拡, 香川 俊輔, 下山 京子, 竹原 清人, 渡邉 めぐみ, 菊地 覚次, 黒田 新士, 野間 和広, 岸本 浩行, 田澤 大, 田邊 俊介, 小林 久隆, 藤原 俊義

    日本外科学会定期学術集会抄録集   115回   OP - 3   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 上部消化管 早期胃癌におけるリンパ節転移データからみた生物学的リンパ節転移アブレーション療法の可能性

    菊地 覚次, 岸本 浩行, 桑田 和也, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   115回   YIA - 4   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 上部消化管 胃癌に対する腹膜洗浄術についての蛍光発現ウイルスTelomescanによる新規細胞学的診断(Novel cytological diagnosis of peritoneal wash for gastric cancer by fluorescence-emitting virus TelomeScan)

    香川 俊輔, 渡邉 めぐみ, 石田 道拡, 黒田 新士, 菊地 覚次, 田澤 大, 岸本 浩行, 桑田 和也, 久保田 哲史, 堀 直人, 田邊 俊介, 西崎 正彦, 浦田 泰生, 藤原 俊義

    日本外科学会定期学術集会抄録集   115回   IS - 6   2015.4

     More details

    Language:English   Publisher:(一社)日本外科学会  

    researchmap

  • 噴門側胃切除術後の再建 空腸間置vs食道胃吻合 上部消化管 食道胃吻合

    西崎 正彦, 黒田 新士, 野間 和広, 菊地 覚次, 桑田 和也, 前田 直見, 田邊 俊介, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   115回   DB - 2   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 胸腔鏡下食道切除術の定型化 上部消化管 腹臥位胸腔鏡下食道切除術における適応拡大に伴う術野展開定型化の工夫

    白川 靖博, 野間 和広, 賀島 肇, 前田 直見, 田辺 俊介, 櫻間 教文, 藤原 俊義

    日本外科学会定期学術集会抄録集   115回   SY - 1   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 当科における食道悪性黒色腫の治療経験

    八木 朝彦, 白川 靖博, 賀島 肇, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    岡山医学会雑誌   127 ( 1 )   77 - 77   2015.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 下部消化管 超高齢者(95歳)の進行盲腸癌に対し腹腔鏡下回盲部切除を施行した1例

    渡邉 彩子, 稲田 涼, 永坂 岳司, 八木 朝彦, 松本 聖, 戸嶋 俊明, 母里 淑子, 近藤 喜太, 岸本 浩行, 藤原 俊義

    日本外科学会定期学術集会抄録集   115回   RS - 1   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 肛門管に発生し印環細胞癌・粘液癌・低分化腺癌が混在した早期大腸癌の1例

    中谷 紳, 脇 直久, 山下 和城, 永坂 岳司, 母里 淑子, 藤原 俊義

    日本大腸肛門病学会雑誌   68 ( 4 )   239 - 245   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    症例は74歳,女性.肛門からの腫瘤脱出を主訴に,当院受診した.肛門管3時方向に小指頭大の柔らかな隆起性病変を認め,直腸粘膜脱症候群の診断にて,経肛門的に腫瘤切除した.病理組織検査では病変は径10mm,充実型低分化腺癌・印環細胞癌・粘液癌が混在(por1>sig>muc)し,深達度SM200μm,水平断端陽性で,腹腔鏡下Miles手術を施行した.右鼡径リンパ節転移を認め,最終診断はanal canal adenocarcinoma and its inguinal lymph node metastasis,pT1aNxM1a stage IVだった.術後放射線化学療法を行い,現在慎重に経過観察中である.大腸印環細胞癌は腹膜播種・リンパ節転移を伴いやすく,進行癌の状態で発見されることが多いため,予後不良である.われわれは本疾患を早期に診断・治療するよう努めなければならない.(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J01146&link_issn=&doc_id=20150402340005&doc_link_id=10.3862%2Fjcoloproctology.68.239&url=https%3A%2F%2Fdoi.org%2F10.3862%2Fjcoloproctology.68.239&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 食道胃接合部癌の治療戦略 内視鏡治療から集学的治療まで 当科における食道胃接合部癌の治療経験

    野間 和広, 白川 靖博, 加藤 卓也, 竹原 清人, 前田 直見, 田辺 俊介, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   87回   180 - 180   2015.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 非機能性HER2抗原で遺伝子修飾したHER2陰性癌細胞に対する分子標的光免疫療法

    石田 道拡, 香川 俊輔, 下山 京子, 竹原 清人, 渡邉 めぐみ, 菊地 覚次, 黒田 新士, 野間 和広, 岸本 浩行, 西崎 正彦, 田澤 大, 田邊 俊介, 小林 久隆, 藤原 俊義

    日本胃癌学会総会記事   87回   402 - 402   2015.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • Netrin-1 RecepterのGenetic/Epigenetic変異の腫瘍進展による相加的欠損と胃癌の染色体不安定性との関連

    竹原 裕子, 永坂 岳司, 岸本 浩行, 竹原 清人, 菊地 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 合地 明, 藤原 俊義

    日本胃癌学会総会記事   87回   289 - 289   2015.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 上部胃癌に対する腹腔鏡下脾温存リンパ節郭清手技の工夫

    西崎 正彦, 黒田 新士, 菊地 覚次, 桑田 和也, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本胃癌学会総会記事   87回   233 - 233   2015.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • ESD後遺残・再発病変の現状とその対応 当院におけるESD後遺残・再発症例および非治癒切除症例の検討

    菊地 覚次, 阿部 真, 神崎 洋光, 桑田 和也, 石田 道拡, 黒田 新士, 西崎 正彦, 香川 俊輔, 岡田 裕之, 藤原 俊義

    日本胃癌学会総会記事   87回   214 - 214   2015.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 腹腔鏡下噴門側胃切除術の再建手技 3D内視鏡システムを用いた完全体腔内「観音開き法」食道残胃吻合

    黒田 新士, 西崎 正彦, 桑田 和也, 菊地 覚次, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本胃癌学会総会記事   87回   204 - 204   2015.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 高齢化社会に向けたこれからの胃癌治療戦略 治療すべきか経過観察か サルコペニアが高齢胃癌患者の予後に及ぼす影響

    桑田 和也, 高木 弘誠, 菊地 覚次, 黒田 新士, 吉田 龍一, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   87回   175 - 175   2015.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 腹腔内の遊離胃がん細胞のウイルス標識による蛍光イメージング(Virus-guided fluorescence imaging of intraperitoneal free gastric cancer cells)

    Watanabe Megumi, Kagawa Shunsuke, Ishida Michihiro, Hashimoto Yuuri, Hori Naoto, Kikuchi Satoru, Kuroda Shinji, Kishimoto Hiroyuki, Nishizaki Masahiko, Tazawa Hiroshi, Urata Yasuo, Fujiwara Toshiyoshi

    日本胃癌学会総会記事   87回   497 - 497   2015.3

     More details

    Language:English   Publisher:(一社)日本胃癌学会  

    researchmap

  • 食道癌術後再建胃管癌症例の検討

    田辺 俊介, 白川 靖博, 賀島 肇, 前田 直見, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   87回   302 - 302   2015.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • HER2陽性進行・再発胃癌に対するTrastuzumabを含む化学療法

    香川 俊輔, 黒田 新士, 菊地 覚次, 桑田 和也, 久保田 哲史, 堀 直人, 渡邉 めぐみ, 石田 道拡, 岸本 浩行, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本胃癌学会総会記事   87回   442 - 442   2015.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 骨・軟部肉腫に対する腫瘍融解アデノウイルスと放射線療法の併用効果

    大森 敏規, 山川 泰明, 長谷井 嬢, 田澤 大, 尾崎 修平, 杉生 和久, 藤原 智洋, 国定 俊之, 浦田 泰夫, 藤原 俊義

    日本整形外科学会雑誌   89 ( 2 )   S142 - S142   2015.3

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 原発不明癌として治療を受けていた虫垂癌の1例

    松本 聖, 稲田 涼, 永坂 岳司, 渡邉 彩子, 八木 朝彦, 戸嶋 俊明, 母里 淑子, 近藤 喜太, 岸本 浩行, 藤原 俊義

    癌と化学療法   42 ( 2 )   229 - 231   2015.2

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    われわれは原発不明癌として治療を受けていたが増悪し、開腹手術による確定診断後にmodified FOLFOX6(mFOLFOX6)+panitumumab療法を施行し、部分寛解となり原発巣切除となった症例を経験したので報告する。症例は50歳台、男性。腹部膨満、食思不振を主訴に前医受診。腹水貯留を伴う腹膜結節を認め癌性腹膜炎と診断された。腹水細胞診の結果、消化管由来と診断される腺癌を認めたが、PET-CT検査、上下部消化管内視鏡検査にて原発巣の診断は得られなかった。原発不明癌としてCBDCA+PTX療法、GEM療法にて加療するも腹水増大し、播種結節に伴う腸管閉塞を認め、2013年1月当院を紹介された。腸閉塞解除目的で開腹手術施行。腹腔内は虫垂の壁肥厚および播種による回腸末端付近の閉塞を認めたため、回腸人工肛門造設および播種結節切除を行った。虫垂癌の診断を得て、mFOLFOX6+panitumumab療法を3コース施行し、部分寛解を得た後、再び開腹し、拡大右半結腸切除術にて原発巣および一部播種結節を切除した。現在、原発不明癌に対しては標準的治療レジメンが存在しないばかりか、化学療法によって患者の予後改善を得られるのかも明確ではない。確定診断を得るためにも可能であれば開腹手術を考慮する必要がある。(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J00296&link_issn=&doc_id=20150219340019&doc_link_id=%2Fab8gtkrc%2F2015%2F004202%2F020%2F0229-0231%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2015%2F004202%2F020%2F0229-0231%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 集学的治療にて長期生存を得たKRAS遺伝子変異を伴う再発直腸癌の1例

    渡邉 彩子, 稲田 涼, 永坂 岳司, 八木 朝彦, 松本 聖, 戸嶋 俊明, 母里 淑子, 近藤 喜太, 岸本 浩行, 藤原 俊義

    癌と化学療法   42 ( 2 )   237 - 239   2015.2

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    進行・再発大腸癌に対する新規抗癌剤や分子標的薬の登場により多くの患者が生存期間の延長を得られるようになった。しかしさらなる長期生存を得るためには全身化学療法のみではなく、転移巣に対する局所療法も組み合わせる必要がある。とりわけKRAS変異を伴う大腸癌は有効薬剤が限られるため、より集学的な治療が必要となる。今回われわれは、KRAS変異を伴う直腸癌術後肺再発・骨盤内リンパ節再発を来した50代の男性に対して全身化学療法に加え、肺切除、経皮的ラジオ波焼灼術(radiofrequency ablation:RFA)、リンパ節切除といった集学的治療を行うことにより、初回再発時より3年以上、活動性病変のない状態で生存している症例を報告する。(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J00296&link_issn=&doc_id=20150219340021&doc_link_id=%2Fab8gtkrc%2F2015%2F004202%2F022%2F0237-0239%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2015%2F004202%2F022%2F0237-0239%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • A Case of Intestinal Penetration Due to Small Intestinal Recurrence of Cecal Cancer

    Watanabe Ayako, Inada Ryo, Nagasaka Takeshi, Yagi Tomohiko, Matsumoto Hijiri, Toshima Toshiaki, Mori Yoshiko, Kondo Yoshitaka, Kishimoto Hiroyuki, Fujiwara Toshiyoshi

    Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)   40 ( 2 )   251 - 255   2015

     More details

    Language:Japanese   Publisher:Japanese College of Surgeons  

    We report herein a case of solitary small intestinal recurrence of colorectal cancer. A man in his 70s underwent ileocecal resection with regional lymph node dissection for cecal cancer at Okayama University Hospital in December 2004. The tumor was diagnosed as moderately differentiated adenocarcinoma, and graded as pStage Ⅱ (pT2pN0cM0) according to the Japanese Classification of Colorectal Carcinoma, eighth edition. Thirty-six months after initial surgery, he presented complaining of severe abdominal pain and high fever. Abdominal computed tomography showed localized intra-abdominal abscess. Based on the diagnosis of intestinal penetration, we performed an emergent operation. Intraoperatively, a small intestinal tumor was found to be the cause of the penetration; therefore, both partial resection of the ileum and abscess drainage were performed. Although the patient underwent adjuvant chemotherapy, the tumor recurred in the retroperitoneum in November 2008. He then underwent multimodal therapy, including palliative local resection, radiotherapy, and systemic chemotherapy, to the site of recurrence; however, he died of the cancer about six years after initial recurrence.

    DOI: 10.4030/jjcs.40.251

    CiNii Article

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2015332071

  • [False-positive local recurrences on FDG-PET/CT due to postoperative infection - a case report].

    Yoshiko Mori, Takeshi Nagasaka, Ryo Inada, Ayako Watanabe, Hiroyuki Kishimoto, Yoshitaka Kondou, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   41 ( 12 )   1599 - 601   2014.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Although ¹⁸F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is a powerful tool for detecting the recurrence of colorectal cancer, FDG uptake is not tumor specific. Herein, we report a case of a 65-year- old man who underwent emergency colectomy for perforation of colon cancer. FDG-PET/CT after surgery showed 2 tumors that were difficult to differentiate from peritoneal metastases with invasion to the spleen. Splenectomy was performed, and the histopathology revealed that the tumors in fact were abscesses. This is a clinically thought-provoking case that showed the difficulty of the differential diagnosis between early recurrence after emergent surgery of colorectal cancer and the postoperative changes.

    PubMed

    researchmap

  • 内視鏡外科の低侵襲性を評価する 腹臥位胸腔鏡下食道切除術の栄養学的評価の検討

    白川 靖博, 賀島 肇, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   19 ( 7 )   316 - 316   2014.10

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 早期胃癌に対するESD非治癒切除後の追加治療としてのLADGの治療成績の検討

    菊地 覚次, 堀 直人, 桑田 和也, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   19 ( 7 )   681 - 681   2014.10

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡下胃切除術後の利尿期への早期移行は低侵襲性を反映する

    桑田 和也, 吉田 龍一, 菊池 覚次, 黒田 新士, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   19 ( 7 )   674 - 674   2014.10

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡下手術の低侵襲性は胃切除術後の癒着性腸閉塞の低減に寄与する

    香川 俊輔, 黒田 新士, 菊地 覚次, 岸本 浩行, 桑田 和也, 久保田 哲史, 堀 直人, 渡邉 めぐみ, 石田 道拡, 浅野 博昭, 永坂 岳司, 佃 和憲, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   19 ( 7 )   674 - 674   2014.10

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 高齢者胃癌(75歳以上)に対する腹腔鏡手術の妥当性

    黒田 新士, 桑田 和也, 菊地 覚次, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   19 ( 7 )   632 - 632   2014.10

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • ロボット支援胃切除術 Pros and Cons ロボット支援下胃切除術における郭清と体腔内手縫い吻合

    西崎 正彦, 黒田 新士, 菊地 覚次, 桑田 和也, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   19 ( 7 )   316 - 316   2014.10

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 手術の教育法 開胸・開腹vs内視鏡下 手術教育におけるカダバートレーニングの有用性と可能性

    近藤 喜太, 信岡 大輔, 黒田 新士, 前田 直見, 藤原 俊義

    日本臨床外科学会雑誌   75 ( 増刊 )   311 - 311   2014.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 小児先天性食道狭窄症に対する下部食道・噴門側胃切除後漿膜筋層フラップによる噴門形成術(観音開き法)

    野田 卓男, 尾山 貴徳, 谷本 光隆, 野間 和広, 田邊 俊介, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   75 ( 増刊 )   458 - 458   2014.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 高齢者大腸癌に対するD3郭清の短期・長期成績の検討

    稲田 涼, 永坂 岳司, 渡邉 彩子, 八木 朝彦, 松本 聖, 母里 淑子, 近藤 喜太, 岸本 浩行, 浅野 博昭, 佃 和憲, 藤原 俊義

    日本臨床外科学会雑誌   75 ( 増刊 )   640 - 640   2014.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • Colitic cancer/high grade dysplasiaを合併した潰瘍性大腸炎に対する腹腔鏡下大腸全摘の治療成績の検討

    稲田 涼, 近藤 喜太, 母里 淑子, 岸本 浩行, 永坂 岳司, 藤原 俊義

    日本内視鏡外科学会雑誌   19 ( 7 )   506 - 506   2014.10

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • クローン病に対する腹腔鏡下手術の成績 開腹手術と比較して

    戸嶋 俊明, 近藤 喜太, 稲田 涼, 母里 淑子, 岸本 浩行, 永坂 岳司, 藤原 俊義

    日本内視鏡外科学会雑誌   19 ( 7 )   578 - 578   2014.10

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 集学的治療にて長期生存を得たKRAS遺伝子変異を伴う再発直腸癌の1例

    渡邉 彩子, 稲田 涼, 永坂 岳司, 八木 朝彦, 松本 聖, 戸嶋 俊明, 母里 淑子, 近藤 喜太, 岸本 浩行, 藤原 俊義

    日本臨床外科学会雑誌   75 ( 増刊 )   843 - 843   2014.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 結腸腸間膜デスモイド線維腫症の1例

    八木 朝彦, 稲田 涼, 永坂 岳司, 渡邉 彩子, 松本 聖, 戸嶋 俊明, 母里 淑子, 近藤 喜太, 岸本 浩行, 藤原 俊義

    日本臨床外科学会雑誌   75 ( 増刊 )   859 - 859   2014.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 進行直腸癌術後再発に対して積極的な集学的治療によって長期生存を得た1例

    松本 聖, 稲田 涼, 永坂 岳司, 八木 朝彦, 渡邉 彩子, 戸嶋 俊明, 母里 淑子, 近藤 喜太, 岸本 浩行, 藤原 俊義

    日本臨床外科学会雑誌   75 ( 増刊 )   843 - 843   2014.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • Miles手術における会陰創のSSIに対するVAC療法の経験

    戸嶋 俊明, 近藤 喜太, 稲田 涼, 母里 淑子, 岸本 浩行, 永坂 岳司, 藤原 俊義

    日本臨床外科学会雑誌   75 ( 増刊 )   440 - 440   2014.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 大腸癌の遠隔転移(肝以外)の切除の限界とは 大腸癌肺転移に対するCTガイド下経皮的ラジオ波焼灼術(RFA)の短期・長期成績の検討

    稲田 涼, 永坂 岳司, 母里 淑子, 竹原 裕子, 竹原 清人, 佃 和憲, 平木 隆夫, 金澤 右, 藤原 俊義

    日本大腸肛門病学会雑誌   67 ( 9 )   634 - 634   2014.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • ヒトスキルス胃癌細胞に対する腫瘍融解アデノウイルスの抗腫瘍効果(Antitumor effect of tumor-specific oncolytic adenovirus in human scirrhous gastric cancer cells)

    堀 直人, 田澤 大, 西崎 正彦, 菊地 覚次, 矢野 修也, 石田 道拡, 渡辺 めぐみ, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   73回   P - 2355   2014.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 全身送達を目指したリポソーム抱合テロメラーゼ特異的腫瘍融解アデノウイルスプラスミドDNA(Telomerase-specific oncolytic adenoviral plasmid DNA conjugated with liposome for systemic delivery)

    青山 克幸, 黒田 新士, 田澤 大, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   73回   P - 3420   2014.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • HER2抗原で修飾された癌細胞に対するTrastuzumabを用いた近赤外線光線免疫療法の効果(Genetic decoration with HER2-antigen makes cancer cells vulnerable to trastuzumab-based photoimmunotherapy)

    石田 道拡, 香川 俊輔, 下山 京子, 竹原 清人, 野間 和広, 田澤 大, 黒田 新士, 岸本 浩行, 田邊 俊介, 小林 久隆, 藤原 俊義

    日本癌学会総会記事   73回   E - 3040   2014.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 蛍光発現ウイルスを用いた腹腔内がん細胞の検出技術の開発(A FEASIBILITY STUDY TO VISUALIZE INTRAPERITONEAL DESSEMINATED GASTRIC CANCER BY FLUORESCENCE-EMITTING VIRUS, TELOMESCAN)

    渡邉 めぐみ, 香川 俊輔, 石田 道拡, 橋本 悠里, 堀 直人, 菊地 覚次, 黒田 新士, 岸本 浩行, 西崎 正彦, 田澤 大, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   73回   E - 2019   2014.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌の微小リンパ節転移制御(The eradication of lymph node metastasis of early colorectal cancers using telomerase-dependent replicating adenovirus)

    菊地 覚次, 岸本 浩行, 田澤 大, 黒田 新士, 西崎 正彦, 香川 俊輔, 浦田 泰生, ロバート・ホフマン, 藤原 俊義

    日本癌学会総会記事   73回   E - 1115   2014.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • StageIV大腸がんの予後マーカーとしてのMGMTメチル化ステータスの有用性

    母里 淑子, 永坂 岳史, 稲田 涼, 戸嶋 俊明, 竹原 裕子, 中谷 紳, 竹原 清人, 森川 達也, 久保田 暢人, 宇野 太, 滝上 隆夫, 嶋村 廣視, 森谷 行利, 富岡 憲明, 藤原 俊義

    日本大腸肛門病学会雑誌   67 ( 9 )   752 - 752   2014.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 肛門管に発生した早期印環細胞癌の1例

    中谷 紳, 脇 直久, 山下 和城, 永坂 岳司, 母里 淑子, 藤原 俊義

    日本大腸肛門病学会雑誌   67 ( 9 )   782 - 782   2014.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • Colitic cancerおよびhigh grade dysplasiaを合併した潰瘍性大腸炎の臨床病理学的特徴

    稲田 涼, 近藤 喜太, 母里 淑子, 岸本 浩行, 永坂 岳司, 平岡 佐規子, 藤原 俊義

    日本消化器病学会雑誌   111 ( 臨増大会 )   A889 - A889   2014.9

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  • 大腸癌検診の短期・長期治療成績における有用性の検討

    戸嶋 俊明, 稲田 涼, 永坂 岳司, 母里 淑子, 竹原 裕子, 竹原 清人, 佃 和憲, 藤原 俊義

    日本大腸肛門病学会雑誌   67 ( 9 )   688 - 688   2014.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 超高齢者における胃癌術後せん妄の検討

    久保田 哲史, 香川 俊輔, 菊地 覚次, 黒田 新士, 西崎 正彦, 藤原 俊義

    岡山医学会雑誌   126 ( 2 )   179 - 179   2014.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 腫瘍融解アデノウイルスと放射線療法を併用した骨・軟部肉腫に対する新規治療戦略

    大森 敏規, 長谷井 嬢, 杉生 和久, 山川 泰明, 尾崎 修平, 藤原 智洋, 武田 健, 吉田 晶, 国定 俊之, 田澤 大, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   88 ( 8 )   S1362 - S1362   2014.8

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 骨転移におけるゾレドロン酸と腫瘍融解アデノウイルスの併用治療

    山川 泰明, 長谷井 嬢, 杉生 和久, 大森 敏規, 尾崎 修平, 吉田 晶, 藤原 智洋, 国定 俊之, 浦田 泰生, 田澤 大, 藤原 俊義, 尾崎 敏文

    日本整形外科学会雑誌   88 ( 8 )   S1684 - S1684   2014.8

     More details

    Language:Japanese   Publisher:(公社)日本整形外科学会  

    researchmap

  • 進行食道癌による食道狭窄に起因した経口摂取困難症例に対して、PEGを用いた術前栄養療法の有用性 Reviewed

    國府島 健, 白川 靖博, 前田 直見, 田邊 俊介, 大原 利章, 野間 和広, 櫻間 教文, 藤原 俊義

    日本消化器外科学会総会   69回   P - 3   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • ANTITUMOR EFFECT OF TELOMERASE-SPECIFIC ONCOLYTIC ADENOVIRUS ON HUMAN BONE AND SOFT TISSUE SARCOMA CELLS Reviewed

    Tazawa Hiroshi, Sasaki Tsuyoshi, Hasei Jo, Hashimoto Yuuri, Urata Yasuo, Ozaki Toshifumi, Fujiwara Toshiyoshi

    JOURNAL OF GENE MEDICINE   16 ( 7-8 )   261 - 262   2014.7

  • 当科における食道胃接合部癌の経験および治療戦略 Reviewed

    野間 和広, 白川 靖博, 国府島 健, 前田 直見, 大原 利章, 田辺 俊介, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   69回   O - 2   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道癌手術における安全な吻合法 空腸を用いた食道再建及び吻合の工夫 全例に血管吻合が必要か? Reviewed

    白川 靖博, 國府島 健, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   69回   VSY - 8   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道切除・再建術におけるリスク評価と治療成績向上に向けた対策 食食道癌術前の呼吸機能管理目標設定とチーム介入の成果 Reviewed

    大原 利章, 白川 靖博, 國府島 健, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   69回   PD - 12   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 鏡視下手術導入と多職種組織横断的周術期管理による高齢者食道癌手術への取り組み Reviewed

    田辺 俊介, 白川 靖博, 國府島 健, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   68回   78 - 78   2014.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道がん手術患者の集中治療体験とその後の心理状態<第二報> Reviewed

    足羽 孝子, 伊藤 真理, 岩谷 美貴子, 國府島 健, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   68回   131 - 131   2014.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • ウイルスを用いたHER2陰性胃癌の強制的HER2標識化とTrastuzumabによる分子標的光免疫療法

    香川 俊輔, 石田 道拡, 田澤 大, 下山 京子, 竹原 清人, 野間 和広, 渡辺 めぐみ, 田辺 俊介, 小林 久隆, 藤原 俊義

    日本消化器外科学会総会   69回   O - 4   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 高齢者胃癌(80歳以上)に対する根治手術の治療成績

    黒田 新士, 久保田 哲史, 菊地 覚次, 岸本 浩行, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   69回   RS - 5   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • HER2陽性進行再発胃癌に対するTrastuzumabを用いた集学的治療の有効性

    菊地 覚次, 香川 俊輔, 黒田 新士, 久保田 哲史, 岸本 浩行, 西崎 正彦, 藤原 俊義

    日本消化器外科学会総会   69回   RS - 3   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胃切除術におけるda Vinciを用いたリンパ節郭清および体腔内手縫い吻合

    西崎 正彦, 黒田 新士, 菊地 覚次, 久保田 哲史, 野間 和広, 永坂 岳司, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   69回   O - 2   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • リポソームを用いた全身投与可能なテロメラーゼ特異的腫瘍融解ウイルス製剤の開発

    青山 克幸, 黒田 新士, 田澤 大, 香川 俊輔, 藤原 俊義

    日本DDS学会学術集会プログラム予稿集   30回   221 - 221   2014.7

     More details

    Language:Japanese   Publisher:日本DDS学会  

    researchmap

  • 外科専門教育における献体を使用した臨床応用解剖実習および多視点多層解剖映像の有用性

    近藤 喜太, 信岡 大輔, 黒田 新士, 前田 直見, 藤原 俊義, 大塚 愛二

    医学教育   45 ( Suppl. )   158 - 158   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本医学教育学会  

    researchmap

  • 局所進行直腸癌に対する術前放射線化学療法CapeOx RTの有効性・安全性の検討

    母里 淑子, 永坂 岳司, 稲田 涼, 岸本 浩行, 近藤 喜太, 藤 智和, 谷口 崇文, 浅野 博昭, 佃 和憲, 藤原 俊義

    日本消化器外科学会総会   69回   O - 4   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 大腸癌におけるprognostic factorとしてのmiRNAの検討

    久保田 暢人, 永坂 岳司, 吉田 一博, 竹原 裕子, 竹原 清人, 稲田 涼, 河合 毅, 谷口 文崇, 藤 智和, 藤原 俊義

    日本消化器外科学会総会   69回   O - 5   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 消化器癌に対する個別化治療 Genetic/epigenetic変異を基盤とした大腸癌個別化治療の構築

    永坂 岳司, 母里 淑子, 稲田 涼, 岸本 浩行, 近藤 喜太, 浅野 博昭, 佃 和憲, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   69回   SY - 8   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 切除可能高リスク直腸癌に対する術前CapeOX+RTの安全性・有効性の検討

    母里 淑子, 永坂 岳司, 稲田 涼, 岸本 浩行, 近藤 喜太, 竹原 裕子, 河合 毅, 藤 智和, 谷口 文崇, 藤原 俊義

    日本癌治療学会誌   49 ( 3 )   1316 - 1316   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • HER2陽性胃癌に対するtrastuzumabを含む化学療法施行症例の解析

    香川 俊輔, 黒田 新士, 菊地 覚次, 西崎 正彦, 渡辺 めぐみ, 石田 道拡, 堀 直人, 岸本 浩行, 藤原 俊義

    日本癌治療学会誌   49 ( 3 )   2376 - 2376   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 化学療法後切除により組織学的完全奏効が得られた高度進行胃癌の3例

    菊地 覚次, 香川 俊輔, 久保田 哲史, 黒田 新士, 西崎 正彦, 藤原 俊義

    日本癌治療学会誌   49 ( 3 )   1977 - 1977   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • Colitic cancerおよびhigh grade dysplasiaを合併した潰瘍性大腸炎の臨床病理学的検討

    稲田 涼, 近藤 喜太, 母里 淑子, 岸本 浩行, 永坂 岳司, 平岡 佐規子, 藤原 俊義

    日本癌治療学会誌   49 ( 3 )   904 - 904   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 消化器外科領域におけるマイクロサージェリー 空腸を用いた食道再建おけるマイクロサージェリーの適応とその工夫 Reviewed

    白川 靖博, 國府島 健, 前田 直見, 田辺 俊介, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科系連合学会誌   39 ( 3 )   506 - 506   2014.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    researchmap

  • 食道癌の狭窄による経口摂取困難症例に対するPEGを用いた術前管理の利点 Reviewed

    田辺 俊介, 白川 靖博, 國府島 健, 前田 直見, 勝部 亮一, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    Gastroenterological Endoscopy   56 ( Suppl.1 )   1220 - 1220   2014.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 食道癌周術期における外科医の負担軽減に対しチーム医療が果たした役割 Reviewed

    白川 靖博, 二宮 卓之, 前田 直見, 大原 利章, 田辺 俊助, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   379 - 379   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • がん関連線維芽細胞(Cancer Associated Fibroblasts)を標的とした新規癌治療法の開発 Reviewed

    野間 和広, 白川 靖博, 二宮 卓之, 勝部 亮一, 前田 直見, 田辺 俊介, 大原 利章, 田澤 大, 香川 俊輔, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   678 - 678   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 肝臓癌における除鉄併用分子標的薬治療の可能性 Reviewed

    浦野 真一, 大原 利章, 白川 靖博, 勝部 亮一, 前田 直見, 田辺 俊介, 友野 靖子, 野間 和広, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   489 - 489   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 高度狭窄を伴う進行食道癌患者におけるPEGを用いた術前栄養管理の効果 術前後筋肉量変化に着目して Reviewed

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   464 - 464   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 胃腫瘍に対する腹腔鏡内視鏡合同手術の可能性 当院におけるLECSの工夫 Closed LECSの可能性

    西崎 正彦, 黒田 新士, 堀 直人, 岸本 浩行, 香川 俊輔, 岡田 裕之, 藤原 俊義

    日本胃癌学会総会記事   86回   170 - 170   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • ハイリスク患者に対する腹腔鏡下胃切除の意義 高リスク症例に対する腹腔鏡下胃切除術と開腹胃切除の短期成績に関する比較検討

    黒田 新士, 香川 俊輔, 堀 直人, 岸本 浩行, 西崎 正彦, 藤原 俊義

    日本胃癌学会総会記事   86回   166 - 166   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • HER2陽性進行再発胃癌に対するTrastuzumabの使用経験とその有効性について

    黒田 新士, 香川 俊輔, 渡邊 めぐみ, 堀 直人, 石田 道拡, 岸本 浩行, 西崎 正彦, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   692 - 692   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道癌・胃癌におけるロボット支援手術の有用性 ロボット支援下噴門側胃切除術後のロボットによる体腔内手縫い食道残胃吻合

    西崎 正彦, 黒田 新士, 岸本 浩行, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   189 - 189   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌に対する低侵襲治療の開発

    菊地 覚次, 岸本 浩行, 田澤 大, 西崎 正彦, 香川 俊輔, 浦田 泰生, Hoffman Robert, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   401 - 401   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 私の工夫 エンドクローズによるポート孔閉創のコツ

    二宮 卓之, 田辺 俊介, 前田 直見, 野間 和広, 白川 靖博, 藤原 俊義

    臨床外科   69 ( 3 )   382 - 383   2014.3

     More details

    Language:Japanese   Publisher:(株)医学書院  

    researchmap

  • HER2陰性胃癌におけるウイルスベクターを用いたHER2標識化とそれに対する分子標的光免疫療法

    石田 道拡, 香川 俊輔, 田澤 大, 下山 京子, 竹原 清人, 黒田 新士, 野間 和広, 岸本 浩行, 西崎 正彦, 小林 久隆, 藤原 俊義

    日本胃癌学会総会記事   86回   316 - 316   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • ESD/EMR非治癒切除後の外科切除症例の検討

    堀 直人, 香川 俊輔, 黒田 新士, 岸本 浩行, 西崎 正彦, 藤原 俊義

    日本胃癌学会総会記事   86回   224 - 224   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 術前診断に難渋した原発性小腸癌の1例

    松本 聖, 稲田 涼, 近藤 喜太, 母里 淑子, 永坂 岳司, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   1039 - 1039   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • イマチニブで長期病勢コントロール中の再発消化管間質腫瘍に胃癌を発症した1例

    宇野 太, 岸本 浩行, 香川 俊輔, 藤原 俊義

    日本外科系連合学会誌   39 ( 1 )   45 - 51   2014.2

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    症例は81歳女性で,当院で同時性肝転移を伴う胃の消化管間質腫瘍(gastrointestinal stromal tumor:GIST)に対し,胃局所切除と肝切除が施行されていた.その後術後8ヵ月で肝転移再発し,イマチニブ投与され4年間病勢コントロールされていたが,胃癌を発症し胃全摘術施行した.病理結果では高分化型腺癌とともに局所再発と思われるGISTも併存していた.胃全摘1ヵ月後からイマチニブ投与を再開し,現在外来通院にて経過観察中である.当院での胃癌切除症例の685例のうち切除胃に同時性GISTを指摘した症例が11例(1.6%)あったが,胃GIST術後再発加療中に胃癌を発症した例は初めて経験した.しかし切除不能再発GISTもイマチニブなどの分子標的薬出現により長期の生存が期待されることを考えると,再発GIST症例においても2次癌を念頭においた慎重な経過観察が重要であると思われる.(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J01066&link_issn=&doc_id=20140306110009&doc_link_id=10.4030%2Fjjcs.39.45&url=https%3A%2F%2Fdoi.org%2F10.4030%2Fjjcs.39.45&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 進行食道癌狭窄症例に対する術前栄養管理 経鼻胃管からPEGへの変遷 Reviewed

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 櫻間 教文, 野間 和広, 長谷川 祐子, 平 健太郎, 名和 秀起, 岡田 恵子, 坂本 八千代, 藤原 俊義

    静脈経腸栄養   29 ( 1 )   552 - 552   2014.1

     More details

    Language:Japanese   Publisher:(株)ジェフコーポレーション  

    researchmap

  • A Case of Gastric Cancer with Stable Disease Controlled Recurrence of Gastrointestinal Stromal Tumor with Imatinib

    Uno Futoshi, Kishimoto Hiroyuki, Kagawa Shunsuke, Fujiwara Toshiyoshi

    Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)   39 ( 1 )   45 - 51   2014

     More details

    Language:Japanese   Publisher:Japanese College of Surgeons  

    A case was 81-year-old woman with gastrointestinal stromal tumor (GIST) of stomach accompanied by liver metastases, who underwent partial gastrectomy and hepatectomy. Multiple liver metastases were diagnosed 8 months after R0 surgery. While metastases disease was well controlled with administration of imatinib for 4 years, gastric cancer in remnant stomach was diagnosed. Total gastrectomy was undergone, pathological findings were that well differentiated tubular adenocarcinoma cells were localized in mucosa and no lymph node metastases was found but local recurrence of GIST was pointed out. One month after total gastrectomy, she resumed administration of imatinib and she has no sign of progression with neither gastric cancer nor GIST. Only 11 synchronous GIST cases of 685 gastric cancer cases were found and it is first case for our institution that gastric cancer was occurred during imatinib therapy for recurrence GIST. But secondary cancer should be concern because of long survival time for unresectable metastases GIST patients with imatinib.

    DOI: 10.4030/jjcs.39.45

    DOI: 10.3919/jjsa.81.2225_references_DOI_HvAPNRy8vi3arMN5Gv9eBAuRYyx

    CiNii Article

    researchmap

  • 当科における進行食道癌における合理的胸腔鏡下手術の試み Reviewed

    野間 和広, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   549 - 549   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 胸部食道癌に対する合理的縦隔郭清 腹臥位胸腔鏡下食道切除術における縦隔リンパ節郭清での助手による積極的術野展開とその定型化 Reviewed

    白川 靖博, 二宮 卓之, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   339 - 339   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 80歳以上の超高齢者食道癌症例に対する胸腔鏡下手術の現況 Reviewed

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   502 - 502   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • [Current status of neoadjuvant chemotherapy for advanced esophageal cancer]. Reviewed

    Shunsuke Tanabe, Yasuhiro Shirakawa, Naoaki Maeda, Ryoichi Katsube, Toshiaki Ohara, Kazufumi Sakurama, Kazuhiro Noma, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   40 ( 12 )   1612 - 4   2013.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Since reported in the JCOG9907 trial, neoadjuvant chemotherapy prior to surgery has become the standard treatment for advanced (Stage II/III) esophageal cancers. However, more powerful neoadjuvant chemotherapy is required for the treatment of locally advanced cases or cases involving multiple lymph node metastases. At our institute, DCF therapy (docetaxel, cisplatin, and 5-fluorouracil) is administered selectively for the treatment of patients with far-advanced esophageal cancer. We treated 53 thoracic esophageal cancer patients who underwent surgery following neoadjuvant chemotherapy between January 2010 and December 2012. FP therapy (cisplatin and 5-fluorouracil) was administered to 43 patients, and DCF therapy to 7 patients who had far-advanced esophageal cancer. All patients treated with DCF therapy experienced grade 3 and 4 adverse events. With the exception of 1 patient, all patients who received DCF therapy could undergo curative surgery. DCF therapy could become an effective preoperative chemotherapy.

    PubMed

    researchmap

  • 腹臥位胸腔鏡下食道亜全摘のための新しい解剖教材の開発 多視点3D解剖システム Reviewed

    前田 直見, 白川 靖博, 二宮 卓之, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   508 - 508   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 胃癌切除 #8〜#13の郭清法(開腹術と同等に行えるか) 神経解剖を軸とした膵上縁郭清の工夫と実際

    黒田 新士, 西崎 正彦, 堀 直人, 岸本 浩行, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   371 - 371   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • Closed LECSの開発と臨床応用

    西崎 正彦, 加藤 大, 黒田 新士, 田邊 俊介, 堀 直人, 岸本 浩行, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   499 - 499   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡下有茎直腸による腟形成術の3例

    永坂 岳司, 宇野 太, 稲田 涼, 杉本 盛人, 母里 淑子, 近藤 喜太, 黒田 新二, 浅野 博昭, 岸本 浩行, 西崎 正彦, 佃 和憲, 香川 俊輔, 長谷川 健二郎, 難波 祐三郎, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   757 - 757   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 潰瘍性大腸炎に対する腹腔鏡下大腸全摘術のmatched case control studyによる開腹群との治療成績の比較

    稲田 涼, 近藤 喜太, 久保田 暢人, 森川 達也, 母里 淑子, 永坂 岳司, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   613 - 613   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 成人Bochdalek孔ヘルニアを合併した胃癌に対し腹腔鏡手術にて一期的に根治手術し得た1例

    堀 直人, 香川 俊輔, 黒田 信士, 岸本 浩行, 西崎 正彦, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   639 - 639   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 食道胃接合部癌の手術 当科における食道胃接合部癌の治療経験 郭清範囲と再建法について Reviewed

    野間 和広, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊介, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   467 - 467   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • Zenker憩室症の8例 Reviewed

    二宮 卓之, 田辺 俊介, 前田 直見, 大原 利章, 野間 和広, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   842 - 842   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道癌に対するESDの適応と限界 食道癌ESD後再発症例から考えるESDの適応と補助治療のあり方について Reviewed

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   369 - 369   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道癌のサルベージ手術(適応と手技と成績と) 当科における食道癌サルベージ手術の検討 Reviewed

    前田 直見, 白川 靖博, 二宮 卓之, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   413 - 413   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 吻合、再建の手術手技(食道) 当科における食道胃管吻合の変遷とその工夫 Reviewed

    白川 靖博, 二宮 卓之, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   360 - 360   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道癌患者のより良い周術期医療のために歯科はどのような貢献ができるのか? 周術期管理センター(PERIO) Reviewed

    山中 玲子, 曽我 賢彦, 前田 直見, 田辺 俊介, 大原 利章, 野間 和広, 白川 靖博, 森田 学, 佐藤 健治, 森松 博史, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   478 - 478   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 鉄欠乏状態は肝細胞癌におけるソラフェニブの感受性を改善しうる(Iron depletion status has a possibility to improve the sensitivity of sorafenib in HCC) Reviewed

    浦野 真一, 大原 利章, 勝部 亮一, 渡邉 伸一郎, 野間 和広, 友野 靖子, 田澤 大, 能祖 一裕, 白川 靖博, 貞森 裕, 藤原 俊義

    日本癌学会総会記事   72回   345 - 345   2013.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 食道癌術後亜急性期の後方支援病院におけるスコアリング化されたがんリハビリテーションの取り組み

    櫻間 教文, 平松 聡, 杉生 久実, 前田 直見, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   479 - 479   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 胃癌患者の腹腔洗浄液における蛍光発現ウイルス試薬による新たな生物学的診断(Biological assessment of peritoneal lavage cytology of gastric cancer by fluorescence-expressing virus TelomeScan)

    香川 俊輔, 石田 道拡, 渡邉 めぐみ, 田澤 大, 黒田 新士, 岸本 浩行, 橋本 悠里, 西崎 正彦, 藤原 俊義

    日本癌学会総会記事   72回   187 - 187   2013.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 進行胃癌に対する手術 進行胃癌に対し自律神経解剖を郭清範囲決定に応用したD2郭清

    西崎 正彦, 黒田 新士, 堀 直人, 岸本 浩行, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   461 - 461   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 早期大腸癌のリンパ節転移制御に向けた新規治療(Novel strategy for eradicating lymph node metastasis of earlystage colorectal cancers)

    菊地 覚次, 岸本 浩行, 田澤 大, 橋本 悠里, 宇野 太, 西崎 正彦, 香川 俊輔, 浦田 泰生, ロバート・ホフマン, 藤原 俊義

    日本癌学会総会記事   72回   178 - 178   2013.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 術後難治性創感染に対しVAC療法にて創し開を回避し創治癒を得た3例

    濱田 侑紀, 稲田 涼, 母里 淑子, 近藤 喜太, 宇野 太, 永坂 岳司, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   1034 - 1034   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 原発不明癌として治療を受けていた、診断に苦慮した虫垂癌の1例

    松本 聖, 稲田 涼, 母里 淑子, 近藤 喜太, 永坂 岳司, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   594 - 594   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 新規光線力学療法を目指したウイルスを用いた光感受性細胞傷害性蛍光タンパク質KillerRedの治療効果(Virus-mediated delivery system of photosensitive cytotoxic fluorescent protein KillerRed for novel photodynamic therapy)

    竹原 清人, 田澤 大, 橋本 悠里, 岸本 浩行, 水口 裕之, 藤原 俊義

    日本癌学会総会記事   72回   503 - 503   2013.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 蛍光標識による血中遊離癌細胞のLiquid Biopsy技術のバイオマーカー解析への応用 Reviewed

    重安 邦俊, 橋本 悠里, 竹原 清人, 宇野 太, 永坂 岳司, 田澤 大, 香川 俊輔, 浦田 泰生, 藤原 俊義

    日本癌治療学会誌   48 ( 3 )   2759 - 2759   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 透視を用いず位置確認が可能な内視鏡的バルーン拡張術の工夫 Reviewed

    田辺 俊介, 白川 靖博, 前田 直見, 勝部 亮一, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    Gastroenterological Endoscopy   55 ( Suppl.2 )   2890 - 2890   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • がん選択的生物製剤を用いた早期大腸癌の低侵襲治療の開発

    菊地 覚次, 岸本 浩行, 田澤 大, 西崎 正彦, 香川 俊輔, 浦田 泰生, Hoffman Robert M., 藤原 俊義

    日本癌治療学会誌   48 ( 3 )   1918 - 1918   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 異時性/同時性多発大腸がん症例の遺伝子変異不均一性の検討

    永坂 岳司, 森川 達也, 母里 淑子, 稲田 涼, 久保田 暢人, 竹原 祐子, 竹原 清人, 宇野 太, 佃 和憲, 中谷 紳, 冨岡 憲明, 嶋村 廣視, 森谷 行利, 瀧上 隆夫, 藤原 俊義

    日本大腸肛門病学会雑誌   66 ( 9 )   743 - 743   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 大腸癌予後不良因子BRAF変異のvariation BRAF VK600-601E変異大腸癌の一例

    母里 淑子, 永坂 岳司, 稲田 涼, 竹原 裕子, 竹原 清人, 森川 達也, 久保田 暢人, 宇野 太, 佃 和憲, 瀧上 隆夫, 嶋村 廣視, 森谷 行利, 冨岡 憲明, 中谷 紳, 藤原 俊義

    日本大腸肛門病学会雑誌   66 ( 9 )   910 - 910   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 直腸癌術後尿管再発の一例

    松本 聖, 稲田 涼, 母里 淑子, 近藤 喜太, 永坂 岳司, 江原 伸, 戸田 博子, 柳井 広之, 藤原 俊義

    日本癌治療学会誌   48 ( 3 )   2310 - 2310   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 遺伝子情報を用いたStage IV大腸癌の治療戦略の構築

    稲田 涼, 永坂 岳司, 母里 淑子, 竹原 裕子, 竹原 清人, 森川 達也, 久保田 暢人, 宇野 太, 佃 和憲, 瀧上 隆夫, 嶋村 廣視, 森谷 行利, 冨岡 憲明, 中谷 紳, 藤原 俊義

    日本大腸肛門病学会雑誌   66 ( 9 )   743 - 743   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 肛門脱出を契機に診断された同時性6多発大腸癌の一例

    森谷 行利, 高木 敏行, 冨岡 憲明, 森川 達也, 永坂 岳司, 白川 靖博, 瀧上 隆夫, 藤原 俊義

    日本大腸肛門病学会雑誌   66 ( 9 )   876 - 876   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • Selectively Replicating Oncolytic Adenoviruses Combined with Chemotherapy, Radiotherapy, or Molecular Targeted Therapy for Treatment of Human Cancers Reviewed

    Shinji Kuroda, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition   171 - 183   2013.8

     More details

    Language:English   Publishing type:Part of collection (book)   Publisher:Elsevier Inc.  

    Oncolytic adenovirotherapy presents a novel approach for cancer therapy. Oncolytic adenoviruses are modified to replicate and induce oncolytic cell death in cancer cells but not in normal somatic cells. The first oncolytic adenovirus to be developed was ONYX-015, an E1B-55. kDa gene-deleted oncolytic adenovirus
    after which many inventive oncolytic adenoviruses have followed. H101, an oncolytic adenovirus with very similar gene constructs as ONYX-015, was approved in China as the world's first adenovirus cancer treatment in humans in 2005. Many clinical trials have revealed that oncolytic adenoviruses produce synergistic antitumor effects in combination with conventional chemotherapeutic agents, radiation, and some molecular targeted agents, although monotherapy with oncolytic adenoviruses shows limited effects. In this chapter, we discuss the developments of oncolytic adenoviruses, focusing on their synergistic effects when combined with other treatment modalities. Then we discuss the problems that must be overcome for adenoviruses to become more attractive as cancer treatment agents and to expand their clinical applications. © 2014 Elsevier Inc. All rights reserved.

    DOI: 10.1016/B978-0-12-394295-1.00012-3

    Scopus

    researchmap

  • 当科における腹臥位胸腔鏡下食道切除術定型化の工夫 Reviewed

    青山 克幸, 白川 靖博, 勝部 亮一, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   68回   O - 6   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胃が使用できない食道癌症例における空腸による食道再建術の工夫 血管吻合は全例に必要か? Reviewed

    渡邊 伸一郎, 白川 靖博, 勝部 亮一, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   68回   RV - 5   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 当科における低侵襲再建術の試み 用手補助的腹腔鏡下胃管作製の60例の検討 Reviewed

    前田 直見, 白川 靖博, 勝部 亮一, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本消化器外科学会総会   68回   RV - 3   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胸部食道癌のよりよい周術期管理を目指して PERIOと鏡視下手術の融合 Reviewed

    白川 靖博, 勝部 亮一, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   68回   O - 1   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 食道胃接合部癌の外科治療戦略 当科における食道胃接合部癌の治療経験 下縦隔リンパ節転移症例の検討 Reviewed

    野間 和広, 白川 靖博, 前田 直見, 勝部 亮一, 大原 利章, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   68回   PD - 5   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 患者負担軽減のためのPEGを用いた食道癌術前補助栄養療法の現状について Reviewed

    勝部 亮一, 白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和宏, 藤原 俊義

    日本消化器外科学会総会   68回   RS - 1   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌の低侵襲治療の開発

    菊地 覚次, 岸本 浩行, 田澤 大, 橋本 悠里, 宇野 太, 西崎 正彦, 香川 俊輔, 浦田 泰生, ロバート・ホフマン, 藤原 俊義

    日本消化器外科学会総会   68回   RS - 2   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 腹腔鏡補助下噴門側胃切除術における郭清手技と「観音開き法」食道残胃吻合

    西崎 正彦, 黒田 新士, 野間 和広, 渡邉 めぐみ, 岸本 浩行, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   68回   O - 6   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • HER2陽性胃癌の臨床病理学的特徴と当院におけるtrastuzumabの使用経験

    渡辺 めぐみ, 香川 俊輔, 石田 道拡, 黒田 新士, 岸本 浩行, 宇野 太, 西崎 正彦, 藤原 俊義

    日本消化器外科学会総会   68回   RS - 2   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • LADG、D2における神経解剖を軸とした膵上縁リンパ節郭清

    黒田 新士, 西崎 正彦, 渡邊 めぐみ, 石田 道拡, 岸本 浩行, 宇野 太, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   68回   RV - 2   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 三次元解剖映像教材を用いた次世代の手術解剖教育

    近藤 喜太, 稲田 涼, 宇野 太, 永坂 岳司, 武田 吉正, 大塚 愛二, 藤原 俊義

    日本消化器外科学会総会   68回   O - 6   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 地域一体型NSTの取り組みと効果について

    西川 みか, 櫻間 教文, 多田 仁美, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   67回   224 - 224   2013.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • Accumulation of Epigenetic Alteration Could Predict Malignant Formation in Intraductal Papillary Mucinous Neoplasm (IPMN) Reviewed

    Yoshida Kazuhiro, Nagasaka Takeshi, Umeda Yuzo, Yokomichi Naosuke, Mori Yoshiko, Kubota Nobuhito, Morikawa Tatsuya, Takehara Yuko, Takehara Kiyoto, Shigeyasu Kunitoshi, Nyuya Akihiro, Shiwaku Rikiya, Suno Manabu, Nishida Naoshi, Fujiwara Toshiyoshi, Goel Ajay

    GASTROENTEROLOGY   144 ( 5 )   S98 - S98   2013.5

     More details

    Language:English   Publisher:W B SAUNDERS CO-ELSEVIER INC  

    0

    Web of Science

    researchmap

  • Fecal DNA Methylation Assay for the Identification of a Multiple Gastrointestinal Cancers Including Pancreatic Caner Reviewed

    Morikawa Tatsuya, Nagasaka Takeshi, Yoshida Kazuhiro, Mori Yoshiko, Kubota Nobuhito, Takehara Yuko, Yokomichi Naosuke, Nishida Naoshi, Takehara Kiyoto, Shigeyasu Kunitoshi, Nyuya Akihiro, Shiwaku Rikiya, Suno Manabu, Fujiwara Toshiyoshi, Goel Ajay

    GASTROENTEROLOGY   144 ( 5 )   S601 - S602   2013.5

  • Genetic and Epigenetic Alterations in the Netrin-1 Receptors, UNC5c and DCC, Constitutes a Previously Unrecognized Pathway in Gastric Cancer Progression Reviewed

    Kubota Nobuhito, Nagasaka Takeshi, Toda Keisuke, Mori Yoshiko, Morikawa Tatsuya, Umeda Yuzo, Yokomichi Naosuke, Yoshida Kazuhiro, Takehara Yuko, Takehara Kiyoto, Nyuya Akihiro, Shiwaku Rikiya, Shigeyasu Kunitoshi, Suno Manabu, Nishida Naoshi, Fujiwara Toshiyoshi, Goel Ajay

    GASTROENTEROLOGY   144 ( 5 )   S527   2013.5

  • Cytokeratin 19 Staining Is a Novel, Predictive Biomarker for Extra-Hepatic Metastasis in Hepatocellular Carcinoma Reviewed

    Yokomichi Naosuke, Nagasaka Takeshi, Nishida Naoshi, Umeda Yuzo, Mori Yoshiko, Morikawa Tatsuya, Kubota Nobuhito, Yoshida Kazuhiro, Takehara Yuko, Takehara Kiyoto, Shigeyasu Kunitoshi, Nyuya Akihiro, Shiwaku Rikiya, Suno Manabu, Fujiwara Toshiyoshi, Goel Ajay

    GASTROENTEROLOGY   144 ( 5 )   S719 - S720   2013.5

     More details

    Language:English   Publisher:W B SAUNDERS CO-ELSEVIER INC  

    0

    Web of Science

    researchmap

  • MGMT Methylation As a Novel Biomarker for the Identification of Stage III Colorectal Cancers At High-Risk of Disease Recurrence Following Curative Surgery Reviewed

    Mori Yoshiko, Nagasaka Takeshi, Tazawa Hiroshi, Umeda Yuzo, Morikawa Tatsuya, Kubota Nobuhito, Yoshida Kazuhiro, Takehara Yuko, Yokomichi Naosuke, Takehara Kiyoto, Shigeyasu Kunitoshi, Nyuya Akihiro, Shiwaku Rikiya, Suno Manabu, Nishida Naoshi, Fujiwara Toshiyoshi, Goel Ajay

    GASTROENTEROLOGY   144 ( 5 )   S85 - S85   2013.5

     More details

    Language:English   Publisher:W B SAUNDERS CO-ELSEVIER INC  

    0

    Web of Science

    researchmap

  • 食道癌手術の周術期管理におけるチーム医療 当院での胸部食道癌周術期管理におけるPERIO導入についての検討 Reviewed

    白川 靖博, 勝部 亮一, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科系連合学会誌   38 ( 3 )   605 - 605   2013.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    researchmap

  • 術後難治性創感染に対し、VAC療法にて創し開を回避し創治癒を得た2例

    濱田 侑紀, 稲田 涼, 母里 淑子, 近藤 喜太, 宇野 太, 永坂 岳司, 藤原 俊義

    日本外科系連合学会誌   38 ( 3 )   651 - 651   2013.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    researchmap

  • 病期診断に難渋した早期食道癌の一例 術前PET-CT偽陽性症例の検討 Reviewed

    山辻 知樹, 平林 葉子, 高岡 宗徳, 深澤 拓也, 繁光 薫, 林 次郎, 浦上 淳, 吉田 和弘, 中島 一毅, 森田 一郎, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 白川 靖博, 藤原 俊義, 河本 博文, 猶本 良夫

    Gastroenterological Endoscopy   55 ( Suppl.1 )   1160 - 1160   2013.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 術後5年を経過して発症した肛門管粘液癌局所再発に対して治癒切除を施行した1例

    濱田 侑紀, 稲田 涼, 母里 淑子, 近藤 喜太, 宇野 太, 永坂 岳司, 藤原 俊義

    岡山医学会雑誌   125 ( 1 )   93 - 93   2013.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • Gene therapy for cancer treatment Reviewed

    Shunsuke Kagawa, Toshiyoshi Fujiwara

    Gene Therapy: Technologies and Applications   70 - 83   2013.3

     More details

    Language:English   Publishing type:Part of collection (book)   Publisher:Future Medicine Ltd.  

    DOI: 10.2217/EBO.12.279

    Scopus

    researchmap

  • 血清鉄コントロールを用いた新たな肝細胞癌治療戦略 Reviewed

    大原 利章, 白川 靖博, 浦野 真一, 前田 直見, 渡邊 伸一郎, 田辺 俊介, 野間 和広, 能祖 一裕, 貞森 裕, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   634 - 634   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • パラチノースを主糖質源とした流動食MHN-01を用いた食道癌周術期管理の意義 Reviewed

    山辻 知樹, 田村 卓也, 小池 良和, 平林 葉子, 高岡 宗徳, 深澤 拓也, 林 次郎, 繁光 薫, 浦上 淳, 吉田 和弘, 大原 利章, 田辺 俊介, 藤原 康宏, 櫻間 教文, 野間 和広, 白川 靖博, 羽井佐 実, 中島 一毅, 森田 一郎, 藤原 俊義, 猶本 良夫

    日本外科学会雑誌   114 ( 臨増2 )   919 - 919   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 消化器癌における血中遊離癌細胞の検出と臨床応用 テロメラーゼ活性を指標とする血中遊離癌細胞の高感度検出法の開発と遺伝子解析技術への応用 Reviewed

    重安 邦俊, 橋本 悠里, 宇野 太, 永坂 岳司, 田澤 大, 香川 俊輔, 水口 裕之, 浦田 泰生, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   338 - 338   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 超高齢者に対する外科治療の問題点 消化管外科、術式の選択 当科における80歳以上の超高齢者食道癌症例に対する外科治療の変遷 Reviewed

    田辺 俊介, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   317 - 317   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 腹臥位胸腔鏡下食道亜全摘術においてEndoCAMeleonがもたらした新たな視野展開 Reviewed

    野間 和広, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   451 - 451   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 血清鉄コントロールによる食道癌細胞の浸潤・転移能制御の可能性 Reviewed

    浦野 真一, 野間 和広, 大原 利章, 西谷 正史, 前田 直見, 渡邉 伸一郎, 田辺 俊介, 櫻間 教文, 友野 靖子, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   747 - 747   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 高リスクGIST症例の検討 無作為化比較試験SSGXVIII/AIOの報告をうけて Reviewed

    宇野 太, 永坂 岳司, 香川 俊輔, 西崎 正彦, 岸本 浩行, 黒田 新士, 石田 道拡, 青山 克幸, 稲田 涼, 前田 直見, 大原 利章, 近藤 喜太, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   891 - 891   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 再発食道がんに対する新しい集学的アプローチとその意義

    猶本 良夫, 山辻 知樹, 繁光 薫, 高岡 宗徳, 吉田 和弘, 林 次郎, 田村 卓也, 浦上 淳, 深澤 拓也, 平林 葉子, 小池 良和, 中島 一毅, 白川 靖博, 田辺 俊介, 野間 和広, 藤原 康宏, 櫻間 教文, 羽井佐 実, 藤原 俊義, 森田 一郎

    日本外科学会雑誌   114 ( 臨増2 )   756 - 756   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • ロボット支援下幽門側胃切除術におけるリンパ節郭清手技

    西崎 正彦, 香川 俊輔, 石田 道拡, 黒田 新士, 近藤 喜太, 野間 和広, 岸本 浩行, 宇野 太, 永坂 岳司, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   438 - 438   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌の低侵襲治療の開発

    菊地 覚次, 岸本 浩行, 田澤 大, 橋本 悠里, 宇野 太, 西崎 正彦, 香川 俊輔, 浦田 泰生, Robert Hoffman, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   612 - 612   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 直腸癌術後10年を経過して発症した局所再発に対して治癒切除を施行した1例

    西江 尚貴, 稲田 涼, 近藤 喜太, 宇野 太, 永坂 岳司, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   1071 - 1071   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 若手外科医のための3次元立体解剖教材の有用性

    近藤 喜太, 稲田 涼, 永坂 岳司, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   982 - 982   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 腹腔鏡下胃切除術におけるリンパ節郭清のコツ da Vinci手術からLADGへのfeedback 幽門下リンパ節郭清

    西崎 正彦, 香川 俊輔, 宇野 太, 石田 道拡, 黒田 新士, 岸本 浩行, 白川 靖博, 藤原 俊義

    日本胃癌学会総会記事   85回   202 - 202   2013.2

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 腹腔細胞診陽性胃癌症例に対する外科的切除の検討

    香川 俊輔, 岸本 浩行, 宇野 太, 西崎 正彦, 黒田 新士, 石田 道拡, 藤原 俊義

    日本胃癌学会総会記事   85回   283 - 283   2013.2

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • [Development of a detection system for circulating tumor cells in peripheral blood using a next generation conditionally-replicating adenovirus]. Reviewed

    Fuminori Sakurai, Toshiyoshi Fujiwara, Hiroyuki Mizuguchi

    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan   133 ( 3 )   291 - 6   2013

     More details

    Language:Japanese  

    An easy and sensitive detection method for circulating tumor cells (CTC) is expected to be developed because CTC are a promising biomarker for early diagnosis of tumors and prognosis prediction of tumor patients. Our group has already developed a CTC detection method using a conditionally replicating adenovirus (Ad) which efficiently replicates and expresses GFP in telomerase-positive tumor cells. However, malignant tumor cells express much low levels of coxsackievirus and adenovirus receptor (CAR), leading to inefficient infection with a conventional conditionally replicating Ad. In addition, a tiny fraction of normal blood cells, including lymphocytes, express GFP following infection. To overcome these problems, we have developed a next-generation conditionally replicating Ad. The next-generation conditionally replicating Ad possesses the fiber protein derived from Ad serotype 35, leading to efficient infection in both CAR-positive and -negative tumor cells, because the fiber protein of Ad serotype 35 binds to CD46, which is expressed on almost all human cells. Furthermore, sequences complementary to blood cell-specific miRNA (miR-142-3p) were inserted into the 3' untranslated region of the E1 gene and GFP gene, leading to the suppression of GFP expression in normal blood cells. In this symposium, we will not only introduce the importance of CTC as a biomarker and conventional CTC detection methods but also show our data of the novel CTC detection using the next-generation conditionally replicating Ad.

    PubMed

    researchmap

  • 内視鏡外科におけるチーム医療の在り方 食道癌鏡視下手術の周術期におけるチーム医療の関わり Reviewed

    白川 靖博, 青山 克幸, 前田 直見, 田辺 俊介, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   17 ( 7 )   313 - 313   2012.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • Non-recurrent inferior laryngeal nerveを伴う胸部食道癌に対して胸腔鏡下食道亜全摘を施行した1例 Reviewed

    前田 直見, 白川 靖博, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本内視鏡外科学会雑誌   17 ( 7 )   696 - 696   2012.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 我々の目指すチーム内視鏡外科 当科における腹臥位胸腔鏡下食道亜全摘における術者助手のコラボレーション Reviewed

    野間 和広, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 田辺 俊介, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   17 ( 7 )   604 - 604   2012.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • Robotic Surgeryによる胃切除 Double bipolar techniqueによる術野展開の工夫と郭清手技

    西崎 正彦, 石田 道拡, 黒田 新士, 岸本 浩行, 宇野 太, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   17 ( 7 )   296 - 296   2012.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 腹腔鏡手術における腹腔内癒着マッピングの有用性と意義

    近藤 喜太, 稲田 涼, 永坂 岳司, 西崎 正彦, 藤原 俊義

    日本内視鏡外科学会雑誌   17 ( 7 )   537 - 537   2012.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • [A case of transverse myelopathy due to spinal bone metastasis of gastric cancer].

    Aiko Kono, Shunsuke Kagawa, Hiroyuki Kishimoto, Futoshi Uno, Masahiko Nishizaki, Masahiko Oiwa, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   39 ( 12 )   2357 - 9   2012.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    We report a case of gastric cancer that presented as transverse myelopathy due to spinal bone metastasis. A 45-year- old man with advanced gastric cancer underwent distal gastrectomy and lymph node dissection for curative intent. However, pathological examination of the specimen revealed positive cytological findings in the peritoneal lavage fluid in addition to serosal invasion and lymph node metastasis(pT4aN3bCY1, stage IV). Three months after the operation, during the second course of chemotherapy with S-1, he began to complain of back pain, and positron emission tomography-computed tomography revealed spinal bone metastasis. Despite immediate radiotherapy for the bone metastasis, he soon suffered from paraplegia in the lower extremities followed by disturbances of bladder and bowel function. We created a sigmoid colostomy, which enabled self-care for defecation, and resumed radiotherapy and chemotherapy. Bone metastasis of gastric cancer is rare but the prognosis is very poor. Because of a rapidly deteriorating clinical course, early diagnosis and multidisciplinary approaches are important for gastric cancer patients with spinal metastasis.

    PubMed

    researchmap

  • [Stent placement using a double-balloon endoscope for malignant duodenal obstruction with Roux-en-Y Anastomosis-a case report].

    Masahiko Oiwa, Shunsuke Kagawa, Hiroyuki Kishimoto, Futoshi Uno, Masahiko Nishizaki, Aiko Kono, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   39 ( 12 )   2372 - 4   2012.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    A 79-year-old man who had previously undergone partial resection of the remnant stomach and Roux-en-Y reconstruction was diagnosed as having peritoneal recurrence near the ligament of Treitz. In the course of chemotherapy for recurrent gastric cancer, he complained of colic pain. CT examination revealed a marked dilation of the duodenum suggesting the presence of a distal duodenal stricture resulting from the known recurrent tumor. To palliate this intestinal obstruction, we successfully placed an expandable metal stent(EMS) using a double-balloon enteroscope(DBE), which achieved immediate relief of the obstruction and enabled the resumption of oral intake and chemotherapy. While the endoscopic placement of an EMS is available for malignant gastro-intestinal obstruction, it is considerably more difficult to approach the duodenum with Roux-en-Y anastomosis. A DBE has made it possible to place an EMS deep in the small intestine. In the present case, this minimally invasive procedure avoided the need for surgery and greatly contributed to palliation. Thus, EMS placement using a DBE is a possible palliative treatment for malignant small bowel obstruction.

    PubMed

    researchmap

  • 当科における食道胃接合部癌に対する再建法の工夫 胸腔内観音開き法吻合の経験 Reviewed

    野間 和広, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 田辺 俊介, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   525 - 525   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 出血性ショックをきたした回腸静脈瘤破裂に対しバルーン下逆行性経静脈的塞栓術(BRTO)が奏功した1例

    濱田 侑紀, 竹原 裕子, 竹原 清人, 大原 利章, 近藤 喜太, 永坂 岳司, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   1084 - 1084   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 低肺機能合併の胸部食道癌症例に対する腹臥位胸腔鏡下食道切除の経験 Reviewed

    前田 直見, 白川 靖博, 青山 克幸, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   706 - 706   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • Zenker憩室に合併した頸部食道表在癌の1例 Reviewed

    大原 利章, 白川 靖博, 青山 克幸, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   945 - 945   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道癌手術における再建法の安全性とQOL 胃が使用できない食道癌症例におけるQOL向上を目指した腸管による食道再建法 Reviewed

    田辺 俊介, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   383 - 383   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • チームで乗り切る食道癌手術(当院での周術期管理センター:PERIOの取り組み) Reviewed

    白川 靖博, 青山 克幸, 前田 直見, 田辺 俊介, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   481 - 481   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • コンポジットメッシュと非吸収性タックを用い腹腔鏡下にて修復した腹壁瘢痕ヘルニアの一例

    石田 道拡, 香川 俊輔, 岸本 浩行, 黒田 新士, 西崎 正彦, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   947 - 947   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 腹腔鏡下胃全摘術・噴門切除術とその再建術式 腹腔鏡補助下噴門側胃切除術のための「観音開き法」食道残胃吻合の工夫

    西崎 正彦, 石田 道拡, 黒田 新士, 岸本 浩行, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   372 - 372   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 大腸癌の悪性度診断と臨床応用 Genetic/epigenetic変異を基盤とした大腸癌個別化治療の構築と臨床応用

    永坂 岳司, 母里 淑子, 森川 達也, 久保田 暢人, 竹原 清人, 稲田 涼, 宇野 太, 三嶋 秀行, 藤原 俊義

    日本大腸肛門病学会雑誌   65 ( 9 )   539 - 539   2012.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 消化器がん検診における新しい診断法の展開 便中メチル化CpG検出による消化器癌スクリーニング

    永坂 岳司, 森川 達也, 藤原 俊義

    Gastroenterological Endoscopy   54 ( Suppl.2 )   2625 - 2625   2012.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 腫瘍特異的制限増殖型アデノウイルスを用いた血液循環腫瘍細胞の遺伝子解析技術の開発(Development of genetic analysis of circulating tumor cells using a telomerase-specific replication-competent adenovirus) Reviewed

    重安 邦俊, 橋本 悠里, 宇野 太, 永坂 岳司, 田澤 大, 香川 俊輔, 水口 裕之, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   71回   50 - 50   2012.8

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 頭頸部表在癌のESDにおける工夫 Reviewed

    田辺 俊介, 白川 靖博, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    耳鼻咽喉科展望   55 ( 4 )   262 - 263   2012.8

     More details

    Language:Japanese   Publisher:耳鼻咽喉科展望会  

    researchmap

  • 癌関連線維芽細胞が食道癌の増殖に寄与する(Cancer-associated fibroblasts contribute to progression of esophageal cancer) Reviewed

    渡邉 伸一郎, 野間 和広, 浦野 真一, 大原 利章, 橋本 悠里, 田澤 大, 藤原 俊義

    日本癌学会総会記事   71回   143 - 143   2012.8

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌の低侵襲治療の開発(Less invasive therapeutic intervention for early colorectal cancers using telomerase-dependent replicating adenovirus)

    菊地 覚次, 岸本 浩行, 田澤 大, 橋本 悠里, 宇野 太, 西崎 正彦, 香川 俊輔, 浦田 泰生, ロバート・ホフマン, 藤原 俊義

    日本癌学会総会記事   71回   202 - 202   2012.8

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道癌転移診断におけるPET-CT検査の限界 PET-CT偽陽性症例の検討

    山辻 知樹, 櫻間 教文, 高岡 宗徳, 林 次郎, 繁光 薫, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義, 猶本 良夫

    日本消化器外科学会総会   67回   2 - 2   2012.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • がん特異的増殖アデノウイルス製剤OBP-401を用いた生体内癌組織蛍光イメージング

    岸本 浩行, 菊地 覚次, 橋本 悠里, 宇野 太, 田澤 大, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   67回   1 - 1   2012.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 同時性/異時性多発大腸癌に認められたsomatic mutation spectrumの不均一性

    森川 達也, 永坂 岳司, 母里 淑子, 久保田 暢人, 杉原 正大, 竹原 清人, 吉田 一博, 富岡 憲明, 森谷 行利, 藤原 俊義

    日本消化器外科学会総会   67回   2 - 2   2012.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • ロボット支援下胃切除術の術野展開と郭清手技

    西崎 正彦, 香川 俊輔, 宇野 太, 岸本 浩行, 藤原 俊義

    日本消化器外科学会総会   67回   1 - 1   2012.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 鉄コントロールによる新しい食道癌治療法の開発 Reviewed

    大原 利章, 白川 靖博, 青山 克幸, 前田 直見, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   66回   196 - 196   2012.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌転移診断におけるPET-CT偽陽性症例の検討

    山辻 知樹, 高岡 宗徳, 繁光 薫, 田辺 俊介, 野間 和広, 櫻間 教文, 白川 靖博, 羽井佐 実, 藤原 俊義, 猶本 良夫

    日本食道学会学術集会プログラム・抄録集   66回   261 - 261   2012.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道疾患;最良の手術とは 胸部食道癌に対する適切な頸部・上縦隔郭清とその意義

    猶本 良夫, 高岡 宗徳, 繁光 薫, 田辺 俊介, 野間 和広, 櫻間 教文, 白川 靖博, 山辻 知樹, 藤原 俊義, 羽井佐 実

    日本食道学会学術集会プログラム・抄録集   66回   143 - 143   2012.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道アカラシアに対する腹腔鏡下手術

    尾山 貴徳, 野田 卓男, 西崎 正彦, 田辺 俊介, 藤原 俊義

    日本小児外科学会雑誌   48 ( 3 )   446 - 446   2012.5

  • 大学病院の特殊な疾患群に対する胃瘻造設の現況 Reviewed

    田辺 俊介, 白川 靖博, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    Gastroenterological Endoscopy   54 ( Suppl.1 )   1201 - 1201   2012.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 当科における中下咽頭表在癌に対するESDの工夫 Reviewed

    白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    Gastroenterological Endoscopy   54 ( Suppl.1 )   1154 - 1154   2012.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 高齢者食道癌症例に対する手術術式と周術期管理 Reviewed

    田辺 俊介, 白川 靖博, 前田 直見, 大原 利章, 野間 和広, 櫻間 教文, 藤原 俊義

    日本外科学会雑誌   113 ( 臨増2 )   362 - 362   2012.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 当科での胸部食道癌手術の低侵襲化の推移とその成果 Reviewed

    白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本外科学会雑誌   113 ( 臨増2 )   736 - 736   2012.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • ロボット支援下幽門側胃切除術の安全な導入 Reviewed

    西崎 正彦, 香川 俊輔, 宇野 太, 岸本 浩行, 近藤 喜太, 田邊 俊介, 大原 利章, 野間 和広, 永坂 岳志, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   113 ( 臨増2 )   490 - 490   2012.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 胃癌術後再発症例に対する放射線療法の経験

    香川 俊輔, 宇野 太, 岸本 浩行, 西崎 まさひこ, 白川 靖博, 永坂 岳司, 野間 和広, 藤原 俊義

    日本胃癌学会総会記事   84回   334 - 334   2012.2

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 当院における胃GISTに対するイマチニブ投与の位置づけ

    宇野 太, 香川 俊輔, 西崎 正彦, 岸本 浩行, 藤原 俊義

    日本胃癌学会総会記事   84回   359 - 359   2012.2

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 各領域におけるロボット手術 現状と今後の展望(消化器) ロボット支援下幽門側胃切除術の安全な導入を目指して 導入初期3例の検討

    西崎 正彦, 香川 俊輔, 宇野 太, 岸本 浩行, 近藤 喜太, 田邊 俊介, 野間 和広, 永坂 岳司, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌   16 ( 7 )   247 - 247   2011.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 当科における高齢者食道癌手術症例の術式選択の工夫 Reviewed

    田辺 俊介, 白川 靖博, 前田 直見, 大原 利章, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   533 - 533   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 当科における胃管再建作成および吻合における工夫 Reviewed

    野間 和広, 白川 康博, 前田 直見, 大原 利章, 田辺 俊介, 永坂 岳司, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   517 - 517   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 当科における食道胃接合部の食道癌についての検討 Reviewed

    白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   501 - 501   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 当科における食道癌頭頸部癌重複症例の検討 Reviewed

    前田 直見, 白川 靖博, 田辺 俊介, 大原 利章, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   557 - 557   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 当科におけるT4食道癌に対する治療戦略についての検討 Reviewed

    大原 利章, 白川 靖博, 前田 直見, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   531 - 531   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 当科における食道及び中下咽頭表在癌に対するESDの工夫 Reviewed

    白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   593 - 593   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 当科における後期高齢者食道癌手術症例に対する術式選択の検討

    白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本消化器外科学会雑誌   44 ( Suppl.2 )   267 - 267   2011.10

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 胸部食道癌における縦隔郭清 左反回神経沿い106recLの郭清について

    猶本 良夫, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義, 羽井佐 実, 木下 真一郎, 山田 貴子, 高岡 宗徳, 深澤 拓也, 林 次郎, 繁光 薫, 山辻 知樹, 吉田 和弘, 森田 一郎

    日本臨床外科学会雑誌   72 ( 増刊 )   515 - 515   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 胃癌に対するRobot Assisted Gastrectomyの導入経験

    西崎 正彦, 近藤 喜太, 田邊 俊介, 野間 和広, 岸本 浩行, 宇野 太, 永坂 岳司, 香川 俊輔, 白川 靖弘, 藤原 俊義

    日本消化器外科学会雑誌   44 ( Suppl.2 )   185 - 185   2011.10

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • HER2陰性胃癌細胞におけるHER2細胞外ドメイン発現によるトラスツズマブへの感受性誘導

    吉田 亮介, 田澤 大, 橋本 悠里, 大西 哲平, 岸本 浩行, 宇野 太, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本癌治療学会誌   46 ( 2 )   655 - 655   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 胃癌幹細胞に対するテロメラーゼ特異的腫瘍融解ウイルス治療

    香川 俊輔, 矢野 修也, 田澤 大, 橋本 悠里, 宇野 太, 岸本 浩行, 西崎 正彦, 浦田 泰生, 藤原 俊義

    日本癌治療学会誌   46 ( 2 )   395 - 395   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 鉄欠乏状態は食道がんにおいてNカドヘリンを低下させることでEMTを抑制する(Iron deficiency suppress EMT through downregulation of N-cadherin in esophageal cancer) Reviewed

    西谷 正史, 野間 和広, 大原 利章, 長谷井 嬢, 佐々木 剛, 渡邊 伸一郎, 大西 哲平, 吉田 亮介, 橋本 悠里, 田澤 大, 宇野 太, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   70回   467 - 468   2011.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 胸部食道癌術後の早期抜管を目指したチーム医療の取り組み

    足羽 孝子, 伊藤 真理, 白川 靖博, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   65回   185 - 185   2011.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 胸部食道癌に対する頸部・上縦隔郭清術とその意義

    猶本 良夫, 田辺 俊介, 野間 和広, 櫻間 教文, 高岡 宗徳, 繁光 薫, 白川 靖博, 山辻 知樹, 藤原 俊義, 羽井佐 実

    日本食道学会学術集会プログラム・抄録集   65回   262 - 262   2011.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌術後再発症例・異時性重複癌症例の集学的治療におけるPET/CTの活用

    田辺 俊介, 白川 靖博, 野間 和広, 櫻間 教文, 山辻 知樹, 羽井佐 実, 猶本 良夫, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   65回   236 - 236   2011.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌転移診断におけるPET-CT検査の有用性と限界 PET-CT偽陽性症例の検討から

    山辻 知樹, 田辺 俊介, 野間 和広, 櫻間 教文, 高岡 宗徳, 繁光 薫, 白川 靖博, 羽井佐 実, 藤原 俊義, 猶本 良夫

    日本食道学会学術集会プログラム・抄録集   65回   289 - 289   2011.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 当科における食道胃接合部癌に対する治療方針とその成績

    白川 靖博, 田辺 俊介, 野間 和広, 櫻間 教文, 羽井佐 実, 山辻 知樹, 猶本 良夫, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   65回   271 - 271   2011.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 当科において胃管作成および再建術における最近の取り組み

    野間 和広, 白川 靖博, 横道 直佑, 田辺 俊介, 櫻間 教文, 山辻 知樹, 羽井佐 実, 猶本 良夫, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   65回   297 - 297   2011.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 当科において胃管作成および再建術における最近の取り組み

    野間 和広, 白川 靖博, 横道 直佑, 田辺 俊介, 櫻間 教文, 山辻 知樹, 羽井佐 実, 猶本 良夫, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   65回   297 - 297   2011.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 【食道癌-基礎・臨床研究の進歩-】食道癌の治療 外科治療 食道胃接合部癌・Barrett食道癌に対する手術

    白川 靖博, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床   69 ( 増刊6 食道癌 )   322 - 328   2011.8

  • 岡山大学病院における胃癌に対するダビンチS(da Vinci S surgical system)によるロボット支援腹腔鏡下手術の導入

    香川 俊輔, 西崎 正彦, 宇野 太, 岸本 浩行, 白川 靖博, 永坂 岳司, 野間 和広, 田辺 俊介, 近藤 喜太, 横道 直佑, 森川 達也, 佃 和憲, 浅野 博昭, 内藤 稔, 藤原 俊義

    岡山医学会雑誌   123 ( 2 )   167 - 167   2011.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 悪性リンパ腫合併胸部食道癌症例の治療経験

    横道 直佑, 白川 靖博, 野間 和広, 田辺 俊介, 森川 達也, 近藤 喜太, 櫻間 教文, 岸本 浩行, 宇野 太, 永坂 岳司, 西崎 正彦, 香川 俊輔, 藤原 俊義

    岡山医学会雑誌   123 ( 2 )   166 - 166   2011.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 頭頸部癌・食道癌におけるPEGを用いた栄養管理の有用性の検討

    田辺 俊介, 白川 靖博, 野間 和広, 横道 直佑, 森川 達也, 近藤 喜太, 櫻間 教文, 岸本 浩行, 宇野 太, 永坂 岳司, 西崎 正彦, 香川 俊輔, 藤原 俊義

    岡山医学会雑誌   123 ( 2 )   166 - 166   2011.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 胃癌に対する腹腔鏡下手術の新たな考え方と工夫 肝十二指腸間膜左側アプローチによるNo.12a郭清

    西崎 正彦, 香川 俊輔, 宇野 太, 岸本 浩行, 合地 明, 藤原 俊義

    日本消化器外科学会総会   66回   276 - 276   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 消化器外科周術期における栄養療法の進歩 FITMATEを用いて呼吸商から基礎代謝を測定し、術後栄養管理に利用する新しい試み

    櫻間 教文, 西川 みか, 平松 聡, 繁光 薫, 山辻 知樹, 猶本 良夫, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   66回   263 - 263   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 当科における胃管作成および再建術の工夫

    野間 和広, 白川 靖博, 横道 直佑, 田辺 俊介, 櫻間 教文, 山辻 知樹, 羽井佐 実, 猶本 良夫, 藤原 俊義

    日本消化器外科学会総会   66回   499 - 499   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 同時多発性胃癌術後の残胃癌に関する検討

    香川 俊輔, 宇野 太, 岸本 浩行, 西崎 正彦, 白川 靖博, 永坂 岳司, 野間 和広, 近藤 喜太, 田辺 俊介, 藤原 俊義

    日本消化器外科学会総会   66回   297 - 297   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 岡山大学外科研修マネージメントセンター 医局を超えた外科研修教育の取り組み

    菊地 覚次, 香川 俊輔, 篠浦 先, 野間 和広, 松岡 順治, 土井原 博義, 八木 孝仁, 佐野 俊二, 三好 新一郎, 藤原 俊義

    日本消化器外科学会総会   66回   185 - 185   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 当科における食道胃接合部領域の食道癌に対する治療

    白川 靖博, 横道 直佑, 田辺 俊介, 野間 和広, 櫻間 教文, 山辻 知樹, 猶本 良夫, 羽井佐 実, 藤原 俊義

    日本消化器外科学会総会   66回   774 - 774   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 体内鉄コントロールによるN-cadheinの発現低下が癌細胞の浸潤・転移能にどのような影響を与えるかについての検討 Reviewed

    西谷 正史, 野間 和広, 大原 利章, 友野 靖子, 田邊 俊介, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   112 ( 臨増1-2 )   595 - 595   2011.5

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 体内鉄コントロールを利用したBevacizumabの新規治療法 Reviewed

    大原 利章, 野間 和広, 友野 靖子, 西谷 正史, 田辺 俊介, 田澤 大, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   112 ( 臨増1-2 )   771 - 771   2011.5

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 食道癌転移診断におけるPET-CT偽陽性症例の検討 Reviewed

    山辻 知樹, 関 亮太, 木下 真一郎, 深澤 拓也, 林 次郎, 繁光 薫, 吉田 和弘, 森田 一郎, 山田 英司, 西谷 正史, 大原 利章, 田邊 俊介, 藤原 康宏, 櫻間 教文, 野間 和広, 高岡 宗徳, 白川 靖博, 松岡 順治, 羽井佐 実, 藤原 俊義, 猶本 良夫

    日本外科学会雑誌   112 ( 臨増1-2 )   837 - 837   2011.5

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Preclinical Evaluation of Telomerase-Specific Oncolytic Virotherapy for Human Bone and Soft Tissue Sarcomas Reviewed

    Tsuyoshi Sasaki, Hiroshi Tazawa, Jo Hasei, Toshiyuki Kunisada, Aki Yoshida, Yuuri Hashimoto, Shuya Yano, Ryosuke Yoshida, Futoshi Uno, Shunsuke Kagawa, Yuki Morimoto, Yasuo Urata, Toshifumi Ozaki, Toshiyoshi Fujiwara

    CLINICAL CANCER RESEARCH   17 ( 7 )   1828 - 1838   2011.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER ASSOC CANCER RESEARCH  

    Purpose: Tumor-specific replication-selective oncolytic virotherapy is a promising antitumor therapy for induction of cell death in tumor cells but not of normal cells. We previously developed an oncolytic adenovirus, OBP-301, that kills human epithelial malignant cells in a telomerase-dependent manner. Recent evidence suggests that nonepithelial malignant cells, which have low telomerase activity, maintain telomere length through alternative lengthening of telomeres (ALT). However, it remains unclear whether OBP-301 is cytopathic for nonepithelial malignant cells. Here, we evaluated the antitumor effect of OBP-301 on human bone and soft tissue sarcoma cells.
    Experimental Design: The cytopathic activity of OBP-301, coxsackie and adenovirus receptor (CAR) expression, and telomerase activity were examined in 10 bone (OST, U2OS, HOS, HuO9, MNNG/HOS, SaOS-2, NOS-2, NOS-10, NDCS-1, and OUMS-27) and in 4 soft tissue (CCS, NMS-2, SYO-1, and NMFH-1) sarcoma cell lines. OBP-301 antitumor effects were assessed using orthotopic tumor xenograft models. The fiber-modified OBP-301 (termed OBP-405) was used to confirm an antitumor effect on OBP-301-resistant sarcomas.
    Results: OBP-301 was cytopathic for 12 sarcoma cell lines but not for the non-CAR-expressing OUMS27 and NMFH-1 cells. Sensitivity to OBP-301 was dependent on CAR expression and not on telomerase activity. ALT-type sarcomas were also sensitive to OBP-301 because of upregulation of human telomerase reverse transcriptase (hTERT) mRNA following virus infection. Intratumoral injection of OBP-301 significantly suppressed the growth of OST and SYO-1 tumors. Furthermore, fiber-modified OBP-405 showed antitumor effects on OBP-301-resistant OUMS-27 and NMFH-1 cells.
    Conclusions: A telomerase-specific oncolytic adenovirus is a promising antitumor reagent for the treatment of bone and soft tissue sarcomas. Clin Cancer Res; 17(7); 1828-38. (C) 2011 AACR.

    DOI: 10.1158/1078-0432.CCR-10-2066

    Web of Science

    researchmap

  • Treatment of gastric cancer with situs inversus totalis: a case report

    Journal of Okayama Medical Association   123 ( 1 )   45 - 48   2011.4

  • 食道GISTの切除例2例の経験

    井筒 将斗, 白川 靖博, 田辺 俊介, 近藤 喜太, 野間 和広, 櫻間 教文, 宇野 太, 永坂 岳司, 香川 俊輔, 繁光 薫, 山辻 知樹, 羽井佐 実, 松岡 順治, 猶本 良夫, 藤原 俊義

    岡山医学会雑誌   123 ( 1 )   74 - 74   2011.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • Stage IVa食道癌の治療方針の検討

    田辺 俊介, 白川 靖博, 井筒 将斗, 近藤 喜太, 野間 和広, 櫻間 教文, 宇野 太, 永坂 岳司, 香川 俊輔, 繁光 薫, 山辻 知樹, 羽井佐 実, 松岡 順治, 猶本 良夫, 藤原 俊義

    岡山医学会雑誌   123 ( 1 )   74 - 74   2011.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • KRAS/BRAF/MSI分類による術前からの大腸癌治療戦略構築の提案

    永坂 岳司, 近藤 喜太, 母里 淑子, 神原 健, 松原 長秀, 田中 紀章, 三嶋 秀行, 藤原 俊義

    日本大腸肛門病学会雑誌   64 ( 4 )   266 - 266   2011.4

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • MicroRNAs as potential target gene in cancer gene therapy of gastrointestinal tumors Reviewed

    Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    EXPERT OPINION ON BIOLOGICAL THERAPY   11 ( 2 )   145 - 155   2011.2

     More details

    Language:English   Publisher:INFORMA HEALTHCARE  

    Introduction: MicroRNA (miRNA) is a small non-coding RNA, which negatively regulates the expression of many target genes, thereby contributing to the modulation of diverse cell fates. Recent advances in molecular biology have revealed the potential role of miRNAs in tumor initiation, progression and metastasis. Aberrant regulation of miRNAs has been frequently reported in a variety of cancers, including gastrointestinal tumors, suggesting that cancer-related miRNAs are promising as novel biomarkers for tumor diagnosis and are potential target genes for cancer gene therapy against gastrointestinal tumors.
    Areas covered: The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21, miR-17-92 cluster) in gastrointestinal tumors. Furthermore, the potential role of miRNAs as novel biomarkers and target genes for cancer gene therapy against gastrointestinal tumors are discussed. We will also outline the potential clinical application of miRNAs for tumor diagnosis and cancer gene therapy against gastrointestinal tumors.
    Expert opinion: Exploration of tumor-related miRNAs would provide important opportunities for the development of novel cancer gene therapies aimed at normalizing the critical miRNAs that are deregulated in gastrointestinal tumors.

    DOI: 10.1517/14712598.2011.542749

    Web of Science

    researchmap

  • 右鎖骨下動脈起始異常と反回神経走行異常を伴う食道癌に対する手術経験

    二萬 英斗, 白川 靖博, 渡邉 伸一郎, 田辺 俊介, 野間 和広, 櫻間 教文, 繁光 薫, 山辻 知樹, 羽井佐 実, 松岡 順治, 猶本 良夫, 藤原 俊義

    岡山医学会雑誌   122 ( 3 )   281 - 281   2010.12

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 大腸ポリペクトミー後の横行結腸穿孔症例に対し、腹腔鏡下手術が有効であった一例

    伏見 卓郎, 近藤 喜太, 母里 淑子, 永坂 岳司, 藤原 俊義

    岡山医学会雑誌   122 ( 3 )   281 - 281   2010.12

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Reviewed International journal

    Kuroda S, Fujiwara T, Shirakawa Y, Yamasaki Y, Yano S, Uno F, Tazawa H, Hashimoto Y, Watanabe Y, Noma K, Urata Y, Kagawa S, Fujiwara T

    Cancer research   70 ( 22 )   9339 - 9348   2010.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The inability to repair DNA double-strand breaks (DSB) leads to radiosensitization, such that ionizing radiation combined with molecular inhibition of cellular DSB processing may greatly affect treatment of human cancer. As a variety of viral products interact with the DNA repair machinery, oncolytic virotherapy may improve the therapeutic window of conventional radiotherapy. Here, we describe the mechanistic basis for synergy of irradiation and OBP-301 (Telomelysin), an attenuated type-5 adenovirus with oncolytic potency that contains the human telomerase reverse transcriptase promoter to regulate viral replication. OBP-301 infection led to E1B55kDa viral protein expression that degraded the complex formed by Mre11, Rad50, and NBS1, which senses DSBs. Subsequently, the phosphorylation of cellular ataxia-telangiectasia mutated protein was inhibited, disrupting the signaling pathway controlling DNA repair. Thus, tumor cells infected with OBP-301 could be rendered sensitive to ionizing radiation. Moreover, by using noninvasive whole-body imaging, we showed that intratumoral injection of OBP-301 followed by regional irradiation induces a substantial antitumor effect, resulting from tumor cell-specific radiosensitization, in an orthotopic human esophageal cancer xenograft model. These results illustrate the potential of combining oncolytic virotherapy and ionizing radiation as a promising strategy in the management of human cancer.

    DOI: 10.1158/0008-5472.CAN-10-2333

    PubMed

    researchmap

  • 食道原発小細胞癌の一治療例

    井筒 将斗, 白川 靖博, 田辺 俊介, 野間 和広, 櫻間 教文, 山辻 知樹, 羽井佐 実, 猶本 良夫, 藤原 俊義

    日本臨床外科学会雑誌   71 ( 増刊 )   956 - 956   2010.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • クリニカルパスを用いた食道癌患者周術期管理 術後離床状況に着目して

    田辺 俊介, 白川 靖博, 足羽 孝子, 伊藤 真理, 野間 和広, 櫻間 教文, 山辻 知樹, 羽井佐 実, 猶本 良夫, 藤原 俊義

    日本臨床外科学会雑誌   71 ( 増刊 )   736 - 736   2010.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 5つのモノヌクレオチドマーカーを用いたPentaplex PCR法のミスマッチ修復タンパク欠損大腸癌に対するスクリーニング効果

    永坂 岳司, 白川 靖博, 中谷 紳, 松原 長秀, 藤原 俊義

    日本大腸肛門病学会雑誌   63 ( 9 )   641 - 641   2010.9

     More details

    Language:Japanese   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • The 2009 Okayama Medical Association Awards: Analysis of fecal DNA methylation to detect gastrointestinal neoplasia

    Journal of Okayama Medical Association   122 ( 2 )   107 - 112   2010.8

  • 食道疾患に対する前向き比較試験、多施設研究、全国登録報告 パラチノースを糖質源とした調整流動食MHN-01を用いた食道癌周術期管理の有用性

    山辻 知樹, 田辺 俊介, 藤原 康宏, 野間 和広, 櫻間 教文, 白川 靖博, 繁光 薫, 藤原 俊義, 羽井佐 実, 猶本 良夫

    日本食道学会学術集会プログラム・抄録集   64回   95 - 95   2010.8

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 当科における食道憩室手術症例の報告

    田辺 俊介, 藤原 裕子, 近藤 喜太, 藤原 康宏, 野間 和広, 櫻間 教文, 宇野 太, 永坂 岳司, 香川 俊輔, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 羽井佐 実, 松岡 順治, 猶本 良夫

    岡山医学会雑誌   122 ( 2 )   180 - 180   2010.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 再発食道癌の診断と治療におけるPET-CTの意義

    山辻 知樹, 田辺 俊介, 藤原 康宏, 野間 和広, 櫻間 教文, 繁光 薫, 白川 靖博, 羽井佐 実, 藤原 俊義, 猶本 良夫

    日本食道学会学術集会プログラム・抄録集   64回   180 - 180   2010.8

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道再建術・吻合法の工夫 小腸間置による胃機能温存食道切除術Gastric function preserving esophagectomy:GPE

    猶本 良夫, 山田 英司, 田辺 俊介, 藤原 康宏, 野間 和広, 白川 靖博, 繁光 薫, 山辻 知樹, 羽井佐 実, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   64回   108 - 108   2010.8

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 当科におけるStage4a食道癌の治療方針の検討

    田辺 俊介, 白川 靖博, 渡邉 伸一郎, 野間 和広, 櫻間 教文, 繁光 薫, 山辻 知樹, 羽井佐 実, 猶本 良夫, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   64回   230 - 230   2010.8

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌患者におけるクリニカルパスを用いた術前オリエンテーション効果と術後離床状況

    伊藤 真理, 足羽 孝子, 田辺 俊介, 白川 靖博, 渡邉 伸一郎, 野間 和広, 櫻間 教文, 山辻 知樹, 猶本 良夫, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   64回   199 - 199   2010.8

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • Lynch症候群大腸癌とMSH2メチル化(Somatic hypermethylation of MSH2 is a frequent event in lynch syndrome colorectal cancers)

    永坂 岳司, 田中 紀章, 松原 長秀, 藤原 俊義

    日本癌学会総会記事   69回   351 - 351   2010.8

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • パラチノースを糖質源とした調整流動食MHN-01による周術期管理 基礎実験から臨床試験まで

    山辻 知樹, 田辺 俊介, 藤原 康宏, 野間 和広, 櫻間 教文, 白川 靖博, 藤原 俊義, 八木 孝仁, 羽井佐 実, 猶本 良夫

    日本消化器外科学会総会   65回   798 - 798   2010.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. Reviewed

    Kojima T, Watanabe Y, Hashimoto Y, Kuroda S, Yamasaki Y, Yano S, Ouchi M, Tazawa H, Uno F, Kagawa S, Kyo S, Mizuguchi H, Urata Y, Tanaka N, Fujiwara T

    Annals of surgery   251 ( 6 )   1079 - 1086   2010.6

  • 当科における食道癌を含む三重複癌の検討

    井筒 将斗, 田辺 俊介, 藤原 康宏, 野間 和広, 櫻間 教文, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 貞森 裕, 八木 孝仁, 松岡 順治, 猶本 良夫

    岡山医学会雑誌   122 ( 1 )   90 - 90   2010.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 当科における食道憩室切除症例の検討 Reviewed

    山辻 知樹, 山田 英司, 西谷 正史, 大原 利章, 田辺 俊介, 藤原 康宏, 野間 和広, 櫻間 一史, 高岡 宗徳, 白川 靖博, 貞森 裕, 小林 直哉, 藤原 俊義, 八木 孝仁, 羽井佐 実, 松岡 順治, 猶本 良夫

    日本外科学会雑誌   111 ( 臨増2 )   582 - 582   2010.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 腹腔鏡補助下胃切除術における術野展開の工夫

    香川 俊輔, 宇野 太, 合地 明, 小林 直哉, 山辻 知樹, 白川 靖博, 永坂 岳司, 野間 和広, 藤原 康宏, 田辺 俊介, 近藤 喜太, 猶本 良夫, 藤原 俊義

    日本内視鏡外科学会雑誌   14 ( 7 )   562 - 562   2009.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 当院における内視鏡的胃瘻造設の現況

    田辺 俊介, 白川 靖博, 近藤 喜太, 藤原 康宏, 野間 和広, 宇野 太, 永坂 岳司, 香川 俊輔, 山辻 知樹, 小林 直哉, 藤原 俊義, 内藤 稔, 猶本 良夫

    岡山医学会雑誌   121 ( 3 )   230 - 231   2009.12

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 分子標的治療薬に伴うOncologic Emergencyに対する外科手術の適応

    山辻 知樹, 田辺 俊介, 藤原 康宏, 野間 和広, 櫻間 一史, 高岡 宗徳, 白川 靖博, 小林 直哉, 藤原 俊義, 松岡 順治, 羽井佐 実

    日本臨床外科学会雑誌   70 ( 増刊 )   658 - 658   2009.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • Bevacizumab化学療法により回腸-腸骨動脈瘻を来たした大腸癌腹膜播種再発の1例

    藤原 康宏, 猶本 良夫, 田辺 俊介, 櫻間 一史, 野間 和広, 元木 崇之, 永坂 岳志, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 羽井佐 実, 松岡 順治, 田中 紀章

    日本消化器病学会雑誌   106 ( 臨増大会 )   A857 - A857   2009.9

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  • ゲノム研究が切り開く肺がんの新たな予防・治療戦略 肺癌に対する遺伝子およびベクターを用いた分子治療(Novel therapeutic and preventive strategies blazed by genome research on lung cancer Gene and Vector-based Molecular Therapy for Lung Cancer)

    香川 俊輔, 黒田 新士, 宇野 太, 田澤 大, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   68回   56 - 56   2009.8

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道原発小細胞癌の一治療例の報告

    田辺 俊介, 猶本 良夫, 近藤 喜太, 藤原 康宏, 野間 和広, 櫻間 一史, 高岡 宗徳, 宇野 太, 永坂 岳司, 香川 俊輔, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松岡 順治, 田中 紀章, 羽井佐 実

    岡山医学会雑誌   121 ( 2 )   132 - 132   2009.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 進行再発大腸癌に対するセツキシマブの治療経験

    藤原 康宏, 猶本 良夫, 近藤 喜太, 田辺 俊介, 桜間 一史, 野間 和広, 高岡 宗徳, 宇野 太, 永坂 岳司, 香川 俊輔, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松岡 順治, 田中 紀章, 羽井佐 実

    岡山医学会雑誌   121 ( 2 )   133 - 133   2009.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 当科におけるバレット食道癌症例の検討

    野間 和広, 猶本 良夫, 田辺 俊介, 近藤 喜太, 藤原 康宏, 櫻間 一史, 高岡 宗徳, 宇野 太, 永坂 岳司, 香川 俊輔, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松岡 順治, 田中 紀章, 羽井佐 実

    岡山医学会雑誌   121 ( 2 )   133 - 133   2009.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • テロメラーゼ依存的制限増殖型GFP発現アデノウイルスによる末梢血中ヒト循環がん細胞の検出(A simple biological imaging method for detection of viable human circulating tumor cells in the blood)

    橋本 悠里, 児島 亨, 宇野 太, 香川 俊輔, 渡邉 雄一, 黒田 新士, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   68回   244 - 244   2009.8

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • オーバーチューブによる頸部食道穿孔に対して手術を施行した2症例の検討

    田辺 俊介, 猶本 良夫, 西谷 正史, 近藤 喜太, 藤原 康宏, 野間 和広, 櫻間 一史, 高岡 宗徳, 宇野 太, 香川 俊輔, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 羽井佐 実, 松岡 順治, 田中 紀章

    岡山医学会雑誌   121 ( 1 )   65 - 66   2009.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 当科における胃機能温存食道切除再建術の工夫

    野間 和広, 藤原 康宏, 田辺 俊介, 猶本 良夫, 西谷 正史, 近藤 喜太, 櫻間 一史, 高岡 宗徳, 宇野 太, 香川 俊輔, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 羽井佐 実, 松岡 順治, 田中 紀章

    岡山医学会雑誌   121 ( 1 )   66 - 66   2009.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 分子標的薬治療中のOncologic emergencyに対する対応

    山辻 知樹, 猶本 良夫, 西谷 正史, 田辺 俊介, 近藤 喜太, 藤原 康宏, 野間 和広, 櫻間 一史, 高岡 宗徳, 宇野 太, 香川 俊輔, 白川 靖博, 小林 直哉, 藤原 俊義, 松原 長秀, 松岡 順治, 田中 紀章

    岡山医学会雑誌   121 ( 1 )   65 - 65   2009.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • イマチニブ抵抗性GISTに対するスニチニブの使用経験

    藤原 康宏, 田辺 俊介, 猶本 良夫, 西谷 正史, 近藤 喜太, 野間 和広, 櫻間 一史, 高岡 宗徳, 宇野 太, 香川 俊輔, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 松岡 順治, 田中 紀章

    岡山医学会雑誌   121 ( 1 )   64 - 64   2009.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 食道原発悪性黒色腫 長期生存症例の検討

    山辻 知樹, 猶本 良夫, 田辺 俊介, 藤原 康宏, 櫻間 一史, 野間 和広, 高岡 宗徳, 元木 崇之, 白川 靖博, 藤原 俊義, 小林 直哉, 松原 長秀, 松岡 順治, 羽井佐 実, 田中 紀章

    日本臨床外科学会雑誌   69 ( 増刊 )   359 - 359   2008.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • テロメアーゼ特異的制限増殖型アデノウイルスによる末梢血中ヒトがん細胞検出方法の開発(A three-step simple imaging method to detect viable human circulating tumor cells in the peripheral blood)

    橋本 悠里, 児島 亨, 渡邉 雄一, 黒田 新士, 宇野 太, 香川 俊輔, 水口 裕之, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   67回   486 - 486   2008.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 肺癌細胞株に対するテロメラーゼ特異的腫瘍溶解性アデノウイルス製剤とゲムシタビンの併用効果の検討(Preclinical study of multidisciplinary approach with telomerase-specific virotherapy and gemcitabine for lung cancer)

    大内 正明, 劉 東, 児島 亨, 黒田 新士, 橋本 悠里, 鬼松 秀樹, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   67回   72 - 72   2008.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 当院における早期胃癌に対する腹腔鏡補助下胃切除術と開腹胃切除術との比較検討

    香川 俊輔, 宇野 太, 合地 明, 松原 長秀, 小林 直哉, 山辻 知樹, 白川 靖博, 藤原 康宏, 近藤 喜太, 田辺 俊介, 猶本 良夫, 藤原 俊義, 田中 紀章

    日本内視鏡外科学会雑誌   13 ( 7 )   232 - 232   2008.9

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • テロメラーゼ依存性腫瘍融解アデノウイルスによる放射線感受性増強 E1B55kDaによるATMリン酸化阻害(Radiosensitization by telomerase-specific oncolytic adenovirus via E1B 55kDa-mediated inhibition of ATM phosphorylation)

    黒田 新士, 藤原 俊哉, 矢野 修也, 山崎 泰源, 児島 亨, 宇野 太, 香川 俊輔, 田澤 大, 橋本 悠里, 大内 正明, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   67回   90 - 90   2008.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 胃癌幹細胞に対する新規治療 テロメラーゼ特異的腫瘍融解ウイルス治療(A Novel Telomerase-Specific Oncolytic Virotherapy Targeting Human Gastric Cancer Stem Cells)

    矢野 修也, 橋本 悠里, 山崎 泰源, 黒田 新士, 児島 亨, 田澤 大, 宇野 太, 香川 俊輔, 大内 正明, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   67回   73 - 74   2008.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • テロメラーゼ特異的腫瘍融解ウイルスによる大腸がんモデルにおけるリンパ節内転移癌細胞の粛清効果の検討(In vivo Purging of Lymph Node Metastasis by Telomerase-Specific Virotherapy in an Orthotopic Colorectal Cancer Model)

    児島 亨, 渡辺 雄一, 橋本 悠里, 黒田 新士, 宇野 太, 大川 俊輔, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   67回   420 - 420   2008.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • テロメラーゼ依存性腫瘍融解ウイルスの抗腫瘍活性における抗がん剤併用の相乗効果(Preclinical study of telomerase-selective oncolytic adenovirus in combination with chemotherapeutic agents)

    田澤 大, 橋本 悠里, 黒田 新士, 浦田 泰生, 藤原 俊義

    日本癌学会総会記事   67回   239 - 239   2008.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道癌化学療法中にウェルニッケ脳症を発症した1例

    藤原 康宏, 猶本 良夫, 田辺 俊介, 近藤 喜太, 河本 洋伸, 元木 崇之, 宇野 太, 香川 俊輔, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 松岡 順治, 田中 紀章

    岡山医学会雑誌   120 ( 2 )   241 - 241   2008.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 当科における食道類基底細胞癌切除症例の検討

    田辺 俊介, 猶本 良夫, 近藤 喜太, 河本 洋伸, 藤原 康宏, 櫻間 一史, 宇野 太, 高岡 宗徳, 香川 俊輔, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 羽井佐 実, 松岡 順治, 田中 紀章

    岡山医学会雑誌   120 ( 2 )   241 - 241   2008.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • EUS-FNA後の出血により緊急手術を行った胃GISTの1例

    藤 智和, 猶本 良夫, 田邊 俊介, 近藤 喜太, 藤原 康宏, 吉田 亮介, 野間 和広, 櫻間 一史, 宇野 太, 香川 俊輔, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 松岡 順治, 田中 紀章

    岡山医学会雑誌   120 ( 2 )   249 - 250   2008.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 気管合併切除を行い遺残なく切除し得た頸部食道癌の1例

    田辺 俊介, 猶本 良夫, 藤原 康宏, 櫻間 一史, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 羽井佐 実, 松岡 順治, 田中 紀章

    岡山医学会雑誌   120 ( 1 )   111 - 111   2008.5

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • ESD後急激にリンパ節転移が増大した食道表在癌の1例

    白川 靖博, 猶本 良夫, 田辺 俊介, 藤原 康宏, 櫻間 一史, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 羽井佐 実, 松岡 順治, 田中 紀章

    岡山医学会雑誌   120 ( 1 )   111 - 111   2008.5

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 術前に鑑別診断が困難であった空腸癌の1切除例

    櫻間 一史, 猶本 良夫, 田辺 俊介, 藤原 康宏, 高岡 宗徳, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 岩垣 博巳, 松岡 順治, 平松 聡, 田中 紀章

    岡山医学会雑誌   119 ( 3 )   339 - 339   2008.1

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 食道癌術後に発生した肺小細胞癌の2例

    高岡 宗徳, 猶本 良夫, 田辺 俊介, 桜間 一史, 藤原 康宏, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 岩垣 博巳, 松岡 順治, 羽井佐 実, 田中 紀章

    岡山医学会雑誌   119 ( 3 )   337 - 337   2008.1

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 大腿骨軟骨肉腫術後の巨大腹壁ヘルニア内に発生した大腸癌の1例

    田辺 俊介, 猶本 良夫, 桜間 一史, 藤原 康宏, 高岡 宗徳, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 岩垣 博巳, 松岡 順治, 羽井佐 実, 田中 紀章

    岡山医学会雑誌   119 ( 3 )   340 - 340   2008.1

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 食道癌術前診断におけるPET/CTの有用性ならびに術後病理組織診断との整合性についての検討

    田辺 俊介, 猶本 良夫, 藤原 康宏, 櫻間 一史, 高岡 宗徳, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 羽井佐 実, 松岡 順治, 田中 紀章

    日本臨床外科学会雑誌   68 ( 増刊 )   437 - 437   2007.11

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • テロメラーゼ依存性腫瘍融解ウイルス療法と放射線療法の相互増感作用(Mutual sensitization with telomerase-specific oncolytic virotherapy and ionizing radiation in antitumor activity)

    黒田 新士, 藤原 俊哉, 児島 亨, 渡邊 雄一, 橋本 悠里, 宇野 太, 香川 俊輔, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   66回   385 - 385   2007.8

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • リンパ節微小転移を標的としたテロメラーゼ依存性腫瘍融解ウイルス療法(Telomerase-specific virotherapy targeting lymph node micrometastasis of human cancer)

    児島 亨, 渡辺 雄一, 橋本 悠里, 黒田 新士, 宇野 太, 香川 俊輔, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   66回   91 - 91   2007.8

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 食道癌化学療法後骨髄異形成症候群の検討

    田辺 俊介, 猶本 良夫, 藤原 康宏, 高岡 宗徳, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 岩垣 博巳, 松岡 順治, 羽井佐 実, 田中 紀章

    岡山医学会雑誌   119 ( 1 )   99 - 99   2007.5

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • G-CSF産生食道癌の1例

    高岡 宗徳, 猶本 良夫, 田辺 俊介, 藤原 康宏, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 岩垣 博巳, 松岡 順治, 羽井佐 実, 田中 紀章

    岡山医学会雑誌   119 ( 1 )   99 - 99   2007.5

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 食道癌と甲状腺癌同時切除例の検討

    藤原 康宏, 猶本 良夫, 田辺 俊介, 高岡 宗徳, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 岩垣 博巳, 松岡 順治, 羽井佐 実, 田中 紀章

    岡山医学会雑誌   119 ( 1 )   99 - 99   2007.5

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • テロメラーゼ特異的GFP発現ナノバイオ・ウイルス製剤(OBP-401)を用いた微小癌組織のin vivoイメージング・システム

    児島 亨, 藤原 俊義, 岸本 浩行, 橋本 悠里, 香川 俊輔, 宇野 太, 浦田 泰生, 田中 紀章

    日本癌学会総会記事   65回   258 - 258   2006.9

     More details

    Language:Japanese   Publisher:(一社)日本癌学会  

    researchmap

  • テロメラーゼ依存性GFP蛍光発現ウイルス製剤OBP-401を用いた微小癌組織ナビゲーション・システムの開発

    藤原 俊義, 岸本 浩行, 香川 俊輔, 宇野 太, 田中 紀章, 河村 仁, 浦田 泰生

    日本癌治療学会誌   40 ( 2 )   350 - 350   2005.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 抗癌剤耐性細胞におけるテロメラーゼ特異的制限増殖型アデノウイルスTelomelysin(OBP-301)の抗腫瘍効果の検討

    藤原 俊哉, 藤原 俊義, 香川 俊輔, 岸本 浩行, 遠藤 芳克, 酒井 亮, 日置 勝義, 池田 義博, 浦田 泰生, 田中 紀章

    日本癌学会総会記事   64回   434 - 434   2005.9

     More details

    Language:Japanese   Publisher:(一社)日本癌学会  

    researchmap

  • テロメラーゼ特異的腫瘍融解アデノウイルス(Telomelysin:OBP301)新たな抗腫瘍分子機構 腫瘍免疫系への影響の解析

    遠藤 芳克, 徳永 尚之, 池田 義博, 酒井 亮, 日置 勝義, 岸本 浩行, 藤原 俊哉, 香川 俊輔, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   64回   484 - 484   2005.9

     More details

    Language:Japanese   Publisher:(一社)日本癌学会  

    researchmap

  • がん特異的増殖可能アデノウイルス製剤OBP-401を用いた生体内癌組織診断 がん特異的GFP蛍光イメージング技術の開発

    岸本 浩行, 香川 俊輔, 藤原 俊哉, 遠藤 芳克, 池田 義博, 日置 義勝, 酒井 亮, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   64回   447 - 448   2005.9

     More details

    Language:Japanese   Publisher:(一社)日本癌学会  

    researchmap

  • 食道癌縦隔再発に対するラジオ波焼灼術

    浅海 信也, 猶本 良夫, 櫻間 一史, 野間 和広, 白川 靖博, 山辻 知樹, 藤原 俊義, 松原 長秀, 羽井佐 実, 岩垣 博巳, 田中 紀章, 花崎 元彦, 多賀 直行, 中塚 秀輝, 森田 潔, 郷原 英夫, 三村 秀文, 金澤 右

    岡山医学会雑誌   116 ( 3 )   318 - 318   2005.1

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • HDAC阻害剤FR901228によるテロメラーゼ特異的制限増殖型アデノウイルスTelomelysinの選択的抗腫瘍効果の増強

    渡邉 貴紀, 西崎 正彦, 香川 俊輔, 滝 正樹, 岸本 浩行, 藤原 俊哉, 遠藤 芳克, 京 哲, 水口 裕之, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   63回   499 - 499   2004.9

     More details

    Language:Japanese   Publisher:(一社)日本癌学会  

    researchmap

  • GFP発現テロメラーゼ特異的制限増殖型ウイルスTelomelysin-GFPを用いた腫瘍組織ナビゲーション・システム

    岸本 浩行, 香川 俊輔, 滝 正樹, 藤原 俊哉, 渡辺 貴紀, 遠藤 芳克, 京 哲, 水口 裕之, 田中 紀章, 藤原 俊義

    日本癌学会総会記事   63回   454 - 454   2004.9

     More details

    Language:Japanese   Publisher:(一社)日本癌学会  

    researchmap

  • 制限増殖型アデノウイルスによる非増殖型p53遺伝子発現アデノウイルスベクター(Ad5CMV-p53)の腫瘍選択的増殖

    谷本 光隆, 藤原 俊義, 高田 佳子, 大谷 彰一郎, 川嶋 健, 香川 俊輔, 西崎 正彦, 田中 紀章

    日本癌学会総会記事   61回   187 - 187   2002.10

     More details

    Language:Japanese   Publisher:(一社)日本癌学会  

    researchmap

  • G162 Vanishing Lungを呈し、手術にて軽快した高IgE症候群の1治験例(胸腔鏡c,示説,第14回日本呼吸器外科学会総会号)

    井上 文之, 舟木 直人, 藤原 俊義, 上川 康明, 田中 紀章

    日本呼吸器外科学会雑誌   11 ( 3 )   453 - 453   1997

     More details

    Language:Japanese   Publisher:特定非営利活動法人 日本呼吸器外科学会  

    DOI: 10.2995/jacsurg.11.453_2

    CiNii Article

    researchmap

▼display all

Books

  • 希少がん:がん診療の新たな課題

    日本臨床社  2021 

     More details

  • よくわかるがん免疫療法ガイドブック

    金原出版  2020 

     More details

  • いま、本格化する遺伝子治療(実験医学 増刊)

    羊土社  2020 

     More details

  • 消化器外科専門医の心得

    一般社団法人 日本消化器外科学会  2020 

     More details

  • 分子細胞治療フロンティア2020

    飯田橋パピルス  2020 

     More details

  • 入門 腫瘍内科学(改訂第3版)

    南江堂  2020 

     More details

  • 別冊・医学の歩み 遺伝子治療の新局面

    医歯薬出版株式会社  2019 

     More details

  • 消化管吻合法バイブル

    医学書院  2018 

     More details

  • 次世代がん治療

    エヌ・ティー・エス  2017 

     More details

  • 次世代のがん治療薬・診断のための研究開発~免疫療法・遺伝子治療・がん幹細胞~

    技術情報協会  2016 

     More details

  • 新人ナースのための消化器外科 術前術後ケアQ&A102

    メディカ出版  2016 

     More details

  • Current Strategies in Cancer Gene Therapy

    Springer International Publishing  2016 

     More details

  • Advances inMedicine and Biology. Vol.110

    Nova Publishers, Inc.  2016 

     More details

  • 今,着実に実り始めた遺伝子治療 - 最新研究と今後の展開

    株式会社メディカルドゥ  2016 

     More details

  • 消化器外科学レビュー2015-’16

    総合医学社  2015 

     More details

  • LECS−イラストと写真で見る内視鏡医と外科医のコラボレーション手術

    メジカルビュー社  2015 

     More details

  • 分子細胞治療フロンティア2015

    株式会社パピルス  2014 

     More details

  • 消化器病診療(第2版)

    医学書院  2014 

     More details

  • 肝移植後グラフト機能不全/アルコール性肝不全の肝移植適応<第10回伊豆肝臓カンファレンス記録>

    株式会社アークメディア  2014 

     More details

  • Gene Therapy: Technologies & Applications

    Future Medicine Ltd  2013 

     More details

  • OGS NOW

    メジカルビュー社  2013 

     More details

  • Gene Therapy of Cancer, 3rd Edition

    Academic Press  2013 

     More details

  • Hemodynamics: Monitoring, Theory and Applications

    Nova science publishers, Inc.  2013 

     More details

  • OGS NOW

    メジカルビュー社  2013 

     More details

  • Tumor Suppressor Genes: Functions, Regulation and Health Effects

    Nova science publishers, Inc.  2013 

     More details

  • 消化器外科学レビュー2012

    総合医学社  2012 

     More details

  • Liver Transplantation

    INTEC  2012 

     More details

  • In Vivo Vellular Imaging Using Fluorescent Proteins

    Human Press, c/o Springer Science+Business Media  2012 

     More details

  • 新臨床腫瘍学 改訂第3版

    南江堂  2012 

     More details

  • 示唆に富む肝移植症例の総合討論 / 第7回 伊豆肝臓カンファレンス記録

    アークメディア  2012 

     More details

  • Telomeres and Telomerase in Cancer

    Humana Press  2009 

     More details

  • 別冊・医学の歩み 呼吸器疾患 -State of arts

    医歯薬出版株式会社,東京  2007 

     More details

  • 呼吸器commondiseaseの診療:肺癌のすべて

    文光堂  2006 

     More details

  • 新しい診断と治療のABC(最新医学 別冊)

    最新医学社  2005 

     More details

  • プラクティカル内科シリーズ:肺癌 改訂第2版

    南江堂,東京  2003 

     More details

  • 先端医療シリーズ20・癌 肺癌の最新医療

    先端医学社,東京  2003 

     More details

  • 厚生科学研究研究費補助金 ヒトゲノム・再生医療等研究事業 平成13年度総括研究報告書

    2002 

     More details

  • TECHNICAL TERM 緩和医療

    先端医学社,東京  2002 

     More details

  • 平成11年度-平成12年度 科学研究費補助金(基盤研究C2)研究成果報告書

    2002 

     More details

  • 肺癌診療ガイド特集 肺癌の新しい検査と治療

    リノ・メディカル株式会社,東京  2002 

     More details

  • 先端医療シリーズ10・呼吸器疾患-最新医療と21世紀への展望-

    先端医療技術研究所  2001 

     More details

  • 新臨床医のための分子医学シリーズ 遺伝子治療の新展開:ベクター開発と臨床応用の最前線

    羊土社  2001 

     More details

  • p53研究の新たな挑戦

    羊土社  2001 

     More details

  • 実験医学増刊 癌治療の先端に迫る!

    羊土社  2001 

     More details

  • がん治療におけるアポトーシスの応用

    医薬ジャーナル社  2001 

     More details

▼display all

MISC

  • Esophageal reconstruction with free jejunal flap

    野間和広, 野間和広, 田邊俊介, 田邊俊介, 藤原俊義, 藤原俊義, 藤原俊義

    消化器外科   46 ( 2 )   2023

  • 岡山大学消化器外科の大腸がん診療におけるがんゲノムプロファイリング検査の活用

    重安邦俊, 香川俊輔, 寺石文則, 楳田祐三, 岡田尚大, 半澤俊哉, 橋本将志, 垣内慶彦, 松三雄騎, 菊地覚次, 黒田新士, 近藤喜太, 二宮貴一朗, 遠西大輔, 平沢晃, 藤原俊義

    日本遺伝性腫瘍学会学術集会プログラム・抄録集   29th   2023

  • A new subtype of colorectal cancer based of RAS/RAF, micro-satellite status, and mesenchymal type for far-advanced CRC

    矢野修也, 矢野修也, 重安邦俊, 谷岡洋亮, 山崎泰史, 河内麻里子, 平沢晃, 武田正, 香川俊輔, 藤原俊義, 永坂岳司

    日本臨床腫瘍学会学術集会(CD-ROM)   19th   2022

  • 家族性大腸腺腫症における2チームでの経肛門的直腸間膜切除術(Trans anal Total Mesorectal Excision:TaTME)を用いた大腸全摘

    重安邦俊, 武田正, 近藤喜太, 寺石文則, 二川摩周, 加藤芙美乃, 十川麗美, 堀口繁, 香川俊輔, 平沢晃, 藤原俊義

    日本遺伝性腫瘍学会学術集会プログラム・抄録集   28th   2022

  • Elucidation for the mechanism of lymph node metastasis of esophageal squamous cell carcinoma by extracellular vesicles

    木谷嘉孝, 吉岡祐亮, 賀島肇, 野間和広, 田澤大, 田澤大, 藤原俊義, 永川裕一, 落谷孝広

    日本癌学会学術総会抄録集(Web)   81st   2022

  • Minimally invasive approach for gastric tumors depending on the characteristics or location of tumor

    菊地覚次, 西崎正彦, 神崎洋光, 黒田新士, 田辺俊介, 野間和広, 楳田祐三, 岡田裕之, 藤原俊義

    日本消化管学会雑誌(CD-ROM)   6 ( Supplement (CD-ROM) )   2022

  • 患者参加型継続的栄養指導による胃癌術後のサルコペニア予防効果

    菊地覚次, 高田暢夫, 黒田新士, 田辺俊介, 前田直見, 賀島肇, 垣内慶彦, 野間和広, 香川俊輔, 高橋絢子, 楳田祐三, 四方賢一, 四方賢一, 藤原俊義

    日本癌治療学会学術集会(Web)   60th   2022

  • ペムブロリズマブ使用中に下垂体機能低下症と間質性肺炎を発症したが診療科横断的に加療できた高頻度マイクロサテライト不安定性大腸癌の1例

    重安邦俊, 矢野修也, 武田正, 山崎泰史, 河内麻里子, 平沢晃, 香川俊輔, 藤原俊義

    日本臨床腫瘍学会学術集会(CD-ROM)   19th   2022

  • Oncolytic virus-mediated p53 gene therapy enhances anti-tumor immunity against peritoneal metastasis of gastric cancer

    Motoyasu Tabuchi, Satoru Kikuchi, Toshihiro Ogawa, Hiroshi Tazawa, Shinji Kuroda, Kazuhiro Noma, Masahiko Nishizaki, Shunsuke Kagawa, Junko Ohtsuka, Rieko Ohki, Yasuo Urata, Toshiyoshi Fujiwara

    CANCER SCIENCE   112   426 - 426   2021.2

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Oncolytic virus-mediated p53 overexpression interrupts tumor-stromal network in pancreatic tumor microenvironment

    Takeyoshi Nishiyama, Hiroshi Tazawa, Yoshinori Kajiwara, Ryohei Shoji, Satoru Kikuchi, Shinji Kuroda, Kazuhiro Noma, Ryuichi Yoshida, Masahiko Nishizaki, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   112   440 - 440   2021.2

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Gemcitabine-resistant pancreatic ductal adenocarcinoma cells promote immunosuppressive tumor microenvironment

    Yoshinori Kajiwara, Hiroshi Tazawa, Takeyoshi Nishiyama, Ryohei Shoji, Takuro Fushimi, Satoru Kikuchi, Shinji Kuroda, Kazuhiro Noma, Ryuichi Yoshida, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   112   560 - 560   2021.2

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • 消化器系遺伝性腫瘍のスクリーニングとサーベイランスのための早期介入プログラムの構築

    重安邦俊, 武田正, 矢野修也, 二川摩周, 山本英喜, 近藤喜太, 寺石文則, 香川俊輔, 平沢晃, 藤原俊義

    日本外科学会定期学術集会(Web)   121st   2021

  • 進行胆嚢癌に対する外科治療-手術成績を踏まえ,その限界を考える-

    吉田一博, 楳田祐三, 吉田龍一, 杭瀬崇, 安井和也, 高木弘誠, 荒木宏之, 谷悠真, 實金悠, 八木孝仁, 藤原俊義

    日本外科学会定期学術集会(Web)   121st   2021

  • 診療科横断的な遺伝性大腸癌診療体制の構築

    重安邦俊, 武田正, 矢野修也, 二川摩周, 加藤芙美乃, 十川麗美, 山本英喜, 香川俊輔, 平沢晃, 藤原俊義

    日本遺伝性腫瘍学会学術集会プログラム・抄録集   27th   2021

  • BRCA1およびSMAD4に病的バリアントを認めた一家系

    加藤芙美乃, 山本英喜, 山本英喜, 坂井美佳, 坂井美佳, 河内麻里子, 河内麻里子, 二川摩周, 十川麗美, 間森智加, 笹原麻子, 重安邦俊, 香川俊輔, 藤原俊義, 土井原博義, 平沢晃, 平沢晃

    日本遺伝性腫瘍学会学術集会プログラム・抄録集   27th   2021

  • ハイリスク高齢者大腸癌への周術期管理チーム介入による術後アウトカムの変化

    寺石文則, 垣内慶彦, 武田正, 重安邦俊, 矢野修也, 近藤喜太, 香川俊輔, 藤原俊義

    日本外科学会定期学術集会(Web)   121st   2021

  • Treatment for colorectal liver metastasis: evolving paradigms and future perspectives

    楳田祐三, 田澤大, 矢野修也, 重安邦俊, 神崎洋光, 寺石文則, 黒田新士, 香川俊輔, 八木孝仁, 平沢晃, 岡田裕之, 藤原俊義

    日本がん転移学会学術集会・総会プログラム抄録集   30th   2021

  • 高齢者pStageIII大腸癌の予後と転帰から術後化学療法について考察する

    寺石文則, 成田周平, 武田正, 垣内慶彦, 重安邦俊, 矢野修也, 近藤喜太, 野間和広, 楳田祐三, 香川俊輔, 藤原俊義

    大腸癌研究会プログラム・抄録集   95th   2021

  • 局所進行直腸癌に対する術前CAPOX+RT療法の治療成績

    武田正, 寺石文則, 坂本真樹, 重安邦俊, 矢野修也, 近藤喜太, 黒田新士, 香川俊輔, 藤原俊義

    大腸癌研究会プログラム・抄録集   94th   2021

  • 直腸癌の同時性肝転移と肺転移症例における原発巣の臨床病理学的特徴の比較

    重安邦俊, 武田正, 矢野修也, 近藤喜太, 寺石文則, 香川俊輔, 藤原俊義

    大腸癌研究会プログラム・抄録集   94th   2021

  • 再発直腸癌に対する腹腔鏡下骨盤内臓全摘術への蛍光ガイド下手術

    矢野修也, 矢野修也, 近藤喜太, 重安邦俊, 寺石文則, 武田正, 坂本真樹, 菊地覚次, 黒田新士, 香川俊輔, 藤原俊義

    大腸癌研究会プログラム・抄録集   94th   2021

  • ロボット支援下膵頭十二指腸切除術の安全な導入と術式の定型化

    高木弘誠, 楳田祐三, 吉田龍一, 杭瀬崇, 吉田一博, 安井和也, 八木孝仁, 藤原俊義

    日本外科学会定期学術集会(Web)   121st   2021

  • R/BR膵癌術前化学療法施行症例における術直前CA19-9値の意義に関する検討

    安井和也, 吉田龍一, 楳田祐三, 杭瀬崇, 吉田一博, 高木弘誠, 八木孝仁, 藤原俊義

    日本外科学会定期学術集会(Web)   121st   2021

  • 食道癌周術期管理における早期介入の有用性 岡山大学病院におけるPERiOの取り組み

    野間和広, 最所公平, 前田直見, 田辺俊介, 白川靖博, 白川靖博, 藤原俊義

    外科と代謝・栄養   55 ( 4 )   2021

  • p53発現による線維性微小環境の再プログラム化は膵臓癌における腫瘍融解ウイルス療法の治療効果を増強する

    西山岳芳, 田澤大, 田澤大, 梶原義典, 庄司良平, 永井康雄, 菊地覚次, 黒田新士, 黒田新士, 野間和広, 吉田龍一, 西崎正彦, 田中啓祥, 狩野光伸, 浦田泰生, 香川俊輔, 藤原俊義

    日本癌学会学術総会抄録集(Web)   80th   2021

  • 頭頚部癌集学的治療に対する胃瘻を有効に活用した栄養管理確立への道のり

    田辺俊介, 田辺俊介, 今井祥子, 今井祥子, 開原裕子, 開原裕子, 長谷川祐子, 長谷川祐子, 岡野寛子, 岡野寛子, 大木晴美, 大木晴美, 三浦太郎, 三浦太郎, 金聖暎, 金聖暎, 前田直見, 前田直見, 菊地覚次, 菊地覚次, 野間和広, 白川靖博, 四方賢一, 四方賢一, 藤原俊義

    学会誌JSPEN(Web)   3 ( Supplement 1 )   2021

  • 進化する外科マネージメントセンター それぞれの夢を実現するためのキャリアパス支援システム

    菊地 覚次, 黒田 新士, 吉田 龍一, 香川 俊輔, 山根 正修, 小谷 恭弘, 笠原 真悟, 豊岡 伸一, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SP - 8   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 地域枠医師に対する外科専門研修のあり方 充実した地域医療の実現を目指して

    黒田 新士, 吉田 龍一, 池田 宏国, 岡崎 幹生, 大澤 晋, 小谷 恭弘, 山根 正修, 杉本 誠一郎, 菊地 覚次, 安井 和也, 野田 卓男, 笠原 真悟, 豊岡 伸一, 土井原 博義, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SP - 4   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • RNA editing activated by chemoradiation therapy artificially generates neoantigen in colorectal cancer

    小松泰浩, 重安邦俊, 重安邦俊, 武田正, 高橋一剛, 畑七々子, 吉田一博, 矢野修也, 矢野修也, 大原利章, 野間和広, 楳田祐三, 黒田新士, 黒田新士, 近藤喜太, 寺石文則, 寺石文則, 田澤大, 香川俊輔, 香川俊輔, 藤原俊義

    日本癌学会学術総会抄録集(Web)   79th   2020

  • 希少MSI-H大腸癌患者由来組織片を用いたマウスモデル(PDX)による擬似クローン化の試み

    矢野修也, 矢野修也, 重安邦俊, 三村直毅, 岸本浩行, 母里淑子, 黒田新士, 近藤喜太, 寺石文則, 香川俊輔, 平沢晃, 藤原俊義

    日本遺伝性腫瘍学会学術集会プログラム・抄録集   26th   2020

  • ペムブロリズマブ使用中に下垂体機能低下症を来たしステロイド投与が著効した高頻度マイクロサテライト不安定性大腸癌の1例

    重安邦俊, 岸本浩行, 母里淑子, 武田正, 矢野修也, 黒田新士, 近藤喜太, 寺石文則, 香川俊輔, 平沢晃, 藤原俊義

    日本遺伝性腫瘍学会学術集会プログラム・抄録集   26th   2020

  • Reversible EMT-MET biosensor-mediated imaging visualizes inducible resistance to chemotherapy with hybrid E/M phase

    三村直毅, 矢野修也, 矢野修也, 田澤大, 家田偉史, 岡林大樹, 重安邦俊, 重安邦俊, 武田正, 吉田一博, 寺石文則, 寺石文則, 楳田祐三, 香川俊輔, 香川俊輔, 藤原俊義

    日本癌学会学術総会抄録集(Web)   79th   2020

  • Perspective and prospective of RNA editing in colorectal cancer microenvironme

    武田正, 重安邦俊, 重安邦俊, 小松泰浩, 高橋一剛, 畑七々子, 吉田一博, 矢野修也, 矢野修也, 近藤喜太, 寺石文則, 寺石文則, 楳田祐三, 田澤大, 香川俊輔, 香川俊輔, 藤原俊義

    日本癌学会学術総会抄録集(Web)   79th   2020

  • Development of novel photoimmunotherapy targeting cancer associated fibroblasts.

    小林照貴, 野間和広, 河崎健人, 赤井正明, 西脇紀之, 大原利章, 田澤大, 藤原俊義

    日本癌学会学術総会抄録集(Web)   79th   2020

  • 癌微小環境が引き起こす腫瘍免疫抑制の解明“Drug repositioning′′による免疫応答賦活化の可能性

    西脇紀之, 野間和広, 赤井正明, 小林照貴, 鳴坂徹, 河本慧, 加藤卓也, 前田直見, 田辺俊介, 大原利章, 田澤大, 白川靖博, 藤原俊義

    日本外科学会定期学術集会(Web)   120th   2020

  • 新世代の外科医の苦悩と挑戦

    西脇紀之, 野間和広, 赤井正明, 小林照貴, 鳴坂徹, 河本慧, 大原利章, 田澤大, 藤原俊義

    日本外科学会定期学術集会(Web)   120th   2020

  • Fibroblast activation protein-α(FAP)を標的とした癌関連線維芽細胞(CAFs)に対する光免疫療法~Sunrise of targeting tumor microenvironment therapy~

    小林照貴, 野間和広, 赤井正明, 西脇紀之, 鳴坂徹, 河本慧, 前田直見, 大原利章, 田辺俊介, 田澤大, 白川靖博, 藤原俊義

    日本外科学会定期学術集会(Web)   120th   2020

  • Interplay between gastric cancer subtypes and cancer-associated fibroblasts

    李云成, 田澤大, 野間和広, 大原利章, 黒田新士, 黒田新士, 菊地覚次, 菊地覚次, 香川俊輔, 香川俊輔, 藤原俊義

    日本癌学会学術総会抄録集(Web)   79th   2020

  • Overcoming cancer-associated fibroblasts induced immunosuppression by blocking IL-6-Exploring for Drug Repositioning-

    西脇紀之, 野間和広, 大原利章, 小林照貴, 菊地覚次, 菊地覚次, 田澤大, 藤原俊義

    日本癌学会学術総会抄録集(Web)   79th   2020

  • The Six National University Consortium in Liver Transplant Professionals Training Program (SNUC-LT Program) in Japan: Experiences as a trainee

    高木弘誠, 杭瀬崇, 楳田祐三, 藤原俊義, 八木孝仁

    移植(Web)   55 ( 4 )   2020

  • 鼠径ヘルニア術後の難治性疼痛およびACNESに対する神経切離術の経験

    近藤喜太, 垣内慶彦, 矢野修也, 武田正, 重安邦俊, 菊地覚次, 黒田新士, 寺石文則, 香川俊輔, 藤原俊義

    日本ヘルニア学会学術集会抄録集(CD-ROM)   18th   2020

  • CDDP+VP-16療法を根治術後に施行し長期無再発生存している十二指腸乳頭部MANECの1例

    谷悠真, 杭瀬崇, 堀口繁, 實金悠, 荒木宏之, 高木弘誠, 安井和也, 吉田一博, 吉田龍一, 楳田祐三, 八木孝仁, 藤原俊義

    日本癌治療学会学術集会(Web)   58th   2020

  • 局所進行切除不能膵癌conversion surgeryにおける結腸動脈を用いた肝動脈再建

    吉田龍一, 楳田祐三, 杭瀬崇, 吉田一博, 安井和也, 高木弘誠, 荒木宏之, 八木孝仁, 藤原俊義

    日本膵切研究会プログラム・抄録集   47th   2020

  • 胃が使用不可能な場合の空腸を用いた食道再建の工夫

    白川靖博, 野間和広, 前田直見, 田辺俊介, 櫻間教文, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   73rd   2020

  • A novel photoimmunotherapy for cancer cells and cancer-associated-fibroblasts

    小林照貴, 野間和広, 大原利章, 河崎健人, 赤井正明, 西脇紀之, 前田直見, 菊地覚次, 矢野修也, 田辺俊介, 田澤大, 白川靖博, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   31st   2020

  • 食道癌根治手術10年後に発症した肝転移を伴うStageIV胃管癌の一治療例

    田辺俊介, 野間和広, 前田直見, 白川靖博, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   73rd   2020

  • 生体肝移植後に発症した食道癌の一治療例

    田辺俊介, 野間和広, 前田直見, 白川靖博, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   73rd   2020

  • 食道癌手術における臨床応用解剖実習の現状と展望

    前田直見, 白川靖博, 田辺俊介, 野間和広, 櫻間教文, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   73rd   2020

  • 保存的に治癒し得た食道癌胸骨後経路再建術後に発症した胃管気管瘻の一例

    西村星多郎, 白川靖博, 菅野令子, 光井恵麻, 國友知義, 前田直見, 田邊俊介, 野間和広, 櫻間教文, 藤原俊義

    日本臨床外科学会雑誌   81   2020

  • T4bに対する導入DCF-RT療法~高い局所制御率とその課題~

    橋本将志, 白川靖博, 前田直見, 田邊俊介, 櫻間教文, 野間和広, 西崎正彦, 勝井邦彰, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   74th   2020

  • 再手術症例から学ぶ形成外科的手技を用いた合併症回避のための術式の工夫

    松本洋, 太田智之, 川本幸司, 木股敬裕, 白川靖博, 野間和広, 田邊俊介, 前田直見, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   74th   2020

  • 食道胃接合部癌の術式選択

    野間和広, 白川靖博, 白川靖博, 藤原俊義

    日本消化器外科学会雑誌(Web)   53 ( Supplement2 )   2020

  • Activation of AZIN1 RNA editing facilitates and promotes invasive potential of cancer associated fibroblasts in colorectal cancer

    Sho Takeda, Kunitoshi Shigeyasu, Yoshinaga Okugawa, Kazuhiro Yoshida, Yoshiko Mori, Shuya Yano, Kazuhiro Noma, Yuzo Umeda, Yoshitaka Kondo, Hiroyuki Kishimoto, Fuminori Teraishi, Hiroshi Tazawa, Shunsuke Kagawa, Ajay Goel, Toshiyoshi Fujiwara

    CANCER RESEARCH   79 ( 13 )   2019.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.SABCS18-4330

    Web of Science

    researchmap

  • Overcoming resistance of conventional therapies by targeting cancer-associated fibroblasts (CAFs) with near-infrared photoimmunotherapy (NIR-PIT)

    Satoshi Komoto, Kazuhiro Noma, Ryoichi Katsube, Takuya Kato, Toshiaki Ohara, Hiroaki Sato, Toru Narusaka, Noriyuki Nisiwaki, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   79 ( 13 )   2019.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2019-LB-310

    Web of Science

    researchmap

  • Boosting replication and penetration of telomerase-specific replicative virus by paclitaxel induces synthetic lethality in peritoneal metastasis of gastric cancer

    Toshihiro Ogawa, Satoru Kikuchi, Wataru Ishikawa, Hiroshi Tazawa, Motoyasu Tabuchi, Shinji Kuroda, Kazuhiro Noma, Masahiko Nishizaki, Shunsuke Kagawa, Yasuo Urata, Toshiyoshi Fujiwara

    CANCER RESEARCH   79 ( 13 )   2019.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.SABCS18-2979

    Web of Science

    researchmap

  • Sternness control by iron chelator is a novel therapeutic strategy for esophageal cancer

    Toru Narusaka, Toshiaki Ohara, Kazuhiro Noma, Yuki Katsura, Noriyuki Nishiwaki, Motoyasu Tabuchi, Takuro Fushimi, Toshihiro Ogawa, Sho Takeda, Satoshi Komoto, Hiroaki Sato, Satoru Kikuchi, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   79 ( 13 )   2019.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2019-1155

    Web of Science

    researchmap

  • Endoscopic intratumoral injection of OBP-301 (telomelysin) with radiotherapy in esophageal cancer patients unfit for standard treatments.

    Shunsuke Tanabe, Hiroshi Tazawa, Nobuhiko Kanaya, Kazuhiro Noma, Shunsuke Kagawa, Shinji Kuroda, Yasuo Urata, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    JOURNAL OF CLINICAL ONCOLOGY   37 ( 4 )   2019.2

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2019.37.4_suppl.130

    Web of Science

    researchmap

  • RNA編集とマイクロサテライト不安定性の関連および免疫療法に与える影響について

    重安邦俊, 武田正, 小松泰浩, 母里淑子, 矢野修也, 近藤喜太, 寺石文則, 香川俊輔, 藤原俊義

    日本家族性腫瘍学会学術集会プログラム・抄録集   25th   2019

  • 同時性肝転移を有する大腸癌症例における原発巣切除の意義

    寺石文則, 藤本卓也, 重安邦俊, 矢野修也, 母里淑子, 近藤喜太, 香川俊輔, 尾崎和秀, 藤原俊義

    大腸癌研究会プログラム・抄録集   91st   2019

  • Multiple gastrointestinal stromal tumors of the small intestine in a patient with neurofibromatosis type 1: a case report

    母里淑子, 重安邦俊, 吉岡貴裕, 永坂岳司, 原賀順子, 香川俊輔, 寺石文則, 豊岡伸一, 平沢晃, 藤原俊義

    家族性腫瘍(Web)   19 ( 2 )   2019

  • 周術期管理チーム介入によるリスク評価が高齢者大腸癌患者の術後アウトカムに与える影響

    寺石文則, 重安邦俊, 矢野修也, 母里淑子, 近藤喜太, 藤原俊義, 藤原俊義

    日本消化器外科学会雑誌(Web)   52 ( Supplement2 )   2019

  • T1大腸癌手術症例の病理組織学的特徴と予後の検討

    寺石文則, 戸嶋俊明, 重安邦俊, 母里淑子, 矢野修也, 近藤喜太, 岸本浩行, 藤原俊義

    日本大腸肛門病学会雑誌(Web)   72 ( 5 )   2019

  • 小腸腺癌2症例の治療経験

    母里淑子, 近藤喜太, 重安邦俊, 小松泰造, 三村直毅, 戸嶋俊明, 矢野修也, 岸本浩行, 寺石文則, 香川俊輔, 藤原俊義

    日本大腸肛門病学会雑誌(Web)   72 ( 5 )   2019

  • Fluorescence-guided novel therapeutic strategy for therapy-refractory tumor cells identified by cell cycle imaging

    矢野修也, 矢野修也, 田澤大, 重安邦俊, 香川俊輔, 藤原俊義

    日本癌学会学術総会抄録集(Web)   78th   2019

  • StageIV大腸癌における腫瘍占拠部位別の予後の検討

    寺石文則, 寺石文則, 公文剣斗, 戸嶋俊明, 重安邦俊, 矢野修也, 母里淑子, 近藤喜太, 浅野博昭, 岸本浩行, 稲田涼, 尾崎和秀, 志摩泰生, 西岡豊, 藤原俊義

    日本大腸肛門病学会雑誌(Web)   72 ( 5 )   2019

  • Effect of an enhanced recovery after surgery protocol in patients undergoing pancreaticoduodenectomy: A randomized controlled trial

    高木弘誠, 吉田龍一, 八木孝仁, 楳田祐三, 信岡大輔, 杭瀬崇, 樋之津史郎, 松崎孝, 森松博史, 江口潤, 和田淳, 千田益生, 藤原俊義

    学会誌JSPEN(Web)   1 ( Supplement )   2019

  • 術前化学療法を行った頸胸境界部食道癌の治療成績

    橋本将志, 白川靖博, 梅田将志, 小林照貴, 前田直見, 田邊俊介, 野間和広, 楳田祐三, 藤原俊義

    日本消化器外科学会雑誌(Web)   52 ( Supplement1 )   2019

  • Minimally invasive telomerase-targeted molecular therapy in esophageal cancer patients unfit for standard treatments

    田澤大, 田澤大, 田辺俊介, 野間和広, 黒田新士, 黒田新士, 香川俊輔, 香川俊輔, 浦田泰生, 白川靖博, 藤原俊義

    日本癌学会学術総会抄録集(Web)   78th   2019

  • 食道癌に対する鏡視下手術導入による周術期管理の変遷と多職種介入による外科感染対策の現況

    田辺俊介, 白川靖博, 前田直見, 野間和広, 藤原俊義

    日本外科感染症学会雑誌(Web)   16 ( 5 )   2019

  • 心負荷軽減の観点からみた混合型食道裂孔ヘルニア手術の新たな手術適応と手術手技の工夫

    田邊俊介, 白川靖博, 梅田将志, 橋本将志, 小林照貴, 前田直見, 櫻間教文, 野間和広, 楳田祐三, 藤原俊義

    日本消化器外科学会雑誌(Web)   52 ( Supplement1 )   2019

  • 高度食道裂孔ヘルニア手術における心負荷に着目した新たな手術適応と手術手技の工夫

    田辺俊介, 白川靖博, 前田直見, 野間和広, 藤原俊義

    日本ヘルニア学会学術集会抄録集(CD-ROM)   17th   2019

  • 食道癌周術期管理におけるPERiOの現況とエビデンス創出に向けた課題

    田辺俊介, 白川靖博, 前田直見, 野間和広, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   72nd   2019

  • 食道領域cadaver surgical trainingの取り組みについて

    白川靖博, 前田直見, 田辺俊介, 野間和広, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   72nd   2019

  • Visualization of epithelial-mesenchymal transition in inflammatory microenvironment-colorectal cancer crosstalk

    Hiroshi Tazawa, Takeshi Ieda, Shuya Yano, Kunitoshi Shigeyasu, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Masahiko Nishizaki, Shunsuke Kagawa, Takashi Saitou, Takeshi Imamura, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   669 - 669   2018.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Novel virotherapy for scirrhous gastric cancer with peritoneal metastasis

    Wataru Ishikawa, Satoru Kikuchi, Hiroshi Tazawa, Shinji Kuroda, Kazuhiro Noma, Hiroyuki Kishimoto, Masahiko Nishizaki, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   761 - 761   2018.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Dual-targeting Photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in tumor microenvironment

    Hiroaki Sato, Kazuhiro Noma, Toru Narusaka, Satoshi Komoto, Toshiaki Ohara, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   371 - 371   2018.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Stemness control by iron chelator is a novel strategy for cancer treatment

    Toshiaki Ohara, Yuki Katsura, Kazuhiro Noma, Toru Narusaka, Hiroaki Sato, Satoshi Komoto, Takuya Kato, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   1309 - 1309   2018.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Near-infrared photoimmunotherapy using anti-GD2 antibody-photosensitizer conjugate for neuroblastoma

    Hiroshi Nouso, Hiroshi Tazawa, Terutaka Tanimoto, Morimochi Tani, Takanori Oyama, Hiroaki Sato, Kazuhiro Noma, Shunsuke Kagawa, Hisataka Kobayashi, Takuo Noda, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   1140 - 1140   2018.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Oncolytic virotherapy for inhibition of epithelial- mesenchymal transition in esophageal cancer

    Tomoya Masuda, Hiroshi Tazawa, Takeshi Ieda, Yuuri Hashimoto, Shunsuke Tanabe, Kazuhiro Noma, Yasuo Urata, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   868 - 868   2018.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Cancer-associated fibroblasts affect the intra-tumoral infiltration of CD8+and FoxP3+T cells via IL-6

    Takuya Kato, Kazuhiro Noma, Hiroaki Sato, Satoshi Komoto, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   1120 - 1120   2018.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Novel theranostic strategy against peritoneal metastasis of scirrhous gastric cancer: Combination with fluorescence oncolytic adenovirus and chemotherapy

    Wataru Ishikawa, Satoru Kikuchi, Hiroshi Tazawa, Toshiaki Ohara, Shinji Kuroda, Kazuhiro Noma, Hiroyuki Kishimoto, Masahiko Nishizaki, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-4807

    Web of Science

    researchmap

  • Visualization of epithelial-mesenchymal transition in inflammatory microenvironment-colorectal cancer network in vitro and in vivo

    Hiroshi Tazawa, Takeshi Ieda, Shuya Yano, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Masahiko Nishizaki, Shunsuke Kagawa, Takashi Saitou, Takeshi Imamura, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-1101

    Web of Science

    researchmap

  • Dual-targeting photoimmunotherapy (NIR-PIT) for esophageal cancer cells and cancer-associated fibroblasts (CAFs)

    Hiroaki Sato, Kazuhiro Noma, Toru Narusaka, Satoshi Komoto, Yuki Katsura, Takuya Kato, Takayuki Ninomiya, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Hisataka Kobayashi, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-5066

    Web of Science

    researchmap

  • Iron depletion suppress the stemness markers and functions of cancer stem cells

    Toshiaki Ohara, Yuki Katsura, Kazuhiro Noma, Toru Narusaka, Takuya Kato, Hiroaki Sato, Satoshi Komoto, Yasuko Tomono, Takayuki Ninomiya, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-LB-045

    Web of Science

    researchmap

  • Development of near-infrared photoimmunotherapy targeting GD2-positive neuroblastoma

    Hiroshi Nouso, Hiroshi Tazawa, Terutaka Tanimoto, Morimichi Tani, Takanori Oyama, Hiroaki Sato, Kazuhiro Noma, Shunsuke Kagawa, Hisataka Kobayashi, Takuo Noda, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-3831

    Web of Science

    researchmap

  • Transforming growth factor-b-induced epithelial-mesenchymal transition is attenuated by telomerase-specific oncolytic virotherapy in human esophageal cancer

    Tomoya Masuda, Hiroshi Tazawa, Takeshi Ieda, Yuuri Hashimoto, Shunsuke Tanabe, Kazuhiro Noma, Yasuo Urata, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-2033

    Web of Science

    researchmap

  • Cancer-associated fibroblasts regulate intratumoral CD8(+)/FoxP3(+) T cells via interleukin 6 in the tumor immune microenvironment

    Takuya Kato, Kazuhiro Noma, Yuki Katsura, Hiroaki Sato, Satoshi Kohmoto, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Masaru Inagaki, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-1741

    Web of Science

    researchmap

  • 【膵癌に挑む】 膵癌に対するウイルス療法の実用化に向けて

    國府島 健, 田澤 大, 杭瀬 崇, 吉田 龍一, 楳田 祐三, 藤原 俊義

    消化器外科   41 ( 6 )   931 - 938   2018.5

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  • 腫瘍融解ウイルス併用放射線療法による食道癌治療成績向上への取り組み

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 黒田 新士, 野間 和広, 楳田 祐三, 田澤 大, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   118回   944 - 944   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study)

    Shunsuke Kagawa, Atsushi Muraoka, Takeshi Kambara, Hiroshi Nakayama, Ryosuke Hamano, Norimitsu Tanaka, Kazuhiro Noma, Kohji Tanakaya, Hiroyuki Kishimoto, Kunitoshi Shigeyasu, Shinji Kuroda, Satoru Kikuchi, Kazuya Kuwada, Masahiko Nishizaki, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Cancer Chemotherapy and Pharmacology   81 ( 2 )   387 - 392   2018.2

     More details

    Language:English   Publisher:Springer Verlag  

    Background: Trastuzumab when combined with fluoropyrimidine and cisplatin was proven to improve survival in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) in the ToGA study. The safety and efficacy of trastuzumab in combination with docetaxel and S-1 have not yet been evaluated. Methods: This study was a multicenter, phase II study. Patients with chemotherapy-naïve HER2-positive advanced or metastatic GC were eligible. Trastuzumab was administered intravenously on day 1 of the first cycle at 8 and 6 mg/kg in subsequent cycles. Docetaxel was administered intravenously at 40 mg/m2 on day 1 of each cycle. S-1 was administered at a dosage based on body surface area for 14 days in a 3-weekly cycle. The primary endpoint was progression-free survival (PFS). Results: A total of 23 patients were enrolled. Median PFS was 6.7 months (95% CI 4.1–10.1). The response rate (RR) was 39.1%. Median overall survival (OS) and time to treatment failure (TTF) were 17.5 and 4.4 months, respectively. Major grade 3–4 adverse events were neutropenia (39.1%), leukopenia (30.4%), and febrile neutropenia (8.7%). Conclusion: Trastuzumab in combination with docetaxel and S-1 showed effective antitumor activity and manageable toxicities as first-line treatment for patients with HER2-positive GC.

    DOI: 10.1007/s00280-017-3505-4

    Scopus

    researchmap

  • Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer

    Mariko Kochi, Takayuki Iwamoto, Naoki Niikura, Giampaolo Bianchini, Shinobu Masuda, Taeko Mizoo, Tomohiro Nogami, Tadahiko Shien, Takayuki Motoki, Naruto Taira, Yutaka Tokuda, Hiroyoshi Doihara, Junji Matsuoka, Toshiyoshi Fujiwara

    Breast Cancer Research and Treatment   167 ( 1 )   39 - 47   2018.1

     More details

    Language:English   Publisher:Springer New York LLC  

    Purpose: The present study evaluated whether morphological-measured stromal and intra-tumour tumour-infiltrating lymphocytes (TILs) levels were associated with gene expression profiles, and whether TILs-associated genomic signature (GS) could be used to predict clinical outcomes and response to therapies in several breast cancer subtypes. Methods: We retrospectively evaluated haematoxylin eosin (HE)-TILs levels and gene expression profiling data from 40 patients with primary breast cancer and extracted the 22 overexpressed genes in cases with high TILs scores as the TILs-GS. The TILs-GS were compared with breast cancer subtype and were evaluated predictive values for prognosis and response to therapies. Results: Higher TILs-GS expressions were observed for triple-negative and human epidermal growth factor receptor 2 (HER2) positive (+) breast cancers, compared to the luminal types (P &lt
     0.001). With the exception of HER2+, the TILs-GS had no prognostic value in subtypes of breast cancers. The Wilcoxon test revealed significantly different TILs-GS levels between the cases with pathological complete response (pCR) and residual disease after anthracycline and taxane-based neoadjuvant chemotherapy, with the exception of the luminal-low proliferation subtype. In the multivariate analysis, pCR was independently associated with smaller tumour size, higher histological grade, ER negativity, HER2 positivity and higher TILs-GS scores (OR 2.02, 95% CI 1.30–3.14, P = 0.025). Conclusions: TILs-GS was associated with stromal and intra-tumour TILs levels, as evaluated using HE, which predicted prognosis and chemotherapy response in several breast cancer subtypes. Further studies are needed to perform stratification according to TILs-GS levels and the conventional breast cancer subtypes.

    DOI: 10.1007/s10549-017-4502-3

    Scopus

    researchmap

  • Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer

    Mariko Kochi, Takayuki Iwamoto, Naoki Niikura, Giampaolo Bianchini, Shinobu Masuda, Taeko Mizoo, Tomohiro Nogami, Tadahiko Shien, Takayuki Motoki, Naruto Taira, Yutaka Tokuda, Hiroyoshi Doihara, Junji Matsuoka, Toshiyoshi Fujiwara

    Breast Cancer Research and Treatment   167 ( 1 )   39 - 47   2018.1

     More details

    Language:English   Publisher:Springer New York LLC  

    Purpose: The present study evaluated whether morphological-measured stromal and intra-tumour tumour-infiltrating lymphocytes (TILs) levels were associated with gene expression profiles, and whether TILs-associated genomic signature (GS) could be used to predict clinical outcomes and response to therapies in several breast cancer subtypes. Methods: We retrospectively evaluated haematoxylin eosin (HE)-TILs levels and gene expression profiling data from 40 patients with primary breast cancer and extracted the 22 overexpressed genes in cases with high TILs scores as the TILs-GS. The TILs-GS were compared with breast cancer subtype and were evaluated predictive values for prognosis and response to therapies. Results: Higher TILs-GS expressions were observed for triple-negative and human epidermal growth factor receptor 2 (HER2) positive (+) breast cancers, compared to the luminal types (P &lt
     0.001). With the exception of HER2+, the TILs-GS had no prognostic value in subtypes of breast cancers. The Wilcoxon test revealed significantly different TILs-GS levels between the cases with pathological complete response (pCR) and residual disease after anthracycline and taxane-based neoadjuvant chemotherapy, with the exception of the luminal-low proliferation subtype. In the multivariate analysis, pCR was independently associated with smaller tumour size, higher histological grade, ER negativity, HER2 positivity and higher TILs-GS scores (OR 2.02, 95% CI 1.30–3.14, P = 0.025). Conclusions: TILs-GS was associated with stromal and intra-tumour TILs levels, as evaluated using HE, which predicted prognosis and chemotherapy response in several breast cancer subtypes. Further studies are needed to perform stratification according to TILs-GS levels and the conventional breast cancer subtypes.

    DOI: 10.1007/s10549-017-4502-3

    Scopus

    researchmap

  • Molecular radiosensitization of p53-armed telomerase-dependent oncolytic adenovirus against human soft-tissue sarcoma

    Tadashi Komatsubara, Hiroshi Tazawa, Yusuke Mochizuki, Kazuhisa Sugiu, Toshinori Omori, Yasuaki Yamakawa, Syuhei Osaki, Joe Hasei, Tomohiro Fujiwara, Toshiyuki Kunisada, Yasuo Urata, Toshifumi Ozaki, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   454 - 454   2018.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Detection of circulating tumor cells in cervical cancer using a conditionally replicative adenovirus targeting telomerase-positive cells. International journal

    Masahiro Takakura, Takeo Matsumoto, Mitsuhiro Nakamura, Yasunari Mizumoto, Subaru Myojyo, Rena Yamazaki, Jyunpei Iwadare, Yukiko Bono, Shunsuke Orisaka, Takeshi Obata, Takashi Iizuka, Kyosuke Kagami, Kentaro Nakayama, Hideki Hayakawa, Fuminori Sakurai, Hiroyuki Mizuguchi, Yasuo Urata, Toshiyoshi Fujiwara, Satoru Kyo, Toshiyuki Sasagawa, Hiroshi Fujiwara

    Cancer science   109 ( 1 )   231 - 240   2018.1

     More details

    Language:English  

    Circulating tumor cells (CTC) are newly discovered biomarkers of cancers. Although many systems detect CTC, a gold standard has not yet been established. We analyzed CTC in uterine cervical cancer patients using an advanced version of conditionally replicative adenovirus targeting telomerase-positive cells, which was enabled to infect coxsackievirus-adenovirus receptor-negative cells and to reduce false-positive signals in myeloid cells. Blood samples from cervical cancer patients were hemolyzed and infected with the virus and then labeled with fluorescent anti-CD45 and anti-pan cytokeratin antibodies. GFP (+)/CD45 (-) cells were isolated and subjected to whole-genome amplification followed by polymerase chain reaction analysis of human papillomavirus (HPV) DNA. CTC were detected in 6 of 23 patients with cervical cancers (26.0%). Expression of CTC did not correlate with the stage of cancer or other clinicopathological factors. In 5 of the 6 CTC-positive cases, the same subtype of HPV DNA as that of the corresponding primary lesion was detected, indicating that the CTC originated from HPV-infected cancer cells. These CTC were all negative for cytokeratins. The CTC detected by our system were genetically confirmed. CTC derived from uterine cervical cancers had lost epithelial characteristics, indicating that epithelial marker-dependent systems do not have the capacity to detect these cells in cervical cancer patients.

    DOI: 10.1111/cas.13449

    PubMed

    researchmap

  • Novel evidence for AZIN1 RNA editing-mediated oncogenic role in colorectal cancer

    Kunitoshi Shigeyasu, Sho Takeda, Yoshinaga Okugawa, Yuji Toiyama, Takeshi Nagasaka, Hiroshi Tazawa, Shunsuke Kagawa, Ajay Goel, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   529 - 529   2018.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Focusing on the antitumor effect of iron chelator, specifically suppressing the stemness of cancer stem cell.

    Yuki Katsura, Toshiaki Ohara, Hajime Kashima, Hiroaki Sato, Takuya Kato, Takayuki Ninomiya, Kazuhiro Noma, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   87 - 87   2018.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Cancer-associated fibroblasts (CAFs) promote to tumor immunosuppression via IL-6 secretion.

    Takuya Kato, Kazuhiro Noma, Hajime Kashima, Yuki Katsura, Hiroaki Sato, Takayuki Ninomiya, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   299 - 299   2018.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Novel theranostic strategy: combination of fluorescence oncolytic virus and chemotherapy for scirrhous gastric cancer

    Wataru Ishikawa, Satoru Kikuchi, Hiroshi Tazawa, Shinji Kuroda, Kazuhiro Noma, Hiroyuki Kishimoto, Takeshi Nagasaka, Masahiko Nishizaki, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   912 - 912   2018.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Fluorescence-guided live cell imaging system of EMT-tumor microenvironment network in gastrointestinal cancer

    Takeshi Ieda, Hiroshi Tazawa, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Takeshi Nagasaka, Masahiko Nishizaki, Shunsuke Kagawa, Takeshi Imamura, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   557 - 557   2018.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Liposomally formulated indocyanine green derivative encapsulating anticancer drugs for photoinduced immunotherapy

    Tetsuya Kagawa, Hiroyuki Kishimoto, Yuki Matsumi, Hiroshi Tazawa, Toshiaki Ohara, Takeshi Nagasaka, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   755 - 755   2018.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • 鉄キレート剤の幹細胞性制御による新規癌治療法の確立

    大原利章, 大原利章, 桂佑貴, 野間和広, 鳴坂徹, 二宮卓之, 友野靖子, 田澤大, 香川俊輔, 白川靖博, 松川昭博, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   29th   2018

  • 食道癌におけるがん細胞及びがん関連線維芽細胞に対するDual-targeting Photoimmunotherapy

    佐藤浩明, 野間和宏, 鳴坂徹, 河本慧, 大原利章, 田澤大, 白川靖博, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   29th   2018

  • 回腸人工肛門狭窄のリスク因子の抽出と予防

    重安邦俊, 母里淑子, 戸嶋俊明, 矢野修也, 近藤喜太, 岸本浩行, 寺石文則, 藤原俊義

    日本大腸肛門病学会雑誌(Web)   71 ( 9 )   2018

  • 骨肉腫に対するp53誘導性腫瘍融解ウイルス療法による免疫原性細胞死の誘導効果

    出宮光二, 田澤大, 田澤大, 望月雄介, 小松原将, 長谷井嬢, 中田英二, 国定俊之, 浦田泰生, 藤原俊義, 尾崎敏文

    日本整形外科学会雑誌   92 ( 8 )   2018

  • 軟部肉腫に対するp53発現腫瘍融解アデノウイルスによるアポトーシス抑制遺伝子発現の制御を介した放射線感受性増感作用の検討

    小松原将, 出宮光二, 望月雄介, 長谷井嬢, 吉田晶, 中田英二, 国定俊之, 浦田泰生, 田澤大, 藤原俊義, 尾崎敏文

    日本整形外科学会雑誌   92 ( 8 )   2018

  • 大腸癌におけるAZIN1RNA編集の意義

    重安邦俊, 重安邦俊, GOEL A., 藤原俊義

    肝臓   59 ( Supplement 2 )   2018

  • Bevacizumab+mFOLFOX6療法が有効であった肝内胆管癌の一例

    母里淑子, 永坂岳司, 楳田祐三, 重安邦俊, 吉田一博, 岸本浩行, 香川俊輔, 藤原俊義

    日本臨床腫瘍学会学術集会(CD-ROM)   16th   2018

  • 大腸癌における新規oncogenic small nucleolar RNA(oncSNOR)の探求

    吉田一博, 重安邦俊, 楳田祐三, 吉田龍一, 信岡大輔, 杭瀬崇, 安井和也, 香川俊輔, 白川靖博, 八木孝仁, GOEL Ajay, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   29th   2018

  • 消化管外瘻を伴う炎症性腸疾患に対する腹腔鏡下手術の安全性

    戸嶋俊明, 近藤善太, 小松泰浩, 三村直毅, 重安邦俊, 矢野修也, 母里淑子, 寺石文則, 岸本浩行, 香川俊輔, 藤原俊義

    日本大腸肛門病学会雑誌(Web)   71 ( 9 )   2018

  • StageIV大腸癌の原発巣切除後に長期予後が期待できる症例とは

    寺石文則, 戸嶋俊明, 重安邦俊, 矢野修也, 母里淑子, 近藤喜太, 岸本浩行, 尾崎和秀, 藤原俊義

    日本大腸肛門病学会雑誌(Web)   71 ( 9 )   2018

  • A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study)

    Shunsuke Kagawa, Atsushi Muraoka, Takeshi Kambara, Hiroshi Nakayama, Ryosuke Hamano, Norimitsu Tanaka, Kazuhiro Noma, Kohji Tanakaya, Hiroyuki Kishimoto, Kunitoshi Shigeyasu, Shinji Kuroda, Satoru Kikuchi, Kazuya Kuwada, Masahiko Nishizaki, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   81 ( 2 )   387 - 392   2018

     More details

    Language:English   Publisher:SPRINGER  

    Trastuzumab when combined with fluoropyrimidine and cisplatin was proven to improve survival in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) in the ToGA study. The safety and efficacy of trastuzumab in combination with docetaxel and S-1 have not yet been evaluated.This study was a multicenter, phase II study. Patients with chemotherapy-na < ve HER2-positive advanced or metastatic GC were eligible. Trastuzumab was administered intravenously on day 1 of the first cycle at 8 and 6 mg/kg in subsequent cycles. Docetaxel was administered intravenously at 40 mg/m(2) on day 1 of each cycle. S-1 was administered at a dosage based on body surface area for 14 days in a 3-weekly cycle. The primary endpoint was progression-free survival (PFS).A total of 23 patients were enrolled. Median PFS was 6.7 months (95% CI 4.1-10.1). The response rate (RR) was 39.1%. Median overall survival (OS) and time to treatment failure (TTF) were 17.5 and 4.4 months, respectively. Major grade 3-4 adverse events were neutropenia (39.1%), leukopenia (30.4%), and febrile neutropenia (8.7%).Trastuzumab in combination with docetaxel and S-1 showed effective antitumor activity and manageable toxicities as first-line treatment for patients with HER2-positive GC.

    DOI: 10.1007/s00280-017-3505-4

    Web of Science

    researchmap

  • Visualized Evaluation of Blood Flow to the Gastric Conduit and Complications in Esophageal Reconstruction. International journal

    Kazuhiro Noma, Yasuhiro Shirakawa, Nobuhiko Kanaya, Tsuyoshi Okada, Naoaki Maeda, Takayuki Ninomiya, Shunsuke Tanabe, Kazufumi Sakurama, Toshiyoshi Fujiwara

    Journal of the American College of Surgeons   226 ( 3 )   241 - 251   2018

     More details

    Language:English  

    BACKGROUND: Evaluation of the blood supply to gastric conduits is critically important to avoid complications after esophagectomy. We began visual evaluation of blood flow using indocyanine green (ICG) fluorescent imaging in July 2015, to reduce reconstructive complications. In this study, we aimed to statistically verify the efficacy of blood flow evaluation using our simplified ICG method. STUDY DESIGN: A total of 285 consecutive patients who underwent esophagectomy and gastric conduit reconstruction were reviewed and divided into 2 groups: before and after introduction of ICG evaluation. The entire cohort and 68 patient pairs after propensity score matching (PS-M) were evaluated for clinical outcomes and the effect of visualized evaluation on reducing the risk of complication. RESULTS: The leakage rate in the ICG group was significantly lower than in the non-ICG group for each severity grade, both in the entire cohort (285 subjects) and after PS-M; the rates of other major complications, including recurrent laryngeal nerve palsy and pneumonia, were not different. The duration of postoperative ICU stay was approximately 1 day shorter in the ICG group than in the non-ICG group in the entire cohort, and approximately 2 days shorter after PS-M. Visualized evaluation of blood flow with ICG methods significantly reduced the rate of anastomotic complications of all Clavien-Dindo (CD) grades. Odds ratios for ICG evaluation decreased with CD grade (0.3419 for CD ≥ 1; 0.241 for CD ≥ 2; and 0.2153 for CD ≥ 3). CONCLUSIONS: Objective evaluation of blood supply to the reconstructed conduit using ICG fluorescent imaging reduces the risk and degree of anastomotic complication.

    DOI: 10.1016/j.jamcollsurg.2017.11.007

    PubMed

    researchmap

  • 集学的治療を要する肺瘻合併胸部進行食道癌の一例

    田辺俊介, 白川靖博, 前田直見, 野間和広, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   71st   2018

  • 癌関連線維芽細胞は腫瘍浸潤リンパ球を制御することにより食道癌の予後に寄与する

    加藤卓也, 加藤卓也, 野間和広, 賀島肇, 賀島肇, 桂佑貴, 桂佑貴, 前田直見, 二宮卓之, 田邊俊介, 白川靖博, 稲垣優, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   72nd   2018

  • 食道亜全摘手術患者における術前筋肉量が術後経過に与える影響

    園井みか, 伊藤真理, 足羽孝子, 前田直見, 二宮卓之, 田邊俊介, 野間和広, 白川靖博, 藤原俊義, 森松博史

    日本食道学会学術集会抄録集(CD-ROM)   72nd   2018

  • 食道癌患者に対する腫瘍融解ウイルスの内視鏡的投与の実際-感染対策の取り組み-

    矢野朋美, 采女典子, 森隆弘, 笠原由美子, 田辺俊介, 黒田新士, 野間和広, 田澤大, 香川俊輔, 白川靖博, 藤原俊義

    日本消化器内視鏡技師学会プログラム・講演抄録   81st   2018

  • 気道瘻を有する局所進行食道癌の開胸手術における合併症予防の工夫

    田辺俊輔, 白川靖博, 西脇紀之, 松田達雄, 前田直見, 野間和広, 楳田祐三, 藤原俊義

    日本臨床外科学会雑誌   79   2018

  • 食道胃接合部癌切除後の観音開き法を用いた腹腔鏡下経裂孔食道残胃吻合

    西崎正彦, 野間和広, 田邊俊介, 二宮卓之, 前田直見, 白川靖博, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   72nd   2018

  • 鞘と層の微細解剖に留意した左反回神経周囲リンパ節郭清手技定型化の工夫

    白川靖博, 前田直見, 田辺俊介, 野間和広, 楳田祐三, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   71st   2018

  • 食道癌外科診療における周術期チーム連携PERiO:Perioperative management center

    白川靖博, 小川俊博, 前田直見, 二宮卓之, 田辺俊介, 野間和広, 楳田祐三, 西崎正彦, 香川俊輔, 藤原俊義

    日本消化器外科学会雑誌(Web)   51 ( Supplement1 )   2018

  • 胸部食道癌手術における血流評価を元に行う安全な胃管・空腸再建法

    野間和広, 白川靖博, 西脇紀之, 松田達雄, 前田直見, 田辺俊介, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   71st   2018

  • Suppression of Oncolytic Adenovirus-Mediated Hepatotoxicity by Liver-Specific Inhibition of NF-κB. International journal

    Mitsuhiro Machitani, Fuminori Sakurai, Keisaku Wakabayashi, Kosuke Nakatani, Masashi Tachibana, Nobuyuki Kato, Toshiyoshi Fujiwara, Hiroyuki Mizuguchi

    Molecular therapy oncolytics   7   76 - 85   2017.12

     More details

    Language:English  

    Telomerase-specific replication-competent adenoviruses (Ads), i.e., TRADs, which possess an E1 gene expression cassette driven by the human telomerase reverse transcriptase promoter, are promising agents for cancer treatment. However, even though oncolytic Ads, including TRAD, are intratumorally administered, they are disseminated from the tumor to systemic circulation, causing concern about oncolytic Ad-mediated hepatotoxicity (due mainly to leaky expression of Ad genes in liver). We reported that inhibition of nuclear factor-κB (NF-κB) leads to the suppression of replication-incompetent Ad vector-mediated hepatotoxicity via reduction of the leaky expression of Ad genes in liver. Here, to develop a TRAD with an improved safety profile, we designed a TRAD that carries a liver-specific promoter-driven dominant-negative IκBα (DNIκBα) expression cassette (TRAD-DNIκBα). Compared with a conventional TRAD, TRAD-DNIκBα showed hepatocyte-specific inhibition of NF-κB signaling and significantly reduced Ad gene expression and replication in the normal human hepatocyte cell line. TRAD-induced hepatotoxicity was largely suppressed in mice following intravenous administration of TRAD-DNIκBα. However, the replication profiles and oncolytic activities of TRAD-DNIκBα were comparable with those of the conventional TRAD in human non-hepatic tumor cells. These results indicate that oncolytic Ads containing the liver-specific DNIκBα expression cassette have improved safety profiles without inhibiting oncolytic activities.

    DOI: 10.1016/j.omto.2017.10.003

    PubMed

    researchmap

  • Suppression of Oncolytic Adenovirus-Mediated Hepatotoxicity by Liver-Specific Inhibition of NF-κB. International journal

    Mitsuhiro Machitani, Fuminori Sakurai, Keisaku Wakabayashi, Kosuke Nakatani, Masashi Tachibana, Nobuyuki Kato, Toshiyoshi Fujiwara, Hiroyuki Mizuguchi

    Molecular therapy oncolytics   7   76 - 85   2017.12

     More details

    Language:English  

    Telomerase-specific replication-competent adenoviruses (Ads), i.e., TRADs, which possess an E1 gene expression cassette driven by the human telomerase reverse transcriptase promoter, are promising agents for cancer treatment. However, even though oncolytic Ads, including TRAD, are intratumorally administered, they are disseminated from the tumor to systemic circulation, causing concern about oncolytic Ad-mediated hepatotoxicity (due mainly to leaky expression of Ad genes in liver). We reported that inhibition of nuclear factor-κB (NF-κB) leads to the suppression of replication-incompetent Ad vector-mediated hepatotoxicity via reduction of the leaky expression of Ad genes in liver. Here, to develop a TRAD with an improved safety profile, we designed a TRAD that carries a liver-specific promoter-driven dominant-negative IκBα (DNIκBα) expression cassette (TRAD-DNIκBα). Compared with a conventional TRAD, TRAD-DNIκBα showed hepatocyte-specific inhibition of NF-κB signaling and significantly reduced Ad gene expression and replication in the normal human hepatocyte cell line. TRAD-induced hepatotoxicity was largely suppressed in mice following intravenous administration of TRAD-DNIκBα. However, the replication profiles and oncolytic activities of TRAD-DNIκBα were comparable with those of the conventional TRAD in human non-hepatic tumor cells. These results indicate that oncolytic Ads containing the liver-specific DNIκBα expression cassette have improved safety profiles without inhibiting oncolytic activities.

    DOI: 10.1016/j.omto.2017.10.003

    PubMed

    researchmap

  • Iron depletion is a novel therapeutic strategy to target cancer stem cells. International journal

    Takayuki Ninomiya, Toshiaki Ohara, Kazuhiro Noma, Yuki Katsura, Ryoichi Katsube, Hajime Kashima, Takuya Kato, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Fumiaki Kimura, Ling Chen, Tomonari Kasai, Masaharu Seno, Akihiro Matsukawa, Toshiyoshi Fujiwara

    Oncotarget   8 ( 58 )   98405 - 98416   2017.11

     More details

    Language:English  

    Adequate iron levels are essential for human health. However, iron overload can act as catalyst for the formation of free radicals, which may cause cancer. Cancer stem cells (CSCs), which maintain the hallmark stem cell characteristics of self-renewal and differentiation capacity, have been proposed as a driving force of tumorigenesis and metastases. In the present study, we investigated the role of iron in the proliferation and stemness of CSCs, using the miPS-LLCcm cell model. Although the anti-cancer agents fluorouracil and cisplatin suppressed the proliferation of miPS-LLCcm cells, these drugs did not alter the expression of stemness markers, including Nanog, SOX2, c-Myc, Oct3/4 and Klf4. In contrast, iron depletion by the iron chelators deferasirox and deferoxamine suppressed the proliferation of miPS-LLCcm cells and the expression of stemness markers. In an allograft model, deferasirox inhibited the growth of miPS-LLCcm implants, which was associated with decreased expression of Nanog and Sox2. Altogether, iron appears to be crucial for the proliferation and maintenance of stemness of CSCs, and iron depletion may be a novel therapeutic strategy to target CSCs.

    DOI: 10.18632/oncotarget.21846

    PubMed

    researchmap

  • Iron depletion is a novel therapeutic strategy to target cancer stem cells. International journal

    Takayuki Ninomiya, Toshiaki Ohara, Kazuhiro Noma, Yuki Katsura, Ryoichi Katsube, Hajime Kashima, Takuya Kato, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Fumiaki Kimura, Ling Chen, Tomonari Kasai, Masaharu Seno, Akihiro Matsukawa, Toshiyoshi Fujiwara

    Oncotarget   8 ( 58 )   98405 - 98416   2017.11

     More details

    Language:English  

    Adequate iron levels are essential for human health. However, iron overload can act as catalyst for the formation of free radicals, which may cause cancer. Cancer stem cells (CSCs), which maintain the hallmark stem cell characteristics of self-renewal and differentiation capacity, have been proposed as a driving force of tumorigenesis and metastases. In the present study, we investigated the role of iron in the proliferation and stemness of CSCs, using the miPS-LLCcm cell model. Although the anti-cancer agents fluorouracil and cisplatin suppressed the proliferation of miPS-LLCcm cells, these drugs did not alter the expression of stemness markers, including Nanog, SOX2, c-Myc, Oct3/4 and Klf4. In contrast, iron depletion by the iron chelators deferasirox and deferoxamine suppressed the proliferation of miPS-LLCcm cells and the expression of stemness markers. In an allograft model, deferasirox inhibited the growth of miPS-LLCcm implants, which was associated with decreased expression of Nanog and Sox2. Altogether, iron appears to be crucial for the proliferation and maintenance of stemness of CSCs, and iron depletion may be a novel therapeutic strategy to target CSCs.

    DOI: 10.18632/oncotarget.21846

    PubMed

    researchmap

  • The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study

    Hiroyuki Sakae, Hiromitsu Kanzaki, Junichiro Nasu, Yutaka Akimoto, Kazuhiro Matsueda, Masao Yoshioka, Masahiro Nakagawa, Shinichiro Hori, Masafumi Inoue, Tomoki Inaba, Atsushi Imagawa, Masahiro Takatani, Ryuta Takenaka, Seiyu Suzuki, Toshiyoshi Fujiwara, Hiroyuki Okada

    BRITISH JOURNAL OF CANCER   117 ( 11 )   1607 - 1613   2017.11

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Background: Small bowel adenocarcinoma (SBA) is a rare malignancy that accounts for 1-2% of gastrointestinal tumours. We investigated the clinical characteristics, outcomes, and prognostic factors of primary SBA.
    Methods: We retrospectively analysed the characteristics and clinical courses of 205 SBA patients from 11 institutions in Japan between June 2002 and August 2013.
    Results: The primary tumour was in the duodenum and jejunum/ileum in 149 (72.7%) and 56 (27.3%) patients, respectively. Sixty-four patients (43.0%) with duodenal adenocarcinoma were asymptomatic and most cases were detected by oesophagogastroduodenoscopy (EGD), which was not specifically performed for the detection or surveillance of duodenal tumours. In contrast, 47 patients (83.9%) with jejunoileal carcinoma were symptomatic. The 3-year survival rate for stage 0/I, II, III, and IV cancers was 93.4%, 73.1%, 50.9%, and 15.1%, respectively. Multivariate analysis revealed performance status 3-4, high carcinoembryonic antigen, high lactate dehydrogenase (LDH), low albumin, symptomatic at diagnosis, and stage III/IV disease were independent factors for overall survival (OS). Ten patients (18.5%) with stage IV disease were treated with a combination of resection of primary tumour, local treatment of metastasis, and chemotherapy; this group had a median OS of 36.9 months.
    Conclusions: Although most SBA patients were diagnosed with symptomatic, advanced stage disease, some patients with duodenal carcinoma were detected in early stage by EGD. High LDH and symptomatic at diagnosis were identified as novel independent prognostic factors for OS. The prognosis of advanced SBA was poor, but combined modality therapy with local treatment of metastasis might prolong patient survival.

    DOI: 10.1038/bjc.2017.338

    Web of Science

    researchmap

  • Novel therapeutic strategy for human epidermal growth factor receptor 2-positive gastric cancer

    Nobuhiko Kanaya, Shinji Kuroda, Tetsushi Kubota, Toshiaki Morihiro, Satoru Kikuchi, Masahiko Nishizaki, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Japanese Journal of Cancer and Chemotherapy   44 ( 10 )   883 - 885   2017.10

     More details

    Language:Japanese   Publishing type:Book review, literature introduction, etc.   Publisher:Japanese Journal of Cancer and Chemotherapy Publishers Inc.  

    Trastuzumab (Tmab), a humanized monoclonal antibody that selectively targets human epidermal growth factor receptor 2 (HER2), is currently used in the clinical setting for the treatment of both breast and gastric cancer. While Tmab has shown improvements in patient prognoses, acquired resistance to this agent remains an issue. While some novel HER2-targeted agents have been approved for clinical use in breast cancer, no such agent has shown treatment efficacy for gastric malignancies with Tmab-resistance. Nanotechnology, which has progressed rapidly, has been applied to medical fields in recent years. Gold nanopartides, which are characterized by their in vivo stability and ease of surface modification, have been reported to show efficacy as the carriers of therapeutic agents, such as drugs, antibodies, peptides, and nucleic acids. In this work, we developed Tmab-conjugated gold nanopartides and demonstrate their efficacy for the treatment of HER2-positive, Tmab-resistant gastric cancer cell lines. Our findings demonstrate that Tmab-conjugated gold nanopartides have the potential to be a novel HER2-targeted therapeutic agent.

    Scopus

    PubMed

    researchmap

  • 食道胃接合部癌に対する胸腔鏡下下縦隔郭清・腹腔鏡下下部食道噴門側胃切除 (特集 食道胃接合部癌の手術) -- (経裂孔アプローチ)

    野間 和広, 白川 靖博, 田辺 俊介, 黒田 新士, 西﨑 正彦, 藤原 俊義

    手術 = Operation   71 ( 11 )   1525 - 1529   2017.10

     More details

    Language:Japanese   Publisher:金原出版  

    CiNii Article

    CiNii Books

    researchmap

  • Living Donor Liver Transplantation for Acute Liver Failure: Comparing Guidelines on the Prediction of Liver Transplantation

    Kazuhiro Yoshida, Yuzo Umeda, Akinobu Takaki, Takeshi Nagasaka, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Kosei Takagi, Tetsuya Yasunaka, Hiroyuki Okada, Takahito Yagi, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   71 ( 5 )   381 - 390   2017.10

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    Determining the indications for and timing of liver transplantation (LT) for acute liver failure (ALF) is essential. The King's College Hospital (KCH) guidelines and Japanese guidelines are used to predict the need for LT and the outcomes in ALF. These guidelines' accuracy when applied to ALF in different regional and etiological backgrounds may differ. Here we compared the accuracy of new (2010) Japanese guidelines that use a simple scoring system with the 1996 Japanese guidelines and the KCH criteria for living donor liver transplantation (LDLT). We retrospectively analyzed 24 adult ALF patients (18 acute type, 6 sub-acute type) who underwent LDLT in 1998-2009 at our institution. We assessed the accuracies of the 3 guidelines' criteria for ALF. The overall 1-year survival rate was 87.5%. The new and previous Japanese guidelines were superior to the KCH criteria for accurately predicting LT for acute-type ALF (72% vs. 17%). The new Japanese guidelines could identify 13 acute-type ALF patients for LT, based on the timing of encephalopathy onset. Using the previous Japanese guidelines, although the same 13 acute-type ALF patients (72%) had indications for LT, only 4 patients were indicated at the 1st step, and it took an additional 5 days to decide the indication at the 2nd step in the other 9 cases. Our findings showed that the new Japanese guidelines can predict the indications for LT and provide a reliable alternative to the previous Japanese and KCH guidelines.

    Web of Science

    researchmap

  • Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system

    Katsuyuki Aoyama, Shinji Kuroda, Toshiaki Morihiro, Nobuhiko Kanaya, Tetsushi Kubota, Yoshihiko Kakiuchi, Satoru Kikuchi, Masahiko Nishizaki, Shunsuke Kagawa, Hiroshi Tazawa, Toshiyoshi Fujiwara

    SCIENTIFIC REPORTS   7 ( 1 )   1 - 8   2017.10

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Oncolytic virotherapy has the disadvantage of being unsuitable for systemic delivery due to immune elimination. Liposomal encapsulation is well-recognized to reduce immune elimination and enhance the stability of drugs in the bloodstream. In the present study, the potential of liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus (TelomeScan) expressing GFP (Lipo-pTS) as an oncolytic adenoviral agent suitable for systemic delivery was investigated. Lipo-pTS, which has a diameter of 40-50 nm, showed potent antitumor effects on HCT116 colon carcinoma cells in vitro and in vivo. Tumor selectivity of Lipo-pTS was independent of coxsackie and adenovirus receptor (CAR). Importantly, Lipo-pTS reduced production of adenovirus-neutralizing antibodies (AdNAbs) after intravenous administration into immune-competent mice compared to TelomeScan, and even in the presence of AdNAbs, Lipo-pTS maintained strong cytotoxicity. In conclusion, Lipo-pTS has the potential to become an oncolytic adenoviral agent suitable for systemic delivery with the characteristics of CAR-independent antitumor activity and a stealth effect on the immune system.

    DOI: 10.1038/s41598-017-14717-x

    Web of Science

    researchmap

  • Preoperative Controlling Nutritional Status (CONUT) Score for Assessment of Prognosis Following Hepatectomy for Hepatocellular Carcinoma

    Kosei Takagi, Takahito Yagi, Yuzo Umeda, Susumu Shinoura, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Hiroyuki Araki, Toshiyoshi Fujiwara

    WORLD JOURNAL OF SURGERY   41 ( 9 )   2353 - 2360   2017.9

     More details

    Language:English   Publisher:SPRINGER  

    Immune-nutritional status has been recently reported as a prognostic factor in hepatocellular carcinoma (HCC). The controlling nutritional status (CONUT) score has been established as a useful tool to evaluate immune-nutritional status. This study aimed to investigate the efficacy of the CONUT score as a prognostic factor in patients undergoing hepatectomy for HCC.
    A total of 295 patients who underwent curative hepatectomy for HCC between January 2007 and December 2014 were retrospectively analyzed. Patients were divided into two groups according to the CONUT score. The impact of the CONUT score on clinicopathological, surgical, and long-term outcomes was evaluated. Subsequently, the impact of prognostic factors, including the CONUT score, associated with outcomes was assessed using multivariate analyses.
    Of 295 patients, 118 (40%) belonged to the high CONUT group (CONUT score 3). The high CONUT group had a significantly lower 5-year recurrence-free survival rate than the low CONUT group (27.9 vs. 41.4%, p = 0.011) and a significantly lower 5-year overall survival rate (61.9 vs. 74.9%, p = 0.006). In multivariate analyses of prognostic factors, the CONUT score was an independent predictor of recurrence-free survival (hazard ratio = 1.64, p = 0.006) and overall survival (hazard ratio = 2.50, p = 0.001).
    The CONUT score is a valuable preoperative predictor of survival in patients undergoing hepatectomy for HCC.

    DOI: 10.1007/s00268-017-3985-8

    Web of Science

    researchmap

  • IS POOR OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS THE NATURE OF THE DISEASE ITSELF OR INSUFFICIENT IMMUNOSUPPRESSION?

    Takahito Yagi, Daisuke Nobuoka, Yuzo Umeda, Ryuichi Yoshida, Takashi Kuise, Kosei Takagi, Kenjiro Kumano, Toshiyoshi Fujiwara

    TRANSPLANT INTERNATIONAL   30   288 - 289   2017.9

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • SURGICAL OUTCOMES OF LIVING DONOR LIVER SURGERY: TECHNICAL KNACK FOR ZERO MORBIDITY

    Takashi Kuise, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Kenjiro Kumano, Takeshi Koujima, Kosei Takagi, Toshiyoshi Fujiwara, Takahito Yagi

    TRANSPLANT INTERNATIONAL   30   128 - 129   2017.9

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • PREDICTION OF SALVAGE LIVER TRANSPLANTATION FOR HCC RECURRENCE: WHEN AND WHICH PATIENT SHOULD WE DECIDE TRANSPLANT?

    Yuzo Umeda, Takahito Yagi, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Kenjiro Kumano, Takeshi Koujima, Kosei Takagi, Takeshi Nagasaka, Toshiyoshi Fujiwara

    TRANSPLANT INTERNATIONAL   30   180 - 180   2017.9

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • ANALYSIS OF PROGNOSTIC FACTORS OF PEDIATRIC LIVING DONOR LIVER TRANSPLANTATION: A SINGLE CENTER EXPERIENCE OF MORTALITY ZERO TRANSPLANTATION FOR CHOLESTATIC DISEASE

    Takahito Yagi, Kosei Takagi, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Kenjiro Kumano, Mari Yoshida, Toshiyoshi Fujiwara

    TRANSPLANT INTERNATIONAL   30   158 - 159   2017.9

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction

    Yasuaki Yamakawa, Hiroshi Tazawa, Joe Hasei, Shuhei Osaki, Toshinori Omori, Kazuhisa Sugiu, Tadashi Komatsubara, Kouji Uotani, Tomohiro Fujiwara, Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    CANCER SCIENCE   108 ( 9 )   1870 - 1880   2017.9

     More details

    Language:English   Publisher:WILEY  

    Osteosarcoma is an aggressive malignant bone tumor that causes bone destruction. Although tumor-specific replicating oncolytic adenovirus OBP-301 induces an antitumor effect in an osteosarcoma tumor, it cannot prevent bone destruction. Zoledronic acid (ZOL) is a clinically available agent that inhibits bone destruction. In this study, we investigated the potential of combination therapy with OBP-301 and ZOL against osteosarcomas with bone destruction. The antitumor activity of OBP-301 and ZOL in monotherapy or combination therapy was assessed using three human osteosarcoma cell lines (143B, MNNG/HOS, SaOS-2). The cytotoxic effect of OBP-301 and/or ZOL was measured by assay of cell apoptosis. The effect of OBP-301 and ZOL on osteoclast activation was investigated. The potential of combination therapy against tumor growth and bone destruction was analyzed using an orthotopic 143B osteosarcoma xenograft tumor model. OBP-301 and ZOL decreased the viability of human osteosarcoma cells. Combination therapy with OBP-301 and ZOL displayed a synergistic antitumor effect, in which OBP-301 promoted apoptosis through suppression of anti-apoptotic myeloid cell leukemia 1 (MCL1). Combination therapy significantly inhibited tumor-mediated osteoclast activation, tumor growth and bone destruction compared to monotherapy. These results suggest that combination therapy of OBP-301 and ZOL suppresses osteosarcoma progression via suppression of MCL1 and osteoclast activation.

    DOI: 10.1111/cas.13316

    Web of Science

    researchmap

  • SNORA21 - An Oncogenic Small Nucleolar RNA, with a Prognostic Biomarker Potential in Human Colorectal Cancer

    Kazuhiro Yoshida, Shusuke Toden, Wenhao Weng, Kunitoshi Shigeyasu, Jinsei Miyoshi, Jacob Turner, Takeshi Nagasaka, Yanlei Ma, Tetsuji Takayama, Toshiyoshi Fujiwara, Ajay Goel

    EBIOMEDICINE   22   68 - 77   2017.8

     More details

    Language:English   Publisher:ELSEVIER SCIENCE BV  

    Background: Emerging evidence indicates that small nucleolar RNAs (snoRNAs) play a central role in oncogenesis. Herein, we systematically evaluated expression profiles of snoRNAs in colorectal cancer (CRC) and investigated their clinical and functional role in this malignancy.
    Methods: We compared expression levels of snoRNAs between cancer and normal tissues using publicly available datasets and identified the most differentially expressed and commonly upregulated snoRNAs in CRC. These results were examined in 489 colorectal tissues to assess their clinical significance, followed by a series of in vitro and in vivo experiments to evaluate the functional role of candidate snoRNAs.
    Results: Usingmultiple RNA profiling datasets, we identified consistent overexpression of SNORA21 in CRC. In the clinical validation cohorts, the expression level of SNORA21was upregulated in colorectal adenomas and cancers. Furthermore, elevated SNORA21 emerged as an independent factor for predicting poor survival. Both in vitro and in vivo experiments revealed that CRISPR/Cas9-mediated inhibition of SNORA21 expression resulted in decreased cell proliferation and invasion through modulation of multiple cancer related pathways.
    Conclusions: Wesystematically identified SNORA21 as a key oncogenic snoRNA in CRC, which plays an important role in cancer progression, and might serve as an important prognostic biomarker in CRC. (C) 2017 The Authors. Published by Elsevier B.V.

    DOI: 10.1016/j.ebiom.2017.07.009

    Web of Science

    researchmap

  • SNORA21 - An Oncogenic Small Nucleolar RNA, with a Prognostic Biomarker Potential in Human Colorectal Cancer

    Kazuhiro Yoshida, Shusuke Toden, Wenhao Weng, Kunitoshi Shigeyasu, Jinsei Miyoshi, Jacob Turner, Takeshi Nagasaka, Yanlei Ma, Tetsuji Takayama, Toshiyoshi Fujiwara, Ajay Goel

    EBIOMEDICINE   22   68 - 77   2017.8

     More details

    Language:English   Publisher:ELSEVIER SCIENCE BV  

    Background: Emerging evidence indicates that small nucleolar RNAs (snoRNAs) play a central role in oncogenesis. Herein, we systematically evaluated expression profiles of snoRNAs in colorectal cancer (CRC) and investigated their clinical and functional role in this malignancy.
    Methods: We compared expression levels of snoRNAs between cancer and normal tissues using publicly available datasets and identified the most differentially expressed and commonly upregulated snoRNAs in CRC. These results were examined in 489 colorectal tissues to assess their clinical significance, followed by a series of in vitro and in vivo experiments to evaluate the functional role of candidate snoRNAs.
    Results: Usingmultiple RNA profiling datasets, we identified consistent overexpression of SNORA21 in CRC. In the clinical validation cohorts, the expression level of SNORA21was upregulated in colorectal adenomas and cancers. Furthermore, elevated SNORA21 emerged as an independent factor for predicting poor survival. Both in vitro and in vivo experiments revealed that CRISPR/Cas9-mediated inhibition of SNORA21 expression resulted in decreased cell proliferation and invasion through modulation of multiple cancer related pathways.
    Conclusions: Wesystematically identified SNORA21 as a key oncogenic snoRNA in CRC, which plays an important role in cancer progression, and might serve as an important prognostic biomarker in CRC. (C) 2017 The Authors. Published by Elsevier B.V.

    DOI: 10.1016/j.ebiom.2017.07.009

    Web of Science

    researchmap

  • Training system for laparoscopy-assisted distal gastrectomy

    Shinji Kuroda, Satoru Kikuchi, Naoto Hori, Shuichi Sakamoto, Tetsuya Kagawa, Megumi Watanabe, Tetsushi Kubota, Kazuya Kuwada, Michihiro Ishida, Hiroyuki Kishimoto, Futoshi Uno, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    SURGERY TODAY   47 ( 7 )   802 - 809   2017.7

     More details

    Language:English   Publisher:SPRINGER  

    Purpose Laparoscopy-assisted distal gastrectomy (LADG) is likely to become a standard procedure for gastric cancer, which highlights the importance of establishing a training system in which even inexperienced surgeons can perform this procedure safely. This study assesses our training system for LADG based on short-term surgical outcomes.
    Methods We evaluated retrospectively the short-term outcomes of 100 consecutive LADGs with curative D1/D1+ lymph node dissection. Our training system was assessed based on the learning curve of trainees, and factors related to achieving good-quality operations were analyzed statistically.
    Results Overall, postoperative complications developed in 10 patients (10%), and included one case of anastomotic leakage (1%) and one case of pancreatic fistula (1%). The learning curve of the trainees plateaued after 10 operator cases in terms of operation time. The importance of the trainer's position was also confirmed by the result that the operation time was significantly longer when trainees with &lt;= 10 operator cases performed LADG with a trainer as scopist vs. a trainer as the first assistant. Univariate and multivariate analyses revealed that &gt; 10 operator cases were the most important factor for achieving good-quality operations.
    Conclusion These results show that our current LADG procedure and training system are appropriate and effective.

    DOI: 10.1007/s00595-016-1439-9

    Web of Science

    researchmap

  • Training system for laparoscopy-assisted distal gastrectomy

    Shinji Kuroda, Satoru Kikuchi, Naoto Hori, Shuichi Sakamoto, Tetsuya Kagawa, Megumi Watanabe, Tetsushi Kubota, Kazuya Kuwada, Michihiro Ishida, Hiroyuki Kishimoto, Futoshi Uno, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    SURGERY TODAY   47 ( 7 )   802 - 809   2017.7

     More details

    Language:English   Publisher:SPRINGER  

    Purpose Laparoscopy-assisted distal gastrectomy (LADG) is likely to become a standard procedure for gastric cancer, which highlights the importance of establishing a training system in which even inexperienced surgeons can perform this procedure safely. This study assesses our training system for LADG based on short-term surgical outcomes.
    Methods We evaluated retrospectively the short-term outcomes of 100 consecutive LADGs with curative D1/D1+ lymph node dissection. Our training system was assessed based on the learning curve of trainees, and factors related to achieving good-quality operations were analyzed statistically.
    Results Overall, postoperative complications developed in 10 patients (10%), and included one case of anastomotic leakage (1%) and one case of pancreatic fistula (1%). The learning curve of the trainees plateaued after 10 operator cases in terms of operation time. The importance of the trainer's position was also confirmed by the result that the operation time was significantly longer when trainees with &lt;= 10 operator cases performed LADG with a trainer as scopist vs. a trainer as the first assistant. Univariate and multivariate analyses revealed that &gt; 10 operator cases were the most important factor for achieving good-quality operations.
    Conclusion These results show that our current LADG procedure and training system are appropriate and effective.

    DOI: 10.1007/s00595-016-1439-9

    Web of Science

    researchmap

  • Circular RNA ciRS-7-A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer

    Wenhao Weng, Qing Wei, Shusuke Toden, Kazuhiro Yoshida, Takeshi Nagasaka, Toshiyoshi Fujiwara, Sanjun Cai, Huanlong Qin, Yanlei Ma, Ajay Goel

    CLINICAL CANCER RESEARCH   23 ( 14 )   3918 - 3928   2017.7

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Purpose: Colorectal cancer is one of themost common malignancies worldwide. Recently, a novel circular RNA, ciRS-7, was proposed to be a potential miR-7 sponge. As miR-7, a putative tumor-suppressor, regulates the expression of several important drivers of colorectal cancer, we analyzed the clinical significance of ciRS-7 in colorectal cancer patients.
    Experimental Design: Initially, we evaluated the expression levels of ciRS-7 in a training cohort comprising of 153 primary colorectal cancer tissues and 44 matched normal mucosae. We subsequently confirmed its clinical relevance in an independent validation cohort (n = 165), and evaluated the effect of ciRS-7 on miR-7, and its target genes EGFR and RAF1. Functional analyses were performed in cell lines and an animal model to support clinical findings.
    Results: Our data revealed that ciRS-7 was significantly upregulated in colorectal cancer tissues compared with matched normal mucosae (P = 0.0018), and its overexpression was associated with poor patient survival (P = 0.0224 and 0.0061 in the training and validation cohorts, respectively). Multivariate survival analysis revealed that ciRS-7 emerged as an independent risk factor for overall survival (P = 0.0656 and 0.0324 in the training and validation cohorts, respectively). Overexpression of ciRS-7 in HCT116 and HT29 cells led to the blocking of miR-7 and resulted in a more aggressive oncogenic phenotype, and ciRS-7 overexpression permitted the inhibition of miR-7 and subsequent activation of EGFR and RAF1 oncogenes.
    Conclusions: CiRS-7 is a promising prognostic biomarker in colorectal cancer patients and may serve as a therapeutic target for reducing EGFR-RAF1 activity in colorectal cancer patients. (C) 2017 AACR.

    DOI: 10.1158/1078-0432.CCR-16-2541

    Web of Science

    researchmap

  • Gene expression profiles in BRAF V600E mutant colorectal cancer and association with SFRP2 methylation status

    Kazuya Yasui, Takeshi Nagasaka, Toshiaki Toshima, Takashi Kawai, Kunitoshi Shigeyasu, Yoshiko Mori, Junko Haraga, Keiichiro Nakamura, Yuzo Umeda, Hiroshi Tazawa, Ajay Goel, Toshiyoshi Fujiwara

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-5711

    Web of Science

    researchmap

  • Novel evidence for AZIN1 RNA editing-mediated oncogenic role in colorectal cancer

    Kunitoshi Shigeyasu, Shusuke Toden, Yoshinaga Okugawa, Jinsei Miyoshi, Takeshi Nagasaka, Toshiyoshi Fujiwara, Leilei Chen, Ajay Goel

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-3356

    Web of Science

    researchmap

  • Fluorescence-guided spatiotemporal dynamics of epithelial-mesenchymal transition under inflammatory microenvironment during colorectal cancer progression

    Takeshi Ieda, Hiroshi Tazawa, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Takeshi Nagasaka, Masahiko Nishizaki, Shunsuke Kagawa, Takeshi Imamura, Toshiyoshi Fujiwara

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-5809

    Web of Science

    researchmap

  • Tumorigenesis of murine iPS cell is prevented by iron depletion with downregulation of stemness markers

    Yuki Katsura, Toshiaki Ohara, Hajime Kashima, Hiroaki Sato, Takuya Kato, Takayuki Ninomiya, Kazuhiro Noma, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-925

    Web of Science

    researchmap

  • Cancer-associated fibroblasts contribute to tumor immunosuppression by regulating tumor-infiltrating lymphocytes

    Takuya Kato, Kazuhiro Noma, Hajime Kashima, Yuki Katsura, Hiroaki Sato, Takayuki Ninomiya, Toshiaki Ohara, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-5934

    Web of Science

    researchmap

  • Cancer associated fibroblasts promote tumor metastasis coexisting with cancer cells in blood circulation

    Hajime Kashima, Kazuhiro Noma, Hiroaki Sato, Yuki Katsura, Takuya Kato, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-5905

    Web of Science

    researchmap

  • Novel theranostic strategy against scirrhous gastric cancer; combination of chemotherapy and fluorescence oncolytic adenovirus

    Wataru Ishikawa, Satoru Kikuchi, Hiroshi Tazawa, Shinji Kuroda, Kazuhiro Noma, Hiroyuki Kishimoto, Takeshi Nagasaka, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-1103

    Web of Science

    researchmap

  • Clinicopathological significance of endometrial cancer with MSH2 deficiency

    Junko Haraga, Takeshi Nagasaka, Keiichirou Nakamura, Tomoko Haruma, Takeshi Nishida, Akihiro Nyuya, Kazuya Yasui, Hisashi Masuyama, Toshiyoshi Fujiwara, Yuji Hiramatsu

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-4277

    Web of Science

    researchmap

  • Hyperthermia at the single-cell level for disseminated cancer disease with immuno-magnetic nanoparticles

    Tetsuya Kagawa, Hiroyuki Kishimoto, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Takeshi Nagasaka, Satoshi Nohara, Ichiro Kato, Adarsh Sandhu, Hiromichi Aono, Toshiyoshi Fujiwara

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-3101

    Web of Science

    researchmap

  • Primary pancreatic-type acinar cell carcinoma of the jejunum with tumor thrombus extending into the mesenteric venous system: a case report and literature review

    Kosei Takagi, Takahito Yagi, Takehiro Tanaka, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Toshiyoshi Fujiwara

    BMC SURGERY   17 ( 1 )   237 - 243   2017.6

     More details

    Language:English   Publisher:BIOMED CENTRAL LTD  

    Background: Although ectopic pancreatic tissue is common in the upper gastrointestinal tract, the incidence of ectopic pancreatic tissue in the jejunum is low, and malignant transformation in ectopic pancreatic tissue is rare. Furthermore, pancreatic-type acinar cell carcinoma (ACC) developing in the jejunum and ACC accompanied by tumor thrombus are extremely rare.
    Case presentation: A 78-year-old-woman presented with melena. Abdominal computed tomography images and endoscopic examination revealed a submucosal jejunal mass with tumor thrombus extending into a jejunal vein. The patient underwent a curative resection combined with a partial jejunectomy and partial pancreatectomy. Histopathological examination of the resected tissue showed tumor cells with a homogeneous acinar architecture identical to pancreatic-type ACC and tumor thrombus. Postoperatively, she was followed for 10 months and had no recurrence.
    Conclusion: We present an extremely rare case of pancreatic-type ACC in the jejunum with extensive tumor thrombus invading into the mesenteric venous system. This type of cancer has not been reported previously but should be considered in the differential diagnosis of a jejunal mass.

    DOI: 10.1186/s12893-017-0273-3

    Web of Science

    researchmap

  • Management of early gastric cancer that meet the indication for radical lymph node dissection following endoscopic resection: a retrospective cohort analysis

    Satoru Kikuchi, Shinji Kuroda, Masahiko Nishizaki, Tetsuya Kagawa, Hiromitsu Kanzaki, Yoshiro Kawahara, Shunsuke Kagawa, Takehiro Tanaka, Hiroyuki Okada, Toshiyoshi Fujiwara

    BMC SURGERY   17 ( 1 )   687 - 694   2017.6

     More details

    Language:English   Publisher:BIOMED CENTRAL LTD  

    Background: Endoscopic resection (ER) has been widely accepted as the standard treatment for early gastric cancer (EGC). However, in patients considered to have undergone non-curative ER due to their potential risk of lymph node metastasis (LNM), additional gastrectomy is recommended. The aim of the present study was to identify EGC patients after non-curative ER at high risk of LNM.
    Methods: A total of 150 patients who had undergone ER for EGC were diagnosed as non-curative ER due to their potential risk of LNM. Clinicopathological data and clinical outcomes were examined retrospectively.
    Results: Additional gastrectomy with lymph node dissection was performed in 73 patients, and the remaining 77 patients were followed-up without additional gastrectomy. In patients who underwent additional gastrectomy, 8 patients had local residual tumor, and 8 patients had LNM, which were limited in the peritumoral nodes. Only lymphatic invasion (p = 0.012) was a statistically significant factor for LNM. The 5-year overall survival and recurrence-free survival were not significantly different between patients with and without additional gastrectomy.
    Conclusion: Additional gastrectomy with lymph node dissection is recommended for patients who were diagnosed as non-curative ER with lymphatic invasion, and minimizing the extent of lymph node dissection may be allowed for these patients.

    DOI: 10.1186/s12893-017-0268-0

    Web of Science

    researchmap

  • Radiographic sarcopenia predicts postoperative infectious complications in patients undergoing pancreaticoduodenectomy

    Kosei Takagi, Ryuichi Yoshida, Takahito Yagi, Yuzo Umeda, Daisuke Nobuoka, Takashi Kuise, Toshiyoshi Fujiwara

    BMC SURGERY   17 ( 1 )   453 - 466   2017.5

     More details

    Language:English   Publisher:BIOMED CENTRAL LTD  

    Background: Recently, skeletal muscle depletion (sarcopenia) has been reported to influence postoperative outcomes after certain procedures. This study investigated the impact of sarcopenia on postoperative outcomes following pancreaticoduodenectomy (PD).
    Methods: We performed a retrospective study of consecutive patients (n = 219) who underwent PD at our institution between January 2007 and May 2013. Sarcopenia was evaluated using preoperative computed tomography. We evaluated postoperative outcomes and the influence of sarcopenia on short-term outcomes, especially infectious complications. Subsequently, multivariate analysis was used to assess the impact of prognostic factors (including sarcopenia) on postoperative infections.
    Results: The mortality, major complication, and infectious complication rates for all patients were 1.4%, 16.4%, and 47.0%, respectively. Fifty-five patients met the criteria for sarcopenia. Sarcopenia was significantly associated with a higher incidence of in-hospital mortality (P = 0.004) and infectious complications (P &lt; 0.001). In multivariate analyses, sarcopenia (odds ratio = 3.43; P &lt; 0.001), preoperative biliary drainage (odds ratio = 2.20; P = 0.014), blood loss (odds ratio = 1.92; P = 0.048), and soft pancreatic texture (odds ratio = 3.71; P &lt; 0.001) were independent predictors of postoperative infections.
    Conclusions: Sarcopenia is an independent preoperative predictor of infectious complications after PD. Clinical assessment combined with sarcopenia may be helpful for understanding the risk of postoperative outcomes and determining perioperative management strategies.

    DOI: 10.1186/s12893-017-0261-7

    Web of Science

    researchmap

  • Nonexposure laparoscopic and endoscopic cooperative surgery (closed laparoscopic and endoscopic cooperative surgery) for gastric submucosal tumor

    Satoru Kikuchi, Masahiko Nishizaki, Shinji Kuroda, Shunsuke Tanabe, Kazuhiro Noma, Shunsuke Kagawa, Yasuhiro Shirakawa, Hiroshi Kato, Hiroyuki Okada, Toshiyoshi Fujiwara

    GASTRIC CANCER   20 ( 3 )   553 - 557   2017.5

     More details

    Language:English   Publisher:SPRINGER  

    Laparoscopic and endoscopic cooperative surgery (LECS) is increasingly applied for gastric submucosal tumors (SMTs) such as gastrointestinal stromal tumors. However, the conventional LECS procedure has the potential risk that gastric contents and even tumor cells could spread into the abdominal cavity because the gastric wall has to be opened during the resection. To avoid this problem, we have developed a modified LECS procedure named "closed LECS." Ten patients underwent closed LECS for the resection of gastric SMTs. Closed LECS consists of the following steps: endoscopic submucosal layer dissection around the tumor, laparoscopic marking of a resection line on the serosal surface along submucosal dissection line, seromuscular suturing with the marked lesion inverted into the inside of the stomach, endoscopic circumferential seromuscular dissection, and peroral retrieval. In three of the initial five cases, the closed LECS procedure was not completed as planned because of the tumor size and endoscopic inappropriate seromuscular dissection. After modification of the procedure, the entire procedure was successful in all five cases. The mean resected tumor diameter was 24.1 +/- 7.6 mm. The mean operation time was 253 +/- 45 min. One patient experienced an intra-abdominal abscess potentially related to delayed perforation as a postoperative complication. The closed LECS procedure for gastric SMTs can theoretically be applied without contamination and tumor cell dissemination into the abdominal cavity.

    DOI: 10.1007/s10120-016-0641-1

    Web of Science

    researchmap

  • Nonexposure laparoscopic and endoscopic cooperative surgery (closed laparoscopic and endoscopic cooperative surgery) for gastric submucosal tumor

    Satoru Kikuchi, Masahiko Nishizaki, Shinji Kuroda, Shunsuke Tanabe, Kazuhiro Noma, Shunsuke Kagawa, Yasuhiro Shirakawa, Hiroshi Kato, Hiroyuki Okada, Toshiyoshi Fujiwara

    GASTRIC CANCER   20 ( 3 )   553 - 557   2017.5

     More details

    Language:English   Publisher:SPRINGER  

    Laparoscopic and endoscopic cooperative surgery (LECS) is increasingly applied for gastric submucosal tumors (SMTs) such as gastrointestinal stromal tumors. However, the conventional LECS procedure has the potential risk that gastric contents and even tumor cells could spread into the abdominal cavity because the gastric wall has to be opened during the resection. To avoid this problem, we have developed a modified LECS procedure named "closed LECS." Ten patients underwent closed LECS for the resection of gastric SMTs. Closed LECS consists of the following steps: endoscopic submucosal layer dissection around the tumor, laparoscopic marking of a resection line on the serosal surface along submucosal dissection line, seromuscular suturing with the marked lesion inverted into the inside of the stomach, endoscopic circumferential seromuscular dissection, and peroral retrieval. In three of the initial five cases, the closed LECS procedure was not completed as planned because of the tumor size and endoscopic inappropriate seromuscular dissection. After modification of the procedure, the entire procedure was successful in all five cases. The mean resected tumor diameter was 24.1 +/- 7.6 mm. The mean operation time was 253 +/- 45 min. One patient experienced an intra-abdominal abscess potentially related to delayed perforation as a postoperative complication. The closed LECS procedure for gastric SMTs can theoretically be applied without contamination and tumor cell dissemination into the abdominal cavity.

    DOI: 10.1007/s10120-016-0641-1

    Web of Science

    researchmap

  • Outcome of Radiation Monotherapy for High-risk Patients with Stage I Esophageal Cancer

    Yasuhiro Shirakawa, Kazuhiro Noma, Naoaki Maeda, Shunsuke Tanabe, Shinji Kuroda, Shunsuke Kagawa, Kuniaki Katsui, Norihisa Katayama, Susumu Kanazawa, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   71 ( 2 )   127 - 133   2017.4

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    Currently, chemoradiation is the most widely used nonsurgical treatment for esophageal cancer. However, some patients, particularly the very elderly or those with severe vital organ dysfunction, face difficulty with the chemotherapy component. We therefore examined the outcome of radiation therapy (RT) alone for patients with esophageal cancer at our facility. Between January 2005 and December 2014, 84 patients underwent RT at our hospital, and 78 of these patients received concomitant chemotherapy. The remaining 6 patients underwent RT alone; these patients were considered to be high-risk and to have no lymph node metastasis (stage I). Five of them received irradiation up to a curative dose: 4 showed a complete response (CR) and 1 showed a partial response (PR). Of the patients exhibiting CR, 3 are currently living recurrence-free, whereas 1 patient underwent endoscopic submucosal dissection (ESD) as salvage therapy for local recurrence, with no subsequent recurrence. High-risk stage I esophageal cancer patients can be treated radically with RT alone under certain conditions. In the future, to broaden the indications for RT monotherapy to include some degree of advanced cancers, a novel concurrent therapy should be identified.

    Web of Science

    researchmap

  • Outcome of Radiation Monotherapy for High-risk Patients with Stage I Esophageal Cancer

    Yasuhiro Shirakawa, Kazuhiro Noma, Naoaki Maeda, Shunsuke Tanabe, Shinji Kuroda, Shunsuke Kagawa, Kuniaki Katsui, Norihisa Katayama, Susumu Kanazawa, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   71 ( 2 )   127 - 133   2017.4

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    Currently, chemoradiation is the most widely used nonsurgical treatment for esophageal cancer. However, some patients, particularly the very elderly or those with severe vital organ dysfunction, face difficulty with the chemotherapy component. We therefore examined the outcome of radiation therapy (RT) alone for patients with esophageal cancer at our facility. Between January 2005 and December 2014, 84 patients underwent RT at our hospital, and 78 of these patients received concomitant chemotherapy. The remaining 6 patients underwent RT alone; these patients were considered to be high-risk and to have no lymph node metastasis (stage I). Five of them received irradiation up to a curative dose: 4 showed a complete response (CR) and 1 showed a partial response (PR). Of the patients exhibiting CR, 3 are currently living recurrence-free, whereas 1 patient underwent endoscopic submucosal dissection (ESD) as salvage therapy for local recurrence, with no subsequent recurrence. High-risk stage I esophageal cancer patients can be treated radically with RT alone under certain conditions. In the future, to broaden the indications for RT monotherapy to include some degree of advanced cancers, a novel concurrent therapy should be identified.

    Web of Science

    researchmap

  • Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers

    Takayuki Iwamoto, Toyomasa Katagiri, Naoki Niikura, Yuichiro Miyoshi, Mariko Kochi, Tomohiro Nogami, Tadahiko Shien, Takayuki Motoki, Naruto Taira, Masako Omori, Yutaka Tokuda, Toshiyoshi Fujiwara, Hiroyoshi Doihara, Balazs Gyorffy, Junji Matsuoka

    ONCOTARGET   8 ( 16 )   26122 - 26128   2017.4

     More details

    Language:English   Publisher:IMPACT JOURNALS LLC  

    Background: The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers.
    Results: Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P &lt; 0.001). PostKi67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate signature(GSS) (66.7%: 20/30), but the difference in predictive power was not significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly downregulated after therapy (P &lt; 0.001 and 0.041, respectively).
    Materials and Methods: Core needle biopsy specimens of primary breast cancer were collected at Okayama University Hospital from hormone receptor-positive and human epidermal growth factor 2-negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from surgical samples were also collected. IHC Ki67 levels and GSS were compared between pre-and post-hormone treatment samples. Changes of gene expression pattern in short-term hormone therapy were also assessed.
    Conclusions: IHC based post-Ki67 levels may have distinct predictive power compared with the naive IHC Ki67. Future studies with larger cohorts and longer follow-up periods may be needed to validate our results.

    DOI: 10.18632/oncotarget.15385

    Web of Science

    researchmap

  • Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers

    Takayuki Iwamoto, Toyomasa Katagiri, Naoki Niikura, Yuichiro Miyoshi, Mariko Kochi, Tomohiro Nogami, Tadahiko Shien, Takayuki Motoki, Naruto Taira, Masako Omori, Yutaka Tokuda, Toshiyoshi Fujiwara, Hiroyoshi Doihara, Balazs Gyorffy, Junji Matsuoka

    ONCOTARGET   8 ( 16 )   26122 - 26128   2017.4

     More details

    Language:English   Publisher:IMPACT JOURNALS LLC  

    Background: The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers.
    Results: Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P &lt; 0.001). PostKi67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate signature(GSS) (66.7%: 20/30), but the difference in predictive power was not significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly downregulated after therapy (P &lt; 0.001 and 0.041, respectively).
    Materials and Methods: Core needle biopsy specimens of primary breast cancer were collected at Okayama University Hospital from hormone receptor-positive and human epidermal growth factor 2-negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from surgical samples were also collected. IHC Ki67 levels and GSS were compared between pre-and post-hormone treatment samples. Changes of gene expression pattern in short-term hormone therapy were also assessed.
    Conclusions: IHC based post-Ki67 levels may have distinct predictive power compared with the naive IHC Ki67. Future studies with larger cohorts and longer follow-up periods may be needed to validate our results.

    DOI: 10.18632/oncotarget.15385

    Web of Science

    researchmap

  • High-metastatic triple-negative breast-cancer variants selected in vivo become chemoresistant in vitro

    Shuya Yano, Kiyoto Takehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL   53 ( 4 )   285 - 287   2017.4

     More details

    Language:English   Publisher:SPRINGER  

    DOI: 10.1007/s11626-016-0117-y

    Web of Science

    researchmap

  • IDENTIFICATION OF A CIRCULATING MIRNA DIAGNOSTIC SIGNATURE IN PANCREATIC DUCTAL ADENOCARCINOMA

    Kazuhiro Yoshida, Shusuke Toden, Haiyong Han, Susan Tsai, Murtaza Muhammed, Scott Celinski, Carlos Becerra, Takeshi Nagasaka, Toshiyoshi Fujiwara, Douglas B. Evans, Danniel V. Hoff, Ajay Goel

    GASTROENTEROLOGY   152 ( 5 )   S273 - S273   2017.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:W B SAUNDERS CO-ELSEVIER INC  

    0

    DOI: 10.1016/S0016-5085(17)31212-X

    Web of Science

    researchmap

  • Enhanced Metastatic Recurrence Via Lymphatic Trafficking of a High-Metastatic Variant of Human Triple-Negative Breast Cancer After Surgical Resection in Orthotopic Nude Mouse Models

    Shuya Yano, Kiyoto Takehara, Hiroshi Tazawa, Hiroyuki Kishimoto, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    JOURNAL OF CELLULAR BIOCHEMISTRY   118 ( 3 )   559 - 569   2017.3

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    We previously developed and characterized a highly invasive and metastatic triple-negative breast cancer (TNBC) variant by serial orthotopic implantation of MDA-MB-231 human breast cancer cells in nude mice. Eventually, a highly invasive and metastatic variant of human TNBC was isolated after lymph node metastases was harvested and orthotopically re-implanted into the mammary gland of nude mice for two cycles. The variant thereby isolated is highly invasive in the mammary gland and metastasized to lymph nodes in 10 of 12 mice compared to 2 of 12 of the parental cell line. In the present report, we observed that high-metastatic MDA-MB-231H-RFP cells produced significantly larger subcutaneous tumors compared with parental MDA-MB-231 cells in nude mice. Extensive lymphatic trafficking by high-metastatic MDA-MB-231 cells was also observed. High-metastatic MDA-MB-231 developed larger recurrent tumors 2 weeks after tumor resection compared with tumors that were not resected in orthotopic models. Surgical resection of the MDA-MB-231 high-metastatic variant primary tumor in orthotopic models also resulted in rapid and enhanced lymphatic trafficking of residual cancer cells and extensive lymph node and lung metastasis that did not occur in the non-surgical mice. These results suggest that surgical resection of high metastatic TNBC can greatly increase the malignancy of residual cancer. J. Cell. Biochem. 118: 559-569, 2017. (c) 2016 Wiley Periodicals, Inc.

    DOI: 10.1002/jcb.25735

    Web of Science

    researchmap

  • Early Chimerism After Liver Transplantation Reflects the Clinical Course of Recurrent Hepatitis C

    Masashi Utsumi, Akinobu Takaki, Yuzo Umeda, Kazuko Koike, Stephanie C. Napier, Nobukazu Watanabe, Susumu Shinoura, Ryuichi Yoshida, Daisuke Nobuoka, Tetsuya Yasunaka, Takahiro Oto, Motoo Araki, Kazuhide Yamamoto, Toshiyoshi Fujiwara, Takahito Yagi

    ANNALS OF TRANSPLANTATION   22   156 - 165   2017.3

     More details

    Language:English   Publisher:INT SCIENTIFIC LITERATURE, INC  

    Background: Human leukocyte antigen (HLA) mismatch is a characteristic feature of post-orthotopic liver transplantation (OLT) hepatitis C. To investigate the importance of donor HLA-restricted immune cells in post-OLT hepatitis C recurrence, we analyzed the frequency of donor chimerism and the clinical course of post-OLT hepatitis C.
    Material/Methods: We analyzed peripheral blood chimerism in 11 HCV-reinfected patients with post-HLA mismatched OLT. Patients were divided into 2 groups: the OLT chronic hepatitis C (CHC) group (n=8), exhibiting active hepatitis C recurrence; and the OLT-persistently normal ALT (PNALT) group (n=3), without active hepatitis. Chimerism was analyzed by flow cytometry using donor-specific anti-HLA antibodies in peripheral blood mononuclear cells from 1-100 days after OLT. Kidney (n=7) and lung (n=7) transplant recipients were also analyzed for comparison. As immune cells from the donor liver might contribute to post-OLT chimerism, the characteristics of perfusates from donor livers (n=10) were analyzed and defined.
    Results: Donor-derived cells were frequently observed in liver and lung transplant recipients. The frequency of donor-derived cells from the B cell subset was significantly higher in peripheral blood from OLT-CHC group than in that of the OLT-PNALT group. B cells, however, were not the predominant subset in the perfusates, indicating that inflow of donor-derived cells alone did not cause the chimerism.
    Conclusions: Chimerism of B cells is frequent in liver transplant patients with early recurrence of hepatitis C. We propose that monitoring of early chimerism could facilitate early detection of chronic hepatitis C recurrence, although we need more cases to investigate.

    DOI: 10.12659/AOT.900494

    Web of Science

    researchmap

  • Early Chimerism After Liver Transplantation Reflects the Clinical Course of Recurrent Hepatitis C

    Masashi Utsumi, Akinobu Takaki, Yuzo Umeda, Kazuko Koike, Stephanie C. Napier, Nobukazu Watanabe, Susumu Shinoura, Ryuichi Yoshida, Daisuke Nobuoka, Tetsuya Yasunaka, Takahiro Oto, Motoo Araki, Kazuhide Yamamoto, Toshiyoshi Fujiwara, Takahito Yagi

    ANNALS OF TRANSPLANTATION   22   156 - 165   2017.3

     More details

    Language:English   Publisher:INT SCIENTIFIC LITERATURE, INC  

    Background: Human leukocyte antigen (HLA) mismatch is a characteristic feature of post-orthotopic liver transplantation (OLT) hepatitis C. To investigate the importance of donor HLA-restricted immune cells in post-OLT hepatitis C recurrence, we analyzed the frequency of donor chimerism and the clinical course of post-OLT hepatitis C.
    Material/Methods: We analyzed peripheral blood chimerism in 11 HCV-reinfected patients with post-HLA mismatched OLT. Patients were divided into 2 groups: the OLT chronic hepatitis C (CHC) group (n=8), exhibiting active hepatitis C recurrence; and the OLT-persistently normal ALT (PNALT) group (n=3), without active hepatitis. Chimerism was analyzed by flow cytometry using donor-specific anti-HLA antibodies in peripheral blood mononuclear cells from 1-100 days after OLT. Kidney (n=7) and lung (n=7) transplant recipients were also analyzed for comparison. As immune cells from the donor liver might contribute to post-OLT chimerism, the characteristics of perfusates from donor livers (n=10) were analyzed and defined.
    Results: Donor-derived cells were frequently observed in liver and lung transplant recipients. The frequency of donor-derived cells from the B cell subset was significantly higher in peripheral blood from OLT-CHC group than in that of the OLT-PNALT group. B cells, however, were not the predominant subset in the perfusates, indicating that inflow of donor-derived cells alone did not cause the chimerism.
    Conclusions: Chimerism of B cells is frequent in liver transplant patients with early recurrence of hepatitis C. We propose that monitoring of early chimerism could facilitate early detection of chronic hepatitis C recurrence, although we need more cases to investigate.

    DOI: 10.12659/AOT.900494

    Web of Science

    researchmap

  • A Novel "Shrug Technique" for Totally Implantable Venous Access Devices via the External Jugular Vein: A Consecutive Series of 254 Patients

    Tetsuya Kagawa, Satoshi Ueyama, Tatsunori Kobayashi, Hiroki Okabayashi, Shinji Kuroda, Toshiyoshi Fujiwara

    JOURNAL OF SURGICAL ONCOLOGY   115 ( 3 )   291 - 295   2017.3

     More details

    Language:English   Publisher:WILEY  

    Background: The external jugular vein (EJV) approach for totally implantable venous access devices (TIVADs) is safe. However, the success rate is unsatisfactory because of the difficulty in catheterization due to the acute angle between the EJV and the subclavian vein (SCV). A novel "shrug technique" to overcome this difficulty was developed, and its efficacy was assessed in a consecutive case series.
    Methods: TIVAD placement was performed via the EJV cut-down approach. "Shrug technique," a simple way to straighten the EJV-SVC angle by shrugging the patient's shoulder, was applied to facilitate the passage of the guidewire and sheath-introducer when there was acute angulation between the EJV and SCV.
    Results: A total of 254 patients underwent TIVAD implantation by the EJV cut-down approach. The " shrug technique" was applied in 51 cases (20%), and catheterization was successful in all cases. Thus, TIVAD implantation was successfully completed in all 254 cases (100%) in a single operative setting. The median operating time was 38 [IQR 30-45] min. Eleven complications (4%) were observed, but none of them were EJV-specific.
    Conclusion: The " shrug technique" is simple but very useful to achieve a higher success rate and safer insertion of TIVADs from the EJV. (C) 2016 Wiley Periodicals, Inc.

    DOI: 10.1002/jso.24504

    Web of Science

    researchmap

  • A Novel "Shrug Technique" for Totally Implantable Venous Access Devices via the External Jugular Vein: A Consecutive Series of 254 Patients

    Tetsuya Kagawa, Satoshi Ueyama, Tatsunori Kobayashi, Hiroki Okabayashi, Shinji Kuroda, Toshiyoshi Fujiwara

    JOURNAL OF SURGICAL ONCOLOGY   115 ( 3 )   291 - 295   2017.3

     More details

    Language:English   Publisher:WILEY  

    Background: The external jugular vein (EJV) approach for totally implantable venous access devices (TIVADs) is safe. However, the success rate is unsatisfactory because of the difficulty in catheterization due to the acute angle between the EJV and the subclavian vein (SCV). A novel "shrug technique" to overcome this difficulty was developed, and its efficacy was assessed in a consecutive case series.
    Methods: TIVAD placement was performed via the EJV cut-down approach. "Shrug technique," a simple way to straighten the EJV-SVC angle by shrugging the patient's shoulder, was applied to facilitate the passage of the guidewire and sheath-introducer when there was acute angulation between the EJV and SCV.
    Results: A total of 254 patients underwent TIVAD implantation by the EJV cut-down approach. The " shrug technique" was applied in 51 cases (20%), and catheterization was successful in all cases. Thus, TIVAD implantation was successfully completed in all 254 cases (100%) in a single operative setting. The median operating time was 38 [IQR 30-45] min. Eleven complications (4%) were observed, but none of them were EJV-specific.
    Conclusion: The " shrug technique" is simple but very useful to achieve a higher success rate and safer insertion of TIVADs from the EJV. (C) 2016 Wiley Periodicals, Inc.

    DOI: 10.1002/jso.24504

    Web of Science

    researchmap

  • OBP-401-GFP telomerase-dependent adenovirus illuminates and kills high-metastatic more effectively than low-metastatic triple-negative breast cancer in vitro

    S. Yano, K. Takehara, H. Kishimoto, H. Tazawa, Y. Urata, S. Kagawa, M. Bouvet, T. Fujiwara, R. M. Hoffman

    CANCER GENE THERAPY   24 ( 2 )   45 - 47   2017.2

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    We previously described the development of a highly-invasive, triple-negative breast cancer (TNBC) variant using serial orthotopic implantation of MDA-MB-231 human breast cancer in nude mice. The isolated variant is highly invasive in the mammary gland and Metastasized to lymph nodes in 10 of 12 mice compared with 2 of 12 of the parental cell line. OBP-401 is a telomerase-dependent cancer-specific, green fluorescent protein (GFP)-expressing adenovirus. OBP-401 was used to infect parental MDA-MB-231P cells and high-metastatic MDA-MB-231H and MDA-MB-231HLN isolated from a lymph node metastasis and MDA-MB-231HLM isolated from a lung metastasis. Time-course imaging showed that OBP-401 labeled MDA-MB-231HP, MDA-MB-231HLN, and MDA-MB-231HLM cells more brightly than MDA-MB-231 parental cells. OBP-401 killed MDA-MB-231H, MDA-MB-231HLN, and MDA-MB-231HLM cells more efficiently than MDA-MB-231P parental cells. These results indicate that OBP-401 could infect, label and then kill high-metastatic MDA-MB-231 more efficiently than low-metastatic MDA-MB-231.

    DOI: 10.1038/cgt.2016.67

    Web of Science

    researchmap

  • Comparison of in vitro invasiveness of high- and low-metastatic triple-negative human breast cancer visualized by color-coded imaging

    Shuya Yano, Kiyoto Takehara, Hiroshi Tazawa, Hiroyuki Kishimoto, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert M. Hoffman

    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL   53 ( 2 )   96 - 98   2017.2

     More details

    Language:English   Publisher:SPRINGER  

    DOI: 10.1007/s11626-016-0092-3

    Web of Science

    researchmap

  • Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Liver Transplantation

    Kosei Takagi, Takahito Yagi, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Nobuyuki Watanabe, Takashi Kuise, Tomokazu Fuji, Hiroyuki Araki, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   71 ( 1 )   85 - 89   2017.2

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is an extremely rare cause of hyponatremia post-liver transplantation. A 15-year-old Japanese girl with recurrent cholangitis after Kasai surgery for biliary atresia underwent successful living donor liver transplantation. Peritonitis due to gastrointestinal perforation occurred. Hyponatremia gradually developed but improved after hypertonic sodium treatment. One month later, severe hyponatremia rapidly recurred. We considered the hyponatremia's cause as SIADH. We suspected that tacrolimus was the disease's cause, so we used cyclosporine instead, plus hypertonic sodium plus water intake restriction, which improved the hyponatremia. Symptomatic hyponatremia manifested by SIADH is a rare, serious complication post-liver transplantation.

    Web of Science

    researchmap

  • Comparison of Tumor Recurrence After Resection of Highly- and Poorly-Metastatic Triple-negative Breast Cancer in Orthotopic Nude-Mouse Models

    Shuya Yano, Kiyoto Takehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara, Michael Bouvet, Robert M. Hoffman

    ANTICANCER RESEARCH   37 ( 1 )   57 - 60   2017.1

     More details

    Language:English   Publisher:INT INST ANTICANCER RESEARCH  

    Background: Triple-negative breast cancer (TNBC), defined by the absence of receptors for estrogen, progesterone and human epithelial receptor 2, is a recalcitrant disease in need of effective therapy. We previously isolated highly-metastatic variants of the human TNBC cell line MDA-MB-231 using serial orthotopic implantation in nude mice. Materials and Methods: In the present report, we compared local and metastatic recurrence in lymph nodes in orthotopic nude-mouse models after bright-light surgery (BLS) of tumors from highly-metastatic variants or poorly-metastatic parental MDA-MB-231-RFP cells. Orthotopic tumors from parental MDA-MB-231 or highly-metastatic MDA-MB-231 were resected under bright light similar to an operating room. Results: After resection of primary tumors, local recurrence from highly-metastatic MDA-MB-231 cells grew more rapidly than did parental MDA-MB-231 cells. Lymph-node metastasis from highly-metastatic MDA-MB-231 cells occurred after primary tumor resection much more extensively than after parental MDAMB- 231 tumors were resected. Conclusion: The results of the present report suggest that conventional surgery under bright light was unable to control highly-metastatic compared with poorly-metastatic MDA-MB-231 TNBC.

    DOI: 10.21873/anticanres.11288

    Web of Science

    researchmap

  • Comparison of Tumor Recurrence After Resection of Highly- and Poorly-Metastatic Triple-negative Breast Cancer in Orthotopic Nude-Mouse Models

    Shuya Yano, Kiyoto Takehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara, Michael Bouvet, Robert M. Hoffman

    ANTICANCER RESEARCH   37 ( 1 )   57 - 60   2017.1

     More details

    Language:English   Publisher:INT INST ANTICANCER RESEARCH  

    Background: Triple-negative breast cancer (TNBC), defined by the absence of receptors for estrogen, progesterone and human epithelial receptor 2, is a recalcitrant disease in need of effective therapy. We previously isolated highly-metastatic variants of the human TNBC cell line MDA-MB-231 using serial orthotopic implantation in nude mice. Materials and Methods: In the present report, we compared local and metastatic recurrence in lymph nodes in orthotopic nude-mouse models after bright-light surgery (BLS) of tumors from highly-metastatic variants or poorly-metastatic parental MDA-MB-231-RFP cells. Orthotopic tumors from parental MDA-MB-231 or highly-metastatic MDA-MB-231 were resected under bright light similar to an operating room. Results: After resection of primary tumors, local recurrence from highly-metastatic MDA-MB-231 cells grew more rapidly than did parental MDA-MB-231 cells. Lymph-node metastasis from highly-metastatic MDA-MB-231 cells occurred after primary tumor resection much more extensively than after parental MDAMB- 231 tumors were resected. Conclusion: The results of the present report suggest that conventional surgery under bright light was unable to control highly-metastatic compared with poorly-metastatic MDA-MB-231 TNBC.

    DOI: 10.21873/anticanres.11288

    Web of Science

    researchmap

  • Enhanced Oncolytic Activities of the Telomerase-Specific Replication-Competent Adenovirus Expressing Short-Hairpin RNA against Dicer

    Mitsuhiro Machitani, Fuminori Sakurai, Keisaku Wakabayashi, Masashi Tachibana, Toshiyoshi Fujiwara, Hiroyuki Mizuguchi

    MOLECULAR CANCER THERAPEUTICS   16 ( 1 )   251 - 259   2017.1

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Oncolytic viruses have been receiving much attention as potential agents for cancer treatment. Among the various types of oncolytic viruses, the telomerase-specific replication-competent adenovirus (TRAD), which carries the tumor-specific promoter- driven E1 gene expression cassette, exhibits efficient antitumor effects. The development of a novel TRAD that shows higher replication efficiency and antitumor activity would be highly beneficial for safer and more efficient cancer therapy. We recently demonstrated that the endoribonuclease Dicer significantly inhibits the replication of wild-type adenovirus (Ad) via the processing of viral-associated (VA)-RNAs, which are Ad-encoded small noncoding RNAs, and that the knockdown of Dicer leads to enhanced VA-RNA expression and Ad replication after infection with wild-type Ad. Based on these findings, we herein developed a novel TRAD expressing shorthairpin RNA against Dicer (shDicer; TRAD-shDicer). After infection, TRAD-shDicer efficiently induced the knockdown of Dicer. TRAD-shDicer showed significantly higher replication efficiency and tumor cell lysis activity compared with the conventional TRAD in tumor cells. The Dicer expression levels and viabilities of normal cells were not altered by infection with TRAD-shDicer. These results indicate that TRAD-shDicer is a potent antitumor reagent by virtue of its enhanced oncolytic activity. (C) 2016 AACR.

    DOI: 10.1158/1535-7163.MCT-16-0383

    Web of Science

    researchmap

  • Enhanced Oncolytic Activities of the Telomerase-Specific Replication-Competent Adenovirus Expressing Short-Hairpin RNA against Dicer

    Mitsuhiro Machitani, Fuminori Sakurai, Keisaku Wakabayashi, Masashi Tachibana, Toshiyoshi Fujiwara, Hiroyuki Mizuguchi

    MOLECULAR CANCER THERAPEUTICS   16 ( 1 )   251 - 259   2017.1

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Oncolytic viruses have been receiving much attention as potential agents for cancer treatment. Among the various types of oncolytic viruses, the telomerase-specific replication-competent adenovirus (TRAD), which carries the tumor-specific promoter- driven E1 gene expression cassette, exhibits efficient antitumor effects. The development of a novel TRAD that shows higher replication efficiency and antitumor activity would be highly beneficial for safer and more efficient cancer therapy. We recently demonstrated that the endoribonuclease Dicer significantly inhibits the replication of wild-type adenovirus (Ad) via the processing of viral-associated (VA)-RNAs, which are Ad-encoded small noncoding RNAs, and that the knockdown of Dicer leads to enhanced VA-RNA expression and Ad replication after infection with wild-type Ad. Based on these findings, we herein developed a novel TRAD expressing shorthairpin RNA against Dicer (shDicer; TRAD-shDicer). After infection, TRAD-shDicer efficiently induced the knockdown of Dicer. TRAD-shDicer showed significantly higher replication efficiency and tumor cell lysis activity compared with the conventional TRAD in tumor cells. The Dicer expression levels and viabilities of normal cells were not altered by infection with TRAD-shDicer. These results indicate that TRAD-shDicer is a potent antitumor reagent by virtue of its enhanced oncolytic activity. (C) 2016 AACR.

    DOI: 10.1158/1535-7163.MCT-16-0383

    Web of Science

    researchmap

  • Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study

    Nobuaki Suzuki, Shoichi Hazama, Haruo Iguchi, Kazuhiro Uesugi, Hiroaki Tanaka, Kosei Hirakawa, Atsushi Aruga, Takashi Hatori, Hidenobu Ishizaki, Yuzo Umeda, Toshiyoshi Fujiwara, Tetsuya Ikemoto, Mitsuo Shimada, Kazuhiko Yoshimatsu, Ryoichi Shimizu, Hiroto Hayashi, Koichiro Sakata, Hiroko Takenouchi, Hiroto Matsui, Yoshitaro Shindo, Michihisa Iida, Yasunobu Koki, Hideki Arima, Hiroyuki Furukawa, Tomio Ueno, Shigefumi Yoshino, Yusuke Nakamura, Masaaki Oka, Hiroaki Nagano

    CANCER SCIENCE   108 ( 1 )   73 - 80   2017.1

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    We previously conducted a phase I clinical trial combining the HLA-A*2402-restricted KIF20A-derived peptide vaccine with gemcitabine for advanced pancreatic cancer (PC) and confirmed its safety and immunogenicity in cancer patients. In this study, we conducted a multicenter, single-armed, phase II trial using two antiangiogenic cancer vaccines targeting VEGFR1 and VEGFR2 in addition to the KIF20A peptide. We attempted to evaluate the clinical benefit of the cancer vaccination in combination with gemcitabine. Chemotherapy naive PC patients were enrolled to evaluate primarily the 1-year survival rate, and secondarily overall survival (OS), progression free survival (PFS), response rate (RR), disease control rate (DCR) and the peptide-specific immune responses. All enrolled patients received therapy without the HLA-A information, and the HLA genotypes were used for classification of the patients. Between June 2012 and May 2013, a total of 68 patients were enrolled. No severe systemic adverse effects of Grade 3 or higher related to these three peptides were observed. The 1-year survival rates between the HLA-A*2402-matched and -unmatched groups were not significantly different. In the HLA-A*2402 matched group, patients showing peptide-specific CTL induction for KIF20A or VEGFR1 showed a better prognosis compared to those without such induction (P = 0.023, P = 0.009, respectively). In the HLA-A*2402-matched group, the patients who showed a strong injection site reaction had a better survival rate (P = 0.017) compared to those with a weak or no injection site reaction. This phase II study demonstrated that this therapeutic peptide cocktail might be effective in patients who demonstrate peptide-specific immune reactions although predictive biomarkers are needed for patient selection in its further clinical application.

    DOI: 10.1111/cas.13113

    Web of Science

    researchmap

  • Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study

    Nobuaki Suzuki, Shoichi Hazama, Haruo Iguchi, Kazuhiro Uesugi, Hiroaki Tanaka, Kosei Hirakawa, Atsushi Aruga, Takashi Hatori, Hidenobu Ishizaki, Yuzo Umeda, Toshiyoshi Fujiwara, Tetsuya Ikemoto, Mitsuo Shimada, Kazuhiko Yoshimatsu, Ryoichi Shimizu, Hiroto Hayashi, Koichiro Sakata, Hiroko Takenouchi, Hiroto Matsui, Yoshitaro Shindo, Michihisa Iida, Yasunobu Koki, Hideki Arima, Hiroyuki Furukawa, Tomio Ueno, Shigefumi Yoshino, Yusuke Nakamura, Masaaki Oka, Hiroaki Nagano

    CANCER SCIENCE   108 ( 1 )   73 - 80   2017.1

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    We previously conducted a phase I clinical trial combining the HLA-A*2402-restricted KIF20A-derived peptide vaccine with gemcitabine for advanced pancreatic cancer (PC) and confirmed its safety and immunogenicity in cancer patients. In this study, we conducted a multicenter, single-armed, phase II trial using two antiangiogenic cancer vaccines targeting VEGFR1 and VEGFR2 in addition to the KIF20A peptide. We attempted to evaluate the clinical benefit of the cancer vaccination in combination with gemcitabine. Chemotherapy naive PC patients were enrolled to evaluate primarily the 1-year survival rate, and secondarily overall survival (OS), progression free survival (PFS), response rate (RR), disease control rate (DCR) and the peptide-specific immune responses. All enrolled patients received therapy without the HLA-A information, and the HLA genotypes were used for classification of the patients. Between June 2012 and May 2013, a total of 68 patients were enrolled. No severe systemic adverse effects of Grade 3 or higher related to these three peptides were observed. The 1-year survival rates between the HLA-A*2402-matched and -unmatched groups were not significantly different. In the HLA-A*2402 matched group, patients showing peptide-specific CTL induction for KIF20A or VEGFR1 showed a better prognosis compared to those without such induction (P = 0.023, P = 0.009, respectively). In the HLA-A*2402-matched group, the patients who showed a strong injection site reaction had a better survival rate (P = 0.017) compared to those with a weak or no injection site reaction. This phase II study demonstrated that this therapeutic peptide cocktail might be effective in patients who demonstrate peptide-specific immune reactions although predictive biomarkers are needed for patient selection in its further clinical application.

    DOI: 10.1111/cas.13113

    Web of Science

    researchmap

  • Therapeutic Cell-Cycle-Decoy Efficacy of a Telomerase-Dependent Adenovirus in an Orthotopic Model of Chemotherapy-Resistant Human Stomach Carcinomatosis Peritonitis Visualized With FUCCI Imaging

    Shuya Yano, Kiyoto Takehara, Hiroshi Tazawa, Hiroyuki Kishimoto, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert, M. Hoffman

    Journal of Cellular Biochemistry, Journal of Supramolecular and Cellular Biochemistry, Journal of supramolecular structure   476 - 479   2017

     More details

  • Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

    Shindo Y, Hazama S, Suzuki N, Iguchi H, Uesugi K, Tanaka H, Aruga A, Hatori T, Ishizaki H, Umeda Y, Fujiwara T, Ikemoto T, Shimada M, Yoshimatsu K, Takenouchi H, Matsui H, Kanekiyo S, Iida M, Koki Y, Arima H, Furukawa H, Ueno T, Yoshino S, Fujita T, Kawakami Y, Nakamura Y, Oka M, Nagano H

    J Exp Clin Cancer Res   36 ( 1 )   doi: 10.1186/s13046-017-0509-1   2017

     More details

  • OBP-401-GFP telomerase-dependent adenovirus illuminates and kills high-metastatic more effectively than low-metastatic triple-negative breast cancer in vitro.

    Yano S, Takehara K, Kishimoto H, Tazawa H, Urata Y, Kagawa S, Bouvet M, Fujiwara T, Hoffman R.M

    Cancer Gene Therapy   20 ( 2 )   45 - 47   2017

     More details

  • Living donor liver transplantation for acute liver failure

    Kazuhiro Yoshida, Yuzo Umeda, Akinobu Takaki, Takeshi Nagasaka, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Kosei Takagi, Tetsuya Yasunaka, Hiroyuki Okada, Takahito Yagi, Toshiyoshi Fujiwara

    Acta Medica Okayama, Acta. Medica Okayama, Acta medicinae Okayama, Acta medica Okayama   71 ( 5 )   381 - 390   2017

     More details

  • Sarcopenia predicts postoperative infection in patients undergoing hepato-biliary-pancreatic surgery

    Kosei Takagi, Takahito Yagi, Ryuichi Yoshida, Yuzo Umeda, Daisuke Nobuoka, Takashi Kuise, Toshiyoshi Fujiwara

    International Journal of Surgery Open   6   12 - 18   2017

     More details

    Language:English   Publisher:Elsevier Ltd  

    Background Operative mortality and morbidity rates after hepato-biliary-pancreatic (BILI) surgery remain high. This study evaluated clinical characteristics and surgical outcomes of patients who underwent BILI surgery and investigated predictors of outcomes by focusing on sarcopenia. Materials and methods A prospective observational study was performed for consecutive patients who underwent BILI surgery at our institution between June 2013 and May 2014. Sarcopenia was evaluated using computed tomography. Surgical outcomes and the influence of sarcopenia on outcomes were evaluated. Subsequently, the impact of prognostic factors, including sarcopenia, associated with postoperative infections was assessed using multivariate analyses. Results Total mortality, major complications, and infectious disease rates for all 157 patients were 0%, 9.6%, and 21.7%, respectively. Thirty-eight patients met the criteria for sarcopenia. The sarcopenic group had a significantly higher incidence of infectious complications compared to the non-sarcopenic group (36.8% vs. 17.2%
    P = 0.015). During multivariate analyses of prognostic factors, sarcopenia (hazard ratio = 2.44
    P = 0.043) and diabetes mellitus (hazard ratio = 3.07
    P = 0.01) were detected as independent predictors of postoperative infections. Conclusions Sarcopenia is an independent preoperative predictor of infection after BILI surgery. Earlier diagnosis and therapeutic intervention for patients with sarcopenia could be useful in the development of comprehensive approaches for perioperative care.

    DOI: 10.1016/j.ijso.2016.12.002

    Scopus

    researchmap

  • Preoperative Controlling Nutritional Status (CONUT) Score for Assessment of Prognosis Following Hepatectomy for Hepatocellular Carcinoma

    Kosei Takagi, Takahito Yagi, Yuzo Umeda, Susumu Shinoura, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Hiroyuki Araki, Toshiyoshi Fujiwara

    World Journal of Surgery, Bulletin de la Societe internationale de chirurgie   1 - 8   2017

  • Primary pancreatic-type acinar cell carcinoma of the jejunum with tumor thrombus extending into the mesenteric venous system: a case report and literature review

    Takagi K, Yagi T, Tanaka T, Umeda Y, Yoshida R, Nobuoka D, Kuise T, Fujiwara T

    BMC Surg   17 ( 75 )   doi: 10.1186/s12893-017-0273-3   2017

     More details

  • Management of early gastric cancer that meet the indication for radical lymph node dissection following endoscopic resection: a retrospective cohort analysis

    Kikuchi S, Kuroda S, Nishizaki M, Kagawa T, Kanzaki H, Kawahara Y, Kagawa S, Tanaka T, Okada H, Fujiwara T

    BMC Surg   17 ( 1 )   doi: 10.1186/s12893-017-0268-0   2017

     More details

  • GFP labeling kinetics of triple-negative human breast cancer by a killer-reporter adenovirus in 3D Gelfoam® histoculture

    Yano S, Takehara K, Miwa S, Kishimoto H, Tazawa H, Urata Y, Kagawa S, Bouvet M, Fujiwara T, Hoffman RM

    In Vitro Cell Dev Biol Anim   53 ( 6 )   479 - 482   2017

     More details

  • 胃癌術後再発病変に対する複数回の放射線療法が奏功し長期生存が得られた1例

    堀 直人, 香川俊輔, 菊地覚次, 黒田新士, 渡邉めぐみ, 坂本修一, 香川哲也, 桒田和也, 久保田哲史, 岸本浩行, 西﨑正彦, 片山敬久, 藤原俊義

    癌と化学療法   44 ( 2 )   165 - 167   2017

     More details

  • [Multiple Salvage Radiotherapies for Metachronous Lymph Node Metastasis from Gastric Cancer Contributed to Long-Term Management of Disease].

    Naoto Hori, Shunsuke Kagawa, Satoru Kikuchi, Shinji Kuroda, Megumi Watanabe, Shuichi Sakamoto, Tetsuya Kagawa, Kazuya Kuwada, Tetsushi Kubota, Hiroyuki Kishimoto, Masahiko Nishizaki, Norihisa Katayama, Toshiyoshi Fujiwara

    Gan to kagaku ryoho. Cancer & chemotherapy   44 ( 2 )   165 - 167   2017

     More details

    Language:Japanese  

    A 70-year-old man who underwent gastrectomy for Stage III C gastric cancer developed lymph node(LN)metastasis posterior to the pancreatic head 3 years after the radical surgery.He was first treated with radiotherapy(RT)followed by chemotherapy.The irradiated tumor regressed completely.However, the cancer relapsed in a single para-aortic LN and he was treated with RT to the lesion followed by chemotherapy.Although it completely regressed, later, lung metastasis was observed.The lung lesions were well suppressed by switching to docetaxel; however, the cancer relapsed again in a mediastinal LN, and it was not responsive to docetaxel.The growing mediastinal lesion was irradiated again, which resulted in stable disease.The patient has been treated for 4 years and 7 months with all lesions being well-managed, and chemotherapy is being continued.Recurrent gastric cancer after surgery tends to present as multiple lesions; therefore, the principle therapy is systemic chemotherapy and RT is unlikely to be suitable.However, especially in cases of a solitary lesion that is chemo-resistant, RT could be an optimal option and contribute to long-term survival even in patients with recurrent gastric cancer.

    PubMed

    researchmap

  • GFP labeling kinetics of triple-negative human breast cancer by a killer-reporter adenovirus in 3D Gelfoam? histoculture

    Shuya Yano, Kiyoto Takehara, Shinji Miwa, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert, M. Hoffman

    In Vitro Cellular and Developmental Biology - Plant, In Vitro Cellular and Developmental Biology - Animal   1 - 4   2017

  • Cell-cycle-dependent drug-resistant quiescent cancer cells induce tumor angiogenesis after chemotherapy as visualized by real-time FUCCI imaging

    Shuya Yano, Kiyoto Takehara, Hiroshi Tazawa, Hiroyuki Kishimoto, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert M. Hoffman

    CELL CYCLE   16 ( 5 )   406 - 414   2017

     More details

    Language:English   Publisher:TAYLOR & FRANCIS INC  

    We previously demonstrated that quiescent cancer cells in a tumor are resistant to conventional chemotherapy as visualized with a fluorescence ubiquitination cell cycle indicator (FUCCI). We also showed that proliferating cancer cells exist in a tumor only near nascent vessels or on the tumor surface as visualized with FUCCI and green fluorescent protein (GFP)-expressing tumor vessels. In the present study, we show the relationship between cell-cycle phase and chemotherapy-induced tumor angiogenesis using in vivo FUCCI real-time imaging of the cell cycle and nestin-driven GFP to detect nascent blood vessels. We observed that chemotherapy-treated tumors, consisting of mostly of quiescent cancer cells after treatment, had much more and deeper tumor vessels than untreated tumors. These newly-vascularized cancer cells regrew rapidly after chemotherapy. In contrast, formerly quiescent cancer cells decoyed to S/G(2) phase by a telomerase-dependent adenovirus did not induce tumor angiogenesis. The present results further demonstrate the importance of the cancer-cell position in the cell cycle in order that chemotherapy be effective and not have the opposite effect of stimulating tumor angiogenesis and progression.

    DOI: 10.1080/15384101.2016.1220461

    Web of Science

    researchmap

  • Thoracoscopic esophagectomy was effective in a case of lower esophageal stenosis due to recurrence of achalasia after myotomy 40 years previously

    Katsura Yuki, Shirakawa Yasuhiro, Tanabe Shunsuke, Maeda Naomi, Noma Kazuhiro, Fujiwara Toshiyoshi

    Okayama Igakkai Zasshi (Journal of Okayama Medical Association)   129 ( 1 )   41 - 44   2017

     More details

    Language:Japanese   Publisher:Okayama Medical Association  

    When planning surgery for achalasia, it is important to plan for adequate myotomy and prevention of reflux. However, achalasia may recur if the procedure was inadequate or in patients with a long-term course. The present case is a 68-year-old woman who underwent myotomy of the lower esophageal sphincter 40 years ago, but recently reported difficulty in swallowing. Dilatation of the thoracic esophagus and stenosis of the abdominal esophagus were identified by examination, and the patient was diagnosed with recurrence of achalasia. After percutaneous endoscopic gastrostomy was performed to recover nutritional status, thoracoscopic esophagectomy was carried out. The patient's post-operative course was uneventful and oral intake was enabled. At the time of writing, there has been no re-recurrence. There is no standard therapy for post-operative recurrence of achalasia. We believe that thoracoscopic esophagectomy for the recurrence of achalasia is a safe and minimally invasive alternative to conventional surgery.

    DOI: 10.4044/joma.129.41

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2017219750

  • 食道胃接合部癌に対する下部食道噴門側胃切除術-腹臥位胸腔鏡・腹腔鏡アプローチによる完全鏡視下手術-

    野間和広, 白川靖博, 田辺俊介, 黒田新士, 西﨑正彦, 藤原俊義

    手術   71 ( 5 )   767 - 772   2017

     More details

  • Radiographic sarcopenia predicts postoperative infectious complications in patients undergoing pancreaticoduodenectomy

    Takagi K, Yoshida R, Yagi T, Umeda Y, Nobuoka D, Kuise T, Fujiwara T

    BMC Surg   17 ( 64 )   DOI: 10.1186/s12893-017-0261-7   2017

     More details

  • A case of long-term survival after surgical resection for solitary adrenal recurrence of esophageal squamous carcinoma

    Kanaya N, Noma K, Okada T, Maeda N, Tanabe S, Sakurama K, Shirakawa Y, Fujiwara T

    Surg Case Rep   3 ( 61 )   doi: 10.1186/s40792-017-0337-8   2017

     More details

  • Comparison of outcomes between symptomatic and asymptomatic patients with colorectal cancer: a propensity score-matched analysis of surgical invasiveness, medical costs and oncological outcomes. International journal

    Ryo Inada, Takeshi Nagasaka, Ayako Watanabe, Tomohiko Yagi, Yoshiko Mori, Yoshitaka Kondo, Hiroyuki Kishimoto, Yuzo Umeda, Toshiyoshi Fujiwara

    BMJ open gastroenterology   4 ( 1 )   doi: 10.1136/bmjgast-2017-000146   2017

     More details

    Language:English  

    BACKGROUND AND AIMS: Whether asymptomatic patients with colorectal cancer (CRC) who are treated in hospitals show better outcomes than symptomatic patients with CRC still remains unknown. The aim of this study was to evaluate differences in clinical benefits following treatment in asymptomatic and symptomatic patients with CRC. METHODS: This study was a retrospective cohort analysis with data obtained from records. A cohort of 145 asymptomatic and 123 symptomatic patients who underwent CRC surgery between January 2009 and December 2011 was enrolled. To reduce bias in comparing outcomes, propensity score (PS) analysis was used for matching of patients in the symptomatic and asymptomatic groups based on clinicopathological factors. Surgical invasiveness, medical costs and oncological outcomes were examined by unadjusted and PS-matched analysis. RESULTS: Tumours in the symptomatic group were more often diagnosed in advanced stages compared with tumours in the asymptomatic group. Therefore, fewer symptomatic group patients underwent minimally invasive surgery. Short-term outcomes, including amount of blood loss, duration of postoperative hospital stay and perioperative medical costs, were significantly better in the asymptomatic group. Although overall survival was significantly better in the asymptomatic group, there was no significant difference between the groups when the patients were adjusted on the basis of PS. CONCLUSIONS: Though this study was limited by the retrospective nature and small sample size, favourable outcomes in asymptomatic patients were due to the higher proportion of patients in this group who were diagnosed with CRC in earlier stages, due to participation in CRC screening programmes.

    DOI: 10.1136/bmjgast-2017-000146

    PubMed

    researchmap

  • Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer

    Tazawa H, Kuroda S, Hasei J, Kagawa S, Fujiwara T

    Int J Mol Sci   18 ( 7 )   doi:10.3390/ijms18071479   2017

     More details

  • Eradication of melanoma in vitro and in vivo via targeting with a Killer-Red-containing telomerase-dependent adenovirus

    Kiyoto Takehara, Shuya Yano, Hiroshi Tazawa, Hiroyuki Kishimoto, Nobuhiro Narii, Hiroyuki Mizuguchi, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert, M. Hoffman

    Cell Cycle   1 - 7   2017

  • A novel intestinal rotation method for digestive reconstruction after combined pancreaticoduodenectomy and extended right hemicolectomy: A case report and surgical technique

    Kosei Takagi, Takahito Yagi, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Kenjiro Kumano, Takeshi Kojima, Takuro Fushimi, Toshiyoshi Fujiwara

    International Journal of Surgery Case Reports   39   51 - 55   2017

     More details

    Language:English   Publisher:Elsevier Ltd  

    Introduction Pancreaticoduodenectomy (PD) combined with extended right hemicolectomy (RH) is a challenging procedure for locally advanced malignancies. However, information concerning the reconstruction method of the digestive system is limited. Here, we present a case and surgical technique of a novel intestinal rotation method for digestive reconstruction after PD combined with RH. Presentation of case A 62-year-old man with locally advanced pancreatic cancer received conversion surgery combined with PD and RH after preoperative chemotherapy. With respect to the reconstruction of the digestive system, the entire intestinal mesentery was rotated 180° forward counterclockwise around the axis of the superior mesenteric artery, and then the reconstruction, according to Child's method, was performed. The patient recovered without problems in gastroenterological functions after the operation. Discussion With respect to the reconstruction of the digestive system in patients undergoing combined PD and RH, practitioners should pay close attention to twisting of the intestinal mesentery when bringing up the proximal jejunum for pancreatojejunostomy and hepatojejunostomy and the distal ileum for ileocolic anastomosis. This intestinal rotation method enables a smooth and uneventful reconstruction of the digestive system. Conclusion This is the first detailed description of an intestinal rotation method for digestive reconstruction after combined PD and extended RH. The intestinal rotation method can be an alternative and helpful technical option for digestive reconstruction in patients with combined PD and RH.

    DOI: 10.1016/j.ijscr.2017.07.063

    Scopus

    researchmap

  • Role of zoledronic acid in oncolytic virotherapy

    Yasuaki Yamakawa, Hiroshi Tazawa, Joe Hasei, Shuhei Osaki, Toshinori Omori, Kazuhisa Sugiu, Tadashi Komatsubara, Kouji Uotani, Tomohiro Fujiwara, Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    Cancer Science, Japanese Journal of Cancer Research, Gann, The Japanese Journal of Cancer Research   149 - 160   2017

     More details

  • Visualized Evaluation of Blood Flow to the Gastric Conduit and Complications in Esophageal Reconstruction. International journal

    Kazuhiro Noma, Yasuhiro Shirakawa, Nobuhiko Kanaya, Tsuyoshi Okada, Naoaki Maeda, Takayuki Ninomiya, Shunsuke Tanabe, Kazufumi Sakurama, Toshiyoshi Fujiwara

    Journal of the American College of Surgeons   226 ( 3 )   858 - 867   2017

     More details

    Language:English  

    BACKGROUND: Evaluation of the blood supply to gastric conduits is critically important to avoid complications after esophagectomy. We began visual evaluation of blood flow using indocyanine green (ICG) fluorescent imaging in July 2015, to reduce reconstructive complications. In this study, we aimed to statistically verify the efficacy of blood flow evaluation using our simplified ICG method. STUDY DESIGN: A total of 285 consecutive patients who underwent esophagectomy and gastric conduit reconstruction were reviewed and divided into 2 groups: before and after introduction of ICG evaluation. The entire cohort and 68 patient pairs after propensity score matching (PS-M) were evaluated for clinical outcomes and the effect of visualized evaluation on reducing the risk of complication. RESULTS: The leakage rate in the ICG group was significantly lower than in the non-ICG group for each severity grade, both in the entire cohort (285 subjects) and after PS-M; the rates of other major complications, including recurrent laryngeal nerve palsy and pneumonia, were not different. The duration of postoperative ICU stay was approximately 1 day shorter in the ICG group than in the non-ICG group in the entire cohort, and approximately 2 days shorter after PS-M. Visualized evaluation of blood flow with ICG methods significantly reduced the rate of anastomotic complications of all Clavien-Dindo (CD) grades. Odds ratios for ICG evaluation decreased with CD grade (0.3419 for CD ≥ 1; 0.241 for CD ≥ 2; and 0.2153 for CD ≥ 3). CONCLUSIONS: Objective evaluation of blood supply to the reconstructed conduit using ICG fluorescent imaging reduces the risk and degree of anastomotic complication.

    DOI: 10.1016/j.jamcollsurg.2017.11.007

    PubMed

    researchmap

  • 癌関連線維芽細胞はIL-6を分泌しリンパ球の遊走を制御することで腫瘍免疫抑制を誘導する

    加藤卓也, 野間和広, 賀島肇, 桂佑貴, 佐藤浩明, 二宮卓之, 大原利章, 藤原俊義

    日本がん転移学会学術集会・総会プログラム抄録集   26th   2017

  • 癌関連線維芽細胞は食道癌のリンパ節転移を促進するか~臨床検体の解析と同所移植モデルを用いた検証~

    賀島肇, 野間和広, 佐藤浩明, 桂佑貴, 加藤卓也, 大原利章, 田澤大, 白川靖博, 藤原俊義

    日本がん転移学会学術集会・総会プログラム抄録集   26th   2017

  • 遅発性に肝転移・骨盤内リンパ節転移をきたした直腸神経内分泌腫瘍の1例

    重安邦俊, 杭瀬崇, 母里淑子, 河合毅, 矢野修也, 戸嶋俊明, 浅野博昭, 近藤喜太, 佃和憲, 永坂岳司, 八木孝仁, 藤原俊義

    日本大腸肛門病学会雑誌(Web)   70   2017

  • 食道がんに対する放射線併用ウイルス療法の臨床研究

    藤原俊義, 田澤大, 田邊俊介, 香川俊輔, 白川靖博

    日本臨床   75 ( 5 )   746 - 751   2017

     More details

  • 噴門側胃切除術後再建:手縫い 腹腔鏡下体腔内手縫い「観音開き法」食道残胃吻合

    西﨑正彦, 黒田新士, 菊地覚次, 垣内慶彦, 松村年久, 渡邉めぐみ, 香川俊輔, 藤原俊義

    臨床外科   72 ( 4 )   412 - 415   2017

  • 「外科臨床研究の基礎と実践」によせて

    藤原俊義

    日本外科学会雑誌   118 ( 4 )   466 - 466   2017

     More details

  • 胃癌におけるサルコペニアの意義

    桒田和也, 黒田新士, 藤原俊義

    消化器外科   40 ( 7 )   1042 - 1048   2017

     More details

  • HOZOT細胞を用いた腫瘍融解ウイルス製剤のDDS

    田澤 大, 大西哲平, 香川俊輔, 中村修治, 藤原俊義

    BIO INDUSTRY   34 ( 4 )   16 - 23   2017

     More details

  • ウイルス療法第3回 がんウイルス療法の臨床試験

    藤原俊義

    がん免疫療法   1 ( 2 )   118 - 120   2017

     More details

  • 生体肝移植ドナー手術 後区域グラフト採取術

    八木孝仁, 楳田祐三, 吉田龍一, 信岡大輔, 藤原俊義

    手術   71 ( 10 )   1383 - 1388   2017

  • がんウイルス療法

    藤原俊義

    腫瘍内科   20 ( 2 )   171 - 176   2017

     More details

  • ウイルス療法第2回 がん治療に用いられるウイルス

    藤原俊義

    がん免疫療法   1 ( 2 )   115 - 117   2017

     More details

  • 臨床応用されるp53研究 現状と今後の課題 進化するp53遺伝子を用いたがんウイルス療法

    藤原俊義

    実験医学   35 ( 14 )   2364 - 2365   2017

     More details

  • 超高齢者の進行食道癌に対し積極的に集学的治療を行い長期無再発生存中の1例

    松三雄騎, 白川靖博, 田邊俊介, 河本慧, 前田直見, 二宮卓之, 野間和広, 西崎正彦, 香川俊輔, 藤原俊義

    癌と化学療法   44 ( 12 )   1784 - 1786   2017

     More details

  • Successful management of unresectable small bowel lymphoma with laparoscopy-assisted surgical exclusion of the affected intestine

    Kagawa T, Kobayashi T, Ueyama S, Okabayashi H, Ogino T, Fujiwara T

    Asian J Endosc Surg   10 ( 4 )   454 - 458   2017

     More details

  • 観音開き法を用いた噴門機能温存

    西﨑正彦, 黒田新士, 菊地覚次, 垣内慶彦, 香川俊輔, 藤原俊義

    手術   71 ( 1 )   21 - 25   2017

     More details

  • 臨床研究中核病院の現状と今後の展望

    藤原俊義

    岡山医学会雑誌   129 ( 3 )   179 - 184   2017

  • 有茎空腸による食道再建

    白川靖博, 河本 慧, 松三雄騎, 前田直見, 二宮卓之, 田辺俊介, 櫻間教文, 野間和広, 藤原俊義

    臨床雑誌外科   79 ( 4 )   355 - 359   2017

  • 胸部食道癌に対する頸部リンパ節郭清術

    白川靖博, 野間和広, 田辺俊介, 藤原俊義

    消化器外科   40 ( 5 )   508 - 515   2017

     More details

  • Oncolytic virotherapy for osteosarcoma

    Pharm stage   16 ( 12 )   54 - 59   2017

     More details

  • 腹腔鏡内視鏡合同手術 外科医の立場から

    西﨑正彦, 岡田裕之, 藤原俊義

    日本消化器病学会雑誌   114 ( 2 )   218 - 223   2017

  • 気管気管支リンパ節郭清における左気管支動脈温存のための安全なアプローチ

    白川靖博, 前田直見, 二宮卓之, 田辺俊介, 野間和広, 藤原俊義

    手術   71 ( 4 )   367 - 374   2017

     More details

  • ウイルス療法とは

    藤原俊義

    がん免疫療法   1 ( 1 )   51 - 52   2017

     More details

  • HER2陽性胃癌に対する新たな治療戦略

    金谷信彦, 黒田新士, 久保田哲史, 森廣俊昭, 菊地覚次, 西崎正彦, 田澤大, 香川俊輔, 藤原俊義

    癌と化学療法   44 ( 10 )   883 - 885   2017

     More details

  • Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system

    Aoyama K, Kuroda S, Morihiro T, Kanaya N, Kubota T, Kakiuchi Y, Kikuchi S, Nishizaki M, Kagawa S, Tazawa H, Fujiwara T

    Sci Rep   7 ( 14177 )   doi: 10.1038/s41598-017-14717-x   2017

     More details

  • The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study

    Sakae H, Kanzaki H, Nasu J, Akimoto Y, Matsueda K, Yoshioka M, Nakagawa M, Hori S, Inoue M, Inaba T, Imagawa A, Takatani M, Takenaka R, Suzuki S, Fujiwara T, Okada H

    Br J Cancer   117 ( 11 )   1607 - 1613   2017

     More details

  • A novel intestinal rotation method for digestive reconstruction after combined pancreaticoduodenectomy and extended right hemicolectomy: A case report and surgical technique

    Kosei Takagi, Takahito Yagi, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Kenjiro Kumano, Takeshi Kojima, Takuro Fushimi, Toshiyoshi Fujiwara

    International Journal of Surgery Case Reports   39   51 - 55   2017

     More details

    Language:English   Publisher:Elsevier Ltd  

    Introduction Pancreaticoduodenectomy (PD) combined with extended right hemicolectomy (RH) is a challenging procedure for locally advanced malignancies. However, information concerning the reconstruction method of the digestive system is limited. Here, we present a case and surgical technique of a novel intestinal rotation method for digestive reconstruction after PD combined with RH. Presentation of case A 62-year-old man with locally advanced pancreatic cancer received conversion surgery combined with PD and RH after preoperative chemotherapy. With respect to the reconstruction of the digestive system, the entire intestinal mesentery was rotated 180° forward counterclockwise around the axis of the superior mesenteric artery, and then the reconstruction, according to Child's method, was performed. The patient recovered without problems in gastroenterological functions after the operation. Discussion With respect to the reconstruction of the digestive system in patients undergoing combined PD and RH, practitioners should pay close attention to twisting of the intestinal mesentery when bringing up the proximal jejunum for pancreatojejunostomy and hepatojejunostomy and the distal ileum for ileocolic anastomosis. This intestinal rotation method enables a smooth and uneventful reconstruction of the digestive system. Conclusion This is the first detailed description of an intestinal rotation method for digestive reconstruction after combined PD and extended RH. The intestinal rotation method can be an alternative and helpful technical option for digestive reconstruction in patients with combined PD and RH.

    DOI: 10.1016/j.ijscr.2017.07.063

    Scopus

    researchmap

  • Eradication of melanoma in vitro and in vivo via targeting with a Killer-Red-containing telomerase-dependent adenovirus

    Kiyoto Takehara, Shuya Yano, Hiroshi Tazawa, Hiroyuki Kishimoto, Nobuhiro Narii, Hiroyuki Mizuguchi, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert M. Hoffman

    CELL CYCLE   16 ( 16 )   1502 - 1508   2017

     More details

    Language:English   Publisher:TAYLOR & FRANCIS INC  

    Melanoma is a highly recalcitrant cancer and transformative therapy is necessary for the cure of this disease. We recently developed a telomerase-dependent adenovirus containing the fluorescent protein Killer-Red. In the present report, we first determined the efficacy of Killer-Red adenovirus combined with laser irradiation on human melanoma cell lines in vitro. Cell viability of human melanoma cells was reduced in a dose-dependent and irradiation-time-dependent manner. We used an intradermal xenografted melanoma model in nude mice to determine efficacy of the Killer-Red adenovirus. Intratumoral injection of Killer-Red adenovirus, combined with laser irradiation, eradicated the melanoma indicating the potential of a new paradigm of cancer therapy.

    DOI: 10.1080/15384101.2016.1249548

    Web of Science

    researchmap

  • 食道癌手術後に反回神経麻痺を呈した患者における肺炎のリスク因子について

    池田朋大, 野澤康明, 伊藤真理, 足羽孝子, 二宮卓之, 前田直見, 田邊俊介, 野間和広, 白川靖博, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   71st   2017

  • 腎癌の多発膵転移・単発肺転移・下大静脈腫瘍栓に対して膵全摘を含めた一期的切除を施行し良好な術後経過を得た一例

    國府島健, 信岡大輔, 八木孝仁, 楳田祐三, 吉田龍一, 杭瀬崇, 熊野健二郎, 高木弘誠, 伏見卓郎, 谷本竜太, 藤原俊義

    日本膵切研究会プログラム・抄録集   44th   2017

  • 進行食道癌に対するDCF療法を用いた集学的治療

    田邊俊介, 白川靖博, 河本慧, 松三雄騎, 前田直見, 二宮卓之, 野間和広, 西崎正彦, 香川俊輔, 藤原俊義

    日本消化器外科学会雑誌(Web)   50 ( Supplement1 )   2017

  • 食道癌手術における臨床応用解剖の経験

    前田直見, 白川靖博, 田辺俊介, 野間和広, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   70th   2017

  • 80歳以上の超高齢者に対する安全な食道癌治療への取り組み

    田辺俊介, 白川靖博, 前田直見, 野間和広, 香川俊輔, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   70th   2017

  • 腹臥位胸腔鏡下食道切除における微細層構造を意識した安全な上縦隔郭清術

    野間和広, 白川靖博, 鳴坂徹, 前田直見, 二宮卓之, 田辺俊介, 楳田祐三, 西崎正彦, 香川俊輔, 藤原俊義

    日本内視鏡外科学会雑誌   22 ( 7 (CD-ROM) )   2017

  • 胸腔鏡下食道癌手術における膜と層の微細解剖に基づいた上縦隔リンパ節郭清

    白川靖博, 前田直見, 田辺俊介, 野間和広, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   70th   2017

  • 食道鏡視下手術におけるリンパ節郭清のTipsメルクマールとV字郭清法

    野間和広, 白川靖博, 前田直見, 田辺俊介, 藤原俊義

    日本胸部外科学会定期学術集会(Web)   70th   2017

  • 鏡視下食道癌手術におけるピットフォールとトラブルシューティング

    河本慧, 田邊俊介, 白川靖博, 松三雄騎, 前田直見, 二宮卓之, 野間和広, 藤原俊義

    日本消化器外科学会雑誌(Web)   50 ( Supplement1 )   2017

  • 食道がん患者の術前看護外来前と入院時の抑うつ傾向と心理的適応の変化

    廣川万里子, 市川あい, 伊藤真理, 足羽孝子, 前田直見, 二宮卓之, 田邊俊介, 野間和広, 白川靖博, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   71st   2017

  • 食道癌患者における術前目標体重管理への取り組みが術後の食習慣習得に与える影響

    園井みか, 足羽孝子, 伊藤真理, 前田直見, 二宮卓之, 田邊俊介, 野間和広, 白川靖博, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   71st   2017

  • In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models

    Shuya Yano, Kiyoto Takehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    ANTICANCER RESEARCH   36 ( 12 )   6273 - 6277   2016.12

     More details

    Language:English   Publisher:INT INST ANTICANCER RESEARCH  

    Aim: Triple-negative breast cancer (TNBC), defined by the absence of receptors for estrogen, progesterone and human epithelial receptor 2 (HER2), is a recalcitrant disease in need of effective therapy. We previously isolated very-highly metastatic variants of the TNBC cell line MDA-MB-231 using serial orthotopic implantation of MDA-MB-231 human breast cancer cells in nude mice. Materials and Methods: MDA-MB-231 cells expressing red fluorescent protein (MDA-MB-231-RFP) (1x10(7) cells/site) were initially injected subcutaneously in the flank of nude mice. After the subcutaneous tumors grew, they were harvested and cut into small pieces for orthotopic implantation into the right lower mammary gland. After the orthotopic tumors grew, they were resected and cut into small pieces and orthotopically re-implanted into the mammary gland of nude mice. The tumors grew and metastasized to lymph nodes. The lymph node metastases were harvested and cut into small pieces and orthotopically re-implanted into the mammary gland of nude mice. After the orthotopic tumors grew, the tumor was removed leaving residual cancer cells, which grew and metastasized to lymph nodes. The lymph node metastases were harvested, cut into pieces and orthotopically re-implanted into the mammary gland of nude mice for three or seven cycles in order to isolate intermediately, or highly-metastatic variants, respectively. Results: The degree of malignancy of isolated variants of MDA-MB-231 depends on the extent of orthotopic transplantation. Serial transplantation resulted in MDA-MB-231-RFP which significantly produced larger tumors compared with the parental MDA-MB-231-RFP. Serial orthotopic implantation for three cycles resulted in intermediately-metastatic variants of MDA-MB-231-RFP. MDA-MB-231-RFP serially orthotopically transplanted seven times significantly metastasized more to lymph nodes compared with parental MDA-MB-231-RFP cells and the intermediately-metastatic variant. The highly-metastatic variant MDA-MB-231-RFP cells significantly metastasized to the lung to a greater extent compared with parental MDA-MB-231-RFP and intermediate variants of MDA-MB-231-RFP. Conclusion: These results suggest that the number of serial orthotopic transplantations of MDA-MB-231-RFP correlates positively with tumor aggressiveness, and the intermediately- and highly-metastatic variants can serve as models of metastatic progression of TNBC.

    DOI: 10.21873/anticanres.11222

    Web of Science

    researchmap

  • A successful case of deceased donor liver transplantation for a patient with intrahepatic arterioportal fistula

    Kosei Takagi, Takahito Yagi, Ryuichi Yoshida, Susumu Shinoura, Yuzo Umeda, Daisuke Nobuoka, Nobuyuki Watanabe, Takashi Kuise, Kenta Sui, Akira Hirose, Makiko Tsuboi, Mitsunari Ogasawara, Shinji Iwasaki, Toshiji Saibara, Toshiyoshi Fujiwara

    HEPATOLOGY RESEARCH   46 ( 13 )   1409 - 1415   2016.12

     More details

    Language:English   Publisher:WILEY  

    Intrahepatic arterioportal fistula (IAPF) is a rare cause of portal hypertension that is often difficult to treat with interventional radiology or surgery. Liver transplantation for IAPF is extremely rare. We report a case of bilateral diffuse IAPF with severe portal hypertension requiring deceased donor liver transplantation (DDLT). A 51-year-old woman with no past medical history was admitted to another hospital complaining of abdominal distension and marasmus. A computed tomography scan and digital subtraction angiography indicated a massive pleural effusion, ascites, and a very large IAPF. Several attempts of interventional embolization of the feeding artery failed to ameliorate arterioportal shunt flow. As ruptures of the esophageal varices became more frequent, hepatic encephalopathy worsened. After repeated, uncontrollable attacks of hepatic coma, the patient was referred to our facility for further treatment. Surgical approaches to IAPF other than liver transplantation were challenging because of diffuse collateralization; therefore, we placed the patient on the national waiting list for DDLT. Although her Model for End-Stage Liver Disease score was relatively low, she received a DDLT 2 months after the waiting period. The postoperative course was uneventful, and the patient was discharged 44 days after her transplant. Liver transplantation may be a valid treatment option for uncontrollable IAPF with severe portal hypertension.

    DOI: 10.1111/hepr.12701

    Web of Science

    researchmap

  • A successful case of deceased donor liver transplantation for a patient with intrahepatic arterioportal fistula

    Kosei Takagi, Takahito Yagi, Ryuichi Yoshida, Susumu Shinoura, Yuzo Umeda, Daisuke Nobuoka, Nobuyuki Watanabe, Takashi Kuise, Kenta Sui, Akira Hirose, Makiko Tsuboi, Mitsunari Ogasawara, Shinji Iwasaki, Toshiji Saibara, Toshiyoshi Fujiwara

    HEPATOLOGY RESEARCH   46 ( 13 )   1409 - 1415   2016.12

     More details

    Language:English   Publisher:WILEY  

    Intrahepatic arterioportal fistula (IAPF) is a rare cause of portal hypertension that is often difficult to treat with interventional radiology or surgery. Liver transplantation for IAPF is extremely rare. We report a case of bilateral diffuse IAPF with severe portal hypertension requiring deceased donor liver transplantation (DDLT). A 51-year-old woman with no past medical history was admitted to another hospital complaining of abdominal distension and marasmus. A computed tomography scan and digital subtraction angiography indicated a massive pleural effusion, ascites, and a very large IAPF. Several attempts of interventional embolization of the feeding artery failed to ameliorate arterioportal shunt flow. As ruptures of the esophageal varices became more frequent, hepatic encephalopathy worsened. After repeated, uncontrollable attacks of hepatic coma, the patient was referred to our facility for further treatment. Surgical approaches to IAPF other than liver transplantation were challenging because of diffuse collateralization; therefore, we placed the patient on the national waiting list for DDLT. Although her Model for End-Stage Liver Disease score was relatively low, she received a DDLT 2 months after the waiting period. The postoperative course was uneventful, and the patient was discharged 44 days after her transplant. Liver transplantation may be a valid treatment option for uncontrollable IAPF with severe portal hypertension.

    DOI: 10.1111/hepr.12701

    Web of Science

    researchmap

  • Tumor-targeting adenovirus OBP-401 inhibits primary and metastatic tumor growth of triple-negative breast cancer in orthotopic nude-mouse models

    Shuya Yano, Kiyoto Takehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    ONCOTARGET   7 ( 51 )   85273 - 85282   2016.12

     More details

    Language:English   Publisher:IMPACT JOURNALS LLC  

    Our laboratory previously developed a highly-invasive, triple-negative breast cancer (TNBC) variant using serial orthotopic implantation of the human MDA-MB-231 cell line in nude mice. The isolated variant was highly-invasive in the mammary gland and lymphatic channels and metastasized to lymph nodes in 10 of 12 mice compared to 2 of 12 of the parental cell line. In the present study, the tumor-selective telomerase dependent OBP-401 adenovirus was injected intratumorally (i. t.) (1 x 10(8) PFU) when the high-metastatic MDA-MB-231 primary tumor expressing red fluorescent protein (MDA-MB-231-RFP) reached approximately 500 mm3 (diameter; 10 mm). The mockinfected orthotopic primary tumor grew rapidly. After i. t. OBP-401 injection, the growth of the orthotopic tumors was arrested. Six weeks after implantation, the fluorescent area and fluorescence intensity showed no increase from the beginning of treatment. OBP-401 was then injected into high-metastatic MDA-MB-231-RFP primary orthotopic tumor growing in mice which already had developed metastasis within lymphatic ducts. All 7 of 7 control mice subsequently developed lymph node metastasis. In contrast, none of 7 mice which received OBP-401 had lymph node metastasis. Seven of 7 control mice also had gross lung metastasis. In contrast, none of the 7 mice which received OBP-401 had gross lung metastasis. Confocal laser microscopy imaging demonstrated that all control mice had diffuse lung metastases. In contrast, all 7 mice which received OBP-401 only had a few metastatic cells in the lung. OBP-401 treatment significantly extended survival of the treated mice.

    DOI: 10.18632/oncotarget.13296

    Web of Science

    researchmap

  • Tumor-targeting adenovirus OBP-401 inhibits primary and metastatic tumor growth of triple-negative breast cancer in orthotopic nude-mouse models

    Shuya Yano, Kiyoto Takehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    ONCOTARGET   7 ( 51 )   85273 - 85282   2016.12

     More details

    Language:English   Publisher:IMPACT JOURNALS LLC  

    Our laboratory previously developed a highly-invasive, triple-negative breast cancer (TNBC) variant using serial orthotopic implantation of the human MDA-MB-231 cell line in nude mice. The isolated variant was highly-invasive in the mammary gland and lymphatic channels and metastasized to lymph nodes in 10 of 12 mice compared to 2 of 12 of the parental cell line. In the present study, the tumor-selective telomerase dependent OBP-401 adenovirus was injected intratumorally (i. t.) (1 x 10(8) PFU) when the high-metastatic MDA-MB-231 primary tumor expressing red fluorescent protein (MDA-MB-231-RFP) reached approximately 500 mm3 (diameter; 10 mm). The mockinfected orthotopic primary tumor grew rapidly. After i. t. OBP-401 injection, the growth of the orthotopic tumors was arrested. Six weeks after implantation, the fluorescent area and fluorescence intensity showed no increase from the beginning of treatment. OBP-401 was then injected into high-metastatic MDA-MB-231-RFP primary orthotopic tumor growing in mice which already had developed metastasis within lymphatic ducts. All 7 of 7 control mice subsequently developed lymph node metastasis. In contrast, none of 7 mice which received OBP-401 had lymph node metastasis. Seven of 7 control mice also had gross lung metastasis. In contrast, none of the 7 mice which received OBP-401 had gross lung metastasis. Confocal laser microscopy imaging demonstrated that all control mice had diffuse lung metastases. In contrast, all 7 mice which received OBP-401 only had a few metastatic cells in the lung. OBP-401 treatment significantly extended survival of the treated mice.

    DOI: 10.18632/oncotarget.13296

    Web of Science

    researchmap

  • Fluorescence-guided surgery of a highly-metastatic variant of human triple-negative breast cancer targeted with a cancer-specific GFP adenovirus prevents recurrence

    Shuya Yano, Kiyoto Takehara, Shinji Miwa, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    ONCOTARGET   7 ( 46 )   75635 - 75647   2016.11

     More details

    Language:English   Publisher:IMPACT JOURNALS LLC  

    We have previously developed a genetically-engineered GFP-expressing telomerase-dependent adenovirus, OBP-401, which can selectively illuminate cancer cells. In the present report, we demonstrate that targeting a triple-negative highinvasive human breast cancer, orthotopically-growing in nude mice, with OBP-401 enables curative fluorescence-guided surgery (FGS). OBP-401 enabled complete resection and prevented local recurrence and greatly inhibited lymph-node metastasis due to the ability of the virus to selectively label and subsequently kill cancer cells. In contrast, residual breast cancer cells become more aggressive after bright (white)light surgery (BLS). OBP-401-based FGS also improved the overall survival compared with conventional BLS. Thus, metastasis from a highly-aggressive triple-negative breast cancer can be prevented by FGS in a clinically-relevant mouse model.

    DOI: 10.18632/oncotarget.12314

    Web of Science

    researchmap

  • Fluorescence-guided surgery of a highly-metastatic variant of human triple-negative breast cancer targeted with a cancer-specific GFP adenovirus prevents recurrence

    Shuya Yano, Kiyoto Takehara, Shinji Miwa, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    ONCOTARGET   7 ( 46 )   75635 - 75647   2016.11

     More details

    Language:English   Publisher:IMPACT JOURNALS LLC  

    We have previously developed a genetically-engineered GFP-expressing telomerase-dependent adenovirus, OBP-401, which can selectively illuminate cancer cells. In the present report, we demonstrate that targeting a triple-negative highinvasive human breast cancer, orthotopically-growing in nude mice, with OBP-401 enables curative fluorescence-guided surgery (FGS). OBP-401 enabled complete resection and prevented local recurrence and greatly inhibited lymph-node metastasis due to the ability of the virus to selectively label and subsequently kill cancer cells. In contrast, residual breast cancer cells become more aggressive after bright (white)light surgery (BLS). OBP-401-based FGS also improved the overall survival compared with conventional BLS. Thus, metastasis from a highly-aggressive triple-negative breast cancer can be prevented by FGS in a clinically-relevant mouse model.

    DOI: 10.18632/oncotarget.12314

    Web of Science

    researchmap

  • Tumor-specific delivery of biologics by a novel T-cell line HOZOT

    Teppei Onishi, Hiroshi Tazawa, Yuuri Hashimoto, Makoto Takeuchi, Takeshi Otani, Shuji Nakamura, Fuminori Sakurai, Hiroyuki Mizuguchi, Hiroyuki Kishimoto, Yuzo Umeda, Yasuhiro Shirakawa, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Scientific Reports   6 ( 38060 )   doi: 10.1038/srep38060   2016.11

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    "Cell-in-cell" denotes an invasive phenotype in which one cell actively internalizes in another. The novel human T-cell line HOZOT, established from human umbilical cord blood, was shown to penetrate a variety of human cancer cells but not normal cells. Oncolytic viruses are emerging as biological therapies for human cancers; however, efficient viral delivery is limited by a lack of tumor-specific homing and presence of pre-existing or therapy-induced neutralizing antibodies. Here, we report a new, intriguing approach using HOZOT cells to transmit biologics such as oncolytic viruses into human cancer cells by cell-in-cell invasion. HOZOT cells were successfully loaded via human CD46 antigen with an attenuated adenovirus containing the fiber protein of adenovirus serotype 35 (OBP-401/F35), in which the telomerase promoter regulates viral replication. OBP-401/F35-loaded HOZOT cells were efficiently internalized into human cancer cells and exhibited tumor-specific killing by release of viruses, even in the presence of anti-viral neutralizing antibodies. Moreover, intraperitoneal administration of HOZOT cells loaded with OBP-401/F35 significantly suppressed peritoneally disseminated tumor growth in mice. This unique cell-in-cell property provides a platform for selective delivery of biologics into human cancer cells, which has important implications for the treatment of human cancers.

    DOI: 10.1038/srep38060

    Web of Science

    researchmap

  • Tumor-specific delivery of biologics by a novel T-cell line HOZOT

    Teppei Onishi, Hiroshi Tazawa, Yuuri Hashimoto, Makoto Takeuchi, Takeshi Otani, Shuji Nakamura, Fuminori Sakurai, Hiroyuki Mizuguchi, Hiroyuki Kishimoto, Yuzo Umeda, Yasuhiro Shirakawa, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Scientific Reports   6   2016.11

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    "Cell-in-cell" denotes an invasive phenotype in which one cell actively internalizes in another. The novel human T-cell line HOZOT, established from human umbilical cord blood, was shown to penetrate a variety of human cancer cells but not normal cells. Oncolytic viruses are emerging as biological therapies for human cancers; however, efficient viral delivery is limited by a lack of tumor-specific homing and presence of pre-existing or therapy-induced neutralizing antibodies. Here, we report a new, intriguing approach using HOZOT cells to transmit biologics such as oncolytic viruses into human cancer cells by cell-in-cell invasion. HOZOT cells were successfully loaded via human CD46 antigen with an attenuated adenovirus containing the fiber protein of adenovirus serotype 35 (OBP-401/F35), in which the telomerase promoter regulates viral replication. OBP-401/F35-loaded HOZOT cells were efficiently internalized into human cancer cells and exhibited tumor-specific killing by release of viruses, even in the presence of anti-viral neutralizing antibodies. Moreover, intraperitoneal administration of HOZOT cells loaded with OBP-401/F35 significantly suppressed peritoneally disseminated tumor growth in mice. This unique cell-in-cell property provides a platform for selective delivery of biologics into human cancer cells, which has important implications for the treatment of human cancers.

    DOI: 10.1038/srep38060

    Web of Science

    researchmap

  • Real-time in-vivo image-guided cell-cycle perturbation to increase tumor chemosensitivity

    Shuya Yano, Hiroshi Tazawa, Hiroyuki Kishimoto, Shunsuke Kagawa, Yoshihiko Kadowaki, Nobuhiro Ishido, Takahiro Okamoto, Yasuo Urata, Kiyoto Takehara, Robert M. Hoffman, Toshiyoshi Fujiwara

    MOLECULAR CANCER RESEARCH   14   2016.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1557-3125.CELLCYCLE16-PR14

    Web of Science

    researchmap

  • Iron depletion-induced downregulation of N-cadherin expression inhibits invasive malignant phenotypes in human esophageal cancer

    Seishi Nishitani, Kazuhiro Noma, Toshiaki Ohara, Yasuko Tomono, Shinichiro Watanabe, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    INTERNATIONAL JOURNAL OF ONCOLOGY   49 ( 4 )   1351 - 1359   2016.10

     More details

    Language:English   Publisher:SPANDIDOS PUBL LTD  

    Esophageal carcinomas often have a poor prognosis due to early lymph node metastasis. Epithelial-mesenchymal transition (EMT) is strongly associated with the acquisition of cancer metastasis and invasion. However, there is no established treatment to eliminate the EMT of cancer cells. Iron is an essential element for both normal and cancer cells in humans. Recently, iron depletion has been discovered to suppress tumor growth. Therefore, we hypothesized that decreased iron conditions would regulate EMT phenotypes, as well as suppressing tumor growth. The human TE esophageal cancer cell lines and OE19 were used in our study. Decreased iron conditions were made using an iron-depletion diet in mice and the iron chelator deferasirox for cell studies. Migration and invasion abilities of cells were measured using migration, invasion, and sphere formation assays. Esophageal subcutaneous tumor growth was suppressed in decreased iron conditions. In vitro study showed that decreased iron conditions inhibited esophageal cancer cell proliferation as well as migration and invasion abilities, with downregulation of N-cadherin expression. Also, migration and invasion abilities were suppressed by inhibiting expression of N-cadherin. In conclusion, decreased iron conditions revealed a profound anticancer effect by the suppression of tumor growth and the inhibition of migration and invasion abilities via N-cadherin.

    DOI: 10.3892/ijo.2016.3640

    Web of Science

    researchmap

  • Sarcopenia and American Society of Anesthesiologists Physical Status in the Assessment of Outcomes of Hepatocellular Carcinoma Patients Undergoing Hepatectomy

    Kosei Takagi, Takahito Yagi, Ryuichi Yoshida, Susumu Shinoura, Yuzo Umeda, Daisuke Nobuoka, Takashi Kuise, Nobuyuki Watanabe, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   70 ( 5 )   363 - 370   2016.10

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    Sarcopenia following liver surgery has been reported as a predictor of poor prognosis. Here we investigated predictors of outcomes in patients with hepatocellular carcinoma (HCC) and attempted to establish a new comprehensive preoperative assessment protocol. We retrospectively analyzed the cases of 254 patients who underwent curative hepatectomy for HCC with Child-Pugh classification A at our hospital between January 2007 and December 2013. Sarcopenia was evaluated by computed tomography measurement. The influence of sarcopenia on outcomes was evaluated. We used multivariate analyses to assess the impact of prognostic factors associated with outcomes, including sarcopenia. Of the 254 patients, 118 (46.5) met the criteria for sarcopenia, and 32 had an American Society of Anesthesiologists (ASA) physical status &gt;= 3. The sarcopenic group had a significantly lower 5-year overall survival rate than the non-sarcopenic group (58.2 vs. 82.4, p=0.0002). In multivariate analyses of prognostic factors, sarcopenia was an independent predictor of poor survival (hazard ratio [HR]= 2.28, p= 0.002) and poor ASA status (HR= 3.17, p= 0.001). Sarcopenia and poor ASA status are independent preoperative predictors for poor outcomes after hepatectomy. The preoperative identification of sarcopenia and ASA status might enable the development of comprehensive approaches to assess surgical eligibility.

    DOI: 10.18926/AMO/54594

    Web of Science

    researchmap

  • Sarcopenia and American Society of Anesthesiologists Physical Status in the Assessment of Outcomes of Hepatocellular Carcinoma Patients Undergoing Hepatectomy

    Kosei Takagi, Takahito Yagi, Ryuichi Yoshida, Susumu Shinoura, Yuzo Umeda, Daisuke Nobuoka, Takashi Kuise, Nobuyuki Watanabe, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   70 ( 5 )   363 - 370   2016.10

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    Sarcopenia following liver surgery has been reported as a predictor of poor prognosis. Here we investigated predictors of outcomes in patients with hepatocellular carcinoma (HCC) and attempted to establish a new comprehensive preoperative assessment protocol. We retrospectively analyzed the cases of 254 patients who underwent curative hepatectomy for HCC with Child-Pugh classification A at our hospital between January 2007 and December 2013. Sarcopenia was evaluated by computed tomography measurement. The influence of sarcopenia on outcomes was evaluated. We used multivariate analyses to assess the impact of prognostic factors associated with outcomes, including sarcopenia. Of the 254 patients, 118 (46.5) met the criteria for sarcopenia, and 32 had an American Society of Anesthesiologists (ASA) physical status &gt;= 3. The sarcopenic group had a significantly lower 5-year overall survival rate than the non-sarcopenic group (58.2 vs. 82.4, p=0.0002). In multivariate analyses of prognostic factors, sarcopenia was an independent predictor of poor survival (hazard ratio [HR]= 2.28, p= 0.002) and poor ASA status (HR= 3.17, p= 0.001). Sarcopenia and poor ASA status are independent preoperative predictors for poor outcomes after hepatectomy. The preoperative identification of sarcopenia and ASA status might enable the development of comprehensive approaches to assess surgical eligibility.

    DOI: 10.18926/AMO/54594

    Web of Science

    researchmap

  • A Phase II Clinical Trial of the Efficacy and Safety of Short-term (3 days) Enoxaparin for the Prevention of Venous Thromboembolism after Gastric Cancer Surgery

    Shinji Kuroda, Satoru Kikuchi, Masahiko Nishizaki, Shunsuke Kagawa, Shiro Hinotsu, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   70 ( 5 )   401 - 404   2016.10

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    Although intermittent pneumatic compression (IPC) has become common as perioperative prophylaxis for venous thromboembolism (VTE) consisting of pulmonary thromboembolism (PE) and deep vein thrombosis (DVT), the prophylactic effect against VTE, especially lethal PE, is not yet satisfactory. Therefore, pharmacologic prophylaxis, such as with enoxaparin, is desirable. While the efficacy and safety of enoxaparin have been proven in several clinical trials, concern about bleeding with long-term (at least 7 days) use have potentially decreased its widespread adoption. We have launched a phase II study to evaluate the efficacy and safety of short-term (3 days) enoxaparin, in which a total of 70 gastric cancer patients undergoing gastrectomy will be recruited, and the primary endpoint is the incidence of DVT. This study could contribute to making pharmacologic prophylaxis for VTE more common.

    DOI: 10.18926/AMO/54601

    Web of Science

    researchmap

  • Iron depletion-induced downregulation of N-cadherin expression inhibits invasive malignant phenotypes in human esophageal cancer

    Seishi Nishitani, Kazuhiro Noma, Toshiaki Ohara, Yasuko Tomono, Shinichiro Watanabe, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    INTERNATIONAL JOURNAL OF ONCOLOGY   49 ( 4 )   1351 - 1359   2016.10

     More details

    Language:English   Publisher:SPANDIDOS PUBL LTD  

    Esophageal carcinomas often have a poor prognosis due to early lymph node metastasis. Epithelial-mesenchymal transition (EMT) is strongly associated with the acquisition of cancer metastasis and invasion. However, there is no established treatment to eliminate the EMT of cancer cells. Iron is an essential element for both normal and cancer cells in humans. Recently, iron depletion has been discovered to suppress tumor growth. Therefore, we hypothesized that decreased iron conditions would regulate EMT phenotypes, as well as suppressing tumor growth. The human TE esophageal cancer cell lines and OE19 were used in our study. Decreased iron conditions were made using an iron-depletion diet in mice and the iron chelator deferasirox for cell studies. Migration and invasion abilities of cells were measured using migration, invasion, and sphere formation assays. Esophageal subcutaneous tumor growth was suppressed in decreased iron conditions. In vitro study showed that decreased iron conditions inhibited esophageal cancer cell proliferation as well as migration and invasion abilities, with downregulation of N-cadherin expression. Also, migration and invasion abilities were suppressed by inhibiting expression of N-cadherin. In conclusion, decreased iron conditions revealed a profound anticancer effect by the suppression of tumor growth and the inhibition of migration and invasion abilities via N-cadherin.

    DOI: 10.3892/ijo.2016.3640

    Web of Science

    researchmap

  • Efficacy of a Cell-Cycle Decoying Killer Adenovirus on 3-D Gelfoam (R)-Histoculture and Tumor-Sphere Models of Chemo-Resistant Stomach Carcinomatosis Visualized by FUCCI Imaging

    Shuya Yano, Kiyoto Takehara, Hiroshi Tazawa, Hiroyuki Kishimoto, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert M. Hoffman

    PLOS ONE   11 ( 9 )   doi: 10.1371/journal.pone.0162991   2016.9

     More details

    Language:English   Publisher:PUBLIC LIBRARY SCIENCE  

    Stomach cancer carcinomatosis peritonitis (SCCP) is a recalcitrant disease. The goal of the present study was to establish an in vitro-in vivo-like imageable model of SCCP to develop cell-cycle-based therapeutics of SCCP. We established 3-D Gelfoam (R) histoculture and tumor-sphere models of SCCP. FUCCI-expressing MKN-45 stomach cancer cells were transferred to express the fluorescence ubiquinized cell-cycle indicator (FUCCI). FUCCI-expressing MKN-45 cells formed spheres on agarose or on Gelfoam (R) grew into tumor-like structures with G(0)/G(1) cancer cells in the center and S/G(2) cancer cells located in the surface as indicated by FUCCI imaging when the cells fluoresced red or green, respectively. We treated FUCCI-expressing cancer cells forming SCCP tumors in Gelfoam (R) histoculture with OBP-301, cisplatinum (CDDP), or paclitaxel. CDDP or paclitaxel killed only cycling cancer cells and were ineffective against G1/G2 MKN-45 cells in tumors growing on Gelfoam (R). In contrast, the telomerase-dependent adenovirus OBP-301 decoyed the MKN45 cells in tumors on Gelfoam (R) to cycle from G(0)/G(1) phase to S/G(2) phase and reduced their viability. CDDP-or paclitaxel-treated MKN-45 tumors remained quiescent and did not change in size. In contrast, OB-301 reduced the size of the MKN-45 tumors on Gelfoam 1. We examined the cell cycle-related proteins using Western blotting. CDDP increased the expression of p53 and p21 indicating cell cycle arrest. In contrast, OBP-301 decreased the expression of p53 and p21 Furthermore, OBP-301 increased the expression of E2F and pAkt as further indication of cell cycle decoy. This 3-D Gelfoam (R) histoculture and FUCCI imaging are powerful tools to discover effective therapy of SCCP such as OBP-301.

    DOI: 10.1371/journal.pone.0162991

    Web of Science

    researchmap

  • Efficacy of a Cell-Cycle Decoying Killer Adenovirus on 3-D Gelfoam (R)-Histoculture and Tumor-Sphere Models of Chemo-Resistant Stomach Carcinomatosis Visualized by FUCCI Imaging

    Shuya Yano, Kiyoto Takehara, Hiroshi Tazawa, Hiroyuki Kishimoto, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert M. Hoffman

    PLOS ONE   11 ( 9 )   2016.9

     More details

    Language:English   Publisher:PUBLIC LIBRARY SCIENCE  

    Stomach cancer carcinomatosis peritonitis (SCCP) is a recalcitrant disease. The goal of the present study was to establish an in vitro-in vivo-like imageable model of SCCP to develop cell-cycle-based therapeutics of SCCP. We established 3-D Gelfoam (R) histoculture and tumor-sphere models of SCCP. FUCCI-expressing MKN-45 stomach cancer cells were transferred to express the fluorescence ubiquinized cell-cycle indicator (FUCCI). FUCCI-expressing MKN-45 cells formed spheres on agarose or on Gelfoam (R) grew into tumor-like structures with G(0)/G(1) cancer cells in the center and S/G(2) cancer cells located in the surface as indicated by FUCCI imaging when the cells fluoresced red or green, respectively. We treated FUCCI-expressing cancer cells forming SCCP tumors in Gelfoam (R) histoculture with OBP-301, cisplatinum (CDDP), or paclitaxel. CDDP or paclitaxel killed only cycling cancer cells and were ineffective against G1/G2 MKN-45 cells in tumors growing on Gelfoam (R). In contrast, the telomerase-dependent adenovirus OBP-301 decoyed the MKN45 cells in tumors on Gelfoam (R) to cycle from G(0)/G(1) phase to S/G(2) phase and reduced their viability. CDDP-or paclitaxel-treated MKN-45 tumors remained quiescent and did not change in size. In contrast, OB-301 reduced the size of the MKN-45 tumors on Gelfoam 1. We examined the cell cycle-related proteins using Western blotting. CDDP increased the expression of p53 and p21 indicating cell cycle arrest. In contrast, OBP-301 decreased the expression of p53 and p21 Furthermore, OBP-301 increased the expression of E2F and pAkt as further indication of cell cycle decoy. This 3-D Gelfoam (R) histoculture and FUCCI imaging are powerful tools to discover effective therapy of SCCP such as OBP-301.

    DOI: 10.1371/journal.pone.0162991

    Web of Science

    researchmap

  • Double-Flap Technique as an Antireflux Procedure in Esophagogastrostomy after Proximal Gastrectomy

    Shinji Kuroda, Masahiko Nishizaki, Satoru Kikuchi, Kazuhiro Noma, Shunsuke Tanabe, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS   223 ( 2 )   E7 - E13   2016.8

     More details

    Language:English   Publisher:ELSEVIER SCIENCE INC  

    DOI: 10.1016/j.jamcollsurg.2016.04.041

    Web of Science

    researchmap

  • Double-Flap Technique as an Antireflux Procedure in Esophagogastrostomy after Proximal Gastrectomy

    Shinji Kuroda, Masahiko Nishizaki, Satoru Kikuchi, Kazuhiro Noma, Shunsuke Tanabe, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS   223 ( 2 )   E7 - E13   2016.8

     More details

    Language:English   Publisher:ELSEVIER SCIENCE INC  

    DOI: 10.1016/j.jamcollsurg.2016.04.041

    Web of Science

    researchmap

  • In Vivo Isolation of a Highly-aggressive Variant of Triple-negative Human Breast Cancer MDA-MB-231 Using Serial Orthotopic Transplantation

    Shuya Yano, Kiyoto Takehara, Shinji Miwa, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    ANTICANCER RESEARCH   36 ( 8 )   3817 - 3820   2016.8

     More details

    Language:English   Publisher:INT INST ANTICANCER RESEARCH  

    Aim: We describe the development of a highly-invasive, triple-negative breast cancer (TNBC) variant using serial orthotopic implantation of MDA-MB-231 human breast cancer in nude mice. Materials and Methods: MDA-MB-231 cells expressing red fluorescent protein (RFP) (1x10(7) cells/site) were initially injected subcutaneously in the flank of nude mice. After the subcutaneous tumors grew, they were harvested and cut into small pieces for orthotopic implantation in the right lower mammary gland. After the orthotopic tumors grew, they were resected and cut into small pieces and orthotopically reimplanted into the mammary gland of nude mice. The tumors grew and metastasized to lymph nodes. The lymph node metastases were harvested and cut into small pieces and orthotopically re-implanted into the mammary gland of nude mice. After the orthotopic tumors grew, the tumor was removed leaving residual cancer cells, which grew and metastasized to lymph nodes. The lymph node metastases were harvested, cut into pieces and orthotopically re-implanted into the mammary gland of nude mice for two cycles and then isolated. Results: The isolated variant is highly invasive in the mammary gland and metastasized to lymph nodes in 10 of 12 mice compared to 2 of 12 of the parental cell line. Conclusion: The availability of a highly invasive variant of TNBC targeting lymph nodes will be very useful for drug discovery of TNBC, a recalcitrant cancer and for mechanistic studies of its aggressiveness.

    Web of Science

    researchmap

  • Study about the Efficacy of Metformin to Immune Function in Cancer Patients

    Mototsugu Watanabe, Hiromasa Yamamoto, Shingo Eikawa, Kazuhiko Shien, Tadahiko Shien, Junichi Soh, Katsuyuki Hotta, Jun Wada, Shiro Hinotsu, Toshiyoshi Fujiwara, Katsuyuki Kiura, Hiroyoshi Doihara, Shinichiro Miyoshi, Heiichiro Udono, Shinichi Toyooka

    ACTA MEDICA OKAYAMA   70 ( 4 )   327 - 330   2016.8

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8(+) T cells, which produce multiple cytokines.

    DOI: 10.18926/AMO/54514

    Web of Science

    researchmap

  • In Vivo Isolation of a Highly-aggressive Variant of Triple-negative Human Breast Cancer MDA-MB-231 Using Serial Orthotopic Transplantation

    Shuya Yano, Kiyoto Takehara, Shinji Miwa, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    ANTICANCER RESEARCH   36 ( 8 )   3817 - 3820   2016.8

     More details

    Language:English   Publisher:INT INST ANTICANCER RESEARCH  

    Aim: We describe the development of a highly-invasive, triple-negative breast cancer (TNBC) variant using serial orthotopic implantation of MDA-MB-231 human breast cancer in nude mice. Materials and Methods: MDA-MB-231 cells expressing red fluorescent protein (RFP) (1x10(7) cells/site) were initially injected subcutaneously in the flank of nude mice. After the subcutaneous tumors grew, they were harvested and cut into small pieces for orthotopic implantation in the right lower mammary gland. After the orthotopic tumors grew, they were resected and cut into small pieces and orthotopically reimplanted into the mammary gland of nude mice. The tumors grew and metastasized to lymph nodes. The lymph node metastases were harvested and cut into small pieces and orthotopically re-implanted into the mammary gland of nude mice. After the orthotopic tumors grew, the tumor was removed leaving residual cancer cells, which grew and metastasized to lymph nodes. The lymph node metastases were harvested, cut into pieces and orthotopically re-implanted into the mammary gland of nude mice for two cycles and then isolated. Results: The isolated variant is highly invasive in the mammary gland and metastasized to lymph nodes in 10 of 12 mice compared to 2 of 12 of the parental cell line. Conclusion: The availability of a highly invasive variant of TNBC targeting lymph nodes will be very useful for drug discovery of TNBC, a recalcitrant cancer and for mechanistic studies of its aggressiveness.

    Web of Science

    researchmap

  • Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms

    Kazuhiro Yoshida, Takeshi Nagasaka, Yuzo Umeda, Takehiro Tanaka, Keisuke Kimura, Fumitaka Taniguchi, Tomokazu Fuji, Kunitoshi Shigeyasu, Yoshiko Mori, Hiroyuki Yanai, Takahito Yagi, Ajay Goel, Toshiyoshi Fujiwara

    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY   142 ( 7 )   1557 - 1569   2016.7

     More details

    Language:English   Publisher:SPRINGER  

    Although limited understanding exists for the presence of specific genetic mutations and aberrantly methylated genes in pancreatobiliary intraductal papillary mucinous neoplasms (IPMNs), the fundamental understanding of the dynamics of methylation expansion across CpG dinucleotides in specific gene promoters during carcinogenesis remains unexplored. Expansion of DNA methylation in some gene promoter regions, such as EFEMP1, one of the fibulin family, with tumor progression has been reported in several malignancies. We hypothesized that DNA hypermethylation in EFEMP1 promoter would expand with the tumor grade of IPMN.
    A sample of 65 IPMNs and 30 normal pancreatic tissues was analyzed. IPMNs were divided into the following three subsets according to pathological findings: 31 with low-grade dysplasia (low grade), 11 with high-grade dysplasia (high grade), and 23 with associated invasive carcinoma (invasive Ca). Mutations in the KRAS or GNAS genes were analyzed by Sanger sequencing, and methylation status of two discrete regions within the EFEMP1 promoter, namely region 1 and region 2, was analyzed by bisulfite sequencing and fluorescent high-sensitive assay for bisulfite DNA (Hi-SA). Expression status of EFEMP1 was investigated by immunohistochemistry (IHC).
    KRAS mutations were detected in 39, 55, and 70 % of low-grade, high-grade, and invasive Ca, respectively. GNAS mutations were observed in 32, 55, and 22 % of low-grade, high-grade, and invasive Ca, respectively. The methylation of individual regions (region 1 or 2) in the EFEMP1 promoter was observed in 84, 91, and 87 % of low-grade, high-grade, and invasive Ca, respectively. However, simultaneous methylation of both regions (extensive methylation) was exclusively detected in 35 % of invasive Ca (p = 0.001) and five of eight IPMNs (63 %) with extensive methylation, whereas 20 of 57 (35.1 %) tumors of unmethylation or partial methylation of the EFEMP1 promoter region showed weak staining EFEMP1 in extracellular matrix (p = 0.422). In addition, extensive EFEMP1 methylation was particularly present in malignant tumors without GNAS mutations and associated with disease-free survival of patients with IPMNs (p &lt; 0.0001).
    Extensive methylation of the EFEMP1 gene promoter can discriminate invasive from benign IPMNs with superior accuracy owing to their stepwise accumulation of tumor progression.

    DOI: 10.1007/s00432-016-2164-x

    Web of Science

    researchmap

  • PD-L1 expression as a predictive factor for recurrence pattern and prognosis in curatively resected gastric cancer

    Toshiaki Morihiro, Shinji Kuroda, Tetsushi Kubota, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-2649

    Web of Science

    researchmap

  • Prognostic correlation of tumor-infiltrating lymphocytes (TILs) and cancer associated fibroblasts (CAFs) in patients with human esophageal carcinoma

    Takuya Kato, Kazuhiro Noma, Yuki Katsura, Hajime Kashima, Takayuki Ninomiya, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-4160

    Web of Science

    researchmap

  • A novel live imaging system for inflammation-induced epithelial-mesenchymal transition in colorectal cancers

    Takeshi Ieda, Hiroshi Tazawa, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Takeshi Nagasaka, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-1613

    Web of Science

    researchmap

  • Iron control is a novel therapeutic target of cancer stem cells

    Toshiaki Ohara, Takayuki Ninomiya, Kazuhiro Noma, Hajime Kashima, Yuki Katsura, Takuya Kato, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-2510

    Web of Science

    researchmap

  • Functional analysis of tumor associated macrophage utilizing virus-guided fluorescent imaging of pancreatic cancer cells in the peritoneal cavity

    Kazuya Kuwada, Shunsuke Kagawa, Megumi Watanabe, Shuichi Sakamoto, Satoru Kikuchi, Shinji Kuroda, Ryuichi Yoshida, Hiroshi Tazawa, Tetuya Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-4156

    Web of Science

    researchmap

  • Novel HER2-targeted gold nanoparticles; integration of antibody therapy and nanotechnology

    Tetsushi Kubota, Shinji Kuroda, Toshiaki Morihiro, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-4747

    Web of Science

    researchmap

  • Correlation of FAP(fibroblast activation protein)-expressing cancer associated fibroblasts (CAFs) and tumor metastasis in esophageal carcinoma

    Hajime Kashima, Kazuhiro Noma, Yuki Katsura, Takuya Kato, Ryoichi Katsube, Takayuki Ninomiya, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-1560

    Web of Science

    researchmap

  • Genome-wide enhancer analysis identifies PVT1 as an oncogenic enhancer of MYC

    Kunitoshi Shigeyasu, Shusuke Toden, Takeshi Nagasaka, Toshiyoshi Fujiwara, C. Richard Boland, Ajay Goel

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-952

    Web of Science

    researchmap

  • Virally enhanced p53 reactivation impairs KRAS-driven pancreatic cancer invasion

    Takeshi Koujima, Hiroshi Tazawa, Takeshi Leda, Kazuya Kuwada, Terutaka Tanimoto, Shinji Kuroda, Hiroyuki Kishimoto, Masahiko Nishizaki, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-3748

    Web of Science

    researchmap

  • Clinical significance of SNORA21, an H/ACA box snoRNA, as a metastasis predicting and prognostic biomarker in colorectal cancer

    Kazuhiro Yoshida, Shusuke Toden, Wenhao Weng, Takeshi Nagasaka, Toshiyoshi Fujiwara, Ajay Goel

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-4926

    Web of Science

    researchmap

  • Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas

    Shuhei Osaki, Hiroshi Tazawa, Joe Hasei, Yasuaki Yamakawa, Toshinori Omori, Kazuhisa Sugiu, Tadashi Komatsubara, Tomohiro Fujiwara, Tsuyoshi Sasaki, Toshiyuki Kunisada, Aki Yoshida, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    SCIENTIFIC REPORTS   6   2016.6

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Osteosarcoma is a rare disease diagnosed as malignant bone tumor. It is generally refractory to chemotherapy, which contributes to its poor prognosis. The reversal of chemoresistance is a major clinical challenge to improve the prognostic outcome of osteosarcoma patients. We developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301 (telomelysin) and assessed its synergistic effects with chemotherapeutic agents (cisplatin and doxorubicin) using human osteosarcoma cell lines and a xenograft tumor model. The molecular mechanism underlying the chemosensitizing effect of OBP-301 was evaluated in aspects of apoptosis induction. OBP-301 inhibits anti-apoptotic myeloid cell leukemia 1 (MCL1) expression, which in turn leads to chemosensitization in human osteosarcoma cells. The siRNA-mediated knockdown of MCL1 expression sensitized human osteosarcoma cells to common chemotherapeutic agents. We also found that upregulation of microRNA-29 targeting MCL1 via virally induced transcriptional factor E2F-1 activation was critical for the enhancement of chemotherapy-induced apoptosis in osteosarcoma cells. Telomerase-specific oncolytic adenovirus synergistically suppressed the viability of human osteosarcoma cells in combination with chemotherapeutic agents. The combination treatment also significantly inhibited tumor growth, as compared to monotherapy, in an osteosarcoma xenograft tumor model. Our data suggest that replicative virus-mediated tumor-specific MCL1 ablation may be a promising strategy to attenuate chemoresistance in osteosarcoma patients.

    DOI: 10.1038/srep28953

    Web of Science

    researchmap

  • Surgical Outcome of Patients Undergoing Pancreaticoduodenectomy: Analysis of a 17-Year Experience at a Single Center

    Kosei Takagi, Takahito Yagi, Ryuichi Yoshida, Susumu Shinoura, Yuzo Umeda, Daisuke Nobuoka, Takashi Kuise, Nobuyuki Watanabe, Kenta Sui, Tomokazu Fuji, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   70 ( 3 )   197 - 203   2016.6

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    The operative mortality and morbidity of pancreaticoduodenectomy (PD) remain high. We analyzed PD patients' clinical characteristics and surgical outcomes and discuss how PD clinical outcomes could be improved. We retrospectively reviewed the cases of 400 patients who underwent a PD between January 1998 and April 2014 at Okayama University Hospital, a very-high-volume center. We identified and compared the clinical outcomes between two time periods (period 1: 1998-2006 vs. period 2: 2007-2014). The total postoperative mortality and major complication rates were 0.75 and 15.8, respectively, and the median postoperative length of stay (LOS) was 32 days. Subsequently, patients who underwent a PD during period 2 had a significantly shorter LOS than those who underwent a PD during period 1 (29 days vs. 38.5 days, p&lt;0.001). The incidence of mortality and major complications did not differ between the two periods. In our multivariate analysis, period 1 was an independent factor associated with a long LOS (p&lt;0.001). The improvement of the surgical procedure and perioperative care might be related to the shorter LOS in period 2 and to the consistently maintained low mortality rate after PD. The development of multimodal strategies to accelerate postoperative recovery may further improve PD's clinical outcomes.

    DOI: 10.18926/AMO/54419

    Web of Science

    researchmap

  • Recurrence after Endoscopic Curative Resection of Mucosal Gastric Cancer Associated with an Adjacent Neoplastic Precursor Lesion

    Satoru Kikuchi, Shunsuke Kagawa, Toshiaki Ohara, Tetsushi Kubota, Kazuya Kuwada, Tetsuya Kagawa, Shinji Kuroda, Yasuhiro Shirakawa, Masahiko Nishizaki, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   70 ( 3 )   213 - 216   2016.6

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    A 69-year-old man underwent endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) at the lesser curvature in the angle of stomach. Histological examination revealed tub1, pM, ly0, v0, pLM(-), pVM(-), and the resection was considered curative. The scar after ESD was followed by esophagogastroduodenoscopy (EGD) and biopsy. Twenty months later, EGD showed an ulcerative lesion in the vicinity of the ESD scar, and histological examination of the biopsy specimen showed adenocarcinoma. A distal gastrectomy with lymph node dissection was then performed. Postoperative pathology showed tub1, pM, pN0, ly0, v0, and Stage 1A. Skip lesions were seen in the specimen resected by ESD, and the histological review confirmed so-called "dysplasia-like atypia" (DLA) between the lesions. It has been reported recently that in DLA, the dysplasia-like change involves only the bases of the pits, without upper pit or surface epithelium involvement, and it is said that the rate of DLA is higher in gastric cancer patients. We speculated that a precancerous lesion close to the resected cancer developed into a local recurrence.

    DOI: 10.18926/AMO/54421

    Web of Science

    researchmap

  • Recurrence after Endoscopic Curative Resection of Mucosal Gastric Cancer Associated with an Adjacent Neoplastic Precursor Lesion

    Satoru Kikuchi, Shunsuke Kagawa, Toshiaki Ohara, Tetsushi Kubota, Kazuya Kuwada, Tetsuya Kagawa, Shinji Kuroda, Yasuhiro Shirakawa, Masahiko Nishizaki, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   70 ( 3 )   213 - 216   2016.6

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    A 69-year-old man underwent endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) at the lesser curvature in the angle of stomach. Histological examination revealed tub1, pM, ly0, v0, pLM(-), pVM(-), and the resection was considered curative. The scar after ESD was followed by esophagogastroduodenoscopy (EGD) and biopsy. Twenty months later, EGD showed an ulcerative lesion in the vicinity of the ESD scar, and histological examination of the biopsy specimen showed adenocarcinoma. A distal gastrectomy with lymph node dissection was then performed. Postoperative pathology showed tub1, pM, pN0, ly0, v0, and Stage 1A. Skip lesions were seen in the specimen resected by ESD, and the histological review confirmed so-called "dysplasia-like atypia" (DLA) between the lesions. It has been reported recently that in DLA, the dysplasia-like change involves only the bases of the pits, without upper pit or surface epithelium involvement, and it is said that the rate of DLA is higher in gastric cancer patients. We speculated that a precancerous lesion close to the resected cancer developed into a local recurrence.

    DOI: 10.18926/AMO/54421

    Web of Science

    researchmap

  • Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas

    Shuhei Osaki, Hiroshi Tazawa, Joe Hasei, Yasuaki Yamakawa, Toshinori Omori, Kazuhisa Sugiu, Tadashi Komatsubara, Tomohiro Fujiwara, Tsuyoshi Sasaki, Toshiyuki Kunisada, Aki Yoshida, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    SCIENTIFIC REPORTS   6 ( 28953 )   doi: 10.1038/srep28953   2016.6

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Osteosarcoma is a rare disease diagnosed as malignant bone tumor. It is generally refractory to chemotherapy, which contributes to its poor prognosis. The reversal of chemoresistance is a major clinical challenge to improve the prognostic outcome of osteosarcoma patients. We developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301 (telomelysin) and assessed its synergistic effects with chemotherapeutic agents (cisplatin and doxorubicin) using human osteosarcoma cell lines and a xenograft tumor model. The molecular mechanism underlying the chemosensitizing effect of OBP-301 was evaluated in aspects of apoptosis induction. OBP-301 inhibits anti-apoptotic myeloid cell leukemia 1 (MCL1) expression, which in turn leads to chemosensitization in human osteosarcoma cells. The siRNA-mediated knockdown of MCL1 expression sensitized human osteosarcoma cells to common chemotherapeutic agents. We also found that upregulation of microRNA-29 targeting MCL1 via virally induced transcriptional factor E2F-1 activation was critical for the enhancement of chemotherapy-induced apoptosis in osteosarcoma cells. Telomerase-specific oncolytic adenovirus synergistically suppressed the viability of human osteosarcoma cells in combination with chemotherapeutic agents. The combination treatment also significantly inhibited tumor growth, as compared to monotherapy, in an osteosarcoma xenograft tumor model. Our data suggest that replicative virus-mediated tumor-specific MCL1 ablation may be a promising strategy to attenuate chemoresistance in osteosarcoma patients.

    DOI: 10.1038/srep28953

    Web of Science

    researchmap

  • Eradication of osteosarcoma by fluorescence-guided surgery with tumor labeling by a killer-reporter adenovirus

    Shuya Yano, Shinji Miwa, Hiroyuki Kishimoto, Yasuo Urata, Hiroshi Tazawa, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    JOURNAL OF ORTHOPAEDIC RESEARCH   34 ( 5 )   836 - 844   2016.5

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    In a previous study, we developed fluorescence-guided surgery (FGS) for osteosarcoma using an orthotopic model with 143B human osteosarcoma cells expressing red fluorescent protein (RFP) implanted into the intramedullary cavity of the tibia in nude mice. The FGS-treated mice had a significantly higher disease-free survival (DFS) rate than the bright-light surgery (BLS). However, although FGS significantly reduced the recurrence of the primary tumor, it did not reduce lung metastasis. In the present study, we utilized the OBP-401 telomerase-dependent killer-reporter adenovirus, carrying green fluorescent protein (GFP), to label human osteosarcoma in situ in orthotopic mouse models. OBP-401-illuminated human osteosarcoma cell lines, 143B and MNNG/HOS cells in vitro and in vivo. OBP-401 tumor illumination enabled effective FGS of the 143B-derived orthotopic mouse model of human osteosarcoma model as well as FGS eradication of residual cancer cells after BLS. OBP-401-assisted FGS significantly inhibited local recurrence and lung metastasis after surgery, thereby prolonging DFS and overall survival (OS), achieving a very important improvement of therapeutic outcomes over our previously reported FGS study. These therapeutic benefits of FGS were demonstrated using a clinically-viable methodology of direct labeling of human osteosarcoma in situ with the OBP-401 killer-reporter adenovirus in contrast with previous reports, which used genetically engineered labeled cells or antibody-based fluorescent labels for FGS. (c) 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:836-844, 2016.

    DOI: 10.1002/jor.23073

    Web of Science

    researchmap

  • Diminished Gastric Resection Preserves Better Quality of Life in Patients with Early Gastric Cancer

    Hiroshi Isozaki, Sasau Matsumoto, Shigeki Murakami, Takehiro Takama, Tatuo Sho, Kiyohiro Ishihara, Kunihiko Sakai, Masanori Takeda, Koji Nakada, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   70 ( 2 )   119 - 130   2016.4

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    Using the Postgastrectomy Syndrome Assessment Scale (PGSAS)-45, we compared the surgical outcomes and the quality of life (QOL) between patients undergoing limited gastrectomies and those undergoing conventional gastrectomies. In Oomoto Hospital between January 2004 and December 2013, a total of 124 patients who met the eligibility criteria were enrolled. Using the main outcome measures of PGSAS-45, we compared 4 types of limited gastrectomy procedures (1/2 distal gastrectomy [1/2DG] in 21 patients; pylorus-preserving gastrectomy [PPG] in 15 patients; segmental gastrectomy [SG] in 26 patients; and local resection [LR] in 13 patients) with conventional gastrectomy (total gastrectomy [TG] in 24 patients and 2/3 or more distal gastrectomy [WDG] in 25 patients). The TG group showed the worst QOL in almost all items of the main outcome measures. The 1/2DG, PPG, and SG groups showed better QOL than the WDG group in many of the main outcome measures, including the body weight ratio, total symptom score, ingested amount of food per meal, and the dissatisfaction for daily life subscale. The LR group showed a better intake of food than the 1/2DG, PPG, and SG groups. The body weight ratio of the LR group was better than that of the SG group. Diminished gastric resection preserved better QOL in patients with early gastric cancer.

    DOI: 10.18926/AMO/54191

    Web of Science

    researchmap

  • Adenoviral targeting of malignant melanoma for fluorescence-guided surgery prevents recurrence in orthotopic nude-mouse models

    Shuya Yano, Kiyoto Takehara, Hiroyuki Kishimoto, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    ONCOTARGET   7 ( 14 )   18558 - 18572   2016.4

     More details

    Language:English   Publisher:IMPACT JOURNALS LLC  

    Malignant melanoma requires precise resection in order to avoid metastatic recurrence. We report here that the telomerase-dependent, green fluorescent protein (GFP)-containing adenovirus OBP-401 could label malignant melanoma with GFP in situ in orthotopic mouse models. OBP-401-based fluorescence-guided surgery (FGS) resulted in the complete resection of malignant melanoma in the orthotopic models, where conventional bright-light surgery (BLS) could not. High-dose administration of OBP-401 enabled FGS without residual cancer cells or recurrence, due to its dual effect of cancer-cell labeling with GFP and killing.

    DOI: 10.18632/oncotarget.6670

    Web of Science

    researchmap

  • Diminished Gastric Resection Preserves Better Quality of Life in Patients with Early Gastric Cancer

    Hiroshi Isozaki, Sasau Matsumoto, Shigeki Murakami, Takehiro Takama, Tatuo Sho, Kiyohiro Ishihara, Kunihiko Sakai, Masanori Takeda, Koji Nakada, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   70 ( 2 )   119 - 130   2016.4

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    Using the Postgastrectomy Syndrome Assessment Scale (PGSAS)-45, we compared the surgical outcomes and the quality of life (QOL) between patients undergoing limited gastrectomies and those undergoing conventional gastrectomies. In Oomoto Hospital between January 2004 and December 2013, a total of 124 patients who met the eligibility criteria were enrolled. Using the main outcome measures of PGSAS-45, we compared 4 types of limited gastrectomy procedures (1/2 distal gastrectomy [1/2DG] in 21 patients; pylorus-preserving gastrectomy [PPG] in 15 patients; segmental gastrectomy [SG] in 26 patients; and local resection [LR] in 13 patients) with conventional gastrectomy (total gastrectomy [TG] in 24 patients and 2/3 or more distal gastrectomy [WDG] in 25 patients). The TG group showed the worst QOL in almost all items of the main outcome measures. The 1/2DG, PPG, and SG groups showed better QOL than the WDG group in many of the main outcome measures, including the body weight ratio, total symptom score, ingested amount of food per meal, and the dissatisfaction for daily life subscale. The LR group showed a better intake of food than the 1/2DG, PPG, and SG groups. The body weight ratio of the LR group was better than that of the SG group. Diminished gastric resection preserved better QOL in patients with early gastric cancer.

    DOI: 10.18926/AMO/54191

    Web of Science

    researchmap

  • A PARTIAL REVISION OF SURGICAL GLOSSARY (WEB EDITION)

    Fujiwara Toshiyoshi

    Journal of Japan Surgical Society   117 ( 2 )   91 - 91   2016.3

     More details

    Language:Japanese   Publisher:Japan Surgical Society (JSS)  

    CiNii Article

    CiNii Books

    researchmap

  • Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer

    Michihiro Ishida, Shunsuke Kagawa, Kyoko Shimoyama, Kiyoto Takehara, Kazuhiro Noma, Shunsuke Tanabe, Yasuhiro Shirakawa, Hiroshi Tazawa, Hisataka Kobayashi, Toshiyoshi Fujiwara

    MOLECULAR CANCER THERAPEUTICS   15 ( 3 )   402 - 411   2016.3

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Peritoneal dissemination is the most frequent metastasis in gastric cancer and is associated with poor prognosis. The lack of particular target antigens in gastric cancer other than HER2 has hampered the development of treatments for peritoneal dissemination of gastric cancer. Wehypothesized that HER2-extracellular domain (HER2-ECD) gene transduction combined with trastuzumab-based photoimmunotherapy (PIT) might provide excellent and selective antitumor effects for peritoneal dissemination of gastric cancer. In vitro, adenovirus/HER2-ECD (Ad/HER2-ECD) efficiently transduced HER2-ECD into HER2-negative gastric cancer cells. Trastuzumab-IR700 (Tra-IR700)-mediated PIT induced selective cell death of HER2-ECD-transduced tumor cells. Ad/HER2-ECD also induced homogenous expression of HER2 in heterogeneous gastric cancer cells, resulting in uniform sensitivity of the cells to Tra-IR700-mediated PIT. Anti-HER2 PIT integrated with adenoviral HER2-ECD gene transfer was applied in mice bearing peritoneal dissemination of HER2-negative gastric cancer. Intraperitoneal administration of Ad/HER2-ECD and Tra-IR700 with PIT inhibited peritoneal metastasis and prolonged the survival of mice bearing MKN45. Furthermore, minimal side effects allowed the integrated therapy to be used repeatedly, providing better control of peritoneal dissemination. In conclusion, the novel therapy of molecular-targeted PIT integrated with gene transfer technology is a promising approach for the treatment of peritoneal dissemination in gastric cancer. (C) 2016 AACR.

    DOI: 10.1158/1535-7163.MCT-15-0644

    Web of Science

    researchmap

  • Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer

    Michihiro Ishida, Shunsuke Kagawa, Kyoko Shimoyama, Kiyoto Takehara, Kazuhiro Noma, Shunsuke Tanabe, Yasuhiro Shirakawa, Hiroshi Tazawa, Hisataka Kobayashi, Toshiyoshi Fujiwara

    MOLECULAR CANCER THERAPEUTICS   15 ( 3 )   402 - 411   2016.3

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Peritoneal dissemination is the most frequent metastasis in gastric cancer and is associated with poor prognosis. The lack of particular target antigens in gastric cancer other than HER2 has hampered the development of treatments for peritoneal dissemination of gastric cancer. Wehypothesized that HER2-extracellular domain (HER2-ECD) gene transduction combined with trastuzumab-based photoimmunotherapy (PIT) might provide excellent and selective antitumor effects for peritoneal dissemination of gastric cancer. In vitro, adenovirus/HER2-ECD (Ad/HER2-ECD) efficiently transduced HER2-ECD into HER2-negative gastric cancer cells. Trastuzumab-IR700 (Tra-IR700)-mediated PIT induced selective cell death of HER2-ECD-transduced tumor cells. Ad/HER2-ECD also induced homogenous expression of HER2 in heterogeneous gastric cancer cells, resulting in uniform sensitivity of the cells to Tra-IR700-mediated PIT. Anti-HER2 PIT integrated with adenoviral HER2-ECD gene transfer was applied in mice bearing peritoneal dissemination of HER2-negative gastric cancer. Intraperitoneal administration of Ad/HER2-ECD and Tra-IR700 with PIT inhibited peritoneal metastasis and prolonged the survival of mice bearing MKN45. Furthermore, minimal side effects allowed the integrated therapy to be used repeatedly, providing better control of peritoneal dissemination. In conclusion, the novel therapy of molecular-targeted PIT integrated with gene transfer technology is a promising approach for the treatment of peritoneal dissemination in gastric cancer. (C) 2016 AACR.

    DOI: 10.1158/1535-7163.MCT-15-0644

    Web of Science

    researchmap

  • Improved Resection and Outcome of Colon-Cancer Liver Metastasis with Fluorescence-Guided Surgery Using In Situ GFP Labeling with a Telomerase-Dependent Adenovirus in an Orthotopic Mouse Model

    Shuya Yano, Kiyoto Takehara, Shinji Miwa, Hiroyuki Kishimoto, Yukihiko Hiroshima, Takashi Murakami, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    PLOS ONE   11 ( 2 )   doi: 10.1371/journal.pone.0148760.   2016.2

     More details

    Language:English   Publisher:PUBLIC LIBRARY SCIENCE  

    Fluorescence-guided surgery (FGS) of cancer is an area of intense development. In the present report, we demonstrate that the telomerase-dependent green fluorescent protein (GFP)-containing adenovirus OBP-401 could label colon-cancer liver metastasis in situ in an orthotopic mouse model enabling successful FGS. OBP-401-GFP-labeled liver metastasis resulted in complete resection with FGS, in contrast, conventional bright-light surgery (BLS) did not result in complete resection of the metastasis. OBP-401-FGS reduced the recurrence rate and prolonged over-all survival compared with BLS. In conclusion, adenovirus OBP-401 is a powerful tool to label liver metastasis in situ with GFP which enables its complete resection, not possible with conventional BLS.

    DOI: 10.1371/journal.pone.0148760

    Web of Science

    researchmap

  • Improved Resection and Outcome of Colon-Cancer Liver Metastasis with Fluorescence-Guided Surgery Using In Situ GFP Labeling with a Telomerase-Dependent Adenovirus in an Orthotopic Mouse Model

    Shuya Yano, Kiyoto Takehara, Shinji Miwa, Hiroyuki Kishimoto, Yukihiko Hiroshima, Takashi Murakami, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    PLOS ONE   11 ( 2 )   2016.2

     More details

    Language:English   Publisher:PUBLIC LIBRARY SCIENCE  

    Fluorescence-guided surgery (FGS) of cancer is an area of intense development. In the present report, we demonstrate that the telomerase-dependent green fluorescent protein (GFP)-containing adenovirus OBP-401 could label colon-cancer liver metastasis in situ in an orthotopic mouse model enabling successful FGS. OBP-401-GFP-labeled liver metastasis resulted in complete resection with FGS, in contrast, conventional bright-light surgery (BLS) did not result in complete resection of the metastasis. OBP-401-FGS reduced the recurrence rate and prolonged over-all survival compared with BLS. In conclusion, adenovirus OBP-401 is a powerful tool to label liver metastasis in situ with GFP which enables its complete resection, not possible with conventional BLS.

    DOI: 10.1371/journal.pone.0148760

    Web of Science

    researchmap

  • Targeted Photodynamic Virotherapy Armed with a Genetically Encoded Photosensitizer

    Kiyoto Takehara, Hiroshi Tazawa, Naohiro Okada, Yuuri Hashimoto, Satoru Kikuchi, Shinji Kuroda, Hiroyuki Kishimoto, Yasuhiro Shirakawa, Nobuhiro Narii, Hiroyuki Mizuguchi, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    MOLECULAR CANCER THERAPEUTICS   15 ( 1 )   199 - 208   2016.1

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Photodynamic therapy (PDT) is a minimally invasive antitumor therapy that eradicates tumor cells through a photosensitizer-mediated cytotoxic effect upon light irradiation. However, systemic administration of photosensitizer often makes it difficult to avoid a photosensitive adverse effect. The red fluorescent protein KillerRed generates reactive oxygen species (ROS) upon green light irradiation. Here, we show the therapeutic potential of a novel tumor-specific replicating photodynamic viral agent (TelomeKiller) constructed using the human telomerase reverse transcriptase (hTERT) promoter. We investigated the light-induced antitumor effect of TelomeKiller in several types of human cancer cell lines. Relative cell viability was investigated using an XTT assay. The in vivo antitumor effect was assessed using subcutaneous xenografted tumor and lymph node metastasis models. KillerRed accumulation resulted in ROS generation and apoptosis in light-irradiated cancer cells. Intratumoral injection of TelomeKiller efficiently delivered the KillerRed protein throughout the tumors and exhibited a long-lasting antitumor effect with repeated administration and light irradiation in mice. Moreover, intratumorally injected TelomeKiller could spread into the regional lymph node area and eliminate micrometastasis with limited-field laser irradiation. Our results suggest that KillerRed has great potential as a novel photosensitizer if delivered with a tumor-specific virus-mediated delivery system. TelomeKiller-based PDT is a promising antitumor strategy to efficiently eradicate tumor cells. (C) 2015 AACR.

    DOI: 10.1158/1535-7163.MCT-15-0344

    Web of Science

    researchmap

  • Anti-high mobility group box 1 monoclonal antibody improves ischemia/reperfusion injury and mode of liver regeneration after partial hepatectomy

    Masahiro Sugihara, Hiroshi Sadamori, Masahiro Nishibori, Yasuharu Sato, Hiroshi Tazawa, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Masashi Utsumi, Kyotaro Ohno, Takeshi Nagasaka, Tadashi Yoshino, Hideo Kohka Takahashi, Takahito Yagi, Toshiyoshi Fujiwara

    AMERICAN JOURNAL OF SURGERY   211 ( 1 )   179 - 188   2016.1

     More details

    Language:English   Publisher:EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC  

    BACKGROUND: The purpose of this study is to determine the effects of anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) on ischemia/reperfusion injury (IRI) and the mode of liver regeneration.
    METHODS: Rats underwent 70% hepatectomy with IRI caused by clamping the hepatoduodenal ligament for 20 minutes, followed by the administration of anti-HMGB1 mAb immediately before declamping the hepatoduodenal ligament. Five animals were used for each time point. We then evaluated IRI, regeneration parameters and the status of HMGB1 in remnant livers.
    RESULTS: The anti-HMGB1 mAb significantly ameliorated the degree of IRI in the remnant livers in association with the downregulation of HMGB1 protein. The ratio of Ki67-positive hepatocytes at 48 hours after 70% hepatectomy was significantly improved. Mean hepatocyte size was significantly reduced and cyclin-dependent kinase inhibitor 1 expression was significantly attenuated.
    CONCLUSIONS: Anti-HMGB1 mAb ameliorated IRI and improved the mode of liver regeneration after IRI followed by 70% hepatectomy in rats. (C) 2016 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.amjsurg.2015.06.025

    Web of Science

    researchmap

  • Anti-high mobility group box 1 monoclonal antibody improves ischemia/reperfusion injury and mode of liver regeneration after partial hepatectomy

    Masahiro Sugihara, Hiroshi Sadamori, Masahiro Nishibori, Yasuharu Sato, Hiroshi Tazawa, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Masashi Utsumi, Kyotaro Ohno, Takeshi Nagasaka, Tadashi Yoshino, Hideo Kohka Takahashi, Takahito Yagi, Toshiyoshi Fujiwara

    AMERICAN JOURNAL OF SURGERY   211 ( 1 )   179 - 188   2016.1

     More details

    Language:English   Publisher:EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC  

    BACKGROUND: The purpose of this study is to determine the effects of anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) on ischemia/reperfusion injury (IRI) and the mode of liver regeneration.
    METHODS: Rats underwent 70% hepatectomy with IRI caused by clamping the hepatoduodenal ligament for 20 minutes, followed by the administration of anti-HMGB1 mAb immediately before declamping the hepatoduodenal ligament. Five animals were used for each time point. We then evaluated IRI, regeneration parameters and the status of HMGB1 in remnant livers.
    RESULTS: The anti-HMGB1 mAb significantly ameliorated the degree of IRI in the remnant livers in association with the downregulation of HMGB1 protein. The ratio of Ki67-positive hepatocytes at 48 hours after 70% hepatectomy was significantly improved. Mean hepatocyte size was significantly reduced and cyclin-dependent kinase inhibitor 1 expression was significantly attenuated.
    CONCLUSIONS: Anti-HMGB1 mAb ameliorated IRI and improved the mode of liver regeneration after IRI followed by 70% hepatectomy in rats. (C) 2016 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.amjsurg.2015.06.025

    Web of Science

    researchmap

  • Cell-cycle-dependent drug-resistant quiescent cancer cells induce tumor angiogenesis after chemotherapy as visualized by real-time FUCCI imaging

    Yano S, Takehara K, Tazawa H, Kishimoto H, Urata Y, Kagawa S, Fujiwara T, Hoffman RM

    Cell Cycle   DOI: 10.1080/15384101.2016.1220461   2016

     More details

  • Adenoviral targeting of malignant melanoma for fluorescenceguided surgery prevents recurrence in orthotopic nude-mouse models

    Shuya Yano, Kiyoto Takehara, Hiroyuki Kishimoto, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    Oncotarget   7 ( 14 )   18558 - 18572   2016

     More details

    Language:English   Publisher:Impact Journals LLC  

    Malignant melanoma requires precise resection in order to avoid metastatic recurrence. We report here that the telomerase-dependent, green fluorescent protein (GFP)-containing adenovirus OBP-401 could label malignant melanoma with GFP in situ in orthotopic mouse models. OBP-401-based fluorescence-guided surgery (FGS) resulted in the complete resection of malignant melanoma in the orthotopic models, where conventional bright-light surgery (BLS) could not. High-dose administration of OBP-401 enabled FGS without residual cancer cells or recurrence, due to its dual effect of cancer-cell labeling with GFP and killing.

    DOI: 10.18632/oncotarget.6670

    Scopus

    PubMed

    researchmap

  • Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms

    Kazuhiro Yoshida, Takeshi Nagasaka, Yuzo Umeda, Takehiro Tanaka, Keisuke Kimura, Fumitaka Taniguchi, Tomokazu Fuji, Kunitoshi Shigeyasu, Yoshiko Mori, Hiroyuki Yanai, Takahito Yagi, Ajay Goel, Toshiyoshi Fujiwara

    Journal of Cancer Research and Clinical Oncology, Zeitschrift fur Krebsforschung und Klinische Onkologie, Zeitschrift fur Krebsforschung   1 - 13   2016

  • Surgical outcome of patients undergoing pancreaticoduodenectomy

    Kosei Takagi, Takahito Yagi, Ryuichi Yoshida, Susumu Shinoura, Yuzo Umeda, Daisuke Nobuoka, Takashi Kuise, Nobuyuki Watanabe, Kenta Sui, Tomokazu Fuji, Toshiyoshi Fujiwara

    Acta Medica Okayama, Acta. Medica Okayama, Acta medicinae Okayama, Acta medica Okayama   70 ( 3 )   197 - 204   2016

     More details

  • A case of right-sided Bochdalek hernia incidentally diagnosed in a gastric cancer patient

    Kikuchi S, Nishizaki M, Kuroda S, Kagawa S, Fujiwara T

    BMC Surg   16 ( 34 )   doi: 10.1186/s12893-016-0145-2   2016

     More details

  • Iron depletion enhances the effect of sorafenib in hepatocarcinoma

    Shinichi Urano, Toshiaki Ohara, Kazuhiro Noma, Ryoichi Katsube, Takayuki Ninomiya, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Fumiaki Kimura, Kazuhiro Nouso, Akihiro Matsukawa, Kazuhide Yamamoto, Toshiyoshi Fujiwara

    CANCER BIOLOGY & THERAPY   17 ( 6 )   648 - 656   2016

     More details

    Language:English   Publisher:TAYLOR & FRANCIS INC  

    Human hepatocellular carcinoma (HCC) is known to have a poor prognosis. Sorafenib, a molecular targeted drug, is most commonly used for HCC treatment. However, its effect on HCC is limited in clinical use and therefore new strategies regarding sorafenib treatment are required. Iron overload is known to be associated with progression of chronic hepatitis and increased risk of HCC. We previously reported that iron depletion inhibited cancer cell proliferation and conversely induced angiogenesis. Indeed iron depletion therapy including iron chelator needs to be combined with anti-angiogenic drug for its anti-cancer effect. Since sorafenib has an anti-angiogenic effect by its inhibitory targeting VEGFR, we hypothesized that sorafenib could complement the anti-cancer effect of iron depletion. We retrospectively analyzed the relationship between the efficacy of sorafenib and serum iron-related markers in clinical HCC patients. In clinical cases, overall survival was prolonged in total iron binding capacity (TIBC) high- and ferritin low-patients. This result suggested that the low iron-pooled patients, who could have a potential of more angiogenic properties in/around HCC tumors, could be adequate for sorafenib treatment. We determined the effect of sorafenib (Nexavar (R)) and/or deferasirox (EXJADE (R)) on cancer cell viability, and on cell signaling of human hepatocarcinoma HepG2 and HLE cells. Both iron depletion by deferasirox and sorafenib revealed insufficient cytotoxic effect by each monotherapy, however, on the basis of increased angiogenesis by iron depletion, the addition of deferasirox enhanced anti-proliferative effect of sorafenib. Deferasirox was confirmed to increase vascular endothelial growth factor (VEGF) secretion into cellular supernatants by ELISA analysis. In in vivo study sorafenib combined with deferasirox also enhanced sorafenib-induced apoptosis. These results suggested that sorafenib combined with deferasirox could be a novel combination chemotherapy for HCC.

    DOI: 10.1080/15384047.2016.1177677

    Web of Science

    researchmap

  • Iron depletion enhances the effect of sorafenib in hepatocarcinoma

    Shinichi Urano, Toshiaki Ohara, Kazuhiro Noma, Ryoichi Katsube, Takayuki Ninomiya, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Fumiaki Kimura, Kazuhiro Nouso, Akihiro Matsukawa, Kazuhide Yamamoto, Toshiyoshi Fujiwara

    CANCER BIOLOGY & THERAPY   17 ( 6 )   648 - 656   2016

     More details

    Language:English   Publisher:TAYLOR & FRANCIS INC  

    Human hepatocellular carcinoma (HCC) is known to have a poor prognosis. Sorafenib, a molecular targeted drug, is most commonly used for HCC treatment. However, its effect on HCC is limited in clinical use and therefore new strategies regarding sorafenib treatment are required. Iron overload is known to be associated with progression of chronic hepatitis and increased risk of HCC. We previously reported that iron depletion inhibited cancer cell proliferation and conversely induced angiogenesis. Indeed iron depletion therapy including iron chelator needs to be combined with anti-angiogenic drug for its anti-cancer effect. Since sorafenib has an anti-angiogenic effect by its inhibitory targeting VEGFR, we hypothesized that sorafenib could complement the anti-cancer effect of iron depletion. We retrospectively analyzed the relationship between the efficacy of sorafenib and serum iron-related markers in clinical HCC patients. In clinical cases, overall survival was prolonged in total iron binding capacity (TIBC) high- and ferritin low-patients. This result suggested that the low iron-pooled patients, who could have a potential of more angiogenic properties in/around HCC tumors, could be adequate for sorafenib treatment. We determined the effect of sorafenib (Nexavar (R)) and/or deferasirox (EXJADE (R)) on cancer cell viability, and on cell signaling of human hepatocarcinoma HepG2 and HLE cells. Both iron depletion by deferasirox and sorafenib revealed insufficient cytotoxic effect by each monotherapy, however, on the basis of increased angiogenesis by iron depletion, the addition of deferasirox enhanced anti-proliferative effect of sorafenib. Deferasirox was confirmed to increase vascular endothelial growth factor (VEGF) secretion into cellular supernatants by ELISA analysis. In in vivo study sorafenib combined with deferasirox also enhanced sorafenib-induced apoptosis. These results suggested that sorafenib combined with deferasirox could be a novel combination chemotherapy for HCC.

    DOI: 10.1080/15384047.2016.1177677

    Web of Science

    researchmap

  • Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging

    Shuya Yano, Kiyoto Takehara, Ming Zhao, Yuying Tan, Qinghong Han, Shukuan Li, Michael Bouvet, Toshiyoshi Fujiwara, Robert, M. Hoffman

    Cell Cycle   1 - 9   2016

  • Efficient detection of human circulating tumor cells without significant production of false-positive cells by a novel conditionally replicating adenovirus

    Sakurai F, Narii N, Tomita K, Togo S, Takahashi K, Machitani M, Tachibana M, Ouchi M, Katagiri N, Urata Y, Fujiwara T, Mizuguchi H

    Mol. Ther. Methods Clin. Dev   3 ( 16001 )   2016

     More details

  • 肝移植医療を地域と大学が一体としてまとめ上げた実績とさらなる発展

    八木孝仁, 篠浦 先, 楳田祐三, 吉田龍一, 信岡大輔, 杭瀬 崇, 渡辺信之, 高木弘誠, 須井健太, 藤原俊義, 高木章乃夫, 吉田真理, 保田裕子, 森松博史

    肝胆膵   72 ( 3 )   481 - 487   2016

     More details

  • Behçet's disease complicated by ileocecal and esophageal perforation

    Tsukumo Yuta, Kawamoto Kazuyuki, Takagi Kosei, Chin Kai, Matsuba Yuri, Nagahisa Yoshio, Okabe Michio, Shirakawa Yasuhiro, Itoh Tadashi, Fujiwara Toshiyoshi

    Okayama Igakkai Zasshi (Journal of Okayama Medical Association)   128 ( 1 )   27 - 32   2016

     More details

    Language:Japanese   Publisher:Okayama Medical Association  

    A 36-year-old Japanese man known to have incomplete Behçet's disease (oral aphthous ulcers, genital ulcers, skin lesions, and esophageal and ileocecal ulcers) was admitted to our hospital in January 2011 for abdominal pain. We administered corticosteroids and immunosuppressants. Two months later, we performed an ileocecal resection to control gastrointestinal bleeding from the ileocecal ulcers. High fever persisted after this surgery, and upper gastrointestinal endoscopy demonstrated ulcer penetration between the lower and abdominal esophagus. Eighteen days after the initial ileocecal resection, we performed a lower esophagus resection, gastric tube reconstruction and enterostomy, during which we confirmed a 5-mm-dia. perforated site at the posterior wall of the abdominal esophagus. Postoperative anastomotic leakage and empyema occurred, but they were relieved by thoracic drainage and empyema dissection.

    DOI: 10.4044/joma.128.27

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://ousar.lib.okayama-u.ac.jp/metadata/54077

  • Therapeutic efficacy in vivo of a telomerase-dependent adenovirus in an orthotopic model of chemotherapy-resistant human stomach carcinomatosis peritonitis visualized with cell cycle color coding FUCCI imaging

    Yano S, Takehara K, Tazawa H, Kishimoto H, Urata Y, Kagawa S, Fujiwara T, Hoffman RM

    Journal of Cellular Biochemistry   doi: 10.1002/jcb.25593   2016

     More details

  • Pretreatment of donor islets with papain improves allograft survival without systemic immunosuppression in mice

    Kenjiro Kumano, Hitomi Nishinakamura, Toshiyuki Mera, Takeshi Itoh, Hiroyuki Takahashi, Toshiyoshi Fujiwara, Shohta Kodama

    ISLETS   8 ( 5 )   145 - 155   2016

     More details

    Language:English   Publisher:TAYLOR & FRANCIS INC  

    Although current immunosuppression protocols improve the efficacy of clinical allogenic islet transplantation, T cell-mediated allorejection remains unresolved, and major histocompatibility complexes (MHCs) play a crucial role in this process. Papain, a cysteine protease, has the unique ability to cleave the extracellular domain of the MHC class I structure. We hypothesized that pretreatment of donor islets with papain would diminish the expression of MHC class I on islets, reducing allograft immunogenicity and contributing to prolongation of islet allograft survival. BALB/c islets pretreated with papain were transplanted into C57BL/6J mice as an acute allorejection model. Treatment with 1mg/mL papain significantly prolonged islet allograft survival. In vitro, to determine the inhibitory effect on T cell-mediated alloreactions, we performed lymphocyte proliferation assays and mixed lymphocyte reactions. Host T cell activation against allogenic islet cells was remarkably suppressed by pretreatment of donor islet cells with 10mg/mL papain. Flow cytometric analysis was also performed to investigate the effect of papain treatment on the expression of MHC class I on islets. One or 10mg/mL papain treatment reduced MHC class I expression on the islet cell surface. Pretreatment of donor islets with papain suppresses MHC class I-mediated allograft rejection in mice and contributes to prolongation of islet allograft survival without administration of systemic immunosuppressants. These results suggest that pretreatment of human donor islets with papain may reduce the immunogenicity of the donor islets and minimize the dosage of systemic immunosuppressants required in a clinical setting.

    DOI: 10.1080/19382014.2016.1223579

    Web of Science

    researchmap

  • Enhanced Metastatic Recurrence Via Lymphatic Trafficking of a High-Metastatic Variant of Human Triple-Negative Breast Cancer After Surgical Resection in Orthotopic Nude Mouse Models

    Yano S, Takehara K, Tazawa H, Kishimoto H, Kagawa S, Bouvet M, Fujiwara T, Hoffman RM

    Journal of Cellular Biochemistry   doi: 10.1002/jcb.25735   2016

     More details

  • 胃癌術後肝転移再発に対してThird-LineのCPT-11が奏効し長期生存を得た1 例

    菊地覚次, 西﨑正彦, 黒田新士, 香川俊輔, 藤原俊義

    癌と化学療法   43 ( 12 )   2219 - 2221   2016

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    症例は63歳、男性。早期胃癌(pT1bN0M0、pStage IA)術後20ヵ月のCTにて多発肝転移再発を認め、first-lineとしてS-1+CDDP療法2コース施行後、腫瘍は増大し、second-lineとしてnab-PTX6コース施行するも腫瘍増大、肝酵素上昇、体重減少と全身状態の悪化を認めた。しかし、third-lineのCPT-11が奏効し、肝酵素も正常化、体重も増加し全身状態、ADLの改善も認め、8ヵ月PRを維持した。CPT-11合計17コース施行後に腫瘍が増大し、その後S-1+oxaliplatin療法、DTX、再度CPT-11、ramucirumab投与を行い、再発後31ヵ月原病死された。胃癌肝転移に対してCPT-11はkey drugになる可能性があり、また予後延長には胃癌に有効なkey drugをすべて使い切るマネージメントが重要と考えられた。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2016&ichushi_jid=J00296&link_issn=&doc_id=20161222480266&doc_link_id=%2Fab8gtkrc%2F2016%2F004312%2F266%2F2219-2221%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2016%2F004312%2F266%2F2219-2221%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging

    Shuya Yano, Kiyoto Takehara, Ming Zhao, Yuying Tan, Qinghong Han, Shukuan Li, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    CELL CYCLE   15 ( 13 )   1715 - 1723   2016

     More details

    Language:English   Publisher:TAYLOR & FRANCIS INC  

    We previously reported real-time monitoring of cell cycle dynamics of cancer cells throughout a live tumor intravitally using a fluorescence ubiquitination cell cycle indicator (FUCCI). Approximately 90% of cancer cells in the center and 80% of total cells of an established tumor are in G(0)/G(1) phase. Longitudinal real-time FUCCI imaging demonstrated that cytotoxic agents killed only proliferating cancer cells at the surface and, in contrast, and had little effect on the quiescent cancer cells. Resistant quiescent cancer cells restarted cycling after the cessation of chemotherapy. Thus cytotoxic chemotherapy which targets cells in S/G(2)/M, is mostly ineffective on solid tumors, but causes toxic side effects on tissues with high fractions of cycling cells, such as hair follicles, bone marrow and the intestinal lining. We have termed this phenomenon tumor intrinsic chemoresistance (TIC). We previously demonstrated that tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) decoyed quiescent cancer cells in tumors to cycle from G(0)/G(1) to S/G(2)/M demonstrated by FUCCI imaging. We have also previously shown that when cancer cells were treated with recombinant methioninase (rMETase), the cancer cells were selectively trapped in S/G(2), shown by cell sorting as well as by FUCCI. In the present study, we show that sequential treatment of FUCCI-expressing stomach cancer MKN45 in vivo with S. typhimurium A1-R to decoy quiescent cancer cells to cycle, with subsequent rMETase to selectively trap the decoyed cancer cells in S/G(2) phase, followed by cisplatinum (CDDP) or paclitaxel (PTX) chemotherapy to kill the decoyed and trapped cancer cells completely prevented or regressed tumor growth. These results demonstrate the effectiveness of the praradigm of decoy, trap and shoot chemotherapy.

    DOI: 10.1080/15384101.2016.1181240

    Web of Science

    researchmap

  • Oxidative stress balance is dysregulated and represents an additional target for treating cholangiocarcinoma

    Daisuke Uchida, Akinobu Takaki, Hisashi Ishikawa, Yasuko Tomono, Hironari Kato, Koichiro Tsutsumi, Naofumi Tamaki, Takayuki Maruyama, Takaaki Tomofuji, Ryuichiro Tsuzaki, Tetsuya Yasunaka, Kazuko Koike, Hiroshi Matsushita, Fusao Ikeda, Yasuhiro Miyake, Hidenori Shiraha, Kazuhiro Nouso, Ryuichi Yoshida, Yuzo Umeda, Susumu Shinoura, Takahito Yagi, Toshiyoshi Fujiwara, Manabu Morita, Masaki Fukushima, Kazuhide Yamamoto, Hiroyuki Okada

    FREE RADICAL RESEARCH   50 ( 7 )   732 - 743   2016

     More details

    Language:English   Publisher:TAYLOR & FRANCIS LTD  

    Background: Pancreatico-biliary malignancies exhibit similar characteristics, including obesity-related features and poor prognosis, and require new treatment strategies. Oxidative stress is known to induce DNA damage and carcinogenesis, and its reduction is viewed as being favorable. However, it also has anti-infection and anti-cancer functions that need to be maintained. To reveal the effect of oxidative stress on cancer progression, we evaluated oxidative stress and anti-oxidative balance in pancreatic cancer (PC) and cholangiocarcinoma (CC) patients, as well as the effect of add-on antioxidant treatment to chemotherapy in a mouse cholangiocarcinoma model.
    Methods: We recruited 84 CC and 80 PC patients who were admitted to our hospital. Serum levels of reactive oxygen metabolites (ROM) and the anti-oxidative OXY-adsorbent test were determined and the balance of these tests was defined as an oxidative index. A diabetic mouse-based cholangiocarcinoma model was utilized to evaluate the effects of add-on antioxidant therapy on cholangiocarcinoma chemotherapy.
    Results: Serum ROM was higher and anti-oxidant OXY was lower in CC patients with poor outcomes. These parameters were not significantly different in PC patients. In mice, vitamin E administration induced antioxidant hemeoxygenase (HO)-1 protein expression in cancer tissue, while the number of stem-like cells increased. L-carnitine administration improved intestinal microbiome and biliary acid balance, upregulated the hepatic mitochondrial membrane uptake related gene Cpt1 in non-cancerous tissue, and did not alter stem-like cell numbers.
    Conclusion: Oxidative stress balance was dysregulated in cholangiocarcinoma with poor outcome. The mitochondrial function-supporting agent L-carnitine is a good candidate to control oxidative stress conditions.

    DOI: 10.3109/10715762.2016.1172071

    Web of Science

    researchmap

  • Oxidative stress balance is dysregulated and represents an additional target for treating cholangiocarcinoma

    Daisuke Uchida, Akinobu Takaki, Hisashi Ishikawa, Yasuko Tomono, Hironari Kato, Koichiro Tsutsumi, Naofumi Tamaki, Takayuki Maruyama, Takaaki Tomofuji, Ryuichiro Tsuzaki, Tetsuya Yasunaka, Kazuko Koike, Hiroshi Matsushita, Fusao Ikeda, Yasuhiro Miyake, Hidenori Shiraha, Kazuhiro Nouso, Ryuichi Yoshida, Yuzo Umeda, Susumu Shinoura, Takahito Yagi, Toshiyoshi Fujiwara, Manabu Morita, Masaki Fukushima, Kazuhide Yamamoto, Hiroyuki Okada

    FREE RADICAL RESEARCH   50 ( 7 )   732 - 743   2016

     More details

    Language:English   Publisher:TAYLOR & FRANCIS LTD  

    Background: Pancreatico-biliary malignancies exhibit similar characteristics, including obesity-related features and poor prognosis, and require new treatment strategies. Oxidative stress is known to induce DNA damage and carcinogenesis, and its reduction is viewed as being favorable. However, it also has anti-infection and anti-cancer functions that need to be maintained. To reveal the effect of oxidative stress on cancer progression, we evaluated oxidative stress and anti-oxidative balance in pancreatic cancer (PC) and cholangiocarcinoma (CC) patients, as well as the effect of add-on antioxidant treatment to chemotherapy in a mouse cholangiocarcinoma model.
    Methods: We recruited 84 CC and 80 PC patients who were admitted to our hospital. Serum levels of reactive oxygen metabolites (ROM) and the anti-oxidative OXY-adsorbent test were determined and the balance of these tests was defined as an oxidative index. A diabetic mouse-based cholangiocarcinoma model was utilized to evaluate the effects of add-on antioxidant therapy on cholangiocarcinoma chemotherapy.
    Results: Serum ROM was higher and anti-oxidant OXY was lower in CC patients with poor outcomes. These parameters were not significantly different in PC patients. In mice, vitamin E administration induced antioxidant hemeoxygenase (HO)-1 protein expression in cancer tissue, while the number of stem-like cells increased. L-carnitine administration improved intestinal microbiome and biliary acid balance, upregulated the hepatic mitochondrial membrane uptake related gene Cpt1 in non-cancerous tissue, and did not alter stem-like cell numbers.
    Conclusion: Oxidative stress balance was dysregulated in cholangiocarcinoma with poor outcome. The mitochondrial function-supporting agent L-carnitine is a good candidate to control oxidative stress conditions.

    DOI: 10.3109/10715762.2016.1172071

    Web of Science

    researchmap

  • An extended retroperitoneal emphysema with diversion colitis after colonoscopy

    Tetsuya Kagawa, Shin Nakatani, Hiroyuki Kishimoto, Yoshitaka Kondo, Toshiko Mori, Takeshi Nagasaka, Toshiyoshi Fujiwara

    Japanese Journal of Gastroenterological Surgery   49 ( 8 )   804 - 811   2016

     More details

    Language:Japanese   Publisher:Japanese Society of Gastroenterological Surgery  

    A 68-year-old man with a history of intersphincteric resection and transverse colostomy for rectal cancer underwent diagnostic colonoscopy as a post-operative follow up. Colonoscopy revealed diversion colitis of the sigmoid colon. Two hours after the examination, the patient complained of mild abdominal pain. Blumberg sign was negative and no remarkable changes were observed, but abdominal pain did not improve for 6 hours. A CT scan showed retropneumoperitoneum, pneumomediastinum, subcutaneous emphysema and pneumatosis intestinalis of the sigmoid colon without any evidence of perforation. We diagnosed retroperitoneal emphysema with diversion colitis after colonoscopy and the patient was admitted to our hospital. We decided on a conservative treatment method because of the lack of peritonitis and good general condition. The clinical course was uneventful and he was discharged 11 days after the initial observation. Retroperitoneal emphysema is a very rare complication that occurs after colonoscopy. We report our case with a literature review of 25 cases of retroperitoneal emphysema after colonoscopy in Japan.

    DOI: 10.5833/jjgs.2015.0141

    Scopus

    researchmap

  • Incisional hernia repair after wide excision of the iliac bone

    Tsukuda Kazunori, Asano Hiroaki, Mandai Yasuhiro, Fujiwara Toshiyoshi

    Okayama Igakkai Zasshi (Journal of Okayama Medical Association)   128 ( 2 )   117 - 120   2016

     More details

    Language:Japanese   Publisher:Okayama Medical Association  

    The patient was a 46-year old Japanese female who had undergone wide excision of the iliac bone and hip transposition at our institute's orthopedics department 2 years earlier. She presented with a growing incisional hernia and was transferred to our gastroenterological surgery department for surgical treatment. We planned a mesh repair for the incisional hernia, which protruded over the right iliac bone. The dimensions of the abdominal defect were 15×9 cm, and we used prolene mesh to repair the defect. The mesh was fixed at the inner part of the iliac bone, folded back at the iliac horn and fixed to the abdominal oblique muscles. The postoperative course was smooth, and recurrence was not seen at 3.5 years after the operation. An incisional hernia as seen in this patient's case is very rare, but we found that the underlay technique and prolene mesh were very useful for the three-dimensional hernia repair.

    DOI: 10.4044/joma.128.117

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2016396172

  • 癌関連線維芽細胞が食道癌の浸潤と転移に及ぼす影響の検証

    賀島肇, 野間和広, 桂佑貴, 加藤卓也, 大原利章, 田澤大, 白川靖博, 香川俊輔, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   27th   2016

  • 腫瘍融解ウイルス療法の臨床開発

    藤原俊義

    医学のあゆみ   258 ( 5 )   503 - 508   2016

     More details

  • 腹腔鏡下噴門側胃切除

    西﨑正彦, 藤原俊義

    日本外科学会雑誌   117 ( 6 )   543 - 546   2016

     More details

  • 腹臥位胸腔鏡下食道亜全摘術

    白川靖博, 野間和広, 金谷信彦, 岡田 剛, 前田直見, 田辺俊介, 藤原俊義

    消化器外科   39 ( 9 )   1223 - 1235   2016

     More details

  • Molecular theranostics for gastrointestinal cancer:分子イメージングと治療の融合

    藤原俊義

    JSMI Report   10 ( 1 )   7 - 11   2016

     More details

  • 「臨床研究の基礎と実践」によせて

    藤原俊義

    日本外科学会雑誌   117 ( 6 )   597 - 597   2016

     More details

  • テロメラーゼ標的化がん治療・診断用アデノウイルス

    田澤 大, 香川俊輔, 重安邦俊, 藤原俊義

    実験医学   34 ( 1 )   13 - 18   2016

  • いま「外科臨床研究」に求められていること

    藤原俊義

    臨床外科   71 ( 5 )   524 - 525   2016

     More details

  • 胆管の外科解剖

    八木孝仁, 篠浦 先, 楳田祐三, 吉田龍一, 藤原俊義

    手術   70 ( 4 )   347 - 354   2016

  • 当院における膵頭十二指腸切除術の治療成績

    高木弘誠, 八木孝仁, 吉田龍一, 藤智和, 杭瀬崇, 渡辺信之, 信岡大輔, 楳田祐三, 篠浦先, 藤原俊義

    日本消化器外科学会雑誌(Web)   49 ( Supplement2 )   2016

  • 多視点3D映像システムによる次世代の手術解剖教育

    信岡大輔, 八木孝仁, 近藤喜太, 篠浦先, 楳田祐三, 吉田龍一, 渡辺信之, 杭瀬崇, 藤智和, 高木弘誠, 藤原俊義

    日本消化器外科学会雑誌(Web)   49 ( Supplement2 )   2016

  • 胸腔鏡下食道亜全摘術後に発症した術後リンパ瘻に対し,腹臥位胸腔鏡下胸管結紮術により治療し得た一例

    土生智大, 白川靖博, 升田智也, 前田直見, 二宮卓之, 田邊俊介, 野間和広, 櫻間教文, 藤原俊義

    日本内視鏡外科学会雑誌   21 ( 7 (CD-ROM) )   2016

  • 食道切除術後胃管再建におけるICG蛍光法による胃管血流評価の有用性

    岡田剛, 野間和広, 金谷信彦, 前田直見, 田邊俊介, 白川靖博, 藤原俊義

    日本消化器外科学会雑誌(Web)   49 ( Supplement1 )   2016

  • Multimodality preoperative treatment based on DCF chemotherapy for highly advanced esophageal cancer

    田邊俊介, 白川靖博, 金谷信彦, 岡田剛, 前田直見, 櫻間教文, 野間和広, 西崎正彦, 香川俊輔, 藤原俊義

    日本消化器外科学会雑誌(Web)   49 ( Supplement1 )   2016

  • 胃腫瘍に対するClosed-LECSの定型化と展望

    西崎正彦, 菊地覚次, 黒田新士, 加藤大, 田邊俊介, 野間和広, 香川俊輔, 白川靖博, 岡田裕之, 藤原俊義

    先進内視鏡治療研究会   10th   2016

  • 頭頚部および胸部外科手術後の難治性リンパ漏に対するリンパ管造影の経験

    岡田剛, 野間和広, 金谷信彦, 前田直見, 田邊俊介, 白川靖博, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   70th   2016

  • Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer

    谷口文崇, 永坂岳司, 藤智和, 母里淑子, 岸本浩行, 河合毅, 楳田祐三, 藤原俊義

    日本消化器外科学会雑誌(Web)   49 ( Supplement1 )   2016

  • リンチ症候群における遺伝子変異の特徴とスクリーニング,PD-1を含めた治療標的

    永坂岳司, 谷口文崇, 母里淑子, 藤原俊義

    日本臨床腫瘍学会学術集会(CD-ROM)   14th   2016

  • 遺伝子変異情報を考慮したStage IV大腸癌に対する予後の検討及び治療戦略の構築

    永坂岳司, 母里淑子, 岸本浩行, 神原健, 河合毅, 中谷紳, 嶋村廣視, 富岡憲明, 森谷行利, 瀧上隆夫, 佃和憲, 藤原俊義

    日本大腸肛門病学会雑誌(Web)   69   2016

  • A Case-matched Comparative Study of Laparoscopic and Open Total Proctocolectomy for Ulcerative Colitis

    Ryo Inada, Takeshi Nagasaka, Yoshitaka Kondo, Ayako Watanabe, Toshiaki Toshima, Nobuhito Kubota, Satoru Kikuchi, Michihiro Ishida, Shinji Kuroda, Yoshiko Mori, Hiroyuki Kishimoto, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   69 ( 5 )   267 - 273   2015.10

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    The aim of this single-institution, retrospective, observational case-control study was to evaluate the safety and feasibility of laparoscopic proctocolectomy (PC) for ulcerative colitis (VC), by comparing it with a case-control series of open PC. Twenty UC patients who underwent laparoscopic PC were retrospectively compared with the open PC group of 12 patients matched for age, sex, and urgency of the operation. In the laparoscopic PC group, the operative time was significantly longer, but the amount of blood loss was significantly smaller. The open PC patients underwent an intraoperative blood transfusion significantly more often, and the serum C-reactive protein level on the first postoperative day was significantly higher in the open PC group. In the laparoscopic PC group, the rate of severe postoperative morbidities, grades 3 and 4 on the Clavien-Dindo classification, was significantly lower, and the median length of hospital stay was significantly shorter. Laparoscopic PC for patients with UC showed superior perioperative outcomes to open PC, except for longer operative time.

    DOI: 10.18926/AMO/53672

    Web of Science

    researchmap

  • Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II Trial

    Kumi Sugiu, Takayuki Iwamoto, Catherine M. Kelly, Naoki Watanabe, Takayuki Motoki, Mitsuya Itoh, Shoichiro Ohtani, Kenji Higaki, Takako Imada, Takeshi Yuasa, Masako Omori, Hiroshi Sonobe, Toshiyoshi Fujiwara, Junji Matsuoka

    ACTA MEDICA OKAYAMA   69 ( 5 )   291 - 299   2015.10

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for post-menopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%; 2/16) and the chemotherapy alone group (8.3%; 1112). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.

    DOI: 10.18926/AMO/53675

    Web of Science

    researchmap

  • 宿主正常細胞である癌関連線維芽細胞を標的とした新たな食道癌治療法の開発

    野間 和広, 賀島 肇, 二宮 卓之, 勝部 亮一, 渡邉 伸一郎, 大原 利章, 田澤 大, 香川 俊輔, 白川 靖博, 藤原 俊義

    癌と化学療法   42 ( 10 )   1228 - 1230   2015.10

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    近年の分子細胞生化学の発展により、分子標的治療薬によって飛躍的に予後改善を認める癌腫もでてきている。また、bevacizumabの台頭にみられるように、がん微小環境を制御することでより抗腫瘍効果を上げる例もでてきており、新しい可能性を示唆している。癌とがん微小環境の相互作用については以前より多く報告されており、その中心的な役割を担っているのが癌関連線維芽細胞(cancer-associated fibroblasts:CAFs)といわれている。以前よりわれわれは、食道癌の進展におけるがん微小環境の強い関与を推測し、特にCAFの作用に注目し分子標的となり得るシグナルの解析を行ってきた。しかしながら、CAFの単一のシグナル阻害のみでは癌の治療においては不十分な可能性が考えられた。現在までに多くのCAF細胞におけるシグナルを標的とした治療法が提案されてきたが、未だ十分な結果を得ていない。光線免疫療法は、2011年にMitsunagaらにて発表された近赤外線光を用いた標的分子特異的癌治療である。われわれは、その細胞特異性に殺傷できるシステムに注目し、現在CAFそのものを制御すべくCAFに対する光線化学療法の開発、またその効果を検討している。今後検討結果を随時報告する予定である。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J00296&link_issn=&doc_id=20151027380020&doc_link_id=%2Fab8gtkrc%2F2015%2F004210%2F021%2F1228-1230%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2015%2F004210%2F021%2F1228-1230%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • HER2-targeted gold nanoparticles produce potent antitumor effects on human gastric cancer cells

    Tetsushi Kubota, Shinji Kuroda, Katsuyuki Aoyama, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   75   2015.8

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-5520

    Web of Science

    researchmap

  • Differentiated gastric cancer cells have a potential to induce cancer-associated fibroblasts

    Yuncheng Li, Hiroshi Tazawa, Nishizaki Masahiko, Yuuri Hashimoto, Naoto Hori, Ryoichi Katsube, Shinji Kuroda, Kazuhiro Noma, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   75   2015.8

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-2368

    Web of Science

    researchmap

  • Preclinical study of telomerase-specific p53 tumor suppressor gene overexpression in human scirrhous gastric cancer cells with different p53 status

    Naoto Hori, Hiroshi Tazawa, Masahiko Nishizaki, Satoru Kikuchi, Shuya Yano, Michihiro Ishida, Megumi Watanabe, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   75   2015.8

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-5338

    Web of Science

    researchmap

  • A novel photoimmunotherapy targeting cancer-associated fibroblasts (CAFs) overcomes therapeutic resistance in human esophageal cancer

    Ryoichi Katsube, Kazuhiro Noma, Shinichiro Watanabe, Shinichi Urano, Takayuki Ninomiya, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Hisataka Kobayashi, Toshiyoshi Fujiwara

    CANCER RESEARCH   75   2015.8

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-401

    Web of Science

    researchmap

  • Phase I/II trial of endoscopic intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, with radiation in elderly esophageal cancer patients

    Shunsuke Tanabe, Hiroshi Tazawa, Shunsuke Kagawa, Kazuhiro Noma, Kiyoto Takehara, Takeshi Koujima, Hajime Kashima, Takuya Kato, Shinji Kuroda, Satoru Kikuchi, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   75   2015.8

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-CT123

    Web of Science

    researchmap

  • A novel tumor-specific oncolytic biological therapy against invasive pancreatic cancer

    Takeshi Koujima, Hiroshi Tazawa, Naoto Hori, Shuta Tamura, Shinji Kuroda, Hiroyuki Kishimoto, Masahiko Nishizaki, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   75   2015.8

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-3535

    Web of Science

    researchmap

  • Companion diagnostics-based telomerase-specific oncolytic virotherapy: preclinical evaluation in human colorectal cancer cell lines differentially affected in the RAS/RAF/MEK signaling pathway

    Shuta Tamura, Hiroshi Tazawa, Naoto Hori, Takeshi Koujima, Satoru Kikuchi, Shinji Kuroda, Hiroyuki Kishimoto, Takeshi Nagasaka, Masahiko Nishizaki, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   75   2015.8

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-3531

    Web of Science

    researchmap

  • Virus-guided fluorescence imaging of intraperitoneal free gastric cancer cells: a preliminary clinical study as a potential clinical biomarker

    Megumi Watanabe, Shunsuke Kagawa, Kazuya Kuwata, Michihiro Ishida, Yuuri Hashimoto, Naoto Hori, Satoru Kikuchi, Shinji Kuroda, Hiroyuki Kishimoto, Masahiko Nishizaki, Hiroshi Tazawa, Yasuo Urata, Toshiyoshi Fujiwara

    CANCER RESEARCH   75   2015.8

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-3412

    Web of Science

    researchmap

  • Genetic and epigenetic alterations of netrin-1 receptors in gastric cancer with chromosomal instability

    Keisuke Toda, Takeshi Nagasaka, Yuzo Umeda, Takehiro Tanaka, Takashi Kawai, Tomokazu Fuji, Fumitaka Taniguchi, Kazuya Yasui, Nobuhito Kubota, Yuko Takehara, Hiroshi Tazawa, Shunsuke Kagawa, Dong-Sheng Sun, Naoshi Nishida, Ajay Goel, Toshiyoshi Fujiwara

    CLINICAL EPIGENETICS   7   doi:10.1186/s13148-015-0096-y   2015.7

     More details

    Language:English   Publisher:BIOMED CENTRAL LTD  

    Background: The gene expressions of netrin-1 dependence receptors, DCC and UNC5C, are frequently downregulated in many cancers. We hypothesized that downregulation of DCC and UNC5C has an important growth regulatory function in gastric tumorigenesis.
    Results: In the present study, a series of genetic and epigenetic analyses for DCC and UNC5C were performed in a Japanese cohort of 98 sporadic gastric cancers and corresponding normal gastric mucosa specimens. Loss of heterozygosity (LOH) analyses and microsatellite instability (MSI) analysis was applied to determine chromosomal instability (CIN) and MSI phenotypes, respectively. More than 5 % methylation in the DCC and UNC5C promoters were found in 45 % (44/98) and 32 % (31/98) gastric cancers, respectively, and in 9 % (9/105) and 5 % (5/105) normal gastric mucosa, respectively. Overall, 70 % (58 of 83 informative cases) and 51 % (40 of 79 informative cases) of gastric cancers harbored either LOH or aberrant methylation in the DCC and UNC5C genes, respectively. In total, 77 % (51 of 66 informative cases) of gastric cancers showed cumulative defects in these two dependence receptors and were significantly associated with chromosomal instability. Both DCC and UNC5C were inactivated in 97 % of CIN-positive gastric cancers and in 55 % of CIN-negative gastric cancers.
    Conclusions: Defect in netrin receptors is a common feature in gastric cancers. DCC alterations are apparent in the early stages, and UNC5C alterations escalate with the progression of the disease, suggesting that the cumulative alterations of netrin-1 receptors was a late event in gastric cancer progression and emphasizing the importance of this growth regulatory pathway in gastric carcinogenesis.

    DOI: 10.1186/s13148-015-0096-y

    Web of Science

    researchmap

  • Enhancement of Programmed Death Ligand 2 on Hepatitis C Virus Infected Hepatocytes by Calcineurin Inhibitors

    Kazuko Koike, Akinobu Takaki, Takahito Yagi, Yoshiaki Iwasaki, Tetsuya Yasunaka, Hiroshi Sadamori, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Sato, Daisuke Nobuoka, Masashi Utsumi, Yasuhiro Miyake, Fusao Ikeda, Hidenori Shiraha, Toshiyoshi Fujiwara, Kazuhide Yamamoto

    TRANSPLANTATION   99 ( 7 )   1447 - 1454   2015.7

     More details

    Language:English   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Background. Post orthotopic liver transplantation (OLT) viral hepatitis is an immunological condition where immune cells induce hepatitis during conditions of immune-suppression. The immune-regulatory programmed death-1 (PD-1)/PD-ligand 1 system is acknowledged to play important roles in immune-mediated diseases. However, the PD-1/PD-L2 interaction is not well characterized, with PD-L2 also exhibiting an immunostimulatory function. We hypothesized that this atypical molecule could affect the recurrence of post-OLT hepatitis. To test this hypothesis, we conducted immunohistochemical staining analysis and in vitro analysis of PD-L2. Methods. The expression of PD-L2 was evaluated in liver biopsy specimens from patients with chronic hepatitis B (n = 15), post-OLT hepatitis B (n = 8), chronic hepatitis C (n = 48), and post-OLT hepatitis C (CH-C-OLT) (n = 14). The effect of calcineurin inhibitors (CNIs) and hepatitis C virus (HCV) on PD-L2 expression was investigated in hepatoma cell lines. Results. The PD-L2 was highly expressed on CH-C-OLT hepatocytes. Treatment of hepatoma cell lines with CNIs resulted in increased PD-L2 expression, especially in combination with HCV core or NS3 protein. Transfection of cell lines with PD-L2 containing plasmid resulted in high intercellular adhesion molecule-1 (ICAM-1) expression, which might enhance hepatitis activity. Conclusions. The PD-L2 is highly expressed on CH-C-OLT hepatocytes, whereas HCV proteins, in combination with CNIs, induce high expression of PD-L2 resulting in elevated expression of ICAM-1. These findings demonstrate the effect of CNIs on inducing PD-L2 and subsequent ICAM-1 expression, effects that may produce inflammatory cell infiltration in post-OLT hepatitis C.

    DOI: 10.1097/TP.0000000000000572

    Web of Science

    researchmap

  • Experimental Curative Fluorescence-guided Surgery of Highly Invasive Glioblastoma Multiforme Selectively Labeled With a Killer-reporter Adenovirus

    Shuya Yano, Shinji Miwa, Hiroyuki Kishimoto, Makoto Toneri, Yukihiko Hiroshima, Mako Yamamoto, Michael Bouvet, Yasuo Urata, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert M. Hoffman

    MOLECULAR THERAPY   23 ( 7 )   1182 - 1188   2015.7

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Fluorescence-guided surgery (FGS) of cancer is an area of intense current interest. However, although benefits have been demonstrated with FGS, curative strategies need to be developed. Glioblastoma multiforme (GBM) is one of the most invasive of cancers and is not totally resectable using standard bright-light surgery (BLS) or current FGS strategies. We report here a curative strategy for FGS of GBM. In this study, telomerase-dependent adenovirus OBP-401 infection brightly and selectively labeled GBM with green fluorescent protein (GFP) for FGS in orthotopic nude mouse models. OBP-401-based FGS enabled curative resection of GBM without recurrence for at least 150 days, compared to less than 30 days with BLS.

    DOI: 10.1038/mt.2015.63

    Web of Science

    researchmap

  • Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery

    S. Yano, Y. Hiroshima, A. Maawy, H. Kishimoto, A. Suetsugu, S. Miwa, M. Toneri, M. Yamamoto, M. H. G. Katz, J. B. Fleming, Y. Urata, H. Tazawa, S. Kagawa, M. Bouvet, T. Fujiwara, R. M. Hoffman

    CANCER GENE THERAPY   22 ( 7 )   344 - 350   2015.7

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Precise fluorescence-guided surgery (FGS) for pancreatic canter has the potential to greatly improve the outcome in this recalcitrant disease. To achieve this goal, we have used genetic reporters to-color code cancer and stroma cells in a patient-derived orthotopic xenograft (PDOX) model. The telomerase-dependent green fluorescent protein (GFP)-containing adenovirus OBP-401 was used to label the cancer cells of a pancreatic cancer PDOX. The PDOX was previously grown in a red fluorescent protein (RFP) transgenic Mouse that stably labeled the PDOX stroma cells bright red. The color-coded PDOX Model enabled FGS to to completely resect the pancreatic tumors including stroma. Dual-colored FGS significantly prevented local recurrence; which bright-light surgery or single-color FGS could not. FGS, with color-coded canter and stroma cells has important potential for improving the outcome of recalcitrant-cancer surgery.

    DOI: 10.1038/cgt.2015.26

    Web of Science

    researchmap

  • 緩和医療 乳癌患者スクリーニングシートによる診断時からの緩和医療の導入

    松岡 順治, 元木 崇之, 岩本 高行, 高下 典子, 露無 佑子, 土井原 博, 南 大輔, 藤原 俊義

    日本乳癌学会総会プログラム抄録集   23回   295 - 295   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本乳癌学会  

    researchmap

  • Prone-Position Thoracoscopic Ligation of the Thoracic Duct for Chyle Leak Following Radical Neck Dissection in a Patient with a Right Aortic Arch

    Yasuhiro Shirakawa, Kazuhiro Noma, Toshiaki Ohara, Hajime Kashima, Naoaki Maeda, Shunsuke Tanabe, Shunsuke Kagawa, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   69 ( 3 )   173 - 176   2015.6

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    A chyle leak can occur as a complication after neck or chest surgery. Such a leak prolongs the hospital stay and is sometimes life-threatening. The treatment options are conservative management, interventional radiologic embolization, and surgery. Thoracoscopic ligation of the thoracic duct has emerged as a promising and definitive treatment The case of a 65-year-old Japanese male patient with a rare congenital right aortic arch (type IIIB1 of Edward's classification) and a severe chyle leak that occurred after a total pharyngolaryngo-esophagectomy (TPLE) is described. The chyle leak was successfully managed by thoracoscopic ligation of the thoracic duct via a left-side approach with the patient in the prone position.

    DOI: 10.18926/AMO/53524

    Web of Science

    researchmap

  • Heterogeneous cell-cycle behavior in response to UVB irradiation by a population of single cancer cells visualized by time-lapse FUCCI imaging

    Shinji Miwa, Shuya Yano, Hiroaki Kimura, Mako Yamamoto, Makoto Toneri, Takashi Murakami, Katsuhiro Hayashi, Norio Yamamoto, Toshiyoshi Fujiwara, Hiroyuki Tsuchiya, Robert M. Hoffman

    CELL CYCLE   14 ( 12 )   1932 - 1937   2015.6

     More details

    Language:English   Publisher:TAYLOR & FRANCIS INC  

    The present study analyzed the heterogeneous cell-cycle dependence and fate of single cancer cells in a population treated with UVB using a fluorescence ubiquitination-based cell-cycle (FUCCI) imaging system. HeLa cells expressing FUCCI were irradiated by 100 or 200 J/m(2) UVB. Modulation of the cell-cycle and apoptosis were observed by time-lapse confocal microscopy imaging every 30min for 72h. Correlation between cell survival and factors including cell-cycle phase at the time of the irradiation of UVB, mitosis and the G(1)/S transition were analyzed using the Kaplan-Meier method along with the log rank test. Time-lapse FUCCI imaging of HeLa cells demonstrated that UVB irradiation induced cell-cycle arrest in S/G(2)/M phase in the majority of the cells. The cells irradiated by 100 or 200 J/m(2) UVB during G(0)/G(1) phase had a higher survival rate than the cells irradiated during S/G(2)/M phase. A minority of cells could escape S/G(2)/M arrest and undergo mitosis which significantly correlated with decreased survival of the cells. In contrast, G(1)/S transition significantly correlated with increased survival of the cells after UVB irradiation. UVB at 200 J/m(2) resulted in a greater number of apoptotic cells.

    DOI: 10.1080/15384101.2015.1033598

    Web of Science

    researchmap

  • Clinical Significance of MLH1 Methylation and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer

    Kunitoshi Shigeyasu, Takeshi Nagasaka, Yoshiko Mori, Naosuke Yokomichi, Takashi Kawai, Tomokazu Fuji, Keisuke Kimura, Yuzo Umeda, Shunsuke Kagawa, Ajay Goel, Toshiyoshi Fujiwara

    PLOS ONE   10 ( 6 )   e0130409   2015.6

     More details

    Language:English   Publisher:PUBLIC LIBRARY SCIENCE  

    Background
    To improve the outcome of patients suffering from gastric cancer, a better understanding of underlying genetic and epigenetic events in this malignancy is required. Although CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) have been shown to play pivotal roles in gastric cancer pathogenesis, the clinical significance of these events on survival outcomes in patients with gastric cancer remains unknown.
    Methods
    This study included a patient cohort with pathologically confirmed gastric cancer who had surgical resections. A cohort of 68 gastric cancers was analyzed. CIMP and MSI statuses were determined by analyzing promoter CpG island methylation status of 28 genes/loci, and genomic instability at 10 microsatellite markers, respectively. A Cox's proportional hazards model was performed for multivariate analysis including age, stage, tumor differentiation, KRAS mutation status, and combined CIMP/MLH1methylation status in relation to overall survival (OS).
    Results
    By multivariate analysis, longer OS was significantly correlated with lower pathologic stage (P = 0.0088), better tumor differentiation (P = 0.0267) and CIMP-high and MLH1 3' methylated status (P = 0.0312). Stratification of CIMP status with regards to MLH1 methylation status further enabled prediction of gastric cancer prognosis.
    Conclusions
    CIMP and/or MLH1 methylation status may have a potential to be prognostic biomarkers for patients with gastric cancer.

    DOI: 10.1371/journal.pone.0130409

    Web of Science

    researchmap

  • Targeting tumors with a killer-reporter adenovirus for curative fluorescence-guided surgery of soft-tissue sarcoma

    Shuya Yano, Shinji Miwa, Hiroyuki Kishimoto, Fuminari Uehara, Hiroshi Tazawa, Makoto Toneri, Yukihiko Hiroshima, Mako Yamamoto, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    ONCOTARGET   6 ( 15 )   13133 - 13148   2015.5

     More details

    Language:English   Publisher:IMPACT JOURNALS LLC  

    Fluorescence-guided surgery (FGS) of cancer is an area of intense interest. However, FGS of cancer has not yet been shown to be curative due to residual microscopic disease. Human fibrosarcoma HT1080 expressing red fluorescent protein (RFP) was implanted orthotopically in the quadriceps femoris muscle of nude mice. The tumor-bearing mice were injected with high and low-dose telomerase-dependent, green fluorescent protein (GFP)-containing adenovirus OBP-401, which labeled the tumor with GFP. Fluorescence-guided surgery (FGS) or bright light surgery (BLS) was then performed. OBP-401 could label soft-tissue sarcoma (STS) with GFP in situ, concordant with RFP. OBP-401-based FGS resulted in superior resection of STS in the orthotopic model of soft-tissue sarcoma, compared to BLS. High-dose administration of OBP-401 enabled FGS without residual sarcoma cells or local or metastatic recurrence, due to its dual effect of cancer-cell labeling with GFP and killing. High-dose OBP-401 based-FGS improved disease free survival (p = 0.00049) as well as preserved muscle function compared with BLS. High-dose OBP-401-based FGS could cure STS, a presently incurable disease. Since the parent virus of OBP-401, OBP-301, has been previously proven safe in a Phase I clinical trial, it is expected the OBP-401-FGS technology described in the present report should be translatable to the clinic in the near future.

    Web of Science

    researchmap

  • Effect of methionine-depletion via methioninase-treatment on cancer cells in S/G2 phase and chemosensitivity.

    Shuya Yano, Shukuan Li, Qinghong Han, Yuying Tan, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    JOURNAL OF CLINICAL ONCOLOGY   33 ( 15 )   2015.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    Web of Science

    researchmap

  • MicroRNA as a molecular target for gastrointestinal cancers

    Hiroshi Tazawa, Takeshi Nagasaka, Shunsuke Kagawa, Toshiyoshi Fujiwara

    TRANSLATIONAL GASTROINTESTINAL CANCER   4 ( 3 )   219 - 235   2015.5

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.   Publisher:AME PUBL CO  

    MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally suppress the expression of many target genes, thereby contributing to the modulation of diverse cellular fates in tumor biology. Recent accumulating evidences have demonstrated that aberrant expression of miRNAs is highly associated with tumor initiation, progression and metastasis in various types of cancers including gastrointestinal (GI) cancers. Exploration of precise miRNA-based gene regulatory networks in the pathogenesis of GI cancers will provide important information for the development of novel anticancer strategies aimed at normalizing the critical miRNAs that are deregulated in GI cancers. Recent reports using clinical samples have shown the potential of upregulation of oncogenic miR-21 and of downregulation of the tumor-suppressive miR-34 family as novel molecular biomarkers for the diagnostic and prognostic prediction of GI cancers. In this review, we have focused on the functional roles of these two cancer-related miRNAs, miR-21 and miR-34, that are commonly deregulated during the development and progression of GI cancers. Moreover, the therapeutic potential of miRNA-targeting anticancer therapy is discussed for clinical application as novel anticancer therapy for GI cancers.

    DOI: 10.3978/j.issn.2224-4778.2015.04.01

    Web of Science

    researchmap

  • Aggressive Multimodality Treatment for Advanced Rectal Cancer

    Ryo Inada, Takeshi Nagasaka, Toshiaki Toshima, Yoshiko Mori, Yoshitaka Kondo, Hiroyuki Kishimoto, Takao Hiraki, Taihei Oshiro, Yukihide Kanemitsu, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   69 ( 2 )   113 - 118   2015.4

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    A case of advanced rectal cancer treated by aggressive local and systemic treatment who has survived more than 7 years from initial recurrence is presented. A 55-year-old woman was diagnosed with advanced lower rectal cancer and underwent a low anterior resection with complete removal of all regional lymph nodes and total mesorectal excision. The tumor was diagnosed as a moderately differentiated adenocarcinoma, pStage IIIB (T3, N2a, M0). Twenty-six months after the initial surgery, local recurrence in the pelvis was detected by computed tomography, and total pelvic exenteration with distal sacrectomy (TPES) was performed after systemic chemotherapy with a molecular-targeted drug. Six months after the TPES, multiple lung metastases were detected. Consequently, the patient underwent radiofrequency ablation (RFA) and chemotherapy. The disease has since been controlled for 38 months. As volume control is essential for cancer treatment, it may be important to combine appropriate local therapy with systemic therapy to metastatic or recurrent sites in order to achieve much longer disease control.

    Web of Science

    researchmap

  • Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics

    Kunitoshi Shigeyasu, Hiroshi Tazawa, Yuuri Hashimoto, Yoshiko Mori, Masahiko Nishizaki, Hiroyuki Kishimoto, Takeshi Nagasaka, Shinji Kuroda, Yasuo Urata, Ajay Goel, Shunsuke Kagawa, Toshiyoshi Fujiwara

    GUT   64 ( 4 )   627 - 635   2015.4

     More details

    Language:English   Publisher:BMJ PUBLISHING GROUP  

    Background Molecular-based companion diagnostic tests are being used with increasing frequency to predict their clinical response to various drugs, particularly for molecularly targeted drugs. However, invasive procedures are typically required to obtain tissues for this analysis. Circulating tumour cells (CTCs) are novel biomarkers that can be used for the prediction of disease progression and are also important surrogate sources of cancer cells. Because current CTC detection strategies mainly depend on epithelial cell-surface markers, the presence of heterogeneous populations of CTCs with epithelial and/or mesenchymal characteristics may pose obstacles to the detection of CTCs.
    Methods We developed a new approach to capture live CTCs among millions of peripheral blood leukocytes using a green fluorescent protein (GFP)-expressing attenuated adenovirus, in which the telomerase promoter regulates viral replication (OBP-401, TelomeScan).
    Results Our biological capturing system can image epithelial and mesenchymal tumour cells with telomerase activities as GFP-positive cells. After sorting, direct sequencing or mutation-specific PCR can precisely detect different mutations in KRAS, BRAF and KIT genes in epithelial, mesenchymal or epithelial-mesenchymal transition-induced CTCs, and in clinical blood samples from patients with colorectal cancer.
    Conclusions This fluorescence virus-guided viable CTC capturing method provides a non-invasive alternative to tissue biopsy or surgical resection of primary tumours for companion diagnostics.

    DOI: 10.1136/gutjnl-2014-306957

    Web of Science

    researchmap

  • Correlation of Computed Tomography Imaging Features and Pathological Features of 41 Patients with Pancreatic Neuroendocrine Tumors

    Masashi Utsumi, Yuzo Umeda, Kosei Takagi, Kuise Takashi, Daisuke Nobuoka, Ryuichi Yoshida, Susumu Shinoura, Hiroshi Sadamori, Takahito Yagi, Toshiyoshi Fujiwara

    HEPATO-GASTROENTEROLOGY   62 ( 138 )   441 - 446   2015.3

     More details

    Language:English   Publisher:H G E UPDATE MEDICAL PUBLISHING S A  

    Background:/Aims: Pancreatic neuroendocrine tumors (PNET) are relatively rare. Here, we present clinical and pathological characteristics of PNETs to show a relationship between computed tomography (CT) imaging and the 2010 World Health Organization (WHO) classification. Methodology: We retrospectively reviewed the records of 41 PNET patients who were treated between 2002 and 2012. All tumors were classified as neuroendocrine tumor (NET) grade 1 (121), NET grade 2 (G2), or neuroendocrine carcinoma (NEC) grade 3 (G3) on the basis of the 2010 WHO classification system. Results: Twenty-five tumors were classified as G1, 11 as G2, and five as G3. Mean sizes of the G1, G2 and G3 tumors were 1.84 +/- 0.54, 4.90 +/- 0.84, and 5.62 +/- 1.18 cm, respectively, (P &lt; 0.01). A PNET is typically hypervascular and exhibits contrast enhancement on enhanced CT. Higher percentage of G1 tumors demonstrated typical imaging and showed a significantly greater distinct mass compared with G2 and G3 tumors. Conclusions: Although PNET has many imaging features that appear on CT, G2 and G3 tumors often show atypical imaging features, particularly with large sizes and/or ill-defined features, when compared with G1 tumors. If a PNET has atypical imaging features, possibility of malignancy should be considered.

    DOI: 10.5754/hge14388

    Web of Science

    researchmap

  • Cancer cells mimic in vivo spatial-temporal cell-cycle phase distribution and chemosensitivity in 3-dimensional Gelfoam (R) histoculture but not 2-dimensional culture as visualized with real-time FUCCI imaging

    Shuya Yano, Shinji Miwa, Sumiyuki Mii, Yukihiko Hiroshima, Fuminaru Uehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Ming Zhao, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    CELL CYCLE   14 ( 6 )   808 - 819   2015.3

     More details

    Language:English   Publisher:TAYLOR & FRANCIS INC  

    The phase of the cell cycle can determine whether a cancer cell can respond to a given drug. We previously reported monitoring of real-time cell cycle dynamics of cancer cells throughout a live tumor, intravitally in live mice, using a fluorescence ubiquitination-based cell-cycle indicator (FUCCI). Approximately 90% of cancer cells in the center and 80% of total cells of an established tumor are in G(0)/G(1) phase. Longitudinal real-time imaging demonstrated that cytotoxic agents killed only proliferating cancer cells at the surface and, in contrast, had little effect on quiescent cancer cells, which are the vast majority of an established tumor. Moreover, resistant quiescent cancer cells restarted cycling after cessation of chemotherapy. These results suggested why most drugs currently in clinical use, which target cancer cells in S/G(2)/M, are mostly ineffective on solid tumors. In the present report, we used FUCCI imaging and Gelfoam (R) collagen-sponge-gel histoculture, to demonstrate in real time, that the cell-cycle phase distribution of cancer cells in Gelfoam (R) and in vivo tumors is highly similar, whereby only the surface cells proliferate and interior cells are quiescent in G(0)/G(1). This is in contrast to 2D culture where most cancer cells cycle. Similarly, the cancer cells responded similarly to toxic chemotherapy in Gelfoam (R) culture as in vivo, and very differently than cancer cells in 2D culture which were much more chemosensitive. Gelfoam (R) culture of FUCCI-expressing cancer cells offers the opportunity to image the cell cycle of cancer cells continuously and to screen for novel effective therapies to target quiescent cells, which are the majority in a tumor and which would have a strong probability to be effective in vivo.

    DOI: 10.1080/15384101.2014.1000685

    Web of Science

    researchmap

  • ARID1A expression in gastric adenocarcinoma: Clinicopathological significance and correlation with DNA mismatch repair status

    Ryo Inada, Shigeki Sekine, Hirokazu Taniguchi, Hitoshi Tsuda, Hitoshi Katai, Toshiyoshi Fujiwara, Ryoji Kushima

    WORLD JOURNAL OF GASTROENTEROLOGY   21 ( 7 )   2159 - 2168   2015.2

     More details

    Language:English   Publisher:BAISHIDENG PUBLISHING GROUP INC  

    AIM: To analyze the mismatch repair (MMR) status and the ARID1A expression as well as their clinicopathological significance in gastric adenocarcinomas.
    METHODS: We examined the expressions of MMR proteins and ARID1A by immunohistochemistry in consecutive 489 primary gastric adenocarcinomas. The results were further correlated with clinicopathological variables.
    RESULTS: The loss of any MMR protein expression, indicative of MMR deficiency, was observed in 38 cases (7.8%) and was significantly associated with an older age (68.6 +/- 9.2 vs 60.4 +/- 11.7, P &lt; 0.001), a female sex (55.3% vs 31.3%, P = 0.004), an antral location (44.7% vs 25.7%, P = 0.021), and a differentiated histology (57.9% vs 39.7%, P = 0.023). Abnormal ARID1A expression, including reduced or loss of ARID1A expression, was observed in 109 cases (22.3%) and was significantly correlated with lymphatic invasion (80.7% vs 69.5%, P = 0.022) and lymph node metastasis (83.5% vs 73.7%, P = 0.042). The tumors with abnormal ARID1A expression more frequently indicated MMR deficiency (47.4% vs 20.2%, P &lt; 0.001). A multivariate analysis identified abnormal ARID1A expression as an independent poor prognostic factor (HR = 1.36, 95% CI: 1.01-1.84; P = 0.040).
    CONCLUSION: Our observations suggest that the AIRD1A inactivation is associated with lymphatic invasion, lymph node metastasis, poor prognosis, and MMR deficiency in gastric adenocarcinomas.

    DOI: 10.3748/wjg.v21.i7.2159

    Web of Science

    researchmap

  • Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells

    Kyoko Shimoyama, Shunsuke Kagawa, Michihiro Ishida, Shinichiro Watanabe, Kazuhiro Noma, Kiyoto Takehara, Hiroshi Tazawa, Yuuri Hashimoto, Shunsuke Tanabe, Junji Matsuoka, Hisataka Kobayashi, Toshiyoshi Fujiwara

    BREAST CANCER RESEARCH AND TREATMENT   149 ( 3 )   597 - 605   2015.2

     More details

    Language:English   Publisher:SPRINGER  

    The prognosis of HER2-positive breast cancer has been improved by trastuzumab therapy, which features high specificity and limited side effects. However, trastuzumab-based therapy has shortcomings. Firstly, HER2-targeted therapy is only applicable to HER2-expressing tumors, which comprise only 20-25 % of primary breast cancers. Secondly, many patients who initially respond to trastuzumab ultimately develop disease progression. To overcome these problems, we employed virus-mediated HER2 transduction and photoimmunotherapy (PIT) which involves trastuzumab conjugated with a photosensitizer, trastuzumab-IR700, and irradiation of near-infrared light. We hypothesized that the gene transduction technique together with PIT would expand the range of tumor entities suitable for trastuzumab-based therapy and improve its antitumor activity. The HER2-extracellular domain (ECD) was transduced by the adenoviral vector, Ad-HER2-ECD, and PIT with trastuzumab-IR700 was applied in the HER2-negative cancer cells. Ad-HER2-ECD can efficiently transduce HER2-ECD into HER2-negative human cancer cells. PIT with trastuzumab-IR700 induced direct cell membrane destruction of Ad-HER2-ECD-transduced HER2-negative cancer cells. Novel combination of viral transduction of a target antigen and an antibody-based PIT would expand and potentiate molecular-targeted therapy even for target-negative or attenuated cancer cells.

    DOI: 10.1007/s10549-015-3265-y

    Web of Science

    researchmap

  • Prone-position thoracoscopic resection of posterior mediastinal lymph node metastasis from rectal cancer

    Yasuhiro Shirakawa, Kazuhiro Noma, Takeshi Koujima, Naoaki Maeda, Shunsuke Tanabe, Toshiaki Ohara, Toshiyoshi Fujiwara

    WORLD JOURNAL OF SURGICAL ONCOLOGY   13 ( 45 )   doi:10.1186/s12957-015-0466-0   2015.2

     More details

    Language:English   Publisher:BIOMED CENTRAL LTD  

    Mediastinal lymph node metastasis from colorectal cancer is rare, and barely any reports have described resection of this pathology. We report herein a successful thoracoscopic resection of mediastinal lymph node metastasis in a prone position. A 65-year-old man presented with posterior mediastinal lymph node metastasis after resection of the primary rectal cancer and metachronous hepatic metastasis. Metastatic lymph nodes were resected completely using thoracoscopic surgery in the prone position, which provided advantages of minimal invasiveness, good surgical field, and reduced ergonomic burden on the surgeon. Thoracoscopic resection in the prone position was thought to have the potential to become the standard procedure of posterior mediastinal tumors.

    DOI: 10.1186/s12957-015-0466-0

    Web of Science

    researchmap

  • Cell-cycle fate-monitoring distinguishes individual chemosensitive and chemoresistant cancer cells in drug-treated heterogeneous populations demonstrated by real-time FUCCI imaging

    Shinji Miwa, Shuya Yano, Hiroaki Kimura, Mako Yamamoto, Makoto Toneri, Yasunori Matsumoto, Fuminari Uehara, Yukihiko Hiroshima, Takashi Murakami, Katsuhiro Hayashi, Norio Yamamoto, Michael Bouvet, Toshiyoshi Fujiwara, Hiroyuki Tsuchiya, Robert M. Hoffman

    CELL CYCLE   14 ( 4 )   621 - 629   2015.2

     More details

    Language:English   Publisher:TAYLOR & FRANCIS INC  

    Essentially every population of cancer cells within a tumor is heterogeneous, especially with regard to chemosensitivity and resistance. In the present study, we utilized the fluorescence ubiquitination-based cell cycle indicator (FUCCI) imaging system to investigate the correlation between cell-cycle behavior and apoptosis after treatment of cancer cells with chemotherapeutic drugs. HeLa cells expressing FUCCI were treated with doxorubicin (DOX) (5M) or cisplatinum (CDDP) (5M) for 3h. Cell-cycle progression and apoptosis were monitored by time-lapse FUCCI imaging for 72h. Time-lapse FUCCI imaging demonstrated that both DOX and CDDP could induce cell cycle arrest in S/G(2)/M in almost all the cells, but a subpopulation of the cells could escape the block and undergo mitosis. The subpopulation which went through mitosis subsequently underwent apoptosis, while the cells arrested in S/G(2)/M survived. The present results demonstrate that chemoresistant cells can be readily identified in a heterogeneous population of cancer cells by S/G(2)/M arrest, which can serve in future studies as a visible target for novel agents that kill cell-cycle-arrested cells.

    DOI: 10.4161/15384101.2014.991604

    Web of Science

    researchmap

  • The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma - a report of a case

    Yoshiko Mori, Takeshi Nagasaka, Hideyuki Mishima, Yuzo Umeda, Ryo Inada, Hiroyuki Kishimoto, Ajay Goel, Toshiyoshi Fujiwara

    BMC MEDICAL GENETICS   16 ( 1 )   10.1186/s12881-015-0144-7   2015.1

     More details

    Language:English   Publisher:BIOMED CENTRAL LTD  

    Background: The BRAF V600E mutation is reportedly associated with inferior survival among colon cancer patients. Here we report a patient with rectal cancer who carried the novel BRAF mutation VK600-601E, which has analogous molecular functions to those of the conventional BRAF mutation V600E, and may have potential as a prognostic marker for colorectal cancer (CRC).
    Case presentation: The present 65-year-old male patient was diagnosed with recurrent rectal adenocarcinoma (stage II by AJCC TNM staging 7th edition) 14 months after surgery and was treated with modified FOLFOX6 (fluorouracil, leucovorin, and oxaliplatin), radiation, and FOLFIRI (fluorouracil, leucovorin, and irinotecan). The tumor progressed before further treatment could be initiated, resulting in death after 15 months. This survival period was similar to the median overall survival among patients with metastatic CRC and BRAF mutations who were treated with the FOLFIRI regimen with or without cetuximab.
    Conclusions: Thus, the BRAF VK600-601E mutation may lead to an aggressive clinical course in CRC patients suffering from rapid progression and potential resistance to multiple therapeutic modalities.

    DOI: 10.1186/s12881-015-0144-7

    Web of Science

    researchmap

  • Operative technique of antethoracic esophageal reconstruction with pedicled jejunal flap

    Yasuhiro Shirakawa, Kazuhiro Noma, Takeshi Koujima, Naoaki Maeda, Shunsuke Tanabe, Toshiaki Ohara, Kazufumi Sakurama, Toshiyoshi Fujiwara

    ESOPHAGUS   12 ( 1 )   57 - 64   2015.1

     More details

    Language:English   Publisher:SPRINGER JAPAN KK  

    Esophageal reconstruction using intestine is often performed for esophageal cancer patients in cases where the stomach cannot be used. We have previously performed reconstruction using ileocolon with supercharge and drainage as our first choice in those cases. However, a less invasive, simpler, and safer reconstructive technique using jejunum without vascular anastomosis has recently become popular at our facility. This study describes the technique of esophageal reconstruction with jejunum, compares the surgical outcomes to those of standard reconstruction using ileocolon, and discusses the clinical significance of this new concept.
    Subjects comprised 53 patients (52 males, 1 female) who underwent esophageal reconstruction using jejunum between January 2008 and July 2013. Patient characteristics, technical details, and outcomes were compared with those of 51 subjects who had undergone esophageal reconstruction using ileocolon. When making the pedicled jejunal flap, the first jejunal vascular arcade was preserved, which in most cases allowed it to be pulled up to the cervical region by processing and transection up to the second jejunal vascular branch.
    The vascular anastomosis techniques were used in 80.4 % (41/51) of esophageal reconstructions using colon, compared with only 24.5 % (13/53) of reconstructions using jejunum. No difference in the frequency of postoperative adverse effects was seen between groups, but the frequency of diarrhea was significantly lower with reconstruction using jejunum.
    Esophageal reconstruction using jejunum with the blood vessel processing technique results in both simpler and safer pulling up. Thus the need to perform supercharge and superdrainage is reduced.

    DOI: 10.1007/s10388-014-0455-3

    Web of Science

    researchmap

  • Enlarging lymphoepithelial cyst of the pancreas during 12 months of observation: report of a case

    Daisuke Satoh, Hiroshi Sadamori, Takahito Yagi, Toshiyoshi Fujiwara

    SURGERY TODAY   45 ( 1 )   101 - 104   2015.1

     More details

    Language:English   Publisher:SPRINGER  

    Pancreatic lymphoepithelial cysts (LECs) are rare benign pancreatic cystic lesions, the etiology of which is unknown. We report a case of a pancreatic LEC, discovered incidentally in a 63-year-old man during a follow-up clinic visit for an abdominal aneurysm. Computed tomography showed a multilocular cyst, 60-mm diameter in the body of the pancreas. This cyst increased from 6.0 to 6.5 cm during 12 months of observation. Part of the cyst was also visualized on positron emission tomography imaging. Since a pancreatic cystic neoplasm could not be ruled out, we performed distal pancreatectomy and postoperative pathological examination confirmed that the lesion was an LEC of the pancreas. Despite the conclusive postoperative findings, resection is unavoidable when a true pancreatic neoplasm cannot be excluded.

    DOI: 10.1007/s00595-014-0960-y

    Web of Science

    researchmap

  • Multidisciplinary cancer therapy with telomerase-specific oncolytic adenovirus

    Toshiyoshi Fujiwara, Shunsuke Kagawa, Hiroshi Tazawa

    Current Cancer Therapy Reviews   11 ( 3 )   178 - 187   2015

     More details

    Language:English   Publisher:Bentham Science Publishers B.V.  

    A multidisciplinary approach of combining surgery, chemotherapy and radiotherapy has remained the accepted standard management for various types of human cancer. However, many new treatment options have recently become available, including molecular targeted therapies, immunotherapies and oncolytic virotherapies. Replication-selective tu-mor-specific viruses have been designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. We constructed an attenuated adenovirus 5 vector, telomelysin (OBP-301), in which the telomerase-specific promoter drives expression of viral replication-inducible E1 genes. Although telomelysin alone exhibited substantial antitumor effects both in animal models and in clinical trials, telomelysin has the potential to be the first-in-class oncolytic virus for combination therapy based on our current understanding of the molecular mechanisms. Telomelysin sensitizes human cancer cells to ionizing radiation by inhibiting the radiation-induced DNA repair machinery, and also eliminates radio-resistant quiescent cancer stem-like cells by promoting cell cycle entry. A clinical trial of intratumoral administration of telomelysin with radiotherapy in esophageal cancer patients is currently underway. This article reviews recent highlights in the rapidly evolving field of multidisciplinary therapy with telomelysin.

    DOI: 10.2174/1573394712666160128201822

    Scopus

    researchmap

  • Precise navigation surgery of tumours in the lung in mouse models enabled by in situ fluorescence labelling with a killer-reporter adenovirus

    Shuya Yano, Yong Zhang, Shinji Miwa, Hiroyuki Kishimoto, Yasuo Urata, Michael Bouvet, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert M. Hoffman

    BMJ Open Respiratory Research   2 ( 1 )   1 - 6   2015

     More details

    Language:English   Publisher:BMJ Publishing Group  

    Background: Current methods of image-guided surgery of tumours of the lung mostly rely on CT. A sensitive procedure of selective tumour fluorescence labelling would allow simple and high-resolution visualisation of the tumour for precise surgical navigation. Methods: Human lung cancer cell lines H460 and A549 were genetically transformed to express red fluorescent protein (RFP). Tumours were grown subcutaneously for each cell line and harvested and minced for surgical orthotopic implantation on the left lung of nude mice. Tumour growth was measured by fluorescence imaging. After the tumours reached 5 mm in diameter, they were injected under fluorescence guidance with the telomerase-dependent green fluorescent protein (GFP)-containing adenovirus, OBP-401. Viral labelling of the lung tumours with GFP precisely colocalised with tumour RFP expression. Three days after administration of OBP-401, fluorescence-guided surgery (FGS) was performed. Results: FGS of tumours in the lung was enabled by labelling with a telomerase-dependent adenovirus containing the GFP gene. Tumours in the lung were selectively and brightly labelled. FGS enabled complete lung tumour resection with no residual fluorescent tumour. Conclusions: FGS of tumours in the lung is feasible and more effective than bright-light surgery.

    DOI: 10.1136/bmjresp-2015-000096

    Scopus

    researchmap

  • Eradication of osteosarcoma by fluorescence-guided surgery with tumor labeling by a killer-reporter adenovirus

    Yano S, Miwa S, Kishimoto H, Urata Y, Tazawa H, Kagawa S, Bouvet M, Fujiwara T, Hoffman RM

    J Orthop Res   doi: 10.1002/jor.23073. [Epub ahead of print]   2015

     More details

  • Strategic approach to concurrent aberrant left gastric vein and aberrant left hepatic artery in laparoscopic distal gastrectomy for early gastric cancer: A case report

    Kuwada K, Kuroda S, Kikuchi S, Hori N, Kubota T, Nishizaki M, Kagawa S, Fujiwara T

    Asian J Endosc Surg   8 ( 4 )   454 - 456   2015

     More details

  • 6.血液凝固と線溶現象:b)血栓症の予防,診断および治療

    黒田新士, 藤原俊義

    外科   77 ( 12 )   1385 - 1390   2015

     More details

  • Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor–Positive, HER2-Negative Breast Cancer

    Iwamoto T, Kelly C, Mizoo T, Nogami T, Motoki T, Shien T, Taira N, Hayashi N, Niikura N, Fujiwara T, Doihara H, Matsuoka J

    Clin Breast Cancer   doi: 10.1016/j.clbc.2015.10.004.   2015

     More details

  • Serum Oxidative/anti-oxidative Stress Balance Is Dysregulated in Potentially Pulmonary Hypertensive Patients with Liver Cirrhosis: A Case Control Study

    Masako Terao, Akinobu Takaki, Takayuki Maruyama, Hiroki Oe, Tetsuya Yasunaka, Naofumi Tamaki, Kazufumi Nakamura, Takaaki Tomofuji, Takahito Yagi, Hiroshi Sadamori, Yuzo Umeda, Susumu Shinoura, Ryuichi Yoshida, Kazuhiro Nouso, Daisuke Ekuni, Kazuko Koike, Fusao Ikeda, Hidenori Shiraha, Manabu Morita, Hiroshi Ito, Toshiyoshi Fujiwara, Kazuhide Yamamoto

    INTERNAL MEDICINE   54 ( 22 )   2815 - 2826   2015

     More details

    Language:English   Publisher:JAPAN SOC INTERNAL MEDICINE  

    Objective Hepatopulmonary syndrome (HPS) is characterized by vascular dilatation and hyperdynamic circulation, while portopulmonary hypertension (POPH) is characterized by vasoconstriction with fibrous obliteration of the vascular bed. Vasoactive molecules such as nitric oxide (NO) are candidate factors for cirrhotic complications associated with these diseases. However, oxidative stress balance is not well characterized in HPS and POPH. The present objective is to investigate the oxidative stress and anti-oxidative stress balance and NO pathway balance in patients with potential HPS and POPH.
    Methods We recruited patients with decompensated cirrhosis (n = 69) admitted to our hospital as liver transplantation candidates. Patients exhibiting partial pressure of oxygen lower than 80 mmHg and alveolararterial oxygen gradient (AaDO(2)) &gt;= 15 mmHg were categorized as potentially having HPS (23 of 69 patients). Patients exhibiting a tricuspid regurgitation pressure gradient &gt;= 25 mmHg were categorized as potentially having POPH (29 of 61 patients). Serum reactive oxygen metabolites were measured and anti-oxidative OXY-adsorbent test (OXY) were performed, and the balance of these tests was defined as the oxidative index. The correlation between these values and the clinical characteristics of the patients were assessed in a cross-sectional study.
    Results Potential HPS patients exhibited no correlation with oxidative stress markers. Potential POPH patients exhibited lower OXY (p = 0.037) and higher oxidative index values (p = 0.001). Additionally, the vascular NO synthase enzyme inhibiting protein, asymmetric dimethylarginine, was higher in potential POPH patients (p = 0.049). The potential POPH patients exhibited elevated AaDO(2), suggesting the presence of pulmonary shunting.
    Conclusion Potential POPH patients exhibited elevated oxidative stress with decreased anti-oxidative function accompanied by inhibited NO production. Anti-oxidants represent a candidate treatment for potential POPH patients.

    DOI: 10.2169/internalmedicine.54.4889

    Web of Science

    researchmap

  • Targeted Photodynamic Virotherapy Armed with a Genetically Encoded Photosensitizer

    Takehara K, Tazawa H, Okada N, Hashimoto Y, Kikuchi S, Kuroda S, Kishimoto H, Shirakawa Y, Narii N, Mizuguchi H, Urata Y, Kagawa S, Fujiwara T

    Mol Cancer Ther   DOI: 10.1158/1535-7163   DOI: 10.1158/1535-7163   2015

     More details

  • A Case of Intra-Abdominal Desmoid Tumor Treated by Laparoscopic Surgery

    Yagi Tomohiko, Inada Ryo, Nagasaka Takeshi, Watanabe Ayako, Matsumoto Hijiri, Toshima Toshiaki, Mori Yoshiko, Kondo Yoshitaka, Kishimoto Hiroyuki, Fujiwara Toshiyoshi

    Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)   40 ( 1 )   111 - 115   2015

     More details

    Language:Japanese   Publisher:Japanese College of Surgeons  

    A woman in her 60s had undergone partial nephrectomy for right renal cell carcinoma in 2009. Three years after that resection, a tumor measuring 40mm in diameter was identified near the ascending colon on follow-up computed tomography (CT), and she was referred to our department for management. Positron emission tomography (PET)-CT revealed both abnormal uptake of fluorodeoxyglucose by the tumor and absence of distant metastases. Colonoscopy showed a moderately elevated lesion like a submucosal tumor in the ascending colon. On suspicion of malignancy, laparoscopy-assisted right colectomy with lymphadenectomy was performed for diagnosis and treatment of the tumor. Histopathologically, the tumor was diagnosed as a desmoid tumor occurring in the mesentery of the ascending colon, and surgical margins were negative for tumor cells. The patient is doing well without recurrence as of 13 months postoperatively. We describe herein a relatively rare case of intra-abdominal desmoid tumor treated by laparoscopic surgery. Early surgical intervention should be considered for diagnosis and treatment.

    DOI: 10.4030/jjcs.40.111

    CiNii Article

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2015308089

  • A Case of Primary Small Intestinal Adenocarcinoma with Difficult Preoperative Diagnosis

    Matsumoto Hijiri, Inada Ryo, Kondo Yoshitaka, Watanabe Ayako, Yagi Tomohiko, Toshima Toshiaki, Mori Yoshiko, Kishimoto Hiroyuki, Nagasaka Takeshi, Fujiwara Toshiyoshi

    Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)   40 ( 1 )   61 - 65   2015

     More details

    Language:Japanese   Publisher:Japanese College of Surgeons  

    A 66-year-old man visited an initial hospital with a complaint of abdominal pain, and intra-abdominal abscess near the sigmoid colon was detected by abdominal CT scan. He got well by antibiotic medication. One year later, abdominal abscess recurred, and he was referred to our hospital for management. We performed capsule and double balloon endoscopy, indicating no malignant tumor at the small intestine. Intraoperatively small intestinal cancer with invasion to the rectum, metastases of lymph nodes and peritoneum was firstly diagnosed.Primary small intestinal adenocarcinoma is e a relatively rare disease with poor prognosis. Recently, capsule and double balloon endoscopy was reported to make contribution to get early diagnosis and improve prognosis. On the other hand, some cases remains to be difficult to make an early diagnosis like the case we described.

    DOI: 10.4030/jjcs.40.61

    CiNii Article

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2015308079

  • 遺伝子組換えアデノウイルスを用いたCirculating Tumor Cell検出系の開発と臨床応用

    櫻井文教, 水口裕之, 藤原俊義

    大和証券ヘルス財団研究業績集38号   108 - 112   2015

     More details

  • 食道癌におけるFAP(fibroblast activation protein)陽性癌関連線維芽細胞の発現と癌転移の関係

    賀島肇, 野間和広, 加藤卓也, 勝部亮一, 二宮卓之, 大原利章, 田澤大, 白川靖博, 香川俊輔, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   26th   2015

  • 鉄制御を用いた新しい癌の浸潤・転移抑制治療法の開発

    大原利章, 大原利章, 二宮卓之, 野間和広, 賀島肇, 加藤卓也, 勝部亮一, 白川靖博, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   26th   2015

  • 癌関連線維芽細胞を標的とした新規食道癌治療法の開発

    勝部亮一, 野間和広, 賀島肇, 加藤卓也, 二宮卓之, 大原利章, 田澤大, 白川靖博, 香川俊輔, 小林久隆, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   26th   2015

  • ERASと周術期チーム医療

    白川靖博, 加藤卓也, 竹原清人, 前田直見, 田辺俊介, 櫻間教文, 野間和広, 足羽孝子, 佐藤健治, 森松博史, 藤原俊義

    臨床雑誌外科   77 ( 2 )   142 - 146   2015

     More details

  • 大腸癌早期発見のためのエピジェネティックバイオマーカーの開発

    永坂岳司, 藤原俊義

    G. I. Research   23 ( 1 )   38 - 45   2015

     More details

    Language:Japanese   Publisher:(株)先端医学社  

    癌抑制遺伝子プロモーター領域のCpG island(CGI)に認められるメチル化異常は、当初、癌細胞だけに認められると考えられていたが、正常細胞にも頻度は少ないが認められることが報告されている。そのような癌特異的(と考えられた)DNAメチル化異常を大腸癌早期発見のためのエピジェネティックバイオマーカーに設定した場合、偽陽性率を上昇させることが示唆される。しかし、これらの現象は、注意深く検証していけば、大腸癌の進行度を推測する強力なマーカーに成りうる場合もある。本稿では、大腸癌スクリーニングの現状を概説し、便潜血反応検査(FOBT)を含めて、便から遺伝子変異を検出する方法の歴史的経過を概説したのちに、メチル化DNA検出による大腸癌スクリーニングの可能性について考察する。(著者抄録)

    researchmap

  • MicroRNA as a molecular target for gastrointestinal cancers

    Tazawa H, Nagasaka T, Kagawa S, Fujiwara T

    Transl Gastrointest Cancer   4 ( 3 )   219 - 235   2015

     More details

  • 消化器がん治療の最前線 低侵襲治療と個別化医療

    藤原俊義

    山口県医学会誌   ( 49 )   82 - 91   2015

     More details

  • 放射線併用ウイルス療法による食道癌治療

    藤原俊義

    Isotope News   ( 740 )   2 - 6   2015

     More details

  • 悪性腫瘍のウイルス療法:遺伝子改変ウイルス製剤の開発動向

    藤原俊義

    BIO INDUSTRY   ( 32 )   34 - 40   2015

     More details

  • 消化器外科腹部領域のSSIに対する引き寄せと圧着を意識した局所陰圧閉鎖療法の実際

    浪花崇一, 近藤喜太, 野間和広, 藤原俊義

    日本創傷治癒学会プログラム・抄録集   45th   2015

  • 食道胃接合部手術に対する胸腔内観音開き法再建の検討

    加藤卓也, 野間和広, 竹原清人, 前田直見, 田邊俊介, 櫻間教文, 西崎正彦, 香川俊輔, 白川靖博, 藤原俊義

    日本消化器外科学会雑誌(Web)   48 ( Supplement1 )   2015

  • Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy

    Shuya Yano, Yong Zhang, Ming Zhao, Yukihiko Hiroshima, Shinji Miwa, Fuminari Uehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    CELL CYCLE   13 ( 24 )   3958 - 3963   2014.12

     More details

    Language:English   Publisher:LANDES BIOSCIENCE  

    Quiescent cancer cells are resistant to cytotoxic agents which target only proliferating cancer cells. Time-lapse imaging demonstrated that tumor-targeting Salmonella typhimurium A1-R (A1-R) decoyed cancer cells in monolayer culture and in tumor spheres to cycle from G(0)/G(1) to S/G(2)/M, as demonstrated by fluorescence ubiquitination-based cell cycle indicator (FUCCI) imaging. A1-R infection of FUCCI-expressing subcutaneous tumors growing in nude mice also decoyed quiescent cancer cells, which were the majority of the cells in the tumors, to cycle from G(0)/G(1) to S/G(2)/M, thereby making them sensitive to cytotoxic agents. The combination of A1-R and cisplatinum or paclitaxel reduced tumor size compared with A1-R monotherapy or cisplatinum or paclitaxel alone. The results of this study demonstrate that A1-R can decoy quiescent cancer cells to cycle to S/G(2)/M and sensitize them to cytotoxic chemotherapy. These results suggest a new paradigm of bacterial-decoy chemotherapy of cancer.

    DOI: 10.4161/15384101.2014.964115

    Web of Science

    researchmap

  • Establishment of a Non-Invasive Semi-Quantitative Bioluminescent Imaging Method for Monitoring of an Orthotopic Esophageal Cancer Mouse Model

    Shinji Kuroda, Tetsushi Kubota, Katsuyuki Aoyama, Satoru Kikuchi, Hiroshi Tazawa, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    PLOS ONE   9 ( 12 )   e114562   2014.12

     More details

    Language:English   Publisher:PUBLIC LIBRARY SCIENCE  

    Orthotopic models of various types of tumors are widely used in anti-tumor therapeutic experiments in preclinical studies. However, there are few ways to appropriately monitor therapeutic effect in orthotopic tumor models, especially for tumors invisible from the outside. In this study we aimed to establish a non-invasive semi-quantitative bioluminescent imaging method of monitoring an orthotopic esophageal cancer mouse model. We confirmed that the TE8 esophageal cancer cell line implanted orthotopically into the abdominal esophagus of nu/nu mice (n=5) developed not only a main tumor at the implanted site, but also local lymph node metastases and peritoneal disseminations within 6 weeks after inoculation. We established a TE8 cell line that stably expressed the firefly luciferase gene (TE8-Luc). We showed that TE8-Luc cells implanted subcutaneously into nu/nu mice (n=5) grew over time until 5 weeks after inoculation. Tumor volume was strongly correlated with luminescent intensity emitted from the tumor, which was quantified using the IVIS imaging system. We then showed that TE8-Luc cells implanted orthotopically into the mouse abdominal esophagus (n=8) also formed a tumor and that the luminescent intensity of such a tumor, as detected by IVIS, increased over time until 7 weeks after inoculation and was therefore likely to reflect tumor progression. We therefore propose that this orthotopic esophageal cancer model, monitored using the non-invasive semi-quantitative IVIS imaging system, will be useful for in vivo therapeutic experiments against esophageal cancer. This experimental setting is expected to contribute to the development of novel therapeutic technologies for esophageal cancer in preclinical studies.

    DOI: 10.1371/journal.pone.0114562

    Web of Science

    researchmap

  • Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients

    Shunsuke Kagawa, Kunitoshi Shigeyasu, Michihiro Ishida, Megumi Watanabe, Hiroshi Tazawa, Takeshi Nagasaka, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    WORLD JOURNAL OF GASTROENTEROLOGY   20 ( 47 )   17796 - 17803   2014.12

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.   Publisher:BAISHIDENG PUBLISHING GROUP INC  

    To apply an individualized oncological approach to gastric cancer patients, the accurate diagnosis of disease entities is required. Peritoneal metastasis is the most frequent mode of metastasis in gastric cancer, and the tumor-node-metastasis classification includes cytological detection of intraperitoneal cancer cells as part of the staging process, denoting metastatic disease. The accuracy of cytological diagnosis leaves room for improvement; therefore, highly sensitive molecular diagnostics, such as an enzyme immunoassay, reverse transcription polymerase chain reaction, and virus-guided imaging, have been developed to detect minute cancer cells in the peritoneal cavity. Molecular targeting therapy has also been spun off from basic research in the past decade. Although conventional cytology is still the mainstay, novel approaches could serve as practical complementary diagnostics to cytology in near future. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

    DOI: 10.3748/wjg.v20.i47.17796

    Web of Science

    researchmap

  • Risk Factors of Morbidity and Predictors of Long-term Survival after Hepatopancreatoduodenectomy for Biliary Cancer

    Masashi Utsumi, Hiroshi Sadamori, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Kosei Takagi, Toshiyoshi Fujiwara, Takahito Yagi

    HEPATO-GASTROENTEROLOGY   61 ( 136 )   2167 - 2172   2014.11

     More details

    Language:English   Publisher:H G E UPDATE MEDICAL PUBLISHING S A  

    Background/Aims: Hepatopancreatoduodenectomy (HPD) is performed to achieve radical resection of malignant biliary tumors. We reviewed clinical outcomes to evaluate the utility of HPD in terms of morbidity and mortality. Methodology: A retrospective analysis was conducted on 17 patients underwent HPD between August 1991 and May 2013; 9 bile duct cancel; 5 advanced gallbladder and 3pancreatic tumor with liver metastasis. Results: The morbidity and mortality rates were 88.3% and 0%, respectively. Univariate analysis showed that a body mass index of &gt;= 22 and preoperative total bilirubin level &gt;= 0.8 mg/dl were significantly associated with severe complications. One, 3- and 5-year survival rate were 73.3%, 60.0% and 30.0%. In 14 patients with biliary carcinoma, univariate analysis showed that a histological grade of G1 was significantly associated with survival. Patients without pancreatic invasion or portal vein invasion tended to survive longer than patients with these types of invasion, although the difference was not significant. Conclusions: HPD can be performed with no mortality and provides a survival benefit for some patients with biliary carcinoma undergoing curative resection. In patients with grade G1 biliary carcinoma without pancreatic or portal vein invasion in particular, this aggressive surgery might offer a chance of long-term survival.

    DOI: 10.5754/hge14701

    Web of Science

    researchmap

  • Early detection of metachronous bile duct cancer in Lynch syndrome: report of a case

    Kunitoshi Shigeyasu, Kohji Tanakaya, Takeshi Nagasaka, Hideki Aoki, Toshiyoshi Fujiwara, Kokichi Sugano, Hideki Ishikawa, Teruhiko Yoshida, Yoshihiro Moriya, Yoichi Furukawa, Ajay Goel, Hitoshi Takeuchi

    SURGERY TODAY   44 ( 10 )   1975 - 1981   2014.10

     More details

    Language:English   Publisher:SPRINGER  

    Lynch syndrome is an autosomal dominant disease associated with a high incidence of colorectal, endometrial, stomach, ovarian, pancreatic, ureter and renal pelvis, bile duct and brain tumors. The syndrome can also include sebaceous gland adenomas and keratoacanthomas, and carcinoma of the small bowel. The lifetime risk for bile duct cancer in patients with Lynch syndrome is approximately 2 %. The present report describes a case of Lynch syndrome with metachronous bile duct cancer diagnosed at an early stage. The patient was a 73-year-old Japanese male who underwent a successful left lobectomy of the liver, and there was no sign of recurrence for 2 years postoperative. However, this patient harbored a germline mutation in MLH1, which prompted diagnostic examinations for noncolorectal tumors when a periodic surveillance blood examination showed abnormal values of hepatobiliary enzymes. Although most patients with bile duct cancer are diagnosed at an advanced stage, the bile duct cancer was diagnosed at an early stage in the present patient due to the observation of the gene mutation and the preceding liver tumor. This case illustrates the importance of continuous surveillance for extracolonic tumors, including bile duct cancer, in patients with Lynch syndrome.

    DOI: 10.1007/s00595-013-0669-3

    Web of Science

    researchmap

  • Hepatitis C Virus-specific T-cell Response Correlates with Hepatitis Activity and Donor IL28B Genotype Early after Liver Transplantation

    Ryuichiro Tsuzaki, Akinobu Takaki, Takahito Yagi, Fusao Ikeda, Kazuko Koike, Yoshiaki Iwasaki, Hidenori Shiraha, Yasuhiro Miyake, Hiroshi Sadamori, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Masashi Utsumi, Eiichi Nakayama, Toshiyoshi Fujiwara, Kazuhide Yamamoto

    ACTA MEDICA OKAYAMA   68 ( 5 )   291 - 302   2014.10

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    It is not known how the immune system targets hepatitis C virus (HCV)-infected HLA-mismatched hepatocytes under immune-suppressed conditions after orthotopic liver transplantation (OLT). In addition, the relationship between the HCV-specific immune response and IL28B variants as predictors of HCV clearance has not been well-characterized. We determined the IL28B polymorphisms for 57 post-OLT HCV carriers, and we assessed the HCV-specific immune responses by measuring the peripheral blood mononuclear cell-derived HCV-specific interferon-gamma (IFN-gamma) response using an enzyme-linked immunospot assay. At 1-3 years after OLT, patients with no active hepatitis showed higher total spots on the immunospot assay. At &gt; 3 years after OLT, patients with resolved HCV showed higher levels of core, NS3, NS5A, and total spots compared to the chronic hepatitis patients. The IL28B major genotype in the donors correlated with higher spot counts for NS5A and NS5B proteins at 1-3 years after OLT. In the post-OLT setting, the HCV-specific immune response could be strongly induced in patients with no active hepatitis with an IL28B major donor or sustained virological response. Strong immune responses in the patients with no active hepatitis could only be maintained for 3 years and diminished later. It may be beneficial to administer IFN treatment starting 3 years after OLT, to induce the maximum immunological effect.

    DOI: 10.18926/AMO/52898

    Web of Science

    researchmap

  • Early detection of metachronous bile duct cancer in Lynch syndrome: report of a case

    Kunitoshi Shigeyasu, Kohji Tanakaya, Takeshi Nagasaka, Hideki Aoki, Toshiyoshi Fujiwara, Kokichi Sugano, Hideki Ishikawa, Teruhiko Yoshida, Yoshihiro Moriya, Yoichi Furukawa, Ajay Goel, Hitoshi Takeuchi

    SURGERY TODAY   44 ( 10 )   1975 - 1981   2014.10

     More details

    Language:English   Publisher:SPRINGER  

    Lynch syndrome is an autosomal dominant disease associated with a high incidence of colorectal, endometrial, stomach, ovarian, pancreatic, ureter and renal pelvis, bile duct and brain tumors. The syndrome can also include sebaceous gland adenomas and keratoacanthomas, and carcinoma of the small bowel. The lifetime risk for bile duct cancer in patients with Lynch syndrome is approximately 2 %. The present report describes a case of Lynch syndrome with metachronous bile duct cancer diagnosed at an early stage. The patient was a 73-year-old Japanese male who underwent a successful left lobectomy of the liver, and there was no sign of recurrence for 2 years postoperative. However, this patient harbored a germline mutation in MLH1, which prompted diagnostic examinations for noncolorectal tumors when a periodic surveillance blood examination showed abnormal values of hepatobiliary enzymes. Although most patients with bile duct cancer are diagnosed at an advanced stage, the bile duct cancer was diagnosed at an early stage in the present patient due to the observation of the gene mutation and the preceding liver tumor. This case illustrates the importance of continuous surveillance for extracolonic tumors, including bile duct cancer, in patients with Lynch syndrome.

    DOI: 10.1007/s00595-013-0669-3

    Web of Science

    researchmap

  • Virus-guided fluorescence imaging of intraperitoneal free gastric cancer cells as a potential clinical biomarker

    Megumi Watanabe, Shunsuke Kagawa, Michihiro Ishida, Naoto Hori, Satoru Kikuchi, Shinji Kuroda, Hiroyuki Kishimoto, Masahiko Nishizaki, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   74 ( 19 )   2014.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2014-4726

    Web of Science

    researchmap

  • Novel combination therapy of adenoviral gene transfer of HER2-extracellular domain and trastuzumab-based photoimmunotherapy for HER2 negative cancer cells

    Michihiro Ishida, Shunsuke Kagawa, Kyoko Shimoyama, Kiyoto Takehara, Kazuhiro Noma, Shunsuke Tanabe, Hiroshi Tazawa, Junji Matsuoka, Hisataka Kobayashi, Toshiyoshi Fujiwara

    CANCER RESEARCH   74 ( 19 )   2014.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2014-2615

    Web of Science

    researchmap

  • Combination strategy of endoscopic resection and telomerase-targeting oncolytic virus for eradicating lymph node metastasis of submucosal invasive colorectal cancer

    Naoto Hori, Satoru Kikuchi, Hiroyuki Kishimoto, Hiroshi Tazawa, Yuuri Hashimoto, Shinji Kuroda, Shunsuke Kagawa, Yasuo Urata, Robert M. Hoffman, Toshiyoshi Fujiwara

    CANCER RESEARCH   74 ( 19 )   2014.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2014-4025

    Web of Science

    researchmap

  • Development of systemically-deliverable telomerase-specific oncolytic adenovirus

    Katsuyuki Aoyama, Shinji Kuroda, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   74 ( 19 )   2014.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2014-719

    Web of Science

    researchmap

  • Selective methioninase-induced trap of cancer cells in S/G(2) phase visualized by FUCCI imaging confers chemosensitivity

    Shuya Yano, Shukuan Li, Qinghong Han, Yuying Tan, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    ONCOTARGET   5 ( 18 )   8729 - 8736   2014.9

     More details

    Language:English   Publisher:IMPACT JOURNALS LLC  

    A major impediment to the response of tumors to chemotherapy is that the large majority of cancer cells within a tumor are quiescent in G(0)/G(1), where cancer cells are resistant to chemotherapy. To attempt to solve this problem of quiescent cells in a tumor, cancer cells were treated with recombinant methioninase (rMETase), which selectively traps cancer cells in S/G(2). The cell cycle phase of the cancer cells was visualized with the fluorescence ubiquitination cell cycle indicator (FUCCI). At the time of rMETase-induced S/G(2)-phase blockage, identified by the cancer cells' green fluorescence by FUCCI imaging, the cancer cells were administered S/G(2)-dependent chemotherapy drugs, which interact with DNA or block DNA synthesis such as doxorubicin, cisplatin, or 5-fluorouracil. Treatment of cancer cells with drugs only, without rMETase-induced S/G(2) phase blockage, led to the majority of the cancer-cell population being blocked in G(0)/G(1) phase, identified by the cancer cells becoming red fluorescent in the FUCCI system. The G(0)/G(1) blocked cells were resistant to the chemotherapy. In contrast, trapping of cancer cells in S/G(2) phase by rMETase treatment followed by FUCCI-imaging-guided chemotherapy was highly effective in killing the cancer cells.

    Web of Science

    researchmap

  • Intussusception due to rectal adenocarcinoma in a young adult: A case report

    Ryo Inada, Takeshi Nagasaka, Toshiaki Toshima, Yoshiko Mori, Yoshitaka Kondo, Hiroyuki Kishimoto, Toshiyoshi Fujiwara

    WORLD JOURNAL OF GASTROENTEROLOGY   20 ( 35 )   12678 - 12681   2014.9

     More details

    Language:English   Publisher:BAISHIDENG PUBLISHING GROUP INC  

    An intussusception due to colonic adenocarcinoma has sometimes been reported. However, to the best of our knowledge, reports of intussusception due to rectal adenocarcinoma are extremely rare. In this report, the case of a young man with rectal adenocarcinoma causing intussusception is described. A 24-year-old man visited a hospital complaining of abdominal pain, and an upper rectal cancer was diagnosed by colonoscopy. Computed tomography showed intussusception caused by a large tumor in the pelvis and absence of distant metastases. Locally advanced rectal cancer causing intussusception was diagnosed, and a low anterior resection was performed. Intraoperatively, repair of the invagination could not be accomplished easily; therefore, the repair was abandoned. Instead, the tumor was removed en bloc to avoid dissemination of the cancer. Histopathologically, the tumor was diagnosed as a poorly differentiated adenocarcinoma, pStage. A. The patient has no evidence of recurrence at 10 mo after the operation. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

    DOI: 10.3748/wjg.v20.i35.12678

    Web of Science

    researchmap

  • MafA Is Required for Postnatal Proliferation of Pancreatic beta-Cells

    Koki Eto, Wataru Nishimura, Hisashi Oishi, Haruhide Udagawa, Miho Kawaguchi, Masaki Hiramoto, Toshiyoshi Fujiwara, Satoru Takahashi, Kazuki Yasuda

    PLOS ONE   9 ( 8 )   e104184   2014.8

     More details

    Language:English   Publisher:PUBLIC LIBRARY SCIENCE  

    The postnatal proliferation and maturation of insulin-secreting pancreatic beta-cells are critical for glucose metabolism and disease development in adults. Elucidation of the molecular mechanisms underlying these events will be beneficial to direct the differentiation of stem cells into functional beta-cells. Maturation of beta-cells is accompanied by increased expression of MafA, an insulin gene transcription factor. Transcriptome analysis of MafA knockout islets revealed MafA is required for the expression of several molecules critical for beta-cell function, including Glut2, ZnT8, Granuphilin, Vdr, Pcsk1 and Urocortin 3, as well as Prolactin receptor (Prlr) and its downstream target Cyclin D2 (Ccnd2). Inhibition of MafA expression in mouse islets or beta-cell lines resulted in reduced expression of Prlr and Ccnd2, and MafA transactivated the Prlr promoter. Stimulation of beta-cells by prolactin resulted in the phosphorylation and translocation of Stat5B and an increased nuclear pool of Ccnd2 via Prlr and Jak2. Consistent with these results, the loss of MafA resulted in impaired proliferation of beta-cells at 4 weeks of age. These results suggest that MafA regulates the postnatal proliferation of beta-cells via prolactin signaling.

    DOI: 10.1371/journal.pone.0104184

    Web of Science

    researchmap

  • Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness

    Shuya Yano, Yong Zhang, Shinji Miwa, Yasunori Tome, Yukihiko Hiroshima, Fuminari Uehara, Mako Yamamoto, Atsushi Suetsugu, Hiroyuki Kishimoto, Hiroshi Tazawa, Ming Zhao, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    CELL CYCLE   13 ( 13 )   2110 - 2119   2014.7

     More details

    Language:English   Publisher:LANDES BIOSCIENCE  

    The phase of the cell cycle can determine whether a cancer cell can respond to a given drug. We report here on the results of monitoring of real-time cell cycle dynamics of cancer cells throughout a live tumor intravitally using a fluorescence ubiquitination cell cycle indicator (FUCCI) before, during, and after chemotherapy. In nascent tumors in nude mice, approximately 30% of the cells in the center of the tumor are in G(0)/G(1) and 70% in S/G(2)/M. In contrast, approximately 90% of cancer cells in the center and 80% of total cells of an established tumor are in G(0)/G(1) phase. Similarly, approximately 75% of cancer cells far from (&gt;100 mu m) tumor blood vessels of an established tumor are in G(0)/G(1). Longitudinal real-time imaging demonstrated that cytotoxic agents killed only proliferating cancer cells at the surface and, in contrast, had little effect on quiescent cancer cells, which are the vast majority of an established tumor. Moreover, resistant quiescent cancer cells restarted cycling after the cessation of chemotherapy. Our results suggest why most drugs currently in clinical use, which target cancer cells in S/G(2)/M, are mostly ineffective on solid tumors. The results also suggest that drugs that target quiescent cancer cells are urgently needed.

    DOI: 10.4161/cc.29156

    Web of Science

    researchmap

  • MECHANISM OF RESISTANCE TO TRASTUZUMAB AND MOLECULAR SENSITIZATION VIA ADCC ACTIVATION BY EXOGENOUS EXPRESSION OF HER2 EXTRACELLULAR DOMAIN

    Ryosuke Yoshida, Hiroshi Tazawa, Yuuri Hashimoto, Futoshi Uno, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    JOURNAL OF GENE MEDICINE   16 ( 7-8 )   277 - 278   2014.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • 肝細胞癌治療における外科手術の位置づけ 再発肝細胞癌の治療方針 再肝切除の有効性とSalvage transplantationの可能性

    藤 智和, 楳田 祐三, 貞森 裕, 篠浦 先, 吉田 龍一, 信岡 大輔, 内海 方嗣, 杭瀬 崇, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   69回   WS - 5   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • MiCRORNA-7 INHIBITS THE STEM-LIKE PROPERTIES OF CD133(+) HUMAN GASTRIC CANCER CELLS

    Teppei Onishi, Hiroshi Tazawa, Shuya Yano, Yuuri Hashimoto, Ryosuke Yoshida, Shunsuke Kagawa, Toshiyoshi Fujiwara

    JOURNAL OF GENE MEDICINE   16 ( 7-8 )   266 - 266   2014.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • Frequency of regulatory T-cell and hepatitis C viral antigen-specific immune response in recurrent hepatitis C after liver transplantation

    Masashi Utsumi, Akinobu Takaki, Yuzo Umeda, Kazuko Koike, Stephanie C. Napier, Nobukazu Watanabe, Hiroshi Sadamori, Susumu Shinoura, Ryuichi Yoshida, Daisuke Nobuoka, Tetsuya Yasunaka, Eiichi Nakayama, Kazuhide Yamamoto, Toshiyoshi Fujiwara, Takahito Yagi

    TRANSPLANT IMMUNOLOGY   31 ( 1 )   33 - 41   2014.6

     More details

    Language:English   Publisher:ELSEVIER SCIENCE BV  

    Introduction: Regulatory T (Treg) and type 1 regulatory T (Tr1) cells facilitate hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT). However, their frequencies and effects on HCV-specific immune responses have not been well investigated.
    Methods: We determined Treg and Tr1 frequencies in OLT patients with hepatitis C and assessed their associations with HCV-specific T cell responses. These patients comprised the following groups: an early post-transplantation group (n = 14); an OLT-chronic active hepatitis C group (n = 14) with active hepatitis C (alanine aminotransferase of &gt; upper limit of normal/positive for HCV-RNA); an OLT-persistently normal alanine aminotransferase group (n = 12) without active hepatitis C (not interferon/positive for HCV-RNA); and an OLT-sustained viral response group (n = 6) with sustained viral responses using interferon treatment (negative for HCV-RNA). The frequencies of HCV-specific CD4+ T cells that secreted interferon-gamma were determined by enzyme-linked immunosorbent spot assay (except for the OLT early group).
    Results: Treg and Tr1 frequencies were low during the early post-transplantation period. OLT patients with sustained viral responses had lower Treg frequencies than those with chronic hepatitis C, whereas Tr1 frequencies were significantly reduced in OLT patients with persistently normal alanine aminotransferase levels compared to those with chronic hepatitis C (p &lt; 0.05). Treg frequencies positively correlated with HCV NS3 antigen-specific interferon-gamma responses, which corresponded to HCV clearance.
    Conclusions: Increased Treg frequencies and reduced HCV-NS3 antigen-specific responses recovered after viral eradication in post-OLT chronic hepatitis C patients. Reduced Tr1 frequencies were associated with hepatitis activity control, which may facilitate controlling chronic hepatitis C in patients after OLT. (C) 2014 Elsevier B.V. All rights reserved.

    DOI: 10.1016/j.trim.2014.05.006

    Web of Science

    researchmap

  • 手術手技 食道癌手術における用手補助的腹腔鏡下胃管作成の工夫

    白川 靖博, 前田 直見, 田辺 俊介, 大原 利章, 野間 和広, 藤原 俊義

    手術   68 ( 7 )   951 - 954   2014.6

     More details

    Language:Japanese   Publisher:金原出版(株)  

    researchmap

  • 腫瘍縮小にて膵頭十二指腸切除術を回避できた膵Solid-pseudopapillary neoplasmの1例

    信岡 大輔, 八木 孝仁, 篠浦 先, 高木 弘誠, 杭瀬 崇, 内海 方嗣, 吉田 龍一, 楳田 祐三, 貞森 裕, 藤原 俊義

    日本癌治療学会誌   49 ( 3 )   2101 - 2101   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • Establishment of a pancreatic stem cell line from fibroblast-derived induced pluripotent stem cells

    Takashi Kuise, Hirofumi Noguchi, Hiroshi Tazawa, Takashi Kawai, Masaya Iwamuro, Issei Saitoh, Hitomi Usui Kataoka, Masami Watanabe, Yasufumi Noguchi, Toshiyoshi Fujiwara

    BIOMEDICAL ENGINEERING ONLINE   13   doi:10.1186/1475-925X-13-64   2014.5

     More details

    Language:English   Publisher:BIOMED CENTRAL LTD  

    Background: For cell therapies to treat diabetes, it is important to produce a sufficient number of pancreatic endocrine cells that function similarly to primary islets. Induced pluripotent stem (iPS) cells represent a potentially unlimited source of functional pancreatic endocrine cells. However, the use of iPS cells for laboratory studies and cell-based therapies is hampered by their high tumorigenic potential and limited ability to generate pure populations of differentiated cell types in vitro. The purpose of this study was to establish a pancreatic stem cell line from iPS cells derived from mouse fibroblasts.
    Methods: Mouse iPS cells were induced to differentiate into insulin-producing cells by a multi-step differentiation protocol, which was conducted as described previously with minor modifications. Selection of the pancreatic stem cell was based on morphology and Pdx1 expression. The pancreatic potential of the pancreatic stem cells was evaluated using a reverse transcription PCR, real-time PCR, immunofluorescence, and a glucose challenge test. To assess potential tumorigenicity of the pancreatic stem cells, the cells were injected into the quadriceps femoris muscle of the left hindlimb of nude mice.
    Results: The iPS-derived pancreatic stem cells expressed the transcription factor -Pdx1- a marker of pancreatic development, and continued to divide actively beyond passage 80. Endocrine cells derived from these pancreatic stem cells expressed insulin and pancreatic genes, and they released insulin in response to glucose stimulation. Mice injected with the pancreatic stem cells did not develop tumors, in contrast to mice injected with an equal number of iPS cells.
    Conclusion: This strategy provides a new approach for generation of insulin-producing cells that is more efficient and safer than using iPS cells. We believe that this approach will help to develop a patient-specific cell transplantation therapy for diabetes in the near future.

    DOI: 10.1186/1475-925X-13-64

    Web of Science

    researchmap

  • Molecular surgery using a novel biological agent, OBP-301, for lymph node micrometastasis in human colorectal cancer.

    Satoru Kikuchi, Hiroyuki Kishimoto, Hiroshi Tazawa, Shunsuke Kagawa, Yasuo Urata, Robert M. Hoffman, Toshiyoshi Fujiwara

    JOURNAL OF CLINICAL ONCOLOGY   32 ( 15 )   2014.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    Web of Science

    researchmap

  • Assistant-Based Standardization of Prone Position Thoracoscopic Esophagectomy

    Yasuhiro Shirakawa, Kazuhiro Noma, Naoaki Maeda, Ryoichi Katsube, Shunsuke Tanabe, Toshiaki Ohara, Kazufumi Sakurama, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   68 ( 2 )   111 - 117   2014.4

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    Thoracoscopic esophagectomy in the prone position (TEPP) might enable solo-surgery in cases requiring resection of the esophagus and the surrounding lymph nodes due to the associated advantages of good exposure of the surgical field and ergonomic considerations for the surgeon. However, no one approach can be for all patients requiring extensive lymphadenectomy. We recently developed an assistant-based procedure to standardize exposure of the surgical field. Patients were divided into 1 of 2 groups: a pre-standardization group (n = 37) and a post-standardization group (n = 28). The thoracoscopic operative time was significantly shorter (p= 0.0037)) in the post-standardization group (n = 28; 267 +/- 31min) than in the pre-standardization group (n = 37; 301 +/- 53 min). Further, learning curve analysis using the moving average method showed stabilization of the thoracoscopic operative time after the standardization. No significant differences were found in the number of mediastinal lymph nodes dissected or intraoperative blood loss between the 2 groups. There were also no significant differences in the complication rate. Assistant-based surgery and standardization of the procedure resulted in a well-exposed and safe surgical field. TEPP decreased the operative time, even in patients requiring extensive lymphadenectomy.

    DOI: 10.18926/AMO/52407

    Web of Science

    researchmap

  • 術前DCF療法が著効した食道原発内分泌細胞癌の1切除例

    前田 直見, 白川 靖博, 國府島 健, 大原 利章, 田邊 俊輔, 野間 和広, 櫻間 教文, 藤原 俊義

    岡山医学会雑誌   126 ( 1 )   39 - 43   2014.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    66歳男。心窩部痛を主訴とした。上部消化管造影検査所見で胸部中部食道(Mt)左-前壁に70mm大の周堤隆起明瞭な2型病変が認められた。上部消化管内視鏡検査所見で切歯より25cm〜33cmの食道左-前壁に半周性の2型病変を認められた。同部位の生検を施行し、内分泌細胞癌(小細胞型)と診断された。造影CT検査所見およびPET/CT検査より、胸部食道内分泌細胞癌(小細胞型)cT3cN1cM0:cStage IIIと診断し、術前補助化学療法2コースの後、手術の方針とした。化学療法は、docetaxel、cisplatin、5-fluorouracilの三剤を併用した。手術は腹臥位胸腔鏡下食道亜全摘、用手補助的腹腔鏡下胃管作製、3領域リンパ節郭清、胸骨後経路再建、頸部吻合を施行した。組織所見にて潰瘍部では加療による影響と考えられる線維化とヘモジデリンの沈着を認め、Grade 3と判定した。

    DOI: 10.4044/joma.126.39

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J00175&link_issn=&doc_id=20140415220008&doc_link_id=10.4044%2Fjoma.126.39&url=https%3A%2F%2Fdoi.org%2F10.4044%2Fjoma.126.39&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • RS-2-10 術前診断に難渋した原発性小腸癌の1例(RS-2 研修医の発表セッション(2)大腸,第114回日本外科学会定期学術集会)

    松本 聖, 稲田 涼, 近藤 喜太, 母里 淑子, 永坂 岳司, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   1039 - 1039   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PD-9-3 ロボット支援下噴門側胃切除術後のロボットによる体腔内手縫い食道残胃吻合(PD-9 パネルディスカッション(9)食道癌・胃癌におけるロボット支援手術の有用性,第114回日本外科学会定期学術集会)

    西崎 正彦, 黒田 新士, 岸本 浩行, 野間 和広, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   189 - 189   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • OP-006-5 膵頭十二指腸切除後の完全膵外瘻に対する非手術的内瘻化(OP-006 膵 合併症-1,一般演題,第114回日本外科学会定期学術集会)

    信岡 大輔, 八木 孝仁, 高木 弘誠, 田村 周太, 谷口 文崇, 内海 方嗣, 吉田 龍一, 楳田 祐三, 篠浦 先, 貞森 裕, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   322 - 322   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-027-7 膵頭十二指腸切除症例における創部SSI危険因子の検討 : 術前胆道ドレナージの合併症(PS-027 周術期管理 SSI・感染症,ポスターセッション,第114回日本外科学会定期学術集会)

    谷口 文崇, 八木 仁, 貞森 裕孝, 篠浦 先, 楳田 祐三, 吉田 龍一, 信岡 大輔, 内海 方嗣, 田村 周太, 高木 弘誠, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   629 - 629   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • OP-104-4 生体肝移植患者におけるItraconazoleの真菌感染症予防効果の検討(OP-104 肝 周術期管理,一般演題,第114回日本外科学会定期学術集会)

    内海 方嗣, 貞森 裕, 高木 弘誠, 信岡 大輔, 吉田 龍一, 楳田 祐三, 篠浦 先, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   499 - 499   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • OP-036-7 食道癌周術期における外科医の負担軽減に対しチーム医療が果たした役割(OP-036 周術期管理 術後合併症・その他,一般演題,第114回日本外科学会定期学術集会)

    白川 靖博, 二宮 卓之, 前田 直見, 大原 利章, 田辺 俊助, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   379 - 379   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • YIA-3-3 大腸癌肺転移に対するCTガイド下経皮的ラジオ波焼灼の短期・長期成績の検討(YIA-3 若手優秀演題賞(3)「消化管」,第114回日本外科学会定期学術集会)

    稲田 涼, 永坂 岳司, 松本 聖, 母里 淑子, 近藤 喜太, 岸本 浩行, 楳田 祐三, 浅野 博昭, 佃 和憲, 横道 直佑, 久保田 暢人, 河合 毅, 吉田 一博, 竹原 清人, 森川 達也, 竹原 裕子, 平木 隆夫, 金澤 右, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   309 - 309   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • OP-048-7 テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌に対する低侵襲治療の開発(OP-048 大腸 その他,一般演題,第114回日本外科学会定期学術集会)

    菊地 覚次, 岸本 浩行, 田澤 大, 西崎 正彦, 香川 俊輔, 浦田 泰生, Hoffman Robert, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   401 - 401   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-059-3 HER2陽性進行再発胃癌に対するTrastuzumabの使用経験とその有効性について(PS-059 胃 集学的治療-3,ポスターセッション,第114回日本外科学会定期学術集会)

    黒田 新士, 香川 俊輔, 渡邊 めぐみ, 堀 直人, 石田 道拡, 岸本 浩行, 西崎 正彦, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   692 - 692   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-052-4 がん関連線維芽細胞(Cancer Associated Fibroblasts)を標的とした新規癌治療法の開発(PS-052 食道 基礎-2,ポスターセッション,第114回日本外科学会定期学術集会)

    野間 和広, 白川 靖博, 二宮 卓之, 勝部 亮一, 前田 直見, 田辺 俊介, 大原 利章, 田澤 大, 香川 俊輔, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   678 - 678   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-113-5 大腸癌におけるproenostic factorとしてのmiRNA(PS-113 大腸 基礎-1,ポスターセッション,第114回日本外科学会定期学術集会)

    久保田 暢人, 永坂 岳司, 母里 淑子, 森川 達也, 吉田 一博, 横道 直佑, 稲田 涼, 竹原 裕子, 竹原 清人, 河合 毅, 藤 智和, 楳田 祐三, 田澤 大, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   801 - 801   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • OP-001-6 温阻血再灌流+肝切除モデルにおけるHMGB1制御による再灌流障害および肝再生への影響解析(OP-001 肝 基礎-1,一般演題,第114回日本外科学会定期学術集会)

    杉原 正大, 貞森 裕, 西堀 正洋, 佐藤 康晴, 田澤 大, 吉田 龍一, 楳田 祐三, 篠浦 先, 永坂 岳司, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   313 - 313   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • OP-141-6 遺伝子変異情報を用いた直腸癌局所再発症例に対する治療戦略の検討(OP-141 直腸 局所再発,一般演題,第114回日本外科学会定期学術集会)

    永坂 岳司, 母里 淑子, 楳田 祐三, 稲田 涼, 森川 達也, 横道 直佑, 久保田 暢人, 吉田 一博, 竹原 裕子, 河合 毅, 藤 智和, 竹原 清人, 杭瀬 崇, 谷口 文崇, 近藤 喜太, 岸本 浩行, 浅野 博昭, 佃 憲和, 貞森 裕, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   564 - 564   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • OP-076-6 外科を志す研修医教育に対する多視点多層三次元解剖教材の活用(OP-076 教育-2,一般演題,第114回日本外科学会定期学術集会)

    近藤 喜太, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   450 - 450   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • First successful case of simultaneous liver and kidney transplantation for patients with chronic liver and renal failure in Japan

    Takahito Yagi, Daisuke Nobuoka, Susumu Shinoura, Yuzo Umeda, Daisuke Sato, Ryuichi Yoshida, Masashi Utsumi, Tomokazu Fuji, Hiroshi Sadamori, Toshiyoshi Fujiwara

    HEPATOLOGY RESEARCH   44 ( 3 )   358 - 363   2014.3

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    Establishment of a preferential liver allocation rule for simultaneous liver and kidney transplantation (SLK) and revisions of laws regarding organ transplants from deceased donors have paved the way for SLK in Japan. Very few cases of SLK have been attempted in Japan, and no such recipients have survived for longer than 40 days. The present report describes a case of a 50-year-old woman who had undergone living donor liver transplantation at the age of 38 years for management of post-partum liver failure. After the first transplant surgery, she developed hepatic vein stenosis and severe hypersplenism requiring splenectomy. She was then initiated on hemodialysis (HD) due to the deterioration of renal function after insertion of a hepatic vein stent. She was listed as a candidate for SLK in 2011 because she required frequent plasma exchange for hepatic coma. When her Model for End-stage Liver Disease score reached 46, the new liver was donated 46 days after registration. The reduced trisegment liver and the kidney grafts were simultaneously transplanted under veno-venous bypass and intraoperative HD. The hepatic artery was reconstructed prior to portal reconstruction in order to shorten anhepatic time. Although she developed subcapsular bleeding caused by hepatic contusion on the next day, subsequent hemostasis was obtained by transcatheter embolization. Thereafter, her recovery was uneventful, except for mild rejection and renal tubular acidosis of the kidney graft. This case highlights the need to establish Japanese criteria for SLK.

    DOI: 10.1111/hepr.12122

    Web of Science

    researchmap

  • Invading cancer cells are predominantly in G(0)/G(1) resulting in chemoresistance demonstrated by real-time FUCCI imaging

    Shuya Yano, Shinji Miwa, Sumiyuki Mii, Yukihiko Hiroshima, Fuminari Uehara, Mako Yamamoto, Hiroyuki Kishimoto, Hiroshi Tazawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    CELL CYCLE   13 ( 6 )   953 - 960   2014.3

     More details

    Language:English   Publisher:LANDES BIOSCIENCE  

    Invasive cancer cells are a critical target in order to prevent metastasis. In the present report, we demonstrate real-time visualization of cell cycle kinetics of invading cancer cells in 3-dimensional (3D) Gelfoam (R) histoculture, which is in vivo-like. A fluorescence ubiquitination cell cycle indicator (FUCCI) whereby G(0)/G(1) cells express a red fluorescent protein and S/G(2)/M cells express a green fluorescent protein was used to determine the cell cycle position of invading and non-invading cells. With FUCCI 3D confocal imaging, we observed that cancer cells in G(0)/G(1) phase in Gelfoam (R) histoculture migrated more rapidly and further than cancer cells in S/G(2)/M phases. Cancer cells ceased migrating when they entered S/G(2)/M phases and restarted migrating after cell division when the cells re-entered G(0)/G(1). Migrating cancer cells also were resistant to cytotoxic chemotherapy, since they were preponderantly in G(0)/G(1), where cytotoxic chemotherapy is not effective. The results of the present report suggest that novel therapy targeting G(0)/G(1) cancer cells should be developed to prevent metastasis.

    DOI: 10.4161/cc.27818

    Web of Science

    researchmap

  • Management Of Peritoneal Effusion by Sealing with a Self-Assembling Nanofiber Polypeptide Following Pelvic Surgery

    Yoshitaka Kondo, Takeshi Nagasaka, Satoru Kobayashi, Naoya Kobayashi, Toshiyoshi Fujiwara

    HEPATO-GASTROENTEROLOGY   61 ( 130 )   349 - 353   2014.3

     More details

    Language:English   Publisher:H G E UPDATE MEDICAL PUBLISHING S A  

    Background/Aims: PuraMatrix is a synthetic material consisting of 16-amino acid peptides that self-assemble into nanofibers, previously used as a scaffold for functional cell cultures. We conducted a clinical study to determine the safety and sealing properties of PuraMatrix in post-operative lymphorrhea following pelvic surgery in humans. Methodology: A total of 20 patients who underwent rectal cancer resection were analyzed. The study group (n = 10) consisted of patients who received PuraMatrix, matched with a control group (n = 10) of patients operated on conventionally. Results: During the 2 to 3 month follow-up period, there were no abnormal findings or adverse events in any the patients who received PuraMatrix. We found that the patients who received PuraMatrix had significantly reduced post-operative drainage volumes compared with the patients in the control group. Conclusions: PuraMatrix is a safe and effective bio-compatible sealing material for the management of post-operative peritoneal effusion following pelvic surgery.

    DOI: 10.5754/hge121000

    Web of Science

    researchmap

  • First successful case of simultaneous liver and kidney transplantation for patients with chronic liver and renal failure in Japan

    Takahito Yagi, Daisuke Nobuoka, Susumu Shinoura, Yuzo Umeda, Daisuke Sato, Ryuichi Yoshida, Masashi Utsumi, Tomokazu Fuji, Hiroshi Sadamori, Toshiyoshi Fujiwara

    HEPATOLOGY RESEARCH   44 ( 3 )   358 - 363   2014.3

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    Establishment of a preferential liver allocation rule for simultaneous liver and kidney transplantation (SLK) and revisions of laws regarding organ transplants from deceased donors have paved the way for SLK in Japan. Very few cases of SLK have been attempted in Japan, and no such recipients have survived for longer than 40 days. The present report describes a case of a 50-year-old woman who had undergone living donor liver transplantation at the age of 38 years for management of post-partum liver failure. After the first transplant surgery, she developed hepatic vein stenosis and severe hypersplenism requiring splenectomy. She was then initiated on hemodialysis (HD) due to the deterioration of renal function after insertion of a hepatic vein stent. She was listed as a candidate for SLK in 2011 because she required frequent plasma exchange for hepatic coma. When her Model for End-stage Liver Disease score reached 46, the new liver was donated 46 days after registration. The reduced trisegment liver and the kidney grafts were simultaneously transplanted under veno-venous bypass and intraoperative HD. The hepatic artery was reconstructed prior to portal reconstruction in order to shorten anhepatic time. Although she developed subcapsular bleeding caused by hepatic contusion on the next day, subsequent hemostasis was obtained by transcatheter embolization. Thereafter, her recovery was uneventful, except for mild rejection and renal tubular acidosis of the kidney graft. This case highlights the need to establish Japanese criteria for SLK.

    DOI: 10.1111/hepr.12122

    Web of Science

    researchmap

  • Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers

    Mitsuya Itoh, Takayuki Iwamoto, Junji Matsuoka, Tomohiro Nogami, Takayuki Motoki, Tadahiko Shien, Naruto Taira, Naoki Niikura, Naoki Hayashi, Shoichiro Ohtani, Kenji Higaki, Toshiyoshi Fujiwara, Hiroyoshi Doihara, W. Fraser Symmans, Lajos Pusztai

    BREAST CANCER RESEARCH AND TREATMENT   143 ( 2 )   403 - 409   2014.1

     More details

    Language:English   Publisher:SPRINGER  

    We examined estrogen receptor (ER) mRNA expression and molecular subtypes in stage I-III breast cancers that are progesterone receptor (PR) positive but ER and HER2 negative by immunohistochemistry (IHC) or fluorescent in situ hybridization. The ER, PR, and HER2 status was determined by IHC as part of routine clinical assessment (N = 501). Gene expression profiling was done with the Affymetrix U133A gene chip. We compared expressions of ESR1 and MKI67 mRNA, distribution of molecular subtypes by the PAM50 classifier, the sensitivity to endocrine therapy index, and the DLDA30 chemotherapy response predictor signature among ER/PR-positive (n = 223), ER-positive/PR-negative (&lt;Emphasis Type="ItalicUnderline"&gt;n = 73), ER-negative/PR-positive (n = 20), and triple-negative (n = 185) cancers. All patients received neoadjuvant chemotherapy with an anthracycline and taxane and had adjuvant endocrine therapy only if ER or PR &gt; 10 % positive. ESR1 expression was high in 25 % of ER-negative/PR-positive, in 79 % of ER-positive/PR-negative, in 96 % of ER/PR-positive, and in 12 % of triple-negative cancers by IHC. The average MKI67 expression was significantly higher in the ER-negative/PR-positive and triple-negative cohorts. Among the ER-negative/PR-positive patients, 15 % were luminal A, 5 % were Luminal B, and 65 % were basal like. The relapse-free survival rate of ER-negative/PR-positive patients was equivalent to ER-positive cancers and better than the triple-negative cohort. Only 20-25 % of the ER-negative/PR-positive tumors show molecular features of ER-positive cancers. In this rare subset of patients (i) a second RNA-based assessment may help identifying the minority of ESR1 mRNA-positive, luminal-type cancers and (ii) the safest clinical approach may be to consider both adjuvant endocrine and chemotherapy.

    DOI: 10.1007/s10549-013-2763-z

    Web of Science

    researchmap

  • 腺様嚢胞癌細胞株に対するテロメラーゼ特異的腫瘍融解ウイルスと放射線照射併用による抗腫瘍効果の検討

    佐藤 大典, 栗原 祐史, 加藤 光佑, 近藤 誠二, 代田 達夫, 浦田 泰生, 藤原 俊義, 新谷 悟

    日本口腔科学会雑誌   63 ( 1 )   94 - 94   2014.1

     More details

    Language:Japanese   Publisher:(NPO)日本口腔科学会  

    researchmap

  • 直腸癌術後尿管再発の1例

    松本 聖, 稲田 涼, 近藤喜太, 母里淑子, 岸本浩行, 江原 伸, 戸田博子, 柳井広之, 永坂岳司, 藤原俊義

    癌の臨床   60 ( 5 )   549 - 554   2014

     More details

    Language:Japanese   Publisher:(株)篠原出版新社  

    尿管再発は大腸癌において頻度の低い再発形式である。今回直腸癌術後に血尿を契機に発見された左尿管再発を経験したので報告する。患者は80代男性。2007年1月、上部直腸癌に対して低位前方切除術を施行。病理診断にて中分化管状腺癌(pT4aN0M0、pStage II)と診断。2011年9月、血尿を認め、膀胱および左尿管に腫瘍を指摘。膀胱腫瘍に対してはTUR-BTを、また尿管腫瘍に対しては左腎尿管摘出術を施行。組織診断では膀胱腫瘍は、原発性尿路上皮癌と診断。また尿管腫瘍は腸管由来の分化型腺癌を認め、直腸癌の尿管再発と診断。その後、膀胱癌の局所再発および直腸癌の肺・膀胱内再発をきたすも、2012年5月、癒着性イレウスによる嘔吐に伴う誤嚥性肺炎により永眠された。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2014&ichushi_jid=J00297&link_issn=&doc_id=20141203210011&doc_link_id=%2Fad7gnrsc%2F2014%2F006005%2F011%2F0549-0554%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fad7gnrsc%2F2014%2F006005%2F011%2F0549-0554%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • FDG-PET/CTで再発大腸癌を疑った腹腔内膿瘍の1切除例

    母里淑子, 永坂岳司, 稲田 涼, 渡邉彩子, 岸本浩行, 近藤喜太, 藤原俊義

    癌と化学療法   41 ( 12 )   1599 - 1601   2014

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    症例は65歳、男性。腸穿孔を伴う下行結腸癌術後、補助化学療法中にCT、FDG-PET/CT検査にて脾臓・横隔膜にFDGの集積を認め術後再発と診断し、手術を施行したところ、腫瘍再発でなく膿瘍であった。腹膜播種の画像による確定診断は困難であり、特に腸穿孔後は感染性の集積も鑑別する必要がある。臨床的に示唆に富んだ症例を経験したので、文献的考察を含め報告する。(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J00296&link_issn=&doc_id=20141217480050&doc_link_id=%2Fab8gtkrc%2F2014%2F004112%2F050%2F1599-1601%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2014%2F004112%2F050%2F1599-1601%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 術前補助化学療法によりpCRが得られた高度進行胃癌の1例

    菊地覚次, 香川俊輔, 久保田哲史, 桒田和也, 黒田新士, 西﨑正彦, 田中健大, 藤原俊義

    癌と化学療法   41 ( 12 )   2282 - 2284   2014

     More details

  • 化学療法後に切除しpCRを得たStageⅣ胃癌の2例

    久保田哲史, 香川俊輔, 菊地覚次, 黒田新士, 西﨑正彦, 藤原俊義

    癌と化学療法   41 ( 12 )   2308 - 2310   2014

     More details

  • 分葉膵に付着した消化管重複症

    尾山貴徳, 野田卓男, 谷本光隆, 楳田祐三, 藤智和, 八木孝仁, 藤原俊義

    小児外科   46 ( 12 )   1269 - 1273   2014

     More details

  • A Case of Advanced Esophageal Cancer with Pulmonary Hypertention due to Atrial Septal Defect

    FUJITA Toshihiko, OHARA Toshiaki, TANABE Shunsuke, NOMA Kazuhiro, SHIRAKAWA Yasuhiro, FUJIWARA Toshiyoshi

    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)   75 ( 2 )   384 - 387   2014

     More details

    Language:Japanese   Publisher:Japan Surgical Association  

    A 62-year-old man was detected to have advanced esophageal cancer with pulmonary hypertension (PH) due to atrial septal defect (ASD). We planned to perform radical repair of ASD and neoadjuvant chemotherapy before esophagectomy. However, he went into shock with melena by using an anticoagulant before cardiac catheterization. Endoscopic examination showed hemorrhage from the esophageal tumor, which suggested that ASD repair should be preceded by esophagectomy to remove the hemorrhage source. After esophagectomy, circulatory dynamics was unstable. Pulmonary arterial pressure (PAP) temporarily exceeded arterial pressure (AP) with coughing on the second day after the operation. Strict management with infusion and administration of vasopressin led to stable circulatory dynamics. However, unstable dynamics seemed to recur and we decided to repair ASD. Amplatzer Septal Occluder was inserted with intra cardiac echocardiography (ICE) because trans-esophageal echocardiography could not be used. After amplazter insertion, he became in good condition and was transferred to POD another hospital on 20.

    DOI: 10.3919/jjsa.75.384

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2014159787

  • Hepatopulmonary syndrome in Japanese liver cirrhosis patients

    Hayami Okada, Akinobu Takaki, Takahito Yagi, Tetsuya Yasunaka, Tatsuhiro Gotoda, Hiroki Oe, Kazufumi Nakamura, Shuichi Sato, Hiroshi Sadamori, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Masashi Utsumi, Daisuke Nobuoka, Yuko Yasuda, Fusao Ikeda, Yasuhiro Miyake, Hiroshi Ito, Toshiyoshi Fujiwara, Kazuhide Yamamoto

    Acta Hepatologica Japonica   55 ( 3 )   143 - 154   2014

     More details

    Language:Japanese  

    Hepatopulmonary syndrome is characterized by hypoxemia induced by intrapulmonary vascular dilatations associated with hepatic diseases. We evaluated the frequency and case presentations revealed by general screening before liver transplantation. Sixty-one patients underwent arterial blood gas analysis in both upright and supine positions. Of these, 27 patients (44%) showed Pa0&lt
    inf&gt
    2&lt
    /inf&gt
    &lt
    80 mmHg and AaD0&lt
    inf&gt
    2&lt
    /inf&gt
    &gt
    15 mmHg, reflecting intrapulmonary shunting. Four patients exhibited Pa0&lt
    inf&gt
    2&lt
    /inf&gt
    &lt
    70 mmHg and orthodeoxia, defined as a fall in Pa0&lt
    inf&gt
    2&lt
    /inf&gt
    &gt
    5% or 4 mmHg in an upright position. Finally, two patients showed hepatopulmonary syndrome, with positive findings on perfusion lung scanning. Both patients with hepatopulmonary syndrome had liver cirrhosis type C with habitual alcohol drinking and smoking. Potential pulmonary shunt patients with Pa0&lt
    inf&gt
    2&lt
    /inf&gt
    &lt
    80 mmHg and AaD0&lt
    inf&gt
    2&lt
    /inf&gt
    &gt
    15 mmHg exhibited higher model for end-stage liver disease scores. Care should be taken regarding hepatopulmonary syndrome during liver cirrhosis management in Japanese patients. © 2014 The Japan Society of Hepatology.

    DOI: 10.2957/kanzo.55.143

    Scopus

    researchmap

  • A patient with primary malignant melanoma of the esophagus who underwent esophagectomy

    Maeda Naoaki, Shirakawa Yasuhiro, Koujima Takeshi, Ohara Toshiaki, Tanabe Shunsuke, Noma Kazuhiro, Sakurama Kazuhumi, Fujiwara Toshiyosi

    Okayama Igakkai Zasshi (Journal of Okayama Medical Association)   126 ( 1 )   45 - 48   2014

     More details

    Language:Japanese   Publisher:Okayama Medical Association  

    We report the case of a 61-old-man with a primary malignant melanoma of the esophagus, an extremely rare and highly aggressive malignancy. He presented with dysphagia, and we performed an upper gastrointestinal endoscopy that detected a tumor in the thoracic part of the esophagus. The biopsy showed malignant melanoma. PET/CT, endoscopy and an esophagogram showed that a 70-mm scaled type 2+1 tumor in the thoracic esophagus and no metastases. We diagnosed a cT3cN0cM0 cStage II tumor. We then performed a subtotal esophagectomy with two-field lymph node dissection and esophagogastrostomy via a retrosternal route. The pathological examination of the resected specimens confirmed that the type 2+1 tumor was PMME (pT2N0M0 pStage II). We administered six courses of postoperative adjuvant chemotherapy with dacarbazine, and the patient has had no recurrence for 17 months after the surgery.

    DOI: 10.4044/joma.126.45

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://ousar.lib.okayama-u.ac.jp/52323

  • Biological Ablation of Sentinel Lymph Node Metastasis in Submucosally Invaded Early Gastrointestinal Cancer

    Kikuchi S, Kishimoto H, Tazawa H, Hashimoto Y, Kuroda S, Nishizaki M, Nagasaka T, Shirakawa Y, Kagawa S, Urata Y, Hoffman RM, Fujiwara T

    Mol Ther   doi: 10.1038/mt.2014.244   2014

     More details

  • 縮小手術のコツとピットフォール① 噴門側胃切除術(観音開き法)

    西﨑正彦, 黒田新士, 松村年久, 高嶌寛年, 加藤大, 菊池覚次, 桒田和也, 香川俊輔, 藤原俊義

    臨床外科   69 ( 13 )   1464 - 1471   2014

  • ロボット支援下噴門側胃切除術後のロボットによる体腔内手縫い吻合

    西﨑正彦, 黒田新士, 岸本浩行, 野間和広, 香川俊輔, 白川靖博, 藤原俊義

    癌の臨床   60 ( 3 )   311 - 317   2014

     More details

  • A case of primary hepatic solitary fibrous tumor with simultaneous intrahepatic metastasis and pancreatic metastasis

    Takashi Kuise, Yuzo Umeda, Hiroshi Sadamori, Susumu Shinoura, Ryuichi Yoshida, Daisuke Sato, Daisuke Nobuoka, Masashi Utsumi, Takahito Yagi, Toshiyoshi Fujiwara

    Japanese Journal of Gastroenterological Surgery   47 ( 4 )   215 - 222   2014

     More details

    Language:Japanese   Publisher:Japanese Society of Gastroenterological Surgery  

    Solitary fibrous tumor (SFT) is a relatively rare tumor that develops mostly as an intrathoracic lesion related to the pleura. Hepatic malignant SFTs are rare. Here, we present a case of a 56-year-old man with a bulky tumor in the right hepatic lobe. The tumor was found incidentally by abdominal CT as part of an examination for hepatic dysfunction. The definitive diagnosis of SFT was established after liver biopsy, and the patient was referred to our hospital for surgical treatment. At the first visit, imaging studies revealed the primary focus of the malignancy as well as metastatic lesions in the hepatic S2 segment and pancreatic body. The treatment regimen was as follows: after antecedent TAE, primary hepatic and intrahepatic metastatic foci were first resected by extended resection of the two central areas. Nine months later, the pancreatic head tumor was enucleated and distal pancreatectomy was performed to remove metastatic foci including the new lesion on the pancreatic head. Postoperative adjunctive therapy was not administered, and the patient is currently alive without recurrence 22 months postoperatively. To the best of our knowledge, there have only been a few reports on primary hepatic malignant SFTs and this is the only SFT case involving pancreatic metastases reported thus far. This case indicates that total tumor resection allows patients with distant metastasis to achieve recurrence-free survival. Should recurrence occur, we would proactively consider the use of molecular-targeted drugs (approved in 2012), with re-resection in mind. © 2014 The Japanese Society of Gastroenterological Surgery.

    DOI: 10.5833/jjgs.2013.0002

    Scopus

    researchmap

  • ターナー症候群に合併した若年性大腸癌の一例

    母里淑子, 永坂岳司, 重安邦俊, 豊岡伸一, 藤原俊義

    日本遺伝子診療学会大会プログラム・抄録集   21st   2014

  • 鏡視下手術及び多職種による周術期管理による80歳以上超高齢者食道癌症例に対する手術成績向上の取り組み

    田邊俊介, 白川靖博, 国府島健, 前田直見, 大原利章, 野間和広, 櫻間教文, 藤原俊義

    日本消化器外科学会雑誌(Web)   47 ( Supplement1 )   2014

  • 癌関連線維芽細胞を標的とした光線免疫療法の開発

    野間和広, 勝部亮一, 浦野真一, 大原利章, 白川靖博, 藤原俊義

    日本がん転移学会学術集会・総会プログラム抄録集   23rd   2014

  • 固形癌に対する除鉄誘導による血管新生阻害薬併用療法の確立

    大原利章, 木村文昭, 浦野真一, 二宮卓之, 勝部亮一, 野間和広, 友野靖子, 藤原俊義, 松川昭博

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   38th   2014

  • 非侵襲的肺癌スクリーニング法の開発

    永坂岳司, 母里淑子, 重安邦俊, 豊岡伸一, 藤原俊義

    日本遺伝子診療学会大会プログラム・抄録集   21st   2014

  • 噴門側胃切除後の逆流防止機構を伴った食道残胃吻合法

    西崎正彦, 黒田新士, 菊地覚次, 久保田哲史, 香川俊輔, 藤原俊義

    胃癌perspective   7 ( 1 )   20 - 26   2014

     More details

  • 消化器癌のMolecular Theranostics:分子イメージングと治療の融合

    藤原俊義

    G.I.Research   22 ( 1 )   24 - 30   2014

     More details

  • ウイルスを用いたDDS:悪性腫瘍のウイルス療法

    藤原俊義

    医薬ジャーナル   50 ( 7 )   117 - 122   2014

     More details

  • テロメラーゼ活性依存的腫瘍融解ウイルスによるがん治療

    田澤 大, 矢野修也, 香川俊輔, 白川靖博, 藤原俊義

    腫瘍内科   13 ( 6 )   817 - 823   2014

     More details

  • 腹臥位胸腔鏡下食道切除術における助手の積極的手野展開とその定型化

    白川靖博, 野間和広, 藤原俊義

    Gastroenterological Endoscopy   56 ( Supplement 1 )   2014

  • 噴門側胃切除術における逆流防止弁形成食道残胃吻合法の工夫と問題点

    西崎正彦, 黒田新士, 菊地覚次, 桑田和也, 前田直見, 田邊俊介, 野間和広, 香川俊輔, 白川靖博, 藤原俊義

    胃外科・術後障害研究会プログラム・抄録集   44th   2014

  • 胸部食道癌周術期栄養管理の検討

    前田直見, 白川靖博, 田邊俊介, 野間和広, 櫻間教文, 坂本八千代, 佐野優子, 野口絢子, 藤原俊義

    静脈経腸栄養   29 ( 1 )   2014

  • Direct observation diverticulectomy for Zenker's diverticulum carcinoma

    Toshiaki Ohara, Yasuhiro Shirakawa, Kazuhiro Noma, Naoaki Maeda, Ryouichi Katsube, Shunsuke Tanabe, Toshiyoshi Fujiwara

    ESOPHAGUS   10 ( 4 )   235 - 238   2013.12

     More details

    Language:English   Publisher:SPRINGER JAPAN KK  

    Zenker's diverticulum carcinoma is a rare disease. Recent technological endoscopic innovation has enabled the detection of early stage Zenker's diverticulum carcinoma. Here we report a case in which a 56-year-old woman was diagnosed with early stage Zenker's diverticulum carcinoma. Narrow band imaging (NBI) endoscopic examination was useful for diagnosis and identifying the borders of the carcinoma. A successful surgical treatment was performed using direct observation diverticulectomy. A minimally invasive cervical procedure was used, and the area of the carcinoma was confirmed intraoperatively with Lugol's solution.

    DOI: 10.1007/s10388-013-0376-6

    Web of Science

    researchmap

  • Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation?

    Akinobu Takaki, Takahito Yagi, Tetsuya Yasunaka, Hiroshi Sadamori, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Sato, Daisuke Nobuoka, Masashi Utsumi, Yuko Yasuda, Eiichi Nakayama, Yasuhiro Miyake, Fusao Ikeda, Hidenori Shiraha, Kazuhiro Nouso, Toshiyoshi Fujiwara, Kazuhide Yamamoto

    Journal of Gastroenterology   48 ( 12 )   1373 - 1383   2013.12

     More details

    Language:English  

    Background: A combination of hepatitis B immunoglobulin and nucleos(t)ide analogues is the current standard of care for controlling hepatitis B recurrence after orthotopic liver transplantation (OLT). However, frequent immunoglobulin treatment is expensive and inconvenient. This study investigated the efficacy of hepatitis B virus (HBV) vaccination in preventing the recurrence of hepatitis B after living donor OLT. Methods: Twenty-seven patients who had undergone living donor OLT participated in the study
    five had acute HBV infected liver failure (ALF-OLT) and 22 had HBV related liver cirrhosis (LC-OLT). Hepatitis B surface antigen (HBsAg)-containing vaccine was administered to them for at least 1 year after transplantation and continued once monthly for up to 36 months post-OLT. Patients who had anti-HBs antibody titers above 100 mIU/mL for a minimum of 6 months without immunoglobulin administration were defined as good responders
    the others were defined as poor responders. Interferon-γ enzyme-linked immunospot assays against HBs and HBc antigens were used to assay cellular immune responses. Results: All five of the ALF-OLT patients had good responses after a median of four (range 2.5-5) vaccinations. Nine of the 22 LC-OLT patients had good responses after a median of 19 (range 11.5-30) vaccinations. Among the LC-OLT group, those with livers donated by relatively higher-aged, marital and high-titer anti-HBs antibody donors were good responders. LC-OLT patients classed as good responders showed interferon-γ responses comparable to those of the ALF-OLT patients. Conclusions: The ALF-OLT and LC-OLT patients who received livers from relatively higher-aged, marital, high-titer anti-HBs antibody donors were the best candidates for HBV vaccine administration. Boosting donors before transplantation may facilitate later vaccine response of the recipients. © 2013 The Author(s).

    DOI: 10.1007/s00535-013-0763-8

    Scopus

    PubMed

    researchmap

  • Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines

    Daisuke Sato, Yuji Kurihara, Seiji Kondo, Tatsuo Shirota, Yasuo Urata, Toshiyoshi Fujiwara, Satoru Shintani

    ONCOLOGY REPORTS   30 ( 6 )   2659 - 2664   2013.12

     More details

    Language:English   Publisher:SPANDIDOS PUBL LTD  

    We evaluated the antitumor effect of a telomerase-specific replication-selective adenovirus (Telomelysin, OBP-301) for adenoid cystic carcinoma (ACC) in vitro and in vivo. Adenovirus E1 gene expression was controlled by human telomerase reverse transcription (hTERT). Infection of ACC cells by OBP-301 induced high E1A mRNA expression and subsequent oncolytic cell death in a dose-dependent manner. Using OBP-401 (TelomeScan), a genetically engineered adenovirus that carries the GFP gene under the control of the cytomegalovirus (CMV) promoter at the deleted E3 region of OBP-301, ACC cells expressed bright GFP fluorescence as early as 12 h after OBP-401 infection. The fluorescence intensity gradually increased in a time-dependent manner, followed by rapid cell death due to the cytopathic effect of OBP-401, as evidenced by the floating, highly light-refractive cells using phase-contrast microscopy. Effects of intratumorally injected OBP-401 against established Acc2 xenograft tumors were seen in BALB/c nu/nu mice. The levels of GFP expression following ex vivo infection of OBP-401 may be of value as a positive predictive marker for the outcome of telomerase-specific virotherapy. Our data clearly indicated that telomerase-specific oncolytic adenoviruses have significant therapeutic potential against human ACC in vitro and in vivo. These results suggest that treatment with OBP-301 and OBP-401 may improve the quality of life of oral cancer patients.

    DOI: 10.3892/or.2013.2738

    Web of Science

    researchmap

  • Multicentred surgical site infection surveillance using partitioning analysis

    Y. Fujiwara, T. Yamada, Y. Naomoto, T. Yamatsuji, Y. Shirakawa, S. Tanabe, K. Noma, T. Kimura, H. Aoki, H. Matsukawa, M. Kimura, Y. Nonaka, H. Sasaki, T. Onoda, Y. Otawa, M. Takaoka, T. Fukazawa, Y. Ohno, T. Fujiwara

    JOURNAL OF HOSPITAL INFECTION   85 ( 4 )   282 - 288   2013.12

     More details

    Language:English   Publisher:W B SAUNDERS CO LTD  

    Background: Surgical site infection (SSI) is an ongoing major public health problem throughout the world that increases healthcare costs. Utilizing a methodology that can help clinicians to continuously collect data about SSIs, analyse it and implement the feedback into routine hospital practice has been identified as a top national priority in Japan.
    Aim: To conduct an intervention study through 'operations research' using partitioning at multiple facilities, and to reduce the incidence and consequences of SSI.
    Methods: The Setouchi SSI Surveillance Group, which consists of seven institutes, started SSI surveillance in 2006. Until May of 2008, there were four surveillance periods (A-D). In all, 3089 patients underwent gastrointestinal surgery and were followed up for 30 days after their operations. Twenty-six factors that have been reported to be related to SSI were evaluated for all patients. The top three factors from each surveillance period were determined and then actual practice improvements were planned for each subsequent period.
    Findings: The total SSI occurrence was 6.9% for period A, 6.3% for period B, 6.4% for period C and 3.9% for period D. Comparing periods A and D, there was a statistical significance in the decrease of SSI occurrence (P = 0.012).
    Conclusion: Using the results and partitioning analysis of active SSI surveillance to contribute to action plans for improving clinical practice was effective in significantly reducing SSIs. (C) 2013 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.jhin.2013.08.002

    Web of Science

    researchmap

  • Advanced hepatocellular carcinoma with lymph node metastases showing epithelial to mesenchymal transition effectively treated with systemic chemotherapy: Report of a case. International journal

    Hiroshi Sadamori, Takahito Yagi, Kunitoshi Shigeyasu, Yuzo Umeda, Masahiro Sugihara, Naosuke Yokomichi, Toshiaki Ohara, Naoshi Nishida, Takeshi Nagasaka, Ajay Goel, Toshiyoshi Fujiwara

    Hepatology research : the official journal of the Japan Society of Hepatology   43 ( 12 )   1368 - 73   2013.12

     More details

    Language:English  

    We present a case in which combination chemotherapy was used to successfully treat hepatocellular carcinoma (HCC) with rapid progression of lymph node (LN) metastases after liver resection. In addition, epithelial to mesenchymal transition (EMT) markers were examined immunohistochemically. A 43-year-old man who had been diagnosed with HCC showed an enlarged LN near the hepatic artery proper. After extended left lobectomy with lymphadenectomy in the hepatoduodenal ligament, he experienced rapid progression of metastases to the para-aortic and mediastinal LN. Partial remission was achieved after induction and maintenance of combination chemotherapy using etoposide, carboplatin, epirubicin and 5-fluorouracil. As a consequence of this treatment, the patient survived 10 months. Immunohistochemical studies demonstrated that HCC cells in the metastatic LN showed low expression of E-cadherin and high expression of N-cadherin and vimentin, indicating EMT. Combination chemotherapy may prove effective for patients with HCC accompanied by LN metastases that show features of EMT.

    DOI: 10.1111/hepr.12080

    PubMed

    researchmap

  • A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem-like Cells in S/G(2)/M Phases

    Shuya Yano, Hiroshi Tazawa, Yuuri Hashimoto, Yasuhiro Shirakawa, Shinji Kuroda, Masahiko Nishizaki, Hiroyuki Kishimoto, Futoshi Uno, Takeshi Nagasaka, Yasuo Urata, Shunsuke Kagawa, Robert M. Hoffman, Toshiyoshi Fujiwara

    CLINICAL CANCER RESEARCH   19 ( 23 )   6495 - 6505   2013.12

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Purpose: Because chemoradiotherapy selectively targets proliferating cancer cells, quiescent cancer stem-like cells are resistant. Mobilization of the cell cycle in quiescent leukemia stem cells sensitizes them to cell death signals. However, it is unclear that mobilization of the cell cycle can eliminate quiescent cancer stem-like cells in solid cancers. Thus, we explored the use of a genetically-engineered telomerase-specific oncolytic adenovirus, OBP-301, to mobilize the cell cycle and kill quiescent cancer stem-like cells.
    Experimental Design: We established CD133(+) cancer stem-like cells from human gastric cancer MKN45 and MKN7 cells. We investigated the efficacy of OBP-301 against quiescent cancer stem-like cells. We visualized the treatment dynamics of OBP-301 killing of quiescent cancer stem-like cells in dormant tumor spheres and xenografts using a fluorescent ubiquitination cell-cycle indicator (FUCCI).
    Results: CD133(+) gastric cancer cells had stemness properties. OBP-301 efficiently killed CD133(+) cancer stem-like cells resistant to chemoradiotherapy. OBP-301 induced cell-cycle mobilization from G(0)-G(1) to S/G(2)/M phases and subsequent cell death in quiescent CD133(+) cancer stem-like cells by mobilizing cell-cycle-related proteins. FUCCI enabled visualization of quiescent CD133(+) cancer stem-like cells and proliferating CD133(-) non-cancer stem-like cells. Three-dimensional visualization of the cell-cycle behavior in tumor spheres showed that CD133(+) cancer stem-like cells maintained stemness by remaining in G(0)-G(1) phase. We showed that OBP-301 mobilized quiescent cancer stem-like cells in tumor spheres and xenografts into S/G(2)/M phases where they lost viability and cancer stem-like cell properties and became chemosensitive.
    Conclusion: Oncolytic adenoviralinfection is an effective mechanism of cancer cell killing in solid cancer and can be a new therapeutic paradigm to eliminate quiescent cancer stem-like cells. Clin Cancer Res; 19(23); 6495-505. (C) 2013 AACR.

    DOI: 10.1158/1078-0432.CCR-13-0742

    Web of Science

    researchmap

  • Oncolytic Adenovirus-Induced Autophagy: Tumor-Suppressive Effect and Molecular Basis

    Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   67 ( 6 )   333 - 342   2013.12

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.   Publisher:OKAYAMA UNIV MED SCHOOL  

    Autophagy is a catabolic process that produces energy through lysosomal degradation of intracellular organelles. Autophagy functions as a cytoprotective factor under physiological conditions such as nutrient deprivation, hypoxia, and interruption of growth factors. On the other hand, infection with pathogenic viruses and bacteria also induces autophagy in infected cells. Oncolytic virotherapy with replication-competent viruses is thus a promising strategy to induce tumor-specific cell death. Oncolytic adenoviruses induce autophagy and subsequently contribute to cell death rather than cell survival in tumor cells. We previously developed a telomerase-specific replication-competent oncolytic adenovirus, OBP-301, which induces cell lysis in tumor cells with telomerase activities. OBP-301-mediated cytopathic activity is significantly associated with induction of autophagy biomarkers. In this review, we focus on the tumor-suppressive role and molecular basis of autophagic machinery induced by oncolytic adenoviruses. Addition of tumor-specific promoters and modification of the fiber knob of adenoviruses supports the oncolytic adenovirus-mediated autophagic cell death. Autophagy is cooperatively regulated by the El-dependent activation pathway, E4-dependent inhibitory pathway, and microRNA-dependent fine-tuning. Thus, future exploration of the functional role and molecular mechanisms underlying oncolytic adenovirus-induced autophagy would provide novel insights and improve the therapeutic potential of oncolytic adenoviruses.

    DOI: 10.18926/AMO/52006

    Web of Science

    researchmap

  • Quantitative assessment of Pdx1 promoter activity in vivo using a secreted luciferase reporter system

    Wataru Nishimura, Koki Eto, Atsushi Miki, Motohito Goto, Miho Kawaguchi, Takao Nammo, Haruhide Udagawa, Masaki Hiramoto, Yukiko Shimizu, Tadashi Okamura, Toshiyoshi Fujiwara, Yoshikazu Yasuda, Kazuki Yasuda

    Endocrinology   154 ( 11 )   4388 - 4395   2013.11

     More details

    Language:English  

    The luciferase reporter system is useful for the assessment of various biological processes in vivo. The transcription factor pancreatic and duodenal homeobox 1 (Pdx1) is critical for the formation and the function of pancreatic β-cells. A novel reporter system using secreted Gaussia princeps luciferase (GLuc) under the control of a Pdx1 promoter was generated and activated in rat and mouse β-cell lines. This Pdx1-GLuc construct was used as a transgene for the generation of reporter mice to monitor Pdx1 promoter activity in vivo via the measurement of secreted GLuc activity in a small aliquot of blood. Significantly increased plasma GLuc activity was observed in Pdx1-GLuc mice. Analysis of Pdx1-GLuc mice by bioluminescence imaging, GLuc reporter assays using homogenatesof various organs,andimmunohistochemistryrevealed thatGLucexpressionandactivity were exponentially higher in pancreatic β-cells than in pancreatic non-β-cells, the duodenum, and other organs. In addition, GLuc activity secreted into the culture medium from islets isolated from Pdx1-GLucmicecorrelatedwiththenumberofislets. ThetransplantationofPdx1-GLucisletsintosevere combined immunodeficiency mice elevated their plasma GLuc activity. Conversely, a partial pancreatectomy in Pdx1-GLuc mice reduced plasma GLuc activity. These results suggest that a secreted luciferase reporter system in vivo enables not only the monitoring of promoter activity but also a quantitative and minimally invasive assessment of physiological and pathological changes in small cell masses, such as pancreatic β-cells. Copyright © 2013 by The Endocrine Society.

    DOI: 10.1210/en.2012-2248

    Scopus

    PubMed

    researchmap

  • Development of a Clinically-Precise Mouse Model of Rectal Cancer

    Hiroyuki Kishimoto, Masashi Momiyama, Ryoichi Aki, Hiroaki Kimura, Atsushi Suetsugu, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

    PLOS ONE   8 ( 11 )   2013.11

     More details

    Language:English   Publisher:PUBLIC LIBRARY SCIENCE  

    Currently-used rodent tumor models, including transgenic tumor models, or subcutaneously growing tumors in mice, do not sufficiently represent clinical cancer. We report here development of methods to obtain a highly clinically-accurate rectal cancer model. This model was established by intrarectal transplantation of mouse rectal cancer cells, stably expressing green fluorescent protein (GFP), followed by disrupting the epithelial cell layer of the rectal mucosa by instilling an acetic acid solution. Early-stage tumor was detected in the rectal mucosa by 6 days after transplantation. The tumor then became invasive into the submucosal tissue. The tumor incidence was 100% and mean volume (+/-SD) was 1232.4 +/- 994.7 mm(3) at 4 weeks after transplantation detected by fluorescence imaging. Spontaneous lymph node metastasis and lung metastasis were also found approximately 4 weeks after transplantation in over 90% of mice. This rectal tumor model precisely mimics the natural history of rectal cancer and can be used to study early tumor development, metastasis, and discovery and evaluation of novel therapeutics for this treatment-resistant disease.

    DOI: 10.1371/journal.pone.0079453

    Web of Science

    researchmap

  • Dynamic Color-Coded Fluorescence Imaging of the Cell-Cycle Phase, Mitosis, and Apoptosis Demonstrates How Caffeine Modulates Cisplatinum Efficacy

    Shinji Miwa, Shuya Yano, Yasunori Tome, Naotoshi Sugimoto, Yukihiko Hiroshima, Fuminari Uehara, Sumiyuki Mii, Hiroaki Kimura, Katsuhiro Hayashi, Elena V. Efimova, Toshiyoshi Fujiwara, Hiroyuki Tsuchiya, Robert M. Hoffman

    JOURNAL OF CELLULAR BIOCHEMISTRY   114 ( 11 )   2454 - 2460   2013.11

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    Caffeine enhances the effect of certain anticancer drugs, but the mechanism of modulation is poorly understood. In this study, modulation of cisplatinum efficacy induced by caffeine was visualized at the subcellular level by real-time fluorescent-protein imaging. Mitotic and apoptotic changes were observed by imaging 143B human osteosarcoma dual-color cells, in which GFP is expressed in the nucleus and RFP is expressed in the cytoplasm. Modulation of the cell cycle was imaged using time-lapse imaging of HeLa cells expressing a fluorescent ubiquitination-based cell cycle indicator (FUCCI) in the nucleus. Clonogenic assays showed that caffeine increased the inhibition by cisplatinum on cell proliferation. Subcellular imaging demonstrated that cisplatinum decreased mitosis and induced apoptosis in 143B cells. The combination of cisplatinum and caffeine enhanced mitosis and subsequently increased apoptosis. Time-lapse imaging showed that cisplatinum strongly induced cell-cycle arrest in the S/G(2) phase in HeLa-FUCCI cells. Caffeine overcame the cell-cycle arrest induced by cisplatinum, thereby increasing its efficacy, since cisplatinum is ineffective against quiescent cells. The data in this report indicate that caffeine modulates the cell cycle in cancer cells, thereby enhancing efficacy of cell-cycle-dependent anticancer drugs such as cisplatinum. J. Cell. Biochem. 114: 2454-2460, 2013. (c) 2013 Wiley Periodicals, Inc.

    DOI: 10.1002/jcb.24593

    Web of Science

    researchmap

  • Advances in adenovirus-mediated p53 cancer gene therapy

    Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Expert Opinion on Biological Therapy   13 ( 11 )   1569 - 1583   2013.11

     More details

    Language:English  

    Introduction: The tumor suppressor p53 gene regulates diverse cellular processes, such as cell-cycle arrest, senescence, apoptosis and autophagy, and it is frequently inactivated by genetic alterations in ∼ 50% of all types of human cancers. To restore wild-type p53 function in p53-inactivated tumors, adenovirus-mediated p53 gene therapy has been developed as a promising antitumor strategy in preclinical experiments and clinical studies. Areas covered: This review focuses on the clinical relevance of replication-deficient adenovirus vectors that carry the wild-type p53 gene (Ad-p53
    Advexin, Gendicine and SCH-58500) in clinical studies of patients with various cancers and the future perspectives regarding conditionally replicating adenovirus vectors expressing the wild-type p53 gene (CRAd-p53
    AdDelta24-p53, SG600-p53, OBP-702) in preclinical experiments. Moreover, the recent advances in our understanding of the molecular basis for the p53-mediated tumor suppression network induced by Ad-p53 and CRAd-p53 vectors and the combination therapies for promoting the therapeutic potential of adenovirus-mediated p53 gene therapy are discussed. Expert opinion: Exploration of the molecular mechanism underlying the p53-mediated tumor suppression network and the effective strategy for enhancing the p53-mediated cell death signaling pathway would provide novel insights into the improvement of clinical outcome in p53-based cancer gene therapy. © 2013 Informa UK, Ltd.

    DOI: 10.1517/14712598.2013.845662

    Scopus

    PubMed

    researchmap

  • Serial Changes of Serum Growth Factor Levels and Liver Regeneration after Partial Hepatectomy in Healthy Humans

    Kazuyuki Matsumoto, Yasuhiro Miyake, Yuzo Umeda, Hiroshi Matsushita, Hiroaki Matsuda, Akinobu Takaki, Hiroshi Sadamori, Kazuhiro Nouso, Takahito Yagi, Toshiyoshi Fujiwara, Kazuhide Yamamoto

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES   14 ( 10 )   20877 - 20889   2013.10

     More details

    Language:English   Publisher:MDPI AG  

    This study aimed to investigate the associations of the serial changes of serum levels of various growth factors with liver regeneration after hepatectomy in healthy liver donors. Sixteen healthy liver donors who underwent conventional liver resection were included. Serum levels of various growth factors before hepatectomy and on postoperative day (POD) 1, 3, 5 and 7 were measured. Liver volume data calculated by multi-detector computed tomography using workstation. The ratio of remnant liver volume on POD 0 to liver volume before the operation was 51% +/- 20%. The ratio of liver volume on POD 14 to liver volume on POD 0 were inversely correlated with remnant liver volume on POD 0 (r = -0.91). The ratio of liver volume on POD 14 to liver volume on POD 0 were significantly correlated with serum hepatocyte growth factor (HGF) levels on POD 1 (r = 0.54), serum leptin levels on POD 1 (r = 0.54), and serum macrophage colony-stimulating factor (M-CSF) levels on POD 5 (r = 0.76) and POD 7 (r = 0.80). These results suggest that early-phase elevation of serum levels of HGF, leptin and M-CSF may be associated with the acceleration of liver regeneration after hepatectomy in humans.

    DOI: 10.3390/ijms141020877

    Web of Science

    researchmap

  • Telomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma cells

    Gui-Dong Li, Hiroyuki Kawashima, Akira Ogose, Takashi Ariizumi, Tetsuo Hotta, Ryozo Kuwano, Yasuo Urata, Toshiyoshi Fujiwara, Naoto Endo

    Cancer Science   104 ( 9 )   1178 - 1188   2013.9

     More details

    Language:English  

    This study investigated the pathway underlying the antitumor activity of telomelysin, a telomerase-dependent, replication-selective oncolytic adenovirus, in soft tissue sarcoma cells. Treatment with telomelysin alone resulted in simultaneous induction of apoptosis and autophagy, whereas cotreatment with telomelysin and 3-methyladenine significantly reduced cell viability and increased apoptosis and the cellular ATP level compared to treatment with telomelysin alone, indicating that telomelysin-mediated autophagy is a death-protective but not death-promoting process. Cotreatment with Z-Val-Ala-Asp-CH2F significantly increased cellular ATP depletion compared to telomelysin-alone treatment while inhibiting telomelysin-induced apoptosis and having no significant effect on cell viability, indicating that it promotes transition from apoptotic to necrotic cell death. © 2013 Japanese Cancer Association.

    DOI: 10.1111/cas.12208

    Scopus

    PubMed

    researchmap

  • がんリスクの評価と予防 便中メチル化CpG検出による消化器癌診断

    永坂 岳司, 吉田 一博, 森川 達也, 母里 淑子, 横道 直祐, 久保田 暢人, 竹原 祐子, 稲田 涼, 楳田 祐三, 西崎 正彦, 香川 俊輔, 西田 直生志, 貞森 裕, 八木 孝仁, 藤原 俊義

    日本癌治療学会誌   48 ( 3 )   590 - 590   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 当院におけるパゾパニブの使用経験

    元木 崇之, 松岡 順治, 岩本 高行, 藤原 俊義

    日本癌治療学会誌   48 ( 3 )   2079 - 2079   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • Risk factors for acute renal injury in living donor liver transplantation: Evaluation of the RIFLE criteria

    Masashi Utsumi, Yuzo Umeda, Hiroshi Sadamori, Takeshi Nagasaka, Akinobu Takaki, Hiroaki Matsuda, Susumu Shinoura, Ryuichi Yoshida, Daisuke Nobuoka, Daisuke Satoh, Tomokazu Fuji, Takahito Yagi, Toshiyoshi Fujiwara

    Transplant International   26 ( 8 )   842 - 852   2013.8

     More details

    Language:English  

    Acute renal injury (ARI) is a serious complication after liver transplantation. This study investigated the usefulness of the RIFLE criteria in living donor liver transplantation (LDLT) and the prognostic impact of ARI after LDLT. We analyzed 200 consecutive adult LDLT patients, categorized as risk (R), injury (I), or failure (F), according to the RIFLE criteria. ARI occurred in 60.5% of patients: R-class, 23.5%
    I-class, 21%
    and F-class, 16%. Four patients in Group-A (normal renal function and R-class) and 26 patients in Group-B (severe ARI: I- and F-class) required renal replacement therapy (P &lt
    0.001). Mild ARI did not affect postoperative prognosis regarding hospital mortality rate in Group A (3.2%), which was superior to that in Group B (15.8%
    P = 0.0015). Fourteen patients in Group B developed chronic kidney disease (KDIGO stage 3/4). The 1-, 5- and 10-year survival rates were 96.7%, 90.6%, and 88.1% for Group A and 71.1%, 65.9%, and 59.3% for Group B, respectively (P &lt
    0.0001). Multivariate analysis revealed risk factors for severe ARI as MELD ≥20 [odds ratio (OR) 2.9], small-for-size graft (GW/RBW &lt
    0.7%
    OR 3.1), blood loss/body weight &gt
    55 ml/kg (OR 3.7), overexposure to calcineurin inhibitor (OR 2.5), and preoperative diabetes mellitus (OR 3.2). The RIFLE criteria offer a useful predictive tool after LDLT. Severe ARI, defined beyond class-I, could have negative prognostic impact in the acute and late postoperative phases. Perioperative treatment strategies should be designed and balanced based on the risk factors for the further improvement of transplant prognosis. © 2013 Steunstichting ESOT. Published by John Wiley &amp
    Sons Ltd.

    DOI: 10.1111/tri.12138

    Scopus

    PubMed

    researchmap

  • StageIII大腸癌根治術後の再発予測におけるMGMTプロモーター領域のメチル化解析の有用性

    母里 淑子, 永坂 岳司, 竹原 裕子, 吉田 一博, 重安 邦俊, 楳田 祐三, 田澤 大, 貞森 裕, 藤原 俊義

    日本消化器外科学会総会   68回   O - 39   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 温阻血再灌流+70%肝切除におけるHMGB1の動態解析と制御

    杉原 正大, 貞森 裕, 佐藤 太祐, 吉田 龍一, 楳田 祐三, 篠浦 先, 田澤 大, 永坂 岳司, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   68回   RS - 54   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • A novel synergistic effect of iron depletion on antiangiogenic cancer therapy

    Toshiaki Ohara, Kazuhiro Noma, Shinichi Urano, Shinichiro Watanabe, Seishi Nishitani, Yasuko Tomono, Fumiaki Kimura, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    INTERNATIONAL JOURNAL OF CANCER   132 ( 11 )   2705 - 2713   2013.6

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    Iron is an essential element for both normal and cancer cells in humans. Treatment to reduce iron levels has been shown to suppress tumor growth in vivo. However, iron depletion monotherapy by iron decreased treatment has not been thought to be superior to ordinary chemotherapy and is not part of the standard therapeutic strategy for the treatment of cancer. Iron depletion is also known to reduce serum hemoglobin and oxygen supply to the tissue, which indicates that iron depletion may induce angiogenesis. Therefore, we hypothesized that iron depletion with antiangiogenic therapy can have a novel therapeutic effect in the treatment of cancer. Human nonsmall cell carcinoma cell lines A549 and H1299 were used in our study. An iron-deficient diet and an iron chelator were used to simulate an iron-depleted condition. The antitumor effects of iron depletion and antiangiogenic therapy were determined on A549 xenograft mice. The iron-depleted condition produced by an iron-deficient diet suppressed tumor growth. Tumor tissue from the iron-deficient diet group showed that cancer cell proliferation was suppressed and hypoxia was induced. Microvessel density of this group was increased which suggested that the iron-depleted condition induced angiogenesis. Bevacizumab administration had a synergetic effect on inhibiting the tumor growth on Day 39. An iron-depleted condition inhibited cancer cell proliferation and reciprocally induced angiogenesis. Bevacizumab synergistically enhanced the iron-depleted antitumor effect. Treatment to deplete iron levels combined with anti-angiogenic therapy could induce a novel therapeutic effect in the treatment of cancer.

    DOI: 10.1002/ijc.27943

    Web of Science

    researchmap

  • Peptide intra-tumor injection for cancer immunotherapy Enhancement of tumor cell antigenicity is a novel and attractive strategy

    Daisuke Nobuoka, Toshiaki Yoshikawa, Toshiyoshi Fujiwara, Tetsuya Nakatsura

    HUMAN VACCINES & IMMUNOTHERAPEUTICS   9 ( 6 )   1234 - 1236   2013.6

     More details

    Language:English   Publisher:LANDES BIOSCIENCE  

    One of the problems in antigen-specific cancer immunotherapy is the low density of the tumor antigen-derived peptide endogenously presented on tumor cell surface major histocompatibility complex class I molecules. To overcome this, we are engaged in research on peptide intra-tumor injection to enhance tumor cell antigenicity. In in vivo studies using immunodeficient mice, the peptide injected into a solid mass of subcutaneous tumor was revealed to be loaded onto human leukocyte antigen class I molecules of tumor cells. In a peptide vaccine model and an adoptive cell transfer model using C57BL/6 mice, peptide intra-tumor injection was effective in terms of tumor growth inhibition and prolongation of survival time. Moreover, an antigen-spreading effect was detected after peptide intra-tumor injection. Peptide intra-tumor injection is an effective method of enhancing tumor cell antigenicity. It can induce additional peptide loading onto tumor cells, making tumor cells more antigenic for specific cytotoxic T-lymphocyte activity. Peptide intra-tumor injection may be a useful option for improvement of antigen-specific immunotherapy against solid tumors.

    DOI: 10.4161/hv.23990

    Web of Science

    researchmap

  • Appendicitis during pregnancy

    75 ( 6 )   622 - 625   2013.6

  • CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy

    Daisuke Satoh, Takahito Yagi, Takeshi Nagasaka, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Masashi Utsumi, Takehiro Tanaka, Hiroshi Sadamori, Toshiyoshi Fujiwara

    World Journal of Hepatology   5 ( 4 )   189 - 195   2013.4

     More details

    Language:English  

    Aim: to investigate the pathogenesis of non-alcoholic fatty liver disease (nafld) after pancreatoduodenectomy (pd). methods: a cohort of 82 patients who underwent pd at okayama university hospital between 2003 and 2009 was enrolled and the clinicopathological features were compared between patients with and without nafld after pd. computed tomography (ct) images were evaluated every 6 mo after pd for follow-up. hepatic steatosis was diagnosed on ct when hepatic attenuation values were 40 hounsfield units. liver biopsy was performed for 4 of 30 patients with nafld after pd who consented to undergo biopsies. to compare nafld after pd with nafld associated with metabolic syndrome, liver samples were obtained from 10 patients with nafld associated with metabolic syndrome [fatty liver, n = 5
    non-alcoholic steatohepatitis (nash), n = 5] by percutaneous ultrasonography-guided liver biopsy. double-fluorescence immunohistochemistry was applied to examine cd14 expression as a marker of lipopolysaccharide (lps)-sensitized macrophage cells (kupffer cells) in liver biopsy specimens. results: the incidence of postoperative nafld was 36.6% (30/82). univariate analysis identified cancer of the pancreatic head, sex, diameter of the main pancreatic duct, and dissection of the nerve plexus as factors associated with the development of nafld after pd. those patients who developed nafld after pd demonstrated significantly decreased levels of serum albumin, total protein, cholesterol and triglycerides compared to patients without nafld after pd, but no glucose intolerance or insulin resistance. liver biopsy was performed in four patients with nafld after pd. all four patients showed moderate-to-severe steatosis and nash was diagnosed in two. numbers of cells positive for cd68 (a marker of kupffer cells) and cd14 (a marker of lpssensitized kupffer cells) were counted in all biopsy specimens. the number of cd68+ cells in specimens of nafld after pd was significantly increased from that in specimens of nafld associated with metabolic syndrome specimens, which indicated the presence of significantly more kupffer cells in nafld after pd than in nafld associated with metabolic syndrome. similarly, more cd14+ cells, namely, lps-sensitized kupffer cells, were observed in nafld after pd than in nafld associated with metabolic syndrome. regarding nash, more cd68+ cells and cd14+ cells were observed in nash after pd specimens than in nash associated with metabolic syndrome. this showed that more kupffer cells and more lps-sensitized kupffer cells were present in nash after pd than in nash associated with metabolic syndrome. these observations suggest that after pd, kupffer cells and lps-sensitized kupffer cells were significantly upregulated, not only in nash, but also in simple fatty liver. conclusion: nafld after pd is characterized by both malnutrition and the up-regulation of cd14 on kupffer cells. gut-derived endotoxin appears central to the development of nafld after pd. © 2013 Baishideng.

    DOI: 10.4254/wjh.v5.i4.189

    Scopus

    researchmap

  • Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination

    Kunitoshi Shigeyasu, Shunsuke Kagawa, Futoshi Uno, Masahiko Nishizaki, Hiroyuki Kishimoto, Akira Gochi, Toshikazu Kimura, Takaomi Takahata, Yasuyuki Nonaka, Motoki Ninomiya, Toshiyoshi Fujiwara

    Cancer Chemotherapy and Pharmacology   71 ( 4 )   937 - 943   2013.4

     More details

    Language:English  

    Purpose: Peritoneal dissemination is the most frequent and life-threatening mode of metastasis and recurrence in patients with gastric cancer. A multicenter phase II study was designed to evaluate the efficacy and tolerability of S-1 and docetaxel combination chemotherapy regimen for the treatment of advanced or recurrent gastric cancer patients with peritoneal dissemination. Methods: Nineteen patients with histologically confirmed unresectable or recurrent gastric cancer with peritoneal dissemination were enrolled. Oral S-1 at 80 mg/m2/day was administered twice daily for 2 weeks, followed by 1 drug-free week. Docetaxel infusion at 40 mg/m2 was performed on day 1, simultaneous with S-1 administration. The primary endpoints were overall survival (OS) and time to progression (TTP). The secondary endpoints were the response rates and safety status. Results: Patients received a median of 4 cycles of the S-1 and docetaxel regimen (range 1-43). The disease control rate was 73.7 % (14/19). Median overall survival was 459 days (15.3 months), while median time to progression was 212 days (7.1 months). Neutropenia was the most common type of toxicity (n = 7, 36.8 %). Conclusions: Combination chemotherapy with S-1 and docetaxel is a tolerable and effective treatment for advanced or recurrent gastric cancer patients with peritoneal dissemination. © 2013 Springer-Verlag Berlin Heidelberg.

    DOI: 10.1007/s00280-013-2086-0

    Scopus

    PubMed

    researchmap

  • Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy

    Daisuke Nobuoka, Toshiaki Yoshikawa, Mari Takahashi, Tatsuaki Iwama, Kazutaka Horie, Manami Shimomura, Shiro Suzuki, Noriko Sakemura, Munehide Nakatsugawa, Hiroshi Sadamori, Takahito Yagi, Toshiyoshi Fujiwara, Tetsuya Nakatsura

    CANCER IMMUNOLOGY IMMUNOTHERAPY   62 ( 4 )   639 - 652   2013.4

     More details

    Language:English   Publisher:SPRINGER  

    Antigen-specific cancer immunotherapy is a promising strategy for improving cancer treatment. Recently, many tumor-associated antigens and their epitopes recognized by cytotoxic T lymphocytes (CTLs) have been identified. However, the density of endogenously presented antigen-derived peptides on tumor cells is generally sparse, resulting in the inability of antigen-specific CTLs to work effectively. We hypothesize that increasing the density of an antigen-derived peptide would enhance antigen-specific cancer immunotherapy. Here, we demonstrated that intratumoral peptide injection leads to additional peptide loading onto major histocompatibility complex class I molecules of tumor cells, enhancing tumor cell recognition by antigen-specific CTLs. In in vitro studies, human leukocyte antigen (HLA)-A*02:01-restricted glypican-3(144-152) (FVGEFFTDV) and cytomegalovirus(495-503) (NLVPMVATV) peptide-specific CTLs showed strong activity against all peptide-pulsed cell lines, regardless of whether the tumor cells expressed the antigen. In in vivo studies using immunodeficient mice, glypican-3(144-152) and cytomegalovirus(495-503) peptides injected into a solid mass were loaded onto HLA class I molecules of tumor cells. In a peptide vaccine model and an adoptive cell transfer model using C57BL/6 mice, intratumoral injection of ovalbumin(257-264) peptide (SIINFEKL) was effective for tumor growth inhibition and survival against ovalbumin-negative tumors without adverse reactions. Moreover, we demonstrated an antigen-spreading effect that occurred after intratumoral peptide injection. Intratumoral peptide injection enhances tumor cell antigenicity and may be a useful option for improvement in antigen-specific cancer immunotherapy against solid tumors.

    DOI: 10.1007/s00262-012-1366-6

    Web of Science

    researchmap

  • Novel photoimmunotherapy (PIT) targeting cancer-associated fibroblasts (CAFs) for esophageal cancer.

    Shinichiro Watanabe, Kazuhiro Noma, Shinichi Urano, Toshiaki Ohara, Yuuri Hashimoto, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   73 ( 8 )   2013.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2013-4946

    Web of Science

    researchmap

  • PS-084-5 温阻血再灌流+肝切除モデルにおけるHMGBIの動態解析および肝再生機序の解明(PS ポスターセッション,第113回日本外科学会定期学術集会)

    杉原 正大, 貞森 裕, 西堀 正洋, 佐藤 康晴, 田澤 大, 吉田 龍一, 楳田 祐三, 篠浦 先, 永坂 岳司, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   637 - 637   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • WS-12-1-2 当科における80歳以上の超高齢者食道癌症例に対する外科治療の変遷(WS ワークショップ,第113回日本外科学会定期学術集会)

    田辺 俊介, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   317 - 317   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • SY-2-2 肝細胞癌に対する生体肝移植適応基準についての検討(SY シンポジウム,第113回日本外科学会定期学術集会)

    佐藤 太祐, 八木 孝仁, 貞森 裕, 篠浦 先, 楳田 祐三, 吉田 龍一, 信岡 大輔, 内海 方嗣, 河合 豪, 藤 智和, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   108 - 108   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • RSF-07-1 直腸癌術後10年を経過して発症した局所再発に対して治癒切除を施行した1例(RSF 研修医の発表セッション,第113回日本外科学会定期学術集会)

    西江 尚貴, 稲田 涼, 近藤 喜太, 宇野 太, 永坂 岳司, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   1071 - 1071   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-216-3 遺伝子変異情報を基盤とした大腸癌肝転移の治療戦略(PS ポスターセッション,第113回日本外科学会定期学術集会)

    母里 淑子, 楳田 祐三, 永坂 岳司, 稲田 涼, 森川 達也, 久保田 暢人, 吉田 一博, 篠浦 先, 貞森 裕, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   822 - 822   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-105-4 難治性胆道狭窄・胆汁漏に対するランデブー法を用いた胆管内瘻化(PS ポスターセッション,第113回日本外科学会定期学術集会)

    藤 智和, 楳田 祐三, 貞森 裕, 河合 毅, 内海 方嗣, 信岡 大輔, 佐藤 太祐, 吉田 龍一, 篠浦 先, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   666 - 666   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-067-5 テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌の低侵襲治療の開発(PS ポスターセッション,第113回日本外科学会定期学術集会)

    菊地 覚次, 岸本 浩行, 田澤 大, 橋本 悠里, 宇野 太, 西崎 正彦, 香川 俊輔, 浦田 泰生, Hoffman Robert, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   612 - 612   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PD-12-8 遺伝子情報を用いた多臓器転移大腸癌の検討および治療戦略の構築(PD パネルディスカッション,第113回日本外科学会定期学術集会)

    稲田 涼, 永坂 岳司, 母里 淑子, 楳田 祐三, 森川 達也, 久保田 暢人, 近藤 喜太, 宇野 太, 貞森 祐, 八木 孝仁, 三嶋 秀行, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   261 - 261   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • VF-020-4 ロボット支援下幽門側胃切除術におけるリンパ節郭清手技(VF ビデオフォーラム,第113回日本外科学会定期学術集会)

    西崎 正彦, 香川 俊輔, 石田 道拡, 黒田 新士, 近藤 喜太, 野間 和広, 岸本 浩行, 宇野 太, 永坂 岳司, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   438 - 438   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • VSY-9-7 生体肝移植後に発生した肝・腎不全に対する脳死肝腎同時移植症例における術中リスクマネージ(VSY ビデオシンポジウム,第113回日本外科学会定期学術集会)

    八木 孝仁, 貞森 裕, 楳田 祐三, 篠浦 先, 信岡 大輔, 藤智 和, 佐藤 太柑, 内海 方嗣, 吉田 龍一, 河合 毅, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   194 - 194   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • VF-016-2 生体肝移植における人工血管を用いた血行再建(VF ビデオフォーラム,第113回日本外科学会定期学術集会)

    信岡 大輔, 楳田 祐三, 貞森 裕, 篠浦 先, 吉田 龍一, 佐藤 太祐, 内海 方嗣, 保田 裕子, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   434 - 434   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • VF-079-4 下大静脈合併切除再建を併施した切除不能肝芽腫に対する生体肝移植(VF ビデオフォーラム,第113回日本外科学会定期学術集会)

    吉田 龍一, 藤智 和, 河合 毅, 内海 方嗣, 信岡 大輔, 佐藤 大祐, 楳田 祐三, 篠浦 先, 貞森 裕, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   495 - 495   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PD-3-6 生体肝移植の短期・晩期予後向上に向けた治療戦略個別化の可能性(PD パネルディスカッション,第113回日本外科学会定期学術集会)

    楳田 祐三, 八木 孝仁, 貞森 裕, 内海 方嗣, 篠浦 先, 吉田 龍一, 佐藤 太祐, 信岡 大輔, 藤 智和, 保田 裕子, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   236 - 236   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-227-1 当院で治療を行った膵神経内分泌腫瘍35症例の画像所見と病理組織学的所見の検討(PS ポスターセッション,第113回日本外科学会定期学術集会)

    内海 方嗣, 藤 智, 河合 毅, 佐藤 太祐, 信岡 大輔, 吉田 龍一, 楳田 祐三, 篠浦 先, 貞森 裕, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   837 - 837   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-082-3 血清鉄コントロールを用いた新たな肝細胞癌治療戦略(PS ポスターセッション,第113回日本外科学会定期学術集会)

    大原 利章, 白川 靖博, 浦野 真一, 前田 直見, 渡邊 伸一郎, 田辺 俊介, 野間 和広, 能祖 一裕, 貞森 裕, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   634 - 634   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • VF-018-3 生体肝移植ドナーにおける無血肝切除技術と胆道合併症の予防対策(VF ビデオフォーラム,第113回日本外科学会定期学術集会)

    貞森 裕, 八木 孝仁, 篠浦 先, 楳田 祐三, 吉田 龍一, 佐藤 太祐, 信岡 大輔, 内海 方嗣, 杉原 正大, 藤 智和, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   436 - 436   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-089-4 サイトケラチン19発現は肝細胞癌の上皮間葉移行と肝外転移を予測する(PS ポスターセッション,第113回日本外科学会定期学術集会)

    横道 直佑, 永坂 岳司, 西田 直生志, 楳田 祐三, 母里 淑子, 森川 達也, 久保田 暢人, 吉田 一博, 貞森 裕, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   644 - 644   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • WS-17-7 テロメラーゼ活性を指標とする血中遊離癌細胞の高感度検出法の開発と遺伝子解析技術への応用(WS ワークショップ,第113回日本外科学会定期学術集会)

    重安 邦俊, 橋本 悠里, 宇野 太, 永坂 岳司, 田澤 大2), 香川 俊輔, 水口 裕之, 浦田 泰生, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   338 - 338   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice

    Wei-Hsiang Lin, Shiou-Hwei Yeh, Wan-Jen Yang, Kun-Huei Yeh, Toshiyoshi Fujiwara, Aisuke Nii, Stanley Shi-Chung Chang, Pei-Jer Chen

    INTERNATIONAL JOURNAL OF CANCER   132 ( 6 )   1451 - 1462   2013.3

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    The telomerase-specific replication-competent oncolytic adenovirus, Telomelysin, was developed for virus-mediated preferential lysis of tumor cells. Its selectivity is derived from a human telomerase reverse transcriptase (hTERT) promoter-driven active viral replication, which occurs in cancer cells with high telomerase activity but not in normal cells lacking such activity. Because the TERT activity is elevated in most cases of hepatocellular carcinoma (HCC), the current study aims to investigate whether Telomelysin can be used for treatment of HCC. The oncolytic effect of Telomelysin has been investigated both in vitro using cell culture and in vivo using an immunocompetent in situ orthotopic HCC model. In this model, HCC developed spontaneously in the liver of HBx transgenic mice, which is pathologically and genetically similar to human HCC. In cell culture assay, Telomelysin lyses HCC cell lines at a low multiplicity of infection (MOI), ranging 0.77-6.35 (MOI [PFU/cell]). In the orthotopic HCC model, Telomelysin showed a potent oncolytic effect on HCC but spared normal liver tissue. Dose escalation analysis identified a safety dose of 1.25 X 108 PFU for this model. The effect of multiple injections of Telomelysin was also evaluated in this immunocompetent HCC model. We found that the virus replicates in HCC after a second intratumoral injection despite an immune response induced by the previous injection. This preclinical study shows that Telomelysin can be used for treatment of human HCC at an appropriate dosage and that its tumor-killing activity persists after multiple injections.

    DOI: 10.1002/ijc.27770

    Web of Science

    researchmap

  • Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice. International journal

    Toshio Nishikawa, Munenori Takaoka, Toshiaki Ohara, Yasuko Tomono, Huifang Hao, Xiaohong Bao, Takuya Fukazawa, Zhigang Wang, Kazufumi Sakurama, Yasuhiro Fujiwara, Takayuki Motoki, Yasuhiro Shirakawa, Tomoki Yamatsuji, Noriaki Tanaka, Toshiyoshi Fujiwara, Yoshio Naomoto

    Cancer biology & therapy   14 ( 3 )   230 - 6   2013.3

     More details

    Language:English  

    Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive cancers with poor prognosis regardless of a several reports that indicate a better therapeutic efficacy using some new chemotherapeutic agents. Recent drug development has contributed to an improved specificity to suppress mTOR activity by which many types of malignancies can be explosively progressed. Temsirolimus (CCI-779, TricelTM) is one of recently synthesized analogs of rapamycin and has provided better outcomes for patients with renal cell carcinoma. In this study, we experimentally evaluated an efficacy of targeting mTOR by temsirolimus for ESCC treatment, with an assessment of its survival advantage using an advanced ESCC animal model. First, we confirmed that the expression of phosphorylated mTOR was increased in 46 of 58 clinical ESCC tumor tissues (79.3%) and appeared to get strengthened with tumor progression. All of ESCC cell lines used in this study revealed an increase of mTOR phosphorylation, accompanied with the upregulation of hypoxia inducible factor-I α (HIF-1α), one of the critical effectors regulated by mTOR. Temsirolimus treatment apparently suppressed the activation of mTOR and its downstream effectors, resulting in the reduced ability of ESCC cell proliferation. Finally, the weekly administration of temsirolimus significantly diminished the size of subcutaneous tumors (vehicle, 3261.6 ± 722.0; temsirolimus, 599.2 ± 122.9; p = 0.007) in nude mice and effectively prolonged orthotopic esophageal cancer-bearing mice (median survival periods: control, 31 d; temsirolimus, 43 d; p = 0.0024). These data suggests that targeting mTOR by temsirolimus may become a therapeutic alternative for esophageal cancer, with a contribution to a better outcome.

    DOI: 10.4161/cbt.23294

    PubMed

    researchmap

  • Dual Programmed Cell Death Pathways Induced by p53 Transactivation Overcome Resistance to Oncolytic Adenovirus in Human Osteosarcoma Cells

    Joe Hasei, Tsuyoshi Sasaki, Hiroshi Tazawa, Shuhei Osaki, Yasuaki Yamakawa, Toshiyuki Kunisada, Aki Yoshida, Yuuri Hashimoto, Teppei Onishi, Futoshi Uno, Shunsuke Kagawa, Yasuo Urata, Toshifumi Ozaki, Toshiyoshi Fujiwara

    MOLECULAR CANCER THERAPEUTICS   12 ( 3 )   314 - 325   2013.3

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells. Mol Cancer Ther; 12(3); 314-25. (C)2012 AACR.

    DOI: 10.1158/1535-7163.MCT-12-0869

    Web of Science

    researchmap

  • 下大静脈合併切除再建を併施した切除不能肝芽腫に対する生体肝移植

    吉田 龍一, 藤 智和, 河合 毅, 内海 方嗣, 信岡 大輔, 佐藤 大祐, 楳田 祐三, 篠浦 先, 貞森 裕, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   495 - 495   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 当院で治療を行った膵神経内分泌腫瘍35症例の画像所見と病理組織学的所見の検討

    内海 方嗣, 藤 智, 河合 毅, 佐藤 太祐, 信岡 大輔, 吉田 龍一, 楳田 祐三, 篠浦 先, 貞森 裕, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   837 - 837   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 温阻血再灌流+肝切除モデルにおけるHMGB1の動態解析および肝再生機序の解明

    杉原 正大, 貞森 裕, 西堀 正洋, 佐藤 康晴, 田澤 大, 吉田 龍一, 楳田 祐三, 篠浦 先, 永坂 岳司, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   637 - 637   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 同時性多臓器転移を有する大腸癌の治療戦略 遺伝子情報を用いた多臓器転移大腸癌の検討および治療戦略の構築

    稲田 涼, 永坂 岳司, 母里 淑子, 楳田 祐三, 森川 達也, 久保田 暢人, 近藤 喜太, 宇野 太, 貞森 祐, 八木 孝仁, 三嶋 秀行, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   261 - 261   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • In Vivo Imaging of Transplanted Islets Labeled with a Novel Cationic Nanoparticle

    Koichi Oishi, Yoshitaka Miyamoto, Hiroaki Saito, Katsutoshi Murase, Kenji Ono, Makoto Sawada, Masami Watanabe, Yasufumi Noguchi, Toshiyoshi Fujiwara, Shuji Hayashi, Hirofumi Noguchi

    PLoS ONE   8 ( 2 )   2013.2

     More details

    Language:English  

    To monitor pancreatic islet transplantation efficiency, reliable noninvasive imaging methods, such as magnetic resonance imaging (MRI) are needed. Although an efficient uptake of MRI contrast agent is required for islet cell labeling, commercially-available magnetic nanoparticles are not efficiently transduced into cells. We herein report the in vivo detection of transplanted islets labeled with a novel cationic nanoparticle that allowed for noninvasive monitoring of islet grafts in diabetic mice in real time. The positively-charged nanoparticles were transduced into a β-cell line, MIN6 cells, and into isolated islets for 1 hr. MRI showed a marked decrease in the signal intensity on T1- and T2-weighted images at the implantation site of the labeled MIN 6 cells or islets in the left kidneys of mice. These data suggest that the novel positively-charged nanoparticle could be useful to detect and monitor islet engraftment, which would greatly aid in the clinical management of islet transplant patients. © 2013 Oishi et al.

    DOI: 10.1371/journal.pone.0057046

    Scopus

    PubMed

    researchmap

  • Risk factors for organ/space surgical site infection after hepatectomy for hepatocellular carcinoma in 359 recent cases

    Hiroshi Sadamori, Takahito Yagi, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Satoh, Daisuke Nobuoka, Masashi Utsumi, Kazuhiro Yoshida, Toshiyoshi Fujiwara

    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES   20 ( 2 )   186 - 196   2013.2

     More details

    Language:English   Publisher:SPRINGER JAPAN KK  

    Surgical site infections (SSIs), particularly organ/space SSIs, remain a common cause of major morbidity after hepatectomy for hepatocellular carcinoma (HCC).
    Risk factors for SSIs were analyzed in 359 patients who underwent hepatectomy for HCC between 2001 and 2010. The causative bacteria, management, outcome, and characteristics of organ/space SSIs were investigated.
    Anatomic hepatectomy was performed for 296 patients (82.5%), and repeat hepatectomy was carried out for 59 patients (16.4%). SSIs developed in 52 patients (14.5%; incisional, 24 cases; organ/space, 31 cases [3 patients showed both incisional and organ/space SSIs]). No in-hospital mortality related to incisional or organ/space SSIs was encountered. Independent risk factors for SSIs were repeat hepatectomy and operative time a parts per thousand yen280 min. Independent risk factors for organ/space SSIs were repeat hepatectomy and bile leakage. Methicillin-resistant Staphylococcus aureus was detected more frequently in organ/space SSIs after repeat hepatectomy than after initial hepatectomy.
    Repeat hepatectomy and bile leakage represent independent risk factors for organ/space SSIs after hepatectomy for HCC. Establishing treatment strategies is important for preventing postoperative bile leakage and reducing the high rate of organ/space SSIs after repeat hepatectomy.

    DOI: 10.1007/s00534-011-0503-5

    Web of Science

    researchmap

  • Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability

    Yuzo Umeda, Takeshi Nagasaka, Yoshiko Mori, Hiroshi Sadamori, Dong-Sheng Sun, Susumu Shinoura, Ryuich Yoshida, Daisuke Satoh, Daisuke Nobuoka, Masashi Utsumi, Kazuhiro Yoshida, Takahito Yagi, Toshiyoshi Fujiwara

    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES   20 ( 2 )   223 - 233   2013.2

     More details

    Language:English   Publisher:SPRINGER JAPAN KK  

    The discovery of practical biomarkers is important to realize personalized medicine for patients with malignant neoplasias, including colorectal cancer (CRC).
    The aim of this study was to determine reliable prognostic biomarkers by the analysis of patients with resectable colorectal liver metastases (CRLM).
    Genomic DNA was obtained from the CRLM tissues of a cohort of 126 patients with CRLM with curative hepatic resection. The KRAS/BRAF mutation spectrum and microsatellite instability (MSI) status were successfully analyzed in 100 of the 126 CRLM tissues and these findings were examined in relation to the patients' clinical outcomes.
    The cohort of 100 CRLM patients consisted of 46 with synchronous and 54 with metachronous liver metastasis. Overall survival and disease-free survival at 5 years were 57.4 and 24.9 %, respectively. MSI analysis revealed that none of the 100 CRLM specimens showed any evidence of MSI. By KRAS/BRAF mutation analysis, the analyzed CRLM patients were divided into 3 groups; KRAS-mutant (KRAS-Mt; n = 27), BRAF-mutant (BRAF-Mt; n = 3), and wild-types of both genes (Wild-type; n = 70). In the survival analysis, both KRAS-Mt and BRAF-Mt patients showed significantly poorer prognoses compared with Wild-type patients. Furthermore, although the population with the BRAF mutation was small, this mutation had a significant negative impact on disease-free survival.
    In this study, all tumors in the cohort of CRLM patients were non-MSI tumors, suggesting MSI cancer in primary CRC would rarely reveal metastatic potential. KRAS and BRAF mutations are suggested to be poor prognostic factors in CRLM. Genetic information has an essential role as a prognostic marker and could contribute to the decisions on treatment strategy for CRLM.

    DOI: 10.1007/s00534-012-0531-9

    Web of Science

    researchmap

  • Bloodless Donor Hepatectomy in Living Donor Liver Transplantation: Counterclockwise Liver Rotation and Early Hanging Maneuver

    Hiroshi Sadamori, Takahito Yagi, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Satoh, Daisuke Nobuoka, Masashi Utsumi, Kazuhiro Yoshida, Toshiyoshi Fujiwara

    JOURNAL OF GASTROINTESTINAL SURGERY   17 ( 1 )   203 - 206   2013.1

     More details

    Language:English   Publisher:SPRINGER  

    Living donor hepatectomy is important because it determines donor safety and recipient outcome.
    We applied the counter-clockwise liver rotation method and the hanging maneuver from an early stage in two major types of living donor operations.
    Twenty-eight living donors underwent these procedures with significant reduction in blood loss. Right hepatectomy was performed in 14 of the donors and extended left hepatectomy was performed in the other 14 donors.
    These techniques facilitate safe and bloodless living donor hepatectomy.

    DOI: 10.1007/s11605-012-1907-5

    Web of Science

    researchmap

  • Risk factors for major morbidity after liver resection for hepatocellular carcinoma

    H. Sadamori, T. Yagi, S. Shinoura, Y. Umeda, R. Yoshida, D. Satoh, D. Nobuoka, M. Utsumi, T. Fujiwara

    BRITISH JOURNAL OF SURGERY   100 ( 1 )   122 - 129   2013.1

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    Background: Bile leakage, and organ and/or space surgical-site infection (SSI) are common causes of major morbidity after partial hepatectomy for hepatocellular carcinoma (HCC). The purpose of this study was to analyse risk factors for major morbidity and to explore strategies for its reduction after partial hepatectomy for HCC. Methods: Risk factors for bile leakage and organ/space SSI were analysed in patients who underwent partial hepatectomy for HCC between 2001 and 2010. The causes, management and outcomes of intractable bile leakage requiring endoscopic therapy or percutaneous transhepatic biliary drainage were analysed. In addition, causative bacteria, outcomes and characteristics of organ/space SSI were investigated. Risk factors were identified using multivariable analysis. Results: Some 359 patients were included in the analysis. The prevalence of bile leakage and organ/space SSI was 12.8 and 8.6 per cent respectively. Repeat hepatectomy and an operating time of at least 300 min were identified as independent risk factors for bile leakage. The main causes of intractable bile leakage were latent strictures of the biliary system caused by previous treatments for HCC and intraoperative injury of the hepatic duct during repeat hepatectomy. Independent risk factors for organ/space SSI were repeat hepatectomy and bile leakage. Methicillin-resistant Staphylococcus aureus was detected more frequently in organ/space SSI after repeat hepatectomy than after initial partial hepatectomy. Conclusion: Repeat hepatectomy and prolonged surgery were identified as risk factors for bile leakage after liver resection for HCC. Bile leakage and repeat hepatectomy increased the risk of organ/space SSI. Copyright (c) 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

    DOI: 10.1002/bjs.8957

    Web of Science

    researchmap

  • Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer

    Xiao-Hong Bao, Munenori Takaoka, Hui-Fang Hao, Takuya Fukazawa, Tomoki Yamatsuji, Kazufumi Sakurama, Nagio Takigawa, Motowo Nakajima, Toshiyoshi Fujiwara, Yoshio Naomoto

    ONCOLOGY REPORTS   29 ( 1 )   45 - 50   2013.1

     More details

    Language:English   Publisher:SPANDIDOS PUBL LTD  

    Heat shock protein 90 (HSP90), a molecular chaperone, has provoked great interest as a promising molecular target for cancer treatment, due to its involvement in regulating the conformation, stability and functions of key oncogenic proteins. At present, a variety of chemical compounds targeting HSP90 have been developed and have shown convincing anti-neoplastic activity in various preclinical tumor models. The aim of our study was to evaluate the antitumor effects of a novel HSP90 inhibitor, NVP-AUY922, in esophageal squamous cancer cells (ESCC). Four ESCC cell lines (TE-1, TE-4, TE-8, TE-10) were examined. NVP-AUY922 potently inhibited the proliferation of ESCC, particularly in PTEN-null TE-4 cells with a 2-3 times lower IC50 than the other three cell lines. Western blot analysis showed that PTEN-null TE-4 cells exhibited higher AKT and ERK activity, which contribute to cell proliferation and survival. NVP-AUY922 significantly suppressed the activity of AKT and ERK in TE-4 but not in PTEN-proficient TE-10 cells. Genetic modification experiments demonstrated that the sensitivity to NVP-AUY922 was decreased by exogenous transduction of PTEN in TE-4 and increased by silencing PTEN expression in intact PTEN-expressing TE-10, suggesting that the expression of PTEN may be associated with cell sensitivity in HSP90 inhibition. Furthermore, the enhanced activity of AKT in PTEN-silenced TE-10 was more easily suppressed by NVP-AUY922. Collectively, NVP-AUY922 exhibits a strong antiproliferative effect, revealing its potential as a novel therapeutic alternative to current ESCC treatment. The effect may be improved further by impeding PTEN expression.

    DOI: 10.3892/or.2012.2074

    Web of Science

    researchmap

  • Peptide vaccines for hepatocellular carcinoma

    Daisuke Nobuoka, Toshiaki Yoshikawa, Yu Sawada, Toshiyoshi Fujiwara, Tetsuya Nakatsura

    HUMAN VACCINES & IMMUNOTHERAPEUTICS   9 ( 1 )   210 - 212   2013.1

     More details

    Language:English   Publisher:TAYLOR & FRANCIS INC  

    Immunotherapy is a potentially attractive treatment option for patients with hepatocellular carcinoma (HCC). We have reported that glypican-3 (GPC3) is an ideal target for anticancer immunotherapy against HCC because its expression is specifically detected in &gt; 80% of HCCs, even during the early stages. Further, increased GPC3 expression is correlated with a poor prognosis. Based on results obtained from a preclinical study using mice, we conducted a phase I clinical trial using a GPC3-derived peptide vaccine. Phase I results showed that the GPC3-derived peptide vaccine was well tolerated. Furthermore, this was the first study to show that the frequency of peptide-specific cytotoxic T lymphocytes was correlated with overall survival in patients with HCC receiving a peptide vaccine. Next, we conducted a phase II clinical trial using the GPC3-derived peptide vaccine in patients with HCC after surgery or radiofrequency ablation (adjuvant setting). We are currently evaluating a third trial involving liver biopsies removed from patients with advanced HCC before and after GPC3-derived peptide vaccination. We expect that the results of these trials will result in future drug development.

    DOI: 10.4161/hv.22473

    Web of Science

    researchmap

  • A simple detection system for adenovirus receptor expression using a telomerase-specific replication-competent adenovirus

    T. Sasaki, H. Tazawa, J. Hasei, S. Osaki, T. Kunisada, A. Yoshida, Y. Hashimoto, S. Yano, R. Yoshida, S. Kagawa, F. Uno, Y. Urata, T. Ozaki, T. Fujiwara

    GENE THERAPY   20 ( 1 )   112 - 118   2013.1

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Adenovirus serotype 5 (Ad5) is frequently used as an effective vector for induction of therapeutic transgenes in cancer gene therapy or of tumor cell lysis in oncolytic virotherapy. Ad5 can infect target cells through binding with the coxsackie and adenovirus receptor (CAR). Thus, the infectious ability of Ad5-based vectors depends on the CAR expression level in target cells. There are conventional methods to evaluate the CAR expression level in human target cells, including flow cytometry, western blotting and immunohistochemistry. Here, we show a simple system for detection and assessment of functional CAR expression in human tumor cells, using the green fluorescent protein (GFP)-expressing telomerase-specific replication-competent adenovirus OBP-401. OBP-401 infection induced detectable GFP expression in CAR-expressing tumor cells, but not in CAR-negative tumor cells, nor in CAR-positive normal fibroblasts, 24 h after infection. OBP-401-mediated GFP expression was significantly associated with CAR expression in tumor cells. OBP-401 infection detected tumor cells with low CAR expression more efficiently than conventional methods. OBP-401 also distinguished CAR-positive tumor tissues from CAR-negative tumor and normal tissues in biopsy samples. These results suggest that GFP-expressing telomerase-specific replication-competent adenovirus is a very potent diagnostic tool for assessment of functional CAR expression in tumor cells for Ad5-based antitumor therapy. Gene Therapy (2013) 20, 112-118; doi:10.1038/gt.2011.213; published online 12 January 2012

    DOI: 10.1038/gt.2011.213

    Web of Science

    researchmap

  • 直腸癌術後10年を経て発症した局所再発に対して治癒切除を施行した1例.

    西江尚貴, 稲田涼, 母里淑子, 近藤喜太, 宇野太, 永坂岳司, 藤原俊義

    癌と化学療法   2013

     More details

  • 術後感染予防のための抗菌薬使用ガイドライン.

    篠浦 先, 藤原俊義

    岡山医学会雑誌   2013

  • A case of metastatic cecal cancer with mutation in the BRAF oncogene and poor survival

    125 ( 1 )   47 - 50   2013

  • 癌微小リンパ節転移を標的とするテロメラーゼ特異的制限増殖型ウイルス製剤の開発.

    児島 亨, 渡邉雄一, 橋本悠里, 黒田新士, 山崎泰源, 矢野修也, 田澤 大, 宇野 太, 香川俊輔, 田中紀章, 浦田泰生, 藤原俊義

    岡山医学会雑誌   2013

     More details

  • New Surgical Approach to Large Splenorenal Shunt in Living Donor Liver Transplantation: Diversion of SMV and SPV Blood Flow

    Hiroshi Sadamori, Takahito Yagi, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Satoh, Daisuke Nobuoka, Masashi Utsumi, Toshiyoshi Fujiwara

    Journal of Gastrointestinal Surgery   17 ( 2 )   403 - 407   2013

     More details

    Language:English  

    Introduction: The management of a large splenorenal shunt is important because it affects recipient outcome, particularly in living donor liver transplantation. Methods: To manage large splenorenal shunts in living donor liver transplantation, we diverted superior mesenteric vein and splenic portal vein blood flow by ligation at the root of the splenic portal vein. Result: This procedure was applied for five patients in whom superior mesenteric vein blood flow had been completely stolen by a splenorenal shunt preoperatively. Postoperative course was excellent in all cases. Conclusion: This technique completely prevents morbidity related to large splenorenal shunts after living donor liver transplantation. © 2012 The Society for Surgery of the Alimentary Tract.

    DOI: 10.1007/s11605-012-2006-3

    Scopus

    PubMed

    researchmap

  • Kinetics of high-mobility group box 1 after living donor liver transplantation

    Hiroshi Sadamori, Yasuharu Sato, Masahiro Nishibori, Daisuke Sato, Daisuke Nobuoka, Masahiro Sugihara, Takahito Yagi, Toshiyoshi Fujiwara

    Japanese Journal of Gastroenterological Surgery   46 ( 3 )   232 - 235   2013

     More details

  • The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation.

    Alafate A, Shinya T, Okumura Y, Sato S, Hiraki T, Ishii H, Gobara H, Kato K, Fujiwara T, Miyoshi S, Kaji M, Kanazawa S

    Acta Med Okayama   2013

     More details

  • Successfully treated pneumatosis cystoides intestinalis with pneumoperitoneum onset in a patient administered α-glucosidase inhibitor.

    Tanabe S, Shirakawa Y, Takehara Y, Maeda N, Katsube R, Ohara T, Sakurama K, Noma K, Fujiwara T

    Acta Med Okayama   2013

     More details

  • Living donor liver transplantation to a survivor of liver resection for hepatocellular carcinoma with major portal vein invasion.

    Sadamori H, Yagi T, Shinoura S, Umeda Y, Yoshida R, Sato D, Nobuoka D, Utsumi M, Fujiwara T

    Acta Med Okayama   2013

     More details

  • 進行食道癌における術前化学療法の現況.

    田辺俊介, 白川靖博, 前田直見, 勝部亮一, 大原利章, 櫻間教文, 野間和広, 藤原俊義

    癌と化学療法   2013

     More details

  • 遠隔転帰・再発を伴う進行S状結腸癌に対して集学的治療を行い長期生存を得た1例.

    西江尚貴, 稲田 涼, 母里淑子, 近藤喜太, 宇野 太, 永坂岳司, 内海方嗣, 楳田祐三, 貞森 裕, 八木孝仁, 藤原俊義

    癌と化学療法   2013

     More details

  • Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis

    125 ( 3 )   195 - 199   2013

  • 一次治療でセツキシマブ不耐となった後,三次治療での再使用により奏功した進行大腸癌の一例.

    稲田 涼, 永坂岳司, 母里淑子, 楳田祐三, 久保田暢人, 森川達也, 近藤喜太, 宇野 太, 貞森 裕, 八木孝仁, 藤原俊義

    岡山医学会雑誌   2013

  • イマチニブが長期に奏効している同時性肝転移を伴う消化管間質腫瘍の1例.

    宇野 太, 藤原康宏, 藤原俊義

    岡山医学会雑誌   2013

  • Occult Bleedingの検出により診断に至った, Hemosuccus Pancreaticusの1例.

    杭瀬崇, 楳田祐三, 三村卓司, 金田道弘, 八木孝仁, 藤原俊義

    胆と膵   2013

     More details

  • TWO CASES OF DIAPHRAGMATIC HERNIA FOLLOWING PERCUTANEOUS RADIOFREQUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA

    WATANABE Megumi, HAYASHI Dofu, MATSUMURA Toshihisa, NONAKA Yasuyuki, FUJIMARA Toshiyoshi

    The journal of the Japanese Practical Surgeon Society   74 ( 8 )   2128 - 2133   2013

     More details

    Language:Japanese   Publisher:Japan Surgical Association  

    Reports of diaphragmatic hernia associated with radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) are rare. We report 2 cases of diaphragmatic hernia that developed after RFA for HCC. Case 1 involved a 65-year-old man who had undergone percutaneous RFA for HCC located in the S5 and S7 areas. Three years later, he underwent surgery from the abdominal cavity side based on the diagnosis of right diaphragmatic hernia made by another hospital. One year later, the right diaphragmatic hernia recurred, necessitating the performance of video-assisted thoracic surgery at our hospital. The defect of the diaphragm was covered with mesh. Case 2 involved a 73-year-old woman who had undergone percutaneous RFA for HCC located in the S7 area. Subsequently, she underwent 3 sessions of RFA for HCC localized in the S3, S1, and S4 areas. Seven years after the first RFA, right diaphragmatic hernia occurred, and we performed surgery via thoracotomy. The defect of the diaphragm was repaired by direct suture. The thoracotomic approach may be a safe and useful option for the treatment of diaphragmatic hernia after RFA.

    DOI: 10.3919/jjsa.74.2128

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2014115098

  • A long-term control of gastrointestinal stromal tumor with sunitinib

    Futoshi Uno, Yasuhiro Fujiwara, Toshiyoshi Fujiwara

    Japanese Journal of Cancer and Chemotherapy   40 ( 9 )   1241 - 1244   2013

     More details

    Language:Japanese   Publisher:Japanese Journal of Cancer and Chemotherapy Publishers Inc.  

    The patient was a 70-year-old woman with gastrointestinal stromal tumor (GIST) of the small intestine, accompanied by liver metastasis. Multiple liver metastases were pointed out 3 months after R0 surgery (jejunectomy and hepatectomy). Although she was given radiofrequency ablation (RFA) therapy and imatinib, metastatic tumors progressed. In a further examination at our institution 21 months after R0 surgery, multiple liver, bone, and lung metastases were indicated, and she was given sunitinib once daily at a 50 mg in 6-week courses, with 4 weeks on and 2 weeks off treatment. Although sunitinib dosage was decreased to 25 mg/day because of adverse events, 21 courses of this treatment were administrered, and it took 137 weeks to progress her disease with this sunitinib treatment. At our institution, seven cases of GIST were treated with sunitinib, and the median time to progression was 30-weeks. That was almost the same result as for Japan and international clinical trials. Sunitinb treatment may be one of the most important therapeutic options for unresectable imatinib-resistant GIST.

    Scopus

    PubMed

    researchmap

  • 下部直腸・肛門部疾患の診断と治療 非上皮性悪性腫瘍.

    稲田 涼, 藤田 伸, 谷口浩和, 宇野 太, 永坂岳司, 藤原俊義

    臨床消化器内科   2013

     More details

  • A Case of Local Recurrence of Anal Canal Mucinous Adenocarcinoma at Five Years After an Initial Surgery

    Hamada Yuki, Inada Ryo, Mori Yoshiko, Kondo Yoshitaka, Nagasaka Takeshi, Fujiwara Toshiyoshi

    Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)   38 ( 5 )   1086 - 1090   2013

     More details

    Language:Japanese   Publisher:Japanese College of Surgeons  

    A 61-year-old man underwent curative abdominoperineal resection with lateral lymph node dissection for anal canal mucinous adenocarcinoma at our hospital. Histopathological findings were pA, pN0, pH0, pP0, pM0, pStage Ⅱ, curA on the Japanese Classification of Colorectal Carcinoma, the seventh edition. Five years after the surgery, he complained of perineal pain and CT/MRI scans revealed a substantial recurrent tumor in the pelvis, measuring 90mm in diameter without other metastatic lesions. On the diagnosis of local recurrence of anal canal mucinous adenocarcinoma, we performed total pelvic exenteration (TPE), to eradicate the tumor in an en bloc fashion. He was discharged on the 25th postoperative day without intra- and postoperative complications. Histopathologically, the specimens showed mucinous adenocarcinoma suggesting local recurrence of the primary tumor, and the radial margin was negative for cancer. The patient is doing well without any re-recurrence 28 months after TPE. Colorectal mucinous adenocarcinoma is a poor prognostic disease, compared with differentiated adenocarcinoma, and most of local recurrence arises within three years. We report a case of local recurrence of anal canal mucinous adenocarcinoma at five years after the initial surgery with good course and survival after TPE.

    DOI: 10.4030/jjcs.38.1086

    CiNii Article

    researchmap

  • Isolation Efficiency of Mouse Pancreatic Stem Cells Is Age Dependent

    Kuise T, Noguchi H, Saitoh I, Kataoka H, Watanabe M, Noguchi Y, Fujiwara T

    Cell Medicine   2013

     More details

  • 遺伝子情報を用いた多臓器転移大腸癌の検討および治療戦略の構築.

    稲田 涼, 永坂岳司, 母里淑子, 楳田祐三, 森川達也, 久保田暢人, 竹原裕子, 河合 毅, 宇野 太, 八木孝仁, 藤原俊義

    癌の臨床   2013

     More details

  • 肝臓癌における除鉄併用ソラフェニブ療法の可能性

    浦野真一, 大原利章, 勝部亮一, 友野靖子, 木村文昭, 野間和広, 白川靖博, 藤原俊義

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   37th   2013

  • 予後および病態評価が可能な新規食道癌同所移植性モデル

    大原利章, 白川靖博, 野間和広, 浦野真一, 前田直見, 田辺俊介, 櫻間教文, 田澤大, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   24th   2013

  • 遺伝子異常と癌の多様性 癌遺伝子と癌抑制遺伝子の多様性と治療への応用.

    藤原俊義

    臨床と研究   90 ( 1 )   38 - 42   2013

     More details

  • 肝切除後の肝移植(生体及び脳死ドナー).

    八木孝仁, 藤原俊義

    手術   67 ( 7 )   1071 - 1076   2013

     More details

  • 消化器がんの分子病態に基づいた治療開発.

    藤原俊義

    第100回日本消化器病学会中国支部例会記念誌   181 - 187   2013

     More details

  • Molecular targeted therapies and gastroenterological neoplasia

    125 ( 2 )   145 - 152   2013

  • 肺癌の遺伝子治療の現状.

    藤原俊義

    呼吸と循環   61 ( 6 )   574 - 580   2013

  • 次世代型制限増殖アデノウイルスを利用した血中循環がん細胞検出法の開発.

    櫻井文教, 藤原俊義, 水口裕之

    薬学雑誌   133 ( 3 )   291 - 296   2013

  • 80歳以上の超高齢者食道癌症例に対する外科治療の安全性確保への取り組み

    田邊俊介, 白川靖博, 前田直見, 勝部亮一, 櫻間教文, 野間和広, 藤原俊義

    日本消化器外科学会雑誌(Web)   46 ( Supplement1 )   2013

  • 同時性/異時性多発大腸癌における遺伝子変異の特徴

    永坂岳司, 母里淑子, 豊岡伸一, 藤原俊義

    日本人類遺伝学会大会プログラム・抄録集   58th   2013

  • Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis

    Hiroshi Tazawa, Shuya Yano, Ryosuke Yoshida, Yasumoto Yamasaki, Tsuyoshi Sasaki, Yuuri Hashimoto, Shinji Kuroda, Masaaki Ouchi, Teppei Onishi, Futoshi Uno, Shunsuke Kagawa, Yasuo Urata, Toshiyoshi Fujiwara

    INTERNATIONAL JOURNAL OF CANCER   131 ( 12 )   2939 - 2950   2012.12

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    Autophagy is known to have a cytoprotective role under various cellular stresses; however, it also results in robust cell death as an important safeguard mechanism that protects the organism against invading pathogens and unwanted cancer cells. Autophagy is regulated by cell signalling including microRNA (miRNA), a post-transcriptional regulator of gene expression. Here, we show that genetically engineered telomerase-specific oncolytic adenovirus induced miR-7 expression, which is significantly associated with its cytopathic activity in human cancer cells. Virus-mediated miR-7 upregulation depended on enhanced expression of the E2F1 protein. Ectopic expression of miR-7 suppressed cell viability and induced autophagy by inhibiting epidermal growth factor receptor (EGFR) expression. Our results suggest that oncolytic adenovirus induces autophagic cell death through an E2F1-miR-7-EGFR pathway in human cancer cells, providing a novel insight into the molecular mechanism of an anticancer virotherapy.

    DOI: 10.1002/ijc.27589

    Web of Science

    researchmap

  • Jejunal interposition reconstruction with a stomach preserving esophagectomy improves postoperative weight loss and reflux symptoms for esophageal cancer patients

    Eiji Yamada, Yasuhiro Shirakawa, Tomoki Yamatsuji, Leon Sakuma, Munenori Takaoka, Takako Yamada, Kazuhiro Noma, Kazufumi Sakurama, Yasuhiro Fujiwara, Shunsuke Tanabe, Takeshi Nagasaka, Toshiyoshi Fujiwara, Yoshio Naomoto

    JOURNAL OF SURGICAL RESEARCH   178 ( 2 )   700 - 707   2012.12

     More details

    Language:English   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Background: Conventional reconstruction after an esophagectomy uses a gastric tube, which commonly causes several postoperative complaints such as gastric acid reflux in long-term survival cases. Intestinal interposition between the remnant esophagus and the stomach is an option to reduce complaints, and in this study, the advantages of jejunal interposition reconstruction with a stomach preserving esophagectomy (SPE) were assessed.
    Materials and methods: Eleven cases of jejunal interposition with an SPE and 16 cases with gastric tube reconstruction as a control were subject to a comparison of operation time, amount of bleeding, postoperative quality of life, and endoscopic findings.
    Results: The SPE group had a longer operation time (SPE: 560 +/- 121 min, control 414 +/- 83 min, P = 0.038), whereas there was no significant difference in blood loss. Postoperative weight loss was significantly recovered in the SPE group (SPE versus control = 94.0 +/- 5.4% versus 87.5 +/- 4.7% at 3 mo, P = 0.017; 97.2 +/- 7.5% versus 85.0 +/- 5.2% at 6 mo, P = 0.010), and there was a significant decrease in the occurrence of reflux symptoms such as heartburn, odynophagia, and cough when jejunal interposition with an SPE was done. Furthermore, reflux esophagitis and Barrett's epithelium were found in six out of 12 cases (50%) of the control group by postoperative endoscopy, while no cases in the SPE group had either condition (P &lt; 0.01).
    Conclusions: This reconstruction method is a promising option to improve postoperative quality of life, mainly due to the long-term elimination of reflux esophagitis, which assists in the recovery of postoperative weight loss. (C) 2012 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.jss.2012.07.057

    Web of Science

    researchmap

  • Surgical rationalization of living donor liver transplantation by abolition of hepatic artery reconstruction under a fixed microscope

    Takahito Yagi, Susumu Shinoura, Yuzo Umeda, Daisuke Sato, Ryuichi Yoshida, Kazuhiro Yoshida, Masashi Utsumi, Daisuke Nobuoka, Hiroshi Sadamori, Toshiyoshi Fujiwara

    CLINICAL TRANSPLANTATION   26 ( 6 )   877 - 883   2012.11

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    The small diameter of the hepatic artery is one of the complexities of living donor liver transplantation (LDLT). We analyzed whether the direct suture technique using surgical loupes can simplify the operative process for LDLT compared with fixed microscopic reconstruction. We applied the direct technique to rationalize the operative process and abolished routine microsurgery from 2004. Two hundred and nine LDLT with a postoperative period over 34 months were carried out from 1996 to 2008. The patients were divided into two groups: the micro group (children: 20, adults: 72) and the non-micro group (children: 12, adults: 97). Running anastomosis was undertaken in the non-micro group. The anastomotic size of the children was significantly smaller than that of the adults, but larger than 2 mm (2.38 +/- 0.4 vs. 2.7 +/- 0.47 mm, p = 0.0005). By appropriate choice of the proximal artery, direct anastomosis is possible even in children. Early complications occurred in seven cases in the micro group, but none occurred in the non-micro group (p &lt; 0.05). Significant reductions were observed in operation time (p &lt; 0.0001), blood loss (p &lt; 0.05), and hospital stay (p &lt; 0.01) in the non-micro group. Non-microscopic anastomosis is useful for the rationalization of LDLT.

    DOI: 10.1111/j.1399-0012.2012.01651.x

    Web of Science

    researchmap

  • Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells

    Ryosuke Yoshida, Hiroshi Tazawa, Yuuri Hashimoto, Shuya Yano, Teppei Onishi, Tsuyoshi Sasaki, Yasuhiro Shirakawa, Hiroyuki Kishimoto, Futoshi Uno, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER IMMUNOLOGY IMMUNOTHERAPY   61 ( 11 )   1905 - 1916   2012.11

     More details

    Language:English   Publisher:SPRINGER  

    Trastuzumab, a humanized antibody targeting HER2, exhibits remarkable therapeutic efficacy against HER2-positive breast and gastric cancers; however, acquired resistance presents a formidable obstacle to long-term tumor responses in the majority of patients. Here, we show the mechanism of resistance to trastuzumab in HER2-positive human cancer cells and explore the molecular sensitization by exogenous expression of HER2-extracellular domain (ECD) in HER2-negative or trastuzumab-resistant human cancer cells. We found that long-term exposure to trastuzumab induced resistance in HER2-positive cancer cells; HER2 expression was downregulated, and antibody-dependent cellular cytotoxicity (ADCC) activity was impaired. We next examined the hypothesis that trastuzumab-resistant cells could be re-sensitized by the transfer of non-functional HER2-ECD. Exogenous HER2-ECD expression induced by the stable transfection of a plasmid vector or infection with a replication-deficient adenovirus vector had no apparent effect on the signaling pathway, but strongly enhanced ADCC activity in low HER2-expressing or trastuzumab-resistant human cancer cells. Our data indicate that restoration of HER2-ECD expression sensitizes HER2-negative or HER2-downregulated human cancer cells to trastuzumab-mediated ADCC, an outcome that has important implications for the treatment of human cancers.

    DOI: 10.1007/s00262-012-1249-x

    Web of Science

    researchmap

  • Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells

    Y. Watanabe, Y. Hashimoto, S. Kagawa, H. Kawamura, K. Nagai, N. Tanaka, Y. Urata, T. Fujiwara

    CANCER GENE THERAPY   19 ( 11 )   767 - 772   2012.11

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Replication-selective oncolytic viruses are being developed for human cancer therapy. We previously developed an attenuated adenovirus (OBP-301, Telomelysin), in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site. OBP-301 can replicate in, and causes selective lysis of, human cancer cells. Valproic acid (VPA), which is an effective antiepileptic drug, is known to inhibit the histone deacetylase activities. We determined whether the antitumor effect of OBP-301 could be enhanced by VPA in human lung cancer cells. In an in vitro cell viability assay, OBP-301 infection killed four human lung cancer cell lines, H1299, H1299-R5 (a subline of H1299 with a low level of the coxsackievirus and adenovirus receptor (CAR) expression), H460, and A549, more efficiently in the presence of VPA than in its absence. VPA treatment increased CAR expression in all the four lung cancer cells. Consistent with their CAR upregulation, the infection efficiency of adenoviruses in the presence of VPA was significantly higher than that in its absence. The molecular mechanism of this combined effect could be explained by an increase in adenovirus infectivity via VPA-mediated upregulation of CAR. These results suggest that treatment with OBP-301 in combination with VPA is a promising strategy for human lung cancer.

    DOI: 10.1038/cgt.2012.57

    Web of Science

    researchmap

  • 進行肝細胞癌の治療 高度脈管浸潤を伴う進行肝細胞癌の治療戦略

    藤 智和, 楳田 祐三, 貞森 裕, 篠浦 先, 吉田 龍一, 佐藤 太祐, 信岡 大輔, 内海 方嗣, 河合 毅, 藤原 俊義, 八木 孝仁

    日本臨床外科学会雑誌   73 ( 増刊 )   409 - 409   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 同時性肝内転移、膵転移を伴った肝原発solitary fibrous tumorの一例

    杭瀬 崇, 楳田 祐三, 貞森 裕, 篠浦 先, 吉田 龍一, 佐藤 太祐, 内海 方嗣, 藤 智和, 八木 孝仁, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   696 - 696   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression

    Yasumoto Yamasaki, Hiroshi Tazawa, Yuuri Hashimoto, Toru Kojima, Shinji Kuroda, Shuya Yano, Ryosuke Yoshida, Futoshi Uno, Hiroyuki Mizuguchi, Akira Ohtsuru, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    EUROPEAN JOURNAL OF CANCER   48 ( 14 )   2282 - 2291   2012.9

     More details

    Language:English   Publisher:ELSEVIER SCI LTD  

    Oncolytic viruses engineered to replicate in tumour cells but not in normal cells could be used as tumour-specific vectors carrying the therapeutic genes. We previously developed a telomerase-specific oncolytic adenovirus, OBP-301, that causes cell death in human cancer cells with telomerase activities. Here, we further modified OBP-301 to express the wild-type p53 tumour suppressor gene (OBP-702), and investigated whether OBP-702 induces stronger antitumour activity than OBP-301. The antitumour effect of OBP-702 was compared to that of OBP-301 on OBP-301-sensitive (H358 and H460) and OBP-301-resistant (T.Tn and HSC4) human cancer cells. OBP-702 suppressed the viability of both OBP-301-sensitive and OBP-301-resistant cancer cells more efficiently than OBP-301. OBP-702 caused increased apoptosis compared to OBP-301 or a replication-deficient adenovirus expressing the p53 gene (Ad-p53) in H358 and T.Tn cells. Adenovirus E1A-mediated p21 and MDM2 downregulation was involved in the apoptosis caused by OBP-702. Moreover, OBP-702 significantly suppressed tumour growth in subcutaneous tumour xenograft models compared to monotherapy with OBP-301 or Ad-p53. Our data demonstrated that OBP-702 infection expressed adenovirus E1A and then inhibited p21 and MDM2 expression, which in turn efficiently induced apoptotic cell death. This novel apoptotic mechanism suggests that the p53-expressing OBP-702 is a promising antitumour reagent for human cancer and could improve the clinical outcome. (C) 2011 Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.ejca.2011.12.020

    Web of Science

    researchmap

  • Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer

    Toshiyoshi Fujiwara, Shunsuke Kagawa, Hiroshi Tazawa

    Current Pharmaceutical Biotechnology   13 ( 9 )   1809 - 1816   2012.7

     More details

    Language:English  

    Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is considered to be a critical step in carcinogenesis through the maintenance of telomeres, and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. We constructed an attenuated adenovirus 5 vector, in which the hTERT promoter element drives expression of E1 genes, OBP-301 (Telomelysin). Since only tumor cells that express telomerase activity would activate this promoter, the hTERT proximal promoter allows for preferential expression of viral genes in tumor cells, leading to selective viral replication and oncolytic cell death. OBP-301 alone exhibited substantial antitumor effects both in animal models and in clinical trials
    data regarding combination therapy with OBP-301 and chemotherapeutic agents are preliminary but encouraging. This article reviews synergistic interaction of virotherapy and chemotherapy, and illustrates the potential application for the treatment of human cancer. © 2012 Bentham Science Publishers.

    DOI: 10.2174/138920112800958887

    Scopus

    PubMed

    researchmap

  • Branched-chain amino acid-enriched nutrients improve nutritional and metabolic abnormalities in the early post-transplant period after living donor liver transplantation

    Ryuichi Yoshida, Takahito Yagi, Hiroshi Sadamori, Hiroaki Matsuda, Susumu Shinoura, Yuzo Umeda, Daisuke Sato, Masashi Utsumi, Takeshi Nagasaka, Nami Okazaki, Ai Date, Ayako Noguchi, Akemi Tanaka, Yuko Hasegawa, Yachiyo Sakamoto, Toshiyoshi Fujiwara

    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES   19 ( 4 )   438 - 448   2012.7

     More details

    Language:English   Publisher:SPRINGER TOKYO  

    Malnutrition and metabolic disorder of patients undergoing living donor liver transplantation (LDLT) can affect post-transplant prognosis. The aim of this study was to establish whether perioperative usage of branched-chain amino-acid (BCAA)-enriched nutrients improve metabolic abnormalities of patients undergoing LDLT.
    We designed a randomized pilot study (UMIN registration number; 000004323). Twenty-five consecutive adult elective LDLT recipients were enroled and divided into two groups: the BCAA group (BCAA-enriched nutrients, n = 12) and the control group (standard diet, n = 13). Metabolic and nutritional parameters, including BCAA-to-tyrosine ratio (BTR), retinol binding protein (RBP), and prealbumin were regularly measured from 1 week before to 4 weeks after LDLT. Non-protein respiratory quotient (npRQ) was measured before and 4 weeks after LDLT.
    BTR and RBP improved considerably in the BCAA group compared with the controls. npRQ significantly increased from 1 week before LDLT to 4 weeks after LDLT in the BCAA group (0.77 +/- A 0.05 to 0.84 +/- A 0.06, P = 0.002), but not in the control group (0.78 +/- A 0.04 to 0.81 +/- A 0.05).
    Supplementation with BCAA-enriched nutrients might improve persistent nutritional and metabolic disorders associated with end-stage liver disease in the early post-transplant period, and consequently shorten the post-transplant catabolic phase after LDLT. A larger multicenter trial is needed to confirm these findings.

    DOI: 10.1007/s00534-011-0459-5

    Web of Science

    researchmap

  • Esophageal Cancer Exhibits Resistance to a Novel IGF-1R Inhibitor NVP-AEW541 with Maintained RAS-MAPK Activity

    Xiao-Hong Bao, Munenori Takaoka, Hui-Fang Hao, Zhi-Gang Wang, Takuya Fukazawa, Tomoki Yamatsuji, Kazufumi Sakurama, Dong-Sheng Sun, Takeshi Nagasaka, Toshiyoshi Fujiwara, Yoshio Naomoto

    ANTICANCER RESEARCH   32 ( 7 )   2827 - 2834   2012.7

     More details

    Language:English   Publisher:INT INST ANTICANCER RESEARCH  

    Aim: To assess the effects of a novel type 1 insulin-like growth factor receptor (IGF-1R) inhibitor, NVP-AEW541, on cell proliferation and signal transduction of esophageal cancer. Materials and Methods: Cell proliferation assay and western blot were conducted to assess the antitumor effects of NVP-AEW541. Genetic modification of RAS by expression vector was applied for overexpression of mutant RAS. Results: More than 2 mu mol/l of NVP-AEW541 was required to effectively, inhibit the proliferation of esophageal cancer NVP-AEW541 potently blocked the activation of IGF-IR and protein kinase B (PKB, also known as AKT), but not of mitogen-activated protein kinase kinase (MEK) and extracellular-signal-regulated kinases (ERK). Active RAS was not reduced by NVP-AEW541 in esophageal cancer cells TE-1, suggesting that insensitivity of esophageal cancer to NVP-AEW541 is due to the maintained RAS-MAPK activity, which did not arise from RAS mutation. Moreover, the transduction of mutant RAS reduced the sensitivity of TE-1 cells to NVP-AEW541. Conclusion: Stimulation of RAS-MAPK pathway is associated with resistance to NVP-AEW541 in esophageal cancer. Combining NVP-AEW541 with inhibitors/antibodies against RAS-MAPK signaling molecules might be more effective for use against esophageal cancer.

    Web of Science

    researchmap

  • Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer

    Hui-fang Hao, Munenori Takaoka, Xiao-hong Bao, Zhi-gang Wang, Yasuko Tomono, Kazufumi Sakurama, Toshiaki Ohara, Takuya Fukazawa, Tomoki Yamatsuji, Toshiyoshi Fujiwara, Yoshio Naomoto

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   423 ( 4 )   744 - 749   2012.7

     More details

    Language:English   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Peritoneal dissemination is one of the most terrible types of colorectal cancer progression. Focal adhesion kinase (FAK) plays a crucial role in the biological processes of cancer, such as cell attachment, migration, proliferation and survival, all of which are essential for the progression of peritoneal dissemination. Since we and other groups have reported that the inhibition of FAK activity exhibited a potent anticancer effect in several cancer models, we hypothesized that TAE226, a novel ATP-competitive tyrosine kinase inhibitor designed to target FAK, can prevent the occurrence and progression of peritoneal dissemination. In vitro, TAE226 greatly inhibited the proliferation and migration of HCT116 colon cancer cells, while their adhesion on the matrix surface was minimally inhibited when FAK activity and expression was suppressed by TAE226 and siRNA. In vivo, when HCT116 cells were intraperitoneally inoculated in mice, the cells could attach to the peritoneum and begin to grow within 24 h regardless of the pretreatment of cells with TAE226 or FAK-siRNA, suggesting that FAK is not essential, at least for the initial integrin-matrix contact. Interestingly, the treatment of mice before and after inoculation significantly suppressed cell attachment to the peritoneum. Furthermore, oral administration of TAE226 greatly reduced the size of disseminated tumors and prolonged survival in tumor-bearing mice. Taken together, a possible strategy for inhibiting peritoneal dissemination by targeting FAK with TAE226 appears to be applicable through anti-proliferative and anti-invasion/anti-migration mechanisms. (C) 2012 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbrc.2012.06.030

    Web of Science

    researchmap

  • Circulating tumour cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancers

    M. Takakura, S. Kyo, M. Nakamura, Y. Maida, Y. Mizumoto, Y. Bono, X. Zhang, Y. Hashimoto, Y. Urata, T. Fujiwara, M. Inoue

    BRITISH JOURNAL OF CANCER   107 ( 3 )   448 - 454   2012.7

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    BACKGROUND: Recently developed detection system for circulating tumour cells (CTCs) using a telomerase-specific replicative adenovirus generated nonspecific green fluorescent protein (GFP) signals because of the co-presence of white blood cells (WBCs) nonspecifically infected by viruses. Here, we established a unique detection system for CTCs that completely excludes nonspecific signals.
    METHODS: Blood obtained from the patients was subjected to haemolytic processes to eliminate red blood cells. The cell pellets were then infected with OBP-401, fixed, incubated with fluorescence-labelled anti-CD45 antibody to mark white blood WBCs, and examined on slides under a microscope.
    RESULTS: Preparatory experiments with cancer cells artificially added to healthy donor samples confirmed that CD45 labelling could distinguish GFP-positive cancer cells from WBCs. In 53 patients with gynaecological cancers, CTCs were detected in 21 patients (39.6%) when CD45-positive cells were excluded as WBCs among GFP-positive cells. No CTCs were detected in samples from healthy volunteers. There was no significant correlation between CTC counts and known clinicopathological factors. The CTCs rapidly vanished after surgery or chemotherapy in most patients whose treatments were effective. In contrast, the persistence of CTCs even after treatments was tightly associated with poor response to the treatments (P&lt;0.005).
    CONCLUSION: The presence of CTCs in our system may potentially be a novel therapeutic marker in gynaecological cancers. British Journal of Cancer (2012) 107, 448-454. doi: 10.1038/bjc.2012.276 www.bjcancer.com Published online 26 June 2012 (C) 2012 Cancer Research UK

    DOI: 10.1038/bjc.2012.276

    Web of Science

    researchmap

  • Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer

    Toshiyoshi Fujiwara, Shunsuke Kagawa, Hiroshi Tazawa

    CURRENT PHARMACEUTICAL BIOTECHNOLOGY   13 ( 9 )   1809 - 1816   2012.7

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.   Publisher:BENTHAM SCIENCE PUBL LTD  

    Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is considered to be a critical step in carcinogenesis through the maintenance of telomeres, and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. We constructed an attenuated adenovirus 5 vector, in which the hTERT promoter element drives expression of E1 genes, OBP-301 (Telomelysin). Since only tumor cells that express telomerase activity would activate this promoter, the hTERT proximal promoter allows for preferential expression of viral genes in tumor cells, leading to selective viral replication and oncolytic cell death. OBP-301 alone exhibited substantial antitumor effects both in animal models and in clinical trials; data regarding combination therapy with OBP-301 and chemotherapeutic agents are preliminary but encouraging. This article reviews synergistic interaction of virotherapy and chemotherapy, and illustrates the potential application for the treatment of human cancer.

    DOI: 10.2174/138920112800958887

    Web of Science

    researchmap

  • The hTERT Promoter Enhances the Antitumor Activity of an Oncolytic Adenovirus under a Hypoxic Microenvironment

    Yuuri Hashimoto, Hiroshi Tazawa, Fuminori Teraishi, Toru Kojima, Yuichi Watanabe, Futoshi Uno, Shuya Yano, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    PLOS ONE   7 ( 6 )   1 - 10   2012.6

     More details

    Language:English   Publisher:PUBLIC LIBRARY SCIENCE  

    Hypoxia is a microenvironmental factor that contributes to the invasion, progression and metastasis of tumor cells. Hypoxic tumor cells often show more resistance to conventional chemoradiotherapy than normoxic tumor cells, suggesting the requirement of novel antitumor therapies to efficiently eliminate the hypoxic tumor cells. We previously generated a tumor-specific replication-competent oncolytic adenovirus (OBP-301: Telomelysin), in which the human telomerase reverse transcriptase (hTERT) promoter drives viral E1 expression. Since the promoter activity of the hTERT gene has been shown to be upregulated by hypoxia, we hypothesized that, under hypoxic conditions, the antitumor effect of OBP-301 with the hTERT promoter would be more efficient than that of the wild-type adenovirus 5 (Ad5). In this study, we investigated the antitumor effects of OBP-301 and Ad5 against human cancer cells under a normoxic (20% oxygen) or a hypoxic (1% oxygen) condition. Hypoxic condition induced nuclear accumulation of the hypoxia-inducible factor-1 alpha and upregulation of hTERT promoter activity in human cancer cells. The cytopathic activity of OBP-301 was significantly higher than that of Ad5 under hypoxic condition. Consistent with their cytopathic activity, the replication of OBP-301 was significantly higher than that of Ad5 under the hypoxic condition. OBP-301-mediated E1A was expressed within hypoxic areas of human xenograft tumors in mice. These results suggest that the cytopathic activity of OBP-301 against hypoxic tumor cells is mediated through hypoxia-mediated activation of the hTERT promoter. Regulation of oncolytic adenoviruses by the hTERT promoter is a promising antitumor strategy, not only for induction of tumor-specific oncolysis, but also for efficient elimination of hypoxic tumor cells.

    DOI: 10.1371/journal.pone.0039292

    Web of Science

    researchmap

  • Carcinosarcoma of the Gallbladder Manifesting as Cholangitis Due to Hemobilia

    Hiroshi Sadamori, Hiroyasu Fujiwara, Takehiro Tanaka, Hiroyuki Yanai, Daisuke Satoh, Takahito Yagi, Toshiyoshi Fujiwara

    JOURNAL OF GASTROINTESTINAL SURGERY   16 ( 6 )   1278 - 1281   2012.6

     More details

    Language:English   Publisher:SPRINGER  

    Carcinosarcomas of the gallbladder are rare tumors that are characterized by malignant epithelial and mesenchymal components, and preoperative diagnosis of carcinosarcoma of the gallbladder remains difficult.
    We recently encountered a case of carcinosarcoma of the gallbladder with osteoid and chondroid differentiation, manifesting as cholangitis due to hemobilia.
    Preoperative computed tomography and magnetic resonance imaging indicated the cause of cholangitis and provided qualitative information regarding the two components of the tumor.

    DOI: 10.1007/s11605-012-1836-3

    Web of Science

    researchmap

  • Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis

    Shinichi Toyooka, Katsuyuki Kiura, Mitsuhiro Takemoto, Takahiro Oto, Nagio Takigawa, Toshiyoshi Fujiwara, Shinichiro Miyoshi, Hiroshi Date

    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY   14 ( 5 )   565 - 569   2012.5

     More details

    Language:English   Publisher:OXFORD UNIV PRESS  

    The purpose of this study was to show the long-term outcome of induction chemoradiotherapy, using docetaxel and cisplatin with concurrent radiotherapy followed by surgery for non-small-cell lung cancer (NSCLC) with mediastinal nodal metastasis. Between January 2000 and July 2006, 22 consecutive NSCLC patients with pathologically proven mediastinal nodal metastasis were treated with tri-modality therapy. The regimen consisted of docetaxel and cisplatin plus concurrent radiation at a dose of 40-46 Gy. The induction therapy was followed by surgery 4-6 weeks later. The pulmonary resections were composed of a lobectomy in 19 patients, including 3 with a sleeve lobectomy, a bilobectomy in 2 patients and a left pneumonectomy in 1 patient. With a median follow-up duration of 8.7 years, the 3-year and 7-year overall survival (OS) rates for the entire population were 72.7 and 63.6%, respectively. Our results suggest that tri-modality therapy is promising for NSCLC patients with mediastinal nodal metastasis.

    DOI: 10.1093/icvts/ivs028

    Web of Science

    researchmap

  • Chemotherapy of methioninase-synchronized S/G2 phase-blocked cancer cells identified by cell cycle-specific fluorescent reporters

    Shuya Yano, Shukuan Li, Qinghong Han, Yuying Tan, Toshiyoshi Fujiwara, Robert M. Hoffman

    JOURNAL OF CLINICAL ONCOLOGY   30 ( 15 )   2012.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    Web of Science

    researchmap

  • 腺様嚢胞癌細胞株におけるテロメラーゼ特異的腫瘍融解ウイルスの抗腫瘍効果の検討

    佐藤 大典, 栗原 祐史, 近藤 誠二, 代田 達夫, 浦田 泰生, 藤原 俊義, 新谷 悟

    頭頸部癌   38 ( 2 )   225 - 225   2012.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • Resection of Metachronous Lymph Node Metastases from Hepatocellular Carcinoma after Hepatectomy: Report of Four Cases

    Masashi Utsumi, Hiroaki Matsuda, Hiroshi Sadamori, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Satoh, Masaaki Hashimoto, Takahito Yagi, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   66 ( 2 )   177 - 182   2012.4

     More details

    Language:English   Publisher:OKAYAMA UNIV MED SCHOOL  

    We report 4 cases of surgical resection of metachronous lymph node (LN) metastases from hepatocellular carcinoma (HCC) following hepatectomy. Clinicopathological features and results of LN dissection were investigated in the 4 patients. One patient was found to have a single metastasis in the mediastinal LNs, another had multiple metastases in the mediastinal and abdominal LNs, and the other 2 had single metastases in the abdominal LN. The locations of the abdominal LN metastases were behind the pancreas head in 2 patients and around the abdominal aorta in 1 patient. They all underwent surgical resection of metastatic LNs and had no postoperative complications. The 3 patients whose LN metastases were solitary have been alive for more than 2 years after LN resection, and one of them is free from recurrence. The patient with multiple LN metastases died 13 months after LN resection due to carcinomatosis. With the expectation of long-term survival, a single metachronous LN metastasis from HCC after hepatectomy should be resected in patients without uncontrollable intrahepatic or extrahepatic tumors.

    DOI: 10.18926/AMO/48268

    Web of Science

    researchmap

  • Iron chelator contributes to anti-angiogenic therapy via selective induction of VEGF-A

    Toshiaki Ohara, Kazuhiro Noma, Seishi Nishitani, Shinichiro Watanabe, Yasuko Tomono, Yuuri Hashimoto, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   72   2012.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2012-2323

    Web of Science

    researchmap

  • Inhibitory effect of oncolytic adenovirus on transforming growth factor-beta-induced epithelial-mesenchymal transition in human cancer cells

    Yuuri Hashimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   72   2012.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2012-343

    Web of Science

    researchmap

  • Ataxia-Telangiectasia Mutated and the Mre11-Rad50-NBS1 Complex: Promising Targets for Radiosensitization

    Shinji Kuroda, Yasuo Urata, Toshiyoshi Fujiwara

    ACTA MEDICA OKAYAMA   66 ( 2 )   83 - 92   2012.4

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.   Publisher:OKAYAMA UNIV MED SCHOOL  

    Radiotherapy plays a central part in cancer treatment, and use of radiosensitizing agents can greatly enhance this modality. Although studies have shown that several chemotherapeutic agents have the potential to increase the radiosensitivity of tumor cells, investigators have also studied a number of molecularly targeted agents as radiosensitizers in clinical trials based on reasonably promising preclinical data. Recent intense research into the DNA damage-signaling pathway revealed that ataxia-telangiectasia mutated (ATM) and the Mre11-Rad50-NBS1 (MRN) complex play central roles in DNA repair and cell cycle checkpoints and that these molecules are promising targets for radiosensitization. Researchers recently developed three ATM inhibitors (KU-55913, CGK733, and CP466722) and an MRN complex inhibitor (mirin) and showed that they have great potential as radiosensitizers of tumors in preclinical studies. Additionally, we showed that a telomerase-dependent oncolytic adenovirus that we developed (OBP-301 [telomelysin]) produces profound radiosensitizing effects by inhibiting the MRN complex via the adenoviral E1B55kDa protein. A recent Phase I trial in the United States determined that telomelysin was safe and well tolerated in humans, and this agent is about to be tested in combination with radiotherapy in a clinical trial based on intriguing preclinical data demonstrating that telomelysin and ionizing radiation can potentiate each other. In this review, we highlight the great potential of ATM and MRN complex inhibitors, including telomelysin, as radiosensitizing agents.

    DOI: 10.18926/AMO/48258

    Web of Science

    researchmap

  • Preventive Effect of Omental Flap in Pancreaticoduodenectomy against Postoperative Pseudoaneurysm Formation

    Hiroaki Matsuda, Hiroshi Sadamori, Yuzo Umeda, Susumu Shinoura, Ryuichi Yoshida, Daisuke Satoh, Masashi Utsumi, Takahito Yagi, Toshiyoshi Fujiwara

    HEPATO-GASTROENTEROLOGY   59 ( 114 )   578 - 583   2012.3

     More details

    Language:English   Publisher:H G E UPDATE MEDICAL PUBLISHING S A  

    Background/Aims: An omental flap covering the splanchnic vessels might reduce postoperative intra-abdominal hemorrhage after pancreaticoduodenectomy. However, the efficiency of such a procedure remains to be verified. The purpose of this study was to determine the effect of mental flap placement in pancreaticoduodenectomy on the incidence of postoperative pseudoaneurysms. Methodology: Of 229 consecutive patients who underwent pancreaticoduodenectomy, the most recent 157 patients received the omental flap, while the initial 72 patients had no omental flap placement. Various preoperative factors were considered in the evaluation (age, gender, body mass index, primary disease and concurrent disease), as well as operative factors (operation time, blood loss, operative procedures, pancreatic texture, size of pancreatic duct and surgeon's experience). Results: Eighty-one patients (35.4%) developed pancreatic fistula. Nine patients (3.9%) developed postoperative pseudoaneurysm. Among the patients with pancreatic fistula, those without omental flap developed pseudoaneurysms more frequently (21.7%) than those with omental flap placement (5.2%). Multivariate analysis identified pancreatic fistula, no use of mental flap and hypertension, in that order, as predisposing factors for a pseudoaneurysm. The omental flap significantly prevented pseudoaneurysms (p=0.021; OR=0.151; 95% CI, 0.030-0.751). Conclusions: Omental flap placement over splanchnic vessels could be a feasible and efficient surgical procedure to prevent postoperative pseudoaneurysms following pancreaticoduodenectomy.

    DOI: 10.5754/hge11452

    Web of Science

    researchmap

  • Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes

    Daisuke Nobuoka, Yutaka Motomura, Hirofumi Shirakawa, Toshiaki Yoshikawa, Toshimitsu Kuronuma, Mari Takahashi, Kohei Nakachi, Hiroshi Ishii, Junji Furuse, Naoto Gotohda, Shinichiro Takahashi, Toshio Nakagohri, Masaru Konishi, Taira Kinoshita, Hiroyuki Komori, Hideo Baba, Toshiyoshi Fujiwara, Tetsuya Nakatsura

    INTERNATIONAL JOURNAL OF ONCOLOGY   40 ( 1 )   63 - 70   2012.1

     More details

    Language:English   Publisher:SPANDIDOS PUBL LTD  

    Glypican-3 (GPC3), a carcinoembryonic antigen, is an ideal target for anticancer immunotherapy against hepatocellular carcinoma (HCC). In this study, we attempted to compare the induction of the GPC3-specific T-cell-mediated immune response after locoregional therapies in HCC patients and tumor-bearing mice. Twenty-seven HCC patients treated with locoregional therapies, including radiofrequency ablation (RFA), surgical resection and transcatheter arterial chemoembolization (TACE), were prospectively enrolled in this study. Additionally, we performed RFA experiments using a mouse model. GPC3-specific T-cell response was investigated pretreatment and post-treatment by an interferon-gamma enzyme-linked immunospot assay using peripheral blood mononuclear cells from HCC patients and lymph node cells from tumor-bearing mice. Circulating GPC3-specific cytotoxic T lymphocytes (CTLs) were increased in 5 of 9 patients after RFA and in 4 of 9 patients after TACE, but in only 1 of 9 patients after surgical resection. All 7 patients with GPC3-expressing HCCs exhibited an increase in GPC3-specific CTLs after RFA or TACE, whereas none of the 7 patients did after surgical resection. The number of increased GPC3-specific CTLs after RFA was significantly larger than that after surgical resection (P=0.023). Similarly, the frequency of GPC3-specific CTLs after RFA was significantly greater than that after surgical resection in the mouse model (P=0.049). We validated for the first time the stronger effect on the immune system brought by RFA compared with surgical resection for HCC patients and tumor-bearing mice. Combined treatment of RFA and immunotherapy is a reasonable strategy against HCC.

    DOI: 10.3892/ijo.2011.1202

    Web of Science

    researchmap

  • 胃癌術後脊椎転移による横断性脊髄障害を呈した1例.

    河野藍子, 香川俊輔, 岸本浩行, 宇野 太, 西崎正彦, 大岩雅彦, 藤原俊義

    癌と化学療法   39 ( 12 )   2357 - 2359   2012

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    症例は45歳、男性。心窩部痛・体重減少を主訴に発見された進行胃癌に対して幽門側胃切除術、D2、Roux-en Y再建を行い、術後診断はpT4aN3bCY1、stage IVであった。術後S-1による化学療法を施行中、術後3ヵ月に背部痛が出現した。PET-CTではTh4-6の骨転移を指摘された。直ちに骨転移に対し放射線療法を開始したが、第5治療日より脊髄横断症状を呈し座位保持も不能となった。その後、癒着性の小腸イレウスが発症し小腸部分切除術を施行することとなり、同時に直腸肛門機能低下による排便困難に対しS状結腸ストーマ造設を併施した。その結果、排便の自己管理が可能になり、さらに放射線治療の完遂ならびに、その後の化学療法と緩和治療が在宅で可能であった。胃癌の骨転移はまれであるが、その予後は極めて不良である。胃癌の骨転移の特徴・対策を知り、早期診断と集学的治療は重要であり、本症例の経験に文献的考察を加え報告する。(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2012&ichushi_jid=J00296&link_issn=&doc_id=20121206360200&doc_link_id=%2Fab8gtkrc%2F2012%2F003912%2F200%2F2357-2359%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2012%2F003912%2F200%2F2357-2359%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • Gastric aberrant pancreas with acute pancreatitis treated with surgery

    124 ( 1 )   59 - 62   2012

  • Pathological complete response of advanced gastric cancer with pyloric stenosis to neoadjuvant S-1/CDDP chemotherapy : A case report

    124 ( 1 )   63 - 66   2012

  • Intractable Bile Leakage after Hepatectomy for Hepatocellular Carcinoma in 359 Recent Cases

    Hiroshi Sadamori, Takahito Yagi, Hiroaki Matsuda, Susumu Shinoura, Yuzo Umeda, Toshiyoshi Fujiwara

    DIGESTIVE SURGERY   29 ( 2 )   149 - 156   2012

     More details

    Language:English   Publisher:KARGER  

    Background/Aims: Bile leakage is still a common cause of major morbidity after hepatectomy for hepatocellular carcinoma (HCC). The purpose of this study was to identify characteristics and risk factors for intractable bile leakage after hepatectomy for HCC. Methods: Risk factors for bile leakage were analyzed in 359 patients who underwent hepatectomy for HCC between 2001 and 2010. The causes, management and outcomes of intractable bile leakage which needed endoscopic therapy or percutaneous transhepatic biliary drainage were investigated. Results: A total of 296 patients (82.5%) underwent an anatomic hepatectomy, and a repeat hepatectomy was carried out in 59 patients (16.4%). The prevalence of bile leakage was 12.8%, and 8 patients had intractable bile leakage. An operative time &gt;= 300 min was an independent risk factor for bile leakage after hepatectomy for HCC. The main causes of intractable bile leakage were a latent stricture of the biliary anatomy caused by previous treatments for HCC and intraoperative injury of the hepatic duct related to repeat hepatectomy. Conclusion: To help prevent intractable bile leakage, a preoperative assessment of the biliary anatomy and surgical procedures to decrease the incidence of major bile leakage should be considered for selected patients with a high risk for intractable bile leakage. Copyright (c) 2012 S. Karger AG, Basel

    DOI: 10.1159/000337313

    Web of Science

    researchmap

  • 大学病院におけるrobotic surgery導入の経験.

    香川俊輔, 西崎正彦, 宇野 太, 岸本浩行, 藤原俊義

    外科   74 ( 8 )   809 - 812   2012

     More details

  • A case of esophageal carcinosarcoma with a component of small cell carcinoma

    Tanabe Shunsuke, Fujiwara Toshiyoshi, Shirakawa Yasuhiro, Maeda Naoaki, Ohara Toshiaki, Noma Kazuhiro, Sakurama Kazufumi, Yanai Hiroyuki, Yamatsuji Tomoki, Naomoto Yoshio

    Okayama Igakkai Zasshi (Journal of Okayama Medical Association)   124 ( 2 )   145 - 148   2012

     More details

    Language:Japanese   Publisher:Okayama Medical Association  

    We experienced a case of esophageal carcinosarcoma with a component of small cell carcinoma. The patient was a 73-year-old man. We administered chemotherapy of CDDP+VP-16, and performed an operation after 2 courses of this chemotherapy. Subtotal esophagectomy and reconstruction with the small intestine was performed. More than three years after resection, he remains alive and recurrence-free. There are few cases of esophageal carcinosarcoma and small cell carcinoma. We report this rare case herein.

    DOI: 10.4044/joma.124.145

    CiNii Article

    researchmap

  • 胃癌術後腹膜播種による十二指腸閉塞に対して内視鏡的ステント留置術が奏効した1例.

    大岩雅彦, 香川俊輔, 岸本浩行, 宇野 太, 西崎正彦, 河野藍子, 藤原俊義

    癌と化学療法   39 ( 12 )   2372 - 2374   2012

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    症例は79歳、男性。十二指腸潰瘍の手術既往による残胃の吻合部に残胃癌を指摘され、残胃部分切除・Roux-en-Y再建を行った。術後Treitz靱帯近傍に再発腫瘍を指摘され、化学療法を施行中に腸閉塞症状が出現した。CTで十二指腸の著明な拡張を認め、既知の再発腫瘍によるY脚部の通過障害と診断した。閉塞部位が一ヶ所であったことから、ダブルバルーン小腸内視鏡を用い狭窄部にステントを留置した。ステント留置後腸閉塞は解除され、経口摂取と化学療法の再開が可能となった。近年普及してきたダブルバルーン内視鏡により従来困難であったRoux-en-Y再建後の十二指腸側Y脚へのアプローチが可能となった。本症例では狭窄部へのステント留置により手術を回避し得たことから、緩和治療として悪性腸閉塞症治療の1選択肢になり得ると考え報告する。(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2012&ichushi_jid=J00296&link_issn=&doc_id=20121206360205&doc_link_id=%2Fab8gtkrc%2F2012%2F003912%2F205%2F2372-2374%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2012%2F003912%2F205%2F2372-2374%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • A telomerase-specific oncolytic virotherapy for gastric cancer stem cells

    KAGAWA Shunsuke, YANO Shuya, FUJIWARA Toshiyoshi

    Cytometry Research   22 ( 2 )   21 - 25   2012

     More details

    Language:Japanese   Publisher:Japan Cytometry Society  

    <p>Since cancer stem cells show their resistance to chemo- and radiotherapy, they are thought to be correlated with the treatment resistance of many cancers, and thus help explain recurrence and advanced disease. Here, we examined the therapeutic effect of a genetically engineered telomerase specific oncolytic adenovirus, Telomelysin, (OBP-301) against cancer stem cells. OBP-301 killed CD133+ human gastric cancer, which have a stem cell-like phenotype, more efficiently than conventional therapies. Visualization of cell-cycle behavior in living cells by Fucci showed that tumor spheres of CD133+ cells maintained a G0/G1 state, and that OBP-301 then killed them through virus-induced S phase transition. Mobilization of quiescent CSCs may sensitize them to cell death signals.</p>

    DOI: 10.18947/cytometryresearch.22.2_21

    CiNii Article

    CiNii Books

    researchmap

  • 当科における咽頭喉頭食道全摘症例の検討

    田辺俊介, 白川靖博, 青山克幸, 前田直見, 大原利章, 櫻間教文, 野間和広, 藤原俊義

    General Thoracic and Cardiovascular Surgery   60 ( Supplement )   2012

  • 食道癌における除鉄による遊走,浸潤能抑制作用の検討

    浦野真一, 大原利章, 前田直見, 渡辺伸一郎, 田辺俊介, 野間和広, 友野靖子, 白川康博, 木村文昭, 藤原俊義

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   36th   2012

  • 腹部食道癌に対して左開胸開腹連続切開および観音開き法食道残胃吻合を行った1症例

    野間和広, 白川靖博, 青山克幸, 前田直見, 大原利章, 田辺俊介, 西崎正彦, 香川俊輔, 藤原俊義

    General Thoracic and Cardiovascular Surgery   60 ( Supplement )   2012

  • 当院でのPERIOによる胸部食道癌周術期管理の取り組みについての検討

    白川靖博, 青山克幸, 前田直見, 田辺俊介, 大原利章, 野間和広, 櫻間教文, 藤原俊義

    General Thoracic and Cardiovascular Surgery   60 ( Supplement )   2012

  • アカデミアにおける探索的医薬品開発の方向性 -国産ウイルス製剤の米国での臨床試験への道程-.

    藤原俊義

    薬理と治療   40 ( 4 )   303 - 304   2012

     More details

  • 食事・栄養指導 1前編.

    田辺俊介, 宇野 太, 近藤喜太, 藤原俊義

    消化器外科NURSING   17 ( 8 )   82 - 85   2012

     More details

  • Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas

    124 ( 2 )   105 - 110   2012

     More details

  • 糞便を用いた大腸がんの遺伝子診断(2)~便中メチル化CpG検出による大腸がんスクリーニング~.

    永坂岳司, 藤原俊義

    大腸癌Frontier   5   50 - 57   2012

     More details

  • 特集:最新の疾患バイオマーカー研究 大腸がん.

    永坂岳司, 母里淑子, 楳田祐三, 藤原俊義

    日本臨床   70 ( 5 )   802 - 807   2012

     More details

  • 糖尿病における移植療法の現状.

    野口洋文, 藤原俊義

    岡山医学会雑誌   124 ( 3 )   249 - 252   2012

  • 頸胸境界部進行食道癌に対するDoor open法によるアプローチ

    山辻知樹, 木下真一郎, 山田貴子, 高岡宗徳, 深澤拓也, 林次郎, 繁光薫, 吉田和弘, 森田一郎, 田邉俊介, 藤原康宏, 野間和広, 櫻間教文, 白川靖博, 松岡順治, 藤原俊義, 羽井佐実, 猶本良夫

    日本外科学会雑誌   113   2012

  • 当院における胃上部早期胃癌に対する噴門側胃切除・食道残胃吻合術の検討

    宇野太, 香川俊輔, 西崎正彦, 岸本浩行, 白川靖博, 永坂岳司, 野間和広, 田邊俊介, 合地明, 藤原俊義

    日本消化器外科学会雑誌(Web)   45 ( Supplement1 )   2012

  • パラチノースを主糖質源とした調整流動食MHN-01による食道癌周術期管理の有用性-基礎実験から臨床研究まで-

    山辻知樹, 平林葉子, 高岡宗徳, 林次郎, 深澤拓也, 繁光薫, 吉田和弘, 大原利章, 田辺俊介, 野間和広, 白川靖博, 藤原俊義, 中島一毅, 森田一郎, 猶本良夫

    General Thoracic and Cardiovascular Surgery   60 ( Supplement )   2012

  • 心房中隔欠損症による肺高血圧症を合併した食道癌切除の経験

    大原利章, 白川靖博, 青山克幸, 前田直見, 田辺俊介, 野間和広, 藤原俊義

    General Thoracic and Cardiovascular Surgery   60 ( Supplement )   2012

  • F-18 FDG PET/CT Contributes to More Accurate Detection of Lymph Nodal Metastasis From Actively Proliferating Esophageal Squamous Cell Carcinoma

    Shunsuke Tanabe, Yoshio Naomoto, Yasuhiro Shirakawa, Yasuhiro Fujiwara, Kazufumi Sakurama, Kazuhiro Noma, Munenori Takaoka, Tomoki Yamatsuji, Takao Hiraki, Yoshihiro Okumura, Masahiko Mitani, Mitsumasa Kaji, Susumu Kanazawa, Toshiyoshi Fujiwara

    CLINICAL NUCLEAR MEDICINE   36 ( 10 )   854 - 859   2011.10

     More details

    Language:English   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Purpose: Evaluating the status of disease progression is critical for planning a therapeutic strategy for esophageal cancer. In this regard, F-18 fluorodeoxyglucose-labeled positron emission tomography (PET) is one of the most useful diagnostic modalities. However, there is room to improve its diagnostic performance, such as distinguishing lymph nodal metastases from false positives. In this study, we examined the diagnostic accuracy of fluorodeoxyglucose PET accompanied by computed tomography imaging (PET/CT) to detect regional lymph nodal metastasis from esophageal squamous cell carcinoma (ESCC).
    Methods: A total of 102 patients diagnosed as ESCC were subjected to this study. These patients had a preoperative PET/CT examination to evaluate the existence of metastasis. The values of maximum standardized uptake value (SUVmax) in primary tumors and in metastasized lymph nodes were measured to analyze their relationship with various clinicopathologic characteristics including the status of tumor cell proliferation, which was assessed by immunohistochemistry for Ki-67.
    Results: The SUVmax of the primary tumor was positively correlated with tumor size and vessel invasion, and was positively related with the SUVmax of lymph nodal metastasis, especially in cases of poorly differentiated ESCC. The SUVmax of metastasized lymph nodes was higher in larger-sized metastasized lymph nodes, whereas the Ki-labeling index of lymph nodal metastasis was positively related with the SUVmax per unit area (SUVmax/mm(2)). The diagnostic accuracy of PET/CT (87.3%) was higher than that of conventional CT scans (78.4%).
    Conclusions: The improved diagnostic accuracy of PET/CT can be explained by its ability to detect actively progressive metastasis at an early phase regardless of size.

    DOI: 10.1097/RLU.0b013e318217adc9

    Web of Science

    researchmap

  • 当院における頭頸部癌・食道癌領域におけるPEGの適応と現状

    田辺 俊介, 白川 靖博, 野間 和広, 前田 直見, 大原 利章, 櫻間 教文, 浅野 博昭, 岸本 浩行, 宇野 太, 西崎 正彦, 佃 和憲, 香川 俊輔, 藤原 俊義, 小野田 友男, 勝井 邦彰, 片山 敬久, 吉尾 浩太郎, 武本 充広

    Gastroenterological Endoscopy   53 ( Suppl.2 )   2784 - 2784   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • Tumor-selective adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection

    Hiroyuki Kishimoto, Ryoichi Aki, Yasuo Urata, Michael Bouvet, Masashi Momiyama, Noriaki Tanaka, Toshiyoshi Fujiwara, Robert M. Hoffman

    CELL CYCLE   10 ( 16 )   2737 - 2741   2011.8

     More details

    Language:English   Publisher:LANDES BIOSCIENCE  

    We have previously developed a telomerase-specific replicating adenovirus expressing GFP (OBP-401), which can selectively label tumors in vivo with GFP. Intraperitoneal (i.p.) injection of OBP-401 specifically labeled peritoneal tumors with GFP, enabling fluorescence visualization of the disseminated disease and real-time fluorescence surgical navigation. However, technical problems of removing all cancer cells still remain, even with fluorescence-guided surgery. In this study, we report that in vivo OBP-401 labeling of tumors with GFP before fluorescence-guided surgery reports cancer recurrence after surgery. Recurrent tumor nodules brightly expressed GFP, indicating that initial OBP-401-GFP labeling of peritoneal disease was genetically stable such that proliferating residual cancer cells still express GFP. In situ tumor labeling with a genetic reporter has important advantages over antibody and other non-genetic labeling of tumors, since residual disease remains labeled during recurrence and can be further resected under fluorescence guidance.

    DOI: 10.4161/cc.10.16.16756

    Web of Science

    researchmap

  • 末梢型と肝門型肝内胆管癌における術式の検討

    佐藤 太祐, 楳田 祐三, 貞森 裕, 松田 浩明, 篠浦 先, 吉田 龍一, 内海 方嗣, 杭瀬 崇, 菊池 寛次, 八木 孝仁, 藤原 俊義

    岡山医学会雑誌   123 ( 2 )   168 - 168   2011.8

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells

    Toshiaki Ohara, Munenori Takaoka, Shinichi Toyooka, Yasuko Tomono, Toshio Nishikawa, Yasuhiro Shirakawa, Tomoki Yamatsuji, Noriaki Tanaka, Toshiyoshi Fujiwara, Yoshio Naomoto

    CANCER SCIENCE   102 ( 7 )   1344 - 1349   2011.7

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    Temsirolimus (CCI-779), a recently synthesized analogue of rapamycin, specifically inhibits mTOR and has been approved for clinical use in renal cell carcinoma. Recent reports have indicated the growth inhibitory effect of temsirolimus in some cancers including non-small-cell lung carcinoma (NSCLC). In this study, we aimed to explore the potential therapeutic use of temsirolimus as a treatment for NSCLC. Using cultured NSCLC cells (A549, H1299, and H358), we determined the effect of temsirolimus on cell proliferation and its antitumor effects on subcutaneous tumors, as well as its contribution to the survival of mice having pleural dissemination of cancer cells, mimicking advanced NSCLC. Temsirolimus suppressed proliferation of NSCLC cells in a dose-dependent manner, with an IC(50) of &lt; 1 nM. Western blot analysis revealed that temsirolimus treatment specifically inhibited the phosphorylation of mTOR and its downstream effectors in 1 h, accompanied by an increased cell population in the G(0)/G(1) phase, but according to flow cytometry, the cell population did not increase in the sub-G(0) phase. When NSCLC subcutaneous tumor-bearing mice were treated with temsirolimus, tumor volume was significantly reduced (tumor volume on day 35: vehicle vs temsirolimus = 1239 vs 698 cm(3); P &lt; 0.05). Furthermore, prolonged survival was observed in pleural disseminated tumor-bearing mice with temsirolimus treatment (median survival: vehicle vs temsirolimus = 53.5 vs 72.5 days; P &lt; 0.05). These results suggest that temsirolimus could be useful for NSCLC treatment, due to its antiproliferative effect, and could be a potential treatment for advanced NSCLC, giving prolonged survival. (Cancer Sci 2011; 102: 1344-1349)

    DOI: 10.1111/j.1349-7006.2011.01967.x

    Web of Science

    researchmap

  • 高度脈管侵襲を伴う肝細胞癌に対する治療戦略 高度脈管侵襲肝癌に対する治療戦略 Vp3/4、Vv2/3進行肝癌の治療成績

    杭瀬 崇, 楳田 祐三, 貞森 裕, 松田 浩明, 篠浦 先, 吉田 龍一, 佐藤 太祐, 内海 方嗣, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   66回   200 - 200   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 当院で切除した膵内分泌腫瘍に対する治療成績

    内海 方嗣, 松田 浩明, 杭瀬 崇, 佐藤 太祐, 吉田 龍一, 楳田 祐三, 篠浦 先, 貞森 裕, 八木 孝仁, 藤原 俊義

    日本消化器外科学会総会   66回   314 - 314   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus

    Guidong Li, Hiroyuki Kawashima, Akira Ogose, Takashi Ariizumi, Yongjun Xu, Tetsuo Hotta, Yasuo Urata, Toshiyoshi Fujiwara, Naoto Endo

    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY   137 ( 6 )   1037 - 1051   2011.6

     More details

    Language:English   Publisher:SPRINGER  

    A telomerase-specific oncolytic adenovirus, Telomelysin, can selectively kill cancer cells, and be attenuated in normal cells. We herein describe the oncolytic effect of Telomelysin on human osteosarcoma both in vitro and in vivo.
    The anti-tumor effects of Telomelysin were evaluated on human osteosarcoma cell lines in vitro and in a mouse xenograft model of human osteosarcoma in vivo. The replication efficiencies of Telomelysin in human osteosarcoma cell lines and normal cell lines and in osteosarcoma xenografts were determined by the expression levels of E1 mRNA and E1A protein using real-time quantitative PCR, Western blot analysis and immunohistochemistry. The in vitro telomerase-specific replication and the viral infection rate were also confirmed by TelomeScan (Telomelysin-GFP), using fluorescent microscopy and flow cytometry, respectively. The cell viabilities were examined by XTT assay, and the tumor volumes were measured every 2 days. The induction of apoptosis was assessed by Western blot analysis, as well as by TUNEL assay.
    TelomeScan and Telomelysin were efficiently replicated in human osteosarcoma cell lines and led to a dose- and time-dependent expression of GFP, E1 mRNA and E1A protein. Telomelysin infection induced marked cytolysis and apoptosis in osteosarcoma cell lines in vitro. Neither cytotoxicity nor apoptosis were induced in normal human cell lines. In the human osteosarcoma cell xenograft model, intratumoral injection of Telomelysin resulted in increased viral replication, significant tumor growth suppression and distinct apoptotic cell death.
    This study indicated that virotherapy with Telomelysin may provide a promising strategy for the treatment of human osteosarcoma.

    DOI: 10.1007/s00432-010-0969-6

    Web of Science

    researchmap

  • IS-9-3 Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2 extracellular domain in breast cancer cells(IS-9 Translational research in breast cancer treatment)

    Yoshida Ryosuke

    Journal of Japan Surgical Society   112 ( 1 )   202 - 202   2011.5

     More details

    Language:English   Publisher:Japan Surgical Society (JSS)  

    CiNii Article

    CiNii Books

    researchmap

  • PS-091-7 腹膜播種を伴う進行・再発胃癌患者を対象としたDocetaxelとS-1の併用化学療法の検討(臨床第II相試験)(PS-091 ポスターセッション(91)胃:化学療法-3,第111回日本外科学会定期学術集会)

    宇野 太, 香川 俊輔, 西崎 正彦, 合地 明, 木村 臣一, 高畑 隆臣, 野中 泰幸, 二宮 基樹, 藤原 俊義

    日本外科学会雑誌   112 ( 1 )   663 - 663   2011.5

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Enhanced Safety Profiles of the Telomerase-Specific Replication-Competent Adenovirus by Incorporation of Normal Cell-Specific microRNA-Targeted Sequences

    Kumiko Sugio, Fuminori Sakurai, Kazufumi Katayama, Katsuhisa Tashiro, Hayato Matsui, Kenji Kawabata, Atsushi Kawase, Masahiro Iwaki, Takao Hayakawa, Toshiyoshi Fujiwara, Hiroyuki Mizuguchi

    CLINICAL CANCER RESEARCH   17 ( 9 )   2807 - 2818   2011.5

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Purpose: Oncolytic adenoviruses (Ad) have been actively pursued as potential agents for cancer treatment. Among the various types of oncolytic Ads, the telomerase-specific replication-competent Ad (TRAD), which possesses an E1 gene expression cassette driven by the human telomerase reverse transcriptase promoter, has shown promising results in human clinical trials; however, the E1 gene is also slightly expressed in normal cells, leading to replication of TRAD and cellular toxicity in normal cells.
    Experimental Design: To overcome this problem, we utilized a microRNA (miRNA)-regulated gene expression system. Four copies of complementary sequences for miR-143, -145, -199a, or let-7a, which have been reported to be exclusively downregulated in tumor cells, were incorporated into the 3&apos;-untranslated region of the E1 gene expression cassette.
    Results: Among the TRAD variants (herein called TRADs) constructed, TRADs containing the sequences complementary to miR-143, -145, or -199a showed efficient oncolytic activity comparable to the parental TRAD in the tumor cells. On the other hand, replication of the TRADs containing the miRNA complementary sequences was at most 1,000-fold suppressed in the normal cells, including primary normal cells. In addition, to suppress the replication of the TRADs in hepatocytes as well as other normal cells, we constructed a TRAD containing 2 distinct complementary sequences for miR-199a and liver-specific miR-122a (TRAD-122a/199aT). TRAD-122a/199aT exhibited more than 10-fold reduction in viral replication in all the normal cells examined, including primary hepatocytes.
    Conclusions: This study showed that oncolytic Ads containing the sequences complementary to normal cell-specific miRNAs showed significantly improved safety profiles without altering tumor cell lysis activity. Clin Cancer Res; 17(9); 2807-18. (C)2011 AACR.

    DOI: 10.1158/1078-0432.CCR-10-2008

    Web of Science

    researchmap

  • 再発肝細胞癌の治療方針 再肝切除・RFAの有効性とSalvage transplantation導入の見極め

    楳田 祐三, 八木 孝仁, 貞森 裕, 松田 浩明, 篠浦 先, 吉田 龍一, 佐藤 太祐, 内海 方嗣, 杭瀬 崇, 藤原 俊義

    日本外科学会雑誌   112 ( 臨増1-2 )   356 - 356   2011.5

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 大腸癌肝転移の外科的治療戦略 術前・術後化学療法の意義と問題点

    杭瀬 崇, 楳田 祐三, 貞森 裕, 松田 浩明, 篠浦 先, 吉田 龍一, 佐藤 太祐, 内海 方嗣, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   112 ( 臨増1-2 )   360 - 360   2011.5

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer

    Toshiyoshi Fujiwara, Yasuhiro Shirakawa, Shunsuke Kagawa

    EXPERT REVIEW OF ANTICANCER THERAPY   11 ( 4 )   525 - 532   2011.4

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.   Publisher:EXPERT REVIEWS  

    Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Human telomerase is highly active in more than 85% of primary cancers, regardless of their tissue origins, and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. We constructed an attenuated adenovirus 5 vector (OBP-301), in which the hTERT promoter element drives the expression of El genes. Since only tumor cells that express telomerase activity are able to activate this promoter, the hTERT proximal promoter allows for preferential expression of viral genes in tumor cells, leading to selective viral replication and oncolytic cell death. Lymphatic invasion is a major route for cancer cell dissemination, and adequate treatment of locoregional lymph nodes is required for curative treatment in patients with gastrointestinal tumors. In this article we show that intratumoral injection of OBP-301 mediates effective in vivo purging of metastatic tumor cells from regional lymph nodes, which may help optimize treatment of human gastrointestinal malignancies.

    DOI: 10.1586/ERA.10.200

    Web of Science

    researchmap

  • Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2 extracellular domain in human breast cancer cells

    Ryosuke Yoshida, Hiroshi Tazawa, Yuuri Hashimoto, Futoshi Uno, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   71   2011.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2011-720

    Web of Science

    researchmap

  • 大腸癌肝転移の外科治療 術前・術後化学療法の効果

    杭瀬 崇, 楳田 祐三, 貞森 裕, 松田 浩明, 篠浦 先, 吉田 龍一, 佐藤 太祐, 内海 方嗣, 八木 孝仁, 藤原 俊義

    岡山医学会雑誌   123 ( 1 )   76 - 76   2011.4

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • 手術手技 膵頭十二指腸切除術における血管床に対する大網弁被覆の意義

    松田 浩明, 八木 孝仁, 藤原 俊義

    手術   65 ( 3 )   349 - 352   2011.3

     More details

    Language:Japanese   Publisher:金原出版  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2011144668

  • Glutamine depletion induces murine neonatal melena with increased apoptosis of the intestinal epithelium

    Takayuki Motoki, Yoshio Naomoto, Junji Hoshiba, Yasuhiro Shirakawa, Tomoki Yamatsuji, Junji Matsuoka, Munenori Takaoka, Yasuko Tomono, Yasuhiro Fujiwara, Hiroshi Tsuchita, Mehmet Gunduz, Hitoshi Nagatsuka, Noriaki Tanaka, Toshiyoshi Fujiwara

    WORLD JOURNAL OF GASTROENTEROLOGY   17 ( 6 )   717 - 726   2011.2

     More details

    Language:English   Publisher:BAISHIDENG PUBLISHING GROUP INC  

    AIM: To investigate the possible biological outcome and effect of glutamine depletion in neonatal mice and rodent intestinal epithelial cells.
    METHODS: We developed three kinds of artificial milk with different amounts of glutamine; Complete amino acid milk (CAM), which is based on maternal mouse milk, glutamine-depleted milk (GDM), and glutaminerich milk (GRM). GRM contains three-fold more glutamine than CAM. Eighty-seven newborn mice were divided into three groups and were fed with either of CAM, GDM, or GRM via a recently improved nipple-bottle system for seven days. After the feeding period, the mice were subjected to macroscopic and microscopic observations by immunohistochemistry for 5-bromo-2'-deoxyuridine (BrdU) and Ki-67 as markers of cell proliferation, and for cleaved-caspase-3 as a marker of apoptosis. Moreover, IEC6 rat intestinal epithelial cells were cultured in different concentrations of glutamine and were subject to a 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate cell proliferation assay, flow cytometry, and western blotting to examine the biological effect of glutamine on cell growth and apoptosis.
    RESULTS: During the feeding period, we found colonic hemorrhage in six of 28 GDM-fed mice (21.4%), but not in the GRM-fed mice, with no differences in body weight gain between each group. Microscopic examination showed destruction of microvilli and the disappearance of glycocalyx of the intestinal wall in the colon epithelial tissues taken from GDM-fed mice. Intake of GDM reduced BrdU incorporation (the average percentage of BrdU-positive staining; GRM: 13.8%, CAM: 10.7%, GDM: 1.14%, GRM vs GDM: P &lt; 0.001, CAM vs GDM: P &lt; 0.001) and Ki-67 labeling index (the average percentage of Ki-67-positive staining; GRM: 24.5%, CAM: 22.4% GDM: 19.4%, GRM vs GDM: P = 0.001, CAM vs GDM: P =0.049), suggesting that glutamine depletion inhibited cell proliferation of intestinal epithelial cells. Glutamine deprivation further caused the deformation of the nuclear membrane and the plasma membrane, accompanied by chromatin degeneration and an absence of fat droplets from the colonic epithelia, indicating that the cells underwent apoptosis. Moreover, immunohistochemical analysis revealed the appearance of cleaved caspase-3 in colonic epithelial cells of GDM-fed mice. Finally, when IEC6 rat intestinal epithelial cells were cultured without glutamine, cell proliferation was significantly suppressed after 24 h (relative cell growth; 4 mmol/L: 100.0% 36.1%, 0 mmol/L: 25.3% 25.0%, P &lt; 0.05), with severe cellular damage. The cells underwent apoptosis, accompanied by increased cell population in sub-GO phase (4 mmol/L: 1.68%, 0.4 mmol/L: 1.35%, 0 mmol/L: 5.21%), where dying cells are supposed to accumulate.
    CONCLUSION: Glutamine is an important alimentary component for the maintenance of intestinal mucosa. Glutamine deprivation can cause instability of the intestinal epithelial alignment by increased apoptosis. (C) 2011 Baishideng. All rights reserved.

    DOI: 10.3748/wjg.v17.i6.717

    Web of Science

    researchmap

  • A Prognostic Model and Treatment Strategy for Intrahepatic Recurrence of Hepatocellular Carcinoma after Curative Resection

    Yuzo Umeda, Hiroaki Matsuda, Hiroshi Sadamori, Hiroyoshi Matsukawa, Takahito Yagi, Toshiyoshi Fujiwara

    WORLD JOURNAL OF SURGERY   35 ( 1 )   170 - 177   2011.1

     More details

    Language:English   Publisher:SPRINGER  

    Background The aim of this study was to evaluate the prognostic factors for intrahepatic recurrence of hepatocellular carcinoma (HCC) after curative resection.
    Methods Of 297 patients with HCC who underwent curative resection between 1998 and 2007, 145 had intrahepatic recurrence, and 125 of these were enrolled in this study. We analyzed the relationships between overall survival after HCC recurrence and 20 variables at initial hepatectomy and recurrence.
    Results Recurrent HCC was treated by repeat hepatectomy (Re-Hr, n = 29), radiofrequency ablation (RFA, n = 58), or transarterial chemoembolization (TAE, n = 38). Complete tumor control (CTC) by Re-He and RFA was selected for 70% of patients. RFA-treated patients had more tumors, smaller tumors, and poorer liver function at recurrence than the Re-Hr group. The overall 1-, 3-, and 5-year post-recurrence survival rates (SR) were 93.1, 66.8, 58.1%; 94.7, 75.1, 48.3%; and 80.1, 22.5, 0%, respectively, in the Re-Hr, RFA, and TAE groups. The SR was better for Re-Hr and RFA than for TAE (p &lt; 0.0001). Outcomes were similar in Re-Hr and RFA, regardless of recurrent tumor size. Multivariate analysis identified Child-Pugh grade B, AFP &gt;= 100 ng/ml at recurrence, recurrent tumor size &gt;= 3 cm, tumor number &gt;= 3, and CTC as significant prognostic factors for overall post-recurrence survival. A scoring system using 1 point for each patient-background factor provided a well-categorized predictive model. The overall 3-/5-year post-recurrence SRs were 83.1/59.3%, 64.1/41.9%, 42.0/18.0%, and 13.6/0% at risk number (R) R0, R1, R2, and R3/4, respectively (p &lt; 0.05).
    Conclusions Significant prognostic factors for intrahepatic recurrent HCC are poor hepatic reserve, AFP, recurrent tumor size and number, and CTC. Selection of treatment modality for intrahepatic recurrence requires the clinician to be mindful of the predictive factors and to control tumors aggressively by adequate treatment, selected by balancing various conditions.

    DOI: 10.1007/s00268-010-0794-8

    Web of Science

    researchmap

  • The 2010 Okayama Medical Association Awards: Radiosensitization by telomerase-dependent oncolytic adenovirus

    Journal of Okayama Medical Association   123 ( 2 )   103 - 109   2011.1

  • Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis.

    Takeda M, Nagasaka T, Dong-Sheng S, Nishie H, Oka T, Yamada E, Mori Y, Shigeyasu K, Morikawa T, Mizobuchi S, Fujiwara T

    Acta Med Okayama   2011

     More details

  • 肝細胞癌に対する肝切除359例における胆汁漏危険因子の解析.

    貞森 裕, 八木孝仁, 松田浩明, 篠浦 先, 楳田祐三, 吉田龍一, 佐藤太祐, 信岡大輔, 内海方嗣, 吉田一博, 藤原俊義

    日本臨床外科学会雑誌   2011

  • Leukoencephalopathy syndrome after living-donor liver transplantation.

    Umeda Y, Matsuda H, Sadamori H, Shinoura S, Yoshida R, Sato D, Utsumi M, Yagi T, Fujiwara T

    Exp Clin Transplant   2011

     More details

  • Surgery for cancers at the esophagogastric junction and Barrett's esophageal cancers.

    Shirakawa Y, Tanabe S, Noma K, Sakurama K, Fujiwara T

    Nihon Rinsho   2011

     More details

  • Prolonged complete response obtained by radiation and chemotherapy with paclitaxel in a case of recurrent gastric cancer in the rectovesical pouch.

    Kanaya N, Kagawa S, Uno F, Kunitomi A, Ogawa N, Fujiwara T

    Gan To Kagaku Ryoho   2011

     More details

  • The usefulness of pre-radiofrequency ablation SUV(max) in 18F-FDG PET/CT to predict the risk of a local recurrence of malignant lung tumors after lung radiofrequency ablation.

    Harada S, Sato S, Suzuki E, Okumura Y, Hiraki T, Gobara H, Mimura H, Kanazawa S, Kaji M, Fujiwara T

    Acta Med Okayama   2011

     More details

  • Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas

    Sasaki T, Tazawa H, Hasei J, Kunisada T, Yoshida A, Hashimoto Y, Yano S, Yoshida R, Uno F, Kagawa S, Morimoto Y, Urata Y, Ozaki T, Fujiwara T

    Clin Cancer Res   2011

  • ハイリスク(特に後期高齢者)食道癌症例に対する手術術式の工夫

    田辺俊介, 白川靖博, 前田直見, 大原利章, 野間和広, 櫻間教文, 藤原俊義

    General Thoracic and Cardiovascular Surgery   59 ( Supplement )   2011

  • 鉄欠乏マウスモデルを用いた血管新生阻害薬併用療法の基礎的検討

    大原利章, 野間和広, 木村文昭, 友野靖子, 西谷正史, 渡辺伸一郎, 藤原俊義

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   35th   2011

  • 放射線療法とPaclitaxel化学療法にて長期CRが得られた胃癌直腸膀胱窩再発の1例

    金谷信彦, 香川俊輔, 宇野太, 國富彩, 小川誠之, 藤原俊義

    癌と化学療法   38 ( 12 )   2100 - 2102   2011

     More details

  • センチンネルリンパ節ナビゲーション手術

    がん治療レクチャー:新しい手術のモダリティー   2   788 - 792   2011

     More details

  • 腹腔鏡補助下噴門側胃切除術;観音開き法食道残胃吻合

    消化器外科   34   1687 - 1697   2011

     More details

  • 食道癌周術期管理における多職種スタッフ介入の効果

    白川靖博, 田辺 俊介, 野間 和広, 櫻間 教文, 山辻 知樹, 羽井 佐実, 猶本 良夫, 伊藤 真理, 足羽 孝子, 藤原 俊義

    日外会誌   112   520 - 520   2011

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 胃がん (新しい手術のモダリティ) -- (最新の外科治療総論 : アプローチを中心に)

    西﨑 正彦, 香川 俊輔, 藤原 俊義

    がん治療レクチャー : チーム医療のための   2 ( 4 )   788 - 792   2011

     More details

    Language:Japanese   Publisher:総合医学社  

    CiNii Article

    CiNii Books

    researchmap

  • 高齢者食道癌症例に対する外科治療の現況と成績

    田邊俊介, 白川靖博, 横道直佑, 野間和広, 櫻間教文, 山辻知樹, 羽井佐実, 猶本良夫, 藤原俊義

    日本消化器外科学会雑誌(Web)   44 ( Supplement1 )   2011

  • 食道癌術後患者における基礎代謝量および影響を及ぼす因子の検討

    西川みか, 櫻間教文, 栢下淳, 田邊俊介, 野間和広, 白川靖博, 藤原俊義

    日本食道学会学術集会プログラム・抄録集   65th   2011

  • 当院消化器外科領域におけるRobotic Surgeryの現状

    西崎正彦, 近藤喜太, 田邊俊介, 野間和広, 岸本浩行, 宇野太, 永坂岳司, 香川俊輔, 白川靖弘, 藤原俊義

    日本臨床外科学会雑誌   72   2011

  • まれなBRAF変異-1799-1801(TGA)塩基の欠失(VK600-601E変異)を認めた大腸癌患者の臨床的特徴

    母里淑子, 永坂岳司, 藤原俊義

    日本臨床腫瘍学会学術集会プログラム・抄録集   9th   2011

  • 遺伝子情報に基づいた大腸がん個別化治療へ : KRAS/BRAF/MSI

    永坂 岳司, 近藤 喜太, 藤原 俊義

    ファルマシア   46 ( 12 )   1120 - 1124   2010.12

     More details

    Language:Japanese   Publisher:公益社団法人日本薬学会  

    CiNii Article

    CiNii Books

    researchmap

  • PRECLINICAL STUDY OF TELOMERASE-SELECTIVE ONCOLYTIC ADENOVIRUS (OBP-301) IN COMBINATION WITH CHEMOTHERAPEUTIC AGENT AND RADIATION

    Hiroshi Tazawa, Yuuri Hashimoto, Shinji Kuroda, Yasuo Urata, Toshiyoshi Fujiwara

    JOURNAL OF GENE MEDICINE   12 ( 12 )   1035 - 1036   2010.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:JOHN WILEY & SONS LTD  

    Web of Science

    researchmap

  • 進行膵頭部癌に対する手術治療戦略

    横道 直佑, 楳田 祐三, 松田 浩明, 貞森 裕, 篠浦 先, 吉田 龍一, 佐藤 太祐, 内海 方嗣, 杭瀬 崇, 八木 孝仁, 藤原 俊義

    日本臨床外科学会雑誌   71 ( 増刊 )   705 - 705   2010.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • WS-1-7 テロメラーゼ活性を標的とするウイルス製剤の癌診断・治療への応用(癌治療向上のためのtranslational research,ワークショップ(1),第110回日本外科学会定期学術集会)

    藤原 俊義

    日本外科学会雑誌   111 ( 2 )   157 - 157   2010.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors

    John Nemunaitis, Alex W. Tong, Michael Nemunaitis, Neil Senzer, Anagha P. Phadke, Cynthia Bedell, Ned Adams, Yu-An Zhang, Phillip B. Maples, Salina Chen, Beena Pappen, James Burke, Daiju Ichimaru, Yasuo Urata, Toshiyoshi Fujiwara

    MOLECULAR THERAPY   18 ( 2 )   429 - 434   2010.2

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    A phase I clinical trial was conducted to determine the clinical safety of Telomelysin, a human telomerase reverse transcriptase (hTERT) promoter driven modified oncolytic adenovirus, in patients with advanced solid tumors. A single intratumoral injection (IT) of Telomelysin was administered to three cohorts of patients (1 x 10(10), 1 x 10(11), 1 x 10(12) viral particles). Safety, response and pharmacodynamics were evaluated. Sixteen patients with a variety of solid tumors were enrolled. IT of Telomelysin was well tolerated at all dose levels. Common grade 1 and 2 toxicities included injection site reactions (pain, induration) and systemic reactions (fever, chills). hTERT expression was demonstrated at biopsy in 9 of 12 patients. Viral DNA was transiently detected in plasma in 13 of 16 patients. Viral DNA was detectable in four patients in plasma or sputum at day 7 and 14 post-treatment despite below detectable levels at 24 h, suggesting viral replication. One patient had a partial response of the injected malignant lesion. Seven patients fulfilled Response Evaluation Criteria in Solid Tumors (RECIST) definition for stable disease at day 56 after treatment. Telomelysin was well tolerated. Evidence of antitumor activity was suggested.

    DOI: 10.1038/mt.2009.262

    Web of Science

    researchmap

  • Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination

    M. Takakura, M. Nakamura, S. Kyo, M. Hashimoto, N. Mori, T. Ikoma, Y. Mizumoto, T. Fujiwara, Y. Urata, M. Inoue

    CANCER GENE THERAPY   17 ( 1 )   11 - 19   2010.1

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Despite tremendous development in chemotherapy for ovarian cancer over the past few decades, the prognosis of advanced cases with massive peritoneal dissemination is still unsatisfactory, and novel treatment modalities that can combine with chemotherapy are urgently needed. We recently developed virotherapy for solid tumors using telomerase-specific replication-selective adenoviruses (Telomelysin: OBP-301), in which the human telomerase reverse transcriptase (hTERT) gene promoter has been inserted to direct tumor-specific E1 gene expression. In this study, we investigated the anti-tumor effects of OBP-301, combined with cisplatin (CDDP), on ovarian cancer cells. In vitro treatment of SKOV3 cells with OBP-301 at a multiplicity of infection (MOI) of 0.01-100 induced significant cell death in a dose-dependent manner, with moderate cytotoxicity at an MOI of 1-10 and maximal cytotoxicity at an MOI of 100. In contrast, OBP-301 treatment of normal human cells showed no significant cell death at an MOI of 1- 10 and exhibited modest cytotoxicity at an MOI of 100. The effects of low-dose CDDP at 0.5-1 mu M, which induced only 20% cell death, were significantly augmented by combination with OBP-301 at an MOI of 1- 10, finally achieving 40% cell death. Such enhancement of CDDP sensitivity was also observed in CDDP-resistant ovarian cancer cells. The combinatorial effects were further tested using a xenograft mouse model of SKOV3 with peritoneal dissemination. After intraperitoneal administration of OBP-301, we confirmed that injected OBP-301 fused with the green fluorescent protein (GFP) gene (OBP-401) was preferentially localized to peritoneal disseminations, as determined by fluorescence imaging. Treatment of mice with CDDP at low dose (0.5 mg kg(-1)) had modest effects, showing a 10% decrease in disseminations, whereas combination with intraperitoneal administration of OBP-301 at an MOI of 10 led to enhanced effects, achieving an approximately 80% decrease in disseminations. Kaplan-Meier analysis showed improved overall survival of mice treated with CDDP plus OBP-301 compared with CDDP alone. These findings support the therapeutic potential of intraperitoneal administration of OBP-301 to sensitize ovarian cancer cells to CDDP. Cancer Gene Therapy (2010) 17, 11-19; doi: 10.1038/cgt.2009.44; published online 7 August 2009

    DOI: 10.1038/cgt.2009.44

    Web of Science

    researchmap

  • 保存的加療にて軽快した腸管気腫症の一例

    藤原裕子, 田邊俊介, 白川靖博, 近藤喜太, 野間和広, 宇野太, 永坂岳司, 香川俊輔, 山辻知樹, 貞森裕, 小林直哉, 藤原俊義, 八木孝仁, 猶本良夫

    岡山医学会雑誌   122 ( 2 )   2010

  • 当院のおける中・下咽頭表在癌に対するESDの工夫

    白川靖博, 田邊俊介, 野間和広, 櫻間教文, 山辻知樹, 松岡順治, 高岡宗徳, 河原祥朗, 岡田裕之, 猶本良夫, 藤原俊義

    Gastroenterological Endoscopy   52 ( Supplement 2 )   2010

  • パラチノースを糖質源とした流動食MHN-01を用いた食道癌周術期栄養管理

    山辻知樹, 田邉俊介, 藤原康宏, 藤原康宏, 野間和広, 櫻間教文, 櫻間教文, 高岡宗徳, 白川靖博, 藤原俊義, 木下真一郎, 深澤拓也, 林次郎, 繁光薫, 吉田和弘, 森田一郎, 猶本良夫

    日本臨床外科学会雑誌   71   2010

  • 消化管再建法-合併症ゼロへの工夫-I.食道切除後再建法 5.結腸再建

    山辻知樹, 白川靖博, 繁光薫, 野間和広, 藤原俊義, 猶本良夫

    手術   64 ( 10 )   2010

  • 当科にて経験した食道GISTの2例

    渡邉伸一郎, 白川靖博, 田邊俊介, 野間和広, 櫻間教文, 繁光薫, 山辻知樹, 羽井佐実, 猶本良夫, 藤原俊義

    日本食道学会学術集会プログラム・抄録集   64th   2010

  • 食道癌周術期の新しい栄養管理

    山辻知樹, 田邊俊介, 野間和広, 櫻間教文, 白川靖博, 藤原俊義, 木下真一郎, 林次郎, 繁光薫, 吉田和弘, 森田一郎, 猶本良夫

    岡山医学会雑誌   122 ( 3 )   2010

  • 小腸間置による胃機能温存食道切除再建術とその臨床的評価

    猶本良夫, 山田英司, 田辺俊介, 藤原康宏, 野間和広, 高岡宗徳, 白川靖博, 木下真一郎, 深澤拓也, 繁光薫, 林次郎, 山辻知樹, 吉田和弘, 森田一郎, 藤原俊義

    General Thoracic and Cardiovascular Surgery   58 ( Supplement )   2010

  • 食道原発悪性黒色腫の3例

    渡邉伸一郎, 白川靖博, 田辺俊介, 野間和広, 櫻間教文, 繁光薫, 山辻知樹, 羽井佐実, 松岡順治, 猶本良夫, 藤原俊義

    General Thoracic and Cardiovascular Surgery   58 ( Supplement )   2010

  • 当科における回結腸を用いた食道再建術の工夫

    白川靖博, 渡邉伸一郎, 田邊俊介, 野間和広, 櫻間教文, 重光薫, 山辻知樹, 羽井佐実, 猶本良夫, 藤原俊義

    日本食道学会学術集会プログラム・抄録集   64th   2010

  • 右鎖骨下動脈起始異常と非反回下喉頭神経を伴う食道癌に対する手術経験

    田辺俊介, 白川靖博, 二萬英斗, 渡邉伸一郎, 野間和広, 櫻間教文, 繁光薫, 山辻知樹, 羽井佐実, 松岡順治, 猶本良夫, 藤原俊義

    General Thoracic and Cardiovascular Surgery   58 ( Supplement )   2010

  • 当科におけるハイリスク食道癌症例に対する治療方針

    白川靖博, 田邊俊介, 藤原康宏, 野間和広, 櫻間教文, 山辻知樹, 貞森裕, 藤原俊義, 八木孝仁, 猶本良夫

    日本消化器外科学会雑誌   43 ( Supplement1 (Web) )   2010

  • Imatinib耐性GISTに対するSunitinib使用経験

    藤原康宏, 田邊俊介, 野間和広, 永坂岳司, 白川靖博, 山辻知樹, 貞森裕, 八木孝仁, 藤原俊義, 猶本良夫

    日本消化器外科学会雑誌   43 ( Supplement1 (Web) )   2010

  • 食道癌再発巣に対する治療方針-PET導入後の治療手段の変遷-

    田邊俊介, 藤原康宏, 野間和広, 櫻間教文, 白川靖博, 山辻知樹, 貞森裕, 藤原俊義, 八木孝仁, 猶本良夫

    日本消化器外科学会雑誌   43 ( Supplement1 (Web) )   2010

  • Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer

    Oumi Nakajima, Daiju Ichimaru, Yasuo Urata, Toshiyoshi Fujiwara, Tomohisa Horibe, Masayuki Kohno, Koji Kawakami

    ONCOLOGY REPORTS   22 ( 5 )   1039 - 1043   2009.11

     More details

    Language:English   Publisher:SPANDIDOS PUBL LTD  

    We previously reported that telomerase-specific replication-component adenovirous, Telomelysin (OBP-301) has cytotoxic activity to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro, and investigated the association between cytotoxic activity and adenoviral receptor expression. In this study, we evaluated the most appropriate way to administer telomelysin (OBP-301) in the treatment of squamous cell carcinoma of the head and neck (SCCHN), and assessed the effect of OBP-301 in large subcutaneous KCCT873 human SCCHN tumors in immunodeficient mice. We also compared antitumor responses following three intratumoral (i.t.) injections of OBP-301 given daily, every 2 days or weekly. To investigate the mechanism of the antitumor effect, we evaluated cellular infiltration in treated tumors. OBP-301 showed remarkable antitumor activity against large KCCT873 tumors, and three treatment schedules produced similar antitumor effects. The weekly regimen also significantly reduced the growth of large tumors. Immunochemistry revealed that macrophages, but not natural killer cells, were responsible for tumor regression. A regimen of three weekly injections of OBP-301 has remarkable antitumor effects against large KCCT873 tumors. These results may provide a new platform for treating patients with localized SCCHN.

    DOI: 10.3892/or_00000533

    Web of Science

    researchmap

  • Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses

    Hiroyuki Kishimoto, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara, Robert M. Hoffman

    MOLECULAR CANCER THERAPEUTICS   8 ( 11 )   3001 - 3008   2009.11

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    We previously constructed telomerase-dependent, replication-selective adenoviruses OBP-301 (Telomelysin) and OBP-401 [Telomelysin-green fluorescent protein (GFP); TelomeScan], the replication of which is regulated by the human telomerase reverse transcriptase promoter. By intratumoral injection, these viruses could replicate within the primary tumor and subsequent lymph node metastasis. The aim of the present study was to evaluate the possibility of systemic administration of these telomerase-dependent adenoviruses. We assessed the antitumor efficacy of OBP-301 and the ability of OBP-401 to deliver GFP in hepatocellular carcinoma (HCC) and metastatic colon cancer nude mouse models. We showed that i.v. administration of OBP-301 significantly inhibited colon cancer liver metastases and orthotopically implanted HCC. Further, we showed that OBP-401 could visualize liver metastases by tumor-specific expression of the GFP gene after portal venous or i.v. administration. Thus, systemic administration of these adenoviral vectors should have clinical potential to treat and detect liver metastasis and HCC. [Mol Cancer Ther 2009;8(11):3001-8]

    DOI: 10.1158/1535-7163.MCT-09-0556

    Web of Science

    researchmap

  • A simple biological imaging system for detecting viable human circulating tumor cells

    Toru Kojima, Yuuri Hashimoto, Yuichi Watanabe, Shunsuke Kagawa, Futoshi Uno, Shinji Kuroda, Hiroshi Tazawa, Satoru Kyo, Hiroyuki Mizuguchi, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara

    JOURNAL OF CLINICAL INVESTIGATION   119 ( 10 )   3172 - 3181   2009.10

     More details

    Language:English   Publisher:AMER SOC CLINICAL INVESTIGATION INC  

    The presence of circulating tumor cells (CTCs) in the peripheral blood is associated with short survival, making the detection of CTCs clinically useful as a prognostic factor of disease outcome and/or a surrogate marker of treatment response. Recent technical advances in immunocytometric analysis and quantitative real-time PCR have made it possible to detect a few CTCs in the blood; however, there is no sensitive assay to specifically detect viable CTCs. Here, we report what we believe to be a new approach to visually detect live human CTCs among millions of peripheral blood leukocytes, using a telomerase-specific replication-selective adenovirus expressing GFP. First, we constructed a GFP-expressing attenuated adenovirus, in which the telomerase promoter regulates viral replication (OBP-401; TelomeScan). We then used OBP-401 to establish a simple ex vivo method that was able to detect viable human CTCs in the peripheral blood. The detection method involved a 3-step procedure, including the lysis of rbc, the subsequent addition of OBP-401 to the cell pellets, and an automated scan using fluorescence microscopy. OBP-401 infection increased the signal-to-background ratio as a tumor-specific probe, because the fluorescent signal was amplified only in viable, infected human tumor cells, by viral replication. This GFP-expressing virus-based method is remarkably simple and allows precise enumeration of CTCs.

    DOI: 10.1172/JCI38609

    Web of Science

    researchmap

  • In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation

    Hiroyuki Kishimoto, Ming Zhao, Katsuhiro Hayashi, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara, Sheldon Penman, Robert M. Hoffman

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   106 ( 34 )   14514 - 14517   2009.8

     More details

    Language:English   Publisher:NATL ACAD SCIENCES  

    Cancer surgery requires the complete and precise identification of malignant tissue margins including the smallest disseminated lesions. Internal green fluorescent protein (GFP) fluorescence can intensely illuminate even single cells but requires GFP sequence transcription within the cell. Introducing and selectively activating the GFP gene in malignant tissue in vivo is made possible by the development of OBP-401, a telomerase-dependent, replication-competent adenovirus expressing GFP. This potentially powerful adjunct to surgical navigation was demonstrated in 2 nude mouse models that represent difficult surgical challenges-the resection of widely disseminated cancer. HCT-116, a model of intraperitoneal disseminated human colon cancer, was labeled by virus injection into the peritoneal cavity. A549, a model of pleural dissemination of human lung cancer, was labeled by virus administered into the pleural cavity. Only the malignant tissue fluoresced brightly in both models. In the intraperitoneal model of disseminated cancer, fluorescence-guided surgery enabled resection of all tumor nodules labeled with GFP by OBP-401. The data in this report suggest that adenoviral-GFP labeling tumors in patients can enable fluorescence-guided surgical navigation.

    DOI: 10.1073/pnas.0906388106

    Web of Science

    researchmap

  • Diagnostic potential and limitation of imaging cancer cells in cytological samples using telomerase-specific replicative adenovirus

    Yoshiko Maida, Satoru Kyo, Junko Sakaguchi, Yasunari Mizumoto, Manabu Hashimoto, Noriko Mori, Tomomi Ikoma, Mitsuhiro Nakamura, Masahiro Takakura, Yasuo Urata, Toshiyoshi Fujiwara, Masaki Inoue

    INTERNATIONAL JOURNAL OF ONCOLOGY   34 ( 6 )   1549 - 1556   2009.6

     More details

    Language:English   Publisher:SPANDIDOS PUBL LTD  

    Cytological cancer screening that targets genetic or epigenetic abnormalities may be a viable alternative to morphological screening. Detecting cancer cells by specific genetic markers helps their easy detection in cytological samples. We recently established the telomerase-specific replication-selective adenovirus OBP-401, in which the human telomerase reverse transcriptase (hTERT) gene promoter has been inserted upstream of the El genes, and in which the green fluorescent protein (GFP) gene is driven by the CMV promoter. This virus selectively replicates only in telomerase-positive cells, expressing GFP, and therefore may be a toot for cancer screening. In the present study, we first confirmed that cytological samples can easily be infected with OBP-401, allowing visualization of GFP-positive cells under fluorescent microscopy 24 h after infection. After 32 cytological samples from patients with cervical, endometrial or ovarian cancers were infected with OBP-401, GFP signals were detected in 31 (96%) of the samples. However, some normal endometrial scrapings exhibited GFP-signals, possibly due to endometrial glandular cells with constitutive telomerase activity. The ability of OBP-401 to enrich cancer cells was then tested. Cytological samples containing cervical or endometrial cancer cells were infected with OBP-401, and GFP-positive cells were sorted by flow cytometry; DNA was extracted from the GFP-positive cells. Direct DNA sequencing or methylation-specific PCR identified cancer-derived mutations or hypermethylations of tumor suppressor genes more efficiently than analyses using crude cytological samples. Thus, OBP-401-Z, based sorting of GFP-positive cells successfully enriched cancer cells, allowing efficient detection of genetic or epigenetic abnormalities in cytological samples.

    DOI: 10.3892/ijo_00000284

    Web of Science

    researchmap

  • Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)

    Masaaki Ouchi, Hitoshi Kawamura, Yasuo Urata, Toshiyoshi Fujiwara

    INVESTIGATIONAL NEW DRUGS   27 ( 3 )   241 - 245   2009.6

     More details

    Language:English   Publisher:SPRINGER  

    We constructed a replication-competent oncolytic adenovirus, OBP-301 (Telomelysin), in which human telomerase reverse transcriptase (hTERT) promoter drives E1 genes. OBP-301 is currently being used in a phase-I clinical trial for various types of tumors. Under such conditions, anti-adenoviral agents should be available for safety use against OBP-301 since any adenoviral viremia could cause severe adverse effects. Cidofovir (CDV) is an acyclic nucleoside phosphonate that has a broad antiviral activity against DNA viruses. Here, we examined the antiviral effects of CDV against OBP-301. The in vitro cytopathic effects of OBP-301 were suppressed by CDV. Moreover, CDV decreased the adenoviral E1A gene copy number after OBP-301 infection. These results suggest that CDV is a potentially useful antiviral agent for OBP-301.

    DOI: 10.1007/s10637-008-9169-5

    Web of Science

    researchmap

  • Preclinical study of telomerase-selective oncolytic adenovirus (OBP-301) in combination with chemotherapeutic agents

    Hiroshi Tazawa, Yuuri Hashimoto, Shinji Kuroda, Yasuo Urata, Toshiyoshi Fujiwara

    CANCER RESEARCH   69   2009.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    Web of Science

    researchmap

  • Preclinical evaluation of telomerase-specific virotheranostics for human head and neck cancer

    Yuji Kurihara, Toru Kojima, Tatsuo Shirota, Masashi Hatori, Yasuo Urata, Toshiyoshi Fujiwara, Satoru Shintani

    CANCER RESEARCH   69   2009.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    Web of Science

    researchmap

  • Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer

    Dong Liu, Toru Kojima, Masaaki Ouchi, Shinji Kuroda, Yuichi Watanabe, Yuuri Hashimoto, Hideki Onimatsu, Yasuo Urata, Toshiyoshi Fujiwara

    MOLECULAR CANCER THERAPEUTICS   8 ( 4 )   980 - 987   2009.4

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    A phase I dose-escalation study of telomerase-specific oncolytic adenovirus, OBP-301 (Telomelysin), is now under way in the United States to assess feasibility and to characterize its pharmacokinetics in patients with advanced solid tumors. The present preclinical study investigates whether OBP-301 and a chemotherapeutic agent that is commonly used for lung cancer treatment, gemcitabine, are able to enhance antitumor effects in vitro and in vivo. The antitumor effects of OBP-301 infection and gemcitabine were evaluated by 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt assay. In vivo antitumor effects of intratumoral injection of OBP-301 in combination with systemic administration of gemcitabine were assessed on nu/nu mice s.c. xenografted with human lung tumors. OBP-301 infection combined with gemcitabine resulted in very potent synergistic cytotoxicity in human lung cancer cells. The three human lung cancer cell lines treated with OBP-301 for 24 hours tended to accumulate in S phase compared with controls. The proportion of cells in S phase increased from 43.85% to 56.41% in H460 cells, from 46.72% to 67.09% in H322 cells, and from 38.22% to 57.67% in H358 cells. Intratumoral injection of OBP-301 combined with systemic administration of gemcitabine showed therapeutic synergism in human lung tumor xenografts. Our data suggest that the combination of OBP-301 and gemcitabine enhances the antitumor effects against human lung cancer. We also found that the synergistic mechanism may be due to OBP-301-mediated cell cycle accumulation in S phase. These results have important implications for the treatment of human lung cancer. [Mol Cancer Ther 2009;8(4):980-7]

    DOI: 10.1158/1535-7163.MCT-08-0901

    Web of Science

    researchmap

  • Telomerase-Specific Virotheranostics for Human Head and Neck Cancer

    Yuji Kurihara, Yuichi Watanabe, Hideki Onimatsu, Toru Kojima, Tatsuo Shirota, Masashi Hatori, Dong Liu, Satoru Kyo, Hiroyuki Mizuguchi, Yasuo Urata, Satoru Shintani, Toshiyoshi Fujiwara

    CLINICAL CANCER RESEARCH   15 ( 7 )   2335 - 2343   2009.4

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Purpose: Long-term outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) remain unsatisfactory despite advances in combination of treatment modalities. SCCHN is characterized by locoregional spread and it is clinically accessible, making it an attractive target for intratumoral biological therapies.
    Experimental Design: OBP-301 is a type 5 adenovirus that contains the replication cassette in which the human telomerase reverse transcriptase promoter drives expression of the E1 genes. OBP-401 contained the replication cassette and the green fluorescent protein (GFP) gene. The antitumor effects of OBP-301 were evaluated in vitro by the sodium 30-[1-(phenylaminocarbonyl) -3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate assay and in vivo in an orthotopic xenograft model. Virus spread into the lymphatics was also orthotopically assessed by using OBP-401.
    Results: Intratumoral injection of OBP-301 resulted in the shrinkage of human SCCHN tumors orthotopically implanted into the tongues of BALB/c nu/nu mice and significantly recovered weight loss by enabling oral ingestion. The levels of GFP expression following ex vivo infection of OBP-401 may be of value as a positive predictive marker for the outcome of telomerase-specific virotherapy. Moreover, whole-body fluorescent imaging revealed that intratumorally injected OBP-401 Could visualize the metastatic lymph nodes, indicating the ability of the virus to traffic to the regional lymphatic area and to selectively replicate in neoplastic lesions, resulting in GFP expression and cell death in metastatic lymph nodes.
    Conclusions: These results illustrate the potential of telomerase-specific oncolytic viruses for a novel therapeutic and diagnostic approach, termed theranostics, for human SCCHN.

    DOI: 10.1158/1078-0432.CCR-08-2690

    Web of Science

    researchmap

  • SY-1-3 テロメラーゼ活性を標的とするウイルス製剤OBP-301の臨床応用 : 固形腫瘍に対する第1相臨床試験(外科領域における遺伝子治療・再生医療の問題点と今後の展開,シンポジウム,第109回日本外科学会定期学術集会)

    香川 俊輔, 宇野 太, 橋本 悠里, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本外科学会雑誌   110 ( 2 )   82 - 82   2009.2

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Telomerase-specific virotherapy in an animal model of human head and neck cancer

    Oumi Nakajima, Atsuko Matsunaga, Daiju Ichimaru, Yasuo Urata, Toshiyoshi Fujiwara, Koji Kawakami

    MOLECULAR CANCER THERAPEUTICS   8 ( 1 )   171 - 177   2009.1

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Telomerase-specific replication-competent adenovirus, Telomelysin (OBP-301), has a human telomerase reverse transcriptase promoter that regulates viral replication and efficiently kills human cancer cells. The objectives of this study are to examine the effects of OBP-301 in squamous cell carcinoma of the head and neck cells in vitro and in xenografted animals in vivo. OBP-301 was found to be cytotoxic to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro. However, the level of cytotoxicity is not correlated with the expression levels of adenoviral receptors, which may be required for adenoviral infection in squamous cell carcinoma of the head and neck cells. OBP-301 shows remarkable antitumor activity against established s.c. KCCT873 tumors in immunodeficient animals in a dose-dependent manner. In addition, no significant toxicity was observed in animals receiving treatment. These results suggest that OBP-301 is a novel therapeutic agent with promise for the treatment of human head and neck cancers. [Mol Cancer Ther 2009(1): 171 - 7]

    DOI: 10.1158/1535-7163.MCT-08-0620

    Web of Science

    researchmap

  • Gene therapy and virotherapy for human cancer

    Japanese journal of clinical medicine   67   306 - 313   2009.1

  • A novel antiangiogenic effect for telomerase-specific virotherapy through host immune system

    Ikeda Y, Kojima T, Kuroda S, Endo Y, Sakai R, Hioki M, Kishimoto H, Uno F, Kagawa S, Watanabe Y, Hashimoto Y, Urata Y, Tanaka N, Fujiwara T

    J Immunol   182   1763 - 1769   2009

     More details

  • 肺癌RFA3,6カ月後のPET/CTの集積程度の検討

    奥村能啓, 郷原英夫, 井上大作, 平木隆夫, 三村秀文, 金澤右, 佐野由文, 藤原俊義, 加地充昌

    IVR   24 ( 4 )   2009

  • RFA前のPET/CTにおけるSUVとRFA後の腫瘍再発との関連性について

    原田聡介, 奥村能啓, 郷原英夫, 平木隆夫, 加藤勝也, 佐藤修平, 三村秀文, 丸中三菜子, 佐野由文, 藤原俊義, 加地充昌, 金澤右

    肺癌   49 ( 5 )   2009

  • Autophagy-inducing agents augment the antitumor effect of telomerase-selective oncolytic adenovirus OBP-405 on glioblastoma cells

    T. Yokoyama, E. Iwado, Y. Kondo, H. Aoki, Y. Hayashi, M. M. Georgescu, R. Sawaya, K. R. Hess, G. B. Mills, H. Kawamura, Y. Hashimoto, Y. Urata, T. Fujiwara, S. Kondo

    GENE THERAPY   15 ( 17 )   1233 - 1239   2008.9

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Oncolytic adenoviruses are a promising tool in cancer therapy. In this study, we characterized the role of autophagy in oncolytic adenovirus-induced therapeutic effects. OBP-405, an oncolytic adenovirus regulated by the human telomerase reverse transcriptase promoter (hTERT-Ad, OBP-301) with a tropism modification (RGD) exhibited a strong antitumor effect on glioblastoma cells. When autophagy was inhibited pharmacologically, the cytotoxicity of OBP-405 was attenuated. In addition, autophagy-deficient Atg5 mouse embryonic fibroblasts (MEFs) were less sensitive than wild-type MEFs to OBP-405. These findings indicate that OBP-405-induced autophagy is a cell killing effect. Moreover, autophagy-inducing therapies (temozolomide and rapamycin) synergistically sensitized tumor cells to OBP-405 by stimulating the autophagic pathway without altering OBP-405 replication. Mice harboring intracranial tumors treated with OBP-405 and temozolomide survived significantly longer than those treated with temozolomide alone, and mice treated with OBP-405 and the rapamycin analog RAD001 survived significantly longer than those treated with RAD001 alone. The observation that autophagy inducers increase OBP-405 antitumor activity suggests a novel strategy for treating patients with glioblastoma.

    DOI: 10.1038/gt.2008.98

    Web of Science

    researchmap

  • Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers

    Satoru Kyo, Masahiro Takakura, Toshiyoshi Fujiwara, Masaki Inoue

    CANCER SCIENCE   99 ( 8 )   1528 - 1538   2008.8

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.   Publisher:WILEY-BLACKWELL  

    Telomerase activation is a critical step for human carcinogenesis through the maintenance of telomeres, but the activation mechanism during carcinogenesis remains unclear. Transcriptional regulation of the human telomerase reverse transcriptase (hTERT) gene is the major mechanism for cancer-specific activation of telomerase, and a number of factors have been identified to directly or indirectly regulate the hTERT promoter, including cellular transcriptional activators (c-Myc, Sp1, HIF-1, AP2, ER, Ets, etc.) as well as the repressors, most of which comprise tumor suppressor gene products, such as p53, WT1, and Menin. Nevertheless, none of them can clearly account for the cancer specificity of hTERT expression. The chromatin structure via the DNA methylation or modulation of nucleosome histones has recently been suggested to be important for regulation of the hTERT promoter. DNA unmethylation or histone methylation around the transcription start site of the hTERT promoter triggers the recruitment of histone acetyltransferase (HAT) activity, allowing hTERT transcription. These facts prompted us to apply these regulatory mechanisms to cancer diagnostics and therapeutics. Telomerase-specific replicative adenovirus (Telomelysin, OBP-301), in which E1A and E1B genes are driven by the hTERT promoter, has been developed as an oncolytic virus that replicates specifically in cancer cells and causes cell death via viral toxicity. Direct administration of Telomelysin was proved to effectively eradicate solid tumors in vivo, without apparent adverse effects. Clinical trials using Telomelysin for cancer patients with progressive stages are currently ongoing. Furthermore, we incorporated green fluorescent protein gene (GFP) into Telomelysin (TelomeScan, OBP-401). Administration of TelomeScan into the primary tumor enabled the visualization of cancer cells under the cooled charged-coupled device (CCD) camera, not only in primary tumors but also the metastatic foci. This technology can be applied to intraoperative imaging of metastatic lymphnodes. Thus, we found novel tools for cancer diagnostics and therapeutics by utilizing the hTERT promoter. (Cancer Sci 2008; 99: 1528-1538)

    DOI: 10.1111/j.1349-7006.2008.00878.x

    Web of Science

    researchmap

  • Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy

    Masayoshi Hioki, Shunsuke Kagawa, Toshiya Fujiwara, Ryo Sakai, Turn Kojima, Yuichi Watanabe, Yuuri Hashimoto, Futoshi Uno, Norialki Tanaka, Toshiyoshi Fujiwara

    INTERNATIONAL JOURNAL OF CANCER   122 ( 11 )   2628 - 2633   2008.6

     More details

    Language:English   Publisher:WILEY-LISS  

    Cancer gene therapy and oncolytic virotherapy have been studied extensively. However, their clinical application is hampered by their weak anticancer activity. We previously constructed a replicating adenovirus (OBP-301, Telomelysin), in which the human telomerase reverse transcriptase (hTERT) promoter drives expression of the adenoviral El genes, and causes selective lysis of human cancer cells. We hypothesized that combination adenoviral therapy containing OBP-301 and a nonreplicating adenovirus expressing the proapoptotic Bax gene could overcome the weakness and augment the anticancer efficacy of each modality. Combination treatment resulted in marked Bax protein expression and enhanced efficacy in in vitro cell viability assay, when compared with either single treatment. However, combination treatment was not as effective in suppressing both subcutaneous and pleural disseminated tumors compared with OBP-301 treatment alone. Further investigation revealed that combination treatment resulted in suppressed EIA protein expression associated with reduced viral replication. Our results suggest that Bax gene therapy in combination with oncolytic adenovirotherapy potentially augments their antitumor activity, but further improvements may be required to maximize the combinatorial effect in vivo, for the Bax gene expression to avoid interference with production of the oncolytic virus. (c) 2008 Wiley-Liss, Inc.

    DOI: 10.1002/ijc.23438

    Web of Science

    researchmap

  • Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model

    P. Huang, M. Watanabe, H. Kaku, Y. Kashiwakura, J. Chen, T. Saika, Y. Nasu, T. Fujiwara, Y. Urata, H. Kumon

    CANCER GENE THERAPY   15 ( 5 )   315 - 322   2008.5

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    We previously constructed OBP-301 ( Telomelysin, a telomerase-specific replication-competent adenovirus with human telomerase reverse transcriptase ( hTERT) promoter), which showed a strong anticancer effect by inducing cell lysis of human non-small cell lung cancer and colorectal cancer cells. To investigate the utility of OBP-301 for prostate cancer treatment, we herein evaluate the cell killing and antitumor effects. First, in vitro hTERT-specific adenovirus transduction in human prostate cancer cells ( LNCaP, PC3, DU145) was confirmed using OBP-401 ( Telomelysin-green fluorescent protein ( GFP)). There was no detectable GFP transduction in the human prostate normal cells ( PrEC, PrSC). Consistently, the cell-killing effect of OBP-301 was observed only in the cancer cells. Second, using an in vivo subcutaneous LNCaP tumor model in nude mice, we demonstrated that three intratumoral OBP-301 injections ( 10(7) PFU per tumor x 3 days) were sufficient to eradicate the detectable LNCaP prostate tumor. We also demonstrated that the ispilateral treatment with OBP-301 significantly suppressed contralateral LNCaP tumor growth in both sides of the tumor model. Histological and immunohistochemical analyses revealed diffuse oncolytic degeneration and adenoviral E1A protein expression in both sides of the tumors. Therefore, in situ OBP-301 administration could be a promising therapeutic strategy against prostate cancer and its metastatic lesions.

    DOI: 10.1038/cgt.2008.3

    Web of Science

    researchmap

  • DP-141-5 当科における食道癌術後深部静脈血栓症の発症要因とリスク解析(第108回日本外科学会定期学術集会)

    山辻 知樹, 猶本 良夫, 田邊 俊介, 藤原 康弘, 渡辺 信之, 櫻間 一史, 伊藤 充矢, 西川 敏雄, 元木 崇之, 田渕 陽子, 高岡 宗徳, 白川 靖博, 小林 直哉, 藤原 俊義, 松原 長秀, 平松 聡, 羽井 佐実, 松岡 順治, 田中 紀章

    日本外科学会雑誌   109 ( 2 )   626 - 626   2008.4

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • WS-4-1 テロメラーゼ活性を標的とした新規ウイルス製剤Telomelysin/TelomeScanの癌診断・治療への応用(第108回日本外科学会定期学術集会)

    藤原 俊義, 香川 俊輔, 宇野 太, 浦田 泰生, 田中 紀章

    日本外科学会雑誌   109 ( 2 )   146 - 146   2008.4

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • DP-086-2 食道癌術前診断におけるPET/CTの有用性についての検討(第108回日本外科学会定期学術集会)

    田辺 俊介, 猶本 良夫, 藤原 康宏, 櫻間 一史, 野間 和広, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 羽井 佐実, 松岡 順治, 田中 紀章

    日本外科学会雑誌   109 ( 2 )   516 - 516   2008.4

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation

    Y. Endo, R. Sakai, M. Ouchi, H. Onimatsu, M. Hioki, S. Kagawa, F. Uno, Y. Watanabe, Y. Urata, N. Tanaka, T. Fujiwara

    ONCOGENE   27 ( 17 )   2375 - 2381   2008.4

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Dendritic cells ( DCs) are the most potent antigen-presenting cells and acquire cellular antigens and danger signals from dying cells to initiate antitumor immune responses via direct cell- to- cell interaction and cytokine production. The optimal forms of tumor cell death for priming DCs for the release of danger signals are not fully understood. OBP- 301 ( Telomelysin) is a telomerase-specific replication- competent adenovirus that induces selective E1 expression and exclusively kills human cancer cells. Here, we show that OBP- 301 replication produced the endogenous danger signaling molecule, uric acid, in infected human tumor cells, which in turn stimulated DCs to produce interferon-gamma ( IFN-gamma) and interleukin 12 ( IL- 12). Subsequently, IFN-gamma release upregulated the endogenous expression of the proteasome activator PA28 in tumor cells and resulted in the induction of cytotoxic T- lymphocytes. Our data suggest that virus- mediated oncolysis might be the effective stimulus for immature DCs to induce specific activity against human cancer cells.

    DOI: 10.1038/sj.onc.1210884

    Web of Science

    researchmap

  • Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus

    Yuuri Hashimoto, Yuichi Watanabe, Yoshiko Shirakiya, Futoshi Uno, Shunsuke Kagawa, Hitoshi Kawamura, Katsuyuki Nagai, Noriaki Tanaka, Horomi Kumon, Yasuo Urata, Toshiyoshi Fujiwara

    CANCER SCIENCE   99 ( 2 )   385 - 390   2008.2

     More details

    Language:English   Publisher:BLACKWELL PUBLISHING  

    The use of replication-selective tumor-specific viruses represents a novel approach for the treatment of neoplastic disease. We constructed an attenuated adenovirus, telomerase-specific replication-selective adenovirus (TRAD), in which the human telomerase reverse transcriptase promoter element drives the expression of the E1A and E1B genes linked with an internal ribosome entry site (IRES). Forty-eight hours after TRAD infection at a multiplicity of infection of 1.0, the cell viability of H1299 human lung cancer cells was consistently less than 50% and therefore this procedure could be used as a potency assay to assess the biological activity of TRAD. We also established a quantitative real-time polymerase chain reaction (PCR) analysis with consensus primers for either the adenovirus E1A or IRES sequence. The linear ranges of quantitation with E1A and IRES primers were 10(3)-10(8) and 10(2)-10(8) plaque-forming units/mL in the plasma, respectively. The PCR analysis demonstrated that the levels of E1A in normal tissues were more than 10(3) lower than in the tumors of A549 human lung tumor xenografts in nu/n mu mice at 28 days after intratumoral injection. Our results suggest that the cell-killing assay against H1299 cells and real-time PCR can be used to assess the biological activity and biodistribution of TRAD in clinical trials.

    DOI: 10.1111/j.1349-7006.2007.00665.x

    Web of Science

    researchmap

  • Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents

    Toshiyoshi Fujiwara, Yasuo Urata, Noriaki Tanaka

    FRONTIERS IN BIOSCIENCE-LANDMARK   13   1881 - 1886   2008.1

     More details

    Language:English   Publisher:FRONTIERS IN BIOSCIENCE INC  

    Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is considered to be a critical step in carcinogenesis and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. Since only tumor cells that express telomerase activity would activate this promoter, the hTERT proximal promoter allows for preferential expression of viral genes in tumor cells, leading to selective viral replication. We constructed an attenuated adenovirus 5 vector (Telomelysin, OBP-301), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site (IRES). Telomelysin replicated efficiently and induced marked cell killing in a panel of human cancer cell lines, whereas replication as well as cytotoxicity was highly attenuated in normal human cells lacking telomerase activity. We further modified the E3 region of OBP-301 to contain green fluorescent protein (GFP) gene for monitoring viral replication (TelomeScan, OBP-401). When TelomeScan was intratumorally injected into human tumors orthotopically implanted into the rectum in mice, para-aortic lymph node metastasis could be visualized at laparotomy under a three-chip color cooled charged-coupled device camera. Our results indicate that TelomeScan causes viral spread into the regional lymphatic area and selectively replicates in neoplastic lesions, resulting in GFP expression in metastatic lymph nodes. This article reviews recent highlights in this rapidly evolving field: cancer therapeutic and cancer diagnostic approaches using the telomerase-specific oncolytic adenoviruses.

    DOI: 10.2741/2807

    Web of Science

    researchmap

  • 微小癌転移のin vivoイメージング技術.

    藤原俊義, 田中紀章

    Medical Science Digest   34 ( 2 )   48 - 49   2008

     More details

  • 腫瘍融解ウイルスによる細胞死であるオンコライシスは細胞内にdanger signalを発生させ、プロテアソームアクチベーター(PA28)発現を増強することで細胞障害性Tリンパ球による免疫応答を活性化する.

    遠藤芳克, 酒井亮, 大内正明, 鬼松秀樹, 日置勝義, 香川俊輔, 宇野太, 渡邉雄一, 浦田泰生, 田中紀章, 藤原俊義

    岡山医学会雑誌   120 ( 3 )   259 - 264   2008

  • テロメラーゼ活性を標的とした腫瘍融解ウイルスのがん診断・治療への応用.

    藤原俊義, 田中紀章

    Cancer Frontier   10 ( 1 )   49 - 56   2008

     More details

    Language:Japanese   Publisher:医薬ジャーナル社  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2009006303

  • 遺伝子治療.

    藤原俊義, 田中紀章

    日本臨床   66 ( Suppl 6 )   173 - 179   2008

     More details

  • ウイルスによる細胞死とがん治療への応用.

    藤原俊義, 田中紀章

    がん分子標的治療   6 ( 3 )   152 - 159   2008

     More details

  • がんに対する遺伝子治療の現況と展望.

    藤原俊義, 田中紀章

    岡山医学会雑誌   120 ( 3 )   321 - 327   2008

  • Telomerase-Specific Oncolytic Virotherapy for Human Cancer with the hTERT Promoter

    FUJIWARA Toshiyoshi, TANAKA Noriaki

    Uirusu   58 ( 1 )   11 - 18   2008

     More details

    Language:Japanese   Publisher:The Japanese Society for Virology  

    Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. Telomerase activation is considered to be a critical step in carcinogenesis and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. We constructed an attenuated adenovirus 5 vector (Telomelysin, OBP-301), in which the hTERT promoter element drives expression of E1 genes. Telomelysin replicated efficiently and induced marked cell killing in a panel of human cancer cell lines, whereas replication as well as cytotoxicity was highly attenuated in normal human cells lacking telomerase activity. We further modified the E3 region of OBP-301 to contain green fluorescent protein (GFP) gene for monitoring viral replication (TelomeScan, OBP-401). When TelomeScan was intratumorally injected into human tumors orthotopically implanted into the rectum in mice, para-aortic lymph node metastasis could be visualized at laparotomy under a three-chip color cooled charged-coupled device camera. This article reviews recent highlights in this rapidly evolving field: cancer therapeutic and cancer diagnostic approaches using the telomerase-specific oncolytic adenoviruses.

    DOI: 10.2222/jsv.58.11

    CiNii Article

    CiNii Books

    researchmap

    Other Link: https://jlc.jst.go.jp/DN/JALC/00323509631?from=CiNii

  • In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus

    KISHIMOTO Hiroyuki, KOJIMA Toru, WATANABE Yuichi, KAGAWA Shunsuke, FUJIWARA Toshiya, UNO Futoshi, TERAISHI Fuminori, KYO Satoru, MIZUGUCHI Hiroyuki, HASHIMOTO Yuuri, URATA Yasuo, TANAKA Noriaki, FUJIWARA Toshiyoshi

    120 ( 1 )   13 - 21   2008

  • 制限増殖型アデノウイルス製剤を用いた、消化器癌微小リンパ節転移の診断、および治療への応用.

    児島亨, 田中紀章, 浦田泰生, 藤原俊義

    癌の臨床   54 ( 3 )   163 - 168   2008

     More details

  • 微小リンパ節転移を標的とするテロメラーゼ特異的腫瘍融解ナノバイオウイルス製剤によるイメージングシステムおよび治療法の開発.

    児島亨, 田中紀章, 浦田泰生, 藤原俊義

    Biotherapy   22 ( 2 )   87 - 95   2008

     More details

  • PET/CTによる肺癌RFA後の再発診断の至適時期の検討

    奥村能啓, 郷原英夫, 井上大作, 平木隆夫, 三村秀文, 佐藤修平, 加藤勝也, 加地充昌, 佐野由文, 藤原俊義, 金澤右

    肺癌   48 ( 5 )   2008

  • 当科における食道切除後,遺残食道癌症例の検討

    野間和広, 猶本良夫, 藤智和, 田邊俊介, 近藤喜太, 藤原康宏, 吉田亮介, 櫻間一史, 宇野太, 香川俊輔, 白川靖博, 山辻知樹, 小林直哉, 藤原俊義, 松原長秀, 松岡順治, 田中紀章

    岡山医学会雑誌   120 ( 2 )   2008

  • 当科における食道切除後,再建胃管癌症例の検討

    田邊俊介, 猶本良夫, 藤智和, 近藤喜太, 藤原康宏, 吉田亮介, 野間和広, 櫻間一史, 宇野太, 香川俊輔, 白川靖博, 山辻知樹, 小林直哉, 藤原俊義, 松原長秀, 松岡順治, 田中紀章

    岡山医学会雑誌   120 ( 2 )   2008

  • Adenomyoma of the stomach presenting as localized peritonitis

    Shunsuke Kagawa, Toshiyoshi Fujiwara, Masahiko Nishizaki, Yoshio Naomoto, Isozaki Hiroshi, Noriaki Tanaka

    DIGESTIVE DISEASES AND SCIENCES   52 ( 11 )   3184 - 3187   2007.11

     More details

    Language:English   Publisher:SPRINGER  

    DOI: 10.1007/s10620-006-9390-z

    Web of Science

    researchmap

  • Knock down of hSNF5/Ini1 causes cell cycle arrest and apoptosis in a p53-dependent manner

    Hiroyuki Kato, Reiko Honma, Takaomi Sanda, Toshiyoshi Fujiwara, Emi Ito, Yuka Yanagisawa, Jun-ichi Imai, Takashi Okamoto, Shinya Watanabe

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   361 ( 3 )   580 - 585   2007.9

     More details

    Language:English   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    hSNF5/Inil is a core component of the SWI/SNF complex and the gene is frequently mutated in aggressive pediatric rhabdoid tumors. Mechanisms of the malignant transformation, however, remain poorly understood. We analyzed HeLa cells treated with siRNA to the hSNF5/Inil mRNA. The resulting efficient and long-term suppression caused characteristic cell enlargement, cell cycle arrest in G1 phase, and subsequent modest apoptosis. Gene expression profiling of the hSNF5-down-regulated cells by cDNA microarray analysis revealed that a limited number of p53-responsive genes, especially p21, were up-regulated. The p53 protein level was also greatly enhanced, suggesting that loss of hSNF5/Inil induces a p53 signaling pathway irrelevant to the chk1/2 phosphorylation pathway. Some rhabdoid tumors with very low or no ARF expression were induced to undergo cell enlargement, growth arrest, and, in one case, apoptosis by ectopic expression of the p14ARF protein. These results may in part account for molecular mechanisms of rhabdoid tumor formation. (c) 2007 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbrc.2007.07.035

    Web of Science

    researchmap

  • Clonality and heterogeneity of pulmonary blastoma from the viewpoint of genetic alterations: A case report

    Kenji Takahashi, Takashi Kohno, Shingo Matsumoto, Yukihiro Nakanishi, Yasuhito Arai, Toshiyoshi Fujiwara, Noriaki Tanaka, Jun Yokota

    LUNG CANCER   57 ( 1 )   103 - 108   2007.7

     More details

    Language:English   Publisher:ELSEVIER IRELAND LTD  

    Biphasic pulmonary blastoma is a rare lung tumor with epithelia[ and mesenchymal components. Genetic alterations in this tumor are largely unknown, except for the presence of beta-catenin and p53 mutations and the absence of KRAS mutation. To understand the molecular process of histogenesis of this tumor, a whole genome allelic imbalance (Al) scanning using a high-resolution single nucleotide polymorphism array as well as mutational analysis of the p53, EGFR, KRAS and beta-catenin genes were performed against the epithelial and mesenchymal components in the primary tumor and a metastatic tumor in a case of pulmonary blastoma. Al at chromosome regions 14q24-q32 and 17p11-p13 and beta-catenin mutation were commonly detected in all tumors. On the other hand, Al at chromosome regions 3p11-p14 and 9p21-p24 and p53 mutation were detected only in the mesenchymal component in the primary tumor but not in the epithelial component in the primary tumor and the brain metastasis. Likewise, Al at chromosome regions 6p24-p25 and 6q14-q27 was detected in the epithelial. component in the primary tumor and the brain metastasis but not in the mesenchymal component in the primary tumor. Furthermore, the genetic alterations detected in the metastatic tumor were completely the same as those in the epithelial component in the primary tumor, indicating that a tumor cell(s) in the epithelial component in the primary tumor selectively metastasized to the brain. These results indicate that this biphasic tumor is of monoclonal origin and the phenotypic heterogeneity of the tumor is due to the differences in the accumulated genetic alterations in each component of the tumor. (c) 2007 Elsevier Ireland Ltd. All rights reserved.

    DOI: 10.1016/j.lungcan.2007.01.026

    Web of Science

    researchmap

  • Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients

    Yuji Sato, Toshiyoshi Fujiwara, Takashi Mine, Hiroki Shomura, Shigenori Homma, Yoshiaki Maeda, Naoyuki Tokunaga, Yoshihiro Ikeda, Yuki Ishihara, Akira Yamada, Noriaki Tanaka, Kyogo Itoh, Mamoru Harada, Satoru Todo

    CANCER SCIENCE   98 ( 7 )   1113 - 1119   2007.7

     More details

    Language:English   Publisher:BLACKWELL PUBLISHING  

    The aim of the present study was to investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of a 5-fluorouracil derivative (TS-1) in advanced gastric or colorectal carcinoma patients. Eleven patients (four with gastric cancer and seven with colorectal cancer) who failed to improve by prior TS-1-based chemotherapies were enrolled in this study. Peptides to be administered to patients were determined based on the presence of peptide-specific cytotoxic T lymphocyte (CTL) precursors in peripheral blood mononuclear cells and peptide-specific IgG in the plasma of cancer patients. Patients were vaccinated with peptides (a maximum of four) biweekly in combination with or without three different doses of TS-1 (20, 40 and 80 mg/m(2)/day). Although grade 3 toxicity, including anemia (one patient) and neutropenia (one patient) were observed, the combination therapy was generally well tolerated. An increase in peptide-specific IgG after the sixth vaccination was observed in the vast majority of patients irrespective of the dose of TS-1 used. In contrast, an increase in peptide-specific interferon-gamma production by CTL was most evident in patients who were administered the highest dose of TS-1. Furthermore, in the patients who received 80 mg/m(2)/day TS-1, CTL-mediated cytotoxicity against cancer cells was maintained at the prevaccination level. These results indicate that administration of the standard dose (80 mg/m(2)/day) of TS-1 in combination with a personalized peptide vaccination does not necessarily impede immunological responses in cancer patients, and could actually maintain or augment them.

    DOI: 10.1111/j.1349-7006.2007.00498.x

    Web of Science

    researchmap

  • Effects of a novel palatinose based enteral formula (MHN-01) carbohydrate-adjusted fluid diet in improving the metabolism of carbohydrates and lipids in patients with esophageal cancer complicated by diabetes mellitus

    Toshiya Fujiwara, Yoshio Naomoto, Takayuki Motoki, Kaori Shigemitsu, Yasuhiro Shirakawa, Tomoki Yamatsuji, Masafumi Kataoka, Minoru Haisa, Toshiyoshi Fujiwara, Maritoki Egi, Hiroshi Morimatsu, Motohiko Hanazaki, Hiroshi Katayama, Kiyoshi Morita, Kenji Mizumoto, Takanobu Asou, Hirofumi Arima, Hajime Sasaki, Motoi Matsuura, Mehmet Gunduz, Noriaki Tanaka

    JOURNAL OF SURGICAL RESEARCH   138 ( 2 )   231 - 240   2007.4

     More details

    Language:English   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Background. During perioperative management of patients with gastrointestinal cancer complicated by diabetes mellitus, adequate alimentation is required, but we often face difficulties associated with hyperglycemia and other accompanying complications. Recently, we investigated the effects of a novel palatinose based enteral formula (MHN-01) in suppressing post-prandial hyperglycemia and improving lipid metabolism in experimental animals and perioperative management of patients with esophageal cancer complicated by diabetes mellitus.
    Materials and methods. We gave normal rats and rats with type 2 diabetes mellitus a single oral dose of fluid diet, and analyzed comparatively the time course of blood glucose level in each group until 3 h after the dose. In both the normal rat group and the type 2 diabetes group, peak blood glucose level after the MHN-01 dose was significantly lower than after a dose of ordinary fluid diet and was comparable to the peak level after a dose of a fluid diet rich in MUFA (monounsaturated fatty acid). We allowed normal mice free access to fluid diet for 43 days, and measured their body fat levels. Fat accumulation was significantly lower in mice given MHN-01 than in mice given ordinary fluid diet. We also analyzed the respiratory quotient and resting energy expenditure of normal Sprague-Dawley rats fed by MHN-01 or an ordinary fluid diet. The respiratory quotient of the MHN-01 group was significantly lower than the ordinary fluid group, although the resting energy expenditure of both groups was almost the same level. The effect of MHN-01 was estimated to be based on improvement of lipid metabolism.
    Results. Between 2003 and 2005, among 164 patients who underwent radical thoracic esophagectomy and/or reconstruction for esophageal carcinoma at Okayama University Hospital, nine patients (5.5%) were diagnosed with diabetes mellitus in preoperative screening and were treated with MHN-01. Clinical courses of two cases with severe status of diabetes mellitus were presented as successful case reports of MHN-01.
    Conclusion. MHN-01 was very useful in perioperative management of patients complicated by diabetes mellitus, unable to ingest food p.o. such as esophageal cancer or other diseases. (c) 2007 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.jss.2006.06.025

    Web of Science

    researchmap

  • DP-139-6 切除不能gastrointestinalstromaltumor(GIST)に対する制限増殖型アデノウイルス(Telome-lysin)を用いた新規癌ウイルス療法の確立(第107回日本外科学会定期学術集会)

    寺石 文則, 橋本 悠里, 児島 亨, 宇野 太, 香川 俊輔, 合地 明, 田中 紀章, 藤原 俊義

    日本外科学会雑誌   108 ( 2 )   598 - 598   2007.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • DP-190-6 食道癌周術期管理におけるCTの有用性の検討(第107回日本外科学会定期学術集会)

    藤原 康宏, 猶本 良夫, 田辺 俊介, 櫻間 一史, 高岡 宗徳, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 羽井佐 実, 岩垣 博巳, 松岡 順治, 田中 紀章

    日本外科学会雑誌   108 ( 2 )   700 - 700   2007.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 胃癌腹膜播種に対するTRAIL発現 oncolytic adenovirus の抗腫瘍効果

    香川 俊輔, 日置 勝義, 池田 義博, 児島 亨, 酒井 亮, 宇野 太, 寺石 文則, 橋本 悠里, 浦田 泰生, 田中 紀章, 藤原 俊義

    日本外科学会雑誌   108   310 - 310   2007.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • DP-190-1 パラチノースを主糖質源とした調整流動食MHN-01(Inslow)の糖質脂質代謝改善効果 : 糖尿病合併食道癌周術期栄養管理への応用(第107回日本外科学会定期学術集会)

    山辻 知樹, 猶本 良夫, 藤原 俊哉, 田辺 俊介, 藤原 康宏, 元木 崇之, 渡辺 信之, 櫻間 一史, 田淵 陽子, 大多和 泰幸, 鴨 宣之, 西川 敏雄, 高岡 宗徳, 伊藤 充矢, 白川 靖博, 藤原 俊義, 松原 長秀, 岩垣 博巳, 松剛 順治, 羽井佐 実, 田中 紀章

    日本外科学会雑誌   108 ( 2 )   699 - 699   2007.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • DP-180-4 食道癌放射線化学療法施行後に発症した骨髄異形成症候群の検討(第107回日本外科学会定期学術集会)

    田辺 俊介, 猶本 良夫, 藤原 康宏, 櫻間 一史, 高岡 宗徳, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 羽井佐 実, 岩垣 博巳, 松岡 順治, 田中 紀章

    日本外科学会雑誌   108 ( 2 )   679 - 679   2007.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 消化器癌の微小リンパ節転移を標的とする新規ウイルス製剤OBP-301による治療法の開発

    児島 亨, 藤原 俊義, 渡辺 雄一, 橋本 悠里, 酒井 亮, 黒田 新士, 浦田 泰生, 宇野 太, 香川 俊輔, 田中 紀章

    日本外科学会雑誌   108   77 - 77   2007.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter

    Toshiyoshi Fujiwara, Yasuo Urata, Noriaki Tanaka

    CURRENT CANCER DRUG TARGETS   7 ( 2 )   191 - 201   2007.3

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.   Publisher:BENTHAM SCIENCE PUBL LTD  

    Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. For targeting cancer cells, there is a need for tissue- or cell-specific promoters that can express in diverse tumor types and are silent in normal cells. Recent advances in molecular biology have fostered remarkable insights into the molecular basis of neoplasm. Telomerase activation is considered to be a critical step in carcinogenesis and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. Since only tumor cells that express telomerase activity would activate this promoter, the hTERT proximal promoter allows for preferential expression of viral genes in tumor cells, leading to selective viral replication. We constructed an attenuated adenovirus 5 vector (Telotnelysin, OBP-301), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site (IRES). Telomelysin replicated efficiently and induced marked cell killing in a panel of human cancer cell lines, whereas replication as well as cytotoxicity was highly attenuated in normal human cells lacking telomerase activity. Thus, the hTERT promoter confers competence for selective replication of Telomelysin in human cancer cells, an outcome that has important implications for the treatment of human cancers. This article reviews recent findings in this rapidly evolving field: cancer therapeutic and cancer diagnostic approaches using the hTERT promoter.

    DOI: 10.2174/156800907780058835

    Web of Science

    researchmap

  • Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter

    Toshiyoshi Fujiwara, Yasuo Urata, Noriaki Tanaka

    Current Cancer Drug Targets   7 ( 2 )   191 - 201   2007.3

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.  

    Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. For targeting cancer cells, there is a need for tissue- or cell-specific promoters that can express in diverse tumor types and are silent in normal cells. Recent advances in molecular biology have fostered remarkable insights into the molecular basis of neoplasm. Telomerase activation is considered to be a critical step in carcinogenesis and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. Since only tumor cells that express telomerase activity would activate this promoter, the hTERT proximal promoter allows for preferential expression of viral genes in tumor cells, leading to selective viral replication. We constructed an attenuated adenovirus 5 vector (Telomelysin, OBP-301), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site (IRES). Telomelysin replicated efficiently and induced marked cell killing in a panel of human cancer cell lines, whereas replication as well as cytotoxicity was highly attenuated in normal human cells lacking telomerase activity. Thus, the hTERT promoter confers competence for selective replication of Telomelysin in human cancer cells, an outcome that has important implications for the treatment of human cancers. This article reviews recent findings in this rapidly evolving field: cancer therapeutic and cancer diagnostic approaches using the hTERT promoter. © 2007 Bentham Science Publishers Ltd.

    DOI: 10.2174/156800907780058835

    Scopus

    PubMed

    researchmap

  • Clonal and parallel evolution of primary lung cancers and their metastases revealed by molecular dissection of cancer cells

    Kenji Takahashi, Takashi Kohno, Shingo Matsumoto, Yukihiro Nakanishi, Yasuhito Arai, Seiichiro Yamamoto, Toshiyoshi Fujiwara, Noriaki Tanaka, Jun Yokota

    CLINICAL CANCER RESEARCH   13 ( 1 )   111 - 120   2007.1

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Purpose: Several models of cancer progression, including clonal evolution, parallel evolution, and same-gene models, have been proposed to date. The purpose of this study is to investigate the authenticity of these models by comparison of accumulated genetic alterations between primary and corresponding metastatic lung cancers.
    Experimental Design: A whole-genome allelic imbalance scanning using a high-resolution single nucleotide polymorphism array and mutational analysis of the p53, EGFR, and KRAS genes were done on eight sets of primary and metastatic lung cancers. Based on the genotype data, the natural history of each case was deduced, and candidate metastasis suppressor loci were determined.
    Results: Five to 20 chromosomal regions showed allelic imbalance in each tumor. Accumulated genetic alterations were similar between primary and corresponding metastatic tumors, and the majority (&gt;67%) of genetic alterations detected in metastatic tumors was also detected in the corresponding primary tumors. On the other hand, in seven of the eight cases, there were genetic alterations accumulated only in metastatic tumors. Among these alterations, allelic imbalances at chromosome 11p15 and 11p11-p13 regions were the most frequent ones (4 of 8, 50%). Likewise, four cases showed genetic alterations detected only In primary tumors.
    Conclusions: The natural history of each case indicated that the process of metastasis varies among cases, and that all three models are applicable to lung cancer progression. According to the clonal and parallel evolution models, it is possible that a metastasis suppressor gene(s) for lung cancer is present on chromosome 11p.

    DOI: 10.1158/1078-0432.CCR-06-0659

    Web of Science

    researchmap

  • Focal GGO病変に対するCTガイド下肺生検についての検討

    井上大作, 郷原英夫, 三村秀文, 加藤勝也, 平木隆夫, 藤原寛康, 田尻展久, 金澤右, 藤原俊義, 佐野由文, 伊達洋至

    肺癌   47 ( 5 )   2007

  • A case of nodular silicosis mimicking metastatic lung tumors

    62 ( 9 )   1269 - 1271   2007

  • Cisplatin/Docetaxel+同時性放射線照射が奏効し根治手術を施行し得たstage IIIA非小細胞肺癌の1例

    寺石文則, 香川俊輔, 宇野太, 武田洋正, 瀧川奈義夫, 藤原俊義, 田中紀章

    癌と化学療法   34 ( 9 )   1493 - 1495   2007

     More details

  • テロメラーゼ特異的ウイルス製剤の癌診断・治療への応用.

    藤原俊義, 田中紀章

    ゲノム医学   7 ( 2 )   129 - 134   2007

     More details

  • GFP発現ウイルス製剤を用いた消化器癌微小転移のin vivoイメージングシステム.

    藤原俊義, 田中紀章

    医学のあゆみ   220 ( 8 )   659 - 661   2007

     More details

    Language:Japanese   Publisher:医歯薬出版  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2007124851

  • Theranostic application of telomerase-specific oncolytic adenovirus for human cancer

    Japanese journal of clinical medicine   65 ( 10 )   1913 - 1922   2007

  • 「腫瘍外科治療の最前線」癌のウイルス療法.

    藤原俊義, 田中紀章

    外科治療   96 ( Suppl )   368 - 373   2007

     More details

  • Adenoviral p53 Gene Therapy for Lung Cancer

    Fujiwara Toshiyoshi, Tanaka Noriaki

    Okayama Igakkai Zasshi (Journal of Okayama Medical Association)   119 ( 3 )   229?234 - 234   2007

     More details

    Language:Japanese   Publisher:Okayama Medical Association  

    To determine the feasibility, safety, humoral immune response, and biological activity of multiple intratumoral injections of Ad5CMV-p53, and to characterize the pharmacokinetics of Ad5CMV-p53 in patients with advanced non-small cell lung cancer (NSCLC). Fifteen patients with histologically confirmed NSCLC and p53 mutations were enrolled into this phase I trial. Nine patients received escalating dose levels of Ad5CMV-p53 (1 × 109 to 1 × 1011 plaque-forming units[PFU]) as monotherapy once every 4 weeks. Six patients were treated on a 28-day schedule with Ad5CMV-p53 in combination with intravenous administration of cisplatin (80 mg/m2). Patients were monitored for toxicity, vector distribution, antibody formation, and tumor response. Fifteen patients received a total of 63 intratumoral injections of Ad5CMV-p53 without dose-limiting toxicity. The most common treatment-related toxicity was a transient fever. Specific p53 transgene expression was detected using reverse-transcriptase polymerase chain reaction in biopsied tumor tissues throughout the period of treatment despite of the presence of neutralizing anti-adenovirus antibody. Distribution studies revealed that the vector was detected in the gargle and plasma, but rarely in the urine. Thirteen of 15 patients were assessable for efficacy; one patient had a partial response (squamous cell carcinoma at the carina), 10 patients had stable disease, with three lasting ≥9 months, and 2 patients had progressive disease. Multiple courses of intratumoral Ad5CMV-p53 injection alone or in combination with intravenous administration of cisplatin were feasible and well tolerated in advanced NSCLC patients, and appeared to provide clinical benefit.

    DOI: 10.4044/joma.119.229

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://ousar.lib.okayama-u.ac.jp/13215

  • ナノバイオ・ウイルス製剤のがん診断への応用.

    藤原俊義

    Medical Bio   4 ( 7 )   39 - 43   2007

     More details

  • O-8 テロメラーゼ活性を標的とした新規腫瘍融解ウイルスによる悪性胸膜中皮腫の診断と治療(中皮腫, 第47回日本肺癌学会総会)

    藤原 俊義, 渡辺 雄一, 橋本 悠里, 香川 俊輔, 宇野 太, 寺石 文則, 浦田 泰生, 田中 紀章

    肺癌   46 ( 5 )   488 - 488   2006.11

     More details

    Language:Japanese   Publisher:日本肺癌学会  

    CiNii Article

    CiNii Books

    researchmap

  • In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus

    Hiroyuki Kishimoto, Toru Kojima, Yuichi Watanabe, Shunsuke Kagawa, Toshiya Fujiwara, Futoshi Uno, Fuminori Teraishi, Satoru Kyo, Hiroyuki Mizuguchi, Yuuri Hashimoto, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara

    NATURE MEDICINE   12 ( 10 )   1213 - 1219   2006.10

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Currently available methods for detection of tumors in vivo such as computed tomography and magnetic resonance imaging are not specific for tumors. Here we describe a new approach for visualizing tumors whose fluorescence can be detected using telomerase-specific replication-competent adenovirus expressing green fluorescent protein (GFP) (OBP-401). OBP-401 contains the replication cassette, in which the human telomerase reverse transcriptase (hTERT) promoter drives expression of E1 genes, and the GFP gene for monitoring viral replication. When OBP-401 was intratumorally injected into HT29 tumors orthotopically implanted into the rectum in BALB/c nu/nu mice, para-aortic lymph node metastasis could be visualized at laparotomy under a three-chip color cooled charged-coupled device camera. Our results indicate that OBP-401 causes viral spread into the regional lymphatic area and selectively replicates in neoplastic lesions, resulting in GFP expression in metastatic lymph nodes. This technology is adaptable to detect lymph node metastasis in vivo as a preclinical model of surgical navigation.

    DOI: 10.1038/nm1404

    Web of Science

    researchmap

  • Esophageal intramural pseudodiverticulosis with esophageal strictures successfully treated with dilation therapy

    Fuminori Teraishi, Toshiyoshi Fujiwara, Atsushi Jikuhara, Shingo Kamitani, Yasuo Morino, Katsuaki Sato, Noriaki Tanaka

    ANNALS OF THORACIC SURGERY   82 ( 3 )   1119 - 1121   2006.9

     More details

    Language:English   Publisher:ELSEVIER SCIENCE INC  

    We report a rare case of esophageal intramural pseudodiverticulosis with esophageal strictures. Barium esophagogram demonstrated multiple flask-shaped diverticula out of the esophageal wall with comprehensive luminal stenosis involving the proximal 8 cm and distal 4 cm of the esophagus. Chest computed tomographic scan demonstrated round wall thickening and several intramural gas collections of the proximal esophagus. Endoscopy revealed a fibrotic stricture and multiple small orifices of pseudodiverticula with mild inflammatory changes. Biopsy specimens showed active chronic inflammatory changes of the mucosa with candidiasis. Dysphagia improved dramatically with esophageal dilation. However, the tiny diverticula did not resolve after treatment.

    DOI: 10.1016/j.athoracsur.2006.01.062

    Web of Science

    researchmap

  • 1249 慎重な周術期管理を要した重症SLE合併進行食道癌の一例(食道癌治療2,一般演題,第61回日本消化器外科学会定期学術総会)

    藤原 康宏, 猶本 良夫, 岩本 高行, 金澤 卓, 白川 靖博, 山辻 知樹, 藤原 俊義, 岩垣 博巳, 磯崎 博司, 田中 紀章

    日本消化器外科学会雑誌   39 ( 7 )   1196 - 1196   2006.7

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PD-8-3 消化器癌に対するテロメラーゼ活性を標的とした新規ウイルス療法の開発と臨床応用の可能性(消化器癌と分子生物学-臨床応用に向けて-,パネルディスカッション,第61回日本消化器外科学会定期学術総会)

    藤原 俊義, 香川 俊輔, 宇野 太, 寺石 文則, 浦田 泰生, 田中 紀章

    日本消化器外科学会雑誌   39 ( 7 )   975 - 975   2006.7

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 1225 胃原発性GISTの臨床病理学的および免疫組織学的検討 : hTERTの発現の検討を中心に(分子生物学2,一般演題,第61回日本消化器外科学会定期学術総会)

    寺石 文則, 宇野 太, 香川 俊輔, 藤原 俊義, 合地 明, 田中 紀章

    日本消化器外科学会雑誌   39 ( 7 )   1190 - 1190   2006.7

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 0005 放射線治療後に甲状腺低下を認めた食道癌患者の検討(食道良性1,一般演題,第61回日本消化器外科学会定期学術総会)

    金澤 卓, 猶本 良夫, 湯浅 壮司, 白川 靖博, 山辻 知樹, 藤原 俊義, 松原 長秀, 岩垣 博巳, 松岡 順治, 田中 紀章

    日本消化器外科学会雑誌   39 ( 7 )   1037 - 1037   2006.7

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of chemovirotherapy

    Toshiya Fujiwara, Shunsuke Kagawa, Hiroyuki Kishimoto, Yoshikatsu Endo, Masayoshi Hioki, Yoshihiro Ikeda, Ryo Sakai, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara

    INTERNATIONAL JOURNAL OF CANCER   119 ( 2 )   432 - 440   2006.7

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    Oncolytic adenoviruses are being developed as novel anticancer therapeutics and currently undergoing clinical trials. We previously demonstrated that telomerase-specific replication-competent adenovirus (Telomelysin: OBP-301), in which the human telomerase reverse transcriptase (hTERT) promoter regulates viral replication, efficiently killed human tumor cells. We further constructed OBP-401 (Telomelysin-GFP) that expresses the green fluorescent protein (GFP) reporter gene under the control of the cytomegalovirus promoter in the E3 region to monitor viral distribution. Here, we examined the feasibility of a single-agent therapy with OBP-401 as well as of combining OBP-401 with chemotherapeutic agents. Infection of OBP-401 alone or followed by the treatment of a chemotherapeutic drug, docetaxel (Taxotere), resulted in a profound in vitro cytotoxicity and GFP expression in various human cancer cell lines originating from different organs (lung, colon, esophagus, stomach, liver and prostate), although the magnitude of antitumor effect varied among the cell types. Other chemotherapeutic drugs such as vinorelbine (Navelbine) and SN38 (the potent active metabolite of irinotecan) combined with OBP-401 also inhibited the growth of human cancer cells. Quantitative real-time PCR analysis demonstrated that docetaxel did not affect viral replication. For in vivo evaluation, nu/nu mice xenografted with H1299 human lung tumor received intratumoral injection of OBP-401 and intraperitoneal administration of docetaxel. Analysis of growth of implanted tumors showed a significant, therapeutic synergism, although OBP-401 alone and docetaxel alone showed modest inhibition of tumor growth. Thus, OBP-401 in combination with docetaxel efficiently enhances the antitumor efficacy both in vitro and in vivo, and the outcome has important implications for tumor-specific oncolytic chemovirotherapies for human cancers. (c) 2006 Wiley-Liss, Inc.

    DOI: 10.1002/ijc.21846

    Web of Science

    researchmap

  • Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of chemovirotherapy

    Toshiya Fujiwara, Shunsuke Kagawa, Hiroyuki Kishimoto, Yoshikatsu Endo, Masayoshi Hioki, Yoshihiro Ikeda, Ryo Sakai, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara

    INTERNATIONAL JOURNAL OF CANCER   119 ( 2 )   432 - 440   2006.7

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    Oncolytic adenoviruses are being developed as novel anticancer therapeutics and currently undergoing clinical trials. We previously demonstrated that telomerase-specific replication-competent adenovirus (Telomelysin: OBP-301), in which the human telomerase reverse transcriptase (hTERT) promoter regulates viral replication, efficiently killed human tumor cells. We further constructed OBP-401 (Telomelysin-GFP) that expresses the green fluorescent protein (GFP) reporter gene under the control of the cytomegalovirus promoter in the E3 region to monitor viral distribution. Here, we examined the feasibility of a single-agent therapy with OBP-401 as well as of combining OBP-401 with chemotherapeutic agents. Infection of OBP-401 alone or followed by the treatment of a chemotherapeutic drug, docetaxel (Taxotere), resulted in a profound in vitro cytotoxicity and GFP expression in various human cancer cell lines originating from different organs (lung, colon, esophagus, stomach, liver and prostate), although the magnitude of antitumor effect varied among the cell types. Other chemotherapeutic drugs such as vinorelbine (Navelbine) and SN38 (the potent active metabolite of irinotecan) combined with OBP-401 also inhibited the growth of human cancer cells. Quantitative real-time PCR analysis demonstrated that docetaxel did not affect viral replication. For in vivo evaluation, nu/nu mice xenografted with H1299 human lung tumor received intratumoral injection of OBP-401 and intraperitoneal administration of docetaxel. Analysis of growth of implanted tumors showed a significant, therapeutic synergism, although OBP-401 alone and docetaxel alone showed modest inhibition of tumor growth. Thus, OBP-401 in combination with docetaxel efficiently enhances the antitumor efficacy both in vitro and in vivo, and the outcome has important implications for tumor-specific oncolytic chemovirotherapies for human cancers. (c) 2006 Wiley-Liss, Inc.

    DOI: 10.1002/ijc.21846

    Web of Science

    researchmap

  • 当科におけるN4食道癌の治療

    白川 靖博, 猶本 良夫, 岩本 高行, 小林 正彦, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 岩垣 博巳, 松岡 順治, 羽井佐 実, 田中 紀章

    岡山医学会雑誌   118 ( 1 )   85 - 85   2006.5

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • SLEを合併した進行食道癌の一切除例

    岩本 高行, 猶本 良夫, 小林 正彦, 白川 靖博, 山辻 知樹, 小林 直哉, 藤原 俊義, 松原 長秀, 岩垣 博巳, 松岡 順治, 田中 紀章

    岡山医学会雑誌   118 ( 1 )   85 - 85   2006.5

     More details

    Language:Japanese   Publisher:岡山医学会  

    researchmap

  • Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer

    T Fujiwara, N Tanaka, S Kanazawa, S Ohtani, Y Saijo, T Nukiwa, K Yoshimura, T Sato, Y Eto, S Chada, H Nakamura, H Kato

    JOURNAL OF CLINICAL ONCOLOGY   24 ( 11 )   1689 - 1699   2006.4

     More details

    Language:English   Publisher:AMER SOC CLINICAL ONCOLOGY  

    Purpose
    To determine the feasibility, safety, humoral immune response, and biologic activity of multiple intratumoral injections of Ad5CMV-p53, and to characterize the pharmacokinetics of Ad5CMV-p53 in patients with advanced non-small-cell lung cancer (NSCLC).
    Patients and Methods
    Fifteen patients with histologically confirmed NSCLC and p53 mutations were enrolled onto this phase I trial. Nine patients received escalating dose levels of Ad5CMV-p53 (1 X 10(9) to 1 X 10(11) plaque-forming units) as monotherapy once every 4 weeks. Six patients were treated on a 28-day schedule with Ad5CMV-p53 in combination with intravenous administration of cisplatin (80 mg/m(2)). Patients were monitored for toxicity, vector distribution, antibody formation, and tumor response.
    Results
    Fifteen patients received a total of 63 intratumoral injections of Ad5CMV-p53 without dose-limiting toxicity. The most common treatment-related toxicity was a transient fever. Specific p53 transgene expression was detected using reverse-transcriptase polymerase chain reaction in biopsied tumor tissues throughout the period of treatment despite of the presence of neutralizing antiadenovirus antibody. Distribution studies revealed that the vector was detected in the gargle and plasma, but rarely in the urine. Thirteen of 15 patients were assessable for efficacy; one patient had a partial response (squamous cell carcinoma at the Carina), 10 patients had stable disease, with three lasting at least 9 months, and two patients had progressive disease.
    Conclusion
    Multiple courses of intratumoral Ad5CMV-p53 injection alone or in combination with intravenous administration of cisplatin were feasible and well tolerated in advanced NSCLC patients, and appeared to provide clinical benefit.

    DOI: 10.1200/JCO.2005.03.4116

    Web of Science

    researchmap

  • 追加発言 : テロメラーゼ特異的GFP蛍光発現ウイルス製剤OBP-401を用いた消化器癌微小転移のin vivoイメージング・システムの開発

    児島 亨, 藤原 俊義, 岸本 浩行, 橋本 悠里, 香川 俊輔, 宇野 太, 浦田 泰生, 田中 紀章

    日本外科学会雑誌   107 ( 2 )   176 - 176   2006.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • K-ras変異型腫瘍に対するプロテアソームインヒビターbortezomibの有用性およびその作用機序に関する検討

    寺石 文則, Fang Bingliang, Liu Jinsong, 白澤 専二, 笹月 健彦, 香川 俊輔, 藤原 俊義, 田中 紀章

    日本外科学会雑誌   107 ( 2 )   607 - 607   2006.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Three cases of adenocarcinoma arising in extremely long-segment Barrett's esophagus

    T Fujiwara, Y Naomoto, T Yamatsuji, Y Shirakawa, H Noguchi, T Fujiwara, N Oohara, M Gunduz, H Nagatsuka, M Nishie, H Uetsuka, S Hamazaki, N Tanaka

    DIGESTIVE DISEASES AND SCIENCES   51 ( 3 )   533 - 538   2006.3

     More details

    Language:English   Publisher:SPRINGER  

    DOI: 10.1007/s10620-006-3166-3

    Web of Science

    researchmap

  • Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells

    T Watanabe, M Hioki, T Fujiwara, M Nishizaki, S Kagawa, M Taki, H Kishimoto, Y Endo, Y Urata, N Tanaka, T Fujiwara

    EXPERIMENTAL CELL RESEARCH   312 ( 3 )   256 - 265   2006.2

     More details

    Language:English   Publisher:ELSEVIER INC  

    Replication-competent oncolytic viruses are being developed for human cancer therapy. We previously reported that an attenuated adenovirus OBP-301 (Telomelysin), in which the human telomerase reverse transcriptase promoter element drives expression of EIA and El B genes linked with an internal ribosome entry site, could replicate in and causes selective lysis, of human cancer cells. Infection efficiency in target cancer cells is the most important factor that predicts the antitumor effects of OBP-301. The ob objectives of this study are to examine the effects of the histone deacetylase inhibitor FR901228 on the level of coxsackie and adenovirus receptor (CAR) expression and OBP-301-mediated oncolysis in human non-small cell lung cancer cell lines. Flow cytometric analysis revealed up-regulated CAR expression in A549 and H460 cells following treatment with 1 ng/ml of FR901228. which was associated with increased infection efficiency as confirmed by replication-deficient beta-galactosidase-expressing adenovirus vector. In contrast. neither CAR expression nor infection efficiency was affected by FR901228 in H1299 cells. To visualize and quantify viral replication in the presence of FR901228, we used 01311-401 (Telomelysin-GFP) that expresses the green fluorescent protein (GFP) reporter gene under the control of the cytomegalovirus promoter in the E3 region. Fluorescence microscopy and flow cytometry showed that FR901228 increased GFP expression in A549 and 11460 cells following OBP-401 infection in a dose-dependent manner, but this effect did not occur in H1299 cells. In addition. OBP-301 and FR901228 demonstrated a synergistic antitumor effect in A549 cells in vitro, as confirmed by isobologram analysis. Our data indicate that FR901228 preferentially increases adenovirus infectivity via up-regulation of CAR expression, leading to a profound oncolytic effect, which may have a significant impact on the outcome of adenovirus-based oncolytic virotherapy. (c) 2005 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.yexcr.2005.10.026

    Web of Science

    researchmap

  • Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer.

    Takahashi K, Kohno T, Ajima R, Sasaki H, Minna JD, Fujiwara T, Tanaka N, Yokota J

    Int J Oncol   2006

     More details

  • テロメラーゼ特異的に増幅するGFP蛋白を用いたマウスの固形腫瘍の胸膜播種の可視化

    梅岡達生, 川嶋健, 香川俊輔, 寺石文則, 滝正樹, 京哲, 永井勝幸, 浦田泰生, 田中紀章, 藤原俊義

    岡山医学会雑誌   2006

  • 症例報告 多発肝転移を伴う進行性胃癌に対するイリノテカンと低用量シスプラチン化学療法に併用したゲノシタビンに対する顕著な反応

    寺石文則, 宇野太, 香川俊輔, 合地明, 藤原俊義, 田中紀章

    癌と化学療法   2006

     More details

  • CPT-11+Low-Dose 5-FU+CDDP療法が著効した多発肝転移を有する噴門部胃癌の1例

    香川俊輔, 藤原俊義, 徳永尚之, 西崎正彦, 宇野太, 寺石文則, 合地明, 松岡順治, 田中紀章

    癌と化学療法   2006

     More details

  • 早期診断し得た食道癌術後静脈血栓塞栓症の2例

    金澤卓, 渡辺信之, 猶本良夫, 小林正彦, 白川靖博, 山辻知樹, 小林直哉, 藤原俊義, 松原長秀, 岩垣博巳, 松岡順治, 田中紀章

    岡山医学会雑誌   2006

  • 胃癌術後縦隔リンパ節再発による気管狭窄にステント+放射線治療が奏効した1例

    香川俊輔, 藤原俊義, 西崎正彦, 徳永尚之, 合地明, 田中紀章

    癌と化学療法   2006

     More details

  • 主要癌の遺伝子治療研究の現況:肺癌.

    藤原俊義, 田中紀章

    Biotherapy   20: 270-279   2006

     More details

  • 大学発ベンチャーの研究開発-悪性腫瘍に対するウイルス製剤Telomelysinの臨床開発-

    藤原俊義, 田中紀章, 浦田泰生

    Biotherapy   20,3,310-317   2006

     More details

  • 大学発ベンチャーの研究開発:悪性腫瘍に対するウイルス製剤Telomelysinの臨床開発.

    藤原俊義, 田中紀章, 浦田泰生

    Biotherapy   20: 310-317   2006

     More details

  • 主要癌の遺伝子治療研究の現況-肺癌-

    藤原俊義, 田中紀章

    Biotherapy   20,3,270-279   2006

     More details

  • ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma

    F Teralshi, S Kagawa, T Watanabe, Y Tango, T Kawashima, T Umeoka, M Nisizaki, N Tanaka, T Fujiwara

    FEBS LETTERS   579 ( 19 )   4069 - 4075   2005.8

     More details

    Language:English   Publisher:ELSEVIER SCIENCE BV  

    The EGF (epidermal growth factor) receptor-tyrosine kinase inhibitor ZD1839 (Getitinib, 'Iressa') blocks the cell signaling pathways involved in cell proliferation, survival, and angiogenesis in various cancer cells. TNF-related death apoptosis inducing ligand (TRAIL) acts as an anticancer agent. We investigated the antitumor effects of ZD-1839 alone or in combination with TRAIL against human esophageal squamous cell cancer (ESCC) lines. Although all ESCC cells expressed EGF receptor at a protein level, the effect of ZD1839 on cell growth did not correlate with the level of EGFR expression and phosphorylation of EGF receptor protein in ESCC lines. ZD1839 caused a dose-dependent growth arrest at GO-G, phase associated with increased p27 expression. As TE8 cells are resistant to TRAIL, we tested whether ZD1839 combined with TRAIL induced apoptosis of TE8 cells via the inhibition of EGF receptor signaling by ZD1839. ZD1839 inhibited the phosphorylation of Akt, and enhanced TRAIL-induced apoptosis via activation of caspase-3 and caspase-9, and inactivation of Bcl-xL. Our results indicated that ZD1839 has anti-cancer properties against human esophageal cancer cells. ZD1839 also augmented the anti-cancer activity of TRAIL, even in TRAIL-resistant tumors. These results suggest that treatment with ZD1839 and TRAIL may have potential in the treatment of ESCC patients. (c) 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

    DOI: 10.1016/j.febslet.2005.06.031

    Web of Science

    researchmap

  • Alport 症候に合併した食道び漫性平滑筋腫の1例(食道・胃・十二指腸18, 第60回日本消化器外科学会総会)

    西江 学, 猶本 良夫, 山辻 知樹, 白川 靖博, 浅海 信也, 藤原 俊義, 松原 長秀, 岩垣 博巳, 磯崎 博司, 田中 紀章

    日本消化器外科学会雑誌   38 ( 7 )   1209 - 1209   2005.7

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria

    Y Arima, M Nitta, S Kuninaka, DW Zhang, T Fujiwara, Y Taya, M Nakao, H Saya

    JOURNAL OF BIOLOGICAL CHEMISTRY   280 ( 19 )   19166 - 19176   2005.5

     More details

    Language:English   Publisher:AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC  

    The tumor suppressor p53 functions as a transcriptional activator to induce cell cycle arrest and apoptosis in response to DNA damage. Although p53 was also shown to mediate apoptosis in a manner independent of its transactivation activity, the mechanism and conditions that trigger such cell death have remained largely unknown. We have now shown that inhibition of RNA polymerase II-mediated transcription by &alpha;-amanitin or RNA interference induced p53-dependent apoptosis. Inhibition of pol II-mediated transcription resulted in down-regulation of p21(Cip1), which was caused by both transcriptional suppression and protein degradation, despite eliciting p53 accumulation, allowing the cells to progress into S phase and then to undergo apoptosis. This cell death did not require the transcription of p53 target genes and was preceded by translocation of the accumulated p53 to mitochondria. Our data thus suggested that blockade of pol II-mediated transcription induced p53 accumulation in mitochondria and was the critical factor for eliciting p53-dependent but transcription-independent apoptosis.

    DOI: 10.1074/jbc.M410691200

    Web of Science

    researchmap

  • Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD)

    M Taki, S Kagawa, M Nishizaki, H Mizuguchi, T Hayakawa, S Kyo, K Nagai, Y Urata, N Tanaka, T Fujiwara

    ONCOGENE   24 ( 19 )   3130 - 3140   2005.4

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Replication-competent oncolytic viruses are being developed for human cancer therapy. We previously reported that an attenuated adenovirus (OBP-301, 'Telomelysin'), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an IRES, could replicate in cancer cells, and causes selective lysis of cancer cells. We further constructed OBP-405 ('Telomelysin-RGD') that contains an RGD motif in the HI loop of the fiber knob. We examined whether OBP-405 could be effective in overcoming the limitations of OBP-301, specifically their inefficient infection into cells lacking the primary receptor, the coxsackievirus and adenovirus receptor ( CAR). By flow cytometric analysis, H1299 ( lung) and SW620 ( colorectal) tumor cells showed high levels of CAR expression, whereas LN444 ( glioblastoma), LNZ308 ( glioblastoma), and H1299-R5 ( lung) tumor cells were negative for CAR expression. A quantitative realtime PCR analysis demonstrated that fiber-modified OBP-405 infected more efficiently than OBP-301, although the intracellular replication rate of both viruses was consistent. The comparative antitumor effect of fiber-modified OBP-405 and unmodified OBP-301 for human cancer cells was evaluated in vitro by XTT assay as well as in vivo by using athymic mice carrying xenografts. OBP-405 had a profound oncolytic effect on human cancer cell lines compared to OBP-301, in particular on cells with low CAR expression. Intratumoral injection of 107 plaque-forming units of OBP-405 into CAR-negative H1299-R5 lung tumor xenografts in nu/nu mice resulted in a significant inhibition of tumor growth and long-term survival in all treated mice. Moreover, selective replication of OBP-405 in the distant, uninjected H1299-R5 tumors was demonstrated. Our results suggest that fiber-modified replication-competent adenovirus OBP-405 exhibits a broad target range by increasing infection efficiency, an outcome that has important implications for the treatment of human cancers.

    DOI: 10.1038/sj.onc.1208460

    Web of Science

    researchmap

  • 重症糖尿病合併胸部食道癌に対する糖質調整流動食Inslowの糖質・脂質代謝改善効果の検討

    藤原俊哉, 猶本良夫, 元木崇之, 繁光 薫, 白川靖博, 山辻知樹, 片岡正文, 羽井佐実, 羽井佐茂, 藤原俊義, 有馬裕史, 佐々木一, 松浦 基, 田中紀章

    外科治療   2005

     More details

  • Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce cytotoxic T-lymphocytes against p53-overexpressing human cancer cells.

    Tokunaga N, Murakami T, Endo Y, Nishizaki M, Kagawa S, Tanaka N, Fujiwara T

    Cancer Res   2005

     More details

  • 肺悪性腫瘍のラジオ波治療

    金澤 右, 三村秀文, 郷原英夫, 向井 敦, 平木隆夫, 長谷総一郎, 藤原寛康, 田尻展久, 佐野由文, 清水信義, 藤原俊義, 田中紀章

    成人病と生活習慣病   2005

     More details

  • 癌に対する遺伝子治療:肺癌

    藤原俊義, 香川俊輔, 田中紀章

    遺伝子診療学(日本臨床 増刊号)   63,507-511   2005

     More details

  • 悪性腫瘍に対するウイルス製剤:Telomelysinの開発と臨床応用の可能性

    藤原俊義, 田中紀章

    Medical Technology   33,961-966   2005

     More details

  • P53遺伝子発現アデノウイルスベクターを用いた肺癌遺伝子治療

    藤原俊義, 田中紀章

    Surgery Frontier   12,53-56   2005

     More details

  • 遊離空腸パッチグラフトによる頚部食道再建術

    桜間一史, 猶本良夫, 野間和広, 浅海信也, 白川靖博, 山辻知樹, 藤原俊義, 松原長秀, 羽井佐実

    岡山医学会雑誌   116 ( 3 )   2005

  • Alport症候群に合併した食道びまん性平滑筋腫症の一例

    西江学, 猶本良夫, 野間和広, 白川靖博, 浅海信也, 山辻知樹, 藤原俊義, 松原長秀, 羽井佐実, 岩垣博巳, 松岡順治, 田中紀章

    岡山医学会雑誌   117 ( 2 )   2005

  • 食道癌術後にみられたToxic Shock Syndromeの検討

    山辻知樹, 楢本良夫, 渡辺信之, 野間和広, 桜間一史, 小林正彦, 白川靖博, 小林直哉, 藤原俊義, 松原長秀, 羽井佐実, 岩垣博巳, 松岡順治, 田中紀章

    日本臨床外科学会雑誌   66   2005

  • 当科における食道部分切除術の検討

    白川靖博, 猶本良夫, 野間和広, 西江学, 浅海信也, 山辻知樹, 藤原俊義, 松原長秀, 羽井佐実, 岩垣博巳, 松岡順治, 田中紀章

    岡山医学会雑誌   117 ( 2 )   2005

  • DP皮弁を用いた食道再建法

    猶本良夫, 渡辺信之, 野間和広, 桜間一史, 小林正彦, 白川靖博, 山辻知樹, 小林直哉, 藤原俊義, 松原長秀, 岩垣博巳, 田中紀章

    日本臨床外科学会雑誌   66   2005

  • 集学的治療が奏功した胸部大動脈浸潤食道癌の一例

    西江学, 猶本良夫, 野間和弘, 浅海信也, 白川靖博, 山辻知樹, 藤原俊義, 松原長秀, 岩垣博己, 田中紀章

    岡山医学会雑誌   117 ( 2 )   2005

  • Free jejunal graft for hypopharyngeal and esophageal reconstruction

    Y Shirakawa, Y Naomoto, K Noma, R Ono, T Nobuhisa, M Kobayashi, T Fujiwara, H Noguchi, T Ohkawa, T Yamatsuji, M Haisa, J Matsuoka, M Gunduz, N Tanaka

    LANGENBECKS ARCHIVES OF SURGERY   389 ( 5 )   387 - 390   2004.10

     More details

    Language:English   Publisher:SPRINGER  

    Aims: This study assessed the techniques of the free jejunal graft for the reconstruction of hypopharynx or cervical esophagus and discussed the main aspects related to those procedures. Methods and results: By using free jejunal grafts, we reconstructed 54 hypopharyngeal and cervical esophageal cancers. In this study, 23 out of 54 patients had a malignant tumor located in the hypopharynx and 31 in the cervical esophagus (27 primary cases and four secondary cases). Despite the multi-step and time-consuming procedure, we did not incur any trans-operative complication. Furthermore, we undertook the larynx preserving cervical esophagectomy and free jejunal graft reconstruction in six patients with cervical esophageal cancer, and those patients acquired a good quality of life. Conclusion: For the reconstruction of hypopharynx or cervical esophagus, the free jejunal graft is a very useful technique and improves the patient's quality of life.

    DOI: 10.1007/s00423-004-0501-z

    Web of Science

    researchmap

  • Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene

    Tatsuo Umeoka, Takeshi Kawashima, Shunsuke Kagawa, Fuminori Teraishi, Masaki Taki, Masahiko Nishizaki, Satoru Kyo, Katsuyuki Nagai, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara

    Cancer Research   64 ( 17 )   6259 - 6265   2004.9

     More details

    Language:English  

    Currently available methods for detection of tumors in vivo such as X-ray, computed tomography, and ultrasonography are noninvasive and have been well studied
    the images, however, are not specific for tumors. Direct optical imaging of tumor cells in vivo that can clearly distinguish them from surrounding normal tissues may be clinically useful. Here, we describe a new approach to visualizing tumors whose fluorescence can be detected using tumor-specific replication-competent adenovirus (OBP-301, Telomelysin) in combination with Ad-GFP, a replication-deficient adenovirus expressing green fluorescent protein (GFP). Human telomerase reverse transcriptase is the catalytic subunit of telomerase, which is highly active in cancer cells but quiescent in most normal somatic cells. We constructed an adenovirus 5 vector in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site and showed that OBP-301 replicated efficiently in human cancer cells, but not in normal cells such as human fibroblasts. When the human lung and colon cancer cell lines were infected with Ad-GFP at a low multiplicity of infection, GFP expression could not be detected under a fluorescence microscope
    in the presence of OBP-301, however, Ad-GFP replicated in these tumor cells and showed strong green signals. In contrast, coinfection with OBP-301 and Ad-GFP did not show any signals in normal cells such as fibroblasts and vascular endothelial cells. We also found that established subcutaneous tumors could be visualized after intratumoral injection of OBP-301 and Ad-GFP. A549 human lung tumors and SW620 human colon tumors transplanted into BALB/c nu/nu mice were intratumorally injected with 8 × 105 plaque-forming units of Ad-GFP in combination with 8 × 106 plaque-forming units of OBP-301. Within 3 days of treatment, the fluorescence of the expressed GFP became visible by a three-chip color cooled charged-coupled device camera in these tumors, whereas intratumoral injection of Ad-GFP alone could not induce GFP fluorescence. Moreover, intrathoracic administration of Ad-GFP and OBP-301 could visualize disseminated A549 tumor nodules in mice after intrathoracic implantation. Our results indicate that intratumoral or intrathoracic injection of Ad-GFP in combination with OBP-301 might be a useful diagnostic method that provides a foundation for future clinical application.

    DOI: 10.1158/0008-5472.CAN-04-1335

    Scopus

    PubMed

    researchmap

  • Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene

    Tatsuo Umeoka, Takeshi Kawashima, Shunsuke Kagawa, Fuminori Teraishi, Masaki Taki, Masahiko Nishizaki, Satoru Kyo, Katsuyuki Nagai, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara

    Cancer Research   64 ( 17 )   6259 - 6265   2004.9

     More details

    Language:English  

    Currently available methods for detection of tumors in vivo such as X-ray, computed tomography, and ultrasonography are noninvasive and have been well studied
    the images, however, are not specific for tumors. Direct optical imaging of tumor cells in vivo that can clearly distinguish them from surrounding normal tissues may be clinically useful. Here, we describe a new approach to visualizing tumors whose fluorescence can be detected using tumor-specific replication-competent adenovirus (OBP-301, Telomelysin) in combination with Ad-GFP, a replication-deficient adenovirus expressing green fluorescent protein (GFP). Human telomerase reverse transcriptase is the catalytic subunit of telomerase, which is highly active in cancer cells but quiescent in most normal somatic cells. We constructed an adenovirus 5 vector in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site and showed that OBP-301 replicated efficiently in human cancer cells, but not in normal cells such as human fibroblasts. When the human lung and colon cancer cell lines were infected with Ad-GFP at a low multiplicity of infection, GFP expression could not be detected under a fluorescence microscope
    in the presence of OBP-301, however, Ad-GFP replicated in these tumor cells and showed strong green signals. In contrast, coinfection with OBP-301 and Ad-GFP did not show any signals in normal cells such as fibroblasts and vascular endothelial cells. We also found that established subcutaneous tumors could be visualized after intratumoral injection of OBP-301 and Ad-GFP. A549 human lung tumors and SW620 human colon tumors transplanted into BALB/c nu/nu mice were intratumorally injected with 8 × 105 plaque-forming units of Ad-GFP in combination with 8 × 106 plaque-forming units of OBP-301. Within 3 days of treatment, the fluorescence of the expressed GFP became visible by a three-chip color cooled charged-coupled device camera in these tumors, whereas intratumoral injection of Ad-GFP alone could not induce GFP fluorescence. Moreover, intrathoracic administration of Ad-GFP and OBP-301 could visualize disseminated A549 tumor nodules in mice after intrathoracic implantation. Our results indicate that intratumoral or intrathoracic injection of Ad-GFP in combination with OBP-301 might be a useful diagnostic method that provides a foundation for future clinical application.

    DOI: 10.1158/0008-5472.CAN-04-1335

    Scopus

    PubMed

    researchmap

  • Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene

    Tatsuo Umeoka, Takeshi Kawashima, Shunsuke Kagawa, Fuminori Teraishi, Masaki Taki, Masahiko Nishizaki, Satoru Kyo, Katsuyuki Nagai, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara

    Cancer Research   64 ( 17 )   6259 - 6265   2004.9

     More details

    Language:English  

    Currently available methods for detection of tumors in vivo such as X-ray, computed tomography, and ultrasonography are noninvasive and have been well studied
    the images, however, are not specific for tumors. Direct optical imaging of tumor cells in vivo that can clearly distinguish them from surrounding normal tissues may be clinically useful. Here, we describe a new approach to visualizing tumors whose fluorescence can be detected using tumor-specific replication-competent adenovirus (OBP-301, Telomelysin) in combination with Ad-GFP, a replication-deficient adenovirus expressing green fluorescent protein (GFP). Human telomerase reverse transcriptase is the catalytic subunit of telomerase, which is highly active in cancer cells but quiescent in most normal somatic cells. We constructed an adenovirus 5 vector in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site and showed that OBP-301 replicated efficiently in human cancer cells, but not in normal cells such as human fibroblasts. When the human lung and colon cancer cell lines were infected with Ad-GFP at a low multiplicity of infection, GFP expression could not be detected under a fluorescence microscope
    in the presence of OBP-301, however, Ad-GFP replicated in these tumor cells and showed strong green signals. In contrast, coinfection with OBP-301 and Ad-GFP did not show any signals in normal cells such as fibroblasts and vascular endothelial cells. We also found that established subcutaneous tumors could be visualized after intratumoral injection of OBP-301 and Ad-GFP. A549 human lung tumors and SW620 human colon tumors transplanted into BALB/c nu/nu mice were intratumorally injected with 8 × 105 plaque-forming units of Ad-GFP in combination with 8 × 106 plaque-forming units of OBP-301. Within 3 days of treatment, the fluorescence of the expressed GFP became visible by a three-chip color cooled charged-coupled device camera in these tumors, whereas intratumoral injection of Ad-GFP alone could not induce GFP fluorescence. Moreover, intrathoracic administration of Ad-GFP and OBP-301 could visualize disseminated A549 tumor nodules in mice after intrathoracic implantation. Our results indicate that intratumoral or intrathoracic injection of Ad-GFP in combination with OBP-301 might be a useful diagnostic method that provides a foundation for future clinical application.

    DOI: 10.1158/0008-5472.CAN-04-1335

    Scopus

    PubMed

    researchmap

  • テロメラーゼ特異的制限増殖型アデノウイルスTelomelysinと微小管作用型抗癌剤の併用効果の検討

    藤原俊哉, 藤原俊義, 香川俊輔, 滝正樹, 岸本浩行, 渡辺貴紀, 遠藤芳克, 京哲, 水口裕之

    日本癌学会総会記事   63rd   510   2004.8

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • PPS-2-026 p53蛋白質をパルスしたヒト抹消血単核球由来の樹状細胞を用いた胃癌の新しい免疫療法(胃分子生物2)

    香川 俊輔, 藤原 俊義, 徳永 尚之, 西崎 正彦, 松岡 順治, 合地 明, 田中 紀章

    日本消化器外科学会雑誌   37 ( 7 )   1214 - 1214   2004.7

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene

    Takayoshi Murakami, Naoyuki Tokunaga, Toshihiko Waku, Shinya Gomi, Shunsuke Kagawa, Noriaki Tanaka, Toshiyoshi Fujiwara

    Clinical Cancer Research   10 ( 11 )   3871 - 3880   2004.6

     More details

    Language:English  

    Purpose: Dendritic cells (DCs) are attractive effectors for cancer immunotherapy because of their potential to function as professional antigen-presenting cells for initiating cellular immune responses. The tumor suppressor gene p53 is pivotal in the regulation of apoptosis, and ∼50% of human malignancies exhibit mutation and aberrant expression of p53. We investigated the antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene. Experimental Design: We examined whether intratumoral administration of DCs infected with recombinant adenovirus expressing murine wild-type p53 (Ad-mp53) could induce systemic antitumor responses against mutant p53-expressing tumors, highly immunogenic MethA, or weakly immunogenic MCA-207 implanted in syngeneic mice. Results: Accumulation of wild-type p53 protein in bone marrow-derived murine DCs could he successfully achieved by Ad-mp53 infection. Treatment with intratumoral injection of Ad-mp53-transduced DCs caused a marked reduction in the in vivo growth of established MethA and MCA-207 tumors with massive cellular infiltrates. Administration of p53-expressing DCs suppressed the growth of both injected MCA-207 tumors and untreated distant MCA-207 tumors, but not unrelated Lewis lung carcinoma tumors, suggesting the augmentation of systemic immunogenicity against MCA-207 tumor cells. Moreover, intratumoral injection of p53-expressing DCs had a greater antitumor effect than did s.c. immunization. Conclusions: Our results indicate that intratumoral administration of DCs expressing murine wild-type p53 leads to significant systemic immune responses and potent antitumor effects in mutant p53-expressing murine cancer models. These findings raise the possibility of using this strategy of intratumoral injection of p53-expressing DCs for human cancer treatment.

    DOI: 10.1158/1078-0432.CCR-03-0599

    Scopus

    PubMed

    researchmap

  • Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene

    Takayoshi Murakami, Naoyuki Tokunaga, Toshihiko Waku, Shinya Gomi, Shunsuke Kagawa, Noriaki Tanaka, Toshiyoshi Fujiwara

    Clinical Cancer Research   10 ( 11 )   3871 - 3880   2004.6

     More details

    Language:English  

    Purpose: Dendritic cells (DCs) are attractive effectors for cancer immunotherapy because of their potential to function as professional antigen-presenting cells for initiating cellular immune responses. The tumor suppressor gene p53 is pivotal in the regulation of apoptosis, and ∼50% of human malignancies exhibit mutation and aberrant expression of p53. We investigated the antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene. Experimental Design: We examined whether intratumoral administration of DCs infected with recombinant adenovirus expressing murine wild-type p53 (Ad-mp53) could induce systemic antitumor responses against mutant p53-expressing tumors, highly immunogenic MethA, or weakly immunogenic MCA-207 implanted in syngeneic mice. Results: Accumulation of wild-type p53 protein in bone marrow-derived murine DCs could he successfully achieved by Ad-mp53 infection. Treatment with intratumoral injection of Ad-mp53-transduced DCs caused a marked reduction in the in vivo growth of established MethA and MCA-207 tumors with massive cellular infiltrates. Administration of p53-expressing DCs suppressed the growth of both injected MCA-207 tumors and untreated distant MCA-207 tumors, but not unrelated Lewis lung carcinoma tumors, suggesting the augmentation of systemic immunogenicity against MCA-207 tumor cells. Moreover, intratumoral injection of p53-expressing DCs had a greater antitumor effect than did s.c. immunization. Conclusions: Our results indicate that intratumoral administration of DCs expressing murine wild-type p53 leads to significant systemic immune responses and potent antitumor effects in mutant p53-expressing murine cancer models. These findings raise the possibility of using this strategy of intratumoral injection of p53-expressing DCs for human cancer treatment.

    DOI: 10.1158/1078-0432.CCR-03-0599

    Scopus

    PubMed

    researchmap

  • Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene

    Takayoshi Murakami, Naoyuki Tokunaga, Toshihiko Waku, Shinya Gomi, Shunsuke Kagawa, Noriaki Tanaka, Toshiyoshi Fujiwara

    Clinical Cancer Research   10 ( 11 )   3871 - 3880   2004.6

     More details

    Language:English  

    Purpose: Dendritic cells (DCs) are attractive effectors for cancer immunotherapy because of their potential to function as professional antigen-presenting cells for initiating cellular immune responses. The tumor suppressor gene p53 is pivotal in the regulation of apoptosis, and ∼50% of human malignancies exhibit mutation and aberrant expression of p53. We investigated the antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene. Experimental Design: We examined whether intratumoral administration of DCs infected with recombinant adenovirus expressing murine wild-type p53 (Ad-mp53) could induce systemic antitumor responses against mutant p53-expressing tumors, highly immunogenic MethA, or weakly immunogenic MCA-207 implanted in syngeneic mice. Results: Accumulation of wild-type p53 protein in bone marrow-derived murine DCs could he successfully achieved by Ad-mp53 infection. Treatment with intratumoral injection of Ad-mp53-transduced DCs caused a marked reduction in the in vivo growth of established MethA and MCA-207 tumors with massive cellular infiltrates. Administration of p53-expressing DCs suppressed the growth of both injected MCA-207 tumors and untreated distant MCA-207 tumors, but not unrelated Lewis lung carcinoma tumors, suggesting the augmentation of systemic immunogenicity against MCA-207 tumor cells. Moreover, intratumoral injection of p53-expressing DCs had a greater antitumor effect than did s.c. immunization. Conclusions: Our results indicate that intratumoral administration of DCs expressing murine wild-type p53 leads to significant systemic immune responses and potent antitumor effects in mutant p53-expressing murine cancer models. These findings raise the possibility of using this strategy of intratumoral injection of p53-expressing DCs for human cancer treatment.

    DOI: 10.1158/1078-0432.CCR-03-0599

    Scopus

    PubMed

    researchmap

  • Thoracic tumors treated with CT-guided radiofrequency ablation: Initial experience

    K Yasui, S Kanazawa, Y Sano, T Fujiwara, S Kagawa, H Mimura, S Dendo, T Mukai, H Fujiwara, T Iguchi, T Hyodo, N Shimizu, N Tanaka, Y Hiraki

    RADIOLOGY   231 ( 3 )   850 - 857   2004.6

     More details

    Language:English   Publisher:RADIOLOGICAL SOC NORTH AMERICA  

    PURPOSE: To determine the effectiveness of computed tomography (CT)-guided radiofrequency (RF) ablation of malignant thoracic tumors.
    MATERIALS AND METHODS: CT-guided RF ablations of 99 malignant thoracic tumors (3-80 mm in largest diameter; mean, 19.5 mm) were performed in 35 patients in 54 sessions. Ablation was performed with an RF generator by using a single internally cooled electrode. Tumors were both primary (three lesions) and, secondary (pulmonary or pleural metastases, 96 lesions). Follow-up was 1-17 months (mean, 7.1 months). Follow-up CT and histopathologic examinations were evaluated. Univariate analysis was performed with the Fisher exact test and Welch, t test was used to evaluate differences between group means. P &lt; .05 represented a significant difference. The maximal diameter of each residual tumor or local recurrence or the proportion of primary lesions of pulmonary metastatic tumors with recurrence after RF ablation were analyzed. Complications, management, and outcomes of the complications were recorded.
    RESULTS: The appearance of each ablation zone, including the target tumor and surrounding normal lung parenchyma, showed involution at follow-up CT. Local recurrence was demonstrated histopathologically or radiologically in nine tumors. The other 90 tumors showed no growth progression at follow-up CT. Probable complete coagulation necrosis obtained with initial RF ablation was achieved in 91% (90 of 99) of the tumors. The mean maximal diameter of the nine tumors (19.6 mm +/- 7.7 [SD]) was not significantly different (P = .994) from that of the other 90 tumors (19.5 mm +/- 13.0). Primary lesions of those nine metastatic tumors varied and did not demonstrate a specific tendency. Complications included pneumothorax, fever higher than 37.5&DEG;C, hemoptysis, cough, pleural effusion, abscess formation, and hemothorax. The overall complication rate was 76% (41 of 54 sessions).
    CONCLUSION: RF ablation seems to be a promising treatment for malignant (C) RSNA, 2004.

    DOI: 10.1148/radiol.2313030347

    Web of Science

    researchmap

  • Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells

    Yasuhisa Tango, Masaki Taki, Yoshiko Shirakiya, Shoichiro Ohtani, Naoyuki Tokunaga, Yosuke Tsunemitsu, Shunsuke Kagawa, Toru Tani, Noriaki Tanaka, Toshiyoshi Fujiwara

    Cancer Science   95 ( 5 )   459 - 463   2004.5

     More details

    Language:English  

    Adenovirus-mediated wild-type p53 gene transfer induces apoptosis in a variety of human cancer cells. Although clinical trials have demonstrated that a replication-deficient recombinant adenovirus expressing the wild-type p53 gene (Ad-p53) is effective in suppressing growth of non-small cell lung cancer (NSCLC), we often experienced late resistance to this treatment. To elucidate the mechanism of late resistance to Ad-p53 in human lung cancer cells, we generated 5 different resistant variants from p53-susceptible H1299 NSCLC cells by repeated infections with Ad-p53. We first examined the transduction efficiency of adenoviral vector by Ad-LacZ transduction followed by X-gal staining in parental and 5 resistant H1299 cell lines. Their sensitivity to viral infection decreased in correlation with the magnitude of resistance, and Ad-p53-mediated tumor suppression could be restored by dose escalation of Ad-p53 in the resistant variants. The expression of Coxsackie and adenovirus receptor (CAR) and αV integrins, which are cellular receptors for attachment and internalization of the virus, respectively, was next investigated in these cell lines. Flow cytometry revealed that αVβ3 and αVβ5 integrin expression was consistent, while p53-resistant cell lines showed that diminished CAR expression correlated with the magnitude of the resistance. Our results demonstrated that decreased CAR expression could be one of the mechanisms of late resistance to Ad-p53, which may have a significant impact on the outcome of adenovirus-based cancer gene therapy.

    DOI: 10.1111/j.1349-7006.2004.tb03232.x

    Scopus

    PubMed

    researchmap

  • Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells

    Yasuhisa Tango, Masaki Taki, Yoshiko Shirakiya, Shoichiro Ohtani, Naoyuki Tokunaga, Yosuke Tsunemitsu, Shunsuke Kagawa, Toru Tani, Noriaki Tanaka, Toshiyoshi Fujiwara

    Cancer Science   95 ( 5 )   459 - 463   2004.5

     More details

    Language:English  

    Adenovirus-mediated wild-type p53 gene transfer induces apoptosis in a variety of human cancer cells. Although clinical trials have demonstrated that a replication-deficient recombinant adenovirus expressing the wild-type p53 gene (Ad-p53) is effective in suppressing growth of non-small cell lung cancer (NSCLC), we often experienced late resistance to this treatment. To elucidate the mechanism of late resistance to Ad-p53 in human lung cancer cells, we generated 5 different resistant variants from p53-susceptible H1299 NSCLC cells by repeated infections with Ad-p53. We first examined the transduction efficiency of adenoviral vector by Ad-LacZ transduction followed by X-gal staining in parental and 5 resistant H1299 cell lines. Their sensitivity to viral infection decreased in correlation with the magnitude of resistance, and Ad-p53-mediated tumor suppression could be restored by dose escalation of Ad-p53 in the resistant variants. The expression of Coxsackie and adenovirus receptor (CAR) and αV integrins, which are cellular receptors for attachment and internalization of the virus, respectively, was next investigated in these cell lines. Flow cytometry revealed that αVβ3 and αVβ5 integrin expression was consistent, while p53-resistant cell lines showed that diminished CAR expression correlated with the magnitude of the resistance. Our results demonstrated that decreased CAR expression could be one of the mechanisms of late resistance to Ad-p53, which may have a significant impact on the outcome of adenovirus-based cancer gene therapy.

    DOI: 10.1111/j.1349-7006.2004.tb03232.x

    Scopus

    PubMed

    researchmap

  • Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells

    Yasuhisa Tango, Masaki Taki, Yoshiko Shirakiya, Shoichiro Ohtani, Naoyuki Tokunaga, Yosuke Tsunemitsu, Shunsuke Kagawa, Toru Tani, Noriaki Tanaka, Toshiyoshi Fujiwara

    Cancer Science   95 ( 5 )   459 - 463   2004.5

     More details

    Language:English  

    Adenovirus-mediated wild-type p53 gene transfer induces apoptosis in a variety of human cancer cells. Although clinical trials have demonstrated that a replication-deficient recombinant adenovirus expressing the wild-type p53 gene (Ad-p53) is effective in suppressing growth of non-small cell lung cancer (NSCLC), we often experienced late resistance to this treatment. To elucidate the mechanism of late resistance to Ad-p53 in human lung cancer cells, we generated 5 different resistant variants from p53-susceptible H1299 NSCLC cells by repeated infections with Ad-p53. We first examined the transduction efficiency of adenoviral vector by Ad-LacZ transduction followed by X-gal staining in parental and 5 resistant H1299 cell lines. Their sensitivity to viral infection decreased in correlation with the magnitude of resistance, and Ad-p53-mediated tumor suppression could be restored by dose escalation of Ad-p53 in the resistant variants. The expression of Coxsackie and adenovirus receptor (CAR) and αV integrins, which are cellular receptors for attachment and internalization of the virus, respectively, was next investigated in these cell lines. Flow cytometry revealed that αVβ3 and αVβ5 integrin expression was consistent, while p53-resistant cell lines showed that diminished CAR expression correlated with the magnitude of the resistance. Our results demonstrated that decreased CAR expression could be one of the mechanisms of late resistance to Ad-p53, which may have a significant impact on the outcome of adenovirus-based cancer gene therapy.

    DOI: 10.1111/j.1349-7006.2004.tb03232.x

    Scopus

    PubMed

    researchmap

  • Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer

    Y Tsunemitsu, S Kagawa, N Tokunaga, S Otani, T Umeoka, JA Roth, B Fang, N Tanaka, T Fujiwara

    GUT   53 ( 4 )   554 - 560   2004.4

     More details

    Language:English   Publisher:B M J PUBLISHING GROUP  

    Background: Gene therapy is an innovative therapeutic approach for cancer. An adenoviral vector expressing the tumour suppressor p53 gene (Ad/p53) is currently under clinical evaluation for various cancers. We recently developed a binary adenoviral vector system that can express the strong proapoptotic gene Bax (Ad/ PGK-GV16+ Ad/ GT-Bax: Ad/Bax).
    Aims: To evaluate the potential of Bax gene therapy for gastric cancer, we assessed its antitumour effect in comparison with that of p53.
    Methods: The human gastric cancer cell lines MKN-1, MKN-7, MKN-28, and MKN-45 were treated with Ad/ Bax or Ad/ p53, and cell viability, transgene expression, and caspase activation were assessed in vitro. To compare the antitumour effects of Ad/ Bax and Ad/ p53 treatment in vivo, subcutaneous tumours and peritoneal dissemination of MKN-45 cells were generated in nude mice. Each mouse underwent intratumoral or intraperitoneal administration of viruses and the growth of implanted tumours was observed after treatment.
    Results: Treatment with Ad/ Bax and Ad/ p53 resulted in marked Bax and p53 protein expression and effective apoptosis induction in MKN-1, MKN-7, and MKN-28 cells in vitro. In contrast, MKN-45 cells showed resistance to Ad/ p53 and only treatment with Ad/ Bax resulted in activation of caspase 3 expression and massive apoptosis. Ad/ Bax treatment was more effective in suppressing both subcutaneous and peritoneally disseminated MKN-45 tumours compared with Ad/ p53 treatment.
    Conclusion: Ad/ Bax treatment significantly inhibited the growth of even p53 resistant gastric cancer in vitro and in vivo. Therefore, adenovirus mediated Bax gene transfer may be useful in gene therapy for gastric cancers.

    DOI: 10.1136/gut.2003.021683

    Web of Science

    researchmap

  • Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer

    Y Tsunemitsu, S Kagawa, N Tokunaga, S Otani, T Umeoka, JA Roth, B Fang, N Tanaka, T Fujiwara

    GUT   53 ( 4 )   554 - 560   2004.4

     More details

    Language:English   Publisher:B M J PUBLISHING GROUP  

    Background: Gene therapy is an innovative therapeutic approach for cancer. An adenoviral vector expressing the tumour suppressor p53 gene (Ad/p53) is currently under clinical evaluation for various cancers. We recently developed a binary adenoviral vector system that can express the strong proapoptotic gene Bax (Ad/ PGK-GV16+ Ad/ GT-Bax: Ad/Bax).
    Aims: To evaluate the potential of Bax gene therapy for gastric cancer, we assessed its antitumour effect in comparison with that of p53.
    Methods: The human gastric cancer cell lines MKN-1, MKN-7, MKN-28, and MKN-45 were treated with Ad/ Bax or Ad/ p53, and cell viability, transgene expression, and caspase activation were assessed in vitro. To compare the antitumour effects of Ad/ Bax and Ad/ p53 treatment in vivo, subcutaneous tumours and peritoneal dissemination of MKN-45 cells were generated in nude mice. Each mouse underwent intratumoral or intraperitoneal administration of viruses and the growth of implanted tumours was observed after treatment.
    Results: Treatment with Ad/ Bax and Ad/ p53 resulted in marked Bax and p53 protein expression and effective apoptosis induction in MKN-1, MKN-7, and MKN-28 cells in vitro. In contrast, MKN-45 cells showed resistance to Ad/ p53 and only treatment with Ad/ Bax resulted in activation of caspase 3 expression and massive apoptosis. Ad/ Bax treatment was more effective in suppressing both subcutaneous and peritoneally disseminated MKN-45 tumours compared with Ad/ p53 treatment.
    Conclusion: Ad/ Bax treatment significantly inhibited the growth of even p53 resistant gastric cancer in vitro and in vivo. Therefore, adenovirus mediated Bax gene transfer may be useful in gene therapy for gastric cancers.

    DOI: 10.1136/gut.2003.021683

    Web of Science

    researchmap

  • Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer

    Y Tsunemitsu, S Kagawa, N Tokunaga, S Otani, T Umeoka, JA Roth, B Fang, N Tanaka, T Fujiwara

    GUT   53 ( 4 )   554 - 560   2004.4

     More details

    Language:English   Publisher:B M J PUBLISHING GROUP  

    Background: Gene therapy is an innovative therapeutic approach for cancer. An adenoviral vector expressing the tumour suppressor p53 gene (Ad/p53) is currently under clinical evaluation for various cancers. We recently developed a binary adenoviral vector system that can express the strong proapoptotic gene Bax (Ad/ PGK-GV16+ Ad/ GT-Bax: Ad/Bax).
    Aims: To evaluate the potential of Bax gene therapy for gastric cancer, we assessed its antitumour effect in comparison with that of p53.
    Methods: The human gastric cancer cell lines MKN-1, MKN-7, MKN-28, and MKN-45 were treated with Ad/ Bax or Ad/ p53, and cell viability, transgene expression, and caspase activation were assessed in vitro. To compare the antitumour effects of Ad/ Bax and Ad/ p53 treatment in vivo, subcutaneous tumours and peritoneal dissemination of MKN-45 cells were generated in nude mice. Each mouse underwent intratumoral or intraperitoneal administration of viruses and the growth of implanted tumours was observed after treatment.
    Results: Treatment with Ad/ Bax and Ad/ p53 resulted in marked Bax and p53 protein expression and effective apoptosis induction in MKN-1, MKN-7, and MKN-28 cells in vitro. In contrast, MKN-45 cells showed resistance to Ad/ p53 and only treatment with Ad/ Bax resulted in activation of caspase 3 expression and massive apoptosis. Ad/ Bax treatment was more effective in suppressing both subcutaneous and peritoneally disseminated MKN-45 tumours compared with Ad/ p53 treatment.
    Conclusion: Ad/ Bax treatment significantly inhibited the growth of even p53 resistant gastric cancer in vitro and in vivo. Therefore, adenovirus mediated Bax gene transfer may be useful in gene therapy for gastric cancers.

    DOI: 10.1136/gut.2003.021683

    Web of Science

    researchmap

  • Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer

    Y Tsunemitsu, S Kagawa, N Tokunaga, S Otani, T Umeoka, JA Roth, B Fang, N Tanaka, T Fujiwara

    GUT   53 ( 4 )   554 - 560   2004.4

     More details

    Language:English   Publisher:B M J PUBLISHING GROUP  

    Background: Gene therapy is an innovative therapeutic approach for cancer. An adenoviral vector expressing the tumour suppressor p53 gene (Ad/p53) is currently under clinical evaluation for various cancers. We recently developed a binary adenoviral vector system that can express the strong proapoptotic gene Bax (Ad/ PGK-GV16+ Ad/ GT-Bax: Ad/Bax).
    Aims: To evaluate the potential of Bax gene therapy for gastric cancer, we assessed its antitumour effect in comparison with that of p53.
    Methods: The human gastric cancer cell lines MKN-1, MKN-7, MKN-28, and MKN-45 were treated with Ad/ Bax or Ad/ p53, and cell viability, transgene expression, and caspase activation were assessed in vitro. To compare the antitumour effects of Ad/ Bax and Ad/ p53 treatment in vivo, subcutaneous tumours and peritoneal dissemination of MKN-45 cells were generated in nude mice. Each mouse underwent intratumoral or intraperitoneal administration of viruses and the growth of implanted tumours was observed after treatment.
    Results: Treatment with Ad/ Bax and Ad/ p53 resulted in marked Bax and p53 protein expression and effective apoptosis induction in MKN-1, MKN-7, and MKN-28 cells in vitro. In contrast, MKN-45 cells showed resistance to Ad/ p53 and only treatment with Ad/ Bax resulted in activation of caspase 3 expression and massive apoptosis. Ad/ Bax treatment was more effective in suppressing both subcutaneous and peritoneally disseminated MKN-45 tumours compared with Ad/ p53 treatment.
    Conclusion: Ad/ Bax treatment significantly inhibited the growth of even p53 resistant gastric cancer in vitro and in vivo. Therefore, adenovirus mediated Bax gene transfer may be useful in gene therapy for gastric cancers.

    DOI: 10.1136/gut.2003.021683

    Web of Science

    researchmap

  • 制限増殖型ウイルス製剤を用いたMolecular Surgery:癌微小転移に対する治療戦略として

    滝正樹, 藤原俊義, 水口裕之, 岸本浩行, 藤原俊哉, 香川俊輔, 西崎正彦, 京哲, 田中紀章

    日本外科学会雑誌   105   278   2004.3

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • PS-156-3 非小細胞肺癌に対するp53を標的とした新たな遺伝子治療の前臨床試験 : 化学療法/ 放射線療法/ p53遺伝子治療の3者併用療法の基礎実験

    西崎 正彦, 藤原 俊義, 香川 俊輔, Roth Jack A., 田中 紀章

    日本外科学会雑誌   105   580 - 580   2004.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer

    H Katayama, H Ueoka, K Kiura, M Tabata, T Kozuki, M Tanimoto, T Fujiwara, N Tanaka, H Date, M Aoe, N Shimizu, M Takemoto, Y Hiraki

    BRITISH JOURNAL OF CANCER   90 ( 5 )   979 - 984   2004.3

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    The objective of this study was to assess the feasibility and effectiveness of an induction chemoradiotherapy regimen followed by surgery in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). A total of 22 patients with LA-NSCLC were treated with induction chemoradiotherapy consisting of cisplatin (40 mg m(-2)) and docetaxel (40 mg m(-2)) given on days 1, 8, 29 and 36 plus concurrent thoracic irradiation at a dose of 40-60 Gy (2 Gy fraction(-1) day(-1)). Surgical resection was performed within 6 weeks after completion of induction therapy. Objective response to the induction therapy was obtained in 16 patients (73%). In all, 20 patients (91%) underwent surgery and complete resection was achieved in 19 patients (86%). Pathological downstaging and pathological complete response were obtained in 14 (64%) and five (23%) patients, respectively. With a median follow-up period of 32 months, the calculated 3-year overall and progression-free survival rates were 66 and 61%, respectively. It is noteworthy that the 3-year overall survival rate in 14 patients achieving pathological downstaging was extremely high (93%). Toxicity was manageable with standard approaches. No treatment-related deaths occurred. This combined modality treatment is feasible and highly effective in patients with LA-NSCLC. The results warrant further large-scale study to confirm the effectiveness of this regimen.

    DOI: 10.1038/sj.bjc.6601624

    Web of Science

    researchmap

  • Telomerase-Specific Replication-Selective Virotherapy for Human Cancer

    Takeshi Kawashima, Shunsuke Kagawa, Naoya Kobayashi, Yoshiko Shirakiya, Tatsuo Umeoka, Fuminori Teraishi, Masaki Taki, Satoru Kyo, Noriaki Tanaka, Toshiyoshi Fujiwara

    Clinical Cancer Research   10 ( 1 I )   285 - 292   2004.1

     More details

    Language:English  

    Purpose: Replication-selective tumor-specific viruses present a novel approach for treating neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is considered to be a critical step in carcinogenesis, and its activity is closely correlated with human telomerase reverse transcriptase (hTERT) expression. We investigated the antitumor effect of the hTERT-specific replication-competent adenovirus on human cancer cells. Experimental Design: We constructed an adenovirus 5 vector [tumor- or telomerase-specific replication-competent adenovirus (TRAD)], in which the hTERT promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site, and we examined the selective replication and antitumor effect in human cancer cells in vitro and in vivo. Results: TRAD induced selective E1A and E1B expression in human cancer cells, but not in normal cells such as human fibroblasts. TRAD replicated efficiently and induced marked cell killing in a panel of human cancer cell lines, whereas replication as well as cytotoxicity was highly attenuated in normal human fibroblasts lacking telomerase activity. In nu/nu mice carrying s.c. human lung tumor xenografts, intratumoral injection of TRAD resulted in a significant inhibition of tumor growth. No evidence of TRAD was identified in tissues outside of the tumors, despite the presence of TRAD in the circulation. Moreover, TRAD replication in the distant, noninjected tumors was demonstrated. Conclusions: Our results suggest that the hTERT promoter confers competence for selective replication of TRAD in human cancer cells, an outcome that has important implications for the treatment of human cancers.

    DOI: 10.1158/1078-0432.CCR-1075-3

    Scopus

    PubMed

    researchmap

  • Telomerase-Specific Replication-Selective Virotherapy for Human Cancer

    Takeshi Kawashima, Shunsuke Kagawa, Naoya Kobayashi, Yoshiko Shirakiya, Tatsuo Umeoka, Fuminori Teraishi, Masaki Taki, Satoru Kyo, Noriaki Tanaka, Toshiyoshi Fujiwara

    Clinical Cancer Research   10 ( 1 I )   285 - 292   2004.1

     More details

    Language:English  

    Purpose: Replication-selective tumor-specific viruses present a novel approach for treating neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is considered to be a critical step in carcinogenesis, and its activity is closely correlated with human telomerase reverse transcriptase (hTERT) expression. We investigated the antitumor effect of the hTERT-specific replication-competent adenovirus on human cancer cells. Experimental Design: We constructed an adenovirus 5 vector [tumor- or telomerase-specific replication-competent adenovirus (TRAD)], in which the hTERT promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site, and we examined the selective replication and antitumor effect in human cancer cells in vitro and in vivo. Results: TRAD induced selective E1A and E1B expression in human cancer cells, but not in normal cells such as human fibroblasts. TRAD replicated efficiently and induced marked cell killing in a panel of human cancer cell lines, whereas replication as well as cytotoxicity was highly attenuated in normal human fibroblasts lacking telomerase activity. In nu/nu mice carrying s.c. human lung tumor xenografts, intratumoral injection of TRAD resulted in a significant inhibition of tumor growth. No evidence of TRAD was identified in tissues outside of the tumors, despite the presence of TRAD in the circulation. Moreover, TRAD replication in the distant, noninjected tumors was demonstrated. Conclusions: Our results suggest that the hTERT promoter confers competence for selective replication of TRAD in human cancer cells, an outcome that has important implications for the treatment of human cancers.

    DOI: 10.1158/1078-0432.CCR-1075-3

    Scopus

    PubMed

    researchmap

  • Telomerase-Specific Replication-Selective Virotherapy for Human Cancer

    Takeshi Kawashima, Shunsuke Kagawa, Naoya Kobayashi, Yoshiko Shirakiya, Tatsuo Umeoka, Fuminori Teraishi, Masaki Taki, Satoru Kyo, Noriaki Tanaka, Toshiyoshi Fujiwara

    Clinical Cancer Research   10 ( 1 I )   285 - 292   2004.1

     More details

    Language:English  

    Purpose: Replication-selective tumor-specific viruses present a novel approach for treating neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is considered to be a critical step in carcinogenesis, and its activity is closely correlated with human telomerase reverse transcriptase (hTERT) expression. We investigated the antitumor effect of the hTERT-specific replication-competent adenovirus on human cancer cells. Experimental Design: We constructed an adenovirus 5 vector [tumor- or telomerase-specific replication-competent adenovirus (TRAD)], in which the hTERT promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site, and we examined the selective replication and antitumor effect in human cancer cells in vitro and in vivo. Results: TRAD induced selective E1A and E1B expression in human cancer cells, but not in normal cells such as human fibroblasts. TRAD replicated efficiently and induced marked cell killing in a panel of human cancer cell lines, whereas replication as well as cytotoxicity was highly attenuated in normal human fibroblasts lacking telomerase activity. In nu/nu mice carrying s.c. human lung tumor xenografts, intratumoral injection of TRAD resulted in a significant inhibition of tumor growth. No evidence of TRAD was identified in tissues outside of the tumors, despite the presence of TRAD in the circulation. Moreover, TRAD replication in the distant, noninjected tumors was demonstrated. Conclusions: Our results suggest that the hTERT promoter confers competence for selective replication of TRAD in human cancer cells, an outcome that has important implications for the treatment of human cancers.

    DOI: 10.1158/1078-0432.CCR-1075-3

    Scopus

    PubMed

    researchmap

  • Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo.

    Ohtani S, Kagawa S, Tango Y, Umeoka T, Tokunaga N, Tsunemitsu Y, Roth JA, Taya Y, Tanaka N, Fujiwara T

    3: 93-100, 2004   2004.1

     More details

  • Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells

    Tango Y, Taki M, Shirakiya Y, Ohtani S, Tokunaga N, Tsunemitsu Y, Kagawa S, Tani T, Tanaka N, Fujiwara T

    Cancer Sci   2004

  • Visualization of Intrathoracically Disseminated Solid Tumors in Mice with Optical Imaging by Telomerase-Specific Amplification of a Transferred Green Fluorescent Protein Gene

    Umeoka T, Kawashima T, Kagawa S, Teraishi F, Taki M, Nishizaki M, Kyo S, Nagai K, Urata Y, Tanaka N, Fujiwara T

    Cancer Reaserch   2004

  • Antitumoe Effect of Intratumoral Administratio of Bone Marrow-Derived Dendritic Cells Transduced with Wild-Type p53 Gene

    Murakami T, Tokunaga N, Waku T, GOmi S, Kagawa S, Tanaka N, Fujiwara T

    Clinical Cancer Research   2004

  • 臨床:内科再度からみた肺癌診療の最近の話題 ADVEXINによる非詳細某肺癌の遺伝子治療

    藤原俊義, 田中紀章

    現代医療   2004

     More details

  • Long-Barrett食道に発生した表剤型食道腺癌の1例

    水野憲治, 猶本良夫, 山辻知樹, 白川靖博, 大川尚臣, 信久徹治, 松本朝子, 上塚大一, 松原長秀, 藤原俊義, 岩垣博巳, 松岡順治, 田中紀章

    消化器外科   2004

     More details

  • 遺伝子治療の最前線 テロメラーゼ活性を標的とした新規アデノウイルス製剤(Telomelysin:OBP-301)の開発

    藤原俊義, 香川俊輔, 西崎正彦, 徳永尚之, 田中紀章, 永井勝幸, 浦田泰生, 岡山大遺伝子, 細胞治療センター, オンコリスバイオファーマ

    日本癌治療学会誌   2004

     More details

  • 肺癌遺伝子治療,最新の話題.

    藤原俊義

    Pulmonary Oncology Report   2004

     More details

  • 進行非小細胞肺癌に対してp53遺伝子治療を施行し奏効が得られた一例

    香川俊輔, 大谷彰一郎, 田中紀章, 藤原俊義

    癌と化学療法   2004

     More details

  • Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition.

    Arima, Y, Hirota, T, Bronner, C, Mousli, M, Fujiwara, T, Niwa, S, Ishikawa, H, Saya, H

    Genes Cells   2004

  • Quantitative analusis of p53-targeted gene expression and visualization of p53 trascriptional activity following intratumoral administration of adenoviral p53 in vivo

    Ohtani S, Kagawa S, Tango Y, Umeoka T, Tokunaga N, Tsunemitsu Y, Jack A. Roth, Taya Y, Tanaka N, Fujiwara T

    Molecular Cancer Therapeutics   2004

     More details

  • Telomerase-Specific Repliccation-Selective Virotherapy for Human Cancer

    Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N, Fujiwara T

    Clinical Cancer Research   2004

  • 進行非小細胞肺癌に対してp53遺伝子治療を施行し奏効が得られた1例

    香川俊輔, 藤原俊義, 大谷彰一郎, 田中紀章, 岡山大病院, 遺伝子, 細胞治療センタ

    癌と化学療法   2004

     More details

  • 化学療法 3 切除不能再発胃癌患者に対するIFP療法

    松岡順治, 西崎正彦, 香川俊輔, 藤原俊義, 合地明, 猶本良夫, 田中紀章, 大, 消化器腫瘍外

    日本癌治療学会誌   2004

     More details

  • 遺伝子治療 胃癌腹膜播種モデルにおけるBax遺伝子の抗腫瘍効果

    香川俊輔, 藤原俊義, 常光洋輔, 徳永尚之, 大谷彰一郎, 梅岡達生, 西崎正彦, 田中紀章, 岡山大遺伝子, 細胞治療センタ

    日本癌治療学会誌   2004

     More details

  • A novel method for gene delivery and expression in esophageal epithelium with fibrin glues containing replication-deficient adenovirus vector

    F Teraishi, T Umeoka, T Saito, T Tsukagoshi, N Tanaka, T Fujiwara

    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES   17 ( 11 )   1845 - 1848   2003.11

     More details

    Language:English   Publisher:SPRINGER-VERLAG  

    Background: Gene transfer to the esophageal epithelium holds the potential for the therapy of malignant as well as premalignant lesions in the upper gastrointestinal tract. Replication-deficient recombinant adenoviruses represent an efficient means of introducing genes in vivo into cells in a variety of organs. The majority of in vivo studies utilize direct submucosal injection for delivery of the viral vectors into the locoregional area of the gut; transferring genes into epithelial cells, however, is difficult because viruses are retained in the subepithelial space. To establish the efficient method for gene transfer into the epithelial cells, we have developed a multiluminal spray catheter that can be passed through the accessory channel of an endoscope, and we have evaluated the feasibility of fibrin glues as a vehicle of recombinant adenoviruses in a porcine model.
    Methods: The fibrinogen solution and the thrombion solution containing an E1/E3 deleted recombinant adenovirus expressing the bacterial lacZ gene (Ad-lacZ) were endoscopically sprayed on the porcine esophagus through the catheter attached to the dual-barrel syringe. Twenty-four hours after gene delivery, beta-galactosidase activity of the esophagus was determined under the microscope following X-gal staining.
    Results: The fibrin glue could be locally sprayed on the porcine esophagus by using the multichannel catheter through the endoscope. Attachment of the fibrin glue comtining Ad-lacZ caused strong beta-galactosidase staining on epithelial cells in the mucosal surface, but not in the basal cell layer.
    Conclusion: Endoscopic local delivery of recombinant adenoviruses in aerosolized fibrin glues through a multiluminal catheter could provide an optimal technique for gene transfer into epithelial cells in the mucosal surfece, which may have important implications for the treatment of human esophageal premalignant diseases.

    DOI: 10.1007/s00464-003-8146-5

    Web of Science

    researchmap

  • RGDファイバー変異を挿入した腫よう特異的増殖可能アデノウイルス(TRAD)の抗腫よう効果の増強

    滝正樹, 藤原俊義, 川嶋健, 岸本浩行, 藤原俊哉, 水口裕之, 京哲, 香川俊輔, 西崎正彦

    日本癌学会総会記事   62nd   161   2003.8

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 蛍光イメージングによる癌特異的GFP遺伝子発現の検出: 癌特異的増殖可能アデノウイルスを用いた非侵襲的な生体内癌組織診断

    梅岡達生, 藤原俊義, 川嶋健, 常光洋輔, 京哲, 香川俊輔, 西崎正彦, 田中紀章

    日本外科学会雑誌   104   183   2003.4

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 制限増殖型アデノウイルスによる術前・術後補助療法の可能性: テロメラーゼ発現ヒト癌細胞における選択的腫よう融解による抗腫よう効果の検討

    川嶋健, 藤原俊義, 滝正樹, 梅岡達生, 京哲, 西崎正彦, 香川俊輔, 田中紀章

    日本外科学会雑誌   104   530 - 531   2003.4

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 癌に対する遺伝子治療の現況と展望 : 非増殖型ベクターから制限増殖型ベクターへ,さらに局所療法から全身療法へ

    藤原 俊義, 香川 俊輔, 西崎 正彦, 田中 紀章

    日本外科学会雑誌   104   191 - 192   2003.4

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 胃癌細胞に対するBaxアデノウイルスベクターの抗腫瘍効果 : 胃癌腹膜播種に対する補助療法としての可能性

    常光 洋輔, 香川 俊輔, 渡辺 貴紀, 藤原 俊義, 田中 紀章

    日本外科学会雑誌   104   252 - 252   2003.4

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • ヒト末梢血単核球由来の樹状細胞とp53遺伝子あるいはp53蛋白質を用いた新しい免疫療法の開発

    徳永 尚之, 藤原 俊義, 村上 敬祥, 西崎 正彦, 香川 俊輔, 田中 紀章

    日本外科学会雑誌   104   527 - 527   2003.4

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • p53遺伝子治療におけるp53標的遺伝子発現の定量的解析とp53転写活性の可視化の試み : 術前アジュバント療法を目指して

    大谷 彰一郎, 藤原 俊義, 梅岡 達生, 丹後 泰久, 香川 俊輔, 西崎 正彦, 田中 紀章

    日本外科学会雑誌   104   258 - 258   2003.4

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Ectopic p21(sdi1) gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment

    F Teraishi, Y Kadowaki, Y Tango, T Kawashima, T Umeoka, S Kagawa, N Tanaka, T Fujiwara

    INTERNATIONAL JOURNAL OF CANCER   103 ( 6 )   833 - 839   2003.3

     More details

    Language:English   Publisher:WILEY-LISS  

    The biological effects of retinoic acid (RA) are mediated by nuclear retinoic acid receptors (RARs) that function as ligand-activated transcriptional factors. The response of human cancer cells to RA is known to be associated with the expression of RARbeta. Recent studies have demonstrated that the loss of RARbeta expression is involved in the development of a variety of human malignancies. We show that recombinant adenovirus-mediated p21(sdi1) gene transfer enhances RARbeta mRNA expression as well as protein expression and induces the sensitivity to all-trans RA (ATRA) in human cancer cells. Semi-quantitative reverse transcription-polymerase chain reaction analysis demonstrated that infection with adenovirus carrying human p21(sdi1) gene (AdSCMV-p21), which encodes a cyclin-dependent kinase inhibitor, induced RARbeta mRNA and protein expression in H1299 human non-small cell lung cancer cells and DLD-1 human colorectal cancer cells. We also found that exogenous introduction of the p21(sdil) gene transcriptionally activated the upstream promoter function of the RARbeta gene. Treatment with I muM of ATRA showed no significant inhibitory effects on the growth of H 1299 and DLD-1 cells; after Ad5CMV-p21 infection, however, cells underwent apoptosis with ATRA treatment at the same concentration, suggesting that p21(sdil) gene transfer sensitized H1299 and DLD-1 cells, presumably, through RARbeta upregulation. We also demonstrated the efficacy of intratumoral injection of AdSCMV-p21 in combination with systemic administration of ATRA in a nude mice xenograft model. Our results indicate that recombinant adenovirus-mediated p21(sdil) gene transfer could be potentially useful for the local induction of RA sensitivity in human premalignant and malignant lesions lacking appropriate RARbeta expression. (C) 2002 Wiley-Liss, Inc.

    DOI: 10.1002/ijc.10892

    Web of Science

    researchmap

  • Ectopic p21(sdi1) gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment

    F Teraishi, Y Kadowaki, Y Tango, T Kawashima, T Umeoka, S Kagawa, N Tanaka, T Fujiwara

    INTERNATIONAL JOURNAL OF CANCER   103 ( 6 )   833 - 839   2003.3

     More details

    Language:English   Publisher:WILEY-LISS  

    The biological effects of retinoic acid (RA) are mediated by nuclear retinoic acid receptors (RARs) that function as ligand-activated transcriptional factors. The response of human cancer cells to RA is known to be associated with the expression of RARbeta. Recent studies have demonstrated that the loss of RARbeta expression is involved in the development of a variety of human malignancies. We show that recombinant adenovirus-mediated p21(sdi1) gene transfer enhances RARbeta mRNA expression as well as protein expression and induces the sensitivity to all-trans RA (ATRA) in human cancer cells. Semi-quantitative reverse transcription-polymerase chain reaction analysis demonstrated that infection with adenovirus carrying human p21(sdi1) gene (AdSCMV-p21), which encodes a cyclin-dependent kinase inhibitor, induced RARbeta mRNA and protein expression in H1299 human non-small cell lung cancer cells and DLD-1 human colorectal cancer cells. We also found that exogenous introduction of the p21(sdil) gene transcriptionally activated the upstream promoter function of the RARbeta gene. Treatment with I muM of ATRA showed no significant inhibitory effects on the growth of H 1299 and DLD-1 cells; after Ad5CMV-p21 infection, however, cells underwent apoptosis with ATRA treatment at the same concentration, suggesting that p21(sdil) gene transfer sensitized H1299 and DLD-1 cells, presumably, through RARbeta upregulation. We also demonstrated the efficacy of intratumoral injection of AdSCMV-p21 in combination with systemic administration of ATRA in a nude mice xenograft model. Our results indicate that recombinant adenovirus-mediated p21(sdil) gene transfer could be potentially useful for the local induction of RA sensitivity in human premalignant and malignant lesions lacking appropriate RARbeta expression. (C) 2002 Wiley-Liss, Inc.

    DOI: 10.1002/ijc.10892

    Web of Science

    researchmap

  • Ectopic p21(sdi1) gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment

    F Teraishi, Y Kadowaki, Y Tango, T Kawashima, T Umeoka, S Kagawa, N Tanaka, T Fujiwara

    INTERNATIONAL JOURNAL OF CANCER   103 ( 6 )   833 - 839   2003.3

     More details

    Language:English   Publisher:WILEY-LISS  

    The biological effects of retinoic acid (RA) are mediated by nuclear retinoic acid receptors (RARs) that function as ligand-activated transcriptional factors. The response of human cancer cells to RA is known to be associated with the expression of RARbeta. Recent studies have demonstrated that the loss of RARbeta expression is involved in the development of a variety of human malignancies. We show that recombinant adenovirus-mediated p21(sdi1) gene transfer enhances RARbeta mRNA expression as well as protein expression and induces the sensitivity to all-trans RA (ATRA) in human cancer cells. Semi-quantitative reverse transcription-polymerase chain reaction analysis demonstrated that infection with adenovirus carrying human p21(sdi1) gene (AdSCMV-p21), which encodes a cyclin-dependent kinase inhibitor, induced RARbeta mRNA and protein expression in H1299 human non-small cell lung cancer cells and DLD-1 human colorectal cancer cells. We also found that exogenous introduction of the p21(sdil) gene transcriptionally activated the upstream promoter function of the RARbeta gene. Treatment with I muM of ATRA showed no significant inhibitory effects on the growth of H 1299 and DLD-1 cells; after Ad5CMV-p21 infection, however, cells underwent apoptosis with ATRA treatment at the same concentration, suggesting that p21(sdil) gene transfer sensitized H1299 and DLD-1 cells, presumably, through RARbeta upregulation. We also demonstrated the efficacy of intratumoral injection of AdSCMV-p21 in combination with systemic administration of ATRA in a nude mice xenograft model. Our results indicate that recombinant adenovirus-mediated p21(sdil) gene transfer could be potentially useful for the local induction of RA sensitivity in human premalignant and malignant lesions lacking appropriate RARbeta expression. (C) 2002 Wiley-Liss, Inc.

    DOI: 10.1002/ijc.10892

    Web of Science

    researchmap

  • Ectopic p21(sdi1) gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment

    F Teraishi, Y Kadowaki, Y Tango, T Kawashima, T Umeoka, S Kagawa, N Tanaka, T Fujiwara

    INTERNATIONAL JOURNAL OF CANCER   103 ( 6 )   833 - 839   2003.3

     More details

    Language:English   Publisher:WILEY-LISS  

    The biological effects of retinoic acid (RA) are mediated by nuclear retinoic acid receptors (RARs) that function as ligand-activated transcriptional factors. The response of human cancer cells to RA is known to be associated with the expression of RARbeta. Recent studies have demonstrated that the loss of RARbeta expression is involved in the development of a variety of human malignancies. We show that recombinant adenovirus-mediated p21(sdi1) gene transfer enhances RARbeta mRNA expression as well as protein expression and induces the sensitivity to all-trans RA (ATRA) in human cancer cells. Semi-quantitative reverse transcription-polymerase chain reaction analysis demonstrated that infection with adenovirus carrying human p21(sdi1) gene (AdSCMV-p21), which encodes a cyclin-dependent kinase inhibitor, induced RARbeta mRNA and protein expression in H1299 human non-small cell lung cancer cells and DLD-1 human colorectal cancer cells. We also found that exogenous introduction of the p21(sdil) gene transcriptionally activated the upstream promoter function of the RARbeta gene. Treatment with I muM of ATRA showed no significant inhibitory effects on the growth of H 1299 and DLD-1 cells; after Ad5CMV-p21 infection, however, cells underwent apoptosis with ATRA treatment at the same concentration, suggesting that p21(sdil) gene transfer sensitized H1299 and DLD-1 cells, presumably, through RARbeta upregulation. We also demonstrated the efficacy of intratumoral injection of AdSCMV-p21 in combination with systemic administration of ATRA in a nude mice xenograft model. Our results indicate that recombinant adenovirus-mediated p21(sdil) gene transfer could be potentially useful for the local induction of RA sensitivity in human premalignant and malignant lesions lacking appropriate RARbeta expression. (C) 2002 Wiley-Liss, Inc.

    DOI: 10.1002/ijc.10892

    Web of Science

    researchmap

  • Protein transduction domains enable isolated islets to efficiently internalize the target protein

    T Okitsu, N Kobayashi, T Totsugawa, M Maruyama, H Noguchi, T Watanabe, T Matsumura, T Fujiwara, N Tanaka

    TRANSPLANTATION PROCEEDINGS   35 ( 1 )   479 - 479   2003.2

     More details

    Language:English   Publisher:ELSEVIER SCIENCE INC  

    DOI: 10.1016/S0041-1345(02)03775-2

    Web of Science

    researchmap

  • Successful lentivirus-based delivery of a LacZ gene into human endothelial cells

    T Totsugawa, N Kobayashi, M Maruyama, T Okitsu, H Noguchi, T Watanabe, T Matsumura, T Fujiwara, N Tanaka

    TRANSPLANTATION PROCEEDINGS   35 ( 1 )   499 - 500   2003.2

     More details

    Language:English   Publisher:ELSEVIER SCIENCE INC  

    DOI: 10.1016/S0041-1345(02)03799-5

    Web of Science

    researchmap

  • Lentiviral vector mediated gene delivery into non-dividing isolated islet cells

    T Okitsu, N Kobayashi, T Totsugawa, M Maruyama, H Noguchi, T Watanabe, T Matsumura, T Fujiwara, N Tanaka

    TRANSPLANTATION PROCEEDINGS   35 ( 1 )   483 - 483   2003.2

     More details

    Language:English   Publisher:ELSEVIER SCIENCE INC  

    DOI: 10.1016/S0041-1345(02)03785-5

    Web of Science

    researchmap

  • Heparanase expression correlates with invasion and poor prognosis in gastric cancers.

    Takaoka, M, Naomoto, Y, Ohkawa, T, Uetsuka, H, Shirakawa, Y, Uno, F, Fujiwara, T, Gunduz, M, Nagatsuka, H, Nakajima, M, Tanaka, N, Haisa, M

    Lab. Invest.   2003

     More details

  • アデノウイルスを用いた遺伝子治療

    藤原俊義, 田中紀章

    Surgery Frontier   10,372-379   2003

     More details

  • 制癌剤の新しい視点 1)アデノウイルスベクター

    西崎正彦, 藤原俊義, 田中紀章

    Surgery Frontier   10,201-207   2003

     More details

  • 消化器癌におけるmolecular targeting療法としての遺伝子治療

    藤原俊義, 田中紀章

    G. I. Research   11,11-18   2003

     More details

  • 肺癌の遺伝子治療

    香川俊輔, 藤原俊義, 田中紀章

    病理と臨床   21,519-522   2003

     More details

  • 肺癌に対する遺伝子治療:その現況と展望

    藤原俊義, 田中紀章

    癌と化学療法   30,460-467   2003

     More details

  • 遺伝子治療. 「肺癌:診断・治療の最前線」

    藤原俊義, 田中紀章

    癌の臨床(臨時増刊号)   49,1127-1136   2003

     More details

  • 癌の遺伝子治療

    藤原俊義, 田中紀章

    医学のあゆみ「先端外科医療の最前線」   205,575-580   2003

     More details

  • 遺伝子治療の実際

    香川俊輔, 藤原俊義, 田中紀章

    癌と化学療法   30,193-197   2003

     More details

  • 複製可能ウイルスを用いた遺伝子治療の進歩:制限増殖型アデノウイルス

    藤原俊義, 田中紀章

    分子細胞治療   2,249-255   2003

     More details

  • 肺癌治療と遺伝子多型

    藤原俊義, 田中紀章

    癌治療と宿主   15,29-34   2003

     More details

  • p53を標的とした治療

    藤原俊義, 田中紀章

    呼吸器科   4,401-409   2003

     More details

  • p53をターゲットとした肺癌治療

    藤原俊義, 田中紀章

    肺癌の臨床   5,295-302   2003

     More details

  • アポトーシス誘導遺伝子p53による癌の遺伝子治療

    藤原俊義, 田中紀章

    細胞   35,558-560   2003

     More details

  • 肺癌に対する遺伝子治療の現状と展望 : 非増殖型ベクターから制限増殖型ベクターへ(肺癌における遺伝子情報とその応用)(ワークショップ8)

    藤原 俊義, 川嶋 健, 香川 俊輔, 西崎 正彦, 田中 紀章

    肺癌   42 ( 5 )   360 - 360   2002.10

     More details

    Language:Japanese   Publisher:日本肺癌学会  

    CiNii Article

    CiNii Books

    researchmap

  • 非小細胞肺癌に対する集学的治療としてのp53遺伝子治療 : ドセタキセル/放射線療法との併用効果の基礎的検討

    西崎 正彦, 藤原 俊義, 香川 俊輔, 田中 紀章, Ji Lin, Roth Jack

    肺癌   42 ( 5 )   403 - 403   2002.10

     More details

    Language:Japanese   Publisher:日本肺癌学会  

    CiNii Article

    CiNii Books

    researchmap

  • 腫よう特異的増殖可能アデノウイルス(TRAD)の開発 テロメラーゼ発現ヒト癌細胞における選択的腫よう融解の誘導

    川嶋健, 藤原俊義, 梅岡達生, 滝正樹, 京哲, 香川俊輔, 西崎正彦, 田中紀章

    日本癌学会総会記事   61st   186   2002.8

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 蛍光イメージングによる癌特異的GFP遺伝子発現の検出 癌特異的増殖可能アデノウイルスを用いた非侵襲的な生体内癌組織診断

    梅岡達生, 藤原俊義, 川嶋健, 常光洋輔, 京哲, 香川俊輔, 西崎正彦, 田中紀章

    日本癌学会総会記事   61st   404   2002.8

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Adenovirus-mediated p14ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells

    Yasuhisa Tango, Toshiyoshi Fujiwara, Takahiro Itoshima, Yoshiko Takata, Kou Katsuda, Futoshi Uno, Shoichiro Ohtani, Tohru Tani, Jack A. Roth, Noriaki Tanaka

    Human Gene Therapy   13 ( 11 )   1373 - 1382   2002.7

     More details

    Language:English  

    p14ARF, a product of theINK4A/ARF locus, induces p53 upregulation by neutralizing the effects of MDM2, a transcriptional target of p53 that antagonizes its function. Here we report that adenovirus-mediated p14ARF gene transfer leads to the accumulation of ectopically transduced p53 and to apoptosis in human cancer cells. We constructed an adenoviral vector expressing p14ARF (Ad-ARF) and examined its synergistic effect with p53-expressing adenovirus (Ad5CMV-p53 or Ad-p53) in human lung and esophageal cancer cells. Simultaneous Ad-ARF and Ad-p53 infection increased p53 protein levels not only in a wild-type p53-expressing cell line, but also in cell lines with deleted p53. This resulted in a significant in vitro cytotoxicity compared with Ad-p53 infection alone. Coinfection of Ad-ARF and Ad-p53 also resulted in an increase in expression of p53-inducible genes, including p21WAF-1/Cip1, p53R2, and Noxa. In addition, the growth of human lung cancer tumors subcutaneously implanted into nu/nu mice was inhibited significantly by intratumoral injection with Ad-ARF and Ad-p53. Our data demonstrate that overexpression of ectopic p14ARF may render cells more sensitive to p53-mediated apoptosis, an outcome that has important implications for the treatment of human cancers.

    DOI: 10.1089/104303402760128595

    Scopus

    PubMed

    researchmap

  • Adenovirus-mediated p14ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells

    Yasuhisa Tango, Toshiyoshi Fujiwara, Takahiro Itoshima, Yoshiko Takata, Kou Katsuda, Futoshi Uno, Shoichiro Ohtani, Tohru Tani, Jack A. Roth, Noriaki Tanaka

    Human Gene Therapy   13 ( 11 )   1373 - 1382   2002.7

     More details

    Language:English  

    p14ARF, a product of theINK4A/ARF locus, induces p53 upregulation by neutralizing the effects of MDM2, a transcriptional target of p53 that antagonizes its function. Here we report that adenovirus-mediated p14ARF gene transfer leads to the accumulation of ectopically transduced p53 and to apoptosis in human cancer cells. We constructed an adenoviral vector expressing p14ARF (Ad-ARF) and examined its synergistic effect with p53-expressing adenovirus (Ad5CMV-p53 or Ad-p53) in human lung and esophageal cancer cells. Simultaneous Ad-ARF and Ad-p53 infection increased p53 protein levels not only in a wild-type p53-expressing cell line, but also in cell lines with deleted p53. This resulted in a significant in vitro cytotoxicity compared with Ad-p53 infection alone. Coinfection of Ad-ARF and Ad-p53 also resulted in an increase in expression of p53-inducible genes, including p21WAF-1/Cip1, p53R2, and Noxa. In addition, the growth of human lung cancer tumors subcutaneously implanted into nu/nu mice was inhibited significantly by intratumoral injection with Ad-ARF and Ad-p53. Our data demonstrate that overexpression of ectopic p14ARF may render cells more sensitive to p53-mediated apoptosis, an outcome that has important implications for the treatment of human cancers.

    DOI: 10.1089/104303402760128595

    Scopus

    PubMed

    researchmap

  • Adenovirus-mediated p14ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells

    Yasuhisa Tango, Toshiyoshi Fujiwara, Takahiro Itoshima, Yoshiko Takata, Kou Katsuda, Futoshi Uno, Shoichiro Ohtani, Tohru Tani, Jack A. Roth, Noriaki Tanaka

    Human Gene Therapy   13 ( 11 )   1373 - 1382   2002.7

     More details

    Language:English  

    p14ARF, a product of theINK4A/ARF locus, induces p53 upregulation by neutralizing the effects of MDM2, a transcriptional target of p53 that antagonizes its function. Here we report that adenovirus-mediated p14ARF gene transfer leads to the accumulation of ectopically transduced p53 and to apoptosis in human cancer cells. We constructed an adenoviral vector expressing p14ARF (Ad-ARF) and examined its synergistic effect with p53-expressing adenovirus (Ad5CMV-p53 or Ad-p53) in human lung and esophageal cancer cells. Simultaneous Ad-ARF and Ad-p53 infection increased p53 protein levels not only in a wild-type p53-expressing cell line, but also in cell lines with deleted p53. This resulted in a significant in vitro cytotoxicity compared with Ad-p53 infection alone. Coinfection of Ad-ARF and Ad-p53 also resulted in an increase in expression of p53-inducible genes, including p21WAF-1/Cip1, p53R2, and Noxa. In addition, the growth of human lung cancer tumors subcutaneously implanted into nu/nu mice was inhibited significantly by intratumoral injection with Ad-ARF and Ad-p53. Our data demonstrate that overexpression of ectopic p14ARF may render cells more sensitive to p53-mediated apoptosis, an outcome that has important implications for the treatment of human cancers.

    DOI: 10.1089/104303402760128595

    Scopus

    PubMed

    researchmap

  • 肺癌治療において遺伝子治療の目指すもの

    藤原 俊義, 宇野 太, 香川 俊輔, 片岡 正文, 田中 紀章

    日本外科学会雑誌   103   81 - 81   2002.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • TRAIL遺伝子導入による癌細胞特異的apoptosis誘導とbystander効果

    香川 俊輔, 藤原 俊義, 常光 洋輔, 片岡 正文, Fang Bingliang, 田中 紀章

    日本外科学会雑誌   103   127 - 127   2002.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • アデノウイルスベクターを用いたp14ARFおよびp53遺伝子導入による相乗的な抗腫瘍活性 : 作用機構とその臨床的有用性

    丹後 泰久, 藤原 俊義, 糸島 崇博, 片岡 正文, 香川 俊輔, 谷 徹, 田中 紀章

    日本外科学会雑誌   103   237 - 237   2002.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 効果的なヒト細胞への遺伝子導入を目的としたレンチウイルスベクターシステムの開発

    都津川 敏範, 小林 直哉, 興津 輝, 野口 洋文, 松村 年久, 渡辺 剛正, 丸山 昌伸, 藤原 俊義, 田中 紀章

    日本外科学会雑誌   103   527 - 527   2002.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells

    K Katsuda, M Kataoka, F Uno, T Murakami, T Kondo, JA Roth, N Tanaka, T Fujiwara

    ONCOGENE   21 ( 13 )   2108 - 2113   2002.3

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    The p16 tumor suppressor gene is frequently inactivated in human cancer tissues and cell lines. We previously reported that wild-type p16 expression from an adenovirus vector (Adv/p16) induced p53-dependent apoptotic cell death in non-small cell lung cancer (NSCLC) cell fines. Here we show the potential mechanism of apoptosis induced by Adv/p16 infection. Infection of human NSCLC cell line A549, which carries the wild-type p53 gene, with Adv/p16 resulted in activation of caspase-3, accompanied by the cleavage of its substrate poly (ADP-ribose) polymerase (PARP), on day 3 of infection. The retinoblastoma (Rb) cell cycle regulator protein was also cleaved after activation of caspase-3; when the levels of Rb significantly diminished, apoptosis began. When A549 cells were pretreated with the caspase-inhibitory peptide N-acetyl-asp-Glu-Val-Asp-CHO (aldehyde) (Ac-DEVD-CHO), Adv/p16-mediated apoptosis and Rb cleavage were greatly inhibited. Furthermore, MDM2, a negative regulator of p53 expression was upregulated 3 days after Adv/p16 infection, and MDM2 was subsequently cleaved by caspase-3; MDM2 cleavage was inhibited by Ac-DEVD-CHO treatment. These data implied that cleavage of Rb, in addition to activation of caspase-3, represented a mechanism by which Adv/p16 induced apoptotic cell death in human NSCLC cells. Our results support the clinical relevance of Adv/p16 as a treatment for p16-null human NSCLC that express wild-type p53.

    DOI: 10.1038/sj/onc/1205272

    Web of Science

    researchmap

  • Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells

    K Katsuda, M Kataoka, F Uno, T Murakami, T Kondo, JA Roth, N Tanaka, T Fujiwara

    ONCOGENE   21 ( 13 )   2108 - 2113   2002.3

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    The p16 tumor suppressor gene is frequently inactivated in human cancer tissues and cell lines. We previously reported that wild-type p16 expression from an adenovirus vector (Adv/p16) induced p53-dependent apoptotic cell death in non-small cell lung cancer (NSCLC) cell fines. Here we show the potential mechanism of apoptosis induced by Adv/p16 infection. Infection of human NSCLC cell line A549, which carries the wild-type p53 gene, with Adv/p16 resulted in activation of caspase-3, accompanied by the cleavage of its substrate poly (ADP-ribose) polymerase (PARP), on day 3 of infection. The retinoblastoma (Rb) cell cycle regulator protein was also cleaved after activation of caspase-3; when the levels of Rb significantly diminished, apoptosis began. When A549 cells were pretreated with the caspase-inhibitory peptide N-acetyl-asp-Glu-Val-Asp-CHO (aldehyde) (Ac-DEVD-CHO), Adv/p16-mediated apoptosis and Rb cleavage were greatly inhibited. Furthermore, MDM2, a negative regulator of p53 expression was upregulated 3 days after Adv/p16 infection, and MDM2 was subsequently cleaved by caspase-3; MDM2 cleavage was inhibited by Ac-DEVD-CHO treatment. These data implied that cleavage of Rb, in addition to activation of caspase-3, represented a mechanism by which Adv/p16 induced apoptotic cell death in human NSCLC cells. Our results support the clinical relevance of Adv/p16 as a treatment for p16-null human NSCLC that express wild-type p53.

    DOI: 10.1038/sj/onc/1205272

    Web of Science

    researchmap

  • p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells

    JH Shao, F Teraishi, K Katsuda, N Tanaka, T Fujiwara

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   290 ( 3 )   1101 - 1107   2002.1

     More details

    Language:English   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    The tumor suppressor p53 gene product is an essential component of the cytotoxic pathway triggered by DNA-damaging stimuli such as chemotherapeutic agents and ionizing radiation. We previously demonstrated that adenovirus-mediated wild-type p53 gene transfer could enhance the cytotoxic actions of chemotherapeutic drugs both in vitro and in vivo; however, the molecular mechanism of this chemosensitization is still unclear. Cyclin D1 is a major regulator of the progression of cells into the proliferative stage of the cell cycle. Here we show that infection with an adenovirus vector expressing the wild-type p53 gene (Ad-p53) caused an increase in cyclin D1 protein levels in human colorectal cancer cell lines DLD-1 and SW620; treatment with the anti-cancer drug adriamycin, however, down-regulated their cyclin D1 protein expression in a dose-dependent manner. The suppression of cyclin D1 expression following adriamycin treatment could be blocked by simultaneous Ad-p53 infection. Furthermore, DLD-1 and SW620 cells transfected with the cyclin D1 expression construct displayed increased sensitivity to adriamycin compared to that of the vector-transfected control. Our results suggest that ectopic wild-type p53 gene transfer results in increased cyclin D1 expression and, consequently, sensitizes human colorectal cancer cells to chemotherapeutic agents. (C) 2002 Elsevier Science (USA).

    DOI: 10.1006/bbrc.2001.6314

    Web of Science

    researchmap

  • p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells

    JH Shao, F Teraishi, K Katsuda, N Tanaka, T Fujiwara

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   290 ( 3 )   1101 - 1107   2002.1

     More details

    Language:English   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    The tumor suppressor p53 gene product is an essential component of the cytotoxic pathway triggered by DNA-damaging stimuli such as chemotherapeutic agents and ionizing radiation. We previously demonstrated that adenovirus-mediated wild-type p53 gene transfer could enhance the cytotoxic actions of chemotherapeutic drugs both in vitro and in vivo; however, the molecular mechanism of this chemosensitization is still unclear. Cyclin D1 is a major regulator of the progression of cells into the proliferative stage of the cell cycle. Here we show that infection with an adenovirus vector expressing the wild-type p53 gene (Ad-p53) caused an increase in cyclin D1 protein levels in human colorectal cancer cell lines DLD-1 and SW620; treatment with the anti-cancer drug adriamycin, however, down-regulated their cyclin D1 protein expression in a dose-dependent manner. The suppression of cyclin D1 expression following adriamycin treatment could be blocked by simultaneous Ad-p53 infection. Furthermore, DLD-1 and SW620 cells transfected with the cyclin D1 expression construct displayed increased sensitivity to adriamycin compared to that of the vector-transfected control. Our results suggest that ectopic wild-type p53 gene transfer results in increased cyclin D1 expression and, consequently, sensitizes human colorectal cancer cells to chemotherapeutic agents. (C) 2002 Elsevier Science (USA).

    DOI: 10.1006/bbrc.2001.6314

    Web of Science

    researchmap

  • p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells

    JH Shao, F Teraishi, K Katsuda, N Tanaka, T Fujiwara

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   290 ( 3 )   1101 - 1107   2002.1

     More details

    Language:English   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    The tumor suppressor p53 gene product is an essential component of the cytotoxic pathway triggered by DNA-damaging stimuli such as chemotherapeutic agents and ionizing radiation. We previously demonstrated that adenovirus-mediated wild-type p53 gene transfer could enhance the cytotoxic actions of chemotherapeutic drugs both in vitro and in vivo; however, the molecular mechanism of this chemosensitization is still unclear. Cyclin D1 is a major regulator of the progression of cells into the proliferative stage of the cell cycle. Here we show that infection with an adenovirus vector expressing the wild-type p53 gene (Ad-p53) caused an increase in cyclin D1 protein levels in human colorectal cancer cell lines DLD-1 and SW620; treatment with the anti-cancer drug adriamycin, however, down-regulated their cyclin D1 protein expression in a dose-dependent manner. The suppression of cyclin D1 expression following adriamycin treatment could be blocked by simultaneous Ad-p53 infection. Furthermore, DLD-1 and SW620 cells transfected with the cyclin D1 expression construct displayed increased sensitivity to adriamycin compared to that of the vector-transfected control. Our results suggest that ectopic wild-type p53 gene transfer results in increased cyclin D1 expression and, consequently, sensitizes human colorectal cancer cells to chemotherapeutic agents. (C) 2002 Elsevier Science (USA).

    DOI: 10.1006/bbrc.2001.6314

    Web of Science

    researchmap

  • p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells

    JH Shao, F Teraishi, K Katsuda, N Tanaka, T Fujiwara

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   290 ( 3 )   1101 - 1107   2002.1

     More details

    Language:English   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    The tumor suppressor p53 gene product is an essential component of the cytotoxic pathway triggered by DNA-damaging stimuli such as chemotherapeutic agents and ionizing radiation. We previously demonstrated that adenovirus-mediated wild-type p53 gene transfer could enhance the cytotoxic actions of chemotherapeutic drugs both in vitro and in vivo; however, the molecular mechanism of this chemosensitization is still unclear. Cyclin D1 is a major regulator of the progression of cells into the proliferative stage of the cell cycle. Here we show that infection with an adenovirus vector expressing the wild-type p53 gene (Ad-p53) caused an increase in cyclin D1 protein levels in human colorectal cancer cell lines DLD-1 and SW620; treatment with the anti-cancer drug adriamycin, however, down-regulated their cyclin D1 protein expression in a dose-dependent manner. The suppression of cyclin D1 expression following adriamycin treatment could be blocked by simultaneous Ad-p53 infection. Furthermore, DLD-1 and SW620 cells transfected with the cyclin D1 expression construct displayed increased sensitivity to adriamycin compared to that of the vector-transfected control. Our results suggest that ectopic wild-type p53 gene transfer results in increased cyclin D1 expression and, consequently, sensitizes human colorectal cancer cells to chemotherapeutic agents. (C) 2002 Elsevier Science (USA).

    DOI: 10.1006/bbrc.2001.6314

    Web of Science

    researchmap

  • Transduction of immortalized human hepatocytes with p21 to enhance differentiated phenotypes.

    Kunieda T, Kobayashi N, Sakaguchi M, Okitsu T, Totsugawa T, Watanabe T, Matsumura T, Maruyama M, Noguchi H, Takesue M, Shibata N, Ohmoto K, Fujiwara T

    Cell Transplant   2002

     More details

  • Improvement in the differentiated hepatic phenotype of immortalized human hepatocytes by adenovirus mediated p21 gene transfer.

    Kobayashi N, Sakaguchi M, Okitsu T, Totsugawa T, Maruyama M, Matsumura T, Watanabe T, Noguchi H, Kosaka Y, Fujiwara T, Tanaka N

    Asaio J   2002

  • Adenovirus-Mediated p14ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells.

    Tango Y, Fujiwara T, Itoshima T, Takata Y, Katsuda K, Uno F, Ohtani S, Tani T, Roth JA, Tanaka N

    Human Gene Therapy   2002

  • Lentiviral transfer of the LacZ gene into human endothelial cells and human bone marrow mesenchymal stem cells.

    Totsugawa T, Kobayashi N, Okitsu T, Noguchi H, Watanabe T, Matsumura T, Maruyama M, Fujiwara T, Sakaguchi M, Tanaka N

    Cell Transplantation   2002

     More details

  • Controlled expansion of human endothelial cell populations by Cre-loxP- based reversible immortalization.

    Noguchi H, Kobayashi N, Westerman K A, Sakaguchi M, Okitsu T, Totsugawa T, Watanabe T, Matsumura T, Fujiwara T, Ueda T, Miyazaki M, Tanaka N, Leboulch P

    Human Gene Therapy   2002

  • Gene therapy for cancer

    FUJIWARA Toshiyoshi, TANAKA Noriaki

    Nippon Nōgeikagaku Kaishi   76,4,385-387 ( 4 )   385 - 387   2002

     More details

    Language:Japanese   Publisher:Japan Society for Bioscience, Biotechnology, and Agrochemistry  

    DOI: 10.1271/nogeikagaku1924.76.385

    CiNii Article

    CiNii Books

    researchmap

    Other Link: https://jlc.jst.go.jp/DN/JALC/00153106222?from=CiNii

  • 肺癌非手術療法の新しい試み 7.遺伝子治療.

    片岡正文, 藤原俊義, 香川俊輔, 田中紀章

    日本外科学会雑誌   103,2,244-249   2002

     More details

  • 肺癌の遺伝子治療の現状と問題点.

    藤原俊義, 田中紀章

    臨床と研究   79,5,787-792   2002

     More details

  • 肺癌に対する遺伝子治療:p53発現アデノウイルスベクターによる肺癌遺伝子治療臨床試験の現況.

    香川俊輔, 藤原俊義, 田中紀章

    医学のあゆみ   203,5,302-306   2002

     More details

  • p53遺伝子を用いた癌の遺伝子治療.

    藤原俊義, 田中紀章

    癌の臨床   48,6,303-311   2002

     More details

  • p53を用いた肺癌遺伝子治療.

    香川俊輔, 藤原俊義, 田中紀章

    日本臨床   60,Suppl 5, 630-634   2002

     More details

  • 肺癌:局所療法としての遺伝子治療.

    藤原俊義, 田中紀章

    BIO Clinica   17,7,589-592   2002

     More details

  • レンチウイルスベクターシステム樹立に伴う安全配慮.

    都津川敏範, 小林直哉, 丸山昌伸, 小坂芳和, 興津 輝, 荒田 尚, 阪口政清, 藤原俊義, 倉林 譲, 田中紀章

    Organ Biology   9,4,357-364   2002

     More details

  • p53遺伝子治療における抗腫瘍活性増強のストラテジー.

    藤原俊義, 田中紀章

    遺伝子医学   6,1,15-20   2002

     More details

  • 特集 今日の肺癌診療 肺癌遺伝子治療の現状.

    藤原俊義, 田中紀章

    日本医師会雑誌   128,3,378   2002

     More details

  • Combination of tumor necrosis factor alpha and interferon alpha induces apoptotic cell death through a c-myc-dependent pathway in p53 mutant H226br non-small-cell lung cancer cell line

    Y Yasuoka, Y Naomoto, T Yamatsuji, M Takaoka, M Kimura, H Uetsuka, N Matsubara, T Fujiwara, M Gunduz, N Tanaka, M Haisa

    EXPERIMENTAL CELL RESEARCH   271 ( 2 )   214 - 222   2001.12

     More details

    Language:English   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    We investigated the role of wild-type p53 and c-myc activity in apoptosis induced by a combination of natural human tumor necrosis factor alpha (TNF-alpha) and natural human interferon alpha (IFN-alpha). Studies were performed with two human non-small-cell lung cancer cell lines, H226b, which has wild-type p53, and H226br, which has a mutant p53. The combination of IFN-alpha and TNF-alpha significantly inhibited cell growth and induced apoptotic cell death of both H226b and H226br, compared with IFN-alpha or TNF-alpha alone. Treatment with one or both cytokines did not affect the expression level of p53 in both cell lines. These results suggest that the combination of IFN-alpha /TNF-alpha induces apoptotic cell death through a p53- independent pathway. The c-myc oncogene is known to be involved in apoptosis induced by TNF. Antisense c-myc oligonucleotides have been reported to modulate cell growth or apoptosis in several cell lines. Antisense oligodeoxynucleotides were added to the culture of H226br cells before the addition of IFN-alpha /TNF-alpha. Antisense c-myc inhibited IFN-alpha /TNF-alpha cytotoxicity and apoptotic cell death. In conclusion, this study provides support for the speculation that TNF-alpha /TFN-alpha induce apoptosis through a c-myc-dependent pathway rather than a p53-dependent pathway. (C) 2001 Elsevier Science.

    DOI: 10.1006/excr.2001.5383

    Web of Science

    researchmap

  • Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells

    Takuya Fukazawa, Toshiyoshi Fujiwara, Futoshi Uno, Fuminori Teraishi, Yoshihiko Kadowaki, Takahiro Itoshima, Yoshiko Takata, Shunsuke Kagawa, Jack A. Roth, Jürg Tschopp, Noriaki Tanaka

    Oncogene   20 ( 37 )   5225 - 5231   2001.8

     More details

    Language:English  

    Apoptosis is a morphologically distinct form of programmed cell death that plays a major role in cancer treatments. This cellular suicide program is known to be regulated by many different signals from both intracellular and extracellular stimuli. Here we report that p53 suppressed expression of the cellular FLICE-inhibitory protein (FLIP) that potentially blocks apoptotic signaling in human colon cancer cell lines expressing mutated and wild-type p53. In contrast, the expression of the death receptor KILLER/DR5 (TRAIL-R2) had no effect on FLIP expression, although exogenous p53 is known to induce KILLER/DR5 expression. In line with these observations, FLIP-negative cancer cells were sensitive to both p53- and KILLER/DRS-mediated apoptosis, whereas cells containing high levels of FLIP underwent apoptotic cell death when triggered by ectopic p53 expression but not by KILLER/DR5 expression. Treating the cells with a specific inhibitor of the proteasome inhibited the decrease of FLIP by p53, suggesting that p53 enhances the degradation of FLIP via a ubiquitin-proteasome pathway. Thus, the data indicate that p53-mediated downregulation of FLIP may explain the potent sensitization of human cancer cells to the apoptotic suicide program induced by wild-type p53 gene transler.

    DOI: 10.1038/sj.onc.1204673

    Scopus

    PubMed

    researchmap

  • Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells

    Takuya Fukazawa, Toshiyoshi Fujiwara, Futoshi Uno, Fuminori Teraishi, Yoshihiko Kadowaki, Takahiro Itoshima, Yoshiko Takata, Shunsuke Kagawa, Jack A. Roth, Jürg Tschopp, Noriaki Tanaka

    Oncogene   20 ( 37 )   5225 - 5231   2001.8

     More details

    Language:English  

    Apoptosis is a morphologically distinct form of programmed cell death that plays a major role in cancer treatments. This cellular suicide program is known to be regulated by many different signals from both intracellular and extracellular stimuli. Here we report that p53 suppressed expression of the cellular FLICE-inhibitory protein (FLIP) that potentially blocks apoptotic signaling in human colon cancer cell lines expressing mutated and wild-type p53. In contrast, the expression of the death receptor KILLER/DR5 (TRAIL-R2) had no effect on FLIP expression, although exogenous p53 is known to induce KILLER/DR5 expression. In line with these observations, FLIP-negative cancer cells were sensitive to both p53- and KILLER/DRS-mediated apoptosis, whereas cells containing high levels of FLIP underwent apoptotic cell death when triggered by ectopic p53 expression but not by KILLER/DR5 expression. Treating the cells with a specific inhibitor of the proteasome inhibited the decrease of FLIP by p53, suggesting that p53 enhances the degradation of FLIP via a ubiquitin-proteasome pathway. Thus, the data indicate that p53-mediated downregulation of FLIP may explain the potent sensitization of human cancer cells to the apoptotic suicide program induced by wild-type p53 gene transler.

    DOI: 10.1038/sj.onc.1204673

    Scopus

    PubMed

    researchmap

  • S08-03 Cre/loxP部位特異的組換え反応を用いた可逆性不死化ヒト肝臓細胞の再生医療への応用

    小林 直哉, 野口 洋文, 松村 年久, 渡辺 剛正, 都津川 敏範, 藤原 俊義, 田中 紀章

    日本消化器外科学会雑誌   34 ( 7 )   832 - 832   2001.7

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PD3-6 p53遺伝子異常を標的とした遺伝子治療:臨床試験の現況と問題点

    藤原 俊義, 片岡 正文, 香川 俊輔, 田中 紀章

    日本外科学会雑誌   102   51 - 51   2001.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • SF1f-4 SV40TagとhTERTによる不死化ヒト肝類洞内皮細胞株の樹立

    松村 年久, 小林 直哉, 野口 洋文, 渡邉 剛正, 都津川 敏範, 藤原 俊義, 田中 紀章

    日本外科学会雑誌   102   67 - 67   2001.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • SF7c-2 肝細胞移植の発展に向けたテロメラーゼ遺伝子によるヒト肝細胞株の樹立

    都津川 敏範, 小林 直哉, 野口 洋文, 松村 年久, 渡邉 剛正, 藤原 俊義, 田中 紀章

    日本外科学会雑誌   102   95 - 95   2001.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • SF13a-2 高性能バイオ人工肝の実現に向けたヒト肝細胞株の樹立と至適培養担体の開発

    小林 直哉, 野口 洋文, 松村 年久, 渡邉 剛正, 都津川 敏範, 藤原 俊義, 田中 紀章

    日本外科学会雑誌   102   109 - 109   2001.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • SF13a-4 ヒト肝星様細胞へのレトロウイルスベクターによるテロメラーゼ遺伝子(hTERT)導入

    渡辺 剛正, 小林 直哉, 野口 洋文, 松村 年久, 都津川 敏範, 藤原 俊義, 田中 紀章

    日本外科学会雑誌   102   110 - 110   2001.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • p53を用いた遺伝子治療

    藤原俊義, 田中紀章

    「癌治療の先端に迫る!」(実験医学 増刊)(黒木登志夫、編集)pp2564-2571、羊土社、東京、2001.   2001.1

     More details

  • Insertion of suicide gene into an immortalized human hepatocyte cell line.

    Kobayashi N, Noguchi H, Totsugawa T, Watanabe T, Matsumura T, Fujiwara T, Miyazaki M, Fukaya K, Namba M, Tanaka N

    Cell Transplant   2001

     More details

  • Accelerated degradation of cellular FLIP prostein through the ubiquitinproteasome pathway in p53-mediated apoptosis of human cancer cells.

    Fukazawa T, Fujiwara T, Uno F, Teraishi F, Kadowaki Y, Itoshima T, Takata Y, Kagawa S, Roth JA, Tschpp J, Tanaka N

    Oncogene   2001

  • A tightly regulated immortalized human fetal hepatocyte cell line to develop a bioartificial liver.

    Kobayashi N, Noguchi H, Watanabe T, Matsumura T, Totsugawa T, Fujiwara T, Tanaka N

    Transplantation Proceedings   2001

  • Role of immortalized hepatocyte transplantation in acute liver failure.

    Kobayashi N, Noguchi H, Watanabe T, Matsumura T, Totsugawa T, Fujiwara T, Tanaka N

    Transplantation Proceedings   2001

  • Donor dendritic cells and recipient kupffer cells in the induction of donor-specific immune hyporesponsiveness.

    Nakagawa K, Matsuno T, Iwagaki H, Morimoto Y, Fujiwara T, Sadamori H, Inagaki M, Urushihara N, Yagi T, Tanaka N

    The Journal of International Medical Research   2001

     More details

  • A family of multiple endocrine Neoplasia Type 2A with the RET proto-oncogene mutation in codon 618 (Cys→Arg).

    Nakao A, Naomoto Y, Kataoka M, Haisa M, Kataoka K, Saitoh S, Fujiwara T, Yamatsuji T, Shigemitsu K, Umeoka T, Isozaki H, Futami H, Yamaguchi K, Tanaka N

    Japanese Journal of Clinical Oncology   2001

  • Rapidly functional immobilization of immortalized human hepatocytes using cell adhesive GRGDS peptide-carrying cellulose microspheres.

    Kobayashi N, Taguchi T, Noguchi H, Okitsu T, Totsugawa T, Watanabe T, Matsumura T, Fujiwara T, Urata H, Kishimoto N, Hayashi N, Nakaji S, Murakami T, Tanaka N

    Cell Transplantation   2001

     More details

  • Analysis of the immune status in the recipients with long-term well-functioning kidneys allograft.

    Nakagawa K, Matsuno T, Iwagaki H, Fujiwara T, Tanaka N

    Acta Medica Okayama   2001

     More details

  • Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells.

    Uno F, Fujiwara T, Takata Y, Ohtani S, Katsuda K, Takaoka M, Ohkawa T, Naomoto Y, Nakajima M, Tanaka N

    Cancer Research   2001

     More details

  • Expansion of human hepatocyte populations by a retroviral gene transfer of simian virus 40 large T antigen.

    Kobayashi N, Westerman KA, Taguchi T, Sakaguchi M, Fujiwara T, Urata H, Kishimoto N, Hayashi N, Nakaji S, Murakami T, Leboulch P, Tanaka N

    ASAIO Journal   2001

  • 肺犬糸状虫症の1例.

    児島 亨, 片岡和彦, 片岡正文, 渋谷祐一, 安治俊樹, 藤原俊義, 田中紀章

    胸部外科   2001

     More details

  • Asssessment of aortic invasion by pulmonary carcinoma with the use of intra-aortic endovascular sonography: A case report.

    Yasui K, Kanazawa S, Mimura H, Fujiwara T, Kataoka M, Tanaka N, Hiraki Y

    The Journal of Thoratic and Cardiovascular Surgery   2001

  • レンチウイルスベクターによるヒト血管内皮細胞への効果的な遺伝子導入.

    都津川敏範, 小林直哉, 丸山昌伸, 興津 輝, 野口洋文, 松村年久, 渡辺剛正, 阪口政清, 藤原俊義, 田中紀章

    Organ Biology   2001

     More details

  • Alltrans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma.

    Nakashima T, Sun SY, Lotan R, Fujiwara T, Yasumatsu R, Komiyama S, Clayman GL

    Laryngoscope   2001

     More details

  • Successful retroviral gene transfer of simian virus 40 T antigen and herpes simplex virus-thymidne kinase into human hepatocytes.

    Kobayashi N, Noguchi H, Westerman KA, Watanabe T, Matsumura T, Totsugawa T, Fujiwara T, Leboulch P, Tanaka N

    Cell Transplant   2001

     More details

  • Construction of a differentiated human hepatocyte cell line expressing the herpes simplex virus-thymidne kinase gene.

    Kobayashi N, Miyazaki M, Westerman KA, Noguchi H, Sakaguchi M, Totsugawa T, Watanabe T, Matsumura T, Fujiwara T, Leoboulch P, Tanaka N, Namba M

    ASAIO Journal   2001

  • Cre/loxP-based reversible immortalization of human hepatocytes.

    Kobayashi N, Noguchi H, Westerman KA, Watanabe T, Matsumura T, Totsugawa T, Fujiwara T, Leboulch P, Tanaka N

    Cell Transplantation   2001

     More details

  • p53遺伝子を用いた癌の遺伝子治療.

    藤原俊義, 田中紀章

    臨床婦人科   55 ,8,922-927   2001

  • ヒト不死化肝細胞株の樹立 Cre/loxPを用いたヒト肝細胞の増殖法.

    小林直哉, 野口洋文, 都津川敏範, 松村年久, 渡辺剛正, 丸山昌伸, 松本朝子, 藤原俊義, 林 伸幸, 中路修平, 田中紀章

    外科   63 ,5,550-556   2001

     More details

  • アデノウイルスベクターを用いた肺癌の遺伝子治療.

    藤原俊義, 田中紀章

    医学のあゆみ   199,9,673-677   2001

     More details

  • 遺伝子が変える21世紀の医療現場:p53遺伝子を用いた癌の遺伝子治療:肺癌への臨床応用.

    藤原俊義, 片岡正文, 田中紀章

    治療   83,161-166   2001

     More details

  • 悪性腫瘍に対するがん抑制遺伝子治療研究の現状.

    藤原俊義, 田中紀章

    分子細胞治療   2 ,3,247-254   2001

     More details

  • 肺癌の遺伝子治療.

    藤原俊義, 田中紀章

    Practical Oncology   14:,2-4   2001

     More details

  • 肺癌の遺伝子治療.

    藤原俊義, 田中紀章

    外科治療   85,4,463-464   2001

     More details

  • 呼吸器疾患に対する遺伝子治療.

    香川俊輔, 藤原俊義, 片岡正文, 田中紀章

    外科   63, 1740-1747   2001

     More details

  • 局所療法としての遺伝子治療?p53遺伝子製剤の安全性と臨床効果?.

    藤原俊義, 片岡正文, 田中紀章

    最新医学   56 ,増刊号, 262-273   2001

     More details

  • 肺癌の遺伝子治療.

    片岡正文, 藤原俊義, 田中紀章

    呼吸   20 ,3,222-229   2001

     More details

  • 特集 肺癌の診断治療法における最近の進歩 4.化学療法の進歩 肺癌の遺伝子治療.

    片岡正文, 香川俊輔, 藤原俊義, 田中紀章

    肺癌の臨床   4,2,221-230   2001

     More details

  • p53を発現するアデノウイルスベクターを用いたがん治療.

    藤原俊義, 田中紀章

    細胞   33,213-217   2001

     More details

  • Gene therapy approaches for the management of non-small cell lung cancer.

    Roth JA, Grammer SF, Swisher SG, Komaki R, Nemunaitis J, Merritt J, Fujiwara T, Meyn RE Jr

    Seminor of Oncology   28,50-56   2001

     More details

  • p53遺伝子を用いた肺癌の遺伝子治療.

    香川俊輔, 藤原俊義, 片岡正文, 田中紀章

    Lung Cancer Today   1 ,12-16   2001

     More details

  • p53遺伝子を用いた癌の遺伝子治療?Tumor dormancy therapyとしての可能性.

    藤原俊義, 田中紀章

    医学のあゆみ   198 ,6,7,451-455   2001

     More details

  • アデノウイルスベクターを用いた肺癌のp53遺伝子治療.

    藤原俊義, 田中紀章

    治療学   35 ,7,65-69   2001

     More details

  • p53を用いた肺癌の遺伝子治療-遺伝子製剤としての可能性-.

    藤原俊義, 片岡正文, 田中紀章

    肺癌の臨床   3,321-328   2001

     More details

  • p53を用いたがんの遺伝子治療-肺癌治療への応用-.

    藤原俊義, 田中紀章

    分子がん治療   2, 84-91   2001

     More details

  • p53遺伝子を用いた癌の遺伝子治療.

    藤原俊義, 田中紀章

    放射線生物研究   36,4,331-344   2001

     More details

  • 6.肺癌のp53遺伝子導入による分子療法の現況と展望 : 癌の発生と転移の分子機構(第57回卒後教育セミナー講演要旨)

    藤原 俊義

    日本外科学会雑誌   101 ( 9 )   695 - 695   2000.9

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PP1627 消化器癌におけるheparanaseの発現の意義の検討

    高岡 宗徳, 猶本 良夫, 羽井佐 実, 山辻 知樹, 木村 真士, 伴 秀利, 繁光 薫, 松原 長秀, 藤原 俊義, 田中 紀章

    日本消化器外科学会雑誌   33 ( 7 )   1287 - 1287   2000.7

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PP-686 vIL-10導入ラット肝細胞スフェロイドの同種脾内移植

    岡田 豊, 斎藤 信也, 藤澤 憲司, 八木 孝仁, 藤原 俊義, 中尾 篤典, 松川 啓義, 貞森 裕, 稲垣 優, 松野 剛, 田中 紀章

    日本外科学会雑誌   101   379 - 379   2000.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • SP2-1 癌に対する遺伝子治療の現状と展望 : p53遺伝子治療から新しい分化誘導療法まで

    藤原 俊義, 門脇 嘉彦, 香川 俊輔, 片岡 正文, 田中 紀章

    日本外科学会雑誌   101   54 - 54   2000.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • SF20-1 E2F-1遺伝子およびp53遺伝子発現アデノウイルスベクターの併用による効率的な食道癌の遺伝子治療

    糸島 崇博, 藤原 俊義, 片岡 正文, 門脇 嘉彦, 深澤 拓也, 邵 江華, 和久 利彦, 田中 紀章, 小玉 正智

    日本外科学会雑誌   101   155 - 155   2000.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PP-1384 全ての血族者に遺伝子診断を行った多発性内分泌腫瘍症(MEN)2Aの1家系

    小坂 芳和, 中尾 篤典, 猶本 良夫, 片岡 正文, 羽井佐 実, 片岡 正文, 藤原 俊義, 山辻 知樹, 田中 紀章

    日本外科学会雑誌   101   553 - 553   2000.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • SF10-3 不死化ヒト臍帯静脈内皮細胞株(HNKT-1)の樹立

    野口 洋文, 小林 直哉, 宮崎 正博, 井上 祐介, 阪口 政清, 藤原 俊義, 田中 紀章

    日本外科学会雑誌   101   129 - 129   2000.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • A PHASE I TRIAL OF ADENOVIRAL p53 GENE THERAPY FOR NON-SMALL CELL LUNG CANCER

    FUJIWARA Toshiyoshi, KATAOKA Masafumi, KAWAMATA Osamu, TANAKA Noriaki

    Journal of Japan Surgical Society   100 ( 11 )   749 - 755   1999.11

     More details

    Language:Japanese   Publisher:Japan Surgical Society (JSS)  

    CiNii Article

    CiNii Books

    researchmap

  • p53遺伝子導入によるアポトーシス誘導:癌遺伝子治療への応用

    藤原 俊義, 深澤 拓也, 田中 紀章

    Biotherapy today   6 ( 1 )   16 - 22   1999.6

     More details

    Language:Japanese   Publisher:医薬ジャーナル社  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2000034570

  • O-91 遺伝子導入肝細胞の同種、異種移植

    岡田 豊, 斉藤 信也, 中尾 篤典, 松川 啓義, 藤澤 憲司, 遠藤 彰, 松田 浩明, 大石 正博, 藤原 俊義, 八木 孝仁, 田中 紀章

    日本外科学会雑誌   100   130 - 130   1999.2

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • O-314 p53遺伝子導入による腫瘍血管新生の抑制

    西崎 正彦, 藤原 俊義, 片岡 正文, 中村 祐輔, 田中 紀章

    日本外科学会雑誌   100   186 - 186   1999.2

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 365 p21遺伝子導入による分化/老化誘導を作用機構とした癌に対する新しい分子療法

    門脇 嘉彦, 藤原 俊義, 香川 俊輔, 片岡 正文, 西崎 正彦, 深澤 拓也, 和久 利彦, 日伝 晶夫, 田中 紀章

    日本消化器外科学会雑誌   32 ( 2 )   462 - 462   1999.2

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • MOLECULAR SURGERY FOR HUMAN COLORECTAL CANCER WITH TUMOR SUPPRESSOR p53 GENE TRANSFER

    FUJIWARA Toshiyoshi, TANAKA Noriaki

    Journal of Japan Surgical Society   99 ( 7 )   463 - 468   1998.7

     More details

    Language:Japanese   Publisher:Japan Surgical Society (JSS)  

    CiNii Article

    CiNii Books

    researchmap

  • 89 大腸癌に対するp53遺伝子発現アデノウイルスベクターを用いた遺伝子治療の開発(第52回日本消化器外科学会総会)

    邵 江華, 藤原 俊義, 小川 誠之, 深澤 拓也, 日伝 晶夫, 田中 紀章

    日本消化器外科学会雑誌   31 ( 6 )   1413 - 1413   1998.6

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 389 p53遺伝子導入によるアポトーシスへのFas/APO-1(CD95)レセプター/リガンドシステムの関与(第52回日本消化器外科学会総会)

    深澤 拓也, 藤原 俊義, 守本 芳典, 邵 江華, 西崎 正彦, 日伝 晶夫, 田中 紀章

    日本消化器外科学会雑誌   31 ( 6 )   1490 - 1490   1998.6

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • アデノウイルスベクターを用いた肝類洞壁内皮細胞への遺伝子導入の試み

    藤澤 憲司, 斎藤 信也, 岡田 豊, 藤原 俊義, 田中 紀章

    日本外科学会雑誌   99   423 - 423   1998.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • MOLECULAR THERAPY FOR HUMAN CANCER BY WILD-TYPE p53 GENE TRANSFER

    FUJIWARA Toshiyoshi, TANAKA Noriaki

    23 ( 3 )   600 - 605   1997.11

     More details

  • III-A-4 食道扁平上皮癌における p21 と p53 の集積および apoptosis に関する検討(<特集>第50回日本食道疾患研究会)

    濱田 円, 猶本 良夫, 藤原 俊義, 羽井佐 実, 上川 康明, 田中 紀章

    日本消化器外科学会雑誌   30 ( 5 )   1039 - 1039   1997.5

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • p53遺伝子導入によるがん治療の可能性 (特集p53の生理作用--その多様性の源に迫る)

    藤原 俊義, 香川 俊輔, 西崎 正彦

    細胞工学   16 ( 4 )   556 - 563   1997.4

     More details

    Language:Japanese   Publisher:秀潤社  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/1997133200

  • 230 サイトカイン拮抗物質からみた手術侵襲に対する宿主反応(<特集>第49回日本消化器外科学会総会)

    岩垣 博巳, 日伝 晶夫, 宮宗 秀明, 平本 孔彦, 藤原 俊義, 松原 長秀, 斉藤 信也, 田中 紀章

    日本消化器外科学会雑誌   30 ( 2 )   438 - 438   1997.2

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • II-187 イレウスにて発症した腸回転異常を伴った右型傍十二指腸ヘルニアの1治験例(<特集>第48回日本消化器外科学会総会)

    前田 徹也, 佐々木 寛, 江添 弘, 藤原 俊義

    日本消化器外科学会雑誌   29 ( 6 )   1549 - 1549   1996.6

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 63 食道扁平上皮癌における p21 の topological control と p53, Ki67 との関連(<特集>第48回日本消化器外科学会総会)

    濱田 円, 猶本 良夫, 藤原 俊義, 羽井佐 実, 上川 康明, 田中 紀章

    日本消化器外科学会雑誌   29 ( 6 )   1308 - 1308   1996.6

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 207 血中IL-1 receptor antagonist (IL-1ra) 値からみた外科的重症感染症による病態 : SIRSの解析(<特集>第48回日本消化器外科学会総会)

    岩垣 博巳, 日伝 晶夫, 堀木 貞幸, 藤原 俊義, 田中 紀章

    日本消化器外科学会雑誌   29 ( 6 )   1344 - 1344   1996.6

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • I-G-2 食道癌における p53の発現と, p21及びApoptosis との関連についての検討(<特集>第49回食道疾患研究会)

    濱田 円, 猶本 良夫, 藤原 俊義, 上川 康明, 田中 紀章, 折田 薫三

    日本消化器外科学会雑誌   29 ( 4 )   940 - 940   1996.4

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • S4-11 大腸癌に対する p53遺伝子発現アデノウイルスとDNA障害性抗癌剤を用いた遺伝子治療(<特集>第47回日本消化器外科学会総会)

    小川 誠之, 藤原 俊義, 香川 俊輔, 濱田 円, 日伝 晶夫, 合地 明, 田中 紀章, 折田 薫三

    日本消化器外科学会雑誌   29 ( 2 )   241 - 241   1996.2

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 非小細胞肺癌におけるp53遺伝子導入による抗癌剤感受性誘導機構の解析 : 遺伝子治療への応用 : 癌遺伝子2

    香川 俊輔, 藤原 俊義, 井上 文之, 岡林 孝弘, 五味 慎也, 小川 誠之, 保田 立二, 田中 紀章, 折田 薫三, Roth Jack A

    肺癌   35 ( 5 )   624 - 624   1995.9

     More details

    Language:Japanese   Publisher:日本肺癌学会  

    CiNii Article

    CiNii Books

    researchmap

  • W7-8 食道扁平上皮癌における apoptosis と p53 蛋白および p21 蛋白の集積に関する検討(<特集>第46回日本消化器外科学会)

    濱田 円, 猶本 良夫, 藤原 俊義, 羽井佐 実, 上川 康明, 田中 紀章, 折田 薫三

    日本消化器外科学会雑誌   28 ( 6 )   1327 - 1327   1995.6

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • W1-7 消化器癌における徐放性 IL-2(IL-2 ミニペレット) を用いた siteーdirected immunotherapyの試み(<特集>第39回日本消化器外科学会総会)

    松岡 順治, 阪上 賢一, 合地 明, 井谷 史嗣, 小野田 正, 藤原 俊義, 斉藤 信也, 高須 伸治, 松野 剛, 貞森 裕, 光岡 晋太郎, 田中屋 宏爾, 三好 和也, 中川 秀和, 小林 直哉, 日下 敏, 宇田 征史, 藤原 拓造, 折田 薫三

    日本消化器外科学会雑誌   25 ( 2 )   331 - 331   1992.2

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 125. 同所性ブタ肝移植における温阻血障害に対する徐放性 SOD (SMA-SOD) の有用性(<特集>第35回日本消化器外科学会総会)

    蓮岡 英明, 阪上 賢一, 高須 伸治, 河村 武徳, 内田 晋, 大岩 敏彦, 羽井 佐実, 塩崎 滋弘, 黒住 陽一, 藤原 拓造, 小野田 正, 稲垣 優, 藤原 俊義, 仁熊 健文, 小林 直哉, 三好 和也, 日下 敏, 折田 薫三

    日本消化器外科学会雑誌   23 ( 2 )   341 - 341   1990.2

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 180 ブタ同所性肝移植に対する 15-Deoxyspergualin (DSG) の免疫抑制効果(<特集>第31回日本消化器外科学会総会)

    高瀬 伸治, 坂上 賢一, 森崎 太, 見市 登, 森末 正博, 大岩 敏彦, 稲垣 優, 河村 武徳, 内田 晋, 羽井佐 実, 藤原 俊義, 松本 剛昌, 中井 肇, 斎藤 信也, 合地 明, 折田 薫三

    日本消化器外科学会雑誌   21 ( 2 )   453 - 453   1988.2

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 22. 良性胆道疾患における胆管十二指腸端側吻合術と他術式との比較検討(<特集>第16回日本胆道外科研究会)

    筒井 信正, 北村 元男, 文 〓雄, 平本 孔彦, 高石 義浩, 藤原 俊義, 赤在 義浩, 赤松 良彦, 森谷 行利, 木村 秀幸, 大原 利憲, 広瀬 周平, 片岡 和男, 間野 清志

    日本消化器外科学会雑誌   21 ( 1 )   183 - 183   1988.1

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 289 残胃の癌の臨床病理学的検討(<特集>第30回日本消化器外科学会総会)

    藤原 俊義, 広瀬 周平, 片岡 和男, 北村 元男, 筒井 信正, 大原 利憲, 木村 秀幸, 森谷 行利, 赤松 良彦, 赤在 義浩, 高石 義浩, 文 〓雄, 平本 孔彦, 間野 清志

    日本消化器外科学会雑誌   20 ( 6 )   1427 - 1427   1987.6

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 358 大腸穿孔を伴った大腸癌症例の検討(<特集>第28回日本消化器外科学会総会)

    木村 秀幸, 藤原 俊義, 高石 義浩, 中山 文夫, 野田 卓男, 赤在 義浩, 赤松 良彦, 山本 優, 大原 利憲, 筒井 信正, 広瀬 周平, 北村 元男, 片岡 和男, 間野 清志

    日本消化器外科学会雑誌   19 ( 6 )   1350 - 1350   1986.6

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 450 先天性総胆管拡張症手術例の検討(<特集>第28回日本消化器外科学会総会)

    野田 卓男, 筒井 信正, 高石 義浩, 藤原 俊義, 中山 文夫, 赤在 義浩, 赤松 良彦, 山本 優, 木村 秀幸, 大原 利憲, 広瀬 周平, 北村 元男, 片岡 和男, 間野 清志

    日本消化器外科学会雑誌   19 ( 6 )   1397 - 1397   1986.6

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 380 胃癌大腸癌肝転移例に対する治療成績(<特集>第28回日本消化器外科学会総会)

    大原 利憲, 間野 清志, 片岡 和男, 北村 元男, 広瀬 周平, 筒井 信正, 木村 秀幸, 山本 優, 赤松 良彦, 赤在 義浩, 中山 文夫, 野田 卓男, 藤原 俊義, 高石 義浩

    日本消化器外科学会雑誌   19 ( 6 )   1362 - 1362   1986.6

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • 547 胃癌治癒切除後における腹壁再発例の検討 : とくに再発後長期生存例について(<特集>第27回日本消化器外科学会総会)

    中山 文夫, 間野 清志, 片岡 和男, 北村 元男, 広瀬 周平, 筒井 信正, 大原 利憲, 木村 秀幸, 山本 優, 赤松 良彦, 赤在 義浩, 野田 卓男, 藤原 俊義, 高石 義浩

    日本消化器外科学会雑誌   19 ( 2 )   527 - 527   1986.2

     More details

    Language:Japanese   Publisher:一般社団法人日本消化器外科学会  

    CiNii Article

    CiNii Books

    researchmap

▼display all

Presentations

  • Optimal surveillance based on risk factors of remnant- and extra-pancreatic recurrence after resection of intraductal papillary mucinous neoplasms of pancreas

    第34回日本肝胆膵外科学会学術集会  2022 

     More details

  • 食道癌術後に虚血による気管壊死・気管穿孔に対し、診療科横断的なバックアップのもと加療した1例

    第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会  2022 

     More details

  • 見せます!魅せます!伝わる手術記録の描き方

    第25回岡山大学外科MCセミナー/第8回岡山大学外科同窓会  2022 

     More details

  • 小児外科の手術記録

    第25回岡山大学外科MCセミナー/第8回岡山大学外科同窓会  2022 

     More details

  • The tips of DFT(double flap technique)

    GS Gastric Forum North Taiwan  2022 

     More details

  • safe and retional procedure of robotically assisted esophagectomy

    The 10th Haixi Thoracic Surgery Forum and the 4th Haixi Thoracic Surgery Elite Forum and the 4th Hixi Thoracic Nursing Forum  2022 

     More details

  • 肝移植の現状と展望

    第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会  2022 

     More details

  • 術前DCF療法時代における当院での外科医から見た免疫療法使用戦略

    第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会  2022 

     More details

  • 腹腔鏡下食道癌手術の教育

    第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会  2022 

     More details

  • 高度肥満症に対する減量・代謝改善手術の効果と安全性

    第77回日本消化器外科学会総会  2022 

     More details

  • ベーラー大学における膵全摘自家膵島移植200例の検討

    第77回日本消化器外科学会総会  2022 

     More details

  • 術前化学療法を施行した膵癌患者における代謝栄養学的指標の意義に関する検討

    第77回日本消化器外科学会総会  2022 

     More details

  • Three-way approach for safe and high-quality #10 lymph node dissection 3-wayアプローチによる安全で質の高い#10郭清

    第77回日本消化器外科学会総会  2022 

     More details

  • 男性も女性も働きやすい職場を目指して~男性育児休業習得の意義~

    第77回日本消化器外科学会総会  2022 

     More details

  • T4b食道癌に対する治療戦略についての検討 -induction DCF vs. induction DCF-RTを中心に-

    第77回日本消化器外科学会総会  2022 

     More details

  • 継続的な栄養指導と術後早期アミノ酸投与による胃切除術後の体重・筋肉量減少抑制効果

    第77回日本消化器外科学会総会  2022 

     More details

  • 噴門側胃切除術+観音開き法再建を施行した胃癌・食道胃接合部癌症例の長期予後因子に関する検討

    第77回日本消化器外科学会総会  2022 

     More details

  • 狭窄を伴う食道癌患者における術前胃瘻造設と周術期管理チームの有用性

    第77回日本消化器外科学会総会  2022 

     More details

  • 膵癌における術前血中KRAS遺伝子変異情報を用いた予後予測

    第77回日本消化器外科学会総会  2022 

     More details

  • 炎症性腸疾患に対する経肛門的低侵襲手術は患者因子によらない安定した手術を可能にする

    第77回日本消化器外科学会総会  2022 

     More details

  • Biomarkers predicting the antitumor effect of p53-armed telomerase specific oncolytic adenovirus

    第28回日本遺伝子細胞治療学会学術集会  2022 

     More details

  • Immunization with adenovirus-p53-transduced dendritic cell vaccine enhances the antitumor efficacy of p53-armed oncolytic virotherapy in colorectal cancer

    第28回日本遺伝子細胞治療学会学術集会  2022 

     More details

  • Metabolic reprogramming by anti-mitochondrial agent promotes sensitivity to oncolytic adenoviruses in non-glycolytic pancreatic cancer

    第28回日本遺伝子細胞治療学会学術集会  2022 

     More details

  • 80歳以上の高齢者に対する術前GS療法の忍容性はあるか ~dose intensityの視点から~

    第77回日本消化器外科学会総会  2022 

     More details

  • 腎盂形成術後の腎盂内血腫により尿管ステントの閉鎖をきたした1例

    第31回日本小児泌尿器科学会総会・学術集会  2022 

     More details

  • 食道癌周術期における最近の知見~栄養管理の重要性~

    日本外科代謝栄養学会第59回学術集会  2022 

     More details

  • 当院におけるコロナ禍での脳死肝移植の現状と互助制度の活用:当院での経験と欧州での経験を踏まえて

    第40回日本肝移植学会学術集会  2022 

     More details

  • Analysis of resection margin status in pancreatectomy for pancreati ductal adenocarcinoma

    第53回日本膵臓学会大会・第26回国際膵臓学会  2022 

     More details

  • Prognostic significance of GATA6 expression after surgery in patients with pancreatic cancer

    第53回日本膵臓学会大会・第26回国際膵臓学会  2022 

     More details

  • Recent progress in clinical application of telomerase-specific oncolytic virotherapy

    第28回日本遺伝子細胞治療学会学術集会  2022 

     More details

  • Combination analysis of pre- and postoperative KRAS mutation in circulating tumor DNA in patients with pancreatic cancer

    第53回日本膵臓学会大会・第26回国際膵臓学会  2022 

     More details

  • がんについて知ろう 胃がん

    令和4年度 県立図書館とことん活用講座 特別編  2022 

     More details

  • Efficacy of Surgical Management for Recurrent Intrahepatic Cholangiocarcinoma

    APASL Oncology 2022  2022 

     More details

  • 高齢者大腸がん患者の周術期管理

    PNMセミナー4th  2022 

     More details

  • 高齢者大腸がん患者の周術期管/大腸がん患者の化学療法における栄養管理

    PNMセミナー4th  2022 

     More details

  • ロボット支援下肝胆膵高難度手術における教育プログラム

    第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会  2022 

     More details

  • 大腸がん患者の化学療法における栄養管理

    PNMセミナー4th  2022 

     More details

  • ロボット支援下膵頭十二指腸切除術におけるsuperior mesenteric artery(SMA)アプローチ法:A novel SMA first approach

    第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会  2022 

     More details

  • 十二指腸乳頭部癌における至適リンパ節郭清の意義

    第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会  2022 

     More details

  • 進化する胃がん・食道がん診療の今と未来

    第101回G・Iセミナー  2022 

     More details

  • 胸部食道癌低侵襲手術におけるドレーン挿入の意義

    第77回日本消化器外科学会総会  2022 

     More details

  • 進化する胃がん・食道がん治療の今と未来

    第74回愛媛外科会総会  2022 

     More details

  • 食道狭窄,食道気道瘻に対する食道バイパス術の成績と新たな術式の構築

    第77回日本消化器外科学会総会  2022 

     More details

  • 高齢大腸癌患者の手術および長期予後についての検討

    第77回日本消化器外科学会総会  2022 

     More details

  • BR大腸癌肝転移に対する肝切除アプローチ Vessel-Skeletonized Parenchyma-sparing Hepatectomyの有用性

    第77回日本消化器外科学会総会  2022 

     More details

  • 高度局所進行食道癌に対する術前DCF療法 plus ロボット支援下手術

    第77回日本消化器外科学会総会  2022 

     More details

  • 根治的CRT後の食道縦隔瘻を伴う食道癌に対してロボット支援下胸腔鏡下食道切除術を施行した1例

    第77回日本消化器外科学会総会  2022 

     More details

  • Significance of mediastinal esophagectomy for cases the right thoracic approach is difficult.右胸腔アプローチ手術が困難な症例に対する縦隔鏡下食道切除術の意義と合併症低減への工夫

    第77回日本消化器外科学会総会  2022 

     More details

  • 難治性食道狭窄に対して食道亜全摘を施行した関節リウマチ合併Sjogren症候群の1例

    第77回日本消化器外科学会総会  2022 

     More details

  • 食道癌術後肺転移に対して外科的切除を行った16例の検討

    第77回日本消化器外科学会総会  2022 

     More details

  • 食道外科におけるサブサブスペシャリティ取得への取組み

    第77回日本消化器外科学会総会  2022 

     More details

  • 肝胆膵外科高度技能専門医の効率的な育成に向けて -膵頭十二指腸切除のラーニングカーブ解析-

    第77回日本消化器外科学会総会  2022 

     More details

  • 術中神経刺激装置が有用であった右鎖骨下動脈起始異常を合併した胸部食道癌の一例

    第77回日本消化器外科学会総会  2022 

     More details

  • PD各論1:手順の違い

    HPB Expert Meeting  2022 

     More details

  • 難治性膵臓癌に対する代謝調節剤を併⽤した p53 武装化アデノウイルス療法の治療戦略

    第43回癌免疫外科研究会  2022 

     More details

  • ⼤腸癌に対する p53 感作樹状細胞ワクチンを併⽤した p53 ウイルス免疫療法の治療戦略

    第43回癌免疫外科研究会  2022 

     More details

  • The Gastrohepatic Ligament Approach in Robotic Spleen-Preserving Distal Pancreatectomy: the Superior Window Approach

    KSELS2022  2022 

     More details

  • 合併症ゼロを目指した食道再建におけるテクニック

    頭頚部手術の最前線2022  2022 

     More details

  • 位置情報を用いた勤怠管理と働き方改革-働き方改革の課題は何か-

    第59回日本小児外科学会学術集会  2022 

     More details

  • Problems and Advances in Living Donor Liver Transplantation resulting from poorly spreading Deceased Donor Liver Transplantation in Japan

    International Symposium on Liver Transplantation  2022 

     More details

  • 術前化学療法予定の通過障害を伴う胃癌に対する胃空腸バイパス吻合時の工夫 #4sbリンパ節の先行郭清

    第76回日本手術手技研究会  2022 

     More details

  • 先天性胆道拡張症術後合併症の経験とその対処法

    第59回日本小児外科学会学術集会  2022 

     More details

  • p53 搭載腫瘍融解アデノウイルス製剤の膵癌マウスモデルにおける⻑期抗腫瘍免疫増強効果

    第43回癌免疫外科研究会  2022 

     More details

  • 癌関連線維芽細胞は免疫チェックポイント分⼦を介し癌免疫抑制状態へ誘導する。

    第43回癌免疫外科研究会  2022 

     More details

  • 安全な系統的肝切除のための標準手術手技

    第63回中国四国小児がん・小児外科研究会  2022 

     More details

  • 観音開き法再建の手術手技と術後QOLについて

    消化器がんを考える会  2022 

     More details

  • DCF療法とロボット支援下手術を駆使して挑む食道癌T3.5症例に対する根治手術

    第65回関西胸部外科学会学術集会  2022 

     More details

  • Tips on Kamikawa Double-Flap Reconstruction (Originated from Okayama University)

    Ethicon Expert Exchange in Gastric  2022 

     More details

  • ロボット支援下膵切除術におけるトラブルシューティング

    The 9th Summer Seminar in Okinawa(2022)  2022 

     More details

  • 術前から術後まで幅広くサポートする多職種チーム医療による食道がん周術期管理

    第47回日本外科系連合学会学術集会  2022 

     More details

  • 食道胃接合部癌に対する腹臥位胸腔鏡下併用の下縦隔郭清および食道残胃吻合

    第47回日本外科系連合学会学術集会  2022 

     More details

  • みんなで考えよう ゲノム時代の遺伝性腫瘍診療~遺伝子の情報を活かしたがんの治療や予防のあり方を考える~

    第28回日本遺伝性腫瘍学会学術集会  2022 

     More details

  • 家族性大腸腺腫症における2 チームでの経肛門的直腸間膜切除術(Trans anal Total Mesorectal Excision:TaTME)を用いた大腸全摘

    第28回日本遺伝性腫瘍学会学術集会  2022 

     More details

  • DCF療法を軸としたcT4b食道癌に対する治療戦略についての検討

    第65回関西胸部外科学会学術集会  2022 

     More details

  • 血流と挙上性を両立した胃管作製とECHELON CIRCULAR™ Powered Staplerを用いた食道胃管吻合

    第65回関西胸部外科学会学術集会  2022 

     More details

  • 食道癌手術におけるCadaver Surgical Trainingの活用

    第65回関西胸部外科学会学術集会  2022 

     More details

  • Efficacy and safety of everolimus in liver transplant recipients: a single center experience

    第34回日本肝胆膵外科学会学術集会  2022 

     More details

  • Telomerase-specific oncolytic adenoviruses via extracellular vesicles plays an important role in the abscopal effect

    第2回アジア腫瘍学会国際会議と第48回韓国がん学会  2022 

     More details

  • 消化器外科診療の最前線:ロボット・ウイルス・働き方改革

    第104回山口県医学会総会  2022 

     More details

  • 静脈栄養管理患者における脂肪乳剤投与が予後に及ぼす影響

    第37回日本臨床栄養代謝学会学術集会  2022 

     More details

  • ロボット支援下膵切除術の現状と展望

    第54回備後肝胆膵研究会  2022 

     More details

  • Utility of the 5-Item Modified Frailty Index in Liver Resection for the Elderly Patient with hepatocellular carcinoma

    第34回日本肝胆膵外科学会学術集会  2022 

     More details

  • Clinical Practice of NAC-GS Therapy for Resectable Pancreatic Ductal Adenocarcinoma ~dose intensity analysis and comparison of up-front surgery~

    第34回日本肝胆膵外科学会学術集会  2022 

     More details

  • Safe introduction of robotic pancreatectomy from the West to Japan

    第34回日本肝胆膵外科学会学術集会  2022 

     More details

  • Can we identify T1T2 pancreatic cancer before pancreatectomy?: a multicenter retrospective study

    第34回日本肝胆膵外科学会学術集会  2022 

     More details

  • Digital transformation in medical illustration: iPad can be a promising gadget for creating attractive, easy, and rational operative note

    第34回日本肝胆膵外科学会学術集会  2022 

     More details

  • ロボット支援下手術の特性を駆使して挑む局所進行食道癌症例に対する根治手術の有用性

    第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会  2022 

     More details

  • 高齢胃癌患者に対する周術期多職種介入の効果

    第94回日本胃癌学会総会  2022 

     More details

  • Feasibility of laparoscopic and robotic spleen-preserving splenic hilar lymph node dissection

    第94回日本胃癌学会総会  2022 

     More details

  • 進行・再発胃癌患者に対するNivolumabの実臨床での治療成績の検討

    第94回日本胃癌学会総会  2022 

     More details

  • 胃癌患者の予後向上を目指して

    第53回岡山東部消化器内視鏡懇話会  2022 

     More details

  • 早期胃癌の深達度診断におけるAI開発の実現可能性.

    第94回日本胃癌学会総会  2022 

     More details

  • 腹腔鏡下スリーブ状胃切除術導入から4年間での治療成績

    第39回日本肥満症治療学会学術集会  2022 

     More details

  • Sarcoma術後の腹壁欠損に対する腹壁再建

    第2回AWR(Abodominal Wall Reconstruction)Web Seminar  2022 

     More details

  • 当施設におけるロボット支援下直腸手術の導入と短期治療成績

    第14回日本ロボット外科学会学術集会  2022 

     More details

  • CapeOX plus radiotherapy is a useful preoperative therapy for locally advanced rectal cancer

    第19回日本臨床腫瘍学会学術集会  2022 

     More details

  • ペムブロリズマブ使用中に下垂体機能低下症と間質性肺炎を発症したが診療科横断的に加療できた高頻度マイクロサテライト不安定性大腸癌の1例

    第19回日本臨床腫瘍学会学術集会  2022 

     More details

  • 食道癌に対する腫瘍融解ウイルス併用放射線療法の臨床研究の成果と展望

    第76回日本食道学会学術集会  2022 

     More details

  • 食道癌根治切除術後の肝転移、肺転移切除についての検討

    第76回日本食道学会学術集会  2022 

     More details

  • 胃管作製法と吻合法に着目した当科における食道切除後再建の変遷と工夫

    第76回日本食道学会学術集会  2022 

     More details

  • 抗腫瘍免疫賦活を介した腫瘍融解アデノウイルス製剤による免疫チェックポイント阻害薬治療増強効果の検討

    第76回日本食道学会学術集会  2022 

     More details

  • 当院における高齢者進行食道癌に対する治療戦略

    第76回日本食道学会学術集会  2022 

     More details

  • 食道癌に対するサルベージロボット支援下胸腔鏡下食道亜全摘術5症例の検討

    第76回日本食道学会学術集会  2022 

     More details

  • 反回神経麻痺のゼロコンを目指したチーム医療

    第76回日本食道学会学術集会  2022 

     More details

  • 喉頭温存を目指した頸部進行食道癌の集学的治療戦略

    第76回日本食道学会学術集会  2022 

     More details

  • アプローチ法による特性を理解し、安全で確実な胸部操作を行う

    第76回日本食道学会学術集会  2022 

     More details

  • ロボット支援下手術の導入により見えてきた一歩先の食道癌手術とその課題

    第76回日本食道学会学術集会  2022 

     More details

  • 術前DCF療法を施行した食道根治術術後再発に対するNivolumabの有効性

    第76回日本食道学会学術集会  2022 

     More details

  • 腹腔鏡下に治療した滑脱型食道裂孔ヘルニア合併横隔膜傍裂孔ヘルニアの1例

    第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会  2022 

     More details

  • 食道胃接合部癌に対する有茎空腸によるDuble Tract再建

    第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会  2022 

     More details

  • The application of Closed-LECS procedure to duodenal tumors

    第94回日本胃癌学会総会  2022 

     More details

  • 外科医が思う「あったらいいな」をTranslational researchで解決する

    第122回日本外科学会定期学術集会  2022 

     More details

  • 膵癌術前・術後血中循環腫瘍DNA内KRAS遺伝子変異の臨床的意義に関する検討

    第60回日本癌治療学会学術集会  2022 

     More details

  • 食道外科医における技術認定制度、認定医とは? 技術認定合格に必須なコンセプト

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 内視鏡外科手術におけるカダバーサージカルトレーニング遠隔手術指導シミュレーションの実際

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 食道裂孔ヘルニアの腹腔鏡下根治手術における手技の工夫と QOL 改善への貢献

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 肝胆膵外科鏡視下手術における Pfannenstiel 切開からの臓器摘出

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 観音開き法(上川法)再建における吻合部狭窄ゼロを目指した手技の改変

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 食道切離断端を残さず切除する Overlap 法による食道空腸吻合の短期成績と PGSAS-45による術後 1 年の QOL 解析

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 症例数の限られた地方病院での安全かつ有効な新規代謝改善手術導入の課題

    第35回日本内視鏡外科学会総会  2022 

     More details

  • Cadaverを用いた開胸手術トレーニング

    第75回日本胸部外科学会定期学術集会  2022 

     More details

  • 術後補助免疫療法に向けた術前DCF療法の再発リスク解析

    第75回日本胸部外科学会定期学術集会  2022 

     More details

  • 膵神経内分泌腫瘍における領域リンパ節郭清の意義

    第10回日本神経内分泌腫瘍研究会  2022 

     More details

  • 切除可能膵癌における血中循環腫瘍 DNA 内 Kras 遺伝子変異と CA19-9値による予後層別化の試み

    第42回日本分子腫瘍マーカー研究会  2022 

     More details

  • 広島市民病院での小児外科の経験

    第53回小児医療センター合同カンファレンス  2022 

     More details

  • p53 感作樹状細胞ワクチンは大腸癌に対する p53 搭載腫瘍融解ウイルスの治療効果を増強する

    第81回日本癌学会学術総会  2022 

     More details

  • 癌細胞と癌関連線維芽細胞は互いに PD-L1 を増強させ予後に影響する

    第81回日本癌学会学術総会  2022 

     More details

  • 腫瘍免疫の改善に関わる、FAP を標的とした光免疫療法の可能性

    第81回日本癌学会学術総会  2022 

     More details

  • p53 搭載テロメラーゼ特異的腫瘍融解アデノウイルスの抗腫瘍効果予測スコアリングシステム

    第81回日本癌学会学術総会  2022 

     More details

  • 血清エクソソーム E1A-DNA はテロメラーゼ特異的腫瘍融解アデノウイルスの治療効果予測バイオマーカーとして有用である

    第81回日本癌学会学術総会  2022 

     More details

  • EMT バイオセンサーを用いたリアルタイムイメージングによる難治性膵臓癌の治療戦略

    第81回日本癌学会学術総会  2022 

     More details

  • 岡山大学肝移植と肝胆膵外科の歩み

    第49回岡山大学外科肝胆膵研究会  2022 

     More details

  • 腫瘍融解アデノウイルス製剤の免疫賦活薬としての有用性と ICI との併用治療の可能性

    第35回日本バイオセラピィ学会学術集会総会  2022 

     More details

  • マジンドール(Mazindol:MZD)先行導入後に腹腔鏡下スリーブ胃切除術を行った高度肥満の 2 例

    第43回日本肥満学会/第40回日本肥満症治療学会学術集会  2022 

     More details

  • 小児外科における疾患型シミュレーションを用いた手術手技

    第3回外科系教育Research&Design Lab(SERD Lab)  2022 

     More details

  • ロボット支援下・腹腔鏡下 膵切除術

    第49回岡山大学外科肝胆膵研究会  2022 

     More details

  • 腹腔鏡下スリーブ状胃切除(LSG)の安全な導入と普及への課題

    第43回日本肥満学会/第40回日本肥満症治療学会学術集会  2022 

     More details

  • 岡山大学 肝移植と肝胆膵外科の歩み

    第49回岡山大学外科肝胆膵研究会  2022 

     More details

  • 特別講演「岡山大学 肝移植と肝胆膵外科の歩み」

    第49回岡山大学外科肝胆膵研究会  2022 

     More details

  • p53 を抗原とする樹状細胞ワクチンによる前感作は p53 武装化ウイルス免疫療法の治療効果を増強する

    第35回日本バイオセラピィ学会学術集会総会  2022 

     More details

  • 膵癌のがん関連線維芽細胞(CAF)サブタイプに対する腫瘍融解ウイルス療法の感受性の検討

    第35回日本バイオセラピィ学会学術集会総会  2022 

     More details

  • テロメラーゼ特異的腫瘍融解ウイルス製剤の創薬研究:がん免疫療法との協働

    第35回日本バイオセラピィ学会学術集会総会  2022 

     More details

  • 免疫抑制環境を誘導するゲムシタビン耐性膵癌に対する新たな複合免疫療法の開発

    第35回日本バイオセラピィ学会学術集会総会  2022 

     More details

  • 外科医不足に対してCadaver Surgical Trainingが果たす役割

    第84回日本臨床外科学会総会  2022 

     More details

  • 腫瘍の局在や形態に応じたD-LECSのアプローチ法や切除法の工夫

    第84回日本臨床外科学会総会  2022 

     More details

  • 術前DCF療法を行った食道癌切除の再発パターンと再発リスク因子

    第84回日本臨床外科学会総会  2022 

     More details

  • 呼吸筋機能評価と重点的呼吸筋リハビリは食道癌術後呼吸器合併症を低減する

    第84回日本臨床外科学会総会  2022 

     More details

  • 進行食道癌におけるロボット支援下食道手術の有用性

    第84回日本臨床外科学会総会  2022 

     More details

  • 血中循環腫瘍DNA内Kras遺伝子変異情報とCA19-9値による切除可能膵癌層別化の試み

    第84回日本臨床外科学会総会  2022 

     More details

  • 認知行動療法を応用した患者参加型の術後継続的な栄養指導による胃切除後体重、筋肉量減少抑制効果

    第52回胃外科・術後障害研究会  2022 

     More details

  • 高齢 StageIA 胃癌患者の長期予後を得るための適切な評価

    第52回胃外科・術後障害研究会  2022 

     More details

  • 家庭で気がつく外科の病気

    オンライン市民公開講座「身近な子どもの病気を学ぶ」  2022 

     More details

  • ロボット支援下膵体尾部切除術の定型化と初期治療成績

    第16回肝臓内視鏡外科研究会/第14回膵臓内視鏡外科研究会  2022 

     More details

  • 根治性とQOL維持の両立を目指した食道接合部癌に対する至適術式の検討

    第84回日本臨床外科学会総会  2022 

     More details

  • 小網アプローチによるロボット支援下脾温存膵体尾部切除

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 術前治療後の腹腔鏡下直腸癌手術の治療成績

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 胸腔鏡下食道癌手術のコンセプトと成績、教育方法

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 神経モニタリングを用いたより低侵襲なロボット支援下食道手術

    第35回日本内視鏡外科学会総会  2022 

     More details

  • ここまで挑む!化学放射線療法後の局所進行食道癌の根治手術

    頭頚部手術の最前線2022Winter  2022 

     More details

  • 胃癌術後 1 年目に局所リンパ節再発を疑った腹腔内デスモイド腫瘍の 1 例

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 胆道癌に対する外科治療Up to date

    第17回五国胆膵画像診断研究会  2022 

     More details

  • 若手医師による症例提示

    SCSセミナー  2022 

     More details

  • 術後再発困難症例に対する前方臓器温存のための集学的治療を併用した TaAPR の有用性

    第35回日本内視鏡外科学会総会  2022 

     More details

  • ロボット支援下膵頭十二指腸切除術導入期における胆管消化管吻合の成績

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 当院におけるロボット支援下膵頭十二指腸切除術

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 縦隔郭清を伴う食道胃接合部癌に対する岡山大学病院での取り組み

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 膵体尾部癌に対する Supracolic Anterior SMA アプローチを用いたロボット支援下RAMPS の定型化と短期成績

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 効率的な肝胆膵外科修練を考える ~高度技能専門医と内視鏡技術認定医の両立~

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 周術期管理チーム介入により高齢Frail大腸癌患者に対する手術の安全性は向上したか

    第60回日本癌治療学会学術集会  2022 

     More details

  • 当院におけるロボット支援下膵切除術の初期治療成績

    第60回日本癌治療学会学術集会  2022 

     More details

  • 腸内細菌叢は潰瘍性大腸炎においてRNA編集を介し発癌を促進する

    第60回日本癌治療学会学術集会  2022 

     More details

  • RNA編集は大腸癌の発癌や進展を促進するのみならず免疫療法のターゲットとなり得る

    第60回日本癌治療学会学術集会  2022 

     More details

  • CAFsを標的にした光免疫療法による薬物動態改善効果の検証

    第60回日本癌治療学会学術集会  2022 

     More details

  • 難治性膵臓癌に対するミトコンドリア阻害剤と腫瘍融解アデノウイルスの併用療法

    第60回日本癌治療学会学術集会  2022 

     More details

  • 患者参加型継続的栄養指導による胃癌術後のサルコペニア予防効果

    第60回日本癌治療学会学術集会  2022 

     More details

  • Stage IV胃がんのConversion Surgeryを見極める;境界型を含めた3分類の提唱

    第60回日本癌治療学会学術集会  2022 

     More details

  • 切除可能膵癌に対するNAC-GS療法は予後を改善したか?-非切除例を含む全コホート解析-

    第60回日本癌治療学会学術集会  2022 

     More details

  • 創造性を育む外科医の基礎研究

    第75回日本胸部外科学会定期学術集会  2022 

     More details

  • 強力な導入DCF療法とロボット支援下手術を用いたcT3.5食道癌症例に対する治療戦略

    第75回日本胸部外科学会定期学術集会  2022 

     More details

  • 腹腔鏡下スリーブ状胃切除の導入と定型化

    第21回EGI外科治療研究会プログラム  2022 

     More details

  • 骨盤外科手術における合併症予防の取り組み

    第21回EGI外科治療研究会プログラム  2022 

     More details

  • 直腸癌低位前方切除後の縫合不全に対する取り組みと課題

    第77回日本大腸肛門病学会学術集会  2022 

     More details

  • ロボット手術の現在と未来

    オンライン市民公開講座  2022 

     More details

  • 食道癌周術期における最近の知見~亜鉛管理の重要性~

    第476回浅口医師会Web学術講演会  2022 

     More details

  • 腹壁神経解剖の実際を真剣に学ぶ ~アウトカム強化の追及~

    第17回日本腹腔鏡下ヘルニア手術手技研究集会  2022 

     More details

  • 外科領域における感染対策~ BSI、SSI の観点から~

    第35回日本外科感染症学会総会学術集会  2022 

     More details

  • ドラッグデリバリーを改善させるCAFsを標的にした光免疫療法の効果

    第33回日本消化器癌発生学会総会  2022 

     More details

  • 次世代のがん治療のための遺伝子工学に基づく生物製剤の創薬研究

    久留米大学大学院医学研究科 特別講義  2022 

     More details

  • Nuss法とRavitch法を組み合わせた胸骨挙上法の経験

    Nuss法漏斗胸手術手技研究会  2022 

     More details

  • 高度食道裂孔ヘルニア手術の安全な手技と若手教育

    第12回岡山手術手技ビデオフォーラム  2022 

     More details

  • 公開セカンドオピニオン

    世界がん撲滅サミット2022 in OSAKA  2022 

     More details

  • 腸内細菌代謝産物(酪酸)とウイルス治療

    第3回岡山消化器学術セミナー  2022 

     More details

  • 食道疾患治療における最新の知見

    第278回岡山医師会消化器疾患研究会  2022 

     More details

  • 見せます!魅せます!デジタルイラストを用いた手術記録の描き方・活かし方

    手術手技オンラインセミナー  2022 

     More details

  • チームで取り組む食道外科手術における周術期感染症対策

    第35回日本外科感染症学会総会学術集会  2022 

     More details

  • 肝移植後の日和見感染症への対策と課題

    第35回日本外科感染症学会総会学術集会  2022 

     More details

  • 食道浸潤長から導かれる食道胃接合部癌の至適術式と集学的治療の検討

    第30回日本消化器関連学会週間  2022 

     More details

  • 当施設における大腸憩室炎に対する手術治療成績

    第30回日本消化器関連学会週間  2022 

     More details

  • ICG 蛍光法にて血流評価を行ったmesodiverticular band による絞扼性腸閉塞の一例

    第38回日本小児外科学会秋季シンポジウム  2022 

     More details

  • 食道バンディングで食道離断を来たしたC 型食道閉鎖症に対する漿膜筋層フラップを用いた食道・胃吻合術(観音開き法)

    第38回日本小児外科学会秋季シンポジウム  2022 

     More details

  • Surgical technique and ERAS protocol in laparoscopic gastrectomy

    The First Enhanced Recovery after Surgery Annual Meeting  2022 

     More details

  • 食道胃接合部癌に対する集学的治療の後方視的解析と食道浸潤長から導かれる至適術式

    第60回日本癌治療学会学術集会  2022 

     More details

  • Metabolic reprogramming by anti-mitochondrial agent promotes the antitumor efficacy of telomerase-specific oncolytic adenoviruses against virotherapy-resistant pancreatic cancer

    IOVC2022  2022 

     More details

  • Oncolytic sdenovirus-mediated p53 gene therapy targets the tumor-microenvironment to improve anti-tumor efficacy for peritoneal metastasis of gastric canccer

    IOVC2022  2022 

     More details

  • Combination therapy with telomerase-specific oncolytic adenovirus and PD-L1 blockade against gemcitabine-resistant pancreatic cancer

    IOVC2022  2022 

     More details

  • Multidisciplinary oncolytic virotherapy for esophageal cancer patients unfit for standard treatments

    IOVC2022  2022 

     More details

  • ロボット支援下膵切除術の安全な導入と初期成績

    第30回日本消化器関連学会週間  2022 

     More details

  • 肺癌と直腸癌の同時性重複癌にpembrolizumabが著効した1例

    第96回大腸癌研究会  2022 

     More details

  • 80歳以上の高齢者食道癌症例に対する安全性と根治性を担保した外科的治療戦略

    第122回日本外科学会定期学術集会  2022 

     More details

  • ロボット支援下肝胆膵高難度手術の普及と教育システムの確立を目指して

    第122回日本外科学会定期学術集会  2022 

     More details

  • 食道浸潤長から導かれる食道胃接合部癌の至適術式と集学的治療の後方視的解析

    第122回日本外科学会定期学術集会  2022 

     More details

  • 食道バイパス術の有用性に関する検討

    第122回日本外科学会定期学術集会  2022 

     More details

  • ニボルマブ+化学療法への期待~適正使用を含めて~

    胃癌1次治療承認記念講演会  2022 

     More details

  • ナショナルビッグデータを用いた新専門医制度の地域外科医療に及ぼす影響の評価研究

    第122回日本外科学会定期学術集会  2022 

     More details

  • 術前化学療法により安全に切除可能であった肝芽腫の1例

    第63回中国四国小児がん・小児外科研究会  2022 

     More details

  • Optimal treatment for recurrent intrahepatic cholangiocarcinoma: when do we do surgery?

    The 31st conference of the Asian Pacific Association for the study of the liver (APASL) 2022, Seoul  2022 

     More details

  • ベーラー大学における膵全摘自家膵島移植200例の検討

    第122回日本外科学会定期学術集会  2022 

     More details

  • 十二指腸腫瘍の局在や特性に応じた LECS のアプローチ法や切除法の工夫と成績

    第35回日本内視鏡外科学会総会  2022 

     More details

  • 呼吸筋サルコペニア・フレイル評価とリハビリは食道癌術後呼吸器合併症を減少させる

    第60回日本癌治療学会学術集会  2022 

     More details

  • Therapeutic indexによる肝内胆管癌に対するリンパ節郭清の効果の検証多施設共同研究

    第60回日本癌治療学会学術集会  2022 

     More details

  • 食道癌周術期管理における多職種チーム医療の早期介入の有用性と今後の展望

    第60回日本癌治療学会学術集会  2022 

     More details

  • 食道癌術後オリゴ転移に対する集学的治療

    第60回日本癌治療学会学術集会  2022 

     More details

  • 膵癌の代謝サブタイプに基づく p53 誘導性腫瘍融解ウイルス療法の治療戦略

    第34回日本バイオセラピィ学会学術集会総会  2021 

     More details

  • 80歳以上の高齢者に対する食道裂孔ヘルニア手術の安全性と有効性の検討

    第76回日本消化器外科学会総会  2021 

     More details

  • Retrospective study of induction chemotherapy and surgery for esophagogastric junction cancer

    第76回日本消化器外科学会総会  2021 

     More details

  • Standardization of robotic-assisted thoracoscopic esophagectomy

    第76回日本消化器外科学会総会  2021 

     More details

  • cT4食道癌に対する導入療法後手術症例の検討

    第76回日本消化器外科学会総会  2021 

     More details

  • 胆管空腸吻合術後の難治性肝内結石症に対する治療経験

    第76回日本消化器外科学会総会  2021 

     More details

  • 術前診断に苦慮した,稀な形態を呈した胃粘膜下腫瘍の治療経験

    第76回日本消化器外科学会総会  2021 

     More details

  • 大腸癌肝転移における術前化学療法の適応選別-RAS・RAF変異による肝外進展リスク-

    第76回日本消化器外科学会総会  2021 

     More details

  • 高齢者Stage IA胃癌の治療適応を考える

    第76回日本消化器外科学会総会  2021 

     More details

  • 癌および癌関連線維芽細胞を標的とした胃癌腹膜播種の新規治療戦略

    第76回日本消化器外科学会総会  2021 

     More details

  • 高齢者に対する肝切除術前評価における5-Item Modified Frailty Indexの有用性

    第76回日本消化器外科学会総会  2021 

     More details

  • 進行膵癌集学的治療における術前血中KRAS遺伝子変異の新規バイオマーカーとしての有用性に関する検討

    第76回日本消化器外科学会総会  2021 

     More details

  • 岡山大学における過去8年のCSTの傾向から見たCSTプログラム作成における要点

    第76回日本消化器外科学会総会  2021 

     More details

  • 肥満症に対する腹腔鏡下スリーブ状胃切除術の治療成績

    第76回日本消化器外科学会総会  2021 

     More details

  • Pittsburgh styleによるロボット支援下膵頭十二指腸切除術 術式の定型化と手技の工夫

    第76回日本消化器外科学会総会  2021 

     More details

  • ロボット支援下観音開き法再建の手技上の有用性と注意点

    第76回日本消化器外科学会総会  2021 

     More details

  • 次世代リーダーから学ぶ胃がん手術~より安全の手術実現のための私の拘りと工夫~

    第76回日本消化器外科学会総会  2021 

     More details

  • 膵癌術後再発巣に対する局所療法の有用性の検討

    第76回日本消化器外科学会総会  2021 

     More details

  • 男性消化器外科医のワークライフバランス実現に向けて~男性育休を取得した経験から~

    第76回日本消化器外科学会総会  2021 

     More details

  • Frailな高齢者大腸癌患者に対する周術期管理チーム介入後のアウトカムの検証と最近の取り組み

    第76回日本消化器外科学会総会  2021 

     More details

  • 予後を左右する進行大腸癌再発形式の抽出と治療戦略の検討

    第76回日本消化器外科学会総会  2021 

     More details

  • 高齢者食道癌に対する包括的治療戦略

    第76回日本消化器外科学会総会  2021 

     More details

  • シンガポールにて切除不能食道癌StageIVBと診断され、帰国後集学的治療を行った一例

    第74回日本胸部外科学会定期学術集会  2021 

     More details

  • 安全で生理的な食道再建を追求した有茎空腸再建における工夫

    第74回日本胸部外科学会定期学術集会  2021 

     More details

  • 胃を使用できない症例に対する安全で生理的な再建を目指した有茎空腸を用いた食道再建術

    第74回日本胸部外科学会定期学術集会  2021 

     More details

  • ロボット支援下食道手術における合理的な上縦隔郭清術

    第74回日本胸部外科学会定期学術集会  2021 

     More details

  • Prediction of early recurrence of hepatocellular carcinoma afterresection: an international validation of the ERASL risk models

    JDDW2021  2021 

     More details

  • Designed Hepatectomy to Increase Resectability and Safety

    Annual congress of the Korean Surgical Society, Korea  2021 

     More details

  • 肝移植における免疫抑制のニューノーマル-これからの時代を見据えた免疫抑制の最適化-

    第47回日本臓器保存生物医学会学術集会  2021 

     More details

  • 高齢者大腸癌患者に対する周術期管理と術後化学療法の現況

    第76回日本大腸肛門病学会学術集会  2021 

     More details

  • 胸腔鏡下食道癌手術の技術習得と向上への取り組み

    第83回日本臨床外科学会総会  2021 

     More details

  • 術前から術後まで幅広くサポートする多職種による食道がん周術期管理

    第83回日本臨床外科学会総会  2021 

     More details

  • 食道胃接合部癌に対する至適術式と術前療法の有用性に関する検討

    第83回日本臨床外科学会総会  2021 

     More details

  • 生体肝移植ドナー肝切除:成熟段階となった開腹手技

    第83回日本臨床外科学会総会  2021 

     More details

  • 食道原発悪性黒色腫に対して外科的切除を施行した8例の検討

    第83回日本臨床外科学会総会  2021 

     More details

  • 食道癌術後乳糜胸に対する治療マネージメント

    第83回日本臨床外科学会総会  2021 

     More details

  • ロボット支援手術の特性を生かした上縦隔郭清手技

    第83回日本臨床外科学会総会  2021 

     More details

  • 小児外科患者のトランジションの現状と課題

    第83回日本臨床外科学会総会  2021 

     More details

  • 市中病院でのロボット支援下食道悪性腫瘍手術導入における課題と展望

    第83回日本臨床外科学会総会  2021 

     More details

  • 良性疾患に対するTaTME

    第11回岡山手術手技ビデオフォーラム  2021 

     More details

  • 癌関連線維芽細胞がPD-1/PD-L1を制御し予後を不良にする

    第32回日本消化器癌発生学会総会/第10回国際消化器癌発生会議  2021 

     More details

  • 食道癌Tertiary lymphoid structureと腫瘍内免疫との関連

    第32回日本消化器癌発生学会総会/第10回国際消化器癌発生会議  2021 

     More details

  • 腹腔鏡下幽門側胃切除において技術認定医取得は手術成績を改善する

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 術中ドプラ超音波腹腔鏡により腹腔動脈の乱流と流速を評価した正中弓状靭帯圧迫症候群の1例

    第34回日本内視鏡外科学会総会  2021 

     More details

  • Charlson comorbidity indexは80歳高齢者stage IA胃癌の予後因子である

    第59回日本癌治療学会学術集会  2021 

     More details

  • 指導医の目~コーチングスキルを学ぶ~

    第20回EGI外科治療研究会  2021 

     More details

  • 食道外科医が行う頸部食道癌の集学的治療

    頭頚部癌集学的治療セミナーfrom Okayama  2021 

     More details

  • メタアナリシスの読み方、実際のやり方

    OKAYAMA HBP Surge,2021  2021 

     More details

  • 抗GFR抗体薬Rechallengeの現状とこれから

    CRC Cross Talk webinar  2021 

     More details

  • Current status of robotic pancreatectomy in Japan

    12th Worldwide Congress of Clinical Robotic Surgery Association Asia Chapter  2021 

     More details

  • 胃癌免疫療法の現状を振り返る

    起訴と臨床のSYNERGY~Gastric Cancer3L~  2021 

     More details

  • 肝内胆管癌におけるNeutrophil Extracellular Traps産生のための血小板の役割

    第59回日本癌治療学会学術集会  2021 

     More details

  • 胃癌腹膜播種に対する癌関連線維芽細胞を標的としたp53遺伝子治療

    第59回日本癌治療学会学術集会  2021 

     More details

  • テロメラーゼ特異的腫瘍融解ウイルス製剤の創薬研究 がん免疫療法との協働

    第59回日本癌治療学会学術集会  2021 

     More details

  • 左反回神経の自然な走行を意識した左反回神経周囲リンパ節郭清

    第59回日本癌治療学会学術集会  2021 

     More details

  • ロボット支援下手術の導入により見えてきた新たなアプローチ 食道癌左上縦隔郭清術

    第59回日本癌治療学会学術集会  2021 

     More details

  • 80歳以上高齢者食道癌症例に対する外科治療戦略

    第59回日本癌治療学会学術集会  2021 

     More details

  • 骨盤内臓全摘術が高度進行大腸癌へのコンバージョン手術となるかはRAS statusで決まる

    第59回日本癌治療学会学術集会  2021 

     More details

  • 管理栄養士による患者教育プロトコールの胃癌術後体重減少、サルコペニア抑制効果

    第59回日本癌治療学会学術集会  2021 

     More details

  • 局所進行食道がんに対する DCF 併用放射線療法を用いた治療戦略

    第59回日本癌治療学会学術集会  2021 

     More details

  • Safe and rational approach by Robot-assisted thoracoscopic esophagectomy

    The Third Yangtze Forum on Lung Cancer  2021 

     More details

  • 無脾症候群の乳児に対して腹腔鏡下食道裂孔ヘルニア根治術を施行した一例

    第37回日本小児外科学会秋季シンポジウム  2021 

     More details

  • 遊走脾に伴う胃軸捻転症に対し、腹腔鏡下脾固定術・胃固定術を施行した一例

    第37回日本小児外科学会秋季シンポジウム  2021 

     More details

  • 先天性横隔膜ヘルニアに対する内視鏡下施術の経験

    第37回日本小児外科学会秋季シンポジウム  2021 

     More details

  • Safe and rational approach by Robot-assisted thoracoscopic esophagectomy

    The Third Yangtze Forum on Lung Cancer 2021  2021 

     More details

  • 食道癌手術における新たな教育方法

    第74回日本胸部外科学会定期学術集会  2021 

     More details

  • 内視鏡外科技術認定取得報告

    第20回EGI外科治療研究会  2021 

     More details

  • TaTME 手術における New Option ―機器が切り開く可能性―

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 地域基幹病院での高難度鏡視下手術に対するCadaver Surgical Trainingの意義

    第34回日本内視鏡外科学会総会  2021 

     More details

  • ロボット支援下膵切除術のコツとピットフォール

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 右胸腔アプローチ困難例に対する縦隔鏡下食道切除術の治療成

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 高齢Frail大腸癌患者に対する周術期管理チーム介入により腹腔鏡手術の安全性は向上したか

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 胸腔鏡手術の利点を活かした食道癌サルベージ手術の治療成績

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 術前診断が困難であった膵炎を伴った胃異所性膵に対して腹腔鏡下胃切除を行った1例

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 反回神経麻痺軽減のための適切な剥離層の確保

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 内臓錯位症候群における腹腔鏡下食道裂孔ヘルニア手術

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 食道裂孔ヘルニアの腹腔鏡下根治手術による心負荷軽減への貢献

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 腹腔鏡下肝後区域切除の定型化

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 食道食道浸潤が2cmを超える食道胃接合部進行癌に対する胸腔鏡下操作を先行した手術手技

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 術前CAPOX+RTを施行した局所進行直腸癌に対する鏡視下手術成績の検討

    第34回日本内視鏡外科学会総会  2021 

     More details

  • ロボット支援下手術による立体的微細解剖の理解を基礎とした安全で合理的な食道上縦隔郭清術

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 結腸脾弯曲進行癌D3は下腸間膜静脈を軸にする腸間膜化を行うと郭清範囲が明確になる

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 輪状膵を伴う進行胃癌において術式変更にて術中対応した腹腔鏡補助下幽門側胃切除を施行した1例

    第34回日本内視鏡外科学会総会  2021 

     More details

  • 腹腔鏡下噴門側胃切除後の観音開き法再建

    第34回日本内視鏡外科学会総会  2021 

     More details

  • GM-CSF はゲムシタビン耐性膵癌が誘導する免疫抑制性微小環境のバイオマーカーである

    第34回日本バイオセラピィ学会学術集会総会  2021 

     More details

  • 次世代型腫瘍融解アデノウイルス製剤の膵癌マウスモデルにおける長期免疫増強効果の解析

    第34回日本バイオセラピィ学会学術集会総会  2021 

     More details

  • 局所進行切除不能膵癌における予後規定因子の検討 ~非切除例を含めたall cohort解析~

    第76回日本消化器外科学会総会  2021 

     More details

  • ロボット支援下膵頭十二指腸切除術の安全な導入と術式の定型化

    第121回日本外科学会定期学術集会  2021 

     More details

  • 消化器系遺伝性腫瘍のスクリーニングとサーベイランスのための早期介入プログラムの構築

    第121回日本外科学会定期学術集会  2021 

     More details

  • ハイリスク食道癌手術症例に対する包括的治療戦略

    第121回日本外科学会定期学術集会  2021 

     More details

  • 切除不能局所進行食道癌に対するDCFを軸にした集学的治療による根治への挑戦

    第121回日本外科学会定期学術集会  2021 

     More details

  • 消化器外科における多施設共同研究の意義-地方からのevidence発信を目指して-

    第121回日本外科学会定期学術集会  2021 

     More details

  • pT3orpN1以上の局所進行直腸癌に対する術前化学療法の有効性

    第121回日本外科学会定期学術集会  2021 

     More details

  • Siewert type Ⅰ/Ⅱ食道胃接合部癌に対する至適手術 郭清から再建まで

    第121回日本外科学会定期学術集会  2021 

     More details

  • 再発直腸癌に対するICG蛍光ナビゲーション腹腔鏡下骨盤内臓全摘術

    第121回日本外科学会定期学術集会  2021 

     More details

  • Lynch症候群のスクリーニングとサーベイランスを目的とした早期介入プログラムの構築と実践

    第3回がんゲノム医療時代におけるLynch症候群研究会  2021 

     More details

  • 食道癌手術周術期における心合併症の発生とリスク因子の解析

    第121回日本外科学会定期学術集会  2021 

     More details

  • ハイリスク高齢者大腸癌への周術期管理チーム介入による術後アウトカムの変化

    第121回日本外科学会定期学術集会  2021 

     More details

  • 教育における内視鏡手術の利点と問題点

    第58回日本小児外科学会学術集会  2021 

     More details

  • 再肝切除における癒着防止材の意義

    Seprafilm 肝胆膵外科アドバザーミーティング  2021 

     More details

  • 確実に!腹腔鏡下胆嚢摘出術の基礎からアドバイスまで

    瀬戸内腹腔鏡下手術セミナー  2021 

     More details

  • 食道癌に対する食道亜全摘術・胸骨後胃管再建術後に肝拡大左葉切除術を施行した肝細胞癌の一例

    第75回手術手技研究会  2021 

     More details

  • 十二指腸病変に対する LECS の治療成績

    第75回手術手技研究会  2021 

     More details

  • 大動脈浸潤食道癌に対し TEVAR 後に食道亜全摘・大動脈壁・心嚢・肺合併切除と遊離広背筋弁充填を行った一例

    第75回手術手技研究会  2021 

     More details

  • ICG を用いた再発直腸癌に対する腹腔鏡下蛍光ナビゲーション骨盤内臓全摘術

    第75回手術手技研究会  2021 

     More details

  • 観音開き法を極める

    食道残胃吻合を極める  2021 

     More details

  • 要望演題8 新型コロナウイルス感染拡大下の小児外科医療/学術集会の在り方

    第58回日本小児外科学会学術集会  2021 

     More details

  • 停留精巣と移動性精巣の鑑別に迷う症例の治療戦略

    第58回日本小児外科学会学術集会  2021 

     More details

  • Safe laparoscopic surgery for gastric cancer patients with upper abdominal surgical history

    第33回日本内視鏡外科学会総会  2021 

     More details

  • Minimally invasive approach for gastric SMT depending on the characteristics of tumor

    第33回日本内視鏡外科学会総会  2021 

     More details

  • 岡山大学における消化器外科領域鏡視下カダバートトレーニングの現状と未来

    第33回日本内視鏡外科学会総会  2021 

     More details

  • カタバーサージカルトレーニングにおける遠隔手術指導の実際

    第33回日本内視鏡外科学会総会  2021 

     More details

  • A nobel difficulty grading system for laparoscopic livimg donor nephrectomy:Analysis of 1741 donors

    第33回日本内視鏡外科学会総会  2021 

     More details

  • Perioperative management in octogenarian with elective laparoscopic surgery for colorectal cancer

    第33回日本内視鏡外科学会総会  2021 

     More details

  • 腹腔鏡下噴門側胃切除術における観音開き法食道残胃吻合

    第33回日本内視鏡外科学会総会  2021 

     More details

  • Radical endoscopic surgery can reduce heart failure due to giant esophageal hiatal hernia

    第33回日本内視鏡外科学会総会  2021 

     More details

  • 腹腔鏡下噴門形成術における種々の器具を用いた肝挙上法の検討

    第33回日本内視鏡外科学会総会  2021 

     More details

  • Current status and perspective of minimally invasive surgery for esophageal cancer

    第33回日本内視鏡外科学会総会  2021 

     More details

  • 術前療法が直腸癌鏡視下手術に与える短期、長期治療成績の検討

    第33回日本内視鏡外科学会総会  2021 

     More details

  • Safe and retional approach based on robotically enhanced anatomy for esophagectomy

    第33回日本内視鏡外科学会総会  2021 

     More details

  • Present position and future possibility of the double-flap reconstruction after proximal gastrectomy

    第33回日本内視鏡外科学会総会  2021 

     More details

  • 転移に関わる上皮間葉移行を制御する薬剤スクリーニングシステムの開発と転移予防効果の検討

    第121回日本外科学会定期学術集会  2021 

     More details

  • 腫瘍組織浸潤T細胞は残胃癌の予後予測因子となりえる

    第121回日本外科学会定期学術集会  2021 

     More details

  • 外科マネージメントセンターによる情熱のある外科医教育・育成システム

    第121回日本外科学会定期学術集会  2021 

     More details

  • 進行胆嚢癌に対する外科治療-手術成績を踏まえ、その限界を考える-

    第121回日本外科学会定期学術集会  2021 

     More details

  • T1/T2膵癌の術前治療適応に関する検討-多施設共同後方視的研究-

    第121回日本外科学会定期学術集会  2021 

     More details

  • 外科生涯教育におけるCSTの果たす役割

    第121回日本外科学会定期学術集会  2021 

     More details

  • がん微小環境内のマクロファージ,好中球を癌の治療標的として解析する

    第121回日本外科学会定期学術集会  2021 

     More details

  • 患者教育と栄養・運動強化プロトコールが胃癌術後体重減少に与える影響

    第121回日本外科学会定期学術集会  2021 

     More details

  • R/BR膵癌術前化学療法施行症例における術直前CA19-9値の意義に関する検討

    第121回日本外科学会定期学術集会  2021 

     More details

  • 胃癌手術の最前線

    第78回総合キャンサーボード  2021 

     More details

  • ロボット手術の現状と展望 膵臓

    第9回岡山大学消化器外科フォーラム  2021 

     More details

  • 岡山大学病院における食道疾患センターの開設について

    岡山食道癌リモートセミナー  2021 

     More details

  • 癌免疫療法における町内最近の重要性(座長)

    岡山大学消化器外科WEB講演会  2021 

     More details

  • 肝移植におけるエベロリムス~これからの時代を見据え、免疫抑制を考える~

    第38回日本肝移植学会学術集会  2021 

     More details

  • 生体肝移植ドナー408例の手術成績の検討

    第38回日本肝移植学会学術集会  2021 

     More details

  • First experience of complete regional lymph ode dissection during pavreatduodenectomy~the process to perform highly advanced hepatobiliary pancreatic surgery~

    第32回日本肝胆膵外科学会  2021 

     More details

  • The utilization of PNI in preoperative assessment for advanced Hepatobiliary and Pancreatic surgery in super elder patients.

    第32回日本肝胆膵外科学会  2021 

     More details

  • Preoperative and postoperative mutKRAS in ctDNA from the patients with pancreatic adenocarcinoma could be a prognostic biomarker independent of CA19-9

    第32回日本肝胆膵外科学会  2021 

     More details

  • Impact of tumor size and nodal status on outcomes in patients surgically treated for non-functional pancreatic neuroendocrine neoplasms

    第32回日本肝胆膵外科学会  2021 

     More details

  • Middle segment preserving remnant pancreatectomy for metachronous intraductal papillary mucinous neoplasm (IPMN) after distal pancreatectomy: A case report

    第32回日本肝胆膵外科学会  2021 

     More details

  • Knack & Pitfalls in living donor liver surgery. How to minimize the complication rate?

    第32回日本肝胆膵外科学会  2021 

     More details

  • Impact of lymph node dissection on clinical outcomes of intrahepatic cholangiocarcinoma: inverse probability of treatment weighting with survival analysis

    第32回日本肝胆膵外科学会  2021 

     More details

  • 癌細胞および癌関連線維芽細胞を標的とした腹腔内ウイルス療法

    第93回日本胃癌学会総会  2021 

     More details

  • 進行・再発胃癌に対するNivolumabの実臨床での治療成績

    第93回日本胃癌学会総会  2021 

     More details

  • 患者教育プログラムが胃癌術後の体および骨格筋量の変化に及ぼす影響

    第93回日本胃癌学会総会  2021 

     More details

  • 観音開き法再建の技術的進化:更なる患者QOLの向上を目指して

    第93回日本胃癌学会総会  2021 

     More details

  • パネルディスカッション2 胃癌周術期薬物治療の挑戦

    第93回日本胃癌学会総会  2021 

     More details

  • 医師の立場から

    5th TSEP~Team Building Seminar for Esophageal Professionals~多職種でつくる周術期管理チーム  2021 

     More details

  • コロナ禍の学生教育2

    日本外科教育研究会 WEB-SES2021  2021 

     More details

  • Recent Progress on Laparoscopic Reconstruction by Double-Flap Technique after Proximal Gastrectomy

    15th Korea-Japan-China Laparoscopic Gastrectomy Symposium (web)  2021 

     More details

  • LECS施行後に再発した 十二指腸粘膜内癌の1例

    第21回腹腔鏡内視鏡合同手術(LECS)研究会  2021 

     More details

  • 直腸癌の同時性肝転移と肺転移症例における原発巣の臨床病理学的特徴の比較

    第94回大腸癌研究会  2021 

     More details

  • 再発直腸癌に対する腹腔鏡下骨盤内臓全摘術への蛍光ガイド下手術

    第94回大腸癌研究会  2021 

     More details

  • 局所進行直腸癌に対する術前CAPOX+RT療法の治療成績

    第94回大腸癌研究会  2021 

     More details

  • 癌関連線維芽細胞による免疫抑制環境での免疫チェックポイント阻害薬の有効性の探求

    第42回癌免疫外科研究会  2021 

     More details

  • p53搭載腫瘍融解ウイルスはゲムシタビン耐性膵癌が誘導する免疫抑制性の腫瘍微小環境を改善する

    第42回癌免疫外科研究会  2021 

     More details

  • 膵癌患者における生体試料を用いたctDNA遺伝子解析の取り組み~診療施設併設型バイオバンク利用の現状と実際~

    第6回クリニカルバイオバンク学会シンポジウム  2021 

     More details

  • Procedure of partial-graftectomy in living donor liver transplantation: Focusing on prohibited technique of hepatectomy for trainee of certified expert surgeons

    第33回日本肝胆膵外科学会学術集会  2021 

     More details

  • Enhanced one-stage removal of multiple scattered colorectal liver metastasis by parenchymal sparing & skeletonized hepatectomy

    第33回日本肝胆膵外科学会学術集会  2021 

     More details

  • Clinical Significance of KRAS Mutations in Circulating Tumor DNA for Appropriate Surgical Indication and Timing in Patients with Borderline Resectable or Unresectable Pancreatic Cancer

    第33回日本肝胆膵外科学会学術集会  2021 

     More details

  • 噴門測胃切除術の再建法~これまでの経験から観音開き法・ダブルトラクト法を考える~

    第43日本癌局所療法研究会  2021 

     More details

  • ロボット手術で見えてきた 新しいアプローチ 食道癌上縦隔郭清術

    第2回UGIミレニアムの会  2021 

     More details

  • 次世代のがん治療のための遺伝子工学に基づく生物製剤の創薬研究

    第42回癌免疫外科研究会  2021 

     More details

  • 膵癌に対するp53搭載腫瘍融解アデノウイルス製剤のCD8陽性エフェクターメモリーT細胞増加による長期的抗腫瘍免疫増強効果

    第42回癌免疫外科研究会  2021 

     More details

  • Analysis of Resection Margin Status in Pancreatectomy for Pancreatic Ductal Adenocarcinoma

    第33回日本肝胆膵外科学会学術集会  2021 

     More details

  • Difficulty prediction of laparoscopic liver resection with M2BPGi

    第33回日本肝胆膵外科学会学術集会  2021 

     More details

  • The feasibility of surgical resection for distant recurrence of pancreatic cancer

    第33回日本肝胆膵外科学会学術集会  2021 

     More details

  • A novel double hepaticojejunostomy technique in a patient with complicated hepatolithiasis after iatrogenic bile duct injury

    第33回日本肝胆膵外科学会学術集会  2021 

     More details

  • 進行食道がんに対するNAC-DCF療法の治療効果とNAC前から始める早期多職種介入の取り組み

    第64回関西胸部外科学会学術集会  2021 

     More details

  • 血管鞘との位置関係を意識した左反回神経の愛護的操作

    第64回関西胸部外科学会学術集会  2021 

     More details

  • 肝移植における免疫抑制 - 臨床課題とエベロリムスへの期待-

    第39回日本肝移植学会学術集会  2021 

     More details

  • Liver transplantation in Europe(experiences from ESOT)-Organ donation and allocation in Europe

    第39回日本肝移植学会学術集会  2021 

     More details

  • 移植医負担軽減のために脳死臓器摘出互助制度を発展させるか:自施設での経験と欧州での経験を踏まえて

    第39回日本肝移植学会学術集会  2021 

     More details

  • 遅発性グラフト機能不全に対する脳死再肝移植の問題点

    第39回日本肝移植学会学術集会  2021 

     More details

  • 高度進行幹細胞癌に対する根治的粒子線治療後の肝移植

    第39回日本肝移植学会学術集会  2021 

     More details

  • 大腸肝転移に対する肝移植の可能性

    第39回日本肝移植学会学術集会  2021 

     More details

  • 高齢者に対する生体肝移植:移植耐術能からみた至適Graft/Donorの選別

    第39回日本肝移植学会学術集会  2021 

     More details

  • 当院における脳死肝移植マージナルドナーの移植予後の解明

    第39回日本肝移植学会学術集会  2021 

     More details

  • 肝移植後の遅発性肝動脈仮性瘤破裂に対し肝動脈塞栓術を行った1例~血行動態を見極めたIVR治療戦略~

    第39回日本肝移植学会学術集会  2021 

     More details

  • 胆道閉鎖症患児の黄疸重症度が生誕肝移植に及ぼす影響

    第39回日本肝移植学会学術集会  2021 

     More details

  • εγδβサラセミアと新生児へモクロマトーシスに起因する肝硬変に対して生体肝移植をした1例

    第39回日本肝移植学会学術集会  2021 

     More details

  • 生体肝移植術後、ステロイド抵抗性急性細胞性拒絶反応に対するサイモグロブリンの使用経験

    第39回日本肝移植学会学術集会  2021 

     More details

  • 胃瘻周囲漏れを起こした症例の検討

    第35回日本小児ストーマ・排泄・創傷管理研究会  2021 

     More details

  • 腹膜透析患者に発生した腹膜鞘状突起に起因する陰嚢浮腫・陰茎浮腫の 1 例

    第30回日本小児泌尿器科学会総会・学術集会  2021 

     More details

  • 高齢者pStageⅢ大腸癌の予後と転帰から術後化学療法について考察する

    第95回大腸癌研究会  2021 

     More details

  • 高度肥満症に対する外科治療

    日医障害教育講座  2021 

     More details

  • De novo Malignancies after Liver Transplantation

    第33回日本肝胆膵外科学会学術集会  2021 

     More details

  • Surgical training model and safe implementation of robotic pancreatoduodenectomy in Japan:learning from the Dutch training system

    第33回日本肝胆膵外科学会学術集会  2021 

     More details

  • Drug repositioning による新規がん治療の開発に向けて -がん関連線維芽細胞由来 IL-6 の作用と制御

    第80回日本癌学会学術総会  2021 

     More details

  • Onco surgeons who have performed more than 20 open esophagectomies

    VIRTUAL ICOE - Dr Noma - Minimally Invasive Esophagectomy  2021 

     More details

  • BRAF変異型の結腸癌に対する治療について

    岡山大腸癌リモートセミナー  2021 

     More details

  • 食道がん手術における安全なロボット手術の導入と定型化について

    Robotic Assisted Esophagectomy Seminar(中国エリアWeb Seminar)  2021 

     More details

  • 電子カルテ情報の学術活動への効率的な利活用を目指したテンプレート整備

    第47回日本診療情報管理学学会学術大会  2021 

     More details

  • 食道癌周術期管理における早期介入の有用性 岡山大学病院におけるPERiOの取り組み

    日本外科代謝栄養学会第58回学術集会  2021 

     More details

  • エネルギーデバイスの特性を熟知し、左反回神経周囲リンパ節郭清を安全に行う

    第20回EGI外科治療研究会  2021 

     More details

  • 腸内細菌が誘導する RNA 編集は炎症関連発癌における fieldcancerization を促進する

    第80回日本癌学会学術総会  2021 

     More details

  • 膵臓癌の代謝サブタイプが腫瘍融解アデノウイルスに対する感受性を運命づける

    第80回日本癌学会学術総会  2021 

     More details

  • p53 発現による線維性微小環境の再プログラム化は膵臓癌における腫瘍融解ウイルス療法の治療効果を増強する

    第80回日本癌学会学術総会  2021 

     More details

  • Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles

    第27回日本遺伝子細胞治療学会学術集会  2021 

     More details

  • p53-armed Telomerase-Specific Oncolytic Adenovirus Modulates Long-Lived Memory CD8 T Cells in Neoadjuvant Therapy for Pancreatic Cancer

    第27回日本遺伝子細胞治療学会学術集会  2021 

     More details

  • 先天性胆道拡張症術後の肝内結石症に対して肝門部胆管形成・切石・肝管空腸再吻合を施行した1例

    第44回日本膵・胆管合流異常研究会  2021 

     More details

  • 膵・胆管合流異常に対する術後中長期的な経過観察の検討

    第44回日本膵・胆管合流異常研究会  2021 

     More details

  • 多職種介入による胃切除術後のERASおサルコペニア予防

    PNMセミナー 2nd  2021 

     More details

  • 小児外科領域で用いられる漢方

    第24回Kampo Conference in 鹿田  2021 

     More details

  • 本邦初のロボット支援下肝胆膵外科手術におけるトレーニングプログラムの確立にむけて

    8th Surgical Education Summit  2021 

     More details

  • 腹腔鏡下幽門側胃切除における技術認定医取得は手術成績を改善する

    8th Surgical Education Summit  2021 

     More details

  • 特別講演

    痛みの評価を考えるWEBセミナー  2021 

     More details

  • 食道胃接合部癌に対する至適術式と集学的治療に関する後方視的解析

    第75回日本食道学会学術集会  2021 

     More details

  • p53-armed oncolytic adenovius reverses immunosuppressive tumor microenvironment in gemcitabine-resistant pancreatic cancer

    第27回日本遺伝子細胞治療学会学術集会  2021 

     More details

  • 食道切除における合理的な上縦隔郭清 da Vinci導入により見えてきた新たなアプローチ

    第75回日本食道学会学術集会  2021 

     More details

  • 80歳以上の高齢者食道癌症例に対する安全性と根治性を担保した外科治療戦略

    第75回日本食道学会学術集会  2021 

     More details

  • 当院で経験した食道異物の検討

    第75回日本食道学会学術集会  2021 

     More details

  • 食道癌術後再建胃管切除の諸問題と対策

    第75回日本食道学会学術集会  2021 

     More details

  • Laparoscopic Double-Flap (KAMIKAWA) Reconstruction after Proximal Gastrectomy

    5th LEAPS  2021 

     More details

  • 大腸癌肝転移における RNA 編集酵素 ADAR1 発現は肝転移切除後の残肝再発を予測するバイオマーカーになる

    第41回日本分子腫瘍マーカー研究会  2021 

     More details

  • 腫瘍融解アデノウイルスによる治療機序の次なる一手;細胞外小胞を介して全身免疫賦活と局所細胞毒性を誘発するウイルス療法

    第80回日本癌学会学術総会  2021 

     More details

  • テロメラーゼ特異的腫瘍融解アデノウイルス製剤の免疫賦活剤としての有用性と抗 PD-1 抗体との相乗効果

    第80回日本癌学会学術総会  2021 

     More details

  • 腫瘍溶解性ウイルスを介した p53 遺伝子治療は胃癌腹膜播種に対する抗腫瘍効果を増強する

    第80回日本癌学会学術総会  2021 

     More details

  • 高齢者食道裂孔ヘルニアの安全でQOL改善に貢献する至適な腹腔鏡下根治術

    第75回日本食道学会学術集会  2021 

     More details

  • 食道外科専門医育成に向けた当院の取り組み

    第75回日本食道学会学術集会  2021 

     More details

  • 多数の併存疾患によって周術期ハイリスクと診断された胸部食道癌に対して縦隔鏡下食道切除術を施行した1例

    第76回日本消化器外科学会総会  2021 

     More details

  • 術後アミノ酸輸液投与による胃切除後体重・筋肉量減少抑制効果

    第76回日本消化器外科学会総会  2021 

     More details

  • 肝癌肝移植の長期予後に向けて肝移植適応の選別と再発時治療

    第76回日本消化器外科学会総会  2021 

     More details

  • cT4食道癌に対する導入療法後手術症例の検討

    第76回日本消化器外科学会総会  2021 

     More details

  • 局所進行直腸癌における術前FOLFOXIRIおよびCAPOX+RT療法の治療成績

    第76回日本消化器外科学会総会  2021 

     More details

  • 横行結腸癌D3郭清範囲の明確化に発生由来の理解が,術式の定型化には大腸,胃,膵臓外科の融合が重要である

    第76回日本消化器外科学会総会  2021 

     More details

  • Colitis-associated neoplasiaに対する早期治療介入を目指した診療科横断的連携の重要性

    第76回日本消化器外科学会総会  2021 

     More details

  • 食道癌に対する腫瘍融解ウイルス併用放射線療法の臨床研究-高リスク症例の治療成績向上を目指して-

    第126回日本消化器内視鏡学会中国支部例会  2021 

     More details

  • 腫瘍の局在や特性に応じた胃粘膜下腫瘍に対する低侵襲治療

    第126回日本消化器内視鏡学会中国支部例会  2021 

     More details

  • 頭頸部癌集学的治療い対する胃瘻を有効に活用した栄養管理確立への道のり

    第36回日本臨床栄養代謝学会学術集会  2021 

     More details

  • Safe and retional approach by Robot-assisted thoracoscopic esophagectomy

    中国胸心血管外科临床杂志  2021 

     More details

  • 小児外科と漢方

    第47回小児医療センター 合同カンファレンス  2021 

     More details

  • 大腸癌転移に対する外科治療:治療予後向上に向けた臨床と研究の取り組み

    第30回日本がん転移学術集会・総会  2021 

     More details

  • 岡山大学における肝移植~小児肝移植と肝腎同時移植を中心に

    第28回瀬戸内肝胆膵治療懇話会  2021 

     More details

  • 肝胆膵外科を謳歌する:肝移植、進行・再発癌への挑戦

    第73回愛媛外科会総会 第7回日本臨床外科学会愛媛県支部例会  2021 

     More details

  • 胃領域での技術認定取得にむけての取り組み

    第96回中国四国外科学会総会  2021 

     More details

  • ロボット支援下膵切除術の安全な導入と術式の定型化

    第96回中国四国外科学会総会  2021 

     More details

  • 80 歳以上のハイリスク高齢者大腸癌患者の術後合併症軽減を目指した周術期管理チームの取り組み

    第96回中国四国外科学会総会  2021 

     More details

  • 超音波凝固切開装置の特性を熟知し、左反回神経周囲リンパ節郭清を安全に行う

    第96回中国四国外科学会総会  2021 

     More details

  • 食道癌周術期管理における多職種チーム医療介入の現況と展望

    第96回中国四国外科学会総会  2021 

     More details

  • 術前化学療法が奏功した食道神経内分泌癌の 1 例

    第96回中国四国外科学会総会  2021 

     More details

  • 食道異所性胃粘膜腺癌の一例

    第96回中国四国外科学会総会  2021 

     More details

  • 消化器がんに対するバイオセラピィの最前線

    第34回日本バイオセラピィ学会学術集会総会  2021 

     More details

  • 効率的で効果的なデジタルオペレコの描き方

    筑波大学消化器外科ユニオン事業「Friday Night Seminar」  2021 

     More details

  • 膵頭十二指腸切除術における周術期栄養療法のエビデンス

    第75回日本消化器外科学会  2020 

     More details

  • 直腸癌術前後の白血球数は予防的回腸人工肛門の閉塞やHigh output stoma発症を予測する指標となる

    第75回日本消化器外科学会  2020 

     More details

  • 周術期管理チーム介入後の高齢者大腸癌症例のアウトカムの検証~PERIO介入によりアウトカムは向上したか~

    第75回日本消化器外科学会  2020 

     More details

  • 局所進行食道癌に対するDCF-RT 後の食道切除術の有用性と安全性の検討

    第75回日本消化器外科学会  2020 

     More details

  • プレシジョンメディシン時代に備えた大腸癌リンパ節郭清範囲の統一化

    第75回日本消化器外科学会  2020 

     More details

  • OS延長を目指した局所進行直腸癌に対するoxaliplatinを用いた術前化学放射線療法の治療成績

    第75回日本消化器外科学会  2020 

     More details

  • Type3,4 食道裂孔ヘルニア症例に対するQOL 改善に着目した至適な手術適応

    第75回日本消化器外科学会  2020 

     More details

  • 腹臥位胸腔鏡下食道切除における微細解剖に基づいた上縦隔リンパ節郭清手技の定形化

    第75回日本消化器外科学会  2020 

     More details

  • 術前化学療法後に手術を行った食道胃接合部癌症例の検討

    第75回日本消化器外科学会  2020 

     More details

  • 切除可能膵癌における術後早期再発予測因子の解析 多施設共同後方視的研究

    第75回日本消化器外科学会  2020 

     More details

  • フェルカルボトランを用いた胃癌腹膜播種に対する磁気温熱療法

    第75回日本消化器外科学会  2020 

     More details

  • 食道がん症例におけるチームによる周術期管理の介入開始の至適時期の検討

    第75回日本消化器外科学会  2020 

     More details

  • 再手術症例から学ぶ形成外科的手技を用いた合併症回避のための術式の工夫

    第74回日本食道学会学術集会  2020 

     More details

  • 主題3「微小環境をターゲットにした癌治療」

    第42回日本癌局所療法研究会  2020 

     More details

  • 腹腔鏡下噴門測胃切除

    第92回日本胃癌学会総会  2020 

     More details

  • 高齢者胃癌の治療成績と栄養状態向上を目指した治療戦略

    第92回日本胃癌学会総会  2020 

     More details

  • Evolution of the double-flap reconstruction through understanding of the pros and cons

    第92回日本胃癌学会総会  2020 

     More details

  • Intraperitoneal virotherapy for disseminated gastric cancer targeting cancer cells and CAFs

    第92回日本胃癌学会総会  2020 

     More details

  • 術前SOX療法を施工した進行胃癌症例の治療成績

    第92回日本胃癌学会総会  2020 

     More details

  • 肝動脈浸潤を伴う局所進行切除不能膵頭部癌に対する膵頭十二指腸切除術~結腸動脈を用いた肝動脈再建の適応と手術手技~

    第120回日本外科学会学術集会  2020 

     More details

  • 解熱剤のアスピリン投与によるEMT 阻害作用を介した大腸がん腹膜播種の抑制効果

    第120回日本外科学会学術集会  2020 

     More details

  • 若手外科医が基礎研究を行う意義:理想的なAcademic Surgeon を目指して

    第120回日本外科学会学術集会  2020 

     More details

  • CAFs由来IL-6制御による腫瘍免疫の賦活化-Drug repositioningによる癌治療の可能性-

    第42回日本癌局所療法研究会  2020 

     More details

  • 癌細胞及び癌関連線維芽細胞を標的とした光免疫療法

    第42回日本癌局所療法研究会  2020 

     More details

  • 腹腔鏡下低位前方切除・側方郭清に必要な手技および解剖知識の習得

    岡山大学 臨床応用解剖実習セミナー  2020 

     More details

  • taTMEに必要な手技および解剖知識の習得

    岡山大学 臨床応用解剖実習セミナー  2020 

     More details

  • 腹腔鏡下食道切除に必要な手技・解剖知識の習得

    岡山大学 臨床応用解剖実習セミナー 第11回 食道手術臨床解剖実習  2020 

     More details

  • 肺癌と直腸癌の同時性重複癌にpembrolizumabが著効した1例

    第92回大腸癌研究会  2020 

     More details

  • 大腸癌治療の最前線

    第92回大腸癌研究会  2020 

     More details

  • 噴門部粘膜下腫瘍に対する細径鉗子を用いた腹腔鏡下胃局所切除術の工夫

    第22回Needlescopic Surgery Meeting  2020 

     More details

  • 腹壁膿瘍を伴うクローン病に対する細径鉗子使用の経験

    第22回Needlescopic Surgery Meeting  2020 

     More details

  • 岡山大学病院の消化器外科病棟の現状 地域連携病院の現状と課題 後方支援病院の現状と課題

    第1回 おかやま地域医療連携講演会  2020 

     More details

  • 新専門医制度の実際 新専門医制度における地域医療研修 新専門医制度の受け入れについて

    第1回 おかやま地域医療連携講演会  2020 

     More details

  • 新専門医制度の実際

    第1回 おかやま地域医療連携講演会  2020 

     More details

  • がん診療におけるKAMPO

    第1回 おかやま地域医療連携講演会  2020 

     More details

  • 次世代の消化管がん診療に向けた創薬研究・分子イメージング研究

    第16回日本消化管学会総会学術集会  2020 

     More details

  • 過度の空気嚥下によるイレウス症を繰り返す重症心身障がい児の1例

    第50回日本小児消化管機能研究会  2020 

     More details

  • 開腹手術の機械出しに必要な基本スキルと知識の習得

    岡山大学 臨床応用解剖実習セミナー  2020 

     More details

  • これからの膵癌外科治療~切除可能性分類の再考~

    Pancreatic Cancer Symposuim in Okayama  2020 

     More details

  • ロボット支援下食道癌手術の現況と展望

    第12回日本ロボット外科学会  2020 

     More details

  • Robotic total pancreatectomy:A new approach

    第12回日本ロボット外科学会  2020 

     More details

  • 超高齢者食道癌症例のサルコペニアと術後合併症の関連の検討

    第35回日本臨床栄養代謝学会学術集会  2020 

     More details

  • 食道手術に必要な縦隔解剖知識の習得 (基本手技からトラブルシューティングまで)

    岡山大学 臨床解剖実習セミナー 第12回 食道手術臨床解剖実習  2020 

     More details

  • すい臓癌の外科治療

    第19回 岡山医療フォーラム  2020 

     More details

  • 開腹胃切除術に必要な基本手技と解剖知識の習得

    岡山大学 臨床応用解剖実習セミナー  2020 

     More details

  • 標準的肝切除/膵切除から高難度手術まで-手術手技および解剖知識の習得-

    岡山大学 臨床応用解剖実習セミナー  2020 

     More details

  • 胃癌術後の深部静脈血栓症の予防と治療について

    消化器がんと血栓症を考える会  2020 

     More details

  • 肝膵癌に対するわれわれの取り組み

    消化器がんと血栓症を考える会  2020 

     More details

  • EMT-MET 可視化バイオセンサーを用いてhybridE/M 状態での化学療法抵抗性をリアルタイムイメージングにより解き明かす

    第79回日本癌学会学術総会  2020 

     More details

  • エクソソームを用いた革新的治療法;腫瘍融解アデノウイルス局所療法後に産生されるエクソソームはアブスコパル効果を起こす

    第79回日本癌学会学術総会  2020 

     More details

  • 大腸癌化学放射線療法で活性化されるRNA 編集によるネオアンチゲンの人工的生成

    第79回日本癌学会学術総会  2020 

     More details

  • 好中球と血小板の相互作用が胆管癌の悪性形質転換を促進する

    第79回日本癌学会学術総会  2020 

     More details

  • 腫瘍融解アデノウイルスで治療した腫瘍から得られる細胞外小胞は樹状細胞を活性化する能力を有する

    第79回日本癌学会学術総会  2020 

     More details

  • 癌関連線維芽細胞由来IL-6 制御による免疫応答の効率化-“Drug repositioning”による癌治療の可能性-

    第79回日本癌学会学術総会  2020 

     More details

  • テロメラーゼ特異的腫瘍融解アデノウイルス製剤の併用による抗PD-1 抗体治療効果の増強

    第79回日本癌学会学術総会  2020 

     More details

  • 癌関連線維芽細胞を標的とした光免疫療法の新たな開発

    第79回日本癌学会学術総会  2020 

     More details

  • 腫瘍溶解ウイルスを介したp53 遺伝子治療による腹腔内免疫環境改善を利用した胃癌腹膜播種治療

    第79回日本癌学会学術総会  2020 

     More details

  • 胃癌サブタイプと癌関連線維芽細胞の相互作用

    第79回日本癌学会学術総会  2020 

     More details

  • 腫瘍融解ウイルスによるp53 の発現増強は膵癌微小環境における腫瘍間質ネットワークを遮断する

    第79回日本癌学会学術総会  2020 

     More details

  • 大腸癌微小環境におけるRNA 編集の可能性と展望

    第79回日本癌学会学術総会  2020 

     More details

  • ゲムシタビン耐性膵癌細胞は免疫抑制性の微小環境を増強する

    第79回日本癌学会学術総会  2020 

     More details

  • Exploring the mechanism of cancer-associated fibroblasts induced immunosuppression via IL-6 in tumor microenvironment

    第24回日本がん免疫学会総会  2020 

     More details

  • 解剖学的奇形にを有する食道癌症例に対する縦隔鏡下食道切除術の経験

    第74回手術手技研究科  2020 

     More details

  • 発生学アプローチにより横行結腸癌のD3郭清範囲を統一化し、郭清手技を単純化し、手術方法を定型化する

    第74回手術手技研究科  2020 

     More details

  • 形成外科とのコラボレーションによる食道癌手術

    第74回手術手技研究科  2020 

     More details

  • 内視鏡外科技術認定取得報告

    第19回EGI外科治療研究会  2020 

     More details

  • JSES技術認定医取得報告(食道悪性)

    第19回EGI外科治療研究会  2020 

     More details

  • 会長企画シンポジウム9 免疫チェックポイント阻害薬、分子標的薬を用いた術前・術後治療

    第58回日本癌治療学会学術集会  2020 

     More details

  • Royal Marsden HospitalにおけるESMO JSCOフェローシッププログラム2019

    第58回日本癌治療学会学術集会  2020 

     More details

  • 食道癌術後肺転移によ外科的切除の意義

    第58回日本癌治療学会学術集会  2020 

     More details

  • 腹臥位胸腔鏡下食道癌手術における微細解剖に基づいた上縦隔リンパ節郭清定型化の工夫

    第120回日本外科学会学術集会  2020 

     More details

  • 大腸癌以外の肝転移の切除成績―切除適応を見極める―

    第120回日本外科学会学術集会  2020 

     More details

  • Risk factor for mediastinal lymph node metastasis of siewert type I and II esophagogastric junctiontumors

    第120回日本外科学会学術集会  2020 

     More details

  • 外科医として生きる(6):若手外科医の苦悩,渇望―今,何を解決すべきか―

    第120回日本外科学会学術集会  2020 

     More details

  • 先天性胆道拡張症術後長期成績からみた腹腔鏡下手術の妥当性について

    第120回日本外科学会学術集会  2020 

     More details

  • 進行横行結腸癌に対する複雑な幅広いD3 郭清手技を結腸の成り立ちから理解することにより単純化し定型手術として言語化する

    第120回日本外科学会学術集会  2020 

     More details

  • 外科の輝ける「未来」のために,我々が「今」できること

    第120回日本外科学会学術集会  2020 

     More details

  • 好中球細胞外トラップはHMGB1 を介して膵癌にEMT を誘導し,肝転移を助長する

    第120回日本外科学会学術集会  2020 

     More details

  • 食道癌術後の冠動脈破裂の1救命例

    第63回関西胸部外科学会学術集会  2020 

     More details

  • 術前術後の専門的嚥下評価を用いた食道癌術度肺炎減少を目指した多職種周術期管理

    第63回関西胸部外科学会学術集会  2020 

     More details

  • 食道癌に対する低侵襲手術の導入、現況、そして展望

    第63回関西胸部外科学会学術集会  2020 

     More details

  • 食道切除術における胸骨後経路胃管再建での合併症低減の工夫

    第63回関西胸部外科学会学術集会  2020 

     More details

  • 局所進行切除不能膵癌conversion surgeryにおける結腸動脈を用いた冠動脈再建

    第47回日本膵切研究会  2020 

     More details

  • 切除可能膵癌における術後早期再発予測因子の解析:多施設共同後方視的研究

    第47回日本膵切研究会  2020 

     More details

  • がん治療用ウイルス製剤「テロメライシン」の治験とがん微小環境研究

    第22回外科分子細胞治療研究会  2020 

     More details

  • リアルタイムイメージングによる予後不良間葉型大腸癌の治療抵抗性EMTマーカーの発言の時空間的意義

    第40回日本分子腫瘍マーカー研究会  2020 

     More details

  • がん関連線維芽細胞由来IL-6制御による免疫応答の効率化バイオメーカーとしてのIL-6の可能性

    第40回日本分子腫瘍マーカー研究会  2020 

     More details

  • 超ハイリスク食道癌症例に対する低侵襲治療としての縦隔鏡下食道切除術

    第95回中国四国外科学会総会  2020 

     More details

  • 臨床応用解剖実習による食道外科教育

    第95回中国四国外科学会総会  2020 

     More details

  • 高齢者大腸癌への周術期管理チーム介入により術後アウトカムは向上したか

    第95回中国四国外科学会総会  2020 

     More details

  • 皮膚筋炎と間質性肺炎を合併した胸部食道癌に対して手術加療を行い得た一例

    第95回中国四国外科学会総会  2020 

     More details

  • 術前術後の歯科専門的嚥下機能評価に基づく食道癌術後肺炎減少を目指した周術期管理

    第95回中国四国外科学会総会  2020 

     More details

  • 病的肥満症に対する腹腔鏡下スリーブ状胃切除術導入と初期10 例の治療成績

    第120回日本外科学会学術集会  2020 

     More details

  • 【食道残胃】噴門側胃切除術後標準再建法としての観音開き法再建の可能性

    第120回日本外科学会学術集会  2020 

     More details

  • 胃粘膜下腫瘍に対するClosed-LECS の成績と早期胃癌,十二指腸病変への応用

    第120回日本外科学会学術集会  2020 

     More details

  • 進化する外科マネージメントセンター~それぞれの夢を実現するためのキャリアパス支援システム~

    第120回日本外科学会学術集会  2020 

     More details

  • 脳死肝移植マージナルドナーの移植予後の解明と活用への提言

    第120回日本外科学会学術集会  2020 

     More details

  • 局所進行膵癌治療中のliquid biopsy によるKRAS遺伝子変異検出とCA19-9 値推移の意義に関する検討

    第120回日本外科学会学術集会  2020 

     More details

  • 【第2 部】未来を担う外科医からのメッセージ

    第120回日本外科学会学術集会  2020 

     More details

  • 解剖学的知識と内視鏡技術に卓越しなければtaTME の意義はない

    第120回日本外科学会学術集会  2020 

     More details

  • Cadaver surgical training が果たすべき役割と未来

    第120回日本外科学会学術集会  2020 

     More details

  • 一人前の肝胆膵外科医をめざして―中堅肝胆膵外科医からみる岡山大学育成システムの回顧と展望―

    第120回日本外科学会学術集会  2020 

     More details

  • Multidisciplinary immunotherapy with telomerase-specific oncolytic adenovirus and anti-PD-1 antibody

    第120回日本外科学会学術集会  2020 

     More details

  • 術前化学療法開始前から始めるチームによる食道がん周術期管理の有用性についての検討

    第120回日本外科学会学術集会  2020 

     More details

  • 地域枠医師に対する外科専門研修のあり方:充実した地域医療の実現を目指して

    第120回日本外科学会学術集会  2020 

     More details

  • 局所進行直腸癌に対する術前治療における放射線治療の意義~放射線療法を併用しない術前化学療法との治療成績の比較~

    第120回日本外科学会学術集会  2020 

     More details

  • 肝内胆管癌における免疫微小環境と治療予後の関連性

    第120回日本外科学会学術集会  2020 

     More details

  • Fibroblast activation protein-α(FAP)を標的とした癌関連線維芽細胞(CAFs)に対する光免疫療法~Sunrise of targeting tumor microenvironmenttherapy~

    第120回日本外科学会学術集会  2020 

     More details

  • 化学療法反応性の症例に対するR0 切除はstageIV 胃癌の予後を改善する

    第120回日本外科学会学術集会  2020 

     More details

  • 癌微小環境が引き起こす腫瘍免疫抑制の解明“Drug repositioning”による免疫応答賦活化の可能性

    第120回日本外科学会学術集会  2020 

     More details

  • 新世代の外科医の苦悩と挑戦

    第120回日本外科学会学術集会  2020 

     More details

  • 気管前リンパ節転移,心膜T4 症例に対する胸腔鏡下食道切除術

    第120回日本外科学会学術集会  2020 

     More details

  • 腹腔内アプローチ困難と予想される症例に対する,taTME の役割と安全性

    第120回日本外科学会学術集会  2020 

     More details

  • Promising surgical innovation and perioperative management in living donor liver transplantation.

    第120回日本外科学会学術集会  2020 

     More details

  • 食道癌手術におけるCadaver Surgical Trainingの現状と課題

    第74回日本食道学会学術集会  2020 

     More details

  • 有茎広背筋弁移植による胸部食道癌術後気管瘻の予防

    第74回日本食道学会学術集会  2020 

     More details

  • 食道癌に対する低侵襲手術の現況と展望

    第74回日本食道学会学術集会  2020 

     More details

  • 食道癌周術期チーム医療の現況と将来展望

    第74回日本食道学会学術集会  2020 

     More details

  • より安全で生理的な経路を追求した有茎空腸を用いた食道再建術における工夫

    第74回日本食道学会学術集会  2020 

     More details

  • 重度呼吸機能障害のある食道がん患者の意思決定支援を振りかえる

    第74回日本食道学会学術集会  2020 

     More details

  • 観音開き法(上川法)再建における胃食道逆流予防と吻合部狭窄予防に重要な手技上のポイント

    第75回日本消化器外科学会  2020 

     More details

  • 局所進行切除不能膵癌における予後規定因子の検討 ~非切除例を含めたall cohort解析~

    第75回日本消化器外科学会  2020 

     More details

  • 胃癌周術期の継続的な栄養指導が術後体重や栄養指標に与える影響

    第75回日本消化器外科学会  2020 

     More details

  • 切除可能切除可能境界膵癌における術前後血中KRAS遺伝子変異検出とその意義に関する検討

    第75回日本消化器外科学会  2020 

     More details

  • 食道ESD後追加手術例と再発後手術例から考える食道ESD後の適切な追加治療

    第74回日本食道学会学術集会  2020 

     More details

  • ERASプロトコールにおける腹腔鏡下胃切除術後の最適な鎮痛法

    第75回日本消化器外科学会  2020 

     More details

  • 食道胃接合部癌に対する術前化学療法治療効果予測因子の解析

    第58回日本癌治療学会学術集会  2020 

     More details

  • CDDP+VP-16療法を根治術後に施行し長期無再発生存している十二指腸乳頭部MANECの1例

    第58回日本癌治療学会学術集会  2020 

     More details

  • シンポジウム13

    第82回日本臨床外科学会総会  2020 

     More details

  • 胃管作成不能例に対する有茎空腸を用いた食道再建術の工夫と成績

    第82回日本臨床外科学会総会  2020 

     More details

  • 肝癌肝移植の長期予後に向けて:肝移植適応の選別と再発時治療

    第82回日本臨床外科学会総会  2020 

     More details

  • 食道癌術後肺転移再発に対する外科的切除の役割

    第82回日本臨床外科学会総会  2020 

     More details

  • 大腸癌肝/肺転移に対する治療戦略

    第82回日本臨床外科学会総会  2020 

     More details

  • 保存的に治癒し得た食道癌胸骨後経路再建術後に発症した胃管気管癭の一例

    第82回日本臨床外科学会総会  2020 

     More details

  • 食道癌手術における臨床応用解剖実習の現状と展望

    第73回日本胸部外科学会定期学術集会  2020 

     More details

  • 腹腔鏡下食道切除に対する合併症ゼロへの挑戦-鏡視下からロボット支援手術導入-

    第73回日本胸部外科学会定期学術集会  2020 

     More details

  • 食道癌根治手術10年後に発症した肝転移を伴うStageIV胃管癌例

    第73回日本胸部外科学会定期学術集会  2020 

     More details

  • 生体肝移植後に発症した食道癌の一治療例

    第73回日本胸部外科学会定期学術集会  2020 

     More details

  • 超高齢者食道癌症例のサルコペニアと術後合併症の関連の検討

    第73回日本胸部外科学会定期学術集会  2020 

     More details

  • アルコール性肝障害(ALD alcogolic liver disease)により生体肝移植を受けた患者が断酒を継続するプロセス

    第56回日本移植学会総会  2020 

     More details

  • 食道胃接合部癌における縦隔リンパ節転移の危険因子 経胸部操作が必要な症例は?

    第28回日本消化器関連学会週間  2020 

     More details

  • 癌細胞及び癌関連線維芽細胞(CAFs)を標的とした光免疫療法

    第31回日本消化器癌発生学会総会  2020 

     More details

  • がん関連線維芽細胞由来IL-6制御による免疫応答の効率化 “Drug repositioning”によるがん治療の可能性

    第31回日本消化器癌発生学会総会  2020 

     More details

  • 栄養投与経路の選択と投与の実際

    第176回岡山大学病院 栄養サポートチーム(NST)勉強会  2020 

     More details

  • 消化器疾患診療:内科と外科治療のクロスオーバー

    第114回日本消化器病学会中国支部例会 第125回日本消化器内視鏡学会中国支部例会  2020 

     More details

  • 岡山大学における肝移植 肝移植25年の知見集積と今日のnew normal

    第114回日本消化器病学会中国支部例会 第125回日本消化器内視鏡学会中国支部例会  2020 

     More details

  • T4bに対する導入DCF-RT療法~高い局所制御率とその課題~

    第74回日本食道学会学術集会  2020 

     More details

  • テロメラーゼ依存性腫瘍融解ウィルスは化学療法抵抗性の膵臓がん細胞を破壊する

    第78回日本癌学会学術総会  2019 

     More details

  • 胃癌手術患者における術前・術後サルコペニアの予後に与える影響

    第91回日本胃癌学会総会  2019 

     More details

  • 切除不能大腸癌肝転移に対するConversion therapy

    岡山大腸がん肝転移治療研究会(岡山)  2019 

     More details

  • Early safety from an open label Phase I study to evaluate the safety and efficacy of a telomerase-specific oncolytic adenovirus (OBP-301) with pembrolizumab in patients with advanced solid tumors

    AACR Annual Meeting 2019  2019 

     More details

  • Stemness control by iron chelator is a novel therapeutic strategy for esophageal cancer

    AACR Annual Meeting 2019  2019 

     More details

  • Activation of AZIN1 RNA editing facilitates and promotes invasive potential of cancer associated fibroblasts in colorectal cancer

    AACR Annual Meeting 2019  2019 

     More details

  • Oncolytic immunotherapy with PD-1 blockade and telomerase-specific oncolytic adenovirus in osteosarcoma

    AACR Annual Meeting 2019  2019 

     More details

  • Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (telomelysin) with radiotherapy in esophageal cancer patients unfit for standard treatments

    AACR Annual Meeting 2019  2019 

     More details

  • Trastuzumab-conjugated gold nanoparticles as novel HER2-targeted therapeutics against trastuzumab-resistant gastric cancer

    AACR Annual Meeting 2019  2019 

     More details

  • The reciprocal interaction between neutrophil extracellular traps and cancer cells impacts on their malignant potentials

    AACR Annual Meeting 2019  2019 

     More details

  • Elimination of MYCN-amplified neuroblastoma cells by telomerase-targeted oncolytic virotherapy as novel precision medicine

    AACR Annual Meeting 2019  2019 

     More details

  • 慢性肝疾患のトータルマネージメント

    第13回岡山地域連携肝疾患カンファレンス  2019 

     More details

  • 癌ゲノム医療時代の臨床医の在り方を問う

    第18回OKAYAMA CANCER FORUM  2019 

     More details

  • Endoscopic intratumoral injection of OBP-301 (telomelysin) with radiotherapy in esophageal cancer patients unfit for standard treatments

    2019 Gastrointestinal Cancers Symposium  2019 

     More details

  • 局所進行下部直腸癌に対する術前化学療法の治療成績

    第90回大腸癌研究会  2019 

     More details

  • 将来へ向けての食道癌治療

    第7回岡山大学消化器外科フォーラム  2019 

     More details

  • 噴門部胃癌に対する観音開き再建法

    第7回岡山大学消化器外科フォーラム  2019 

     More details

  • 食道癌に対するウイルス療法

    第7回岡山大学消化器外科フォーラム  2019 

     More details

  • 「外科医があまり知らない胃癌手術後のビタミン変動について」と「上川法でない噴門側胃切除の再建について」

    消化器がんと血栓を考える会  2019 

     More details

  • エクソソーム創薬の最前線

    第18回OKAYAMA CANCER FORUM  2019 

     More details

  • 腹腔鏡下観音開き法再建 ~手技の変遷~

    第9回岡山手術手技ビデオフォーラム  2019 

     More details

  • 直腸癌とCRM

    第9回岡山手術手技ビデオフォーラム  2019 

     More details

  • How to tackle scattered colorectal liver metastasis:One-stage removal by parenchymal sparing & skeletonized hepatectomy

    第31回日本肝胆膵外科学会  2019 

     More details

  • Pancreaticoduodenectomy with systematic mesopancreas excision by an infra-colic left lateral approach

    第31回日本肝胆膵外科学会  2019 

     More details

  • Postoperative surveillance for IPMN focusing on cumulative risk of remnant pancreatic recurrence

    第31回日本肝胆膵外科学会  2019 

     More details

  • Utility of KRAS mutation in cell-free DNA for appropriate indication of pancreatectomy from patients with advanced pancreatic cancer receiving systemic chemotherapy

    第31回日本肝胆膵外科学会  2019 

     More details

  • Training for board-certified expert surgeon incorporated with LAP- HBP surgery

    第31回日本肝胆膵外科学会  2019 

     More details

  • Two resected cases of giant hepatocellular carcinoma with tumor thrombus extending through inferior vena cava into the right atrium

    第31回日本肝胆膵外科学会  2019 

     More details

  • A case of intraluminal papillary neoplasm of the biliary duct (IPNB) difficult to differentiate from intraductal growth (IG) type of intrahepatic cholangiocarcinoma (ICC)

    第31回日本肝胆膵外科学会  2019 

     More details

  • Prognostic impact of RAS/RAF status in colorectal liver metastasis: potential of extra-hepatic spreading and variable implication according to sidedness

    第31回日本肝胆膵外科学会  2019 

     More details

  • Prognostic Impact of lymph node dissection in intrahepatic cholangiocarcinoma: A multicenter analysis and the inverse probability of treatment weighting (IPTW) approach

    第31回日本肝胆膵外科学会  2019 

     More details

  • Sustained Elevation of CA19-9 after Resection is a Strong Prognostic Factor for Resectable Pancreatic Cancer

    第31回日本肝胆膵外科学会  2019 

     More details

  • Surgical strategy for pNET: boundary line for minimal invasive resection and lymphadenectomy

    第31回日本肝胆膵外科学会  2019 

     More details

  • 各種ガイドラインから読み解く大腸癌治療の展望

    第7回岡山大腸腫瘍研究会  2019 

     More details

  • 腹腔鏡下胃瘻再造設術における既存胃瘻切除法の工夫

    第33回日本小児ストーマ・排泄・創傷・管理研究会  2019 

     More details

  • 創傷治療における陰圧閉鎖療法の勧め -最大の効果を発揮するタイミングとは-

    第33回日本小児ストーマ・排泄・創傷・管理研究会  2019 

     More details

  • 小児慢性便秘症の治療戦略 ~パラダイムシフトはあるのか~

    第33回日本小児ストーマ・排泄・創傷・管理研究会  2019 

     More details

  • Postoperative surveillance for IPMN focusing on cumulative risk of remnant pancreatic recurrence

    第31回日本肝胆膵外科学会学術集会  2019 

     More details

  • 胸腔鏡下食道切除における安全な郭清手技反回神経麻痺ゼロを目指すserendipity

    第62回関西西胸部外科学会学術集会  2019 

     More details

  • 局所進行食道癌に対するDCFを用いた化学放射線治療法による集学的治療と最適な救済手術のあり方の検討

    第62回関西西胸部外科学会学術集会  2019 

     More details

  • 胸腔鏡下食道切除の定型化と段階的若手育成

    第62回関西西胸部外科学会学術集会  2019 

     More details

  • 当院食道外科におけるCadaver Surgical Trainingの現状と展望 -臨床解剖の教育と安全な医療技術の習得を目指して-

    第62回関西西胸部外科学会学術集会  2019 

     More details

  • 大腸癌治療におけるtripletの検討

    第7回岡山大腸腫瘍研究会  2019 

     More details

  • トラスツズマブ耐性胃癌に対するHER2標的金ナノ粒子製剤の開発

    第35回日本DDS学会学術集会  2019 

     More details

  • 同時性肝転移を有する大腸癌症例における原発巣切除の意義

    第91回大腸癌研究会  2019 

     More details

  • 世代別対抗戦・肝胆膵外科修練の現状

    OKAYAMA HBP Surge,2019  2019 

     More details

  • 腹壁導尿路からの自己導尿自立まで膀胱瘻に胃瘻ボタンを使用した一例

    第33回日本小児ストーマ・排泄・創傷・管理研究会  2019 

     More details

  • ジェムシタビン抵抗性膵癌に対する薬剤感受性改善の試み

    第28回日本癌病態治療研究会  2019 

     More details

  • 長期経過から見た大腸癌卵巣転移に対する化学療法後手術と遺伝子変異プロファイル

    第28回日本癌病態治療研究会  2019 

     More details

  • 敗血症病態における宿主応答の正体に迫る

    第10回岡山敗血症治療学術講演会  2019 

     More details

  • アスピリンの予防投与によるEMT阻害作用を介した大腸がん腹膜播種の抑制効果

    第26回日本がん予防学会学術大会  2019 

     More details

  • 小児の希少固形腫瘍

    2019年度日本小児血液・がん学会社員総会教育セミナー  2019 

     More details

  • 腫瘍融解ウイルス療法によるエクソソームを介したアブスコパル効果の可能性

    第35回日本DDS学会学術集会  2019 

     More details

  • PREOPERATIVE PROXIMAL SPLENIC ARTERY EMBOLIZATION:ALTERNATIVE PRTAL MODULATION FOR PROPHYLAXIS OF SMALL-FOR-SIZE SYNDROME

    ESOT CONGRESS2019  2019 

     More details

  • A RESCUE RECONSTRUCTION TECHNIQUE OF DISSECTIN HEPATIC ARTERY THROMBOSIS USING MIDDLE COLIO ARTERY AFTER LIVING DONOR LIVER TRASPLANTATION:REPORT OF TWO CASES

    ESOT CONGRESS2019  2019 

     More details

  • Management of HCC-recurrence after liver transplantation: Lessons from aggressive and tenacious surgical approach

    ESOT CONGRESS2019  2019 

     More details

  • 日就月将なる外科デバイスの現在 -そして未来へ-

    第19回岡山大学外科MCセミナー  2019 

     More details

  • 小児先進医療チーム NO limits to what we can do!

    岡山大学病院小児医療センター 第5回市民公開講座  2019 

     More details

  • 小児の内視鏡下手術

    岡山大学病院小児医療センター 第5回市民公開講座  2019 

     More details

  • 戸谷V型先天性胆道拡張症の2例

    第42回日本膵・胆管合流異常研究会  2019 

     More details

  • 除鉄による幹細胞性制御による新規食道癌治療法の開発

    第43回日本鉄バイオサイエンス学会学術集会  2019 

     More details

  • Stemness control by iron chelator is a novel therapeutic strategy for esophageal cancer treatment

    第78回日本癌学会学術総会  2019 

     More details

  • 消化器外科領域に応用可能な分子レベルの技術開発/Molecular Technology Development for Gastroenterological Diseases」

    第78回日本癌学会学術総会  2019 

     More details

  • 標準治療が困難な食道がん患者に対する低侵襲なテロメラーゼ標的型分子治療法の開発.

    第78回日本癌学会学術総会  2019 

     More details

  • 解熱剤のアスピリンはEMT阻害作用を介して大腸がんの腹膜播種を抑制する

    第78回日本癌学会学術総会  2019 

     More details

  • 化学放射線療法は線維芽細胞の活性化を介して癌細胞の悪性度を向上させる

    第78回日本癌学会学術総会  2019 

     More details

  • 腫瘍融解ウイルス療法にて認められるアブスコパル効果と細胞外小胞の関連性についてリバーストランスレーショナルリサーチ

    第78回日本癌学会学術総会  2019 

     More details

  • 胃癌術後補助化学療法について

    岡山がん集学的治療カンファレンス2019  2019 

     More details

  • 消化器癌における移植・再生医療の新展開

    岡山がん集学的治療カンファレンス2019  2019 

     More details

  • がんウィルス療法の実用化に向けて

    中外製薬株式会社 社内研修会  2019 

     More details

  • 乳児期発症の鼠径ヘルニアの問題点

    第49回九州洙鬼外科研究会  2019 

     More details

  • 岡山大学広域外科専門研修プログラムの現状と今後の展望

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 地域がん診療の問題と対策

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 岡山県における地域がん診療の現状と対策

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 切除不能T4食道癌に対するDCFを用いた化学放射線治療による集学的治療の検討

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • OS延長およびRO切除を目指した局所進行直腸癌に対する当科の取り組みと治療成績

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 局所進行切除不能膵頭部癌に対する肝動脈・門脈合切を伴う膵頭十二指腸切除 ~結腸動脈を用いた肝動脈再建の適応と手術手技~

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • Push the limits.大腸癌高度肝転移への挑戦:化学療法による適応拡大と肝切除の工夫

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 肝胆膵外科高度技術専門医所得への道 ~安全で確実な手術手技の習得にむけて~

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 胃癌手術後に生じた難治性リンパ漏の治療経験

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 術後早期回復をめざした腹腔鏡下胃切除術後の最適な鎮痛法

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 安全かつ根治性を確保するための再肝切除術の工夫

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 肝胆管合流異常症に対する術後中長期的な経過観察の検討

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 切除可能膵癌における術前後CA19-9値の変化とその意義

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 胸腔鏡下食道切除に対するロボット支援手術の導入

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 食道癌手術におけるCadaver Surgical Trainingの経験

    第94回中国四国外科学会総会 第24回中国四国内視鏡外科研修会  2019 

     More details

  • 食道癌診療ガイドライン

    第27回日本外科学会生涯教育セミナー  2019 

     More details

  • 臨床医から見たザバクサの特徴と期待される役割 ~外科・救急・集中治療域における新しいグラム陰性菌感染症治療薬~

    腹腔内感染症学術講演会  2019 

     More details

  • Efficacy of Self-Expandable metallic stent for Hepatic Vein Stenosis after living donor liver transplantation.

    ESOT CONGRESS2019  2019 

     More details

  • 非大腸癌・非内分泌腫瘍由来肝転移の切除成績 - 切除適応となる癌腫を見極める -

    第74回日本消化器外科学会総会  2019 

     More details

  • 消化器がんに対するテロメラーゼ特異的集学的ウイルス療法"Multidisciplinary telomerase-specific oncolytic virotherapy for gastrointestinal cancer"

    第25回日本遺伝子細胞治療学会学術集会  2019 

     More details

  • 消化器がんの分子病態に基づいた診断・治療法の開発研究“Development of diagnosis and treatment based on molecular pathogenesis of gastrointestinal cancer”

    第25回日本遺伝子細胞治療学会学術集会  2019 

     More details

  • Elimination of chemoresistant pancreatic ductal adenocarcinoma cells by telomerase-specific oncolytic virotherapy

    第25回日本遺伝子細胞治療学会学術集会  2019 

     More details

  • Tumor suppressor p53-armed oncolytic adenovirus induces profound immunogenic cell death in neuroblastoma cells

    第25回日本遺伝子細胞治療学会学術集会  2019 

     More details

  • A novel intraperitoneal theranostic virotherapy with paclitaxel for peritoneal metastasis of gastric cancer

    第25回日本遺伝子細胞治療学会学術集会  2019 

     More details

  • Extracellular vesicles involve in the abscopal effect induced by telomerase-specific oncolytic

    第25回日本遺伝子細胞治療学会学術集会  2019 

     More details

  • 肝移植を見据えた急性肝不全の内科的治療

    第37回日本肝移植学会  2019 

     More details

  • 肝移植における真菌感染 -周術期リスク因子を踏まえた侵襲性真菌症の予防と治療-

    第37回日本肝移植学会  2019 

     More details

  • 当院における脳死肝移植マージナルドナーの移植予後

    第37回日本肝移植学会  2019 

     More details

  • 肝移植外科医の育成にむけて ー岡山大学の取り組みを修練医の立場から考えるー

    第37回日本肝移植学会  2019 

     More details

  • 生体肝移植後2年半で発症した敗血症性ショックを契機に、1年間高ビリルビン血症が遷延した症例

    第37回日本肝移植学会  2019 

     More details

  • 脳死肝移植における働き方改革

    第37回日本肝移植学会  2019 

     More details

  • 肝移植における移植後二次発癌とがん検診プロトコルに向けた提言

    第37回日本肝移植学会  2019 

     More details

  • 生体肝移植後の中結腸動脈を用いた解離性肝動脈血栓症の再建術:2症例の報告

    第37回日本肝移植学会  2019 

     More details

  • AIは専門医の思考を学べるか? ~AIを用いた透析時の貧血管理システムの開発~

    第79回メディカルテクノおかやま・サロン  2019 

     More details

  • 胆道悪性腫瘍治療:新たな知見と治療戦略 ~内科、外科、放射線科から~

    第27回瀬戸内肝胆膵治療懇話会  2019 

     More details

  • 小児生体肝移植の手術成績

    第27回瀬戸内肝胆膵治療懇話会  2019 

     More details

  • RP-Closed LECSの開発と成績

    8th Reduced Port Surgery Forum  2019 

     More details

  • 「周術期チーム医療の現況と展望-岡山大学病院での食道癌外科診療における周術期管理センター(PERiO)の役割-」

    第12回日本静脈経腸栄養学会 中国支部学術集会  2019 

     More details

  • IPMN術後残膵再発に対する残膵全摘の対応と意義

    第46回日本膵切研究会  2019 

     More details

  • BR/UR膵癌における術前ctDNA内KRAS遺伝子変異検出の意義

    第46回日本膵切研究会  2019 

     More details

  • 生体肝移植におけるハイリスク症例 - MELDは移植予後を反映するか -

    第74回日本消化器外科学会総会  2019 

     More details

  • 膵IPMN術後残膵再発累積リスクに着目した術後至適surveillance法の検討

    第74回日本消化器外科学会総会  2019 

     More details

  • 膵臓がんに対する腹腔鏡下手術

    OKAYAMA HBP Surge,2019  2019 

     More details

  • 先達に学ぶ肝胆膵外科手術

    OKAYAMA HBP Surge,2019  2019 

     More details

  • The surgical strategy for wider D3 area due to skew and distortion of a base of transvers mesocolon.

    第74回日本消化器外科学会総会  2019 

     More details

  • 上腹部開腹歴を有する胃癌症例への腹腔鏡手術:ポート挿入までの定型化と短期治療成績

    第74回日本消化器外科学会総会  2019 

     More details

  • 術前化学療法を行った頸胸境界部食道癌の治療成績

    第74回日本消化器外科学会総会  2019 

     More details

  • BR/UR膵癌における末梢血中KRAS遺伝子変異の新規バイオマーカーとしての有用性に関する検討

    第74回日本消化器外科学会総会  2019 

     More details

  • 切除可能膵頭部癌における早期再発予測因子と転移形式の解析

    第74回日本消化器外科学会総会  2019 

     More details

  • Frailな大腸癌患者の術後早期回復を目指した周術期管理チームの取り組みとアウトカム

    第74回日本消化器外科学会総会  2019 

     More details

  • 生体肝移植後における脾動脈盗血症候群に対する治療介入の意義

    第74回日本消化器外科学会総会  2019 

     More details

  • クローン病に対する手術介入の至適時期と術後QOLの検討

    第74回日本消化器外科学会総会  2019 

     More details

  • 有茎空腸を用いた食道再建術

    第74回日本消化器外科学会総会  2019 

     More details

  • 心負荷軽減の観点からみた混合型食道裂孔ヘルニア手術の新たな手術適応と手術手技の工夫

    第74回日本消化器外科学会総会  2019 

     More details

  • Standardization of upper mediastinal lymph node resection in thoracoscopic esophagectomy

    第74回日本消化器外科学会総会  2019 

     More details

  • 神経解剖・層構造より解き明かす腹腔鏡下胃癌リンパ節郭清のポイント

    第74回日本消化器外科学会総会  2019 

     More details

  • 回腸双孔式人工肛門の2大合併症である閉塞とhigh output stomaのリスク因子同定と回避のための工夫

    第74回日本消化器外科学会総会  2019 

     More details

  • 医原性胆道損傷に対する修復術 -Immediate repairと手技の要点-

    第74回日本消化器外科学会総会  2019 

     More details

  • 再肝切除における根治性確保と合併症軽減に向けた工夫

    第74回日本消化器外科学会総会  2019 

     More details

  • ERASにおける腹腔鏡下胃切除術後の最適な鎮痛法

    第74回日本消化器外科学会総会  2019 

     More details

  • “伝わる” 肝胆膵外科手術記録―iPad を用いた効率的で効果的なイラスト作成法―

    第74回日本消化器外科学会総会  2019 

     More details

  • 切除不能食道癌に対し化学放射線療法(CRT)を行いConversion Surgeryを行った11例の検討

    第74回日本消化器外科学会総会  2019 

     More details

  • 岡山大学での肝移植免疫抑制プロトコールと周術期の拒絶および感染症

    第55回日本移植学会総会  2019 

     More details

  • 岡山大学病院における膵癌周術期チーム医療の現状と工夫 ~術前治療開始時から始まる組織横断的多職種チーム介入

    第14回膵癌術前治療研究会  2019 

     More details

  • 切除不能膵癌に対するCONVERSION SURGERY 施行症例の治療成績 ~ITT解析の立場から~

    第14回膵癌術前治療研究会  2019 

     More details

  • Simultaneous liver and kidney transplantation in Japan

    CAST2019  2019 

     More details

  • PREOPERATIVE PROXIMAL SPLENIC ARTERY EMBOLIZATION:ALTERNATIVE PRTAL MODULATION FOR PROPHYLAXIS OF SMALL-FOR-SIZE SYNDROME

    CAST2019  2019 

     More details

  • 胃癌治療の新展開 -根治と予後の改善を目指して-

    Gastric Cancer Forum in Okayama  2019 

     More details

  • 解剖学的特徴から進行横行結腸癌の幅広いリンパ節郭清の定型化

    第18回EGI外科治療研究会プログラム  2019 

     More details

  • 右側大動脈弓を伴う胸部食道癌症例に対する縦隔鏡下食道亜全摘術の経験

    第18回EGI外科治療研究会プログラム  2019 

     More details

  • ロボット支援下噴門側胃切除術+観音開き法再建:腹腔鏡下手術との比較

    第18回EGI外科治療研究会プログラム  2019 

     More details

  • 肝移植におけるエベロリムスへの期待 ~新規移植例への導入と慢性期導入~

    第55回日本移植学会総会  2019 

     More details

  • 食道癌の周術期管理におけるチーム医療の進歩

    第72回日本胸部外科学会定期学術集会  2019 

     More details

  • 食道癌周術期管理におけるPERiOの現況とエビデンス創出に向けた課題

    第72回日本胸部外科学会定期学術集会  2019 

     More details

  • 術前化学療法(GS療法)により病理組織学的完全奏効が得られた切除可能膵頭部癌の1例

    第14回膵癌術前治療研究会  2019 

     More details

  • 当院における腹腔鏡下噴門形成の再手術における工夫

    PS-PIC2019 OSAKA  2019 

     More details

  • 進行・再発胃癌に対するNivolumab投与例の検討

    第57回日本癌治療学会学術集会  2019 

     More details

  • がんペプチドワクチン作用機序解明を目的とした探索的臨床試験

    第57回日本癌治療学会学術集会  2019 

     More details

  • 胃癌術後患者の栄養指標・体組成の評価と術後サルコペニア防止の試み

    第49回胃外科・術後障害研究会  2019 

     More details

  • 匠の思考をAIは学べるか ~AI投薬管理システムの開発経験から~

    高砂熱学工業講演会  2019 

     More details

  • 食道癌の周術期管理におけるチーム医療の進歩

    第72回日本胸部外科学会定期学術集会  2019 

     More details

  • 食道癌周術期管理におけるPERiOの現況とエビデンス創出に向けた課題

    第72回日本胸部外科学会定期学術集会  2019 

     More details

  • 食道癌周術期におけるチーム医療の実際

    第72回日本胸部外科学会定期学術集会  2019 

     More details

  • がん関連線維芽細胞(CAFs)による腫瘍免疫抑制のメカニズムについて

    第78回日本癌学会学術総会  2019 

     More details

  • 神経芽腫に対するp53発現性腫瘍融解アデノウィルスによる免疫原性細胞死の誘導効果

    第78回日本癌学会学術総会  2019 

     More details

  • 消化器外科領域に応用可能な分子レベルの技術開発

    第78回日本癌学会学術総会  2019 

     More details

  • 胸腔鏡下食道切除に対する合併症ゼロへの挑戦 胸腔鏡下食道切除に対する合併症ゼロへの挑戦 鏡視下からロボット支援手術導入.

    第81回日本臨床外科学会総会  2019 

     More details

  • 有茎空腸を用いた食道再建術における工夫

    第81回日本臨床外科学会総会  2019 

     More details

  • 好中球細胞外トラップによるEMTを介した消化器癌肝転移促進メカニズムの解明

    第78回日本癌学会学術総会  2019 

     More details

  • ヒト悪性腫瘍に対する集学的腫瘍融解ウィルス療法:現状と次世代の展望

    第78回日本癌学会学術総会  2019 

     More details

  • 膵癌に対する免疫チェックポイント阻害剤を併用したテロメラーゼ特異的腫瘍融解免疫療法

    第78回日本癌学会学術総会  2019 

     More details

  • 食道がん治療と腫瘍関連マクロファージ

    第78回日本癌学会学術総会  2019 

     More details

  • 癌微小環境での胃癌に対するp53武装化腫瘍溶解アデノウィルスの影響

    第78回日本癌学会学術総会  2019 

     More details

  • 鉄キレート材による幹細胞性制御による新規食道癌治療法

    第78回日本癌学会学術総会  2019 

     More details

  • 食道がん微小環境と新たな治療

    第78回日本癌学会学術総会  2019 

     More details

  • 細胞周期の可視化から見えてきた難治性がん細胞の存在と新規治療戦略

    第78回日本癌学会学術総会  2019 

     More details

  • De novo Maligmamcy after Liver Transplantation

    CAST2019  2019 

     More details

  • 標準治療が困難な食道がん患者に対する低侵襲なテロメラーゼ標的型分子治療法の開発

    第78回日本癌学会学術総会  2019 

     More details

  • 消化器外科領域に応用可能な分子レベルの技術開発

    第78回日本癌学会学術総会  2019 

     More details

  • 好中球細胞外トラップによるEMTを介した消化器癌肝転移促進メカニズムの解明

    第78回日本癌学会学術総会  2019 

     More details

  • ヒト悪性腫瘍に対する集学的腫瘍融解ウィルス療法:現状と次世代の展望

    第78回日本癌学会学術総会  2019 

     More details

  • AZIN1RNA編集は大腸癌微小環境の再構成を促進し癌の進展に寄与する新たなメカニズムである

    第78回日本癌学会学術総会  2019 

     More details

  • 胃癌腹膜播種に対する腹腔内ウイルス療法

    第91回日本胃癌学会総会  2019 

     More details

  • IBDセンターにおける外科感染症対策10年の推移,感染率低下のbreakthrough

    第119回日本外科学会定期学術集会  2019 

     More details

  • 肥満症に対する腹腔鏡下スリーブ状胃切除術の導入とその効果

    第119回日本外科学会定期学術集会  2019 

     More details

  • 切除率向上を目指した転移再発大腸癌に対するFOLFOXIRI療法の治療成績

    第119回日本外科学会定期学術集会  2019 

     More details

  • 80歳以上の超高齢者食道癌に対する包括的治療戦略

    第119回日本外科学会定期学術集会  2019 

     More details

  • 臨床研究の基礎講座

    第22回臨床研究セミナー  2019 

     More details

  • 外科領域のカダバートレーニングの取り組みについて

    第30回日本医学会総会2019中部  2019 

     More details

  • 切除不能大腸がん肝転移への挑戦:分子標的薬によるConversionとPush the Limits

    姫路大腸癌エキスパートセミナー  2019 

     More details

  • 癌関連線維芽細胞が引き起こす腫瘍免疫抑制とその制御

    第40回癌免疫外科研究会  2019 

     More details

  • 化学放射線療法は線維芽細胞の活性化を介して癌細胞の悪性度を向上させる

    第40回癌免疫外科研究会  2019 

     More details

  • ロボット支援食道癌手術導入のおけるわれわれの工夫

    第73回手術手技研究会  2019 

     More details

  • 胸腔鏡下食道癌手術における上縦隔リンパ節郭清でのわれわれのコンセプトと工夫

    第73回手術手技研究会  2019 

     More details

  • 基礎疾患を有する小児の胆嚢結石賞20例の検討

    第56回日本小児外科学会学術集会  2019 

     More details

  • 腹腔鏡下胃瘻再造設術における既存胃瘻切除法の工夫

    第56回日本小児外科学会学術集会  2019 

     More details

  • 高度食道裂孔ヘルニア手術における心負荷に着目した新たな手術適応と手術手技の工夫

    第17回日本ヘルニア学会学術集会  2019 

     More details

  • 超高齢者食道癌症例のサルコペニアの有無は術後合併症の予測因子となり得るか?

    第73回日本食道学会学術集会  2019 

     More details

  • 食道癌周術期管理におけるエビデンス創出に向けたPERiOの現況と課題

    第73回日本食道学会学術集会  2019 

     More details

  • 食道癌術後再発例の治療成績 ~治癒を目指した治療は可能か~

    第73回日本食道学会学術集会  2019 

     More details

  • 食道切除における血流評価を元に行う安全な胃管・空腸再建法

    第73回日本食道学会学術集会  2019 

     More details

  • Standardization of thoracoscopic esophagectomy in a robotic-assisted surgery

    第73回日本食道学会学術集会  2019 

     More details

  • 高度局所進行食道癌に対するサルベージ手術の治療成績

    第73回日本食道学会学術集会  2019 

     More details

  • 混合型食道裂孔ヘルニアに対する心負荷軽減に着目した新たな手術適応

    第73回日本食道学会学術集会  2019 

     More details

  • 腹腔鏡下肝切除術の基本手技 -私のポート位置プランニングと肝離断法-

    第9回岡山手術手技ビデオフォーラム  2019 

     More details

  • Boosting replication and penetration of telomerase-specific replicative virus by paclitaxel induces synthetic lethality in peritoneal metastasis of gastric cancer

    AACR Annual Meeting 2019  2019 

     More details

  • Boosting immunity against pancreatic cancer by OBP-702 (Pfifteloxin), telomerase-specific replicative adenovirus armed with wild-type p53 gene

    AACR Annual Meeting 2019  2019 

     More details

  • Overcoming resistance of conventional therapies by targeting cancer-associated fibroblasts (CAFs) with near-infrared photoimmunotherapy (NIR-PIT)

    AACR Annual Meeting 2019  2019 

     More details

  • Elimination of invasive pancreatic cancer cells by p53-activating oncolytic virotherapy as novel precision medicine

    AACR Annual Meeting 2019  2019 

     More details

  • Involvement of extracellular vesicles in the abscopal effect induced by oncolytic adenovirotherapy

    AACR Annual Meeting 2019  2019 

     More details

  • テロメラーゼ特異的腫瘍融解アフェノウイルス製剤と抗PD-1抗体との複合免疫療法

    第21回外科分子細胞治療研究会  2019 

     More details

  • あなたのメタボ手術で治せるかも

    岡山大学・山陽新聞 健康フェスタ in Okayama  2019 

     More details

  • 体にやさしい胃がんの手術

    岡山大学・山陽新聞 健康フェスタ in Okayama  2019 

     More details

  • 多医療圏にまたがる広域外科専門研修プログラム運営の現状と課題

    第119回日本外科学会定期学術集会  2019 

     More details

  • 噴門側胃切除術後の逆流防止機能を付加した観音開き法(上川法)食道残胃吻合の有効性と安全性を評価する多施設共同後向き研究(rD-FLAP Study)

    第119回日本外科学会定期学術集会  2019 

     More details

  • 多医療圏にまたがる広域外科専門研修フプログラム運営の現状と課題

    第119回日本外科学会定期学術集会  2019 

     More details

  • 外科医が行うべき研究のありかたとは

    第119回日本外科学会定期学術集会  2019 

     More details

  • トランスレーショナルリサーチとしての外科治療を補完する新たな集学的治療の開発研究

    第119回日本外科学会定期学術集会  2019 

     More details

  • 噴門側胃切除術後に食道胃接合部の逆流防止機構を再構築する観音開き法(上川法)再建

    第119回日本外科学会定期学術集会  2019 

     More details

  • ナショナルビッグデータを用いた新専門医制度の地域外科医療に及ぼす影響の評価と人工知能(AI)を用いた適正医師配置シミュレーションプラットフォームの確立

    第119回日本外科学会定期学術集会  2019 

     More details

  • 切除不能T4食道癌に対するDCFを用いた化学放射線療法による集学的治療と最適な救済手術のタイミングの検討

    第119回日本外科学会定期学術集会  2019 

     More details

  • 食道外科・頭頚部外科・形成外科の三科合同で行う頸胸部食道癌の拡大切除と消化管・気道再建術におけるチームワークの重要性

    第119回日本外科学会定期学術集会  2019 

     More details

  • 肝移植患者の移植後二次発癌

    第119回日本外科学会定期学術集会  2019 

     More details

  • 生体肝移植におけるMELD/重症度に応じたDonor/Graft選択の重要性

    第119回日本外科学会定期学術集会  2019 

     More details

  • 岡山大学病院における大腸癌エキスパーアトパネル診療

    第119回日本外科学会定期学術集会  2019 

     More details

  • 食道胃接合部癌168例の治療経験から導かれる最適な集学的治療

    第119回日本外科学会定期学術集会  2019 

     More details

  • 遺伝子改変ウィルスを用いた胃癌腹膜播種に対する腹腔内治療の可能性

    第119回日本外科学会定期学術集会  2019 

     More details

  • ロボット支援下胃切除術

    第91回日本胃癌学会総会  2019 

     More details

  • Society5.0時代の外科医療~情報技術により外科の可視化と最適化、そして自動化~

    第18回岡山大学外科MCセミナー  2019 

     More details

  • 胃癌に対するオプジーボの使用経験

    消化器がんスキルアップセミナー  2019 

     More details

  • 肺移植患者に対する多職種によるNST介入の取り組み

    第34回日本静脈経腸栄養学会学術集会  2019 

     More details

  • 嚥下障害を呈した肺癌術後患者が経口摂取可能となるまでのNST・嚥下チームでの関わり

    第34回日本静脈経腸栄養学会学術集会  2019 

     More details

  • カバーリング回腸ストーマ閉鎖後の合併症の検討

    第36回日本ストーマ・排泄リハビリテーション学会総会  2019 

     More details

  • OE-10-6 Valvuloplastic esophagogastrostomy using DFT for EGJC after proximal gastrectomy

    第91回日本胃癌学会総会  2019 

     More details

  • 食道胃接合部癌に対する噴門側胃切除後の観音開き法食道胃吻合

    第91回日本胃癌学会総会  2019 

     More details

  • 術前補助化学療法を施行した進行胃癌症例の治療成績

    第91回日本胃癌学会総会  2019 

     More details

  • 進化する胃癌治療 ~胃癌化学療法の今~

    Hiroshima Gastric Cancer Meeting  2019 

     More details

  • 観音開き法再建を伴う腹腔鏡下噴門側胃切除術と腹腔鏡下胃全摘術の中長期的比較検討

    第91回日本胃癌学会総会  2019 

     More details

  • GD2陽性神経芽腫に対する近赤外線光を用いた光線免疫療法の開発

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 右鎖骨下動脈起始異常を合併した食道癌症例に対する横隔鏡下食道亜全摘術の経験

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • ICG色素蛍光法を用いた再肝切除症例に対する腹腔鏡下肝S2亜区域切除術

    第13回肝臓内視鏡外科研究会  2019 

     More details

  • 直腸癌に対する新たな選択肢 ~ロボット手術とtaTME~

    第32回岡山ロータリークラブ例会  2019 

     More details

  • ゲムシタビン耐性膵癌に対するP53誘導性腫瘍融解ウィルス療法

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 胃癌腹膜播腫に対するp53搭載腫瘍融解アデノウィルス治療

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • p53搭載腫瘍溶解アデノウィルスを用いた胃癌腹膜播腫に対する治療戦略と癌微小環境に与える影響

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 市民公開講座「誰にでも分かるがん免疫療法」

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 3D画像構築を元に検討した胸腔鏡下食道癌手術において留意すべき解剖学的亜型

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 胸腔鏡下手術における反回神経周囲微細解剖に留意した定型化手技

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • Closed-LECSの新展開:早期胃癌、十二指腸病変への応用

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • ロボット支援下食道癌手術導入におけるわれわれの工夫と今後の展望

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • わが国におけるCadaver Surgical Training の現状と将来

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 内視鏡手術における周術期管理チームの役割

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 中結腸動静脈根部の上下左右のズレと副右結腸静脈のねじれの位置を意識した結腸右半切除D3郭清

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 腹腔鏡下観音開き法(上川法)再建の治療成績と吻合部狭窄予防のための取り組み

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 高齢化のすすむ地域がん診療連携拠点病院2施設での高齢者胃癌手術の検討

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 噴門形成術後の食道通過障害に対して上部消化管内視鏡を併用した腹腔鏡下再手術が有効であった1例

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 残胃癌に対する腹腔鏡下残胃全摘術の検討

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 直腸癌腹腔鏡手術における縫合不全と回腸人工肛門合併症の因果関係についての検討

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 安全なtaTME手術手技のためのカダバーサージカルトレーニングの有用性

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 直腸癌に対する新たな選択肢 ~ロボット手術とtaTME~

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 当院における急性虫垂炎に対する術式と治療成績の検討

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 食道胃接合部癌に対するCtla(combined thoracoscopic laparoscopic approach)の検討

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • 食道裂孔ヘルニア根治術による心負荷改善への貢献

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • LTGにおける食道空腸吻合の手技と治療成績

    第32回日本内視鏡外科学会学術総会  2019 

     More details

  • Roux-Y脚が原因で上行性胆管炎を繰り返した1例

    第46回日本胆道閉鎖症研究会  2019 

     More details

  • 食道領域cadaver surgical training の取り組みについて

    第72回日本胸部外科学会定期学術集会  2019 

     More details

  • リンパ節郭清

    第72回日本胸部外科学会定期学術集会  2019 

     More details

  • 消化器外科医の英語トレーニング

    第72回日本胸部外科学会定期学術集会  2019 

     More details

  • Concept of Esophagectomy in Japan

    The 15th OESO World Conference for Esophageal Diseases  2019 

     More details

  • Case Introduction and introducing speeches

    The 15th OESO World Conference for Esophageal Diseases  2019 

     More details

  • Multidisciplinary oncolytic virotherapy for gastrointestinal cancer

    Cell & Gene Therapy Asia 2019  2019 

     More details

  • 第3部 外科臨床研究の実践

    第81回日本臨床外科学会総会  2019 

     More details

  • トランスレーショナルリサーチについて考える:臨床現場のアイデアをどう生かすか

    第81回日本臨床外科学会総会  2019 

     More details

  • 胆道閉鎖症患児の黄疸重症度が生体肝移植に及ぼす影響

    第46回日本胆道閉鎖症研究会  2019 

     More details

  • 癌関連線維芽細胞を標的とした新たな抗体療法の開発

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • がんの近赤外光線免疫療法

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 進化するバイオセラピィ ~がん克服の夢の途中~

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • テロメラーゼ特異的腫瘍融解アデノウィルスは食道癌における上皮間葉転換を減弱させる

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 好中球細胞外トラップは膵癌にEMTを誘導し肝転移を促進する。

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 化学放射線療法は線維芽細胞の活性化を介して食道癌細胞の悪性度を向上させる

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 腫瘍融解ウィルス療法によるアブスコパル効果におかえるエクソソームの関与

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 解熱剤のアスピリンはEMT阻害によって大腸がん腹膜播種を抑制する。

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 神経芽腫に対するp53誘導性腫瘍ウィルス療法の免疫原性細胞死誘導効果

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 難治性膵癌に対するp53誘導性腫瘍融解ウィルス療法の腫瘍免疫応答の増強効果

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • 胃癌腹膜播腫に対する腹腔内ウィルス療法

    第32回日本バイオセラピィ学会学術集会総会  2019 

     More details

  • インピーダンスモニタリングを用いた難治性胃食道逆流症の手術適応診断

    第25回日本消化器関連学会週間(JDDW 2017)  2017 

     More details

  • 術後補助化学療法としてNEC治療を行った、十二指腸乳頭部原発MANECの1例

    第5回日本神経内分泌腫瘍研究会学術集会  2017 

     More details

  • 腹臥位胸腔鏡下食道切除における膜構造を意識した安全な上縦隔郭清術

    第27回九州内視鏡下外科手術研究会  2017 

     More details

  • 特別講演 自己紹介-これまでの軌跡と今後の抱負-

    第4回岡山大学外科同窓会  2017 

     More details

  • 遺体を用いた膵頭十二指腸切除術の手術教育

    第44回日本膵切研究会  2017 

     More details

  • テロメラーゼ標的蛍光発現ウィルスを用いた腹腔内遊離膵癌細胞診断技術の開発

    第44回日本膵切研究会  2017 

     More details

  • 膵切除周術期VTE 発症予測因子の解析

    第44回日本膵切研究会  2017 

     More details

  • 腎癌の多発膵転移・単発肺転移・下大静脈腫瘍栓に対して膵全摘を含めた一期的切除を施行し良好な術後経過を得た一例

    第44回日本膵切研究会  2017 

     More details

  • 抗体関連型拒絶反応の関与が示唆された遅発性拒絶反応の一例

    第35回中国四国臨床臓器移植研究会  2017 

     More details

  • 複数回使用可能なシリコンレプリカ膵臓モデルを用いた膵管空腸吻合トレーニングキットの開発

    第44回日本膵切研究会  2017 

     More details

  • 胆道閉鎖症に対するABO不適合移植術後に遷延する肝機能異常を認めた一例

    第35回中国四国臨床臓器移植研究会  2017 

     More details

  • Clinical prevalence of microsatellite instability colorectal cancer and lynch syndrome cancer

    第23回家族性腫瘍学会学術集会  2017 

     More details

  • 進行胃癌に対する術前補助化学療法施行症例の検討

    第15回日本臨床腫瘍学会学術集会  2017 

     More details

  • 食道癌手術における周術期筋減少症に関する術式と栄養学的因子の検討

    第10回日本静脈経腸栄養学会中国支部学術集会  2017 

     More details

  • ミスマッチ修復の観点からみた、大腸癌におけるExportin-5 の臨床的意義

    第23回家族性腫瘍学会学術集会  2017 

     More details

  • 癌関連線維芽細胞はIL-6を分泌しリンパ球の遊走を制御することで腫瘍免疫抑制を誘導する

    第26回日本がん転移学会学術集会・総会  2017 

     More details

  • 膵癌に対するテロメラーゼ特異的腫瘍融解ウイルス療法

    第72回日本消化器外科学会総会  2017 

     More details

  • 食道がんに対するテロメラーゼ依存性腫瘍融解ウイルス製剤を用いた集学的治療

    第15回日本臨床腫瘍学会学術集会  2017 

     More details

  • ワークショップ3 転移と細胞動態

    第26回日本がん転移学会学術集会・総会  2017 

     More details

  • 術前多角的な画像診断を行ったSclerosing angiomatoid nodular transformation of the spleenの一例

    第72回日本消化器外科学会総会  2017 

     More details

  • 当院における根治的放射線化学療法後の食道切除術(サルベージ治療) の検討

    第72回日本消化器外科学会総会  2017 

     More details

  • Analysis of prognostic factors of pediatric living donor liver transplantation: a single center experience of mortality zero transplantation for cholestatic disease

    18th Congress of the European Society for Organ Transplantation  2017 

     More details

  • Prediction of salvage liver transplantation for hcc recurrence: when and which patient should we decide transplant?

    18th Congress of the European Society for Organ Transplantation  2017 

     More details

  • 特別講演 ダビンチ胃切除導入におけるコツとピットフォール

    OKAYAMA Robot-Assisted Gastrectomy Symposium~ロボット支援下胃切除術の安全な導入を目指して~  2017 

     More details

  • Surgical outcomes of living donor liver surgery: technical knack for zero morbidity

    18th Congress of the European Society for Organ Transplantation  2017 

     More details

  • Is poor outcome of living donor liver transplantation for primary sclerosing cholangitis the nature of the disease itself or insufficient immunosuppression?

    18th Congress of the European Society for Organ Transplantation  2017 

     More details

  • Randomized controlled trial of an enhanced recovery after surgery protocol in patients undergoing pancreaticoduodenectomy

    39th Espen Congress  2017 

     More details

  • Significance of MSH2 promoter methylation in endometrial cancer with MSH2 deficiency

    ESMO 2017 Congress  2017 

     More details

  • 生体肝移植特有の肝移植周術期門脈圧亢進症対策

    第24回日本門脈圧亢進症学会総会  2017 

     More details

  • 胃がん・食道がんの診断・治療とチーム医療

    第215回福山外科会  2017 

     More details

  • POLE mutations and MSI were positive predictive factors for progression free survival in endometrial cancer patients at the risk of recurrence

    ESMO 2017 Congress  2017 

     More details

  • A novel circulating cell free DNA-based assay can predict tumor response to systematic chemotherapy

    ESMO 2017 Congress  2017 

     More details

  • Gene expression signatures in BRAF V600E mutant colorectal cancer in relation to WNT signaling cascade

    ESMO 2017 Congress  2017 

     More details

  • 当科におけるロボット支援下胃切除術の短期・長期成績と今後の展望

    第22回中国四国内視鏡外科研究会  2017 

     More details

  • 肥満症に対する腹腔鏡下スリーブ状胃切除術導入とチーム医療

    第92回中国四国外科学会総会  2017 

     More details

  • Heterogenity of epigenetic and EMT marks observed in hepatocellular carcinoma with keratin 19 proficiency

    ESMO 2017 Congress  2017 

     More details

  • 腹臥位胸腔鏡下食道切除における膜構造に基づいた安全な上縦隔郭清術

    第22回中国四国内視鏡外科研究会  2017 

     More details

  • 脾摘の功罪からみた生体肝移植における術前脾動脈塞栓術の意義

    第53回日本移植学会総会  2017 

     More details

  • PSCに対する生体肝移植におけるintensive inductionは後の再燃性Graft loss を防げるか?

    第53回日本移植学会総会  2017 

     More details

  • 食道癌手術症例における同時性異時性重複癌の検討

    第92回中国四国外科学会総会  2017 

     More details

  • 新専門医制度と地域の外科 岡山県

    第92回中国四国外科学会総会  2017 

     More details

  • 胃がん・食道がん診療の今と未来

    美作医会学術講演会~CCセミナー~  2017 

     More details

  • Metabolism of Tumor Infiltrating Immune Cells regulates anti-Tumor Immunity

    第76回日本癌学会学術総会  2017 

     More details

  • Q&Aトークセッション~希望を持って治療を受けるために~

    もっと知ってほしい胃がんのこと2017 in 岡山  2017 

     More details

  • Novel evidence for AZIN1RNAediting-mediated oncogenicrole in colorectal cancer

    第76回日本癌学会学術総会  2017 

     More details

  • Fluorescence-guided live cell imaging system of EMT-tumor microenvironment network in gastrointestinal cancer

    第76回日本癌学会学術総会  2017 

     More details

  • Novel theranostic strategy : combination of fluorescence oncolytic virus and chemotherapy for scirrhous gastric cancer

    第76回日本癌学会学術総会  2017 

     More details

  • Telomerase-specificoncolyticadenovirotherapy targetingMYCN addiction in MYCN-amplified neuroblastoma

    第76回日本癌学会学術総会  2017 

     More details

  • 胃癌患者の腹腔内マクロファージは分化し胃癌細胞の悪性形質を促進する

    第76回日本癌学会学術総会  2017 

     More details

  • Focusing on the antitumor effect of iron chelator, specifically suppressing the stemness of cancer stem cell

    第76回日本癌学会学術総会  2017 

     More details

  • 新規光線力学療法としての蛍光タンパク質KillerRed 誘導腫瘍融解ウイルスのin vivo 抗腫瘍効果

    第76回日本癌学会学術総会  2017 

     More details

  • HER2 陽性胃癌に対するアファチニブ・ネラチニブの抗腫瘍効果

    第76回日本癌学会学術総会  2017 

     More details

  • 軟部肉腫に対するp53 発現テロメラーゼ依存型腫瘍融解アデノウイルスの放射線効果増強

    第76回日本癌学会学術総会  2017 

     More details

  • 抗PD-1 抗体の新たな治療戦略:腫瘍選択的融解アデノウイルス療法との相乗効果の可能性

    第76回日本癌学会学術総会  2017 

     More details

  • 抗体結合磁性ナノ粒子による温熱療法-癌播種病変への治療応用へ向けて-

    第76回日本癌学会学術総会  2017 

     More details

  • 食道癌手術における臨床応用解剖の経験

    第70回日本胸部外科学会定期学術集会  2017 

     More details

  • 80歳以上の超高齢者に対する安全な食道癌治療への取り組み

    第70回日本胸部外科学会定期学術集会  2017 

     More details

  • 癌関連線維芽細胞(CAFs)により放出されるIL-6 が腫瘍免疫抑制を引き起こす

    第76回日本癌学会学術総会  2017 

     More details

  • 胃癌患者における末梢血中CD8T 細胞の多機能性と代謝の解析

    第76回日本癌学会学術総会  2017 

     More details

  • 食道鏡視下手術におけるリンパ節郭清のTips メルクマールとV字郭清法

    第70回日本胸部外科学会定期学術集会  2017 

     More details

  • 胸腔鏡下食道癌手術における膜と層の微細解剖に基づいた上縦隔リンパ節郭清

    第70回日本胸部外科学会定期学術集会  2017 

     More details

  • The importance of optimal drug sequencing in mCRC:biological rationales for the patients benefit

    Meet the Expert Seminar in Okayama  2017 

     More details

  • 多彩な合併症を呈するBeckwith-Wiedemann 症候群に発症した乳児肝芽腫の一例

    第59回日本小児血液・がん学会学術集会  2017 

     More details

  • Microanatomy based standardization for the upper mediastinal lymph node dissection in thoracoscopic esophagectomy in the prone position

    ESDE 2017  2017 

     More details

  • Liver transplantation for primary sclerosing cholangitis

    IASGO World Congress 2017  2017 

     More details

  • 遅発性に肝転移・骨盤内リンパ節転移をきたした直腸神経内分泌腫瘍の1例

    第72回日本大腸肛門病学会学術集会  2017 

     More details

  • 蛍光標識ウイルスTelomeScanによるがん細胞検出システムの臨床応用

    第55回日本癌治療学会学術集会  2017 

     More details

  • 切除困難局所進行食道癌に対するDCF併用放射線療法を用いた集学的治療

    第55回日本癌治療学会学術集会  2017 

     More details

  • 「観音開き法再建」を伴う腹腔鏡下噴門側胃切除術と腹腔鏡下胃全摘術の術後体重減少とQOL 維持における中長期的比較検討

    第47回胃外科・術後障害研究会  2017 

     More details

  • 小児胆汁鬱滞性肝疾患に対するZero-mortality 肝移植

    第44回日本胆道閉鎖症研究会  2017 

     More details

  • 切除不能進行再発大腸がんの2次治療以降における Ramcirumab + FOLFIRI 療法の治療成績

    第55回日本癌治療学会学術集会  2017 

     More details

  • HER2 陽性胃癌に対する S-1+ docetaxel + trastuzumab 併用療法の多施設共同第Ⅱ相試験

    第55回日本癌治療学会学術集会  2017 

     More details

  • がん診療ガイドラインが果たす更なる役割の認識へ向けて

    第55回日本癌治療学会学術集会  2017 

     More details

  • がん診療ガイドライン統括・連絡委員会企画シンポジウム 進化するがん診療ガイドライン

    第55回日本癌治療学会学術集会  2017 

     More details

  • シンポジウム1 新規バイオマーカーが拓くがん治療の近未来

    第55回日本癌治療学会学術集会  2017 

     More details

  • 希少癌診療ガイドラインの作成を通した医療提供体制の質向上

    第55回日本癌治療学会学術集会  2017 

     More details

  • 日本癌治療学会「がん診療ガイドライン(jsco-cpg.jp)」アクセス状況

    第55回日本癌治療学会学術集会  2017 

     More details

  • 早期胃癌症例に対するClosed-LECS手技の可能性

    第25回日本消化器関連学会週間(JDDW 2017)  2017 

     More details

  • ブレックファーストセミナー32 新規薬剤ナルデメジンによるオピオイド誘発性便秘症(OIC)管理の実際

    第25回日本消化器関連学会週間(JDDW 2017)  2017 

     More details

  • Prediction of salvage liver transplantation for hepatocellular carcinoma recurrence: when and for which patient should we decide transplant?

    Asian Transplantation Week 2017 (ATW 2017)  2017 

     More details

  • 鉄キレート剤による幹細胞性制御を介した新規癌幹細胞の治療法の開発

    第28回日本消化器癌発生学会総会  2017 

     More details

  • 腹臥位胸腔鏡下食道切除における食道(気管)間膜のコンセプトに基づいた安全な上縦隔郭清術

    第71回手術手技研究会  2017 

     More details

  • 腹臥位胸腔鏡下食道切除における臓器鞘を意識した安全な右上縦隔郭清手技

    第71回手術手技研究会  2017 

     More details

  • Telomerase-targeted oncolytic virotherapy for MYCN-amplified neuroblastoma

    PAPS 50th Annual Scientific Meeting  2017 

     More details

  • 癌関連線維芽細胞は腫瘍浸潤リンパ球を制御することにより腫瘍免疫抑制を調整する

    第38回癌免疫外科研究会  2017 

     More details

  • トラスツズマブ抵抗性胃癌に対する挑戦:金ナノ技術を導入した新規HER2 標的抗体医薬の開発

    第38回癌免疫外科研究会  2017 

     More details

  • 右側肝円索・門脈分枝走行異常を伴う進行胆嚢癌に対する系統的肝切除の経験

    第71回手術手技研究会  2017 

     More details

  • 胸腔鏡下食道癌手術における膜と層に留意した左上縦リンパ節隔郭清の手技

    第71回手術手技研究会  2017 

     More details

  • 高リスク食道癌症例に対する放射線併用ウイルス療法の臨床研究の中間報告

    第93回日本消化器内視鏡学会総会  2017 

     More details

  • 要望演題1「バイオマーカー1」

    第38回癌免疫外科研究会  2017 

     More details

  • 総合司会

    第6回E-Lapセミナー  2017 

     More details

  • 食道癌術後早期にAeromonas hydrophila による壊死性軟部組織感染症を発症した1 例

    第30回日本外科感染症学会総会学術集会  2017 

     More details

  • 放射線治療後の手術創に対する計画的陰圧閉鎖療法の経験

    第47回日本創傷治癒学会  2017 

     More details

  • 癌関連線維芽細胞(CAFs)が過剰放出するIL-6の制御は腫瘍免疫抑制の改善に寄与する

    第30回日本バイオセラピィ学会学術集会総会  2017 

     More details

  • 胆嚢癌に対する至適肝切除域の見極め ~ICG 蛍光法を用いた胆嚢静脈還流域切除~

    第79回日本臨床外科学会総会  2017 

     More details

  • 腹臥位胸腔鏡下手術での合併症を起こさせない手術手技

    第79回日本臨床外科学会総会  2017 

     More details

  • 第1部 臨床研究の基礎講座

    日本臨床外科学会・日本外科学会共催 第19回臨床研究セミナー  2017 

     More details

  • 虫垂炎術後発症したと考えられる傍上行結腸窩ヘルニアによるイレウスの1例

    第79回日本臨床外科学会総会  2017 

     More details

  • 汚染・化膿手術におけるSSI防止に対するストマ対策を意識した計画的陰圧閉鎖療法

    第79回日本臨床外科学会総会  2017 

     More details

  • Closed LECSの開発と早期胃癌への応用

    第79回日本臨床外科学会総会  2017 

     More details

  • 進行食道癌に対するDCF 療法を軸にした集学的治療戦略―著効例にも根治手術は必要か?―

    第79回日本臨床外科学会総会  2017 

     More details

  • 安全で正確な系統的肝切除の実践に向けて:Knack & Pitfalls

    第79回日本臨床外科学会総会  2017 

     More details

  • 高齢者に対する食道裂孔ヘルニア手術によるQOL改善への貢献

    第29回日本老年医学会中国地方会  2017 

     More details

  • 食道癌手術における術後合併症ゼロを目指したわれわれの工夫

    第79回日本臨床外科学会総会  2017 

     More details

  • Fusionに留意した食道癌に対する胸腔鏡下上縦隔リンパ節郭清

    第79回日本臨床外科学会総会  2017 

     More details

  • 上部消化管腫瘍に対するClosed-LECS

    第16回EGI外科治療研究会  2017 

     More details

  • 肝胆膵領域における系統的リンパ節郭清-胃外科・食道外科からの学びと応用-

    第16回EGI外科治療研究会  2017 

     More details

  • 特別講演 「食道胃接合部腫瘍に対する外科治療」

    第16回EGI外科治療研究会  2017 

     More details

  • 食道胃接合部癌に対する胸腔内観音開き方再建の有効性

    第16回EGI外科治療研究会  2017 

     More details

  • 郭清操作からみたポート、術者配置による腹腔鏡下右側結腸切除術

    第16回EGI外科治療研究会  2017 

     More details

  • 特別講演2 「StageIV胃癌の集学的治療 NACかconversionか?」

    岡山がん集学的治療カンファレンス  2017 

     More details

  • 食道癌周術期におけるチーム医療導入の成果と展望

    第42回日本外科系連合学会学術集会  2017 

     More details

  • シンポジウム2 周術期連携による術後合併症の予防と早期離床をめざして

    第42回日本外科系連合学会学術集会  2017 

     More details

  • 便中メチル化CpG検出による非侵襲的大腸癌スクリーニング技術の実用化を目指して

    第87回大腸癌研究会  2017 

     More details

  • Ovarian metastasectomy in colorectal cancer may improve the clinical outcomes of patients with metastatic colorectal cancer regardless of BRAF or KRAS mutational profiles

    ESMO 19th World Congress on Gastrointestinal Cancer  2017 

     More details

  • 胃癌術後骨再発にゾレドロン酸を併用したramucirumab 単独投与で長期寛解状態を得た1 例

    第39回日本癌局所療法研究会  2017 

     More details

  • 3 期分割手術を含む集学的治療にて根治切除しえた食道癌縦隔瘻の一例

    第39回日本癌局所療法研究会  2017 

     More details

  • 食道癌診療におけるoncological emergencyに対する外科手術の役割

    第42回日本外科系連合学会学術集会  2017 

     More details

  • 超高齢者のStage Ⅳa 食道癌に対し積極的に局所療法を行い長期無再発生存がえられた1 例

    第39回日本癌局所療法研究会  2017 

     More details

  • 80歳以上の超高齢者に対する食道癌根治手術-鏡視下手術と周術期肺理学療法による呼吸器合併症軽減への取り組み-

    第60回関西胸部外科学会学術集会  2017 

     More details

  • 宿主正常細胞である癌関連線維芽細胞を標的とした新たな食道癌治療法の開発

    第60回関西胸部外科学会学術集会  2017 

     More details

  • 潰瘍性大腸炎合併癌の診断と治療(モーニングセミナー)

    日本消化器病学会中国支部第25回教育講演会  2017 

     More details

  • 病態別に考える食道裂孔ヘルニア症例の手術適応と治療成績

    第71回日本食道学会学術集会  2017 

     More details

  • 同時性胃癌合併食道癌に対する治療戦略

    第71回日本食道学会学術集会  2017 

     More details

  • 原発性小腸癌に対する診断・治療戦略~原発性小腸癌の多施設共同観察研究の結果から~

    第107回日本消化器病学会中国支部例会  2017 

     More details

  • 特別講演「大腸癌化学療法~ASCO2017での話題~」

    第5回岡山大腸腫瘍研究会  2017 

     More details

  • 80歳以上の超高齢者に対する食道癌手術の成績と周術期管理の工夫

    第71回日本食道学会学術集会  2017 

     More details

  • 標準的治療困難な食道癌症例に対する放射線併用ウイルス療法臨床研究の中間報告

    第71回日本食道学会学術集会  2017 

     More details

  • 当科におけるサルベージ食道切除術の検討

    第71回日本食道学会学術集会  2017 

     More details

  • 胸腔鏡下食道癌手術における膜と層に留意した上縦隔リンパ節郭清の定型化

    第71回日本食道学会学術集会  2017 

     More details

  • 食道胃接合部癌137例の経験から導かれる手術 根治性と術後QOL の両立

    第71回日本食道学会学術集会  2017 

     More details

  • 食道胃接合部癌125例から導かれる最適な術式根治性と術後QOLの併存を求めて

    第72回日本消化器外科学会総会  2017 

     More details

  • 食道癌根治術後Oligometastasisに対する治療戦略

    第72回日本消化器外科学会総会  2017 

     More details

  • 原発性硬化性胆管炎に対する肝移植の治療成績

    第72回日本消化器外科学会総会  2017 

     More details

  • 胸腔鏡下食道癌手術における微細解剖に基づいた上縦隔リンパ節郭清

    第72回日本消化器外科学会総会  2017 

     More details

  • 鏡視下食道癌手術におけるピットフォールとトラブルシューティング

    第72回日本消化器外科学会総会  2017 

     More details

  • 膵切除における周術期VTE発症予測因子の解析

    第72回日本消化器外科学会総会  2017 

     More details

  • 胃上部早期胃癌に対する逆流防止弁形成食道残胃吻合(観音開き法) 再建の定型化

    第72回日本消化器外科学会総会  2017 

     More details

  • 特別企画5 消化器癌の診断・治療を含めた新規分子腫瘍マーカーの意義と展望

    第72回日本消化器外科学会総会  2017 

     More details

  • 膵全摘患者に対するインスリンポンプ療法を用いた新たな血糖管理

    第72回日本消化器外科学会総会  2017 

     More details

  • R0手術例の予後因子からみた残胃癌の治療戦略

    第72回日本消化器外科学会総会  2017 

     More details

  • 当院IBDチームにおけるNPWT 導入後のSSI 対策の推移

    第72回日本消化器外科学会総会  2017 

     More details

  • 局所進行直腸癌に対する術前化学療法の有用性

    第72回日本消化器外科学会総会  2017 

     More details

  • 癌細胞内特異的蛍光発現製剤による浸潤部の蛍光標識と殺細胞性を兼ね備えた高精度な低侵襲手術の開発

    第72回日本消化器外科学会総会  2017 

     More details

  • 胃管作製不能例に対する有茎空腸を用いた食道再建術

    第72回日本消化器外科学会総会  2017 

     More details

  • 進行食道癌に対するDCF 療法を用いた集学的治療

    第72回日本消化器外科学会総会  2017 

     More details

  • 大腸癌多発肝転移におけるRAS/RAF変異の意義~生物学的悪性度から術前化学療法適応を見極める~

    第72回日本消化器外科学会総会  2017 

     More details

  • 腹腔内腫瘍微小環境におけるマクロファージの消化器癌悪性形質への影響

    第72回日本消化器外科学会総会  2017 

     More details

  • 特別講演 胃癌治療ガイドライン改訂の動向~薬物療法と手術の何が変わるのか~

    第5回Clinical Cancer Symposium in OKAYAMA  2017 

     More details

  • PVT1 は癌遺伝子MYC を駆動するエンハンサーでありStage II, III 大腸癌の予後予測マーカーになりうる

    第72回日本消化器外科学会総会  2017 

     More details

  • 神経解剖に基づいたD2 リンパ節郭清を伴う腹腔鏡下幽門側胃切除術の短期・長期成績

    第72回日本消化器外科学会総会  2017 

     More details

  • Combination of PD-L1 expression and microsatellite instability status is a useful prognostic factor in gastric cancer

    AACR Annual Meeting 2017  2017 

     More details

  • Antitumor activity of multikinase inhibitors in HER2-positive gastric cancer cells

    AACR Annual Meeting 2017  2017 

     More details

  • Cancer-associated fibroblasts contribute to tumor immunosuppression by regulating tumor-infiltrating lymphocytes

    AACR Annual Meeting 2017  2017 

     More details

  • Tumorigenesis of murine iPS cell is prevented by iron depletion with downregulation of stemness markers

    AACR Annual Meeting 2017  2017 

     More details

  • Molecular radiosensitization in soft tissue sarcomas by telomerase-specific oncolytic adenovirus

    AACR Annual Meeting 2017  2017 

     More details

  • Cancer associated fibroblasts promote tumor metastasis coexisting with cancer cells in blood circulation

    AACR Annual Meeting 2017  2017 

     More details

  • Fluorescence-guided spatiotemporal dynamics of epithelial-mesenchymal transition under inflammatory microenvironment during colorectal cancer progression

    AACR Annual Meeting 2017  2017 

     More details

  • Gene expression profiles in BRAF V600E mutant colorectal cancer and association with SFRP2 methylation status

    AACR Annual Meeting 2017  2017 

     More details

  • Hyperthermia at the single-cell level for disseminated cancer disease with immuno-magnetic nanoparticles

    AACR Annual Meeting 2017  2017 

     More details

  • Novel evidence for AZIN1 RNA editing-mediated oncogenic role in colorectal cancer

    AACR Annual Meeting 2017  2017 

     More details

  • CK19陽性肝細胞癌の予後と分子生物学的特徴の検討

    第50回制癌剤適応研究会  2017 

     More details

  • BRAF 変異大腸癌の特徴~その特異なる転移形式と予後~1070例の解析から

    第50回制癌剤適応研究会  2017 

     More details

  • Ablation of oncogenic MYCN expression by hTERT-driven oncolytic adenovirus induces cell death in MYCN-amplified neuroblastoma

    AACR Annual Meeting 2017  2017 

     More details

  • 一般演題 ビデオ / LECS、GIST

    第89回日本胃癌学会総会  2017 

     More details

  • 食道胃接合部癌に対する腹腔鏡下観音開き法食道残胃吻合

    第89回日本胃癌学会総会  2017 

     More details

  • Standardization and modification of Closed-LECS procedure for gastric submucosal tumor

    第89回日本胃癌学会総会  2017 

     More details

  • Standardization and training system of laparoscopy-assisted distal gastrectomy

    第89回日本胃癌学会総会  2017 

     More details

  • 食道癌手術における鏡視下手術導入による術前後の身体的・栄養学的変化についての検討

    第32回日本静脈経腸栄養学会学術集会  2017 

     More details

  • 進行胃癌に対するSOX療法の経験と術前補助化学療法への期待

    第89回日本胃癌学会総会  2017 

     More details

  • 頭頚部癌に対する化学放射線療法完遂率向上を目指したPEGによる栄養管理

    第32回日本静脈経腸栄養学会学術集会  2017 

     More details

  • 食道癌周術期管理におけるPERIO の取り組みと成果,そしてその新展開

    第117回日本外科学会定期学術集会  2017 

     More details

  • D ダイマーと造影CT 検査を併用した胸部食道癌術後の潜在性血栓症に対するスクリーニングの有用性

    第117回日本外科学会定期学術集会  2017 

     More details

  • ePTFEを用いた新規透析用カテーテル挿入補助デバイスの開発

    第117回日本外科学会定期学術集会  2017 

     More details

  • 胃管作製不能例に対する空腸を用いた食道再建術

    第117回日本外科学会定期学術集会  2017 

     More details

  • StageIV大腸癌に対するPrecision Medicineの構築

    第117回日本外科学会定期学術集会  2017 

     More details

  • 胃癌における組織型とPD L1 発現の患者予後および術後再発予測因子としての有用性

    第117回日本外科学会定期学術集会  2017 

     More details

  • Outcome of locally advanced rectal cancer with or without preoperative treatments

    第117回日本外科学会定期学術集会  2017 

     More details

  • 進行胃癌に対する術前補助化学療法施行症例の検討

    第117回日本外科学会定期学術集会  2017 

     More details

  • テロメラーゼ標的蛍光発現ウイルスを用いた膵癌腹腔内微小環境の解析

    第117回日本外科学会定期学術集会  2017 

     More details

  • 根治困難な局所進行食道癌に対するDCF併用放射線療法を用いた集学的治療

    第117回日本外科学会定期学術集会  2017 

     More details

  • 噴門側胃切除

    第117回日本外科学会定期学術集会  2017 

     More details

  • 遺伝子変異情報に基づいた大腸癌肝転移の治療戦略―原発巣の左右局在とRAS/RAF 変異の意義―

    第117回日本外科学会定期学術集会  2017 

     More details

  • 外科研修の現状からみえた若手外科医の求めるもの~大規模survey より~

    第117回日本外科学会定期学術集会  2017 

     More details

  • 下部消化管領域におけるカダバートレーニングの実際

    第117回日本外科学会定期学術集会  2017 

     More details

  • 食道胃接合部癌に対する術式の進化腹臥位併用完全鏡視下観音開き法再建の導入

    第117回日本外科学会定期学術集会  2017 

     More details

  • Clinicopathological significance of endometrial cancer with MSH2 deficiency

    AACR Annual Meeting 2017  2017 

     More details

  • Tumor associated macrophages promote malignant phenotypes of disseminated human gastric cancer cells in intraperitoneal cancer immune microenvironment

    AACR Annual Meeting 2017  2017 

     More details

  • 胃癌に対する低侵襲治療と個別化医療の試み

    福島県消化器癌講演会  2017 

     More details

  • 多発肺転移を伴う甲状腺乳頭癌の自閉症児例

    第58回中国四国小児がん研究会  2017 

     More details

  • Novel theranostic strategy against scirrhous gastric cancer; combination of chemotherapy and fluorescence oncolytic adenovirus

    AACR Annual Meeting 2017  2017 

     More details

  • Challenges of controversial cases in pediatric liver transplantation from our 20 years’experience

    Joint Congress of The 6th Biennial Congress of the Asian-Pacific Hepato-Pancreato-Biliary Association & The 29th Meeting of Japanese Society of Hepato-Biliary-Pancreatic Surgery  2017 

     More details

  • Surgical approach to cirrhotic patients with hepatocellular carcinoma: splenectomy ameliorates liver function which could expand the chance of hepatectomy

    Joint Congress of The 6th Biennial Congress of the Asian-Pacific Hepato-Pancreato-Biliary Association & The 29th Meeting of Japanese Society of Hepato-Biliary-Pancreatic Surgery  2017 

     More details

  • Hepatectomy for multiple colorectal liver metastasis - precise tumor removal and parenchymal sparing -

    Joint Congress of The 6th Biennial Congress of the Asian-Pacific Hepato-Pancreato-Biliary Association & The 29th Meeting of Japanese Society of Hepato-Biliary-Pancreatic Surgery  2017 

     More details

  • The utility of cadaver-based surgical training in hepatobiliary and pancreatic surgery

    Joint Congress of The 6th Biennial Congress of the Asian-Pacific Hepato-Pancreato-Biliary Association & The 29th Meeting of Japanese Society of Hepato-Biliary-Pancreatic Surgery  2017 

     More details

  • Clinical significance of radical lymphadenectomy for intrahepatic cholangiocarcinoma - analysis based on tumor location and recurrence pattern -

    Joint Congress of The 6th Biennial Congress of the Asian-Pacific Hepato-Pancreato-Biliary Association & The 29th Meeting of Japanese Society of Hepato-Biliary-Pancreatic Surgery  2017 

     More details

  • A successful anatomical liver resection using intrabiliary injection ICG-fluorescence imaging to identify hepatic segments containing dilated intrahepatic bile duct

    Joint Congress of The 6th Biennial Congress of the Asian-Pacific Hepato-Pancreato-Biliary Association & The 29th Meeting of Japanese Society of Hepato-Biliary-Pancreatic Surgery  2017 

     More details

  • 再発肝癌に対する治療戦略 ーSalvage transplantation の見極め ー

    第35回日本肝移植研究会  2017 

     More details

  • 生体肝移植における非顕微鏡下肝動脈再建 手技的要点とその安全性

    第35回日本肝移植研究会  2017 

     More details

  • Radical distal pancreatectomy with en block celiac axis resection and retroperitoneal dissection for advanced pancreatic cancer

    Joint Congress of The 6th Biennial Congress of the Asian-Pacific Hepato-Pancreato-Biliary Association & The 29th Meeting of Japanese Society of Hepato-Biliary-Pancreatic Surgery  2017 

     More details

  • 当院におけるpT1a/b 大腸癌リンパ節転移予測因子の検討

    第86回大腸癌研究会  2017 

     More details

  • 特別講演 Dr.PPの魅せるプレゼンテーション

    第14回岡山大学外科MCセミナー  2017 

     More details

  • 消化器がんの診断・治療とチーム医療

    姫路赤十字病院学術講演会  2017 

     More details

  • 食道癌に対する放射線併用ウイルス療法の臨床応用の実際

    第17回医薬品等ウイルス安全性シンポジウム  2017 

     More details

  • 第二部「創傷治療」

    第2回岡山大学消化器外科地域医療連携の集い  2017 

     More details

  • 胃がん・食道がんの診断・治療とチーム医療

    Meet the Professor in 岩国  2017 

     More details

  • 消化器がんの低侵襲治療と個別化医療

    Cancer Symposium in 麻田総合病院  2017 

     More details

  • 特別講演Ⅱ「敗血症性臓器障害の病態を科学的に再考する!~Sepsis-induced coagulopathy(SIC)と免疫麻痺を正しく理解し、早期の治療介入を!~」

    第5回岡山大学消化器外科フォーラム  2017 

     More details

  • テロメラーゼ依存的腫瘍選択的融解アデノウイルス製剤の免疫原性薬剤としての可能性と抗PD-1抗体との併用療法の有用性

    第30回日本バイオセラピィ学会学術集会総会  2017 

     More details

  • 多発筋炎/ 皮膚筋炎でみつかり腹腔鏡下に切除し得た直腸癌の一例

    第30回日本内視鏡外科学会総会  2017 

     More details

  • 腹臥位胸腔鏡下食道亜全摘における臨床応用解剖実習の有用性

    第30回日本内視鏡外科学会総会  2017 

     More details

  • 内視鏡手術教育における術前解剖シミュレーターの重要性

    第30回日本内視鏡外科学会総会  2017 

     More details

  • 完全鏡視下手縫いによる逆流防止弁形成食道残胃吻合(観音開き法)

    第30回日本内視鏡外科学会総会  2017 

     More details

  • 腹臥位胸腔鏡下食道癌手術における困難症例に対する挑戦

    第30回日本内視鏡外科学会総会  2017 

     More details

  • 腹臥位胸腔鏡下食道切除における微細層構造を意識した安全な上縦隔郭清術

    第30回日本内視鏡外科学会総会  2017 

     More details

  • 完全鏡視下幽門側胃切除におけるBook-binding technique によるBillroth-I 法再建の検討

    第30回日本内視鏡外科学会総会  2017 

     More details

  • Cadaver training による腹腔鏡下膵頭十二指腸切除術の修練

    第30回日本内視鏡外科学会総会  2017 

     More details

  • ワークショップ4「がんの分子機構の解明」

    第30回日本バイオセラピィ学会学術集会総会  2017 

     More details

  • 食道癌におけるがん細胞及びがん関連線維芽細胞に対するDual target PITの検討

    第30回日本バイオセラピィ学会学術集会総会  2017 

     More details

  • 混合型食道裂孔ヘルニア手術のQOL 改善への貢献

    第30回日本内視鏡外科学会総会  2017 

     More details

  • 切離断端の安全域を向上させる殺細胞性を兼ね備えた癌細胞特異的蛍光発現製剤を用いた内視鏡外科手術の開発

    第30回日本内視鏡外科学会総会  2017 

     More details

  • 講演1「局所進行直腸癌に対する集学的治療戦略」

    第15回OKAYAMA CANCER FORUM  2016 

     More details

  • Clinical Significance of MLH1 Methylation and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer

    ICHG2016 第13回国際人類遺伝学会  2016 

     More details

  • Genetic and epigenetic alterations of netrin-1 receptors in gastric cancer

    ICHG2016 第13回国際人類遺伝学会  2016 

     More details

  • 肝移植後5日目に急激な敗血症性ショックをきたした1例

    第16回京都肝移植周術期研究会学術集会  2016 

     More details

  • Fluorescence-guided imaging of gastric cancer cells for an insight into peritoneal dissemination

    第88回日本胃癌学会総会  2016 

     More details

  • スキルス胃癌細胞に対するテロメラーゼ依存的腫瘍融解ウイルス治療の前臨床評価

    第88回日本胃癌学会総会  2016 

     More details

  • 低侵襲性と高QOLを追求した腹腔鏡下噴門側胃切除+観音開き法再建の食道胃接合部癌への適応拡大

    第88回日本胃癌学会総会  2016 

     More details

  • 腹腔鏡下・ロボット支援下噴門側胃切除後「観音開き法」再建

    第88回日本胃癌学会総会  2016 

     More details

  • 「全国腸管不全登録患者データベース」における成人腸管不全の成人発症例とCarry over症例の比較

    第28回日本小腸移植研究会  2016 

     More details

  • 残胃癌手術症例の予後因子の検討

    第88回日本胃癌学会総会  2016 

     More details

  • Lecture1「当科における大建中湯の使用経験」

    第15回岡山大学Kampo Conference  2016 

     More details

  • 特別講演「生体深部観察のための革新的蛍光イメージング技術開発とがん研究・医療応用」

    第52回臨床遺伝子医学研究会  2016 

     More details

  • Real-time in vivo image-guided cell-cycle perturbation to increase tumor chemosensitivity

    AACR Precision Medicine Series 2016  2016 

     More details

  • 局所陰圧閉鎖療法

    第1回岡山大学消化器外科地域医療連携の集い  2016 

     More details

  • 消化器がんの低侵襲治療と個別化医療の最前線

    鶴翔会鳥取県支部総会  2016 

     More details

  • 食道癌手術における鏡視下手術導入による術前後の身体的変化についての検討

    第31回日本静脈経腸栄養学会学術集会  2016 

     More details

  • 肝胆膵外科手術における術後感染性合併症の指標としてSarcopeniaは有用な術前指標である

    第31回日本静脈経腸栄養学会学術集会  2016 

     More details

  • Extended RAS/BRAF/MSI genetic変異、MGMT epigenetic変異を用いたStageⅣ大腸癌Precision Strategy

    第84回大腸癌研究会  2016 

     More details

  • ワークショップ(7)「次世代の外科治療における早期探索的医療研究の役割」

    第116回日本外科学会定期学術集会  2016 

     More details

  • 日本外科学会臨床研究推進委員会報告:研究助成の方針と新しい募集要項

    第116回日本外科学会定期学術集会(第16回臨床研究セミナー)  2016 

     More details

  • 治癒切除し得た腺癌成分をともなった胃yolk sac tumor の1例

    第116回日本外科学会定期学術集会  2016 

     More details

  • アデノウイルス製剤の光線力学療法への応用

    第18回外科分子細胞治療研究会  2016 

     More details

  • 胸部食道癌手術における食道胃管吻合法の比較―Gambee 吻合法と三角吻合法―

    第116回日本外科学会定期学術集会  2016 

     More details

  • 食道癌ESD 後の追加治療としての手術症例ならびにESD 後再発手術症例の検討―ESD後の適切な追加・補助治療とは―

    第116回日本外科学会定期学術集会  2016 

     More details

  • 鉄コントロールによる新規がん幹細胞治療

    第116回日本外科学会定期学術集会  2016 

     More details

  • 食道癌困難症例に対する腹臥位胸腔鏡下手術の工夫

    第116回日本外科学会定期学術集会  2016 

     More details

  • 切除可能局所進行直腸癌に対する術前化学療法および術前放射線化学療法の検討

    第116回日本外科学会定期学術集会  2016 

     More details

  • 当院成人生体肝移植術後菌血症症例の検討

    第116回日本外科学会定期学術集会  2016 

     More details

  • 胃癌におけるPDL1 の臨床病理学的特徴

    第116回日本外科学会定期学術集会  2016 

     More details

  • 膵癌切除症例における免疫チェックポイント分子の発現解析~膵癌切除例とTCGA dataを対象とした免疫チェックポイント機構の解析~

    第116回日本外科学会定期学術集会  2016 

     More details

  • 癌部および非癌部におけるHLA class I 発現強度の検討

    第116回日本外科学会定期学術集会  2016 

     More details

  • 複数回使用可能なシリコンレプリカ膵臓モデルを用いた膵管空腸吻合トレーニングキットの開発

    第116回日本外科学会定期学術集会  2016 

     More details

  • 肝内胆管癌の外科治療~リンパ節郭清結果を踏まえ手術戦略を再考する~

    第116回日本外科学会定期学術集会  2016 

     More details

  • 第16回臨床研究セミナー 「第3部 外科臨床研究の実践」

    第116回日本外科学会定期学術集会  2016 

     More details

  • 食道癌外科治療を補完する新たな治療戦略としての腫瘍融解ウイルスと放射線との新規併用療法の臨床研究

    第116回日本外科学会定期学術集会  2016 

     More details

  • Efficacy of Tolvaptan for refractory ascites and hyponatremia in perioperative management in liver transplantation

    TSS Asian Regional Meeting 2016  2016 

     More details

  • Iron metabolism is a novel therapeutic target of cancer stem cells

    第75回日本癌学会学術総会  2016 

     More details

  • 高齢化社会における食道裂孔ヘルニア手術の積極的適応

    第78回日本臨床外科学会総会  2016 

     More details

  • 遺伝子変異情報を考慮したStageⅣ大腸癌に対する予後の検討及び治療戦略の構築

    第71回日本大腸肛門病学会学術集会  2016 

     More details

  • ランチョンセミナー4 逆流性食道炎診療の今後の展開~ボノプラザンの位置づけについて考える~

    第106回日本消化器病学会中国支部例会  2016 

     More details

  • ビデオシンポジウム08 高度肥満症例に対する消化器癌手術のコツ

    第78回日本臨床外科学会総会  2016 

     More details

  • Modified FOLFOXIRI の当院における有効性と安全性

    第71回日本大腸肛門病学会学術集会  2016 

     More details

  • 特別講演「外科医の立場から」

    岡山肥満・糖尿病外科治療セミナー  2016 

     More details

  • 胃粘膜下腫瘍に対するClosed-LECS 手技の定型化

    第14回腹腔鏡内視鏡合同手術研究会  2016 

     More details

  • 脾 sclerosing angiomatoid nodular transformation の一例

    第106回日本消化器病学会中国支部例会  2016 

     More details

  • 新たな食道癌治療戦略としての放射線併用腫瘍融解ウイルス療法の臨床研究

    第106回日本消化器病学会中国支部例会  2016 

     More details

  • 多視点3D映像システムによる次世代の手術解剖教育

    2016年度日本消化器関連学会週間(JDDW 2016)  2016 

     More details

  • 当院における膵頭十二指腸切除術の治療成績

    2016年度日本消化器関連学会週間(JDDW 2016)  2016 

     More details

  • 腹腔鏡下「観音開き法」食道残胃吻合:手技の定型化と工夫

    2016年度日本消化器関連学会週間(JDDW 2016)  2016 

     More details

  • A Case Series of Salvage Surgery for Stage IV Gastric Cancer

    40th World Congress of the International College of Surgeons  2016 

     More details

  • Non-exposure laparoscopic endoscopic cooperative surgery (Closed-LECS) for gastric GIST

    40th World Congress of the International College of Surgeons  2016 

     More details

  • 胃粘膜下腫瘍に対するClosed-LECS手技の確立と早期胃癌への応用

    2016年度日本消化器関連学会週間(JDDW 2016)  2016 

     More details

  • 一般演題 高齢者手術1

    第46回胃外科・術後障害研究会  2016 

     More details

  • Anastomotic leakage might increase recurrence and median-term mortality after curative resection for esophageal cancer

    40th World Congress of the International College of Surgeons  2016 

     More details

  • Impact of Negative Pressure Wound Therapy for Surgical Site Infection of Crohn’s Disease

    40th World Congress of the International College of Surgeons  2016 

     More details

  • The Utility of Cadaver-Based Approaches for the Surgical Training in Hepatobiliary and Pancreatic Surgery

    40th World Congress of the International College of Surgeons  2016 

     More details

  • Risk Factors for Recurrence in the Remnant Pancreas after Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasms (IPMNs)

    40th World Congress of the International College of Surgeons  2016 

     More details

  • 癌関連線維芽細胞と腫瘍浸潤リンパ球の関連性についてー食道癌手術標本とマウス皮下腫瘍モデルの検討ー

    第29回日本バイオセラピィ学会学術集会総会  2016 

     More details

  • 一般演題3 ウイルス療法、サイトカイン療法、分子標的治療

    第29回日本バイオセラピィ学会学術集会総会  2016 

     More details

  • 胃癌PD-L1発現の予後および再発予測因子としての有用性

    第29回日本バイオセラピィ学会学術集会総会  2016 

     More details

  • 第1部 臨床研究の基礎講座

    日本臨床外科学会・日本外科学会共催 第17回臨床研究セミナー  2016 

     More details

  • 気管浸潤を伴う局所進行食道癌CRT後遺残に対してsalvage手術を施行した一例

    第78回日本臨床外科学会総会  2016 

     More details

  • テロメラーゼ依存性腫瘍融解ウイルス製剤を用いた食道癌に対する集学的治療

    第39回日本分子生物学会年会  2016 

     More details

  • ウイルス製剤の内視鏡的投与によるがん治療

    第21回呼吸器インターベンションセミナー  2016 

     More details

  • Stage 4胃癌の化学療法奏効例に対するconversion surgery

    第78回日本臨床外科学会総会  2016 

     More details

  • 急性胆嚢炎を発症した乳癌胆嚢転移の1例

    第78回日本臨床外科学会総会  2016 

     More details

  • 胆膵領域手術における病理医との連携強化の取り組み

    第78回日本臨床外科学会総会  2016 

     More details

  • 安全で正確な肝切除:ICG 蛍光法によるfusion imagingとSoft凝固付CUSA による肝静脈露出

    第78回日本臨床外科学会総会  2016 

     More details

  • 合併症ゼロを目指した食道癌周術期チーム医療成功のための外科医の役割

    第78回日本臨床外科学会総会  2016 

     More details

  • 肝硬変合併肝細胞癌に対する脾摘の肝機能改善効果

    第78回日本臨床外科学会総会  2016 

     More details

  • 高齢者胃癌治療の検討-根治性と術後QOL の面から-

    第78回日本臨床外科学会総会  2016 

     More details

  • NPWT 療法の予防的使用の有用性と今後の課題

    第78回日本臨床外科学会総会  2016 

     More details

  • 胃粘膜下腫瘍に対するClosed-LECSの治療成績と今後の展望

    第78回日本臨床外科学会総会  2016 

     More details

  • 胃癌外科治療におけるサルコペニアの予後予測因子としての重要性

    第78回日本臨床外科学会総会  2016 

     More details

  • 脾門部の解剖に基づく腹腔鏡下脾温存リンパ節郭清

    第78回日本臨床外科学会総会  2016 

     More details

  • 膵IPMNに対する膵全摘適応について~残膵再発リスク因子解析を用いた検討~

    第78回日本臨床外科学会総会  2016 

     More details

  • 内視鏡手術におけるカダバートレーニングシステムの構築

    第78回日本臨床外科学会総会  2016 

     More details

  • 外頸静脈経路で⾏う安全・確実な中⼼静脈ポート留置術

    第5回血管内留置カテーテル管理研究会  2016 

     More details

  • Update results of a novel assay for the detection of methylated CpGs from sputum to screen patients with lung cancer

    ESMO ASIA 2016  2016 

     More details

  • 高リスク神経芽腫に対するhTERT 標的化腫瘍融解ウイルス療法

    第58回日本小児血液・がん学会学術集会  2016 

     More details

  • 胸腔鏡下食道亜全摘術後に発症した術後リンパ瘻に対し、腹臥位胸腔鏡下胸管結紮術により治療し得た一例

    第29回日本内視鏡外科学会総会  2016 

     More details

  • 腹腔鏡下幽門側胃切除におけるHand-sewn Book-Binding Technique による鏡視下Billroth-I 法再建

    第29回日本内視鏡外科学会総会  2016 

     More details

  • 噴門側胃切除のデメリットを克服する逆流防止弁形成食道残胃吻合

    第29回日本内視鏡外科学会総会  2016 

     More details

  • 腹腔鏡下胃切除術の定型化および若手医師への教育と進行癌への挑戦

    第29回日本内視鏡外科学会総会  2016 

     More details

  • 炎症性腸疾患における経肛門的低侵襲手術(TAMIS)の可能性と有用性

    第29回日本内視鏡外科学会総会  2016 

     More details

  • 胸部食道癌に対する胸腔鏡下手術の短期成績についての検討

    第29回日本内視鏡外科学会総会  2016 

     More details

  • 胃腫瘍に対するClosed-LECSの定型化と展望

    第10回J-CASE(NOTES)研究会  2016 

     More details

  • 食道裂孔ヘルニアに対する積極的手術適応

    第29回日本内視鏡外科学会総会  2016 

     More details

  • 臓器鞘を意識した腹臥位胸腔鏡下上縦隔郭清手技

    第29回日本内視鏡外科学会総会  2016 

     More details

  • The elucidation of the tumor immunosuppression affected by cancer-associated fibroblasts (CAFs) in esophageal cancer

    第75回日本癌学会学術総会  2016 

     More details

  • 根治困難な超進行食道癌に対する胸腔鏡下手術の利点を生かした食道切除術

    第69回日本胸部外科学会定期学術集会  2016 

     More details

  • さらなる微細解剖の理解から目指す定型化鏡視下食道手術 根治性と低侵襲性の共存

    第69回日本胸部外科学会定期学術集会  2016 

     More details

  • 観音開き法による噴門形成術を行った先天性食道狭窄症の1例

    第55回日本小児外科学会中国四国地方会  2016 

     More details

  • 全国腸管不全登録患者データベースにおける成人腸管不全の成人発症例とCarry over症例の比較

    第52回日本移植学会総会  2016 

     More details

  • 胃癌の低侵襲治療と個別化医療

    第30回術後管理研究会  2016 

     More details

  • 癌関連線維芽細胞が食道癌の浸潤と転移に及ぼす影響の検証

    第27回日本消化器癌発生学会総会  2016 

     More details

  • 食道外科における教育

    第69回日本胸部外科学会定期学術集会  2016 

     More details

  • 多発肝転移で発見された原発不明NETG3の1例

    第4回日本神経内分泌腫瘍研究会学術集会  2016 

     More details

  • シンポジウム2 消化器癌の遺伝子異常と抗癌剤や放射線感受性・耐性

    第27回日本消化器癌発生学会総会  2016 

     More details

  • 大腸癌化学療法における最近の知見

    Colorectal Cancer Therapy Summit in Okayama  2016 

     More details

  • 胃癌

    平成28年度第24回日本外科学会生涯教育セミナー(中国・四国地区)  2016 

     More details

  • 食道悪性腫瘍根治術後,D ダイマー測定と術後ルーチンCT 検査が早期診断に有用であった血栓症の3 例

    第91回中国四国外科学会総会  2016 

     More details

  • 食道原発神経内分泌癌(小細胞癌)の5 切除例の検討

    第91回中国四国外科学会総会  2016 

     More details

  • 膵全摘患者に対するインスリンポンプ療法を用いた新たな術後血糖管理 ~膵全摘術の適応拡大を目指して~

    第91回中国四国外科学会総会  2016 

     More details

  • IPMN 切除後再発形式の検討 ~再発形式を踏まえ外科治療方針を再考する~

    第91回中国四国外科学会総会  2016 

     More details

  • 同時性重複癌を有する食道癌症例に対する治療方針

    第91回中国四国外科学会総会  2016 

     More details

  • 腹腔鏡下膵頭十二指腸切除術の実施に向けたcadaver trainingの取り組み

    第23回中国四国内視鏡外科研究会  2016 

     More details

  • 大腸内視鏡検査後に広範な後腹膜気腫を来したdiversion colitis の1 例

    第91回中国四国外科学会総会  2016 

     More details

  • 食道悪性黒色腫の1例

    第91回中国四国外科学会総会  2016 

     More details

  • Multimodality preoperative treatment using the DCF therapy for far advanced esophageal cancer

    40th World Congress of the International College of Surgeons  2016 

     More details

  • Efficacy of PD-L1 as a potential predictive factor for recurrence pattern in gastric cancer

    40th World Congress of the International College of Surgeons  2016 

     More details

  • Rational endoscopic surgery for EGJ tumors combined thoracoscopic and laparoscopic approach

    40th World Congress of the International College of Surgeons  2016 

     More details

  • スポンサードシンポジウム3 日米の腫瘍溶解性ウイルス療法(Oncolytic Virus Immunotherapy)最前線

    第54回日本癌治療学会学術集会  2016 

     More details

  • がん診療ガイドラインの運用実態把握および標準的治療の実施に影響を与える因子の分析

    第54回日本癌治療学会学術集会  2016 

     More details

  • Prediction of salvage liver transplantation for hepatocellular carcinoma recurrence:until when are we tenacious of locoregional therapy?

    40th World Congress of the International College of Surgeons  2016 

     More details

  • Multidisciplinary Therapy with Telomerase-Specific Oncolytic Adenovirus for Human Gastrointestinal Cancer

    第54回日本癌治療学会学術集会  2016 

     More details

  • Hand-sewn Book-Binding Technique を用いた三角吻合による完全鏡視下Billroth-l 法再建

    第15回EGI外科治療研究会  2016 

     More details

  • がん診療ガイドラインのアウトカムの検証

    第54回日本癌治療学会学術集会  2016 

     More details

  • 産官学連携/医工連携/がん特区

    第54回日本癌治療学会学術集会  2016 

     More details

  • 消化器がんに対するテロメラーゼ依存性腫瘍融解ウイルス製剤を用いた集学的治療

    第75回日本癌学会学術総会  2016 

     More details

  • Prediction of prognosis and recurrence pattern based on PDL1 expression in curatively resected gastric cancer

    第75回日本癌学会学術総会  2016 

     More details

  • 自験例から学ぶ転移性小腸腫瘍

    第15回EGI外科治療研究会  2016 

     More details

  • 局所進行食道癌に対する腹臥位胸腔鏡下Salvage手術の工夫

    第15回EGI外科治療研究会  2016 

     More details

  • IDH1/2 およびKRAS 遺伝子の変異ステータスによる肝内胆管癌の層別化

    第75回日本癌学会学術総会  2016 

     More details

  • 転移性大腸癌における治療標的となりうるマイクロRNA の同定

    第75回日本癌学会学術総会  2016 

     More details

  • 炎症性微小環境によって誘導されるEMT の蛍光生細胞イメージングシステム

    第75回日本癌学会学術総会  2016 

     More details

  • 腫瘍融解ウイルス療法による骨肉腫のABC Transporter を介した薬剤耐性の克服

    第75回日本癌学会学術総会  2016 

     More details

  • circulating cell free DNA のメチル化解析による大腸癌化学療法の治療効果判定の診断

    第75回日本癌学会学術総会  2016 

     More details

  • A novel circulating cell free DNA-based assay in colorectal cancer patients during treatment with systematic chemotherapy

    AACR Annual Meeting 2016  2016 

     More details

  • 食道切除術後胃管再建におけるICG 蛍光法による胃管血流評価の有用性

    第71回日本消化器外科学会総会  2016 

     More details

  • 肝胆膵外科手術教育におけるcadaver training の有用性

    第71回日本消化器外科学会総会  2016 

     More details

  • 当院における膵頭十二指腸切除術周術期におけるERAS の取り組み

    第71回日本消化器外科学会総会  2016 

     More details

  • 鉄コントロールによる新規癌幹細胞治療

    第71回日本消化器外科学会総会  2016 

     More details

  • Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer

    第71回日本消化器外科学会総会  2016 

     More details

  • 膵上縁リンパ節郭清における自律神経解剖の役割

    第71回日本消化器外科学会総会  2016 

     More details

  • クローン病術後創における局所陰圧閉鎖療法の適応と今後の方向性

    第71回日本消化器外科学会総会  2016 

     More details

  • 膵全摘患者に対するインスリンポンプ療法を用いた新たな術後血糖管理~膵全摘術の適応拡大を目指して~

    第71回日本消化器外科学会総会  2016 

     More details

  • Multimodality preoperative treatment based on DCF chemotherapy for highly advanced esophageal cancer

    第71回日本消化器外科学会総会  2016 

     More details

  • 食道癌に対する放射線併用ウイルス療法の臨床研究:低用量群(Level 1) の薬理動態解析

    第71回日本消化器外科学会総会  2016 

     More details

  • シンポジウム2Innovation of cell transplantation, tissue engineering and artificial organ -Orthodox & Serendipity-

    第71回日本消化器外科学会総会  2016 

     More details

  • 胃癌個別化治療に向けた腹腔内遊離癌細胞イメージング技術の応用

    第71回日本消化器外科学会総会  2016 

     More details

  • 肝細胞癌切除術後長期成績に対する術前Controlling Nutritional Status(CONUT)Score の意義

    日本外科代謝栄養学会第53回学術集会  2016 

     More details

  • 当科におけるカタバートレーニング運用の実際とその効用

    第71回日本消化器外科学会総会  2016 

     More details

  • 「観音開き法」食道残胃吻合:噴門機能の再構築を目指した形態的・機能的再建法

    第71回日本消化器外科学会総会  2016 

     More details

  • 胃切除後腹腔内膿瘍に対する超音波内視鏡下経胃ドレナージ術

    第91回中国四国外科学会総会  2016 

     More details

  • 再肝切除から肝移植まで、長期生存を目指した肝癌に対する集学的治療戦略

    第91回中国四国外科学会総会  2016 

     More details

  • 腹腔鏡補助下幽門側胃切除術の手技定型化による教育と安全性の担保

    第22回中国四国内視鏡外科研究会  2016 

     More details

  • 当科における微細解剖知識を生かした安全に行うための食道癌鏡視下手術

    第21回中国四国内視鏡外科研究会  2016 

     More details

  • 血液型不適合・術前抗ドナー抗体陽性 生体肝移植の経験

    第34回中国四国臨床臓器移植研究会  2016 

     More details

  • 膵IPMN 切除後残膵再発リスク因子の検討

    第43回日本膵切研究会  2016 

     More details

  • 進行食道癌に対するDCF 療法を軸にした集学的治療戦略

    第91回中国四国外科学会総会  2016 

     More details

  • ランチョンセミナー2 大腸癌治療における最新手術手技と化学療法

    第91回中国四国外科学会総会  2016 

     More details

  • 切除検体の正確な断端評価を目的としたインキングの導入

    第43回日本膵切研究会  2016 

     More details

  • Inhibition of hTERT-positive neuroblastoma malignant phenotype by h TERT-driven oncolytic adenovirus-mediated tumor suppressor p53 transactivation and oncogenic MYCN suppression

    The 22nd Annual Meeting of Japan Society of Gene and Cell Therapy  2016 

     More details

  • Virus-guided fluorescent imaging of pancreatic cancer cells in the peritoneal cavity for an insight into roles of tumor-associated macrophage

    The 22nd Annual Meeting of Japan Society of Gene and Cell Therapy  2016 

     More details

  • Next-Generation Telomelysin: multifunctional telomerase-specific oncolytic adenovirus armed with thewild-type p53 tumor suppressor gene

    The 22nd Annual Meeting of Japan Society of Gene and Cell Therapy  2016 

     More details

  • AMED develops medical arts for patients with rare and undiagnosed diseases

    The 22nd Annual Meeting of Japan Society of Gene and Cell Therapy  2016 

     More details

  • Impairment of KRAS-driven pancreatic cancer growth and invasion by tumor-specific oncolytic adenoviruses

    The 22nd Annual Meeting of Japan Society of Gene and Cell Therapy  2016 

     More details

  • Inhibition of peritoneal dissemination of scirrhous gastric cancer by oncolytic adenovirus-mediated activation of tumor suppressor p53 and suppression of oncogenic receptor tyrosine kinases

    The 22nd Annual Meeting of Japan Society of Gene and Cell Therapy  2016 

     More details

  • IPMN 由来浸潤癌の進展様式と再発形態の検討

    第71回日本消化器外科学会総会  2016 

     More details

  • 生体肝移植ドナー340 例の手術成績

    第71回日本消化器外科学会総会  2016 

     More details

  • リンチ症候群における遺伝子変異の特徴とスクリーニング, PD-1 を含めた治療標的

    第14回日本臨床腫瘍学会学術集会  2016 

     More details

  • 特別講演「pNETの集学的治療 アップデート」

    第5回中国四国消化器希少腫瘍講演会  2016 

     More details

  • 食道ESD後追加手術例と再発後手術例から考える食道ESD後の適切な補助療法

    第91回日本消化器内視鏡学会総会  2016 

     More details

  • 総合司会

    第5回E-Lapセミナー  2016 

     More details

  • 腹腔鏡下噴門側胃切除術、「観音開き法」再建

    第70回手術手技研究会  2016 

     More details

  • 乳児劇症肝炎に対して生体肝移植術を施行した1例

    第42回日本急性肝不全研究会  2016 

     More details

  • Novel HER2-targeted gold nanoparticles; integration of antibody therapy and nanotechnology

    AACR Annual Meeting 2016  2016 

     More details

  • Tumor suppressor p53 reactivation by oncolytic adenovirus reverses chemoresistance in human osteosarcomas

    AACR Annual Meeting 2016  2016 

     More details

  • PD-L1 expression as a predictive factor for recurrence pattern and prognosis in curatively resected gastric cancer

    AACR Annual Meeting 2016  2016 

     More details

  • Clinical significance of SNORA21, an H/ACA box snoRNA, as a metastasis predicting and prognostic biomarker in colorectal cancer

    AACR Annual Meeting 2016  2016 

     More details

  • Virally enhanced p53 reactivation impairs KRAS-driven pancreatic cancer invasion

    AACR Annual Meeting 2016  2016 

     More details

  • Prognostic correlation of tumor-infiltrating lymphocytes (TILs) and cancer associated fibroblasts (CAFs) in patients with human esophageal carcinoma

    AACR Annual Meeting 2016  2016 

     More details

  • Functional analysis of tumor-associated macrophage utilizing virus-guided fluorescent imaging of pancreatic cancer cells in the peritoneal cavity

    AACR Annual Meeting 2016  2016 

     More details

  • Suppression of MYCN-driven neuroblastoma malignant phenotype by telomerase-targeted tumor suppressor p53 transactivation

    AACR Annual Meeting 2016  2016 

     More details

  • PD-1 and PD-L1 expression patterns and DNA mismatch repair status for precision management of patients with gastric cancer

    AACR Annual Meeting 2016  2016 

     More details

  • Comprehensive analysis of intrahepatic cholangiocarcinoma based on viral infections and mutational status in the IDH1/2 and KRAS genes

    AACR Annual Meeting 2016  2016 

     More details

  • Iron control is a novel therapeutic target of cancer stem cells

    AACR Annual Meeting 2016  2016 

     More details

  • Correlation of FAP(fibroblast activation protein)-expressing cancer associated fibroblasts (CAFs) and tumor metastasis in esophageal carcinoma

    AACR Annual Meeting 2016  2016 

     More details

  • A novel live imaging system for inflammation-induced epithelial-mesenchymal transition in colorectal cancers

    AACR Annual Meeting 2016  2016 

     More details

  • Micro RNAs as promising therapeutic targets for anti-metastatic therapy in colorectal cancer

    AACR Annual Meeting 2016  2016 

     More details

  • Genome-wide enhancer analysis identifies PVT1 as an oncogenic enhancer of MYC

    AACR Annual Meeting 2016  2016 

     More details

  • 食道癌術後の縫合不全は再発・予後を増悪させるのか

    第71回日本消化器外科学会総会  2016 

     More details

  • 食道癌術後合併症における積極的造影CT 検査の有用性〜縫合不全の早期発見・軽症化を目指して〜

    第59回関西胸部外科学会学術集会  2016 

     More details

  • 膜を意識した食道癌に対する上縦隔リンパ節郭清 低侵襲性と根治性の共存

    第59回関西胸部外科学会学術集会  2016 

     More details

  • 胃粘膜下腫瘍に対するClosed-LECS

    第105回日本消化器病学会中国支部例会  2016 

     More details

  • 胃癌術後再発病変に対する複数回の放射線療法が奏効し長期生存が得られた1 例

    第38回日本癌局所療法研究会  2016 

     More details

  • 食道癌ESD 後追加治療としての食道根治術症例の検討 - ESD 後再発症例をふまえて-

    第59回関西胸部外科学会学術集会  2016 

     More details

  • 食道癌治療成績向上へ向けて

    日本消化器病学会中国支部第23回教育講演会  2016 

     More details

  • 4つのモノヌクレオチドリピートマーカーを用いたマイクロサテライト不安定性腫瘍検出方法の検討

    第22回日本家族性腫瘍学会学術集会  2016 

     More details

  • 肝細胞癌切除患者におけるsarcopenia が長期予後に及ぼす影響に関する検討

    第28回日本肝胆膵外科学会・学術集会  2016 

     More details

  • 胃癌術後肝転移に対して3rd line のCPT-11 が奏功し長期生存を得た1例

    第38回日本癌局所療法研究会  2016 

     More details

  • 一般演題 食道

    第38回日本癌局所療法研究会  2016 

     More details

  • 右側肝円索・門脈分枝走行異常を伴った進行胆嚢癌切除の経験

    第28回日本肝胆膵外科学会・学術集会  2016 

     More details

  • 再肝切除における根治性確保と合併症軽減に向けた手術手技と工夫

    第28回日本肝胆膵外科学会・学術集会  2016 

     More details

  • von Hippel-Lindau 病に合併した膵NET の治療戦略

    第28回日本肝胆膵外科学会・学術集会  2016 

     More details

  • MGMT Inactivation Arrest Tumor Growth and Serves As a Promising Predictive Biomarker for Treatment Response in Colorectal Cancer

    Digestive Disease Week (DDW) 2016  2016 

     More details

  • 肝内胆管癌に対するリンパ節郭清の意義

    第70回手術手技研究会  2016 

     More details

  • Clinical implications of fluorescence-emitting virus guided peritoneal cytology in gastrointestinal cancer

    The 19th International Congress of Cytology  2016 

     More details

  • Molecular Theranostics for gastrointestinal cancer

    第11回日本分子イメージング学会総会・学術集会  2016 

     More details

  • 「観音開き法」による腹腔鏡下食道残胃吻合

    第70回手術手技研究会  2016 

     More details

  • 当科における食道胃接合部癌に対する術式の進化 完全鏡視下手術の導入

    第70回手術手技研究会  2016 

     More details

  • 腹腔鏡下幽門側胃切除におけるHand-sewn Book Binding Technique によるBillroth-I 法再建

    第70回手術手技研究会  2016 

     More details

  • 生体肝移植術後, SIADH(syndrome of inappropriate secretion of ADH)を発症した一例

    第34回日本肝移植研究会  2016 

     More details

  • 再肝移植症例の特徴と、適応判断および技術的対策

    第34回日本肝移植研究会  2016 

     More details

  • 血液型不適合・術前ドナー抗体陽性 生体肝移植後に肝機能障害が遷延した1例

    第34回日本肝移植研究会  2016 

     More details

  • 小児胆汁うっ帯性肝疾患に対する Mortality zero 生体肝移植

    第34回日本肝移植研究会  2016 

     More details

  • 食道癌術後患者に分粥食は必要か?

    第70回日本食道学会学術集会  2016 

     More details

  • 頭頚部および胸部外科手術後の難治性リンパ漏に対するリンパ管造影の経験

    第70回日本食道学会学術集会  2016 

     More details

  • 食道癌患者の口腔感染管理と咬合回復が周術期の体重変化に影響した可能性のある一症例

    第70回日本食道学会学術集会  2016 

     More details

  • 術前食道がん患者の抑うつ傾向と心理的適応に関する因子

    第70回日本食道学会学術集会  2016 

     More details

  • あきらめない食道癌治療~Oligometastasisへの挑戦~

    第70回日本食道学会学術集会  2016 

     More details

  • 腹臥位胸腔鏡下食道切除術における拡大視効果と術視野共有の利点と成果

    第70回日本食道学会学術集会  2016 

     More details

  • 食道癌に対する放射線併用ウイルス療法の臨床研究の中間報告

    第70回日本食道学会学術集会  2016 

     More details

  • 食道がん周術期チーム医療成功のための外科医の役割

    第70回日本食道学会学術集会  2016 

     More details

  • 4つのモノヌクレオチドリピートマーカーのミスマッチ修復タンパク欠損を伴う大腸癌・子宮体癌スクリーニングの精確性の検討

    第85回大腸癌研究会  2016 

     More details

  • 胃管作製不能例に対する空腸を用いた食道再建術

    第70回日本食道学会学術集会  2016 

     More details

  • 食道胃接合部癌125 例の検討から導かれる最適な手術

    第70回日本食道学会学術集会  2016 

     More details

  • Expert Lecture2 「胃癌周術期化学療法の最前線」

    Gastric Cancer Seminar in Okayama ~みんなで考える胃癌治療の今~  2016 

     More details

  • エベロリムス投与における有害事象の評価 患者と医療者の認識の違い、各職種間における認識の違い

    第24回日本乳癌学会学術総会  2016 

     More details

  • Lynch症候群および家族性大腸腺腫症の系統的遺伝子解析

    第85回大腸癌研究会  2016 

     More details

  • 特別講演2 「福島プロジェクトにおける大腸がんの診療について」

    第4回岡山大腸腫瘍研究会  2016 

     More details

  • TIL関連遺伝子アッセイを用いた化学療法効果予測および予後予測に関する検討

    第24回日本乳癌学会学術総会  2016 

     More details

  • リンパ節転移分布からみた残胃進行癌の治療戦略

    第71回日本消化器外科学会総会  2016 

     More details

  • さらなる微細解剖の理解から目指す鏡視下食道手術根治性と低侵襲性の共存

    第71回日本消化器外科学会総会  2016 

     More details

  • Surgical technique for minimal invasiveness in living donor liver surgery: Knack & Pitfalls

    第71回日本消化器外科学会総会  2016 

     More details

  • 胃管作成不能例に対する空腸を用いた食道再建術における工夫

    第71回日本消化器外科学会総会  2016 

     More details

  • 標的陰性癌に対するPhotoimmunotherapy.抗原修飾による抗原陽転化と不均一性の克服

    第71回日本消化器外科学会総会  2016 

     More details

  • 鏡視下膵頭十二指腸切除実施に向けたCadaver trainingの取組み

    第28回日本内視鏡外科学会総会  2015 

     More details

  • 気管周囲微細解剖に留意した反回神経リンパ節郭清の工夫

    第77回日本臨床外科学会総会  2015 

     More details

  • 腹腔鏡下噴門側胃切除術におけるリンパ節郭清手技の定型化

    第77回日本臨床外科学会総会  2015 

     More details

  • 白血病治療中の骨髄抑制期に発症した急性虫垂炎の1例

    第178回岡山外科会/第1回日本臨床外科学会岡山県支部会  2015 

     More details

  • 高難度手術におけるカダバートレーニングの意義と当科における実際

    第178回岡山外科会/第1回日本臨床外科学会岡山県支部会  2015 

     More details

  • シンポジウム1 消化器領域の腫瘍免疫研究の新展開

    第26回日本消化器癌発生学会総会  2015 

     More details

  • 食道癌術後早期にAeromonas hydrophilaによる壊死性軟部組織感染症を発症した1例

    第178回岡山外科会/第1回日本臨床外科学会岡山県支部会  2015 

     More details

  • 癌関連線維芽細胞を標的とした新規食道癌治療法の開発

    第26回日本消化器癌発生学会総会  2015 

     More details

  • スキルス胃癌に対する腫瘍選択的な癌抑制遺伝子p53遺伝子治療の前臨床評価

    第26回日本消化器癌発生学会総会  2015 

     More details

  • 食道癌におけるFAP(fibroblast activation protein)陽性癌関連線維芽細胞の発現と癌転移の関係

    第26回日本消化器癌発生学会総会  2015 

     More details

  • 腹腔内遊離胃癌細胞の検出と腹膜播種に対する光線免疫療法

    第26回日本消化器癌発生学会総会  2015 

     More details

  • 鉄制御を用いた新しい癌の浸潤・転移抑制治療法の開発

    第26回日本消化器癌発生学会総会  2015 

     More details

  • 大腸癌卵巣転移に対する治療と予後

    第70回日本大腸肛門病学会学術集会  2015 

     More details

  • Stage IV 大腸癌に対する集学的治療戦略の構築

    第70回日本大腸肛門病学会学術集会  2015 

     More details

  • 微小浸潤を認めた膵管内管状腺癌の1例

    第53回日本癌治療学会学術集会  2015 

     More details

  • 噴門機能の再構築を追求した「観音開き法」による食道残胃吻合

    第45回胃外科・術後障害研究会  2015 

     More details

  • 胃4:高齢者胃がんの治療ストラテジー

    第53回日本癌治療学会学術集会  2015 

     More details

  • がん診療ガイドラインのアウトカムの検証

    第53回日本癌治療学会学術集会  2015 

     More details

  • The possibility of biological ablation of lymphatic metastasis for early gastrointestinal cancer patients

    第53回日本癌治療学会学術集会  2015 

     More details

  • 大腸癌ゲノム情報を用いた肝転移治療戦略

    第53回日本癌治療学会学術集会  2015 

     More details

  • 安全で確実な腹腔鏡下肝切除を目指して~開腹肝切除からのKnow-how~

    第28回日本内視鏡外科学会総会  2015 

     More details

  • 腹臥位胸腔鏡下食道切除における偶発症と当科におけるその対策

    第28回日本内視鏡外科学会総会  2015 

     More details

  • 完全体腔内「観音開き法」食道残胃吻合

    第28回日本内視鏡外科学会総会  2015 

     More details

  • 食道癌手術における胸腔鏡手術導入による低侵襲化の検討 -術後超短期評価と長期評価-

    第28回日本内視鏡外科学会総会  2015 

     More details

  • カダバートレーニングにおける指導経験の効用

    第28回日本内視鏡外科学会総会  2015 

     More details

  • Tumor Infiltrating Lymphocytes (TIL) related genomic signature associated with Chemotherapy Response and Prognosis in Subtypes of Breast Cancer

    2015 San Antonio Breast Cancer Symposium  2015 

     More details

  • 逆流防止弁形成食道残胃吻合(観音開き法)

    第28回日本内視鏡外科学会総会  2015 

     More details

  • 食道癌ESD後の手術症例から考えるESD後追加・補助治療のあり方

    第104回日本消化器病学会中国支部例会  2015 

     More details

  • 生体肝移植後8年後の血液透析導入時にサイトメガロウイルスの再活性化を来したC型肝硬変の1例

    第104回日本消化器病学会中国支部例会  2015 

     More details

  • 当院におけるESD非治癒切除症例の検討からみる追加外科切除の意義

    第104回日本消化器病学会中国支部例会  2015 

     More details

  • 特別講演 胃癌における新規治療開発の動向

    第104回日本消化器病学会中国支部例会  2015 

     More details

  • 表在型頭頸部癌の治療成績と重複癌発症についての検討

    第104回日本消化器病学会中国支部例会  2015 

     More details

  • 消化器外科腹部領域のSSIに対する引き寄せと圧着を意識した局所陰圧閉鎖療法の実際

    第45回日本創傷治癒学会  2015 

     More details

  • 次世代のがん治療に向けた探索的創薬研究

    第104回日本消化器病学会中国支部例会  2015 

     More details

  • 第15回臨床研究セミナー 第1部「臨床研究の基礎講座」

    第77回日本臨床外科学会総会  2015 

     More details

  • 腹会陰式直腸切断術の術後会陰感染創に対する局所陰圧閉鎖療法の有用性

    第45回日本創傷治癒学会  2015 

     More details

  • 化学療法にて組織学的CRが得られた切除不能肝内胆管原発小細胞癌の1例

    第77回日本臨床外科学会総会  2015 

     More details

  • あるべき外科系クリニカルクラークシップの実際

    第77回日本臨床外科学会総会  2015 

     More details

  • 合併症ゼロを目指した再建、吻合手術手技(食道・胃)4

    第77回日本臨床外科学会総会  2015 

     More details

  • 肝切除術後難治性胆汁瘻に対し無水エタノール注入によるbiliary ablationが有効であった2例

    第77回日本臨床外科学会総会  2015 

     More details

  • 気管周囲微細解剖に留意した左反回神経リンパ節郭清の工夫

    第28回日本内視鏡外科学会総会  2015 

     More details

  • 進行胃癌に対する審査腹腔鏡のルチーン化と新たな探索的研究

    第28回日本内視鏡外科学会総会  2015 

     More details

  • Cadaver trainingによる腹腔鏡下肝切除の修練

    第28回日本内視鏡外科学会総会  2015 

     More details

  • 胃管作成不能例に対する空腸を用いた食道再建および吻合の工夫

    第77回日本臨床外科学会総会  2015 

     More details

  • A phaseⅠ/Ⅱ study of endoscopic intratumoral administration of a telomerase targeted oncolytic virus, OBP-301, in combination with radiotherapy for esophageal cancer

    第53回日本癌治療学会学術集会  2015 

     More details

  • 胃癌組織におけるPD-L1発現と予後との関連

    第53回日本癌治療学会学術集会  2015 

     More details

  • Trastuzumab-conjugated gold nanoparticles as a novel HER2-targeted therapy

    第53回日本癌治療学会学術集会  2015 

     More details

  • What is the best procedure for T1 tumors of esophago-gastric junction?

    23rd United European Gastroenterology Week  2015 

     More details

  • Novel effects of surgical field exposure and lymph node dissection on recurrent nerve palsy in prone position thoracoscopic esophagectomy

    23rd United European Gastroenterology Week  2015 

     More details

  • 80歳以上超高齢者食道癌症例に対する肺合併症軽減と手術成績向上のための取り組み

    第68回日本胸部外科学会定期学術集会  2015 

     More details

  • 当科で経験した食道類基底細胞癌10切除症例の臨床病理学的検討

    第68回日本胸部外科学会定期学術集会  2015 

     More details

  • 腹腔鏡下肝切除の適応拡大に向けたcadaver trainingの実際

    第13回日本消化器外科学会大会  2015 

     More details

  • 食道癌に対する腹臥位胸腔鏡下食道切除術適応拡大後の工夫

    第68回日本胸部外科学会定期学術集会  2015 

     More details

  • 結腸右半切除を伴う拡大膵頭十二指腸切除術後の再建の工夫

    第13回日本消化器外科学会大会  2015 

     More details

  • 喀痰を用いたCpGのメチル化検出による非侵襲的なスクリーニングの開発

    第74回日本癌学会学術総会  2015 

     More details

  • 当科における表在型頭頸部癌の長期成績と重複癌の検討

    第90回日本消化器内視鏡学会総会  2015 

     More details

  • 分化型胃癌細胞による癌関連線維芽細胞の活性化機構

    第74回日本癌学会学術総会  2015 

     More details

  • 循環Ago2-miRNA検出技術を用いた化学療法効果予測の検証

    第74回日本癌学会学術総会  2015 

     More details

  • ナノ技術と抗体療法の融合による新規HER2標的金ナノ製剤の開発と治療効果の検討

    第74回日本癌学会学術総会  2015 

     More details

  • 胃癌個別化治療に向けた、蛍光ウイルスによる腹腔内遊離胃癌細胞の検出技術の開発

    第74回日本癌学会学術総会  2015 

     More details

  • スキルス胃癌細胞に対する腫瘍特異的p53遺伝子治療の前臨床評価

    第74回日本癌学会学術総会  2015 

     More details

  • 一般口演英語 ドラッグデリバリーシステム・抗がん剤耐性

    第74回日本癌学会学術総会  2015 

     More details

  • ヒト癌細胞におけるEMT可視化生体イメージング技術の開発

    第74回日本癌学会学術総会  2015 

     More details

  • 骨軟部肉腫細胞に対する腫瘍融解ウイルスの放射線増感作用

    第74回日本癌学会学術総会  2015 

     More details

  • 宿主正常細胞である癌関連線維芽細胞を標的とした新たな食道癌治療法の開発

    第36回癌免疫外科研究会  2015 

     More details

  • A novel tumor-specific oncolytic biological therapy against invasive pancreatic cancer

    AACR Annual Meeting 2015  2015 

     More details

  • HLA class I expression in a tumor is higher than that out of a tumor: Promising new findings for antigen-specific cancer immunotherapy

    AACR Annual Meeting 2015  2015 

     More details

  • Preclinical study of telomerase-specific p53 tumor suppressor gene overexpression in human scirrhous gastric cancer cells with different p53 status

    AACR Annual Meeting 2015  2015 

     More details

  • HER2-targeted gold nanoparticles produce potent antitumor effects on human gastric cancer cells

    AACR Annual Meeting 2015  2015 

     More details

  • 胃癌におけるPD-L1発現と予後との検討

    第36回癌免疫外科研究会  2015 

     More details

  • Preclinical evaluation of radiotherapy in combination with radio-sensitizing telomerase-specific oncolytic virus for human bone and soft tissue sarcomas

    AACR Annual Meeting 2015  2015 

     More details

  • Phase I/II trial of endoscopic intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, with radiation in elderly esophageal cancer patients

    AACR Annual Meeting 2015  2015 

     More details

  • Differentiated gastric cancer cells have a potential to induce cancer-associated fibroblasts

    AACR Annual Meeting 2015  2015 

     More details

  • 非機能性HER2抗原で遺伝子修飾したHER2陰性癌細胞に対する分子標的光免疫療法

    第87回日本胃癌学会総会  2015 

     More details

  • HER2陽性進行・再発胃癌に対するTrastuzumabを含む化学療法

    第87回日本胃癌学会総会  2015 

     More details

  • ランチョンセミナー14:胃癌化学療法の新潮流~期待と不安~

    第87回日本胃癌学会総会  2015 

     More details

  • Virus-guided fluorescence imaging of itraperitoneal free gastric cancer cells

    第87回日本胃癌学会総会  2015 

     More details

  • シンポジウム1「高齢化社会に向けたこれからの胃癌治療戦略~治療すべきか経過観察か~」

    第87回日本胃癌学会総会  2015 

     More details

  • BRAF mutation as a selective biomarker for intensive preoperative chemotherapy in stage Ⅳ colorectal cancer

    第48回制癌剤適応研究会  2015 

     More details

  • 3D内視鏡システムを用いた完全体腔内「観音開き法」食道残胃吻合

    第87回日本胃癌学会総会  2015 

     More details

  • 当院におけるESD後遺残・再発症例および非治癒切除症例の検討

    第87回日本胃癌学会総会  2015 

     More details

  • 上部胃癌に対する腹腔鏡下脾温存リンパ節郭清手技の工夫

    第87回日本胃癌学会総会  2015 

     More details

  • Netrin-1 Recepterの Genetic/Epigenetic変異の腫瘍進展による相加的欠損と胃癌の染色体不安定性との関連

    第87回日本胃癌学会総会  2015 

     More details

  • 食道癌術後再建胃管癌症例の検討

    第87回日本胃癌学会総会  2015 

     More details

  • Novel cytological diagnosis of peritoneal wash for gastric cancer by fluorescence-emitting virus TelomeScan

    第115回日本外科学会定期学術集会  2015 

     More details

  • 移植困難症例に対する手技的工夫:無肝期Veno-venous bypass使用による循環安定化の試み

    第115回日本外科学会定期学術集会  2015 

     More details

  • 腹臥位胸腔鏡下食道切除術における適応拡大に伴う術野展開定型化の工夫

    第115回日本外科学会定期学術集会  2015 

     More details

  • 噴門側胃切除術後の再建―空腸間置vs 食道胃吻合―

    第115回日本外科学会定期学術集会  2015 

     More details

  • 超高齢者食道癌手術への取り組みと放射線併用ウイルス療法の可能性

    第115回日本外科学会定期学術集会  2015 

     More details

  • 膵頭十二指腸切除術の手技習得に向けたcadaver trainingの実際

    第115回日本外科学会定期学術集会  2015 

     More details

  • 当科における膵頭十二指腸切除術におけるERAS(術後回復力強化:Enhanced recovery after surgery)の取り組み

    第115回日本外科学会定期学術集会  2015 

     More details

  • シメプレビル加療中に急速進行する肝不全を呈し、再移植にて救命した1例

    第15回京都肝移植周術期研究会学術集会  2015 

     More details

  • 胃癌・食道癌の低侵襲治療と個別化医療の最前線

    赤磐医師会学術講演会  2015 

     More details

  • 総合司会

    第4回E-Lapセミナー  2015 

     More details

  • International Session (7) 「Upper gastrointestinal tract surgery」

    第115回日本外科学会定期学術集会  2015 

     More details

  • Systematic Genomic Characterization of Normal Mucosa, Adenomatous Polyps, and Cancer in Patients With Familial Adenomatous Polyposis

    Digestive Disease Week2015  2015 

     More details

  • 肝腎同時移植の適応と問題点 ―3例の脳死下肝腎同時移植の経験から―

    第33回日本肝移植研究会  2015 

     More details

  • 急性肝不全に対する内科的治療と肝移植の現状

    第33回日本肝移植研究会  2015 

     More details

  • 家族性大腸線腫症におけるデスモイド腫瘍に対するタモキシフェンの有効性の検討

    第21回日本家族性腫瘍学会学術集会  2015 

     More details

  • 家族性大腸線腫症における系統的遺伝子解析

    第22回日本家族性腫瘍学会学術集会  2015 

     More details

  • 次世代シーケンサーによるリンチ症候群の解析

    第24回日本家族性腫瘍学会学術集会  2015 

     More details

  • 特別講演

    第6回岡山大腸がん治療セミナー  2015 

     More details

  • 遺伝子変異解析によるIPMN悪性度診断の新展開

    第27回日本肝胆膵外科学会・学術集会  2015 

     More details

  • 主題3 免疫制御機構Ⅱ

    第36回癌免疫外科研究会  2015 

     More details

  • Inherent Single Nucleotide Variants in the TBX21 Gene As Novel Prognostic Markers in Patients With Pancreatic Ductal & Adenocarcinoma

    Digestive Disease Week2015  2015 

     More details

  • Companion diagnostics-based telomerase-specific oncolytic virotherapy: preclinical evaluation in human colorectal cancer cell lines differentially affected in the RAS/RAF/MEK signaling pathway

    AACR Annual Meeting 2015  2015 

     More details

  • 当院における膵頭十二指腸切除術周術期におけるERAS(術後回復力強化:Enhanced recovery after surgery)プロトコールの取り組み

    第30回日本静脈経腸栄養学会学術集会  2015 

     More details

  • 特別講演

    第11回岡山上部消化管外科懇話会  2015 

     More details

  • 鉄制御を用いた新しいがん治療法の開発

    平成26年度日本消化器癌発生学会特別推進研究「癌の浸潤・転移の新たなメカニズム」発表会  2015 

     More details

  • サルコペニアが高齢胃癌患者の予後に及ぼす影響

    第87回日本胃癌学会総会  2015 

     More details

  • 当科における食道胃接合部癌の治療経験

    第87回日本胃癌学会総会  2015 

     More details

  • Iron control is a novel therapeutic target of cancer stem cells

    The 8th International Symposium for Future Technology Creating Better Human Health and Society  2015 

     More details

  • 鉄コントロールによるがん幹細胞に対する新規治療

    第115回日本外科学会定期学術集会  2015 

     More details

  • 膵癌における外科治療戦略〜先行手術の問題点と術前療法の適応選別〜

    第115回日本外科学会定期学術集会  2015 

     More details

  • 肝細胞癌におけるサイトケラチン19の意義とメチル化の役割

    第115回日本外科学会定期学術集会  2015 

     More details

  • 早期胃癌におけるリンパ節転移データからみた生物学的リンパ節転移アブレーション療法の可能性

    第115回日本外科学会定期学術集会  2015 

     More details

  • 超高齢者(95歳)の進行盲腸癌に対し腹腔鏡下回盲部切除を施行した1例

    第115回日本外科学会定期学術集会  2015 

     More details

  • オピオイドによる悪心・嘔吐に対するオランザピンの有効性の検討

    第115回日本外科学会定期学術集会  2015 

     More details

  • 第14回臨床研究セミナー 第1部「臨床研究の在り方」

    第115回日本外科学会定期学術集会  2015 

     More details

  • A novel photoimmunotherapy targeting cancer-associated fibroblasts (CAFs) overcomes therapeutic resistance in human esophageal cancer

    AACR Annual Meeting 2015  2015 

     More details

  • 膵切除後の残膵腫瘍に対する再膵切除

    第115回日本外科学会定期学術集会  2015 

     More details

  • 生体肝移植後の制御性T細胞とマイクロキメリズムの相関

    第115回日本外科学会定期学術集会  2015 

     More details

  • HER2陰性癌細胞に対するHER2細胞外ドメインによる非機能性HER2抗原遺伝子修飾とTrastuzumabを用いた分子標的光免疫療法を併用した治療戦略

    第115回日本外科学会定期学術集会  2015 

     More details

  • Iron control is a novel therapeutic target of cancer stem cells

    AACR Annual Meeting 2015  2015 

     More details

  • Virus-guided fluorescence imaging of intraperitoneal free gastric cancer cells: a preliminary clinical study as a potential clinical biomarker

    AACR Annual Meeting 2015  2015 

     More details

  • 腹壁子宮内膜症の1手術例

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • 膵癌術後局所再発に対し腹腔動脈合切尾側膵切除にて再膵切除可能であった一例

    第46回日本膵臓学会大会  2015 

     More details

  • 鉄制御を応用した新たな食道癌治療法の開発

    第58回関西胸部外科学会学術集会  2015 

     More details

  • New technique of esophgogastrostomy using double gastric seromuscular flaps for prevention of postoperative gastroesophageal reflux

    16th Congress of the European Paediatric Surgeons' Association  2015 

     More details

  • 再使用可能なシリコンレプリカ膵臓を用いた膵管空腸吻合を用いた吻合トレーニングモデルの開発

    第27回日本肝胆膵外科学会・学術集会  2015 

     More details

  • 肝内胆管癌の外科治療~リンパ節郭清結果を踏まえ手術戦略を見直す~

    第27回日本肝胆膵外科学会・学術集会  2015 

     More details

  • 腹腔鏡下肝嚢胞開窓術のポイント

    第27回日本肝胆膵外科学会・学術集会  2015 

     More details

  • 難治性手術部位感染に対する局所陰圧閉鎖療法の工夫

    第27回日本肝胆膵外科学会・学術集会  2015 

     More details

  • 当院における十二指腸乳頭部腺腫/早期癌に対する治療成績

    第27回日本肝胆膵外科学会・学術集会  2015 

     More details

  • 胆管拡張を伴わない胆管内乳頭状腫瘍(IPNB)由来肝内胆管癌の1例

    第27回日本肝胆膵外科学会・学術集会  2015 

     More details

  • 保全的加療にて軽快した食道癌術後気管穿孔の2例

    第58回関西胸部外科学会学術集会  2015 

     More details

  • 食道癌手術における術前後筋肉量変化の検討-鏡視下手術がより体に優しいか?

    第58回関西胸部外科学会学術集会  2015 

     More details

  • リポソームを用いたテロメラーゼ特異的全身ウイルス療法の可能性

    第31回日本DDS学会学術集会  2015 

     More details

  • 当院における膵頭十二指腸切除術周術期ERASプロトコールの有効性に関する臨床試験の取組み

    日本外科代謝栄養学会第52回学術集会  2015 

     More details

  • 金ナノ粒子を用いたHER2標的抗体療法:新標的化技術の応用

    第31回日本DDS学会学術集会  2015 

     More details

  • 消化器がんの低侵襲治療と個別化医療の最前線

    尾道市立市民病院がん診療統括部学術講演会  2015 

     More details

  • 特別講演「新時代の胃癌手術」

    第5回岡山手術手技ビデオフォーラム  2015 

     More details

  • 当科における腹臥位胸腔鏡下食道手術200例の総括

    第69回日本食道学会学術集会  2015 

     More details

  • 胃管作成不能例に対する至適再建の検討 手術侵襲とQOLを考慮した空腸再建の有用性

    第69回日本食道学会学術集会  2015 

     More details

  • 迅速果断な術後合併症対応を目指して~術後3日目造影CT検査の有用性~

    第69回日本食道学会学術集会  2015 

     More details

  • Y字胃管を用いた食道バイパス術8例の経験―食道ステントと比較して優位性は?―

    第69回日本食道学会学術集会  2015 

     More details

  • 多視点3D解剖システムを用いた臨床教育

    第69回日本食道学会学術集会  2015 

     More details

  • 肝胆膵外科領域における周術期栄養管理1

    日本外科代謝栄養学会第52回学術集会  2015 

     More details

  • Plenary Session

    The 21st Annual Meeting of the Japan Society of Gene Therapy  2015 

     More details

  • Phase I/II trial of endoscopic intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, with radiation in esophageal cancer patients

    The 21st Annual Meeting of the Japan Society of Gene Therapy  2015 

     More details

  • Preclinical evaluation of tumor-specific oncolytic virotherapy against pancreatic cancer cells with different invasion ability

    The 21st Annual Meeting of the Japan Society of Gene Therapy  2015 

     More details

  • RADIOSENSITIZATION OF BONE AND SOFT TISSUE SARCOMA CELLS BY TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS

    The 21st Annual Meeting of the Japan Society of Gene Therapy  2015 

     More details

  • Preclinical evaluation of tumor-specific oncolytic virotherapy against human colorectal cancer cells with different KRAS/BRAF mutation and microsatellite stability

    The 21st Annual Meeting of the Japan Society of Gene Therapy  2015 

     More details

  • 腫瘍特異的蛍光発現 virus 試薬による腹腔洗浄液中の遊離胃癌細胞診断の臨床的意義

    第70回日本消化器外科学会総会  2015 

     More details

  • 膵神経内分泌腫瘍の Dynamic CT 画像所見についての検討

    第70回日本消化器外科学会総会  2015 

     More details

  • 切除血行再建により治癒した固有肝動脈瘤の1例

    第70回日本消化器外科学会総会  2015 

     More details

  • 企画関連口演1「大腸腫瘍と遺伝・遺伝子」

    第70回日本消化器外科学会総会  2015 

     More details

  • ワークショップ2「早期食道胃接合部癌に対する治療戦略」

    第70回日本消化器外科学会総会  2015 

     More details

  • 特別講演 座長

    Gastric Cancer Symposium in 岡山  2015 

     More details

  • 消化器がんのMolecular Theranostics:分子イメージングと治療の融合

    TRCシリーズセミナー&第60回分子病態医学合同セミナー  2015 

     More details

  • 膵頭十二指腸切除術における周術期管理の標準化:安全性を担保して治療成績を改善するために何が必要か?

    第42回日本膵切研究会  2015 

     More details

  • 上腸間膜動脈周囲神経叢浸潤という稀な進展形式を来した横行結腸癌局所再発の1例

    第42回日本膵切研究会  2015 

     More details

  • Cadaver trainingによる膵頭十二指腸切除術の手術教育

    第42回日本膵切研究会  2015 

     More details

  • 肝移植後肝癌再発に対する治療成績

    第33回中国四国臨床臓器移植研究会  2015 

     More details

  • 消化器がんの低侵襲治療と個別化医療

    第13回中海消化器懇話会  2015 

     More details

  • Preclinical evaluation of telomerase-specific p53 tumor suppressor gene overexpression in human scirrhous gastric cancer cells with different p53 status

    The 21st Annual Meeting of the Japan Society of Gene Therapy  2015 

     More details

  • VIRUS-GUIDED FLUORESCENCE IMAGING OF INTRAPERITONEAL FREE GASTRIC CANCER CELLS

    The 21st Annual Meeting of the Japan Society of Gene Therapy  2015 

     More details

  • ウイルスでがんを見て治す!

    第21回日本遺伝子治療学会学術集会 市民公開講座  2015 

     More details

  • 特別講演

    第3回岡山大腸腫瘍研究会  2015 

     More details

  • 次代に紡ぐ外科の臨床と研究

    大阪大学外科学講座同窓会平成27年度総会  2015 

     More details

  • 直腸肛門部悪性黒色腫に対し, 3rd line に Nivolumab を導入した1例

    第70回日本消化器外科学会総会  2015 

     More details

  • 噴門側胃切除 + 観音開き法再建の術後QOLに及ぼす影響

    第70回日本消化器外科学会総会  2015 

     More details

  • 再肝切除における根治性確保と合併症軽減に向けた工夫

    第70回日本消化器外科学会総会  2015 

     More details

  • 大腸癌卵巣転移に対する外科治療の検討

    第83回大腸癌研究会  2015 

     More details

  • HLA class I expression in and out of a tumor:Promising new findings for antigen-specific cancer immunotherapy

    International Conference of Cancer Immunotherapy and Macrophages 2015  2015 

     More details

  • 主題関連演題S-I-2

    第37回日本癌局所療法研究会  2015 

     More details

  • DCF vs. CF ~StageⅡ/Ⅲ食道癌100例の検討~

    第70回日本消化器外科学会総会  2015 

     More details

  • 当院における家族性大腸腺腫症に合併したデスモイド腫瘍の治療と予後

    第70回日本消化器外科学会総会  2015 

     More details

  • 当院における胃GIST手術症例の検討

    第70回日本消化器外科学会総会  2015 

     More details

  • ターナー症候群に合併した若年性進行大腸癌の1例

    第70回日本消化器外科学会総会  2015 

     More details

  • 80歳以上超高齢者食道癌症例に対する安全な外科治療と手術成績向上のための取り組み

    第70回日本消化器外科学会総会  2015 

     More details

  • 腹臥位胸腔鏡下食道切除術における反回神経麻痺を起こさない術野展開と郭清の工夫

    第70回日本消化器外科学会総会  2015 

     More details

  • 膵臓癌切除患者における sarcopenia が長期予後に及ぼす影響に関する検討

    第70回日本消化器外科学会総会  2015 

     More details

  • Closed LECS 手術手技のコツとピットフォール

    第70回日本消化器外科学会総会  2015 

     More details

  • 生体肝移植の更なる発展を目指して~技術革新と手術戦略による移植予後の向上~

    第70回日本消化器外科学会総会  2015 

     More details

  • 潰瘍性大腸炎における緊急手術症例の検討

    第70回日本消化器外科学会総会  2015 

     More details

  • 早期胃癌に対する遺伝子改変ウイルスを用いたリンパ節転移アブレーションによる低侵襲治療の開発

    第70回日本消化器外科学会総会  2015 

     More details

  • 食道癌に対する放射線併用ウイルス療法の臨床研究:レベル1投与量群の中間報告

    第70回日本消化器外科学会総会  2015 

     More details

  • 食道胃接合部手術に対する胸腔内観音開き法再建の検討

    第70回日本消化器外科学会総会  2015 

     More details

  • 当科における食道憩室手術症例の検討

    第70回日本消化器外科学会総会  2015 

     More details

  • 消化器外科内視鏡手術教育におけるカダバートレーニングの有用性

    第70回日本消化器外科学会総会  2015 

     More details

  • 当科における cT1 食道胃接合部癌に対する治療戦略

    第70回日本消化器外科学会総会  2015 

     More details

  • 食道癌に対する放射線併用ウイルス療法の臨床研究

    第74回日本癌学会学術総会  2015 

     More details

  • 遊走能・浸潤能を有する膵臓癌細胞に対する新たな腫瘍融解ウイルス療法の開発

    第74回日本癌学会学術総会  2015 

     More details

  • KRAS/BRAF変異を持つ大腸癌に対する新たな腫瘍融解ウイルス療法の開発

    第74回日本癌学会学術総会  2015 

     More details

  • 治療耐性食道癌に対する新規CAF標的療法

    第74回日本癌学会学術総会  2015 

     More details

  • 鉄コントロールによる新規がん幹細胞治療

    第74回日本癌学会学術総会  2015 

     More details

  • 遺伝性大腸癌における系統的遺伝子解析

    第74回日本癌学会学術総会  2015 

     More details

  • 骨肉腫に対するドキソルビシンとp53発現腫瘍融解アデノウイルス製剤の併用療法

    第74回日本癌学会学術総会  2015 

     More details

  • 早期消化管がんに対する新規リンパ節転移治療の可能性

    第74回日本癌学会学術総会  2015 

     More details

  • 特別講演

    第8回大腸がん分子標的薬治療研究会  2015 

     More details

  • 肝移植術前管理と肝移植後の難治性腹水におけるトルバプタンの有効性

    第51回日本移植学会総会  2015 

     More details

  • Intrahepatic arterioportal fistulaに伴う門脈圧亢進症に対して脳死肝移植術を施行した1例

    第51回日本移植学会総会  2015 

     More details

  • 血中のcirculating cell-freeDNAのメチル化検出による大腸癌の同定

    第74回日本癌学会学術総会  2015 

     More details

  • 進行胃癌に対する腹腔鏡手術、D2郭清の定型化と成績

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • 噴門側胃切除後のQOL低下防止を目指した「観音開き法」食道残胃吻合

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • 内視鏡外科教育における施設連携の重要性

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • 保全的加療にて軽快した食道癌術後気管穿孔の2例

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • 腹臥位胸腔鏡下食道亜全摘により経口摂取が可能となった,食道アカラシア術後40 年経過後の食道拡張症,下部食道狭窄の1 例

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • 当院における残胃癌症例の検討

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • 進行胃癌に対する当院の審査腹腔鏡の現状

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • ランチョンセミナー1「外科医が行う進行再発胃癌化学療法-SOX承認をふまえた最新の話題-」

    第90回中国四国外科学会総会  2015 

     More details

  • 臓器移植の現状と展望:肝移植

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • 当院における進行胃癌に対する術前化学療法の現状

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • 進行食道癌に対する治療戦略

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • pNETの外科治療方針~外科切除40症例の検討から至適術式を再考する~

    第3回日本神経内分泌腫瘍研究会  2015 

     More details

  • Opening Remarks

    サイラムザ発売記念講演会in岡山  2015 

     More details

  • 胃癌に対する低侵襲治療と個別化医療

    第26回腫瘍セミナー  2015 

     More details

  • Non invasive detection of methylated CpGs from sputum can predict patiets with lung cancer

    The European Cancer Congress 2015  2015 

     More details

  • Systematic genetic analysis of familial adenomatous polyposis and lynch syndrome

    The European Cancer Congress 2015  2015 

     More details

  • Detection of circulating Ago2-miRNAs predict tumor response to anti-tumor therapies

    The European Cancer Congress 2015  2015 

     More details

  • 肝臓移植における血管吻合とくに非顕微鏡的肝動脈再建と肝静脈・下大静脈置換の手技

    第51回日本移植学会総会  2015 

     More details

  • 移植医療人の役割分担と協調はどうあるべきか:外科医、内科医、コーディネーターの関係

    第51回日本移植学会総会  2015 

     More details

  • 術前診断が困難であった多発性脾血管腫の一例

    第90回中国四国外科学会総会・第20回中国四国内視鏡外科研究会  2015 

     More details

  • 特別講演3「癌幹細胞を標的とした治療戦略」

    第90回中国四国外科学会総会  2015 

     More details

  • A novel photodynamic therapy with virus-mediated delivery of photosensitive cytotoxic fluorescent protein KillerRed for human cancers

    2014 Annual Meeting of the American Association for Cancer Research  2014 

     More details

  • Cetuximabを用いたSequential Approach

    第6回大腸がん分子標的薬治療研究会  2014 

     More details

  • 進行食道癌狭窄症例に対する術前栄養管理 --経鼻胃管からPEGへの変遷--

    第29回日本静脈経腸栄養学会学術集会  2014 

     More details

  • 胸部食道癌周術期栄養管理の検討

    第29回日本静脈経腸栄養学会学術集会  2014 

     More details

  • 高リスク症例に対する腹腔鏡下胃切除術と開腹胃切除の短期成績に関する比較検討

    第86回日本胃癌学会総会  2014 

     More details

  • 当院におけるLECSの工夫--Closed LECSの可能性 --

    第86回日本胃癌学会総会  2014 

     More details

  • ESD/EMR非治癒切除後の外科切除症例の検討

    第86回日本胃癌学会総会  2014 

     More details

  • 消化器がんの低侵襲治療と個別化医療

    第35回長崎DOCCフォーラム  2014 

     More details

  • 直腸癌術後肺再発に対するCTガイド下経皮的ラジオ波焼灼の短期・長期成績の検討

    第80回大腸癌研究会  2014 

     More details

  • 消化器がんの低侵襲治療と個別化医療

    熊本外科治療講演会  2014 

     More details

  • 消化器がんの低侵襲治療と個別化医療

    第61回弘前癌治療懇話会  2014 

     More details

  • テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌に対する低侵襲治療の開発

    第114回日本外科学会定期学術集会  2014 

     More details

  • 膵頭十二指腸切除後の完全膵外瘻に対する非手術的内瘻化

    第114回日本外科学会定期学術集会  2014 

     More details

  • HER2陽性進行再発胃癌に対するTrastuzumabの使用経験とその有効性について

    第114回日本外科学会定期学術集会  2014 

     More details

  • 膵頭十二指腸切除症例における創部SSI危険因子の検討〜術前胆道ドレナージの合併症〜

    第114回日本外科学会定期学術集会  2014 

     More details

  • がん関連繊維芽細胞(Cancer Associated Fibroblasts)を標的とした新規癌治療法の開発

    第114回日本外科学会定期学術集会  2014 

     More details

  • 若手優秀演題賞(3)「消化管」

    第114回日本外科学会定期学術集会  2014 

     More details

  • 外科を志す研修医教育に対する多視点多層三次元解剖教材の活用

    第114回日本外科学会定期学術集会  2014 

     More details

  • HER2陰性胃癌におけるウイルスベクターを用いたHER2標識化とそれに対する分子標的光免疫療法

    第86回日本胃癌学会総会  2014 

     More details

  • Treatment strategy on the basis of risk analysis for small-for-size syndrome and acute renal injury after living donor liver transplantation

    第114回日本外科学会定期学術集会  2014 

     More details

  • 食道癌周術期における外科医の負担軽減に対しチーム医療が果たした役割

    第114回日本外科学会定期学術集会  2014 

     More details

  • 温阻血再灌流+肝切除モデルにおけるHMGB1制御による再灌流障害および肝再生への影響解析

    第114回日本外科学会定期学術集会  2014 

     More details

  • 肝細胞癌におけるサイトケラチン19の発現とメチル化の意義

    第51回日本肝癌研究会  2014 

     More details

  • 腹臥位胸腔鏡下食道切除術における合併症予防対策と術中トラブルに対する対応

    第57回関西胸部外科学会学術集会  2014 

     More details

  • 術前DCF療法が著効した食道原発内分泌細胞癌の1切除術

    第57回関西胸部外科学会学術集会  2014 

     More details

  • 食道再建における胸腔内食道胃管観音開き法の工夫

    第57回関西胸部外科学会学術集会  2014 

     More details

  • 腹臥位胸腔鏡下手術による食道癌手術の低侵襲化と呼吸器合併症軽減への取り組み

    第57回関西胸部外科学会学術集会  2014 

     More details

  • 空腸を用いた食道再建おけるマイクロサージェリーの適応とその工夫

    第39回日本外科系連合学会学術集会  2014 

     More details

  • Assistant-based standardization of prone position thoracoscopic esophagectomy

    14th World Congress of Endoscopic Surgery  2014 

     More details

  • New teaching materials of three dimentional anatomical images

    14th World Congress of Endoscopic Surgery  2014 

     More details

  • 一般演題(口演)(12)「幹細胞」

    第35回癌免疫外科研究会  2014 

     More details

  • 肝移植後肝癌再発に対する集学的治療

    第50回日本肝癌研究会  2014 

     More details

  • HER2細胞外ドメインに対する分子標的光免疫療法

    第35回癌免疫外科研究会  2014 

     More details

  • FDG-PET/CTで再発大腸癌を疑った腹腔内腫瘍の一切除例

    第36回日本癌局所療法研究会  2014 

     More details

  • 一般演題「胃9」

    第36回日本癌局所療法研究会  2014 

     More details

  • 消化器がん治療における臨床研究と個別化医療

    平成26年度第2回鶴翔会高知県支部総会  2014 

     More details

  • 消化器がん治療における臨床研究と個別化医療

    四国がんセンター 第10回臨床研究セミナーフォーラム「臨床研究中核病院整備事業:岡山大学」  2014 

     More details

  • 安全・確実な腹腔鏡下肝切除~開腹肝切除からのKnow-how~

    第5回 岡山手術手技ビデオフォーラム  2014 

     More details

  • 肝癌に対する生体肝移植intention to treat(移植前肝癌治療)は移植成績のリスク因子か?

    第32回日本肝移植研究会  2014 

     More details

  • 生体肝移植におけるリスク因子としての高齢ドナーと背景疾患との関連性

    第32回日本肝移植研究会  2014 

     More details

  • 大腸癌肺再発に対するCTガイド下RFAの短期・長期成績の検討

    第36回日本癌局所療法研究会  2014 

     More details

  • 化学療法後に切除しpCRを得たStage4胃癌の2例

    第36回日本癌局所療法研究会  2014 

     More details

  • 術前補助化学療法後切除によりpCRが得られた高度進行胃癌の1例

    第36回日本癌局所療法研究会  2014 

     More details

  • 大腸癌におけるprognostic factorとしてのmiRNA

    第114回日本外科学会定期学術集会  2014 

     More details

  • 舌海綿状リンパ管種に対するラジオ波焼灼術

    第114回日本外科学会定期学術集会  2014 

     More details

  • 生体肝移植患者におけるItraconazoleの真菌感染症予防効果の検討

    第114回日本外科学会定期学術集会  2014 

     More details

  • 肝臓癌における除鉄併用分子標的薬治療の可能性

    第114回日本外科学会定期学術集会  2014 

     More details

  • 遺伝子変異情報を用いた直腸癌局所再発症例に対する治療戦略の検討

    第114回日本外科学会定期学術集会  2014 

     More details

  • ロボット支援下噴門側胃切除術後のロボットによる体腔内手縫い食道残胃吻合

    第114回日本外科学会定期学術集会  2014 

     More details

  • 術前診断に難渋した原発性小腸癌の1例

    第114回日本外科学会定期学術集会  2014 

     More details

  • Combination therapy of telomerase-specific oncolytic adenovirus and zoledronic acid in human osteosarcoma cells

    2014 Annual Meeting of the American Association for Cancer Research  2014 

     More details

  • 大腸癌肺転移に対するCTガイド下経皮的ラジオ波焼却の短期・長期成績の検討

    第114回日本外科学会定期学術集会  2014 

     More details

  • 高度狭窄を伴う進行食道癌患者におけるPEGを用いた術前栄養管理の効果--術前後筋肉量変化に着目して--

    第114回日本外科学会定期学術集会  2014 

     More details

  • 幹細胞癌におけるサイトケラチン19の発現とメチル化の意義

    第114回日本外科学会定期学術集会  2014 

     More details

  • Novel combination therapy of adenoviral gene transfer of HER2-extracellular domain and trastuzumab-based photoimmunotherapy for HER2 negative cancer cells

    2014 Annual Meeting of the American Association for Cancer Research  2014 

     More details

  • Iron chelation therapy increased the anticancer effect of sorafenib in hepatocarcinoma

    2014 Annual Meeting of the American Association for Cancer Research  2014 

     More details

  • Combination strategy of endoscopic resection and telomerase-targeting oncolytic virus for eradicating lymph node metastasis of submucosal invasive colorectal cancer

    2014 Annual Meeting of the American Association for Cancer Research  2014 

     More details

  • Virus-guided fluorescence imaging of intraperitoneal free gastric cancer cells as a potential clinical biomarker

    2014 Annual Meeting of the American Association for Cancer Research  2014 

     More details

  • 食道癌の狭窄による経口摂取困難症例に対するPEGを用いた術前管理の利点

    第87回日本消化器内視鏡学会総会  2014 

     More details

  • 大腸癌肝転移に対する再肝切除~根治性確保と合併症軽減に向けた工夫~

    第68回手術手技研究会  2014 

     More details

  • 食道胃接合部癌に対する胸腔内食道胃管吻合「観音開き法」の有用性

    第68回手術手技研究会  2014 

     More details

  • 慢性炎症に伴う一酸化窒素生成はヒト大腸腺腫細胞から大腸癌細胞を誘導する

    第14回日本NO学会学術集会  2014 

     More details

  • Telomerase-dependent oncolytic adenovirus sensitizes human osteosarcoma cells to chemotherapy through Mcl-1 downregulation

    2014 Annual Meeting of the American Association for Cancer Research  2014 

     More details

  • Development of systemically-deliverable telomerase-specific oncolytic adenovirus

    2014 Annual Meeting of the American Association for Cancer Research  2014 

     More details

  • 生体肝移植患者におけるItraconazoleの長期内服による真菌感染症予防効果、安全性の検討

    第32回日本肝移植研究会  2014 

     More details

  • 当科におけるバレット食道表在癌の治療経験

    第68回日本食道学会学術集会  2014 

     More details

  • 空腸を用いた食道再建術の手技と成績

    第89回中国四国外科学会総会  2014 

     More details

  • 右側大動脈弓の破格を伴う下咽頭癌術後難治性リンパ漏に対し左胸腔アプローチによる腹臥位胸腔鏡下胸管結紮術にて治癒し得た一例

    第89回中国四国外科学会総会  2014 

     More details

  • 小児領域における噴門形成術の検討

    第89回中国四国外科学会総会  2014 

     More details

  • 当科におけるY字胃管を用いた食道バイパス手術の6例

    第89回中国四国外科学会総会  2014 

     More details

  • 腹腔鏡下肝嚢胞開窓術におけるピットフォールとトラブルシューティング

    第19回中国四国内視鏡外科研究会  2014 

     More details

  • 胃癌に対する幽門側胃切除術における腹腔鏡下手術の低侵襲性

    第19回中国四国内視鏡外科研究会  2014 

     More details

  • HER2陽性胃癌に対するS-1+docetaxel+trastuzumabの治療経験

    第89回中国四国外科学会総会  2014 

     More details

  • 臨床病期Ⅱ&Ⅲ直腸癌の遺伝子変異情報及び臨床病理学的所見と予後の検討

    第52回日本癌治療学会学術集会  2014 

     More details

  • HER2陽性胃癌に対するtrastuzumabを含む化学療法施行症例の解析

    第52回日本癌治療学会学術集会  2014 

     More details

  • International Symposium 04 「The Future of Cancer Therapy -Translational Approaches Targeting for Anti-cancer Therapy-」

    第52回日本癌治療学会学術集会  2014 

     More details

  • ランチョンセミナー3「プロバイオティックスの可能性と課題」

    第89回中国四国外科学会総会  2014 

     More details

  • 生体肝移植における人工血管の使用経験

    第50回日本移植学会総会  2014 

     More details

  • 肝腎同時移植の2症例

    第50回日本移植学会総会  2014 

     More details

  • Risk analysis for small-for-size syndrome and acute renal injury after living donor liver transplantation

    14th Congress of the Middle East Society for Organ Transplantation  2014 

     More details

  • Risk factors for invasive fungal infection after living donor liver transplantation : impact of meld score and acute renal injury

    14th Congress of the Middle East Society for Organ Transplantation  2014 

     More details

  • 消化器がん克服を目指した探索的医療開発

    第10回神戸がん研究会  2014 

     More details

  • 消化器がんにおける遺伝子改変ウイルスを用いたセンチネルリンパ節転移アブレーション

    第16回SNNS研究会学術集会  2014 

     More details

  • 膵神経内分泌腫瘍のCT画像所見とWHO分類との相関に対する検討

    第2回日本神経内分泌腫瘍研究会学術集会  2014 

     More details

  • ホルモン受容体陽性乳がんに対する術前短期ホルモン剤投与による遺伝子マーカーの変化とその生物学的影響

    第11回日本乳癌学会中国四国地方会  2014 

     More details

  • 当科における腹臥位食道切除の際のトラブルシューティング

    第19回中国四国内視鏡外科研究会  2014 

     More details

  • 固形癌に対する除鉄誘導による血管新生阻害薬併用療法の確立

    第38回日本鉄バイオサイエンス学会学術集会  2014 

     More details

  • 消化器がん治療の最前線:低侵襲治療と個別化医療

    第133回山口県医師会生涯研修セミナー  2014 

     More details

  • Liposome-based delivery system of telomerase-specific oncolytic adenoviral plasmid DNA

    第20回日本遺伝子治療学会学術集会  2014 

     More details

  • Novel combination therapy of adenoviral gene transfer of HER2-extracellular domain and trastuzumab-based photoimmunotherapy for HER2 negative gastric cancer cells

    第20回日本遺伝子治療学会学術集会  2014 

     More details

  • Virus-mediated delivery system of photosensitive cytotoxic fluorescent protein Killer Red in novel photodynamic therapy for human cancers

    第20回日本遺伝子治療学会学術集会  2014 

     More details

  • Combination effect of telomerase-specific oncolytic adenovirus and zoledronic acid in human osteosarcoma cells

    第20回日本遺伝子治療学会学術集会  2014 

     More details

  • Virus-guided fluorescence imaging of intraperitoneal gastric cancer cells as an alternative to cytology

    第20回日本遺伝子治療学会学術集会  2014 

     More details

  • 局所進行直腸癌に対する術前放射線化学療法CapeOx RTの有効性・安全性の検討

    第69回日本消化器外科学会総会  2014 

     More details

  • 高齢者胃癌(80歳以上)に対する根治手術の治療成績

    第69回日本消化器外科学会総会  2014 

     More details

  • 企画関連口演11「消化器癌の基礎研究3」

    第69回日本消化器外科学会総会  2014 

     More details

  • 外科専門教育における献体を使用した臨床応用解剖実習および多視点多層解剖映像の有用性

    第46回日本医学教育学会大会 in Wakayama  2014 

     More details

  • マイクロRNAプロセシング因子の制御による腫瘍溶解性アデノウイルスの機能向上

    第30回日本DDS学会学術集会  2014 

     More details

  • リポソームを用いた全身投与可能なテロメラーゼ特異的腫瘍融解ウイルス製剤の開発

    第30回日本DDS学会学術集会  2014 

     More details

  • Somatic mutation profiling in the RAS-RAF signal cascade: Promising predictive markers for extra-hepatic spreading in colorectal liver metastases

    The 52nd Annual Meeting of JSCO, 2014  2014 

     More details

  • Colitic cancerおよびhigh grade dysplasiaを合併した潰瘍性大腸炎の臨床病理学的検討

    第52回日本癌治療学会学術集会  2014 

     More details

  • 切除可能高リスク直腸癌に対する術前CapeOX+RTの安全性・有効性の検討

    第52回日本癌治療学会学術集会  2014 

     More details

  • 膵臓癌切除患者におけるSarcopeniaの存在とその意義に関する検討

    第52回日本癌治療学会学術集会  2014 

     More details

  • 腫瘍縮小にて膵頭十二指腸切除術を回避できた膵Solid-pseudopapillary neoplasmの1例

    第52回日本癌治療学会学術集会  2014 

     More details

  • 化学療法後切除により組織学的完全奏効が得られた高度進行胃癌の3例

    第52回日本癌治療学会学術集会  2014 

     More details

  • Plenary Session I

    第20回日本遺伝子治療学会学術集会  2014 

     More details

  • 当科における鏡視下膵切除の段階的導入

    第41回日本膵切研究会  2014 

     More details

  • 膵頭十二指腸切除後の完全膵外瘻に対するリカバリーショット

    第41回日本膵切研究会  2014 

     More details

  • 小児生体肝移植後ステロイド抵抗性急性拒絶反応に対するサイモグロブリンの使用経験

    第32回中国四国臨床臓器移植研究会  2014 

     More details

  • 生体肝移植における後区域グラフトの有用性

    第32回中国四国臨床臓器移植研究会  2014 

     More details

  • 腹臥位胸腔鏡下食道切除術がもたらしたもの

    第67回日本胸部外科学会定期学術集会  2014 

     More details

  • 喉頭温存を目指した頸胸境界部食道癌に対する集学的治療の現況

    第67回日本胸部外科学会定期学術集会  2014 

     More details

  • Closed LECSの臨床応用と成績

    第8回J-CASW(NOTES)研究会  2014 

     More details

  • 肝移植周術期管理におけるトルバプタンの有用性

    肝疾患のトータルマネージメントを考える会  2014 

     More details

  • ロボット支援下胃切除術における郭清と体腔内手縫い吻合

    第27回日本内視鏡外科学会総会  2014 

     More details

  • 腹臥位胸腔鏡下食道切除術の栄養学的評価の検討

    第27回日本内視鏡外科学会総会  2014 

     More details

  • 岡山大学病院における安全な鏡視下膵切除の段階的導入

    第27回日本内視鏡外科学会総会  2014 

     More details

  • Cytokeratin 19, a novel prognostic biomarker for hepatocellular carcinoma, is regulated by DNA methylation

    ESMO 2014 Congress  2014 

     More details

  • Extensive methylation of epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) promoter could predict malignant formation in intraductal papillary mucinous neoplasms (IPMN)

    ESMO 2014 Congress  2014 

     More details

  • 低肺機能合併食道癌患者に対する鏡視下手術導入と周術期呼吸理学療法による肺合併症軽減への取り組み

    第67回日本胸部外科学会定期学術集会  2014 

     More details

  • A feasibility study to visualize intraperitoneal desseminated gastric cancer by fluorescenceemitting virus, telomescan

    第73回日本癌学会学術総会  2014 

     More details

  • FUCCI imaging demonstrates dormant cancer-cell spheres are decoyed to proliferate by adenovirus and bacteria treatment

    第73回日本癌学会学術総会  2014 

     More details

  • Salmonella typhimurium A1-R decoys quiescent FUCCI-expressing cancer cells in tumors to cycle and become chemosensitive

    第73回日本癌学会学術総会  2014 

     More details

  • FUCCI imaging demonstrates invading cancer cells are mostly in G1/G0 and resist cytotoxic chemotherapy

    第73回日本癌学会学術総会  2014 

     More details

  • FUCCI imaging demonstrates that 3D Gelfoam® histoculture enables cancer cells to mimic in vivo cancer cell cycling

    第73回日本癌学会学術総会  2014 

     More details

  • 鉄コントロールによるがん幹細胞の新規治療法

    第73回日本癌学会学術総会  2014 

     More details

  • 鉄キレート療法は肝癌におけるソラフェニブの抗腫瘍効果を増強する

    第73回日本癌学会学術総会  2014 

     More details

  • ヒトスキルス胃癌細胞に対する腫瘍融解アデノウイルスの抗腫瘍効果

    第73回日本癌学会学術総会  2014 

     More details

  • FUCCI imaging demonstrates locational dependence of proliferation of cancer cells within tumors

    第73回日本癌学会学術総会  2014 

     More details

  • Current condition preoperative nutritional support for patients with esophageal cancer using percutaneous endoscopic gastrostomy

    The 14th World Congress of the International Society for Diseases of the Esophagus  2014 

     More details

  • The eradication of lymph node metastasis of early colorectal cancers using telomerase-dependant replicating adenovirau

    第73回日本癌学会学術総会  2014 

     More details

  • 食道癌の悪性化に対するCAF標的光免疫療法の開発

    第73回日本癌学会学術総会  2014 

     More details

  • 骨・軟部肉腫細胞に対する腫瘍融解アデノウイルスと放射線療法の併用効果

    第73回日本癌学会学術総会  2014 

     More details

  • 骨肉腫細胞に対する腫瘍融解アデノウイルスOBP-301とゾレドロン酸の併用効果

    第73回日本癌学会学術総会  2014 

     More details

  • 全身送達を目指したリポソーム抱合テロメラーゼ特異的腫瘍融解アデノウイルスプラスミドDNA

    第73回日本癌学会学術総会  2014 

     More details

  • 大腸がん(2)

    第73回日本癌学会学術総会  2014 

     More details

  • 休眠がん幹細胞を目覚めさせる腫瘍融解ウイルス製剤テロメライシンの臨床研究

    第73回日本癌学会学術総会  2014 

     More details

  • Hypermethylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter as a prognostic biomarker for stage Ⅱ,Ⅲ and Ⅳcolorectal cancers

    ESMO 2014 Congress  2014 

     More details

  • MicroRNA-89 expression as a promising prognostic biomarker for advanced colorectal cancer

    ESMO 2014 Congress  2014 

     More details

  • MicroRNA経路に関わる遺伝子に対するshRNA発現カセットを搭載した新規腫瘍溶解性アデノウイルスの開発

    第73回日本癌学会学術総会  2014 

     More details

  • ER2抗原で修飾された癌細胞に対するTrastuzumabを用いた近赤外線光線免疫療法の効果

    第73回日本癌学会学術総会  2014 

     More details

  • ウイルスベクターを用いた光感受性細胞傷害性蛍光タンパク質KillerRedによる新規光線力学療法

    第73回日本癌学会学術総会  2014 

     More details

  • 小児領域における噴門形成術の検討

    第68回日本食道学会学術集会  2014 

     More details

  • 鏡視下手術導入と多職種組織横断的周術期管理による高齢者食道癌手術への取り組み

    第68回日本食道学会学術集会  2014 

     More details

  • cT1bNOMO cStage Ⅰ食道癌に対する外科治療についての検討

    第68回日本食道学会学術集会  2014 

     More details

  • 食道癌手術患者の術前胸郭拡張差についての基礎的検討

    第68回日本食道学会学術集会  2014 

     More details

  • 食道がん手術患者の集中治療体験とその後の心理状態<第二報>

    第68回日本食道学会学術集会  2014 

     More details

  • 食道癌手術における歯科の役割

    第68回日本食道学会学術集会  2014 

     More details

  • 再肝移植症例に対する手技的工夫

    第32回日本肝移植研究会  2014 

     More details

  • 脳死肝腎同時移植2例の経験

    第32回日本肝移植研究会  2014 

     More details

  • 生体肝移植術後致死的経過を辿ったムコール症の2例

    第32回日本肝移植研究会  2014 

     More details

  • 局所進行食道癌に対する治療戦略

    第68回日本食道学会学術集会  2014 

     More details

  • Tape re-positioningとEnergy deviceを活用した安全な高難度肝切除技術

    第69回日本消化器外科学会総会  2014 

     More details

  • 進行食道癌による食道狭窄に起因した経口摂取困難症例に対して, PEGを用いた術前栄養療法の有用性

    第69回日本消化器外科学会総会  2014 

     More details

  • Genetic/epigenetic変異を基盤とした大腸癌個別化治療の構築

    第69回日本消化器外科学会総会  2014 

     More details

  • 頚部食道癌の治療戦略~喉頭温存を目指して~

    第68回日本食道学会学術集会  2014 

     More details

  • 肝移植後の腎機能の経過と降圧療法について

    第32回日本肝移植研究会  2014 

     More details

  • 高齢者大腸癌に対するD3の廓清の短期・長期成績の検討

    第81回大腸癌研究会  2014 

     More details

  • 癌関連線維芽細胞を標的とした光線免疫療法の開発

    第23回日本がん転移学会学術集会・総会 in 金沢  2014 

     More details

  • 遺伝子マーカー時代における臨床病理学的マーカーの位置づけ:1,373例の検討

    The 22th Annual Meeting of the Japanese Breast Cancer Society  2014 

     More details

  • 食道癌術前の呼吸機能管理目標設定とチーム介入の成果

    第69回日本消化器外科学会総会  2014 

     More details

  • ウイルスを用いたHER2陰性胃癌の強制的HER2標識化とTrastuzumabによる分子標的光免疫療法

    第69回日本消化器外科学会総会  2014 

     More details

  • KRAS/NRAS/BRAF/PIK3CA/MSI解析による多発大腸癌の遺伝子変異の不均一性の検討と臨床的意義

    第69回日本消化器外科学会総会  2014 

     More details

  • 肝臓内視鏡外科手術に有用な局所止血材の開発

    第69回日本消化器外科学会総会  2014 

     More details

  • HER2陽性進行再発胃癌に対するTrastuzumabを用いた集学的治療の有効性

    第69回日本消化器外科学会総会  2014 

     More details

  • 肝移植術後における真菌感染症に対する危険因子の解析

    第69回日本消化器外科学会総会  2014 

     More details

  • 鏡視下手術及び多職種による周術期管理による80歳以上超高齢者食道癌症例に対する手術成績向上の取り組み

    第69回日本消化器外科学会総会  2014 

     More details

  • 大腸癌におけるprognostic factorとしてのmiRNAの検討

    第69回日本消化器外科学会総会  2014 

     More details

  • 再発肝細胞癌の治療方針~再肝切除の有効性とSalvage transplantationの可能性~

    第69回日本消化器外科学会総会  2014 

     More details

  • 当科における進行胆嚢癌症例に対する外科切除成績~拡大手術の意義と限界~

    第69回日本消化器外科学会総会  2014 

     More details

  • 当科における食道胃接合部癌の経験および治療戦略

    第69回日本消化器外科学会総会  2014 

     More details

  • 空腸を用いた食道再建及び吻合の工夫ー全例に血管吻合が必要か?ー

    第69回日本消化器外科学会総会  2014 

     More details

  • 術後感染性合併症に繋がる脆弱性を識別する指標としてのSarcopenia~年齢区分を超えたリスク因子を求めて~

    第69回日本消化器外科学会総会  2014 

     More details

  • 胃切除術におけるda Vinciを用いたリンパ節郭清および体腔内手縫い吻合

    第69回日本消化器外科学会総会  2014 

     More details

  • StageⅣ大腸がんの予後マーカーとしてのMGMTメチル化ステータスの有用性

    第69回日本大腸肛門病学会学術集会  2014 

     More details

  • 内視鏡外科手術技術教育におけるカダバートレーニングの意義

    第27回日本内視鏡外科学会総会  2014 

     More details

  • Miles手術における会陰創のSSIに対するVAC療法の経験

    第76回日本臨床外科学会総会  2014 

     More details

  • 高齢者大腸癌に対するD3廓清の短期・長期成績の検討

    第76回日本臨床外科学会総会  2014 

     More details

  • 結腸腸間膜デスモイド線維腫症の1例

    第76回日本臨床外科学会総会  2014 

     More details

  • 集学的治療にて長期生存を得たKRAS遺伝子変異を伴う再発直腸癌の1例

    第76回日本臨床外科学会総会  2014 

     More details

  • Clinical role of promoter hypermethylation in the MGMT gene during colorectal tumorigenesis

    第25回日本消化器癌発生学会総会・第8回国際消化器癌発生会議  2014 

     More details

  • 企画関連講演6 発がん研究(1)

    第25回日本消化器癌発生学会総会・第8回国際消化器癌発生会議  2014 

     More details

  • 慢性炎症に伴うNO生成はアノイキス抵抗性を介し大腸腺腫細胞から大腸癌細胞を誘導する

    第25回日本消化器癌発生学会総会・第8回国際消化器癌発生会議  2014 

     More details

  • 小児先天性食道狭窄症に対する下部食道・噴門側胃切除後漿膜筋層フラップによる噴門形成術(観音開き法)

    第76回日本臨床外科学会総会  2014 

     More details

  • 遺体を用いた肝胆膵外科手術教育

    第76回日本臨床外科学会総会  2014 

     More details

  • 腹腔鏡下肝嚢胞開窓術における注意点

    第76回日本臨床外科学会総会  2014 

     More details

  • 手術教育におけるカダバートレーニングの有用性と可能性

    第76回日本臨床外科学会総会  2014 

     More details

  • 直腸癌術後再発に対して積極的な集学的治療によって長期生存を得た1例

    第76回日本臨床外科学会総会  2014 

     More details

  • 第13回臨床研究セミナー

    第76回日本臨床外科学会総会  2014 

     More details

  • 消化器がんの低侵襲治療と個別化医療

    平成26年度岡山大学医学部第一内科同門会  2014 

     More details

  • Assessment of the prognostic and predictive ability of a gene signature compared to histological grade in estrogen receptor positive, HER2 negative breast cancer

    SABCS(San Antonio breast cancer symposium)  2014 

     More details

  • 脳死ドナー多臓器摘出術 -- Multiorgan procurement from Deceased Donor -

    岡山県臓器移植ワーキンググループ会議  2014 

     More details

  • pNET治療の最近の話題

    第3回中国消化器希少腫瘍講演会  2014 

     More details

  • Colitic cancerおよびhigh grade dysplasiaを合併した潰瘍性大腸炎の臨床病理学的特徴

    第22回JDDW  2014 

     More details

  • 当科における腹臥位胸腔鏡下食道亜全摘の際のトラブルシューティング

    第13回EGI外科治療研究会  2014 

     More details

  • Colitic Cancer / High Grade Dysplasia を合併した潰瘍性大腸炎に対する腹腔鏡下大腸全摘の治療成績の検討

    第27回日本内視鏡外科学会総会  2014 

     More details

  • クローン病に対する腹腔鏡下手術の成績‐開腹手術と比較して‐

    第27回日本内視鏡外科学会総会  2014 

     More details

  • 高齢者胃癌(75歳以上)に対する腹腔鏡手術の妥当性

    第27回日本内視鏡外科学会総会  2014 

     More details

  • 腹腔鏡下手術の低侵襲性は胃切除術後の癒着性腸閉塞の低減に寄与する

    第27回日本内視鏡外科学会総会  2014 

     More details

  • 腹腔鏡下胃切除術後の利尿期への早期移行は低侵襲性を反映する

    第27回日本内視鏡外科学会総会  2014 

     More details

  • 早期胃癌に対するESD非治癒切除後の追加治療としてのLADGの治療成績の検討

    第27回日本内視鏡外科学会総会  2014 

     More details

  • ペプチドゲルを用いた新規局所止血剤の開発と腹腔鏡下肝切除における使用法

    第27回日本内視鏡外科学会総会  2014 

     More details

  • 一般演題219 胃・十二指腸悪性 進行癌

    第27回日本内視鏡外科学会総会  2014 

     More details

  • 大腸癌検診の短期・長期治療成績における有用性の検討

    第69回日本大腸肛門病学会学術集会  2014 

     More details

  • 大腸癌肺転移に対するCTガイド下経皮的ラジオ波焼灼術の短期・長期成績の検討

    第69回日本大腸肛門病学会  2014 

     More details

  • Study on new concept of iron controlled therapy for cancer stem cell

    第25回日本消化器癌発生学会総会・第8回国際消化器癌発生会議  2014 

     More details

  • 噴門側胃切除術における逆流防止弁形成食道残胃吻合法の工夫と問題点

    第44回胃外科・術後障害研究会  2014 

     More details

  • 左副腎腺によるCushing症候群にて腹腔鏡下副腎摘出術を施行した一例

    第34回日本小児内視鏡外科・手術手技研究会  2014 

     More details

  • 消化器がんの低侵襲治療と個別化医療の最前線

    第177回兵庫県外科医会総会  2014 

     More details

  • 解剖学教室とのコラボレーションによる肝胆膵外科手術教育

    第177回岡山外科会  2014 

     More details

  • 腹腔鏡下肝嚢胞開窓術のピットフォール

    第177回岡山外科会  2014 

     More details

  • 特別講演

    第51回臨床遺伝子医学研究会  2014 

     More details

  • 遺伝子変異情報の大腸癌肝転移治療戦略への応用

    第69回日本大腸肛門病学会学術集会  2014 

     More details

  • 腹臥位胸腔鏡下食道亜全摘のための新しい解剖教材の開発~多視点 3D解剖システム

    第26回日本内視鏡外科学会総会  2013 

     More details

  • 再発肝細胞癌に対する再肝切除の有効性とSalvage Transplantationの適応選別

    第75回日本臨床外科学会総会  2013 

     More details

  • 食道癌ESD後再発症例から考えるESDの適応と補助治療のあり方について

    第75回日本臨床外科学会総会  2013 

     More details

  • 食道癌低肺機能患者に対する術前呼吸器チーム医療

    第75回日本臨床外科学会総会  2013 

     More details

  • 腹腔鏡下有茎直腸による膣形成術の3例

    第26回日本内視鏡外科学会総会  2013 

     More details

  • 原発不明癌として治療を受けていた、診断に苦慮した虫垂癌の1例

    第75回日本臨床外科学会総会  2013 

     More details

  • Zenker憩室症の8例

    第75回日本臨床外科学会総会  2013 

     More details

  • 卵巣悪性 Brenner 腫瘍を伴った大腸癌の1例

    第75回日本臨床外科学会総会  2013 

     More details

  • 術後難治性創感染に対しVAC療法にて創し開を回避し創治癒を得た3例

    第75回日本臨床外科学会総会  2013 

     More details

  • 当科における食道癌サルベージ手術の検討

    第75回日本臨床外科学会総会  2013 

     More details

  • 遺伝子情報によるバイオマーカーを用いたStage IV大腸癌の治療戦略の構築

    第75回日本臨床外科学会総会  2013 

     More details

  • IVC合併切除を伴う肝細胞癌手術~人工血管を用いたIVC再建~

    第75回日本臨床外科学会総会  2013 

     More details

  • 進行胃癌に対し自律神経解剖を郭清範囲決定に応用したD2郭清

    第75回日本臨床外科学会総会  2013 

     More details

  • 当科における食道胃接合部癌の治療経験 郭清範囲と再建法について

    第75回日本臨床外科学会総会  2013 

     More details

  • 食道癌術後亜急性期の後方支援病院におけるスコアリング化されたがんリハビリテーションの取り組み

    第75回日本臨床外科学会総会  2013 

     More details

  • 進行・再発S状結腸癌に対して集学的治療にて長期生存を得た1例

    第75回日本臨床外科学会総会  2013 

     More details

  • 多視点多層三次元解剖教材および E-learning を利用した内視鏡外科解剖教育システムの構築

    第26回日本内視鏡外科学会総会  2013 

     More details

  • 当科における進行食道癌における合理的胸腔鏡下手術の試み

    第26回日本内視鏡外科学会総会  2013 

     More details

  • 潰瘍性大腸炎に対する腹腔鏡下大腸全摘術の matched case control study による開腹群との治療成績の比較

    第26回日本内視鏡外科学会総会  2013 

     More details

  • 成人 Bochdalek 孔ヘルニアを合併した胃癌に対し腹腔鏡手術にて一期的に根治手術し得た 1 例

    第26回日本内視鏡外科学会総会  2013 

     More details

  • 腹腔鏡下に切除を行った上行結腸神経鞘腫の 1 例

    第26回日本内視鏡外科学会総会  2013 

     More details

  • 腹臥位胸腔鏡下食道切除術における縦隔リンパ節郭清での助手による積極的術野展開とその定型化

    第26回日本内視鏡外科学会総会  2013 

     More details

  • 神経解剖を軸とした膵上縁郭清の工夫と実際

    第26回日本内視鏡外科学会総会  2013 

     More details

  • 要望演題 20 ハイブリッド・LECS LECS・関連手技

    第26回日本内視鏡外科学会総会  2013 

     More details

  • Closed LECS の開発と臨床応用

    第26回日本内視鏡外科学会総会  2013 

     More details

  • 80歳以上の超高齢者食道癌症例に対する胸腔鏡下手術の現況

    第26回日本内視鏡外科学会総会  2013 

     More details

  • S-1胃癌術後補助化学療法のfeasibility;4週投与2週休薬法vs2週投薬1週休薬法

    第85回日本胃癌学会総会  2013 

     More details

  • Telomerase-specific oncolytic adenovirus OBP-301 kills quiescent peritonially disseminated cancer cells

    2013 Annual Meeting of the American Association for Cancer Research  2013 

     More details

  • Dormant cancer cells are resistant to conventional therapies and induce tumor vessels after chemotherapy

    2013 Annual Meeting of the American Association for Cancer Research  2013 

     More details

  • Invasive cancer cells are mostly in the G0/G1 phase of the cell cycle

    2013 Annual Meeting of the American Association for Cancer Research  2013 

     More details

  • 生体肝移植後に発生した肝・腎不全に対する脳死肝腎同時移植症例における術中リスクマネージ

    第113回日本外科学会定期学術集会  2013 

     More details

  • 遺伝子情報を用いた多臓器転移大腸癌の検討および治療戦略の構築

    第113回日本外科学会定期学術集会  2013 

     More details

  • 特別講演

    Colorectal Cancer Symposium  2013 

     More details

  • 肺多形癌切除症例5例の検討

    第30回日本呼吸器外科学会総会  2013 

     More details

  • 講演1

    Cancer Pain Forum  2013 

     More details

  • 主題2-3 癌免疫(化学)療法の臨床評価(評価法、治療成績)

    第34回癌免疫外科研究会  2013 

     More details

  • 当科における食道胃管吻合法の変遷と工夫

    第67回手術手技研究会  2013 

     More details

  • MGMT Methylation As a Novel Biomarker for the Identification of Stage III Colorectal Cancers At High-Risk of Disease Recurrence Following Curative Surgery

    Digestive Disease Week 2013  2013 

     More details

  • Accumulation of Epigenetic Alteration Could Predict Malignant Formation in Intraductal Papillary Mucinous Neoplasm(IPMN)

    Digestive Disease Week 2013  2013 

     More details

  • Genetic and Epigenetic Alterations in the Netrin-1 Receptors, UNC5c and DCC, Constitutes a Previously Unrecognized Pathway in Gastric Cancer Progression

    Digestive Disease Week 2013  2013 

     More details

  • 当科における80歳以上の超高齢者食道癌症例に対する外科治療の変遷

    第113回日本外科学会定期学術集会  2013 

     More details

  • 生体肝移植における人工血管を用いた血行再建

    第113回日本外科学会定期学術集会  2013 

     More details

  • テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌の低侵襲治療の開発

    第113回日本外科学会定期学術集会  2013 

     More details

  • 分葉膵に付着した消化管重複症の1例

    第50回日本小児外科学会学術集会  2013 

     More details

  • 遺伝子解析を用いたStageIV大腸癌に対する術前化学療法の検討および確立

    第35回日本癌局所療法研究会  2013 

     More details

  • 進行S状結腸癌に対して集学的治療にて長期生存を得た1例

    第35回日本癌局所療法研究会  2013 

     More details

  • 術前放射線化学療法を施行した後、骨盤内臓全摘術にて治癒切除を得た局所進行痔瘻癌の1例

    第35回日本癌局所療法研究会  2013 

     More details

  • 主題Ⅱ「新旧分子マーカーの癌局所療法における位置づけ」

    第35回日本癌局所療法研究会  2013 

     More details

  • ENDOSCOPIC RADIAL INCISION AND CUTTING METHOD FOR REFRACTRY ESOPHAGEAL STRICTURE AFTER PRIMARY REPAIR OF ESOPHAGEAL ATRESIA

    The 14th European Congres of Pediatric Surgery  2013 

     More details

  • 遺伝子解析を用いたStageIV大腸癌に対する術前化学療法の検討および確立

    第38回日本外科系連合学会学術集会  2013 

     More details

  • 当院での胸部食道癌周術期管理におけるPERIO導入についての検討

    第38回日本外科系連合学会学術集会  2013 

     More details

  • 特別講演

    Clinical Cancer Symposium in Okayama  2013 

     More details

  • Fecal DNA Methylation Assay for the Identification of a Multiple Gastrointestinal Cancers Including Pancreatic Cancer

    Digestive Disease Week 2013  2013 

     More details

  • Cytokeratin 19 Staining Is a Novel, Predictive Biomarker for Extra-Hepatic Metastasis in Hepatocellular Carcinoma

    Digestive Disease Week 2013  2013 

     More details

  • 当院で治療を行った膵神経内分泌腫瘍35症例の画像所見と病理組織学的所見の検討

    第113回日本外科学会定期学術集会  2013 

     More details

  • 遺伝子変異情報を基盤とした大腸癌肝転移の治療戦略

    第113回日本外科学会定期学術集会  2013 

     More details

  • 難治性胆道狭窄・胆汁漏に対するランデブー法を用いた胆管内瘻化

    第113回日本外科学会定期学術集会  2013 

     More details

  • サイトケラチン19発現は肝細胞癌の上皮間葉移行と肝外転移を予測する

    第113回日本外科学会定期学術集会  2013 

     More details

  • 温阻血再灌流+肝切除モデルにおけるHMGB1の動態解析および肝再生機序の解明

    第113回日本外科学会定期学術集会  2013 

     More details

  • 血清鉄コントロールを用いた新たな肝細胞癌治療戦略

    第113回日本外科学会定期学術集会  2013 

     More details

  • テロメラーゼ活性を指標とする血中遊離癌細胞の高感度検出法の開発と遺伝子解析技術への応用

    第113回日本外科学会定期学術集会  2013 

     More details

  • 下大静脈合併切除再建を併施した切除不能肝芽腫に対する生体肝移植

    第113回日本外科学会定期学術集会  2013 

     More details

  • 若手外科医のための3次元立体解剖教材の有用性

    第113回日本外科学会定期学術集会  2013 

     More details

  • 血清鉄コントロールによる食道癌細胞の浸潤・転移能制御の可能性

    第113回日本外科学会定期学術集会  2013 

     More details

  • 高リスクGIST症例の検討ー無作為化比較試験SSGXVIII/AIOの報告をうけてー

    第113回日本外科学会定期学術集会  2013 

     More details

  • 生体肝移植ドナーにおける無血肝切除技術と胆道合併症の予防対策

    第113回日本外科学会定期学術集会  2013 

     More details

  • メチル化プロファイリングを用いたIntraductal papillary mucinous neoplasm(IPMN)

    第113回日本外科学会定期学術集会  2013 

     More details

  • 生体肝移植の短期・晩期予後向上に向けた治療戦略個別化の可能性

    第113回日本外科学会定期学術集会  2013 

     More details

  • 胃癌における蛍光発現ウイルスによる腹腔洗浄液診断:生物学的悪性度指標としての可能性

    第113回日本外科学会定期学術集会  2013 

     More details

  • 肝細胞癌に対する生体肝移植適応基準についての検討

    第113回日本外科学会定期学術集会  2013 

     More details

  • ワークショップ(17)

    第113回日本外科学会定期学術集会  2013 

     More details

  • 消化器癌の低侵襲外科治療と副作用を抑えた薬物療法

    第113回日本外科学会定期学術集会  2013 

     More details

  • 同時性多発大腸癌のsomatic mutation spectrumに対する検証

    第113回日本外科学会定期学術集会  2013 

     More details

  • 直腸癌術後10年を経過して発症した局所再発に対して治癒切除を施行した1例

    第113回日本外科学会定期学術集会  2013 

     More details

  • 腹臥位胸腔鏡下食道亜全摘術においてEndoCAMeleonがもたらした新たな視野展開

    第113回日本外科学会定期学術集会  2013 

     More details

  • ロボット支援下幽門側胃切除術におけるリンパ節郭清手技

    第113回日本外科学会定期学術集会  2013 

     More details

  • Novel photoimmunotherapy (PIT) targeting cancer-associated fibroblasts (CAFs) for esophageal cancer

    2013 Annual Meeting of the American Association for Cancer Research  2013 

     More details

  • Oncolytic adenovirus-armed p53 induces apoptosis significantly through upregulating miR-93 and 106b in human osteosarcoma cells

    2013 Annual Meeting of the American Association for Cancer Research  2013 

     More details

  • Cytotoxic effect of photosensitive fluorescent protein KillerRed-expressing adenovirus against human cancer cells

    2013 Annual Meeting of the American Association for Cancer Research  2013 

     More details

  • 巨大副脾捻転の1例

    第26回日本小児脾臓研究会  2013 

     More details

  • 講演2

    第12回OKAYAMA CANCER FORUM  2013 

     More details

  • Combined effect of zoledronic acid and telomerase-specific oncolytic virotherapy for human osteosarcoma cells

    2013 Annual Meeting of the American Association for Cancer Research  2013 

     More details

  • Enhanced chemosensitivity of osteosarcoma cells by telomerase-specific oncolytic adenovirus in combination therapy

    2013 Annual Meeting of the American Association for Cancer Research  2013 

     More details

  • Iron depletion by deferasirox have a synergistic effect on sorafenib in hepatocellular carcinoma

    2013 Annual Meeting of the American Association for Cancer Research  2013 

     More details

  • Neotargeting HER2 negative cancer cells with Trastuzumab-based photoimmunotherapy by viral transduction of HER2-extracellular domain

    2013 Annual Meeting of the American Association for Cancer Research  2013 

     More details

  • Novel strategy for eradicating lymph node metastasis of early-stage colorectal cancers using telomerase-dependent replicating adenoviral agent

    2013 Annual Meeting of the American Association for Cancer Research  2013 

     More details

  • 特別講演2 最近の外科医の動向とこれからの外科医教育について

    第1回岡山大学消化器外科フォーラム  2013 

     More details

  • BRAF変異を伴うStageIV大腸癌の臨床病理学的特徴の検討

    第78回大腸癌研究会  2013 

     More details

  • 腹腔細胞診陽性胃癌症例に対する外科的切除の検討

    第85回日本胃癌学会総会  2013 

     More details

  • da Vinci手術からLADGへのfeedback-幽門下リンパ節郭清-

    第85回日本胃癌学会総会  2013 

     More details

  • 岡山大学での臨床膵島移植へ向けた分離技術改変の取り組み

    第40回日本膵・膵島移植研究会  2013 

     More details

  • 遺伝子変異解析によるIPMN悪性度診断の新展開

    第31回烏城消化器カンファレンス  2013 

     More details

  • 当院におけるロボット支援下胃切除術の現状と展望

    第5回日本ロボット外科学会学術集会  2013 

     More details

  • 小児食道閉鎖症術後吻合部狭窄に対するradial incision and cutting(RIC)法の経験

    第175回岡山外科会  2013 

     More details

  • 食道癌における除鉄による浸潤・転移能抑制の可能性

    文部科学省新学術領域研究 平成24年度「個体レベルでのがん研究支援活動」  2013 

     More details

  • 消化器がん治療における最新の話題

    第195回岡山腹腔鏡研究会  2013 

     More details

  • ESD後に遠位側胃管切除再建を行った胸腔内胃管癌の一例

    第85回日本胃癌学会総会  2013 

     More details

  • 胃切除術後の難治性腹水に対して腹腔・静脈シャントが有用であった1例

    第68回日本消化器外科学会総会  2013 

     More details

  • 当科における食道胃接合部がんの治療経験 ー下縦隔廓清と再建法についてー

    第67回日本食道学会学術集会  2013 

     More details

  • 食道癌手術患者の術前禁煙に対する医療連携による包括的取り組みとその効果

    第67回日本食道学会学術集会  2013 

     More details

  • 食道原発小細胞癌及び食道原発悪性黒色腫の治療における手術療法の位置付け

    第67回日本食道学会学術集会  2013 

     More details

  • Virally tagging of HER2 extracellular domain sensitizes her2-negative gastric cancer cells to Trastuzumab-based photoimmunotherapy.

    the 10th International Gastric Cancer Congress  2013 

     More details

  • 分葉膵に付着した消化管重複症の1例

    第49回日本放射線学会学術集会  2013 

     More details

  • 除鉄効果を利用した新たな消化器癌治療 要望演題9

    第68回日本消化器外科学会総会  2013 

     More details

  • 再肝移植症例に対する肝腎同時移植経験と、本邦の複数臓器分配におけるMELD scoreのもつ問題点

    第31回日本肝移植研究会  2013 

     More details

  • 当科での腹臥位胸腔鏡下食道切除術における助手操作定型化の工夫

    第67回日本食道学会学術集会  2013 

     More details

  • 当科における空腸を用いた食道再建術の工夫

    第67回日本食道学会学術集会  2013 

     More details

  • 進行食道癌に対する術前化学療法の現況~DCFの位置づけを中心に~

    第67回日本食道学会学術集会  2013 

     More details

  • 遺伝子情報を用いたStage IV大腸癌の検討および治療戦略

    第68回日本消化器外科学会総会  2013 

     More details

  • 癌特異的蛍光発現ウイルスによる胃癌症例腹腔洗浄液中での癌細胞検出法とその意義

    第68回日本消化器外科学会総会  2013 

     More details

  • 遺伝子変異情報を基盤とした大腸癌肝転移の治療戦略

    第68回日本消化器外科学会総会  2013 

     More details

  • 当院における肝切除術前PVE症例の検討

    第68回日本消化器外科学会総会  2013 

     More details

  • 当科における腹臥位胸腔鏡下食道切除術定型化の工夫

    第68回日本消化器外科学会総会  2013 

     More details

  • 主膵管型・混合型IPMNに対する術式の検討

    第68回日本消化器外科学会総会  2013 

     More details

  • 遺伝子変異解析によるIPMN悪性度診断の新展開

    第68回日本消化器外科学会総会  2013 

     More details

  • 高齢者膵頭十二指腸切除におけるsarcopeniaの及ぼす影響

    第68回日本消化器外科学会総会  2013 

     More details

  • StageIII大腸癌根治術後の再発予測におけるMGMTプロモーター領域のメチル化解析の有用性

    第68回日本消化器外科学会総会  2013 

     More details

  • 術後難治性創感染に対し,VAC療法にて創し開を回避し創治癒を得た2例

    第38回日本外科系連合学会学術集会  2013 

     More details

  • 胸部食道癌のよりよい周術期管理を目指して-PERIOと鏡視下手術の融合-

    第68回日本消化器外科学会総会  2013 

     More details

  • 腹腔鏡補助下噴門側胃切除術における郭清手技と「観音開き法」食道残胃吻合

    第68回日本消化器外科学会総会  2013 

     More details

  • 温阻血再灌流+70%肝切除におけるHMGB1の動態解析と制御

    第68回日本消化器外科学会総会  2013 

     More details

  • 80歳以上の超高齢者食道癌症例に対する外科治療の安全性確保への取り組み

    第68回日本消化器外科学会総会  2013 

     More details

  • 患者負担軽減のためのPEGを用いた食道癌術前補助栄養療法の現状について

    第68回日本消化器外科学会総会  2013 

     More details

  • 当科における食道胃接合部癌の治療経験 ー下縦隔リンパ節転移症例の検討ー

    第68回日本消化器外科学会総会  2013 

     More details

  • 肝移植手術の血行再建における人工血管の使用経験

    第68回日本消化器外科学会総会  2013 

     More details

  • 膵神経内分泌腫瘍41症例のWHO2010分類とCT画像所見,予後に関する検討

    第68回日本消化器外科学会総会  2013 

     More details

  • LADG, D2における神経解剖を軸とした膵上縁リンパ節郭清

    第68回日本消化器外科学会総会  2013 

     More details

  • HER2陽性胃癌の臨床病理学的特徴と当院におけるtrastuzumabの使用経験

    第68回日本消化器外科学会総会  2013 

     More details

  • 再発肝細胞癌の治療戦略〜再肝切除・RFAの長期予後と予後予測モデルの有用性〜

    第68回日本消化器外科学会総会  2013 

     More details

  • 乳児急性リンパ性白血病臍帯血移植後に発症した肝中心静脈閉塞症に対し生体肝移植,骨髄移植を施行した1例

    第31回中国四国臨床臓器移植研究会  2013 

     More details

  • 遺伝子情報によるバイオマーカーを用いた切除不能進行大腸癌の検討および治療戦略の構築

    第11回日本臨床腫瘍学会学術集会  2013 

     More details

  • MGMT メチル化は大腸癌 StageIII治癒切除後再発を予測するバイオマーカーである

    第11回日本臨床腫瘍学会学術集会  2013 

     More details

  • 消化器がんの低侵襲治療と個別化医療

    第4回山口県消化管セミナー  2013 

     More details

  • The outcome of prophylatic surgical managements for spontaneous large splenorenal shunts adult living donor liver transplantation

    The 13th Congress of the Asian Society of Transplantation  2013 

     More details

  • A case of Wilson's disease completely recovered from severe neurologic manifestations after living related-donor liver transplantation

    The 13th Congress of the Asian Society of Transplantation  2013 

     More details

  • サイトケラチン19は肝細胞癌の肝外転移や術後再発を予測する

    第68回日本消化器外科学会総会  2013 

     More details

  • 除鉄効果を利用した新たな消化器癌治療

    第68回日本消化器外科学会総会  2013 

     More details

  • 企画関連口演115:消化器癌個別化治療 6 (総論)

    第68回日本消化器外科学会総会  2013 

     More details

  • 肝腎不全に対する脳死肝腎同時移植の一例

    第31回中国四国臨床臓器移植研究会  2013 

     More details

  • 劇症肝炎に対する肝移植

    第31回中国四国臨床臓器移植研究会  2013 

     More details

  • 肝移植におけるERASプロトコル確立を目指して〜周術期栄養療法による早期回復効果を可視化する試み〜

    第68回日本消化器外科学会総会  2013 

     More details

  • 当科における低侵襲再建術の試み ー用手補助的腹腔鏡下胃管作製の60例の検討ー

    第68回日本消化器外科学会総会  2013 

     More details

  • 三次元解剖映像教材を用いた次世代の手術解剖教育

    第68回日本消化器外科学会総会  2013 

     More details

  • 胃が使用できない食道癌症例における空腸による食道再建術の工夫-血管吻合は全例に必要か?-

    第68回日本消化器外科学会総会  2013 

     More details

  • 骨肉腫に対する腫瘍融解アデノウイルスの抗がん剤感受性亢進作用

    第72回日本癌学会学術総会  2013 

     More details

  • Netrin-1 recepter であるUNC5C とDCC の胃がん進行における遺伝子学的変化

    第72回日本癌学会学術総会  2013 

     More details

  • 同時性多発大腸癌のsomatic mutation spectrumに対する検証

    第72回日本癌学会学術総会  2013 

     More details

  • 胃癌患者の腹腔洗浄液における蛍光発現ウイルス試薬による新たな生物学的診断

    第72回日本癌学会学術総会  2013 

     More details

  • 早期大腸癌のリンパ節転移制御に向けた新規治療

    第72回日本癌学会学術総会  2013 

     More details

  • 大腸癌予後因子としてのMGMTプロモーターメチル化

    第72回日本癌学会学術総会  2013 

     More details

  • ヒト骨肉腫細胞に対するゾレドロン酸と腫瘍融解アデノウイルス併用療法の抗腫瘍効果

    第72回日本癌学会学術総会  2013 

     More details

  • 新規光線力学療法を目指したウイルスを用いた光感受性細胞傷害性蛍光タンパク質KillerRedの治療効果

    第72回日本癌学会学術総会  2013 

     More details

  • 消化器がんの低侵襲治療と個別化医療の最前線

    まにわ消化器フォーラム2013  2013 

     More details

  • 食道閉鎖症術後吻合部狭窄に対するRadial Incision and Cutting (RIC)法

    第52回日本小児外科学会中国四国地方会  2013 

     More details

  • 消化器がんのMolecular Theranostics:分子イメージングと治療の融合

    第6回蛍光Navigation Surgery研究会  2013 

     More details

  • メチル化プロファイリングによるIPMNの悪性度予測

    第72回日本癌学会学術総会  2013 

     More details

  • 鉄欠乏状態は肝細胞癌におけるソラフェニブの感受性を改善しうる

    第72回日本癌学会学術総会  2013 

     More details

  • がん関連線維芽細胞を標的とした新たな癌治療法の可能性 光線免疫療法を用いて

    第72回日本癌学会学術総会  2013 

     More details

  • p53武装化腫瘍融解アデノウイルスはヒト骨肉腫細胞に2種類のプログラム細胞死を誘導する

    第72回日本癌学会学術総会  2013 

     More details

  • サイトケラチン19は肝細胞癌の新規予後予測マーカーである

    第72回日本癌学会学術総会  2013 

     More details

  • HER2遺伝子導入技術を用いたHER2陰性癌細胞に対する分子標的 光免疫療法

    第72回日本癌学会学術総会  2013 

     More details

  • The Influence of Ischemia/Reperfusion Injury on HMGB1 State and Liver Regeneration after Partial Hepatectomy in Rats

    Merinoff World Congress 2013  2013 

     More details

  • 消化器外科学会特別企画(依頼) 11 ポスターレビュー6(胃・十二指腸)

    第11回日本消化器外科学会大会  2013 

     More details

  • 骨・軟部肉腫細胞に対するテロメラーゼ特異的制限増殖型アデノウイルス療法

    第72回日本癌学会学術総会  2013 

     More details

  • 腫瘍融解ウイルス療法におけるE2F1誘導性マイクロRNAの腫瘍抑制的機能

    第72回日本癌学会学術総会  2013 

     More details

  • Invasive cancer cells are not cycling

    第72回日本癌学会学術総会  2013 

     More details

  • 臓器移植におけるHMGB-1を介した自然免疫機構の解析と制御

    第49回日本移植学会総会  2013 

     More details

  • Frequency of regulatory T cell and HCV antigen-specific immune response in recurrent hepatitis C after liver transplantation

    第49回日本移植学会総会  2013 

     More details

  • 肝臓の虚血再灌流障害+肝切除モデルにおけるHMGB-1の動態・機能解析と制御

    第49回日本移植学会総会  2013 

     More details

  • アルコール性肝硬変患者に対する肝移植適応基準確立に向けた岡山大学病院での取組み

    第49回日本移植学会総会  2013 

     More details

  • 肝臓癌における除鉄併用ソラフェニブ療法の可能性

    第37回日本鉄バイオサイエンス学会  2013 

     More details

  • 再発肝細胞癌の治療方針 ~再肝切除の有効性とSalvage transplantationの可能性~

    第88回中国四国外科学会総会  2013 

     More details

  • 低肺機能合併食道癌症例に対する胸腔鏡手術による低侵襲化と術前理学療法による呼吸器合併症軽減への取り組み

    第88回中国四国外科学会総会  2013 

     More details

  • The risk factors for fungal infection after living donor liver transplantation

    The 13th Congress of the Asian Society of Transplantation  2013 

     More details

  • 鉄代謝を利用した新規分子標的薬併用療法

    第24回日本消化器癌発生学会総会  2013 

     More details

  • 予後および病態評価が可能な新規食道癌同所移植性モデル

    第24回日本消化器癌発生学会総会  2013 

     More details

  • 生体肝移植後の肝腎不全に対する肝腎同時移植移植の適応

    第49回日本移植学会総会  2013 

     More details

  • シンポジウム2 「進行癌に対する鏡視下手術の適応と拡大」

    第18回中国四国内視鏡外科研究会  2013 

     More details

  • 進行胃癌に対する鏡視下手術の郭清手技と成績

    第18回中国四国内視鏡外科研究会  2013 

     More details

  • 当科における鏡視下食道亜全摘術の適応拡大について

    第18回中国四国内視鏡外科研究会  2013 

     More details

  • 腹腔鏡補助下直腸低位前方切除術後に発生した門脈血栓症の1例

    第18回中国四国内視鏡外科研究会  2013 

     More details

  • 左肝静脈に近接する原発性肝細胞癌に対し腹腔鏡補助下外側区域切除を施行した1例

    第18回中国四国内視鏡外科研究会  2013 

     More details

  • 膵・胆管合流異常症に対する分流手術 ―鏡視下手術導入に際して―

    第36回日本膵・胆管合流異常研究会  2013 

     More details

  • Iron-controlled cancer therapy: A new concept for anti-angiogenic drug(bevacizumab and sorafenib)

    European Cancer Congress  2013 

     More details

  • 膵管癌と膵神経内分泌腫瘍の合併・併存腫瘍についての検討

    第1回日本神経内分泌腫瘍研究会学術集会  2013 

     More details

  • 腹臥位胸腔鏡下食道切除術100例の検討

    第88回中国四国外科学会総会  2013 

     More details

  • 胸腔鏡下食道亜全摘術後に両側性自然気胸をきたした1例

    第88回中国四国外科学会総会  2013 

     More details

  • 当科における食道癌サルベージ手術の検討

    第88回中国四国外科学会総会  2013 

     More details

  • NASH肝硬変における肝移植後の経過

    第31回日本肝移植研究会  2013 

     More details

  • HMGB1制御による阻血再灌流障害の軽減効果と肝再生機序への影響解析

    第31回日本肝移植研究会  2013 

     More details

  • Cancer Gene Therapy: Two Decades and Future

    第19回日本遺伝子治療学会学術集会  2013 

     More details

  • Educational Lecture I

    第19回日本遺伝子治療学会学術集会  2013 

     More details

  • Novel immuno-virotherapy: Tumor-specific killer activity of oncolytic adenovirus-loaded T cell line HOZOT

    第19回日本遺伝子治療学会学術集会  2013 

     More details

  • Efficient detection of circulating tumor cells using an oncolytic adenovirus containing microRNA-regulated gene expression system

    第19回日本遺伝子治療学会学術集会  2013 

     More details

  • 生体肝移植におけるドナー年齢限界の見極めと個別化治療戦略

    第31回日本肝移植研究会  2013 

     More details

  • 肝移植後の真菌感染症の危険因子の解析

    第31回日本肝移植研究会  2013 

     More details

  • 生体肝移植後拒絶反応およびC型肝炎再発におけるHigh Mobility Group Box-1の動態解析

    第31回日本肝移植研究会  2013 

     More details

  • 乳児急性リンパ性白血病臍帯血移植後に発症した肝中心静脈閉塞症に対し生体肝移植,骨髄移植を施行した1例

    第31回日本肝移植研究会  2013 

     More details

  • Chemosensitizing effects of telomerase-specific oncolytic adenovirus in human osteosarcoma cells.

    第19回日本遺伝子治療学会学術集会  2013 

     More details

  • A biological imaging system for detecting genetic alterations in circulating tumor cells using telomerase-specific replication-competent adenovirus.

    第19回日本遺伝子治療学会学術集会  2013 

     More details

  • Tumor suppressor FHIT regulates tumor invasion of pancreatic cancer cells via inhibiting association of Ezrin and Actin cytoskeleton

    第19回日本遺伝子治療学会  2013 

     More details

  • 遺伝子情報によるバイオマーカーを用いたStage IV大腸癌の検討

    第69回大腸癌研究会  2013 

     More details

  • テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌の低侵襲治療の開発

    第68回日本消化器外科学会総会  2013 

     More details

  • Differential treatment strategies for advanced colorectal cancer according to mutation spectrum in the Ras-Raf signaling pathway and micosatellite instability

    第19回日本遺伝子治療学会学術集会  2013 

     More details

  • Preclinical evaluation of cytotoxic fluorescent protein KillerRed as novel photosensitizer in photodynamic therapy for cancer

    第19回日本遺伝子治療学会学術集会  2013 

     More details

  • A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumor-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.

    第19回日本遺伝子治療学会学術集会  2013 

     More details

  • A simple detection system for adenovirus receptor expression using a telomerase-specific replication-competent adenovirus.

    第19回日本遺伝子治療学会学術集会  2013 

     More details

  • Adenovirus-mediated induction of exogenous HER2 extracellular domain overcomes resistance to trastuzumab via ADCC activation in human cancer cells.

    第19回日本遺伝子治療学会学術集会  2013 

     More details

  • 肝腫瘍および生体肝移植ドナーにおける肝切離法の工夫

    第25回日本肝胆膵外科学会・学術集会  2013 

     More details

  • 脳死肝移植成績~当院15症例の検討~

    第25回日本肝胆膵外科学会・学術集会  2013 

     More details

  • 再発肝細胞癌の治療戦略~予後予測モデルとSalvage Transplantationの適応選別~

    第25回日本肝胆膵外科学会・学術集会  2013 

     More details

  • 膵頭部癌に対する膵頭十二指腸切除・門脈合併切除再建手技

    第25回日本肝胆膵外科学会・学術集会  2013 

     More details

  • 肝膵同時切除術施行症例の合併症,予後についての検討

    第25回日本肝胆膵外科学会・学術集会  2013 

     More details

  • PpPD術後に生じた未破裂動脈瘤に対してステント留置が有効であった一例

    第25回日本肝胆膵外科学会・学術集会  2013 

     More details

  • 肝切除後胆道・動脈合併症に対するリカバリーショット~総胆管離開を伴う胆汁漏と肝内外多発動脈瘤の1例~

    第25回日本肝胆膵外科学会・学術集会  2013 

     More details

  • 高リスク食道癌手術症例・特に低肺機能合併症例に対する食道癌手術・周術期管理の現況

    第56回関西胸部外科学会学術集会  2013 

     More details

  • 一般演題(口演) 術前化学療法

    第38回日本外科系連合学会学術集会  2013 

     More details

  • 低体重児に対するS2移植 + in situ reductionをもちいたsub-monosegment liver transplantation

    第25回日本肝胆膵外科学会・学術集会  2013 

     More details

  • 当院におけるパゾパニブの使用経験

    第51回日本癌治療学会学術集会  2013 

     More details

  • 鏡視下胃切除における神経解剖を軸としたD2郭清

    第12回EGI研究会  2013 

     More details

  • 遺伝子情報を用いたStage IV大腸癌の治療戦略の構築

    第68回日本大腸肛門病学会  2013 

     More details

  • 同時性/異時性多発大腸癌における遺伝子変異の特徴

    日本人類遺伝学会第58回大会  2013 

     More details

  • MRの診断

    第75回日本臨床外科学会総会  2013 

     More details

  • 当科における食道胃管吻合の変遷とその工夫

    第75回日本臨床外科学会総会  2013 

     More details

  • 蛍光標識による血中遊離癌細胞のLiquid Biopsy技術のバイオマーカー解析への応用

    第51回日本癌治療学会学術集会  2013 

     More details

  • 遺伝子情報によるバイオマーカーを用いた進行・再発大腸癌の検討および治療戦略の確立

    第51回日本癌治療学会学術集会  2013 

     More details

  • 遺伝子情報によるバイオマーカーを用いた進行・再発大腸癌の検討および治療戦略の確立

    第51回日本癌治療学会  2013 

     More details

  • Telomerase-targeting oncolytic adenovirus as the therapeutic and diagnostic agent.

    the 21st European Society of Gene and Cell Therapy 2013 Annual Meeting  2013 

     More details

  • 潰瘍性大腸炎に対する腹腔鏡下大腸全摘術のmatched case control studyによる開腹群との治療成績の比較

    EGI研究会  2013 

     More details

  • ASSISTANT-BASED STANDARDIZATION OF PRONE POSITION THORACOSCOPIC ESOPHAGECTOMY

    21st United European Gastroenterology Week  2013 

     More details

  • TREATMENT STRATEGY FOR COLORECTAL LIVER METASTASIS BASED ON GENETIC PROFILES

    21st United European Gastroenterology Week  2013 

     More details

  • 当科における気道系と瘻孔を形成した食道癌に対する集学的治療の経験

    第66回日本胸部外科学会定期学術集会  2013 

     More details

  • リンパ管造影にて治癒した食道癌術後難治性乳び胸症例の経験

    第66回日本胸部外科学会定期学術集会  2013 

     More details

  • 多視点3D解剖システム〜食道手術〜

    第66回日本胸部外科学会定期学術集会  2013 

     More details

  • 食道残胃吻合における手縫い「観音開き法」の胸腔内吻合への応用

    第66回日本胸部外科学会定期学術集会  2013 

     More details

  • 食道閉鎖症根治術後難治性吻合部狭窄に対するRadial Incision and Cutting(RIC)法の経験

    第33回日本小児内視鏡外科・手術手技研究会  2013 

     More details

  • 透視を用いず位置確認が可能な内視鏡的バルーン拡張術の工夫

    第86回日本消化器内視鏡学会総会  2013 

     More details

  • LECS変法(Closed LECS)の開発と臨床応用

    第8回LECS研究会  2013 

     More details

  • FREQUENCY OF REGULATORY T CELL AND HCV ANTIGEN SPECIFIC IMMUNE RESPONSE IN RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION

    21st United European Gastroenterology Week  2013 

     More details

  • 直腸癌術後尿管再発の一例

    第51回日本癌治療学会学術集会  2013 

     More details

  • 臓器別シンポジウム22 がんと臓器移植

    第51回日本癌治療学会学術集会  2013 

     More details

  • 肝移植・肺移植における移植後二次発癌

    第51回日本癌治療学会学術集会  2013 

     More details

  • 口演142 胃・十二指腸 化学療法4

    第51回日本癌治療学会学術集会  2013 

     More details

  • ER陰性/PR陽性乳がんにおけるER mRNAの発現とMolecularサブタイプ

    第51回日本癌治療学会学術集会  2013 

     More details

  • 大腸癌根治切除後の予後因子としてのMGMTプロモーターメチル化

    第51回日本癌治療学会学術集会  2013 

     More details

  • 便中メチル化CpG検出による消化器癌診断

    第51回日本癌治療学会学術集会  2013 

     More details

  • がん選択的生物製剤を用いた早期大腸癌の低侵襲治療の開発

    第51回日本癌治療学会学術集会  2013 

     More details

  • 除鉄を用いた新たな肝細胞癌治療

    第51回日本癌治療学会学術集会  2013 

     More details

  • Lecture 1, Special Lecture

    岡山大学 Kampo Conference  2012 

     More details

  • 膵神経内分泌腫瘍切除症例のWHO分類と画像所見、予後に関する検討

    第7回NET Work Japan  2012 

     More details

  • 胃粘膜下腫瘍に対するGelPOINT®を用いた腹腔鏡内視鏡合同手術(LECS)の1例

    第5回単孔式内視鏡外科研究会  2012 

     More details

  • 最新のからだに優しい消化器がん治療:低侵襲手術から未来医療まで

    第192回福山外科会  2012 

     More details

  • 大腸癌の再発を予測する新規バイオマーカーの検討-Stage II/III根治切除症例の検討から

    第45回制癌剤適応研究会  2012 

     More details

  • Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection : Our Initial Experience

    SAGES 2012 Annual Meeting  2012 

     More details

  • The Establishment of a Training System for Single Port Surgery (SPS) Using a Tissue Laboratory Model

    SAGES 2012 Annual Meeting  2012 

     More details

  • TANKO-Closed LECSの開発

    Reduced Port Surgery Forum  2012 

     More details

  • 先天性食道閉鎖症に合併した食道アカラシアの1例

    第51回日本小児外科学会中国四国地方会  2012 

     More details

  • 巨大副脾捻転の1例

    第51回日本小児外科学会中国四国地方会  2012 

     More details

  • microRNAによる発現制御システムを搭載した制限増殖型アデノウイルスによる血中循環癌細胞検出法の開発

    第71回日本癌学会学術総会  2012 

     More details

  • 骨肉腫に対するテロメラーゼ依存性腫瘍融解ウイルス製剤と化学療法の併用療法

    第71回日本癌学会学術総会  2012 

     More details

  • 癌関連線維芽細胞が食道癌の増殖に寄与する

    第71回日本癌学会学術総会  2012 

     More details

  • テロメラーゼ依存性増殖型アデノウイルス製剤を用いた早期大腸癌の低侵襲治療の開発

    第71回日本癌学会学術総会  2012 

     More details

  • FUCCI imaging visualizes S-phase blockage by methioninase in real time

    第71回日本癌学会学術総会  2012 

     More details

  • 低肺機能の胸部食道癌症例に対する腹臥位胸腔鏡下食道切除の経験

    第17回中国四国内視鏡外科研究会  2012 

     More details

  • 先天性食道閉鎖症に合併した食道アカラシアの小児例

    第17回中国四国内視鏡外科研究会  2012 

     More details

  • 内視鏡手術のピット・フォールとリカバリー

    第17回中国四国内視鏡外科研究会  2012 

     More details

  • 初期治療でセツキシマブ不応となった後三次治療での再使用により奏功した進行大腸癌の一例

    第3回大腸癌分子標的薬治療研究会  2012 

     More details

  • サイトケラチン19発現はEMT変化と肝細胞癌の肝外転移を予測する

    第71回日本癌学会学術総会  2012 

     More details

  • 腫瘍特異的cell-in-cell活性をもつHOZOT細胞を用いた腫瘍融解アデノウイルスのデリバリー技術の開発

    第71回日本癌学会学術総会  2012 

     More details

  • p53関連アポトーシス経路の誘導はヒト骨肉腫細胞における腫瘍融解アデノウイルスに対する抵抗性を減弱する

    第71回日本癌学会学術総会  2012 

     More details

  • 膵がんに対する非侵襲的スクリーニング技術の開発

    第71回日本癌学会学術総会  2012 

     More details

  • 腫瘍特異的制限増殖型アデノウイルスを用いた血液循環腫瘍細胞の遺伝子解析技術の開発

    第71回日本癌学会学術総会  2012 

     More details

  • 生体肝移植における人工血管の安全性と有用性の検討

    第48回日本移植学会総会  2012 

     More details

  • アルコール性肝硬変患者に対する肝移植適応基準確立に向けた岡山大学病院での取組み

    第48回日本移植学会総会  2012 

     More details

  • 改正臓器移植法後の脳死肝移植の現状と問題点

    第48回日本移植学会総会  2012 

     More details

  • 胃がんにおけるNetrin-1 recepterの遺伝子学的変化

    第71回日本癌学会学術総会  2012 

     More details

  • Cancer cellls blocked in S-phase of the cell cycle are effectively treated by cytotoxic chemotherapy

    第71回日本癌学会学術総会  2012 

     More details

  • Stage II, III大腸がん根治術後の再発予測マーカーとしてMGMTメチル化検査の意義

    第71回日本癌学会学術総会  2012 

     More details

  • 食道癌における除鉄による遊走、浸潤能抑制作用の検討

    第36回日本鉄バイオサイエンス学会学術集会  2012 

     More details

  • ULTRAPRO Plugを用いて修復した白線ヘルニアの1例

    第87回中国四国外科学会総会  2012 

     More details

  • IVRにて保存的に経過した外傷性腸間膜損傷の1例

    第87回中国四国外科学会総会  2012 

     More details

  • 咽頭喉頭食道全摘術を施行した症例における集学的治療の検討

    第87回中国四国外科学会総会  2012 

     More details

  • Zenker憩室に合併した頚部食道癌の1例

    第87回中国四国外科学会総会  2012 

     More details

  • 腹臥位胸腔鏡下食道亜全摘の際のピットフォール 当科での経験

    第17回中国四国内視鏡外科研究会  2012 

     More details

  • 当科での胸部食道癌手術の低侵襲化の推移とその成果

    第112回日本外科学会定期学術集会  2012 

     More details

  • 頸胸境界部進行食道癌に対するDoor open法によるアプローチ

    第112回日本外科学会定期学術集会  2012 

     More details

  • シンポジウム(2)「外科領域における先端技術・治療の開発」

    第112回日本外科学会定期学術集会  2012 

     More details

  • 特別講演

    Colorectal Cancer Symposium in Okayama  2012 

     More details

  • 大学病院の特殊な疾患群に対する胃瘻増設の現況

    第83回日本消化器内視鏡学会総会  2012 

     More details

  • 当科における中下咽頭表在癌に対するESDの工夫

    第83回日本消化器内視鏡学会総会  2012 

     More details

  • 食道アカラシアに対する腹腔鏡下手術

    第49回日本小児外科学会学術集会  2012 

     More details

  • I cyst 型胆道閉鎖症術後に肝細胞癌を合併し,生体肝移植術を施行した1例

    第49回日本小児外科学会学術集会  2012 

     More details

  • ロボット支援下幽門側胃切除術の安全な導入

    第112回日本外科学会定期学術集会  2012 

     More details

  • 高齢者肝細胞癌における肝切除の意義

    第112回日本外科学会定期学術集会  2012 

     More details

  • 抗原特異的免疫療法の効果増強に向けた新戦略

    第112回日本外科学会定期学術集会  2012 

     More details

  • 高度の脾腎シャントを有する生体肝移植におけるシャント処理法と成績

    第24回日本肝胆膵外科学会・学術集会  2012 

     More details

  • 大腸癌肝転移における治療戦略 -遺伝子変異情報を基盤とした治療戦略構築の可能性-

    第24回日本肝胆膵外科学会・学術集会  2012 

     More details

  • 当科における生体肝移植後肝静脈狭窄症例の検討

    第24回日本肝胆膵外科学会・学術集会  2012 

     More details

  • PBCに対する生体部分肝移植術後の再発、長期予後についての検討

    第24回日本肝胆膵外科学会・学術集会  2012 

     More details

  • 自然経過で腫瘍が縮小し臓器機能温存手術にて切除しえた膵Solid-pseudopapillary neoplasmの1例

    第24回日本肝胆膵外科学会・学術集会  2012 

     More details

  • 肝細胞癌に対する肝切除359例における胆汁漏およびorgan/space SSI危険因子の解析

    第24回日本肝胆膵外科学会・学術集会  2012 

     More details

  • リサーチワークショップ

    第24回日本肝胆膵外科学会・学術集会  2012 

     More details

  • シンポジウム テーマ: 「消化器病研究の最前線-今後の臨床への展開」

    第97回日本消化器病学会中国支部例会  2012 

     More details

  • 胃切除Roux-Y再建後の胃癌再発による十二指腸閉塞に対しダブルバルーン内視鏡用いたステント治療が有効であった1例

    第97回日本消化器病学会中国支部例会  2012 

     More details

  • 特別講演

    第50回岡山ストーマリハビリテーション研究会  2012 

     More details

  • Methioninase S-phase block of cancer cells imaged in real time by cell-cycle-specific fluorescence reporters

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • Preclinical evaluation of cytotoxic effect of photosensitive fluorescent protein in human cancer cells

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • Imaging cell cycle progression in gastric cancer lymph node metastasis indicates large fraction of proliferating cancer cells

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • A precise orthotopic rectal tumor model for evaluating therapeutic response of cancer treatment

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • A highly sensitive detection system of genetic alterations in circulating tumor cells using a telomerase-specific replication-competent adenovirus

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • Inhibitory effect of oncolytic adenovirus on transforming growth factor- β-induced epithelial-mesenchymal transition in human cancer cells

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • A simple biological imaging system for detecting adenovirus receptor expression in tumor cells using a telomerase-specific replication-competent adenovirus

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • Iron deficiency suppresses EMT through down-regulation of N-cadherin in esophageal cancer

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • Color-coded selective chemotherapy of methioninase-synchronized S-phase cancer cells expressing cell-cycle-specific fluorescent reporters: A general approach to the treatment of cancer

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • p53-mediated apoptotic signaling overcomes the resistance to oncolytic adenovirus in human osteosarcoma cells

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • Iron chelator contributes to anti-angiogenic therapy via selective induction of VEGF-A

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • 胃がん治療の最前線:最新治療から未来医療まで

    健康増進プロジェクト第7回岡山健康フォーラム「消化器がん治療の最前線」  2012 

     More details

  • マウス誘導膵幹細胞(Induced Pancreatic Stem(iPaS)Cells)の樹立

    第112回日本外科学会定期学術集会  2012 

     More details

  • Small for size syndrome に対する治療戦略-Portal modulation の意義と発症 Risk を踏まえた治療個別化の可能性-

    第112回日本外科学会定期学術集会  2012 

     More details

  • 大腸癌予後・再発を予測するエピジェネテックマークスの探索と臨床検体による再現性の検討

    第112回日本外科学会定期学術集会  2012 

     More details

  • 高齢者食道癌症例に対する手術術式と周術期管理

    第112回日本外科学会定期学術集会  2012 

     More details

  • 消化管間質腫瘍における血中浮遊腫瘍細胞検出の試み

    第112回日本外科学会定期学術集会  2012 

     More details

  • 再発肝細胞癌に対する治療戦略-予後予測モデルと再肝切除・RFA・Salvage Transplantationの適応-

    第112回日本外科学会定期学術集会  2012 

     More details

  • 遺伝子変異情報を基盤とした大腸癌個別化治療~治療前分類の重要性

    第112回日本外科学会定期学術集会  2012 

     More details

  • 胃がん治療の最前線:標準治療から未来医療まで

    赤穂市医師会学術講演会  2012 

     More details

  • Telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • Telomerase-specific replication-selective virotherapy combined with radiation therapy for oral squamous cell carcinoma cells

    2012 Annual Meeting of the American Association for Cancer Research  2012 

     More details

  • Safety and Feasibility of the Artificial Vascular Graft for Hepatic Outflow Reconstruction in Living Donor Liver Transplantation

    24th International Congress of The Transplantation Society  2012 

     More details

  • Safety and Feasibility of the Artifisial Vascular Graft for Hepatic Outflow Reconstruction in Living Donor Liver Transplantation (poster exhibiton)

    24th International Congress of The Transplantation Society  2012 

     More details

  • 遺伝子変異情報を用いた補助化学療法の適応の確立に向けて

    第67回日本消化器外科学会総会  2012 

     More details

  • 当科における胸部食道癌に対する鏡視下手術導入の成果についての検討

    第67回日本消化器外科学会総会  2012 

     More details

  • Telomerase-specific oncolytic adenovirus suppresses the stem-like properties of CD133+ human gastric cancer MKN45 cells through microRNA modulation

    第18回日本遺伝子治療学会  2012 

     More details

  • Oncolytic adenovirus-mediated p53 gene transfer induces antitumor effect in human osteosarcoma cells

    第18回日本遺伝子治療学会  2012 

     More details

  • The hTERT promoter enhances antitumor activity of oncolytic adenovirus under a hypoxic microenvironment

    第18回日本遺伝子治療学会  2012 

     More details

  • Symposium II Recent Cancer Gene Therapy Translational Research Program in Japan

    第18回日本遺伝子治療学会  2012 

     More details

  • 診断に苦慮した巨大副脾捻転の1例

    第48回日本小児放射線学会学術集会  2012 

     More details

  • 腹腔鏡下腹壁瘢痕ヘルニア修復術の経験

    第9回中国四国ヘルニア手術研究会  2012 

     More details

  • 当科におけるBarrett食道癌手術症例の検討

    第67回日本消化器外科学会総会  2012 

     More details

  • 同時性/異時性多発大腸癌に認められたsomatic mutation spectrumの不均一性

    第67回日本消化器外科学会総会  2012 

     More details

  • 生体肝移植ドナー手術における無血肝切除技術と胆道合併症予防対策の確立

    第67回日本消化器外科学会総会  2012 

     More details

  • 当院における胃上部早期胃癌に対する噴門側胃切除・食道残胃吻合術の検討

    第67回日本消化器外科学会総会  2012 

     More details

  • 急性肝不全に対する生体肝移植の展望

    第67回日本消化器外科学会総会  2012 

     More details

  • 当院で生体部分肝移植術を施行したPBC26症例の再発,長期予後についての検討

    第67回日本消化器外科学会総会  2012 

     More details

  • ロボット支援下胃切除術の術野展開と郭清手技

    第67回日本消化器外科学会総会  2012 

     More details

  • 遺伝子変異情報を基盤とした大腸癌肝転移の治療戦略構築の可能性

    第67回日本消化器外科学会総会  2012 

     More details

  • がん特異的増殖アデノウイルス製剤OBP-401を用いた生体内癌組織蛍光イメージング

    第67回日本消化器外科学会総会  2012 

     More details

  • 喫煙食道癌患者の治療マネジメント

    第67回日本消化器外科学会総会  2012 

     More details

  • 一般演題 胃3

    第34回日本癌局所療法研究会  2012 

     More details

  • 健常者における肝部分切除後の血清中増殖因子変化と肝再生

    第11回日本再生医療学会総会  2012 

     More details

  • 改正臓器移植法後の脳死肝移植の現状と問題点

    第30回日本肝移植研究会  2012 

     More details

  • 食道がん周術期合併症対策と栄養管理

    周術期栄養療法研究会  2012 

     More details

  • ROBOT-ASSISTED DISTAL GASTRECTOMY: OUR INITIAL EXPERIENCE

    20th International Congress of the European Association for Endoscopic Surgery  2012 

     More details

  • HIGH SENSITIVITY AND SPECIFICITY OF ADHESION MAPPING BY ULTRASOUND EXAMINATION

    20th International Congress of the European Association for Endoscopic Surgery  2012 

     More details

  • 消化器がん治療における最新の話題

    第17回癌と遺伝子・大分外科フォーラム  2012 

     More details

  • Living-donor liver transplantation for hepatocellular carcinoma in billiary atresia (type 1 cyst): a case report

    The 45th Annual Meeting of the Pacific Association of Pediatric Surgeons  2012 

     More details

  • Roux-Y再建後の十二指腸閉塞にステント治療が有効であった一例

    第34回日本癌局所療法研究会  2012 

     More details

  • 術後早期に脊椎骨転移による横断性脊髄障害を認めた胃癌の1例

    第34回日本癌局所療法研究会  2012 

     More details

  • 心嚢開窓術後心嚢内ヘルニア嵌頓の症例

    第55回関西胸部外科学会学術集会  2012 

     More details

  • パネルディスカッション7 がんと診断された時からの緩和ケアの実践のために~がん治療と緩和ケアの両立~

    第17回日本緩和医療学会学術大会  2012 

     More details

  • モーニングセミナー8

    第17回日本緩和医療学会学術大会  2012 

     More details

  • New method for investigating genetic mutations of circulating tumor cells using a telomerase-specific replication-competent adenovirus

    第18回日本遺伝子治療学会  2012 

     More details

  • Novel less invasive therapeutic intervention for earl telomerase-dependent replicating adenoviral agent

    第18回日本遺伝子治療学会  2012 

     More details

  • 胃が使用不能な食道癌症例における腸管による最良の再建術を目指した工夫

    第66回日本食道学会学術集会  2012 

     More details

  • 当科における Barrett 食道癌手術症例の検討

    第66回日本食道学会学術集会  2012 

     More details

  • 鉄コントロールによる新しい食道癌治療法の開発

    第66回日本食道学会学術集会  2012 

     More details

  • 当科における高齢者食道癌症例の治療への取り組み

    第66回日本食道学会学術集会  2012 

     More details

  • 手術を施行した食道小細胞癌の2症例

    第55回関西胸部外科学会学術集会  2012 

     More details

  • DEVELOPMENT OF NON-INVASIVE SCREENING BY FECAL DNA METHYLATION ANALYSIS TO DETECT GASTROINTESTINAL NEOPLASIA

    2012 WORLD CANCER CONGRESS  2012 

     More details

  • English Oral Sessions「21E Gene Therapy (1)」

    第71回日本癌学会学術総会  2012 

     More details

  • 食道癌転移診断におけるPET-CT検査の限界-PET-CT偽陽性症例の検討-

    第67回日本消化器外科学会総会  2012 

     More details

  • 生体肝移植周術期栄養療法の有用性に関する検討~生体肝移植における至適ERASの確立を目指して~

    第67回日本消化器外科学会総会  2012 

     More details

  • BRAF変異 大腸癌Stage IV症例の検討

    第67回日本消化器外科学会総会  2012 

     More details

  • 要望演題

    第67回日本消化器外科学会総会  2012 

     More details

  • 特別講演

    第2回岡山手術手技ビデオフォーラム  2012 

     More details

  • 肝転移を伴う切除不能大腸癌に対する1次治療としてのSOX+パニツムマブ療法の検討

    Colorectal Conference in Okayama  2012 

     More details

  • 特別講演

    Colorectal Conference in Okayama  2012 

     More details

  • Non-recurrent inferior laryngeal nerveを伴う胸部食道癌に対して胸腔鏡下食道亜全摘を施行した1例

    第25回日本内視鏡外科学会総会  2012 

     More details

  • 生体肝移植ドナーにおけるCounterclockwise Liver RotationとEarly Hanging Maneuverを併用した肝切除技術

    第74回日本臨床外科学会総会  2012 

     More details

  • 胃が使用できない食道癌症例におけるQOL向上を目指した腸管による食道再建法

    第74回日本臨床外科学会総会  2012 

     More details

  • 高度脈管浸潤を伴う進行肝細胞癌の治療戦略

    第74回日本臨床外科学会総会  2012 

     More details

  • Energy device併用による肝腫瘍に対する無血肝切除技術

    第74回日本臨床外科学会総会  2012 

     More details

  • 多発外傷(骨盤開放骨折)に対する治療戦略

    第74回日本臨床外科学会総会  2012 

     More details

  • チームで乗り切る食道癌手術(当院での周術期管理センター:PERIO の取り組み)

    第74回日本臨床外科学会総会  2012 

     More details

  • 当科における食道胃接合部癌に対する再建法の工夫 胸腔内観音開き法吻合の経験

    第74回日本臨床外科学会総会  2012 

     More details

  • Genetic/epigenetic 変異を基盤とした大腸癌個別化治療の構築と臨床応用

    第67回日本大腸肛門病学会学術集会  2012 

     More details

  • 消化器癌を遺伝子改変ウイルスで見て治す方法

    第73回未来医療セミナー  2012 

     More details

  • 腹腔鏡補助下噴門側胃切除術のための「観音開き法」食道残胃吻合の工夫

    第74回日本臨床外科学会総会  2012 

     More details

  • コンポジットメッシュと非吸収性タックを用い腹腔鏡下にて修復した腹壁瘢痕ヘルニアの一例

    第74回日本臨床外科学会総会  2012 

     More details

  • 出血性ショックをきたした回腸静脈瘤破裂に対しバルーン下逆行性経静脈的塞栓術(BRTO)が奏功した1例

    第74回日本臨床外科学会総会  2012 

     More details

  • 胸部食道癌に対する頸部/上縦隔郭清-至適郭清範囲の設定とその根拠-

    第74回日本臨床外科学会総会  2012 

     More details

  • 主題関連演題 各領域手術における様々なエネルギーデバイスの用い方3

    第74回日本臨床外科学会総会  2012 

     More details

  • 脳死肝移植登録患者の経過よりわかるドナーアクションの必要性

    第98回日本消化器病学会中国支部例会  2012 

     More details

  • 生体肝移植における人工血管を利用した血行再建

    第Ⅲ期(1回)Liver Transplant Winter Seminar  2012 

     More details

  • 高度技能医修練における膵消化管吻合と膵液瘻への対策

    第74回日本臨床外科学会総会  2012 

     More details

  • 同時性肝内転移、膵転移を伴った肝原発solitary fibrous tumorの一例

    第74回日本臨床外科学会総会  2012 

     More details

  • 低肺機能合併の胸部食道癌症例に対する腹臥位胸腔鏡下食道切除の経験

    第74回日本臨床外科学会総会  2012 

     More details

  • Zenker憩室に合併した頚部食道表在癌の1例

    第74回日本臨床外科学会総会  2012 

     More details

  • Initial Experience of Robot-Assisted Distal Gastrectomy for Early Gastric Cancer in Our Institution

    4th Worldwide Congress of CRSA(Clinical Robotic Surgery Association)  2012 

     More details

  • 胃がん・食道がん治療の最前線

    第17回横浜胃癌個別化治療勉強会  2012 

     More details

  • 便中メチル化CpG検出による消化器癌スクリーニング

    第20回日本消化器関連学会週間  2012 

     More details

  • 消化器がん治療における遺伝子工学技術に基づく先端医療開発

    第20回日本消化器関連学会週間(第10回日本消化器外科学会大会)  2012 

     More details

  • パラチノースを糖質源とした調整流動食MHN-01を用いた食道癌周術期管理

    第10回日本消化器外科学会大会  2012 

     More details

  • 当院でのPERIOによる胸部食道癌周術期管理の取り組みについての検討

    第65回日本胸部外科学会定期学術集会  2012 

     More details

  • 当科における咽頭食道全摘症例の検討

    第65回日本胸部外科学会定期学術集会  2012 

     More details

  • 腹部食道癌に対して左開胸開腹連続切開および観音開き法食道残胃吻合を行った1症例

    第65回日本胸部外科学会定期学術集会  2012 

     More details

  • 更なる安全性確保を求めた生体肝移植ドナー手術手技

    第48回日本移植学会総会  2012 

     More details

  • 成人生体肝移植の短期予後解析~Small-for-size syndrome発症リスクを踏まえた治療戦略の提言~

    第48回日本移植学会総会  2012 

     More details

  • 臓器移植におけるHigh morbidity group box-1の動態および機能解析

    第48回日本移植学会総会  2012 

     More details

  • TREATMENT STRATEGY FOR ADVANCED HEPATOCELLULAR CARCINOMA WITH MAJOR PORTAL OR HEPATIC VEIN INVASION

    20th United European Gastroenterology Week  2012 

     More details

  • CLINICAL STRATEGY OF BARRETT‘S ESOPHAGEAL ADENOCARCINOMA – ANALYSIS OF 20 CASES

    20th United European Gastroenterology Week  2012 

     More details

  • 一般演題 胃3

    第50回日本癌治療学会学術集会  2012 

     More details

  • 血管新生阻害作用を有する抗がん剤の抗腫瘍作用増強剤

    岡山大学知恵の見本市2012  2012 

     More details

  • 一般演題(口演)82「癌関連遺伝子1」

    第53回日本肺癌学会総会  2012 

     More details

  • 先天性胆道拡張症に対する鏡視下手術の経験

    第32回日本小児内視鏡外科・手術手技研究会  2012 

     More details

  • 逆流性食道炎を徹底的に防ぐための「観音開き法」食道・胃吻合の工夫

    第42回胃外科・術後障害研究会  2012 

     More details

  • 体内鉄の食道癌における新規バイオマーカーとしての可能性

    第23回日本消化器癌発生学会総会  2012 

     More details

  • 気管浸潤食道癌に対してCRT後の局所再発巣も根治切除し得た一例

    第5回日本胸部外科学会食道困難症例検討会  2012 

     More details

  • OUTCOME AND PROGNOSTIC FACTORS OF ELDERLY PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING HEPATECTOMY

    20th United European Gastroenterology Week  2012 

     More details

  • 心房中隔欠損症による肺高血圧症を合併した食道癌切除の経験

    第65回日本胸部外科学会定期学術集会  2012 

     More details

  • 新規がんワクチン療法の開発を見据えた癌部・非癌部のHLA class I発現強度の検討

    第25回日本バイオセラピィ学会学術集会総会  2012 

     More details

  • ワークショップ1 サイトカインと遺伝子治療

    第25回日本バイオセラピィ学会学術集会総会  2012 

     More details

  • 大学病院におけるNST活動の現況と課題

    第5回日本静脈経腸栄養学会中国支部学術集会  2012 

     More details

  • 食道癌鏡視下手術の周術期におけるチーム医療の関わり

    第25回日本内視鏡外科学会総会  2012 

     More details

  • Double bipolar techniqueによる術野展開の工夫と郭清手技

    第25回日本内視鏡外科学会総会  2012 

     More details

  • 腹腔鏡手術における腹腔内癒着マッピングの有用性と意義

    第25回日本内視鏡外科学会総会  2012 

     More details

  • 我々の目指すチーム内視鏡外科 当科における腹臥位胸腔鏡下食道亜全摘における術者助手のコラボレーション

    第25回日本内視鏡外科学会総会  2012 

     More details

  • 当科において経験した食道癌術後胃管癌18例の検討

    第84回日本胃癌学会総会  2012 

     More details

  • 当院における胃GISTに対するイマチニブ投与の位置づけ

    第84回日本胃癌学会総会  2012 

     More details

  • 異時性及び同時性大腸がん肝転移治療における遺伝子情報の使い方ーKRAS変異を中心に。

    第76回大腸癌研究会  2012 

     More details

  • 遺伝子改変ウイルスの先進的がん診断・治療への応用

    第3回先進医療フォーラム  2012 

     More details

  • 肝移植手術における人工血管を用いた血行再建とその術後管理

    第13回肝移植術後管理検討会  2012 

     More details

  • Laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for advanced gastric cancer in our institution

    第84回日本胃癌学会総会  2012 

     More details

  • 胃癌術後再発症例に対する放射線療法の経験

    第84回日本胃癌学会総会  2012 

     More details

  • 「癌遺伝子治療臨床研究」

    第9回遺伝子治療シンポジウム  2011 

     More details

  • 胃がん・食道がんの最先端治療

    第9回芳医会特別企画 市民公開講座「がんと闘う医療:最先端の治療現場から」  2011 

     More details

  • 胃がん治療の最前線.

    都窪医師会学術講演会  2011 

     More details

  • Splenic aeteru syndrome after living donor liver transplantation with ligation of the splenic arteru: a case report

    12th Congress of the Asian Society of Transplantation  2011 

     More details

  • Oncolytic adenovirus induces autophagic cell death through an E2F-1 microRNA7-epidermal growth factor receptor axis in human cancer cells

    14th Annual Meeting of American Society of Gene & Cell Therapy  2011 

     More details

  • Biological effects of oncolytic adenovirus on epithelial-mesenchymal transition in human lung cancer cells.

    14th Annual Meeting of American Society of Gene & Cell Therapy  2011 

     More details

  • 生体肝移植後の免疫不全状態に発症した深在性トリコスポロン症の1例

    第24回日本外科感染症学会総会学術集会  2011 

     More details

  • 「J21-2 遺伝子治療」

    第70回日本癌学会学術総会  2011 

     More details

  • 「ワークショップ1 最新の遺伝子治療」

    第24回日本バイオセラピィ学会学術集会総会  2011 

     More details

  • da Vinciによるロボット支援下幽門側胃切除術

    第10回EGI外科治療研究会  2011 

     More details

  • 消化器がん治療における先端医療開発.

    第3回四国消化器癌フォーラム  2011 

     More details

  • 消化器がん治療の最前線.

    三原医師会講演会  2011 

     More details

  • 消化器がん治療の最前線.

    平成22年度鶴翔会(岡山大学医学部同窓会)香川支部総会  2011 

     More details

  • ウイルス製剤のがん治療ならびにがんイメージング臨床研究の最前線.

    熊本大学大学院講義「名医に学ぶセミナー」  2011 

     More details

  • 消化器がん治療における先端医療開発.

    第8回外科学フォーラム  2011 

     More details

  • 消化器がん治療における先端医療開発.

    平成23年度楷風会(高知大学医学部外科1同門会)特別講演会  2011 

     More details

  • 消化器がん治療における先端医療開発

    第110回岡山医学会総会  2011 

     More details

  • 遺伝子改変ウイルスを用いたがんの分子イメージングおよび集学的治療の臨床応用.

    第18回阪大医療組織工学フォーラム  2011 

     More details

  • 消化器がん治療における先端医療開発.

    横浜市立大学大学院医学研究科大学院医学セミナー  2011 

     More details

  • 消化器がん治療における先端医療開発.

    平成22年度鶴翔会(岡山大学医学部同窓会)近畿総支部総会  2011 

     More details

  • 「Session II Gene Therapy in East Asia」

    アジアンスタディー岡山’11  2011 

     More details

  • 特別講演

    Gastric cancer Symposium in Okayama  2011 

     More details

  • A novel synergistic effect of iron depletion on anti-angiogenic therapy

    第9回がんとハイポキシア研究会  2011 

     More details

  • 当院消化器外科領域におけるRobotic Surgeryの現状

    第73回日本臨床外科学会総会  2011 

     More details

  • Detection of viable human circulating tumor cells using telomerase-specific GFP-expressing bioengineered adenovirus in patients with gastric cancer: A fiesibility study.

    2011 ASCO Gastrointestinal Cancer Symposium  2011 

     More details

  • 特別講演

    岡山消化器神経内分泌腫瘍セミナー  2011 

     More details

  • 生体肝移植周術期栄養療法に関する探索的臨床研究

    第26回日本静脈経腸栄養学会  2011 

     More details

  • 頭頸部癌・食道癌におけるPEGを用いた栄養管理の有用性の検討

    第174回岡山外科会  2011 

     More details

  • 消化器がん治療における先端医療開発.

    第5回千葉オンコロジーセミナー  2011 

     More details

  • テロメラーゼ活性を標的とした増殖ウイルスTelomelysinの臨床応用

    第24回日本バイオセラピィ学会学術集会総会  2011 

     More details

  • Iron deficiency suppress EMT through downregulation of N-cadherin in esophageal cancer

    102nd Annual meeting of American Association for Cancer Research  2011 

     More details

  • Iron controlled treatment can be novel therapeutic agent and biomarker of Bevacizumab

    102nd Annual meeting of American Association for Cancer Research  2011 

     More details

  • SENSITIZATION TO TRASTUZUMAN VIA ADCC ACTIVATION BY EXOGENOUS EXPRESSION OF HER2 EZTRACELLULAR DOMAIN IN HER2-NEGATIVE HUMAN GASTRIC CANCER CELLS

    9th interunational gastric cancer congress  2011 

     More details

  • THREE-DIMENSIONAL VISUALIZATION OF ELIMIATING HUMAN CANCER STEM CELL BY ONCOLITYC ADENOVIRUS

    9th interunational gastric cancer congress  2011 

     More details

  • A MODIFIED OVERLAP METHOD FOR PERFORMING BILLROTH-I ANASTOMOSIS AFTER LAPAROSCOPIC DISTAL GASTRECTOMY

    9th interunational gastric cancer congress  2011 

     More details

  • PHASE II STUDY OF S-1 AND DECETAXEL COMBINATION CHEMOTHERAPY FOR ADVANCED OR RECURRENT GASTRIC CANCER WITH PERITONEAL DISSEMINATION

    9th interunational gastric cancer congress  2011 

     More details

  • Telomerase-specific oncolytic adenovirus for human cancer therapy and diagnostic imaging. “Viral Vecors for Immunomodulation of Cancer: From Bench to Bed”

    14th Annual Meeting of American Society of Gene & Cell Therapy: Scientific Symposium  2011 

     More details

  • 乳がんのトラスツズマブ耐性機構の解析とHER2細胞外ドメイン発現によるADCC活性増強を介した感受性誘導

    第32回癌免疫外科研究会  2011 

     More details

  • Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2 extracellular domain in human breast cancer cells

    102nd Annual meeting of American Association for Cancer Research  2011 

     More details

  • Clinical utility of circulating tumor cell monitoring for therapeutic response in gastric cancer patients

    102nd Annual meeting of American Association for Cancer Research  2011 

     More details

  • Bioengineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis

    102nd Annual meeting of American Association for Cancer Research  2011 

     More details

  • 生体肝移植周術期栄養療法に関する探索的臨床研究

    第23回日本肝胆膵外科学会・学術集会  2011 

     More details

  • 高度技能医修練における肝切除術前シミュレーションの有用性 -高度技能医修練者の肝前区域切除術-

    第23回日本肝胆膵外科学会・学術集会  2011 

     More details

  • 脾動脈結紮を伴う生体肝移植後に脾動脈症候群を呈した一例

    第24回日本小児脾臓研究会  2011 

     More details

  • 未定

    岡山大腸がん治療セミナー  2011 

     More details

  • 放射線化学療法にて長期CRが得られた胃癌直腸膀胱窩再発の1例

    第33回日本局所療法研究会  2011 

     More details

  • PURAMATRIX IS A NEW AND USEFUL HEMOSTAT IN ENDOSCOPIC SURGERY

    19th International Congress of the European Association for Endoscopic Surgery  2011 

     More details

  • RECOGNITION OF DOESAL DIVIDING LINES FOR SUPRAPANCREATIC LYMPH NODE DISSECTION IN LAPAROSCOPIC DISTAL GASTRECTOMY FOR ADVANCED GASTRIC CANCER

    19th International Congress of the European Association for Endoscopic Surgery  2011 

     More details

  • テロメラーゼ活性を標的とするウイルス製剤の癌診断・治療への応用

    第20回日本癌病態治療研究会  2011 

     More details

  • Power of fecal DNA methylation analysis: Does it lead to development of a noninvasive screening tool for pancreatic cancer?

    2011 ASCO Meeting  2011 

     More details

  • A mouse model of rectal cancer that mimics the clinical disease.

    2011 ASCO Meeting  2011 

     More details

  • II部最前線の手術

    第1回岡山手術手技ビデオフォーラム  2011 

     More details

  • 悪性リンパ腫合併胸部食道癌症例の治療経験

    第174回岡山外科会  2011 

     More details

  • 岡山大学病院における胃癌に対するダビンチS(da Vinci S Surgical System)によるロボット支援腹腔鏡下手術の導入

    第174回岡山外科会  2011 

     More details

  • 成人生体肝移植における胆道合併症の傾向とその対策

    第174回岡山外科会  2011 

     More details

  • 特別講演

    第2回岡山大学外科研修MCセミナー  2011 

     More details

  • 遺伝子変異情報に基づいた大腸がん制癌剤治療選択の必要性

    第44回制癌剤適応研究会  2011 

     More details

  • 特別講演

    大腸癌治療学術講演会  2011 

     More details

  • Inhibition of mammalian target of rapamycin (mTOR) signaling by Temsirolimus as a potential therapeutic strategy for esophageal cancer treatment

    102nd Annual meeting of American Association for Cancer Research  2011 

     More details

  • Selective GFP labeling of cancer with a telomerase-specific adenovirus (OBP-401) to report future recurrence after resection

    102nd Annual meeting of American Association for Cancer Research  2011 

     More details

  • 当科における食道バイパス術の経験

    第86回中国四国外科学会総会,第16回中国四国内視鏡外科研究会  2011 

     More details

  • 食道小細胞癌の一手術例の経験

    第86回中国四国外科学会総会,第16回中国四国内視鏡外科研究会  2011 

     More details

  • 当科における胃管作成の工夫、鏡視下導入を中心に

    第86回中国四国外科学会総会,第16回中国四国内視鏡外科研究会  2011 

     More details

  • Roux Stasisの長期保存的加療においてPEG-Jが有効であった一例

    第86回中国四国外科学会総会,第16回中国四国内視鏡外科研究会  2011 

     More details

  • 胸部食道癌手術における交感神経と副交感神経の走行を念頭に置いた縦隔リンパ節郭清

    第86回中国四国外科学会総会  2011 

     More details

  • 肝十二指腸間膜左側アプローチによるNo.12a郭清

    第66回日本消化器外科学会総会  2011 

     More details

  • 改正臓器移植法施行後の脳死肝移植における問題点

    第29回日本肝移植研究会  2011 

     More details

  • 岡山大学病院における肝移植患者に対する全科横断的な取り組み

    第29回日本肝移植研究会  2011 

     More details

  • 移植後肝疾患における末梢制御性T細胞の頻度の検討

    第29回日本肝移植研究会  2011 

     More details

  • 脳死肝移植5例の経験

    第29回中国四国臨床臓器移植研究会  2011 

     More details

  • アカデミアにおける探索的医薬品開発の方向性~国産ウイルス製剤の米国での臨床試験への道程~.

    第11回CRCと臨床試験のあり方を考える会議  2011 

     More details

  • 遺伝子治療

    第70回日本癌学会学術総会  2011 

     More details

  • Oncolytic adenovirus suppresses TGE-β-induced epithelial mesenchymal transition and invasiveness in human cancer cells

    第70回日本癌学会学術総会  2011 

     More details

  • 劇症肝炎に対する肝移植の展望

    第47回日本移植学会総会  2011 

     More details

  • ランチョンセミナー2

    第86回中国四国外科学会総会,第16回中国四国内視鏡外科研究会  2011 

     More details

  • BRANCHED-CHAIN AMINO ACID-ENRICHED NUTRIENTS IMPROVE NUTRITIONAL AND METABOLIC ABNORMALITIES IN THE EARLY POST-TRANSPLANT PERIOD AFTER LIVING DONOR LIVER TRANSPLANTATION

    33rd Congress of Clinical Nutrition and Metabolism!  2011 

     More details

  • EARLY GRAFT FUNCTION IN LIVING DONOR LIVER TRANSPLANTATION IS NOT PREDICTED BY GRAFT SIZE ALONE, BUT IS DETERMINED BY THE CORRELATION BETWEEN GRAFT SIZE, DONOR AGE, AND RECIPIENT STATUS

    15th Congress of the European Society for Organ Transplantation  2011 

     More details

  • IMPACT OF ACUTE RENAL DISEASE DEFINED BY RIFLE CRITERIA IN LIVING DONOR LIVER TRANSPLANTATION

    15th Congress of the European Society for Organ Transplantation  2011 

     More details

  • 鉄欠乏マウスモデルを用いた血管新生阻害薬併用療法の基礎的検討

    第35回日本鉄バイオサイエンス学会学術集会  2011 

     More details

  • 特別講演

    第1回胃癌TVネットワークセミナー  2011 

     More details

  • 脳死肝移植登録医学的緊急性9点症例の経過と問題点

    第95回日本消化器病学会中国支部例会  2011 

     More details

  • 未定

    Cancer Pain Forum  2011 

     More details

  • 特別講演

    べくティビックス発売1周年記念講演会  2011 

     More details

  • 胃癌幹細胞に対するテロメラーゼ特異的腫瘍融解ウイルス治療とその作用機序の解析

    第21回日本サイトメトリー学会学術集会  2011 

     More details

  • 当科における胃管作成および再建の工夫

    第54回関西胸部外科学会学術集会  2011 

     More details

  • 食道癌術後気管穿孔に対するDP flapによる修復の経験

    第54回関西胸部外科学会学術集会  2011 

     More details

  • 抗原特異的免疫療法の効果増強を目指した基礎研究:ペプチド腫瘍内注入

    第15回日本がん免疫学会総会  2011 

     More details

  • テロメラーゼ活性を標的とするウイルス製剤の癌診断・治療への応用.

    第20回癌病態治療研究会  2011 

     More details

  • 遺伝子変異を基盤とした大腸癌個別化治療戦略の可能性

    第95回日本消化器病学会中国支部例会  2011 

     More details

  • 大腸癌肝転移における治療戦略

    第95回日本消化器病学会中国支部例会  2011 

     More details

  • 高度脈管侵襲肝癌に対する治療戦略-Vp3/4, Vv2/3振興肝癌の治療成績

    第66回日本消化器外科学会総会  2011 

     More details

  • 岡山大学外科研修マネジメントセンター:医局を超えた外科研修教育の取り組み

    第66回日本消化器外科学会総会  2011 

     More details

  • パラチノースを糖質源とした調整流動食MHN-01による食道癌周術期栄養管理の有用性

    第66回日本消化器外科学会総会  2011 

     More details

  • 当科における胃管作成および再建術の工夫

    第66回日本消化器外科学会総会  2011 

     More details

  • 大腸癌肝転移における治療戦略ー遺伝子変異情報を基盤とした治療戦略構築の可能性ー

    第66回日本消化器外科学会総会  2011 

     More details

  • 同時多発性胃癌術後の残胃癌に関する検討

    第66回日本消化器外科学会総会  2011 

     More details

  • 当院で切除した膵内分泌腫瘍に対する治療成績

    第66回日本消化器外科学会総会  2011 

     More details

  • 高齢者食道癌症例に対する外科治療の現況と成績

    第66回日本消化器外科学会総会  2011 

     More details

  • 当科における食道胃接合部の食道癌に対する治療

    第66回日本消化器外科学会総会  2011 

     More details

  • FITMATEを用いて呼吸商から基礎代謝を測定し,術後管理に利用する新しい試み

    第66回日本消化器外科学会総会  2011 

     More details

  • ロボット支援下幽門側胃切除術の安全な導入を目指して―導入初期3例の検討―

    第24回日本内視鏡外科学会総会  2011 

     More details

  • 当院における頭頚部癌治療症例に対するPEGの現況

    第4回日本静脈経腸栄養学会中国支部学術集会  2011 

     More details

  • Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1%-10% ER-positive by immunohistochemistry

    The 2011 CTRC-AACR San Antonio Breast Cancer Symposium  2011 

     More details

  • 当科における高齢者食道癌手術症例の術式選択の工夫

    第73回日本臨床外科学会総会  2011 

     More details

  • 当科における食道癌頭頸部癌重複症例の検討

    第73回日本臨床外科学会総会  2011 

     More details

  • 当科における食道癌に対する胃管再建作成および吻合における工夫

    第73回日本臨床外科学会総会  2011 

     More details

  • 生体肝移植術後の腎障害に対するRifle分類の有用性

    第47回日本移植学会総会  2011 

     More details

  • ブタ膵島分離における組織内膵島の定量分析

    第47回日本移植学会総会  2011 

     More details

  • 胃癌に対するRobot Assisted Gastrectomyの導入経験

    第19回日本消化器関連学会週間 第9回日本消化器外科学会大会  2011 

     More details

  • UPREGULATION OF CD14 ON KUPFFER CELLS IS A DISTINCT FEATURE NON-ALCOHOLIC STEATOHEPATITIS AFTER PANCREATODUODENECTOMY

    19th United Europian Gastroenterology Week  2011 

     More details

  • 口演7 胃3

    第49回日本癌治療学会学術集会  2011 

     More details

  • 当科における食道胃接合部の諸行動癌についての検討

    第73回日本臨床外科学会総会  2011 

     More details

  • 当科におけるT4食道癌に対する治療戦略についての検討

    第73回日本臨床外科学会総会  2011 

     More details

  • ペプチド特異的免疫療法の効果増強を目指したペプチド腫瘍内注入

    第24回日本バイオセラピィ学会学術集会総会  2011 

     More details

  • 早期胃癌を大正としたda Vinci SHD surgical systemの導入経験

    第4回日本ロボット外科学会学術集会  2011 

     More details

  • 当科における食道及び中下咽喉表在癌に対するESDの工夫

    第73回日本臨床外科学会総会  2011 

     More details

  • 高難度肝切除における無血肝摂理技術の確立

    第73回日本臨床外科学会総会  2011 

     More details

  • 肺高血圧症を伴ったC型肝硬変患者に生体肝移植を施行し得た1例

    第73回日本臨床外科学会総会  2011 

     More details

  • 肝胆膵外科高度技能医育成における肝切除シミュレーションの有用性

    第73回日本臨床外科学会総会  2011 

     More details

  • HCCに対する安全・確実な門脈腫瘍栓摘出・再建術

    第73回日本臨床外科学会総会  2011 

     More details

  • マウス膵幹細胞の培養条件の検討

    第38回日本臓器保存生物医学会学術集会  2011 

     More details

  • マウス膵幹細胞の樹立効率の検討

    第38回日本臓器保存生物医学会学術集会  2011 

     More details

  • テロメラーゼ特異的腫瘍融解ウイルスはより多く複製することで胃癌幹細胞を効率的に破壊する.

    第68回日本癌学会学術総会  2009 

     More details

  • テロメラーゼ活性を標的とするウイルス製剤の癌診断・治療への応用

    広島大学平成20年度非常勤講師講演会  2009 

     More details

  • Telomerase-specific oncolytic virotherapy for human cancer.

    Japan-Denmark Joint Workshop “Molecular Cancer Research”  2009 

     More details

  • 「癌治療への応用」の座長

    第7回遺伝子治療シンポジウム「幹細胞の機能制御と難病治療への応用」  2009 

     More details

  • 腹腔鏡補助下胃切除術における小開腹先行の有用性. 小開腹創からの肝臓鈎による術野展開.

    第81回日本胃癌学会総会  2009 

     More details

  • Preclinical study of telomerase-selective oncolytic adenovirus (OBP-301) in combination with chemotherapeutic agents.

    100th Annual Meeting American Association for Cancer Research  2009 

     More details

  • Telomerase-specific oncolytic adenovirus armed with wild-type p53 gene (CGCT-04) efficiently induces apoptosis in human cancer cells.

    100th Annual Meeting American Association for Cancer Research  2009 

     More details

  • Biological imaging system to detect viable circulating tumor cells is useful for monitoring the efficacy of treatment in cancer patients.

    100th Annual Meeting American Association for Cancer Research  2009 

     More details

  • Telomerase-specific oncolytic adenovirus mediates molecular sensitization to ionizing radiation in human cancer cells through E1B55kDa expression.

    100th Annual Meeting American Association for Cancer Research  2009 

     More details

  • Biological purging of lymph node metastasis of gastrointestinal cancer by telomerase-specific virotherapy.

    100th Annual Meeting American Association for Cancer Research  2009 

     More details

  • 胃癌患者の血漿アミノ酸バランスとその意義 -進行度予測の可能性について-.

    第81回日本胃癌学会総会  2009 

     More details

  • 腹腔鏡補助下胃切除術における我々の工夫

    第8回EGI外科治療研究会  2009 

     More details

  • テロメラーゼ活性を標的とするウイルス製剤OBP-301の臨床応用:固形腫瘍に対する第Ⅰ相臨床試験.

    第109回日本外科学会定期学術集会  2009 

     More details

  • 「シンポジウム1 外科領域における遺伝子治療・再生医療の問題点と今後の展開」 の座長

    第109回日本外科学会定期学術集会  2009 

     More details

  • Telomerase-specific oncolytic virotherapy purging cancer stem cells.

    100th Annual Meeting American Association for Cancer Research  2009 

     More details

  • 腹腔鏡補助下胃切除術における術野展開の工夫

    第22回日本内視鏡外科学会総会  2009 

     More details

  • Preclinical study of telomerase-selective oncolytic adenovirus (OBP-301) in combination with chemotherapeutic agent and radiation.

    第15回日本遺伝子治療学会  2009 

     More details

  • テロメラーゼ特異的腫瘍融解アデノウイルスによる放射線感受性増強とその分子機構の解析.

    第39回放射線による制癌シンポジウム  2009 

     More details

  • 悪性腫瘍に対するテロメラーゼ特異的腫瘍融解ウイルス療法.

    第68回日本癌学会学術総会  2009 

     More details

  • テロメラーゼ特異的腫瘍融解アデノウイルスによるp53の過剰発現はAdE1Aによるp21不活化によりアポトーシスを誘導する.

    第68回日本癌学会学術総会  2009 

     More details

  • Preclinical evaluation of telomerase-specific virotheranostics for human head and neck cancer.

    100th Annual Meeting American Association for Cancer Research  2009 

     More details

  • Systemic tumor targeting by a telomerase-specific replicating adenovirus (OBP-301) results in inhibition of metastasis.

    100th Annual Meeting American Association for Cancer Research  2009 

     More details

  • 早期胃癌に対する腹腔鏡補助下胃切除術 我々の取り組み

    第1回せとうちMISを極める会  2009 

     More details

  • テロメラーゼ活性を標的とするアデノウイルス製剤の癌診断・治療への応用.

    第25回日本DDS学会  2009 

     More details

  • 遺伝子改変ウイルス製剤による創薬研究.

    第36回BMSコンファレンス  2009 

     More details

  • Telomerase-specific oncolytic adenovirus armed with wild-type p53 gene (CGCT-04) efficiently induces apoptosis in human cancer cells.

    第15回日本遺伝子治療学会  2009 

     More details

  • テロメラーゼ依存的制限増殖型GFP発現アデノウイルスによる末梢血中ヒト循環がん細胞の検出.

    第68回日本癌学会学術総会  2009 

     More details

  • 「腫瘍溶解ウイルス」の座長

    第68回日本癌学会学術総会  2009 

     More details

  • A novel telomerase-specific oncolytic virotherapy targeting cancer stem cells.

    The 8th Japan-China Joint Conference for Cancer Research “Cancer Stem Cell, microRNA, and Cancer Immunology”  2009 

     More details

  • テロメラーゼ活性を標的とした骨肉腫に対するウイルス療法.

    第68回日本癌学会学術総会  2009 

     More details

  • リンパ節可視化のための新しい体内光学イメージングシステムのブタにおける前臨床的評価.

    第68回日本癌学会学術総会  2009 

     More details

  • テロメラーゼ依存性腫瘍融解ウイルスの細胞障害に伴うマイクロRNA-7の発現誘導はオートファジー細胞死を引き起こす.

    第68回日本癌学会学術総会  2009 

     More details

  • 腫瘍特異的増殖性アデノウイルスの薬剤耐性卵巣癌への効果の検討.

    第68回日本癌学会学術総会  2009 

     More details

  • 肺癌に対する分子療法.

    第68回日本癌学会学術総会  2009 

     More details

  • テロメラーゼ依存性腫瘍融解ウイルス製剤と温熱療法の併用.

    第68回日本癌学会学術総会  2009 

     More details

  • テロメラーゼ活性を標的とするウイルス製剤のがん診断・治療への応用

    遺伝子・デリバリー研究会 第8回シンポジウム  2008 

     More details

  • Telomerase-specific oncolytic virotherapy for human cancer.

    The 2nd Annual Meeting of Korean Society of Gene Therapy  2008 

     More details

  • Telomerase-specific oncolytic virotherapy for human cancer.

    Japan-Denmark Joint Workshop “Molecular Cancer Research”  2008 

     More details

  • Phase I trial of intratumoral administration of telomerase-specific oncolytic adenovirus OBP-301 in patients with advanced solid cancer

    第14回日本遺伝子治療学会  2008 

     More details

  • Telomerase-specific oncolytic adenovirus for theranostic application

    第67回日本癌学会学術総会  2008 

     More details

  • テロメラーゼ活性を標的とするウイルス製剤のがん診断・治療への応用

    第23回日本薬物動態学会年会  2008 

     More details

  • テロメラーゼ活性を標的とするナノバイオ・ウイルス製剤の癌診断への応用

    第31回日本分子生物学会年会/第81回日本生化学会大会合同大会  2008 

     More details

  • テロメラーゼ活性を標的とした新規ウイルス製剤Telomelysin/TelomeScanの癌診断・治療への応用

    第108回日本外科学会定期学術集会  2008 

     More details

  • Antiviral activity of cidofovir against telomerase-specific replication-competent adenovirus, Telomelysin (OBP-301)

    10th Annual Meeting of American Society of Gene Therapy  2007 

     More details

  • 胃癌腹膜播種に対するTRAIL発現oncolytic adenovirusの抗腫瘍効果

    第107回日本外科学会定期学術集会  2007 

     More details

  • 切除不能gastrointestinal stromal tumor (GIST)に対する制限増殖型アデノウイルス(Telomelysin)を用いた新規癌ウイルス療法の確立

    第107回日本外科学会定期学術集会  2007 

     More details

  • Enhanced antitumor efficacy of telomerase-specific replication-competent adenoviral agent OBP-301 with valproic acid (VPA) in human lung cancer cells

    第13回日本遺伝子治療学会  2007 

     More details

  • Assessment for antitumor activity of telomerase-specific oncolytic virotherapy in the hypoxic microenvironment

    第13回日本遺伝子治療学会  2007 

     More details

  • Telomerase-specific virotherapy targeting lymph node micrometastasis of human cancer

    第66回日本癌学会学術総会  2007 

     More details

  • Telomerase-specific oncolytic virotherapy for human tumor cells in the hypoxic microenvironment

    第66回日本癌学会学術総会  2007 

     More details

  • Preclinical characterization of OBP-301: in vitro and in vivo cytopathic activity with or without E3 region

    第66回日本癌学会学術総会  2007 

     More details

  • Antiviral activity of cidofovir against telomerase-specific replication-competent adenovirus, OBP-301 (Telomelysin)

    第66回日本癌学会学術総会  2007 

     More details

  • テロメラーゼ活性を標的とするウイルス製剤のがん診断・治療への応用

    昭和大学歯学部セミナー  2007 

     More details

  • テロメラーゼ活性を標的とする新規ウイルス製剤のがん診断・治療への応用

    21世紀COEプログラム「消化器扁平上皮癌に対する最先端多戦略治療拠点形成」成果発表会・講演会  2007 

     More details

  • テロメラーゼ活性を標的とするウイルス製剤の癌診断・治療への応用

    第2回新潟骨軟部腫瘍セミナー  2007 

     More details

  • Valproic acid (VPA) enhances the antitumor effect of telomerase-specific replication-competent adenoviral agent OBP-301 (Telomelysin) in human lung cancer cells

    10th Annual Meeting of American Society of Gene Therapy  2007 

     More details

  • Assessment for antitumor activity of telomerase-specific oncolytic virotherapy in the hypoxic microenvironment

    10th Annual Meeting of American Society of Gene Therapy  2007 

     More details

  • Mutual sensitization with telomerase-specific oncolytic virotherapy and ionizing radiation in cytotoxic activity against human cancer

    10th Annual Meeting of American Society of Gene Therapy  2007 

     More details

  • Mutual sensitization with telomerase-specific oncolytic virotherapy and ionizing radiation in cytotoxic activity against human cancer

    12th World Conference on Lung Cancer  2007 

     More details

  • Antitumor effect of telomerase-selective oncolytic adenoviral agent OBP-301 (Telomelysin) in pleural dissemination of human malignant mesothelioma

    12th World Conference on Lung Cancer  2007 

     More details

  • Mutual sesitization with telomerase-specific oncolytic virotherapy and ionizing radiation in antitumor activity

    第66回日本癌学会学術総会  2007 

     More details

  • Telomerase-specific virotherapy targeting lymph node metastasis of gastrointestinal cancer

    10th Annual Meeting of American Society of Gene Therapy  2007 

     More details

  • ヒト胃癌細胞に対するTRAIL発現腫瘍溶解ウイルス療法

    第79回日本胃癌学会総会  2007 

     More details

  • 消化器癌の微小リンパ節転移を標的とする新規ウイルス製剤OBP-301による治療開発

    第107回日本外科学会定期学術集会  2007 

     More details

  • Theranostic application of telomerase-specific oncolytic adenoviral agents

    第13回日本遺伝子治療学会  2007 

     More details

  • In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus expressing GFP gene

    第66回日本癌学会学術総会  2007 

     More details

  • Telomerase-specific oncolytic virotherapy for human cancer with hTERT promoter

    15th International Conference on Gene Therapy of Cancer  2007 

     More details

  • Vector shedding and biodistribution following intratumoral delivery of adenoviral p53 (ADVEXIN) in patients with advanced non-small cell lung cancer

    EMEA/ICH Workshop on Viral/Vector Shedding  2007 

     More details

  • テロメラーゼ特異的ウイルス製剤の癌診断・治療への応用:米国での臨床試験への道程

    第5回遺伝子治療シンポジウム“遺伝子医薬品の実用化に向けて”  2007 

     More details

  • テロメラーゼ活性を標的とするウイルス製剤の癌診断・治療への応用

    第1回次世代バイオマーカー研究会  2007 

     More details

  • テロメラーゼ活性を標的とするウイルス製剤のがん診断・治療への応用

    第10回骨軟部腫瘍研究会  2007 

     More details

  • 分子病態に基づいたウイルス製剤のがん診断・治療への応用

    第2回癌治療先端開発研究シンポジウム  2006 

     More details

  • がんの分子病態に基づいたウイルス製剤のがん診断・治療への応用

    第4回21世紀COE国内シンポジウム「新たなトランスレーショナルリサーチの展開」  2006 

     More details

  • 悪性胸膜中皮腫に対するテロメラーゼ活性を標的とした新規腫瘍融解ウイルス療法の開発と臨床応用の可能性

    第44回日本癌治療学会総会  2006 

     More details

  • テロメラーゼ特異的腫瘍融解ウイルスTelomelysinの開発との癌診断・治療への応用

    第4回日本臨床腫瘍学会総会  2006 

     More details

  • 消化器癌に対するテロメラーゼ活性を標的とした新規ウイルス療法の開発と臨床応用の可能性

    第61回日本消化器外科学会定期学術総会  2006 

     More details

  • 肺癌治療に有用な分子標的とその臨床応用の可能性

    第44回日本肺癌学会総会  2003 

     More details

  • 非小細胞肺癌に対するp53遺伝子発現アデノウイルスベクター(ADVEXIN)による遺伝子治療臨床研究

    第26回日本気管支学会総会(呼吸器内視鏡学会)  2003 

     More details

  • 癌に対する遺伝子治療の現状と展望:非増殖型ベクターから制限増殖型ベクターへ、さらに局所療法から全身療法へ

    第103回日本外科学会定期学術集会  2003 

     More details

  • p53遺伝子発現アデノウイルスベクター(ADVEXIN)を用いた肺癌の遺伝子治療:多施設共同による第I相臨床試験

    第41回日本癌治療学会総会  2003 

     More details

▼display all

Awards

  • JSGS Science of the Year

    2017  

     More details

  • 日本消化器外科学会 学会賞(学術部門)受賞

    2017  

     More details

    Country:Japan

    researchmap

  • 岡山医学会賞(林原賞)

    2007  

     More details

    Country:Japan

    researchmap

  • (財)岡山医学振興会第7回助成

    2007  

     More details

    Country:Japan

    researchmap

  • 第5回遺伝子治療学会賞

    2000  

     More details

    Country:Japan

    researchmap

  • AACR-Upjohn Young Investigator Scholar Awards

    1992  

     More details

▼display all

Research Projects

  • Immune molecular mechanism for enhancing antitumor potency of a next-generation oncolytic virus by pre-immunization

    Grant number:22H03148  2022.04 - 2025.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    藤原 俊義, 田澤 大, 黒田 新士

      More details

    Grant amount:\17680000 ( Direct expense: \13600000 、 Indirect expense:\4080000 )

    researchmap

  • 胆管癌のmolecular subtype分類の構築

    Grant number:22K08775  2022.04 - 2025.03

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    楳田 祐三, 藤原 俊義, 八木 孝仁, 永坂 岳司, 吉田 一博, 重安 邦俊

      More details

    Grant amount:\4030000 ( Direct expense: \3100000 、 Indirect expense:\930000 )

    researchmap

  • Non-clinical study of wild-type p53-expressing armed adenovirus for refractory cancer

    2020.04 - 2023.03

    Japan Agency for Medical Research and Development  革新的がん医療実用化研究事業 

    Toshiyoshi Fujiwara

      More details

    Authorship:Principal investigator 

    researchmap

  • Development of a next-generation viral agent targeting immunosuppression by crosstalk in the pancreatic cancer microenvironment

    Grant number:19H03731  2019.04 - 2022.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    Fujiwara Toshiyoshi

      More details

    Grant amount:\17550000 ( Direct expense: \13500000 、 Indirect expense:\4050000 )

    We examined the effect of OBP-702, a next-generation armed adenovirus OBP-702, which carries the multifunctional tumor suppressor p53 gene, on the immunosuppressive pancreatic cancer microenvironment. Pancreatic cancer stromal cells (human pancreatic stellate cells: hPSC) promoted tumor growth by coexisting with pancreatic cancer cells in the pancreatic cancer microenvironment, and OBP-702 produced strong p53 gene expression in hPSC. By inducing selective apoptosis, in addition to the antitumor effect on the pancreatic cancer cells, OBP-702 exhibited a profound antitumor activity through the control of the pancreatic cancer microenvironment.

    researchmap

  • Development of boron neutron capture therapy targeting gastrointestinal cancer and search for biomarkers of its efficacy

    Grant number:19K09122  2019.04 - 2022.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Teraishi Fuminori

      More details

    Grant amount:\4160000 ( Direct expense: \3200000 、 Indirect expense:\960000 )

    Boron Neutron Capture Therapy (BNCT) is a next-generation particle therapy in which boron is incorporated into cancer cells and selectively killed by neutron irradiation. In this study, glucose BSH, a novel BNCT agent, was administered to a pancreatic cancer cell lines, and boron uptake in cancer cells was confirmed. Subsequently, as a BNCT evaluation experiment in vitro using the novel BNCT agent, pancreatic cancer cell lines that had taken up glucose BSH were irradiated with neutrons, and the high cell-killing effect was confirmed. Furthermore, in vivo experiments were conducted in a mouse model of subcutaneous tumor of a pancreatic cancer cell line, in which glucose BSH was administered followed by neutron irradiation, and it was confirmed that the agent had a tumor growth inhibitory effect.

    researchmap

  • Practical classification of molecular subtype of intrahepatic cholangiocarcinoma including liquid biopsy

    Grant number:19K09217  2019.04 - 2022.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Umeda Yuzo

      More details

    Grant amount:\4420000 ( Direct expense: \3400000 、 Indirect expense:\1020000 )

    Using multicenter clinical database, we have demonstrated that immuno-nutritional status is a prognostic factor for intrahepatic cholangiocarcinoma (ICC). We also analyzed public genomic datasets (Gene Expression Omnibus microarray database : GSE 89749) by the Cancer Immunome Atlas (TCIA) calculator and identified CD8, forkhead box P3 (FoxP-3), T-cell immunoglobulin , mucin domain 3 (TIM3), and HLA-A in highly immunogenic ICCs. In addition, we evaluated tumor-associated immune responses in resected specimens and demonstrated that tumor-infiltrating lymphocytes (TILs) Foxp3/CD8 ratio correlates with lymph node metastasis and prognosis for resection. Combined with the continuous monitoring of circulating miRNAs/ct DNA in the peripheral blood, we would improve the accuracy of noninvasive tumor assessment. The tumor immune assessment technology validated in this study may serve as a promising technology to promote precision medicine for ICC.

    researchmap

  • Detection of Circulating MicroRNAs with Ago2 Complexes to Monitor the Tumor Dynamics of Colorectal Liver Metastasis Patients during Chemotherapy

    Grant number:16K10573  2016.04 - 2019.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    Umeda Yuzo, FUJI Tomokazu, MORI Yoshiko, YASUI Kazuya

      More details

    Grant amount:\4810000 ( Direct expense: \3700000 、 Indirect expense:\1110000 )

    We examined Two different forms of circulating miRNAs in plasma: Argonaute2 (Ago2)-miRNAs and extracellular vesicles (EVmiRNAs). Ago2-miR-21 could be released into the extracellular fluid by active export from viable cancer cells and cytolysis in vitro. As miR-21 and miR-200c were expressed in both liver metastasis and primary lesions, we evaluated Ago2-miR-21 as a candidate biomarker of both active export and cytolysis while Ago2-miR-200c as a biomarker of cytolysis in a series of plasma obtained from colorectal cancer (CRC) patients with liver metastasis who received systemic chemotherapy. Ago2-miR-21 allowed us to distinguish CRC from subjects without CRC. The trend in ΔCt values for Ago2-miR-21 and miR-200c during chemotherapy could predict tumor response to ongoing treatment. Thus, capturing circulating Ago2-miRNAs from active export can screen patients with tumor burdens, while capturing them from passive release by cytolysis can monitor tumor dynamics during chemotherapy.

    researchmap

  • Development of the Dual fluorescent cytology with tumor-specific viruses for gastrointestinal cancer precision medicine

    Grant number:16H05416  2016.04 - 2019.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    FUJIWARA Toshiyoshi

      More details

    Grant amount:\17680000 ( Direct expense: \13600000 、 Indirect expense:\4080000 )

    Peritoneal dissemination is the most common form of metastasis in gastrointestinal cancer, and is associated with an extremely poor prognosis. We developed a new approach to visualize floating tumor cells using a green fluorescent protein (GFP)-expressing attenuated adenovirus in which the telomerase promoter regulates viral replication (TelomeScan, OBP-401). Moreover, we used a unique TelomeScan derivative (TelomeScan-F45, OBP-1101) that have a strict replication control function by micro-RNA together with targeting properties through CD46; however, unfortunately, the combination strategy was not able to show the usefulness.

    researchmap

  • Preclinical analysis of oncolytic adenovirus infection to patient-derived tumor specimens of bone and soft tissue tumors

    Grant number:15K10444  2015.04 - 2018.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    Koji Uotani

      More details

    Grant amount:\4680000 ( Direct expense: \3600000 、 Indirect expense:\1080000 )

    The oncolytic adenovirus (Telomelysin) developed at our university replicates under the presence of CAR and hTERT for the expression of its effect, and it is necessary to evaluate the presense for screening of the adaptive case for clinical application of the viral therapy against the bone soft tissue tumor. TelomeScan was also developed at our university, which was integrated with GFP gene and emitted green fluorescence by intracellular virus multiplication. In this study,malignant bone soft malignant / intermediate malignant tumor was infected with TelomeScan and fluorescence expression was evaluated. The correlation between the fluorescence positive number at 24 hours after viral administration and the expression intensity of CAR was significantly observed. The expression of hTERT tended to be related to the enhancement of fluorescence time-dependently. The adaptable cases with sarcoma for Telomelysin could be evaluated only by administration of TelomeScan to clinical specimens.

    researchmap

  • Development of oncolytic virotherapy against both cancer cells and cancer-associated fibroblasts

    Grant number:15K15183  2015.04 - 2018.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research  Grant-in-Aid for Challenging Exploratory Research

    SAKURAI FUMINORI, FUJIWARA TOSHIYOSHI

      More details

    Grant amount:\3640000 ( Direct expense: \2800000 、 Indirect expense:\840000 )

    Cancer-associted fibroblasts (CAF) are an important target for cancer therapy because CAF are involved in growth, survival, and mallignant alteration of cancer cells. In this study, we examined whether reovirus kills CAF. Reovirus reduced the viabilities of mouse CAF isolated from subcataneous tumors to 50-60%, indicating that reovirus mediates cell killing effects on mouse CAF. On the other hand, viabilities of normal mouse CAF were not significantly altered by reovirus. In addition, apoptotic CAF were detected in the tumor following intravenous administration of reovirus.

    researchmap

  • Development of novel treatment strategy against bone and soft tissue sarcoma by combination of tumor-specific oncolytic adenovirus and radiotherapy

    Grant number:15K10446  2015.04 - 2018.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    Sugiu Kazuhisa

      More details

    Grant amount:\4680000 ( Direct expense: \3600000 、 Indirect expense:\1080000 )

    Despite major advances in the treatment of bone and soft tissue sarcoma, those patients often show the refractory to conventional treatment, leading to poor prognosis. Therefore, the enhancement of sensitivity to radiotherapy is needed to improve the clinical outcome of bone and soft tissue sarcoma patients. We recently revealed that a tumor-specific, replication-competent oncolytic adenovirus Telomelysin (OBP-301) kills human sarcoma cells. In this study, we investigated the combination effect of Telomelysin and radiotherapy against human bone and soft tissue sarcoma cells. Combination with Telomelysin and radiotherapy showed more profound antitumor effect compared to monotherapy in vitro and in vivo. These results suggest that combination with Telomelysin and radiotherapy provides a novel therapeutic strategy for bone and soft tissue sarcoma.

    researchmap

  • Analysis for intraperitoneal cancer microenvironment to elucidate the biological mechanism of peritoneal metastasis of gastrointestinal cancer

    Grant number:15K15193  2015.04 - 2017.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research  Grant-in-Aid for Challenging Exploratory Research

    Shunsuke Kagawa, KURODA Shinji, NAGASAKA Takeshi, TAZAWA Hiroshi, FUJIWARA Toshiyoshi

      More details

    Grant amount:\3770000 ( Direct expense: \2900000 、 Indirect expense:\870000 )

    Gastrointestinal cancer develops peritoneal dissemination, which is known to be refractory to current therapy. To overcome it, cancer microenvironment is need to be analyzed. For analysis of cells constituting the intraperitoneal microenvironment, we obtained peritoneal lavage fluid from patients with stomach cancer and pancreatic cancer and employed cancer-specific GFP expression virus TelomeScan to label cancer cell and immunostaining, which revealed the prevalence of tumor-associated macrophages (TAM) in the peritoneal cavity. Under the co-culture of stomach cancer or pancreatic cancer cells with TAM, the epithelial to mesenchymal transition of cancer cells, the enhancement of malignant phenotypes such as infiltration, migration, and acquired resistance to the chemotherapeutic agents were observed. These results suggested that intraperitoneal microenvironment, especially TAM, may contribute to the refractoriness of gastrointestinal tumor peritoneal dissemination.

    researchmap

  • Novel targeting therapy to cancer-associated fibroblasts for treatment-resistant carcinomas

    Grant number:26861077  2014.04 - 2016.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)  Grant-in-Aid for Young Scientists (B)

    Noma Kazuhiro, KATSUBE Ryoichi, SHIRAKAWA Yasuhiro, OHARA Toshiaki, FUJIWARA Toshiyoshi, TAZAWA Hiroshi

      More details

    Grant amount:\3770000 ( Direct expense: \2900000 、 Indirect expense:\870000 )

    CAF of fibroblast cells by esophageal cancer and the promoted malignancy of cancer cells by the CAF were verified. Fibroblasts turned into CAF in the interaction of the cancer cells, the cancer cells by stimulation of the CAF enhanced the malignancy. In addition, cancer cells which are stimulated by CAF had acquired a treatment-resistant phenotype to chemotherapy and radiation therapy. In animal studies it was observed a decreased anti-tumor effect of 5-FU in the group inoculated with CAF, showing treatment-resistant as well as in vitro. It has been predicted that controlling the CAF can suppress the acquisition of growth and therapy-resistant cancers. Subsequently, we have succeeded in developing selectively Photoimmunotherapy that target the CAF.

    researchmap

  • Novel treatment strategy for colorectal cancer based on genetic/ epigenetic information

    Grant number:25860409  2013.04 - 2016.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)  Grant-in-Aid for Young Scientists (B)

    Umeda Yuzo, FUJIWARA Toshiyoshi, YAGI Takahito, NAGASAKA Takeshi

      More details

    Grant amount:\4160000 ( Direct expense: \3200000 、 Indirect expense:\960000 )

    We previously reported that genetic information has an essential role as a prognostic/predictive marker in treatment strategy for colorectal cancer (CRC).
    The aim of the research was to discover novel epigenetic biomarkers. BRAF V600E was initially focused on because microsatellite stable (MSS) CRC with BRAF V600E mutation(mt) fails to extremely poor outcome. We analyzed 17-gene methylation panel that consists of different methylation loci in BRAF V600E with MSS and microsatellite instability (MSI). This analysis identified demethylation of O6-methylguanine DNA methyltransferase (MGMT). BRAF V600E-mt with MSS didn’t show MGMT methylation, while that with MSI showed partial or extensive methylation of MGMT promoter. And this could be observed in KRAS-mt and wild type CRC. In utilization to the patient cohort of stage II/III CRC (n=223), MGMT hyper methylation associated with improved relapse-free survival.
    In conclusion, MGMT methylation status could be a promising biomarker of CRC.

    researchmap

  • p53-expressing oncolytic adenovirus enhances the anti-tumor effect of chemotherapy and radiotherapy

    Grant number:25293323  2013.04 - 2016.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    Ozaki Toshifumi, KUNISADA TOSHIYUKI, FUJIWARA TOSHIYOSHI, FURUMATSU TAKAYUKI, TAKEDA KEN

      More details

    Grant amount:\17810000 ( Direct expense: \13700000 、 Indirect expense:\4110000 )

    Despite major advances in the treatment of bone and soft tissue sarcomas, some patients show a poor response to chemotherapy and radiotherapy, leading to a poor prognosis. We recently developed the p53-expressing oncolytic adenovirus, OBP-702. And we confirmed OBP-702 effectively killed human osteosarcoma cells. In the present study, we evaluated the efficacy of combined treatment with OBP-702 and chemotherapy or radiotherapy on human bone and soft tissue sarcoma cells. OBP-702 enhanced the anti-tumor effect of chemotherapy and radiotherapy.

    researchmap

  • Therapeutic potential of circulating tumor microenvironment based on metastatic mechanism

    Grant number:25462020  2013.04 - 2016.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    Shirakawa Yasuhiro, FUJIWARA Toshiyoshi, NOMA Kazuhiro, KASHIMA Hajime

      More details

    Grant amount:\4940000 ( Direct expense: \3800000 、 Indirect expense:\1140000 )

    The FACS analysis showed the significant increase in the number of cCAF in patients with esophageal cancer specimens compared to a healthy person specimen of the control group. The ELIZA analysis indicated the over-expression of FAP in the supernatant of CAF which is the activated fibroblasts in vitro. FAP expression at tumoral stroma was a significant predictive factor for tumor size, lymph node metastasis and vessel invasion. In survival analysis of DFS (disease free survival) and OS (overall survival), FAP high stroma was associated with shorter period to recurrence and death than those of FAP low stroma.

    researchmap

  • Photoimmunotherapy for gastrointestinal cancer

    Grant number:25462021  2013.04 - 2016.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    Tanabe Shunsuke, KAGAWA Shunsuke, OYAMA Takanori, FUJIWARA Toshiyoshi, TAZAWA Hiroshi

      More details

    Grant amount:\4940000 ( Direct expense: \3800000 、 Indirect expense:\1140000 )

    The lack of particular target antigens in gastric cancer other than HER2 has hampered the development of new treatments for gastric cancer.We hypothesized that HER2-extracellular domain (HER2-ECD) gene transduction combined with trastuzumab-based photoimmunotherapy (PIT) might provide excellent and selective antitumor effects for peritoneal dissemination of gastric cancer. Adenovirus/HER2-ECD(Ad/HER2-ECD) efficiently transduced HER2-ECD into HER2-negative gastric cancer cells. Trastuzumab-mediated PIT induced selective cell death of HER2-ECD-transduced tumor cells, even in heterogeneous gastric cancer cells.Anti-HER2 PIT integrated with adenoviral HER2-ECD gene transfer was applied in mice bearing peritoneal dissemination of HER2-negative gastric cancer. Intraperitoneal administration of Ad/HER2-ECD and Tra-IR700 with PIT inhibited peritoneal metastasis and prolonged the survival of mice. Molecular-targeted PIT integrated with gene transfer technology is a promising strategy.

    researchmap

  • "Cell-in-cell" activity-based tumor-specific delivery of biologics

    Grant number:25293283  2013.04 - 2016.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    FUJIWARA Toshiyoshi, KAGAWA Shunsuke, SHIRAKAWA Yasuhiro

      More details

    Grant amount:\18330000 ( Direct expense: \14100000 、 Indirect expense:\4230000 )

    "Cell-in-cell" denotes an invasive phenotype in which one cell actively internalizes in another. The novel human T-cell line HOZOT, established from human umbilical cord blood, was shown to penetrate a variety of human cancer cells but not normal cells. Here, we report a new, intriguing approach using HOZOT cells to transmit biologics such as oncolytic viruses into human cancer cells by cell-in-cell invasion. HOZOT cells were successfully loaded via human CD46 antigen with an attenuated adenovirus containing the fiber protein of adenovirus serotype 35 (OBP-401/F35), in which the telomerase promoter regulates viral replication. OBP-401/F35&#8211;loaded HOZOT cells were efficiently internalized into human cancer cells and exhibited tumor-specific killing by release of viruses, even in the presence of anti-viral neutralizing antibodies. Moreover, intraperitoneal administration of HOZOT cells loaded with OBP-401/F35 significantly suppressed peritoneally disseminated tumor growth in mice.

    researchmap

  • Fluorescent virus-guided capturing of epithelial-mesenchymal transition (EMT)-induced circulating tumor cells (CTCs) for genetic analysis

    Grant number:25670580  2013.04 - 2015.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research  Grant-in-Aid for Challenging Exploratory Research

    FUJIWARA Toshiyoshi, KAGAWA Shunsuke, SHIRAKAWA Yasuhiro

      More details

    Grant amount:\3770000 ( Direct expense: \2900000 、 Indirect expense:\870000 )

    Molecular-based companion diagnostic tests are being used with increasing frequency to predict their clinical response to various drugs. However, invasive procedures are typically required to obtain tissues for this analysis. Here we established a new approach to capture live circulating tumor cells (CTCs) among millions of peripheral blood leukocytes using a GFP-expressing attenuated adenovirus, in which the telomerase promoter regulates viral replication (TelomeScan). Because current CTC detection strategies mainly depend on epithelial cell surface markers, the presence of heterogeneous populations of CTCs with epithelial and/or mesenchymal characteristics may pose obstacles to the detection of CTCs. Our biological capturing system can image both epithelial and mesenchymal tumor cells with telomerase activities as GFP-positive cells. This fluorescent virus-guided viable CTC capturing method provides a non-invasive alternative to tissue biopsy.

    researchmap

  • Establishment of 4th generation of islet isolation and the clinical application

    Grant number:24390316  2012.04 - 2015.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    NOGUCHI Hirofumi, SAITOH Issei

      More details

    Grant amount:\18330000 ( Direct expense: \14100000 、 Indirect expense:\4230000 )

    We previously established a new islet isolation protocol(3rd generation) based on the Ricordi method. It includes pancreatic ductal protection, a MK preservation solution, the two-layer method of pancreas preservation, a new islet purification solution (Iodixanol-based solution), supplemental purification, and cold preservation of isolated islets. In this study, we established 4th generation of islet isolation protocol, including HN-1 preservation solution, ductal injection with JNK inhibitor, and controll-density and osmolality solution for islet purification. Establishment of this method enables us to make diabetic patients insulin independent using islets not only from 2 or 3 pancreata of NHBDs, but also from a pancreas from a brain-dead donor.

    researchmap

  • Development of an efficient gene expression vector utilizing RNA-binding proteins and antisense transcripts

    Grant number:23689010  2011.04 - 2015.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (A)  Grant-in-Aid for Young Scientists (A)

    SAKURAI FUMINORI, MIZUGUCHI Hiroyuki, TACHIBANA Masashi, NAKAMURA Shin-ichiro, FUJIWARA Toshiyoshi, SHIMIZU Kahori, OKAMOTO Sayuri, HOSOYAMADA Eri, MACHITANI Mitsuhiro, HAYASHI Kohei, BENNETT David Mark Gilfedder, IIZUKA Syunsuke

      More details

    Grant amount:\27430000 ( Direct expense: \21100000 、 Indirect expense:\6330000 )

    A novel gene expression vector which efficiently mediates transgene expression in a targeted organ-specific manner is required for achievement of safe and effective gene therapy.In this study, we tried to improve transgene expression profiles and therapeutic effects by regulating stability of mRNA. Dramatic improvement of transgene expression profiles was not found by utilizing HuR or AU-rich sequences. On the other hand, adenovirus (Ad) vector-mediated transgene expression profike was significantly improved by suppression of leaky expression of Ad genes utilizing non-coding RNA. This novel Ad vector also meidated efficient transduction in neonatal mice.

    researchmap

  • Establishment of non-invasive cancer screening paradigm

    Grant number:23390323  2011.04 - 2014.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    NAGASAKA Takeshi

      More details

    Grant amount:\19110000 ( Direct expense: \14700000 、 Indirect expense:\4410000 )

    In this study, we developed a new extremely simple procedure of detecting methylated DNA in the 8 CpGs regions in human DNA recovered from very small quantity of feces and sputum.Moreover, the procedure easily modifies the cut-off value suitable for various conditions for screening not only people with lung and colorectal cancer but also other gastrointestinal cancers.
    Our technology could provide a possibility of building an effective medical screening strategy. Additionally, we searched for biomarkers of various cancer leading to accumulation of very important knowledge and discover new seeds, affected not only cancer diagnostic paradigm but also cancer treatment system.

    researchmap

  • Tumor suppressor FHIT regulates tumor invasion of pancreatic cancer cells via inhibiting association of Ezrin and Actin cytoskeleton

    Grant number:23592009  2011 - 2013

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    NISHIZAKI Masahiko, FUJIWARA Toshiyoshi, KAGAWA Shunsuke, NAGASAKA Takeshi, TAZAWA Hiroshi

      More details

    Grant amount:\5070000 ( Direct expense: \3900000 、 Indirect expense:\1170000 )

    Ezrin is recognized as a key component in tumor metastasis and regulated by PKC. Abnormalities of tumor suppressor FHIT, whitch shares homology with PKCI (PKC-interacting protein), have been found in pancreatic cancers. In this study, we showed that FHIT overexpression in S2-VP10 pancreatic adenocarcinoma cells by transfection of Ad- FHIT suppressed migratory/invasive capacities of tumor cells. We observed that overexpression of FHIT largely reduced threonine-phosphorylated Ezrin. Furthermore, FHIT overexpression interrupted not only Ezrin and Actin cytoskeleton interaction but also Ezrin and PKC alpha interaction. We also found Fhit and PKC alpha binding in the immunoprecipitation analysis. Ectopic activation of FHIT significantly reduced the invasive potential in S2-VP10 cells. These findings suggested that overexpression of FHIT protein might regulate tumor invasion via inhibiting Ezrin and Actin cytoskeleton interaction.

    researchmap

  • Fluorescence-guided detection and genetic analysis of circulating tumor cells

    Grant number:23591932  2011 - 2013

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    KAGAWA Shunsuke, FUJIWARA Toshiyoshi, TAZAWA Hiroshi, SHIGEYASU Kunitoshi

      More details

    Grant amount:\5200000 ( Direct expense: \4000000 、 Indirect expense:\1200000 )

    In addition to the conventional clinical information, molecular information obtained from cancer tissue is being used for proper selection of cancer therapy. The circulating tumor cells in the blood of cancer patients, if available, might be valuable source for such molecular information. We tried and succeeded to capture and analyze the rare tumor cells in the blood using a virus that can detect cancer cells with a fluorescent dye. This technology must be a novel molecular diagnostic method for cancer.

    researchmap

  • Circulating Tumor Cell of Gastrointestinal Stromal Tumor

    Grant number:23659651  2011 - 2012

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research  Grant-in-Aid for Challenging Exploratory Research

    UNO Futoshi, FUJIWARA Toshiyoshi, KAGAWA Shunsuke, NISHIZAKI Masahiko, NAGASAKA Takeshi, TAZAWA Hiroshi, SHIGEYAU Kunitoshi, HASHIMOTO Yuuri

      More details

    Grant amount:\3640000 ( Direct expense: \2800000 、 Indirect expense:\840000 )

    We detected circulating tumor cells (CTCs) in the peripheral blood of Gastrointestinal Stromal Tumor (GIST) patients after some fundamental research useing a green fluorescent protein (GFP)-expressing attenuated adenovirus-5 vector, in which the hTERT promoter regulates viral replication (TelomeScan). CTCs were identified in samples from 6 of 12 patients with GIST. These results suggest that CTSs detection with our method might be a new bio-marker for GIST which frequently accompanied liver metastases.

    researchmap

  • Development of new diagnostic methods for bladder cancer using GFP expressing adenovirus vector

    Grant number:22591767  2010 - 2012

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    KAKU Haruki, WATANABE Masami, HUJIWARA Toshiyuki, KAGAWA Shunnsuke

      More details

    Grant amount:\4420000 ( Direct expense: \3400000 、 Indirect expense:\1020000 )

    Usefulness of a diagnostic novel adenoviralvector Telomescan, which proliferates specifically in cancer cells and expresses green fluorescent protein (GFP), in the detection of various bladder cancer cells, was demonstrated. In addition, the usefulness of the luciferase and GFP expression plasmids (hTERT-AdTSTA-luciferase and GFP) as next-generation cancer-specific expression systems was also demonstrated in a various types of bladder cancer cells. Using these tools, we expect that detection of disseminating cancer cells becomes possible in a wide range of cancer diseases.

    researchmap

  • Circulating tumor cell-based tailor-made therapy for hepatocellular carcinoma

    Grant number:22590736  2010 - 2012

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    NAKAMURA Shinichiro, FUJIWARA Toshiyoshi, NOUSO Kazuhiro, SHIRAHA Hidenori

      More details

    Grant amount:\4420000 ( Direct expense: \3400000 、 Indirect expense:\1020000 )

    We detected telomerase-positive cells in the peripheral blood of hepatocellular carcinoma using a new method “TelomeScan”. We confirmed that most of the cells we detected were circulating tumor cells, which was a promising marker of metastasis. Interestingly, we detected the cells even in early stages, indicating another factor is needed to form metastatic lesions. We could not completely overcome the problems of false-positive and false negative and they must be addressed in the future.

    researchmap

  • Molecular therapy for gastric cancer using HER2-extracellular domain-expressing adenovirus

    Grant number:22390256  2010 - 2012

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    FUJIWARA Toshiyoshi

      More details

    Grant amount:\19370000 ( Direct expense: \14900000 、 Indirect expense:\4470000 )

    Trastuzumab, a humanized antibody targeting HER2, exhibits remarkable therapeutic efficacy against HER2-positive breast and gastric cancers. We found that exogenous HER2-extracellular domain (ECD) expression had no apparent effect on the signaling pathway, but strongly enhanced antibody-dependent cellular cytotoxicity (ADCC) activity in low HER2-expressing or trastuzumab-resistant human cancer cells.

    researchmap

  • Development of an adenovirus vector containing microRNA-regulated gene expression system

    Grant number:20689004  2008 - 2010

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (A)  Grant-in-Aid for Young Scientists (A)

    SAKURAI Fuminori, MIZUGUCHI Hiroyuki, KAWABATA Kenji, KATAYAMA Kazufumi, TASHIRO Katsuhisa, KONDOH Masuo, YAGI Kiyohito, NAKAMURA Shin-ichiro, KAWASE Atsushi, IWAKI Masahiro, HAYAKAWA Takao, FUJIWARA Toshiyoshi, SUZUKI Takayuki, SUGIO Kumiko, SHIMIZU Kahori, BENNETT David Mark Gilfedder, TOMITA Kyoko

      More details

    Grant amount:\25350000 ( Direct expense: \19500000 、 Indirect expense:\5850000 )

    In this study, we developed the adenovirus (Ad) vectors which exhibited enhanced safety profiles by incorporating microRNA (miRNA)-regulated gene expression system. For example, (1)an Ad vector which shows reduction in the transgene expression in the liver and spleen by insertion of sequences complementary to liver- and spleen-specific miRNA, respectively, (2) an Ad vector which exhibits reduction in the leaky expression of Ad genes by insertion of miRNA complementary sequences into 3'-untranslated region of E2A or E4 genes, (3) a oncolytic Ad which shows reduced replication in normal cells by insertion of sequences complementary to normal cell-specific miRNAs, were developed.

    researchmap

  • 進行食道癌に対するテロメラーゼ活性を標的とする新規アデノウイルス製剤の創薬研究

    Grant number:20015030  2008 - 2009

    日本学術振興会  科学研究費助成事業 特定領域研究  特定領域研究

    藤原 俊義

      More details

    Grant amount:\11000000 ( Direct expense: \11000000 )

    局所進行食道癌は難治癌の一つであり、安全性と有効性を兼ね備えた新たな標準治療の確立が望まれている。Telomelysinは、「かぜ」症状の原因となるアデノウイルス5型を基本骨格とし、ウイルス増殖に必須のE1遺伝子をテロメラーゼ構成分子であるhTERT(human telomerase reverse transcriptase)遺伝子のプロモーターで制御することで、癌細胞のみで増殖し細胞死を生じるように改変された国産のウイルス製剤である。本研究では、局所進行食道癌を対象としたTelomelysinの第II相臨床試験の理論的根拠となる前臨床研究として、同所性ヒト食道癌モデルを用いてTelomelysinの抗腫瘍活性を検討することを目的とする。本年度は、まずヒト食道癌ヌードマウス背部移植モデルにおけるTelomelysinの抗腫瘍効果を検討した。ヒト食道扁平上皮癌細胞TE8およびヒト食道腺癌細胞SEG-1をヌードマウス背部皮下に移植し、Telomelysin単独、放射線単独、およびTelomelysinと放射線併用の抗腫瘍効果を比較したところ、併用群で最も顕著な増殖抑制効果がみられた。また、昨年度に確立した同所性食道癌モデルを用いてTelomelysinの抗腫瘍活性を検証した。ルシフェラーゼ遺伝子発現食道癌細胞株TE8を食道壁内に移植し、Telomelysin単独腫瘍内投与、放射線単独、およびTelomelysinと放射線併用を3回施行し、リアルタイムin vivoイメージング装置IVISを用いて経時的な腫瘍増殖と進展を体外的に評価した。やはり、Telomelysin腫瘍内投与と放射線照射を併用した群で有意な抗腫瘍効果の増強が認められた。この併用治療によって明らかな体重減少はみられず、本治療が安全に施行可能であることが示唆された。現在、臨床プロトコールを学内審査委員会に申請中である。

    researchmap

  • Telomerase-specific virotherapy for malignant mesothelioma

    Grant number:19390365  2007 - 2008

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    FUJIWARA Toshiyoshi, KAGAWA Syunsuke

      More details

    Grant amount:\15600000 ( Direct expense: \12000000 、 Indirect expense:\3600000 )

    悪性胸膜中皮腫は比較的稀な腫瘍であるが、多くの治療の抵抗性と浸潤性の局所進展、極めて不良な平均生存期間などから、何らかの新しい治療戦略の開発が必須と考えられる。本研究では、テロメラーゼ依存性腫瘍融解ウイルス製剤テロメライシンによる治療効果、および蛍光発現同製剤テロメスキャンによる診断機能について検討した。テロメライシンの胸腔内投与は同所性マウスモデルにおいて顕著な抗腫瘍活性を示し、テロメスキャンにて微小胸膜播種巣を可視化することが可能であった。これらのウイルス製剤は、悪性胸膜中皮腫の診断・治療に有用と考えられる。

    researchmap

  • Telomerase specific oncolytic virotherapy to purge lymph node metastasis for minimizing invasiveness of gastrointestinal surgery

    Grant number:19591543  2007 - 2008

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    KAGAWA Syunsuke, FUJIWARA Toshiyoshi

      More details

    Grant amount:\4420000 ( Direct expense: \3400000 、 Indirect expense:\1020000 )

    これまで癌細胞を選択的に破壊するウイルス製剤テロメライシンの研究開発をおこなってきた。消化器癌治療における病態に応じた低侵襲手術の実現を目指し、癌のリンパ節転移に対するテロメライシンの治療効果を検討した。癌の原発巣に投与したテロメライシンはリンパ流に乗ってリンパ節に到達し、転移病巣内で治療効果を発揮することが確認された。テロメライシンは癌の原発巣とともにリンパ節転移をも治療できる可能性が示された。

    researchmap

  • The development study of the new gene therapy that assumed telomerase activity for urinary cancers.

    Grant number:18591754  2006 - 2008

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    KAKU Haruki, NASU Yasutomo, FUJIWARA Toshiyoshi, KAGAWA Syunsuke, HUANG Peng

      More details

    Grant amount:\3970000 ( Direct expense: \3400000 、 Indirect expense:\570000 )

    本研究は尿路性器癌に対するテロメラーゼ活性を標的とした新規ウイルス療法の開発研究を目的とした。研究期間内に転移癌を含む前立腺癌、腎癌に対する有効性、他の療法との併用効果の増強が確認された。一方、Telomelysinと新規癌抑制遺伝子REICとの併用効果は癌種によって効果は一定ではなく、新規ウイルスArmed-Telomelysin(Telomelysin-REIC)の作製に至らなかった。

    researchmap

  • Development of immortalized allogenic dendritic cells expressing telomerase for treatment of gastroenterological cancer

    Grant number:17591401  2005 - 2006

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    KAGAWA Shunsuke, FUJIWARA Toshiyoshi

      More details

    Grant amount:\3500000 ( Direct expense: \3500000 )

    Dendritic cells (DCs) are the most potent antigen-presenting cells and acquire cellular antigens and danger signals from dying cells to initiate antitumor immune responses via direct cell to cell interaction and cytokine production. Despite such antitumor efficacy, the optimal means of DC priming is unknown. In the present study, we compared three methods of tumor preparation as a source of cell-derived antigen for DC priming: virus-induced oncolysis, drug-induced apoptosis, and freeze thaw lysis. We reported previously that that telomerase-specific replication-competent adenovirus (Telomelysin, OBP-301) induces selective El expression and efficiently kills human cancer cells but not normal human fibroblasts. Morphological analysis showed that OBP-301-mediated cell death is different from apoptosis. Immature DCs generated in the presence of IL-4 and GM-CSF from monocytes of healthy individuals were pulsed with either H1299 human lung cancer cells infected with OBP-301, H1299 cells treated with chemotherapeutic agent (docetaxel), or freeze-thawed H1299 cells. IFN-y release into the supernatants, determined by ELISA, was used to assess the expression of antigens by DCs. OBP-301-infected cells stimulated DCs to produce approximately eight-fold more IFN-7 than docetaxel-treated apoptotic cells. In contrast, freeze-thaw lysis did not stimulate IFN-y release. We further examined by mixed lymphocyte tumor culture (MLTC) whether OBP-301-infected H 1299 cells could induce cytotoxic T-lymphocytes (CTL). The CTL assay demonstrated that OBP-301-infected H1299 cells efficiently induced CTL specific for H1299 cells. We found that the supernatants of MLTC with oncolytic cells up-regulated the endogenous expression of the proteasome activator PA28 in tumor cells. Furthermore, uric acid levels were elevated in OBP-301-infected H 1299 cells compared with docetaxel-treated cells, suggesting that uric acid acts as a danger signal triggering the immune response to the tumor. Our data suggest that oncolysis caused by conditionally replication-selective adenovirus might be the most effective stimulus for immature DCs to induce specific activity against human cancer cells.

    researchmap

  • Telomerase-specific fluorescent navigation system for lung cancer surgery

    Grant number:17390381  2005 - 2006

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    FUJIWARA Toshiyoshi, KAGAWA Shunsuke

      More details

    Grant amount:\15400000 ( Direct expense: \15400000 )

    Currently available methods for detection of tumors in vivo such as X-ray, computed tomography, and ultrasonography are noninvasive and well studied; the images, however, are not specific for tumors. Direct optical imaging of tumor cells in vivo that can clearly distinguish them from surrounding normal tissues may be clinically useful. Here, we describe a new approach to visualizing tumors whose fluorescence can be detected using telomerase-specific replication-competent adenovirus expressing green fluorescent protein (GFP) (OBP-401). OBP-401 contains the replication cassette, in which the human telomerase reverse transcriptase (hTERT) promoter drives expression of El genes, and the GFP gene for monitoring viral replication. The hTERT is the catalytic subunit of telomerase, which is highly active in cancer cells, but is quiescent in most normal somatic cells. When the human lung cancer cell line H1299 was infected with OBP-401, the virus replicated in tumor cells and showed strong green signals. In contrast, infection of OBP-401 did not show any signals in normal cells such as fibroblasts. We also found that established subcutaneous tumors could be visualized following intratumoral injection of OBP-401. H1299 human lung tumors transplanted into BALB/c nu/nu mice were intratumorally injected with 1 x 10^8 plaque forming units (PFU) of OBP-401. Within 24 hours of treatment, the fluorescence of the expressed GFP became visible by 3CCD camera in these tumors. Moreover, intrathoracic administration of OBP-401 could visualize disseminated A549 tumor nodules in mice following intrathoracic implantation. Our results indicate that intratumoral or intrathoracic injection of OBP-401 might be a useful diagnostic method that provides a foundation for future clinical application.

    researchmap

  • Development of cell therapies using reversibly immortalized human pancreatic beta cell lines

    Grant number:16390380  2004 - 2005

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    KOBAYASHI Naoya, IWAGAKI Hiromi, KAGAWA Shunsuke, SHIRAKAWA Yasuhiro, MOCHITATE Katsumi, MATSUKAWA Hiroyoshi

      More details

    Grant amount:\14400000 ( Direct expense: \14400000 )

    After thawing the cryopreserved islets with UW solution, the islet cells showed an efficient monolayer formation and facilitated effective lentivirus-mediated transduction. Monolayer formation of mouse islets was efficiently achieved by the use of extracellular matrices derived from 804G cells. We successfully made a diabetes model in pigs to perform total pancreatectomy. Such diabetic pigs died of ketoacidosis within 10 days after surgery. The model would be useful to assess the efficacy of diabetes-targeted cell therapies. A human pancreatic beta cell line that is functionally equivalent to primary beta cells has not been available. We established a reversibly immortalized human beta cell clone (NAKT-15) by transfection of primary human beta cells with a retroviral vector containing simian virus 40 large T antigen (SV40T) and human telomerase reverse transcriptase (hTERT) cDNAs flanked by paired recombination target loxPs, which allows deletion of SV40T and hTERT genes by Cre recombinase. Reverted NAKT-15 cells expressed beta cell transcription factors (Isl-1,Pax 6,Nkx 6.1,Pdx-1), prohormone convertases 1/3 and 2, and secretory granule proteins, and secreted insulin in response to glucose, similar to normal human islets. Transplantation of NAKT-15 cells into streptozotocin-induced diabetic SCID mice resulted in perfect control of blood glucose within 2 weeks ; mice remained normoglycemic for longer than 30 weeks. The establishment of a beta cell line is one step toward the potential cure of diabetes by transplantation.

    researchmap

  • DEVELOPMENT OF TAILORED-MADE TYPE PROSTATE CANCER GENE THERAPY AIMING AT SYSTEMIC IMMUNE-ACTIVATION

    Grant number:15209052  2003 - 2005

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (A)  Grant-in-Aid for Scientific Research (A)

    KUMON Hiromi, NASU Yasutomo, NAKAYAMA Eiichi, YAMADA Masao, FUJIWARA Toshiyoshi, EBARA Shin

      More details

    Grant amount:\41470000 ( Direct expense: \31900000 、 Indirect expense:\9570000 )

    This research has been conducted for the purpose of developing the tailored-made type of prostate cancer gene therapy activating tumor specific systemic immunity. We achieved following resuts
    1)Clinical trial of prostate cancer gene therapy
    We performed prostate cancer gene therapy using intraprostatic injection of adenoviral vector expressing HSV-tk gene and systemic administration of Ganciclovir and analyzed immunological profile of each patient in addition to clinical safety and efficacy. Clinical safety and efficacy were confirmed in 9 cases. Serum cytokine level did not change significantly before and after gene therapy. Interestingly peripheral blood CD8+/HLA-DR+ increased after treatment indicating systemic activation of cell mediated immunity.
    2)Expression analysis of tumor associated antigen in prostate cancer
    Expression of NY-ESO-1,SSX in prostate cancer were analyzed and its host immune reaction based of tissue expression were also checked. As a result it was suggested that NY-ESO-1,SSX can be a target for the prostate cancer immunotherapy.
    3)Clinical trial of immunotherapy
    Peptid pulsed dendritic cell therapy and NY-ESO-1 protein immuno-therapy were conducted. Clinical safety and clinical activity were confirmed. Tumor specific immune response were also observed in some cases.
    4)Interleukin-12 immuno gene therapy(extensive research)
    Usefulness of adjuvant and neo-adjuvant application of IL- 12 gene therapy was confirmed as a extensive collaboration Baylor College of Medicine.

    researchmap

  • Molecular Fluorescent Imaging of Metastatic Tumors with Conditionally Replication-Selective Adenovirus and GFP Gene

    Grant number:15591475  2003 - 2004

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    FUJIWARA Toshiyoshi, NISHIZAKI Masahiko

      More details

    Grant amount:\3500000 ( Direct expense: \3500000 )

    Currently available methods for detection of tumors in vivo such as X-ray, computed tomography, and ultrasonography are noninvasive and well studied ; the images, however, are not specific for tumors. Direct optical imaging of tumor cells in vivo that can clearly distinguish them from surrounding normal tissues may be clinically useful. Here, we describe a new approach to visualizing tumors whose fluorescence can be detected using tumor-specific replication-competent adenovirus (OBP-301, "Telomelysin") in combination with replication-deficient adenovirus expressing GFP (Ad-GFP). Human telomerase reverse transcriptase (hTERT) is the catalytic subunit of telomerase, which is highly active in cancer cells, but is quiescent in most normal somatic cells. We constructed an adenovirus 5 vector, in which the hTERT promoter element drives expression of E1A and E1B genes linked with an IRES, and showed that OBP-301 replicated efficiently exclusively in human cancer cells, but not in normal cells such as human fibroblasts. When the human lung and colon cancer cell lines H1299 and SW620 were infected with Ad-GFP at low multiplicity of infection(MOI), GFP expression could not be detected under a fluorescence microscope ; in the presence of OBP-301, however, Ad-GFP replicated in these tumor cells and showed strong green signals. In contrast, co-infection of OBP-301 and Ad-GFP did not show any signals in normal cells such as WI-38 fibroblasts. We also found that established subcutaneous tumors could be visualized following intratumoral injection of OBP-301 and Ad-GFP. A549 human lung tumors and SW620 human colon tumors transplanted into BALB/c nu/nu mice were intratumorally injected with 8 x 10^5 plaque forming units(PFU) of Ad-GFP in combination with 8 x 10^6 PFU of OBP-301. Within 3 days of treatment, the fluorescence of the expressed GFP became visible by 3CCD camera in these tumors, whereas intratumoral injection of Ad-GFP alone could not induce GFP fluorescence. Moreover, intrathoracic administration of Ad-GFP and OBP-301 could visualize disseminated A549 tumor nodules in mice following intrathoracic implantation. Our results indicate that intratumoral or intrathoracic injection of Ad-GFP in combination with OBP-301 might be a useful diagnostic method that provides a foundation for future clinical application.

    researchmap

  • テロメラーゼ活性を標的とした新規ウイルス療法の開発と化学療法との相互作用の解明

    Grant number:15025250  2003

    日本学術振興会  科学研究費助成事業 特定領域研究  特定領域研究

    藤原 俊義, 西崎 正彦

      More details

    Grant amount:\3000000 ( Direct expense: \3000000 )

    染色体DNA末端の短い塩基配列の繰り返しで構成されるテロメア長を保つ作用を持つ酵素テロメラーゼは、きわめて多くの癌細胞でその活性の上昇が知られている。構成分子hTERTの発現とテロメラーゼ活性が相関することが明らかになっており、多くの癌細胞ではhTERTプロモーターのスイッチがオンになり、その下流に組込まれた遺伝子が発現すると考えられる。アデノウイルスの増殖に必要なE1A遺伝子とE1B遺伝子をIRES配列で結合した発現カセットをhTERTプロモーターにより選択的に発現するTumor-specific Replication-competent Adenovirus(TRAD)を作成した。各種ヒト癌細胞においてテロメラーゼ活性は陽性であり、一方、線維芽細胞などの正常細胞では陰性であった。実際に、ヒト大腸癌細胞SW620およびヒト肺癌細胞H1299にTRADを感染させると、mRNAレベルおよび蛋白質レベルで選択的E1発現が認められた。それに一致して、TRAD感染後3日までに各種癌細胞においては10^5-10^8倍のウイルス複製増殖が認められたが、正常細胞では100-1000倍に抑えられていた。癌細胞では1 multiplicity of infection(MOI)のTRAD感染で、3日以内にcytopathic effect(CPE)が誘導され完全な細胞死が観察されたが、正常細胞ではTRAD感染後7日目でも細胞数の減少はみられなかった。ヌードマウス背部皮下に移植したH1299ヒト肺癌腫瘍にTRADを局所投与したところ、有意な増殖抑制が認められた。今後、TRADの生体内分布、免疫反応、各種抗癌剤との併用効果とその作用機序などを検討していく。

    researchmap

  • Molecular Analysis of Resistance to p53 Gene Therapy in Human Lung Cancer

    Grant number:13671390  2001 - 2002

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    FUJIWARA Toshiyoshi

      More details

    Grant amount:\4100000 ( Direct expense: \4100000 )

    To analyze the mechanism of the antitumor effect of an adenoviral vector expressing the p53 tumor suppressor (Ad-p53) in vivo, we quantitatively assessed p53-targeted gene expression and visualized transcriptional activity of p53 in tumors in nude mice treated with Ad-p53. Human lung cancer (H1299) xenografts established in nude mice were treated by intratumoral administration of Ad-p53. The levels of expression of exogenous p53 and p53-targeted genes p21, MDM2, Noxa, and p53AIP1 were quantified by real-time reverse-transcriptase polymerase chain reaction (RT-PCR) and induction of apoptosis was observed histochemically on days 1, 2, 3, 7 and 14 after treatment. Expression of mRNAs of exogenous p53 and p53-targeted genes (except p53AIP1) was at its maximum 1 day after Ad-p53 treatment, then decreased rapidly ; apoptosis was evident in situ 2-3 days after treatment. We developed a noninvasive and simple method for monitoring the transcriptional activity of exogenous p53 following intratumoral administration of Ad-p53 in nude mice. We established H1299 cells that express the green fluorescent protein (GFP) reporter gene under the control of p53-responsive p21 promotes (i.e., the p53R-GFP reporter system). Xenografts of these cells in nude mice were treated by intratumoral administration of Ad-p53, and the transcriptional activity of exogenous p53 could be visualized as intratumoral GFP expression in real time by 3-CCD_camera. Expression of GFP was maximal 3 days after treatment, and it decreased remarkably by 7 days after treatment. We demonstrated that Ad-p53 treatment rapidly induced p53-targeted genes and apoptosis in tumors. We also succeeded in visualizing p53 transcriptional activity in vivo. Quantitative analysis of p53-targeted gene expression by real-time quantitative RT-PCR and visualization of p53 transcriptional activity in fresh xenografts by using the p53R-GFP reporter system may be useful in assessing the mechanisms of the antitumor effects of Ad-pS3 and novel therapeutic approaches.

    researchmap

  • 臨床応用可能なウイルスベクター製造のための企画調査

    Grant number:13897011  2001

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    市川 直哉, 河上 裕, 濱田 洋文, 田原 秀晃, 藤原 俊義

      More details

    Grant amount:\3400000 ( Direct expense: \3400000 )

    本企画調査により,ウイルスベクター製造のためのコアプロセスをフローチャート化し,各プロセスにおける業務を明確に記述し,各作業員の業務分担と責任および権限を明らかにすることが,臨床グレードの細胞治療または遺伝子治療用の製剤を生産するために重要であることが指摘された.まず,コアプロセスとして(1)細胞またはウイルスベクター製造部門,(2)品質管理部門,(3)ベクター設計・開発部門,(4)業務部門をあげ,それぞれのプロセスを必要に応じて細かく分類し,設備,要員の配置を行った.cGMP基準を満たすための文書管理に十分な人的資源を配分することが必要と考えられた.また,ベクター製造施設に携わる全ての職員に品質管理の重要性を認識するためのセミナーを行った.各部門間のコミュニケーションの重要性も指摘されたので,週1回の全体会議において自由な意見交換が行われるよう留意した.その一方で,トップダウン式の意志決定の重要性も指摘された.特に製造物の品質に関して,材料の購入から製剤の搬出まで一貫して高い品質を保つことが重要であり,仮に最終検査で不適合品が出現した場合でも,製剤にトレーサビリティを持たせておくことにより,是正処置がとれるように配慮した.これらのプロセスが正しく行われているかどうかを監査するために,定期的な内部監査を行うことも必要とされた.このシステムが全体として円滑に運営されるためのマネジメント・システムを構築することが重要であることが指摘された.

    researchmap

  • Development of Gene Therapy for Lung Cancer using a Novel Antiangiogenic Factor BAI1

    Grant number:11671325  1999 - 2000

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    FUJIWARA Toshiyoshi, KATAOKA Masafumi

      More details

    Grant amount:\3500000 ( Direct expense: \3500000 )

    Heparan sulfate proteoglycans is a major component of the cell surface and extracellular matrix and functions as a barrier against cationic molecules and macromolecules. Heparanase is an endoglucuronidase capable of specifically degrading heparan sulfate and its activity is associated with metastatic potential of tumor cells. To inhibit human heparanase expression in human cancer cells, we constructed an adenoviral vector carrying a full-length human heparanase cDNA in an antisense orientation (Ad-AS/hep). Increased heparanase expression in T.Tn human esophageal cancer cells and A549 human lung cancer cells following infection with an adenovirus vector expressing human heparanase gene (Ad-S/hep) was specifically inhibited by simultaneous infection with Ad-AS/hep in a dose-dependent manner. A modified Boyden chamber assay demonstrated that infection with Ad-AS/hep significantly inhibited in vitro invasion of A549 cells following Ad-S/hep infection. Moreover, intrathoracic administration of Ad-AS/hep reduced the number and size of heparanase-expressing A549 tumors implanted intrathoracically into BALB/c nu/nu mice. Our results suggest that heparanase contributes to the invasive phenotype of tumor cells and that antisense-mediated inhibition of heparanase activity may be efficacious in the prevention of pleural dissemination.

    researchmap

  • Development of Differentiation-directed Cancer Gene Therapy with p21

    Grant number:09671310  1997 - 1998

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    HIZUTA Akio, FUJIWARA Toshioshi

      More details

    Grant amount:\3600000 ( Direct expense: \3600000 )

    A cycline-dependent kinase inhibitor p21 is induced in thc process of differentiation. To develop a novel gene-based anti-cancer therapy that can induce a welI-differentiated state in cancer cells, we examined antitumor offeet of the p21 gene transfer on human cancer cells. A recombinant adenovirus-mediated transient overexpression of p21 on TE-1 human esophageal cancer cells exhibited morphological changes indicative of differentiation, such as enlarged nuclei and flattened shape. Moreover, expression of involucrin protein, a differentiation marker of squamous cells, was up-regulated after the p21 gene transfer. We also found that retinoic acid receptor (RAR) was positively regulated by the p21 gene transfer in DLD-1 (colon), 1-11299 (lung), H460 (lung), and TE-13 (esophagus) human cancer cell lines. Increased expression of RAR induced the sensitivity to retinoic acid (RA) in RA-resistant DLD-1 cancer cells, resulting in the synergistic antitumor effect of the p21 gene transfer and RA treatment. These observations suggest that adenovirus-mediated p21 gene transfer can induce differentiation in human cancer cells and that the p21 gene has important implications for a differentiation-directed molecular therapy.

    researchmap

  • Basic and Clinical Research of p53 Gene Therapy for Human Cancer

    Grant number:08671529  1996 - 1997

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    INOUE Fumiyuki, YASUDA Tatsuji, FUJIWARA Toshiyoshi

      More details

    Grant amount:\2200000 ( Direct expense: \2200000 )

    Angiogenesis is required for the growth and progression of malignancies. Recent studies have demonstrated that genetic alterations may accompany acquisition of the angiogenic phenotype. The tumor suppressor p53 gene is most frequently mutated in human cancers and is also known to be a transcriptional regulator of a variety of genes. Here we investigated the antiangiogenic effect of the wild-type p53 gene transfer on a human non-small-cell lung cancer cell line. Mutant p53-expressing H226Br NSCLC cells were transduced with the wild-type p53 gene using a recombinant adenoviral vector (Ad5CMVp53) and applied to semi-quantitative reverse transcription-polymerase chain reactions to detect altered mRNA expression of angiogenic and/or antiangiogenic factors. In vivo neovascularization assay of Ad5CMVp53-infected cells was then performed using a membrane-diffusion chamber system subcutaneously transplanted in nu/nu mice. We also evaluated the effect of Ad5CMVp53-infected H226Br cells on nontransduced tumor cells in vivo by subcutaneously inoculating mixture of cells into nu/nu mice. Ad5CMVp53 infection markedly inhibited the expression of an angiogenic factor, vascular endothelial growth factor (VEGF), and increased the expression of a novel antiangiogenic factor, brain-specific angiogenesis inhibitor 1 (BAI1), resulting in the reduced neovascularization in vivo. Mixing experiments showed that tumor cells transduced with the wild-type p53 gene inhibited the in vivo tumor growth of adjacent nontransduced cells. Our data suggest that a recombinant adenovirus expressing the wild-type p53 gene is antiangiogenic, which may explain in part the mechanism of the bystander effect induced by the wild-type p53 gene transfer on adjacent tumor cells.

    researchmap

  • Gene Therapy for Colon Cancer with Adenoviral Vector Expressing Tumor Suppressor p53 Gene

    Grant number:07671393  1995 - 1996

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    HIZUTA Akio, YASUDA Tatsuji, FUJIWARA Toshiyoshi

      More details

    Grant amount:\2300000 ( Direct expense: \2300000 )

    The alteration of wild-type p53 gene by mutations, deletions, or rearrangements is a major factor in the development of human colon cancer. Recent studies have demonstrated that p53 might be an essential component of the cytotoxic pathway triggered by DNA-damaging stimuli such as chemotherapeutic agents and ionizing radiation. We examined the antitumor effect of adenovirus-mediated wild-type p53 gene transfer in combination with a chemotherapeutic drug on human colon cancer cell line WiDr, which has a homozygous mutated p53 gene. The treatment with a chemotherapeutic drug, cisplatin, following the infection of a replication-deficient, recombinant adenoviral vector expressing wt-p53 (termed AdCMV p53) significantly suppressed the growth of WiDr cells compared to any single treatments. To evaluate the in vivo efficacy of AdCMV p53 and cisplatin given in a sequential combination, WiDr cells were subcutaneously inoculated in nu/nu mice, and after 3 days AdCMV p53 was subcutaneously injected into the area where tumor cells were implanted followed by intraperitoneal administration of cisplatin. Analysis of initial growth inhibition at 21 days demonstrated a profound, therapeutic cooperativity, although AdCMV p53 alone or cisplatin alone showed a modest slowing of the tumor growth. These results suggest that the gene therapy using wt-p53-expressing a denovirus in combination with a chemotherapeutic DNA-damaging drug is a useful strategy for human colon cancer therapy.

    researchmap

▼display all

 

Class subject in charge

  • Cancer Basic Science / Clinical Pharmacology (2023academic year) special  - その他

  • Team Oncology Practice (2023academic year) special  - その他

  • Palliative Care (2023academic year) special  - その他

  • Research Presentation in Regenerative Medicine (2023academic year) special  - その他

  • General Surgery 1 (2023academic year) Second semester  - 金4,金5

  • General Surgery (2023academic year) special  - その他

  • Management and Treatment of Malignant Tumors (2023academic year) special  - その他

  • Practicals: Gastroenterological Surgery (2023academic year) special  - その他

  • Research Projects: Gastroenterological Surgery (2023academic year) special  - その他

  • Surgery (1) (Core Clinical Practice) (2023academic year) special  - その他

  • Research Projects and Practicals: Gastroenterological Surgery I (2023academic year) special  - その他

  • Lecture and Research Projects: Gastroenterological Surgery I (2023academic year) special  - その他

  • Research Projects and Practicals: Gastroenterological Surgery II (2023academic year) special  - その他

  • Lecture and Research Projects: Gastroenterological Surgery II (2023academic year) special  - その他

  • Organ-specific Cancer Management (2023academic year) special  - その他

  • Introduction to Clinical Medicine and Dentistry (2023academic year) Concentration  - その他

  • Elective Clinical Practice (Surgery (1)) (2023academic year) special  - その他

  • Elective Clinical Practice (Surgery(1)) (2023academic year) special  - その他

  • Cancer Basic Science / Clinical Pharmacology (2022academic year) special  - その他

  • Team Oncology Practice (2022academic year) special  - その他

  • Palliative Care (2022academic year) special  - その他

  • Research Presentation in Regenerative Medicine (2022academic year) special  - その他

  • Medical Ethics and Legal and Economic Issues (2022academic year) special  - その他

  • Medical Informatics (2022academic year) special  - その他

  • General Surgery 1 (2022academic year) Second semester  - 金4,金5

  • General Surgery (2022academic year) special  - その他

  • Management and Treatment of Malignant Tumors (2022academic year) special  - その他

  • Surgery (1) (Core Clinical Practice) (2022academic year) special  - その他

  • Research Projects and Practicals: Gastroenterological Surgery I (2022academic year) special  - その他

  • Lecture and Research Projects: Gastroenterological Surgery I (2022academic year) special  - その他

  • Research Projects and Practicals: Gastroenterological Surgery II (2022academic year) special  - その他

  • Lecture and Research Projects: Gastroenterological Surgery II (2022academic year) special  - その他

  • Organ-specific Cancer Management (2022academic year) special  - その他

  • Introduction to Clinical Medicine and Dentistry (2022academic year) Concentration  - その他

  • Elective Clinical Practice (Surgery (1)) (2022academic year) special  - その他

  • Elective Clinical Practice (Surgery(1)) (2022academic year) special  - その他

  • Cancer Basic Science / Clinical Pharmacology (2021academic year) special  - その他

  • Team Oncology Practice (2021academic year) special  - その他

  • Palliative Care (2021academic year) special  - その他

  • Research Presentation in Regenerative Medicine (2021academic year) special  - その他

  • Medical Ethics and Legal and Economic Issues (2021academic year) special  - その他

  • Medical Informatics (2021academic year) special  - その他

  • General Surgery 1 (2021academic year) Second semester  - 金4,金5

  • General Surgery 1 (2021academic year) Second semester  - 金4,金5

  • General Surgery (2021academic year) special  - その他

  • Management and Treatment of Malignant Tumors (2021academic year) special  - その他

  • Surgery (1) (Core Clinical Practice) (2021academic year) special  - その他

  • Research Projects and Practicals: Gastroenterological Surgery I (2021academic year) special  - その他

  • Lecture and Research Projects: Gastroenterological Surgery I (2021academic year) special  - その他

  • Research Projects and Practicals: Gastroenterological Surgery II (2021academic year) special  - その他

  • Lecture and Research Projects: Gastroenterological Surgery II (2021academic year) special  - その他

  • Organ-specific Cancer Management (2021academic year) special  - その他

  • Introduction to Clinical Medicine and Dentistry (2021academic year) Concentration  - その他

  • Elective Clinical Practice (Surgery (1)) (2021academic year) special  - その他

  • Elective Clinical Practice (Surgery(1)) (2021academic year) special  - その他

  • Cancer Basic Science / Clinical Pharmacology (2020academic year) special  - その他

  • Team Oncology Practice (2020academic year) special  - その他

  • Palliative Care (2020academic year) special  - その他

  • Research Presentation in Regenerative Medicine (2020academic year) Year-round  - その他

  • Regenerative Medicine (2020academic year) Year-round  - その他

  • Medical Ethics and Legal and Economic Issues (2020academic year) special  - その他

  • Medical Informatics (2020academic year) special  - その他

  • General Surgery 1 (2020academic year) Second semester  - 金4,金5

  • General Surgery 1 (2020academic year) Second semester  - 金4,金5

  • General Surgery (2020academic year) special  - その他

  • Management and Treatment of Malignant Tumors (2020academic year) special  - その他

  • Surgery (1) (Core Clinical Practice) (2020academic year) special  - その他

  • Research Projects and Practicals: Gastroenterological Surgery I (2020academic year) special  - その他

  • Lecture and Research Projects: Gastroenterological Surgery I (2020academic year) special  - その他

  • Research Projects and Practicals: Gastroenterological Surgery II (2020academic year) special  - その他

  • Lecture and Research Projects: Gastroenterological Surgery II (2020academic year) special  - その他

  • Organ-specific Cancer Management (2020academic year) special  - その他

  • Introduction to Clinical Medicine and Dentistry (2020academic year) Concentration  - その他

  • Elective Clinical Practice (Surgery (1)) (2020academic year) special  - その他

  • Elective Clinical Practice (Surgery(1)) (2020academic year) special  - その他

▼display all